19392810
D003932_D012206 CID heroin_7\NN| (r_npadvmod) dependent_9\JJ|heroin|- (r_amod) male_10\NN|a|dependent (r_pobj) in_5\IN|male (r_prep) stroke_4\NN|rhabdomyolysis|ischemic|in|under|. (l_nmod) Rhabdomyolysis_0\NNP|and|brain
D003932_D012206 CID heroin_14\NN|intravenous (r_pobj) after_12\IN|heroin (r_prep) presented_5\VBN|man|with|after|. (l_prep) with_6\IN|rhabdomyolysis (l_pobj) rhabdomyolysis_7\NN|and|stroke
D003932_D012206 CID heroin_4\NN| (r_conj) methadone_2\NN|and|heroin (r_dobj) using_1\VBG|methadone|simultaneously (r_acl) Those_0\DT|using (r_nsubj) increase_7\VB|those|may|risk|. (l_dobj) risk_8\NN|of (l_prep) of_9\IN|rhabdomyolysis (l_pobj) rhabdomyolysis_10\NN|and|stroke
D003932_D012206 CID heroin_2\NN| (r_npadvmod) related_4\VBN|heroin|- (r_amod) rhabdomyolysis_5\NN|related|and|stroke
D003932_D012206 CID heroin_9\NN| (r_compound) abusers_10\NNS|heroin (r_pobj) in_8\IN|abusers (r_prep) stroke_7\NN|in (r_conj) rhabdomyolysis_5\NN|related|and|stroke
D003932_D002544 NONE heroin_7\NN| (r_npadvmod) dependent_9\JJ|heroin|- (r_amod) male_10\NN|a|dependent (r_pobj) in_5\IN|male (r_prep) stroke_4\NN|rhabdomyolysis|ischemic|in|under|.
D003932_D002544 NONE heroin_14\NN|intravenous (r_pobj) after_12\IN|heroin (r_prep) presented_5\VBN|man|with|after|. (l_prep) with_6\IN|rhabdomyolysis (l_pobj) rhabdomyolysis_7\NN|and|stroke (l_conj) stroke_11\NN|cerebral|ischemic
D003932_D002544 NONE heroin_4\NN| (r_conj) methadone_2\NN|and|heroin (r_dobj) using_1\VBG|methadone|simultaneously (r_acl) Those_0\DT|using (r_nsubj) increase_7\VB|those|may|risk|. (l_dobj) risk_8\NN|of (l_prep) of_9\IN|rhabdomyolysis (l_pobj) rhabdomyolysis_10\NN|and|stroke (l_conj) stroke_13\NN|ischemic
D008691_D012206 CID methadone_12\NN| (r_compound) therapy_14\NN|methadone|maintenance (r_pobj) under_11\IN|therapy (r_prep) stroke_4\NN|rhabdomyolysis|ischemic|in|under|. (l_nmod) Rhabdomyolysis_0\NNP|and|brain
D008691_D012206 CID methadone_2\NN|and|heroin (r_dobj) using_1\VBG|methadone|simultaneously (r_acl) Those_0\DT|using (r_nsubj) increase_7\VB|those|may|risk|. (l_dobj) risk_8\NN|of (l_prep) of_9\IN|rhabdomyolysis (l_pobj) rhabdomyolysis_10\NN|and|stroke
D008691_D002544 NONE methadone_12\NN| (r_compound) therapy_14\NN|methadone|maintenance (r_pobj) under_11\IN|therapy (r_prep) stroke_4\NN|rhabdomyolysis|ischemic|in|under|.
D008691_D002544 NONE methadone_2\NN|and|heroin (r_dobj) using_1\VBG|methadone|simultaneously (r_acl) Those_0\DT|using (r_nsubj) increase_7\VB|those|may|risk|. (l_dobj) risk_8\NN|of (l_prep) of_9\IN|rhabdomyolysis (l_pobj) rhabdomyolysis_10\NN|and|stroke (l_conj) stroke_13\NN|ischemic
D003932_D020521 CID heroin_2\NN| (r_npadvmod) related_4\VBN|heroin|- (r_amod) rhabdomyolysis_5\NN|related|and|stroke (l_conj) stroke_7\NN|in
D003932_D020521 CID heroin_9\NN| (r_compound) abusers_10\NNS|heroin (r_pobj) in_8\IN|abusers (r_prep) stroke_7\NN|in
9646784
D006493_D013921 CID Heparin_0\NNP| (r_npadvmod) induced_2\VBN|heparin|- (r_amod) thrombocytopenia_3\NN|induced|,|thromboembolism|.
D006493_D013921 CID heparin_13\JJ| (r_compound) therapy_14\NN|heparin (r_pobj) of_12\IN|therapy (r_prep) effects_11\NNS|other|side|of (r_conj) thromboembolism_6\NN|paradoxical|,|and|effects (r_conj) thrombocytopenia_3\NN|induced|,|thromboembolism|.
D006493_D013921 CID heparin_4\JJ| (r_compound) therapy_5\NN|heparin|including (l_prep) including_6\VBG|thrombocytopenia (l_pobj) thrombocytopenia_10\NN|induced|,|osteoporosis
D006493_D013921 CID heparin_4\JJ| (r_compound) therapy_5\NN|heparin|including (l_prep) including_6\VBG|thrombocytopenia (l_pobj) thrombocytopenia_10\NN|induced|,|osteoporosis (l_conj) osteoporosis_15\NN|associated|,|eosinophilia (l_conj) eosinophilia_17\NN|,|reactions (l_conj) reactions_20\NNS|skin|,|reactions (l_conj) reactions_23\NNS|allergic|other (l_amod) other_24\JJ|than (l_prep) than_25\IN|thrombocytopenia (l_pobj) thrombocytopenia_26\JJ|and|alopecia
D006493_D013921 CID heparin_7\NN| (r_npadvmod) induced_9\VBN|heparin|- (r_amod) thrombocytopenia_10\NN|induced|,|osteoporosis
D006493_D013921 CID heparin_7\NN| (r_npadvmod) induced_9\VBN|heparin|- (r_amod) thrombocytopenia_10\NN|induced|,|osteoporosis (l_conj) osteoporosis_15\NN|associated|,|eosinophilia (l_conj) eosinophilia_17\NN|,|reactions (l_conj) reactions_20\NNS|skin|,|reactions (l_conj) reactions_23\NNS|allergic|other (l_amod) other_24\JJ|than (l_prep) than_25\IN|thrombocytopenia (l_pobj) thrombocytopenia_26\JJ|and|alopecia
D006493_D013921 CID heparin_12\NN| (r_npadvmod) associated_14\VBN|heparin|- (r_amod) osteoporosis_15\NN|associated|,|eosinophilia (r_conj) thrombocytopenia_10\NN|induced|,|osteoporosis
D006493_D013921 CID heparin_12\NN| (r_npadvmod) associated_14\VBN|heparin|- (r_amod) osteoporosis_15\NN|associated|,|eosinophilia (l_conj) eosinophilia_17\NN|,|reactions (l_conj) reactions_20\NNS|skin|,|reactions (l_conj) reactions_23\NNS|allergic|other (l_amod) other_24\JJ|than (l_prep) than_25\IN|thrombocytopenia (l_pobj) thrombocytopenia_26\JJ|and|alopecia
D006493_D013923 CID Heparin_0\NNP| (r_npadvmod) induced_2\VBN|heparin|- (r_amod) thrombocytopenia_3\NN|induced|,|thromboembolism|. (l_conj) thromboembolism_6\NN|paradoxical|,|and|effects
D006493_D013923 CID heparin_13\JJ| (r_compound) therapy_14\NN|heparin (r_pobj) of_12\IN|therapy (r_prep) effects_11\NNS|other|side|of (r_conj) thromboembolism_6\NN|paradoxical|,|and|effects
D006493_D010024 CID heparin_4\JJ| (r_compound) therapy_5\NN|heparin|including (l_prep) including_6\VBG|thrombocytopenia (l_pobj) thrombocytopenia_10\NN|induced|,|osteoporosis (l_conj) osteoporosis_15\NN|associated|,|eosinophilia
D006493_D010024 CID heparin_7\NN| (r_npadvmod) induced_9\VBN|heparin|- (r_amod) thrombocytopenia_10\NN|induced|,|osteoporosis (l_conj) osteoporosis_15\NN|associated|,|eosinophilia
D006493_D010024 CID heparin_12\NN| (r_npadvmod) associated_14\VBN|heparin|- (r_amod) osteoporosis_15\NN|associated|,|eosinophilia
D006493_D004802 CID heparin_4\JJ| (r_compound) therapy_5\NN|heparin|including (l_prep) including_6\VBG|thrombocytopenia (l_pobj) thrombocytopenia_10\NN|induced|,|osteoporosis (l_conj) osteoporosis_15\NN|associated|,|eosinophilia (l_conj) eosinophilia_17\NN|,|reactions
D006493_D004802 CID heparin_7\NN| (r_npadvmod) induced_9\VBN|heparin|- (r_amod) thrombocytopenia_10\NN|induced|,|osteoporosis (l_conj) osteoporosis_15\NN|associated|,|eosinophilia (l_conj) eosinophilia_17\NN|,|reactions
D006493_D004802 CID heparin_12\NN| (r_npadvmod) associated_14\VBN|heparin|- (r_amod) osteoporosis_15\NN|associated|,|eosinophilia (l_conj) eosinophilia_17\NN|,|reactions
D006493_D012871 CID heparin_4\JJ| (r_compound) therapy_5\NN|heparin|including (l_prep) including_6\VBG|thrombocytopenia (l_pobj) thrombocytopenia_10\NN|induced|,|osteoporosis (l_conj) osteoporosis_15\NN|associated|,|eosinophilia (l_conj) eosinophilia_17\NN|,|reactions (l_conj) reactions_20\NNS|skin|,|reactions
D006493_D012871 CID heparin_7\NN| (r_npadvmod) induced_9\VBN|heparin|- (r_amod) thrombocytopenia_10\NN|induced|,|osteoporosis (l_conj) osteoporosis_15\NN|associated|,|eosinophilia (l_conj) eosinophilia_17\NN|,|reactions (l_conj) reactions_20\NNS|skin|,|reactions
D006493_D012871 CID heparin_12\NN| (r_npadvmod) associated_14\VBN|heparin|- (r_amod) osteoporosis_15\NN|associated|,|eosinophilia (l_conj) eosinophilia_17\NN|,|reactions (l_conj) reactions_20\NNS|skin|,|reactions
D006493_D004342 CID heparin_4\JJ| (r_compound) therapy_5\NN|heparin|including (l_prep) including_6\VBG|thrombocytopenia (l_pobj) thrombocytopenia_10\NN|induced|,|osteoporosis (l_conj) osteoporosis_15\NN|associated|,|eosinophilia (l_conj) eosinophilia_17\NN|,|reactions (l_conj) reactions_20\NNS|skin|,|reactions (l_conj) reactions_23\NNS|allergic|other
D006493_D004342 CID heparin_7\NN| (r_npadvmod) induced_9\VBN|heparin|- (r_amod) thrombocytopenia_10\NN|induced|,|osteoporosis (l_conj) osteoporosis_15\NN|associated|,|eosinophilia (l_conj) eosinophilia_17\NN|,|reactions (l_conj) reactions_20\NNS|skin|,|reactions (l_conj) reactions_23\NNS|allergic|other
D006493_D004342 CID heparin_12\NN| (r_npadvmod) associated_14\VBN|heparin|- (r_amod) osteoporosis_15\NN|associated|,|eosinophilia (l_conj) eosinophilia_17\NN|,|reactions (l_conj) reactions_20\NNS|skin|,|reactions (l_conj) reactions_23\NNS|allergic|other
D006493_D000505 CID heparin_4\JJ| (r_compound) therapy_5\NN|heparin|including (l_prep) including_6\VBG|thrombocytopenia (l_pobj) thrombocytopenia_10\NN|induced|,|osteoporosis (l_conj) osteoporosis_15\NN|associated|,|eosinophilia (l_conj) eosinophilia_17\NN|,|reactions (l_conj) reactions_20\NNS|skin|,|reactions (l_conj) reactions_23\NNS|allergic|other (l_amod) other_24\JJ|than (l_prep) than_25\IN|thrombocytopenia (l_pobj) thrombocytopenia_26\JJ|and|alopecia (l_conj) alopecia_28\NN|
D006493_D000505 CID heparin_7\NN| (r_npadvmod) induced_9\VBN|heparin|- (r_amod) thrombocytopenia_10\NN|induced|,|osteoporosis (l_conj) osteoporosis_15\NN|associated|,|eosinophilia (l_conj) eosinophilia_17\NN|,|reactions (l_conj) reactions_20\NNS|skin|,|reactions (l_conj) reactions_23\NNS|allergic|other (l_amod) other_24\JJ|than (l_prep) than_25\IN|thrombocytopenia (l_pobj) thrombocytopenia_26\JJ|and|alopecia (l_conj) alopecia_28\NN|
D006493_D000505 CID heparin_12\NN| (r_npadvmod) associated_14\VBN|heparin|- (r_amod) osteoporosis_15\NN|associated|,|eosinophilia (l_conj) eosinophilia_17\NN|,|reactions (l_conj) reactions_20\NNS|skin|,|reactions (l_conj) reactions_23\NNS|allergic|other (l_amod) other_24\JJ|than (l_prep) than_25\IN|thrombocytopenia (l_pobj) thrombocytopenia_26\JJ|and|alopecia (l_conj) alopecia_28\NN|
895432
D007545_D009203 CID isoproterenol_7\NN| (r_npadvmod) induced_9\VBN|isoproterenol|- (r_amod) infarction_11\NN|induced|myocardial
D007545_D009203 CID isoproterenol_8\NN| (r_npadvmod) induced_10\VBN|isoproterenol|- (r_amod) infarction_12\NN|induced|myocardial
D007545_D007238 NONE isoproterenol_16\NN| (r_pobj) of_15\IN|isoproterenol (r_prep) dosages_14\NNS|large|of (r_pobj) of_12\IN|dosages (r_prep) effects_11\NNS|the|of (r_pobj) with_9\IN|effects (r_prep) associated_8\VBN|with (r_acl) mortality_7\NN|the|associated (r_dobj) reduced_5\VBD|that|exercise|mortality|but|had (l_conj) had_18\VBD|little|on (l_prep) on_20\IN|severity (l_pobj) severity_22\NN|the|of (l_prep) of_23\IN|infarction (l_pobj) infarction_25\NN|the
11936424
C055603_D007674 NONE Temocapril_0\NNP|,|angiotensin|, (r_nsubj) modulates_15\VBZ|temocapril|injury|. (l_dobj) injury_17\NN|glomerular|in
C055603_D009401 NONE Temocapril_0\NNP|,|angiotensin|, (r_nsubj) modulates_15\VBZ|temocapril|injury|. (l_dobj) injury_17\NN|glomerular|in (l_prep) in_18\IN|nephrosis (l_pobj) nephrosis_22\NN|puromycin|aminonucleoside
C055603_D009401 NONE temocapril_3\NN| (r_nsubj) was_4\VBD|that|temocapril|effective (l_acomp) effective_5\JJ|in (l_prep) in_6\IN|retarding (l_pcomp) retarding_7\VBG|progression|and|protected (l_conj) protected_11\VBD|function (l_dobj) function_13\NN|renal|in (l_prep) in_14\IN|rats (l_pobj) rats_17\NNS|pan|neprotic (l_amod) neprotic_16\JJ|
D000809_D007674 NONE angiotensin_10\NN|a|group|converting (r_appos) Temocapril_0\NNP|,|angiotensin|, (r_nsubj) modulates_15\VBZ|temocapril|injury|. (l_dobj) injury_17\NN|glomerular|in
D000809_D009401 NONE angiotensin_10\NN|a|group|converting (r_appos) Temocapril_0\NNP|,|angiotensin|, (r_nsubj) modulates_15\VBZ|temocapril|injury|. (l_dobj) injury_17\NN|glomerular|in (l_prep) in_18\IN|nephrosis (l_pobj) nephrosis_22\NN|puromycin|aminonucleoside
D011692_D007674 NONE aminonucleoside_21\JJ| (r_amod) nephrosis_22\NN|puromycin|aminonucleoside (r_pobj) in_18\IN|nephrosis (r_prep) injury_17\NN|glomerular|in
D011692_D009401 CID aminonucleoside_21\JJ| (r_amod) nephrosis_22\NN|puromycin|aminonucleoside
D011692_D009401 CID PAN_6\NNP|(|15mg/100|weight|) (r_pobj) of_5\IN|pan (r_prep) injection_4\NN|of|in (r_pobj) by_3\IN|injection (r_agent) induced_2\VBN|nephrosis|was|by|. (l_nsubjpass) Nephrosis_0\NNP|
D011692_D009401 CID PAN_15\NNP| (r_compound) rats_17\NNS|pan|neprotic (l_amod) neprotic_16\JJ|
C055603_D011507 NONE temocapril_13\NN| (r_pobj) of_12\IN|temocapril (r_prep) administration_11\NN|chronic|of|,|angiotensin (l_appos) angiotensin_23\NN|a|group|converting|,|reduced|, (l_acl) reduced_31\VBN|proteinuria (l_dobj) proteinuria_32\NN|
C055603_D011507 NONE Temocapril_0\NNP| (r_nsubj) attenuate_3\VB|temocapril|did|not|proteinuria|at|,|but|lower (l_dobj) proteinuria_4\NN|
C055603_D006984 NONE temocapril_13\NN| (r_pobj) of_12\IN|temocapril (r_prep) administration_11\NN|chronic|of|,|angiotensin (r_nsubj) inhibited_34\VBD|whether|administration|hypertrophy|and|prevented (l_dobj) hypertrophy_36\NN|glomerular
C055603_D005921 NONE temocapril_13\NN| (r_pobj) of_12\IN|temocapril (r_prep) administration_11\NN|chronic|of|,|angiotensin (r_nsubj) inhibited_34\VBD|whether|administration|hypertrophy|and|prevented (l_conj) prevented_38\VBN|glomerulosclerosis|in|pan (l_dobj) glomerulosclerosis_39\NN|
C055603_D009404 NONE temocapril_13\NN| (r_pobj) of_12\IN|temocapril (r_prep) administration_11\NN|chronic|of|,|angiotensin (r_nsubj) inhibited_34\VBD|whether|administration|hypertrophy|and|prevented (r_ccomp) determine_8\VB|to|inhibited (r_xcomp) was_6\VBD|purpose|determine|induced|. (l_conj) induced_48\VBN|-|rats (l_dobj) rats_50\NNS|nephrotic (l_amod) nephrotic_49\JJ|
D000809_D011507 NONE angiotensin_23\NN|a|group|converting|,|reduced|, (l_acl) reduced_31\VBN|proteinuria (l_dobj) proteinuria_32\NN|
D000809_D006984 NONE angiotensin_23\NN|a|group|converting|,|reduced|, (r_appos) administration_11\NN|chronic|of|,|angiotensin (r_nsubj) inhibited_34\VBD|whether|administration|hypertrophy|and|prevented (l_dobj) hypertrophy_36\NN|glomerular
D000809_D005921 NONE angiotensin_23\NN|a|group|converting|,|reduced|, (r_appos) administration_11\NN|chronic|of|,|angiotensin (r_nsubj) inhibited_34\VBD|whether|administration|hypertrophy|and|prevented (l_conj) prevented_38\VBN|glomerulosclerosis|in|pan (l_dobj) glomerulosclerosis_39\NN|
D000809_D009404 NONE angiotensin_23\NN|a|group|converting|,|reduced|, (r_appos) administration_11\NN|chronic|of|,|angiotensin (r_nsubj) inhibited_34\VBD|whether|administration|hypertrophy|and|prevented (r_ccomp) determine_8\VB|to|inhibited (r_xcomp) was_6\VBD|purpose|determine|induced|. (l_conj) induced_48\VBN|-|rats (l_dobj) rats_50\NNS|nephrotic (l_amod) nephrotic_49\JJ|
D011692_D011507 CID aminonucleoside_43\NN| (r_nmod) PAN_45\NNP|aminonucleoside|(|) (r_npadvmod) prevented_38\VBN|glomerulosclerosis|in|pan (r_conj) inhibited_34\VBD|whether|administration|hypertrophy|and|prevented (l_nsubj) administration_11\NN|chronic|of|,|angiotensin (l_appos) angiotensin_23\NN|a|group|converting|,|reduced|, (l_acl) reduced_31\VBN|proteinuria (l_dobj) proteinuria_32\NN|
D011692_D011507 CID PAN_45\NNP|aminonucleoside|(|) (r_npadvmod) prevented_38\VBN|glomerulosclerosis|in|pan (r_conj) inhibited_34\VBD|whether|administration|hypertrophy|and|prevented (l_nsubj) administration_11\NN|chronic|of|,|angiotensin (l_appos) angiotensin_23\NN|a|group|converting|,|reduced|, (l_acl) reduced_31\VBN|proteinuria (l_dobj) proteinuria_32\NN|
D011692_D006984 NONE aminonucleoside_43\NN| (r_nmod) PAN_45\NNP|aminonucleoside|(|) (r_npadvmod) prevented_38\VBN|glomerulosclerosis|in|pan (r_conj) inhibited_34\VBD|whether|administration|hypertrophy|and|prevented (l_dobj) hypertrophy_36\NN|glomerular
D011692_D006984 NONE PAN_45\NNP|aminonucleoside|(|) (r_npadvmod) prevented_38\VBN|glomerulosclerosis|in|pan (r_conj) inhibited_34\VBD|whether|administration|hypertrophy|and|prevented (l_dobj) hypertrophy_36\NN|glomerular
D011692_D005921 NONE aminonucleoside_43\NN| (r_nmod) PAN_45\NNP|aminonucleoside|(|) (r_npadvmod) prevented_38\VBN|glomerulosclerosis|in|pan (l_dobj) glomerulosclerosis_39\NN|
D011692_D005921 NONE PAN_45\NNP|aminonucleoside|(|) (r_npadvmod) prevented_38\VBN|glomerulosclerosis|in|pan (l_dobj) glomerulosclerosis_39\NN|
D011692_D005921 NONE PAN_26\NNP| (r_compound) group_27\NN|the|pan (r_pobj) in_24\IN|group (r_prep) weeks_23\NNS|14|in (r_pobj) at_19\IN|weeks (r_prep) was_6\VBD|index|%|at|at|. (l_nsubj) index_2\NN|the|glomerulosclerosis|(|gsi|) (l_compound) glomerulosclerosis_1\NN|
D011692_D009404 NONE aminonucleoside_43\NN| (r_nmod) PAN_45\NNP|aminonucleoside|(|) (r_npadvmod) prevented_38\VBN|glomerulosclerosis|in|pan (r_conj) inhibited_34\VBD|whether|administration|hypertrophy|and|prevented (r_ccomp) determine_8\VB|to|inhibited (r_xcomp) was_6\VBD|purpose|determine|induced|. (l_conj) induced_48\VBN|-|rats (l_dobj) rats_50\NNS|nephrotic (l_amod) nephrotic_49\JJ|
D011692_D009404 NONE PAN_45\NNP|aminonucleoside|(|) (r_npadvmod) prevented_38\VBN|glomerulosclerosis|in|pan (r_conj) inhibited_34\VBD|whether|administration|hypertrophy|and|prevented (r_ccomp) determine_8\VB|to|inhibited (r_xcomp) was_6\VBD|purpose|determine|induced|. (l_conj) induced_48\VBN|-|rats (l_dobj) rats_50\NNS|nephrotic (l_amod) nephrotic_49\JJ|
19553912
D020123_D000740 CID sirolimus_6\NN| (r_pobj) of_5\IN|sirolimus (r_prep) role_4\NN|the|of (r_appos) anemia_1\NN|posttransplant|:|role|.
D020123_D000740 CID Sirolimus_0\NNP|,|target|, (r_nsubjpass) implicated_11\VBN|sirolimus|has|been|as|. (l_prep) as_12\IN|playing (l_pcomp) playing_13\VBG|role (l_dobj) role_16\NN|a|special|in (l_prep) in_17\IN|anemia (l_pobj) anemia_19\NN|posttransplant
D020123_D000740 CID rapamycin_6\NNS| (r_compound) inhibitor_7\NN|rapamycin (r_pobj) of_5\IN|inhibitor (r_prep) target_4\NN|a|mammalian|of (r_appos) Sirolimus_0\NNP|,|target|, (r_nsubjpass) implicated_11\VBN|sirolimus|has|been|as|. (l_prep) as_12\IN|playing (l_pcomp) playing_13\VBG|role (l_dobj) role_16\NN|a|special|in (l_prep) in_17\IN|anemia (l_pobj) anemia_19\NN|posttransplant
D020123_D000740 CID sirolimus_6\NN| (r_pobj) with_5\IN|sirolimus (r_prep) associated_4\VBN|with (r_acl) anemia_3\NN|associated|,|including
19920070
D010634_D006529 CID phenobarbital_21\JJ| (r_amod) administration_22\NN|phenobarbital (r_pobj) after_20\IN|administration (r_prep) hepatomegaly_19\NN|after
4082192
C026729_D007674 NONE aminophenol_5\NN|p|- (r_pobj) of_2\IN|aminophenol (r_prep) role_1\NN|the|of|in|:|effect|. (l_prep) in_6\IN|nephrotoxicity (l_pobj) nephrotoxicity_10\NN|induced
C026729_D007674 NONE aminophenol_5\NN|p|- (r_pobj) of_2\IN|aminophenol (r_prep) role_1\NN|the|of|in|:|effect|. (l_appos) effect_12\NN|of (l_prep) of_13\IN|phosphate (l_pobj) phosphate_18\NN|nitrophenyl|)|on|and|nephrotoxicity (l_conj) nephrotoxicity_25\NN|aminophenol|and|metabolism|in
C026729_D007674 NONE aminophenol_24\NN|p|- (r_amod) nephrotoxicity_25\NN|aminophenol|and|metabolism|in (r_conj) phosphate_18\NN|nitrophenyl|)|on|and|nephrotoxicity (r_pobj) of_13\IN|phosphate (r_prep) effect_12\NN|of (r_appos) role_1\NN|the|of|in|:|effect|. (l_prep) in_6\IN|nephrotoxicity (l_pobj) nephrotoxicity_10\NN|induced
C026729_D007674 NONE aminophenol_24\NN|p|- (r_amod) nephrotoxicity_25\NN|aminophenol|and|metabolism|in
C026729_D007674 NONE PAP_9\NNP| (r_compound) formation_10\NN|pap (r_nsubj) is_11\VBZ|if|formation|step (l_attr) step_14\NN|a|requisite|in (l_prep) in_15\IN|nephrotoxicity (l_pobj) nephrotoxicity_19\NN|induced
C026729_D007674 NONE PAP_21\NNP| (r_compound) nephrotoxicity_22\NN|pap|and|metabolism
C026729_D007674 NONE PAP_9\NNP| (r_compound) administration_10\NN|pap (r_conj) APAP_7\NNP|or|administration (r_pobj) to_6\IN|apap (r_prep) prior_5\RB|to (r_advmod) Pretreatment_0\NN|of|prior (r_nsubj) resulted_11\VBD|pretreatment|in|. (l_prep) in_12\IN|reduction (l_pobj) reduction_14\NN|marked|of|nephrotoxicity (l_appos) nephrotoxicity_25\NN|nephrotoxicity|not|pap (l_nmod) nephrotoxicity_21\NN|(|mg/kg|)|but
C026729_D007674 NONE PAP_9\NNP| (r_compound) administration_10\NN|pap (r_conj) APAP_7\NNP|or|administration (r_pobj) to_6\IN|apap (r_prep) prior_5\RB|to (r_advmod) Pretreatment_0\NN|of|prior (r_nsubj) resulted_11\VBD|pretreatment|in|. (l_prep) in_12\IN|reduction (l_pobj) reduction_14\NN|marked|of|nephrotoxicity (l_appos) nephrotoxicity_25\NN|nephrotoxicity|not|pap
C026729_D007674 NONE PAP_24\NNP| (r_compound) nephrotoxicity_25\NN|nephrotoxicity|not|pap (l_nmod) nephrotoxicity_21\NN|(|mg/kg|)|but
C026729_D007674 NONE PAP_24\NNP| (r_compound) nephrotoxicity_25\NN|nephrotoxicity|not|pap
D000082_D007674 NONE acetaminophen_7\RB| (r_advmod) induced_9\VBN|acetaminophen|- (r_amod) nephrotoxicity_10\NN|induced
D000082_D007674 NONE acetaminophen_7\RB| (r_advmod) induced_9\VBN|acetaminophen|- (r_amod) nephrotoxicity_10\NN|induced (r_pobj) in_6\IN|nephrotoxicity (r_prep) role_1\NN|the|of|in|:|effect|. (l_appos) effect_12\NN|of (l_prep) of_13\IN|phosphate (l_pobj) phosphate_18\NN|nitrophenyl|)|on|and|nephrotoxicity (l_conj) nephrotoxicity_25\NN|aminophenol|and|metabolism|in
D000082_D007674 NONE acetaminophen_20\NN| (r_pobj) on_19\IN|acetaminophen (r_prep) phosphate_18\NN|nitrophenyl|)|on|and|nephrotoxicity (r_pobj) of_13\IN|phosphate (r_prep) effect_12\NN|of (r_appos) role_1\NN|the|of|in|:|effect|. (l_prep) in_6\IN|nephrotoxicity (l_pobj) nephrotoxicity_10\NN|induced
D000082_D007674 NONE acetaminophen_20\NN| (r_pobj) on_19\IN|acetaminophen (r_prep) phosphate_18\NN|nitrophenyl|)|on|and|nephrotoxicity (l_conj) nephrotoxicity_25\NN|aminophenol|and|metabolism|in
D000082_D007674 NONE APAP_16\NNP| (r_npadvmod) induced_18\VBN|apap|- (r_amod) nephrotoxicity_19\NN|induced
D000082_D007674 NONE APAP_19\NNP|and|nephrotoxicity (l_conj) nephrotoxicity_22\NN|pap|and|metabolism
D000082_D007674 NONE APAP_7\NNP|or|administration (r_pobj) to_6\IN|apap (r_prep) prior_5\RB|to (r_advmod) Pretreatment_0\NN|of|prior (r_nsubj) resulted_11\VBD|pretreatment|in|. (l_prep) in_12\IN|reduction (l_pobj) reduction_14\NN|marked|of|nephrotoxicity (l_appos) nephrotoxicity_25\NN|nephrotoxicity|not|pap (l_nmod) nephrotoxicity_21\NN|(|mg/kg|)|but
D000082_D007674 NONE APAP_7\NNP|or|administration (r_pobj) to_6\IN|apap (r_prep) prior_5\RB|to (r_advmod) Pretreatment_0\NN|of|prior (r_nsubj) resulted_11\VBD|pretreatment|in|. (l_prep) in_12\IN|reduction (l_pobj) reduction_14\NN|marked|of|nephrotoxicity (l_appos) nephrotoxicity_25\NN|nephrotoxicity|not|pap
D000082_D007674 NONE APAP_16\NNP| (r_pobj) of_15\IN|apap (r_prep) reduction_14\NN|marked|of|nephrotoxicity (l_appos) nephrotoxicity_25\NN|nephrotoxicity|not|pap (l_nmod) nephrotoxicity_21\NN|(|mg/kg|)|but
D000082_D007674 NONE APAP_16\NNP| (r_pobj) of_15\IN|apap (r_prep) reduction_14\NN|marked|of|nephrotoxicity (l_appos) nephrotoxicity_25\NN|nephrotoxicity|not|pap
D000082_D007674 NONE APAP_8\NNP| (r_npadvmod) induced_10\VBN|apap|- (r_amod) nephrotoxicity_11\NN|induced
D000082_D007674 NONE APAP_19\NNP| (r_compound) deacetylation_20\NN|apap (r_pobj) of_18\IN|deacetylation (r_prep) inhibition_17\NN|of (r_pobj) due_15\JJ|to|inhibition (r_acomp) be_14\VB|to|due (r_xcomp) appears_12\VBZ|therefore|,|reduction|be|. (l_nsubj) reduction_6\NN|the|induced|in (l_prep) in_7\IN|nephrotoxicity (l_pobj) nephrotoxicity_11\NN|induced
C002887_D007674 NONE phosphate_18\NN|nitrophenyl|)|on|and|nephrotoxicity (r_pobj) of_13\IN|phosphate (r_prep) effect_12\NN|of (r_appos) role_1\NN|the|of|in|:|effect|. (l_prep) in_6\IN|nephrotoxicity (l_pobj) nephrotoxicity_10\NN|induced
C002887_D007674 NONE phosphate_18\NN|nitrophenyl|)|on|and|nephrotoxicity (l_conj) nephrotoxicity_25\NN|aminophenol|and|metabolism|in
C002887_D007674 NONE phosphate_9\NN|nitrophenyl|bnpp|,|inhibitor|, (r_pobj) of_4\IN|phosphate (r_prep) effect_3\NN|the|of|on (l_prep) on_18\IN|apap (l_pobj) APAP_19\NNP|and|nephrotoxicity (l_conj) nephrotoxicity_22\NN|pap|and|metabolism
C002887_D007674 NONE BNPP_11\NNP|(|) (r_appos) phosphate_9\NN|nitrophenyl|bnpp|,|inhibitor|, (r_pobj) of_4\IN|phosphate (r_prep) effect_3\NN|the|of|on (l_prep) on_18\IN|apap (l_pobj) APAP_19\NNP|and|nephrotoxicity (l_conj) nephrotoxicity_22\NN|pap|and|metabolism
C002887_D007674 NONE BNPP_4\NNP| (r_pobj) with_3\IN|bnpp (r_prep) animals_2\NNS|with (r_pobj) of_1\IN|animals (r_prep) Pretreatment_0\NN|of|prior (r_nsubj) resulted_11\VBD|pretreatment|in|. (l_prep) in_12\IN|reduction (l_pobj) reduction_14\NN|marked|of|nephrotoxicity (l_appos) nephrotoxicity_25\NN|nephrotoxicity|not|pap (l_nmod) nephrotoxicity_21\NN|(|mg/kg|)|but
C002887_D007674 NONE BNPP_4\NNP| (r_pobj) with_3\IN|bnpp (r_prep) animals_2\NNS|with (r_pobj) of_1\IN|animals (r_prep) Pretreatment_0\NN|of|prior (r_nsubj) resulted_11\VBD|pretreatment|in|. (l_prep) in_12\IN|reduction (l_pobj) reduction_14\NN|marked|of|nephrotoxicity (l_appos) nephrotoxicity_25\NN|nephrotoxicity|not|pap
C002887_D007674 NONE BNPP_3\NNP| (r_npadvmod) induced_5\VBN|bnpp|- (r_amod) reduction_6\NN|the|induced|in (l_prep) in_7\IN|nephrotoxicity (l_pobj) nephrotoxicity_11\NN|induced
D000082_D007683 CID Acetaminophen_0\NNP|(|apap|) (r_nsubj) produces_4\VBZ|acetaminophen|necrosis|in|. (l_dobj) necrosis_7\NN|proximal|tubular
D000082_D007683 CID APAP_2\NNP| (r_appos) Acetaminophen_0\NNP|(|apap|) (r_nsubj) produces_4\VBZ|acetaminophen|necrosis|in|. (l_dobj) necrosis_7\NN|proximal|tubular
D000082_D007683 CID APAP_18\NNP| (r_npadvmod) induced_20\VBN|apap|- (r_amod) necrosis_23\NN|induced|renal|tubular
C026729_D007683 CID PAP_4\NNP| (r_compound) formation_5\NN|pap (r_nsubj) accounts_10\NNS|that|formation|,|in|,|,|in|,|for (l_prep) for_17\IN|necrosis (l_pobj) necrosis_23\NN|induced|renal|tubular
15605432
D004317_D028361 CID adriamycin_6\NNS| (r_npadvmod) induced_8\VBN|adriamycin|- (r_amod) injury_11\NN|induced|cardiac|mitochondrial
D004317_D028361 CID ADR_3\NNP| (r_nsubj) induced_4\VBD|adr|adducts|at (l_prep) at_11\IN|point (l_pobj) point_15\NN|the|same|time|as (l_prep) as_16\IN|appeared (l_pcomp) appeared_21\VBD|when|injury|initially (l_nsubj) injury_19\NN|mitochondrial
D010100_D066126 NONE oxygen_12\NN|elevated|reactive|species (r_nsubj) reported_19\VBD|if|oxygen|be (r_ccomp) determine_8\VB|to|reported (r_xcomp) was_6\VBD|purpose|determine|adriamycin|resulted|. (l_conj) resulted_29\VBD|cardiotoxicity|actually|in|,|and|determine (l_nsubj) cardiotoxicity_27\NN|(|adr)-induced
D009584_D066126 NONE ROS)/nitrogen_14\NN| (r_compound) species_15\NNS|(|ros)/nitrogen|(|rns|) (r_appos) oxygen_12\NN|elevated|reactive|species (r_nsubj) reported_19\VBD|if|oxygen|be (r_ccomp) determine_8\VB|to|reported (r_xcomp) was_6\VBD|purpose|determine|adriamycin|resulted|. (l_conj) resulted_29\VBD|cardiotoxicity|actually|in|,|and|determine (l_nsubj) cardiotoxicity_27\NN|(|adr)-induced
D004317_D066126 NONE adriamycin_24\NNS| (r_acomp) was_6\VBD|purpose|determine|adriamycin|resulted|. (l_conj) resulted_29\VBD|cardiotoxicity|actually|in|,|and|determine (l_nsubj) cardiotoxicity_27\NN|(|adr)-induced
D004317_D066126 NONE ADR)-induced_26\JJ| (r_compound) cardiotoxicity_27\NN|(|adr)-induced
C027576_D028361 NONE 4HNE_5\CD| (r_compound) protein_7\NN|4hne|- (r_compound) adducts_8\NNS|protein|in (r_dobj) induced_4\VBD|adr|adducts|at (l_prep) at_11\IN|point (l_pobj) point_15\NN|the|same|time|as (l_prep) as_16\IN|appeared (l_pcomp) appeared_21\VBD|when|injury|initially (l_nsubj) injury_19\NN|mitochondrial
16876986
D010862_D012640 CID pilocarpine_6\NN| (r_npadvmod) induced_8\VBN|pilocarpine|- (r_amod) seizures_9\NNS|subsequent|induced|in
D010862_D012640 CID pilocarpine_6\NN| (r_amod) injections_7\NNS|pilocarpine|in (r_pobj) by_5\IN|injections (r_agent) induced_4\VBN|thereafter|,|seizures|were|by|. (l_nsubjpass) seizures_2\NNS|
3538855
D000617_D007674 CID aminoglycoside_5\NN| (r_compound) nephrotoxicity_6\NN|aminoglycoside
D000617_D007674 CID aminoglycoside_3\NN| (r_pobj) of_2\IN|aminoglycoside (r_prep) epidemiology_1\NN|the|of (r_nsubj) induced_5\VBN|epidemiology|- (r_amod) nephrotoxicity_6\NN|induced
D000617_D007674 CID aminoglycosides_7\NNS| (r_dobj) indicate_6\VBP|studies|aminoglycosides|cause|. (l_conj) cause_8\VBP|damage|,|but|cause (l_conj) cause_22\VB|rarely|,|ever|,|dysfunction (l_dobj) dysfunction_26\NN|glomerular
D000617_D007674 CID aminoglycoside_13\NN|plasma (r_compound) levels_14\NNS|therapy|aminoglycoside (r_pobj) of_9\IN|levels (r_prep) duration_8\NN|the|of|,|disease|gender (r_nsubj) increase_34\VBP|that|duration|all|risk (l_dobj) risk_36\NN|the|for (l_prep) for_37\IN|nephrotoxicity (l_pobj) nephrotoxicity_38\NN|
D000617_D007674 CID aminoglycoside_13\NN| (r_npadvmod) induced_15\VBN|aminoglycoside|- (r_amod) nephrotoxicity_16\NN|induced
D000617_D058186 NONE aminoglycosides_3\NNS| (r_pobj) of_2\IN|aminoglycosides (r_prep) trials_1\NNS|clinical|of|in (r_nsubj) indicate_8\VBP|trials|ranges|. (l_ccomp) ranges_20\VBZ|that|risk|from|and|is (l_nsubj) risk_12\NN|the|relative|for (l_prep) for_13\IN|developing (l_pcomp) developing_14\VBG|failure|during (l_dobj) failure_17\NN|acute|renal
D000617_D008107 NONE aminoglycoside_13\NN|plasma (r_compound) levels_14\NNS|therapy|aminoglycoside (r_pobj) of_9\IN|levels (r_prep) duration_8\NN|the|of|,|disease|gender (l_appos) disease_17\NN|liver|,|age
D003404_D008107 NONE creatinine_25\NN| (r_compound) clearance_26\NN|high|initial|estimated|creatinine|and|,|possibly (r_conj) age_20\NN|advanced|,|clearance (r_conj) disease_17\NN|liver|,|age
D003404_D007674 NONE creatinine_25\NN| (r_compound) clearance_26\NN|high|initial|estimated|creatinine|and|,|possibly (r_conj) age_20\NN|advanced|,|clearance (r_conj) disease_17\NN|liver|,|age (r_appos) duration_8\NN|the|of|,|disease|gender (r_nsubj) increase_34\VBP|that|duration|all|risk (l_dobj) risk_36\NN|the|for (l_prep) for_37\IN|nephrotoxicity (l_pobj) nephrotoxicity_38\NN|
7248895
D003520_D010386 NONE cyclophosphamide_7\NN| (r_compound) therapy_8\NN|cyclophosphamide (r_dobj) following_6\VBG|therapy|for (r_prep) pelvis_5\NN|the|renal|following
D003520_D010386 NONE cyclophosphamide_15\NN| (r_compound) treatment_16\NN|cyclophosphamide (r_pobj) with_14\IN|treatment (r_prep) association_13\NN|with (r_pobj) in_12\IN|association (r_prep) reported_11\VBD|in (r_acl) pelvis_10\NN|the|renal|reported
D003520_D006869 NONE cyclophosphamide_23\NN| (r_pobj) wtih_22\IN|cyclophosphamide (r_prep) treated_18\VBN|being|for|wtih|for (r_pcomp) after_16\IN|treated (r_prep) had_13\VBD|woman|hematuria|after|. (l_nsubj) woman_4\NN|a|old|with (l_prep) with_5\IN|hydroureteronephrosis (l_pobj) hydroureteronephrosis_7\NN|right|due
D003520_D006869 NONE cyclophosphamide_21\NN| (r_pobj) to_20\IN|cyclophosphamide (r_prep) epithelium_19\NN|upper|urinary|tract|to (r_pobj) of_15\IN|epithelium (r_prep) exposure_14\NN|of (r_dobj) intensified_13\VBN|exposure (r_conj) prolonged_11\VBN|that|stasis|and|intensified (r_ccomp) suggests_8\VBZ|association|prolonged|. (l_nsubj) association_1\NN|the|of|with (l_prep) with_5\IN|hydroureteronephrosis (l_pobj) hydroureteronephrosis_7\NN|preexisting
D003520_D006417 CID cyclophosphamide_23\NN| (r_pobj) wtih_22\IN|cyclophosphamide (r_prep) treated_18\VBN|being|for|wtih|for (r_pcomp) after_16\IN|treated (r_prep) had_13\VBD|woman|hematuria|after|. (l_dobj) hematuria_15\NN|gross
D003520_D020293 NONE cyclophosphamide_23\NN| (r_pobj) wtih_22\IN|cyclophosphamide (r_prep) treated_18\VBN|being|for|wtih|for (l_prep) for_24\IN|vasculitis (l_pobj) vasculitis_26\NN|cerebral
D003520_D006470 NONE cyclophosphamide_4\NN| (r_pobj) of_3\IN|cyclophosphamide (r_prep) ability_2\NN|the|of|cause (l_acl) cause_6\VB|to|cystitis|and|urine (l_dobj) cystitis_8\NN|hemorrhagic
D003520_D003556 NONE cyclophosphamide_4\NN| (r_pobj) of_3\IN|cyclophosphamide (r_prep) ability_2\NN|the|of|cause (l_acl) cause_6\VB|to|cystitis|and|urine (l_dobj) cystitis_8\NN|hemorrhagic
D003520_D002277 CID cyclophosphamide_4\NN| (r_pobj) of_3\IN|cyclophosphamide (r_prep) ability_2\NN|the|of|cause (l_acl) cause_6\VB|to|cystitis|and|urine (l_conj) urine_10\NN|abnormalities (l_dobj) abnormalities_12\NNS|cytologic|indistinguishable (l_amod) indistinguishable_13\JJ|from (l_prep) from_14\IN|carcinoma (l_pobj) carcinoma_17\NN|grade
D003520_D014571 NONE cyclophosphamide_4\NN| (r_pobj) of_3\IN|cyclophosphamide (r_prep) ability_2\NN|the|of|cause (r_nsubj) is_18\VBZ|although|ability|known (r_advcl) is_23\VBZ|is|,|it (r_auxpass) appreciated_26\VBN|is|widely|associated|. (l_ccomp) associated_31\VBN|that|it|is|also|with (l_prep) with_32\IN|carcinoma (l_pobj) carcinoma_33\NN|of (l_prep) of_34\IN|tract (l_pobj) tract_37\NN|the|urinary
D003520_D014571 NONE cyclophosphamide_11\JJ| (r_compound) treatment_12\NN|cyclophosphamide|for (r_pobj) with_10\IN|treatment (r_prep) association_9\NN|with (r_pobj) in_8\IN|association (r_prep) reported_7\VBN|in (r_acl) cancer_6\NN|the|third|urinary|tract|reported
D003520_D009369 NONE cyclophosphamide_21\NN| (r_pobj) to_20\IN|cyclophosphamide (r_prep) epithelium_19\NN|upper|urinary|tract|to (r_pobj) of_15\IN|epithelium (r_prep) exposure_14\NN|of (r_dobj) intensified_13\VBN|exposure (r_conj) prolonged_11\VBN|that|stasis|and|intensified (r_ccomp) suggests_8\VBZ|association|prolonged|. (l_nsubj) association_1\NN|the|of|with (l_prep) of_2\IN|tumor (l_pobj) tumor_4\NN|the
D003520_-1 NONE cyclophosphamide_8\NN| (r_compound) treatment_9\NN|term|cyclophosphamide (r_pobj) for_4\IN|treatment (r_prep) candidates_3\NNS|for (r_attr) are_2\VBP|who|candidates (r_relcl) Patients_0\NNS|are (r_nsubjpass) evaluated_13\VBN|patients|should|be|routinely|for|. (l_prep) for_14\IN|uropathy (l_pobj) uropathy_16\NN|obstructive
6673474
D009599_D007022 CID nitroprusside_14\NN|snp (r_amod) sodium_13\NN|nitroprusside (r_pobj) under_12\IN|sodium (r_prep) dogs_11\NNS|under (r_pobj) in_10\IN|dogs (r_prep) studied_9\VBN|flow|were|in|and|trimetaphan|. (l_conj) trimetaphan_19\NN|hypotension (l_pobj) hypotension_24\NN|(|tmp|)|deliberate|(|%|decrease
D009599_D007022 CID SNP_16\NNP|(|) (r_appos) nitroprusside_14\NN|snp (r_amod) sodium_13\NN|nitroprusside (r_pobj) under_12\IN|sodium (r_prep) dogs_11\NNS|under (r_pobj) in_10\IN|dogs (r_prep) studied_9\VBN|flow|were|in|and|trimetaphan|. (l_conj) trimetaphan_19\NN|hypotension (l_pobj) hypotension_24\NN|(|tmp|)|deliberate|(|%|decrease
D009599_D007022 CID nitroprusside_30\JJ| (r_amod) hypotension_31\NN|nitroprusside (r_nsubjpass) used_35\VBN|that|hypotension|could|be|safely|to|decrease (r_ccomp) confirm_28\VB|regarding|we|could|used|. (l_prep) Regarding_0\VBG|effects (l_pobj) effects_2\NNS|the|of (l_prep) of_3\IN|hypotension (l_pobj) hypotension_7\NN|induced|on
D009599_D007022 CID nitroprusside_30\JJ| (r_amod) hypotension_31\NN|nitroprusside
D009599_D007022 CID nitroprusside_30\JJ| (r_amod) hypotension_31\NN|nitroprusside (r_nsubjpass) used_35\VBN|that|hypotension|could|be|safely|to|decrease (l_advcl) decrease_42\NN|mean|pressure|from|,|decrease (l_conj) decrease_54\NN|trimetaphan|hypotension|mean|pressure (l_dep) hypotension_47\NN|to
D009599_D007022 CID SNP_6\NNP| (r_compound) hypotension_7\NN|snp
D014294_D007022 CID trimetaphan_19\NN|hypotension (l_pobj) hypotension_24\NN|(|tmp|)|deliberate|(|%|decrease
D014294_D007022 CID TMP_21\NNP| (r_nmod) hypotension_24\NN|(|tmp|)|deliberate|(|%|decrease
D014294_D007022 CID trimetaphan_46\NN| (r_mark) decrease_54\NN|trimetaphan|hypotension|mean|pressure (r_conj) decrease_42\NN|mean|pressure|from|,|decrease (r_advcl) used_35\VBN|that|hypotension|could|be|safely|to|decrease (r_ccomp) confirm_28\VB|regarding|we|could|used|. (l_prep) Regarding_0\VBG|effects (l_pobj) effects_2\NNS|the|of (l_prep) of_3\IN|hypotension (l_pobj) hypotension_7\NN|induced|on
D014294_D007022 CID trimetaphan_46\NN| (r_mark) decrease_54\NN|trimetaphan|hypotension|mean|pressure (r_conj) decrease_42\NN|mean|pressure|from|,|decrease (r_advcl) used_35\VBN|that|hypotension|could|be|safely|to|decrease (l_nsubjpass) hypotension_31\NN|nitroprusside
D014294_D007022 CID trimetaphan_46\NN| (r_mark) decrease_54\NN|trimetaphan|hypotension|mean|pressure (l_dep) hypotension_47\NN|to
24434397
D014148_D012640 NONE acid_1\NN|tranexamic (r_compound) seizure_6\NN|acid|induced|generalized|in|.
D014148_D012640 NONE TNA_14\NNP| (r_pobj) of_13\IN|tna (r_prep) overdose_12\NN|an|of (r_attr) be_10\VB|to|overdose (r_xcomp) believed_8\VBN|thus|,|cause|was|be|. (l_nsubjpass) cause_4\NN|the|precipitating|of (l_prep) of_5\IN|convulsions (l_pobj) convulsions_6\NNS|
D014148_D051437 NONE acid_1\NN|tranexamic (r_compound) seizure_6\NN|acid|induced|generalized|in|. (l_prep) in_7\IN|failure (l_pobj) failure_9\NN|renal
D014148_D006470 NONE acid_1\NN|tranexamic|tna|g (r_nsubjpass) administered_9\VBN|acid|8-hourly|was|to|control|. (l_advcl) control_13\VB|to|bleeding (l_xcomp) bleeding_14\NN|per
D014148_D006470 NONE TNA_3\NNP|(|) (r_appos) acid_1\NN|tranexamic|tna|g (r_nsubjpass) administered_9\VBN|acid|8-hourly|was|to|control|. (l_advcl) control_13\VB|to|bleeding (l_xcomp) bleeding_14\NN|per
D014148_D004830 CID TNA_7\NNP| (r_pobj) of_6\IN|tna (r_prep) dose_5\NN|the|sixth|of (r_pobj) after_2\IN|hours|dose (r_prep) had_10\VBD|after|,|she|episode|. (l_dobj) episode_12\NN|an|of (l_prep) of_13\IN|convulsions (l_pobj) convulsions_17\NNS|generalized|tonic|clonic
D014148_D062787 NONE TNA_14\NNP| (r_pobj) of_13\IN|tna (r_prep) overdose_12\NN|an|of
1449452
D004077_D001281 NONE digoxin_5\NN|fibrillation (l_compound) fibrillation_4\NN|atrial
D004077_D001145 CID digoxin_2\NN| (r_nsubj) has_3\VBZ|also|,|digoxin|effects|. (l_dobj) effects_5\NNS|undesirable|as (l_prep) as_7\IN|such|increasing (l_pcomp) increasing_8\VBG|resistance|,|and|causing (l_conj) causing_16\VBG|arrhythmias (l_dobj) arrhythmias_17\NNS|
D004077_D009203 NONE digoxin_19\NN| (r_nsubj) increase_21\VB|that|digoxin|may|mortality|after (l_prep) after_23\IN|infarction (l_pobj) infarction_25\NN|myocardial|(|mi|)
D004077_D009203 NONE digoxin_19\NN| (r_nsubj) increase_21\VB|that|digoxin|may|mortality|after (l_prep) after_23\IN|infarction (l_pobj) infarction_25\NN|myocardial|(|mi|) (l_appos) MI_27\NNP|
20169779
D015632_D010302 NONE MPTP_4\NNP| (r_nmod) model_6\NN|the|mptp|marmoset|of (l_prep) of_7\IN|disease (l_pobj) disease_10\NN|parkinson
D015632_D010302 NONE MPTP_4\NNP| (r_npadvmod) lesioned_6\VBN|mptp|- (r_amod) marmoset_7\NN|the|treated|lesioned (r_nsubjpass) used_9\VBN|marmoset|was|as|. (l_prep) as_10\IN|model (l_pobj) model_12\NN|a|of (l_prep) of_13\IN|symptoms (l_pobj) symptoms_15\NNS|neuropsychiatric|in (l_prep) in_16\IN|patients (l_pobj) patients_18\NNS|pd (l_compound) PD_17\NNP|
D015632_D010302 NONE 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine_3\CD| (r_oprd) administered_2\VBN|marmosets|were|1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine|s.c.|)|for|,|resulting|. (l_advcl) resulting_13\VBG|in (l_prep) in_14\IN|parkinsonism (l_pobj) parkinsonism_16\NN|stable
D007980_D001523 NONE levodopa_1\RB| (r_npadvmod) treated_3\VBN|levodopa|- (r_amod) marmoset_7\NN|the|treated|lesioned (r_nsubjpass) used_9\VBN|marmoset|was|as|. (l_prep) as_10\IN|model (l_pobj) model_12\NN|a|of (l_prep) of_13\IN|symptoms (l_pobj) symptoms_15\NNS|neuropsychiatric|in
D007980_D001523 NONE levodopa_7\NN| (r_npadvmod) induced_9\VBN|levodopa|- (r_amod) fluctuations_11\NNS|induced|motor|and|behaviors (l_conj) behaviors_16\NNS|like
D007980_D001523 NONE levodopa_27\VB| (r_pobj) to_26\IN|levodopa (r_prep) prior_25\RB|(|to|)|and|on (r_advmod) hoc_45\FW|prior|analysis|,|blind (r_prep) evaluated_2\VBN|animals|were|for|on|hoc|. (l_prep) for_3\IN|disability (l_pobj) disability_5\NN|parkinsonian|,|dyskinesia (l_conj) dyskinesia_7\JJ|and|on|(|fluctuations|)|and|behaviors (l_conj) behaviors_20\NNS|like
D007980_D001523 NONE levodopa_3\RB| (r_npadvmod) induced_5\VBN|levodopa|- (r_amod) behaviors_9\NNS|induced|like
D007980_D001523 NONE levodopa_16\JJ| (r_compound) treatment_17\NN|levodopa (r_pobj) of_15\IN|treatment (r_prep) 1_14\CD|of (r_nummod) Day_13\NN|1 (r_pobj) on_12\IN|day (r_prep) present_11\JJ|on (r_acomp) were_10\VBD|in|,|behaviors|present|and|correlate (l_nsubj) behaviors_9\NNS|induced|like
D007980_D001523 NONE levodopa_14\NN|and|state (r_pobj) between_13\IN|levodopa (r_prep) interaction_12\NN|an|between|than (r_attr) are_8\VBP|that|disorders|likely|interaction|therapy (l_nsubj) disorders_5\NNS|neuropsychiatric|in
D007980_D010302 NONE levodopa_1\RB| (r_npadvmod) treated_3\VBN|levodopa|- (r_amod) marmoset_7\NN|the|treated|lesioned (r_nsubjpass) used_9\VBN|marmoset|was|as|. (l_prep) as_10\IN|model (l_pobj) model_12\NN|a|of (l_prep) of_13\IN|symptoms (l_pobj) symptoms_15\NNS|neuropsychiatric|in (l_prep) in_16\IN|patients (l_pobj) patients_18\NNS|pd (l_compound) PD_17\NNP|
D007980_D010302 NONE levodopa_14\NN|and|state (r_pobj) between_13\IN|levodopa (r_prep) interaction_12\NN|an|between|than (r_attr) are_8\VBP|that|disorders|likely|interaction|therapy (l_nsubj) disorders_5\NNS|neuropsychiatric|in (l_prep) in_6\IN|pd (l_pobj) PD_7\NNP|
D015632_D001523 NONE MPTP_4\NNP| (r_npadvmod) lesioned_6\VBN|mptp|- (r_amod) marmoset_7\NN|the|treated|lesioned (r_nsubjpass) used_9\VBN|marmoset|was|as|. (l_prep) as_10\IN|model (l_pobj) model_12\NN|a|of (l_prep) of_13\IN|symptoms (l_pobj) symptoms_15\NNS|neuropsychiatric|in
D007980_D020734 NONE levodopa_27\VB| (r_pobj) to_26\IN|levodopa (r_prep) prior_25\RB|(|to|)|and|on (r_advmod) hoc_45\FW|prior|analysis|,|blind (r_prep) evaluated_2\VBN|animals|were|for|on|hoc|. (l_prep) for_3\IN|disability (l_pobj) disability_5\NN|parkinsonian|,|dyskinesia
D007980_D004409 CID levodopa_27\VB| (r_pobj) to_26\IN|levodopa (r_prep) prior_25\RB|(|to|)|and|on (r_advmod) hoc_45\FW|prior|analysis|,|blind (r_prep) evaluated_2\VBN|animals|were|for|on|hoc|. (l_prep) for_3\IN|disability (l_pobj) disability_5\NN|parkinsonian|,|dyskinesia (l_conj) dyskinesia_7\JJ|and|on|(|fluctuations|)|and|behaviors
D007980_D004409 CID levodopa_9\NN| (r_npadvmod) induced_11\VBN|levodopa|- (r_amod) fluctuations_13\NNS|induced|motor|,|dyskinesia (l_conj) dyskinesia_15\JJ|and|wearing
D007980_D004409 CID levodopa_27\NN| (r_compound) therapy_28\NN|levodopa (r_pobj) of_26\IN|therapy (r_prep) duration_25\NN|the|of (r_pobj) with_23\IN|duration (r_prep) correlated_22\VBD|that|with (r_relcl) increase_7\NN|a|progressive|in|correlated (l_prep) in_8\IN|fluctuations (l_pobj) fluctuations_13\NNS|induced|motor|,|dyskinesia (l_conj) dyskinesia_15\JJ|and|wearing
17879217
D012293_D005921 CID Rifampicin_0\NNS| (r_npadvmod) associated_2\VBN|rifampicin|- (r_amod) glomerulonephritis_5\NN|associated|necrotizing|in|.
D012293_D005921 CID rifampicin_9\NNS| (r_compound) therapy_10\NN|rifampicin (r_pobj) of_8\IN|therapy (r_prep) complication_7\NN|of|in (r_pobj) as_6\IN|complication (r_prep) reported_5\VBN|glomerulonephritis|has|been|as|. (l_nsubjpass) glomerulonephritis_2\NN|segmental|necrotising
D012293_D005921 CID rifampicin_25\NNS| (r_pobj) with_24\IN|rifampicin (r_prep) treated_23\VBN|while|being|with (r_advcl) developed_11\VBD|who|failure|treated|,|and|review (l_dobj) failure_14\NN|acute|renal|secondary (l_amod) secondary_15\JJ|to (l_prep) to_16\IN|glomerulonephritis (l_pobj) glomerulonephritis_20\NN|a|segmental|necrotising
D012293_D005921 CID rifampicin_35\NNS| (r_compound) therapy_36\NN|rifampicin (r_pobj) of_34\IN|therapy (r_prep) complication_33\NN|this|of (r_pobj) regarding_31\VBG|complication (r_prep) review_28\VB|literature|regarding (r_conj) developed_11\VBD|who|failure|treated|,|and|review (l_dobj) failure_14\NN|acute|renal|secondary (l_amod) secondary_15\JJ|to (l_prep) to_16\IN|glomerulonephritis (l_pobj) glomerulonephritis_20\NN|a|segmental|necrotising
D012293_D013203 NONE Rifampicin_0\NNS| (r_npadvmod) associated_2\VBN|rifampicin|- (r_amod) glomerulonephritis_5\NN|associated|necrotizing|in|. (l_prep) in_6\IN|endocarditis (l_pobj) endocarditis_8\NN|staphylococcal
D012293_D013203 NONE rifampicin_20\NNS|for (l_prep) for_21\IN|infections (l_pobj) infections_23\NNS|staphylococcal
D012293_D013203 NONE rifampicin_25\NNS| (r_pobj) with_24\IN|rifampicin (r_prep) treated_23\VBN|while|being|with (r_advcl) developed_11\VBD|who|failure|treated|,|and|review (r_relcl) IE_9\NNP|staphylococcal|developed
D012293_D013203 NONE rifampicin_35\NNS| (r_compound) therapy_36\NN|rifampicin (r_pobj) of_34\IN|therapy (r_prep) complication_33\NN|this|of (r_pobj) regarding_31\VBG|complication (r_prep) review_28\VB|literature|regarding (r_conj) developed_11\VBD|who|failure|treated|,|and|review (r_relcl) IE_9\NNP|staphylococcal|developed
D012293_D004696 NONE Rifampicin_0\NNS| (r_npadvmod) associated_2\VBN|rifampicin|- (r_amod) glomerulonephritis_5\NN|associated|necrotizing|in|. (l_prep) in_6\IN|endocarditis (l_pobj) endocarditis_8\NN|staphylococcal
D012293_D004696 NONE rifampicin_20\NNS|for (r_pobj) of_19\IN|rifampicin (r_prep) use_18\NN|the|of (r_pobj) in_16\IN|use (r_prep) increase_15\NN|an|in (r_pobj) to_13\IN|increase (r_prep) led_12\VBN|changing|has|to|. (l_csubj) Changing_0\VBG|epidemiology (l_dobj) epidemiology_1\NN|of (l_prep) of_2\IN|infections (l_pobj) infections_3\NNS|as (l_prep) as_5\IN|such|endocarditis (l_pobj) endocarditis_7\NN|infective|(|ie|)
D012293_D004696 NONE rifampicin_20\NNS|for (r_pobj) of_19\IN|rifampicin (r_prep) use_18\NN|the|of (r_pobj) in_16\IN|use (r_prep) increase_15\NN|an|in (r_pobj) to_13\IN|increase (r_prep) led_12\VBN|changing|has|to|. (l_csubj) Changing_0\VBG|epidemiology (l_dobj) epidemiology_1\NN|of (l_prep) of_2\IN|infections (l_pobj) infections_3\NNS|as (l_prep) as_5\IN|such|endocarditis (l_pobj) endocarditis_7\NN|infective|(|ie|) (l_appos) IE_9\NNP|
D012293_D004696 NONE rifampicin_25\NNS| (r_pobj) with_24\IN|rifampicin (r_prep) treated_23\VBN|while|being|with (r_advcl) developed_11\VBD|who|failure|treated|,|and|review (r_relcl) IE_9\NNP|staphylococcal|developed
D012293_D004696 NONE rifampicin_35\NNS| (r_compound) therapy_36\NN|rifampicin (r_pobj) of_34\IN|therapy (r_prep) complication_33\NN|this|of (r_pobj) regarding_31\VBG|complication (r_prep) review_28\VB|literature|regarding (r_conj) developed_11\VBD|who|failure|treated|,|and|review (r_relcl) IE_9\NNP|staphylococcal|developed
D012293_D014376 NONE rifampicin_9\NNS| (r_compound) therapy_10\NN|rifampicin (r_pobj) of_8\IN|therapy (r_prep) complication_7\NN|of|in (l_prep) in_11\IN|patients (l_pobj) patients_12\NNS|receiving (l_acl) receiving_13\VBG|treatment (l_dobj) treatment_14\NN|for (l_prep) for_15\IN|tuberculosis (l_pobj) tuberculosis_16\NN|
D012293_D007239 NONE rifampicin_20\NNS|for (r_pobj) of_19\IN|rifampicin (r_prep) use_18\NN|the|of (r_pobj) in_16\IN|use (r_prep) increase_15\NN|an|in (r_pobj) to_13\IN|increase (r_prep) led_12\VBN|changing|has|to|. (l_csubj) Changing_0\VBG|epidemiology (l_dobj) epidemiology_1\NN|of (l_prep) of_2\IN|infections (l_pobj) infections_3\NNS|as
D012293_D058186 CID rifampicin_25\NNS| (r_pobj) with_24\IN|rifampicin (r_prep) treated_23\VBN|while|being|with (r_advcl) developed_11\VBD|who|failure|treated|,|and|review (l_dobj) failure_14\NN|acute|renal|secondary
D012293_D058186 CID rifampicin_35\NNS| (r_compound) therapy_36\NN|rifampicin (r_pobj) of_34\IN|therapy (r_prep) complication_33\NN|this|of (r_pobj) regarding_31\VBG|complication (r_prep) review_28\VB|literature|regarding (r_conj) developed_11\VBD|who|failure|treated|,|and|review (l_dobj) failure_14\NN|acute|renal|secondary
20828385
C401859_D020522 NONE temsirolimus_7\NN| (r_pobj) of_6\IN|temsirolimus (r_prep) effects_5\NNS|cytostatic|angiogenic|of|in|. (l_prep) in_8\IN|lymphoma (l_pobj) lymphoma_12\NN|refractory|cell
C401859_D020522 NONE temsirolimus_16\NN|,|inhibitor (r_pobj) with_15\IN|temsirolimus (r_prep) treated_14\VBN|with (r_advcl) reported_10\VBN|however|,|rate|has|been|recently|in|treated|. (l_prep) in_11\IN|mcl (l_pobj) MCL_13\NN|refractory
C401859_D020522 NONE temsirolimus_19\NN| (r_compound) treatment_20\NN|temsirolimus (r_pobj) after_18\IN|months|treatment (r_prep) had_13\VBD|who|regression|after|, (r_relcl) MCL_11\NNP|refractory|had
C401859_D020522 NONE temsirolimus_4\NN| (r_pobj) of_3\IN|temsirolimus (r_prep) effect_2\NN|this|dual|of|on (r_nsubj) contribute_9\VB|effect|could|to|. (l_prep) to_10\IN|efficiency (l_pobj) efficiency_14\NN|its|reported|in|resistant (l_prep) in_15\IN|mcl (l_pobj) MCL_17\NN|refractory
C401859_D009369 NONE temsirolimus_19\NN| (r_compound) treatment_20\NN|temsirolimus (r_pobj) after_18\IN|months|treatment (r_prep) had_13\VBD|who|regression|after|, (l_dobj) regression_15\NN|tumor (l_compound) tumor_14\NN|
C401859_D009369 NONE temsirolimus_7\NN| (r_nsubj) inhibited_8\JJ|that|temsirolimus|proliferation|through|,|but|induce (l_dobj) proliferation_11\NN|cell (l_compound) cell_10\NN|tumor (l_compound) tumor_9\NN|
C401859_D009369 NONE temsirolimus_7\NN| (r_nsubj) inhibited_8\JJ|that|temsirolimus|proliferation|through|,|but|induce (l_conj) induce_20\VB|did|not|change (l_dobj) change_22\NN|any|in (l_prep) in_23\IN|number (l_pobj) number_25\NN|the|of (l_prep) of_26\IN|cells (l_pobj) cells_29\NNS|apoptotic|tumor (l_compound) tumor_28\NN|
C401859_D009369 NONE temsirolimus_6\NNS| (r_nsubj) had_7\VBD|apart|,|temsirolimus|effect|. (l_dobj) effect_10\NN|an|antiangiogenic|with (l_prep) with_11\IN|decrease|and|of (l_pobj) decrease_12\NN|of (l_prep) of_13\IN|density (l_pobj) density_16\NN|tumor|microvessel (l_compound) tumor_14\NN|
C401859_D009369 NONE temsirolimus_2\NNS| (r_nsubj) reduced_3\VBN|thus|,|temsirolimus|burden|through|. (l_dobj) burden_5\NN|tumor (l_compound) tumor_4\NN|
C401859_D009369 NONE temsirolimus_4\NN| (r_pobj) of_3\IN|temsirolimus (r_prep) effect_2\NN|this|dual|of|on (l_prep) on_5\IN|tissue (l_pobj) tissue_7\NN|tumor (l_compound) tumor_6\NN|
C401859_D009336 CID temsirolimus_23\NN| (r_compound) therapy_24\NN|6-month|temsirolimus (r_pobj) after_21\IN|therapy (r_prep) found_20\VBN|moreover|,|areas|,|were|after|. (l_nsubjpass) areas_9\NNS|numerous|patchy|,|limited|fibrotic|,|compatible (l_amod) compatible_11\JJ|with (l_prep) with_12\IN|repair (l_pobj) repair_17\NN|necrotic|tissue (l_amod) necrotic_15\JJ|post|-
24309294
D012844_D000647 NONE CCK-8_5\NNP| (r_punct) alleviated_7\VBN|that|cck-8|significantly|amnesia|and|reversed|decreases (l_dobj) amnesia_11\NN|induced
D009020_D000647 CID morphine_8\NN| (r_npadvmod) induced_10\VBN|morphine|- (r_amod) amnesia_11\NN|induced
D009020_D000647 CID morphine_25\NN| (r_npadvmod) treated_27\VBN|morphine|- (r_amod) animals_28\NNS|treated (r_pobj) in_24\IN|animals (r_prep) region_20\NN|the|ca1|of|in (r_pobj) in_17\IN|region (r_prep) decreases_16\VBZ|in (r_conj) alleviated_7\VBN|that|cck-8|significantly|amnesia|and|reversed|decreases (l_dobj) amnesia_11\NN|induced
D012844_D008569 NONE CCK-8_5\NNP| (r_nsubj) attenuates_6\VBZ|that|cck-8|effect|and|suggest (l_conj) suggest_18\VBP|function (l_dobj) function_21\NN|an|ameliorative|of|on (l_prep) on_24\IN|cck-8|impairment (l_pobj) impairment_29\NN|induced|memory
D012844_D008569 NONE CCK-8_23\NNP| (r_punct) on_24\IN|cck-8|impairment (l_pobj) impairment_29\NN|induced|memory
D009020_D008569 NONE morphine_10\NN| (r_pobj) of_9\IN|morphine (r_prep) effect_8\NN|the|of|on|through (r_dobj) attenuates_6\VBZ|that|cck-8|effect|and|suggest (l_conj) suggest_18\VBP|function (l_dobj) function_21\NN|an|ameliorative|of|on (l_prep) on_24\IN|cck-8|impairment (l_pobj) impairment_29\NN|induced|memory
D009020_D008569 NONE morphine_25\NN| (r_npadvmod) induced_27\VBN|morphine|- (r_amod) impairment_29\NN|induced|memory
11380496
D011441_D006111 NONE propylthiouracil_21\NN|and|relationship (r_pobj) with_20\IN|propylthiouracil (r_prep) treated_19\VBN|with (r_acl) patients_18\NNS|graves|disease|treated (l_compound) disease_17\NN|
D011441_D006111 NONE propylthiouracil_22\NN|ptu (r_pobj) with_21\IN|propylthiouracil (r_prep) treated_20\VBN|who|were|with (r_relcl) disease_17\NN|graves|treated
D011441_D006111 NONE PTU_24\NNP|(|) (r_appos) propylthiouracil_22\NN|ptu (r_pobj) with_21\IN|propylthiouracil (r_prep) treated_20\VBN|who|were|with (r_relcl) disease_17\NN|graves|treated
D011441_D006111 NONE PTU_21\NNP| (r_compound) therapy_22\NN|ptu (r_pobj) during_20\IN|therapy (r_prep) appearance_13\NN|the|of|during (r_pobj) between_11\IN|appearance (r_prep) relationship_10\NN|the|temporal|between (r_pobj) on_7\IN|relationship (r_prep) studies_6\NNS|no|on (r_attr) been_4\VBN|nevertheless|,|there|have|studies|,|or|on|. (l_conj) on_25\IN|incidence|-|anca (l_pobj) ANCA_31\NNP|in (l_prep) in_32\IN|patients (l_pobj) patients_37\NNS|graves|disease (l_compound) disease_36\NN|
D011441_D006111 NONE PTU_27\NNP| (r_compound) therapy_28\NN|ptu (r_dobj) starting_26\VBG|therapy (r_pcomp) after_25\IN|starting (r_prep) vasculitis_24\NN|the|development|after (r_pobj) for_21\IN|vasculitis (r_conj) investigated_1\VBD|we|patients|due|,|and|for|. (l_prep) due_7\IN|to|disease (l_pobj) disease_11\NN|graves|for
D011441_D014657 NONE propylthiouracil_22\NN|ptu (r_pobj) with_21\IN|propylthiouracil (r_prep) treated_20\VBN|who|were|with (r_relcl) disease_17\NN|graves|treated (r_pobj) with_14\IN|disease (r_prep) patients_13\NNS|with (r_pobj) in_12\IN|patients (r_prep) reported_11\VBN|vasculitis|has|been|in|. (l_nsubjpass) vasculitis_8\NN|myeloperoxidase|antibody|(|anca)-positive
D011441_D014657 NONE PTU_24\NNP|(|) (r_appos) propylthiouracil_22\NN|ptu (r_pobj) with_21\IN|propylthiouracil (r_prep) treated_20\VBN|who|were|with (r_relcl) disease_17\NN|graves|treated (r_pobj) with_14\IN|disease (r_prep) patients_13\NNS|with (r_pobj) in_12\IN|patients (r_prep) reported_11\VBN|vasculitis|has|been|in|. (l_nsubjpass) vasculitis_8\NN|myeloperoxidase|antibody|(|anca)-positive
D011441_D014657 NONE PTU_21\NNP| (r_compound) therapy_22\NN|ptu (r_pobj) during_20\IN|therapy (r_prep) appearance_13\NN|the|of|during (l_prep) of_14\IN|mpo (l_pobj) MPO_15\NNP|-|anca (l_appos) ANCA_17\NNP|and|vasculitis (l_conj) vasculitis_19\NN|
D011441_D014657 NONE PTU_27\NNP| (r_compound) therapy_28\NN|ptu (r_dobj) starting_26\VBG|therapy (r_pcomp) after_25\IN|starting (r_prep) vasculitis_24\NN|the|development|after
D011441_D006980 NONE PTU_27\NNP| (r_compound) therapy_28\NN|ptu (r_dobj) starting_26\VBG|therapy (r_pcomp) after_25\IN|starting (r_prep) vasculitis_24\NN|the|development|after (r_pobj) for_21\IN|vasculitis (r_conj) investigated_1\VBD|we|patients|due|,|and|for|. (l_dobj) patients_4\NNS|102|untreated|with (l_prep) with_5\IN|hyperthyroidism (l_pobj) hyperthyroidism_6\NN|
D011441_D014652 NONE PTU_24\NNP| (r_compound) therapy_25\NN|continued|ptu (r_pobj) despite_22\IN|therapy (r_prep) increased_11\VBD|in|,|titres|transiently|to|,|respectively|,|despite|,|but|developed (l_conj) developed_31\VBD|disorders|. (l_nsubj) disorders_30\NNS|no|vasculitic
D011441_D005334 CID PTU_36\NNP| (r_compound) therapy_37\NN|ptu (r_dobj) stopping_35\VBG|therapy (r_pcomp) after_34\IN|weeks|stopping (r_prep) resolved_31\VBD|symptoms|after|,|and|decreased (r_conj) developed_18\VBD|she|fever|,|but|resolved (l_dobj) fever_21\NN|a|higher|,|ulcers
D011441_D005334 CID PTU_56\NNP| (r_dobj) discontinuing_55\VBG|ptu (r_pcomp) after_54\IN|discontinuing (r_prep) decreased_45\VBD|titre|to|by|after|. (r_conj) resolved_31\VBD|symptoms|after|,|and|decreased (r_conj) developed_18\VBD|she|fever|,|but|resolved (l_dobj) fever_21\NN|a|higher|,|ulcers
D011441_D019226 CID PTU_36\NNP| (r_compound) therapy_37\NN|ptu (r_dobj) stopping_35\VBG|therapy (r_pcomp) after_34\IN|weeks|stopping (r_prep) resolved_31\VBD|symptoms|after|,|and|decreased (r_conj) developed_18\VBD|she|fever|,|but|resolved (l_dobj) fever_21\NN|a|higher|,|ulcers (l_conj) ulcers_24\NNS|oral|and|polyarthralgia
D011441_D019226 CID PTU_56\NNP| (r_dobj) discontinuing_55\VBG|ptu (r_pcomp) after_54\IN|discontinuing (r_prep) decreased_45\VBD|titre|to|by|after|. (r_conj) resolved_31\VBD|symptoms|after|,|and|decreased (r_conj) developed_18\VBD|she|fever|,|but|resolved (l_dobj) fever_21\NN|a|higher|,|ulcers (l_conj) ulcers_24\NNS|oral|and|polyarthralgia
D011441_D018771 CID PTU_36\NNP| (r_compound) therapy_37\NN|ptu (r_dobj) stopping_35\VBG|therapy (r_pcomp) after_34\IN|weeks|stopping (r_prep) resolved_31\VBD|symptoms|after|,|and|decreased (r_conj) developed_18\VBD|she|fever|,|but|resolved (l_dobj) fever_21\NN|a|higher|,|ulcers (l_conj) ulcers_24\NNS|oral|and|polyarthralgia (l_conj) polyarthralgia_26\NN|
D011441_D018771 CID PTU_56\NNP| (r_dobj) discontinuing_55\VBG|ptu (r_pcomp) after_54\IN|discontinuing (r_prep) decreased_45\VBD|titre|to|by|after|. (r_conj) resolved_31\VBD|symptoms|after|,|and|decreased (r_conj) developed_18\VBD|she|fever|,|but|resolved (l_dobj) fever_21\NN|a|higher|,|ulcers (l_conj) ulcers_24\NNS|oral|and|polyarthralgia (l_conj) polyarthralgia_26\NN|
11135381
D008729_D014550 NONE methoxamine_2\NN|on (l_prep) on_3\IN|pressure (l_pobj) pressure_6\NN|maximum|urethral|in|with (l_prep) with_9\IN|incontinence (l_pobj) incontinence_12\NN|genuine|stress|:|study
D008729_D014550 NONE methoxamine_6\NN|intravenous|or|placebo (r_pobj) of_4\IN|methoxamine (r_prep) doses_3\NNS|incremental|of|(|saline|) (r_dobj) log_1\NN|half|doses (r_csubjpass) administered_13\VBN|log|were|to|measuring|. (l_prep) to_14\IN|group (l_pobj) group_16\NN|a|of|with (l_prep) with_19\IN|incontinence (l_pobj) incontinence_22\NN|genuine|stress
D008729_D006973 CID Methoxamine_0\NNP| (r_nsubj) evoked_1\VBD|methoxamine|increases|but|caused|. (l_conj) caused_13\VBD|rise (l_dobj) rise_16\NN|a|significant|in|and|fall (l_prep) in_17\IN|pressure (l_pobj) pressure_20\NN|systolic|blood
25006369
C061870_D005207 NONE rocuronium_4\NN| (r_pobj) of_3\IN|rocuronium (r_prep) dose_2\NN|optimal|precurarizing|of|decrease|. (l_acl) decrease_6\VB|to|fasciculation|following (l_dobj) fasciculation_7\NN|and|myalgia
C061870_D005207 NONE rocuronium_8\NN| (r_pobj) of_7\IN|rocuronium (r_prep) dose_6\NN|the|optimal|of (r_dobj) identified_3\VBD|study|dose|prevent|and|evaluated|. (l_advcl) prevent_10\VB|to|fasciculation (l_dobj) fasciculation_14\NN|induced|and|myalgia
C061870_D005207 NONE rocuronium_22\NN|on (r_pobj) of_21\IN|rocuronium (r_prep) influence_20\NN|the|of (r_dobj) evaluated_18\VBD|influence (r_conj) identified_3\VBD|study|dose|prevent|and|evaluated|. (l_advcl) prevent_10\VB|to|fasciculation (l_dobj) fasciculation_14\NN|induced|and|myalgia
C061870_D005207 NONE rocuronium_19\NN| (r_pobj) of_18\IN|rocuronium (r_prep) dose_17\NN|of (r_dobj) precurarizing_16\VBG|dose (r_pcomp) of_15\IN|precurarizing (r_prep) amount_14\NN|the|of|(|p|) (r_dobj) increasing_12\VBG|amount (r_pcomp) with_11\IN|increasing (r_prep) less_10\JJR|significantly|with (r_acomp) was_8\VBD|incidence|less|. (l_nsubj) incidence_1\NN|the|and|severity|of (l_prep) of_4\IN|fasciculation (l_pobj) fasciculation_7\NN|visible|muscle
C061870_D005207 NONE rocuronium_4\NN|mg/kg (r_pobj) with_1\IN|rocuronium (r_prep) Precurarization_0\NN|with (r_nsubj) was_5\VBD|precurarization|dose|,|and|precurarization|. (l_attr) dose_8\NN|the|optimal|considering (l_acl) considering_9\VBG|reduction (l_dobj) reduction_11\NN|the|in (l_prep) in_12\IN|incidence (l_pobj) incidence_14\NN|the|and|severity|of (l_prep) of_17\IN|fasciculation (l_pobj) fasciculation_18\NN|and|myalgia
C061870_D063806 NONE rocuronium_4\NN| (r_pobj) of_3\IN|rocuronium (r_prep) dose_2\NN|optimal|precurarizing|of|decrease|. (l_acl) decrease_6\VB|to|fasciculation|following (l_dobj) fasciculation_7\NN|and|myalgia (l_conj) myalgia_9\NN|
C061870_D063806 NONE rocuronium_8\NN| (r_pobj) of_7\IN|rocuronium (r_prep) dose_6\NN|the|optimal|of (r_dobj) identified_3\VBD|study|dose|prevent|and|evaluated|. (l_advcl) prevent_10\VB|to|fasciculation (l_dobj) fasciculation_14\NN|induced|and|myalgia (l_conj) myalgia_16\NN|
C061870_D063806 NONE rocuronium_22\NN|on (r_pobj) of_21\IN|rocuronium (r_prep) influence_20\NN|the|of (r_dobj) evaluated_18\VBD|influence (r_conj) identified_3\VBD|study|dose|prevent|and|evaluated|. (l_advcl) prevent_10\VB|to|fasciculation (l_dobj) fasciculation_14\NN|induced|and|myalgia (l_conj) myalgia_16\NN|
C061870_D063806 NONE rocuronium_15\NN| (r_pobj) of_14\IN|rocuronium (r_prep) dose_13\NN|of (r_dobj) precurarizing_12\VBG|dose (r_pcomp) of_11\IN|precurarizing (r_prep) amount_10\NN|the|of (r_dobj) increasing_8\VBG|amount (r_pcomp) to_7\IN|increasing (r_prep) according_6\VBG|to (r_prep) decrease_5\VB|to|according (r_xcomp) tend_3\VBP|those|decrease|,|but|was (l_nsubj) Those_0\DT|of (l_prep) of_1\IN|myalgia (l_pobj) myalgia_2\NN|
C061870_D063806 NONE rocuronium_4\NN|mg/kg (r_pobj) with_1\IN|rocuronium (r_prep) Precurarization_0\NN|with (r_nsubj) was_5\VBD|precurarization|dose|,|and|precurarization|. (l_attr) dose_8\NN|the|optimal|considering (l_acl) considering_9\VBG|reduction (l_dobj) reduction_11\NN|the|in (l_prep) in_12\IN|incidence (l_pobj) incidence_14\NN|the|and|severity|of (l_prep) of_17\IN|fasciculation (l_pobj) fasciculation_18\NN|and|myalgia (l_conj) myalgia_20\NN|with
D013390_D005207 CID succinylcholine_11\NN| (r_compound) administration_12\NN|succinylcholine (r_pobj) following_10\VBG|administration (r_prep) decrease_6\VB|to|fasciculation|following (l_dobj) fasciculation_7\NN|and|myalgia
D013390_D005207 CID Succinylcholine_0\NNP| (r_nsubj) produces_2\VBZ|succinylcholine|commonly|effects|. (l_dobj) effects_5\NNS|frequent|adverse|,|including (l_prep) including_7\VBG|fasciculation (l_pobj) fasciculation_9\NN|muscle|and|myalgia
D013390_D005207 CID succinylcholine_11\NN| (r_npadvmod) induced_13\VBN|succinylcholine|- (r_amod) fasciculation_14\NN|induced|and|myalgia
D013390_D005207 CID succinylcholine_30\NN| (r_pobj) by_29\IN|succinylcholine (r_agent) produced_28\VBN|by (r_acl) onset_27\NN|produced (r_pobj) of_26\IN|onset (r_prep) speed_25\NN|the|of (r_pobj) on_23\IN|speed (r_prep) rocuronium_22\NN|on (r_pobj) of_21\IN|rocuronium (r_prep) influence_20\NN|the|of (r_dobj) evaluated_18\VBD|influence (r_conj) identified_3\VBD|study|dose|prevent|and|evaluated|. (l_advcl) prevent_10\VB|to|fasciculation (l_dobj) fasciculation_14\NN|induced|and|myalgia
D013390_D005207 CID succinylcholine_3\NN|after (r_dobj) received_2\VBD|patients|succinylcholine|,|and|assessed|. (l_conj) assessed_15\VBN|were|incidence|,|assessed (l_dobj) incidence_17\NN|the|and|severity|of (l_prep) of_20\IN|fasciculations (l_pobj) fasciculations_21\NNS|
D013390_D063806 CID succinylcholine_11\NN| (r_compound) administration_12\NN|succinylcholine (r_pobj) following_10\VBG|administration (r_prep) decrease_6\VB|to|fasciculation|following (l_dobj) fasciculation_7\NN|and|myalgia (l_conj) myalgia_9\NN|
D013390_D063806 CID Succinylcholine_0\NNP| (r_nsubj) produces_2\VBZ|succinylcholine|commonly|effects|. (l_dobj) effects_5\NNS|frequent|adverse|,|including (l_prep) including_7\VBG|fasciculation (l_pobj) fasciculation_9\NN|muscle|and|myalgia (l_conj) myalgia_11\NN|
D013390_D063806 CID succinylcholine_11\NN| (r_npadvmod) induced_13\VBN|succinylcholine|- (r_amod) fasciculation_14\NN|induced|and|myalgia (l_conj) myalgia_16\NN|
D013390_D063806 CID succinylcholine_30\NN| (r_pobj) by_29\IN|succinylcholine (r_agent) produced_28\VBN|by (r_acl) onset_27\NN|produced (r_pobj) of_26\IN|onset (r_prep) speed_25\NN|the|of (r_pobj) on_23\IN|speed (r_prep) rocuronium_22\NN|on (r_pobj) of_21\IN|rocuronium (r_prep) influence_20\NN|the|of (r_dobj) evaluated_18\VBD|influence (r_conj) identified_3\VBD|study|dose|prevent|and|evaluated|. (l_advcl) prevent_10\VB|to|fasciculation (l_dobj) fasciculation_14\NN|induced|and|myalgia (l_conj) myalgia_16\NN|
D013390_D063806 CID succinylcholine_3\NN|after (r_dobj) received_2\VBD|patients|succinylcholine|,|and|assessed|. (l_conj) assessed_15\VBN|were|incidence|,|assessed (l_advcl) assessed_26\VBN|while|myalgia|was|at (l_nsubjpass) myalgia_24\NN|
24894748
D008790_D001919 CID metoprolol_1\NN|- (r_compound) terbinafine_3\NN|metoprolol (r_compound) combination_4\NN|a|terbinafine (r_nsubj) induced_5\VBN|combination|bradycardia|. (l_dobj) bradycardia_6\NN|
C041359_D001919 CID terbinafine_3\NN|metoprolol (r_compound) combination_4\NN|a|terbinafine (r_nsubj) induced_5\VBN|combination|bradycardia|. (l_dobj) bradycardia_6\NN|
D008790_D012804 NONE metoprolol_7\NN|and|interaction (r_pobj) by_6\IN|metoprolol (r_agent) induced_5\VBN|report|by|. (l_advcl) report_1\VB|to|sinus|bradycardia (l_dobj) bradycardia_4\NN|
D008790_D012804 NONE metoprolol_27\NN|and|terbinafine (r_pobj) between_26\IN|metoprolol (r_prep) interaction_25\NN|the|drug|between (r_conj) bradycardia_21\NNP|sinus|and|interaction
D008790_D012804 NONE metoprolol_10\NN|'s (r_poss) clearance_12\NN|metoprolol (r_dobj) decreased_9\VBN|by|,|terbinafine|had|clearance|,|leading|. (l_advcl) leading_14\VBG|in (l_prep) in_15\IN|accumulation (l_pobj) accumulation_17\NN|metoprolol|resulted (l_relcl) resulted_20\VBN|which|has|in (l_prep) in_21\IN|bradycardia (l_pobj) bradycardia_25\NN|significant|sinus
D008790_D012804 NONE metoprolol_16\NN| (r_compound) accumulation_17\NN|metoprolol|resulted (l_relcl) resulted_20\VBN|which|has|in (l_prep) in_21\IN|bradycardia (l_pobj) bradycardia_25\NN|significant|sinus
C041359_D012804 NONE terbinafine_9\NN| (r_compound) interaction_13\NN|terbinafine|drug|and|management (r_conj) metoprolol_7\NN|and|interaction (r_pobj) by_6\IN|metoprolol (r_agent) induced_5\VBN|report|by|. (l_advcl) report_1\VB|to|sinus|bradycardia (l_dobj) bradycardia_4\NN|
C041359_D012804 NONE terbinafine_29\NN| (r_conj) metoprolol_27\NN|and|terbinafine (r_pobj) between_26\IN|metoprolol (r_prep) interaction_25\NN|the|drug|between (r_conj) bradycardia_21\NNP|sinus|and|interaction
C041359_D012804 NONE terbinafine_7\NN| (r_nsubj) decreased_9\VBN|by|,|terbinafine|had|clearance|,|leading|. (l_advcl) leading_14\VBG|in (l_prep) in_15\IN|accumulation (l_pobj) accumulation_17\NN|metoprolol|resulted (l_relcl) resulted_20\VBN|which|has|in (l_prep) in_21\IN|bradycardia (l_pobj) bradycardia_25\NN|significant|sinus
D008790_D003324 NONE metoprolol_8\NN|man|day|for (l_prep) for_13\IN|disease (l_pobj) disease_17\NN|stable|coronary|artery
D008790_D014009 NONE metoprolol_8\NN|man|day|for (r_nsubjpass) prescribed_19\VBN|metoprolol|was|course|day|. (l_npadvmod) day_29\NN|250|mg|/|for (l_prep) for_30\IN|onychomycosis (l_pobj) onychomycosis_31\NN|
C041359_D003324 NONE terbinafine_25\NN|oral (r_pobj) of_23\IN|terbinafine (r_prep) course_22\NN|a|90-day|of (r_dobj) prescribed_19\VBN|metoprolol|was|course|day|. (l_nsubjpass) metoprolol_8\NN|man|day|for (l_prep) for_13\IN|disease (l_pobj) disease_17\NN|stable|coronary|artery
C041359_D014009 NONE terbinafine_25\NN|oral (r_pobj) of_23\IN|terbinafine (r_prep) course_22\NN|a|90-day|of (r_dobj) prescribed_19\VBN|metoprolol|was|course|day|. (l_npadvmod) day_29\NN|250|mg|/|for (l_prep) for_30\IN|onychomycosis (l_pobj) onychomycosis_31\NN|
C041359_D003221 NONE terbinafine_5\NN| (r_compound) therapy_6\NN|terbinafine (r_pobj) of_4\IN|therapy (r_prep) day_3\NN|the|49th|of (r_pobj) On_0\IN|day (r_prep) brought_10\VBN|on|,|he|was|to|for|. (l_prep) for_15\IN|decrease (l_pobj) decrease_17\NN|a|of (l_prep) of_18\IN|status (l_pobj) status_22\NN|his|global|health|,|confusion (l_conj) confusion_24\NN|and|falls
D008790_D064420 NONE metoprolol_27\NN|and|terbinafine (r_pobj) between_26\IN|metoprolol (r_prep) interaction_25\NN|the|drug|between (r_conj) bradycardia_21\NNP|sinus|and|interaction (r_pobj) between_16\IN|bradycardia (r_prep) relationship_15\NN|a|probable|between (r_dobj) indicates_12\VBZ|score|relationship|. (l_nsubj) score_1\NN|a|of|on (l_prep) on_4\IN|scale (l_pobj) scale_11\NN|the|naranjo|probability (l_compound) probability_10\NN|reaction (l_compound) reaction_9\NN|drug
C041359_D064420 NONE terbinafine_29\NN| (r_conj) metoprolol_27\NN|and|terbinafine (r_pobj) between_26\IN|metoprolol (r_prep) interaction_25\NN|the|drug|between (r_conj) bradycardia_21\NNP|sinus|and|interaction (r_pobj) between_16\IN|bradycardia (r_prep) relationship_15\NN|a|probable|between (r_dobj) indicates_12\VBZ|score|relationship|. (l_nsubj) score_1\NN|a|of|on (l_prep) on_4\IN|scale (l_pobj) scale_11\NN|the|naranjo|probability (l_compound) probability_10\NN|reaction (l_compound) reaction_9\NN|drug
16112787
D014640_D007674 CID vancomycin_12\NNP| (r_npadvmod) induced_14\VBN|vancomycin|- (r_amod) nephrotoxicity_15\NN|induced|:|protection
D014640_D007674 CID vancomycin_8\NNP| (r_det) stress_12\NN|vancomycin|(|vcm)-induced|oxidative|promotes|and (r_dobj) examine_7\VB|to|stress|investigate (l_advcl) investigate_25\VB|to|role (l_dobj) role_27\NN|the|of|,|agent (l_appos) agent_33\NN|an|expectorant|,|has|,|on (l_prep) on_41\IN|tissue (l_pobj) tissue_43\NN|kidney|against (l_prep) against_44\IN|impairment (l_pobj) impairment_51\NN|the|possible|induced|renal|in
D014640_D007674 CID VCM)-induced_10\VBN| (r_amod) stress_12\NN|vancomycin|(|vcm)-induced|oxidative|promotes|and (r_dobj) examine_7\VB|to|stress|investigate (l_advcl) investigate_25\VB|to|role (l_dobj) role_27\NN|the|of|,|agent (l_appos) agent_33\NN|an|expectorant|,|has|,|on (l_prep) on_41\IN|tissue (l_pobj) tissue_43\NN|kidney|against (l_prep) against_44\IN|impairment (l_pobj) impairment_51\NN|the|possible|induced|renal|in
D014640_D007674 CID VCM_47\NN| (r_npadvmod) induced_49\VBN|vcm|- (r_amod) impairment_51\NN|the|possible|induced|renal|in
D014640_D007674 CID VCM_0\NN| (r_compound) administration_1\NN|vcm (r_nsubj) control_3\VB|administration|to|rats|malondialdehyde|but|decreased|. (l_dobj) malondialdehyde_8\NN|increased|renal|(|mda|excretion (l_appos) excretion_33\NN|glucosaminidase (l_nmod) glucosaminidase_22\NN|urinary|beta|-|d|-|(|nag|) (l_appos) NAG_24\NN|,|marker (l_appos) marker_27\NN|a|of (l_prep) of_28\IN|injury (l_pobj) injury_31\NN|renal|tubular
D014640_D007674 CID VCM_5\NNP| (r_npadvmod) induced_7\VBN|vcm|- (r_amod) nephrotoxicity_8\NN|induced
D014640_D007674 CID VCM_13\NNP| (r_npadvmod) induced_15\VBN|vcm|- (r_amod) nephrotoxicity_16\NN|the|induced
D014640_D007674 CID VCM_13\NNP| (r_npadvmod) induced_15\VBN|vcm|- (r_amod) nephrotoxicity_16\NN|the|induced (r_pobj) in_11\IN|nephrotoxicity (r_prep) role_10\NN|an|important|in|and|modulation (r_dobj) plays_7\VBZ|that|damage|role (r_ccomp) concluded_2\VBN|it|is|plays|reduces|. (l_conj) reduces_25\VBZ|damage (l_dobj) damage_31\NN|the|induced|kidney|at
D014640_D007674 CID VCM_27\NNP| (r_npadvmod) induced_29\VBN|vcm|- (r_amod) damage_31\NN|the|induced|kidney|at (r_dobj) reduces_25\VBZ|damage (r_conj) concluded_2\VBN|it|is|plays|reduces|. (l_ccomp) plays_7\VBZ|that|damage|role (l_dobj) role_10\NN|an|important|in|and|modulation (l_prep) in_11\IN|nephrotoxicity (l_pobj) nephrotoxicity_16\NN|the|induced
D014640_D007674 CID VCM_27\NNP| (r_npadvmod) induced_29\VBN|vcm|- (r_amod) damage_31\NN|the|induced|kidney|at
C048498_D007674 NONE erdosteine_19\NN| (r_pobj) by_18\IN|erdosteine (r_prep) protection_17\NN|by (r_appos) nephrotoxicity_15\NN|induced|:|protection
C048498_D007674 NONE erdosteine_29\NN| (r_pobj) of_28\IN|erdosteine (r_prep) role_27\NN|the|of|,|agent (l_appos) agent_33\NN|an|expectorant|,|has|,|on (l_prep) on_41\IN|tissue (l_pobj) tissue_43\NN|kidney|against (l_prep) against_44\IN|impairment (l_pobj) impairment_51\NN|the|possible|induced|renal|in
C048498_D007674 NONE Erdosteine_0\NNP| (r_nsubj) showed_1\VBD|erdosteine|protection|. (l_dobj) protection_3\NN|histopathological|against (l_prep) against_4\IN|nephrotoxicity (l_pobj) nephrotoxicity_8\NN|induced
C048498_D007674 NONE erdosteine_24\NN| (r_pobj) with_23\IN|erdosteine (r_prep) modulation_19\NN|the|of|with (r_conj) role_10\NN|an|important|in|and|modulation (l_prep) in_11\IN|nephrotoxicity (l_pobj) nephrotoxicity_16\NN|the|induced
C048498_D007674 NONE erdosteine_24\NN| (r_pobj) with_23\IN|erdosteine (r_prep) modulation_19\NN|the|of|with (r_conj) role_10\NN|an|important|in|and|modulation (r_dobj) plays_7\VBZ|that|damage|role (r_ccomp) concluded_2\VBN|it|is|plays|reduces|. (l_conj) reduces_25\VBZ|damage (l_dobj) damage_31\NN|the|induced|kidney|at
D010100_D007674 NONE oxygen_18\NN| (r_compound) species_19\NNS|reactive|oxygen|(|ros|) (r_pobj) of_16\IN|species (r_prep) production_15\NN|of (r_dobj) promotes_14\VBZ|that|production (r_relcl) stress_12\NN|vancomycin|(|vcm)-induced|oxidative|promotes|and (r_dobj) examine_7\VB|to|stress|investigate (l_advcl) investigate_25\VB|to|role (l_dobj) role_27\NN|the|of|,|agent (l_appos) agent_33\NN|an|expectorant|,|has|,|on (l_prep) on_41\IN|tissue (l_pobj) tissue_43\NN|kidney|against (l_prep) against_44\IN|impairment (l_pobj) impairment_51\NN|the|possible|induced|renal|in
D008315_D007674 NONE malondialdehyde_8\NN|increased|renal|(|mda|excretion (l_appos) excretion_33\NN|glucosaminidase (l_nmod) glucosaminidase_22\NN|urinary|beta|-|d|-|(|nag|) (l_appos) NAG_24\NN|,|marker (l_appos) marker_27\NN|a|of (l_prep) of_28\IN|injury (l_pobj) injury_31\NN|renal|tubular
D008315_D007674 NONE MDA_10\NNP|)|and (r_appos) malondialdehyde_8\NN|increased|renal|(|mda|excretion (l_appos) excretion_33\NN|glucosaminidase (l_nmod) glucosaminidase_22\NN|urinary|beta|-|d|-|(|nag|) (l_appos) NAG_24\NN|,|marker (l_appos) marker_27\NN|a|of (l_prep) of_28\IN|injury (l_pobj) injury_31\NN|renal|tubular
D013481_D007674 NONE superoxide_36\NN| (r_amod) dismutase_37\NN|superoxide|(|sod|)|and|activities (r_dobj) decreased_35\VBD|dismutase (r_conj) control_3\VB|administration|to|rats|malondialdehyde|but|decreased|. (l_dobj) malondialdehyde_8\NN|increased|renal|(|mda|excretion (l_appos) excretion_33\NN|glucosaminidase (l_nmod) glucosaminidase_22\NN|urinary|beta|-|d|-|(|nag|) (l_appos) NAG_24\NN|,|marker (l_appos) marker_27\NN|a|of (l_prep) of_28\IN|injury (l_pobj) injury_31\NN|renal|tubular
D014640_D001284 NONE VCM_21\NNP| (r_npadvmod) treated_23\VBN|vcm|- (r_amod) rats_24\NNS|treated (r_pobj) in_20\IN|rats (r_prep) vacuolization_12\NN|extensive|epithelial|cell|,|atrophy|in (l_conj) atrophy_14\NN|,|desquamation
D014640_-1 NONE VCM_21\NNP| (r_npadvmod) treated_23\VBN|vcm|- (r_amod) rats_24\NNS|treated (r_pobj) in_20\IN|rats (r_prep) vacuolization_12\NN|extensive|epithelial|cell|,|atrophy|in (l_conj) atrophy_14\NN|,|desquamation (l_conj) desquamation_16\NN|,|and|necrosis
D014640_D009336 NONE VCM_21\NNP| (r_npadvmod) treated_23\VBN|vcm|- (r_amod) rats_24\NNS|treated (r_pobj) in_20\IN|rats (r_prep) vacuolization_12\NN|extensive|epithelial|cell|,|atrophy|in (l_conj) atrophy_14\NN|,|desquamation (l_conj) desquamation_16\NN|,|and|necrosis (l_conj) necrosis_19\NN|
C048498_D001284 NONE erdosteine_33\NN| (r_amod) groups_34\NNS|the|erdosteine (r_conj) control_30\NN|the|and|groups (r_pobj) of_28\IN|control (r_prep) those_27\DT|of (r_pobj) than_26\IN|those (r_prep) more_25\JJR|than (r_amod) dilatation_4\NN|a|significant|of|,|vacuolization|more (l_conj) vacuolization_12\NN|extensive|epithelial|cell|,|atrophy|in (l_conj) atrophy_14\NN|,|desquamation
C048498_-1 NONE erdosteine_33\NN| (r_amod) groups_34\NNS|the|erdosteine (r_conj) control_30\NN|the|and|groups (r_pobj) of_28\IN|control (r_prep) those_27\DT|of (r_pobj) than_26\IN|those (r_prep) more_25\JJR|than (r_amod) dilatation_4\NN|a|significant|of|,|vacuolization|more (l_conj) vacuolization_12\NN|extensive|epithelial|cell|,|atrophy|in (l_conj) atrophy_14\NN|,|desquamation (l_conj) desquamation_16\NN|,|and|necrosis
C048498_D009336 NONE erdosteine_33\NN| (r_amod) groups_34\NNS|the|erdosteine (r_conj) control_30\NN|the|and|groups (r_pobj) of_28\IN|control (r_prep) those_27\DT|of (r_pobj) than_26\IN|those (r_prep) more_25\JJR|than (r_amod) dilatation_4\NN|a|significant|of|,|vacuolization|more (l_conj) vacuolization_12\NN|extensive|epithelial|cell|,|atrophy|in (l_conj) atrophy_14\NN|,|desquamation (l_conj) desquamation_16\NN|,|and|necrosis (l_conj) necrosis_19\NN|
6806735
D002945_D010051 NONE platinum_10\NN|cis|- (r_nmod) adriamycin_12\NNS|platinum|,|,|cyclophosphamide (r_pobj) of_7\IN|adriamycin (r_prep) combination_6\NN|a|of (r_pobj) with_4\IN|combination (r_prep) Treatment_0\NN|of|with|. (l_prep) of_1\IN|cancer (l_pobj) cancer_3\NN|ovarian
D002945_D010051 NONE cisplatinum_18\NN|cpdd (r_pobj) of_17\IN|cisplatinum (r_prep) combination_16\NN|a|of (r_pobj) with_14\IN|combination (r_prep) treated_13\VBN|during|,|patients|were|with|,|m2|. (l_nsubjpass) patients_8\NNS|38|with (l_prep) with_9\IN|cancer (l_pobj) cancer_11\NN|ovarian
D004317_D010051 NONE adriamycin_12\NNS|platinum|,|,|cyclophosphamide (r_pobj) of_7\IN|adriamycin (r_prep) combination_6\NN|a|of (r_pobj) with_4\IN|combination (r_prep) Treatment_0\NN|of|with|. (l_prep) of_1\IN|cancer (l_pobj) cancer_3\NN|ovarian
D004317_D010051 NONE adriamycin_28\NNS|,|m2 (r_amod) m2_26\NN|50|mg|/|,|adriamycin|,|m2|,|on|;|and|hexamethylmelamine (r_npadvmod) treated_13\VBN|during|,|patients|were|with|,|m2|. (l_nsubjpass) patients_8\NNS|38|with (l_prep) with_9\IN|cancer (l_pobj) cancer_11\NN|ovarian
D003520_D010051 NONE cyclophosphamide_14\NN|and|hexamethylmelamine (r_conj) adriamycin_12\NNS|platinum|,|,|cyclophosphamide (r_pobj) of_7\IN|adriamycin (r_prep) combination_6\NN|a|of (r_pobj) with_4\IN|combination (r_prep) Treatment_0\NN|of|with|. (l_prep) of_1\IN|cancer (l_pobj) cancer_3\NN|ovarian
D003520_D010051 NONE cyclophosphamide_35\NN| (r_conj) m2_33\NN|30|mg|/|,|cyclophosphamide (r_conj) adriamycin_28\NNS|,|m2 (r_amod) m2_26\NN|50|mg|/|,|adriamycin|,|m2|,|on|;|and|hexamethylmelamine (r_npadvmod) treated_13\VBN|during|,|patients|were|with|,|m2|. (l_nsubjpass) patients_8\NNS|38|with (l_prep) with_9\IN|cancer (l_pobj) cancer_11\NN|ovarian
D006585_D010051 NONE hexamethylmelamine_16\NN| (r_conj) cyclophosphamide_14\NN|and|hexamethylmelamine (r_conj) adriamycin_12\NNS|platinum|,|,|cyclophosphamide (r_pobj) of_7\IN|adriamycin (r_prep) combination_6\NN|a|of (r_pobj) with_4\IN|combination (r_prep) Treatment_0\NN|of|with|. (l_prep) of_1\IN|cancer (l_pobj) cancer_3\NN|ovarian
D006585_D010051 NONE hexamethylmelamine_47\NN|hmm|,|daily|,|for (r_conj) m2_26\NN|50|mg|/|,|adriamycin|,|m2|,|on|;|and|hexamethylmelamine (r_npadvmod) treated_13\VBN|during|,|patients|were|with|,|m2|. (l_nsubjpass) patients_8\NNS|38|with (l_prep) with_9\IN|cancer (l_pobj) cancer_11\NN|ovarian
D006585_D010051 NONE HMM_49\NNP|(|) (r_appos) hexamethylmelamine_47\NN|hmm|,|daily|,|for (r_conj) m2_26\NN|50|mg|/|,|adriamycin|,|m2|,|on|;|and|hexamethylmelamine (r_npadvmod) treated_13\VBN|during|,|patients|were|with|,|m2|. (l_nsubjpass) patients_8\NNS|38|with (l_prep) with_9\IN|cancer (l_pobj) cancer_11\NN|ovarian
C034868_D010051 NONE CPDD_20\NNP|(|) (r_appos) cisplatinum_18\NN|cpdd (r_pobj) of_17\IN|cisplatinum (r_prep) combination_16\NN|a|of (r_pobj) with_14\IN|combination (r_prep) treated_13\VBN|during|,|patients|were|with|,|m2|. (l_nsubjpass) patients_8\NNS|38|with (l_prep) with_9\IN|cancer (l_pobj) cancer_11\NN|ovarian
D006585_D005767 NONE HMM_0\UH| (r_compound) toxicity_2\NN|hmm|gastrointestinal
3074291
C017590_D001249 NONE bromide_6\NN|oxitropium (r_pobj) of_4\IN|bromide (r_prep) effect_3\NN|the|of (r_pobj) of_1\IN|effect (r_prep) Comparison_0\NN|of|and|of|. (l_conj) of_8\IN|theophylline (l_pobj) theophylline_12\NN|release|on (l_prep) on_13\IN|asthma (l_pobj) asthma_15\NN|nocturnal
C017590_D001249 NONE bromide_10\NN|oxitropium|, (r_appos) drug_7\NN|a|new|inhaled|antimuscarinic|,|bromide (r_pobj) of_2\IN|drug|and|of (l_conj) of_13\IN|preparation (l_pobj) preparation_19\NN|a|release|theophylline|upon (l_prep) upon_20\IN|asthma (l_pobj) asthma_22\NN|nocturnal
C017590_D001249 NONE Oxitropium_0\NNP| (r_nsubj) proves_1\VBZ|oxitropium|be|,|is|. (l_xcomp) be_3\VB|to|alternative (l_attr) alternative_6\NN|a|valuable|to|in (l_prep) in_9\IN|asthma (l_pobj) asthma_11\NN|nocturnal
D013806_D001249 NONE theophylline_12\NN|release|on (l_prep) on_13\IN|asthma (l_pobj) asthma_15\NN|nocturnal
D013806_D001249 NONE theophylline_18\NN| (r_amod) preparation_19\NN|a|release|theophylline|upon (l_prep) upon_20\IN|asthma (l_pobj) asthma_22\NN|nocturnal
D013806_D001249 NONE theophylline_8\NN| (r_pobj) to_7\IN|theophylline (r_prep) alternative_6\NN|a|valuable|to|in (l_prep) in_9\IN|asthma (l_pobj) asthma_11\NN|nocturnal
C017590_D009325 NONE oxitropium_6\NN| (r_pobj) of_5\IN|oxitropium (r_prep) effects_4\NNS|side|of (r_dobj) reported_2\VBN|subject|effects|,|compared|. (l_advcl) compared_9\VBN|as|to (l_prep) to_10\IN|subjects (l_pobj) subjects_12\NNS|three|reporting (l_acl) reporting_13\VBG|nausea|after (l_dobj) nausea_14\NN|,|vomiting
C017590_D014839 NONE oxitropium_6\NN| (r_pobj) of_5\IN|oxitropium (r_prep) effects_4\NNS|side|of (r_dobj) reported_2\VBN|subject|effects|,|compared|. (l_advcl) compared_9\VBN|as|to (l_prep) to_10\IN|subjects (l_pobj) subjects_12\NNS|three|reporting (l_acl) reporting_13\VBG|nausea|after (l_dobj) nausea_14\NN|,|vomiting (l_conj) vomiting_16\VBG|and|tremors
C017590_D014202 NONE oxitropium_6\NN| (r_pobj) of_5\IN|oxitropium (r_prep) effects_4\NNS|side|of (r_dobj) reported_2\VBN|subject|effects|,|compared|. (l_advcl) compared_9\VBN|as|to (l_prep) to_10\IN|subjects (l_pobj) subjects_12\NNS|three|reporting (l_acl) reporting_13\VBG|nausea|after (l_dobj) nausea_14\NN|,|vomiting (l_conj) vomiting_16\VBG|and|tremors (l_conj) tremors_18\NNS|
D013806_D009325 CID theophylline_20\NN| (r_pobj) after_19\IN|theophylline (r_prep) reporting_13\VBG|nausea|after (l_dobj) nausea_14\NN|,|vomiting
D013806_D014839 CID theophylline_20\NN| (r_pobj) after_19\IN|theophylline (r_prep) reporting_13\VBG|nausea|after (l_dobj) nausea_14\NN|,|vomiting (l_conj) vomiting_16\VBG|and|tremors
D013806_D014202 CID theophylline_20\NN| (r_pobj) after_19\IN|theophylline (r_prep) reporting_13\VBG|nausea|after (l_dobj) nausea_14\NN|,|vomiting (l_conj) vomiting_16\VBG|and|tremors (l_conj) tremors_18\NNS|
24739405
D003687_D012559 NONE dehydroepiandrosterone_2\NN|in (l_prep) in_3\IN|models (l_pobj) models_8\NNS|induced|schizophrenia|in (l_compound) schizophrenia_7\NN|
D003687_D012559 NONE dehydroepiandrosterone_5\NN|dhea (r_pobj) of_4\IN|dehydroepiandrosterone (r_prep) effects_3\NNS|the|of|on (l_prep) on_9\IN|models (l_pobj) models_11\NNS|animal|of (l_prep) of_12\IN|schizophrenia (l_pobj) schizophrenia_13\NN|
D003687_D012559 NONE DHEA_7\NNP|(|) (r_appos) dehydroepiandrosterone_5\NN|dhea (r_pobj) of_4\IN|dehydroepiandrosterone (r_prep) effects_3\NNS|the|of|on (l_prep) on_9\IN|models (l_pobj) models_11\NNS|animal|of (l_prep) of_12\IN|schizophrenia (l_pobj) schizophrenia_13\NN|
D003687_D012559 NONE DHEA_3\NNP| (r_nsubj) displays_4\VBZ|that|dhea|effects|,|and|used (l_conj) used_14\VBN|may|be|in (l_prep) in_15\IN|treatment (l_pobj) treatment_17\NN|the|of (l_prep) of_18\IN|schizophrenia (l_pobj) schizophrenia_19\NN|
D000661_D012559 CID amphetamine_4\NN| (r_npadvmod) induced_6\VBN|amphetamine|- (r_amod) models_8\NNS|induced|schizophrenia|in (l_compound) schizophrenia_7\NN|
D000661_D012559 CID Amphetamine_0\NN|(|ip|) (r_nsubj) induced_6\VBD|amphetamine|locomotion|sc|)|induced|. (l_conj) induced_19\VBN|climbing|,|and|induced (l_conj) induced_29\VBD|haloperidol|used (l_ccomp) used_33\VBN|tests|were|as (l_prep) as_34\IN|models (l_pobj) models_36\NNS|animal|of (l_prep) of_37\IN|schizophrenia (l_pobj) schizophrenia_38\NN|
D000661_D006948 NONE Amphetamine_0\NN|(|ip|) (r_nsubj) induced_6\VBD|amphetamine|locomotion|sc|)|induced|. (l_dobj) locomotion_8\NN|hyper|,|apomorphine (l_amod) hyper_7\JJ|
D000661_D002375 NONE Amphetamine_0\NN|(|ip|) (r_nsubj) induced_6\VBD|amphetamine|locomotion|sc|)|induced|. (l_conj) induced_19\VBN|climbing|,|and|induced (l_conj) induced_29\VBD|haloperidol|used (l_ccomp) used_33\VBN|tests|were|as (l_nsubjpass) tests_31\NNS|catalepsy (l_compound) catalepsy_30\NN|
D001058_D006948 NONE apomorphine_10\NN| (r_conj) locomotion_8\NN|hyper|,|apomorphine (l_amod) hyper_7\JJ|
D001058_D002375 NONE apomorphine_10\NN| (r_conj) locomotion_8\NN|hyper|,|apomorphine (r_dobj) induced_6\VBD|amphetamine|locomotion|sc|)|induced|. (l_conj) induced_19\VBN|climbing|,|and|induced (l_conj) induced_29\VBD|haloperidol|used (l_ccomp) used_33\VBN|tests|were|as (l_nsubjpass) tests_31\NNS|catalepsy (l_compound) catalepsy_30\NN|
D001058_D012559 CID apomorphine_10\NN| (r_conj) locomotion_8\NN|hyper|,|apomorphine (r_dobj) induced_6\VBD|amphetamine|locomotion|sc|)|induced|. (l_conj) induced_19\VBN|climbing|,|and|induced (l_conj) induced_29\VBD|haloperidol|used (l_ccomp) used_33\VBN|tests|were|as (l_prep) as_34\IN|models (l_pobj) models_36\NNS|animal|of (l_prep) of_37\IN|schizophrenia (l_pobj) schizophrenia_38\NN|
D006220_D006948 NONE haloperidol_23\NN|sc|) (r_nsubj) induced_29\VBD|haloperidol|used (r_conj) induced_19\VBN|climbing|,|and|induced (r_conj) induced_6\VBD|amphetamine|locomotion|sc|)|induced|. (l_dobj) locomotion_8\NN|hyper|,|apomorphine (l_amod) hyper_7\JJ|
D006220_D002375 CID haloperidol_23\NN|sc|) (r_nsubj) induced_29\VBD|haloperidol|used (l_ccomp) used_33\VBN|tests|were|as (l_nsubjpass) tests_31\NNS|catalepsy (l_compound) catalepsy_30\NN|
D006220_D002375 CID haloperidol_9\NN| (r_npadvmod) induced_11\VBN|haloperidol|- (r_amod) test_13\NN|the|induced|catalepsy|(|p<0.05|) (l_compound) catalepsy_12\NN|
D006220_D012559 CID haloperidol_23\NN|sc|) (r_nsubj) induced_29\VBD|haloperidol|used (l_ccomp) used_33\VBN|tests|were|as (l_prep) as_34\IN|models (l_pobj) models_36\NNS|animal|of (l_prep) of_37\IN|schizophrenia (l_pobj) schizophrenia_38\NN|
D003687_D002375 NONE DHEA_3\NNP| (r_nsubj) activity_6\NN|dhea|reduced|locomotor|and|catalepsy (l_conj) catalepsy_9\NN|increased|at
11745287
D016190_D002294 NONE carboplatin_4\NN| (r_pobj) of_3\IN|carboplatin (r_prep) study_2\NN|ii|of|and|liposomal|. (l_conj) liposomal_6\JJ|doxorubicin|in (l_prep) in_8\IN|patients (l_pobj) patients_9\NNS|with (l_prep) with_10\IN|carcinoma (l_pobj) carcinoma_14\NN|recurrent|cell|of (l_prep) of_15\IN|cervix (l_pobj) cervix_17\NN|the
D016190_D002294 NONE carboplatin_3\NN| (r_nmod) area_5\NN|carboplatin|(|under (r_pobj) of_2\IN|area (r_prep) combination_1\NN|the|of (r_nsubj) liposomal_17\JJ|combination|doxorubicin|; (r_ccomp) administered_32\VBN|liposomal|dose|was|intravenously|days|to|determine|. (l_prep) to_37\IN|patients (l_pobj) patients_39\NNS|37|with (l_prep) with_40\IN|carcinoma (l_pobj) carcinoma_45\NN|recurrent|cell|cervical
D016190_D002583 NONE carboplatin_4\NN| (r_pobj) of_3\IN|carboplatin (r_prep) study_2\NN|ii|of|and|liposomal|. (l_conj) liposomal_6\JJ|doxorubicin|in (l_prep) in_8\IN|patients (l_pobj) patients_9\NNS|with (l_prep) with_10\IN|carcinoma (l_pobj) carcinoma_14\NN|recurrent|cell|of (l_prep) of_15\IN|cervix (l_pobj) cervix_17\NN|the
D016190_D002583 NONE carboplatin_6\NN|and|doxorubicin (r_pobj) of_5\IN|carboplatin (r_prep) combination_4\NN|the|of (r_pobj) of_2\IN|combination (r_prep) activity_1\NN|the|of (r_nsubjpass) tested_11\VBN|activity|was|in|. (l_prep) in_12\IN|study (l_pobj) study_16\NN|a|ii|of (l_prep) of_17\IN|patients (l_pobj) patients_18\NNS|with (l_prep) with_19\IN|carcinoma (l_pobj) carcinoma_22\NN|recurrent|cervical
D016190_D002583 NONE carboplatin_3\NN| (r_nmod) area_5\NN|carboplatin|(|under (r_pobj) of_2\IN|area (r_prep) combination_1\NN|the|of (r_nsubj) liposomal_17\JJ|combination|doxorubicin|; (r_ccomp) administered_32\VBN|liposomal|dose|was|intravenously|days|to|determine|. (l_prep) to_37\IN|patients (l_pobj) patients_39\NNS|37|with (l_prep) with_40\IN|carcinoma (l_pobj) carcinoma_45\NN|recurrent|cell|cervical
D016190_D002583 NONE carboplatin_3\NN|and|liposomal (r_pobj) of_2\IN|carboplatin|doxorubicin (r_prep) combination_1\NN|the|of (r_nsubj) has_7\VBZ|combination|activity|. (l_dobj) activity_9\NN|modest|in (l_prep) in_10\IN|patients (l_pobj) patients_11\NNS|with (l_prep) with_12\IN|carcinoma (l_pobj) carcinoma_15\NN|recurrent|cervical
D004317_D002294 NONE doxorubicin_7\NN| (r_dobj) liposomal_6\JJ|doxorubicin|in (l_prep) in_8\IN|patients (l_pobj) patients_9\NNS|with (l_prep) with_10\IN|carcinoma (l_pobj) carcinoma_14\NN|recurrent|cell|of (l_prep) of_15\IN|cervix (l_pobj) cervix_17\NN|the
D004317_D002294 NONE doxorubicin_18\NN|doxil (r_dobj) liposomal_17\JJ|combination|doxorubicin|; (r_ccomp) administered_32\VBN|liposomal|dose|was|intravenously|days|to|determine|. (l_prep) to_37\IN|patients (l_pobj) patients_39\NNS|37|with (l_prep) with_40\IN|carcinoma (l_pobj) carcinoma_45\NN|recurrent|cell|cervical
D004317_D002294 NONE Doxil_20\NNS|( (r_appos) doxorubicin_18\NN|doxil (r_dobj) liposomal_17\JJ|combination|doxorubicin|; (r_ccomp) administered_32\VBN|liposomal|dose|was|intravenously|days|to|determine|. (l_prep) to_37\IN|patients (l_pobj) patients_39\NNS|37|with (l_prep) with_40\IN|carcinoma (l_pobj) carcinoma_45\NN|recurrent|cell|cervical
D004317_D002583 NONE doxorubicin_7\NN| (r_dobj) liposomal_6\JJ|doxorubicin|in (l_prep) in_8\IN|patients (l_pobj) patients_9\NNS|with (l_prep) with_10\IN|carcinoma (l_pobj) carcinoma_14\NN|recurrent|cell|of (l_prep) of_15\IN|cervix (l_pobj) cervix_17\NN|the
D004317_D002583 NONE doxorubicin_9\NN|liposomal (r_conj) carboplatin_6\NN|and|doxorubicin (r_pobj) of_5\IN|carboplatin (r_prep) combination_4\NN|the|of (r_pobj) of_2\IN|combination (r_prep) activity_1\NN|the|of (r_nsubjpass) tested_11\VBN|activity|was|in|. (l_prep) in_12\IN|study (l_pobj) study_16\NN|a|ii|of (l_prep) of_17\IN|patients (l_pobj) patients_18\NNS|with (l_prep) with_19\IN|carcinoma (l_pobj) carcinoma_22\NN|recurrent|cervical
D004317_D002583 NONE doxorubicin_18\NN|doxil (r_dobj) liposomal_17\JJ|combination|doxorubicin|; (r_ccomp) administered_32\VBN|liposomal|dose|was|intravenously|days|to|determine|. (l_prep) to_37\IN|patients (l_pobj) patients_39\NNS|37|with (l_prep) with_40\IN|carcinoma (l_pobj) carcinoma_45\NN|recurrent|cell|cervical
D004317_D002583 NONE Doxil_20\NNS|( (r_appos) doxorubicin_18\NN|doxil (r_dobj) liposomal_17\JJ|combination|doxorubicin|; (r_ccomp) administered_32\VBN|liposomal|dose|was|intravenously|days|to|determine|. (l_prep) to_37\IN|patients (l_pobj) patients_39\NNS|37|with (l_prep) with_40\IN|carcinoma (l_pobj) carcinoma_45\NN|recurrent|cell|cervical
D004317_D002583 NONE doxorubicin_6\NN| (r_pobj) of_2\IN|carboplatin|doxorubicin (r_prep) combination_1\NN|the|of (r_nsubj) has_7\VBZ|combination|activity|. (l_dobj) activity_9\NN|modest|in (l_prep) in_10\IN|patients (l_pobj) patients_11\NNS|with (l_prep) with_12\IN|carcinoma (l_pobj) carcinoma_15\NN|recurrent|cervical
D016190_D064420 NONE carboplatin_3\NN| (r_nmod) area_5\NN|carboplatin|(|under (r_pobj) of_2\IN|area (r_prep) combination_1\NN|the|of (r_nsubj) liposomal_17\JJ|combination|doxorubicin|; (r_ccomp) administered_32\VBN|liposomal|dose|was|intravenously|days|to|determine|. (l_advcl) determine_47\VB|to|activity (l_dobj) activity_49\NN|antitumor|and|profile (l_conj) profile_52\NN|toxicity (l_compound) toxicity_51\NN|
D004317_D064420 NONE doxorubicin_18\NN|doxil (r_dobj) liposomal_17\JJ|combination|doxorubicin|; (r_ccomp) administered_32\VBN|liposomal|dose|was|intravenously|days|to|determine|. (l_advcl) determine_47\VB|to|activity (l_dobj) activity_49\NN|antitumor|and|profile (l_conj) profile_52\NN|toxicity (l_compound) toxicity_51\NN|
D004317_D064420 NONE Doxil_20\NNS|( (r_appos) doxorubicin_18\NN|doxil (r_dobj) liposomal_17\JJ|combination|doxorubicin|; (r_ccomp) administered_32\VBN|liposomal|dose|was|intravenously|days|to|determine|. (l_advcl) determine_47\VB|to|activity (l_dobj) activity_49\NN|antitumor|and|profile (l_conj) profile_52\NN|toxicity (l_compound) toxicity_51\NN|
21195121
D009569_D012640 NONE oxide_4\NN|nitric (r_pobj) of_2\IN|oxide (r_prep) role_1\NN|the|of|in|induced|. (l_prep) in_5\IN|convulsions (l_pobj) convulsions_6\NNS|
D009569_D012640 NONE NO_6\DT| (r_nsubj) plays_7\VBZ|that|no|role (l_dobj) role_9\NN|a|of|in (l_prep) in_13\IN|model (l_pobj) model_15\NN|rat|of (l_prep) of_16\IN|seizures (l_pobj) seizures_18\NNS|lindane
D001556_D012640 CID lindane_9\NN|in (r_pobj) by_8\IN|lindane (r_agent) induced_7\VBN|by (r_acl) role_1\NN|the|of|in|induced|. (l_prep) in_5\IN|convulsions (l_pobj) convulsions_6\NNS|
D001556_D012640 CID lindane_37\NN| (r_compound) dose_38\NN|lower|lindane|mg/kg (r_pobj) by_35\IN|dose (r_agent) elicited_34\VBN|by (r_acl) convulsion_33\NN|first|elicited (r_pobj) to_31\IN|convulsion (r_prep) shortened_28\VBN|time|to (r_conj) increased_22\VBD|administration|significantly|incidence|and|shortened|. (l_dobj) incidence_24\NN|convulsion|and|severity (l_compound) convulsion_23\NN|
D001556_D012640 CID lindane_37\NN| (r_compound) dose_38\NN|lower|lindane|mg/kg (r_pobj) by_35\IN|dose (r_agent) elicited_34\VBN|by (r_acl) convulsion_33\NN|first|elicited
D001556_D012640 CID lindane_37\NN| (r_pobj) of_36\IN|lindane (r_prep) dose_35\NN|a|convulsive|of|(|mg/kg|) (r_pobj) with_32\IN|dose (r_prep) injection_31\NN|with (r_pobj) following_30\VBG|injection (r_prep) decreased_19\VBD|on|,|pretreatment|incidence|following|. (l_npadvmod) incidence_21\NN|convulsion|and|severity|and|time (l_compound) convulsion_20\NN|
D001556_D012640 CID lindane_37\NN| (r_pobj) of_36\IN|lindane (r_prep) dose_35\NN|a|convulsive|of|(|mg/kg|) (r_pobj) with_32\IN|dose (r_prep) injection_31\NN|with (r_pobj) following_30\VBG|injection (r_prep) decreased_19\VBD|on|,|pretreatment|incidence|following|. (l_npadvmod) incidence_21\NN|convulsion|and|severity|and|time (l_conj) time_27\NN|prolonged|latency|to (l_prep) to_28\IN|convulsion (l_pobj) convulsion_29\NN|
D001556_D012640 CID lindane_37\NN| (r_pobj) of_36\IN|lindane (r_prep) dose_35\NN|a|convulsive|of|(|mg/kg|) (l_amod) convulsive_34\JJ|
D001556_D012640 CID lindane_17\NN| (r_compound) seizures_18\NNS|lindane
D005680_D012640 NONE GABA(A_8\NNP| (r_nmod) receptors_10\NNS|gaba(a|) (r_pobj) of_7\IN|receptors (r_prep) blockage_6\NN|the|of (r_dobj) trough_4\VB|convulsions|mainly|blockage (l_nsubj) convulsions_2\NNS|
D009569_D004827 NONE oxide_1\NN|nitric|(|no|)|,|neurotransmitter|, (r_nsubj) has_9\VBZ|oxide|role|in|due|,|and|observed (l_conj) observed_39\VBN|name|in|. (l_prep) in_40\IN|models (l_pobj) models_43\NNS|different|epilepsy (l_compound) epilepsy_42\NN|
D009569_D004827 NONE NO_3\NNP| (r_intj) oxide_1\NN|nitric|(|no|)|,|neurotransmitter|, (r_nsubj) has_9\VBZ|oxide|role|in|due|,|and|observed (l_conj) observed_39\VBN|name|in|. (l_prep) in_40\IN|models (l_pobj) models_43\NNS|different|epilepsy (l_compound) epilepsy_42\NN|
D009569_D004827 NONE NO_25\DT| (r_det) syntheses_26\NNS|no|nos (r_pobj) of_24\IN|syntheses (r_prep) precursor_23\NN|arginine|of (r_pobj) of_18\IN|precursor (r_prep) effects_17\NNS|opposite|of (r_pobj) due_14\IN|to|effects (r_prep) has_9\VBZ|oxide|role|in|due|,|and|observed (l_conj) observed_39\VBN|name|in|. (l_prep) in_40\IN|models (l_pobj) models_43\NNS|different|epilepsy (l_compound) epilepsy_42\NN|
D009569_D004827 NONE NO_12\DT| (r_pobj) of_11\IN|no (r_prep) effects_10\NNS|the|of|on (l_prep) on_13\IN|characteristics (l_pobj) characteristics_18\NNS|the|behavioral|of|in (l_prep) of_19\IN|epilepsy (l_pobj) epilepsy_23\NN|induced
D001120_D004827 NONE arginine_21\NN|l|-|, (r_nmod) precursor_23\NN|arginine|of (r_pobj) of_18\IN|precursor (r_prep) effects_17\NNS|opposite|of (r_pobj) due_14\IN|to|effects (r_prep) has_9\VBZ|oxide|role|in|due|,|and|observed (l_conj) observed_39\VBN|name|in|. (l_prep) in_40\IN|models (l_pobj) models_43\NNS|different|epilepsy (l_compound) epilepsy_42\NN|
D019331_D004827 NONE NAME_34\NNP|l|-|inhibitor|) (r_nsubj) observed_39\VBN|name|in|. (l_prep) in_40\IN|models (l_pobj) models_43\NNS|different|epilepsy (l_compound) epilepsy_42\NN|
D001556_D004827 NONE lindane_20\NN| (r_npadvmod) induced_22\VBN|lindane|- (r_amod) epilepsy_23\NN|induced
D001120_D012640 NONE arginine_5\NN|l|-|800 (r_pobj) of_2\IN|arginine (r_prep) administration_1\NN|the|of|mg/kg|,|i.p.|)|in (r_nsubj) increased_22\VBD|administration|significantly|incidence|and|shortened|. (l_dobj) incidence_24\NN|convulsion|and|severity (l_compound) convulsion_23\NN|
D001120_D012640 NONE arginine_5\NN|l|-|800 (r_pobj) of_2\IN|arginine (r_prep) administration_1\NN|the|of|mg/kg|,|i.p.|)|in (r_nsubj) increased_22\VBD|administration|significantly|incidence|and|shortened|. (l_conj) shortened_28\VBN|time|to (l_prep) to_31\IN|convulsion (l_pobj) convulsion_33\NN|first|elicited
D019331_D012640 NONE NAME_8\NNP|l|- (r_pobj) with_5\IN|name (r_prep) pretreatment_4\NN|with|mg/kg (r_nsubj) decreased_19\VBD|on|,|pretreatment|incidence|following|. (l_npadvmod) incidence_21\NN|convulsion|and|severity|and|time (l_compound) convulsion_20\NN|
D019331_D012640 NONE NAME_8\NNP|l|- (r_pobj) with_5\IN|name (r_prep) pretreatment_4\NN|with|mg/kg (r_nsubj) decreased_19\VBD|on|,|pretreatment|incidence|following|. (l_npadvmod) incidence_21\NN|convulsion|and|severity|and|time (l_conj) time_27\NN|prolonged|latency|to (l_prep) to_28\IN|convulsion (l_pobj) convulsion_29\NN|
D019331_D012640 NONE NAME_8\NNP|l|- (r_pobj) with_5\IN|name (r_prep) pretreatment_4\NN|with|mg/kg (r_nsubj) decreased_19\VBD|on|,|pretreatment|incidence|following|. (l_prep) following_30\VBG|injection (l_pobj) injection_31\NN|with (l_prep) with_32\IN|dose (l_pobj) dose_35\NN|a|convulsive|of|(|mg/kg|) (l_amod) convulsive_34\JJ|
19447152
D010042_D001714 CID ouabain_6\NN| (r_pobj) by_5\IN|ouabain (r_prep) induced_4\VBN|model|by|:|evidence|. (l_nsubj) model_1\NN|animal|of (l_prep) of_2\IN|mania (l_pobj) mania_3\NN|
D010042_D001714 CID ouabain_7\NN| (r_pobj) of_6\IN|ouabain (r_prep) administration_5\NN|(|icv|)|of|(|inhibitor|)|in (r_appos) intracerebroventricular_1\JJ|the|administration (r_nsubjpass) suggested_17\VBN|intracerebroventricular|has|been|mimic|. (l_xcomp) mimic_19\VB|to|symptoms (l_dobj) symptoms_21\NNS|some|of (l_prep) of_22\IN|mania (l_pobj) mania_25\NN|human|bipolar
D010042_D001714 CID ouabain_3\NN| (r_npadvmod) induced_5\VBN|ouabain|- (r_amod) behavior_9\NN|induced|mania (l_nmod) mania_6\NN|-|like
D010042_D001714 CID ouabain_3\NN| (r_npadvmod) induced_5\VBN|ouabain|- (r_amod) behavior_9\NN|induced|mania (r_nsubj) provide_11\VB|in|,|behavior|may|model|. (l_dobj) model_15\NN|a|useful|animal|test (l_relcl) test_17\VB|to|hypothesis (l_dobj) hypothesis_19\NN|the|of (l_prep) of_20\IN|involvement (l_pobj) involvement_22\NN|the|of (l_prep) of_23\IN|stress (l_pobj) stress_25\NN|oxidative|in (l_prep) in_26\IN|disorder (l_pobj) disorder_28\NN|bipolar
D012964_D001714 NONE Na(+)/K(+)-ATPase_10\NNP| (r_compound) inhibitor_11\NN|a|na(+)/k(+)-atpase (r_appos) administration_5\NN|(|icv|)|of|(|inhibitor|)|in (r_appos) intracerebroventricular_1\JJ|the|administration (r_nsubjpass) suggested_17\VBN|intracerebroventricular|has|been|mimic|. (l_xcomp) mimic_19\VB|to|symptoms (l_dobj) symptoms_21\NNS|some|of (l_prep) of_22\IN|mania (l_pobj) mania_25\NN|human|bipolar
D011188_D001714 NONE Na(+)/K(+)-ATPase_10\NNP| (r_compound) inhibitor_11\NN|a|na(+)/k(+)-atpase (r_appos) administration_5\NN|(|icv|)|of|(|inhibitor|)|in (r_appos) intracerebroventricular_1\JJ|the|administration (r_nsubjpass) suggested_17\VBN|intracerebroventricular|has|been|mimic|. (l_xcomp) mimic_19\VB|to|symptoms (l_dobj) symptoms_21\NNS|some|of (l_prep) of_22\IN|mania (l_pobj) mania_25\NN|human|bipolar
D010042_D009069 NONE ouabain_4\NN|at|)|and|10(-3)m (r_nsubj) induced_10\VBN|that|ouabain|hyperlocomotion (l_dobj) hyperlocomotion_11\NN|in
19914299
D005473_D008569 NONE Fluoxetine_0\NNP| (r_nsubj) improves_1\VBZ|fluoxetine|deficits|5-fluorouracil|. (l_dobj) deficits_4\NNS|the|memory|caused
D005472_D008569 CID 5-fluorouracil_10\CD| (r_punct) improves_1\VBZ|fluoxetine|deficits|5-fluorouracil|. (l_dobj) deficits_4\NNS|the|memory|caused
24582773
C069541_D011595 CID quetiapine_11\NN| (r_amod) doses_10\NNS|add|high|-|quetiapine|in (r_pobj) by_4\IN|doses (r_prep) induced_3\VBN|agitation|by|. (l_nsubj) agitation_2\NN|paradoxical|severe
C069541_D011595 CID quetiapine_9\NN| (r_pobj) of_8\IN|quetiapine (r_prep) introduction_7\NN|the|gradual|of|(|day|) (r_pobj) following_4\VBG|introduction (r_prep) h_3\NN|the|48|following (r_pobj) Within_0\IN|h (r_prep) presented_21\VBD|within|,|patient|agitation|without|,|contrasting|. (l_dobj) agitation_23\NN|severe
C069541_D011595 CID quetiapine_7\NN| (r_pobj) of_6\IN|quetiapine (r_prep) reintroduction_5\NN|the|gradual|of|later|,|led|, (l_relcl) led_13\VBD|which|to (l_prep) to_14\IN|agitation (l_pobj) agitation_17\NN|another|severe
C069541_D011595 CID quetiapine_7\NN| (r_pobj) of_6\IN|quetiapine (r_prep) reintroduction_5\NN|the|gradual|of|later|,|led|, (r_conj) withdrawal_1\NN|the|and|reintroduction (r_nsubj) enabled_19\VBD|withdrawal|us|attribute|. (l_xcomp) attribute_22\VB|to|agitation|to (l_dobj) agitation_24\NN|the
C069541_D011595 CID quetiapine_27\NN| (r_pobj) to_26\IN|specifically|quetiapine (r_prep) attribute_22\VB|to|agitation|to (r_xcomp) enabled_19\VBD|withdrawal|us|attribute|. (l_nsubj) withdrawal_1\NN|the|and|reintroduction (l_conj) reintroduction_5\NN|the|gradual|of|later|,|led|, (l_relcl) led_13\VBD|which|to (l_prep) to_14\IN|agitation (l_pobj) agitation_17\NN|another|severe
C069541_D011595 CID quetiapine_27\NN| (r_pobj) to_26\IN|specifically|quetiapine (r_prep) attribute_22\VB|to|agitation|to (l_dobj) agitation_24\NN|the
C069541_D011618 NONE quetiapine_11\NN| (r_amod) doses_10\NNS|add|high|-|quetiapine|in (l_prep) in_12\IN|disorder (l_pobj) disorder_16\NN|affective
D003006_D011618 NONE zuclopenthixol_33\NN|day|and|lithium (r_appos) antipsychotics_31\NNS|generation|,|zuclopenthixol (r_pobj) of_27\IN|antipsychotics (r_prep) combination_26\NN|a|of (r_pobj) by_24\IN|combination (r_agent) treated_23\VBN|by|serum (r_acl) case_3\NN|the|of|since|,|treated (l_prep) of_4\IN|suffering (l_pobj) suffering_10\NN|a|old|patient|from (l_prep) from_11\IN|disorder (l_pobj) disorder_15\NN|affective
D008094_D011618 NONE lithium_41\NN|(|day|) (r_conj) zuclopenthixol_33\NN|day|and|lithium (r_appos) antipsychotics_31\NNS|generation|,|zuclopenthixol (r_pobj) of_27\IN|antipsychotics (r_prep) combination_26\NN|a|of (r_pobj) by_24\IN|combination (r_agent) treated_23\VBN|by|serum (r_acl) case_3\NN|the|of|since|,|treated (l_prep) of_4\IN|suffering (l_pobj) suffering_10\NN|a|old|patient|from (l_prep) from_11\IN|disorder (l_pobj) disorder_15\NN|affective
D008094_D011618 NONE lithium=0.85_50\NN| (r_punct) serum_49\NN|(|lithium=0.85|l|) (r_parataxis) treated_23\VBN|by|serum (r_acl) case_3\NN|the|of|since|,|treated (l_prep) of_4\IN|suffering (l_pobj) suffering_10\NN|a|old|patient|from (l_prep) from_11\IN|disorder (l_pobj) disorder_15\NN|affective
C069541_D010554 NONE quetiapine_9\NN| (r_pobj) of_8\IN|quetiapine (r_prep) introduction_7\NN|the|gradual|of|(|day|) (r_pobj) following_4\VBG|introduction (r_prep) h_3\NN|the|48|following (r_pobj) Within_0\IN|h (r_prep) presented_21\VBD|within|,|patient|agitation|without|,|contrasting|. (l_advcl) contrasting_29\VBG|with (l_prep) with_30\IN|absence (l_pobj) absence_32\NN|the|of (l_prep) of_33\IN|history (l_pobj) history_35\NN|a|of (l_prep) of_36\IN|aggressiveness (l_pobj) aggressiveness_37\NN|or|disorder
C069541_D010554 NONE quetiapine_9\NN| (r_pobj) of_8\IN|quetiapine (r_prep) introduction_7\NN|the|gradual|of|(|day|) (r_pobj) following_4\VBG|introduction (r_prep) h_3\NN|the|48|following (r_pobj) Within_0\IN|h (r_prep) presented_21\VBD|within|,|patient|agitation|without|,|contrasting|. (l_advcl) contrasting_29\VBG|with (l_prep) with_30\IN|absence (l_pobj) absence_32\NN|the|of (l_prep) of_33\IN|history (l_pobj) history_35\NN|a|of (l_prep) of_36\IN|aggressiveness (l_pobj) aggressiveness_37\NN|or|disorder (l_conj) disorder_40\NN|personality
17379047
C081489_D006973 NONE valsartan_2\JJ| (r_nmod) therapy_6\NN|valsartan|hydrochlorothiazide|combination (r_pobj) of_1\IN|therapy (r_prep) Comparison_0\NN|of|at|:|study|. (l_appos) study_24\NN|a|blind|,|controlled|followed (l_acl) followed_25\VBN|by (l_agent) by_26\IN|therapy (l_pobj) therapy_31\NN|term|combination|in (l_prep) in_32\IN|adults (l_pobj) adults_34\NNS|hypertensive (l_amod) hypertensive_33\JJ|
D006852_D006973 NONE hydrochlorothiazide_4\JJ|/ (r_compound) therapy_6\NN|valsartan|hydrochlorothiazide|combination (r_pobj) of_1\IN|therapy (r_prep) Comparison_0\NN|of|at|:|study|. (l_appos) study_24\NN|a|blind|,|controlled|followed (l_acl) followed_25\VBN|by (l_agent) by_26\IN|therapy (l_pobj) therapy_31\NN|term|combination|in (l_prep) in_32\IN|adults (l_pobj) adults_34\NNS|hypertensive (l_amod) hypertensive_33\JJ|
C081489_C562386 NONE valsartan_10\JJ|val|(|hctz)-monotherapy (l_appos) HCTZ)-monotherapy_17\NN|and|combinations (l_conj) combinations_22\NNS|dose|in (l_prep) in_23\IN|patients (l_pobj) patients_24\NNS|with (l_prep) with_25\IN|hypertension (l_pobj) hypertension_27\NN|essential
C081489_C562386 NONE VAL_12\NNP|(|)|or|hydrochlorothiazide (r_appos) valsartan_10\JJ|val|(|hctz)-monotherapy (l_appos) HCTZ)-monotherapy_17\NN|and|combinations (l_conj) combinations_22\NNS|dose|in (l_prep) in_23\IN|patients (l_pobj) patients_24\NNS|with (l_prep) with_25\IN|hypertension (l_pobj) hypertension_27\NN|essential
C081489_C562386 NONE VAL_34\NNP|160|mg|;|hctz|;|hctz (r_appos) groups_32\NNS|8|treatment|:|val (r_pobj) to_27\IN|groups (r_prep) randomized_26\VBN|patients|mean|sitting|were|to|. (l_nsubjpass) Patients_0\NNS|with (l_prep) with_1\IN|hypertension (l_pobj) hypertension_3\NN|essential
C081489_C562386 NONE VAL_46\NNP| (r_nmod) HCTZ_48\NNP|val|/|160/12.5|,|320/12.5|;|or|placebo (r_appos) VAL_34\NNP|160|mg|;|hctz|;|hctz (r_appos) groups_32\NNS|8|treatment|:|val (r_pobj) to_27\IN|groups (r_prep) randomized_26\VBN|patients|mean|sitting|were|to|. (l_nsubjpass) Patients_0\NNS|with (l_prep) with_1\IN|hypertension (l_pobj) hypertension_3\NN|essential
D006852_C562386 NONE hydrochlorothiazide_15\NN| (r_conj) VAL_12\NNP|(|)|or|hydrochlorothiazide (r_appos) valsartan_10\JJ|val|(|hctz)-monotherapy (l_appos) HCTZ)-monotherapy_17\NN|and|combinations (l_conj) combinations_22\NNS|dose|in (l_prep) in_23\IN|patients (l_pobj) patients_24\NNS|with (l_prep) with_25\IN|hypertension (l_pobj) hypertension_27\NN|essential
D006852_C562386 NONE HCTZ)-monotherapy_17\NN|and|combinations (l_conj) combinations_22\NNS|dose|in (l_prep) in_23\IN|patients (l_pobj) patients_24\NNS|with (l_prep) with_25\IN|hypertension (l_pobj) hypertension_27\NN|essential
D006852_C562386 NONE HCTZ_40\NNP|mg (r_appos) VAL_34\NNP|160|mg|;|hctz|;|hctz (r_appos) groups_32\NNS|8|treatment|:|val (r_pobj) to_27\IN|groups (r_prep) randomized_26\VBN|patients|mean|sitting|were|to|. (l_nsubjpass) Patients_0\NNS|with (l_prep) with_1\IN|hypertension (l_pobj) hypertension_3\NN|essential
D006852_C562386 NONE HCTZ_48\NNP|val|/|160/12.5|,|320/12.5|;|or|placebo (r_appos) VAL_34\NNP|160|mg|;|hctz|;|hctz (r_appos) groups_32\NNS|8|treatment|:|val (r_pobj) to_27\IN|groups (r_prep) randomized_26\VBN|patients|mean|sitting|were|to|. (l_nsubjpass) Patients_0\NNS|with (l_prep) with_1\IN|hypertension (l_pobj) hypertension_3\NN|essential
C081489_D007008 NONE VAL_7\NNP| (r_nmod) HCTZ_9\NNP|val|/ (r_compound) combinations_10\NNS|hctz|(|%|) (r_pobj) with_6\IN|combinations (r_prep) lower_5\JJR|with|than (r_acomp) was_4\VBD|incidence|lower|. (l_nsubj) incidence_1\NN|the|of (l_prep) of_2\IN|hypokalemia (l_pobj) hypokalemia_3\NN|
C081489_D007008 NONE VAL_8\NNP| (r_nmod) HCTZ_10\NNP|val|/ (r_pobj) with_7\IN|hctz (r_prep) therapies_6\NNS|combination|with (r_nsubjpass) associated_12\VBN|in|,|therapies|were|with|,|tolerated|. (l_conj) tolerated_25\VBN|were|well|,|and|associated (l_conj) associated_29\VBN|were|with (l_prep) with_30\IN|hypokalemia (l_pobj) hypokalemia_32\NN|less|than
D006852_D007008 CID HCTZ_9\NNP|val|/ (r_compound) combinations_10\NNS|hctz|(|%|) (r_pobj) with_6\IN|combinations (r_prep) lower_5\JJR|with|than (r_acomp) was_4\VBD|incidence|lower|. (l_nsubj) incidence_1\NN|the|of (l_prep) of_2\IN|hypokalemia (l_pobj) hypokalemia_3\NN|
D006852_D007008 CID HCTZ_17\NNP| (r_compound) monotherapies_18\NNS|hctz|(|%|) (r_pobj) with_16\IN|monotherapies (r_prep) than_15\IN|with (r_prep) lower_5\JJR|with|than (r_acomp) was_4\VBD|incidence|lower|. (l_nsubj) incidence_1\NN|the|of (l_prep) of_2\IN|hypokalemia (l_pobj) hypokalemia_3\NN|
D006852_D007008 CID HCTZ_10\NNP|val|/ (r_pobj) with_7\IN|hctz (r_prep) therapies_6\NNS|combination|with (r_nsubjpass) associated_12\VBN|in|,|therapies|were|with|,|tolerated|. (l_conj) tolerated_25\VBN|were|well|,|and|associated (l_conj) associated_29\VBN|were|with (l_prep) with_30\IN|hypokalemia (l_pobj) hypokalemia_32\NN|less|than
D006852_D007008 CID HCTZ_34\NNP|alone (r_pobj) than_33\IN|hctz (r_prep) hypokalemia_32\NN|less|than
10770468
D008094_D001714 NONE lithium_8\NN|maintenance (r_compound) therapy_9\NN|lithium|developed (r_dobj) receiving_6\VBG|therapy (r_acl) patient_5\NN|a|bipolar|receiving (l_amod) bipolar_4\JJ|
D008094_D001714 NONE lithium_8\NN|maintenance (r_compound) therapy_9\NN|lithium|developed (r_dobj) receiving_6\VBG|therapy (r_acl) patient_5\NN|a|bipolar|receiving (r_pobj) in_2\IN|patient (r_prep) findings_1\NNS|recent|in (r_nsubj) prompted_16\VBD|findings|authors|conduct|. (l_xcomp) conduct_20\VB|to|study (l_dobj) study_23\NN|a|retrospective|of|with (l_prep) of_24\IN|patients (l_pobj) patients_26\NNS|bipolar (l_amod) bipolar_25\JJ|
D008094_D001714 NONE lithium_28\NN| (r_npadvmod) associated_30\VBN|lithium|- (r_amod) hypercalcemia_31\NN|associated (r_pobj) with_27\IN|hypercalcemia (r_prep) study_23\NN|a|retrospective|of|with (r_dobj) conduct_20\VB|to|study (r_xcomp) prompted_16\VBD|findings|authors|conduct|. (l_nsubj) findings_1\NNS|recent|in (l_prep) in_2\IN|patient (l_pobj) patient_5\NN|a|bipolar|receiving (l_amod) bipolar_4\JJ|
D008094_D001714 NONE lithium_28\NN| (r_npadvmod) associated_30\VBN|lithium|- (r_amod) hypercalcemia_31\NN|associated (r_pobj) with_27\IN|hypercalcemia (r_prep) study_23\NN|a|retrospective|of|with (l_prep) of_24\IN|patients (l_pobj) patients_26\NNS|bipolar (l_amod) bipolar_25\JJ|
D008094_D001714 NONE lithium_18\NN| (r_npadvmod) treated_20\VBN|lithium|- (r_amod) patients_23\NNS|age-|comparable|treated|bipolar|normocalcemic (l_amod) bipolar_21\JJ|
D008094_D001714 NONE lithium_18\NN| (r_npadvmod) treated_20\VBN|lithium|- (r_amod) patients_23\NNS|age-|comparable|treated|bipolar|normocalcemic (r_dobj) included_12\VBD|which|patients (r_relcl) C1_9\NN|:|group|,|included|,|and|c2 (l_conj) C2_27\NNP|group|,|included (l_relcl) included_30\VBD|which|patients (l_dobj) patients_33\NNS|bipolar|normocalcemic|treated (l_amod) bipolar_31\JJ|
D008094_D001714 NONE lithium_11\NN| (r_npadvmod) associated_13\VBN|lithium|- (r_amod) hypercalcemia_14\NN|associated (r_pobj) with_10\IN|hypercalcemia (r_prep) diseases_6\NNS|medical|and|patients|with (l_conj) patients_9\NNS|bipolar (l_amod) bipolar_8\JJ|
D008094_D006934 CID lithium_8\NN|maintenance (r_compound) therapy_9\NN|lithium|developed (l_relcl) developed_11\VBD|who|hypercalcemia (l_dobj) hypercalcemia_12\NN|and|bradyarrhythmia
D008094_D006934 CID lithium_8\NN|maintenance (r_compound) therapy_9\NN|lithium|developed (r_dobj) receiving_6\VBG|therapy (r_acl) patient_5\NN|a|bipolar|receiving (r_pobj) in_2\IN|patient (r_prep) findings_1\NNS|recent|in (r_nsubj) prompted_16\VBD|findings|authors|conduct|. (l_xcomp) conduct_20\VB|to|study (l_dobj) study_23\NN|a|retrospective|of|with (l_prep) with_27\IN|hypercalcemia (l_pobj) hypercalcemia_31\NN|associated
D008094_D006934 CID lithium_28\NN| (r_npadvmod) associated_30\VBN|lithium|- (r_amod) hypercalcemia_31\NN|associated (r_pobj) with_27\IN|hypercalcemia (r_prep) study_23\NN|a|retrospective|of|with (r_dobj) conduct_20\VB|to|study (r_xcomp) prompted_16\VBD|findings|authors|conduct|. (l_nsubj) findings_1\NNS|recent|in (l_prep) in_2\IN|patient (l_pobj) patient_5\NN|a|bipolar|receiving (l_acl) receiving_6\VBG|therapy (l_dobj) therapy_9\NN|lithium|developed (l_relcl) developed_11\VBD|who|hypercalcemia (l_dobj) hypercalcemia_12\NN|and|bradyarrhythmia
D008094_D006934 CID lithium_28\NN| (r_npadvmod) associated_30\VBN|lithium|- (r_amod) hypercalcemia_31\NN|associated
D008094_D006934 CID lithium_17\NN|non|- (r_npadvmod) treated_19\VBN|lithium|- (r_amod) patients_20\NNS|18|treated|with|and|patients (r_dobj) identified_13\VBD|after|,|authors|patients|. (l_prep) After_0\IN|eliminating (l_pcomp) eliminating_1\VBG|hypercalcemias (l_dobj) hypercalcemias_3\NNS|spurious|or|those
D008094_D006934 CID lithium_17\NN|non|- (r_npadvmod) treated_19\VBN|lithium|- (r_amod) patients_20\NNS|18|treated|with|and|patients (l_prep) with_21\IN|hypercalcemias (l_pobj) hypercalcemias_22\NNS|related
D008094_D006934 CID lithium_17\NN|non|- (r_npadvmod) treated_19\VBN|lithium|- (r_amod) patients_20\NNS|18|treated|with|and|patients (l_conj) patients_36\NNS|12|with (l_prep) with_37\IN|hypercalcemia (l_pobj) hypercalcemia_41\NN|associated|(|b|)
D008094_D006934 CID lithium_38\NN| (r_npadvmod) associated_40\VBN|lithium|- (r_amod) hypercalcemia_41\NN|associated|(|b|) (r_pobj) with_37\IN|hypercalcemia (r_prep) patients_36\NNS|12|with (r_conj) patients_20\NNS|18|treated|with|and|patients (r_dobj) identified_13\VBD|after|,|authors|patients|. (l_prep) After_0\IN|eliminating (l_pcomp) eliminating_1\VBG|hypercalcemias (l_dobj) hypercalcemias_3\NNS|spurious|or|those
D008094_D006934 CID lithium_38\NN| (r_npadvmod) associated_40\VBN|lithium|- (r_amod) hypercalcemia_41\NN|associated|(|b|) (r_pobj) with_37\IN|hypercalcemia (r_prep) patients_36\NNS|12|with (r_conj) patients_20\NNS|18|treated|with|and|patients (l_prep) with_21\IN|hypercalcemias (l_pobj) hypercalcemias_22\NNS|related
D008094_D006934 CID lithium_38\NN| (r_npadvmod) associated_40\VBN|lithium|- (r_amod) hypercalcemia_41\NN|associated|(|b|)
D008094_D006934 CID lithium_11\NN| (r_npadvmod) associated_13\VBN|lithium|- (r_amod) hypercalcemia_14\NN|associated (r_pobj) with_10\IN|hypercalcemia (r_prep) diseases_6\NNS|medical|and|patients|with (r_pobj) from_4\IN|diseases (r_prep) resulting_3\VBG|from (r_acl) hypercalcemia_2\NN|resulting
D008094_D006934 CID lithium_11\NN| (r_npadvmod) associated_13\VBN|lithium|- (r_amod) hypercalcemia_14\NN|associated
D008094_D001919 NONE lithium_8\NN|maintenance (r_compound) therapy_9\NN|lithium|developed (l_relcl) developed_11\VBD|who|hypercalcemia (l_dobj) hypercalcemia_12\NN|and|bradyarrhythmia (l_conj) bradyarrhythmia_15\NN|severe
D008094_D001919 NONE lithium_28\NN| (r_npadvmod) associated_30\VBN|lithium|- (r_amod) hypercalcemia_31\NN|associated (r_pobj) with_27\IN|hypercalcemia (r_prep) study_23\NN|a|retrospective|of|with (r_dobj) conduct_20\VB|to|study (r_xcomp) prompted_16\VBD|findings|authors|conduct|. (l_nsubj) findings_1\NNS|recent|in (l_prep) in_2\IN|patient (l_pobj) patient_5\NN|a|bipolar|receiving (l_acl) receiving_6\VBG|therapy (l_dobj) therapy_9\NN|lithium|developed (l_relcl) developed_11\VBD|who|hypercalcemia (l_dobj) hypercalcemia_12\NN|and|bradyarrhythmia (l_conj) bradyarrhythmia_15\NN|severe
D008094_D009369 NONE lithium_17\NN|non|- (r_npadvmod) treated_19\VBN|lithium|- (r_amod) patients_20\NNS|18|treated|with|and|patients (l_prep) with_21\IN|hypercalcemias (l_pobj) hypercalcemias_22\NNS|related (l_acl) related_23\VBN|to (l_prep) to_24\IN|malignancies (l_pobj) malignancies_25\NNS|and|conditions
D008094_D009369 NONE lithium_38\NN| (r_npadvmod) associated_40\VBN|lithium|- (r_amod) hypercalcemia_41\NN|associated|(|b|) (r_pobj) with_37\IN|hypercalcemia (r_prep) patients_36\NNS|12|with (r_conj) patients_20\NNS|18|treated|with|and|patients (l_prep) with_21\IN|hypercalcemias (l_pobj) hypercalcemias_22\NNS|related (l_acl) related_23\VBN|to (l_prep) to_24\IN|malignancies (l_pobj) malignancies_25\NNS|and|conditions
2083961
D012293_D058186 CID rifampicin_5\NNS| (r_pobj) due_3\IN|to|rifampicin (r_prep) failure_2\NN|acute|renal|due|.
D012293_D009325 NONE Rifampicin_0\NNP| (r_nsubjpass) administered_2\VBN|rifampicin|was|thrice|as|and|developed (l_conj) developed_17\VBD|time|he|effects|. (l_dobj) effects_20\NNS|untoward|side|like (l_prep) like_21\IN|nausea (l_pobj) nausea_22\NN|,|vomiting
D012293_D014839 NONE Rifampicin_0\NNP| (r_nsubjpass) administered_2\VBN|rifampicin|was|thrice|as|and|developed (l_conj) developed_17\VBD|time|he|effects|. (l_dobj) effects_20\NNS|untoward|side|like (l_prep) like_21\IN|nausea (l_pobj) nausea_22\NN|,|vomiting (l_conj) vomiting_24\NN|and|fever
D012293_D005334 NONE Rifampicin_0\NNP| (r_nsubjpass) administered_2\VBN|rifampicin|was|thrice|as|and|developed (l_conj) developed_17\VBD|time|he|effects|. (l_dobj) effects_20\NNS|untoward|side|like (l_prep) like_21\IN|nausea (l_pobj) nausea_22\NN|,|vomiting (l_conj) vomiting_24\NN|and|fever (l_conj) fever_26\NN|with
24664478
C104457_D020258 NONE Nelarabine_0\JJ| (r_compound) neurotoxicity_1\NN|nelarabine|with|:
C104457_D020258 NONE nelarabine_1\JJ| (r_compound) neurotoxicity_2\NN|severe|nelarabine|in
C104457_D020258 NONE nelarabine_16\NN|in (r_pobj) by_15\IN|nelarabine (r_agent) caused_14\VBN|by (r_acl) neurotoxicity_13\NN|severe|caused
24902786
D013739_D008569 NONE Testosterone_0\NN| (r_nsubj) ameliorates_1\VBZ|testosterone|impairment|. (l_dobj) impairment_6\NN|induced|memory|in
D013739_D008569 NONE testosterone_7\NN| (r_pobj) of_6\IN|testosterone (r_prep) effects_5\NNS|the|of|on (l_prep) on_8\IN|impairment (l_pobj) impairment_13\NN|streptozotocin|(|memory|in
D013739_D008569 NONE testosterone_19\NN| (r_compound) replacement_20\NN|the|testosterone|in (r_dobj) attenuated_17\VBD|significantly|replacement (r_conj) impaired_8\VBD|administration|significantly|memory|,|and|attenuated|. (l_dobj) memory_10\NN|the|in
D013739_D008569 NONE testosterone_19\NN| (r_compound) replacement_20\NN|the|testosterone|in (l_prep) in_21\IN|improving (l_pcomp) improving_22\VBG|impairment (l_dobj) impairment_29\NN|stz-|memory
D013739_D008569 NONE Testosterone_0\NN| (r_compound) administration_1\NN|testosterone (r_nsubj) ameliorates_2\VBZ|administration|impairment|. (l_dobj) impairment_9\NN|stz-|induced|memory|in
D013311_D008569 CID streptozotocin_2\RB| (r_npadvmod) induced_4\VBN|streptozotocin|- (r_amod) impairment_6\NN|induced|memory|in
D013311_D008569 CID streptozotocin_9\JJ| (r_nmod) impairment_13\NN|streptozotocin|(|memory|in
D013311_D008569 CID STZ)-induced_11\VBN| (r_amod) memory_12\NN|stz)-induced (r_compound) impairment_13\NN|streptozotocin|(|memory|in
D013311_D008569 CID STZ-_23\NNP|and (r_nmod) impairment_29\NN|stz-|memory (r_dobj) improving_22\VBG|impairment (r_pcomp) in_21\IN|improving (r_prep) replacement_20\NN|the|testosterone|in (r_dobj) attenuated_17\VBD|significantly|replacement (r_conj) impaired_8\VBD|administration|significantly|memory|,|and|attenuated|. (l_dobj) memory_10\NN|the|in
D013311_D008569 CID STZ-_23\NNP|and (r_nmod) impairment_29\NN|stz-|memory
D013311_D008569 CID STZ-_3\NNP|and (r_nmod) impairment_9\NN|stz-|induced|memory|in
D005485_D008569 CID flutamide_2\NN| (r_pobj) of_1\IN|flutamide (r_prep) Administration_0\NN|of|,|letrozole (r_nsubj) impaired_8\VBD|administration|significantly|memory|,|and|attenuated|. (l_dobj) memory_10\NN|the|in
D005485_D008569 CID flutamide_2\NN| (r_pobj) of_1\IN|flutamide (r_prep) Administration_0\NN|of|,|letrozole (r_nsubj) impaired_8\VBD|administration|significantly|memory|,|and|attenuated|. (l_conj) attenuated_17\VBD|significantly|replacement (l_dobj) replacement_20\NN|the|testosterone|in (l_prep) in_21\IN|improving (l_pcomp) improving_22\VBG|impairment (l_dobj) impairment_29\NN|stz-|memory
C067431_D008569 CID letrozole_4\NN|or|tamoxifen (r_conj) Administration_0\NN|of|,|letrozole (r_nsubj) impaired_8\VBD|administration|significantly|memory|,|and|attenuated|. (l_dobj) memory_10\NN|the|in
C067431_D008569 CID letrozole_4\NN|or|tamoxifen (r_conj) Administration_0\NN|of|,|letrozole (r_nsubj) impaired_8\VBD|administration|significantly|memory|,|and|attenuated|. (l_conj) attenuated_17\VBD|significantly|replacement (l_dobj) replacement_20\NN|the|testosterone|in (l_prep) in_21\IN|improving (l_pcomp) improving_22\VBG|impairment (l_dobj) impairment_29\NN|stz-|memory
D013629_D008569 CID tamoxifen_6\NN| (r_conj) letrozole_4\NN|or|tamoxifen (r_conj) Administration_0\NN|of|,|letrozole (r_nsubj) impaired_8\VBD|administration|significantly|memory|,|and|attenuated|. (l_dobj) memory_10\NN|the|in
D013629_D008569 CID tamoxifen_6\NN| (r_conj) letrozole_4\NN|or|tamoxifen (r_conj) Administration_0\NN|of|,|letrozole (r_nsubj) impaired_8\VBD|administration|significantly|memory|,|and|attenuated|. (l_conj) attenuated_17\VBD|significantly|replacement (l_dobj) replacement_20\NN|the|testosterone|in (l_prep) in_21\IN|improving (l_pcomp) improving_22\VBG|impairment (l_dobj) impairment_29\NN|stz-|memory
24665854
D014635_D022124 CID Valproate_0\NNP| (r_npadvmod) induced_2\VBN|valproate|-|encephalopathy|. (l_dobj) encephalopathy_4\NN|hyperammonemic|in (l_det) hyperammonemic_3\JJ|
D014635_D022124 CID Valproate_0\NNP| (r_npadvmod) induced_2\VBN|valproate|- (r_amod) encephalopathy_4\NN|induced|hyperammonemic (l_det) hyperammonemic_3\JJ|
D014635_D022124 CID valproate_12\NN| (r_amod) treatment_13\NN|valproate (r_pobj) of_11\IN|treatment (r_prep) effect_10\NN|an|uncommon|of (r_attr) is_5\VBZ|encephalopathy|effect|. (l_nsubj) encephalopathy_4\NN|induced|hyperammonemic (l_det) hyperammonemic_3\JJ|
D014635_D022124 CID valproate_21\NN|due|and|revealed (l_conj) revealed_26\VBN|consciousness|after (l_dobj) consciousness_28\NN|impaired|with (l_prep) with_29\IN|hyperammonemia (l_pobj) hyperammonemia_30\NN|
D014635_D001927 NONE Valproate_0\NNP| (r_npadvmod) induced_2\VBN|valproate|-|encephalopathy|. (l_dobj) encephalopathy_4\NN|hyperammonemic|in
D014635_D001927 NONE Valproate_0\NNP| (r_npadvmod) induced_2\VBN|valproate|- (r_amod) encephalopathy_4\NN|induced|hyperammonemic
D014635_D001927 NONE valproate_12\NN| (r_amod) treatment_13\NN|valproate (r_pobj) of_11\IN|treatment (r_prep) effect_10\NN|an|uncommon|of (r_attr) is_5\VBZ|encephalopathy|effect|. (l_nsubj) encephalopathy_4\NN|induced|hyperammonemic
D014635_D004827 NONE valproate_21\NN|due|and|revealed (l_prep) due_22\JJ|to (l_prep) to_23\IN|epilepsy (l_pobj) epilepsy_24\NN|
D014635_D003244 CID valproate_21\NN|due|and|revealed (l_conj) revealed_26\VBN|consciousness|after (l_dobj) consciousness_28\NN|impaired|with
14748761
C030852_D009369 NONE VNR_21\VBN| (r_dobj) comparing_20\VBG|vnr|with (l_prep) with_22\IN|agents (l_pobj) agents_25\NNS|other|chemotherapeutic|in (l_prep) in_26\IN|treatment (l_pobj) treatment_28\NN|the|of (l_prep) of_29\IN|malignancies (l_pobj) malignancies_31\NNS|various
C030852_D009369 NONE VNR_4\VBN| (r_dobj) comparing_3\VBG|vnr|with|in (l_prep) in_8\IN|treatment (l_pobj) treatment_10\NN|the|of (l_prep) of_11\IN|cancer (l_pobj) cancer_12\NN|
C030852_D066126 CID VNR_3\VBN| (r_nmod) events_5\NNS|vnr|cardiac (r_pobj) of_2\IN|events (r_prep) risk_1\NN|the|of (r_nsubj) was_6\VBD|risk|similar|and|drugs|. (l_conj) drugs_16\NNS|other|cardiotoxic|anthracyclines|gemcitabine|leader (l_amod) cardiotoxic_15\JJ|
D014751_D066126 NONE vindesine_9\NN|to|(|vds|) (r_xcomp) similar_7\JJ|vindesine (r_acomp) was_6\VBD|risk|similar|and|drugs|. (l_conj) drugs_16\NNS|other|cardiotoxic|anthracyclines|gemcitabine|leader (l_amod) cardiotoxic_15\JJ|
D014751_D066126 NONE VDS_11\NNP| (r_appos) vindesine_9\NN|to|(|vds|) (r_xcomp) similar_7\JJ|vindesine (r_acomp) was_6\VBD|risk|similar|and|drugs|. (l_conj) drugs_16\NNS|other|cardiotoxic|anthracyclines|gemcitabine|leader (l_amod) cardiotoxic_15\JJ|
D005472_D066126 NONE fluorouracil_18\NN|[|, (r_nmod) anthracyclines_20\NNS|fluorouracil|, (r_appos) drugs_16\NNS|other|cardiotoxic|anthracyclines|gemcitabine|leader (l_amod) cardiotoxic_15\JJ|
D018943_D066126 NONE anthracyclines_20\NNS|fluorouracil|, (r_appos) drugs_16\NNS|other|cardiotoxic|anthracyclines|gemcitabine|leader (l_amod) cardiotoxic_15\JJ|
C056507_D066126 NONE gemcitabine_22\NN|gem (r_appos) drugs_16\NNS|other|cardiotoxic|anthracyclines|gemcitabine|leader (l_amod) cardiotoxic_15\JJ|
C056507_D066126 NONE GEM_24\NNP|(|) (r_appos) gemcitabine_22\NN|gem (r_appos) drugs_16\NNS|other|cardiotoxic|anthracyclines|gemcitabine|leader (l_amod) cardiotoxic_15\JJ|
11395263
D000431_D009203 NONE ethanol_5\NN| (r_compound) extract_6\NN|the|ethanol|of (r_pobj) of_3\IN|extract (r_prep) effect_2\NN|the|cardioprotective|of|rhizomes|on (l_prep) on_16\IN|infarction (l_pobj) infarction_21\NN|induced|myocardial|in
D007545_D009203 CID isoproterenol_17\NN| (r_npadvmod) induced_19\VBN|isoproterenol|- (r_amod) infarction_21\NN|induced|myocardial|in
D007545_D009203 CID isoproterenol_9\NN| (r_npadvmod) induced_11\VBN|isoproterenol|- (r_amod) infarction_13\NN|the|induced|myocardial
8603459
D004317_D066126 CID Doxorubicin_0\NNP| (r_npadvmod) induced_2\VBN|doxorubicin|- (r_amod) cardiotoxicity_3\NN|induced|monitored|.
D004317_D066126 CID doxorubicin_11\RB| (r_npadvmod) induced_13\VBN|doxorubicin|- (r_amod) cardiotoxicity_14\NN|induced
D004317_D066126 CID doxorubicin_13\NN| (r_npadvmod) induced_15\VBN|doxorubicin|- (r_amod) cardiotoxicity_16\NN|induced
D004317_D006984 NONE doxorubicin_5\RB| (r_npadvmod) treated_7\VBN|doxorubicin|- (r_amod) animals_8\NNS|treated (r_pobj) of_4\IN|animals (r_prep) hearts_3\NNS|the|of (r_dobj) sacrifice_1\NN|hearts (r_pcomp) After_0\IN|sacrifice (r_prep) enlarged_10\VBN|after|were|and|were (l_conj) were_14\VBD|atria|hypertrophic|. (l_acomp) hypertrophic_15\JJ|
D064730_D064420 NONE ICRF-187_16\NNP| (r_pobj) of_15\IN|icrf-187 (r_prep) protection_14\NN|the|of (r_nsubjpass) determined_18\VBN|exerted|,|protection|was|using|)|. (l_advcl) exerted_3\VBD|as|schedule|toxicity (l_dobj) toxicity_5\NN|more|needed
D064730_D064420 NONE ICRF-187_16\NNP| (r_pobj) of_15\IN|icrf-187 (r_prep) protection_14\NN|the|of (r_nsubjpass) determined_18\VBN|exerted|,|protection|was|using|)|. (l_xcomp) using_19\VBG|schedule (l_dobj) schedule_22\NN|a|dose|with (l_prep) with_23\IN|toxicity (l_pobj) toxicity_26\NN|lower|general|(|doses|doxorubicin
D004317_D064420 NONE doxorubicin_34\NN|given (r_punct) toxicity_26\NN|lower|general|(|doses|doxorubicin (r_pobj) with_23\IN|toxicity (r_prep) schedule_22\NN|a|dose|with (r_dobj) using_19\VBG|schedule (r_xcomp) determined_18\VBN|exerted|,|protection|was|using|)|. (l_advcl) exerted_3\VBD|as|schedule|toxicity (l_dobj) toxicity_5\NN|more|needed
D004317_D064420 NONE doxorubicin_34\NN|given (r_punct) toxicity_26\NN|lower|general|(|doses|doxorubicin
D064730_D066126 NONE ICRF-187_24\NNP| (r_pobj) by_23\IN|icrf-187 (r_agent) provided_22\VBN|by (r_acl) protection_21\NN|the|provided (r_pobj) by_19\IN|protection (r_agent) demonstrated_18\VBN|testing|as|by (l_nsubj) testing_9\NN|the|of (l_prep) of_10\IN|protectors (l_pobj) protectors_11\NNS|against (l_prep) against_12\IN|cardiotoxicity (l_pobj) cardiotoxicity_16\NN|induced
11423811
D004280_D002637 NONE dobutamine_8\NN| (r_compound) stress_9\NN|dobutamine|echocardiography (l_dobj) echocardiography_10\RB|in (l_prep) in_11\IN|evaluation (l_pobj) evaluation_15\NN|the|department|of (l_prep) of_16\IN|pain (l_pobj) pain_21\NN|associated|chest
D004280_D002637 NONE dobutamine_8\NN|in (r_pobj) of_7\IN|dobutamine (r_prep) administration_6\NN|of (r_pobj) regarding_5\VBG|administration (r_prep) concern_4\NN|the|theoretical|regarding (r_pobj) Because_0\IN|of|concern (r_prep) conducted_17\VBD|because|,|we|study|. (l_dobj) study_20\NN|a|pilot|assess (l_relcl) assess_22\VB|to|safety (l_dobj) safety_24\NN|the|of|in (l_prep) in_27\IN|patients (l_pobj) patients_30\NNS|department|with (l_prep) with_31\IN|pain (l_pobj) pain_36\NN|associated|chest
D004280_D002637 NONE dobutamine_7\NN| (r_nsubjpass) administered_9\VBN|when|dobutamine|was|to (l_prep) to_10\IN|patients (l_pobj) patients_11\NNS|with (l_prep) with_12\IN|pain (l_pobj) pain_17\NN|related|chest
D003042_D002637 CID cocaine_17\NN| (r_npadvmod) associated_19\VBN|cocaine|- (r_amod) pain_21\NN|associated|chest
D003042_D002637 CID cocaine_9\NN| (r_compound) use_10\NN|cocaine (r_pobj) of_8\IN|use (r_prep) setting_7\NN|the|of (r_pobj) in_5\IN|setting (r_prep) pain_4\NN|chest|in
D003042_D002637 CID cocaine_13\NN| (r_compound) use_14\NN|cocaine (r_pobj) of_12\IN|use (r_prep) setting_11\NN|the|of (r_pobj) in_9\IN|setting (r_prep) dobutamine_8\NN|in (r_pobj) of_7\IN|dobutamine (r_prep) administration_6\NN|of (r_pobj) regarding_5\VBG|administration (r_prep) concern_4\NN|the|theoretical|regarding (r_pobj) Because_0\IN|of|concern (r_prep) conducted_17\VBD|because|,|we|study|. (l_dobj) study_20\NN|a|pilot|assess (l_relcl) assess_22\VB|to|safety (l_dobj) safety_24\NN|the|of|in (l_prep) in_27\IN|patients (l_pobj) patients_30\NNS|department|with (l_prep) with_31\IN|pain (l_pobj) pain_36\NN|associated|chest
D003042_D002637 CID cocaine_32\NN| (r_npadvmod) associated_34\VBN|cocaine|- (r_amod) pain_36\NN|associated|chest
D003042_D002637 CID cocaine_9\NN| (r_dobj) used_8\VBN|if|they|had|cocaine|within|preceding|and|had (l_advcl) preceding_13\VBG|onset (l_dobj) onset_15\NN|the|of (l_prep) of_16\IN|pain (l_pobj) pain_18\NN|chest
D003042_D002637 CID cocaine_13\NN| (r_npadvmod) related_15\VBN|cocaine|- (r_amod) pain_17\NN|related|chest
D004280_D007511 NONE Dobutamine_0\NNP| (r_nsubj) stress_1\NN|dobutamine|echocardiography (r_nsubj) is_6\VBZ|stress|test|. (l_attr) test_12\NN|a|available|for (l_prep) for_13\IN|evaluating (l_pcomp) evaluating_14\VBG|ischemia (l_dobj) ischemia_16\NN|cardiac
D003042_D064420 NONE cocaine_5\NN| (r_compound) toxicity_6\NN|continuing|cocaine
8659767
D002045_D001145 NONE bupivacaine_1\NN|and|epinephrine (r_pobj) Since_0\IN|bupivacaine (r_prep) potentiate_15\VB|since|dysrhythmias|could|effects|. (l_nsubj) dysrhythmias_7\NNS|may|both|precipitate|,|bupivacaine
D002045_D001145 NONE bupivacaine_10\NN|circulating|during (r_appos) dysrhythmias_7\NNS|may|both|precipitate|,|bupivacaine
D002045_D001145 NONE Bupivacaine_0\NNP| (r_nsubj) antagonizes_1\VBZ|bupivacaine|dysrhythmogenicity|. (l_dobj) dysrhythmogenicity_3\NN|epinephrine|in (l_prep) in_4\IN|dogs|and|in (l_conj) in_11\IN|dogs (l_pobj) dogs_13\NNS|anesthetized|with (l_prep) with_14\IN|dysrhythmias (l_pobj) dysrhythmias_17\NNS|spontaneous|postinfarct
D004837_D001145 NONE epinephrine_3\NN| (r_conj) bupivacaine_1\NN|and|epinephrine (r_pobj) Since_0\IN|bupivacaine (r_prep) potentiate_15\VB|since|dysrhythmias|could|effects|. (l_nsubj) dysrhythmias_7\NNS|may|both|precipitate|,|bupivacaine
D004837_D001145 NONE epinephrine_19\NN| (r_pobj) of_18\IN|epinephrine (r_prep) effects_17\NNS|dysrhythmogenic|of (r_dobj) potentiate_15\VB|since|dysrhythmias|could|effects|. (l_nsubj) dysrhythmias_7\NNS|may|both|precipitate|,|bupivacaine
D004837_D001145 NONE epinephrine_2\NN| (r_amod) dysrhythmogenicity_3\NN|epinephrine|in (l_prep) in_4\IN|dogs|and|in (l_conj) in_11\IN|dogs (l_pobj) dogs_13\NNS|anesthetized|with (l_prep) with_14\IN|dysrhythmias (l_pobj) dysrhythmias_17\NNS|spontaneous|postinfarct
D002045_D009203 NONE bupivacaine_4\NN| (r_nsubj) alters_5\VBZ|whether|bupivacaine|dysrhythmogenicity|in (l_prep) in_13\IN|dogs|and|in (l_conj) in_19\IN|dogs (l_pobj) dogs_21\NNS|anesthetized|with (l_prep) with_22\IN|infarction (l_pobj) infarction_24\NN|myocardial
D004837_D009203 NONE epinephrine_12\NN| (r_pobj) of_11\IN|epinephrine (r_prep) administration_10\NN|subsequent|of (r_pobj) of_8\IN|administration (r_prep) dysrhythmogenicity_7\NN|the|of (r_dobj) alters_5\VBZ|whether|bupivacaine|dysrhythmogenicity|in (l_prep) in_13\IN|dogs|and|in (l_conj) in_19\IN|dogs (l_pobj) dogs_21\NNS|anesthetized|with (l_prep) with_22\IN|infarction (l_pobj) infarction_24\NN|myocardial
D004837_D009203 NONE epinephrine_16\NN|micrograms.kg-1.min-1 (r_dobj) received_13\VBD|after|,|dogs|epinephrine|appeared|. (l_prep) after_2\IN|day|infarction (l_pobj) infarction_5\NN|experimental|myocardial
D006221_D009203 NONE halothane_9\NN| (r_npadvmod) anesthetized_11\VBN|halothane|- (r_amod) dogs_12\NNS|six|additional|anesthetized (r_nsubj) received_13\VBD|after|,|dogs|epinephrine|appeared|. (l_prep) after_2\IN|day|infarction (l_pobj) infarction_5\NN|experimental|myocardial
D006221_D017180 NONE halothane_9\NN| (r_npadvmod) anesthetized_11\VBN|halothane|- (r_amod) dogs_12\NNS|six|additional|anesthetized (r_nsubj) received_13\VBD|after|,|dogs|epinephrine|appeared|. (l_advcl) appeared_19\VBD|until|vt (l_nsubj) VT_18\NNP|
D004837_D017180 CID epinephrine_16\NN|micrograms.kg-1.min-1 (r_dobj) received_13\VBD|after|,|dogs|epinephrine|appeared|. (l_advcl) appeared_19\VBD|until|vt (l_nsubj) VT_18\NNP|
D004837_D017180 CID epinephrine_2\NN| (r_amod) dysrhythmogenicity_3\NN|epinephrine|in (l_prep) in_4\IN|dogs|and|in (l_pobj) dogs_6\NNS|conscious|susceptible (l_amod) susceptible_7\JJ|to (l_prep) to_8\IN|vt (l_pobj) VT_9\NNP|
D002045_D017180 NONE Bupivacaine_0\NNP| (r_nsubj) antagonizes_1\VBZ|bupivacaine|dysrhythmogenicity|. (l_dobj) dysrhythmogenicity_3\NN|epinephrine|in (l_prep) in_4\IN|dogs|and|in (l_pobj) dogs_6\NNS|conscious|susceptible (l_amod) susceptible_7\JJ|to (l_prep) to_8\IN|vt (l_pobj) VT_9\NNP|
15859361
C105934_D003875 NONE celecoxib_2\NN| (r_pobj) of_1\IN|celecoxib (r_prep) Safety_0\NN|of|in|. (l_prep) in_3\IN|patients (l_pobj) patients_4\NNS|with (l_prep) with_5\IN|reactions (l_pobj) reactions_8\NNS|adverse|skin|to|paracetamol
C105934_D003875 NONE CE_6\NNP| (r_pobj) of_5\IN|ce (r_prep) tolerability_4\NN|the|of (r_dobj) evaluated_2\VBD|:|we|tolerability|in|. (l_prep) in_7\IN|group (l_pobj) group_9\NN|a|of (l_prep) of_10\IN|patients (l_pobj) patients_11\NNS|with (l_prep) with_12\IN|history (l_pobj) history_14\NN|documented|of (l_prep) of_15\IN|reactions (l_pobj) reactions_18\NNS|adverse|cutaneous|to|associated
D000082_D003875 CID acetaminophen_10\RB| (r_pobj) to_9\IN|acetaminophen (r_prep) reactions_8\NNS|adverse|skin|to|paracetamol
D000082_D003875 CID paracetamol_12\NNP|(|)|and|nimesulide (r_appos) reactions_8\NNS|adverse|skin|to|paracetamol
D000082_D003875 CID P_20\NN|and|n (r_pobj) to_19\IN|p (r_prep) reactions_18\NNS|adverse|cutaneous|to|associated
D000082_D003875 CID P_3\NN|and|induced (r_nmod) reactions_9\NNS|p|skin
C012655_D003875 CID nimesulide_15\NN|associated|or|with (r_conj) paracetamol_12\NNP|(|)|and|nimesulide (r_appos) reactions_8\NNS|adverse|skin|to|paracetamol
C012655_D003875 CID N_22\NNP| (r_conj) P_20\NN|and|n (r_pobj) to_19\IN|p (r_prep) reactions_18\NNS|adverse|cutaneous|to|associated
C012655_D003875 CID N_5\NN| (r_npadvmod) induced_7\VBN|n|- (r_conj) P_3\NN|and|induced (r_nmod) reactions_9\NNS|p|skin
D000082_D004342 NONE P_7\NN|and|n (r_pobj) to_6\IN|p (r_prep) hypersensitivity_5\NN|to|with
D000082_D004342 NONE P_10\NN|and|n (r_nmod) patients_17\NNS|9|p|nsaids|intolerant (r_pobj) among_8\IN|patients (r_prep) documented_7\VBN|reaction|was|among|. (l_nsubjpass) reaction_3\NN|one|hypersensitivity|to (l_compound) hypersensitivity_2\NN|
C012655_D004342 NONE N_9\NN| (r_conj) P_7\NN|and|n (r_pobj) to_6\IN|p (r_prep) hypersensitivity_5\NN|to|with
C012655_D004342 NONE N_12\NN| (r_conj) P_10\NN|and|n (r_nmod) patients_17\NNS|9|p|nsaids|intolerant (r_pobj) among_8\IN|patients (r_prep) documented_7\VBN|reaction|was|among|. (l_nsubjpass) reaction_3\NN|one|hypersensitivity|to (l_compound) hypersensitivity_2\NN|
C105934_D004342 NONE CE_5\NNP| (r_pobj) to_4\IN|ce (r_prep) reaction_3\NN|one|hypersensitivity|to (l_compound) hypersensitivity_2\NN|
15991002
D009538_D001008 NONE nicotine_7\NN| (r_pobj) of_6\IN|nicotine (r_prep) effects_5\NNS|the|of|on (l_prep) on_8\IN|anxiety (l_pobj) anxiety_9\NN|induced
D009538_D001008 NONE Nicotine_0\NNP|pretreatment (r_nsubj) blocked_6\VBD|nicotine|caffeine-|but|anxiety|. (l_conj) anxiety_14\NN|induced
D009538_D001008 NONE nicotine_8\NN| (r_pobj) of_7\IN|nicotine (r_prep) effect_6\NN|the|antagonistic|of|on (l_prep) on_9\IN|anxiety (l_pobj) anxiety_13\NN|induced
D002110_D001008 CID caffeine_12\NN|and|drug (r_pobj) by_11\IN|caffeine (r_agent) induced_10\VBN|by (r_acl) anxiety_9\NN|induced
D002110_D001008 CID caffeine-_8\NN|the (r_dobj) blocked_6\VBD|nicotine|caffeine-|but|anxiety|. (l_conj) anxiety_14\NN|induced
D002110_D001008 CID caffeine_10\NN| (r_npadvmod) induced_12\VBN|caffeine|- (r_amod) anxiety_13\NN|induced
D002110_D001008 CID caffeine_17\NN| (r_pobj) to_16\IN|caffeine (r_prep) specific_15\JJ|to (r_acomp) is_14\VBZ|that|effect|specific|,|of (l_nsubj) effect_6\NN|the|antagonistic|of|on (l_prep) on_9\IN|anxiety (l_pobj) anxiety_13\NN|induced
D010433_D001008 CID pentylenetetrazole_18\NN| (r_appos) drug_16\NN|another|anxiogenic|,|pentylenetetrazole|,|in (r_conj) caffeine_12\NN|and|drug (r_pobj) by_11\IN|caffeine (r_agent) induced_10\VBN|by (r_acl) anxiety_9\NN|induced
D010433_D001008 CID pentylenetetrazole_11\NN| (r_advmod) induced_13\VBN|not|pentylenetetrazole|- (r_amod) anxiety_14\NN|induced
19139825
D019772_D005909 NONE Topotecan_0\JJ|in|. (l_prep) in_1\IN|combination (l_pobj) combination_2\NN|with (l_prep) with_3\IN|radiotherapy (l_pobj) radiotherapy_4\NN|in (l_prep) in_5\IN|glioblastoma (l_pobj) glioblastoma_7\NN|unresectable|:|study
D019772_D005909 NONE topotecan_15\JJ|m(2)/day|in (l_prep) in_34\IN|adults (l_pobj) adults_36\NNS|50|with (l_prep) with_37\IN|gbm (l_pobj) GBM_42\NNP|proven
D019772_D005910 NONE Topotecan_0\NNP| (r_nsubj) is_1\VBZ|topotecan|option|exhibits|. (l_advcl) exhibits_7\VBZ|as|it|inhibition (l_dobj) inhibition_9\NN|growth|of (l_prep) of_10\IN|glioma (l_pobj) glioma_12\NN|human|as|penetration
23433219
D008694_D011605 CID methamphetamine_6\NN| (r_compound) psychosis_7\NN|methamphetamine|in
D008694_D011605 CID methamphetamine_9\NN| (r_npadvmod) dependent_11\JJ|methamphetamine|- (r_amod) patients_12\NNS|dependent|in (r_pobj) in_8\IN|patients (r_prep) psychosis_7\NN|methamphetamine|in
D008694_D011605 CID methamphetamine_14\NN| (r_npadvmod) induced_16\VBN|methamphetamine|- (r_amod) psychosis_17\NN|current|induced
D008694_D011605 CID methamphetamine_21\NN| (r_compound) dependence_22\NN|methamphetamine (r_pobj) with_20\IN|dependence (r_prep) patients_19\NNS|with (r_pobj) in_18\IN|patients (r_prep) lifetime_11\NN|and|psychosis|in (l_conj) psychosis_17\NN|current|induced
D008694_D011605 CID methamphetamine_8\NN| (r_punct) -_9\HYPH|methamphetamine (r_punct) induced_10\VBN|morbidity|- (r_amod) psychosis_11\NN|induced
D008694_D011605 CID methamphetamine_5\NN|based (r_pobj) of_4\IN|methamphetamine (r_prep) diagnosis_3\NN|the|of (r_pobj) with_1\IN|diagnosis (r_prep) Patients_0\NNS|with (r_nsubjpass) interviewed_12\VBN|patients|were|using (l_advcl) using_13\VBG|interview|for (l_prep) for_22\IN|psychosis (l_pobj) psychosis_26\NN|induced|and|axis
D008694_D011605 CID methamphetamine_23\NN| (r_npadvmod) induced_25\VBN|methamphetamine|- (r_amod) psychosis_26\NN|induced|and|axis
D008694_D011605 CID methamphetamine_39\NN| (r_compound) uses_40\NNS|heavy|methamphetamine (r_conj) disorder_28\NN|antisocial|personality|(|or=12.619|and|uses (r_appos) disorder_5\NN|morbid|major|depressive|(|or=7.18|,|disorder|,|disorder (r_nsubjpass) associated_43\VBN|disorder|were|significantly|with|adjusted|. (l_prep) with_44\IN|psychosis (l_pobj) psychosis_49\NN|lifetime|induced
D008694_D011605 CID methamphetamine_46\NN| (r_npadvmod) induced_48\VBN|methamphetamine|- (r_amod) psychosis_49\NN|lifetime|induced
D008694_D011605 CID methamphetamine_10\NN| (r_compound) dependence_11\NN|methamphetamine (r_pobj) with_9\IN|dependence (r_prep) patients_8\NNS|with (r_pobj) in_7\IN|patients (r_prep) risk_4\NN|a|high|of|in (l_prep) of_5\IN|psychosis (l_pobj) psychosis_6\NN|
D008694_D011605 CID methamphetamine_7\NN| (r_compound) dependence_8\NN|methamphetamine (r_pobj) of_6\IN|dependence (r_prep) cases_5\NNS|all|of (r_nsubjpass) screened_11\VBN|that|cases|should|be|for (l_prep) for_12\IN|symptoms (l_pobj) symptoms_14\NNS|psychotic
D008694_D003866 NONE methamphetamine_39\NN| (r_compound) uses_40\NNS|heavy|methamphetamine (r_conj) disorder_28\NN|antisocial|personality|(|or=12.619|and|uses (r_appos) disorder_5\NN|morbid|major|depressive|(|or=7.18|,|disorder|,|disorder
D008694_D003866 NONE methamphetamine_46\NN| (r_npadvmod) induced_48\VBN|methamphetamine|- (r_amod) psychosis_49\NN|lifetime|induced (r_pobj) with_44\IN|psychosis (r_prep) associated_43\VBN|disorder|were|significantly|with|adjusted|. (l_nsubjpass) disorder_5\NN|morbid|major|depressive|(|or=7.18|,|disorder|,|disorder
D008694_D001714 CID methamphetamine_39\NN| (r_compound) uses_40\NNS|heavy|methamphetamine (r_conj) disorder_28\NN|antisocial|personality|(|or=12.619|and|uses (r_appos) disorder_5\NN|morbid|major|depressive|(|or=7.18|,|disorder|,|disorder (l_appos) disorder_16\NN|bipolar|ci=5.194
D008694_D001714 CID methamphetamine_46\NN| (r_npadvmod) induced_48\VBN|methamphetamine|- (r_amod) psychosis_49\NN|lifetime|induced (r_pobj) with_44\IN|psychosis (r_prep) associated_43\VBN|disorder|were|significantly|with|adjusted|. (l_nsubjpass) disorder_5\NN|morbid|major|depressive|(|or=7.18|,|disorder|,|disorder (l_appos) disorder_16\NN|bipolar|ci=5.194
D008694_D000987 CID methamphetamine_39\NN| (r_compound) uses_40\NNS|heavy|methamphetamine (r_conj) disorder_28\NN|antisocial|personality|(|or=12.619|and|uses
D008694_D000987 CID methamphetamine_46\NN| (r_npadvmod) induced_48\VBN|methamphetamine|- (r_amod) psychosis_49\NN|lifetime|induced (r_pobj) with_44\IN|psychosis (r_prep) associated_43\VBN|disorder|were|significantly|with|adjusted|. (l_nsubjpass) disorder_5\NN|morbid|major|depressive|(|or=7.18|,|disorder|,|disorder (l_appos) disorder_28\NN|antisocial|personality|(|or=12.619|and|uses
D008694_D000987 CID methamphetamine_15\NN| (r_compound) use_16\NN|heavy|methamphetamine (r_conj) personality_11\NN|antisocial|,|and|use
D008694_D019964 NONE methamphetamine_15\NN| (r_compound) use_16\NN|heavy|methamphetamine (r_conj) personality_11\NN|antisocial|,|and|use (r_conj) disorder_8\NN|morbid|affective|,|personality
15265979
D000638_D056486 CID Amiodarone_0\NNP|,|agent|, (r_nsubjpass) reported_12\VBN|amiodarone|has|been|cause|. (l_xcomp) cause_14\VB|to|hepatotoxicity|in (l_dobj) hepatotoxicity_15\NN|
D000638_D056486 CID amiodarone_12\NN| (r_pobj) of_11\IN|amiodarone (r_prep) effects_10\NNS|the|hepatotoxic|of (l_amod) hepatotoxic_9\JJ|
D000638_D056486 CID amiodarone_12\NN| (r_pobj) of_11\IN|amiodarone (r_prep) effects_10\NNS|the|hepatotoxic|of (r_pobj) regarding_7\VBG|effects (r_prep) information_6\NN|important|new|mechanistic|regarding (r_dobj) provide_2\VBP|results|information|and|indicate|. (l_conj) indicate_14\VBP|protects (l_ccomp) protects_17\VBZ|that|pparalpha|against (l_prep) against_18\IN|hepatotoxicity (l_pobj) hepatotoxicity_22\NN|induced
D000638_D056486 CID amiodarone_19\NN| (r_npadvmod) induced_21\VBN|amiodarone|- (r_amod) hepatotoxicity_22\NN|induced (r_pobj) against_18\IN|hepatotoxicity (r_prep) protects_17\VBZ|that|pparalpha|against (r_ccomp) indicate_14\VBP|protects (r_conj) provide_2\VBP|results|information|and|indicate|. (l_dobj) information_6\NN|important|new|mechanistic|regarding (l_prep) regarding_7\VBG|effects (l_pobj) effects_10\NNS|the|hepatotoxic|of (l_amod) hepatotoxic_9\JJ|
D000638_D056486 CID amiodarone_19\NN| (r_npadvmod) induced_21\VBN|amiodarone|- (r_amod) hepatotoxicity_22\NN|induced
D000638_D006529 CID Amiodarone_0\NN| (r_nsubj) induced_1\VBD|amiodarone|accumulation|,|and|decrease|. (l_dobj) accumulation_7\NN|hepatomegaly|,|hepatocyte|microvesicular|lipid (l_amod) hepatomegaly_2\NN|
D014280_D006529 NONE triglycerides_15\NNS|serum|and|glucose (r_pobj) in_13\IN|triglycerides (r_prep) decrease_12\NN|a|significant|in (r_conj) induced_1\VBD|amiodarone|accumulation|,|and|decrease|. (l_dobj) accumulation_7\NN|hepatomegaly|,|hepatocyte|microvesicular|lipid (l_amod) hepatomegaly_2\NN|
D005947_D006529 NONE glucose_17\NN| (r_conj) triglycerides_15\NNS|serum|and|glucose (r_pobj) in_13\IN|triglycerides (r_prep) decrease_12\NN|a|significant|in (r_conj) induced_1\VBD|amiodarone|accumulation|,|and|decrease|. (l_dobj) accumulation_7\NN|hepatomegaly|,|hepatocyte|microvesicular|lipid (l_amod) hepatomegaly_2\NN|
D000638_D015431 NONE amiodarone_12\NN| (r_pobj) with_11\IN|amiodarone (r_prep) treatment_7\NN|of|with (r_appos) mice_5\NNS|type|,|treatment (r_pobj) to_1\IN|mice (r_prep) Compared_0\VBN|to (r_prep) resulted_13\VBD|compared|in|. (l_prep) in_14\IN|rate (l_pobj) rate_17\NN|an|increased|and|extent (l_conj) extent_19\NN|of (l_prep) of_20\IN|loss (l_pobj) loss_24\NN|total|body|weight
D000638_D006528 NONE amiodarone_3\NN| (r_pobj) of_2\IN|amiodarone (r_prep) inability_1\NN|the|of|activate (r_nsubj) expressed_13\VBN|inability|transiently|in (l_prep) in_14\IN|cells (l_pobj) cells_18\NNS|human|hepg2|hepatoma (l_compound) hepatoma_17\NN|
D000638_D006528 NONE amiodarone_24\NN|on (r_pobj) of_23\IN|amiodarone (r_prep) effects_22\NNS|the|of (r_nsubj) were_31\VBD|that|effects|indirect (r_ccomp) indicates_19\VBZ|expressed|were|. (l_csubj) expressed_13\VBN|inability|transiently|in (l_prep) in_14\IN|cells (l_pobj) cells_18\NNS|human|hepg2|hepatoma (l_compound) hepatoma_17\NN|
24554916
D010758_D002779 CID phosphorus_4\NN| (r_compound) poisoning_5\NN|yellow|phosphorus (r_pobj) of_2\IN|poisoning (r_prep) presentation_1\NN|cholestatic|of|. (l_amod) Cholestatic_0\JJ|
D010758_D002779 CID phosphorus_6\NN| (r_compound) poisoning_7\NN|yellow|phosphorus|presented (l_relcl) presented_12\VBN|in|patient|with|highlighting (l_prep) with_13\IN|features (l_pobj) features_16\NNS|florid|clinical|of (l_prep) of_17\IN|cholestasis (l_pobj) cholestasis_18\NN|
D010758_D002779 CID phosphorus_6\NN| (r_compound) poisoning_7\NN|yellow|phosphorus|presented (l_relcl) presented_12\VBN|in|patient|with|highlighting (l_advcl) highlighting_19\VBG|fact (l_dobj) fact_21\NN|the|be (l_acl) be_26\VB|that|cholestasis|can|rarely|feature (l_nsubj) cholestasis_23\NN|
D010758_D002779 CID phosphorus_32\NN|yellow (r_compound) hepatotoxicity_33\NN|phosphorus (r_pobj) of_30\IN|hepatotoxicity (r_prep) feature_29\NN|a|presenting|of (r_attr) be_26\VB|that|cholestasis|can|rarely|feature (r_acl) fact_21\NN|the|be (r_dobj) highlighting_19\VBG|fact (r_advcl) presented_12\VBN|in|patient|with|highlighting (l_prep) with_13\IN|features (l_pobj) features_16\NNS|florid|clinical|of (l_prep) of_17\IN|cholestasis (l_pobj) cholestasis_18\NN|
D010758_D002779 CID phosphorus_32\NN|yellow (r_compound) hepatotoxicity_33\NN|phosphorus (r_pobj) of_30\IN|hepatotoxicity (r_prep) feature_29\NN|a|presenting|of (r_attr) be_26\VB|that|cholestasis|can|rarely|feature (l_nsubj) cholestasis_23\NN|
D010758_D011041 NONE phosphorus_4\NN| (r_compound) poisoning_5\NN|yellow|phosphorus
D010758_D011041 NONE phosphorus_3\NN|yellow (r_pobj) with_1\IN|phosphorus (r_prep) Poisoning_0\VBG|with
D010758_D011041 NONE phosphorus_6\NN| (r_compound) poisoning_7\NN|yellow|phosphorus|presented
D010758_D011041 NONE phosphorus_32\NN|yellow (r_compound) hepatotoxicity_33\NN|phosphorus (r_pobj) of_30\IN|hepatotoxicity (r_prep) feature_29\NN|a|presenting|of (r_attr) be_26\VB|that|cholestasis|can|rarely|feature (r_acl) fact_21\NN|the|be (r_dobj) highlighting_19\VBG|fact (r_advcl) presented_12\VBN|in|patient|with|highlighting (r_relcl) poisoning_7\NN|yellow|phosphorus|presented
D010758_D056486 NONE phosphorus_1\NN|yellow|,|component|, (r_nsubj) is_12\VBZ|phosphorus|known|. (l_acomp) known_14\JJ|well|cause (l_xcomp) cause_16\VB|to|hepatotoxicity (l_dobj) hepatotoxicity_17\NN|
D010758_D056486 NONE phosphorus_6\NN| (r_compound) poisoning_7\NN|yellow|phosphorus|presented (l_relcl) presented_12\VBN|in|patient|with|highlighting (l_advcl) highlighting_19\VBG|fact (l_dobj) fact_21\NN|the|be (l_acl) be_26\VB|that|cholestasis|can|rarely|feature (l_attr) feature_29\NN|a|presenting|of (l_prep) of_30\IN|hepatotoxicity (l_pobj) hepatotoxicity_33\NN|phosphorus
D010758_D056486 NONE phosphorus_32\NN|yellow (r_compound) hepatotoxicity_33\NN|phosphorus
D010758_D006505 CID phosphorus_3\NN|yellow (r_pobj) with_1\IN|phosphorus (r_prep) Poisoning_0\VBG|with (r_nsubj) manifests_5\VBZ|poisoning|classically|with|. (l_prep) with_6\IN|hepatitis (l_pobj) hepatitis_8\NN|acute|leading
D010758_D017114 CID phosphorus_3\NN|yellow (r_pobj) with_1\IN|phosphorus (r_prep) Poisoning_0\VBG|with (r_nsubj) manifests_5\VBZ|poisoning|classically|with|. (l_prep) with_6\IN|hepatitis (l_pobj) hepatitis_8\NN|acute|leading (l_acl) leading_9\VBG|to (l_prep) to_10\IN|failure (l_pobj) failure_13\NN|acute|liver|need
18025637
D005473_D012170 CID fluoxetine_5\NN| (r_conj) occlusion_3\NN|branch|vein|and|fluoxetine|.
D005473_D012170 CID fluoxetine_9\NN| (r_advmod) induced_11\VBN|fluoxetine|- (r_amod) hypertension_13\NN|induced|secondary (r_pobj) with_8\IN|hypertension (r_prep) associated_7\VBN|with (r_acl) occlusion_6\NN|branch|vein|associated
D005473_D006973 CID fluoxetine_9\NN| (r_advmod) induced_11\VBN|fluoxetine|- (r_amod) hypertension_13\NN|induced|secondary
D012701_D006973 NONE serotonin_6\NN| (r_compound) therapy_9\NN|selective|serotonin|reuptake|inhibitor (r_pobj) of_4\IN|therapy (r_prep) complication_3\NN|an|infrequent|of (r_pobj) Although_0\IN|complication (r_prep) is_12\VBZ|although|,|it|important|are|. (l_ccomp) are_16\VBP|that|ophthalmologists|aware (l_acomp) aware_17\JJ|cause (l_ccomp) cause_22\VB|that|agents|can|hypertension|prescribed (l_dobj) hypertension_23\NN|
9197951
D003042_D001714 NONE cocaine_4\NN| (r_npadvmod) dependent_6\JJ|cocaine|- (r_amod) man_7\NN|a|old|dependent|was (r_nsubj) became_27\VBD|man|manic|during|. (l_acomp) manic_28\JJ|
D004053_D001714 CID diethylpropion_23\NN|the|stimulant|medication|dep (r_pobj) of_19\IN|diethylpropion (r_prep) efficacy_18\NN|the|anticraving|of (r_dobj) evaluating_15\VBG|efficacy (r_acl) study_14\NN|a|evaluating (r_pobj) in_12\IN|study (r_prep) subject_11\NN|a|in (r_attr) was_9\VBD|who|subject (r_relcl) man_7\NN|a|old|dependent|was (r_nsubj) became_27\VBD|man|manic|during|. (l_acomp) manic_28\JJ|
D004053_D001714 CID DEP_25\NNP|(|) (r_appos) diethylpropion_23\NN|the|stimulant|medication|dep (r_pobj) of_19\IN|diethylpropion (r_prep) efficacy_18\NN|the|anticraving|of (r_dobj) evaluating_15\VBG|efficacy (r_acl) study_14\NN|a|evaluating (r_pobj) in_12\IN|study (r_prep) subject_11\NN|a|in (r_attr) was_9\VBD|who|subject (r_relcl) man_7\NN|a|old|dependent|was (r_nsubj) became_27\VBD|man|manic|during|. (l_acomp) manic_28\JJ|
D004053_D001714 CID DEP_4\NNP|,|changes (r_pobj) on_3\IN|while|dep (r_prep) changes_1\NNS|pupillometric|on (r_nsubj) were_16\VBD|changes|,|different|. (l_acomp) different_18\JJ|dramatically|than (l_prep) than_19\IN|those (l_pobj) those_20\DT|observed (l_acl) observed_21\VBN|in (l_prep) in_22\IN|subjects (l_pobj) subjects_27\NNS|the|eight|other|study|become (l_relcl) become_31\VB|who|did|not|manic (l_acomp) manic_32\JJ|
D004053_D011681 NONE DEP_4\NNP|,|changes (l_appos) changes_7\NNS|especially|in (l_prep) in_8\IN|power (l_pobj) power_11\NN|the|total|of (l_prep) of_12\IN|oscillation (l_pobj) oscillation_14\NN|pupillary
6585590
D004317_D066126 NONE doxorubicin_8\NN| (r_pobj) of_7\IN|doxorubicin (r_prep) nephrotoxicity_6\NN|of (r_conj) cardiotoxicity_3\NN|,|and|nephrotoxicity|in
D004317_D066126 NONE doxorubicin_9\NN| (r_pobj) by_8\IN|doxorubicin (r_agent) induced_7\VBN|by (r_acl) nephrotoxicity_6\NN|induced (r_conj) cardiotoxicity_3\NN|,|and|nephrotoxicity
D004317_D066126 NONE doxorubicin_17\NN| (r_nmod) kg_19\NNS|mg|doxorubicin|/ (r_pobj) of_14\IN|kg (r_prep) dose_13\NN|a|of (r_pobj) at_11\IN|dose (r_prep) observed_10\VBN|scored|was|only|at|. (l_ccomp) scored_4\VBD|evidence|as (l_nsubj) evidence_1\NN|histologic|of (l_prep) of_2\IN|cardiotoxicity (l_pobj) cardiotoxicity_3\NN|
D004317_D007674 NONE doxorubicin_8\NN| (r_pobj) of_7\IN|doxorubicin (r_prep) nephrotoxicity_6\NN|of
D004317_D007674 NONE doxorubicin_9\NN| (r_pobj) by_8\IN|doxorubicin (r_agent) induced_7\VBN|by (r_acl) nephrotoxicity_6\NN|induced
D004317_D007674 NONE doxorubicin_14\NN| (r_nmod) kg_16\NNS|mg|doxorubicin|/ (r_pobj) of_11\IN|kg (r_prep) dose_10\NN|a|of|,|resulted (r_pobj) above_8\IN|dose (r_prep) seen_7\VBN|evidence|was|above|. (l_nsubjpass) evidence_2\NN|light|microscopic|of (l_prep) of_3\IN|damage (l_pobj) damage_5\NN|renal
D004317_-1 NONE doxorubicin_8\NN| (r_pobj) of_7\IN|doxorubicin (r_prep) nephrotoxicity_6\NN|of (r_conj) cardiotoxicity_3\NN|,|and|nephrotoxicity|in (l_prep) in_9\IN|rat (l_pobj) rat_21\NN|the|igm|solid|bearing|wsl (l_amod) bearing_15\VBG|immunocytoma|- (l_compound) immunocytoma_13\NN|
D004317_-1 NONE doxorubicin_9\NN| (r_pobj) by_8\IN|doxorubicin (r_agent) induced_7\VBN|by (r_acl) nephrotoxicity_6\NN|induced (r_conj) cardiotoxicity_3\NN|,|and|nephrotoxicity (r_conj) activity_1\NN|antitumor|,|cardiotoxicity (r_nsubjpass) studied_11\VBN|activity|were|in|bearing|. (l_advcl) bearing_21\VBG|each|immunocytoma (l_dobj) immunocytoma_26\NN|a|igm
D004317_D009369 NONE doxorubicin_18\NN| (r_pobj) of_17\IN|doxorubicin (r_prep) injections_16\NNS|iv|of (r_pobj) with_14\IN|injections (r_prep) treated_13\VBN|animals|were|with|on|,|followed|body|)|. (l_nsubjpass) Animals_0\NNS|with|,|+/-|) (l_prep) with_1\IN|tumor (l_pobj) tumor_3\NN|a|diameter
D004317_D009369 NONE doxorubicin_7\NN| (r_nmod) kg_9\NNS|mg|doxorubicin|/ (r_pobj) with_4\IN|kg (r_prep) observed_3\VBN|regression|was|with|. (l_nsubjpass) regression_1\NN|tumor (l_compound) Tumor_0\NN|
D004317_D009369 NONE doxorubicin_10\NN| (r_nmod) kg_12\NNS|mg|doxorubicin|/ (r_pobj) with_7\IN|kg (r_prep) induced_6\VBN|disappearance|was|with|. (l_nsubjpass) disappearance_1\NN|complete|of (l_prep) of_2\IN|tumor (l_pobj) tumor_4\NN|the
D004317_D000419 CID doxorubicin_14\NN| (r_nmod) kg_16\NNS|mg|doxorubicin|/ (r_pobj) of_11\IN|kg (r_prep) dose_10\NN|a|of|,|resulted (l_relcl) resulted_19\VBD|which|in (l_prep) in_20\IN|albuminuria (l_pobj) albuminuria_21\NN|and|levels
1289188
D003676_D058186 NONE desferrioxamine_6\NN| (r_compound) therapy_7\NN|intravenous|desferrioxamine (r_pobj) during_4\IN|therapy (r_prep) occurring_3\VBG|during (r_acl) failure_2\NN|acute|renal|occurring|:|recovery|.
D003676_D058186 NONE desferrioxamine_24\NN| (r_pobj) by_23\IN|desferrioxamine (r_agent) caused_22\VBN|by (r_acl) failure_21\NN|progressive|acute|renal|caused
D003676_D013789 NONE desferrioxamine_11\NN|home|intravenous|treatment (r_dobj) undergoing_8\VBG|patient|was|desferrioxamine|because|. (l_nsubj) patient_1\NN|a|with (l_prep) with_2\IN|thalassemia (l_pobj) thalassemia_6\NN|dependent
D003676_D013789 NONE DFX_13\NNP| (r_nmod) treatment_15\NN|(|dfx|)|by (r_appos) desferrioxamine_11\NN|home|intravenous|treatment (r_dobj) undergoing_8\VBG|patient|was|desferrioxamine|because|. (l_nsubj) patient_1\NN|a|with (l_prep) with_2\IN|thalassemia (l_pobj) thalassemia_6\NN|dependent
16309808
D004294_D012148 NONE domperidone_1\NN| (r_nsubj) potentiate_2\VB|does|domperidone|syndrome|? (l_dobj) syndrome_8\NN|associated|legs
D004294_D012148 NONE domperidone_11\NN|,|antagonist (r_nsubj) induce_22\VB|whether|domperidone|,|can|also|or|aggravate (l_conj) aggravate_24\VBP|symptoms (l_dobj) symptoms_25\NNS|of (l_prep) of_26\IN|rls (l_pobj) RLS_27\NNP|
D004294_D012148 NONE domperidone_21\NN| (r_compound) therapy_22\NN|his|domperidone (r_pobj) to_19\IN|therapy (r_prep) added_18\VBN|had|been|to (r_ccomp) report_2\VBP|authors|here|comorbid|added|. (l_dobj) comorbid_7\JJ|a|depressed|patient|with (l_prep) with_8\IN|dyspepsia (l_pobj) dyspepsia_10\NN|postprandial|developed (l_relcl) developed_12\VBD|who|rls|after (l_dobj) RLS_13\NNP|
D004294_D012148 NONE domperione_24\NN|on (r_pobj) of_23\IN|domperione (r_prep) effect_22\NN|a|potentiating|of (r_dobj) support_19\VB|relationship|did|not|effect|. (l_nsubj) relationship_3\NN|such|a|temporal|between (l_prep) between_4\IN|use (l_pobj) use_6\NN|the|of|and|symptoms (l_conj) symptoms_11\NNS|the|of|in (l_prep) of_12\IN|rls (l_pobj) RLS_13\NNP|
D004294_D012148 NONE domperione_24\NN|on (l_prep) on_25\IN|rls (l_pobj) RLS_29\NNP|associated
C035133_D012148 CID mirtazapine_3\RB| (r_advmod) associated_5\VBN|mirtazapine|- (r_amod) syndrome_8\NN|associated|legs
C035133_D012148 CID Mirtazapine_0\NNP|,|antidepressant|, (r_nsubjpass) associated_15\VBN|mirtazapine|has|been|with|in|. (l_prep) with_16\IN|rls (l_pobj) RLS_17\NNP|
C035133_D012148 CID mirtazapine_15\RB| (r_pobj) after_14\IN|mirtazapine (r_prep) developed_12\VBD|who|rls|after (l_dobj) RLS_13\NNP|
C035133_D012148 CID mirtazapine_15\NN| (r_pobj) with_14\IN|mirtazapine (r_prep) treated_13\VBN|only|after|he|had|been|with (r_advcl) have_4\VB|to|symptoms|treated (l_dobj) symptoms_5\NNS|of (l_prep) of_6\IN|rls (l_pobj) RLS_7\NNP|
C035133_D012148 CID mirtazapine_15\NN| (r_pobj) with_14\IN|mirtazapine (r_prep) treated_13\VBN|only|after|he|had|been|with (r_advcl) have_4\VB|to|symptoms|treated (r_xcomp) started_2\VBD|patient|have|,|and|resolved (l_conj) resolved_21\VBD|symptoms|completely|upon|. (l_nsubj) symptoms_20\NNS|his|rls (l_compound) RLS_19\NNP|
C035133_D012148 CID mirtazapine_27\NN|his (r_pobj) of_25\IN|mirtazapine (r_prep) discontinuation_24\NN|of (r_pobj) upon_23\IN|discontinuation (r_prep) resolved_21\VBD|symptoms|completely|upon|. (r_conj) started_2\VBD|patient|have|,|and|resolved (l_xcomp) have_4\VB|to|symptoms|treated (l_dobj) symptoms_5\NNS|of (l_prep) of_6\IN|rls (l_pobj) RLS_7\NNP|
C035133_D012148 CID mirtazapine_27\NN|his (r_pobj) of_25\IN|mirtazapine (r_prep) discontinuation_24\NN|of (r_pobj) upon_23\IN|discontinuation (r_prep) resolved_21\VBD|symptoms|completely|upon|. (l_nsubj) symptoms_20\NNS|his|rls (l_compound) RLS_19\NNP|
C035133_D012148 CID mirtazapine_8\NN| (r_pobj) of_7\IN|mirtazapine (r_prep) use_6\NN|the|of|and|symptoms (l_conj) symptoms_11\NNS|the|of|in (l_prep) of_12\IN|rls (l_pobj) RLS_13\NNP|
C035133_D012148 CID mirtazapine_8\NN| (r_pobj) of_7\IN|mirtazapine (r_prep) use_6\NN|the|of|and|symptoms (r_pobj) between_4\IN|use (r_prep) relationship_3\NN|such|a|temporal|between (r_nsubj) support_19\VB|relationship|did|not|effect|. (l_dobj) effect_22\NN|a|potentiating|of (l_prep) of_23\IN|domperione (l_pobj) domperione_24\NN|on (l_prep) on_25\IN|rls (l_pobj) RLS_29\NNP|associated
C035133_D012148 CID mirtazapine_26\RB| (r_npadvmod) associated_28\VBN|mirtazapine|- (r_amod) RLS_29\NNP|associated (r_pobj) on_25\IN|rls (r_prep) domperione_24\NN|on (r_pobj) of_23\IN|domperione (r_prep) effect_22\NN|a|potentiating|of (r_dobj) support_19\VB|relationship|did|not|effect|. (l_nsubj) relationship_3\NN|such|a|temporal|between (l_prep) between_4\IN|use (l_pobj) use_6\NN|the|of|and|symptoms (l_conj) symptoms_11\NNS|the|of|in (l_prep) of_12\IN|rls (l_pobj) RLS_13\NNP|
C035133_D012148 CID mirtazapine_26\RB| (r_npadvmod) associated_28\VBN|mirtazapine|- (r_amod) RLS_29\NNP|associated
C035133_D012148 CID mirtazapine_10\NN| (r_nsubjpass) associated_13\VBN|that|mirtazapine|can|be|with|in (l_prep) with_14\IN|rls (l_pobj) RLS_15\NNP|
D007980_D012148 NONE levodopa_12\NN|and (r_nmod) agonists_15\NNS|levodopa|dopamine (r_pobj) by_11\IN|agonists (r_agent) improved_10\VBN|for|,|symptoms|can|be|dramatically|by|,|induce|. (l_nsubjpass) symptoms_4\NNS|the|of (l_prep) of_5\IN|rls (l_pobj) RLS_6\NNP|
D007980_D012148 NONE levodopa_12\NN|and (r_nmod) agonists_15\NNS|levodopa|dopamine (r_pobj) by_11\IN|agonists (r_agent) improved_10\VBN|for|,|symptoms|can|be|dramatically|by|,|induce|. (l_advcl) induce_24\VB|whereas|antagonists|can|or|aggravate (l_conj) aggravate_26\VB|symptoms (l_dobj) symptoms_28\NNS|rls (l_compound) RLS_27\NNP|
D004298_D012148 NONE dopamine_14\NN| (r_compound) agonists_15\NNS|levodopa|dopamine (r_pobj) by_11\IN|agonists (r_agent) improved_10\VBN|for|,|symptoms|can|be|dramatically|by|,|induce|. (l_nsubjpass) symptoms_4\NNS|the|of (l_prep) of_5\IN|rls (l_pobj) RLS_6\NNP|
D004298_D012148 NONE dopamine_14\NN| (r_compound) agonists_15\NNS|levodopa|dopamine (r_pobj) by_11\IN|agonists (r_agent) improved_10\VBN|for|,|symptoms|can|be|dramatically|by|,|induce|. (l_advcl) induce_24\VB|whereas|antagonists|can|or|aggravate (l_conj) aggravate_26\VB|symptoms (l_dobj) symptoms_28\NNS|rls (l_compound) RLS_27\NNP|
D004298_D012148 NONE dopamine_19\NN|central (r_compound) antagonists_22\NNS|dopamine|receptor (r_nsubj) induce_24\VB|whereas|antagonists|can|or|aggravate (r_advcl) improved_10\VBN|for|,|symptoms|can|be|dramatically|by|,|induce|. (l_nsubjpass) symptoms_4\NNS|the|of (l_prep) of_5\IN|rls (l_pobj) RLS_6\NNP|
D004298_D012148 NONE dopamine_19\NN|central (r_compound) antagonists_22\NNS|dopamine|receptor (r_nsubj) induce_24\VB|whereas|antagonists|can|or|aggravate (l_conj) aggravate_26\VB|symptoms (l_dobj) symptoms_28\NNS|rls (l_compound) RLS_27\NNP|
D004298_D012148 NONE dopamine_15\NN|peripheral (r_compound) antagonist_18\NN|a|dopamine|d2|receptor (r_appos) domperidone_11\NN|,|antagonist (r_nsubj) induce_22\VB|whether|domperidone|,|can|also|or|aggravate (l_conj) aggravate_24\VBP|symptoms (l_dobj) symptoms_25\NNS|of (l_prep) of_26\IN|rls (l_pobj) RLS_27\NNP|
D004298_D012148 NONE dopamine_24\NN| (r_compound) antagonists_27\NNS|concomitant|dopamine|receptor (r_dobj) receiving_22\VBG|antagonists (r_acl) those_21\DT|especially|receiving (r_appos) possibility_8\NN|the|associated|,|those (l_acl) associated_13\VBN|that|mirtazapine|can|be|with|in (l_prep) with_14\IN|rls (l_pobj) RLS_15\NNP|
C035133_D004415 NONE mirtazapine_15\RB| (r_pobj) after_14\IN|mirtazapine (r_prep) developed_12\VBD|who|rls|after (r_relcl) dyspepsia_10\NN|postprandial|developed
D004294_D004415 NONE domperidone_21\NN| (r_compound) therapy_22\NN|his|domperidone (r_pobj) to_19\IN|therapy (r_prep) added_18\VBN|had|been|to (r_ccomp) report_2\VBP|authors|here|comorbid|added|. (l_dobj) comorbid_7\JJ|a|depressed|patient|with (l_prep) with_8\IN|dyspepsia (l_pobj) dyspepsia_10\NN|postprandial|developed
7727612
D008140_D009207 CID lorazepam_3\NN| (r_amod) therapy_4\NN|lorazepam (r_pobj) with_2\IN|therapy (r_prep) associated_1\VBN|with|in (r_acl) Myoclonus_0\NNP|associated|.
D008140_D009207 CID lorazepam_19\NN| (r_pobj) of_18\IN|lorazepam (r_prep) administration_17\NN|the|intravenous|of (r_pobj) following_14\VBG|administration (r_prep) myoclonus_13\NN|following
20589632
D014295_D000743 CID Trimethoprim_0\NNP| (r_npadvmod) induced_2\VBN|trimethoprim|- (r_amod) anemia_5\NN|induced|immune|hemolytic|in|.
24971338
D020123_D007674 NONE sirolimus_2\VB|to (r_relcl) Conversion_0\NN|sirolimus (r_nsubj) ameliorates_3\VBZ|conversion|nephropathy|in (l_dobj) nephropathy_7\NN|induced
D020123_D007674 NONE sirolimus_10\VB| (r_pobj) to_9\TO|sirolimus (r_prep) conversion_2\NN|from|to (r_pobj) of_1\IN|conversion (r_prep) Protocols_0\NNS|of (r_nsubjpass) used_17\VBN|protocols|(|srl|)|have|been|widely|in|after|,|but|remain (l_prep) after_20\IN|transplantation (l_pobj) transplantation_21\NN|prevent (l_relcl) prevent_23\VB|to|nephropathy (l_dobj) nephropathy_27\NN|induced
D020123_D007674 NONE SRL_12\NN| (r_nsubjpass) used_17\VBN|protocols|(|srl|)|have|been|widely|in|after|,|but|remain (l_prep) after_20\IN|transplantation (l_pobj) transplantation_21\NN|prevent (l_relcl) prevent_23\VB|to|nephropathy (l_dobj) nephropathy_27\NN|induced
D020123_D007674 NONE SRL_0\NN| (r_npadvmod) treated_2\VBN|srl|- (r_amod) rats_3\NNS|treated (r_nsubj) presented_4\VBD|rats|proteinuria|)|as|. (l_prep) as_13\IN|markers (l_pobj) markers_16\NNS|the|best|of (l_prep) of_17\IN|impairment (l_pobj) impairment_19\NN|renal
D020123_D007674 NONE SRL_2\NNP| (r_pobj) to_1\IN|srl (r_prep) Conversion_0\NN|to (r_nsubj) prevented_3\VBN|conversion|evolution|,|seems|. (l_dobj) evolution_9\NN|induced|renal|damage|lesions (l_compound) damage_8\NN|
D020123_D007674 NONE SRL_35\NNP| (r_pobj) to_34\IN|srl (r_prep) replacement_33\NN|csa|to (r_pobj) of_31\IN|replacement (r_prep) biomarker_30\NN|a|feasible|of (r_attr) be_27\VB|to|biomarker (r_xcomp) seems_25\VBZ|while|ngal|be (r_advcl) prevented_3\VBN|conversion|evolution|,|seems|. (l_dobj) evolution_9\NN|induced|renal|damage|lesions (l_compound) damage_8\NN|
D016572_D007674 CID cyclosporine_4\NN| (r_npadvmod) induced_6\VBN|cyclosporine|- (r_amod) nephropathy_7\NN|induced
D016572_D007674 CID A_5\NNP|cyclosporin|csa (r_pobj) from_3\IN|a (r_prep) conversion_2\NN|from|to (r_pobj) of_1\IN|conversion (r_prep) Protocols_0\NNS|of (r_nsubjpass) used_17\VBN|protocols|(|srl|)|have|been|widely|in|after|,|but|remain (l_prep) after_20\IN|transplantation (l_pobj) transplantation_21\NN|prevent (l_relcl) prevent_23\VB|to|nephropathy (l_dobj) nephropathy_27\NN|induced
D016572_D007674 CID CsA_7\NNP|(|) (r_appos) A_5\NNP|cyclosporin|csa (r_pobj) from_3\IN|a (r_prep) conversion_2\NN|from|to (r_pobj) of_1\IN|conversion (r_prep) Protocols_0\NNS|of (r_nsubjpass) used_17\VBN|protocols|(|srl|)|have|been|widely|in|after|,|but|remain (l_prep) after_20\IN|transplantation (l_pobj) transplantation_21\NN|prevent (l_relcl) prevent_23\VB|to|nephropathy (l_dobj) nephropathy_27\NN|induced
D016572_D007674 CID CsA_24\NNP| (r_npadvmod) induced_26\VBN|csa|- (r_amod) nephropathy_27\NN|induced
D016572_D007674 CID CsA_1\NNP| (r_compound) treatment_2\NN|short|csa (r_nsubj) presented_3\VBD|treatment|lesions|kim-1|,|and|ctgf|. (l_dobj) lesions_9\NNS|slight|kidney|and|b|kb
D016572_D007674 CID CsA_1\NNP| (r_compound) exposure_2\NN|prolonged|csa (r_nsubj) aggravated_3\VBD|exposure|damage|,|without|b|. (l_dobj) damage_5\NN|renal
D016572_D007674 CID CsA_4\NNP| (r_npadvmod) induced_6\VBN|csa|- (r_amod) evolution_9\NN|induced|renal|damage|lesions (l_compound) damage_8\NN|
D016572_D007674 CID CsA_32\NNP| (r_compound) replacement_33\NN|csa|to (r_pobj) of_31\IN|replacement (r_prep) biomarker_30\NN|a|feasible|of (r_attr) be_27\VB|to|biomarker (r_xcomp) seems_25\VBZ|while|ngal|be (r_advcl) prevented_3\VBN|conversion|evolution|,|seems|. (l_dobj) evolution_9\NN|induced|renal|damage|lesions (l_compound) damage_8\NN|
D006416_D007674 NONE hematoxylin_5\NN|and|eosin|,|schiff (r_pobj) in_4\IN|hematoxylin (r_prep) analyzed_3\VBN|lesions|were|in|. (l_nsubjpass) lesions_1\NNS|renal
D004801_D007674 NONE eosin_7\NN| (r_conj) hematoxylin_5\NN|and|eosin|,|schiff (r_pobj) in_4\IN|hematoxylin (r_prep) analyzed_3\VBN|lesions|were|in|. (l_nsubjpass) lesions_1\NNS|renal
D020123_D011507 CID SRL_0\NN| (r_npadvmod) treated_2\VBN|srl|- (r_amod) rats_3\NNS|treated (r_nsubj) presented_4\VBD|rats|proteinuria|)|as|. (l_dobj) proteinuria_5\NN|and|ngal|serum
19020118
17255138
D052246_D009203 CID inhibitors_11\NNS|cox-2 (r_pobj) with_9\IN|inhibitors (r_prep) infarction_5\NN|acute|myocardial|(|ami|)|with
D052246_D009203 CID inhibitors_11\NNS|cox-2 (r_pobj) with_9\IN|inhibitors (r_prep) infarction_5\NN|acute|myocardial|(|ami|)|with (l_appos) AMI_7\NNP|
D052246_D009203 CID inhibitors_18\NNS|cox-2|,|nsaids (r_dobj) using_16\VBG|inhibitors (r_acl) patients_15\NNS|elderly|using (r_pobj) among_13\IN|patients (r_prep) bleeding_12\VBG|among (r_acl) risks_5\NNS|the|of|bleeding (l_prep) of_6\IN|hospitalization (l_pobj) hospitalization_7\NN|for (l_prep) for_8\IN|ami (l_pobj) AMI_9\NNP|and|gi
D000894_D009203 CID drugs_34\NNS|non|-|selective|inflammatory|nsaids (r_pobj) with_21\IN|drugs (r_prep) compared_20\VBN|with (r_prep) offset_13\VB|risk|may|benefit|compared|. (l_nsubj) risk_1\NN|the|of (l_prep) of_2\IN|infarction (l_pobj) infarction_5\NN|acute|myocardial|(|ami|)|with
D000894_D009203 CID drugs_34\NNS|non|-|selective|inflammatory|nsaids (r_pobj) with_21\IN|drugs (r_prep) compared_20\VBN|with (r_prep) offset_13\VB|risk|may|benefit|compared|. (l_nsubj) risk_1\NN|the|of (l_prep) of_2\IN|infarction (l_pobj) infarction_5\NN|acute|myocardial|(|ami|)|with (l_appos) AMI_7\NNP|
D052246_D006471 NONE inhibitors_18\NNS|cox-2|,|nsaids (r_dobj) using_16\VBG|inhibitors (r_acl) patients_15\NNS|elderly|using (r_pobj) among_13\IN|patients (r_prep) bleeding_12\VBG|among
D000082_D009203 NONE acetaminophen_24\RB| (r_conj) NSAIDs_22\NNPS|ns|-|and|acetaminophen (r_conj) inhibitors_18\NNS|cox-2|,|nsaids (r_dobj) using_16\VBG|inhibitors (r_acl) patients_15\NNS|elderly|using (r_pobj) among_13\IN|patients (r_prep) bleeding_12\VBG|among (r_acl) risks_5\NNS|the|of|bleeding (l_prep) of_6\IN|hospitalization (l_pobj) hospitalization_7\NN|for (l_prep) for_8\IN|ami (l_pobj) AMI_9\NNP|and|gi
D000082_D009203 NONE acetaminophen_25\NN|the (r_pobj) vs_23\IN|acetaminophen (r_prep) GI_22\NNP|ami|/|vs|with (l_nmod) AMI_20\NNP|
D000082_D009203 NONE acetaminophen_12\RB| (r_pobj) of_11\IN|acetaminophen (r_prep) that_10\DT|of (r_pobj) to_9\IN|that (r_prep) similar_8\JJ|to (r_acomp) was_7\VBD|toxicity|similar|and|seemed|. (l_nsubj) toxicity_4\NN|the|gi|of (l_compound) GI_3\NNP|ami|/ (l_nmod) AMI_1\NNP|
D000082_D006471 NONE acetaminophen_24\RB| (r_conj) NSAIDs_22\NNPS|ns|-|and|acetaminophen (r_conj) inhibitors_18\NNS|cox-2|,|nsaids (r_dobj) using_16\VBG|inhibitors (r_acl) patients_15\NNS|elderly|using (r_pobj) among_13\IN|patients (r_prep) bleeding_12\VBG|among
D001241_D009203 NONE aspirin_5\NN| (r_pobj) of_4\IN|aspirin (r_prep) users_3\NNS|non|-|of (r_punct) ,_6\,|users (r_punct) were_32\VBD|among|,|group|:|rofecoxib|. (l_nsubj) group_31\NN|ratios (l_nmod) ratios_10\NNS|the|adjusted|hazard|interval|) (l_appos) interval_15\NN|(|%|confidence|)|of (l_prep) of_17\IN|hospitalization (l_pobj) hospitalization_18\NN|for (l_prep) for_19\IN|gi (l_pobj) GI_22\NNP|ami|/|vs|with (l_nmod) AMI_20\NNP|
D001241_D009203 NONE aspirin_29\NN|no (r_pobj) with_27\IN|(|aspirin (r_parataxis) GI_22\NNP|ami|/|vs|with (l_nmod) AMI_20\NNP|
D001241_D009203 NONE aspirin_5\NN| (r_pobj) of_4\IN|aspirin (r_prep) users_3\NNS|non|-|of (r_punct) ,_6\,|users (r_punct) seemed_8\VBD|among|,|naproxen|carry|. (l_xcomp) carry_10\VB|to|risk (l_dobj) risk_13\NN|the|highest|for (l_prep) for_14\IN|bleeding (l_pobj) bleeding_18\NN|gi (l_compound) GI_17\NNP|ami|/ (l_nmod) AMI_15\NNP|
C116926_D009203 CID rofecoxib_34\XX|1.27|(|1.13|)|,|celecoxib|,|naproxen (r_nsubj) were_32\VBD|among|,|group|:|rofecoxib|. (l_nsubj) group_31\NN|ratios (l_nmod) ratios_10\NNS|the|adjusted|hazard|interval|) (l_appos) interval_15\NN|(|%|confidence|)|of (l_prep) of_17\IN|hospitalization (l_pobj) hospitalization_18\NN|for (l_prep) for_19\IN|gi (l_pobj) GI_22\NNP|ami|/|vs|with (l_nmod) AMI_20\NNP|
C116926_D009203 CID rofecoxib_21\NN|and|nsaids (r_pobj) of_20\IN|rofecoxib (r_prep) those_19\DT|of (r_pobj) than_18\IN|those (r_prep) better_17\JJR|than (r_acomp) be_16\VB|to|better (r_xcomp) seemed_14\VBD|be (r_conj) was_7\VBD|toxicity|similar|and|seemed|. (l_nsubj) toxicity_4\NN|the|gi|of (l_compound) GI_3\NNP|ami|/ (l_nmod) AMI_1\NNP|
C105934_D009203 NONE celecoxib_42\NN|0.93 (r_conj) rofecoxib_34\XX|1.27|(|1.13|)|,|celecoxib|,|naproxen (r_nsubj) were_32\VBD|among|,|group|:|rofecoxib|. (l_nsubj) group_31\NN|ratios (l_nmod) ratios_10\NNS|the|adjusted|hazard|interval|) (l_appos) interval_15\NN|(|%|confidence|)|of (l_prep) of_17\IN|hospitalization (l_pobj) hospitalization_18\NN|for (l_prep) for_19\IN|gi (l_pobj) GI_22\NNP|ami|/|vs|with (l_nmod) AMI_20\NNP|
C105934_D009203 NONE celecoxib_6\NN| (r_pobj) of_5\IN|celecoxib (r_prep) toxicity_4\NN|the|gi|of (l_compound) GI_3\NNP|ami|/ (l_nmod) AMI_1\NNP|
D009288_D009203 CID naproxen_50\NN|1.59|,|diclofenac (r_appos) rofecoxib_34\XX|1.27|(|1.13|)|,|celecoxib|,|naproxen (r_nsubj) were_32\VBD|among|,|group|:|rofecoxib|. (l_nsubj) group_31\NN|ratios (l_nmod) ratios_10\NNS|the|adjusted|hazard|interval|) (l_appos) interval_15\NN|(|%|confidence|)|of (l_prep) of_17\IN|hospitalization (l_pobj) hospitalization_18\NN|for (l_prep) for_19\IN|gi (l_pobj) GI_22\NNP|ami|/|vs|with (l_nmod) AMI_20\NNP|
D009288_D009203 CID naproxen_7\NN| (r_nsubj) seemed_8\VBD|among|,|naproxen|carry|. (l_xcomp) carry_10\VB|to|risk (l_dobj) risk_13\NN|the|highest|for (l_prep) for_14\IN|bleeding (l_pobj) bleeding_18\NN|gi (l_compound) GI_17\NNP|ami|/ (l_nmod) AMI_15\NNP|
D004008_D009203 NONE diclofenac_58\NN|1.17|and|ibuprofen (r_conj) naproxen_50\NN|1.59|,|diclofenac (r_appos) rofecoxib_34\XX|1.27|(|1.13|)|,|celecoxib|,|naproxen (r_nsubj) were_32\VBD|among|,|group|:|rofecoxib|. (l_nsubj) group_31\NN|ratios (l_nmod) ratios_10\NNS|the|adjusted|hazard|interval|) (l_appos) interval_15\NN|(|%|confidence|)|of (l_prep) of_17\IN|hospitalization (l_pobj) hospitalization_18\NN|for (l_prep) for_19\IN|gi (l_pobj) GI_22\NNP|ami|/|vs|with (l_nmod) AMI_20\NNP|
D007052_D009203 NONE ibuprofen_66\NNP|1.05|0.74 (r_conj) diclofenac_58\NN|1.17|and|ibuprofen (r_conj) naproxen_50\NN|1.59|,|diclofenac (r_appos) rofecoxib_34\XX|1.27|(|1.13|)|,|celecoxib|,|naproxen (r_nsubj) were_32\VBD|among|,|group|:|rofecoxib|. (l_nsubj) group_31\NN|ratios (l_nmod) ratios_10\NNS|the|adjusted|hazard|interval|) (l_appos) interval_15\NN|(|%|confidence|)|of (l_prep) of_17\IN|hospitalization (l_pobj) hospitalization_18\NN|for (l_prep) for_19\IN|gi (l_pobj) GI_22\NNP|ami|/|vs|with (l_nmod) AMI_20\NNP|
D001241_D006471 NONE aspirin_5\NN| (r_pobj) of_4\IN|aspirin (r_prep) users_3\NNS|non|-|of (r_punct) ,_6\,|users (r_punct) seemed_8\VBD|among|,|naproxen|carry|. (l_xcomp) carry_10\VB|to|risk (l_dobj) risk_13\NN|the|highest|for (l_prep) for_14\IN|bleeding (l_pobj) bleeding_18\NN|gi
D009288_D006471 CID naproxen_7\NN| (r_nsubj) seemed_8\VBD|among|,|naproxen|carry|. (l_xcomp) carry_10\VB|to|risk (l_dobj) risk_13\NN|the|highest|for (l_prep) for_14\IN|bleeding (l_pobj) bleeding_18\NN|gi
C105934_D064420 NONE celecoxib_6\NN| (r_pobj) of_5\IN|celecoxib (r_prep) toxicity_4\NN|the|gi|of
D000082_D064420 NONE acetaminophen_12\RB| (r_pobj) of_11\IN|acetaminophen (r_prep) that_10\DT|of (r_pobj) to_9\IN|that (r_prep) similar_8\JJ|to (r_acomp) was_7\VBD|toxicity|similar|and|seemed|. (l_nsubj) toxicity_4\NN|the|gi|of
C116926_D064420 NONE rofecoxib_21\NN|and|nsaids (r_pobj) of_20\IN|rofecoxib (r_prep) those_19\DT|of (r_pobj) than_18\IN|those (r_prep) better_17\JJR|than (r_acomp) be_16\VB|to|better (r_xcomp) seemed_14\VBD|be (r_conj) was_7\VBD|toxicity|similar|and|seemed|. (l_nsubj) toxicity_4\NN|the|gi|of
19419794
D016627_D004409 NONE 6-hydroxydopamine_3\CD| (r_compound) lesion_4\NN|6-hydroxydopamine|and|development (l_conj) development_7\NN|reduced|of|in (l_prep) of_8\IN|dyskinesias (l_pobj) dyskinesias_9\NNS|
C005177_D004409 NONE DOPA+benserazide_4\NNP|l|-|weeks (r_pobj) with_1\IN|dopa+benserazide (r_prep) Treatment_0\NN|with|) (r_nsubj) resulted_9\VBD|treatment|in|. (l_prep) in_10\IN|dyskinesias (l_pobj) dyskinesias_13\NNS|severe|in|than
D004298_D004409 NONE DA_17\NNP| (r_compound) lesion_18\NN|da (r_conj) impairment_15\NN|motor|and|lesion (r_pobj) of_13\IN|impairment (r_prep) severity_12\NN|the|of (r_dobj) increased_10\VBD|that|lack|severity|,|and|reduced (l_conj) reduced_21\VBN|dyskinesias (l_dobj) dyskinesias_27\NNS|induced
D007980_D004409 CID DOPA_24\NNP| (r_compound) induced_26\VBN|l|-|dopa|- (r_amod) dyskinesias_27\NNS|induced
D007980_D004409 CID DOPA_19\NNP| (r_compound) induced_21\VBN|l|-|dopa|- (r_amod) dyskinesias_22\NNS|induced
9869655
D004997_D002780 CID ethinylestradiol_6\NNP|17alpha|-|cholestasis (l_appos) cholestasis_10\NN|(|ee)-induced|intrahepatic|in
D004997_D002780 CID EE)-induced_8\VBN| (r_nmod) cholestasis_10\NN|(|ee)-induced|intrahepatic|in
D001647_D002780 NONE salt_24\NN|bile (r_nmod) synthesis_28\NN|salt|bs (r_pobj) of_22\IN|synthesis (r_prep) pathway_21\NN|the|neutral|of (r_pobj) of_18\IN|pathway (r_prep) inhibition_17\NN|selective|of (r_pobj) with_15\IN|inhibition (r_prep) associated_14\VBN|that|ethinylestradiol|is|with (l_nsubjpass) ethinylestradiol_6\NNP|17alpha|-|cholestasis (l_appos) cholestasis_10\NN|(|ee)-induced|intrahepatic|in
D001647_D002780 NONE BS_26\NN|(|) (r_nmod) synthesis_28\NN|salt|bs (r_pobj) of_22\IN|synthesis (r_prep) pathway_21\NN|the|neutral|of (r_pobj) of_18\IN|pathway (r_prep) inhibition_17\NN|selective|of (r_pobj) with_15\IN|inhibition (r_prep) associated_14\VBN|that|ethinylestradiol|is|with (l_nsubjpass) ethinylestradiol_6\NNP|17alpha|-|cholestasis (l_appos) cholestasis_10\NN|(|ee)-induced|intrahepatic|in
3323259
D002118_D002318 NONE calcium_6\NN| (r_pobj) of_5\IN|calcium (r_prep) importance_4\NN|the|of|in (l_prep) in_7\IN|pathogenesis (l_pobj) pathogenesis_9\NN|the|of (l_prep) of_10\IN|disease (l_pobj) disease_12\NN|cardiovascular
D002118_D002318 NONE calcium_6\NN| (r_pobj) of_5\IN|calcium (r_prep) importance_4\NN|the|of|in (r_pobj) of_2\IN|importance (r_prep) recognition_1\NN|increasing|of (r_nsubj) stimulated_14\VBN|recognition|has|research|into|. (l_prep) into_16\IN|use (l_pobj) use_18\NN|the|of|blocking (l_acl) blocking_22\VBG|agents|for (l_prep) for_24\IN|treatment (l_pobj) treatment_25\NN|of (l_prep) of_26\IN|variety (l_pobj) variety_28\NN|a|of (l_prep) of_29\IN|diseases (l_pobj) diseases_31\NNS|cardiovascular
D002121_D002318 NONE agents_23\NNS| (r_dobj) blocking_22\VBG|agents|for (r_acl) use_18\NN|the|of|blocking (r_pobj) into_16\IN|use (r_prep) stimulated_14\VBN|recognition|has|research|into|. (l_nsubj) recognition_1\NN|increasing|of (l_prep) of_2\IN|importance (l_pobj) importance_4\NN|the|of|in (l_prep) in_7\IN|pathogenesis (l_pobj) pathogenesis_9\NN|the|of (l_prep) of_10\IN|disease (l_pobj) disease_12\NN|cardiovascular
D002121_D002318 NONE agents_23\NNS| (r_dobj) blocking_22\VBG|agents|for (l_prep) for_24\IN|treatment (l_pobj) treatment_25\NN|of (l_prep) of_26\IN|variety (l_pobj) variety_28\NN|a|of (l_prep) of_29\IN|diseases (l_pobj) diseases_31\NNS|cardiovascular
C038806_D000787 NONE dihydropyridine_3\NN| (r_advmod) available_4\JJ|as|the|first|dihydropyridine|for (r_advcl) controls_13\NNS|available|,|nifedipine|angina|. (l_dobj) angina_14\NN|and|hypertension|with
C038806_D006973 NONE dihydropyridine_3\NN| (r_advmod) available_4\JJ|as|the|first|dihydropyridine|for (r_advcl) controls_13\NNS|available|,|nifedipine|angina|. (l_dobj) angina_14\NN|and|hypertension|with (l_conj) hypertension_16\NN|
D009543_D000787 NONE nifedipine_12\NN| (r_amod) controls_13\NNS|available|,|nifedipine|angina|. (l_dobj) angina_14\NN|and|hypertension|with
D009543_D006973 NONE nifedipine_12\NN| (r_amod) controls_13\NNS|available|,|nifedipine|angina|. (l_dobj) angina_14\NN|and|hypertension|with (l_conj) hypertension_16\NN|
D009568_D006973 NONE nitrendipine_7\NN|and|nisoldipine (r_pobj) with_6\IN|nitrendipine (r_prep) dosage_4\NN|once|daily|possible|with (r_nsubj) offers_10\VBZ|dosage|schedule|. (l_dobj) schedule_14\NN|a|convenient|administration|,|encourages (l_relcl) encourages_17\VBZ|which|compliance (l_dobj) compliance_19\NN|patient|in (l_prep) in_20\IN|therapy (l_pobj) therapy_24\NN|term|of (l_prep) of_25\IN|hypertension (l_pobj) hypertension_26\NN|
D015737_D006973 NONE nisoldipine_9\NN| (r_conj) nitrendipine_7\NN|and|nisoldipine (r_pobj) with_6\IN|nitrendipine (r_prep) dosage_4\NN|once|daily|possible|with (r_nsubj) offers_10\VBZ|dosage|schedule|. (l_dobj) schedule_14\NN|a|convenient|administration|,|encourages (l_relcl) encourages_17\VBZ|which|compliance (l_dobj) compliance_19\NN|patient|in (l_prep) in_20\IN|therapy (l_pobj) therapy_24\NN|term|of (l_prep) of_25\IN|hypertension (l_pobj) hypertension_26\NN|
D015737_D000787 NONE nisoldipine_5\NN| (r_pobj) of_4\IN|nisoldipine (r_prep) properties_3\NNS|the|coronary|vasodilating|of (r_nsubj) led_7\VBN|properties|have|to|. (l_prep) to_8\IN|investigation (l_pobj) investigation_10\NN|the|of|for (l_prep) for_14\IN|use (l_pobj) use_15\NN|in (l_prep) in_16\IN|angina (l_pobj) angina_17\NN|
D009553_D013345 NONE nimodipine_6\RB| (r_nsubj) useful_8\JJ|nimodipine|potentially|in (l_prep) in_9\IN|treatment (l_pobj) treatment_11\NN|the|of (l_prep) of_12\IN|hemorrhage (l_pobj) hemorrhage_14\NN|subarachnoid|,|headache
D009553_D008881 NONE nimodipine_6\RB| (r_nsubj) useful_8\JJ|nimodipine|potentially|in (l_prep) in_9\IN|treatment (l_pobj) treatment_11\NN|the|of (l_prep) of_12\IN|hemorrhage (l_pobj) hemorrhage_14\NN|subarachnoid|,|headache (l_conj) headache_17\NN|migraine|,|dementia
D009553_D003704 NONE nimodipine_6\RB| (r_nsubj) useful_8\JJ|nimodipine|potentially|in (l_prep) in_9\IN|treatment (l_pobj) treatment_11\NN|the|of (l_prep) of_12\IN|hemorrhage (l_pobj) hemorrhage_14\NN|subarachnoid|,|headache (l_conj) headache_17\NN|migraine|,|dementia (l_conj) dementia_19\NN|,|and|stroke
D009553_D020521 NONE nimodipine_6\RB| (r_nsubj) useful_8\JJ|nimodipine|potentially|in (l_prep) in_9\IN|treatment (l_pobj) treatment_11\NN|the|of (l_prep) of_12\IN|hemorrhage (l_pobj) hemorrhage_14\NN|subarachnoid|,|headache (l_conj) headache_17\NN|migraine|,|dementia (l_conj) dementia_19\NN|,|and|stroke (l_conj) stroke_22\NN|
C038806_D006261 NONE dihydropyridine_4\JJ| (r_compound) calcium_5\NN|dihydropyridine (r_compound) channel_6\NN|the|calcium (r_compound) blockers_7\NNS|channel (r_nsubjpass) tolerated_11\VBN|in|,|blockers|are|usually|well|,|with|. (l_prep) with_13\IN|headache|being (l_pobj) headache_14\NN|,|flushing
C038806_D005483 NONE dihydropyridine_4\JJ| (r_compound) calcium_5\NN|dihydropyridine (r_compound) channel_6\NN|the|calcium (r_compound) blockers_7\NNS|channel (r_nsubjpass) tolerated_11\VBN|in|,|blockers|are|usually|well|,|with|. (l_prep) with_13\IN|headache|being (l_pobj) headache_14\NN|,|flushing (l_conj) flushing_17\NN|facial|,|palpitations
C038806_-1 NONE dihydropyridine_4\JJ| (r_compound) calcium_5\NN|dihydropyridine (r_compound) channel_6\NN|the|calcium (r_compound) blockers_7\NNS|channel (r_nsubjpass) tolerated_11\VBN|in|,|blockers|are|usually|well|,|with|. (l_prep) with_13\IN|headache|being (l_pobj) headache_14\NN|,|flushing (l_conj) flushing_17\NN|facial|,|palpitations (l_conj) palpitations_19\NNS|,|edema
C038806_D004487 NONE dihydropyridine_4\JJ| (r_compound) calcium_5\NN|dihydropyridine (r_compound) channel_6\NN|the|calcium (r_compound) blockers_7\NNS|channel (r_nsubjpass) tolerated_11\VBN|in|,|blockers|are|usually|well|,|with|. (l_prep) with_13\IN|headache|being (l_pobj) headache_14\NN|,|flushing (l_conj) flushing_17\NN|facial|,|palpitations (l_conj) palpitations_19\NNS|,|edema (l_conj) edema_21\NN|,|nausea
C038806_D009325 NONE dihydropyridine_4\JJ| (r_compound) calcium_5\NN|dihydropyridine (r_compound) channel_6\NN|the|calcium (r_compound) blockers_7\NNS|channel (r_nsubjpass) tolerated_11\VBN|in|,|blockers|are|usually|well|,|with|. (l_prep) with_13\IN|headache|being (l_pobj) headache_14\NN|,|flushing (l_conj) flushing_17\NN|facial|,|palpitations (l_conj) palpitations_19\NNS|,|edema (l_conj) edema_21\NN|,|nausea (l_conj) nausea_23\NN|,|anorexia
C038806_D000855 NONE dihydropyridine_4\JJ| (r_compound) calcium_5\NN|dihydropyridine (r_compound) channel_6\NN|the|calcium (r_compound) blockers_7\NNS|channel (r_nsubjpass) tolerated_11\VBN|in|,|blockers|are|usually|well|,|with|. (l_prep) with_13\IN|headache|being (l_pobj) headache_14\NN|,|flushing (l_conj) flushing_17\NN|facial|,|palpitations (l_conj) palpitations_19\NNS|,|edema (l_conj) edema_21\NN|,|nausea (l_conj) nausea_23\NN|,|anorexia (l_conj) anorexia_25\NN|,|and|dizziness
C038806_D004244 NONE dihydropyridine_4\JJ| (r_compound) calcium_5\NN|dihydropyridine (r_compound) channel_6\NN|the|calcium (r_compound) blockers_7\NNS|channel (r_nsubjpass) tolerated_11\VBN|in|,|blockers|are|usually|well|,|with|. (l_prep) with_13\IN|headache|being (l_pobj) headache_14\NN|,|flushing (l_conj) flushing_17\NN|facial|,|palpitations (l_conj) palpitations_19\NNS|,|edema (l_conj) edema_21\NN|,|nausea (l_conj) nausea_23\NN|,|anorexia (l_conj) anorexia_25\NN|,|and|dizziness (l_conj) dizziness_28\NN|
D002121_D006261 CID blockers_7\NNS|channel (r_nsubjpass) tolerated_11\VBN|in|,|blockers|are|usually|well|,|with|. (l_prep) with_13\IN|headache|being (l_pobj) headache_14\NN|,|flushing
D002121_D005483 CID blockers_7\NNS|channel (r_nsubjpass) tolerated_11\VBN|in|,|blockers|are|usually|well|,|with|. (l_prep) with_13\IN|headache|being (l_pobj) headache_14\NN|,|flushing (l_conj) flushing_17\NN|facial|,|palpitations
D002121_-1 NONE blockers_7\NNS|channel (r_nsubjpass) tolerated_11\VBN|in|,|blockers|are|usually|well|,|with|. (l_prep) with_13\IN|headache|being (l_pobj) headache_14\NN|,|flushing (l_conj) flushing_17\NN|facial|,|palpitations (l_conj) palpitations_19\NNS|,|edema
D002121_D004487 CID blockers_7\NNS|channel (r_nsubjpass) tolerated_11\VBN|in|,|blockers|are|usually|well|,|with|. (l_prep) with_13\IN|headache|being (l_pobj) headache_14\NN|,|flushing (l_conj) flushing_17\NN|facial|,|palpitations (l_conj) palpitations_19\NNS|,|edema (l_conj) edema_21\NN|,|nausea
D002121_D009325 CID blockers_7\NNS|channel (r_nsubjpass) tolerated_11\VBN|in|,|blockers|are|usually|well|,|with|. (l_prep) with_13\IN|headache|being (l_pobj) headache_14\NN|,|flushing (l_conj) flushing_17\NN|facial|,|palpitations (l_conj) palpitations_19\NNS|,|edema (l_conj) edema_21\NN|,|nausea (l_conj) nausea_23\NN|,|anorexia
D002121_D000855 CID blockers_7\NNS|channel (r_nsubjpass) tolerated_11\VBN|in|,|blockers|are|usually|well|,|with|. (l_prep) with_13\IN|headache|being (l_pobj) headache_14\NN|,|flushing (l_conj) flushing_17\NN|facial|,|palpitations (l_conj) palpitations_19\NNS|,|edema (l_conj) edema_21\NN|,|nausea (l_conj) nausea_23\NN|,|anorexia (l_conj) anorexia_25\NN|,|and|dizziness
D002121_D004244 CID blockers_7\NNS|channel (r_nsubjpass) tolerated_11\VBN|in|,|blockers|are|usually|well|,|with|. (l_prep) with_13\IN|headache|being (l_pobj) headache_14\NN|,|flushing (l_conj) flushing_17\NN|facial|,|palpitations (l_conj) palpitations_19\NNS|,|edema (l_conj) edema_21\NN|,|nausea (l_conj) nausea_23\NN|,|anorexia (l_conj) anorexia_25\NN|,|and|dizziness (l_conj) dizziness_28\NN|
15482540
D012254_D000740 NONE ribavirin_3\RB| (r_npadvmod) induced_5\VBN|ribavirin|- (r_amod) anemia_6\NN|induced
D012254_D000740 NONE ribavirin_10\RB| (r_npadvmod) induced_12\VBN|ribavirin|- (r_amod) anemia_13\NN|induced
D012254_D000740 NONE ribavirin_12\RB| (r_npadvmod) induced_14\VBN|ribavirin|- (r_amod) anemia_15\NN|induced
D012254_D000740 NONE Ribavirin_0\RB| (r_npadvmod) induced_2\VBN|ribavirin|- (r_amod) anemia_3\NN|induced
D016898_D019698 NONE Interferon_0\NNP|and|ribavirin (r_nmod) therapy_4\NN|interferon|combination|for (l_prep) for_5\IN|c (l_pobj) C_8\NNP|chronic|hepatitis
D016898_D019698 NONE alpha-2b_12\NN|interferon|- (r_dobj) received_9\VBD|who|alpha-2b|at (r_relcl) C_7\NNP|chronic|hepatitis|received
D016898_D000743 CID Interferon_0\NNP|and|ribavirin (r_nmod) therapy_4\NN|interferon|combination|for (r_nsubj) produces_9\VBZ|therapy|anemia|. (l_dobj) anemia_11\NN|hemolytic
D012254_D019698 NONE ribavirin_2\RB| (r_conj) Interferon_0\NNP|and|ribavirin (r_nmod) therapy_4\NN|interferon|combination|for (l_prep) for_5\IN|c (l_pobj) C_8\NNP|chronic|hepatitis
D012254_D019698 NONE ribavirin_27\RB|administered (r_pobj) with_26\IN|ribavirin (r_prep) combination_25\NN|with (r_pobj) in_24\IN|combination (r_prep) administered_19\VBN|intramuscularly|for|in (r_acl) dose_15\NN|a|of|administered (r_pobj) at_13\IN|dose (r_prep) received_9\VBD|who|alpha-2b|at (r_relcl) C_7\NNP|chronic|hepatitis|received
D012254_D000743 CID ribavirin_2\RB| (r_conj) Interferon_0\NNP|and|ribavirin (r_nmod) therapy_4\NN|interferon|combination|for (r_nsubj) produces_9\VBZ|therapy|anemia|. (l_dobj) anemia_11\NN|hemolytic
19815465
D020888_D014786 CID vigabatrin_8\NN| (r_pobj) to_7\TO|vigabatrin (r_prep) specific_6\JJ|to (r_acomp) are_4\VBP|defects|not|specific|. (l_nsubj) defects_3\NNS|binasal|visual|field
D020888_D014786 CID vigabatrin_11\NN|the|antiepileptic|drug|(|vgb|) (r_pobj) with_7\IN|vigabatrin (r_prep) associated_6\VBN|with (r_acl) defects_5\NNS|the|visual|associated
D020888_D014786 CID VGB_13\NNP| (r_appos) vigabatrin_11\NN|the|antiepileptic|drug|(|vgb|) (r_pobj) with_7\IN|vigabatrin (r_prep) associated_6\VBN|with (r_acl) defects_5\NNS|the|visual|associated
D020888_D004827 NONE VGB_24\NNP| (r_pobj) to_23\IN|vgb (r_prep) exposure_22\NN|current|no|to (r_appos) therapy_14\NN|antiepileptic|drug|(|exposure|) (r_pobj) of_11\IN|therapy (r_prep) basis_10\NN|the|of (r_pobj) on_8\IN|basis (r_prep) grouped_7\VBN|people|were|on|. (l_nsubjpass) people_3\NNS|four|with (l_prep) with_4\IN|epilepsy (l_pobj) epilepsy_5\NN|
D020888_D012164 CID VGB_19\NNP| (r_pobj) with_18\IN|vgb (r_prep) associated_17\VBN|with (r_acl) toxicity_16\NN|retinal|associated
1837756
D012701_D010259 NONE Serotonin_0\NNP| (r_compound) inhibitors_2\NNS|serotonin|reuptake|,|paranoia|. (l_appos) paranoia_4\NN|,|and|ganglia
D012701_D010259 NONE serotonin_7\NN| (r_compound) inhibitors_9\NNS|the|serotonin|reuptake (r_pobj) with_5\IN|inhibitors (r_prep) exacerbation_4\NN|paranoid|with (l_amod) paranoid_3\JJ|
D012701_D010259 NONE serotonin_37\NN| (r_compound) inhibitors_39\NNS|serotonin|reuptake (r_pobj) with_36\IN|inhibitors (r_prep) associated_35\VBN|with (r_acl) exacerbations_34\NNS|paranoid|associated (l_amod) paranoid_33\JJ|
D012701_D010259 NONE serotonin_9\NN| (r_compound) blockers_11\NNS|serotonin|reuptake (r_pobj) with_8\IN|blockers (r_prep) exacerbations_7\NNS|possible|paranoid|with|in (l_amod) paranoid_6\JJ|
D012701_D010259 NONE serotonin_9\NN| (r_compound) blockers_11\NNS|serotonin|reuptake (r_pobj) with_8\IN|blockers (r_prep) exacerbations_7\NNS|possible|paranoid|with|in (r_pobj) to_4\IN|exacerbations (r_prep) call_2\VBP|cases|attention|to|and|raise|. (l_conj) raise_16\VB|considerations (l_dobj) considerations_18\NNS|neurobiological|regarding (l_acl) regarding_19\VBG|paranoia (l_pobj) paranoia_20\NN|
D005473_D010259 CID fluoxetine_10\NN|and|amitriptyline (r_advmod) cases_1\NNS|five|of|fluoxetine (l_prep) of_2\IN|exacerbation (l_pobj) exacerbation_4\NN|paranoid|with (l_amod) paranoid_3\JJ|
D000639_D010259 CID amitriptyline_12\NN| (r_conj) fluoxetine_10\NN|and|amitriptyline (r_advmod) cases_1\NNS|five|of|fluoxetine (l_prep) of_2\IN|exacerbation (l_pobj) exacerbation_4\NN|paranoid|with (l_amod) paranoid_3\JJ|
D012701_D003866 NONE serotonin_37\NN| (r_compound) inhibitors_39\NNS|serotonin|reuptake (r_pobj) with_36\IN|inhibitors (r_prep) associated_35\VBN|with (r_acl) exacerbations_34\NNS|paranoid|associated (r_pobj) to_32\IN|exacerbations (r_prep) present_29\VB|disorders|may|vulnerability|to|. (l_nsubj) disorders_2\NNS|complicated|depressive|(|including|)
D012701_D011605 NONE serotonin_37\NN| (r_compound) inhibitors_39\NNS|serotonin|reuptake (r_pobj) with_36\IN|inhibitors (r_prep) associated_35\VBN|with (r_acl) exacerbations_34\NNS|paranoid|associated (r_pobj) to_32\IN|exacerbations (r_prep) present_29\VB|disorders|may|vulnerability|to|. (l_nsubj) disorders_2\NNS|complicated|depressive|(|including|) (l_prep) including_4\VBG|atypicality|in (l_pobj) atypicality_5\NN|of|,|chronicity (l_conj) chronicity_11\NN|,|psychosis (l_conj) psychosis_13\NN|,|bipolarity
D012701_D011605 NONE serotonin_37\NN| (r_compound) inhibitors_39\NNS|serotonin|reuptake (r_pobj) with_36\IN|inhibitors (r_prep) associated_35\VBN|with (r_acl) exacerbations_34\NNS|paranoid|associated (r_pobj) to_32\IN|exacerbations (r_prep) present_29\VB|disorders|may|vulnerability|to|. (l_nsubj) disorders_2\NNS|complicated|depressive|(|including|) (l_prep) including_4\VBG|atypicality|in (l_prep) in_20\IN|course (l_pobj) course_22\NN|the|of (l_prep) of_23\IN|psychosis (l_pobj) psychosis_26\NN|a|primary
D004298_D010259 NONE dopamine_18\NN| (r_compound) release_19\NN|5ht3|mediated|dopamine (r_pobj) including_13\VBG|release (r_prep) mechanisms_11\NNS|cryptic|,|several|,|including (r_attr) remain_7\VBP|although|pharmacology|mechanisms (l_nsubj) pharmacology_2\NN|the|and|neurobiology|of (l_prep) of_5\IN|paranoia (l_pobj) paranoia_6\NN|
48835
D011433_D007003 NONE propranolol_2\NN|of (l_prep) of_3\IN|effects (l_pobj) effects_5\NNS|cardiovascular|of (l_prep) of_6\IN|hypoglycaemia (l_pobj) hypoglycaemia_8\NN|induced
15321332
D004329_D001008 CID droperidol_9\NN|low|dose|used (r_pobj) due_5\IN|to|droperidol (r_prep) case_1\NN|a|of|due|. (l_prep) of_2\IN|anxiety (l_pobj) anxiety_4\NN|postoperative
D004329_D001008 CID droperidol_3\NN| (r_npadvmod) induced_5\VBN|droperidol|- (r_amod) disturbance_7\NN|induced|psychological
24816962
D008795_D001927 CID Metronidazole_0\NNP| (r_npadvmod) induced_2\VBN|metronidazole|- (r_amod) encephalopathy_3\NN|induced|:|scenario|.
D008795_D001927 CID metronidazole_13\NN| (r_compound) intake_14\NN|prolonged|metronidazole (r_pobj) following_11\VBG|intake (r_prep) features_8\NNS|where|a|patient|developed|of|following (l_prep) of_9\IN|encephalopathy (l_pobj) encephalopathy_10\JJ|
D008795_D064420 NONE metronidazole_3\JJ| (r_amod) toxicity_4\NN|metronidazole
3990093
D011692_D007674 NONE aminonucleoside_8\JJ| (r_amod) nephrosis_9\NN|aminonucleoside (r_pobj) with_7\IN|nephrosis (r_prep) rats_6\NNS|with (r_pobj) in_5\IN|rats (r_prep) sclerosis_4\NN|glomerular|in
D011692_D007674 NONE aminonucleoside_16\NN| (r_nmod) model_20\NN|aminonucleoside|(|pan|) (r_advcl) studied_12\VBN|relationship|was|in|model|. (l_nsubjpass) relationship_2\NN|the|possible|between (l_prep) between_3\IN|dysfunction (l_pobj) dysfunction_5\NN|mesangial|and|development|of
D011692_D007674 NONE aminonucleoside_16\NN| (r_nmod) model_20\NN|aminonucleoside|(|pan|) (r_advcl) studied_12\VBN|relationship|was|in|model|. (l_nsubjpass) relationship_2\NN|the|possible|between (l_prep) between_3\IN|dysfunction (l_pobj) dysfunction_5\NN|mesangial|and|development|of (l_prep) of_8\IN|sclerosis (l_pobj) sclerosis_10\NN|glomerular
D011692_D007674 NONE PAN_18\NNP| (r_nmod) model_20\NN|aminonucleoside|(|pan|) (r_advcl) studied_12\VBN|relationship|was|in|model|. (l_nsubjpass) relationship_2\NN|the|possible|between (l_prep) between_3\IN|dysfunction (l_pobj) dysfunction_5\NN|mesangial|and|development|of
D011692_D007674 NONE PAN_18\NNP| (r_nmod) model_20\NN|aminonucleoside|(|pan|) (r_advcl) studied_12\VBN|relationship|was|in|model|. (l_nsubjpass) relationship_2\NN|the|possible|between (l_prep) between_3\IN|dysfunction (l_pobj) dysfunction_5\NN|mesangial|and|development|of (l_prep) of_8\IN|sclerosis (l_pobj) sclerosis_10\NN|glomerular
D011692_D007674 NONE PAN_16\NNP| (r_compound) rats_17\NNS|pan (r_pobj) of_15\IN|rats (r_prep) glomeruli_14\NN|the|of (r_pobj) of_12\IN|glomeruli (r_prep) %_11\NN|7.6|+/-|3.4|of (r_pobj) in_7\IN|% (r_prep) found_6\VBN|at|sclerosis|was|in|;|were (l_nsubjpass) sclerosis_4\NN|glomerular
D011692_D007674 NONE PAN_7\NNP| (r_compound) nephrosis_8\NN|pan (r_pobj) in_6\IN|nephrosis (r_prep) model_5\NN|the|remnant|kidney|in (r_pobj) to_1\IN|model (r_prep) Similar_0\JJ|to (r_nsubjpass) related_16\VBN|similar|development|may|be|to|.|" (l_nsubjpass) development_10\NN|the|of (l_prep) of_11\IN|sclerosis (l_pobj) sclerosis_13\NN|glomerular
D011692_D009401 NONE aminonucleoside_8\JJ| (r_amod) nephrosis_9\NN|aminonucleoside
D011692_D009401 NONE PAN_7\NNP| (r_compound) nephrosis_8\NN|pan
D011692_D011507 CID PAN_4\NNP| (r_compound) rats_5\NNS|the|pan (r_nsubj) were_6\VBD|rats (r_auxpass) proteinuric_8\JJ|after|were|severely|hr|,|and|given
D002244_D011507 NONE carbon_23\NN|colloidal|(|cc|) (r_dobj) given_21\VBN|rats|were|carbon|intravenously|. (r_conj) proteinuric_8\JJ|after|were|severely|hr|,|and|given
D011692_D012598 NONE PAN_12\NNP| (r_compound) treatment_13\NN|chronic|pan (r_pobj) during_10\IN|treatment (r_prep) change_9\VB|since|clearance|did|not|during (r_advcl) conclude_16\VBP|change|,|we|caused|. (l_ccomp) caused_26\VBN|that|localization|is|by (l_agent) by_27\IN|uptake (l_pobj) uptake_31\NN|an|increased|cc|after (l_prep) after_33\IN|shortly|injection (l_pobj) injection_34\NN|in (l_prep) in_35\IN|areas (l_pobj) areas_38\NNS|apparent|vulnerable|develop (l_relcl) develop_42\VB|where|sclerosis|will|subsequently (l_nsubj) sclerosis_40\NN|
6517710
D011796_D003328 CID hydrochloride_10\NN|quinacrine (r_dobj) ingesting_8\VBG|hydrochloride (r_acl) rats_7\NNS|f-344|ingesting (r_pobj) of_5\IN|rats (r_prep) heart_4\NN|the|of (r_dobj) involving_2\VBG|heart (r_acl) thrombosis_1\NN|atrial|involving|.
D011796_D003328 CID hydrochloride_6\NN| (r_appos) quinacrine_5\NN|ppm|hydrochloride|in (r_pobj) with_2\IN|quinacrine (r_prep) treated_1\VBD|rats|with|developed|. (l_conj) developed_11\VBD|all|incidence (l_dobj) incidence_14\NN|a|high|of (l_prep) of_15\IN|thrombosis (l_pobj) thrombosis_18\NN|left|atrial
D011796_D003328 CID hydrochloride_8\NN|and|nitrite (r_appos) quinacrine_7\NN|ppm|hydrochloride (r_dobj) given_4\VBN|percent|quinacrine|simultaneously|in (r_csubj) had_18\VBD|given|thrombosis|,|have|. (l_advcl) have_36\VB|while|rats|did|not|thrombosis (l_dobj) thrombosis_38\NN|atrial
D011796_D013927 NONE hydrochloride_8\NN|and|nitrite (r_appos) quinacrine_7\NN|ppm|hydrochloride (r_dobj) given_4\VBN|percent|quinacrine|simultaneously|in (r_csubj) had_18\VBD|given|thrombosis|,|have|. (l_dobj) thrombosis_19\NN|of
D012977_D013927 NONE nitrite_13\NN|ppm|sodium (r_conj) hydrochloride_8\NN|and|nitrite (r_appos) quinacrine_7\NN|ppm|hydrochloride (r_dobj) given_4\VBN|percent|quinacrine|simultaneously|in (r_csubj) had_18\VBD|given|thrombosis|,|have|. (l_dobj) thrombosis_19\NN|of
D012977_D003328 NONE nitrite_13\NN|ppm|sodium (r_conj) hydrochloride_8\NN|and|nitrite (r_appos) quinacrine_7\NN|ppm|hydrochloride (r_dobj) given_4\VBN|percent|quinacrine|simultaneously|in (r_csubj) had_18\VBD|given|thrombosis|,|have|. (l_advcl) have_36\VB|while|rats|did|not|thrombosis (l_dobj) thrombosis_38\NN|atrial
6310832
D016572_D007239 CID cyclosporine_12\NN| (r_pobj) on_11\IN|cyclosporine (r_prep) recipients_10\NNS|transplant|on (r_conj) heart_5\NN|,|and|recipients (r_conj) kidney_3\NN|,|heart (r_pobj) in_2\IN|kidney (r_prep) infections_1\NNS|early|in|.
D016572_D007239 CID cyclosporine_27\NN| (r_compound) patients_28\NNS|the|randomized|cyclosporine (r_pobj) than_24\IN|patients (r_prep) had_4\VBD|patients|infections|than|. (l_dobj) infections_7\NNS|overall|(|p|(|p|)
D016572_D007239 CID cyclosporine_27\NN| (r_compound) patients_28\NNS|the|randomized|cyclosporine (r_pobj) than_24\IN|patients (r_prep) had_4\VBD|patients|infections|than|. (l_dobj) infections_7\NNS|overall|(|p|(|p|) (l_appos) P_9\NN|0.05|)|and|infections (l_conj) infections_17\NNS|nonviral
D016572_D007239 CID cyclosporine_8\JJ| (r_nmod) patients_10\NNS|cyclosporine|renal (r_pobj) than_7\IN|patients (r_prep) infections_6\NNS|more|than|but|infections
D016572_D007239 CID cyclosporine_8\JJ| (r_nmod) patients_10\NNS|cyclosporine|renal (r_pobj) than_7\IN|patients (r_prep) infections_6\NNS|more|than|but|infections (l_conj) infections_13\NNS|fewer|than
D016572_D007239 CID cyclosporine_10\NN|or|aza (r_pobj) on_9\IN|cyclosporine (r_prep) patients_8\NNS|renal|transplant|on (r_pobj) in_5\IN|patients (r_prep) deaths_4\NNS|no|infectious|in (r_attr) were_1\VBD|there|deaths|,|but|played (l_conj) played_16\VBD|infection|role|in|out|out|. (l_nsubj) infection_15\NN|
D016572_D007239 CID cyclosporine_6\NN| (r_npadvmod) treated_8\VBN|cyclosporine|- (r_amod) patients_10\NNS|treated|renal (r_pobj) in_5\IN|patients (r_prep) were_2\VBD|infections|common|in|than|. (l_nsubj) infections_1\NNS|pulmonary
D001379_D007239 CID Aza_2\NNP| (r_compound) patients_3\NNS|the|randomized|aza (r_nsubj) had_4\VBD|patients|infections|than|. (l_dobj) infections_7\NNS|overall|(|p|(|p|)
D001379_D007239 CID Aza_2\NNP| (r_compound) patients_3\NNS|the|randomized|aza (r_nsubj) had_4\VBD|patients|infections|than|. (l_dobj) infections_7\NNS|overall|(|p|(|p|) (l_appos) P_9\NN|0.05|)|and|infections (l_conj) infections_17\NNS|nonviral
D001379_D007239 CID Aza_16\NNP| (r_nmod) patients_18\NNS|the|aza|renal (r_pobj) than_14\IN|patients (r_prep) infections_13\NNS|fewer|than (r_conj) infections_6\NNS|more|than|but|infections
D001379_D007239 CID Aza_16\NNP| (r_nmod) patients_18\NNS|the|aza|renal (r_pobj) than_14\IN|patients (r_prep) infections_13\NNS|fewer|than
D001379_D007239 CID Aza_12\NNP| (r_conj) cyclosporine_10\NN|or|aza (r_pobj) on_9\IN|cyclosporine (r_prep) patients_8\NNS|renal|transplant|on (r_pobj) in_5\IN|patients (r_prep) deaths_4\NNS|no|infectious|in (r_attr) were_1\VBD|there|deaths|,|but|played (l_conj) played_16\VBD|infection|role|in|out|out|. (l_nsubj) infection_15\NN|
D001379_D007239 CID Aza_13\NNP| (r_npadvmod) treated_15\VBN|aza|- (r_amod) patients_16\NNS|treated|(|p|) (r_pobj) in_12\IN|patients (r_prep) than_11\IN|in (r_prep) were_2\VBD|infections|common|in|than|. (l_nsubj) infections_1\NNS|pulmonary
D016572_D016470 NONE cyclosporine_3\NN| (r_pobj) on_2\IN|cyclosporine (r_prep) patients_1\NNS|renal|on (r_nsubj) had_4\VBD|patients|bacteremias|. (l_dobj) bacteremias_7\NNS|the|fewest
D001379_D013203 NONE Aza_0\NNP| (r_compound) patients_1\NNS|aza (r_nsubj) had_2\VBD|patients|infections|,|and|occurred (l_dobj) infections_6\NNS|more|staphylococcal|than
D001379_D009181 NONE Aza_0\NNP| (r_compound) patients_1\NNS|aza (r_nsubj) had_2\VBD|patients|infections|,|and|occurred (l_conj) occurred_23\VBD|infections|in|. (l_nsubj) infections_22\NNS|systemic|fungal
D016572_D003586 NONE cyclosporine_2\JJ| (r_compound) patients_3\NNS|the|cyclosporine (r_pobj) Of_0\IN|patients (r_prep) %_6\NN|of|15 (r_nsubj) had_7\VBD|,|%|symptoms|. (l_dobj) symptoms_8\NNS|related (l_acl) related_9\VBN|to (l_prep) to_10\IN|infection (l_pobj) infection_12\NN|cmv
D016572_D020031 NONE cyclosporine_14\NN| (r_compound) patients_15\NNS|65|cyclosporine|studied (r_pobj) of_12\IN|patients (r_prep) %_11\NN|20|of (r_pobj) in_9\IN|% (r_prep) found_8\VBN|evidence|was|in|. (l_nsubjpass) evidence_1\NN|serological|for (l_prep) for_2\IN|infection (l_pobj) infection_6\NN|virus
15953230
C012052_D062787 NONE amisulpride_3\JJ| (r_amod) overdose_4\NN|amisulpride
C012052_D008133 CID amisulpride_3\JJ| (r_amod) overdose_4\NN|amisulpride (r_pobj) of_2\IN|overdose (r_prep) cases_1\NNS|two|of|:|cause|. (l_appos) cause_7\NN|a|for (l_prep) for_8\IN|syndrome (l_pobj) syndrome_11\NN|prolonged|qt
C012052_D011041 NONE amisulpride_14\NN| (r_pobj) of_13\IN|amisulpride (r_prep) g_12\NN|3.6|of|,|respectively (r_conj) poisoning_6\NN|deliberate|self|-|with|and|g
D002125_D008133 NONE gluconate_11\VBN|i.v.|calcium (r_pobj) of_8\IN|gluconate (r_prep) administration_7\NN|of (r_pobj) to_6\IN|administration (r_prep) respond_5\VB|to|to (r_xcomp) appeared_3\VBD|prolongation|respond|. (l_nsubj) prolongation_2\NN|the|qt
7173007
C025504_D009325 CID X_3\NNP|dimer|- (r_compound) group_4\NN|the|x (r_nsubj) had_5\VBD|group|incidence|. (l_dobj) incidence_8\NN|a|higher|of (l_prep) of_9\IN|nausea (l_pobj) nausea_10\NN|and|dizziness
C025504_D004244 CID X_3\NNP|dimer|- (r_compound) group_4\NN|the|x (r_nsubj) had_5\VBD|group|incidence|. (l_dobj) incidence_8\NN|a|higher|of (l_prep) of_9\IN|nausea (l_pobj) nausea_10\NN|and|dizziness (l_conj) dizziness_12\NN|
C006753_D015746 CID Endografine_1\NNP| (r_compound) group_2\NN|the|endografine (r_nsubj) had_3\VBD|group|incidence|. (l_dobj) incidence_6\NN|a|higher|of (l_prep) of_7\IN|pain (l_pobj) pain_9\NN|abdominal
D007485_D064420 NONE Hexabrix_0\NNP|and|vasurix (r_nmod) polyvidone_3\NN|hexabrix (r_nsubjpass) considered_5\VBN|polyvidone|are|media|and|preferred|. (l_conj) preferred_22\VBN|because|hexabrix|should|be (l_prep) because_14\IN|perhaps|of|toxicity (l_pobj) toxicity_18\NN|its|low
D007485_D064420 NONE Hexabrix_19\NNP| (r_nsubjpass) preferred_22\VBN|because|hexabrix|should|be (l_prep) because_14\IN|perhaps|of|toxicity (l_pobj) toxicity_18\NN|its|low
D000100_D064420 NONE polyvidone_3\NN|hexabrix (r_nsubjpass) considered_5\VBN|polyvidone|are|media|and|preferred|. (l_conj) preferred_22\VBN|because|hexabrix|should|be (l_prep) because_14\IN|perhaps|of|toxicity (l_pobj) toxicity_18\NN|its|low
D003287_D064420 NONE media_9\NNS|the|contrast|for (r_oprd) considered_5\VBN|polyvidone|are|media|and|preferred|. (l_conj) preferred_22\VBN|because|hexabrix|should|be (l_prep) because_14\IN|perhaps|of|toxicity (l_pobj) toxicity_18\NN|its|low
11385188
D003042_D006331 NONE cocaine_7\NN| (r_compound) users_8\NNS|asymptomatic|chronic|cocaine (r_pobj) in_4\IN|users (r_prep) Prevalence_0\NN|of|in|. (l_prep) of_1\IN|disease (l_pobj) disease_3\NN|heart
D003042_D006331 NONE cocaine_12\NN| (r_compound) users_13\NNS|young|asymptomatic|chronic|cocaine (r_pobj) in_7\IN|users (r_prep) disease_6\NN|heart|in
D003042_D006331 NONE cocaine_16\NN| (r_compound) users_17\NNS|35|cocaine|and|controls (r_conj) prevalence_3\NN|the|of|,|users (l_prep) of_4\IN|disease (l_pobj) disease_6\NN|heart|in
D003042_D003324 CID cocaine_18\NN| (r_compound) users_19\NNS|young|asymptomatic|chronic|cocaine (r_pobj) in_14\IN|users (r_prep) common_9\JJ|%|in (r_acomp) is_8\VBZ|that|disease|common (l_nsubj) disease_7\NN|artery|myocardial
D003042_D009202 CID cocaine_18\NN| (r_compound) users_19\NNS|young|asymptomatic|chronic|cocaine (r_pobj) in_14\IN|users (r_prep) common_9\JJ|%|in (r_acomp) is_8\VBZ|that|disease|common (l_nsubj) disease_7\NN|artery|myocardial
3864191
D012459_D007674 NONE Salicylate_0\NNP| (r_compound) nephropathy_1\NN|salicylate|in|:|role|.
D011453_D007674 NONE prostaglandins_10\NNS| (r_pobj) of_9\IN|prostaglandins (r_prep) role_8\NN|potential|of (r_appos) nephropathy_1\NN|salicylate|in|:|role|.
D011453_D007674 NONE prostaglandins_6\NNS| (r_pobj) of_5\IN|prostaglandins (r_prep) role_4\NN|the|potential|of|in (l_prep) in_7\IN|development (l_pobj) development_9\NN|the|of|in (l_prep) of_10\IN|nephropathy (l_pobj) nephropathy_12\NN|analgesic
D011453_D007674 NONE prostaglandin_4\NN| (r_amod) synthesis_5\NN|renal|prostaglandin (r_pobj) in_2\IN|synthesis (r_prep) changes_1\NNS|the|in (r_nsubjpass) accompanied_7\VBN|changes|were|by|. (l_agent) by_8\IN|evidence (l_pobj) evidence_9\NN|of|but|rats (l_prep) of_10\IN|damage (l_pobj) damage_12\NN|renal|in
D011453_D007674 NONE prostaglandin_5\NN| (r_amod) synthesis_6\NN|enhanced|prostaglandin (r_nsubj) contributes_7\VBZ|that|synthesis|to|,|and|lead (l_conj) lead_24\VB|that|inhibition|may|to (l_prep) to_25\IN|lesions (l_pobj) lesions_29\NNS|pathological|renal|medullary|and|deterioration (l_conj) deterioration_31\NN|of (l_prep) of_32\IN|function (l_pobj) function_34\NN|renal
D011453_D007674 NONE prostaglandin_21\JJ| (r_amod) synthesis_22\NN|prostaglandin (r_pobj) of_20\IN|synthesis (r_prep) inhibition_19\NN|of (r_nsubj) lead_24\VB|that|inhibition|may|to (l_prep) to_25\IN|lesions (l_pobj) lesions_29\NNS|pathological|renal|medullary|and|deterioration (l_conj) deterioration_31\NN|of (l_prep) of_32\IN|function (l_pobj) function_34\NN|renal
-1_D006932 NONE glucuronyl_12\NN| (r_compound) transferase_13\NN|glucuronyl (r_pobj) of_11\IN|transferase (r_prep) absence_10\NN|the|of (r_pobj) due_7\IN|to|absence (r_amod) hyperbilirubinemia_6\NN|unconjugated|due
D001663_D006932 NONE bilirubin_18\NN| (r_amod) deposition_19\NN|marked|bilirubin|in (r_pobj) to_16\IN|deposition (r_prep) leading_15\VBG|to (r_advcl) have_4\VBP|rats|hyperbilirubinemia|,|leading|. (l_dobj) hyperbilirubinemia_6\NN|unconjugated|due
D011453_D006417 NONE prostaglandin_4\NN| (r_amod) synthesis_5\NN|renal|prostaglandin (r_pobj) in_2\IN|synthesis (r_prep) changes_1\NNS|the|in (r_nsubjpass) accompanied_7\VBN|changes|were|by|. (l_agent) by_8\IN|evidence (l_pobj) evidence_9\NN|of|but|rats (l_conj) rats_21\NNS|jj|evidenced|:|incidence|;|creatinine (l_conj) incidence_27\NN|increased|and|severity|of|p (l_prep) of_30\IN|hematuria (l_pobj) hematuria_31\NN|
D001241_D007674 CID aspirin_14\NN| (r_npadvmod) treated_16\VBN|aspirin|- (r_amod) jj_17\UH|treated (r_pobj) in_13\IN|jj (r_prep) damage_12\NN|renal|in
D001241_D007674 CID aspirin_69\NN| (r_npadvmod) treated_71\VBN|aspirin|- (r_amod) jJ_72\NNP|treated (r_conj) jj_67\NNS|either|treated|or|jj (r_pobj) to_62\IN|jj (r_prep) compared_61\VBN|to (r_prep) p_57\XX|0.005|compared|) (r_appos) increase_50\VB|in|(|p (r_conj) creatinine_41\NN|increased|serum|(|0.05|)|;|and|increase (r_conj) rats_21\NNS|jj|evidenced|:|incidence|;|creatinine (r_conj) evidence_9\NN|of|but|rats (l_prep) of_10\IN|damage (l_pobj) damage_12\NN|renal|in
D001241_D006417 NONE aspirin_14\NN| (r_npadvmod) treated_16\VBN|aspirin|- (r_amod) jj_17\UH|treated (r_pobj) in_13\IN|jj (r_prep) damage_12\NN|renal|in (r_pobj) of_10\IN|damage (r_prep) evidence_9\NN|of|but|rats (l_conj) rats_21\NNS|jj|evidenced|:|incidence|;|creatinine (l_conj) incidence_27\NN|increased|and|severity|of|p (l_prep) of_30\IN|hematuria (l_pobj) hematuria_31\NN|
D001241_D006417 NONE aspirin_69\NN| (r_npadvmod) treated_71\VBN|aspirin|- (r_amod) jJ_72\NNP|treated (r_conj) jj_67\NNS|either|treated|or|jj (r_pobj) to_62\IN|jj (r_prep) compared_61\VBN|to (r_prep) p_57\XX|0.005|compared|) (r_appos) increase_50\VB|in|(|p (r_conj) creatinine_41\NN|increased|serum|(|0.05|)|;|and|increase (r_conj) rats_21\NNS|jj|evidenced|:|incidence|;|creatinine (l_conj) incidence_27\NN|increased|and|severity|of|p (l_prep) of_30\IN|hematuria (l_pobj) hematuria_31\NN|
D003404_D007674 NONE creatinine_41\NN|increased|serum|(|0.05|)|;|and|increase (r_conj) rats_21\NNS|jj|evidenced|:|incidence|;|creatinine (r_conj) evidence_9\NN|of|but|rats (l_prep) of_10\IN|damage (l_pobj) damage_12\NN|renal|in
D003404_D006417 NONE creatinine_41\NN|increased|serum|(|0.05|)|;|and|increase (r_conj) rats_21\NNS|jj|evidenced|:|incidence|;|creatinine (l_conj) incidence_27\NN|increased|and|severity|of|p (l_prep) of_30\IN|hematuria (l_pobj) hematuria_31\NN|
D011453_D058186 NONE prostaglandin_5\NN| (r_amod) synthesis_6\NN|enhanced|prostaglandin (r_nsubj) contributes_7\VBZ|that|synthesis|to|,|and|lead (l_conj) lead_24\VB|that|inhibition|may|to (l_prep) to_25\IN|lesions (l_pobj) lesions_29\NNS|pathological|renal|medullary|and|deterioration
D011453_D058186 NONE prostaglandin_21\JJ| (r_amod) synthesis_22\NN|prostaglandin (r_pobj) of_20\IN|synthesis (r_prep) inhibition_19\NN|of (r_nsubj) lead_24\VB|that|inhibition|may|to (l_prep) to_25\IN|lesions (l_pobj) lesions_29\NNS|pathological|renal|medullary|and|deterioration
11366874
D019888_D001145 NONE Viracept_0\NNP|and|irregular (r_amod) warning_4\NN|viracept|heartbeat|. (l_compound) heartbeat_3\NN|
D019888_D001145 NONE Viracept_11\NNP|the|protease|inhibitor (r_nsubj) cause_13\VB|that|viracept|may|beat (l_ccomp) beat_17\VBD|heart|,|known|,|in
D019888_D001919 CID Viracept_11\NNP|the|protease|inhibitor (r_nsubj) cause_13\VB|that|viracept|may|beat (l_ccomp) beat_17\VBD|heart|,|known|,|in (l_advcl) known_19\VBN|as (l_prep) as_20\IN|bradycardia (l_pobj) bradycardia_21\NNP|
D019888_D001919 CID Viracept_11\NNP|in (r_attr) was_10\VBD|who|viracept (r_relcl) patient_8\NN|a|old|male|was (r_pobj) in_2\IN|patient (r_prep) occurred_1\VBD|bradycardia|in|. (l_nsubj) Bradycardia_0\NNS|
6985498
D008733_D056486 CID methoxyflurane_8\NN| (r_pobj) with_7\IN|methoxyflurane (r_prep) anesthesia_6\NN|with (r_pobj) after_5\IN|anesthesia (r_prep) acidosis_4\NN|renal|tubular|after (r_conj) Hepatitis_0\NNP|and|acidosis|.
D008733_D000141 CID methoxyflurane_8\NN| (r_pobj) with_7\IN|methoxyflurane (r_prep) anesthesia_6\NN|with (r_pobj) after_5\IN|anesthesia (r_prep) acidosis_4\NN|renal|tubular|after
D008733_D000141 CID methoxyflurane_10\NN| (r_compound) anesthesia_11\NN|methoxyflurane|developed (l_acl) developed_12\VBD|postoperatively|syndrome (l_dobj) syndrome_17\NN|a|insufficiency|and|acidosis (l_conj) acidosis_21\NN|renal|tubular
D008733_D041881 NONE methoxyflurane_10\NN| (r_compound) anesthesia_11\NN|methoxyflurane|developed (r_pobj) under_9\IN|anesthesia (r_prep) operated_5\VBN|for|under (l_prep) for_6\IN|cholecystitis (l_pobj) cholecystitis_8\NN|acute
D008733_D048550 NONE methoxyflurane_10\NN| (r_compound) anesthesia_11\NN|methoxyflurane|developed (l_acl) developed_12\VBD|postoperatively|syndrome (l_dobj) syndrome_17\NN|a|insufficiency|and|acidosis
3475563
D001507_D002180 CID dipropionate_11\NN|beclomethasone (r_pobj) with_9\IN|dipropionate (r_prep) hoarseness_8\NN|with (r_conj) candidiasis_6\NN|oral|or|hoarseness
D001507_D002180 CID beclomethasone_9\NN|inhaled|,|15|) (r_pobj) on_7\IN|beclomethasone (r_prep) placed_6\VBN|who|were|on (r_relcl) patients_3\NNS|158|asthmatic|placed (r_pobj) Of_0\IN|patients (r_prep) developed_16\VBD|of|hoarseness|. (l_dobj) hoarseness_18\NN|either|(|8) (l_appos) 8)_20\CD|,|thrush (l_appos) thrush_23\NN|oral|6|,|or|both
D001507_D006685 CID dipropionate_11\NN|beclomethasone (r_pobj) with_9\IN|dipropionate (r_prep) hoarseness_8\NN|with
D001507_D006685 CID beclomethasone_9\NN|inhaled|,|15|) (r_pobj) on_7\IN|beclomethasone (r_prep) placed_6\VBN|who|were|on (r_relcl) patients_3\NNS|158|asthmatic|placed (r_pobj) Of_0\IN|patients (r_prep) developed_16\VBD|of|hoarseness|. (l_dobj) hoarseness_18\NN|either|(|8)
D001507_D006685 CID beclomethasone_9\NN|inhaled (r_pobj) on_7\IN|beclomethasone (r_prep) restarted_6\VBN|that|patients|may|be|on|indicated (r_ccomp) conclude_1\VBP|we|restarted (r_ccomp) be_29\VB|conclude|;|however|,|because|should|not (l_prep) because_16\IN|of|rate (l_pobj) rate_21\NN|the|recurrence|,|patients (l_appos) patients_23\NNS|develop (l_relcl) develop_25\VBP|who|hoarseness (l_dobj) hoarseness_26\NN|
D001507_D006685 CID beclomethasone_7\NN|topical (r_conj) prednisone_4\NN|oral|and|beclomethasone (r_pobj) of_2\IN|prednisone (r_prep) use_1\NN|concomitant|of (r_nsubj) increase_9\VB|use|may|risk|. (l_dobj) risk_11\NN|the|of (l_prep) of_12\IN|developing (l_pcomp) developing_13\VBG|hoarseness (l_dobj) hoarseness_14\NN|or|candidiasis
D001507_D001249 NONE beclomethasone_9\NN|inhaled|,|15|) (r_pobj) on_7\IN|beclomethasone (r_prep) placed_6\VBN|who|were|on (r_relcl) patients_3\NNS|158|asthmatic|placed (l_amod) asthmatic_2\JJ|
D011241_D006685 NONE prednisone_4\NN|oral|and|beclomethasone (r_pobj) of_2\IN|prednisone (r_prep) use_1\NN|concomitant|of (r_nsubj) increase_9\VB|use|may|risk|. (l_dobj) risk_11\NN|the|of (l_prep) of_12\IN|developing (l_pcomp) developing_13\VBG|hoarseness (l_dobj) hoarseness_14\NN|or|candidiasis
D011241_D002177 NONE prednisone_4\NN|oral|and|beclomethasone (r_pobj) of_2\IN|prednisone (r_prep) use_1\NN|concomitant|of (r_nsubj) increase_9\VB|use|may|risk|. (l_dobj) risk_11\NN|the|of (l_prep) of_12\IN|developing (l_pcomp) developing_13\VBG|hoarseness (l_dobj) hoarseness_14\NN|or|candidiasis (l_conj) candidiasis_16\NN|
D001507_D002177 NONE beclomethasone_7\NN|topical (r_conj) prednisone_4\NN|oral|and|beclomethasone (r_pobj) of_2\IN|prednisone (r_prep) use_1\NN|concomitant|of (r_nsubj) increase_9\VB|use|may|risk|. (l_dobj) risk_11\NN|the|of (l_prep) of_12\IN|developing (l_pcomp) developing_13\VBG|hoarseness (l_dobj) hoarseness_14\NN|or|candidiasis (l_conj) candidiasis_16\NN|
24691439
D003907_D012173 NONE dexamethasone_9\NN|topical|ocular|% (r_pobj) with_4\IN|dexamethasone (r_prep) Treatment_0\NN|of|with (r_nsubj) led_10\VBN|treatment|to|,|resembling|. (l_prep) to_11\IN|elevation (l_pobj) elevation_12\NN|of (l_prep) of_13\IN|pressure (l_pobj) pressure_15\NN|intraocular|(|iop|loss (l_appos) loss_23\NN|functional|of|,|and|degeneration (l_prep) of_24\IN|cells (l_pobj) cells_27\NNS|retinal|ganglion (l_compound) ganglion_26\NN|
D003907_D009410 CID dexamethasone_9\NN|topical|ocular|% (r_pobj) with_4\IN|dexamethasone (r_prep) Treatment_0\NN|of|with (r_nsubj) led_10\VBN|treatment|to|,|resembling|. (l_prep) to_11\IN|elevation (l_pobj) elevation_12\NN|of (l_prep) of_13\IN|pressure (l_pobj) pressure_15\NN|intraocular|(|iop|loss (l_appos) loss_23\NN|functional|of|,|and|degeneration (l_conj) degeneration_31\NN|axonal
D003907_D005901 CID dexamethasone_9\NN|topical|ocular|% (r_pobj) with_4\IN|dexamethasone (r_prep) Treatment_0\NN|of|with (r_nsubj) led_10\VBN|treatment|to|,|resembling|. (l_advcl) resembling_33\VBG|glaucoma (l_dobj) glaucoma_37\NN|induced|in
D003907_D009798 CID dexamethasone_2\NN| (r_npadvmod) induced_4\VBN|dexamethasone|- (r_amod) hypertension_6\NN|induced|ocular
D003907_D009798 CID Dexamethasone_0\NN| (r_nsubj) induced_1\VBD|dexamethasone|chop|in|,|and|reduced (l_conj) reduced_23\VBN|deletion|stress|in|and|prevented|. (l_conj) prevented_30\VBN|hypertension (l_dobj) hypertension_35\NN|induced|ocular
D003907_D009798 CID dexamethasone_31\NN| (r_npadvmod) induced_33\VBN|dexamethasone|- (r_amod) hypertension_35\NN|induced|ocular
D003907_D009798 CID dexamethasone_13\NN| (r_npadvmod) induced_15\VBN|dexamethasone|- (r_amod) hypertension_17\NN|induced|ocular|in
C075773_D009798 NONE 4-phenylbutyrate_11\RB|sodium (r_pobj) with_9\IN|4-phenylbutyrate (r_prep) reduction_2\NN|of|with (r_nsubj) prevented_12\VBN|furthermore|,|reduction|hypertension|. (l_dobj) hypertension_17\NN|induced|ocular|in
24927617
C486464_D012206 CID telaprevir_10\NNS| (r_pobj) with_9\IN|telaprevir (r_prep) treated_8\VBN|with|and|simvastatin (r_acl) patient_7\NN|infected|treated (r_appos) Rhabdomyolysis_0\NNP|in|patient|.
C486464_D006526 NONE telaprevir_10\NNS| (r_pobj) with_9\IN|telaprevir (r_prep) treated_8\VBN|with|and|simvastatin (r_acl) patient_7\NN|infected|treated (l_amod) infected_6\VBN|
C486464_D006526 NONE telaprevir_20\NNS| (r_conj) interferon_18\NN|and|telaprevir (r_dobj) pegylated_17\VBN|interferon (r_conj) received_11\VBD|man|therapy|with|,|pegylated|. (l_nsubj) man_3\NN|a|46-year|old|with (l_prep) with_4\IN|infection (l_pobj) infection_10\NN|a|chronic|virus
D019821_D012206 CID simvastatin_12\NN| (r_conj) treated_8\VBN|with|and|simvastatin (r_acl) patient_7\NN|infected|treated (r_appos) Rhabdomyolysis_0\NNP|in|patient|.
D019821_D006526 NONE simvastatin_12\NN| (r_conj) treated_8\VBN|with|and|simvastatin (r_acl) patient_7\NN|infected|treated (l_amod) infected_6\VBN|
D012254_D006526 NONE ribavirin_15\RB| (r_pobj) with_14\IN|ribavirin (r_prep) received_11\VBD|man|therapy|with|,|pegylated|. (l_nsubj) man_3\NN|a|46-year|old|with (l_prep) with_4\IN|infection (l_pobj) infection_10\NN|a|chronic|virus
C417083_D006526 NONE interferon_18\NN|and|telaprevir (r_dobj) pegylated_17\VBN|interferon (r_conj) received_11\VBD|man|therapy|with|,|pegylated|. (l_nsubj) man_3\NN|a|46-year|old|with (l_prep) with_4\IN|infection (l_pobj) infection_10\NN|a|chronic|virus
D019821_D064420 NONE simvastatin_2\NN|and|discontinued (l_conj) discontinued_8\VBN|drugs|were|suspected|. (l_advcl) suspected_19\VBN|because|toxicity|was (l_nsubjpass) toxicity_10\NN|due
D019821_D009135 CID Simvastatin_0\NNP| (r_compound) plasma_1\NN|simvastatin (r_compound) concentration_2\NN|plasma (r_nsubj) increased_3\VBD|concentration|times|in|induced|. (l_advcl) induced_11\VBD|related (l_ccomp) related_15\VBN|toxicity|is|to (l_nsubjpass) toxicity_13\NN|muscle
D019821_D009135 CID statin_10\NN| (r_conj) patient_8\NN|this|and|statin (r_pobj) in_6\IN|patient (r_prep) increased_3\VBD|concentration|times|in|induced|. (l_advcl) induced_11\VBD|related (l_ccomp) related_15\VBN|toxicity|is|to (l_nsubjpass) toxicity_13\NN|muscle
D019821_D009135 CID statin_21\NN|the|in (r_pobj) of_19\IN|statin (r_prep) concentration_18\NN|the|of (r_pobj) to_16\IN|concentration (r_prep) related_15\VBN|toxicity|is|to (l_nsubjpass) toxicity_13\NN|muscle
11835460
D007980_D015835 CID Levodopa_0\NNP| (r_npadvmod) induced_2\VBN|levodopa|-|dyskinesias|. (l_dobj) dyskinesias_4\NNS|ocular|in
D007980_D015835 CID Levodopa_0\NNP| (r_npadvmod) induced_2\VBN|levodopa|- (r_amod) dyskinesias_4\NNS|induced|ocular
D007980_D015835 CID levodopa_17\NN| (r_pobj) of_16\IN|levodopa (r_prep) effect_15\NN|the|peak|of (r_pobj) during_12\IN|effect (r_prep) report_1\VBP|we|on|during|,|and|hypothesize|. (l_conj) hypothesize_20\VB|needed (l_ccomp) needed_31\VBN|that|denervation|is|for (l_prep) for_32\IN|appearance (l_pobj) appearance_34\NN|the|of (l_prep) of_35\IN|dyskinesias (l_pobj) dyskinesias_41\NNS|these|induce|ocular
D007980_D015835 CID levodopa_37\NN| (r_npadvmod) induce_39\VB|levodopa|- (r_amod) dyskinesias_41\NNS|these|induce|ocular
D007980_D010300 NONE Levodopa_0\NNP| (r_npadvmod) induced_2\VBN|levodopa|-|dyskinesias|. (l_dobj) dyskinesias_4\NNS|ocular|in (l_prep) in_5\IN|disease (l_pobj) disease_8\NN|parkinson
24618873
D008614_D002526 NONE pethidine_9\NN| (r_pobj) of_8\IN|pethidine (r_prep) infusion_7\NN|rapid|of (r_pobj) by_5\IN|infusion (r_agent) induced_4\VBN|dysfunction|by|. (l_nsubj) dysfunction_3\NN|cerebellar
D008614_D005128 NONE pethidine_9\NN| (r_pobj) of_8\IN|pethidine (r_prep) infusion_7\NN|rapid|of (r_pobj) by_5\IN|infusion (r_agent) induced_4\VBN|dysfunction|by|. (l_nsubj) dysfunction_3\NN|cerebellar
D008614_D010146 NONE Pethidine_0\NNP| (r_nsubj) is_1\VBZ|pethidine|opioid|. (l_attr) opioid_3\NN|an|gains (l_relcl) gains_5\VBZ|that|popularity|for|through (l_prep) for_8\IN|control (l_pobj) control_12\NN|the|effective|pain (l_compound) pain_11\NN|
D008614_D010146 NONE pethidine_19\NN| (r_nsubj) cause_21\VB|in|,|pethidine|may|effects|. (l_prep) In_0\IN|patients|,|and|those (l_conj) those_10\DT|need (l_relcl) need_12\VBP|who|control (l_dobj) control_17\NN|term|pain (l_compound) pain_16\NN|
D008614_D051437 NONE pethidine_19\NN| (r_nsubj) cause_21\VB|in|,|pethidine|may|effects|. (l_prep) In_0\IN|patients|,|and|those (l_pobj) patients_1\NNS|with (l_prep) with_2\IN|function (l_pobj) function_7\NN|impaired|renal
D008614_D017093 NONE pethidine_19\NN| (r_nsubj) cause_21\VB|in|,|pethidine|may|effects|. (l_prep) In_0\IN|patients|,|and|those (l_pobj) patients_1\NNS|with (l_prep) with_2\IN|function (l_pobj) function_7\NN|impaired|renal
D008614_D020258 NONE pethidine_19\NN| (r_nsubj) cause_21\VB|in|,|pethidine|may|effects|. (l_dobj) effects_29\NNS|system|(|cns|)|through|resulting (l_prep) through_30\IN|metabolite (l_pobj) metabolite_33\NN|its|neurotoxic|,|norpethidine|, (l_amod) neurotoxic_32\JJ|
D008614_D001523 NONE pethidine_19\NN| (r_nsubj) cause_21\VB|in|,|pethidine|may|effects|. (l_dobj) effects_29\NNS|system|(|cns|)|through|resulting (l_acl) resulting_37\VBG|in (l_prep) in_38\IN|irritability (l_pobj) irritability_39\NN|and|attack
D008614_D012640 NONE pethidine_19\NN| (r_nsubj) cause_21\VB|in|,|pethidine|may|effects|. (l_dobj) effects_29\NNS|system|(|cns|)|through|resulting (l_acl) resulting_37\VBG|in (l_prep) in_38\IN|irritability (l_pobj) irritability_39\NN|and|attack (l_conj) attack_42\NN|seizure (l_compound) seizure_41\NN|
C002752_D051437 NONE norpethidine_35\NN| (r_appos) metabolite_33\NN|its|neurotoxic|,|norpethidine|, (r_pobj) through_30\IN|metabolite (r_prep) effects_29\NNS|system|(|cns|)|through|resulting (r_dobj) cause_21\VB|in|,|pethidine|may|effects|. (l_prep) In_0\IN|patients|,|and|those (l_pobj) patients_1\NNS|with (l_prep) with_2\IN|function (l_pobj) function_7\NN|impaired|renal
C002752_D017093 NONE norpethidine_35\NN| (r_appos) metabolite_33\NN|its|neurotoxic|,|norpethidine|, (r_pobj) through_30\IN|metabolite (r_prep) effects_29\NNS|system|(|cns|)|through|resulting (r_dobj) cause_21\VB|in|,|pethidine|may|effects|. (l_prep) In_0\IN|patients|,|and|those (l_pobj) patients_1\NNS|with (l_prep) with_2\IN|function (l_pobj) function_7\NN|impaired|renal
C002752_D010146 NONE norpethidine_35\NN| (r_appos) metabolite_33\NN|its|neurotoxic|,|norpethidine|, (r_pobj) through_30\IN|metabolite (r_prep) effects_29\NNS|system|(|cns|)|through|resulting (r_dobj) cause_21\VB|in|,|pethidine|may|effects|. (l_prep) In_0\IN|patients|,|and|those (l_conj) those_10\DT|need (l_relcl) need_12\VBP|who|control (l_dobj) control_17\NN|term|pain (l_compound) pain_16\NN|
C002752_D020258 NONE norpethidine_35\NN| (r_appos) metabolite_33\NN|its|neurotoxic|,|norpethidine|, (l_amod) neurotoxic_32\JJ|
C002752_D001523 NONE norpethidine_35\NN| (r_appos) metabolite_33\NN|its|neurotoxic|,|norpethidine|, (r_pobj) through_30\IN|metabolite (r_prep) effects_29\NNS|system|(|cns|)|through|resulting (l_acl) resulting_37\VBG|in (l_prep) in_38\IN|irritability (l_pobj) irritability_39\NN|and|attack
C002752_D012640 CID norpethidine_35\NN| (r_appos) metabolite_33\NN|its|neurotoxic|,|norpethidine|, (r_pobj) through_30\IN|metabolite (r_prep) effects_29\NNS|system|(|cns|)|through|resulting (l_acl) resulting_37\VBG|in (l_prep) in_38\IN|irritability (l_pobj) irritability_39\NN|and|attack (l_conj) attack_42\NN|seizure (l_compound) seizure_41\NN|
19293073
D001241_D003327 NONE aspirin_17\NN| (r_dobj) discuss_16\VB|that|clinicians|aspirin|with (l_prep) with_18\IN|adults (l_pobj) adults_19\NNS|are (l_relcl) are_21\VBP|who|at (l_prep) at_22\IN|risk (l_pobj) risk_24\NN|increased|for (l_prep) for_25\IN|disease (l_pobj) disease_28\NN|coronary|heart
D001241_D009203 NONE aspirin_8\NN| (r_dobj) taking_7\VBG|aspirin|for (l_prep) for_9\IN|prevention (l_pobj) prevention_12\NN|the|primary|of (l_prep) of_13\IN|infarctions (l_pobj) infarctions_15\NNS|myocardial|,|strokes
D001241_D009203 NONE Aspirin_0\NNP| (r_nsubj) reduces_1\VBZ|aspirin|risk|. (l_dobj) risk_3\NN|the|for (l_prep) for_4\IN|infarction (l_pobj) infarction_6\NN|myocardial|in
D001241_D020521 CID aspirin_8\NN| (r_dobj) taking_7\VBG|aspirin|for (l_prep) for_9\IN|prevention (l_pobj) prevention_12\NN|the|primary|of (l_prep) of_13\IN|infarctions (l_pobj) infarctions_15\NNS|myocardial|,|strokes (l_conj) strokes_17\NNS|,|and|death
D001241_D020521 CID aspirin_24\NN|versus (r_pobj) of_23\IN|aspirin (r_prep) reviews_22\NNS|systematic|of|for (r_conj) analyses_18\NNS|meta|-|;|and|reviews (r_conj) studies_14\NNS|control|;|analyses (r_conj) trials_6\NNS|language|randomized|,|controlled|(|rcts|)|;|studies (r_nsubjpass) selected_38\VBN|trials|were|answer (r_ccomp) decrease_47\NN|selected|:|does|aspirin|events|? (l_dobj) events_50\NNS|coronary|heart|,|strokes (l_conj) strokes_52\NNS|,|death
D001241_D020521 CID aspirin_24\NN|versus (r_pobj) of_23\IN|aspirin (r_prep) reviews_22\NNS|systematic|of|for (r_conj) analyses_18\NNS|meta|-|;|and|reviews (r_conj) studies_14\NNS|control|;|analyses (r_conj) trials_6\NNS|language|randomized|,|controlled|(|rcts|)|;|studies (r_nsubjpass) selected_38\VBN|trials|were|answer (r_ccomp) decrease_47\NN|selected|:|does|aspirin|events|? (l_dobj) events_50\NNS|coronary|heart|,|strokes (l_conj) strokes_52\NNS|,|death (l_conj) death_54\NN|from|,|or|mortality (l_prep) from_55\IN|events (l_pobj) events_58\NNS|coronary|heart|or|stroke (l_conj) stroke_60\NN|
D001241_D020521 CID aspirin_46\NN| (r_nsubj) decrease_47\NN|selected|:|does|aspirin|events|? (l_dobj) events_50\NNS|coronary|heart|,|strokes (l_conj) strokes_52\NNS|,|death
D001241_D020521 CID aspirin_46\NN| (r_nsubj) decrease_47\NN|selected|:|does|aspirin|events|? (l_dobj) events_50\NNS|coronary|heart|,|strokes (l_conj) strokes_52\NNS|,|death (l_conj) death_54\NN|from|,|or|mortality (l_prep) from_55\IN|events (l_pobj) events_58\NNS|coronary|heart|or|stroke (l_conj) stroke_60\NN|
D001241_D020521 CID aspirin_1\NN| (r_nsubj) increase_2\VB|does|aspirin|strokes|? (l_dobj) strokes_7\NNS|bleeding
D001241_D020521 CID aspirin_9\JJ| (r_compound) use_10\NN|aspirin (r_pobj) with_8\IN|use (r_prep) strokes_7\NNS|hemorrhagic|with
D001241_D020521 CID Aspirin_0\NNP| (r_nsubj) reduces_1\VBZ|aspirin|risk|. (l_dobj) risk_3\NN|the|for (l_prep) for_4\IN|infarction (l_pobj) infarction_6\NN|myocardial|in (l_prep) in_7\IN|men (l_pobj) men_8\NNS|and|strokes|in (l_conj) strokes_10\NNS|
D001241_D002318 NONE aspirin_24\NN|versus (r_pobj) of_23\IN|aspirin (r_prep) reviews_22\NNS|systematic|of|for (l_prep) for_27\IN|prevention (l_pobj) prevention_30\NN|the|primary|of (l_prep) of_31\IN|disease (l_pobj) disease_33\NN|cardiovascular|cvd
D001241_D002318 NONE aspirin_24\NN|versus (r_pobj) of_23\IN|aspirin (r_prep) reviews_22\NNS|systematic|of|for (l_prep) for_27\IN|prevention (l_pobj) prevention_30\NN|the|primary|of (l_prep) of_31\IN|disease (l_pobj) disease_33\NN|cardiovascular|cvd (l_appos) CVD_35\NN|(|)
D001241_D002318 NONE aspirin_24\NN|versus (r_pobj) of_23\IN|aspirin (r_prep) reviews_22\NNS|systematic|of|for (r_conj) analyses_18\NNS|meta|-|;|and|reviews (r_conj) studies_14\NNS|control|;|analyses (r_conj) trials_6\NNS|language|randomized|,|controlled|(|rcts|)|;|studies (r_nsubjpass) selected_38\VBN|trials|were|answer (r_ccomp) decrease_47\NN|selected|:|does|aspirin|events|? (l_dobj) events_50\NNS|coronary|heart|,|strokes (l_conj) strokes_52\NNS|,|death (l_conj) death_54\NN|from|,|or|mortality (l_conj) mortality_66\NN|cause|in (l_prep) in_67\IN|adults (l_pobj) adults_68\NNS|without (l_prep) without_69\IN|cvd (l_pobj) CVD_71\NN|known
D001241_D002318 NONE aspirin_46\NN| (r_nsubj) decrease_47\NN|selected|:|does|aspirin|events|? (l_ccomp) selected_38\VBN|trials|were|answer (l_nsubjpass) trials_6\NNS|language|randomized|,|controlled|(|rcts|)|;|studies (l_conj) studies_14\NNS|control|;|analyses (l_conj) analyses_18\NNS|meta|-|;|and|reviews (l_conj) reviews_22\NNS|systematic|of|for (l_prep) for_27\IN|prevention (l_pobj) prevention_30\NN|the|primary|of (l_prep) of_31\IN|disease (l_pobj) disease_33\NN|cardiovascular|cvd
D001241_D002318 NONE aspirin_46\NN| (r_nsubj) decrease_47\NN|selected|:|does|aspirin|events|? (l_ccomp) selected_38\VBN|trials|were|answer (l_nsubjpass) trials_6\NNS|language|randomized|,|controlled|(|rcts|)|;|studies (l_conj) studies_14\NNS|control|;|analyses (l_conj) analyses_18\NNS|meta|-|;|and|reviews (l_conj) reviews_22\NNS|systematic|of|for (l_prep) for_27\IN|prevention (l_pobj) prevention_30\NN|the|primary|of (l_prep) of_31\IN|disease (l_pobj) disease_33\NN|cardiovascular|cvd (l_appos) CVD_35\NN|(|)
D001241_D002318 NONE aspirin_46\NN| (r_nsubj) decrease_47\NN|selected|:|does|aspirin|events|? (l_dobj) events_50\NNS|coronary|heart|,|strokes (l_conj) strokes_52\NNS|,|death (l_conj) death_54\NN|from|,|or|mortality (l_conj) mortality_66\NN|cause|in (l_prep) in_67\IN|adults (l_pobj) adults_68\NNS|without (l_prep) without_69\IN|cvd (l_pobj) CVD_71\NN|known
D001241_D002318 NONE aspirin_27\JJ| (r_compound) use_28\NN|aspirin (r_nsubj) reduces_29\VBZ|that|use|number (l_dobj) number_31\NN|the|of (l_prep) of_32\IN|events (l_pobj) events_34\NNS|cvd|in (l_compound) CVD_33\NN|
D001241_D002318 NONE aspirin_27\JJ| (r_compound) use_28\NN|aspirin (r_nsubj) reduces_29\VBZ|that|use|number (l_dobj) number_31\NN|the|of (l_prep) of_32\IN|events (l_pobj) events_34\NNS|cvd|in (l_prep) in_35\IN|patients (l_pobj) patients_36\NNS|without (l_prep) without_37\IN|cvd (l_pobj) CVD_39\NNP|known
D001241_D002318 NONE Aspirin_0\NNP| (r_nsubj) seem_3\VB|aspirin|does|not|affect|. (l_xcomp) affect_5\VB|to|mortality (l_dobj) mortality_7\NN|cvd|or|mortality (l_compound) CVD_6\NN|
D001241_D002318 NONE aspirin_3\NN|for (l_prep) for_4\IN|prevention (l_pobj) prevention_7\NN|the|primary|of (l_prep) of_8\IN|cvd (l_pobj) CVD_9\NNP|
D001241_D006471 CID aspirin_1\NN| (r_nsubj) increase_2\VB|does|aspirin|strokes|? (l_dobj) strokes_7\NNS|bleeding (l_nmod) bleeding_4\NN|gastrointestinal|or|hemorrhagic
D001241_D006471 CID aspirin_3\NN| (r_pobj) of_2\IN|aspirin (r_prep) use_1\NN|the|of|for (r_nsubj) increases_7\VBZ|use|risk|. (l_dobj) risk_9\NN|the|for (l_prep) for_10\IN|events (l_pobj) events_13\NNS|major|bleeding|,|events|,|in (l_appos) events_18\NNS|gastrointestinal|bleeding (l_compound) bleeding_17\NN|
D001241_D020300 CID aspirin_1\NN| (r_nsubj) increase_2\VB|does|aspirin|strokes|? (l_dobj) strokes_7\NNS|bleeding
D001241_D020300 CID aspirin_9\JJ| (r_compound) use_10\NN|aspirin (r_pobj) with_8\IN|use (r_prep) strokes_7\NNS|hemorrhagic|with
D001241_D006470 NONE aspirin_3\NN| (r_pobj) of_2\IN|aspirin (r_prep) use_1\NN|the|of|for (r_nsubj) increases_7\VBZ|use|risk|. (l_dobj) risk_9\NN|the|for (l_prep) for_10\IN|events (l_pobj) events_13\NNS|major|bleeding|,|events|,|in (l_compound) bleeding_12\NN|
D001241_D006470 NONE Aspirin_0\NNP| (r_compound) use_1\NN|aspirin (r_nsubj) increases_2\VBZ|use|risk|. (l_dobj) risk_4\NN|the|for (l_prep) for_5\IN|events (l_pobj) events_8\NNS|serious|bleeding (l_compound) bleeding_7\NN|
3746148
D004176_D003324 NONE dipyridamole_14\NN| (r_compound) infusion_15\NN|dipyridamole (r_pobj) after_13\IN|infusion (r_prep) detection_3\NN|invasive|of|by|after|. (l_prep) of_4\IN|disease (l_pobj) disease_7\NN|coronary|artery
D004176_D003324 NONE dipyridamole_3\NN| (r_compound) infusion_4\NN|dipyridamole (r_pobj) after_2\IN|infusion (r_prep) changes_1\NNS|electrocardiographic|after|min (r_nsubjpass) studied_13\VBN|changes|were|in|and|compared|. (l_prep) in_14\IN|patients (l_pobj) patients_16\NNS|41|with (l_prep) with_17\IN|disease (l_pobj) disease_20\NN|coronary|artery
D004176_D003324 NONE dipyridamole_4\NN| (r_compound) test_6\NN|the|dipyridamole|ecg (r_nsubj) is_7\VBZ|that|test|useful (l_acomp) useful_9\JJ|as|as (l_prep) as_10\IN|test (l_pobj) test_14\NN|the|ecg|for (l_prep) for_15\IN|assessment (l_pobj) assessment_17\NN|the|of (l_prep) of_18\IN|disease (l_pobj) disease_21\NN|coronary|artery
D004176_D007511 NONE dipyridamole_1\NN| (r_pobj) After_0\IN|dipyridamole (r_prep) observed_15\VBN|after|,|depression|mv|was|in|. (l_nsubjpass) depression_7\NN|ischemic|segment (l_amod) ischemic_3\JJ|
D004176_D003866 NONE dipyridamole_1\NN| (r_pobj) After_0\IN|dipyridamole (r_prep) observed_15\VBN|after|,|depression|mv|was|in|. (l_nsubjpass) depression_7\NN|ischemic|segment
D004176_D009203 NONE dipyridamole_1\NN| (r_pobj) After_0\IN|dipyridamole (r_prep) observed_15\VBN|after|,|depression|mv|was|in|. (l_prep) in_16\IN|% (l_pobj) %_18\NN|84|of|,|% (l_prep) of_19\IN|group (l_pobj) group_24\NN|the|mi (l_compound) MI_23\NNP|non|-
D004176_D056988 NONE dipyridamole_1\NN| (r_pobj) After_0\IN|dipyridamole (r_prep) observed_15\VBN|after|,|depression|mv|was|in|. (l_prep) in_16\IN|% (l_pobj) %_18\NN|84|of|,|% (l_appos) %_27\NN|29|of|,|% (l_prep) of_28\IN|group (l_pobj) group_33\NN|the|mi (l_compound) MI_32\NNP|ant|-
D004176_D056989 NONE dipyridamole_1\NN| (r_pobj) After_0\IN|dipyridamole (r_prep) observed_15\VBN|after|,|depression|mv|was|in|. (l_prep) in_16\IN|% (l_pobj) %_18\NN|84|of|,|% (l_appos) %_27\NN|29|of|,|% (l_appos) %_36\NN|63|of|and|% (l_prep) of_37\IN|group (l_pobj) group_42\NN|the|mi (l_compound) MI_41\NNP|inf|-
D004176_D017202 CID dipyridamole_5\NN| (r_npadvmod) induced_7\VBN|dipyridamole|- (r_amod) ischemia_9\NN|the|induced|myocardial
17151160
C076029_D012559 NONE olanzapine_3\NN|versus (l_prep) versus_4\IN|risperidone (l_pobj) risperidone_5\NN|for (l_prep) for_6\IN|treatment (l_pobj) treatment_8\NN|the|of (l_prep) of_9\IN|schizophrenia (l_pobj) schizophrenia_13\NN|episode
C076029_D012559 NONE olanzapine_9\NN|versus (l_prep) versus_10\IN|risperidone (l_pobj) risperidone_11\NN|in (l_prep) in_12\IN|patients (l_pobj) patients_13\NNS|with (l_prep) with_14\IN|disorders (l_pobj) disorders_20\NNS|episode|schizophrenia|spectrum (l_compound) schizophrenia_18\NN|
C076029_D012559 NONE olanzapine_48\NN| (r_pobj) with_47\IN|olanzapine (r_prep) treatment_46\NN|to|with|(|day|)|or|risperidone (r_xcomp) assigned_44\VBN|,|disorder|were|randomly|treatment (r_conj) mean_9\JJ|subjects|years|)|with|assigned|. (l_prep) with_18\IN|schizophrenia (l_pobj) schizophrenia_22\NN|episode|(|%|)
D018967_D012559 NONE risperidone_5\NN|for (l_prep) for_6\IN|treatment (l_pobj) treatment_8\NN|the|of (l_prep) of_9\IN|schizophrenia (l_pobj) schizophrenia_13\NN|episode
D018967_D012559 NONE risperidone_11\NN|in (l_prep) in_12\IN|patients (l_pobj) patients_13\NNS|with (l_prep) with_14\IN|disorders (l_pobj) disorders_20\NNS|episode|schizophrenia|spectrum (l_compound) schizophrenia_18\NN|
D018967_D012559 NONE risperidone_58\NN|day (r_conj) treatment_46\NN|to|with|(|day|)|or|risperidone (r_xcomp) assigned_44\VBN|,|disorder|were|randomly|treatment (r_conj) mean_9\JJ|subjects|years|)|with|assigned|. (l_prep) with_18\IN|schizophrenia (l_pobj) schizophrenia_22\NN|episode|(|%|)
C076029_D011618 NONE olanzapine_48\NN| (r_pobj) with_47\IN|olanzapine (r_prep) treatment_46\NN|to|with|(|day|)|or|risperidone (r_xcomp) assigned_44\VBN|,|disorder|were|randomly|treatment (l_nsubjpass) disorder_29\NN|schizophreniform|(|%|)|,|or|disorder
C076029_D011618 NONE olanzapine_48\NN| (r_pobj) with_47\IN|olanzapine (r_prep) treatment_46\NN|to|with|(|day|)|or|risperidone (r_xcomp) assigned_44\VBN|,|disorder|were|randomly|treatment (l_nsubjpass) disorder_29\NN|schizophreniform|(|%|)|,|or|disorder (l_conj) disorder_37\NN|schizoaffective|(|%|)
D018967_D011618 NONE risperidone_58\NN|day (r_conj) treatment_46\NN|to|with|(|day|)|or|risperidone (r_xcomp) assigned_44\VBN|,|disorder|were|randomly|treatment (l_nsubjpass) disorder_29\NN|schizophreniform|(|%|)|,|or|disorder
D018967_D011618 NONE risperidone_58\NN|day (r_conj) treatment_46\NN|to|with|(|day|)|or|risperidone (r_xcomp) assigned_44\VBN|,|disorder|were|randomly|treatment (l_nsubjpass) disorder_29\NN|schizophreniform|(|%|)|,|or|disorder (l_conj) disorder_37\NN|schizoaffective|(|%|)
D018967_D010302 NONE risperidone_28\NN|and|%|ci=1.0|)|with (r_pobj) with_27\IN|risperidone (r_prep) were_18\VBD|differ|1.6|)|with|. (l_ccomp) differ_11\VB|outcomes|did|not|between (l_nsubj) outcomes_2\NNS|negative|symptom|and|measures|and|akathisia (l_conj) measures_4\NNS|of (l_prep) of_5\IN|parkinsonism (l_pobj) parkinsonism_6\NN|
D018967_D017109 NONE risperidone_28\NN|and|%|ci=1.0|)|with (r_pobj) with_27\IN|risperidone (r_prep) were_18\VBD|differ|1.6|)|with|. (l_ccomp) differ_11\VB|outcomes|did|not|between (l_nsubj) outcomes_2\NNS|negative|symptom|and|measures|and|akathisia (l_conj) akathisia_8\NN|
D018967_D001480 CID risperidone_28\NN|and|%|ci=1.0|)|with (r_pobj) with_27\IN|risperidone (r_prep) were_18\VBD|differ|1.6|)|with|. (l_ccomp) differ_11\VB|outcomes|did|not|between (l_prep) between_12\IN|scores (l_pobj) scores_17\NNS|extrapyramidal|symptom|severity (l_compound) symptom_15\NN|
C076029_D010302 NONE olanzapine_39\NN| (r_pobj) with_38\IN|olanzapine (r_prep) risperidone_28\NN|and|%|ci=1.0|)|with (r_pobj) with_27\IN|risperidone (r_prep) were_18\VBD|differ|1.6|)|with|. (l_ccomp) differ_11\VB|outcomes|did|not|between (l_nsubj) outcomes_2\NNS|negative|symptom|and|measures|and|akathisia (l_conj) measures_4\NNS|of (l_prep) of_5\IN|parkinsonism (l_pobj) parkinsonism_6\NN|
C076029_D017109 NONE olanzapine_39\NN| (r_pobj) with_38\IN|olanzapine (r_prep) risperidone_28\NN|and|%|ci=1.0|)|with (r_pobj) with_27\IN|risperidone (r_prep) were_18\VBD|differ|1.6|)|with|. (l_ccomp) differ_11\VB|outcomes|did|not|between (l_nsubj) outcomes_2\NNS|negative|symptom|and|measures|and|akathisia (l_conj) akathisia_8\NN|
C076029_D001480 CID olanzapine_39\NN| (r_pobj) with_38\IN|olanzapine (r_prep) risperidone_28\NN|and|%|ci=1.0|)|with (r_pobj) with_27\IN|risperidone (r_prep) were_18\VBD|differ|1.6|)|with|. (l_ccomp) differ_11\VB|outcomes|did|not|between (l_prep) between_12\IN|scores (l_pobj) scores_17\NNS|extrapyramidal|symptom|severity (l_compound) symptom_15\NN|
C076029_D015430 CID olanzapine_6\NN| (r_pobj) with_5\IN|olanzapine (r_prep) occurred_4\VBD|gain|with|than|:|was (l_nsubj) gain_3\NN|more|weight
C076029_D015430 CID olanzapine_32\NN|and|% (r_pobj) with_31\IN|olanzapine (r_prep) %_24\NN|17.3|(|%|with (r_attr) was_22\VBD|increase|%|. (r_conj) occurred_4\VBD|gain|with|than|:|was (l_nsubj) gain_3\NN|more|weight
C076029_D015430 CID olanzapine_14\NN| (r_pobj) with_13\IN|olanzapine (r_prep) greater_12\JJR|with (r_acomp) was_11\VBD|gain|greater|. (r_conj) caused_2\VBD|medications|gain|,|but|was (l_dobj) gain_6\NN|substantial|rapid|weight
C076029_D015430 CID olanzapine_14\NN| (r_pobj) with_13\IN|olanzapine (r_prep) greater_12\JJR|with (r_acomp) was_11\VBD|gain|greater|. (l_nsubj) gain_10\NN|weight
D018967_D015430 CID risperidone_9\NN| (r_pobj) with_8\IN|risperidone (r_prep) than_7\IN|with (r_prep) occurred_4\VBD|gain|with|than|:|was (l_nsubj) gain_3\NN|more|weight
D018967_D015430 CID risperidone_43\NN| (r_pobj) with_42\IN|risperidone (r_prep) %_35\NN|11.3|(|%|)|with (r_conj) olanzapine_32\NN|and|% (r_pobj) with_31\IN|olanzapine (r_prep) %_24\NN|17.3|(|%|with (r_attr) was_22\VBD|increase|%|. (r_conj) occurred_4\VBD|gain|with|than|:|was (l_nsubj) gain_3\NN|more|weight
15630069
D005947_D012559 NONE Glucose_0\NN| (r_nsubj) metabolism_1\NN|glucose|in|:|test|. (l_prep) in_2\IN|patients (l_pobj) patients_3\NNS|with (l_prep) with_4\IN|schizophrenia (l_pobj) schizophrenia_5\NN|treated
D005947_D012559 NONE glucose_16\NN| (r_compound) tolerance_17\NN|glucose (r_compound) test_18\NN|a|sampled|intravenous|tolerance|and|analysis (r_appos) metabolism_1\NN|glucose|in|:|test|. (l_prep) in_2\IN|patients (l_pobj) patients_3\NNS|with (l_prep) with_4\IN|schizophrenia (l_pobj) schizophrenia_5\NN|treated
D005947_D012559 NONE glucose_32\NN| (r_compound) metabolism_33\NN|glucose (r_dobj) affecting_31\VBG|whether|agents|are|directly|metabolism|or|increasing (r_ccomp) remains_24\VBZ|increasing|,|it|unclear|affecting|. (l_advcl) increasing_11\VBG|while|incidence|may|be|in (l_prep) in_12\IN|patients (l_pobj) patients_13\NNS|with (l_prep) with_14\IN|schizophrenia (l_pobj) schizophrenia_15\NN|treated
D005947_D012559 NONE glucose_18\NN| (r_compound) tolerance_19\NN|glucose (r_compound) test_20\NN|a|sampled|intravenous|tolerance|and|analysis (r_dobj) using_13\VBG|test (r_advcl) evaluated_12\VBD|using (r_acl) schizophrenia_11\NN|evaluated
D005947_D003920 NONE glucose_32\NN| (r_compound) metabolism_33\NN|glucose (r_dobj) affecting_31\VBG|whether|agents|are|directly|metabolism|or|increasing (r_ccomp) remains_24\VBZ|increasing|,|it|unclear|affecting|. (l_advcl) increasing_11\VBG|while|incidence|may|be|in (l_nsubj) incidence_2\NN|the|of (l_prep) of_3\IN|mellitus (l_pobj) mellitus_8\NN|diabetes
D005947_D003920 NONE glucose_32\NN| (r_compound) metabolism_33\NN|glucose (r_dobj) affecting_31\VBG|whether|agents|are|directly|metabolism|or|increasing (l_conj) increasing_36\VBG|simply|factors (l_dobj) factors_39\NNS|known|risk|for (l_prep) for_40\IN|diabetes (l_pobj) diabetes_41\NNS|
D003024_D012559 NONE clozapine_20\NN|either|,|olanzapine (r_pobj) with_18\IN|clozapine (r_prep) treated_17\VBN|with (r_conj) matched_11\VBN|by|and|treated (r_acl) subjects_4\NNS|six|nonobese|with|,|matched|, (l_prep) with_5\IN|schizophrenia (l_pobj) schizophrenia_6\NN|or|disorder
D003024_D011618 NONE clozapine_20\NN|either|,|olanzapine (r_pobj) with_18\IN|clozapine (r_prep) treated_17\VBN|with (r_conj) matched_11\VBN|by|and|treated (r_acl) subjects_4\NNS|six|nonobese|with|,|matched|, (l_prep) with_5\IN|schizophrenia (l_pobj) schizophrenia_6\NN|or|disorder (l_conj) disorder_9\NN|schizoaffective
C076029_D012559 NONE olanzapine_22\NN|,|or|risperidone (r_conj) clozapine_20\NN|either|,|olanzapine (r_pobj) with_18\IN|clozapine (r_prep) treated_17\VBN|with (r_conj) matched_11\VBN|by|and|treated (r_acl) subjects_4\NNS|six|nonobese|with|,|matched|, (l_prep) with_5\IN|schizophrenia (l_pobj) schizophrenia_6\NN|or|disorder
C076029_D011618 NONE olanzapine_22\NN|,|or|risperidone (r_conj) clozapine_20\NN|either|,|olanzapine (r_pobj) with_18\IN|clozapine (r_prep) treated_17\VBN|with (r_conj) matched_11\VBN|by|and|treated (r_acl) subjects_4\NNS|six|nonobese|with|,|matched|, (l_prep) with_5\IN|schizophrenia (l_pobj) schizophrenia_6\NN|or|disorder (l_conj) disorder_9\NN|schizoaffective
D018967_D012559 NONE risperidone_25\NN| (r_conj) olanzapine_22\NN|,|or|risperidone (r_conj) clozapine_20\NN|either|,|olanzapine (r_pobj) with_18\IN|clozapine (r_prep) treated_17\VBN|with (r_conj) matched_11\VBN|by|and|treated (r_acl) subjects_4\NNS|six|nonobese|with|,|matched|, (l_prep) with_5\IN|schizophrenia (l_pobj) schizophrenia_6\NN|or|disorder
D018967_D011618 NONE risperidone_25\NN| (r_conj) olanzapine_22\NN|,|or|risperidone (r_conj) clozapine_20\NN|either|,|olanzapine (r_pobj) with_18\IN|clozapine (r_prep) treated_17\VBN|with (r_conj) matched_11\VBN|by|and|treated (r_acl) subjects_4\NNS|six|nonobese|with|,|matched|, (l_prep) with_5\IN|schizophrenia (l_pobj) schizophrenia_6\NN|or|disorder (l_conj) disorder_9\NN|schizoaffective
D005947_D007333 NONE glucose_6\NN|plasma (r_dobj) Fasting_4\VBG|glucose|and|fasting|,|index (l_conj) index_15\NN|sensitivity|,|assessment (l_compound) sensitivity_14\NN|insulin
D005947_D007333 NONE glucose_6\NN|plasma (r_dobj) Fasting_4\VBG|glucose|and|fasting|,|index (l_conj) index_15\NN|sensitivity|,|assessment (l_conj) assessment_19\NN|model|of|,|and|effectiveness (l_prep) of_20\IN|resistance (l_pobj) resistance_22\NN|insulin
D005947_D007333 NONE glucose_25\NN| (r_compound) effectiveness_26\NN|glucose (r_conj) assessment_19\NN|model|of|,|and|effectiveness (r_conj) index_15\NN|sensitivity|,|assessment (l_compound) sensitivity_14\NN|insulin
D005947_D007333 NONE glucose_25\NN| (r_compound) effectiveness_26\NN|glucose (r_conj) assessment_19\NN|model|of|,|and|effectiveness (l_prep) of_20\IN|resistance (l_pobj) resistance_22\NN|insulin
D005947_D007333 NONE glucose_15\NN| (r_compound) effectiveness_16\NN|glucose (r_pobj) of_14\IN|effectiveness (r_prep) impairment_13\NN|of (r_conj) resistance_11\NN|significant|insulin|and|impairment
D003024_D007333 CID clozapine_20\NN| (r_nmod) risperidone_24\NNP|(|clozapine|<|olanzapine|<|) (r_appos) P<.001_17\NNP|)|risperidone|,|with (r_appos) was_1\VBD|there|difference|;|p<.001|= (l_attr) difference_4\NN|a|significant|in|among (l_prep) in_5\IN|index (l_pobj) index_8\NN|sensitivity (l_compound) sensitivity_7\NN|insulin
D003024_D007333 CID clozapine_20\NN| (r_nmod) risperidone_24\NNP|(|clozapine|<|olanzapine|<|) (r_appos) P<.001_17\NNP|)|risperidone|,|with (l_prep) with_27\IN|subjects (l_pobj) subjects_28\NNS|received|exhibiting (l_acl) exhibiting_34\VBG|resistance|compared (l_dobj) resistance_37\NN|significant|insulin
D003024_D007333 CID clozapine_31\NN|and|olanzapine (r_dobj) received_30\VBD|who|clozapine (r_relcl) subjects_28\NNS|received|exhibiting (r_pobj) with_27\IN|subjects (r_prep) P<.001_17\NNP|)|risperidone|,|with (r_appos) was_1\VBD|there|difference|;|p<.001|= (l_attr) difference_4\NN|a|significant|in|among (l_prep) in_5\IN|index (l_pobj) index_8\NN|sensitivity (l_compound) sensitivity_7\NN|insulin
D003024_D007333 CID clozapine_31\NN|and|olanzapine (r_dobj) received_30\VBD|who|clozapine (r_relcl) subjects_28\NNS|received|exhibiting (l_acl) exhibiting_34\VBG|resistance|compared (l_dobj) resistance_37\NN|significant|insulin
D003024_D007333 CID clozapine_47\NN|(|vs|) (r_appos) risperidone_45\NN|clozapine (r_pobj) with_44\IN|risperidone (r_prep) treated_43\VBN|who|were|with (r_relcl) subjects_40\NNS|treated (r_pobj) with_39\IN|subjects (r_prep) compared_38\VBN|with (r_prep) exhibiting_34\VBG|resistance|compared (r_acl) subjects_28\NNS|received|exhibiting (r_pobj) with_27\IN|subjects (r_prep) P<.001_17\NNP|)|risperidone|,|with (r_appos) was_1\VBD|there|difference|;|p<.001|= (l_attr) difference_4\NN|a|significant|in|among (l_prep) in_5\IN|index (l_pobj) index_8\NN|sensitivity (l_compound) sensitivity_7\NN|insulin
D003024_D007333 CID clozapine_47\NN|(|vs|) (r_appos) risperidone_45\NN|clozapine (r_pobj) with_44\IN|risperidone (r_prep) treated_43\VBN|who|were|with (r_relcl) subjects_40\NNS|treated (r_pobj) with_39\IN|subjects (r_prep) compared_38\VBN|with (r_prep) exhibiting_34\VBG|resistance|compared (l_dobj) resistance_37\NN|significant|insulin
D003024_D007333 CID clozapine-_2\NN|both|nonobese|and (r_nmod) groups_7\NNS|clozapine-|treated (r_nsubj) displayed_8\VBD|groups|resistance|compared|. (l_dobj) resistance_11\NN|significant|insulin|and|impairment
D003024_D007333 CID clozapine_2\NN| (r_dobj) taking_1\VBG|clozapine|and|olanzapine (r_acl) Patients_0\NNS|taking (r_nsubjpass) examined_7\VBN|patients|must|be|for|. (l_prep) for_8\IN|resistance (l_pobj) resistance_10\NN|insulin|and|consequences
C076029_D007333 CID olanzapine_22\RB| (r_nmod) risperidone_24\NNP|(|clozapine|<|olanzapine|<|) (r_appos) P<.001_17\NNP|)|risperidone|,|with (r_appos) was_1\VBD|there|difference|;|p<.001|= (l_attr) difference_4\NN|a|significant|in|among (l_prep) in_5\IN|index (l_pobj) index_8\NN|sensitivity (l_compound) sensitivity_7\NN|insulin
C076029_D007333 CID olanzapine_22\RB| (r_nmod) risperidone_24\NNP|(|clozapine|<|olanzapine|<|) (r_appos) P<.001_17\NNP|)|risperidone|,|with (l_prep) with_27\IN|subjects (l_pobj) subjects_28\NNS|received|exhibiting (l_acl) exhibiting_34\VBG|resistance|compared (l_dobj) resistance_37\NN|significant|insulin
C076029_D007333 CID olanzapine_33\RB| (r_conj) clozapine_31\NN|and|olanzapine (r_dobj) received_30\VBD|who|clozapine (r_relcl) subjects_28\NNS|received|exhibiting (r_pobj) with_27\IN|subjects (r_prep) P<.001_17\NNP|)|risperidone|,|with (r_appos) was_1\VBD|there|difference|;|p<.001|= (l_attr) difference_4\NN|a|significant|in|among (l_prep) in_5\IN|index (l_pobj) index_8\NN|sensitivity (l_compound) sensitivity_7\NN|insulin
C076029_D007333 CID olanzapine_33\RB| (r_conj) clozapine_31\NN|and|olanzapine (r_dobj) received_30\VBD|who|clozapine (r_relcl) subjects_28\NNS|received|exhibiting (l_acl) exhibiting_34\VBG|resistance|compared (l_dobj) resistance_37\NN|significant|insulin
C076029_D007333 CID olanzapine_4\RB| (r_npadvmod) treated_6\VBN|olanzapine|- (r_amod) groups_7\NNS|clozapine-|treated (r_nsubj) displayed_8\VBD|groups|resistance|compared|. (l_dobj) resistance_11\NN|significant|insulin|and|impairment
C076029_D007333 CID olanzapine_4\NN| (r_conj) taking_1\VBG|clozapine|and|olanzapine (r_acl) Patients_0\NNS|taking (r_nsubjpass) examined_7\VBN|patients|must|be|for|. (l_prep) for_8\IN|resistance (l_pobj) resistance_10\NN|insulin|and|consequences
D018967_D007333 NONE risperidone_24\NNP|(|clozapine|<|olanzapine|<|) (r_appos) P<.001_17\NNP|)|risperidone|,|with (r_appos) was_1\VBD|there|difference|;|p<.001|= (l_attr) difference_4\NN|a|significant|in|among (l_prep) in_5\IN|index (l_pobj) index_8\NN|sensitivity (l_compound) sensitivity_7\NN|insulin
D018967_D007333 NONE risperidone_24\NNP|(|clozapine|<|olanzapine|<|) (r_appos) P<.001_17\NNP|)|risperidone|,|with (l_prep) with_27\IN|subjects (l_pobj) subjects_28\NNS|received|exhibiting (l_acl) exhibiting_34\VBG|resistance|compared (l_dobj) resistance_37\NN|significant|insulin
D018967_D007333 NONE risperidone_45\NN|clozapine (r_pobj) with_44\IN|risperidone (r_prep) treated_43\VBN|who|were|with (r_relcl) subjects_40\NNS|treated (r_pobj) with_39\IN|subjects (r_prep) compared_38\VBN|with (r_prep) exhibiting_34\VBG|resistance|compared (r_acl) subjects_28\NNS|received|exhibiting (r_pobj) with_27\IN|subjects (r_prep) P<.001_17\NNP|)|risperidone|,|with (r_appos) was_1\VBD|there|difference|;|p<.001|= (l_attr) difference_4\NN|a|significant|in|among (l_prep) in_5\IN|index (l_pobj) index_8\NN|sensitivity (l_compound) sensitivity_7\NN|insulin
D018967_D007333 NONE risperidone_45\NN|clozapine (r_pobj) with_44\IN|risperidone (r_prep) treated_43\VBN|who|were|with (r_relcl) subjects_40\NNS|treated (r_pobj) with_39\IN|subjects (r_prep) compared_38\VBN|with (r_prep) exhibiting_34\VBG|resistance|compared (l_dobj) resistance_37\NN|significant|insulin
D018967_D007333 NONE risperidone_49\NN|,|t(33 (r_pobj) vs_48\IN|risperidone (r_prep) clozapine_47\NN|(|vs|) (r_appos) risperidone_45\NN|clozapine (r_pobj) with_44\IN|risperidone (r_prep) treated_43\VBN|who|were|with (r_relcl) subjects_40\NNS|treated (r_pobj) with_39\IN|subjects (r_prep) compared_38\VBN|with (r_prep) exhibiting_34\VBG|resistance|compared (r_acl) subjects_28\NNS|received|exhibiting (r_pobj) with_27\IN|subjects (r_prep) P<.001_17\NNP|)|risperidone|,|with (r_appos) was_1\VBD|there|difference|;|p<.001|= (l_attr) difference_4\NN|a|significant|in|among (l_prep) in_5\IN|index (l_pobj) index_8\NN|sensitivity (l_compound) sensitivity_7\NN|insulin
D018967_D007333 NONE risperidone_49\NN|,|t(33 (r_pobj) vs_48\IN|risperidone (r_prep) clozapine_47\NN|(|vs|) (r_appos) risperidone_45\NN|clozapine (r_pobj) with_44\IN|risperidone (r_prep) treated_43\VBN|who|were|with (r_relcl) subjects_40\NNS|treated (r_pobj) with_39\IN|subjects (r_prep) compared_38\VBN|with (r_prep) exhibiting_34\VBG|resistance|compared (l_dobj) resistance_37\NN|significant|insulin
D018967_D007333 NONE risperidone_19\NN| (r_npadvmod) treated_21\VBN|risperidone|- (r_amod) subjects_22\NNS|treated (r_pobj) with_18\IN|subjects (r_prep) compared_17\VBN|with (r_prep) displayed_8\VBD|groups|resistance|compared|. (l_dobj) resistance_11\NN|significant|insulin|and|impairment
2239937
D002119_D006934 CID carbonate_8\NN| (r_compound) therapy_9\NN|calcium|carbonate (r_pobj) on_6\IN|therapy (r_prep) patients_5\NNS|hemodialysis|on (r_pobj) in_3\IN|patients (r_prep) hypercalcemia_2\NN|in
D002119_D006934 CID carbonate_15\NN|calcium (r_pobj) to_13\IN|carbonate (r_prep) switching_12\VBG|to|as (r_pcomp) after_11\IN|switching (r_prep) became_9\VBD|patients|hypercalcemic|after|. (l_acomp) hypercalcemic_10\JJ|
D010710_D006934 NONE phosphate_19\NN| (r_compound) binder_20\NN|their|principal|phosphate (r_pobj) as_16\IN|binder (r_prep) switching_12\VBG|to|as (r_pcomp) after_11\IN|switching (r_prep) became_9\VBD|patients|hypercalcemic|after|. (l_acomp) hypercalcemic_10\JJ|
D002118_D006934 NONE calcium_17\NN| (r_compound) reabsorption_18\NN|intestinal|calcium|and|rate (r_pobj) of_15\IN|reabsorption (r_prep) parameters_14\NNS|indirect|of|in (r_appos) factors_5\NNS|risk|associated|,|parameters (l_acl) associated_6\VBN|with (l_prep) with_7\IN|development (l_pobj) development_9\NN|the|of (l_prep) of_10\IN|hypercalcemia (l_pobj) hypercalcemia_11\NN|
D002118_D006934 NONE calcium_8\NN| (r_compound) values_9\NNS|peak|calcium|of (r_pobj) with_6\IN|values (r_prep) episodes_5\NNS|hypercalcemic|with (l_amod) hypercalcemic_4\JJ|
D002118_D006934 NONE calcium_8\NN| (r_compound) values_9\NNS|peak|calcium|of (r_pobj) with_6\IN|values (r_prep) episodes_5\NNS|hypercalcemic|with (r_dobj) experiencing_3\VBG|episodes (r_pcomp) to_2\IN|experiencing (r_prep) addition_1\NN|to (r_pobj) In_0\IN|addition (r_prep) exhibited_31\VBD|in|,|patients|increase|. (l_nsubj) patients_26\NNS|in (l_prep) in_27\IN|group (l_pobj) group_30\NN|the|hypercalcemic (l_amod) hypercalcemic_29\NN|
D002118_D006934 NONE calcium_38\NN| (r_compound) concentration_39\NN|the|mean|calcium (r_pobj) in_35\IN|concentration (r_prep) increase_34\NN|a|significant|in|obtained|,|compared (r_dobj) exhibited_31\VBD|in|,|patients|increase|. (l_prep) In_0\IN|addition (l_pobj) addition_1\NN|to (l_prep) to_2\IN|experiencing (l_pcomp) experiencing_3\VBG|episodes (l_dobj) episodes_5\NNS|hypercalcemic|with (l_amod) hypercalcemic_4\JJ|
D002118_D006934 NONE calcium_38\NN| (r_compound) concentration_39\NN|the|mean|calcium (r_pobj) in_35\IN|concentration (r_prep) increase_34\NN|a|significant|in|obtained|,|compared (r_dobj) exhibited_31\VBD|in|,|patients|increase|. (l_nsubj) patients_26\NNS|in (l_prep) in_27\IN|group (l_pobj) group_30\NN|the|hypercalcemic (l_amod) hypercalcemic_29\NN|
D002118_D007674 NONE calcium_17\NN| (r_compound) reabsorption_18\NN|intestinal|calcium|and|rate (r_pobj) of_15\IN|reabsorption (r_prep) parameters_14\NNS|indirect|of|in (r_appos) factors_5\NNS|risk|associated|,|parameters (r_dobj) identify_3\VB|to|factors (r_acl) order_1\NN|identify (r_pobj) In_0\IN|order (r_prep) compared_28\VBN|in|were|with|. (l_prep) with_29\IN|results (l_pobj) results_30\NNS|in (l_prep) in_31\IN|patients (l_pobj) patients_34\NNS|14|eucalcemic|matched (l_acl) matched_35\VBN|for (l_prep) for_36\IN|age (l_pobj) age_37\NN|,|sex (l_conj) sex_39\NN|,|length (l_conj) length_41\NN|of|on|,|and|etiology (l_conj) etiology_48\NN|of (l_prep) of_49\IN|disease (l_pobj) disease_51\NN|renal
24641119
D007654_-1 NONE ketoconazole_4\NN| (r_pobj) by_3\IN|ketoconazole (r_prep) induced_2\VBN|syndrome|by|. (l_nsubj) syndrome_1\NN|baboon
D007654_-1 NONE ketoconazole_21\NN|topical|,|examination (r_pobj) to_19\IN|ketoconazole (r_prep) sensitivity_18\NN|prior|to (r_dobj) included_16\VBD|which|sensitivity (r_relcl) history_13\NN|his|,|included (r_pobj) on_11\IN|history (r_prep) based_10\VBN|on (r_acl) syndrome_9\NN|induced|baboon|based
D007654_-1 NONE ketoconazole_14\RB| (r_npadvmod) induced_16\VBN|ketoconazole|- (r_amod) syndrome_18\NN|induced|baboon|in
D007654_D003875 CID ketoconazole_20\RB|oral (r_dobj) using_18\VBG|ketoconazole (r_pcomp) after_17\IN|using (r_prep) presented_6\VBN|patient|with|after|. (l_prep) with_7\IN|eruption (l_pobj) eruption_10\NN|a|maculopapular|on
12828076
D000082_D017114 CID paracetamol_12\JJ| (r_compound) overdose_13\NN|paracetamol (r_pobj) due_10\IN|to|overdose (r_prep) serum_1\NN|increased|fas|in|due|. (l_prep) in_4\IN|patients (l_pobj) patients_5\NNS|with (l_prep) with_6\IN|failure (l_pobj) failure_9\NN|acute|liver
D000082_D017114 CID paracetamol_12\JJ| (r_compound) overdose_13\NN|paracetamol|(|median|,|ml|;|range (r_pobj) due_10\IN|to|overdose|than (r_prep) patients_5\NNS|with|due (l_prep) with_6\IN|failure (l_pobj) failure_9\NN|acute|liver
D000082_D062787 NONE paracetamol_12\JJ| (r_compound) overdose_13\NN|paracetamol
D000082_D062787 NONE paracetamol_12\JJ| (r_compound) overdose_13\NN|paracetamol|(|median|,|ml|;|range
D000082_D056486 NONE paracetamol_12\JJ| (r_compound) overdose_13\NN|paracetamol|(|median|,|ml|;|range (r_pobj) due_10\IN|to|overdose|than (r_prep) patients_5\NNS|with|due (r_pobj) in_4\IN|patients (r_prep) greater_3\JJR|significantly|in (r_acomp) were_1\VBD|levels|greater|ml|. (l_npadvmod) mL_51\NN|,|u|/|;|range|p|) (l_punct) ,_47\,|a|to (l_punct) to_42\IN|hepatitis (l_pobj) hepatitis_44\NN|e|median
18340638
D001379_D000740 CID azathioprine_4\NN| (r_pobj) of_3\IN|azathioprine (r_prep) effects_2\NNS|the|side|of (r_nsubj) include_5\VBP|effects|anemia|. (l_dobj) anemia_6\NN|,|attributed
D001379_D000740 CID Azathioprine_0\NN| (r_nsubj) triggers_1\VBZ|azathioprine|death|,|effect|. (l_npadvmod) effect_7\NN|an|contributing (l_acl) contributing_9\VBG|presumably|to (l_prep) to_10\IN|anemia (l_pobj) anemia_14\NN|induced
D001379_D000740 CID azathioprine_11\RB| (r_advmod) induced_13\VBN|azathioprine|- (r_amod) anemia_14\NN|induced
D010718_D000740 NONE phosphatidylserine_19\NN|ps (r_pobj) of_18\IN|phosphatidylserine (r_prep) exposure_17\NN|of|at (r_pobj) by_16\IN|exposure (r_agent) characterized_15\VBN|which|is|by (r_relcl) death_9\NN|accelerated|suicidal|erythrocyte|or|eryptosis|,|characterized (r_pobj) from_5\IN|death (r_prep) result_4\VB|alternatively|,|anemia|could|from|. (l_nsubj) anemia_2\NN|
D010718_D000740 NONE PS_21\NNP|(|) (r_appos) phosphatidylserine_19\NN|ps (r_pobj) of_18\IN|phosphatidylserine (r_prep) exposure_17\NN|of|at (r_pobj) by_16\IN|exposure (r_agent) characterized_15\VBN|which|is|by (r_relcl) death_9\NN|accelerated|suicidal|erythrocyte|or|eryptosis|,|characterized (r_pobj) from_5\IN|death (r_prep) result_4\VB|alternatively|,|anemia|could|from|. (l_nsubj) anemia_2\NN|
15817013
D014859_D001281 NONE warfarin_8\NN| (r_pobj) on_7\IN|warfarin (r_prep) fibrillation_6\NN|atrial|on
D014859_D001281 NONE warfarin_22\NN|dose (r_pobj) on_18\IN|warfarin (r_prep) fibrillation_17\NN|atrial|on
D014859_D001281 NONE warfarin_32\NN| (r_pobj) on_31\IN|warfarin (r_prep) fibrillation_30\NN|atrial|on
D014859_D006470 CID warfarin_8\NN| (r_pobj) on_7\IN|warfarin (r_prep) fibrillation_6\NN|atrial|on (r_pobj) in_4\IN|fibrillation (r_prep) 75_3\CD|over|in (r_dobj) aged_1\VBN|75 (r_acl) People_0\NNS|aged|:|rate|. (l_appos) rate_11\NN|the|of (l_prep) of_12\IN|hemorrhage (l_pobj) hemorrhage_14\NN|major|and|stroke
D014859_D006470 CID warfarin_22\NN|dose (r_pobj) on_18\IN|warfarin (r_prep) fibrillation_17\NN|atrial|on (r_pobj) with_15\IN|fibrillation (r_prep) aged_11\VBN|76|with (r_acl) people_10\NNS|aged|admitted (r_pobj) in_9\IN|people (r_prep) stroke_8\NN|in (r_conj) hemorrhage_6\NN|major|and|stroke
D014859_D006470 CID warfarin_9\JJ| (r_compound) use_10\NN|warfarin (r_conj) strokes_6\NNS|,|and|use (r_conj) episodes_4\NNS|major|bleeding|,|strokes (l_compound) bleeding_3\VBG|
D014859_D006470 CID warfarin_31\NN| (r_pobj) on_30\IN|warfarin (r_prep) rate_29\NN|the|stroke|on (r_nsubj) was_32\VBD|rate|low|, (r_ccomp) resulted_18\VBD|,|in|was|demonstrating|. (r_conj) was_5\VBD|rate|high|in|,|but|excluding|resulted (l_nsubj) rate_1\NN|the|of (l_prep) of_2\IN|hemorrhage (l_pobj) hemorrhage_4\NN|major
D014859_D006470 CID warfarin_38\JJ| (r_compound) treatment_39\NN|warfarin (r_nsubj) is_40\VBZ|effective|treatment (r_ccomp) demonstrating_35\VBG|is (r_advcl) resulted_18\VBD|,|in|was|demonstrating|. (r_conj) was_5\VBD|rate|high|in|,|but|excluding|resulted (l_nsubj) rate_1\NN|the|of (l_prep) of_2\IN|hemorrhage (l_pobj) hemorrhage_4\NN|major
D014859_D020521 NONE warfarin_8\NN| (r_pobj) on_7\IN|warfarin (r_prep) fibrillation_6\NN|atrial|on (r_pobj) in_4\IN|fibrillation (r_prep) 75_3\CD|over|in (r_dobj) aged_1\VBN|75 (r_acl) People_0\NNS|aged|:|rate|. (l_appos) rate_11\NN|the|of (l_prep) of_12\IN|hemorrhage (l_pobj) hemorrhage_14\NN|major|and|stroke (l_conj) stroke_16\NN|in
D014859_D020521 NONE warfarin_22\NN|dose (r_pobj) on_18\IN|warfarin (r_prep) fibrillation_17\NN|atrial|on (r_pobj) with_15\IN|fibrillation (r_prep) aged_11\VBN|76|with (r_acl) people_10\NNS|aged|admitted (r_pobj) in_9\IN|people (r_prep) stroke_8\NN|in
D014859_D020521 NONE warfarin_9\JJ| (r_compound) use_10\NN|warfarin (r_conj) strokes_6\NNS|,|and|use
D014859_D020521 NONE warfarin_7\NN| (r_pobj) of_6\IN|warfarin (r_prep) initiation_5\NN|of (r_pobj) after_4\IN|initiation (r_prep) rate_3\NN|the|annual|stroke|after (l_compound) stroke_2\NN|
D014859_D020521 NONE warfarin_31\NN| (r_pobj) on_30\IN|warfarin (r_prep) rate_29\NN|the|stroke|on (l_compound) stroke_28\NN|
D014859_D020521 NONE warfarin_38\JJ| (r_compound) treatment_39\NN|warfarin (r_nsubj) is_40\VBZ|effective|treatment (r_ccomp) demonstrating_35\VBG|is (r_advcl) resulted_18\VBD|,|in|was|demonstrating|. (l_ccomp) was_32\VBD|rate|low|, (l_nsubj) rate_29\NN|the|stroke|on (l_compound) stroke_28\NN|
35781
D003000_D002375 CID clonidine_3\NN|,|naphazoline (r_pobj) of_2\IN|clonidine|and|on (l_conj) on_21\IN|effect (l_pobj) effect_23\NN|cataleptic|of (l_amod) cataleptic_22\JJ|
D003000_D002375 CID clonidine_5\NN| (r_pobj) by_4\IN|clonidine (r_agent) increased_3\VBN|catalepsy|was|by|and|decreased|. (l_nsubjpass) catalepsy_1\NN|codeine
D009278_D002375 CID naphazoline_5\NN|and|xylometazoline|, (r_conj) clonidine_3\NN|,|naphazoline (r_pobj) of_2\IN|clonidine|and|on (l_conj) on_21\IN|effect (l_pobj) effect_23\NN|cataleptic|of (l_amod) cataleptic_22\JJ|
D009278_D002375 CID naphazoline_9\NN|and|xylometazoline (r_pobj) by_8\IN|naphazoline (r_prep) decreased_7\VBD|by (r_conj) increased_3\VBN|catalepsy|was|by|and|decreased|. (l_nsubjpass) catalepsy_1\NN|codeine
C009695_D002375 CID xylometazoline_7\NN|on (r_conj) naphazoline_5\NN|and|xylometazoline|, (r_conj) clonidine_3\NN|,|naphazoline (r_pobj) of_2\IN|clonidine|and|on (l_conj) on_21\IN|effect (l_pobj) effect_23\NN|cataleptic|of (l_amod) cataleptic_22\JJ|
C009695_D002375 CID xylometazoline_11\NN| (r_conj) naphazoline_9\NN|and|xylometazoline (r_pobj) by_8\IN|naphazoline (r_prep) decreased_7\VBD|by (r_conj) increased_3\VBN|catalepsy|was|by|and|decreased|. (l_nsubjpass) catalepsy_1\NN|codeine
D009020_D002375 CID morphine_12\NN|,|codeine (r_pobj) by_11\IN|morphine (r_agent) induced_10\VBN|by (r_acl) analgesia_9\NN|induced (r_pobj) on_8\IN|analgesia (r_prep) xylometazoline_7\NN|on (r_conj) naphazoline_5\NN|and|xylometazoline|, (r_conj) clonidine_3\NN|,|naphazoline (r_pobj) of_2\IN|clonidine|and|on (l_conj) on_21\IN|effect (l_pobj) effect_23\NN|cataleptic|of (l_amod) cataleptic_22\JJ|
D009020_D002375 CID morphine_25\NN|,|codine (r_pobj) of_24\IN|morphine (r_prep) effect_23\NN|cataleptic|of (l_amod) cataleptic_22\JJ|
D009020_D002375 CID morphine_26\NN|and|fentanyl (r_pobj) by_25\IN|morphine (r_agent) induced_24\VBN|by (r_acl) catalepsy_23\NN|induced
D003061_D002375 CID codeine_14\NN|,|fentanyl (r_conj) morphine_12\NN|,|codeine (r_pobj) by_11\IN|morphine (r_agent) induced_10\VBN|by (r_acl) analgesia_9\NN|induced (r_pobj) on_8\IN|analgesia (r_prep) xylometazoline_7\NN|on (r_conj) naphazoline_5\NN|and|xylometazoline|, (r_conj) clonidine_3\NN|,|naphazoline (r_pobj) of_2\IN|clonidine|and|on (l_conj) on_21\IN|effect (l_pobj) effect_23\NN|cataleptic|of (l_amod) cataleptic_22\JJ|
D003061_D002375 CID codine_27\NN|and|fentanyl (r_conj) morphine_25\NN|,|codine (r_pobj) of_24\IN|morphine (r_prep) effect_23\NN|cataleptic|of (l_amod) cataleptic_22\JJ|
D003061_D002375 CID Codeine_0\NNP| (r_compound) catalepsy_1\NN|codeine
D005283_D002375 CID fentanyl_16\NN|and|pentazocine (r_conj) codeine_14\NN|,|fentanyl (r_conj) morphine_12\NN|,|codeine (r_pobj) by_11\IN|morphine (r_agent) induced_10\VBN|by (r_acl) analgesia_9\NN|induced (r_pobj) on_8\IN|analgesia (r_prep) xylometazoline_7\NN|on (r_conj) naphazoline_5\NN|and|xylometazoline|, (r_conj) clonidine_3\NN|,|naphazoline (r_pobj) of_2\IN|clonidine|and|on (l_conj) on_21\IN|effect (l_pobj) effect_23\NN|cataleptic|of (l_amod) cataleptic_22\JJ|
D005283_D002375 CID fentanyl_29\NN| (r_conj) codine_27\NN|and|fentanyl (r_conj) morphine_25\NN|,|codine (r_pobj) of_24\IN|morphine (r_prep) effect_23\NN|cataleptic|of (l_amod) cataleptic_22\JJ|
D005283_D002375 CID fentanyl_28\NN| (r_conj) morphine_26\NN|and|fentanyl (r_pobj) by_25\IN|morphine (r_agent) induced_24\VBN|by (r_acl) catalepsy_23\NN|induced
D010423_D002375 NONE pentazocine_18\NN| (r_conj) fentanyl_16\NN|and|pentazocine (r_conj) codeine_14\NN|,|fentanyl (r_conj) morphine_12\NN|,|codeine (r_pobj) by_11\IN|morphine (r_agent) induced_10\VBN|by (r_acl) analgesia_9\NN|induced (r_pobj) on_8\IN|analgesia (r_prep) xylometazoline_7\NN|on (r_conj) naphazoline_5\NN|and|xylometazoline|, (r_conj) clonidine_3\NN|,|naphazoline (r_pobj) of_2\IN|clonidine|and|on (l_conj) on_21\IN|effect (l_pobj) effect_23\NN|cataleptic|of (l_amod) cataleptic_22\JJ|
D009638_D002375 NONE NA_8\NNP| (r_compound) receptors_9\NNS|central|na (r_dobj) stimulating_6\VBG|receptors (r_acl) drugs_5\NNS|three|stimulating (r_nsubj) failed_10\VBD|that|drugs|affect|and|enhanced (l_conj) enhanced_22\VBD|they|catalepsy (l_dobj) catalepsy_23\NN|induced
8312343
D004317_D002311 NONE doxorubicin_49\NN|cardiomyopathy|% (r_conj) disease_13\NN|congenital|heart|(|%|)|with|(|%|)|,|cardiomyopathy|,|disease|,|and|doxorubicin (r_appos) Indications_0\NNS|for|disease (r_nsubj) were_3\VBD|indications|cardiomyopathy|,|. (l_attr) cardiomyopathy_5\NN|idiopathic|(|%|)
D004317_D006331 NONE doxorubicin_49\NN|cardiomyopathy|% (r_conj) disease_13\NN|congenital|heart|(|%|)|with|(|%|)|,|cardiomyopathy|,|disease|,|and|doxorubicin
D004317_D002312 NONE doxorubicin_49\NN|cardiomyopathy|% (r_conj) disease_13\NN|congenital|heart|(|%|)|with|(|%|)|,|cardiomyopathy|,|disease|,|and|doxorubicin (l_conj) cardiomyopathy_34\NN|hypertrophic|(|%|)
D004317_D006349 NONE doxorubicin_49\NN|cardiomyopathy|% (r_conj) disease_13\NN|congenital|heart|(|%|)|with|(|%|)|,|cardiomyopathy|,|disease|,|and|doxorubicin (l_appos) disease_42\NN|valvular|heart|(|%|)
D004317_D009202 CID doxorubicin_49\NN|cardiomyopathy|% (l_appos) cardiomyopathy_50\NN|
D015774_D003586 NONE ganciclovir_6\NN|in (r_pobj) with_5\IN|ganciclovir (r_prep) treated_3\VBN|infections|were|successfully|with|. (l_nsubjpass) infections_1\NNS|cytomegalovirus
12119460
D005472_D013274 NONE 5-fluorouracil_3\CD| (r_punct) folinic_5\JJ|5-fluorouracil|/ (r_compound) acid_6\NN|dose|folinic|in|. (l_prep) in_7\IN|combination (l_pobj) combination_8\NN|with (l_prep) with_9\IN|c (l_pobj) C_14\NN|weekly|mitomycin|in (l_prep) in_15\IN|treatment (l_pobj) treatment_17\NN|the|of (l_prep) of_18\IN|cancer (l_pobj) cancer_21\NN|advanced|gastric
D005472_D013274 NONE 5-fluorouracil_5\CD| (r_punct) (_6\-LRB-|5-fluorouracil (r_punct) 5-FU_7\CD|(|)|and|folinic (l_conj) folinic_10\VB|fa|)|as (l_prep) as_15\IN|part (l_pobj) part_16\NN|of (l_prep) of_17\IN|regimens (l_pobj) regimens_22\NNS|several|new|chemotherapy|in (l_prep) in_23\IN|cancer (l_pobj) cancer_26\NN|advanced|gastric
D005472_D013274 NONE 5-fluorouracil_5\CD| (r_punct) (_6\-LRB-|5-fluorouracil (r_punct) 5-FU_7\CD|(|)|and|folinic (r_pobj) of_4\IN|5-fu (r_prep) infusion_3\NN|the|24-hour|continuous|of (r_nsubj) shown_31\VBN|infusion|(|agc|has|be|. (l_nsubj) AGC_28\NNP|)
D005472_D013274 NONE 5-FU_7\CD|(|)|and|folinic (l_conj) folinic_10\VB|fa|)|as (l_prep) as_15\IN|part (l_pobj) part_16\NN|of (l_prep) of_17\IN|regimens (l_pobj) regimens_22\NNS|several|new|chemotherapy|in (l_prep) in_23\IN|cancer (l_pobj) cancer_26\NN|advanced|gastric
D005472_D013274 NONE 5-FU_7\CD|(|)|and|folinic (r_pobj) of_4\IN|5-fu (r_prep) infusion_3\NN|the|24-hour|continuous|of (r_nsubj) shown_31\VBN|infusion|(|agc|has|be|. (l_nsubj) AGC_28\NNP|)
D005472_D013274 NONE 5-FU_18\CD|weekly|24-hour|m(2|) (r_dobj) receive_15\VB|to|5-fu (r_relcl) patients_11\NNS|33|with|receive|preceded|) (l_prep) with_12\IN|agc (l_pobj) AGC_13\NNP|
D005472_D013274 NONE 5-FU_3\CD| (r_nmod) MMC_7\NNP|dose|5-fu|/|fa|/ (r_nsubj) is_8\VBZ|mmc|regimen|. (l_attr) regimen_16\NN|an|effective|outpatient|for (l_prep) for_17\IN|agc (l_pobj) AGC_18\NNP|(|rate|)
D002955_D013274 NONE acid_6\NN|dose|folinic|in|. (l_prep) in_7\IN|combination (l_pobj) combination_8\NN|with (l_prep) with_9\IN|c (l_pobj) C_14\NN|weekly|mitomycin|in (l_prep) in_15\IN|treatment (l_pobj) treatment_17\NN|the|of (l_prep) of_18\IN|cancer (l_pobj) cancer_21\NN|advanced|gastric
D002955_D013274 NONE acid_11\NN| (r_nmod) FA_13\NNP|acid|( (r_dobj) folinic_10\VB|fa|)|as (l_prep) as_15\IN|part (l_pobj) part_16\NN|of (l_prep) of_17\IN|regimens (l_pobj) regimens_22\NNS|several|new|chemotherapy|in (l_prep) in_23\IN|cancer (l_pobj) cancer_26\NN|advanced|gastric
D002955_D013274 NONE acid_11\NN| (r_nmod) FA_13\NNP|acid|( (r_dobj) folinic_10\VB|fa|)|as (r_conj) 5-FU_7\CD|(|)|and|folinic (r_pobj) of_4\IN|5-fu (r_prep) infusion_3\NN|the|24-hour|continuous|of (r_nsubj) shown_31\VBN|infusion|(|agc|has|be|. (l_nsubj) AGC_28\NNP|)
D002955_D013274 NONE FA_13\NNP|acid|( (r_dobj) folinic_10\VB|fa|)|as (l_prep) as_15\IN|part (l_pobj) part_16\NN|of (l_prep) of_17\IN|regimens (l_pobj) regimens_22\NNS|several|new|chemotherapy|in (l_prep) in_23\IN|cancer (l_pobj) cancer_26\NN|advanced|gastric
D002955_D013274 NONE FA_13\NNP|acid|( (r_dobj) folinic_10\VB|fa|)|as (r_conj) 5-FU_7\CD|(|)|and|folinic (r_pobj) of_4\IN|5-fu (r_prep) infusion_3\NN|the|24-hour|continuous|of (r_nsubj) shown_31\VBN|infusion|(|agc|has|be|. (l_nsubj) AGC_28\NNP|)
D002955_D013274 NONE FA_27\NNP| (r_nmod) m(2_31\NN|2-hour|fa|500|mg|/ (r_punct) )_32\-RRB-|m(2 (r_punct) patients_11\NNS|33|with|receive|preceded|) (l_prep) with_12\IN|agc (l_pobj) AGC_13\NNP|
D002955_D013274 NONE FA_5\NNP| (r_nmod) MMC_7\NNP|dose|5-fu|/|fa|/ (r_nsubj) is_8\VBZ|mmc|regimen|. (l_attr) regimen_16\NN|an|effective|outpatient|for (l_prep) for_17\IN|agc (l_pobj) AGC_18\NNP|(|rate|)
D016685_D013274 NONE C_14\NN|weekly|mitomycin|in (l_prep) in_15\IN|treatment (l_pobj) treatment_17\NN|the|of (l_prep) of_18\IN|cancer (l_pobj) cancer_21\NN|advanced|gastric
D016685_D013274 NONE MMC_7\NNP|dose|5-fu|/|fa|/ (r_nsubj) is_8\VBZ|mmc|regimen|. (l_attr) regimen_16\NN|an|effective|outpatient|for (l_prep) for_17\IN|agc (l_pobj) AGC_18\NNP|(|rate|)
D005472_D064420 NONE 5-fluorouracil_5\CD| (r_punct) (_6\-LRB-|5-fluorouracil (r_punct) 5-FU_7\CD|(|)|and|folinic (r_pobj) of_4\IN|5-fu (r_prep) infusion_3\NN|the|24-hour|continuous|of (r_nsubj) shown_31\VBN|infusion|(|agc|has|be|. (l_xcomp) be_33\VB|to|effective|,|with (l_prep) with_36\IN|toxicity (l_pobj) toxicity_38\NN|low
D005472_D064420 NONE 5-FU_7\CD|(|)|and|folinic (r_pobj) of_4\IN|5-fu (r_prep) infusion_3\NN|the|24-hour|continuous|of (r_nsubj) shown_31\VBN|infusion|(|agc|has|be|. (l_xcomp) be_33\VB|to|effective|,|with (l_prep) with_36\IN|toxicity (l_pobj) toxicity_38\NN|low
D002955_D064420 NONE acid_11\NN| (r_nmod) FA_13\NNP|acid|( (r_dobj) folinic_10\VB|fa|)|as (r_conj) 5-FU_7\CD|(|)|and|folinic (r_pobj) of_4\IN|5-fu (r_prep) infusion_3\NN|the|24-hour|continuous|of (r_nsubj) shown_31\VBN|infusion|(|agc|has|be|. (l_xcomp) be_33\VB|to|effective|,|with (l_prep) with_36\IN|toxicity (l_pobj) toxicity_38\NN|low
D002955_D064420 NONE FA_13\NNP|acid|( (r_dobj) folinic_10\VB|fa|)|as (r_conj) 5-FU_7\CD|(|)|and|folinic (r_pobj) of_4\IN|5-fu (r_prep) infusion_3\NN|the|24-hour|continuous|of (r_nsubj) shown_31\VBN|infusion|(|agc|has|be|. (l_xcomp) be_33\VB|to|effective|,|with (l_prep) with_36\IN|toxicity (l_pobj) toxicity_38\NN|low
D002945_D006463 NONE cisplatin_7\NN| (r_advmod) containing_9\VBG|cisplatin|- (r_amod) regimens_10\NNS|containing (r_pobj) to_6\IN|regimens (r_prep) alternative_5\NN|an|to (r_pobj) as_3\IN|alternative (r_prep) serve_2\VB|it|may|as (r_ccomp) has_15\VBZ|serve|;|however|,|it|considered|. (l_xcomp) considered_18\VBN|to|be|occur (l_ccomp) occur_23\VB|that|possibly|hus|may (l_nsubj) HUS_21\NNP|
24840785
D000157_D001145 CID Aconitine_0\NNP| (r_npadvmod) induced_2\VBN|aconitine|- (r_amod) Ca2_3\NN|induced|+|overload (r_nsubj) causes_6\NNS|ca2|arrhythmia|and|apoptosis|. (l_dobj) arrhythmia_7\NN|
D000157_D001145 CID aconitine_6\NN|that (r_nsubj) aggravates_8\VBZ|aconitine|significantly|overload|and|promotes (l_dobj) overload_12\NN|ca(2|)|and|causes (l_conj) causes_14\VBZ|arrhythmia (l_dobj) arrhythmia_15\NN|
D002118_D001145 NONE Ca2_3\NN|induced|+|overload (r_nsubj) causes_6\NNS|ca2|arrhythmia|and|apoptosis|. (l_dobj) arrhythmia_7\NN|
D002118_D001145 NONE Ca(2_3\NNP|+|overload (r_nsubj) lead_7\NN|that|ca(2|accelerated|and|caused (l_conj) caused_18\VBD|arrhythmia|in (l_dobj) arrhythmia_19\NN|
D002118_D001145 NONE Ca(2_9\NNP|+ (r_nmod) overload_12\NN|ca(2|)|and|causes (l_conj) causes_14\VBZ|arrhythmia (l_dobj) arrhythmia_15\NN|
D012964_D066126 NONE Na(+_7\NN| (r_cc) dependent_6\JJ|voltage|-|na(+ (r_nmod) channels_9\NNS|dependent|) (r_nsubj) have_10\VBP|that|channels|roles|in (l_prep) in_13\IN|cardiotoxicity (l_pobj) cardiotoxicity_15\NN|the|of
D000157_D066126 CID aconitine_17\NN| (r_pobj) of_16\IN|aconitine (r_prep) cardiotoxicity_15\NN|the|of
D002118_D011041 NONE Ca(2_10\NNP| (r_pobj) of_9\IN|ca(2 (r_prep) role_8\NN|the|of (r_pobj) on_6\IN|role (r_prep) available_5\JJ|on (r_acomp) are_4\VBP|however|,|reports|available|+|)|in|. (l_prep) in_13\IN|poisoning (l_pobj) poisoning_15\NN|aconitine
D002118_D011041 NONE Ca(2_10\NNP|pathological|+ (r_pobj) of_8\IN|ca(2 (r_prep) importance_7\NN|the|of (r_dobj) explored_5\VBD|in|,|we|importance|)|signaling|. (l_advcl) signaling_13\NN|in|in (l_prep) in_14\IN|poisoning (l_pobj) poisoning_16\NN|aconitine
D000157_D011041 CID aconitine_14\NN| (r_compound) poisoning_15\NN|aconitine
D000157_D011041 CID aconitine_15\NN| (r_compound) poisoning_16\NN|aconitine
D000157_D009202 NONE aconitine_4\NN| (r_pobj) of_3\IN|aconitine (r_prep) effects_2\NNS|of|on (l_prep) on_5\IN|injury (l_pobj) injury_7\NN|myocardial
D000157_D009202 NONE aconitine_4\NN| (r_nsubj) resulted_5\VBD|that|aconitine|in|and|reduced (l_prep) in_6\IN|injury (l_pobj) injury_8\NN|myocardial
D000157_D064420 NONE aconitine_4\NN| (r_pobj) of_3\IN|aconitine (r_prep) effects_2\NNS|of|on (r_dobj) investigate_1\VB|to|effects (r_advcl) performed_10\VBD|investigate|,|we|assay|. (l_dobj) assay_12\NN|cytotoxicity|in|,|as|level (l_compound) cytotoxicity_11\NN|
D019344_D009202 NONE lactate_26\NN| (r_compound) dehydrogenase_27\NN|lactate (r_compound) level_28\NN|measured|dehydrogenase|in (r_conj) assay_12\NN|cytotoxicity|in|,|as|level (r_dobj) performed_10\VBD|investigate|,|we|assay|. (l_advcl) investigate_1\VB|to|effects (l_dobj) effects_2\NNS|of|on (l_prep) on_5\IN|injury (l_pobj) injury_7\NN|myocardial
D019344_D064420 NONE lactate_26\NN| (r_compound) dehydrogenase_27\NN|lactate (r_compound) level_28\NN|measured|dehydrogenase|in (r_conj) assay_12\NN|cytotoxicity|in|,|as|level (l_compound) cytotoxicity_11\NN|
20959502
D017576_D008581 NONE daptomycin_7\NN|dose|in (l_prep) in_8\IN|meningitis (l_pobj) meningitis_12\NN|aureus
D017576_D008581 NONE daptomycin_23\NN|dose|assessed (r_pobj) with_19\IN|daptomycin (r_prep) treated_18\VBD|with (r_acl) meningitis_17\NN|suspected|mssa|treated
D017576_D008581 NONE daptomycin_4\JJ|daily (r_conj) discontinued_2\VBN|nafcillin|was|and|daptomycin|initiated|. (l_conj) initiated_9\VBN|was|for|and|continued (l_prep) for_10\IN|meningitis (l_pobj) meningitis_12\NN|suspected
D008712_D016470 NONE methicillin_5\NN| (r_npadvmod) sensitive_7\JJ|methicillin|- (r_amod) aureus_9\NNP|sensitive|staphylococcus|bacteremia (l_appos) bacteremia_13\XX|(|mssa|)|with
D008712_D008581 NONE methicillin_5\NN| (r_npadvmod) sensitive_7\JJ|methicillin|- (r_amod) aureus_9\NNP|sensitive|staphylococcus|bacteremia (l_appos) bacteremia_13\XX|(|mssa|)|with (l_prep) with_14\IN|meningitis (l_pobj) meningitis_17\NN|suspected|mssa|treated
D017576_D016470 NONE daptomycin_23\NN|dose|assessed (r_pobj) with_19\IN|daptomycin (r_prep) treated_18\VBD|with (r_acl) meningitis_17\NN|suspected|mssa|treated (r_pobj) with_14\IN|meningitis (r_prep) bacteremia_13\XX|(|mssa|)|with
D017576_D016470 NONE Daptomycin_0\NNP| (r_nsubjpass) initiated_2\VBN|daptomycin|was|in|nephritis|. (l_dobj) nephritis_14\NN|induced|acute|interstitial|and|relapsing (l_conj) relapsing_16\VBG|bacteremia (l_dobj) bacteremia_17\NN|
D017576_D016470 NONE daptomycin_3\NN|dose (r_nsubj) be_5\VB|daptomycin|may|option|. (l_attr) option_8\NN|an|alternative|for (l_prep) for_9\IN|bacteremia (l_pobj) bacteremia_11\VBG|mssa|with
D003404_D058186 NONE creatinine_12\JJ|serum|dl (r_appos) failure_9\NN|acute|renal|(|creatinine|,
D009254_D008581 NONE Nafcillin_0\NNP| (r_nsubjpass) discontinued_2\VBN|nafcillin|was|and|daptomycin|initiated|. (l_conj) initiated_9\VBN|was|for|and|continued (l_prep) for_10\IN|meningitis (l_pobj) meningitis_12\NN|suspected
D017576_D009395 NONE Daptomycin_0\NNP| (r_nsubjpass) initiated_2\VBN|daptomycin|was|in|nephritis|. (l_dobj) nephritis_14\NN|induced|acute|interstitial|and|relapsing
D009254_D009395 CID nafcillin_9\NN| (r_npadvmod) induced_11\VBN|nafcillin|- (r_amod) nephritis_14\NN|induced|acute|interstitial|and|relapsing
D009254_D016470 NONE nafcillin_9\NN| (r_npadvmod) induced_11\VBN|nafcillin|- (r_amod) nephritis_14\NN|induced|acute|interstitial|and|relapsing (l_conj) relapsing_16\VBG|bacteremia (l_dobj) bacteremia_17\NN|
3383127
D002945_D007022 CID cisplatin_10\NN|and (r_dobj) receiving_9\VBG|cisplatin (r_acl) patients_8\NNS|three|receiving (r_pobj) in_6\IN|patients (r_prep) manifestation_3\NN|a|of|in (r_pobj) as_1\IN|manifestation (r_prep) Hypotension_0\NN|as|.
D002945_D007022 CID cisplatin_18\NN| (r_pobj) with_17\IN|cisplatin|cddp (r_prep) treated_16\VBN|while|being|with (r_advcl) developed_6\VBN|symptoms|in|treated|5-fu|. (l_nsubj) symptoms_1\NNS|cardiac|,|including|, (l_prep) including_3\VBG|hypotension (l_pobj) hypotension_4\NN|
D002945_D007022 CID CDDP_20\NNP|(|)|and (r_pobj) with_17\IN|cisplatin|cddp (r_prep) treated_16\VBN|while|being|with (r_advcl) developed_6\VBN|symptoms|in|treated|5-fu|. (l_nsubj) symptoms_1\NNS|cardiac|,|including|, (l_prep) including_3\VBG|hypotension (l_pobj) hypotension_4\NN|
D002945_D066126 NONE cisplatin_10\NN|and (r_dobj) receiving_9\VBG|cisplatin (r_acl) patients_8\NNS|three|receiving (r_pobj) in_6\IN|patients (r_prep) manifestation_3\NN|a|of|in (l_prep) of_4\IN|cardiotoxicity (l_pobj) cardiotoxicity_5\NN|
D002945_D066126 NONE CDDP_27\NNP| (r_pobj) by_26\IN|cddp (r_agent) influenced_25\VBN|that|may|be|by (r_relcl) manifestations_18\NNS|new|of|influenced (l_prep) of_19\IN|cardiotoxicity (l_pobj) cardiotoxicity_21\NN|5-fu
D005472_D007022 CID 5-fluorouracil_12\CD| (r_punct) ._13\.|5-fluorouracil (r_punct) Hypotension_0\NN|as|.
D005472_D007022 CID 5-fluorouracil_23\CD| (r_punct) 5-FU_25\CD|5-fluorouracil|(|) (r_npadvmod) developed_6\VBN|symptoms|in|treated|5-fu|. (l_nsubj) symptoms_1\NNS|cardiac|,|including|, (l_prep) including_3\VBG|hypotension (l_pobj) hypotension_4\NN|
D005472_D007022 CID 5-FU_25\CD|5-fluorouracil|(|) (r_npadvmod) developed_6\VBN|symptoms|in|treated|5-fu|. (l_nsubj) symptoms_1\NNS|cardiac|,|including|, (l_prep) including_3\VBG|hypotension (l_pobj) hypotension_4\NN|
D005472_D066126 NONE 5-fluorouracil_12\CD| (r_punct) ._13\.|5-fluorouracil (r_punct) Hypotension_0\NN|as|. (l_prep) as_1\IN|manifestation (l_pobj) manifestation_3\NN|a|of|in (l_prep) of_4\IN|cardiotoxicity (l_pobj) cardiotoxicity_5\NN|
D005472_D066126 NONE 5-FU_20\CD| (r_compound) cardiotoxicity_21\NN|5-fu
D002945_D015179 NONE cisplatin_18\NN| (r_pobj) with_17\IN|cisplatin|cddp (r_prep) treated_16\VBN|while|being|with (r_advcl) developed_6\VBN|symptoms|in|treated|5-fu|. (l_prep) in_7\IN|patients (l_pobj) patients_9\NNS|three|with (l_prep) with_10\IN|carcinoma (l_pobj) carcinoma_13\NN|advanced|colorectal
D002945_D015179 NONE CDDP_20\NNP|(|)|and (r_pobj) with_17\IN|cisplatin|cddp (r_prep) treated_16\VBN|while|being|with (r_advcl) developed_6\VBN|symptoms|in|treated|5-fu|. (l_prep) in_7\IN|patients (l_pobj) patients_9\NNS|three|with (l_prep) with_10\IN|carcinoma (l_pobj) carcinoma_13\NN|advanced|colorectal
D005472_D015179 NONE 5-fluorouracil_23\CD| (r_punct) 5-FU_25\CD|5-fluorouracil|(|) (r_npadvmod) developed_6\VBN|symptoms|in|treated|5-fu|. (l_prep) in_7\IN|patients (l_pobj) patients_9\NNS|three|with (l_prep) with_10\IN|carcinoma (l_pobj) carcinoma_13\NN|advanced|colorectal
D005472_D015179 NONE 5-FU_25\CD|5-fluorouracil|(|) (r_npadvmod) developed_6\VBN|symptoms|in|treated|5-fu|. (l_prep) in_7\IN|patients (l_pobj) patients_9\NNS|three|with (l_prep) with_10\IN|carcinoma (l_pobj) carcinoma_13\NN|advanced|colorectal
7457821
1779253
D002211_D051474 NONE capsaicin_3\NN|topical|%|in|:|efficacy|. (l_prep) in_4\IN|neuralgia (l_pobj) neuralgia_9\NN|chronic|herpetic
D002211_D051474 NONE capsaicin_18\NN|topical (r_pobj) to_16\IN|capsaicin (r_prep) response_15\NN|to (r_pobj) of_14\IN|response (r_prep) action_11\NN|and|predictors|of (r_pobj) of_10\IN|action (r_prep) course_9\NN|time|-|of (r_nmod) patients_21\NNS|course|,|39|with|,|duration (l_prep) with_22\IN|neuralgia (l_pobj) neuralgia_27\NN|chronic|herpetic|(|phn|)
D002211_D051474 NONE capsaicin_18\NN|topical (r_pobj) to_16\IN|capsaicin (r_prep) response_15\NN|to (r_pobj) of_14\IN|response (r_prep) action_11\NN|and|predictors|of (r_pobj) of_10\IN|action (r_prep) course_9\NN|time|-|of (r_nmod) patients_21\NNS|course|,|39|with|,|duration (l_prep) with_22\IN|neuralgia (l_pobj) neuralgia_27\NN|chronic|herpetic|(|phn|) (l_appos) PHN_29\NNP|
D002211_D051474 NONE capsaicin_42\NN| (r_compound) cream_43\NN|%|capsaicin (r_pobj) with_39\IN|cream (r_prep) treated_38\VBN|in|,|patients|,|were|with|for|. (l_nsubjpass) patients_21\NNS|course|,|39|with|,|duration (l_prep) with_22\IN|neuralgia (l_pobj) neuralgia_27\NN|chronic|herpetic|(|phn|)
D002211_D051474 NONE capsaicin_42\NN| (r_compound) cream_43\NN|%|capsaicin (r_pobj) with_39\IN|cream (r_prep) treated_38\VBN|in|,|patients|,|were|with|for|. (l_nsubjpass) patients_21\NNS|course|,|39|with|,|duration (l_prep) with_22\IN|neuralgia (l_pobj) neuralgia_27\NN|chronic|herpetic|(|phn|) (l_appos) PHN_29\NNP|
D002211_D051474 NONE capsaicin_26\NN|in (l_prep) in_27\IN|phn (l_pobj) PHN_28\NNP|
D002211_D008413 CID capsaicin_28\NN| (r_npadvmod) induced_30\VBN|capsaicin|- (r_amod) sensations_32\NNS|intolerable|induced|burning|(|4|;|15 (l_appos) 4_34\CD|)|or|mastitis (l_conj) mastitis_37\NN|1
9128918
D004298_D006966 NONE dopamine_5\NN| (r_compound) neurons_6\NNS|dopamine (r_pobj) in_4\IN|neurons (r_prep) changes_3\NNS|in (r_conj) hyperprolactinemia_1\NN|chronic|and|changes|.
D004298_D006966 NONE dopamine_9\NN| (r_compound) antagonist_11\NN|a|dopamine|receptor|,|and|technique (r_appos) haloperidol_6\NN|,|antagonist (r_pobj) with_5\IN|haloperidol (r_prep) treatment_4\NN|with (r_pobj) by_3\IN|treatment (r_agent) induced_2\VBN|hyperprolactinemia|was|by|used|. (l_nsubjpass) Hyperprolactinemia_0\NNP|
D004298_D006966 NONE dopamine_6\NN| (r_nmod) concentrations_10\NNS|dopamine|(|da|)|in (r_nsubj) increased_18\VBN|after|,|concentrations|by|over|. (l_prep) After_0\IN|months (l_pobj) months_2\NNS|6|of (l_prep) of_3\IN|hyperprolactinemia (l_pobj) hyperprolactinemia_4\NN|
D004298_D006966 NONE DA_8\NNP| (r_nmod) concentrations_10\NNS|dopamine|(|da|)|in (r_nsubj) increased_18\VBN|after|,|concentrations|by|over|. (l_prep) After_0\IN|months (l_pobj) months_2\NNS|6|of (l_prep) of_3\IN|hyperprolactinemia (l_pobj) hyperprolactinemia_4\NN|
D004298_D006966 NONE DA_10\NNP| (r_compound) concentrations_11\NNS|da|in (r_pobj) in_9\IN|concentrations (r_prep) increase_8\NN|a|%|in|over (r_dobj) produced_4\VBD|months|increase|. (l_nsubj) months_1\NNS|nine|of (l_prep) of_2\IN|hyperprolactinemia (l_pobj) hyperprolactinemia_3\NN|
D004298_D006966 NONE DA_2\NNP| (r_compound) response_3\NN|da (r_nsubjpass) lost_5\VBN|however|,|response|was|followed|. (l_advcl) followed_15\VBN|if|hyperprolactinemia|was|by (l_nsubjpass) hyperprolactinemia_13\NN|a|long|induced
D004298_D006966 NONE DA_8\NNP|,|norepinephrine|serotonin (r_pobj) of_7\IN|da (r_prep) levels_6\NNS|the|of (r_pobj) in_4\IN|levels (r_prep) change_3\NN|no|in (r_attr) was_1\VBD|there|change|,|putamen|. (l_attr) putamen_39\NNS|caudate|cp|,|nigra|,|except (l_prep) except_57\IN|for (l_prep) for_58\IN|decrease (l_pobj) decrease_60\NN|a|in|in|after|and|increase (l_prep) after_70\IN|6-months (l_pobj) 6-months_71\IN|of (l_prep) of_72\IN|hyperprolactinemia (l_pobj) hyperprolactinemia_73\NN|
D004298_D006966 NONE DA_8\NNP|,|norepinephrine|serotonin (r_pobj) of_7\IN|da (r_prep) levels_6\NNS|the|of (r_pobj) in_4\IN|levels (r_prep) change_3\NN|no|in (r_attr) was_1\VBD|there|change|,|putamen|. (l_attr) putamen_39\NNS|caudate|cp|,|nigra|,|except (l_prep) except_57\IN|for (l_prep) for_58\IN|decrease (l_pobj) decrease_60\NN|a|in|in|after|and|increase (l_conj) increase_76\NN|an|in|in|after (l_prep) after_83\IN|9-months (l_pobj) 9-months_84\JJ|of (l_prep) of_85\IN|hyperprolactinemia (l_pobj) hyperprolactinemia_86\NN|
D004298_D006966 NONE DA_78\NNP| (r_compound) concentrations_79\NNS|da (r_pobj) in_77\IN|concentrations (r_prep) increase_76\NN|an|in|in|after (r_conj) decrease_60\NN|a|in|in|after|and|increase (l_prep) after_70\IN|6-months (l_pobj) 6-months_71\IN|of (l_prep) of_72\IN|hyperprolactinemia (l_pobj) hyperprolactinemia_73\NN|
D004298_D006966 NONE DA_78\NNP| (r_compound) concentrations_79\NNS|da (r_pobj) in_77\IN|concentrations (r_prep) increase_76\NN|an|in|in|after (l_prep) after_83\IN|9-months (l_pobj) 9-months_84\JJ|of (l_prep) of_85\IN|hyperprolactinemia (l_pobj) hyperprolactinemia_86\NN|
D006220_D006966 CID haloperidol_6\NN|,|antagonist (r_pobj) with_5\IN|haloperidol (r_prep) treatment_4\NN|with (r_pobj) by_3\IN|treatment (r_agent) induced_2\VBN|hyperprolactinemia|was|by|used|. (l_nsubjpass) Hyperprolactinemia_0\NNP|
D006220_D006966 CID haloperidol_10\NN| (r_npadvmod) induced_12\VBN|haloperidol|- (r_amod) hyperprolactinemia_13\NN|a|long|induced
D009638_D006966 NONE norepinephrine_10\NN|ne (r_appos) DA_8\NNP|,|norepinephrine|serotonin (r_pobj) of_7\IN|da (r_prep) levels_6\NNS|the|of (r_pobj) in_4\IN|levels (r_prep) change_3\NN|no|in (r_attr) was_1\VBD|there|change|,|putamen|. (l_attr) putamen_39\NNS|caudate|cp|,|nigra|,|except (l_prep) except_57\IN|for (l_prep) for_58\IN|decrease (l_pobj) decrease_60\NN|a|in|in|after|and|increase (l_prep) after_70\IN|6-months (l_pobj) 6-months_71\IN|of (l_prep) of_72\IN|hyperprolactinemia (l_pobj) hyperprolactinemia_73\NN|
D009638_D006966 NONE norepinephrine_10\NN|ne (r_appos) DA_8\NNP|,|norepinephrine|serotonin (r_pobj) of_7\IN|da (r_prep) levels_6\NNS|the|of (r_pobj) in_4\IN|levels (r_prep) change_3\NN|no|in (r_attr) was_1\VBD|there|change|,|putamen|. (l_attr) putamen_39\NNS|caudate|cp|,|nigra|,|except (l_prep) except_57\IN|for (l_prep) for_58\IN|decrease (l_pobj) decrease_60\NN|a|in|in|after|and|increase (l_conj) increase_76\NN|an|in|in|after (l_prep) after_83\IN|9-months (l_pobj) 9-months_84\JJ|of (l_prep) of_85\IN|hyperprolactinemia (l_pobj) hyperprolactinemia_86\NN|
D009638_D006966 NONE NE_12\NNP|(|)|, (r_appos) norepinephrine_10\NN|ne (r_appos) DA_8\NNP|,|norepinephrine|serotonin (r_pobj) of_7\IN|da (r_prep) levels_6\NNS|the|of (r_pobj) in_4\IN|levels (r_prep) change_3\NN|no|in (r_attr) was_1\VBD|there|change|,|putamen|. (l_attr) putamen_39\NNS|caudate|cp|,|nigra|,|except (l_prep) except_57\IN|for (l_prep) for_58\IN|decrease (l_pobj) decrease_60\NN|a|in|in|after|and|increase (l_prep) after_70\IN|6-months (l_pobj) 6-months_71\IN|of (l_prep) of_72\IN|hyperprolactinemia (l_pobj) hyperprolactinemia_73\NN|
D009638_D006966 NONE NE_12\NNP|(|)|, (r_appos) norepinephrine_10\NN|ne (r_appos) DA_8\NNP|,|norepinephrine|serotonin (r_pobj) of_7\IN|da (r_prep) levels_6\NNS|the|of (r_pobj) in_4\IN|levels (r_prep) change_3\NN|no|in (r_attr) was_1\VBD|there|change|,|putamen|. (l_attr) putamen_39\NNS|caudate|cp|,|nigra|,|except (l_prep) except_57\IN|for (l_prep) for_58\IN|decrease (l_pobj) decrease_60\NN|a|in|in|after|and|increase (l_conj) increase_76\NN|an|in|in|after (l_prep) after_83\IN|9-months (l_pobj) 9-months_84\JJ|of (l_prep) of_85\IN|hyperprolactinemia (l_pobj) hyperprolactinemia_86\NN|
D012701_D006966 NONE serotonin_15\NN|(|5-ht|)|,|or|metabolites (r_appos) DA_8\NNP|,|norepinephrine|serotonin (r_pobj) of_7\IN|da (r_prep) levels_6\NNS|the|of (r_pobj) in_4\IN|levels (r_prep) change_3\NN|no|in (r_attr) was_1\VBD|there|change|,|putamen|. (l_attr) putamen_39\NNS|caudate|cp|,|nigra|,|except (l_prep) except_57\IN|for (l_prep) for_58\IN|decrease (l_pobj) decrease_60\NN|a|in|in|after|and|increase (l_prep) after_70\IN|6-months (l_pobj) 6-months_71\IN|of (l_prep) of_72\IN|hyperprolactinemia (l_pobj) hyperprolactinemia_73\NN|
D012701_D006966 NONE serotonin_15\NN|(|5-ht|)|,|or|metabolites (r_appos) DA_8\NNP|,|norepinephrine|serotonin (r_pobj) of_7\IN|da (r_prep) levels_6\NNS|the|of (r_pobj) in_4\IN|levels (r_prep) change_3\NN|no|in (r_attr) was_1\VBD|there|change|,|putamen|. (l_attr) putamen_39\NNS|caudate|cp|,|nigra|,|except (l_prep) except_57\IN|for (l_prep) for_58\IN|decrease (l_pobj) decrease_60\NN|a|in|in|after|and|increase (l_conj) increase_76\NN|an|in|in|after (l_prep) after_83\IN|9-months (l_pobj) 9-months_84\JJ|of (l_prep) of_85\IN|hyperprolactinemia (l_pobj) hyperprolactinemia_86\NN|
D012701_D006966 NONE 5-HT_17\CD| (r_appos) serotonin_15\NN|(|5-ht|)|,|or|metabolites (r_appos) DA_8\NNP|,|norepinephrine|serotonin (r_pobj) of_7\IN|da (r_prep) levels_6\NNS|the|of (r_pobj) in_4\IN|levels (r_prep) change_3\NN|no|in (r_attr) was_1\VBD|there|change|,|putamen|. (l_attr) putamen_39\NNS|caudate|cp|,|nigra|,|except (l_prep) except_57\IN|for (l_prep) for_58\IN|decrease (l_pobj) decrease_60\NN|a|in|in|after|and|increase (l_prep) after_70\IN|6-months (l_pobj) 6-months_71\IN|of (l_prep) of_72\IN|hyperprolactinemia (l_pobj) hyperprolactinemia_73\NN|
D012701_D006966 NONE 5-HT_17\CD| (r_appos) serotonin_15\NN|(|5-ht|)|,|or|metabolites (r_appos) DA_8\NNP|,|norepinephrine|serotonin (r_pobj) of_7\IN|da (r_prep) levels_6\NNS|the|of (r_pobj) in_4\IN|levels (r_prep) change_3\NN|no|in (r_attr) was_1\VBD|there|change|,|putamen|. (l_attr) putamen_39\NNS|caudate|cp|,|nigra|,|except (l_prep) except_57\IN|for (l_prep) for_58\IN|decrease (l_pobj) decrease_60\NN|a|in|in|after|and|increase (l_conj) increase_76\NN|an|in|in|after (l_prep) after_83\IN|9-months (l_pobj) 9-months_84\JJ|of (l_prep) of_85\IN|hyperprolactinemia (l_pobj) hyperprolactinemia_86\NN|
D006897_D006966 NONE acid_63\NN|5-hydroxyindoleacetic|(|5-hiaa|) (r_pobj) in_61\IN|acid (r_prep) decrease_60\NN|a|in|in|after|and|increase (l_prep) after_70\IN|6-months (l_pobj) 6-months_71\IN|of (l_prep) of_72\IN|hyperprolactinemia (l_pobj) hyperprolactinemia_73\NN|
D006897_D006966 NONE acid_63\NN|5-hydroxyindoleacetic|(|5-hiaa|) (r_pobj) in_61\IN|acid (r_prep) decrease_60\NN|a|in|in|after|and|increase (l_conj) increase_76\NN|an|in|in|after (l_prep) after_83\IN|9-months (l_pobj) 9-months_84\JJ|of (l_prep) of_85\IN|hyperprolactinemia (l_pobj) hyperprolactinemia_86\NN|
D006897_D006966 NONE 5-HIAA_65\CD| (r_appos) acid_63\NN|5-hydroxyindoleacetic|(|5-hiaa|) (r_pobj) in_61\IN|acid (r_prep) decrease_60\NN|a|in|in|after|and|increase (l_prep) after_70\IN|6-months (l_pobj) 6-months_71\IN|of (l_prep) of_72\IN|hyperprolactinemia (l_pobj) hyperprolactinemia_73\NN|
D006897_D006966 NONE 5-HIAA_65\CD| (r_appos) acid_63\NN|5-hydroxyindoleacetic|(|5-hiaa|) (r_pobj) in_61\IN|acid (r_prep) decrease_60\NN|a|in|in|after|and|increase (l_conj) increase_76\NN|an|in|in|after (l_prep) after_83\IN|9-months (l_pobj) 9-months_84\JJ|of (l_prep) of_85\IN|hyperprolactinemia (l_pobj) hyperprolactinemia_86\NN|
7411769
D007213_D006947 CID Indomethacin_0\NNP| (r_npadvmod) induced_2\VBN|indomethacin|- (r_amod) hyperkalemia_3\NN|induced|in|.
D007213_D006947 CID indomethacin_23\NN| (r_pobj) with_22\IN|indomethacin (r_prep) treatment_17\NN|of|with (r_pobj) after_16\IN|treatment (r_prep) developed_15\VBD|after (r_acl) patients_3\NNS|three|hyperkalemia|developed (l_appos) hyperkalemia_11\NN|in|severe|,|threatening|and|insufficiency
D007213_D015210 NONE Indomethacin_0\NNP| (r_npadvmod) induced_2\VBN|indomethacin|- (r_amod) hyperkalemia_3\NN|induced|in|. (l_prep) in_4\IN|patients (l_pobj) patients_6\NNS|three|with (l_prep) with_7\IN|arthritis (l_pobj) arthritis_9\NN|gouty
D007213_D015210 NONE indomethacin_23\NN| (r_pobj) with_22\IN|indomethacin (r_prep) treatment_17\NN|of|with (l_prep) of_18\IN|arthritis (l_pobj) arthritis_21\NN|acute|gouty
D007213_D051437 CID indomethacin_23\NN| (r_pobj) with_22\IN|indomethacin (r_prep) treatment_17\NN|of|with (r_pobj) after_16\IN|treatment (r_prep) developed_15\VBD|after (r_acl) patients_3\NNS|three|hyperkalemia|developed (l_appos) hyperkalemia_11\NN|in|severe|,|threatening|and|insufficiency (l_conj) insufficiency_14\NN|renal
D011453_D006994 NONE prostaglandin_8\JJ| (r_amod) synthesis_9\NN|prostaglandin|and|hypoaidosteronism (l_conj) hypoaidosteronism_13\NN|consequent|hyporeninemic
D011188_D003920 NONE potassium_6\NN| (r_compound) balance_7\NN|potassium (r_conj) function_4\NN|renal|and|balance|in (r_pobj) to_2\IN|function (r_prep) attention_1\NN|careful|to (r_nsubj) help_33\VB|attention|,|in|,|will|prevent|. (l_prep) in_21\IN|particularly|patients (l_pobj) patients_23\NNS|those|with (l_prep) with_24\IN|mellitus (l_pobj) mellitus_26\NN|diabetes|or|disease
D011188_D007674 NONE potassium_6\NN| (r_compound) balance_7\NN|potassium (r_conj) function_4\NN|renal|and|balance|in (r_pobj) to_2\IN|function (r_prep) attention_1\NN|careful|to (r_nsubj) help_33\VB|attention|,|in|,|will|prevent|. (l_prep) in_21\IN|particularly|patients (l_pobj) patients_23\NNS|those|with (l_prep) with_24\IN|mellitus (l_pobj) mellitus_26\NN|diabetes|or|disease (l_conj) disease_30\NN|preexisting|renal
D007213_D003920 NONE indomethacin_11\NN|or|agents (r_dobj) receiving_10\VBG|indomethacin (r_acl) patients_9\NNS|receiving (r_pobj) in_8\IN|patients (r_prep) function_4\NN|renal|and|balance|in (r_pobj) to_2\IN|function (r_prep) attention_1\NN|careful|to (r_nsubj) help_33\VB|attention|,|in|,|will|prevent|. (l_prep) in_21\IN|particularly|patients (l_pobj) patients_23\NNS|those|with (l_prep) with_24\IN|mellitus (l_pobj) mellitus_26\NN|diabetes|or|disease
D007213_D007674 NONE indomethacin_11\NN|or|agents (r_dobj) receiving_10\VBG|indomethacin (r_acl) patients_9\NNS|receiving (r_pobj) in_8\IN|patients (r_prep) function_4\NN|renal|and|balance|in (r_pobj) to_2\IN|function (r_prep) attention_1\NN|careful|to (r_nsubj) help_33\VB|attention|,|in|,|will|prevent|. (l_prep) in_21\IN|particularly|patients (l_pobj) patients_23\NNS|those|with (l_prep) with_24\IN|mellitus (l_pobj) mellitus_26\NN|diabetes|or|disease (l_conj) disease_30\NN|preexisting|renal
9570197
D003042_D018487 CID cocaine_8\NN|intravenous (r_pobj) of_6\IN|cocaine (r_prep) amount_5\NN|a|large|of (r_nsubj) causes_9\VBZ|in|,|amount|deterioration|. (l_dobj) deterioration_12\NN|a|profound|of|and|increase (l_prep) of_13\IN|function (l_pobj) function_20\NN|left|ventricular|(|lv|)|systolic
D003042_D018487 CID cocaine_7\NN| (r_pobj) of_6\IN|cocaine (r_prep) infusion_5\NN|the|intracoronary|of|sufficient (r_nsubj) causes_21\VBZ|in|,|infusion|deterioration|. (l_dobj) deterioration_23\NN|a|of (l_prep) of_24\IN|performance (l_pobj) performance_29\NN|systolic
D003042_D002637 NONE hydrochloride_78\NN|cocaine|min|) (r_conj) subjects_74\NNS|control|)|or|hydrochloride (r_appos) n=10_71\NNP|(|,|subjects (r_appos) volumes_50\NNS|lv|and|fraction|before|n=10 (r_conj) measured_28\VBD|referred|,|we|rate|,|and|volumes|. (l_ccomp) referred_16\VBD|:|in|patients|for (l_prep) for_17\IN|catheterization (l_pobj) catheterization_19\NN|cardiac|for (l_prep) for_20\IN|evaluation (l_pobj) evaluation_22\NN|the|of (l_prep) of_23\IN|pain (l_pobj) pain_25\NN|chest
24341598
D012965_D007674 NONE chloride_6\NN|isotonic|sodium (r_pobj) of_3\IN|chloride (r_prep) effects_2\NNS|of|with (l_prep) with_7\IN|diltiazem (l_pobj) diltiazem_8\NN|in (l_prep) in_9\IN|prevention (l_pobj) prevention_10\NN|of (l_prep) of_11\IN|nephropathy (l_pobj) nephropathy_15\NN|induced
D004110_D007674 NONE diltiazem_8\NN|in (l_prep) in_9\IN|prevention (l_pobj) prevention_10\NN|of (l_prep) of_11\IN|nephropathy (l_pobj) nephropathy_15\NN|induced
D003287_D007674 NONE contrast_12\NN| (r_npadvmod) induced_14\VBN|contrast|- (r_amod) nephropathy_15\NN|induced
D003287_D007674 NONE Contrast_0\RB| (r_npadvmod) induced_2\VBN|contrast|- (r_amod) nephropathy_3\NN|induced|cin
D003287_D058186 CID contrast_25\NN| (r_amod) material_26\NN|contrast (r_nsubjpass) injected_28\VBN|after|material|was|(|%|) (r_advcl) developed_13\VBD|among|,|patients|failure|on|injected|. (l_dobj) failure_16\NN|acute|renal|(|arf|)
D003287_D058186 CID contrast_25\NN| (r_amod) material_26\NN|contrast (r_nsubjpass) injected_28\VBN|after|material|was|(|%|) (r_advcl) developed_13\VBD|among|,|patients|failure|on|injected|. (l_dobj) failure_16\NN|acute|renal|(|arf|) (l_appos) ARF_18\NNP|
25951420
D010126_D010300 CID Ozone_2\NN|and|concentrations (r_pobj) of_1\IN|ozone (r_prep) Associations_0\NNS|of|with|. (l_prep) With_6\IN|disease (l_pobj) Disease_9\NNP|parkinson|among
D010126_D010300 CID ozone_5\NN|and|matter (r_pobj) of_4\IN|ozone (r_prep) associations_3\NNS|of (r_dobj) describes_2\VBZ|study|associations|with|. (l_prep) with_10\IN|disease (l_pobj) disease_13\NN|parkinson|observed
D010126_D010300 CID ozone_10\NN| (r_pobj) with_9\IN|ozone (r_prep) disease_8\NN|parkinson|with
D052638_D010300 CID matter_9\NN|fine|particulate (r_conj) ozone_5\NN|and|matter (r_pobj) of_4\IN|ozone (r_prep) associations_3\NNS|of (r_dobj) describes_2\VBZ|study|associations|with|. (l_prep) with_10\IN|disease (l_pobj) disease_13\NN|parkinson|observed
D052638_D010300 CID matter_28\NN|fine|particulate|(|ratio|:|0.93|in (r_conj) 0.98_21\CD|to|)|and|matter (r_appos) ratio_13\NN|odds|=|1.39|;|ci|:|0.98 (r_appos) associations_4\NNS|positive|of|(|ratio (l_prep) of_5\IN|disease (l_pobj) disease_8\NN|parkinson|with
17828434
C002647_D012640 NONE MIP_4\NNP| (r_compound) inhibition_6\NN|mip|synthase (r_nsubj) replicate_9\VB|that|inhibition|does|not|or|augment (l_conj) augment_11\VB|effects (l_dobj) effects_13\NNS|the|of|in (l_prep) in_16\IN|model (l_pobj) model_24\NN|the|sensitive|seizures (l_compound) seizures_23\NNS|induced
D008094_D012640 NONE lithium_15\NN| (r_pobj) of_14\IN|lithium (r_prep) effects_13\NNS|the|of|in (l_prep) in_16\IN|model (l_pobj) model_24\NN|the|sensitive|seizures (l_compound) seizures_23\NNS|induced
D007294_D012640 NONE inositol_18\JJ| (r_npadvmod) sensitive_19\JJ|inositol (r_amod) model_24\NN|the|sensitive|seizures (l_compound) seizures_23\NNS|induced
D010862_D012640 CID pilocarpine_20\NN| (r_npadvmod) induced_22\VBN|pilocarpine|- (r_amod) seizures_23\NNS|induced
931801
D005937_D007674 NONE Glucarates_4\NNP|d|- (r_pobj) of_1\IN|glucarates (r_prep) Effect_0\NN|of|on|. (l_prep) on_5\IN|damage (l_pobj) damage_11\NN|basic|induced|renal|in
D005937_D007674 NONE Glucarates_2\NNP|d|- (r_nsubj) were_3\VBD|glucarates|effective|antibitocis|. (l_acomp) effective_4\JJ|against (l_prep) against_5\IN|damage (l_pobj) damage_7\NN|renal|induced
D005937_D007674 NONE glucarate_4\NN|a|d|-|of (r_pobj) With_0\IN|glucarate (r_prep) obtained_19\VBN|with|,|degree|was|against|. (l_prep) against_20\IN|damages (l_pobj) damages_22\NNS|renal|induced
D005937_D007674 NONE Glucarates_2\NNP|d|- (r_nsubj) had_3\VBD|glucarates|ability|but|cure|. (l_dobj) ability_5\NN|the|prevent (l_acl) prevent_7\VB|to|damage (l_dobj) damage_9\NN|renal
D005937_D007674 NONE glucarates_6\NNS|d|-|against (l_prep) against_7\IN|nephrotoxicity (l_pobj) nephrotoxicity_8\NN|of
D000617_D003681 NONE aminoglycoside_11\NN| (r_compound) antibiotics_12\NNS|aminoglycoside (r_pobj) of_10\IN|antibiotics (r_prep) injection_9\NN|single|of|combined (r_pobj) following_7\VBG|injection (r_acl) failure_6\NN|acute|renal|following (r_dobj) develop_3\VBP|rats|regularly|failure|. (l_nsubj) rats_1\NNS|dehydrated (l_amod) Dehydrated_0\JJ|
D000617_D058186 CID aminoglycoside_11\NN| (r_compound) antibiotics_12\NNS|aminoglycoside (r_pobj) of_10\IN|antibiotics (r_prep) injection_9\NN|single|of|combined (r_pobj) following_7\VBG|injection (r_acl) failure_6\NN|acute|renal|following
C038936_D051437 NONE 6,3-dilactone_13\CD|glucaro-1,4|- (r_appos) D_9\NNP|-|acetyl|-|-|6,3-dilactone (r_nmod) rats_15\NNS|o|d|protected|against (l_prep) against_16\IN|failure (l_pobj) failure_18\NN|renal|induced
D007612_D051437 NONE kanamycin_21\NN| (r_compound) dextran_23\NN|kanamycin|- (r_pobj) by_20\IN|dextran (r_agent) induced_19\VBN|by (r_acl) failure_18\NN|renal|induced
D000617_D007674 NONE aminoglycoside_16\NN|various (r_conj) antibiotics_11\NNS|peptide|as|aminoglycoside (r_pobj) by_9\IN|antibiotics (r_agent) induced_8\VBN|by (r_acl) damage_7\NN|renal|induced
D009005_D007674 NONE monosaccharides_12\NNS| (r_pobj) by_11\IN|monosaccharides (r_agent) spared_7\VBN|when|they|were|from|by (l_prep) from_8\IN|lesions (l_pobj) lesions_10\NNS|renal
16911931
D019259_D006509 NONE lamivudine_7\NN|in (r_pobj) with_6\IN|lamivudine (r_prep) combined_5\VBN|with|after (r_acl) globulin_4\NN|intramuscular|b|immune|combined|. (l_compound) B_2\NNP|hepatitis
D019259_D006509 NONE lamivudine_7\NN|in (l_prep) in_8\IN|prevention (l_pobj) prevention_9\NN|of (l_prep) of_10\IN|recurrence (l_pobj) recurrence_13\NN|b (l_compound) B_12\NNP|hepatitis
D019259_D006509 NONE lamivudine_9\NN|in (r_conj) HBIg_6\NNP|)|and|lamivudine (r_appos) globulin_4\NN|combined|b|immune|(|hbig|after (l_compound) B_2\NNP|hepatitis
D019259_D006509 NONE lamivudine_9\NN|in (l_prep) in_10\IN|prophylaxis (l_pobj) prophylaxis_11\NN|of (l_prep) of_12\IN|recurrence (l_pobj) recurrence_14\NN|the|of (l_prep) of_15\IN|b (l_pobj) B_17\NNP|hepatitis
D006514_D006509 NONE HBsAg_27\JJ| (r_nmod) patients_29\NNS|hbsag|positive (r_pobj) of_26\IN|patients (r_prep) survival_25\NN|the|of (r_dobj) improved_23\VBN|globulin|has|significantly|survival|. (l_nsubj) globulin_4\NN|combined|b|immune|(|hbig|after (l_compound) B_2\NNP|hepatitis
D006514_D006509 NONE HBsAg_27\JJ| (r_nmod) patients_29\NNS|hbsag|positive (r_pobj) of_26\IN|patients (r_prep) survival_25\NN|the|of (r_dobj) improved_23\VBN|globulin|has|significantly|survival|. (l_nsubj) globulin_4\NN|combined|b|immune|(|hbig|after (l_appos) HBIg_6\NNP|)|and|lamivudine (l_conj) lamivudine_9\NN|in (l_prep) in_10\IN|prophylaxis (l_pobj) prophylaxis_11\NN|of (l_prep) of_12\IN|recurrence (l_pobj) recurrence_14\NN|the|of (l_prep) of_15\IN|b (l_pobj) B_17\NNP|hepatitis
8996419
D003276_D054556 CID contraceptives_13\NNS|various|oral (r_pobj) with_10\IN|contraceptives (r_prep) associated_9\VBN|with (r_acl) thromboembolism_8\NN|venous|associated
D003276_D054556 CID contraceptives_25\NNS|oral|(|ocs|) (r_dobj) used_23\VBD|who|contraceptives (r_relcl) women_21\NNS|used (r_pobj) in_20\IN|women (r_prep) higher_19\JJR|in (r_acomp) was_18\VBD|that|incidence|higher|containing (l_nsubj) incidence_11\NN|the|of (l_prep) of_12\IN|thromboembolism (l_pobj) thromboembolism_14\NN|venous|(|vte|)
D003276_D054556 CID contraceptives_25\NNS|oral|(|ocs|) (r_dobj) used_23\VBD|who|contraceptives (r_relcl) women_21\NNS|used (r_pobj) in_20\IN|women (r_prep) higher_19\JJR|in (r_acomp) was_18\VBD|that|incidence|higher|containing (l_nsubj) incidence_11\NN|the|of (l_prep) of_12\IN|thromboembolism (l_pobj) thromboembolism_14\NN|venous|(|vte|) (l_appos) VTE_16\NNP|
D003276_D054556 CID OCs_27\NNP| (r_appos) contraceptives_25\NNS|oral|(|ocs|) (r_dobj) used_23\VBD|who|contraceptives (r_relcl) women_21\NNS|used (r_pobj) in_20\IN|women (r_prep) higher_19\JJR|in (r_acomp) was_18\VBD|that|incidence|higher|containing (l_nsubj) incidence_11\NN|the|of (l_prep) of_12\IN|thromboembolism (l_pobj) thromboembolism_14\NN|venous|(|vte|)
D003276_D054556 CID OCs_27\NNP| (r_appos) contraceptives_25\NNS|oral|(|ocs|) (r_dobj) used_23\VBD|who|contraceptives (r_relcl) women_21\NNS|used (r_pobj) in_20\IN|women (r_prep) higher_19\JJR|in (r_acomp) was_18\VBD|that|incidence|higher|containing (l_nsubj) incidence_11\NN|the|of (l_prep) of_12\IN|thromboembolism (l_pobj) thromboembolism_14\NN|venous|(|vte|) (l_appos) VTE_16\NNP|
D003276_D054556 CID OCs_42\NNS|containing (r_pobj) of_41\IN|ocs (r_prep) users_40\NNS|of (r_pobj) in_39\IN|users (r_prep) than_38\IN|in (r_prep) gestodene_35\NN|the|generation|progestagens|or|desogestrel|than (r_dobj) containing_29\VBG|gestodene (r_advcl) was_18\VBD|that|incidence|higher|containing (l_nsubj) incidence_11\NN|the|of (l_prep) of_12\IN|thromboembolism (l_pobj) thromboembolism_14\NN|venous|(|vte|)
D003276_D054556 CID OCs_42\NNS|containing (r_pobj) of_41\IN|ocs (r_prep) users_40\NNS|of (r_pobj) in_39\IN|users (r_prep) than_38\IN|in (r_prep) gestodene_35\NN|the|generation|progestagens|or|desogestrel|than (r_dobj) containing_29\VBG|gestodene (r_advcl) was_18\VBD|that|incidence|higher|containing (l_nsubj) incidence_11\NN|the|of (l_prep) of_12\IN|thromboembolism (l_pobj) thromboembolism_14\NN|venous|(|vte|) (l_appos) VTE_16\NNP|
D003276_D054556 CID OC_17\NNP| (r_conj) VTE_15\NNP|and|oc
D003276_D054556 CID OC_17\NNP| (r_compound) preparations_18\NNS|the|main|oc (r_pobj) of_14\IN|preparations (r_prep) users_13\NNS|of (r_pobj) in_12\IN|users (r_prep) compare_8\VB|incidence|in (l_dobj) incidence_9\NN|of (l_prep) of_10\IN|vte (l_pobj) VTE_11\NNP|
D003276_D054556 CID OC_17\NNP| (r_compound) preparations_18\NNS|the|main|oc (r_pobj) of_14\IN|preparations (r_prep) users_13\NNS|of (r_pobj) in_12\IN|users (r_prep) compare_8\VB|incidence|in (r_conj) estimate_6\VB|to|and|compare (r_relcl) analysis_4\NN|a|cohort|estimate (r_dobj) did_1\VBD|we|analysis|,|and|study|. (l_conj) study_26\NN|a|nested|control|calculate|,|after (l_acl) calculate_28\VB|to|ratios (l_dobj) ratios_31\NNS|the|odds|of|associated (l_prep) of_32\IN|vte (l_pobj) VTE_33\NNP|
D003276_D054556 CID OC_41\NNP| (r_pobj) of_40\IN|oc (r_prep) types_39\NNS|different|of (r_pobj) of_37\IN|types (r_prep) use_36\NN|of (r_pobj) with_35\IN|use (r_prep) associated_34\VBN|with (r_acl) ratios_31\NNS|the|odds|of|associated (r_dobj) calculate_28\VB|to|ratios (r_acl) study_26\NN|a|nested|control|calculate|,|after (r_conj) did_1\VBD|we|analysis|,|and|study|. (l_dobj) analysis_4\NN|a|cohort|estimate (l_relcl) estimate_6\VB|to|and|compare (l_conj) compare_8\VB|incidence|in (l_dobj) incidence_9\NN|of (l_prep) of_10\IN|vte (l_pobj) VTE_11\NNP|
D003276_D054556 CID OC_41\NNP| (r_pobj) of_40\IN|oc (r_prep) types_39\NNS|different|of (r_pobj) of_37\IN|types (r_prep) use_36\NN|of (r_pobj) with_35\IN|use (r_prep) associated_34\VBN|with (r_acl) ratios_31\NNS|the|odds|of|associated (l_prep) of_32\IN|vte (l_pobj) VTE_33\NNP|
D003276_D054556 CID OCs_18\NNS|progestagen (r_pobj) of_14\IN|ocs (r_prep) users_13\NNS|of (r_attr) were_12\VBD|two|users (r_relcl) VTE_7\NNP|,|were
D003276_D054556 CID OCs_11\NNS|combined (r_pobj) of_9\IN|ocs (r_prep) use_8\NN|of (r_pobj) with_7\IN|use (r_prep) associated_6\VBN|with (r_acl) cases_3\NNS|the|83|of|associated (l_prep) of_4\IN|vte (l_pobj) VTE_5\NNP|
D003276_D054556 CID OC_17\NNP|any (r_pobj) of_15\IN|oc (r_prep) users_14\NNS|current|of (r_pobj) in_12\IN|users (r_prep) 4.10_11\CD|in|,|3.10 (r_attr) was_10\VBD|rate|4.10|. (l_nsubj) rate_2\NN|the|crude|of|per (l_prep) of_3\IN|vte (l_pobj) VTE_4\NNP|
D003276_D054556 CID OCs_26\NNS|generation (r_pobj) of_22\IN|ocs (r_prep) users_21\NNS|of (r_pobj) in_20\IN|users (r_prep) 3.10_19\CD|in|,|and|4.96 (r_appos) 4.10_11\CD|in|,|3.10 (r_attr) was_10\VBD|rate|4.10|. (l_nsubj) rate_2\NN|the|crude|of|per (l_prep) of_3\IN|vte (l_pobj) VTE_4\NNP|
D003276_D054556 CID OCs_21\NNS|generation (r_pobj) to_17\IN|ocs (r_prep) relative_16\JJ|generation|to (r_pobj) of_12\IN|relative (r_prep) users_11\NNS|of (r_pobj) in_10\IN|users (r_prep) ratio_7\NN|the|rate|of|in (l_prep) of_8\IN|vte (l_pobj) VTE_9\NNP|
D003276_D054556 CID OCs_21\NNS|generation (r_pobj) of_13\IN|ocs (r_prep) users_12\NNS|of (r_pobj) between_11\IN|users (r_prep) risk_8\NN|the|of|between (l_prep) of_9\IN|vte (l_pobj) VTE_10\NNP|
D003276_D054556 CID OCs_5\NNS|all|generation|as (r_pobj) With_0\IN|ocs (r_prep) were_15\VBD|with|,|ratios|3.49|for|. (l_nsubj) ratios_12\NNS|the|odds|for (l_prep) for_13\IN|vte (l_pobj) VTE_14\NNP|
D011374_D054556 NONE progestagens_34\NNS| (r_compound) gestodene_35\NN|the|generation|progestagens|or|desogestrel|than (r_dobj) containing_29\VBG|gestodene (r_advcl) was_18\VBD|that|incidence|higher|containing (l_nsubj) incidence_11\NN|the|of (l_prep) of_12\IN|thromboembolism (l_pobj) thromboembolism_14\NN|venous|(|vte|)
D011374_D054556 NONE progestagens_34\NNS| (r_compound) gestodene_35\NN|the|generation|progestagens|or|desogestrel|than (r_dobj) containing_29\VBG|gestodene (r_advcl) was_18\VBD|that|incidence|higher|containing (l_nsubj) incidence_11\NN|the|of (l_prep) of_12\IN|thromboembolism (l_pobj) thromboembolism_14\NN|venous|(|vte|) (l_appos) VTE_16\NNP|
D011374_D054556 NONE progestagens_47\NNS|generation (r_dobj) containing_43\VBG|progestagens (r_acl) OCs_42\NNS|containing (r_pobj) of_41\IN|ocs (r_prep) users_40\NNS|of (r_pobj) in_39\IN|users (r_prep) than_38\IN|in (r_prep) gestodene_35\NN|the|generation|progestagens|or|desogestrel|than (r_dobj) containing_29\VBG|gestodene (r_advcl) was_18\VBD|that|incidence|higher|containing (l_nsubj) incidence_11\NN|the|of (l_prep) of_12\IN|thromboembolism (l_pobj) thromboembolism_14\NN|venous|(|vte|)
D011374_D054556 NONE progestagens_47\NNS|generation (r_dobj) containing_43\VBG|progestagens (r_acl) OCs_42\NNS|containing (r_pobj) of_41\IN|ocs (r_prep) users_40\NNS|of (r_pobj) in_39\IN|users (r_prep) than_38\IN|in (r_prep) gestodene_35\NN|the|generation|progestagens|or|desogestrel|than (r_dobj) containing_29\VBG|gestodene (r_advcl) was_18\VBD|that|incidence|higher|containing (l_nsubj) incidence_11\NN|the|of (l_prep) of_12\IN|thromboembolism (l_pobj) thromboembolism_14\NN|venous|(|vte|) (l_appos) VTE_16\NNP|
D011374_D054556 NONE progestagens_6\NNS|generation (r_pobj) of_2\IN|progestagens (r_prep) users_1\NNS|of (r_pobj) Among_0\IN|users (r_prep) was_12\VBD|among|,|risk|higher|in|than|. (l_nsubj) risk_9\NN|the|of (l_prep) of_10\IN|vte (l_pobj) VTE_11\NNP|
D011374_D054556 NONE progestagens_41\NNS|the|other|generation (r_pobj) for_35\IN|progestagens (r_prep) were_15\VBD|with|,|ratios|3.49|for|. (l_nsubj) ratios_12\NNS|the|odds|for (l_prep) for_13\IN|vte (l_pobj) VTE_14\NNP|
C033273_D054556 NONE gestodene_35\NN|the|generation|progestagens|or|desogestrel|than (r_dobj) containing_29\VBG|gestodene (r_advcl) was_18\VBD|that|incidence|higher|containing (l_nsubj) incidence_11\NN|the|of (l_prep) of_12\IN|thromboembolism (l_pobj) thromboembolism_14\NN|venous|(|vte|)
C033273_D054556 NONE gestodene_35\NN|the|generation|progestagens|or|desogestrel|than (r_dobj) containing_29\VBG|gestodene (r_advcl) was_18\VBD|that|incidence|higher|containing (l_nsubj) incidence_11\NN|the|of (l_prep) of_12\IN|thromboembolism (l_pobj) thromboembolism_14\NN|venous|(|vte|) (l_appos) VTE_16\NNP|
C033273_D054556 NONE gestodene_26\NN|or|desogestrel (r_pobj) of_25\IN|gestodene (r_prep) users_24\NNS|of|with (r_pobj) in_23\IN|users (r_prep) than_22\IN|in (r_prep) was_12\VBD|among|,|risk|higher|in|than|. (l_nsubj) risk_9\NN|the|of (l_prep) of_10\IN|vte (l_pobj) VTE_11\NNP|
D017135_D054556 NONE desogestrel_37\NN| (r_conj) gestodene_35\NN|the|generation|progestagens|or|desogestrel|than (r_dobj) containing_29\VBG|gestodene (r_advcl) was_18\VBD|that|incidence|higher|containing (l_nsubj) incidence_11\NN|the|of (l_prep) of_12\IN|thromboembolism (l_pobj) thromboembolism_14\NN|venous|(|vte|)
D017135_D054556 NONE desogestrel_37\NN| (r_conj) gestodene_35\NN|the|generation|progestagens|or|desogestrel|than (r_dobj) containing_29\VBG|gestodene (r_advcl) was_18\VBD|that|incidence|higher|containing (l_nsubj) incidence_11\NN|the|of (l_prep) of_12\IN|thromboembolism (l_pobj) thromboembolism_14\NN|venous|(|vte|) (l_appos) VTE_16\NNP|
D017135_D054556 NONE desogestrel_17\NN| (r_pobj) of_16\IN|desogestrel (r_prep) users_15\NNS|of|with (r_pobj) in_14\IN|users (r_prep) was_12\VBD|among|,|risk|higher|in|than|. (l_nsubj) risk_9\NN|the|of (l_prep) of_10\IN|vte (l_pobj) VTE_11\NNP|
D017135_D054556 NONE desogestrel_28\NN| (r_conj) gestodene_26\NN|or|desogestrel (r_pobj) of_25\IN|gestodene (r_prep) users_24\NNS|of|with (r_pobj) in_23\IN|users (r_prep) than_22\IN|in (r_prep) was_12\VBD|among|,|risk|higher|in|than|. (l_nsubj) risk_9\NN|the|of (l_prep) of_10\IN|vte (l_pobj) VTE_11\NNP|
D017135_D054556 NONE desogestrel_23\NN|plus|ethinyloestradiol (r_pobj) for_22\IN|desogestrel (r_prep) 3.49_16\CD|10.12|)|for (r_attr) were_15\VBD|with|,|ratios|3.49|for|. (l_nsubj) ratios_12\NNS|the|odds|for (l_prep) for_13\IN|vte (l_pobj) VTE_14\NNP|
D011372_D054556 NONE progestagen_15\NN|-|only (r_nmod) OCs_18\NNS|progestagen (r_pobj) of_14\IN|ocs (r_prep) users_13\NNS|of (r_attr) were_12\VBD|two|users (r_relcl) VTE_7\NNP|,|were
D003276_D020246 NONE OCs_11\NNS|combined (r_pobj) of_9\IN|ocs (r_prep) use_8\NN|of (r_pobj) with_7\IN|use (r_prep) associated_6\VBN|with (r_acl) cases_3\NNS|the|83|of|associated (r_pobj) Of_0\IN|cases (r_prep) recorded_15\VBN|of|,|43|were|as|and|five|. (l_prep) as_16\IN|thrombosis (l_pobj) thrombosis_20\NN|vein|,|35|,
D003276_D020246 NONE OCs_11\NNS|combined (r_pobj) of_9\IN|ocs (r_prep) use_8\NN|of (r_pobj) with_7\IN|use (r_prep) associated_6\VBN|with (r_acl) cases_3\NNS|the|83|of|associated (r_pobj) Of_0\IN|cases (r_prep) recorded_15\VBN|of|,|43|were|as|and|five|. (l_conj) five_28\CD|as (l_prep) as_29\IN|thrombosis (l_pobj) thrombosis_31\NN|venous|specified
D003276_D013927 NONE OCs_11\NNS|combined (r_pobj) of_9\IN|ocs (r_prep) use_8\NN|of (r_pobj) with_7\IN|use (r_prep) associated_6\VBN|with (r_acl) cases_3\NNS|the|83|of|associated (r_pobj) Of_0\IN|cases (r_prep) recorded_15\VBN|of|,|43|were|as|and|five|. (l_prep) as_16\IN|thrombosis (l_pobj) thrombosis_20\NN|vein|,|35|, (l_appos) 35_22\CD|as (l_prep) as_23\IN|thrombosis (l_pobj) thrombosis_25\NN|pulmonary
D004997_D054556 NONE ethinyloestradiol_21\NN|g (r_pobj) with_18\IN|ethinyloestradiol (r_prep) users_15\NNS|of|with (r_pobj) in_14\IN|users (r_prep) was_12\VBD|among|,|risk|higher|in|than|. (l_nsubj) risk_9\NN|the|of (l_prep) of_10\IN|vte (l_pobj) VTE_11\NNP|
D004997_D054556 NONE ethinyloestradiol_32\NN|30|g (r_pobj) with_29\IN|ethinyloestradiol (r_prep) users_24\NNS|of|with (r_pobj) in_23\IN|users (r_prep) than_22\IN|in (r_prep) was_12\VBD|among|,|risk|higher|in|than|. (l_nsubj) risk_9\NN|the|of (l_prep) of_10\IN|vte (l_pobj) VTE_11\NNP|
D004997_D054556 NONE ethinyloestradiol_27\NN|g|and|1.18|2.17|) (r_appos) desogestrel_23\NN|plus|ethinyloestradiol (r_pobj) for_22\IN|desogestrel (r_prep) 3.49_16\CD|10.12|)|for (r_attr) were_15\VBD|with|,|ratios|3.49|for|. (l_nsubj) ratios_12\NNS|the|odds|for (l_prep) for_13\IN|vte (l_pobj) VTE_14\NNP|
2933998
D017265_D001249 NONE Procaterol_0\NNP|and|terbutaline|. (l_conj) terbutaline_2\NN|in (l_prep) in_3\IN|asthma (l_pobj) asthma_5\NN|bronchial
D017265_D001249 NONE Procaterol_0\NNP|,|stimulant|, (r_nsubjpass) studied_9\VBN|procaterol|was|in|. (l_prep) in_10\IN|trial (l_pobj) trial_23\NN|a|blind|,|controlled|,|cross|in (l_prep) in_24\IN|patients (l_pobj) patients_25\NNS|with (l_prep) with_26\IN|asthma (l_pobj) asthma_28\NN|bronchial
D017265_D001249 NONE procaterol_8\NN| (r_pobj) of_7\IN|procaterol (r_prep) effects_6\NNS|both|asthmatic|of (l_amod) asthmatic_3\JJ|-|and|tremorgenic
D013726_D001249 NONE terbutaline_2\NN|in (l_prep) in_3\IN|asthma (l_pobj) asthma_5\NN|bronchial
D017265_D014202 CID procaterol_8\NN| (r_pobj) of_7\IN|procaterol (r_prep) effects_6\NNS|both|asthmatic|of (l_amod) asthmatic_3\JJ|-|and|tremorgenic (l_conj) tremorgenic_5\JJ|
24658375
D014212_D009220 CID acid_4\NN| (r_npadvmod) induced_6\VBN|acid|- (r_amod) myositis_8\NN|trans|retinoic|induced|inflammatory|in|.
D014212_D009220 CID ATRA_6\NNP| (r_npadvmod) induced_8\VBN|atra|- (r_amod) myositis_9\NN|induced
D014212_D015473 NONE acid_4\NN| (r_npadvmod) induced_6\VBN|acid|- (r_amod) myositis_8\NN|trans|retinoic|induced|inflammatory|in|. (l_prep) in_9\IN|patient (l_pobj) patient_11\NN|a|with (l_prep) with_12\IN|leukemia (l_pobj) leukemia_15\NN|acute|promyelocytic
D014212_D015473 NONE acid_4\NN|trans|retinoic|atra|,|component|, (l_appos) component_10\NN|a|of|for (l_prep) for_14\IN|leukemia (l_pobj) leukemia_17\NN|acute|promyelocytic|(|apl|)
D014212_D015473 NONE acid_4\NN|trans|retinoic|atra|,|component|, (l_appos) component_10\NN|a|of|for (l_prep) for_14\IN|leukemia (l_pobj) leukemia_17\NN|acute|promyelocytic|(|apl|) (l_appos) APL_19\NNP|
D014212_D015473 NONE ATRA_6\NNP|(|) (r_appos) acid_4\NN|trans|retinoic|atra|,|component|, (l_appos) component_10\NN|a|of|for (l_prep) for_14\IN|leukemia (l_pobj) leukemia_17\NN|acute|promyelocytic|(|apl|)
D014212_D015473 NONE ATRA_6\NNP|(|) (r_appos) acid_4\NN|trans|retinoic|atra|,|component|, (l_appos) component_10\NN|a|of|for (l_prep) for_14\IN|leukemia (l_pobj) leukemia_17\NN|acute|promyelocytic|(|apl|) (l_appos) APL_19\NNP|
15882284
D001241_D007676 CID aspirin_11\NN|and|drugs (l_conj) drugs_20\NNS|other|analgesic|inflammatory|(|nsaids (l_appos) NSAIDs_22\NNPS|)|and|disease (l_conj) disease_29\NN|stage|renal|(|esrd|)
D001241_D007676 CID aspirin_11\NN|and|drugs (l_conj) drugs_20\NNS|other|analgesic|inflammatory|(|nsaids (l_appos) NSAIDs_22\NNPS|)|and|disease (l_conj) disease_29\NN|stage|renal|(|esrd|) (l_appos) ESRD_31\NNP|
D001241_D007676 CID aspirin_6\NN| (r_pobj) with_5\IN|aspirin (r_prep) associated_4\VBN|with (r_acl) risk_1\NN|the|of|associated (l_prep) of_2\IN|esrd (l_pobj) ESRD_3\NNS|
D001241_D007676 CID aspirin_6\NN| (r_pobj) of_5\IN|aspirin (r_prep) use_4\NN|the|chronic|of (r_nsubj) increase_8\VB|however|,|use|may|risk|. (l_dobj) risk_10\NN|the|of (l_prep) of_11\IN|esrd (l_pobj) ESRD_12\NNP|
D001241_D007674 NONE aspirin_6\NN| (r_pobj) with_5\IN|aspirin (r_prep) associated_4\VBN|with (r_acl) risk_1\NN|the|of|associated (r_nsubjpass) related_8\VBN|risk|was|to|,|and|was (l_conj) was_20\VBD|it|high|]|. (l_acomp) high_22\JJ|particularly|among (l_prep) among_23\IN|subset (l_pobj) subset_25\NN|the|of (l_prep) of_26\IN|patients (l_pobj) patients_27\NNS|with|as (l_prep) with_28\IN|nephropathy (l_pobj) nephropathy_30\NN|vascular
10672628
D009569_D002375 NONE oxide_7\NN|nitric|- (r_compound) synthesis_8\NN|oxide (r_pobj) of_4\IN|synthesis (r_prep) inhibition_3\NN|chronic|of (r_nsubj) modifies_9\VBZ|inhibition|catalepsy|. (l_dobj) catalepsy_13\NN|induced|and|number
D009569_D002375 NONE oxide_18\NN|nitric|- (r_compound) synthase_19\NN|oxide|(|nos|) (r_pobj) of_15\IN|synthase (r_prep) inhibitor_14\NN|an|of (r_appos) arginine_6\NN|nitro|-|l|-|noarg|,|inhibitor|, (r_nsubj) induces_24\VBZ|arginine|catalepsy|in|. (l_dobj) catalepsy_25\NN|
D006220_D002375 CID haloperidol_10\NN| (r_npadvmod) induced_12\VBN|haloperidol|- (r_amod) catalepsy_13\NN|induced|and|number
D006220_D002375 CID haloperidol_4\NN|,|block|, (r_pobj) as_3\IN|such|haloperidol (r_prep) drugs_1\NNS|neuroleptic|as (r_nsubj) cause_12\VBP|drugs|also|catalepsy|in|. (l_dobj) catalepsy_13\NN|
D006220_D002375 CID haloperidol_11\NN| (r_npadvmod) induced_13\VBN|haloperidol|- (r_amod) catalepsy_14\NN|induced
D006220_D002375 CID haloperidol_16\NN| (r_npadvmod) induced_18\VBN|haloperidol|- (r_amod) catalepsy_19\NN|induced
D009249_D002375 NONE NADPH_18\NNP| (r_compound) diaphorase_20\NN|nadph|- (r_compound) neurons_21\NNS|diaphorase (r_pobj) of_17\IN|neurons (r_prep) number_16\NN|the|of|in (r_conj) catalepsy_13\NN|induced|and|number
D019335_D002375 NONE arginine_6\NN|nitro|-|l|-|noarg|,|inhibitor|, (r_nsubj) induces_24\VBZ|arginine|catalepsy|in|. (l_dobj) catalepsy_25\NN|
D019335_D002375 NONE NOARG_10\NNP|(|l|-|) (r_appos) arginine_6\NN|nitro|-|l|-|noarg|,|inhibitor|, (r_nsubj) induces_24\VBZ|arginine|catalepsy|in|. (l_dobj) catalepsy_25\NN|
D019335_D002375 NONE NOARG_8\NNP|l|- (r_compound) treatment_9\NN|subchronic|noarg|in|and|number (l_prep) in_10\IN|catalepsy (l_pobj) catalepsy_14\NN|induced
D019335_D002375 NONE NOARG_3\NNP|l|- (r_nmod) administration_7\NN|noarg|chronic (r_nsubj) produced_8\VBD|:|administration|tolerance|. (l_dobj) tolerance_9\NN|of (l_prep) of_10\IN|noarg|and|of (l_conj) of_15\IN|catalepsy (l_pobj) catalepsy_19\NN|induced
D019335_D002375 NONE NOARG_13\NNP|l|- (r_pobj) of_10\IN|noarg|and|of (l_conj) of_15\IN|catalepsy (l_pobj) catalepsy_19\NN|induced
D004298_D002375 NONE dopamine_8\NN| (r_compound) receptors_9\NNS|dopamine (r_dobj) block_7\VBP|which|receptors (r_relcl) haloperidol_4\NN|,|block|, (r_pobj) as_3\IN|such|haloperidol (r_prep) drugs_1\NNS|neuroleptic|as (r_nsubj) cause_12\VBP|drugs|also|catalepsy|in|. (l_dobj) catalepsy_13\NN|
24588023
D014148_D012640 CID acid_4\NN|tranexamic|and|seizures (l_conj) seizures_7\NNS|convulsive (l_amod) convulsive_6\JJ|
D014148_D012640 CID acid_4\NN|tranexamic|and|seizures (l_conj) seizures_7\NNS|convulsive
D014148_D012640 CID acid_37\NN|aortic|clamp (r_pobj) of_30\IN|acid (r_prep) duration_29\NN|of (r_conj) arrest_27\NN|deep|hypothermic|circulatory|,|duration (r_conj) failure_22\NN|congestive|heart|,|arrest (r_conj) calcification_15\NN|of|,|failure (r_conj) surgery_13\NN|cardiac|,|calcification (r_dobj) redo_11\VB|surgery (r_conj) included_5\VBD|predictors|age|redo|. (l_nsubj) predictors_1\NNS|independent|of (l_prep) of_2\IN|seizures (l_pobj) seizures_4\NNS|postoperative
D014148_D012640 CID acid_9\NN|tranexamic (r_nsubj) was_10\VBD|tested|,|acid|predictor|)|. (l_attr) predictor_14\NN|a|strong|independent|of|0.001 (l_prep) of_15\IN|seizures (l_pobj) seizures_16\NNS|(|ci|;
D014148_D012640 CID acid_2\NN|tranexamic (r_nsubj) is_3\VBZ|as|acid|factor (r_advcl) weighed_22\VBN|is|,|administration|should|be|against|. (l_prep) against_23\IN|risk (l_pobj) risk_25\NN|the|of (l_prep) of_26\IN|seizures (l_pobj) seizures_28\NNS|postoperative
D014148_D006333 NONE acid_37\NN|aortic|clamp (r_pobj) of_30\IN|acid (r_prep) duration_29\NN|of (r_conj) arrest_27\NN|deep|hypothermic|circulatory|,|duration (r_conj) failure_22\NN|congestive|heart|,|arrest
D014148_D007035 NONE acid_37\NN|aortic|clamp (r_pobj) of_30\IN|acid (r_prep) duration_29\NN|of (r_conj) arrest_27\NN|deep|hypothermic|circulatory|,|duration (l_amod) hypothermic_25\JJ|
1563460
D014859_D020758 CID coumadin_4\NN| (r_amod) therapy_6\NN|coumadin|anticoagulant (r_pobj) to_3\IN|therapy (r_prep) hematomyelia_1\NNS|thoracic|secondary|to|:|report|.
17346443
D010396_D017512 CID Penicillamine_0\NN| (r_npadvmod) related_2\VBN|penicillamine|- (r_amod) dermatitis_4\NN|related|lichenoid|and|utility|in|.
D010396_D017512 CID penicillamine_9\NN| (r_nsubjpass) interrupted_11\VBN|during|,|penicillamine|was|after|,|and|permitted (l_prep) after_12\IN|appearance (l_pobj) appearance_14\NN|the|of (l_prep) of_15\IN|dermatitis (l_pobj) dermatitis_18\NN|a|lichenoid
D010396_D006527 NONE Penicillamine_0\NN| (r_npadvmod) related_2\VBN|penicillamine|- (r_amod) dermatitis_4\NN|related|lichenoid|and|utility|in|. (l_prep) in_10\IN|patient (l_pobj) patient_14\JJ|a|disease|with (l_compound) disease_13\NN|wilson
D010396_D006527 NONE penicillamine_20\NN| (r_npadvmod) related_22\VBN|penicillamine|- (r_amod) effects_24\NNS|related|side (r_nsubj) appeared_25\VBD|in|effects (r_relcl) treatment_11\NN|an|effective|for|appeared (l_prep) for_12\IN|patient (l_pobj) patient_17\NN|wilson|disease (l_compound) disease_16\NN|
D010396_D006527 NONE penicillamine_6\NN| (r_npadvmod) treated_8\VBN|penicillamine|- (r_amod) patients_9\NNS|wilson|disease|treated (l_nmod) disease_5\NN|
D010396_D001008 NONE Penicillamine_0\NN| (r_npadvmod) related_2\VBN|penicillamine|- (r_amod) dermatitis_4\NN|related|lichenoid|and|utility|in|. (l_prep) in_10\IN|patient (l_pobj) patient_14\JJ|a|disease|with (l_prep) with_15\IN|presentation (l_pobj) presentation_17\NN|hepatic|,|anxiety (l_conj) anxiety_19\NN|and|abnormalities
D019345_D017512 NONE acetate_9\NN|zinc (r_pobj) of_7\IN|acetate (r_prep) utility_6\NN|of (r_conj) dermatitis_4\NN|related|lichenoid|and|utility|in|.
D019345_D017512 NONE acetate_22\NN|zinc (r_nsubj) permitted_23\VBD|acetate|continue|. (r_conj) interrupted_11\VBN|during|,|penicillamine|was|after|,|and|permitted (l_prep) after_12\IN|appearance (l_pobj) appearance_14\NN|the|of (l_prep) of_15\IN|dermatitis (l_pobj) dermatitis_18\NN|a|lichenoid
D019345_D006527 NONE acetate_9\NN|zinc (r_pobj) of_7\IN|acetate (r_prep) utility_6\NN|of (r_conj) dermatitis_4\NN|related|lichenoid|and|utility|in|. (l_prep) in_10\IN|patient (l_pobj) patient_14\JJ|a|disease|with (l_compound) disease_13\NN|wilson
D019345_D006527 NONE acetate_7\NN|zinc (r_pobj) with_5\IN|acetate (r_prep) therapy_4\NN|the|with (r_nsubj) represented_8\VBD|in|therapy|treatment|. (l_dobj) treatment_11\NN|an|effective|for|appeared (l_prep) for_12\IN|patient (l_pobj) patient_17\NN|wilson|disease (l_compound) disease_16\NN|
D019345_D006527 NONE acetate_5\NN|the|zinc (r_pobj) of_2\IN|acetate (r_prep) safety_1\NN|the|of (r_nsubj) allowed_6\VBD|safety|avoid (r_ccomp) is_18\VBZ|allowed|;|observation|in|. (l_prep) in_19\IN|line (l_pobj) line_20\NN|with (l_prep) with_21\IN|evidence (l_pobj) evidence_24\NN|the|growing|on (l_prep) on_25\IN|efficacy (l_pobj) efficacy_27\NN|the|of (l_prep) of_28\IN|drug (l_pobj) drug_30\NN|the|in (l_prep) in_31\IN|treatment (l_pobj) treatment_33\NN|the|of (l_prep) of_34\IN|disease (l_pobj) disease_37\NN|wilson
D019345_D001008 NONE acetate_9\NN|zinc (r_pobj) of_7\IN|acetate (r_prep) utility_6\NN|of (r_conj) dermatitis_4\NN|related|lichenoid|and|utility|in|. (l_prep) in_10\IN|patient (l_pobj) patient_14\JJ|a|disease|with (l_prep) with_15\IN|presentation (l_pobj) presentation_17\NN|hepatic|,|anxiety (l_conj) anxiety_19\NN|and|abnormalities
D003300_D006527 NONE copper_10\NN| (r_compound) metabolism_11\NN|hepatic|copper (r_pobj) of_8\IN|metabolism (r_prep) disorder_7\NN|an|autosomal|recessive|of|with (r_attr) is_3\VBZ|disease|disorder|. (l_nsubj) disease_2\NN|wilson
D003300_D006527 NONE copper_14\NN| (r_compound) accumulation_15\NN|consequent|copper|and|toxicity|in (r_pobj) with_12\IN|accumulation (r_prep) disorder_7\NN|an|autosomal|recessive|of|with (r_attr) is_3\VBZ|disease|disorder|. (l_nsubj) disease_2\NN|wilson
D003300_D064420 NONE copper_10\NN| (r_compound) metabolism_11\NN|hepatic|copper (r_pobj) of_8\IN|metabolism (r_prep) disorder_7\NN|an|autosomal|recessive|of|with (l_prep) with_12\IN|accumulation (l_pobj) accumulation_15\NN|consequent|copper|and|toxicity|in (l_conj) toxicity_17\NN|
D003300_D064420 NONE copper_14\NN| (r_compound) accumulation_15\NN|consequent|copper|and|toxicity|in (l_conj) toxicity_17\NN|
D003300_D056486 NONE copper_10\NN| (r_compound) metabolism_11\NN|hepatic|copper (r_pobj) of_8\IN|metabolism (r_prep) disorder_7\NN|an|autosomal|recessive|of|with (l_prep) with_12\IN|accumulation (l_pobj) accumulation_15\NN|consequent|copper|and|toxicity|in (l_prep) in_18\IN|tissues (l_pobj) tissues_20\NNS|many|and|disorders (l_conj) disorders_28\NNS|consequent|hepatic
D003300_D056486 NONE copper_14\NN| (r_compound) accumulation_15\NN|consequent|copper|and|toxicity|in (l_prep) in_18\IN|tissues (l_pobj) tissues_20\NNS|many|and|disorders (l_conj) disorders_28\NNS|consequent|hepatic
D003300_D009422 NONE copper_10\NN| (r_compound) metabolism_11\NN|hepatic|copper (r_pobj) of_8\IN|metabolism (r_prep) disorder_7\NN|an|autosomal|recessive|of|with (l_prep) with_12\IN|accumulation (l_pobj) accumulation_15\NN|consequent|copper|and|toxicity|in (l_prep) in_18\IN|tissues (l_pobj) tissues_20\NNS|many|and|disorders (l_conj) disorders_28\NNS|consequent|hepatic
D003300_D009422 NONE copper_14\NN| (r_compound) accumulation_15\NN|consequent|copper|and|toxicity|in (l_prep) in_18\IN|tissues (l_pobj) tissues_20\NNS|many|and|disorders (l_conj) disorders_28\NNS|consequent|hepatic
D003300_D001523 NONE copper_10\NN| (r_compound) metabolism_11\NN|hepatic|copper (r_pobj) of_8\IN|metabolism (r_prep) disorder_7\NN|an|autosomal|recessive|of|with (l_prep) with_12\IN|accumulation (l_pobj) accumulation_15\NN|consequent|copper|and|toxicity|in (l_prep) in_18\IN|tissues (l_pobj) tissues_20\NNS|many|and|disorders (l_conj) disorders_28\NNS|consequent|hepatic
D003300_D001523 NONE copper_14\NN| (r_compound) accumulation_15\NN|consequent|copper|and|toxicity|in (l_prep) in_18\IN|tissues (l_pobj) tissues_20\NNS|many|and|disorders (l_conj) disorders_28\NNS|consequent|hepatic
D010396_D012871 NONE penicillamine_6\NN| (r_npadvmod) treated_8\VBN|penicillamine|- (r_amod) patients_9\NNS|wilson|disease|treated (r_pobj) of_2\IN|patients (r_prep) most_1\JJS|of (r_nsubj) seem_12\VB|since|most|do|not|develop (l_xcomp) develop_14\VB|to|lesion (l_dobj) lesion_17\NN|this|skin
7671401
D000806_D000799 CID inhibitor_19\NN|converting|enzyme|in (r_pobj) with_14\IN|inhibitor (r_prep) therapy_13\NN|term|with (r_pobj) to_9\IN|therapy (r_prep) related_8\VBN|to (r_acl) oedema_7\NN|angio|-|related
D000806_D000799 CID inhibitors_6\NNS|ace (r_pobj) of_4\IN|inhibitors (r_prep) introduction_3\NN|the|of (r_pobj) after_1\IN|introduction (r_prep) reported_15\VBN|soon|after|,|bouts|were|in|. (l_nsubjpass) bouts_9\NNS|acute|of (l_prep) of_10\IN|oedema (l_pobj) oedema_13\NN|angio|-
D000806_D000799 CID inhibitors_13\NNS|ace (r_pobj) to_11\IN|inhibitors (r_prep) reactions_10\NNS|adverse|to|after (l_prep) after_14\IN|use|and|in (l_conj) in_20\IN|patients (l_pobj) patients_21\NNS|with (l_prep) with_22\IN|oedema (l_pobj) oedema_28\NN|existing|angio|-
D000806_D006973 NONE inhibitors_7\NNS|(|ace|)|,|used|, (l_acl) used_9\VBD|treat (l_xcomp) treat_11\VB|to|hypertension (l_dobj) hypertension_12\NN|and|failure
D000806_D006333 NONE inhibitors_7\NNS|(|ace|)|,|used|, (l_acl) used_9\VBD|treat (l_xcomp) treat_11\VB|to|hypertension (l_dobj) hypertension_12\NN|and|failure (l_conj) failure_16\NN|congestive|heart
20927253
D019386_D010146 CID alendronate_6\NN| (r_pobj) of_5\IN|alendronate (r_prep) administration_4\NN|of (r_pobj) after_3\IN|administration (r_prep) pain_2\NN|diffuse|skeletal|after|.
D019386_D010146 CID alendronate_20\NN| (r_pobj) of_19\IN|alendronate (r_prep) administration_18\NN|three|consecutive|of (r_pobj) after_15\IN|administration (r_prep) admitted_4\VBN|to|with|after (l_prep) with_11\IN|pain (l_pobj) pain_14\NN|diffuse|skeletal
D004164_D010024 NONE bisphosphonates_13\NNS| (r_nsubjpass) used_16\VBN|bisphosphonates|,|are|inhibit|. (r_conj) caused_2\VBN|osteoporosis|is|by|,|and|used (l_nsubjpass) Osteoporosis_0\NN|
D004164_D010024 NONE bisphosphonate_11\NN| (r_npadvmod) related_13\VBN|bisphosphonate|- (r_amod) pain_14\NN|related (r_nsubjpass) considered_18\VBN|pain|should|also|be|before (r_conj) report_7\VB|that|patients|can|pain|and|considered (l_nsubj) patients_3\NNS|with (l_prep) with_4\IN|osteoporosis (l_pobj) osteoporosis_5\NN|
D004164_D010024 NONE bisphosphonate_11\NN| (r_npadvmod) related_13\VBN|bisphosphonate|- (r_amod) pain_14\NN|related (r_nsubjpass) considered_18\VBN|pain|should|also|be|before (l_prep) before_19\IN|ascribing (l_pcomp) ascribing_20\VBG|complaint|to (l_prep) to_23\IN|osteoporosis (l_pobj) osteoporosis_24\NN|
D019386_D010024 NONE Alendronate_0\NNP|,|biphosphonate|, (r_nsubj) is_5\VBZ|alendronate|effective|. (l_acomp) effective_6\JJ|for (l_prep) for_7\IN|treatment (l_pobj) treatment_10\NN|both|the|and|prevention|of (l_prep) of_13\IN|osteoporosis (l_pobj) osteoporosis_14\NN|in
-1_D010024 NONE biphosphonate_3\NN|a (r_appos) Alendronate_0\NNP|,|biphosphonate|, (r_nsubj) is_5\VBZ|alendronate|effective|. (l_acomp) effective_6\JJ|for (l_prep) for_7\IN|treatment (l_pobj) treatment_10\NN|both|the|and|prevention|of (l_prep) of_13\IN|osteoporosis (l_pobj) osteoporosis_14\NN|in
D004164_D010146 NONE bisphosphonate_11\NN| (r_npadvmod) related_13\VBN|bisphosphonate|- (r_amod) pain_14\NN|related (r_nsubjpass) considered_18\VBN|pain|should|also|be|before (r_conj) report_7\VB|that|patients|can|pain|and|considered (l_dobj) pain_8\NN|,
D004164_D010146 NONE bisphosphonate_11\NN| (r_npadvmod) related_13\VBN|bisphosphonate|- (r_amod) pain_14\NN|related
24653743
C042288_D016757 CID Pilsicainide_8\NNP| (r_npadvmod) Induced_10\VBN|pilsicainide|- (r_amod) Pointes_13\NNP|induced|torsades|de (r_pobj) due_6\IN|to|pointes (r_amod) Case_1\NN|a|of|due|. (l_prep) of_2\IN|death (l_pobj) Death_5\NNP|sudden|cardiac
C042288_D016757 CID pilsicainide_7\NN|oral|,|blocker|, (r_dobj) received_5\VBD|male|pilsicainide|convert (r_ccomp) developed_32\VBD|received|;|patient|death|later|. (l_dobj) death_35\NN|sudden|cardiac
C042288_D016171 CID Pilsicainide_8\NNP| (r_npadvmod) Induced_10\VBN|pilsicainide|- (r_amod) Pointes_13\NNP|induced|torsades|de
C042288_D016171 CID pilsicainide_14\NN| (r_pobj) of_13\IN|pilsicainide (r_prep) dose_12\NN|the|of (r_nsubj) was_15\VBD|dose|low (r_conj) was_6\VBD|although|function|not|impaired|and|was (r_advcl) been_25\VBN|was|,|concentration|may|have|high|,|produce|. (l_advcl) produce_30\VB|which|can|pointes (l_dobj) pointes_33\FW|torsades|de|in
C042288_D016171 CID pilsicainide_22\NN| (r_pobj) of_21\IN|pilsicainide (r_prep) concentration_20\NN|the|plasma|of (r_nsubj) been_25\VBN|was|,|concentration|may|have|high|,|produce|. (l_advcl) produce_30\VB|which|can|pointes (l_dobj) pointes_33\FW|torsades|de|in
C042288_D001281 NONE pilsicainide_7\NN|oral|,|blocker|, (r_dobj) received_5\VBD|male|pilsicainide|convert (l_advcl) convert_20\VB|to|fibrillation|to (l_dobj) fibrillation_24\NN|his|paroxysmal|atrial
C042288_D001281 NONE pilsicainide_10\NN| (r_pobj) including_9\VBG|pilsicainide (r_prep) administration_3\NN|the|oral|of|,|including (r_nsubj) is_12\VBZ|although|administration|,|effective (l_acomp) effective_13\JJ|terminate (l_xcomp) terminate_15\VB|to|fibrillation (l_dobj) fibrillation_17\NN|atrial
D012964_D001281 NONE sodium_11\NN| (r_compound) channel_12\NN|pure|sodium (r_compound) blocker_13\NN|a|channel|with (r_appos) pilsicainide_7\NN|oral|,|blocker|, (r_dobj) received_5\VBD|male|pilsicainide|convert (l_advcl) convert_20\VB|to|fibrillation|to (l_dobj) fibrillation_24\NN|his|paroxysmal|atrial
D012964_D016757 NONE sodium_11\NN| (r_compound) channel_12\NN|pure|sodium (r_compound) blocker_13\NN|a|channel|with (r_appos) pilsicainide_7\NN|oral|,|blocker|, (r_dobj) received_5\VBD|male|pilsicainide|convert (r_ccomp) developed_32\VBD|received|;|patient|death|later|. (l_dobj) death_35\NN|sudden|cardiac
2358093
D003613_D054179 NONE danazol_6\NN| (r_pobj) of_5\IN|danazol (r_prep) safety_4\NN|the|term|of|in|with|. (l_prep) with_9\IN|angioedema (l_pobj) angioedema_11\NN|hereditary
D003613_D054179 NONE danazol_9\NN| (r_pobj) of_8\IN|danazol (r_prep) safety_7\NN|the|term|of (r_dobj) investigated_2\VBD|we|therefore|safety|by|. (l_prep) by_10\IN|performing (l_pcomp) performing_11\VBG|review (l_dobj) review_15\NN|a|retrospective|chart|of|treated (l_prep) of_16\IN|patients (l_pobj) patients_19\NNS|60|female|with (l_prep) with_20\IN|angioedema (l_pobj) angioedema_22\NN|hereditary
D003613_D054179 NONE danazol_25\NN| (r_pobj) with_24\IN|danazol (r_prep) treated_23\VBN|with|for (r_acl) review_15\NN|a|retrospective|chart|of|treated (l_prep) of_16\IN|patients (l_pobj) patients_19\NNS|60|female|with (l_prep) with_20\IN|angioedema (l_pobj) angioedema_22\NN|hereditary
10219427
17356399
C042705_D020803 NONE asparaginase_11\NN|peg|-|and|cytarabine (r_pobj) including_8\VBG|asparaginase (r_prep) chemotherapy_7\NN|including (r_dobj) multiagent_6\JJ|encephalopathy|after|chemotherapy|for|. (l_nsubj) encephalopathy_1\JJ|acute|and|vasospasm
C042705_D020301 CID asparaginase_11\NN|peg|-|and|cytarabine (r_pobj) including_8\VBG|asparaginase (r_prep) chemotherapy_7\NN|including (r_dobj) multiagent_6\JJ|encephalopathy|after|chemotherapy|for|. (l_nsubj) encephalopathy_1\JJ|acute|and|vasospasm (l_conj) vasospasm_4\NN|cerebral
C042705_D054198 NONE asparaginase_11\NN|peg|-|and|cytarabine (r_pobj) including_8\VBG|asparaginase (r_prep) chemotherapy_7\NN|including (r_dobj) multiagent_6\JJ|encephalopathy|after|chemotherapy|for|. (l_prep) for_15\IN|treatment (l_pobj) treatment_17\NN|the|of (l_prep) of_18\IN|leukemia (l_pobj) leukemia_21\NN|acute|lymphoblastic
D003561_D020803 NONE cytarabine_14\NN|intrathecal (r_conj) asparaginase_11\NN|peg|-|and|cytarabine (r_pobj) including_8\VBG|asparaginase (r_prep) chemotherapy_7\NN|including (r_dobj) multiagent_6\JJ|encephalopathy|after|chemotherapy|for|. (l_nsubj) encephalopathy_1\JJ|acute|and|vasospasm
D003561_D020803 NONE cytarabine_35\NN|intrathecal (r_pobj) of_33\IN|cytarabine (r_prep) administration_32\NN|the|of (r_pobj) after_30\IN|administration (r_prep) vasospasm_25\NN|diffuse|cerebral|on|after (r_pobj) with_22\IN|vasospasm (r_prep) weakness_21\NN|sided|with (r_conj) hallucinations_15\NNS|visual|,|and|weakness (r_conj) incontinence_12\NN|,|hallucinations (r_conj) aphasia_10\NN|,|incontinence (r_conj) changes_8\NNS|behavioral|,|aphasia (r_pobj) by_6\IN|changes (r_agent) evidenced_5\VBN|by (r_acl) encephalopathy_4\NN|acute|evidenced
D003561_D020301 CID cytarabine_14\NN|intrathecal (r_conj) asparaginase_11\NN|peg|-|and|cytarabine (r_pobj) including_8\VBG|asparaginase (r_prep) chemotherapy_7\NN|including (r_dobj) multiagent_6\JJ|encephalopathy|after|chemotherapy|for|. (l_nsubj) encephalopathy_1\JJ|acute|and|vasospasm (l_conj) vasospasm_4\NN|cerebral
D003561_D020301 CID cytarabine_35\NN|intrathecal (r_pobj) of_33\IN|cytarabine (r_prep) administration_32\NN|the|of (r_pobj) after_30\IN|administration (r_prep) vasospasm_25\NN|diffuse|cerebral|on|after
D003561_D054198 NONE cytarabine_14\NN|intrathecal (r_conj) asparaginase_11\NN|peg|-|and|cytarabine (r_pobj) including_8\VBG|asparaginase (r_prep) chemotherapy_7\NN|including (r_dobj) multiagent_6\JJ|encephalopathy|after|chemotherapy|for|. (l_prep) for_15\IN|treatment (l_pobj) treatment_17\NN|the|of (l_prep) of_18\IN|leukemia (l_pobj) leukemia_21\NN|acute|lymphoblastic
D003561_D001037 CID cytarabine_35\NN|intrathecal (r_pobj) of_33\IN|cytarabine (r_prep) administration_32\NN|the|of (r_pobj) after_30\IN|administration (r_prep) vasospasm_25\NN|diffuse|cerebral|on|after (r_pobj) with_22\IN|vasospasm (r_prep) weakness_21\NN|sided|with (r_conj) hallucinations_15\NNS|visual|,|and|weakness (r_conj) incontinence_12\NN|,|hallucinations (r_conj) aphasia_10\NN|,|incontinence
D003561_D014549 CID cytarabine_35\NN|intrathecal (r_pobj) of_33\IN|cytarabine (r_prep) administration_32\NN|the|of (r_pobj) after_30\IN|administration (r_prep) vasospasm_25\NN|diffuse|cerebral|on|after (r_pobj) with_22\IN|vasospasm (r_prep) weakness_21\NN|sided|with (r_conj) hallucinations_15\NNS|visual|,|and|weakness (r_conj) incontinence_12\NN|,|hallucinations
D003561_D006212 CID cytarabine_35\NN|intrathecal (r_pobj) of_33\IN|cytarabine (r_prep) administration_32\NN|the|of (r_pobj) after_30\IN|administration (r_prep) vasospasm_25\NN|diffuse|cerebral|on|after (r_pobj) with_22\IN|vasospasm (r_prep) weakness_21\NN|sided|with (r_conj) hallucinations_15\NNS|visual|,|and|weakness
D003561_D018908 CID cytarabine_35\NN|intrathecal (r_pobj) of_33\IN|cytarabine (r_prep) administration_32\NN|the|of (r_pobj) after_30\IN|administration (r_prep) vasospasm_25\NN|diffuse|cerebral|on|after (r_pobj) with_22\IN|vasospasm (r_prep) weakness_21\NN|sided|with
851038
D007980_D010300 NONE dopa_5\NN|l|- (r_compound) treatment_6\NN|dopa|in (l_prep) in_7\IN|patients (l_pobj) patients_9\NNS|parkinsonian (l_amod) parkinsonian_8\JJ|
D007980_D010300 NONE dopa_11\NN|l|- (r_npadvmod) treated_13\VBN|dopa|- (r_amod) patients_15\NNS|some|treated|parkinsonian (l_amod) parkinsonian_14\JJ|
D007980_D007008 CID dopa_11\NN|l|- (r_npadvmod) treated_13\VBN|dopa|- (r_amod) patients_15\NNS|some|treated|parkinsonian (r_pobj) in_7\IN|patients (r_prep) observed_6\VBN|hypokalemia|was|in|. (l_nsubjpass) Hypokalemia_0\NNP|,|severe|,
D007980_D007008 CID dopa_5\NN|l|-|on (r_pobj) of_2\IN|dopa (r_prep) influence_1\NN|the|of (r_nsubjpass) studied_13\VBN|influence|was|in|. (l_prep) in_14\IN|patients|and|in (l_pobj) patients_16\NNS|3|with (l_prep) with_17\IN|hypokalemia (l_pobj) hypokalemia_18\NN|
D011188_D007008 NONE potassium_11\NN| (r_pobj) of_10\IN|potassium (r_prep) excretion_9\NN|the|renal|of (r_pobj) on_6\IN|excretion (r_prep) dopa_5\NN|l|-|on (r_pobj) of_2\IN|dopa (r_prep) influence_1\NN|the|of (r_nsubjpass) studied_13\VBN|influence|was|in|. (l_prep) in_14\IN|patients|and|in (l_pobj) patients_16\NNS|3|with (l_prep) with_17\IN|hypokalemia (l_pobj) hypokalemia_18\NN|
D011188_D007008 NONE potassium_38\NN|and|sodium|as|excretion (r_pobj) of_37\IN|potassium (r_prep) concentration_36\NN|plasma|of (r_conj) rate_33\NN|glomerular|filtration|,|concentration (r_conj) flow_29\NN|renal|plasma|,|rate (r_pobj) of_26\IN|flow (r_prep) determination_25\NN|of (r_pobj) by_24\IN|determination (r_prep) patients_23\NNS|5|normokalemic|by (r_pobj) in_20\IN|patients (r_conj) in_14\IN|patients|and|in (l_pobj) patients_16\NNS|3|with (l_prep) with_17\IN|hypokalemia (l_pobj) hypokalemia_18\NN|
D011188_D007008 NONE potassium_47\NN|,|sodium (r_pobj) of_46\IN|potassium (r_prep) excretion_45\NN|urinary|of (r_conj) potassium_38\NN|and|sodium|as|excretion (r_pobj) of_37\IN|potassium (r_prep) concentration_36\NN|plasma|of (r_conj) rate_33\NN|glomerular|filtration|,|concentration (r_conj) flow_29\NN|renal|plasma|,|rate (r_pobj) of_26\IN|flow (r_prep) determination_25\NN|of (r_pobj) by_24\IN|determination (r_prep) patients_23\NNS|5|normokalemic|by (r_pobj) in_20\IN|patients (r_conj) in_14\IN|patients|and|in (l_pobj) patients_16\NNS|3|with (l_prep) with_17\IN|hypokalemia (l_pobj) hypokalemia_18\NN|
D012964_D007008 NONE sodium_40\NN| (r_conj) potassium_38\NN|and|sodium|as|excretion (r_pobj) of_37\IN|potassium (r_prep) concentration_36\NN|plasma|of (r_conj) rate_33\NN|glomerular|filtration|,|concentration (r_conj) flow_29\NN|renal|plasma|,|rate (r_pobj) of_26\IN|flow (r_prep) determination_25\NN|of (r_pobj) by_24\IN|determination (r_prep) patients_23\NNS|5|normokalemic|by (r_pobj) in_20\IN|patients (r_conj) in_14\IN|patients|and|in (l_pobj) patients_16\NNS|3|with (l_prep) with_17\IN|hypokalemia (l_pobj) hypokalemia_18\NN|
D012964_D007008 NONE sodium_49\NN|and|aldosterone (r_conj) potassium_47\NN|,|sodium (r_pobj) of_46\IN|potassium (r_prep) excretion_45\NN|urinary|of (r_conj) potassium_38\NN|and|sodium|as|excretion (r_pobj) of_37\IN|potassium (r_prep) concentration_36\NN|plasma|of (r_conj) rate_33\NN|glomerular|filtration|,|concentration (r_conj) flow_29\NN|renal|plasma|,|rate (r_pobj) of_26\IN|flow (r_prep) determination_25\NN|of (r_pobj) by_24\IN|determination (r_prep) patients_23\NNS|5|normokalemic|by (r_pobj) in_20\IN|patients (r_conj) in_14\IN|patients|and|in (l_pobj) patients_16\NNS|3|with (l_prep) with_17\IN|hypokalemia (l_pobj) hypokalemia_18\NN|
D000450_D007008 NONE aldosterone_51\NN| (r_conj) sodium_49\NN|and|aldosterone (r_conj) potassium_47\NN|,|sodium (r_pobj) of_46\IN|potassium (r_prep) excretion_45\NN|urinary|of (r_conj) potassium_38\NN|and|sodium|as|excretion (r_pobj) of_37\IN|potassium (r_prep) concentration_36\NN|plasma|of (r_conj) rate_33\NN|glomerular|filtration|,|concentration (r_conj) flow_29\NN|renal|plasma|,|rate (r_pobj) of_26\IN|flow (r_prep) determination_25\NN|of (r_pobj) by_24\IN|determination (r_prep) patients_23\NNS|5|normokalemic|by (r_pobj) in_20\IN|patients (r_conj) in_14\IN|patients|and|in (l_pobj) patients_16\NNS|3|with (l_prep) with_17\IN|hypokalemia (l_pobj) hypokalemia_18\NN|
18422462
D000409_D000740 NONE alanine_32\NN| (r_compound) aminotransferase_33\FW|alanine (r_pobj) with_31\IN|aminotransferase (r_prep) jaundice_30\NN|(|clinical|with (r_appos) hepatitis_27\NN|jaundice|> (r_nsubj) limits_38\NNS|hepatitis|5|upper|of|)|in|cd4 (r_conj) observed_12\VBN|anemia|was|in|and|limits|. (l_nsubjpass) anemia_2\NN|significant|(|hemoglobin|)
D000409_D056486 NONE alanine_32\NN| (r_compound) aminotransferase_33\FW|alanine (r_pobj) with_31\IN|aminotransferase (r_prep) jaundice_30\NN|(|clinical|with (r_appos) hepatitis_27\NN|jaundice|>
D000409_D007565 NONE alanine_32\NN| (r_compound) aminotransferase_33\FW|alanine (r_pobj) with_31\IN|aminotransferase (r_prep) jaundice_30\NN|(|clinical|with
D019829_D005076 CID NVP_11\NNP| (r_compound) therapy_12\NN|nvp (r_nsubjpass) associated_15\VBN|among|,|therapy|was|significantly|with|. (l_prep) with_16\IN|developing (l_pcomp) developing_17\VBG|rash|and|therapy|with (l_dobj) rash_18\NN|
D019829_D010523 NONE NVP_11\NNP| (r_compound) therapy_12\NN|nvp (r_nsubjpass) associated_15\VBN|among|,|therapy|was|significantly|with|. (l_prep) with_16\IN|developing (l_pcomp) developing_17\VBG|rash|and|therapy|with (l_prep) with_23\IN|developing|0.05 (l_pcomp) developing_24\VBG|neuropathy (l_dobj) neuropathy_26\NN|peripheral
D018119_D005076 NONE T_21\NN| (r_compound) therapy_22\NN|d4|t (r_conj) developing_17\VBG|rash|and|therapy|with (l_dobj) rash_18\NN|
D018119_D010523 CID T_21\NN| (r_compound) therapy_22\NN|d4|t (r_conj) developing_17\VBG|rash|and|therapy|with (l_prep) with_23\IN|developing|0.05 (l_pcomp) developing_24\VBG|neuropathy (l_dobj) neuropathy_26\NN|peripheral
25054547
D013390_D001049 CID suxamethonium_25\NN| (r_pobj) with_24\IN|suxamethonium (r_prep) apnea_23\NN|prolonged|with
D013390_D001049 CID suxamethonium_14\NN|or|mivacurium (r_appos) relaxants_12\NNS|muscle|(|suxamethonium|) (r_pobj) of_10\IN|relaxants (r_prep) use_9\NN|the|of|in (r_pobj) after_7\IN|use (r_prep) characterized_3\VBN|deficiency|is|by|after|. (l_agent) by_4\IN|apnea (l_pobj) apnea_6\NN|prolonged
D013390_C537417 CID suxamethonium_14\NN|or|mivacurium (r_appos) relaxants_12\NNS|muscle|(|suxamethonium|) (r_pobj) of_10\IN|relaxants (r_prep) use_9\NN|the|of|in (r_pobj) after_7\IN|use (r_prep) characterized_3\VBN|deficiency|is|by|after|. (l_nsubjpass) deficiency_1\NN|butyrylcholinesterase
C049430_C537417 CID mivacurium_16\NN| (r_conj) suxamethonium_14\NN|or|mivacurium (r_appos) relaxants_12\NNS|muscle|(|suxamethonium|) (r_pobj) of_10\IN|relaxants (r_prep) use_9\NN|the|of|in (r_pobj) after_7\IN|use (r_prep) characterized_3\VBN|deficiency|is|by|after|. (l_nsubjpass) deficiency_1\NN|butyrylcholinesterase
C049430_D001049 CID mivacurium_16\NN| (r_conj) suxamethonium_14\NN|or|mivacurium (r_appos) relaxants_12\NNS|muscle|(|suxamethonium|) (r_pobj) of_10\IN|relaxants (r_prep) use_9\NN|the|of|in (r_pobj) after_7\IN|use (r_prep) characterized_3\VBN|deficiency|is|by|after|. (l_agent) by_4\IN|apnea (l_pobj) apnea_6\NN|prolonged
10390729
D011188_D009069 NONE K(+)-channel_15\NNP| (r_compound) blockers_16\NNS|the|k(+)-channel (r_pobj) of_13\IN|blockers (r_prep) neither_12\DT|of (r_nsubj) affected_17\VBD|in|neither|hypoactivity|,|but|prevented (l_dobj) hypoactivity_21\NN|induced
D011188_D009069 NONE K(+)-channel_25\NNP| (r_compound) blockers_26\NNS|both|k(+)-channel (r_nsubj) prevented_27\VBD|blockers|hyperactivity|. (r_conj) affected_17\VBD|in|neither|hypoactivity|,|but|prevented (l_dobj) hypoactivity_21\NN|induced
D011188_D009069 NONE K(+)-channels_8\NNPS|sensitive (r_pobj) of_7\IN|k(+)-channels (r_prep) blockade_6\NN|the|of (r_nsubj) is_13\VBZ|that|blockade|not|sufficient|seems (l_acomp) sufficient_15\JJ|prevent (l_xcomp) prevent_17\VB|to|hypoactivity (l_dobj) hypoactivity_21\NN|induced
D011188_D009069 NONE K(+)-channels_38\NNPS|sensitive (r_pobj) to_31\IN|k(+)-channels (r_prep) connected_30\VBN|to|be|to (r_xcomp) seems_27\VBZ|whereas|hyperactivity|connected (r_advcl) is_13\VBZ|that|blockade|not|sufficient|seems (l_acomp) sufficient_15\JJ|prevent (l_xcomp) prevent_17\VB|to|hypoactivity (l_dobj) hypoactivity_21\NN|induced
D011188_D006948 NONE K(+)-channel_15\NNP| (r_compound) blockers_16\NNS|the|k(+)-channel (r_pobj) of_13\IN|blockers (r_prep) neither_12\DT|of (r_nsubj) affected_17\VBD|in|neither|hypoactivity|,|but|prevented (l_conj) prevented_27\VBD|blockers|hyperactivity|. (l_dobj) hyperactivity_32\NN|induced|secondary
D011188_D006948 NONE K(+)-channel_25\NNP| (r_compound) blockers_26\NNS|both|k(+)-channel (r_nsubj) prevented_27\VBD|blockers|hyperactivity|. (l_dobj) hyperactivity_32\NN|induced|secondary
D011188_D006948 NONE K(+)-channels_8\NNPS|sensitive (r_pobj) of_7\IN|k(+)-channels (r_prep) blockade_6\NN|the|of (r_nsubj) is_13\VBZ|that|blockade|not|sufficient|seems (l_advcl) seems_27\VBZ|whereas|hyperactivity|connected (l_nsubj) hyperactivity_26\NN|induced
D011188_D006948 NONE K(+)-channels_38\NNPS|sensitive (r_pobj) to_31\IN|k(+)-channels (r_prep) connected_30\VBN|to|be|to (r_xcomp) seems_27\VBZ|whereas|hyperactivity|connected (l_nsubj) hyperactivity_26\NN|induced
D009020_D009069 NONE morphine_18\NN| (r_npadvmod) induced_20\VBN|morphine|- (r_amod) hypoactivity_21\NN|induced
D009020_D009069 NONE morphine_28\NN| (r_npadvmod) induced_30\VBN|morphine|- (r_amod) hyperactivity_32\NN|induced|secondary (r_dobj) prevented_27\VBD|blockers|hyperactivity|. (r_conj) affected_17\VBD|in|neither|hypoactivity|,|but|prevented (l_dobj) hypoactivity_21\NN|induced
D009020_D009069 NONE morphine_18\NN| (r_npadvmod) induced_20\VBN|morphine|- (r_amod) hypoactivity_21\NN|induced
D009020_D009069 NONE morphine_23\NN| (r_npadvmod) induced_25\VBN|morphine|- (r_amod) hyperactivity_26\NN|induced (r_nsubj) seems_27\VBZ|whereas|hyperactivity|connected (r_advcl) is_13\VBZ|that|blockade|not|sufficient|seems (l_acomp) sufficient_15\JJ|prevent (l_xcomp) prevent_17\VB|to|hypoactivity (l_dobj) hypoactivity_21\NN|induced
D009020_D006948 CID morphine_18\NN| (r_npadvmod) induced_20\VBN|morphine|- (r_amod) hypoactivity_21\NN|induced (r_dobj) affected_17\VBD|in|neither|hypoactivity|,|but|prevented (l_conj) prevented_27\VBD|blockers|hyperactivity|. (l_dobj) hyperactivity_32\NN|induced|secondary
D009020_D006948 CID morphine_28\NN| (r_npadvmod) induced_30\VBN|morphine|- (r_amod) hyperactivity_32\NN|induced|secondary
D009020_D006948 CID morphine_18\NN| (r_npadvmod) induced_20\VBN|morphine|- (r_amod) hypoactivity_21\NN|induced (r_dobj) prevent_17\VB|to|hypoactivity (r_xcomp) sufficient_15\JJ|prevent (r_acomp) is_13\VBZ|that|blockade|not|sufficient|seems (l_advcl) seems_27\VBZ|whereas|hyperactivity|connected (l_nsubj) hyperactivity_26\NN|induced
D009020_D006948 CID morphine_23\NN| (r_npadvmod) induced_25\VBN|morphine|- (r_amod) hyperactivity_26\NN|induced
D011803_D009069 NONE quinine-_33\JJ|both|and (r_npadvmod) sensitive_37\JJ|quinine-|- (r_amod) K(+)-channels_38\NNPS|sensitive (r_pobj) to_31\IN|k(+)-channels (r_prep) connected_30\VBN|to|be|to (r_xcomp) seems_27\VBZ|whereas|hyperactivity|connected (r_advcl) is_13\VBZ|that|blockade|not|sufficient|seems (l_acomp) sufficient_15\JJ|prevent (l_xcomp) prevent_17\VB|to|hypoactivity (l_dobj) hypoactivity_21\NN|induced
D011803_D006948 NONE quinine-_33\JJ|both|and (r_npadvmod) sensitive_37\JJ|quinine-|- (r_amod) K(+)-channels_38\NNPS|sensitive (r_pobj) to_31\IN|k(+)-channels (r_prep) connected_30\VBN|to|be|to (r_xcomp) seems_27\VBZ|whereas|hyperactivity|connected (l_nsubj) hyperactivity_26\NN|induced
D015761_D009069 NONE 4-aminopyridine_35\CD| (r_punct) -_36\HYPH|4-aminopyridine (r_punct) sensitive_37\JJ|quinine-|- (r_amod) K(+)-channels_38\NNPS|sensitive (r_pobj) to_31\IN|k(+)-channels (r_prep) connected_30\VBN|to|be|to (r_xcomp) seems_27\VBZ|whereas|hyperactivity|connected (r_advcl) is_13\VBZ|that|blockade|not|sufficient|seems (l_acomp) sufficient_15\JJ|prevent (l_xcomp) prevent_17\VB|to|hypoactivity (l_dobj) hypoactivity_21\NN|induced
D015761_D006948 NONE 4-aminopyridine_35\CD| (r_punct) -_36\HYPH|4-aminopyridine (r_punct) sensitive_37\JJ|quinine-|- (r_amod) K(+)-channels_38\NNPS|sensitive (r_pobj) to_31\IN|k(+)-channels (r_prep) connected_30\VBN|to|be|to (r_xcomp) seems_27\VBZ|whereas|hyperactivity|connected (l_nsubj) hyperactivity_26\NN|induced
9132810
D008727_D056784 CID methotrexate_34\NN|dose (r_pobj) with_30\IN|methotrexate (r_prep) treated_29\VBN|with (r_acl) leukemia_28\NN|acute|lymphoblastic|treated (r_pobj) from_25\IN|leukemia (r_prep) developed_24\VBD|which|from (r_relcl) leukoencephalopathy_21\JJ|disseminated|necrotizing|,|developed
D008727_D054198 NONE methotrexate_34\NN|dose (r_pobj) with_30\IN|methotrexate (r_prep) treated_29\VBN|with (r_acl) leukemia_28\NN|acute|lymphoblastic|treated
3409843
D002220_D000741 CID carbamazepine_8\NN| (r_pobj) with_7\IN|carbamazepine (r_prep) treated_6\VBN|with (r_acl) patient_5\NN|a|treated (r_pobj) in_3\IN|patient (r_prep) anemia_2\NN|fatal|aplastic|in|.
D002220_D000741 CID carbamazepine_8\NN| (r_compound) treatment_9\NN|carbamazepine|in (r_pobj) due_6\IN|to|treatment (r_amod) case_1\NN|a|of|due (l_prep) of_2\IN|anemia (l_pobj) anemia_5\NN|fatal|aplastic
D002220_D004827 NONE carbamazepine_8\NN| (r_compound) treatment_9\NN|carbamazepine|in (l_prep) in_10\IN|woman (l_pobj) woman_13\NN|an|epileptic (l_amod) epileptic_12\JJ|
D002220_D001855 NONE carbamazepine_9\NN| (r_pobj) to_8\IN|carbamazepine (r_pcomp) due_7\IN|to (r_prep) concerns_1\NNS|of|due (l_prep) of_2\IN|toxicity (l_pobj) toxicity_6\NN|fatal|marrow
3323599
D011692_D009401 NONE aminonucleoside_3\JJ| (r_amod) nephrosis_4\NN|aminonucleoside
D011692_D005923 CID aminonucleoside_22\NN|puromycin|-|amns (r_pobj) of_19\IN|aminonucleoside (r_prep) administration_18\NN|the|combined|of (r_pobj) by_15\IN|administration (r_agent) developed_12\VBN|model|was|in|by|. (l_nsubjpass) model_2\NN|an|experimental|of|(|fsgs|) (l_prep) of_3\IN|sclerosis (l_pobj) sclerosis_7\NN|focal|segmental|glomerular
D011692_D005923 CID aminonucleoside_22\NN|puromycin|-|amns (r_pobj) of_19\IN|aminonucleoside (r_prep) administration_18\NN|the|combined|of (r_pobj) by_15\IN|administration (r_agent) developed_12\VBN|model|was|in|by|. (l_nsubjpass) model_2\NN|an|experimental|of|(|fsgs|) (l_appos) FSGS_9\NNP|
D011692_D005923 CID AMNS_24\NNP|(|)|and|protamine (r_appos) aminonucleoside_22\NN|puromycin|-|amns (r_pobj) of_19\IN|aminonucleoside (r_prep) administration_18\NN|the|combined|of (r_pobj) by_15\IN|administration (r_agent) developed_12\VBN|model|was|in|by|. (l_nsubjpass) model_2\NN|an|experimental|of|(|fsgs|) (l_prep) of_3\IN|sclerosis (l_pobj) sclerosis_7\NN|focal|segmental|glomerular
D011692_D005923 CID AMNS_24\NNP|(|)|and|protamine (r_appos) aminonucleoside_22\NN|puromycin|-|amns (r_pobj) of_19\IN|aminonucleoside (r_prep) administration_18\NN|the|combined|of (r_pobj) by_15\IN|administration (r_agent) developed_12\VBN|model|was|in|by|. (l_nsubjpass) model_2\NN|an|experimental|of|(|fsgs|) (l_appos) FSGS_9\NNP|
D011692_D005923 CID AMNS_14\NNP| (r_pobj) of_13\IN|amns (r_prep) toxicity_12\NN|the|of|on (r_dobj) enhances_10\VBZ|that|administration|toxicity|and|produces (l_conj) produces_20\VBZ|readily|fsgs (l_dobj) FSGS_22\NNS|progressive|in
D011479_D005923 NONE sulfate_28\NN|ps (r_dobj) protamine_27\NN|sulfate|) (r_conj) AMNS_24\NNP|(|)|and|protamine (r_appos) aminonucleoside_22\NN|puromycin|-|amns (r_pobj) of_19\IN|aminonucleoside (r_prep) administration_18\NN|the|combined|of (r_pobj) by_15\IN|administration (r_agent) developed_12\VBN|model|was|in|by|. (l_nsubjpass) model_2\NN|an|experimental|of|(|fsgs|) (l_prep) of_3\IN|sclerosis (l_pobj) sclerosis_7\NN|focal|segmental|glomerular
D011479_D005923 NONE sulfate_28\NN|ps (r_dobj) protamine_27\NN|sulfate|) (r_conj) AMNS_24\NNP|(|)|and|protamine (r_appos) aminonucleoside_22\NN|puromycin|-|amns (r_pobj) of_19\IN|aminonucleoside (r_prep) administration_18\NN|the|combined|of (r_pobj) by_15\IN|administration (r_agent) developed_12\VBN|model|was|in|by|. (l_nsubjpass) model_2\NN|an|experimental|of|(|fsgs|) (l_appos) FSGS_9\NNP|
D011479_D005923 NONE PS_30\NNP|( (r_appos) sulfate_28\NN|ps (r_dobj) protamine_27\NN|sulfate|) (r_conj) AMNS_24\NNP|(|)|and|protamine (r_appos) aminonucleoside_22\NN|puromycin|-|amns (r_pobj) of_19\IN|aminonucleoside (r_prep) administration_18\NN|the|combined|of (r_pobj) by_15\IN|administration (r_agent) developed_12\VBN|model|was|in|by|. (l_nsubjpass) model_2\NN|an|experimental|of|(|fsgs|) (l_prep) of_3\IN|sclerosis (l_pobj) sclerosis_7\NN|focal|segmental|glomerular
D011479_D005923 NONE PS_30\NNP|( (r_appos) sulfate_28\NN|ps (r_dobj) protamine_27\NN|sulfate|) (r_conj) AMNS_24\NNP|(|)|and|protamine (r_appos) aminonucleoside_22\NN|puromycin|-|amns (r_pobj) of_19\IN|aminonucleoside (r_prep) administration_18\NN|the|combined|of (r_pobj) by_15\IN|administration (r_agent) developed_12\VBN|model|was|in|by|. (l_nsubjpass) model_2\NN|an|experimental|of|(|fsgs|) (l_appos) FSGS_9\NNP|
D011479_D005923 NONE PS_9\NNP| (r_pobj) of_8\IN|ps (r_prep) administration_7\NN|the|of (r_nsubj) enhances_10\VBZ|that|administration|toxicity|and|produces (l_conj) produces_20\VBZ|readily|fsgs (l_dobj) FSGS_22\NNS|progressive|in
D011479_D064420 NONE PS_9\NNP| (r_pobj) of_8\IN|ps (r_prep) administration_7\NN|the|of (r_nsubj) enhances_10\VBZ|that|administration|toxicity|and|produces (l_dobj) toxicity_12\NN|the|of|on
D011479_D007676 NONE PS_9\NNP| (r_pobj) of_8\IN|ps (r_prep) administration_7\NN|the|of (r_nsubj) enhances_10\VBZ|that|administration|toxicity|and|produces (l_conj) produces_20\VBZ|readily|fsgs (l_dobj) FSGS_22\NNS|progressive|in (l_prep) in_23\IN|rats (l_pobj) rats_24\NNS|resulting (l_acl) resulting_25\VBG|in (l_prep) in_26\IN|disease (l_pobj) disease_32\NN|the|stage|renal
D011692_D064420 NONE AMNS_14\NNP| (r_pobj) of_13\IN|amns (r_prep) toxicity_12\NN|the|of|on
D011692_D007676 CID AMNS_14\NNP| (r_pobj) of_13\IN|amns (r_prep) toxicity_12\NN|the|of|on (r_dobj) enhances_10\VBZ|that|administration|toxicity|and|produces (l_conj) produces_20\VBZ|readily|fsgs (l_dobj) FSGS_22\NNS|progressive|in (l_prep) in_23\IN|rats (l_pobj) rats_24\NNS|resulting (l_acl) resulting_25\VBG|in (l_prep) in_26\IN|disease (l_pobj) disease_32\NN|the|stage|renal
12452552
D018967_D007676 NONE risperidone_19\NN|and|levomepromazine (r_pobj) of_18\IN|risperidone (r_prep) administration_17\NN|of (r_pobj) after_16\IN|administration (r_prep) syndrome_12\NN|neuroleptic|malignant|nms|after (r_dobj) developed_9\VBD|patient|syndrome|. (l_nsubj) patient_1\NN|a|with (l_prep) with_2\IN|failure (l_pobj) failure_5\NN|chronic|renal|(|crf|)
D018967_D007676 NONE risperidone_19\NN|and|levomepromazine (r_pobj) of_18\IN|risperidone (r_prep) administration_17\NN|of (r_pobj) after_16\IN|administration (r_prep) syndrome_12\NN|neuroleptic|malignant|nms|after (r_dobj) developed_9\VBD|patient|syndrome|. (l_nsubj) patient_1\NN|a|with (l_prep) with_2\IN|failure (l_pobj) failure_5\NN|chronic|renal|(|crf|) (l_appos) CRF_7\NNP|
D018967_D009459 CID risperidone_19\NN|and|levomepromazine (r_pobj) of_18\IN|risperidone (r_prep) administration_17\NN|of (r_pobj) after_16\IN|administration (r_prep) syndrome_12\NN|neuroleptic|malignant|nms|after
D018967_D009459 CID risperidone_19\NN|and|levomepromazine (r_pobj) of_18\IN|risperidone (r_prep) administration_17\NN|of (r_pobj) after_16\IN|administration (r_prep) syndrome_12\NN|neuroleptic|malignant|nms|after (l_appos) NMS_14\NNP|(|)
D008728_D007676 NONE levomepromazine_21\NN| (r_conj) risperidone_19\NN|and|levomepromazine (r_pobj) of_18\IN|risperidone (r_prep) administration_17\NN|of (r_pobj) after_16\IN|administration (r_prep) syndrome_12\NN|neuroleptic|malignant|nms|after (r_dobj) developed_9\VBD|patient|syndrome|. (l_nsubj) patient_1\NN|a|with (l_prep) with_2\IN|failure (l_pobj) failure_5\NN|chronic|renal|(|crf|)
D008728_D007676 NONE levomepromazine_21\NN| (r_conj) risperidone_19\NN|and|levomepromazine (r_pobj) of_18\IN|risperidone (r_prep) administration_17\NN|of (r_pobj) after_16\IN|administration (r_prep) syndrome_12\NN|neuroleptic|malignant|nms|after (r_dobj) developed_9\VBD|patient|syndrome|. (l_nsubj) patient_1\NN|a|with (l_prep) with_2\IN|failure (l_pobj) failure_5\NN|chronic|renal|(|crf|) (l_appos) CRF_7\NNP|
D008728_D009459 CID levomepromazine_21\NN| (r_conj) risperidone_19\NN|and|levomepromazine (r_pobj) of_18\IN|risperidone (r_prep) administration_17\NN|of (r_pobj) after_16\IN|administration (r_prep) syndrome_12\NN|neuroleptic|malignant|nms|after
D008728_D009459 CID levomepromazine_21\NN| (r_conj) risperidone_19\NN|and|levomepromazine (r_pobj) of_18\IN|risperidone (r_prep) administration_17\NN|of (r_pobj) after_16\IN|administration (r_prep) syndrome_12\NN|neuroleptic|malignant|nms|after (l_appos) NMS_14\NNP|(|)
17035713
C004656_D007674 NONE Chloroacetaldehyde_0\NNP|as|:|role|. (l_appos) role_7\NN|the|of (l_prep) of_8\IN|groups (l_pobj) groups_11\NNS|critical|thiol|in (l_prep) in_12\IN|nephropathy (l_pobj) nephropathy_14\NN|ifosfamide
C004656_D007674 NONE Chloroacetaldehyde_0\NNP|(|caa|) (r_nsubj) is_4\VBZ|chloroacetaldehyde|metabolite|. (l_attr) metabolite_6\NN|a|of|and|responsible (l_conj) responsible_17\JJ|putatively|for (l_prep) for_18\IN|damage (l_pobj) damage_20\NN|renal|following
C004656_D007674 NONE CAA_2\NNP| (r_appos) Chloroacetaldehyde_0\NNP|(|caa|) (r_nsubj) is_4\VBZ|chloroacetaldehyde|metabolite|. (l_attr) metabolite_6\NN|a|of|and|responsible (l_conj) responsible_17\JJ|putatively|for (l_prep) for_18\IN|damage (l_pobj) damage_20\NN|renal|following
-1_D007674 NONE sulfhydryl_3\NN| (r_amod) reagent_4\NN|a|sulfhydryl (r_pobj) as_1\IN|reagent (r_prep) Chloroacetaldehyde_0\NNP|as|:|role|. (l_appos) role_7\NN|the|of (l_prep) of_8\IN|groups (l_pobj) groups_11\NNS|critical|thiol|in (l_prep) in_12\IN|nephropathy (l_pobj) nephropathy_14\NN|ifosfamide
D013438_D007674 NONE thiol_10\JJ| (r_compound) groups_11\NNS|critical|thiol|in (l_prep) in_12\IN|nephropathy (l_pobj) nephropathy_14\NN|ifosfamide
D007069_D007674 CID ifosfamide_13\JJ| (r_amod) nephropathy_14\NN|ifosfamide
D007069_D007674 CID ifosfamide_11\NN|the|agent|(|ifo|) (r_pobj) of_7\IN|ifosfamide (r_prep) metabolite_6\NN|a|of|and|responsible (l_conj) responsible_17\JJ|putatively|for (l_prep) for_18\IN|damage (l_pobj) damage_20\NN|renal|following
D007069_D007674 CID IFO_13\NN| (r_appos) ifosfamide_11\NN|the|agent|(|ifo|) (r_pobj) of_7\IN|ifosfamide (r_prep) metabolite_6\NN|a|of|and|responsible (l_conj) responsible_17\JJ|putatively|for (l_prep) for_18\IN|damage (l_pobj) damage_20\NN|renal|following
D007069_D007674 CID IFO_27\NN| (r_pobj) with_26\IN|ifo (r_prep) following_21\VBG|therapy|with (r_prep) damage_20\NN|renal|following
D007069_D007674 CID IFO_10\NN| (r_compound) nephropathy_11\NN|ifo
C004656_D009369 NONE Chloroacetaldehyde_0\NNP|(|caa|) (r_nsubj) is_4\VBZ|chloroacetaldehyde|metabolite|. (l_attr) metabolite_6\NN|a|of|and|responsible (l_conj) responsible_17\JJ|putatively|for (l_prep) for_18\IN|damage (l_pobj) damage_20\NN|renal|following (l_prep) following_21\VBG|therapy|with (l_pobj) therapy_25\NN|tumor (l_compound) tumor_24\NN|anti|-
C004656_D009369 NONE CAA_2\NNP| (r_appos) Chloroacetaldehyde_0\NNP|(|caa|) (r_nsubj) is_4\VBZ|chloroacetaldehyde|metabolite|. (l_attr) metabolite_6\NN|a|of|and|responsible (l_conj) responsible_17\JJ|putatively|for (l_prep) for_18\IN|damage (l_pobj) damage_20\NN|renal|following (l_prep) following_21\VBG|therapy|with (l_pobj) therapy_25\NN|tumor (l_compound) tumor_24\NN|anti|-
D007069_D009369 NONE ifosfamide_11\NN|the|agent|(|ifo|) (r_pobj) of_7\IN|ifosfamide (r_prep) metabolite_6\NN|a|of|and|responsible (l_conj) responsible_17\JJ|putatively|for (l_prep) for_18\IN|damage (l_pobj) damage_20\NN|renal|following (l_prep) following_21\VBG|therapy|with (l_pobj) therapy_25\NN|tumor (l_compound) tumor_24\NN|anti|-
D007069_D009369 NONE IFO_13\NN| (r_appos) ifosfamide_11\NN|the|agent|(|ifo|) (r_pobj) of_7\IN|ifosfamide (r_prep) metabolite_6\NN|a|of|and|responsible (l_conj) responsible_17\JJ|putatively|for (l_prep) for_18\IN|damage (l_pobj) damage_20\NN|renal|following (l_prep) following_21\VBG|therapy|with (l_pobj) therapy_25\NN|tumor (l_compound) tumor_24\NN|anti|-
D007069_D009369 NONE IFO_27\NN| (r_pobj) with_26\IN|ifo (r_prep) following_21\VBG|therapy|with (l_pobj) therapy_25\NN|tumor (l_compound) tumor_24\NN|anti|-
C004656_D064420 NONE CAA_2\NNP| (r_pobj) of_1\IN|caa (r_prep) Toxicity_0\NN|of
C004656_D064420 NONE CAA_2\NNP| (r_nsubj) reacts_4\VBZ|thus|,|caa|directly|with|,|mediating|. (l_advcl) mediating_14\VBG|toxicity (l_dobj) toxicity_16\NN|its|on
D014343_D064420 NONE blue_16\JJ| (r_amod) exclusion_17\NN|blue (r_compound) assay_18\NN|exclusion|and|activity (r_dobj) trypan_15\NN|assay (r_advcl) determined_4\VBN|toxicity|was|by|trypan|. (l_nsubjpass) Toxicity_0\NN|of
C004656_D009336 NONE CAA_0\NNP| (r_nsubj) reduced_1\VBD|caa|number|,|induced|. (l_conj) induced_8\VBD|loss (l_dobj) loss_10\NN|a|in|and|increase (l_conj) increase_17\NN|an|in (l_prep) in_18\IN|markers (l_pobj) markers_20\NNS|necrosis (l_compound) necrosis_19\NN|
C004656_D009336 NONE CAA_7\NNP| (r_pobj) of_6\IN|caa (r_prep) reaction_5\NN|the|of|with (r_dobj) slowed_3\VBD|which|reaction (r_relcl) Acidification_0\NN|,|slowed|, (r_nsubj) attenuate_14\VB|acidification|could|also|effects|. (l_dobj) effects_15\NNS|of|on (l_prep) on_18\IN|markers (l_pobj) markers_20\NNS|necrosis|,|depletion (l_compound) necrosis_19\NN|
C004656_D009336 NONE CAA_17\NNP| (r_pobj) of_16\IN|caa (r_prep) effects_15\NNS|of|on (l_prep) on_18\IN|markers (l_pobj) markers_20\NNS|necrosis|,|depletion (l_compound) necrosis_19\NN|
D013438_D009336 NONE thiols_14\NNS|free|intracellular (r_pobj) in_11\IN|thiols (r_prep) loss_10\NN|a|in|and|increase (l_conj) increase_17\NN|an|in (l_prep) in_18\IN|markers (l_pobj) markers_20\NNS|necrosis (l_compound) necrosis_19\NN|
D013438_D009336 NONE thiol_9\JJ| (r_compound) donors_10\NNS|thiol (r_pobj) with_8\IN|donors (r_prep) reaction_5\NN|the|of|with (r_dobj) slowed_3\VBD|which|reaction (r_relcl) Acidification_0\NN|,|slowed|, (r_nsubj) attenuate_14\VB|acidification|could|also|effects|. (l_dobj) effects_15\NNS|of|on (l_prep) on_18\IN|markers (l_pobj) markers_20\NNS|necrosis|,|depletion (l_compound) necrosis_19\NN|
D013438_D009336 NONE thiol_22\JJ| (r_compound) depletion_23\NN|thiol|and|inhibition (r_conj) markers_20\NNS|necrosis|,|depletion (l_compound) necrosis_19\NN|
D003545_D009336 NONE cysteine_25\NN| (r_compound) protease_26\NN|cysteine (r_compound) inhibition_27\NN|protease|in (r_conj) depletion_23\NN|thiol|and|inhibition (r_conj) markers_20\NNS|necrosis|,|depletion (l_compound) necrosis_19\NN|
D013438_D064420 NONE thiols_12\NNS|cellular|protein|protein (r_pobj) with_5\IN|thiols (r_prep) reacts_4\VBZ|thus|,|caa|directly|with|,|mediating|. (l_advcl) mediating_14\VBG|toxicity (l_dobj) toxicity_16\NN|its|on
11708428
D011241_D001008 CID Prednisone_0\NNP| (r_nsubj) induces_1\VBZ|prednisone|anxiety|. (l_dobj) anxiety_2\NN|and|changes|in
D011241_D001008 CID prednisone_3\NNP|(|pdn|) (r_nsubj) produces_7\VBZ|whether|prednisone|anxiety (l_dobj) anxiety_8\NN|and/or|changes
D011241_D001008 CID PDN_5\NNP| (r_appos) prednisone_3\NNP|(|pdn|) (r_nsubj) produces_7\VBZ|whether|prednisone|anxiety (l_dobj) anxiety_8\NN|and/or|changes
D011241_D001008 CID PDN_7\NNP| (r_pobj) of_6\IN|pdn (r_prep) groups_5\NNS|both|of (r_pobj) in_3\IN|groups (r_prep) documented_2\VBN|anxiety|was|in|treated|. (l_nsubjpass) Anxiety_0\NN|
D011241_D001008 CID PDN_3\NNP| (r_pobj) to_2\IN|pdn (r_prep) exposure_1\NN|subacute|to (r_nsubj) induced_4\VBD|exposure|anxiety|. (l_dobj) anxiety_5\NN|and|reactivity
11026989
D014331_D015878 CID tropicamide_6\NN|on (r_pobj) with_5\IN|tropicamide (r_prep) dilation_4\NN|pupil|with
D014331_D015878 CID tropicamide_28\NN|% (r_advmod) using_26\VBG|guttae|tropicamide (r_acl) dilation_25\NN|pupil|using
3155884
D007545_D066126 NONE isoproterenol_11\NN| (r_pobj) of_10\IN|isoproterenol (r_prep) effect_9\NN|the|cardiotoxic|of|in (l_amod) cardiotoxic_8\JJ|
D007545_D066126 NONE isoproterenol_23\NN| (r_pobj) of_22\IN|isoproterenol (r_prep) doses_21\NNS|high|of|(|iso|) (r_pobj) of_19\IN|doses (r_prep) effect_18\NN|the|cardiotoxic|of (l_amod) cardiotoxic_17\JJ|
D007545_D066126 NONE ISO_25\NN| (r_appos) doses_21\NNS|high|of|(|iso|) (r_pobj) of_19\IN|doses (r_prep) effect_18\NN|the|cardiotoxic|of (l_amod) cardiotoxic_17\JJ|
D007545_D003920 NONE isoproterenol_11\NN| (r_pobj) of_10\IN|isoproterenol (r_prep) effect_9\NN|the|cardiotoxic|of|in (l_prep) in_12\IN|rats (l_pobj) rats_15\NNS|streptozotocin|diabetic (l_amod) diabetic_14\JJ|
D007545_D003920 NONE isoproterenol_23\NN| (r_pobj) of_22\IN|isoproterenol (r_prep) doses_21\NNS|high|of|(|iso|) (r_pobj) of_19\IN|doses (r_prep) effect_18\NN|the|cardiotoxic|of (r_pobj) against_15\IN|effect (r_prep) diabetes_14\NNS|streptozotocin|against
D007545_D003920 NONE ISO_25\NN| (r_appos) doses_21\NNS|high|of|(|iso|) (r_pobj) of_19\IN|doses (r_prep) effect_18\NN|the|cardiotoxic|of (r_pobj) against_15\IN|effect (r_prep) diabetes_14\NNS|streptozotocin|against
D007545_D003920 NONE ISO_15\NN| (r_compound) resistance_16\NN|the|iso|and|points (l_conj) points_18\NNS|towards (l_prep) towards_19\IN|effect (l_pobj) effect_23\NN|a|direct|insulin|on (l_prep) on_24\IN|sensitivity (l_pobj) sensitivity_27\NN|myocardial|catecholamine|in (l_prep) in_28\IN|rats (l_pobj) rats_30\NNS|diabetic (l_amod) diabetic_29\JJ|
D013311_D066126 NONE streptozotocin_13\JJ| (r_nmod) rats_15\NNS|streptozotocin|diabetic (r_pobj) in_12\IN|rats (r_prep) effect_9\NN|the|cardiotoxic|of|in (l_amod) cardiotoxic_8\JJ|
D013311_D066126 NONE streptozotocin_13\JJ| (r_compound) diabetes_14\NNS|streptozotocin|against (l_prep) against_15\IN|effect (l_pobj) effect_18\NN|the|cardiotoxic|of (l_amod) cardiotoxic_17\JJ|
D013311_D003920 CID streptozotocin_13\JJ| (r_nmod) rats_15\NNS|streptozotocin|diabetic (l_amod) diabetic_14\JJ|
D013311_D003920 CID streptozotocin_13\JJ| (r_compound) diabetes_14\NNS|streptozotocin|against
D013311_D003920 CID streptozotocin_10\JJ|in (r_nsubj) causes_13\VBZ|that|streptozotocin|resistance (l_dobj) resistance_16\NN|the|iso|and|points (l_conj) points_18\NNS|towards (l_prep) towards_19\IN|effect (l_pobj) effect_23\NN|a|direct|insulin|on (l_prep) on_24\IN|sensitivity (l_pobj) sensitivity_27\NN|myocardial|catecholamine|in (l_prep) in_28\IN|rats (l_pobj) rats_30\NNS|diabetic (l_amod) diabetic_29\JJ|
D007545_D005355 CID isoproterenol_4\NN| (r_pobj) of_3\IN|isoproterenol (r_prep) study_2\NN|a|morphometric|of (r_nsubj) induced_5\VBN|study|fibrosis|. (l_dobj) fibrosis_7\NN|myocardial
D007545_D005355 CID ISO_11\NN| (r_nsubjpass) given_13\VBN|after|,|iso|was|subcutaneously|and|induced|analyzed|. (l_conj) induced_18\VBD|when|iso|fibrosis|in (l_dobj) fibrosis_19\NN|
D007545_D005355 CID ISO_17\NN| (r_nsubj) induced_18\VBD|when|iso|fibrosis|in (l_dobj) fibrosis_19\NN|
D005947_D005355 NONE glucose_52\NN|blood (r_pobj) in_50\IN|glucose (r_prep) fall_49\NN|the|in (r_pobj) of_47\IN|fall (r_prep) slope_46\NN|the|of (r_pobj) to_44\IN|slope (r_prep) correlation_33\NN|a|significant|(|0.83|to (r_conj) analyzed_25\VBN|was|morphometrically|later|,|correlation|appeared (r_conj) given_13\VBN|after|,|iso|was|subcutaneously|and|induced|analyzed|. (l_conj) induced_18\VBD|when|iso|fibrosis|in (l_dobj) fibrosis_19\NN|
D002395_D003920 NONE catecholamines_4\NNS| (r_pobj) of_3\IN|catecholamines (r_prep) content_2\NN|the|myocardial|of (r_nsubjpass) estimated_6\VBN|content|was|in|. (l_prep) in_7\IN|rats (l_pobj) rats_12\NNS|these|day|diabetic (l_amod) diabetic_11\JJ|
D002395_D003920 NONE catecholamine_26\NN| (r_compound) sensitivity_27\NN|myocardial|catecholamine|in (l_prep) in_28\IN|rats (l_pobj) rats_30\NNS|diabetic (l_amod) diabetic_29\JJ|
23864035
C400082_D009101 NONE Bortezomib_0\NNP|and|dexamethasone|. (l_conj) dexamethasone_2\NN|as|in (l_prep) in_6\IN|patients (l_pobj) patients_7\NNS|with (l_prep) with_8\IN|myeloma (l_pobj) myeloma_13\NN|relapsed|refractory|multiple|:|analysis
C400082_D009101 NONE Bortezomib_0\NNP|dex (r_nsubj) is_6\VBZ|bortezomib|therapy|. (l_attr) therapy_9\NN|an|effective|for (l_prep) for_10\IN|r (l_pobj) R_17\NNP|relapsed|/|refractory|(|r|/|)|myeloma (l_appos) myeloma_20\NN|multiple|mm|)
C400082_D009101 NONE Bortezomib_0\NNP|dex (r_nsubj) is_6\VBZ|bortezomib|therapy|. (l_attr) therapy_9\NN|an|effective|for (l_prep) for_10\IN|r (l_pobj) R_17\NNP|relapsed|/|refractory|(|r|/|)|myeloma (l_appos) myeloma_20\NN|multiple|mm|) (l_appos) MM_22\NNP|(
C400082_D009101 NONE bort)-dexamethasone_2\NNP| (r_nmod) dex_4\NN|(|bort)-dexamethasone|(|) (r_appos) Bortezomib_0\NNP|dex (r_nsubj) is_6\VBZ|bortezomib|therapy|. (l_attr) therapy_9\NN|an|effective|for (l_prep) for_10\IN|r (l_pobj) R_17\NNP|relapsed|/|refractory|(|r|/|)|myeloma (l_appos) myeloma_20\NN|multiple|mm|)
C400082_D009101 NONE bort)-dexamethasone_2\NNP| (r_nmod) dex_4\NN|(|bort)-dexamethasone|(|) (r_appos) Bortezomib_0\NNP|dex (r_nsubj) is_6\VBZ|bortezomib|therapy|. (l_attr) therapy_9\NN|an|effective|for (l_prep) for_10\IN|r (l_pobj) R_17\NNP|relapsed|/|refractory|(|r|/|)|myeloma (l_appos) myeloma_20\NN|multiple|mm|) (l_appos) MM_22\NNP|(
C400082_D009101 NONE bort_7\NN| (r_pobj) of_6\IN|bort (r_prep) combination_5\NN|the|of|(|m(2|)|on (r_dobj) investigated_3\VBD|study|combination|)|and|dex|after|. (l_conj) dex_29\NN|(|mg|and|day|)|as (l_prep) as_43\IN|treatment (l_pobj) treatment_45\NN|salvage|in (l_prep) in_46\IN|patients (l_pobj) patients_48\NNS|85|with (l_prep) with_49\IN|mm (l_pobj) MM_53\NNP|r
C400082_D009101 NONE bort_41\NN| (r_pobj) after_40\IN|bort (r_prep) day_39\NN|the|after (r_conj) dex_29\NN|(|mg|and|day|)|as (l_prep) as_43\IN|treatment (l_pobj) treatment_45\NN|salvage|in (l_prep) in_46\IN|patients (l_pobj) patients_48\NNS|85|with (l_prep) with_49\IN|mm (l_pobj) MM_53\NNP|r
C400082_D009101 NONE Bort_0\NNP| (r_compound) dex_2\NN|bort|- (r_nsubj) was_3\VBD|dex|treatment|. (l_attr) treatment_7\NN|an|effective|salvage|for|,|for (l_prep) for_8\IN|patients (l_pobj) patients_10\NNS|mm (l_compound) MM_9\NNP|
D003907_D009101 NONE dexamethasone_2\NN|as|in (l_prep) in_6\IN|patients (l_pobj) patients_7\NNS|with (l_prep) with_8\IN|myeloma (l_pobj) myeloma_13\NN|relapsed|refractory|multiple|:|analysis
D003907_D009101 NONE bort)-dexamethasone_2\NNP| (r_nmod) dex_4\NN|(|bort)-dexamethasone|(|) (r_appos) Bortezomib_0\NNP|dex (r_nsubj) is_6\VBZ|bortezomib|therapy|. (l_attr) therapy_9\NN|an|effective|for (l_prep) for_10\IN|r (l_pobj) R_17\NNP|relapsed|/|refractory|(|r|/|)|myeloma (l_appos) myeloma_20\NN|multiple|mm|)
D003907_D009101 NONE bort)-dexamethasone_2\NNP| (r_nmod) dex_4\NN|(|bort)-dexamethasone|(|) (r_appos) Bortezomib_0\NNP|dex (r_nsubj) is_6\VBZ|bortezomib|therapy|. (l_attr) therapy_9\NN|an|effective|for (l_prep) for_10\IN|r (l_pobj) R_17\NNP|relapsed|/|refractory|(|r|/|)|myeloma (l_appos) myeloma_20\NN|multiple|mm|) (l_appos) MM_22\NNP|(
D003907_D009101 NONE dex_4\NN|(|bort)-dexamethasone|(|) (r_appos) Bortezomib_0\NNP|dex (r_nsubj) is_6\VBZ|bortezomib|therapy|. (l_attr) therapy_9\NN|an|effective|for (l_prep) for_10\IN|r (l_pobj) R_17\NNP|relapsed|/|refractory|(|r|/|)|myeloma (l_appos) myeloma_20\NN|multiple|mm|)
D003907_D009101 NONE dex_4\NN|(|bort)-dexamethasone|(|) (r_appos) Bortezomib_0\NNP|dex (r_nsubj) is_6\VBZ|bortezomib|therapy|. (l_attr) therapy_9\NN|an|effective|for (l_prep) for_10\IN|r (l_pobj) R_17\NNP|relapsed|/|refractory|(|r|/|)|myeloma (l_appos) myeloma_20\NN|multiple|mm|) (l_appos) MM_22\NNP|(
D003907_D009101 NONE dex_29\NN|(|mg|and|day|)|as (l_prep) as_43\IN|treatment (l_pobj) treatment_45\NN|salvage|in (l_prep) in_46\IN|patients (l_pobj) patients_48\NNS|85|with (l_prep) with_49\IN|mm (l_pobj) MM_53\NNP|r
D003907_D009101 NONE dex_2\NN|bort|- (r_nsubj) was_3\VBD|dex|treatment|. (l_attr) treatment_7\NN|an|effective|salvage|for|,|for (l_prep) for_8\IN|patients (l_pobj) patients_10\NNS|mm (l_compound) MM_9\NNP|
15018178
D015662_D000743 CID sulfomethoxazole_24\NN|trimethoprim|- (r_pobj) by_21\IN|sulfomethoxazole (r_agent) induced_20\VBN|by (r_acl) crisis_19\NN|a|installing|hemolytic|anemia|induced (l_compound) anemia_18\NN|
D015662_D002534 NONE sulfomethoxazole_24\NN|trimethoprim|- (r_pobj) by_21\IN|sulfomethoxazole (r_agent) induced_20\VBN|by (r_acl) crisis_19\NN|a|installing|hemolytic|anemia|induced (r_dobj) had_13\VBD|who|crisis (r_relcl) girl_11\NN|a|old|had (r_pobj) of_6\IN|girl (r_prep) findings_5\NNS|imaging|of (r_dobj) present_1\VBP|we|findings|,|resulting|. (l_advcl) resulting_26\VBG|in (l_prep) in_27\IN|anoxia (l_pobj) anoxia_29\NN|cerebral|leading
8160791
D005839_D007674 CID gentamicin_9\NN| (r_npadvmod) mediated_11\VBN|gentamicin|- (r_amod) nephropathy_12\NN|mediated
D005839_D007674 CID gentamicin_16\NN| (r_nmod) nephropathy_19\NN|gentamicin|(|gm)-mediated
D005839_D007674 CID GM)-mediated_18\JJ| (r_amod) nephropathy_19\NN|gentamicin|(|gm)-mediated
D005839_D007674 CID GM_2\NNP| (r_pobj) of_1\IN|gm (r_prep) Administration_0\NN|of|at|for (r_nsubj) induced_12\VBD|administration|reduction|damage|. (l_dobj) damage_34\NN|marked|tubular
D005839_D007674 CID GM_27\NNP| (r_npadvmod) mediated_29\VBN|gm|- (r_amod) nephropathy_30\NN|mediated
D005839_D007674 CID GM_14\NNP| (r_npadvmod) mediated_16\VBN|gm|- (r_amod) nephropathy_17\NN|mediated|,|2|)
D005839_D007674 CID GM_43\NNP| (r_npadvmod) induced_45\VBN|gm|- (r_amod) vasoconstriction_47\NN|induced|renal (r_pobj) in_42\IN|vasoconstriction (r_prep) role_41\NN|a|critical|in (r_dobj) play_38\VBP|role (r_conj) have_10\VBP|that|1|sod|effects|differ|play (l_dobj) effects_12\NNS|protective|on (l_prep) on_13\IN|nephropathy (l_pobj) nephropathy_17\NN|mediated|,|2|)
D006152_D007674 NONE monophosphate_7\NN|3',5'-cyclic (r_nmod) excretion_11\NN|monophosphate|(|cgmp|)|and|increase (r_appos) reduction_2\NN|a|significant|in|excretion (r_nsubjpass) observed_25\VBN|reduction|were|also|in|. (l_prep) in_26\IN|nephropathy (l_pobj) nephropathy_30\NN|mediated
D006152_D007674 NONE cGMP_9\NN| (r_nmod) excretion_11\NN|monophosphate|(|cgmp|)|and|increase (r_appos) reduction_2\NN|a|significant|in|excretion (r_nsubjpass) observed_25\VBN|reduction|were|also|in|. (l_prep) in_26\IN|nephropathy (l_pobj) nephropathy_30\NN|mediated
C038983_D007674 NONE DMTU_3\NNP| (r_nsubj) reduced_5\VBD|in|,|dmtu|significantly|damage|,|but|affect (l_dobj) damage_8\NN|the|tubular|and|peroxidation
C038983_D007674 NONE DMTU_9\NNP| (r_conj) SOD_7\NNP|both|and|dmtu (r_nsubj) have_10\VBP|that|1|sod|effects|differ|play (l_dobj) effects_12\NNS|protective|on (l_prep) on_13\IN|nephropathy (l_pobj) nephropathy_17\NN|mediated|,|2|)
C038983_D007674 NONE DMTU_31\NNP| (r_conj) SOD_29\NNP|and|dmtu|,|and|3|anions (r_pobj) for_28\IN|sod (r_prep) differ_27\VBP|mechanisms|for (r_conj) have_10\VBP|that|1|sod|effects|differ|play (l_dobj) effects_12\NNS|protective|on (l_prep) on_13\IN|nephropathy (l_pobj) nephropathy_17\NN|mediated|,|2|)
D013481_D007674 NONE superoxide_36\JJ| (r_amod) anions_37\NNS|superoxide (r_conj) SOD_29\NNP|and|dmtu|,|and|3|anions (r_pobj) for_28\IN|sod (r_prep) differ_27\VBP|mechanisms|for (r_conj) have_10\VBP|that|1|sod|effects|differ|play (l_dobj) effects_12\NNS|protective|on (l_prep) on_13\IN|nephropathy (l_pobj) nephropathy_17\NN|mediated|,|2|)
25084821
C069541_D009503 CID Quetiapine_0\NNP| (r_npadvmod) induced_2\VBN|quetiapine|-|neutropenia|in|. (l_dobj) neutropenia_3\NN|
C069541_D009503 CID Quetiapine_1\NNP| (r_nsubj) is_2\VBZ|:|quetiapine|derivative|has|. (l_advcl) has_12\VBZ|which|risk (l_dobj) risk_15\NN|the|highest|of (l_prep) of_16\IN|causing (l_pcomp) causing_17\VBG|dyscrasias (l_dobj) dyscrasias_19\NNS|blood|,|neutropenia (l_appos) neutropenia_22\NN|especially
C069541_D009503 CID quetiapine_14\NN| (r_pobj) with_13\IN|quetiapine (r_prep) treatment_12\NN|with (r_pobj) after_11\IN|treatment (r_prep) developed_9\VBD|that|neutropenia|after (l_dobj) neutropenia_10\NN|
C069541_D009503 CID quetiapine_9\NN| (r_pobj) of_8\IN|quetiapine (r_prep) effect_7\NN|a|common|side|of (r_attr) is_2\VBZ|although|neutropenia|not|effect (l_nsubj) neutropenia_1\NN|
C069541_D001714 NONE Quetiapine_0\NNP| (r_npadvmod) induced_2\VBN|quetiapine|-|neutropenia|in|. (l_prep) in_4\IN|patient (l_pobj) patient_7\NN|a|bipolar|with (l_amod) bipolar_6\JJ|
C069541_D006528 NONE Quetiapine_0\NNP| (r_npadvmod) induced_2\VBN|quetiapine|-|neutropenia|in|. (l_prep) in_4\IN|patient (l_pobj) patient_7\NN|a|bipolar|with (l_prep) with_8\IN|carcinoma (l_pobj) carcinoma_10\NN|hepatocellular
C069541_D006528 NONE quetiapine_14\NN| (r_pobj) with_13\IN|quetiapine (r_prep) treatment_12\NN|with (r_pobj) after_11\IN|treatment (r_prep) developed_9\VBD|that|neutropenia|after (r_relcl) patient_4\NN|a|with|developed (l_prep) with_5\IN|carcinoma (l_pobj) carcinoma_7\NN|hepatocellular
C069541_D006402 NONE Quetiapine_1\NNP| (r_nsubj) is_2\VBZ|:|quetiapine|derivative|has|. (l_advcl) has_12\VBZ|which|risk (l_dobj) risk_15\NN|the|highest|of (l_prep) of_16\IN|causing (l_pcomp) causing_17\VBG|dyscrasias (l_dobj) dyscrasias_19\NNS|blood|,|neutropenia
D003024_D006402 NONE clozapine_9\NN| (r_pobj) to_8\IN|clozapine (r_prep) similar_7\JJ|to (r_amod) derivative_5\JJ|a|dibenzothiazepine|,|similar|, (r_attr) is_2\VBZ|:|quetiapine|derivative|has|. (l_advcl) has_12\VBZ|which|risk (l_dobj) risk_15\NN|the|highest|of (l_prep) of_16\IN|causing (l_pcomp) causing_17\VBG|dyscrasias (l_dobj) dyscrasias_19\NNS|blood|,|neutropenia
D003024_D009503 NONE clozapine_9\NN| (r_pobj) to_8\IN|clozapine (r_prep) similar_7\JJ|to (r_amod) derivative_5\JJ|a|dibenzothiazepine|,|similar|, (r_attr) is_2\VBZ|:|quetiapine|derivative|has|. (l_advcl) has_12\VBZ|which|risk (l_dobj) risk_15\NN|the|highest|of (l_prep) of_16\IN|causing (l_pcomp) causing_17\VBG|dyscrasias (l_dobj) dyscrasias_19\NNS|blood|,|neutropenia (l_appos) neutropenia_22\NN|especially
C069541_D007970 CID quetiapine_7\NN| (r_pobj) with_6\IN|quetiapine (r_prep) treated_5\VBN|being|with (r_pcomp) after_3\IN|treated (r_prep) developed_1\VBD|she|leucopenia|after|. (l_dobj) leucopenia_2\JJ|
C069541_D008107 NONE quetiapine_23\NN| (r_pobj) to_22\IN|quetiapine (r_prep) reaction_21\NN|adverse|to (r_pobj) for_19\IN|reaction (r_prep) marker_18\NN|a|diagnostic|for (r_attr) be_15\VB|fever|may|marker|. (r_conj) be_3\VB|dysfunction|may|one|,|and|be (l_nsubj) dysfunction_1\NN|hepatic
C069541_D005334 CID quetiapine_23\NN| (r_pobj) to_22\IN|quetiapine (r_prep) reaction_21\NN|adverse|to (r_pobj) for_19\IN|reaction (r_prep) marker_18\NN|a|diagnostic|for (r_attr) be_15\VB|fever|may|marker|. (l_nsubj) fever_13\NN|concomitant
16092435
D012266_D066126 NONE ribose_8\NN|d|-|on (l_prep) on_9\IN|cardiotoxicity (l_pobj) cardiotoxicity_13\NN|evoked|in
D012266_D066126 NONE ribose_2\NN|d|-|in (r_nsubj) influence_12\VB|ribose|did|not|cardiotoxicity|. (l_dobj) cardiotoxicity_14\NN|adr
D004317_D066126 NONE adriamycin_10\NNS| (r_npadvmod) evoked_12\VBN|adriamycin|- (r_amod) cardiotoxicity_13\NN|evoked|in
D004317_D066126 NONE Adriamycin_0\NNP| (r_cc) evoked_8\VBN|adriamycin|in|toxicity|. (l_dobj) toxicity_12\NN|developed|cardiac
D004317_D066126 NONE ADR_13\NNP| (r_compound) cardiotoxicity_14\NN|adr
D012266_D009202 NONE ribose_5\NN|d|-|on|in (l_prep) on_6\IN|myocardiopathy (l_pobj) myocardiopathy_10\NN|induced
D004317_D009202 CID adriamycin_7\NNS| (r_npadvmod) induced_9\VBN|adriamycin|- (r_amod) myocardiopathy_10\NN|induced
19338378
C031942_D013921 NONE argatroban_9\JJ| (r_amod) therapy_10\NN|argatroban|in (l_prep) in_11\IN|thrombocytopenia (l_pobj) thrombocytopenia_15\NN|induced
C031942_D013921 NONE Argatroban_0\NNP| (r_nsubj) is_1\VBZ|argatroban|inhibitor|and|for|. (l_attr) inhibitor_8\NN|a|metabolized|,|direct|thrombin|used (l_acl) used_9\VBN|for|in (l_prep) in_16\IN|thrombocytopenia (l_pobj) thrombocytopenia_20\NN|induced|(|hit|)
C031942_D013921 NONE Argatroban_0\NNP| (r_nsubj) is_1\VBZ|argatroban|inhibitor|and|for|. (l_attr) inhibitor_8\NN|a|metabolized|,|direct|thrombin|used (l_acl) used_9\VBN|for|in (l_prep) in_16\IN|thrombocytopenia (l_pobj) thrombocytopenia_20\NN|induced|(|hit|) (l_appos) HIT_22\NNP|
C031942_D013921 NONE Argatroban_0\NNP| (r_nsubj) is_1\VBZ|argatroban|inhibitor|and|for|. (l_conj) for_25\IN|patients (l_pobj) patients_26\NNS|with|undergoing (l_prep) with_27\IN|or|at (l_conj) at_29\IN|risk (l_pobj) risk_30\NN|of (l_prep) of_31\IN|hit (l_pobj) HIT_32\NNP|
C031942_D013921 NONE argatroban_11\JJ| (r_amod) therapy_12\NN|argatroban|in (l_prep) in_13\IN|hit (l_pobj) HIT_14\NNP|
C031942_D013921 NONE argatroban_5\JJ| (r_amod) dose_6\NN|recommended|argatroban|in (l_prep) in_7\IN|hit (l_pobj) HIT_8\NNP|
C031942_D013921 NONE argatroban_6\JJ| (r_amod) therapy_7\NN|argatroban|in|,|including (l_prep) in_8\IN|hit (l_pobj) HIT_9\NNP|
C031942_D013921 NONE argatroban_6\JJ| (r_amod) therapy_7\NN|argatroban|in|,|including (r_pobj) with_5\IN|therapy (r_prep) familiarity_1\NN|improved|of|with (r_nsubj) facilitate_20\VB|familiarity|,|may|reduction|. (l_dobj) reduction_21\NN|of (l_prep) of_22\IN|harm (l_pobj) harm_23\NN|associated (l_acl) associated_24\VBN|with (l_prep) with_25\IN|thromboses (l_pobj) thromboses_30\NNS|hit|(|fewer|)|or|treatment (l_nmod) HIT_26\NNP|
C031942_D013921 NONE argatroban_38\JJ| (r_amod) errors_40\NNS|fewer|argatroban|medication (r_appos) treatment_34\NN|its|(|errors|) (r_conj) thromboses_30\NNS|hit|(|fewer|)|or|treatment (r_pobj) with_25\IN|thromboses (r_prep) associated_24\VBN|with (r_acl) harm_23\NN|associated (r_pobj) of_22\IN|harm (r_prep) reduction_21\NN|of (r_dobj) facilitate_20\VB|familiarity|,|may|reduction|. (l_nsubj) familiarity_1\NN|improved|of|with (l_prep) with_5\IN|therapy (l_pobj) therapy_7\NN|argatroban|in|,|including (l_prep) in_8\IN|hit (l_pobj) HIT_9\NNP|
C031942_D013921 NONE argatroban_38\JJ| (r_amod) errors_40\NNS|fewer|argatroban|medication (r_appos) treatment_34\NN|its|(|errors|) (r_conj) thromboses_30\NNS|hit|(|fewer|)|or|treatment (l_nmod) HIT_26\NNP|
D006493_D013921 NONE heparin_12\NN| (r_npadvmod) induced_14\VBN|heparin|- (r_amod) thrombocytopenia_15\NN|induced
D006493_D013921 NONE heparin_17\NN| (r_npadvmod) induced_19\VBN|heparin|- (r_amod) thrombocytopenia_20\NN|induced|(|hit|)
D006493_D013921 NONE heparin_17\NN| (r_npadvmod) induced_19\VBN|heparin|- (r_amod) thrombocytopenia_20\NN|induced|(|hit|) (l_appos) HIT_22\NNP|
D006493_D013921 NONE heparin_17\NN| (r_npadvmod) induced_19\VBN|heparin|- (r_amod) thrombocytopenia_20\NN|induced|(|hit|) (r_pobj) in_16\IN|thrombocytopenia (r_prep) used_9\VBN|for|in (r_acl) inhibitor_8\NN|a|metabolized|,|direct|thrombin|used (r_attr) is_1\VBZ|argatroban|inhibitor|and|for|. (l_conj) for_25\IN|patients (l_pobj) patients_26\NNS|with|undergoing (l_prep) with_27\IN|or|at (l_conj) at_29\IN|risk (l_pobj) risk_30\NN|of (l_prep) of_31\IN|hit (l_pobj) HIT_32\NNP|
C031942_D013927 NONE Argatroban_0\NNP| (r_nsubj) is_1\VBZ|argatroban|inhibitor|and|for|. (l_attr) inhibitor_8\NN|a|metabolized|,|direct|thrombin|used (l_acl) used_9\VBN|for|in (l_prep) for_10\IN|prophylaxis (l_pobj) prophylaxis_11\NN|or|treatment (l_conj) treatment_13\NN|of (l_prep) of_14\IN|thrombosis (l_pobj) thrombosis_15\NN|
D006493_D013927 NONE heparin_17\NN| (r_npadvmod) induced_19\VBN|heparin|- (r_amod) thrombocytopenia_20\NN|induced|(|hit|) (r_pobj) in_16\IN|thrombocytopenia (r_prep) used_9\VBN|for|in (l_prep) for_10\IN|prophylaxis (l_pobj) prophylaxis_11\NN|or|treatment (l_conj) treatment_13\NN|of (l_prep) of_14\IN|thrombosis (l_pobj) thrombosis_15\NN|
C031942_D008107 NONE argatroban_5\JJ| (r_amod) dose_6\NN|recommended|argatroban|in (r_nsubj) is_9\VBZ|dose|min|( (l_attr) min_15\NN|2|microg|kg|/|(|reduced|)|,|adjusted (l_acl) reduced_17\VBN|in (l_prep) in_18\IN|patients (l_pobj) patients_19\NNS|with (l_prep) with_20\IN|impairment|and|in (l_pobj) impairment_22\NN|hepatic
C031942_D009765 NONE argatroban_3\NN| (r_advmod) investigated_7\VBN|for|,|argatroban|has|not|been|in (r_ccomp) is_15\VBZ|investigated|;|adjustment|unnecessary|,|and|be (l_acomp) unnecessary_16\JJ|for (l_prep) for_17\IN|age (l_pobj) age_19\NN|adult|,|sex (l_conj) sex_21\NN|,|ethnicity (l_conj) ethnicity_25\NN|race|/|or|obesity (l_conj) obesity_27\NN|
C031942_D006470 CID argatroban_3\NN| (r_amod) with_2\IN|argatroban (r_prep) bleeding_1\VBG|with
24595967
D018817_D008569 CID ecstasy_5\NN| (r_compound) users_6\NNS|ecstasy (r_pobj) in_4\IN|users (r_prep) consolidation_3\NN|dysfunctional|overnight|memory|in|. (l_compound) memory_2\NN|
D018817_D008569 CID Ecstasy_0\NNP| (r_compound) users_1\NNS|ecstasy (r_nsubj) demonstrated_2\VBD|users|consolidation|. (l_dobj) consolidation_6\NN|impaired|overnight|memory|,|finding (l_compound) memory_5\NN|
D018817_D008569 CID ecstasy_3\NN| (r_npadvmod) associated_5\VBN|ecstasy|- (r_amod) dysfunction_6\NN|that|associated|in (r_nsubj) underlie_13\VB|dysfunction|may|impairments (l_dobj) impairments_17\NNS|overnight|memory|in
D018817_D008569 CID ecstasy_20\NN| (r_compound) users_21\NNS|regular|ecstasy (r_pobj) in_18\IN|users (r_prep) impairments_17\NNS|overnight|memory|in
D018817_D012893 CID ecstasy_4\NN| (r_compound) users_5\NNS|ecstasy (r_nsubj) marked_7\VBN|that|users|have|and|impairments (l_conj) impairments_15\NNS|persistent|neurocognitive
14616590
D015742_D010146 CID Disoprivan_32\NNP| (r_pobj) with_31\IN|disoprivan (r_prep) than_30\IN|with (r_prep) with_28\IN|am149|than (r_prep) occurred_25\VBD|pain|frequently|with|. (l_nsubj) Pain_0\NN|on|(|%|,|0.01|)|and|thrombophlebitis
D015742_D013924 CID Disoprivan_32\NNP| (r_pobj) with_31\IN|disoprivan (r_prep) than_30\IN|with (r_prep) with_28\IN|am149|than (r_prep) occurred_25\VBD|pain|frequently|with|. (l_nsubj) Pain_0\NN|on|(|%|,|0.01|)|and|thrombophlebitis (l_conj) thrombophlebitis_14\NN|(|93.3|,|0.001|)
24284476
D047310_D000647 NONE apigenin_2\NN| (r_nsubj) prevent_5\VB|furthermore|,|apigenin|did|not|amnesia|)|. (l_dobj) amnesia_7\NN|the|induced
D012601_D000647 CID scopolamine_10\NN|kg (r_pobj) by_9\IN|scopolamine (r_agent) induced_8\VBN|by (r_acl) amnesia_7\NN|the|induced
9578276
17954033
D019259_D019694 NONE lamivudine_6\NN| (r_npadvmod) untreated_8\VBN|lamivudine|- (r_amod) patients_10\NNS|untreated|iranian|with (l_prep) with_11\IN|infection (l_pobj) infection_16\NN|chronic|virus
D019259_D019694 NONE Lamivudine_0\NNP| (r_nsubjpass) used_2\VBN|lamivudine|is|for|. (l_prep) for_3\IN|treatment (l_pobj) treatment_5\NN|the|of (l_prep) of_6\IN|patients (l_pobj) patients_10\NNS|chronic|b (l_compound) B_9\NNP|hepatitis
D019259_D019694 NONE lamivudine_20\NN| (r_npadvmod) untreated_22\VBN|lamivudine|- (r_amod) patients_26\NNS|untreated|chronic|b (l_compound) B_25\NNP|hepatitis
D019259_D019694 NONE lamivudine_14\NN| (r_npadvmod) untreated_16\VBN|lamivudine|- (r_amod) patients_20\NNS|untreated|chronic|b|in (l_compound) B_19\NNP|hepatitis
D019259_D019694 NONE lamivudine_14\NN| (r_pobj) with_13\IN|lamivudine (r_prep) treated_12\VBN|who|had|not|been|with (r_relcl) patients_7\NNS|77|chronic|b|treated (l_compound) B_6\NNP|hepatitis
D019259_D019694 NONE lamivudine_9\NN| (r_npadvmod) untreated_11\VBN|lamivudine|- (r_amod) patients_12\NNS|untreated|with (l_prep) with_13\IN|b (l_pobj) B_16\NNP|chronic|hepatitis
D019259_D019694 NONE lamivudine_9\NN| (r_npadvmod) untreated_11\VBN|lamivudine|- (r_amod) patients_12\NNS|untreated|with (r_pobj) in_8\IN|patients (r_prep) mutants_7\NNS|ymdd|motif|in (r_pobj) of_4\IN|mutants (r_prep) occurrence_3\NN|the|natural|of (r_nsubjpass) reported_19\VBN|although|occurrence|has|been (r_advcl) detected_25\VBN|reported|,|mutants|were|not|in|. (l_prep) in_26\IN|patients (l_pobj) patients_34\NNS|iranian|untreated|chronic|b (l_compound) B_33\NNP|hepatitis
D019259_D019694 NONE lamivudine_28\NN| (r_npadvmod) untreated_30\VBN|lamivudine|- (r_amod) patients_34\NNS|iranian|untreated|chronic|b (r_pobj) in_26\IN|patients (r_prep) detected_25\VBN|reported|,|mutants|were|not|in|. (l_advcl) reported_19\VBN|although|occurrence|has|been (l_nsubjpass) occurrence_3\NN|the|natural|of (l_prep) of_4\IN|mutants (l_pobj) mutants_7\NNS|ymdd|motif|in (l_prep) in_8\IN|patients (l_pobj) patients_12\NNS|untreated|with (l_prep) with_13\IN|b (l_pobj) B_16\NNP|chronic|hepatitis
D019259_D019694 NONE lamivudine_28\NN| (r_npadvmod) untreated_30\VBN|lamivudine|- (r_amod) patients_34\NNS|iranian|untreated|chronic|b (l_compound) B_33\NNP|hepatitis
D019259_D006509 NONE lamivudine_20\NN| (r_npadvmod) untreated_22\VBN|lamivudine|- (r_amod) patients_26\NNS|untreated|chronic|b (r_pobj) in_19\IN|patients (r_prep) variability_18\NN|natural|genome|in (r_pobj) as_15\IN|variability (r_prep) occur_14\VBP|that|mutants|as (l_nsubj) mutants_7\NNS|the|motif|(|virus|) (l_appos) virus_12\NN|resistant|b (l_compound) B_11\NNP|hepatitis
11439380
D013792_D009422 NONE Thalidomide_0\NNP| (r_compound) neuropathy_1\NN|thalidomide|in|.
D013792_D009422 NONE thalidomide_3\NN| (r_npadvmod) induced_5\VBN|thalidomide|- (r_amod) neuropathy_6\NN|induced|using
D013792_D009422 NONE thalidomide_8\NN| (r_pobj) of_7\IN|thalidomide (r_prep) complication_6\NN|a|common|of|in (r_attr) be_3\VB|neuropathy|may|thus|complication|. (l_nsubj) Neuropathy_0\NNP|
D013792_D011471 NONE Thalidomide_0\NNP| (r_compound) neuropathy_1\NN|thalidomide|in|. (l_prep) in_2\IN|patients (l_pobj) patients_3\NNS|treated (l_acl) treated_4\VBN|for (l_prep) for_5\IN|cancer (l_pobj) cancer_8\NN|metastatic|prostate
D013792_D011471 NONE thalidomide_19\NN|oral (r_pobj) of_17\IN|thalidomide (r_prep) trial_16\NN|an|label|of (r_pobj) in_11\IN|trial (r_prep) men_3\NNS|seven|with|in (l_prep) with_4\IN|cancer (l_pobj) cancer_10\NN|metastatic|independent|prostate
D000728_D011471 NONE androgen_6\JJ| (r_npadvmod) independent_8\JJ|androgen|- (r_amod) cancer_10\NN|metastatic|independent|prostate
20034406
D010862_D013226 CID pilocarpine_12\NN| (r_npadvmod) induced_14\VBN|pilocarpine|- (r_amod) status_15\NN|induced|epilepticus (l_amod) epilepticus_16\NN|
D010862_D013226 CID pilocarpine_17\NN| (r_amod) injection_18\NN|pilocarpine (r_pobj) by_16\IN|injection (r_agent) induced_15\VBN|by (r_acl) SE_13\NNP|status|epilepticus|(|)|induced (l_nmod) epilepticus_11\NN|
D010862_D013226 CID pilocarpine_17\NN| (r_amod) injection_18\NN|pilocarpine (r_pobj) by_16\IN|injection (r_agent) induced_15\VBN|by (r_acl) SE_13\NNP|status|epilepticus|(|)|induced
D010862_D013226 CID pilocarpine_4\NN| (r_amod) injection_5\NN|pilocarpine (r_pobj) by_3\IN|injection (r_agent) induced_2\VBN|se|was|by|. (l_nsubjpass) SE_0\NNP|
D010862_D013226 CID pilocarpine_15\NN| (r_npadvmod) induced_17\VBN|pilocarpine|- (r_amod) SE_18\NNP|induced
2718706
D007741_D007022 CID labetalol_4\NN|with (r_pobj) by_3\IN|labetalol (r_agent) induced_2\VBN|by (r_acl) hypotension_1\NN|deliberate|induced|.
D007741_D007022 CID labetalol_4\NN|,|agent|, (r_dobj) using_3\VBG|labetalol|as (l_prep) as_15\IN|agent (l_pobj) agent_18\NN|a|hypotensive|in (l_amod) hypotensive_17\JJ|
D007741_D007022 CID labetalol_4\NN| (r_nsubj) induces_5\VBZ|that|labetalol|hypotension (l_dobj) hypotension_8\NN|adjustable|without|and|hypertension
D006221_D007022 CID halothane_6\NN|,|enflurane (r_pobj) with_5\IN|halothane (r_prep) labetalol_4\NN|with (r_pobj) by_3\IN|labetalol (r_agent) induced_2\VBN|by (r_acl) hypotension_1\NN|deliberate|induced|.
D006221_D007022 CID halothane_25\NN|,|enflurane (r_appos) anaesthetics_23\NNS|inhalation|(|halothane|) (r_pobj) with_21\IN|anaesthetics (r_prep) combination_20\NN|with (r_pobj) in_19\IN|combination (r_prep) agent_18\NN|a|hypotensive|in (l_amod) hypotensive_17\JJ|
D006221_D007022 CID H_2\NN| (r_compound) concentration_3\NN|the|mean|h|during|concentration (l_prep) during_4\IN|hypotension (l_pobj) hypotension_5\NN|in
D004737_D007022 CID enflurane_8\NN|or|isoflurane (r_conj) halothane_6\NN|,|enflurane (r_pobj) with_5\IN|halothane (r_prep) labetalol_4\NN|with (r_pobj) by_3\IN|labetalol (r_agent) induced_2\VBN|by (r_acl) hypotension_1\NN|deliberate|induced|.
D004737_D007022 CID enflurane_27\NN|or|isoflurane (r_conj) halothane_25\NN|,|enflurane (r_appos) anaesthetics_23\NNS|inhalation|(|halothane|) (r_pobj) with_21\IN|anaesthetics (r_prep) combination_20\NN|with (r_pobj) in_19\IN|combination (r_prep) agent_18\NN|a|hypotensive|in (l_amod) hypotensive_17\JJ|
D004737_D007022 CID E_18\NN| (r_compound) concentration_19\NN|the|mean|e|1.6|+/-|,|and|mean (r_appos) concentration_3\NN|the|mean|h|during|concentration (l_prep) during_4\IN|hypotension (l_pobj) hypotension_5\NN|in
D007530_D007022 CID isoflurane_10\RB|for (r_conj) enflurane_8\NN|or|isoflurane (r_conj) halothane_6\NN|,|enflurane (r_pobj) with_5\IN|halothane (r_prep) labetalol_4\NN|with (r_pobj) by_3\IN|labetalol (r_agent) induced_2\VBN|by (r_acl) hypotension_1\NN|deliberate|induced|.
D007530_D007022 CID isoflurane_29\RB| (r_conj) enflurane_27\NN|or|isoflurane (r_conj) halothane_25\NN|,|enflurane (r_appos) anaesthetics_23\NNS|inhalation|(|halothane|) (r_pobj) with_21\IN|anaesthetics (r_prep) combination_20\NN|with (r_pobj) in_19\IN|combination (r_prep) agent_18\NN|a|hypotensive|in (l_amod) hypotensive_17\JJ|
D007530_D007022 CID isoflurane_31\JJ| (r_amod) group_32\NN|the|isoflurane (r_pobj) except_29\IN|group (r_prep) returned_18\VBD|postoperatively|to|,|except (r_conj) rose_7\VBD|during|,|concentration|significantly|in|before|and|returned|. (l_prep) During_0\IN|hypotension (l_pobj) hypotension_1\NN|
D007530_D007022 CID isoflurane_31\JJ| (r_amod) group_32\NN|the|isoflurane (r_pobj) except_29\IN|group (r_prep) returned_18\VBD|postoperatively|to|,|except (r_conj) rose_7\VBD|during|,|concentration|significantly|in|before|and|returned|. (l_prep) before_15\IN|hypotension (l_pobj) hypotension_16\NN|
D003404_D007022 NONE creatinine_5\NN| (r_compound) concentration_6\NN|the|serum|creatinine (r_nsubj) rose_7\VBD|during|,|concentration|significantly|in|before|and|returned|. (l_prep) During_0\IN|hypotension (l_pobj) hypotension_1\NN|
D003404_D007022 NONE creatinine_5\NN| (r_compound) concentration_6\NN|the|serum|creatinine (r_nsubj) rose_7\VBD|during|,|concentration|significantly|in|before|and|returned|. (l_prep) before_15\IN|hypotension (l_pobj) hypotension_16\NN|
D007741_D013610 NONE labetalol_4\NN| (r_nsubj) induces_5\VBZ|that|labetalol|hypotension (l_dobj) hypotension_8\NN|adjustable|without|and|hypertension (l_prep) without_9\IN|tachycardia (l_pobj) tachycardia_11\NNS|compensatory
D007741_D006973 NONE labetalol_4\NN| (r_nsubj) induces_5\VBZ|that|labetalol|hypotension (l_dobj) hypotension_8\NN|adjustable|without|and|hypertension (l_conj) hypertension_14\NN|rebound
17042797
D010862_D013226 CID pilocarpine_14\NN| (r_npadvmod) induced_16\VBN|pilocarpine|- (r_amod) status_17\NN|induced|epilepticus (l_acl) epilepticus_18\NN|in
D010862_D013226 CID pilocarpine_22\NN| (r_npadvmod) induced_24\VBN|pilocarpine|- (r_amod) status_25\NN|induced (r_nsubj) epilepticus_26\NN|status
D010862_D004833 CID pilocarpine_16\NN| (r_amod) model_17\NN|the|pilocarpine|of (l_prep) of_18\IN|epilepsy (l_pobj) epilepsy_21\NN|temporal|lobe
20447294
D009020_D009437 NONE morphine_4\NN|and|blocker (r_pobj) between_3\IN|morphine (r_prep) synergy_2\NN|between (r_pobj) of_1\IN|synergy (r_prep) Studies_0\NNS|of|,|in|. (l_prep) in_14\IN|models (l_pobj) models_16\NNS|rat|of (l_prep) of_17\IN|pain (l_pobj) pain_21\NN|inflammatory
D009020_D009437 NONE morphine_24\NN| (r_pobj) with_23\IN|morphine (r_prep) combinations_22\NNS|with|in (l_prep) in_25\IN|models (l_pobj) models_27\NNS|rat|of (l_prep) of_28\IN|pain (l_pobj) pain_32\NN|inflammatory
D012964_D009437 NONE sodium_8\NN| (r_compound) channel_9\NN|sodium (r_compound) blocker_10\NN|a|novel|channel|,|cnsb002 (r_conj) morphine_4\NN|and|blocker (r_pobj) between_3\IN|morphine (r_prep) synergy_2\NN|between (r_pobj) of_1\IN|synergy (r_prep) Studies_0\NNS|of|,|in|. (l_prep) in_14\IN|models (l_pobj) models_16\NNS|rat|of (l_prep) of_17\IN|pain (l_pobj) pain_21\NN|inflammatory
D012964_D009437 NONE sodium_12\NN| (r_compound) channel_13\NN|sodium (r_compound) blocker_14\NN|a|channel|with (l_prep) with_15\IN|properties|and|in (l_conj) in_21\IN|combinations (l_pobj) combinations_22\NNS|with|in (l_prep) in_25\IN|models (l_pobj) models_27\NNS|rat|of (l_prep) of_28\IN|pain (l_pobj) pain_32\NN|inflammatory
C401121_D009437 NONE CNSB002_12\NNP| (r_appos) blocker_10\NN|a|novel|channel|,|cnsb002 (r_conj) morphine_4\NN|and|blocker (r_pobj) between_3\IN|morphine (r_prep) synergy_2\NN|between (r_pobj) of_1\IN|synergy (r_prep) Studies_0\NNS|of|,|in|. (l_prep) in_14\IN|models (l_pobj) models_16\NNS|rat|of (l_prep) of_17\IN|pain (l_pobj) pain_21\NN|inflammatory
C401121_D009437 NONE CNSB002_9\NNP|,|blocker (l_appos) blocker_14\NN|a|channel|with (l_prep) with_15\IN|properties|and|in (l_conj) in_21\IN|combinations (l_pobj) combinations_22\NNS|with|in (l_prep) in_25\IN|models (l_pobj) models_27\NNS|rat|of (l_prep) of_28\IN|pain (l_pobj) pain_32\NN|inflammatory
D009020_D010146 NONE morphine_7\NN|and|cnsb002 (r_pobj) of_6\IN|morphine (r_prep) doses_5\NNS|nonsedating|of (r_pobj) for_3\IN|doses (r_prep) curves_2\VBZ|response|for|given (r_nsubjpass) constructed_18\VBN|curves|were|for (l_prep) for_19\IN|effect (l_pobj) effect_21\NN|antihyperalgesic|using (l_acl) using_22\VBG|withdrawal|in (l_prep) in_28\IN|models (l_pobj) models_32\NNS|two|rat|pain (l_compound) pain_31\NN|
D009020_D007249 NONE morphine_7\NN|and|cnsb002 (r_pobj) of_6\IN|morphine (r_prep) doses_5\NNS|nonsedating|of (r_pobj) for_3\IN|doses (r_prep) curves_2\VBZ|response|for|given (r_nsubjpass) constructed_18\VBN|curves|were|for (r_ccomp) inflammation_38\NN|constructed|:|induced|paw|and|streptozotocin|neuropathy|.
D009020_D003929 NONE morphine_7\NN|and|cnsb002 (r_pobj) of_6\IN|morphine (r_prep) doses_5\NNS|nonsedating|of (r_pobj) for_3\IN|doses (r_prep) curves_2\VBZ|response|for|given (r_nsubjpass) constructed_18\VBN|curves|were|for (r_ccomp) inflammation_38\NN|constructed|:|induced|paw|and|streptozotocin|neuropathy|. (l_appos) neuropathy_44\NN|(|stz)-induced|diabetic
C401121_D010146 NONE CNSB002_9\NNP| (r_conj) morphine_7\NN|and|cnsb002 (r_pobj) of_6\IN|morphine (r_prep) doses_5\NNS|nonsedating|of (r_pobj) for_3\IN|doses (r_prep) curves_2\VBZ|response|for|given (r_nsubjpass) constructed_18\VBN|curves|were|for (l_prep) for_19\IN|effect (l_pobj) effect_21\NN|antihyperalgesic|using (l_acl) using_22\VBG|withdrawal|in (l_prep) in_28\IN|models (l_pobj) models_32\NNS|two|rat|pain (l_compound) pain_31\NN|
C401121_D007249 NONE CNSB002_9\NNP| (r_conj) morphine_7\NN|and|cnsb002 (r_pobj) of_6\IN|morphine (r_prep) doses_5\NNS|nonsedating|of (r_pobj) for_3\IN|doses (r_prep) curves_2\VBZ|response|for|given (r_nsubjpass) constructed_18\VBN|curves|were|for (r_ccomp) inflammation_38\NN|constructed|:|induced|paw|and|streptozotocin|neuropathy|.
C401121_D003929 NONE CNSB002_9\NNP| (r_conj) morphine_7\NN|and|cnsb002 (r_pobj) of_6\IN|morphine (r_prep) doses_5\NNS|nonsedating|of (r_pobj) for_3\IN|doses (r_prep) curves_2\VBZ|response|for|given (r_nsubjpass) constructed_18\VBN|curves|were|for (r_ccomp) inflammation_38\NN|constructed|:|induced|paw|and|streptozotocin|neuropathy|. (l_appos) neuropathy_44\NN|(|stz)-induced|diabetic
D002351_D010146 NONE carrageenan_34\NN| (r_npadvmod) induced_36\VBN|carrageenan|- (r_amod) inflammation_38\NN|constructed|:|induced|paw|and|streptozotocin|neuropathy|. (l_ccomp) constructed_18\VBN|curves|were|for (l_prep) for_19\IN|effect (l_pobj) effect_21\NN|antihyperalgesic|using (l_acl) using_22\VBG|withdrawal|in (l_prep) in_28\IN|models (l_pobj) models_32\NNS|two|rat|pain (l_compound) pain_31\NN|
D002351_D007249 CID carrageenan_34\NN| (r_npadvmod) induced_36\VBN|carrageenan|- (r_amod) inflammation_38\NN|constructed|:|induced|paw|and|streptozotocin|neuropathy|.
D002351_D003929 NONE carrageenan_34\NN| (r_npadvmod) induced_36\VBN|carrageenan|- (r_amod) inflammation_38\NN|constructed|:|induced|paw|and|streptozotocin|neuropathy|. (l_appos) neuropathy_44\NN|(|stz)-induced|diabetic
D013311_D010146 NONE streptozotocin_40\JJ| (r_conj) inflammation_38\NN|constructed|:|induced|paw|and|streptozotocin|neuropathy|. (l_ccomp) constructed_18\VBN|curves|were|for (l_prep) for_19\IN|effect (l_pobj) effect_21\NN|antihyperalgesic|using (l_acl) using_22\VBG|withdrawal|in (l_prep) in_28\IN|models (l_pobj) models_32\NNS|two|rat|pain (l_compound) pain_31\NN|
D013311_D010146 NONE STZ)-induced_42\VBN| (r_amod) neuropathy_44\NN|(|stz)-induced|diabetic (r_appos) inflammation_38\NN|constructed|:|induced|paw|and|streptozotocin|neuropathy|. (l_ccomp) constructed_18\VBN|curves|were|for (l_prep) for_19\IN|effect (l_pobj) effect_21\NN|antihyperalgesic|using (l_acl) using_22\VBG|withdrawal|in (l_prep) in_28\IN|models (l_pobj) models_32\NNS|two|rat|pain (l_compound) pain_31\NN|
D013311_D007249 NONE streptozotocin_40\JJ| (r_conj) inflammation_38\NN|constructed|:|induced|paw|and|streptozotocin|neuropathy|.
D013311_D007249 NONE STZ)-induced_42\VBN| (r_amod) neuropathy_44\NN|(|stz)-induced|diabetic (r_appos) inflammation_38\NN|constructed|:|induced|paw|and|streptozotocin|neuropathy|.
D013311_D003929 CID streptozotocin_40\JJ| (r_conj) inflammation_38\NN|constructed|:|induced|paw|and|streptozotocin|neuropathy|. (l_appos) neuropathy_44\NN|(|stz)-induced|diabetic
D013311_D003929 CID STZ)-induced_42\VBN| (r_amod) neuropathy_44\NN|(|stz)-induced|diabetic
D002351_D006930 CID carrageenan_25\NN| (r_compound) model_26\NN|the|carrageenan (r_pobj) in_23\IN|model (r_prep) 4.83_19\CD|1.54|in|and|44.18|1.37|and|9.14 (r_conj) 7.54_14\CD|(|1.81|)|and|4.83|in|,|sem|) (r_attr) were_13\VBD|doses|7.54|. (l_nsubj) doses_1\NNS|the|calculated|(|ed50|) (l_acl) calculated_2\VBN|cause (l_advcl) cause_4\VB|to|reversal (l_dobj) reversal_7\NN|%|of (l_prep) of_8\IN|hyperalgesia (l_pobj) hyperalgesia_9\NN|
D002351_D009422 NONE carrageenan_25\NN| (r_compound) model_26\NN|the|carrageenan (r_pobj) in_23\IN|model (r_prep) 4.83_19\CD|1.54|in|and|44.18|1.37|and|9.14 (r_conj) 7.54_14\CD|(|1.81|)|and|4.83|in|,|sem|) (l_prep) in_37\IN|model (l_pobj) model_43\NN|the|induced|neuropathy|for (l_compound) neuropathy_42\NN|
D002351_D009422 NONE carrageenan_29\NN| (r_compound) model_30\NN|the|carrageenan (r_pobj) in_27\IN|model (r_prep) dose_21\NN|the|maximum|nonsedating|1.55|in (r_pobj) than_17\IN|dose (r_prep) less_16\JJR|than|and|1.37 (l_conj) 1.37_32\CD|1.23|in (l_prep) in_36\IN|model|sem (l_pobj) model_39\NN|the|neuropathy (l_compound) neuropathy_38\NN|
D013311_D006930 CID STZ_39\NNP| (r_npadvmod) induced_41\VBN|stz|- (r_amod) model_43\NN|the|induced|neuropathy|for (r_pobj) in_37\IN|model (r_prep) 7.54_14\CD|(|1.81|)|and|4.83|in|,|sem|) (r_attr) were_13\VBD|doses|7.54|. (l_nsubj) doses_1\NNS|the|calculated|(|ed50|) (l_acl) calculated_2\VBN|cause (l_advcl) cause_4\VB|to|reversal (l_dobj) reversal_7\NN|%|of (l_prep) of_8\IN|hyperalgesia (l_pobj) hyperalgesia_9\NN|
D013311_D009422 NONE STZ_39\NNP| (r_npadvmod) induced_41\VBN|stz|- (r_amod) model_43\NN|the|induced|neuropathy|for (l_compound) neuropathy_42\NN|
C401121_D006930 NONE CNSB002_45\NNP|and|morphine (r_pobj) for_44\IN|cnsb002 (r_prep) model_43\NN|the|induced|neuropathy|for (r_pobj) in_37\IN|model (r_prep) 7.54_14\CD|(|1.81|)|and|4.83|in|,|sem|) (r_attr) were_13\VBD|doses|7.54|. (l_nsubj) doses_1\NNS|the|calculated|(|ed50|) (l_acl) calculated_2\VBN|cause (l_advcl) cause_4\VB|to|reversal (l_dobj) reversal_7\NN|%|of (l_prep) of_8\IN|hyperalgesia (l_pobj) hyperalgesia_9\NN|
C401121_D006930 NONE CNSB002_15\NNP| (r_pobj) with_14\IN|administration|cnsb002 (r_punct) from_16\IN|with|28.0|to|and|reversal (l_conj) reversal_26\NN|%|of|in|,|respectively|(|p (l_prep) of_27\IN|hyperalgesia (l_pobj) hyperalgesia_28\NN|
C401121_D009422 NONE CNSB002_45\NNP|and|morphine (r_pobj) for_44\IN|cnsb002 (r_prep) model_43\NN|the|induced|neuropathy|for (l_compound) neuropathy_42\NN|
C401121_D009422 NONE CNSB002_10\NNP| (r_pobj) with_9\IN|cnsb002 (r_prep) combination_8\NN|with (r_pobj) in_7\IN|combination (r_prep) given_6\VBN|when|in|mg/kg (r_advcl) values_2\NNS|the|ed50|for|given (r_nsubj) were_15\VBD|values|less|. (l_acomp) less_16\JJR|than|and|1.37 (l_conj) 1.37_32\CD|1.23|in (l_prep) in_36\IN|model|sem (l_pobj) model_39\NN|the|neuropathy (l_compound) neuropathy_38\NN|
C401121_D009422 NONE CNSB002_15\NNP| (r_pobj) with_14\IN|administration|cnsb002 (r_punct) from_16\IN|with|28.0|to|and|reversal (l_conj) reversal_26\NN|%|of|in|,|respectively|(|p (l_prep) in_29\IN|models (l_pobj) models_34\NNS|the|inflammatory (l_amod) inflammatory_31\JJ|and|neuropathic (l_conj) neuropathic_33\JJ|
D009020_D006930 NONE morphine_47\NN| (r_conj) CNSB002_45\NNP|and|morphine (r_pobj) for_44\IN|cnsb002 (r_prep) model_43\NN|the|induced|neuropathy|for (r_pobj) in_37\IN|model (r_prep) 7.54_14\CD|(|1.81|)|and|4.83|in|,|sem|) (r_attr) were_13\VBD|doses|7.54|. (l_nsubj) doses_1\NNS|the|calculated|(|ed50|) (l_acl) calculated_2\VBN|cause (l_advcl) cause_4\VB|to|reversal (l_dobj) reversal_7\NN|%|of (l_prep) of_8\IN|hyperalgesia (l_pobj) hyperalgesia_9\NN|
D009020_D006930 NONE morphine_3\NN| (r_pobj) after_2\IN|morphine (r_prep) antinociception_1\NN|the|after|(|mg/kg|) (r_nsubjpass) increased_9\VBN|antinociception|was|from|. (l_prep) from_16\IN|with|28.0|to|and|reversal (l_conj) reversal_26\NN|%|of|in|,|respectively|(|p (l_prep) of_27\IN|hyperalgesia (l_pobj) hyperalgesia_28\NN|
D009020_D009422 NONE morphine_47\NN| (r_conj) CNSB002_45\NNP|and|morphine (r_pobj) for_44\IN|cnsb002 (r_prep) model_43\NN|the|induced|neuropathy|for (l_compound) neuropathy_42\NN|
D009020_D009422 NONE morphine_4\NN| (r_pobj) for_3\IN|morphine (r_prep) values_2\NNS|the|ed50|for|given (r_nsubj) were_15\VBD|values|less|. (l_acomp) less_16\JJR|than|and|1.37 (l_conj) 1.37_32\CD|1.23|in (l_prep) in_36\IN|model|sem (l_pobj) model_39\NN|the|neuropathy (l_compound) neuropathy_38\NN|
D009020_D009422 NONE morphine_3\NN| (r_pobj) after_2\IN|morphine (r_prep) antinociception_1\NN|the|after|(|mg/kg|) (r_nsubjpass) increased_9\VBN|antinociception|was|from|. (l_prep) from_16\IN|with|28.0|to|and|reversal (l_conj) reversal_26\NN|%|of|in|,|respectively|(|p (l_prep) in_29\IN|models (l_pobj) models_34\NNS|the|inflammatory (l_amod) inflammatory_31\JJ|and|neuropathic (l_conj) neuropathic_33\JJ|
1760851
D004317_D066126 CID doxorubicin_3\NN|given (r_pobj) of_2\IN|doxorubicin (r_prep) cardiotoxicity_1\NN|reduced|of|:|and|study|.
D004317_D066126 CID doxorubicin_18\NN|mg/kg|dox (r_pobj) of_15\IN|doxorubicin (r_prep) cardiotoxicity_14\NN|the|late|of
D004317_D066126 CID DOX_20\NNP|(|) (r_appos) doxorubicin_18\NN|mg/kg|dox (r_pobj) of_15\IN|doxorubicin (r_prep) cardiotoxicity_14\NN|the|late|of
D004317_D066126 CID DOX_21\NNP|free|or|mixture (r_dobj) received_18\VBD|that|dox (r_relcl) animals_16\NNS|received (r_pobj) in_15\IN|only|animals (r_prep) observed_13\VBN|throughout|,|deaths|were|in (l_nsubjpass) deaths_8\NNS|related (l_acl) related_9\VBN|to (l_prep) to_10\IN|cardiotoxicity (l_pobj) cardiotoxicity_11\NN|
D004317_D066126 CID DOX_21\NNP|free|or|mixture (r_dobj) received_18\VBD|that|dox (r_relcl) animals_16\NNS|received (r_pobj) in_15\IN|only|animals (r_prep) observed_13\VBN|throughout|,|deaths|were|in (r_ccomp) revealed_38\VBD|observed|;|in|,|investigations|changes|. (l_dobj) changes_40\NNS|marked|in|were (l_relcl) were_45\VBD|that|consistent (l_acomp) consistent_46\JJ|with (l_prep) with_47\IN|cardiotoxicity (l_pobj) cardiotoxicity_51\NN|induced
D004317_D066126 CID DOX_30\NNP|free (r_conj) copolymer_27\NN|hpma|and|dox (r_pobj) of_25\IN|copolymer (r_prep) mixture_24\NN|the|of (r_conj) DOX_21\NNP|free|or|mixture (r_dobj) received_18\VBD|that|dox (r_relcl) animals_16\NNS|received (r_pobj) in_15\IN|only|animals (r_prep) observed_13\VBN|throughout|,|deaths|were|in (l_nsubjpass) deaths_8\NNS|related (l_acl) related_9\VBN|to (l_prep) to_10\IN|cardiotoxicity (l_pobj) cardiotoxicity_11\NN|
D004317_D066126 CID DOX_30\NNP|free (r_conj) copolymer_27\NN|hpma|and|dox (r_pobj) of_25\IN|copolymer (r_prep) mixture_24\NN|the|of (r_conj) DOX_21\NNP|free|or|mixture (r_dobj) received_18\VBD|that|dox (r_relcl) animals_16\NNS|received (r_pobj) in_15\IN|only|animals (r_prep) observed_13\VBN|throughout|,|deaths|were|in (r_ccomp) revealed_38\VBD|observed|;|in|,|investigations|changes|. (l_dobj) changes_40\NNS|marked|in|were (l_relcl) were_45\VBD|that|consistent (l_acomp) consistent_46\JJ|with (l_prep) with_47\IN|cardiotoxicity (l_pobj) cardiotoxicity_51\NN|induced
D004317_D066126 CID DOX_48\NNP| (r_npadvmod) induced_50\VBN|dox|- (r_amod) cardiotoxicity_51\NN|induced (r_pobj) with_47\IN|cardiotoxicity (r_prep) consistent_46\JJ|with (r_acomp) were_45\VBD|that|consistent (r_relcl) changes_40\NNS|marked|in|were (r_dobj) revealed_38\VBD|observed|;|in|,|investigations|changes|. (l_ccomp) observed_13\VBN|throughout|,|deaths|were|in (l_nsubjpass) deaths_8\NNS|related (l_acl) related_9\VBN|to (l_prep) to_10\IN|cardiotoxicity (l_pobj) cardiotoxicity_11\NN|
D004317_D066126 CID DOX_48\NNP| (r_npadvmod) induced_50\VBN|dox|- (r_amod) cardiotoxicity_51\NN|induced
C032976_D066126 NONE N-(2-hydroxypropyl)methacrylamide_9\JJ| (r_compound) conjugates_10\NNS|n-(2-hydroxypropyl)methacrylamide (r_pobj) of_8\IN|conjugates (r_prep) form_7\NN|the|of (r_pobj) in_5\IN|form (r_prep) given_4\VBN|in (r_acl) doxorubicin_3\NN|given (r_pobj) of_2\IN|doxorubicin (r_prep) cardiotoxicity_1\NN|reduced|of|:|and|study|.
C032976_D066126 NONE N-(2-hydroxypropyl)methacrylamide_33\NN| (r_nmod) conjugates_38\NNS|three|n-(2-hydroxypropyl)methacrylamide|copolymer (r_pobj) of_31\IN|conjugates (r_prep) form_30\NN|the|of (r_pobj) in_28\IN|form (r_conj) as_24\IN|either|drug|or|in (r_prep) given_22\VBN|as (r_prep) used_4\VBN|model|was|evaluate|given|. (l_xcomp) evaluate_6\VB|to|toxicity (l_dobj) toxicity_10\NN|the|general|acute|and|cardiotoxicity (l_conj) cardiotoxicity_14\NN|the|late|of
C032976_D066126 NONE HPMA_35\NNP| (r_nmod) copolymer_37\NN|(|hpma|) (r_compound) conjugates_38\NNS|three|n-(2-hydroxypropyl)methacrylamide|copolymer (r_pobj) of_31\IN|conjugates (r_prep) form_30\NN|the|of (r_pobj) in_28\IN|form (r_conj) as_24\IN|either|drug|or|in (r_prep) given_22\VBN|as (r_prep) used_4\VBN|model|was|evaluate|given|. (l_xcomp) evaluate_6\VB|to|toxicity (l_dobj) toxicity_10\NN|the|general|acute|and|cardiotoxicity (l_conj) cardiotoxicity_14\NN|the|late|of
C032976_D066126 NONE HPMA_26\NNP| (r_compound) copolymer_27\NN|hpma|and|dox (r_pobj) of_25\IN|copolymer (r_prep) mixture_24\NN|the|of (r_conj) DOX_21\NNP|free|or|mixture (r_dobj) received_18\VBD|that|dox (r_relcl) animals_16\NNS|received (r_pobj) in_15\IN|only|animals (r_prep) observed_13\VBN|throughout|,|deaths|were|in (l_nsubjpass) deaths_8\NNS|related (l_acl) related_9\VBN|to (l_prep) to_10\IN|cardiotoxicity (l_pobj) cardiotoxicity_11\NN|
C032976_D066126 NONE HPMA_26\NNP| (r_compound) copolymer_27\NN|hpma|and|dox (r_pobj) of_25\IN|copolymer (r_prep) mixture_24\NN|the|of (r_conj) DOX_21\NNP|free|or|mixture (r_dobj) received_18\VBD|that|dox (r_relcl) animals_16\NNS|received (r_pobj) in_15\IN|only|animals (r_prep) observed_13\VBN|throughout|,|deaths|were|in (r_ccomp) revealed_38\VBD|observed|;|in|,|investigations|changes|. (l_dobj) changes_40\NNS|marked|in|were (l_relcl) were_45\VBD|that|consistent (l_acomp) consistent_46\JJ|with (l_prep) with_47\IN|cardiotoxicity (l_pobj) cardiotoxicity_51\NN|induced
D004317_D064420 NONE doxorubicin_18\NN|mg/kg|dox (r_pobj) of_15\IN|doxorubicin (r_prep) cardiotoxicity_14\NN|the|late|of (r_conj) toxicity_10\NN|the|general|acute|and|cardiotoxicity
D004317_D064420 NONE DOX_20\NNP|(|) (r_appos) doxorubicin_18\NN|mg/kg|dox (r_pobj) of_15\IN|doxorubicin (r_prep) cardiotoxicity_14\NN|the|late|of (r_conj) toxicity_10\NN|the|general|acute|and|cardiotoxicity
C032976_D064420 NONE N-(2-hydroxypropyl)methacrylamide_33\NN| (r_nmod) conjugates_38\NNS|three|n-(2-hydroxypropyl)methacrylamide|copolymer (r_pobj) of_31\IN|conjugates (r_prep) form_30\NN|the|of (r_pobj) in_28\IN|form (r_conj) as_24\IN|either|drug|or|in (r_prep) given_22\VBN|as (r_prep) used_4\VBN|model|was|evaluate|given|. (l_xcomp) evaluate_6\VB|to|toxicity (l_dobj) toxicity_10\NN|the|general|acute|and|cardiotoxicity
C032976_D064420 NONE HPMA_35\NNP| (r_nmod) copolymer_37\NN|(|hpma|) (r_compound) conjugates_38\NNS|three|n-(2-hydroxypropyl)methacrylamide|copolymer (r_pobj) of_31\IN|conjugates (r_prep) form_30\NN|the|of (r_pobj) in_28\IN|form (r_conj) as_24\IN|either|drug|or|in (r_prep) given_22\VBN|as (r_prep) used_4\VBN|model|was|evaluate|given|. (l_xcomp) evaluate_6\VB|to|toxicity (l_dobj) toxicity_10\NN|the|general|acute|and|cardiotoxicity
6305660
25986755
D002110_D005921 NONE caffeine_18\NN|prenatal (r_compound) exposure_19\NN|caffeine (r_pobj) by_16\IN|exposure (r_agent) induced_15\VBN|by (r_acl) offspring_14\NN|adult|induced (r_pobj) in_12\IN|offspring (r_prep) mediates_6\VBZ|programming|origin|in|. (l_dobj) origin_9\NN|the|developmental|of (l_prep) of_10\IN|glomerulosclerosis (l_pobj) glomerulosclerosis_11\NN|
D002110_D005317 CID caffeine_7\NN|prenatal (r_compound) exposure_8\NN|caffeine|pce (r_nsubj) induce_13\VB|that|exposure|could|retardation (l_dobj) retardation_16\NN|intrauterine|growth|iugr
D002110_D005317 CID caffeine_7\NN|prenatal (r_compound) exposure_8\NN|caffeine|pce (r_nsubj) induce_13\VB|that|exposure|could|retardation (l_dobj) retardation_16\NN|intrauterine|growth|iugr (l_appos) IUGR_18\NNP|(|)|of
D003404_D005921 NONE creatinine_26\NN|serum|and|urine (r_nmod) protein_29\NN|creatinine (r_pobj) of_24\IN|protein (r_prep) levels_23\NNS|elevated|of (r_pobj) by_21\IN|levels (r_agent) accompanied_20\VBN|by (r_advcl) exhibited_12\VBD|that|kidneys|glomerulosclerosis|accompanied (l_dobj) glomerulosclerosis_13\NN|as|fibrosis
D003404_D005355 NONE creatinine_26\NN|serum|and|urine (r_nmod) protein_29\NN|creatinine (r_pobj) of_24\IN|protein (r_prep) levels_23\NNS|elevated|of (r_pobj) by_21\IN|levels (r_agent) accompanied_20\VBN|by (r_advcl) exhibited_12\VBD|that|kidneys|glomerulosclerosis|accompanied (l_dobj) glomerulosclerosis_13\NN|as|fibrosis (l_conj) fibrosis_18\NN|interstitial|,
573555
D011433_D007003 NONE propranolol_27\NN| (r_amod) therapy_28\NN|chronic|propranolol (r_pobj) with_25\IN|therapy (r_prep) correlated_24\VBN|can|not|be|statistically|with (r_conj) are_16\VBP|that|hypoglycemia|not|invariable|and|correlated (l_nsubj) hypoglycemia_5\NN|reported|,|hyperbilirubinemia
D011433_D006932 NONE propranolol_27\NN| (r_amod) therapy_28\NN|chronic|propranolol (r_pobj) with_25\IN|therapy (r_prep) correlated_24\VBN|can|not|be|statistically|with (r_conj) are_16\VBP|that|hypoglycemia|not|invariable|and|correlated (l_nsubj) hypoglycemia_5\NN|reported|,|hyperbilirubinemia (l_conj) hyperbilirubinemia_7\NN|,|polycythemia
D011433_D011086 NONE propranolol_27\NN| (r_amod) therapy_28\NN|chronic|propranolol (r_pobj) with_25\IN|therapy (r_prep) correlated_24\VBN|can|not|be|statistically|with (r_conj) are_16\VBP|that|hypoglycemia|not|invariable|and|correlated (l_nsubj) hypoglycemia_5\NN|reported|,|hyperbilirubinemia (l_conj) hyperbilirubinemia_7\NN|,|polycythemia (l_conj) polycythemia_9\NN|,|apnea
D011433_D001049 NONE propranolol_27\NN| (r_amod) therapy_28\NN|chronic|propranolol (r_pobj) with_25\IN|therapy (r_prep) correlated_24\VBN|can|not|be|statistically|with (r_conj) are_16\VBP|that|hypoglycemia|not|invariable|and|correlated (l_nsubj) hypoglycemia_5\NN|reported|,|hyperbilirubinemia (l_conj) hyperbilirubinemia_7\NN|,|polycythemia (l_conj) polycythemia_9\NN|,|apnea (l_conj) apnea_12\NN|neonatal|,|and|bradycardia
D011433_D001919 NONE propranolol_27\NN| (r_amod) therapy_28\NN|chronic|propranolol (r_pobj) with_25\IN|therapy (r_prep) correlated_24\VBN|can|not|be|statistically|with (r_conj) are_16\VBP|that|hypoglycemia|not|invariable|and|correlated (l_nsubj) hypoglycemia_5\NN|reported|,|hyperbilirubinemia (l_conj) hyperbilirubinemia_7\NN|,|polycythemia (l_conj) polycythemia_9\NN|,|apnea (l_conj) apnea_12\NN|neonatal|,|and|bradycardia (l_conj) bradycardia_15\NN|
9831002
D008774_D009459 CID methylphenidate_4\NN| (r_conj) syndrome_2\NN|neuroleptic|malignant|and|methylphenidate|.
D008774_D009459 CID methylphenidate_13\NN| (r_pobj) by_12\IN|methylphenidate (r_agent) caused_11\VBN|presented|probably|by|. (l_nsubj) presented_5\VBN|female|with (l_prep) with_6\IN|syndrome (l_pobj) syndrome_9\NN|neuroleptic|malignant
D008774_D009459 CID methylphenidate_13\NN| (r_pobj) by_12\IN|methylphenidate (r_agent) caused_11\VBN|probably|by (r_acl) patient_5\JJ|the|first|reported|with|caused (l_prep) with_6\IN|syndrome (l_pobj) syndrome_9\NN|neuroleptic|malignant
2320485
D008750_D000743 CID Methyldopa_0\NNP| (r_nsubj) induced_2\VBN|methyldopa|-|anemia|in|presenting|. (l_dobj) anemia_4\NN|hemolytic
D008750_D000743 CID methyldopa_5\NN| (r_npadvmod) induced_7\VBN|methyldopa|- (r_amod) anemia_9\NN|induced|hemolytic|in
D008750_D013575 NONE Methyldopa_0\NNP| (r_nsubj) induced_2\VBN|methyldopa|-|anemia|in|presenting|. (l_advcl) presenting_10\VBG|as (l_prep) as_11\IN|syncope (l_pobj) syncope_14\NN|near|-
D008750_D013575 NONE methyldopa_5\NN| (r_npadvmod) induced_7\VBN|methyldopa|- (r_amod) anemia_9\NN|induced|hemolytic|in (l_prep) in_10\IN|boy (l_pobj) boy_15\NN|a|old|presented (l_relcl) presented_17\VBD|who|to|with (l_prep) with_22\IN|syncope (l_pobj) syncope_25\NN|near|-
D008750_D000744 NONE Methyldopa_0\NNP| (r_nsubj) causes_1\VBZ|methyldopa|anemia|. (l_dobj) anemia_5\NN|an|autoimmune|hemolytic|in
D008750_D004630 NONE methyldopa_5\NN| (r_npadvmod) induced_7\VBN|methyldopa|- (r_amod) anemia_9\NN|induced|hemolytic|in (l_prep) in_10\IN|boy (l_pobj) boy_15\NN|a|old|presented (l_relcl) presented_17\VBD|who|to|with (l_prep) to_18\IN|department (l_pobj) department_21\NN|the|emergency
D008750_D014947 NONE methyldopa_7\NN|intravenous (r_pobj) with_5\IN|methyldopa (r_prep) treated_4\VBN|boy|had|been|with|during|. (l_prep) during_8\IN|admission (l_pobj) admission_11\NN|a|trauma|prior (l_compound) trauma_10\NN|
1451544
D017275_D006973 NONE Isradipine_0\NNP| (r_compound) treatment_1\NN|isradipine|for|. (l_prep) for_2\IN|hypertension (l_pobj) hypertension_3\NN|in|in
D017275_D006261 CID isradipine_25\NN| (r_pobj) with_24\IN|isradipine|or|with (r_prep) studies_23\NNS|other|with (r_pobj) in_21\IN|studies (r_prep) reported_20\VBN|than|in (r_advcl) frequent_18\JJ|more|reported (r_acomp) were_15\VBD|headache|not|frequent (l_nsubj) headache_6\NN|,|dizziness
D017275_D004244 CID isradipine_25\NN| (r_pobj) with_24\IN|isradipine|or|with (r_prep) studies_23\NNS|other|with (r_pobj) in_21\IN|studies (r_prep) reported_20\VBN|than|in (r_advcl) frequent_18\JJ|more|reported (r_acomp) were_15\VBD|headache|not|frequent (l_nsubj) headache_6\NN|,|dizziness (l_conj) dizziness_8\NN|,|palpitation
D017275_-1 NONE isradipine_25\NN| (r_pobj) with_24\IN|isradipine|or|with (r_prep) studies_23\NNS|other|with (r_pobj) in_21\IN|studies (r_prep) reported_20\VBN|than|in (r_advcl) frequent_18\JJ|more|reported (r_acomp) were_15\VBD|headache|not|frequent (l_nsubj) headache_6\NN|,|dizziness (l_conj) dizziness_8\NN|,|palpitation (l_conj) palpitation_10\NN|and|flushing|and|these
D017275_D005483 CID isradipine_25\NN| (r_pobj) with_24\IN|isradipine|or|with (r_prep) studies_23\NNS|other|with (r_pobj) in_21\IN|studies (r_prep) reported_20\VBN|than|in (r_advcl) frequent_18\JJ|more|reported (r_acomp) were_15\VBD|headache|not|frequent (l_nsubj) headache_6\NN|,|dizziness (l_conj) dizziness_8\NN|,|palpitation (l_conj) palpitation_10\NN|and|flushing|and|these (l_conj) flushing_12\NN|
3083835
D010406_D000707 CID Penicillin_0\NNP| (r_compound) anaphylaxis_1\NN|penicillin|.
D010406_D000707 CID penicillin_4\NN| (r_compound) anaphylaxis_5\NN|oral|penicillin
D010406_D000707 CID penicillin_4\NN| (r_compound) anaphylaxis_5\NN|oral|penicillin (r_pobj) of_2\IN|anaphylaxis (r_prep) case_1\NN|a|of (r_nsubjpass) described_7\VBN|case|is|,|and|reviewed (l_conj) reviewed_27\VBN|terminology|are|. (l_nsubjpass) terminology_11\NN|the|,|occurrence (l_conj) occurrence_13\NN|,|manifestations (l_conj) manifestations_16\NNS|clinical|,|pathogenesis (l_conj) pathogenesis_18\NN|,|prevention (l_conj) prevention_20\NN|,|and|treatment (l_conj) treatment_23\NN|of (l_prep) of_24\IN|anaphylaxis (l_pobj) anaphylaxis_25\NN|
D010406_D000707 CID penicillin_7\NN| (r_compound) anaphylaxis_8\NN|oral|penicillin
16723784
D015764_D001281 NONE bepridil_6\NN| (r_amod) administration_7\NN|bepridil (r_pobj) during_5\IN|administration (r_prep) effects_4\NNS|adverse|during|for (l_prep) for_8\IN|fibrillation (l_pobj) fibrillation_10\NN|atrial|and|flutter (l_conj) flutter_12\JJ|
D015764_D001281 NONE hydrochloride_1\NN|bpd (r_nsubj) attracted_6\VBN|bepridil|hydrochloride|has|attention|as|. (l_prep) as_8\IN|drug (l_pobj) drug_11\NN|an|effective|for (l_prep) for_12\IN|fibrillation (l_pobj) fibrillation_14\NN|atrial|(|af|flutter
D015764_D001281 NONE hydrochloride_1\NN|bpd (r_nsubj) attracted_6\VBN|bepridil|hydrochloride|has|attention|as|. (l_prep) as_8\IN|drug (l_pobj) drug_11\NN|an|effective|for (l_prep) for_12\IN|fibrillation (l_pobj) fibrillation_14\NN|atrial|(|af|flutter (l_appos) AF_16\NNP|)|and
D015764_D001281 NONE Bpd_3\NNP|(|) (r_appos) hydrochloride_1\NN|bpd (r_nsubj) attracted_6\VBN|bepridil|hydrochloride|has|attention|as|. (l_prep) as_8\IN|drug (l_pobj) drug_11\NN|an|effective|for (l_prep) for_12\IN|fibrillation (l_pobj) fibrillation_14\NN|atrial|(|af|flutter
D015764_D001281 NONE Bpd_3\NNP|(|) (r_appos) hydrochloride_1\NN|bpd (r_nsubj) attracted_6\VBN|bepridil|hydrochloride|has|attention|as|. (l_prep) as_8\IN|drug (l_pobj) drug_11\NN|an|effective|for (l_prep) for_12\IN|fibrillation (l_pobj) fibrillation_14\NN|atrial|(|af|flutter (l_appos) AF_16\NNP|)|and
D015764_D001281 NONE Bpd_0\NNP| (r_nsubjpass) administered_2\VBN|bpd|was|to|. (l_prep) to_3\IN|patients (l_pobj) patients_5\NNS|459|(|males|)|comprising (l_acl) comprising_14\VBG|cases (l_dobj) cases_20\NNS|378|af|81|afl (l_nmod) AF_16\NNP|and
D015764_D001282 NONE bepridil_6\NN| (r_amod) administration_7\NN|bepridil (r_pobj) during_5\IN|administration (r_prep) effects_4\NNS|adverse|during|for (l_prep) for_8\IN|fibrillation (l_pobj) fibrillation_10\NN|atrial|and|flutter (l_conj) flutter_12\JJ|
D015764_D001282 NONE hydrochloride_1\NN|bpd (r_nsubj) attracted_6\VBN|bepridil|hydrochloride|has|attention|as|. (l_prep) as_8\IN|drug (l_pobj) drug_11\NN|an|effective|for (l_prep) for_12\IN|fibrillation (l_pobj) fibrillation_14\NN|atrial|(|af|flutter (l_conj) flutter_20\NN|atrial|(|afl|)
D015764_D001282 NONE hydrochloride_1\NN|bpd (r_nsubj) attracted_6\VBN|bepridil|hydrochloride|has|attention|as|. (l_prep) as_8\IN|drug (l_pobj) drug_11\NN|an|effective|for (l_prep) for_12\IN|fibrillation (l_pobj) fibrillation_14\NN|atrial|(|af|flutter (l_conj) flutter_20\NN|atrial|(|afl|) (l_appos) AFL_22\NNP|
D015764_D001282 NONE Bpd_3\NNP|(|) (r_appos) hydrochloride_1\NN|bpd (r_nsubj) attracted_6\VBN|bepridil|hydrochloride|has|attention|as|. (l_prep) as_8\IN|drug (l_pobj) drug_11\NN|an|effective|for (l_prep) for_12\IN|fibrillation (l_pobj) fibrillation_14\NN|atrial|(|af|flutter (l_conj) flutter_20\NN|atrial|(|afl|)
D015764_D001282 NONE Bpd_3\NNP|(|) (r_appos) hydrochloride_1\NN|bpd (r_nsubj) attracted_6\VBN|bepridil|hydrochloride|has|attention|as|. (l_prep) as_8\IN|drug (l_pobj) drug_11\NN|an|effective|for (l_prep) for_12\IN|fibrillation (l_pobj) fibrillation_14\NN|atrial|(|af|flutter (l_conj) flutter_20\NN|atrial|(|afl|) (l_appos) AFL_22\NNP|
D015764_D001282 NONE Bpd_0\NNP| (r_nsubjpass) administered_2\VBN|bpd|was|to|. (l_prep) to_3\IN|patients (l_pobj) patients_5\NNS|459|(|males|)|comprising (l_acl) comprising_14\VBG|cases (l_dobj) cases_20\NNS|378|af|81|afl (l_compound) AFL_19\NNP|
25080425
D001622_D009202 NONE betaine_13\NN| (r_pobj) by_12\IN|betaine (r_prep) Regulation_0\NN|of|by (r_nsubj) attenuates_14\VBZ|regulation|injury|. (l_dobj) injury_20\NN|induced|acute|myocardial|in
D001622_D009202 NONE betaine_4\NN|on (l_prep) on_5\IN|damage (l_pobj) damage_7\NN|myocardial
D007545_D009202 NONE isoproterenol_15\NN| (r_npadvmod) induced_17\VBN|isoproterenol|- (r_amod) injury_20\NN|induced|acute|myocardial|in
D001622_D017202 NONE betaine_11\NN| (r_pobj) of_10\IN|betaine (r_prep) effects_9\NNS|the|cardioprotective|of|on|induced (l_prep) on_12\IN|ischemia (l_pobj) ischemia_15\NN|acute|myocardial
D001622_D017202 NONE betaine_7\NN| (r_compound) pretreatment_8\NN|betaine (r_nsubj) attenuated_9\VBD|pretreatment (r_amod) ischemia_15\NN|that|attenuated|induced|acute|myocardial|via
D007545_D017202 CID isoproterenol_12\NN| (r_pobj) of_11\IN|isoproterenol (r_prep) injection_10\NN|subcutaneous|of|(|mg/kg|) (r_pobj) by_8\IN|injection (r_agent) induced_5\VBN|injury|was|in|by|,|for|. (l_nsubjpass) injury_3\NN|acute|myocardial|ischemic
D007545_D017202 CID isoproterenol_10\NN| (r_npadvmod) induced_12\VBN|isoproterenol|- (r_amod) ischemia_15\NN|that|attenuated|induced|acute|myocardial|via
D001622_D020257 NONE betaine_3\NN| (r_pobj) of_2\IN|betaine (r_prep) administration_1\NN|oral|of|mg/kg (r_nsubj) reduced_11\VBD|administration|significantly|level|and|prevented|. (l_conj) prevented_22\VBN|remodeling (l_dobj) remodeling_25\NN|left|ventricular
2931989
D015474_D000152 NONE isotretinoin_13\JJ| (r_dobj) received_12\VBD|who|isotretinoin (r_relcl) patients_10\NNS|237|received|,|drug (l_appos) drug_18\NN|a|used|in (l_prep) in_19\IN|treatment (l_pobj) treatment_21\NN|the|of (l_prep) of_22\IN|acne (l_pobj) acne_25\NN|severe|cystic
D015474_D000013 NONE Isotretinoin_0\NNP| (r_nsubjpass) contraindicated_2\VBN|isotretinoin|is|in|because|. (l_prep) because_5\IN|of|abnormalities (l_pobj) abnormalities_11\NNS|the|many|reported|congenital|after
D015474_D008850 NONE Isotretinoin_0\NNP| (r_nsubjpass) contraindicated_2\VBN|isotretinoin|is|in|because|. (l_prep) because_5\IN|of|abnormalities (l_pobj) abnormalities_11\NNS|the|many|reported|congenital|after (l_prep) after_12\IN|use (l_pobj) use_14\NN|maternal|(|including|) (l_prep) including_16\VBG|microphthalmos (l_pobj) microphthalmos_17\NNS|,|hypertelorism
D015474_D006972 NONE Isotretinoin_0\NNP| (r_nsubjpass) contraindicated_2\VBN|isotretinoin|is|in|because|. (l_prep) because_5\IN|of|abnormalities (l_pobj) abnormalities_11\NNS|the|many|reported|congenital|after (l_prep) after_12\IN|use (l_pobj) use_14\NN|maternal|(|including|) (l_prep) including_16\VBG|microphthalmos (l_pobj) microphthalmos_17\NNS|,|hypertelorism (l_conj) hypertelorism_20\NN|orbital|,|and|hypoplasia
D015474_C563492 NONE Isotretinoin_0\NNP| (r_nsubjpass) contraindicated_2\VBN|isotretinoin|is|in|because|. (l_prep) because_5\IN|of|abnormalities (l_pobj) abnormalities_11\NNS|the|many|reported|congenital|after (l_prep) after_12\IN|use (l_pobj) use_14\NN|maternal|(|including|) (l_prep) including_16\VBG|microphthalmos (l_pobj) microphthalmos_17\NNS|,|hypertelorism (l_conj) hypertelorism_20\NN|orbital|,|and|hypoplasia (l_conj) hypoplasia_25\NN|optic|nerve
20192893
D003287_D007674 CID medium_1\NN| (r_amod) nephrotoxicity_2\NN|contrast|medium|after|.
D003287_D007674 CID medium_6\NN| (r_amod) CM_8\NNP|iodinated|contrast|medium|( (r_nmod) administration_10\NN|cm|) (r_pobj) by_3\IN|administration (r_agent) induced_2\VBN|by (r_acl) dysfunction_1\NN|renal|induced
D003287_D007674 CID CM_8\NNP|iodinated|contrast|medium|( (r_nmod) administration_10\NN|cm|) (r_pobj) by_3\IN|administration (r_agent) induced_2\VBN|by (r_acl) dysfunction_1\NN|renal|induced
D003287_D007674 CID CM_8\NNP| (r_pobj) of_7\IN|cm (r_prep) effect_6\NN|nephrotoxic|of|in (l_amod) nephrotoxic_5\JJ|
D003287_D007674 CID CM_17\NNP| (r_compound) administration_18\NN|cm|than (r_pobj) by_16\IN|administration (r_agent) induced_15\VBN|by (r_acl) damage_14\NN|renal|induced
D003287_D064420 NONE CM_13\NNP| (r_compound) toxicity_14\NN|cm
611664
D011433_C544351 NONE propranolol_2\NN|in (l_prep) in_3\IN|treatment (l_pobj) treatment_5\NN|the|of (l_prep) of_6\IN|hypotension (l_pobj) hypotension_9\NN|idiopathic|orthostatic
D011433_C544351 NONE propranolol_4\NN| (r_nsubj) is_5\VBZ|that|propranolol|drug (l_attr) drug_8\NN|a|useful|in (l_prep) in_9\IN|patients (l_pobj) patients_11\NNS|selected|with (l_prep) with_12\IN|hypotension (l_pobj) hypotension_16\NN|severe|idiopathic|orthostatic
D002395_D004342 NONE catecholamines_6\NNS|reduced|plasma|and|activity|in (r_dobj) exhibited_2\VBD|they|catecholamines|and|marked|. (l_conj) marked_19\VBN|had|hypersensitivity (l_dobj) hypersensitivity_20\NN|to
D009638_D004342 NONE norepinephrine_27\NN|infused (r_pobj) of_25\IN|norepinephrine (r_prep) effects_24\NNS|the|pressor|of (r_pobj) to_21\IN|effects (r_prep) hypersensitivity_20\NN|to
D011433_D006973 CID propranolol_9\NN| (r_pobj) by_8\IN|propranolol (r_agent) induced_7\VBN|in|,|hypertension|was|by|and|had (l_nsubjpass) hypertension_5\NN|marked
24778426
D002945_D007674 NONE cisplatin_6\JJ| (r_amod) use_7\NN|cisplatin (r_pobj) of_5\IN|use (r_prep) complications_4\NNS|the|major|of (r_pobj) of_1\IN|complications (r_prep) One_0\CD|of (r_nsubj) is_8\VBZ|one|nephrotoxicity|. (l_attr) nephrotoxicity_12\NN|limiting
D002945_D007674 NONE cisplatin_7\NN| (r_advmod) induced_9\VBN|cisplatin|- (r_amod) nephrotoxicity_10\NN|induced|in
D002945_D007674 NONE cisplatin_18\NN|with (r_dobj) receiving_14\VBG|agent|cisplatin (r_acl) patients_13\NNS|cancer|receiving (r_pobj) in_11\IN|patients (r_prep) nephrotoxicity_10\NN|induced|in
D002945_D007674 NONE cisplatin_16\NN|that|patients|are (l_advcl) are_24\VBP|weeks|at|and|benefit (l_prep) at_25\IN|risk (l_pobj) risk_28\NN|the|greatest|of (l_prep) of_29\IN|nephrotoxicity (l_pobj) nephrotoxicity_30\NN|
D008353_D064420 NONE mannitol_13\NN| (r_pobj) of_12\IN|mannitol (r_prep) use_11\NN|the|of|as (r_pobj) including_9\VBG|use (r_prep) prevent_5\VB|to|toxicity|,|including (l_dobj) toxicity_7\NN|this
D002945_D009369 NONE cisplatin_7\NN| (r_advmod) induced_9\VBN|cisplatin|- (r_amod) nephrotoxicity_10\NN|induced|in (l_prep) in_11\IN|patients (l_pobj) patients_13\NNS|cancer|receiving (l_compound) cancer_12\NN|
D002945_D009369 NONE cisplatin_18\NN|with (r_dobj) receiving_14\VBG|agent|cisplatin (r_acl) patients_13\NNS|cancer|receiving (l_compound) cancer_12\NN|
D002945_D009369 NONE cisplatin_11\NN|agent (r_dobj) receiving_7\VBG|cisplatin|as (r_acl) patients_6\NNS|cancer|receiving (l_compound) cancer_5\NN|adult
D002945_D009369 NONE cisplatin_10\NN|agent (r_dobj) received_6\VBD|who|cisplatin (r_relcl) patients_4\NNS|143|received (r_dobj) evaluated_2\VBD|:|we|patients (r_ccomp) had_16\VBD|evaluated|;|%|cancer|as|. (l_prep) as_21\IN|malignancy (l_pobj) malignancy_24\NN|their|primary
D008353_D007674 NONE mannitol_22\NN| (r_pobj) without_21\IN|mannitol (r_conj) with_19\IN|and|without (r_prep) cisplatin_18\NN|with (r_dobj) receiving_14\VBG|agent|cisplatin (r_acl) patients_13\NNS|cancer|receiving (r_pobj) in_11\IN|patients (r_prep) nephrotoxicity_10\NN|induced|in
D008353_D007674 NONE mannitol_5\NN| (r_dobj) receive_4\VB|who|did|not|mannitol (r_relcl) Patients_0\NNS|receive (r_nsubj) were_6\VBD|patients|likely|ratio|. (l_acomp) likely_8\JJ|more|develop (l_xcomp) develop_10\VB|to|nephrotoxicity (l_dobj) nephrotoxicity_11\NN|
D008353_D007674 NONE mannitol_4\NNS| (r_pobj) of_3\IN|mannitol (r_prep) quantities_2\NNS|limited|of (r_nsubj) are_5\VBP|when|quantities|available (r_advcl) given_12\VBN|are|,|it|should|preferentially|be|to|. (l_dative) to_13\IN|patients (l_pobj) patients_14\NNS|at (l_prep) at_15\IN|risk (l_pobj) risk_18\NN|high|of (l_prep) of_19\IN|nephrotoxicity (l_pobj) nephrotoxicity_20\NN|
D008353_D007674 NONE mannitol_38\NN| (r_pobj) of_37\IN|mannitol (r_prep) addition_36\NN|the|of (r_pobj) from_34\IN|addition (r_prep) benefit_33\VB|would|from (r_conj) are_24\VBP|weeks|at|and|benefit (l_prep) at_25\IN|risk (l_pobj) risk_28\NN|the|greatest|of (l_prep) of_29\IN|nephrotoxicity (l_pobj) nephrotoxicity_30\NN|
D008353_D009369 NONE mannitol_22\NN| (r_pobj) without_21\IN|mannitol (r_conj) with_19\IN|and|without (r_prep) cisplatin_18\NN|with (r_dobj) receiving_14\VBG|agent|cisplatin (r_acl) patients_13\NNS|cancer|receiving (l_compound) cancer_12\NN|
D002945_D006258 NONE cisplatin_10\NN|agent (r_dobj) received_6\VBD|who|cisplatin (r_relcl) patients_4\NNS|143|received (r_dobj) evaluated_2\VBD|:|we|patients (r_ccomp) had_16\VBD|evaluated|;|%|cancer|as|. (l_dobj) cancer_20\NN|head|neck
D002945_D006973 NONE cisplatin_16\NN|that|patients|are (l_advcl) are_24\VBP|weeks|at|and|benefit (l_nsubj) weeks_19\NNS|every|3|and|those (l_conj) those_21\DT|with (l_prep) with_22\IN|hypertension (l_pobj) hypertension_23\NN|
D008353_D006973 NONE mannitol_38\NN| (r_pobj) of_37\IN|mannitol (r_prep) addition_36\NN|the|of (r_pobj) from_34\IN|addition (r_prep) benefit_33\VB|would|from (r_conj) are_24\VBP|weeks|at|and|benefit (l_nsubj) weeks_19\NNS|every|3|and|those (l_conj) those_21\DT|with (l_prep) with_22\IN|hypertension (l_pobj) hypertension_23\NN|
9323412
D017294_D003866 NONE ondansetron_7\NN|operative (r_pobj) following_3\VBG|ondansetron (r_prep) depression_2\NN|acute|severe|following|.
D017294_D020250 NONE ondansetron_25\NN| (r_compound) prophylaxis_26\NN|ondansetron (r_nsubjpass) used_29\VBN|where|prophylaxis|had|been (r_relcl) anaesthetic_23\NN|a|previous|used (r_pobj) after_20\IN|months|anaesthetic (r_prep) presented_14\VBN|woman|for|after|. (l_nsubj) woman_4\NN|a|old|with (l_prep) with_5\IN|history (l_pobj) history_8\NN|a|strong|of (l_prep) of_9\IN|nausea (l_pobj) nausea_11\NN|postoperative|and|vomiting (l_conj) vomiting_13\NN|
D012701_D003865 NONE serotonin_20\NN| (r_compound) antagonist_21\NN|a|serotonin (r_pobj) of_18\IN|antagonist (r_prep) use_17\NN|the|of (r_pobj) to_15\IN|use (r_prep) related_14\VBN|possibly|to (r_advcl) developed_2\VBN|she|had|disorder|thereafter|,|related|. (l_dobj) disorder_8\NN|a|severe|acute|major|depression
D015742_D009325 NONE propofol_3\JJ| (r_amod) infusion_4\NN|a|propofol|and|avoidance|of (r_pobj) with_1\IN|infusion (r_prep) Anaesthesia_0\NNP|with (r_nsubj) provided_10\VBD|anaesthesia|course|without|. (l_dobj) course_16\NN|a|free|postoperative (l_amod) free_14\JJ|nausea|- (l_npadvmod) nausea_12\NN|
D015742_D003866 NONE propofol_3\JJ| (r_amod) infusion_4\NN|a|propofol|and|avoidance|of (r_pobj) with_1\IN|infusion (r_prep) Anaesthesia_0\NNP|with (r_nsubj) provided_10\VBD|anaesthesia|course|without|. (l_prep) without_17\IN|exacerbation (l_pobj) exacerbation_18\NN|of (l_prep) of_19\IN|disorder (l_pobj) disorder_22\NN|the|depression
D012701_D009325 NONE serotonin_8\NN| (r_compound) antagonists_9\NNS|serotonin (r_pobj) of_7\IN|antagonists (r_prep) infusion_4\NN|a|propofol|and|avoidance|of (r_pobj) with_1\IN|infusion (r_prep) Anaesthesia_0\NNP|with (r_nsubj) provided_10\VBD|anaesthesia|course|without|. (l_dobj) course_16\NN|a|free|postoperative (l_amod) free_14\JJ|nausea|- (l_npadvmod) nausea_12\NN|
D012701_D003866 NONE serotonin_8\NN| (r_compound) antagonists_9\NNS|serotonin (r_pobj) of_7\IN|antagonists (r_prep) infusion_4\NN|a|propofol|and|avoidance|of (r_pobj) with_1\IN|infusion (r_prep) Anaesthesia_0\NNP|with (r_nsubj) provided_10\VBD|anaesthesia|course|without|. (l_prep) without_17\IN|exacerbation (l_pobj) exacerbation_18\NN|of (l_prep) of_19\IN|disorder (l_pobj) disorder_22\NN|the|depression
7018927
D006220_D006966 CID haloperidol_9\NN| (r_npadvmod) induced_11\VBN|haloperidol|- (r_amod) hyperprolactinemia_12\NN|induced
D006220_D006966 CID haloperidol_4\NN| (r_amod) infusions_5\NNS|haloperidol (r_pobj) of_3\IN|infusions (r_prep) course_2\NN|the|of (r_pobj) During_0\IN|course (r_prep) found_10\VBN|during|,|hyperprolactinemia|was|,|with|,|compared|. (l_nsubjpass) hyperprolactinemia_8\NN|significant
8184922
D007545_D006332 CID isoproterenol_17\NN| (r_npadvmod) induced_19\VBN|isoproterenol|- (r_amod) hypertrophy_21\NN|induced|cardiac
2429800
D006632_D007022 NONE Histamine_0\NN| (r_amod) antagonists_1\NNS|histamine|and|hypotension|. (l_conj) hypotension_8\NN|d|induced|in
D014403_D007022 CID tubocurarine_5\NN|- (r_advmod) induced_7\VBN|tubocurarine|- (r_amod) hypotension_8\NN|d|induced|in
10939760
D013411_D058186 CID sulfadiazine_2\NN| (r_nmod) nephrotoxicity_4\NN|sulfadiazine|acute
D013411_D058186 CID Sulfadiazine_0\NN| (r_nmod) nephrotoxicity_2\NN|sulfadiazine|acute
D013411_D014123 NONE Sulfadiazine_0\NN| (r_nmod) nephrotoxicity_2\NN|sulfadiazine|acute (r_nsubj) reviving_4\VBG|nephrotoxicity|is|because|. (l_prep) because_6\IN|specially|of|use (l_pobj) use_9\NN|its|in|in (l_prep) in_10\IN|toxoplasmosis (l_pobj) toxoplasmosis_11\NN|
25096313
D013256_D009422 NONE steroid_5\NN| (r_compound) injection_6\NN|steroid|at (r_pobj) after_4\IN|injection (r_prep) neuropathy_3\NN|lateral|antebrachial|cutaneous|after|.
D013256_D009422 NONE steroid_19\NN| (r_compound) injection_20\NN|a|steroid|in (r_pobj) after_17\IN|injection (r_prep) occurred_16\VBD|that|after|treat (r_relcl) neuropathy_11\NN|lateral|antebrachial|cutaneous|(|lacnp|)|occurred
D013256_D013716 NONE steroid_19\NN| (r_compound) injection_20\NN|a|steroid|in (r_pobj) after_17\IN|injection (r_prep) occurred_16\VBD|that|after|treat (l_advcl) treat_26\VB|to|epicondylitis|in (l_dobj) epicondylitis_28\NN|lateral
D013256_D013716 NONE steroid_14\NN| (r_compound) injection_15\NN|a|steroid|for (l_prep) for_16\IN|treatment (l_pobj) treatment_18\NN|the|of (l_prep) of_19\IN|epicondylitis (l_pobj) epicondylitis_21\NN|lateral
D013256_D010292 CID steroid_23\NN| (r_compound) injection_24\NN|a|steroid|in|before (r_pobj) after_21\IN|injection (r_prep) occurred_20\VBN|presented|;|paresthesia|had|after|. (l_ccomp) presented_5\VBN|woman|with (l_prep) with_6\IN|sensation (l_pobj) sensation_8\NN|decreased|and|paresthesia|over (l_conj) paresthesia_10\NN|
D013256_D010292 CID steroid_23\NN| (r_compound) injection_24\NN|a|steroid|in|before (r_pobj) after_21\IN|injection (r_prep) occurred_20\VBN|presented|;|paresthesia|had|after|. (l_nsubj) paresthesia_18\NN|the
12372954
D009530_D009395 CID nicergoline_5\NN|sermion (r_pobj) due_3\IN|to|nicergoline (r_prep) nephritis_2\NN|acute|interstitial|due|.
D009530_D009395 CID Sermion_7\NN|(|) (r_appos) nicergoline_5\NN|sermion (r_pobj) due_3\IN|to|nicergoline (r_prep) nephritis_2\NN|acute|interstitial|due|.
D009530_D009395 CID nicergoline_13\NN|sermion (r_pobj) due_11\IN|to|nicergoline (r_prep) report_1\VBP|we|case|due|. (l_dobj) case_3\NN|a|of (l_prep) of_4\IN|nephritis (l_pobj) nephritis_7\NN|acute|interstitial|(|ain|)
D009530_D009395 CID nicergoline_13\NN|sermion (r_pobj) due_11\IN|to|nicergoline (r_prep) report_1\VBP|we|case|due|. (l_dobj) case_3\NN|a|of (l_prep) of_4\IN|nephritis (l_pobj) nephritis_7\NN|acute|interstitial|(|ain|) (l_appos) AIN_9\NNP|
D009530_D009395 CID Sermion_15\NN|(|) (r_appos) nicergoline_13\NN|sermion (r_pobj) due_11\IN|to|nicergoline (r_prep) report_1\VBP|we|case|due|. (l_dobj) case_3\NN|a|of (l_prep) of_4\IN|nephritis (l_pobj) nephritis_7\NN|acute|interstitial|(|ain|)
D009530_D009395 CID Sermion_15\NN|(|) (r_appos) nicergoline_13\NN|sermion (r_pobj) due_11\IN|to|nicergoline (r_prep) report_1\VBP|we|case|due|. (l_dobj) case_3\NN|a|of (l_prep) of_4\IN|nephritis (l_pobj) nephritis_7\NN|acute|interstitial|(|ain|) (l_appos) AIN_9\NNP|
D009530_D009395 CID nicergoline_10\NN| (r_npadvmod) associated_12\VBN|nicergoline|- (r_amod) AIN_13\NNP|associated
D009530_D012170 NONE nicergoline_7\NN| (r_dobj) taking_6\VBG|before|,|he|had|been|nicergoline|and|bendazac|. (l_conj) bendazac_9\VB|lysine|due (l_prep) due_11\IN|to|occlusion (l_pobj) occlusion_15\NN|vein|at
C036067_D012170 NONE lysine_10\NN| (r_dobj) bendazac_9\VB|lysine|due (l_prep) due_11\IN|to|occlusion (l_pobj) occlusion_15\NN|vein|at
15282950
D010936_D009202 NONE chebula_4\NN|effect|against|induced|. (l_prep) against_5\IN|injury (l_pobj) injury_8\NN|experimental|myocardial
D010936_D009202 NONE fruits_8\NNS|terminalia|chebula|(|wt|) (r_pobj) of_5\IN|fruits (r_prep) extract_4\NN|ethanolic|of (r_pobj) of_2\IN|extract (r_prep) effect_1\NN|cardioprotective|of (r_nsubjpass) examined_16\VBN|effect|was|in|body|induced|. (l_conj) induced_25\VBN|damage (l_dobj) damage_27\NN|myocardial|in
D007545_D009202 CID isoproterenol_11\NN| (r_pobj) by_10\IN|isoproterenol (r_agent) induced_9\VBN|by (r_advcl) chebula_4\NN|effect|against|induced|. (l_prep) against_5\IN|injury (l_pobj) injury_8\NN|experimental|myocardial
D007545_D009202 CID isoproterenol_18\NN| (r_pobj) in_17\IN|isoproterenol (r_prep) examined_16\VBN|effect|was|in|body|induced|. (l_conj) induced_25\VBN|damage (l_dobj) damage_27\NN|myocardial|in
19108278
D011433_D001145 NONE propranolol_8\NN| (r_pobj) of_7\IN|propranolol (r_prep) isomers_6\NNS|the|optical|of|and|effects (l_conj) effects_11\NNS|their|on (l_prep) on_12\IN|arrhythmias (l_pobj) arrhythmias_14\NNS|cardiac
D011433_D001145 NONE propranolol_3\NN| (r_pobj) of_2\IN|propranolol (r_prep) isomers_1\NNS|both|of (r_nsubj) were_4\VBD|isomers|capable|,|but|was (l_acomp) capable_5\JJ|of (l_prep) of_6\IN|preventing (l_pcomp) preventing_7\VBG|arrhythmias (l_dobj) arrhythmias_12\NNS|induced|cardiac|in
D011433_D001145 NONE -)-propranolol_25\,|( (r_pobj) of_23\IN|-)-propranolol (r_prep) dose_22\NN|the|mean|of (r_nsubj) was_26\VBD|dose|0.09+/-0.02|mg/kg|was|. (r_conj) were_4\VBD|isomers|capable|,|but|was (l_acomp) capable_5\JJ|of (l_prep) of_6\IN|preventing (l_pcomp) preventing_7\VBG|arrhythmias (l_dobj) arrhythmias_12\NNS|induced|cardiac|in
D011433_D001145 NONE -propranolol_35\,|) (r_conj) of_31\IN|(|+|-propranolol (r_prep) that_30\DT|of (r_nsubj) was_36\VBD|whereas|that|4.2+/-1.2|mg/kg (r_advcl) was_26\VBD|dose|0.09+/-0.02|mg/kg|was|. (r_conj) were_4\VBD|isomers|capable|,|but|was (l_acomp) capable_5\JJ|of (l_prep) of_6\IN|preventing (l_pcomp) preventing_7\VBG|arrhythmias (l_dobj) arrhythmias_12\NNS|induced|cardiac|in
D004837_D001145 CID adrenaline_8\RB| (r_advmod) induced_10\VBN|adrenaline|- (r_amod) arrhythmias_12\NNS|induced|cardiac|in
D004837_D001145 CID adrenaline.7_13\NNS| (r_pobj) of_12\IN|adrenaline.7 (r_prep) dose_11\NN|the|of (r_dobj) increasing_9\VBG|dose (r_pcomp) by_8\IN|increasing (r_prep) was_6\VBD|blockade|surmountable|by|. (l_nsubj) Blockade_0\NN|of (l_prep) of_1\IN|arrhythmias (l_pobj) arrhythmias_2\NNS|with
D006221_D001145 CID halothane_17\NN| (r_pobj) with_16\IN|halothane (r_prep) anaesthetized_15\VBN|with (r_acl) cats_14\NNS|anaesthetized (r_pobj) in_13\IN|cats (r_prep) arrhythmias_12\NNS|induced|cardiac|in
D011433_D017180 NONE propranolol_3\NN| (r_pobj) of_2\IN|propranolol (r_prep) isomers_1\NNS|both|of (r_nsubj) were_4\VBD|isomers|also|capable|. (l_acomp) capable_6\JJ|of (l_prep) of_7\IN|reversing (l_pcomp) reversing_8\VBG|tachycardia (l_dobj) tachycardia_10\NN|ventricular|caused
D010042_D017180 CID ouabain_13\NN|in (r_pobj) by_12\IN|ouabain (r_agent) caused_11\VBN|by (r_acl) tachycardia_10\NN|ventricular|caused
24535067
D005045_D009207 CID etomidate_2\NN| (r_npadvmod) induced_4\VBN|etomidate|- (r_amod) myoclonus_5\NN|induced|:|is|:|fentanyl
D005045_D009207 CID etomidate_26\NN| (r_npadvmod) induced_28\VBN|etomidate|- (r_amod) myoclonus_29\NN|induced
D005045_D009207 CID etomidate_16\NN| (r_npadvmod) induced_18\VBN|etomidate|- (r_amod) myoclonus_19\NN|induced
D005283_D009207 NONE Fentanyl_11\NN|,|midazolam (r_appos) myoclonus_5\NN|induced|:|is|:|fentanyl
D005283_D009207 NONE fentanyl_13\NN|,|midazolam (r_pobj) of_12\IN|fentanyl (r_prep) effectiveness_11\NN|the|of|combination (l_conj) combination_19\NN|a|of|prevent (l_relcl) prevent_25\VB|to|myoclonus (l_dobj) myoclonus_29\NN|induced
D005283_D009207 NONE fentanyl_21\NN|and|midazolam (r_pobj) of_20\IN|fentanyl (r_prep) combination_19\NN|a|of|prevent (l_relcl) prevent_25\VB|to|myoclonus (l_dobj) myoclonus_29\NN|induced
D005283_D009207 NONE fentanyl_5\NN|or|combination|of (r_pobj) with_4\IN|fentanyl (r_prep) pretreatment_3\NN|with (r_nsubj) was_12\VBD|that|pretreatment|effective (l_acomp) effective_13\JJ|in (l_prep) in_14\IN|preventing (l_pcomp) preventing_15\VBG|myoclonus (l_dobj) myoclonus_19\NN|induced
D005283_D009207 NONE fentanyl_9\NN|and|midazolam (r_pobj) of_8\IN|fentanyl (r_prep) fentanyl_5\NN|or|combination|of (r_pobj) with_4\IN|fentanyl (r_prep) pretreatment_3\NN|with (r_nsubj) was_12\VBD|that|pretreatment|effective (l_acomp) effective_13\JJ|in (l_prep) in_14\IN|preventing (l_pcomp) preventing_15\VBG|myoclonus (l_dobj) myoclonus_19\NN|induced
D008874_D009207 NONE midazolam_13\NN|,|or|combination (r_appos) Fentanyl_11\NN|,|midazolam (r_appos) myoclonus_5\NN|induced|:|is|:|fentanyl
D008874_D009207 NONE midazolam_15\NN|,|and (r_conj) fentanyl_13\NN|,|midazolam (r_pobj) of_12\IN|fentanyl (r_prep) effectiveness_11\NN|the|of|combination (l_conj) combination_19\NN|a|of|prevent (l_relcl) prevent_25\VB|to|myoclonus (l_dobj) myoclonus_29\NN|induced
D008874_D009207 NONE midazolam_23\NN| (r_conj) fentanyl_21\NN|and|midazolam (r_pobj) of_20\IN|fentanyl (r_prep) combination_19\NN|a|of|prevent (l_relcl) prevent_25\VB|to|myoclonus (l_dobj) myoclonus_29\NN|induced
D008874_D009207 NONE midazolam_11\NN| (r_conj) fentanyl_9\NN|and|midazolam (r_pobj) of_8\IN|fentanyl (r_prep) fentanyl_5\NN|or|combination|of (r_pobj) with_4\IN|fentanyl (r_prep) pretreatment_3\NN|with (r_nsubj) was_12\VBD|that|pretreatment|effective (l_acomp) effective_13\JJ|in (l_prep) in_14\IN|preventing (l_pcomp) preventing_15\VBG|myoclonus (l_dobj) myoclonus_19\NN|induced
D005045_D009069 NONE etomidate_19\NN|after|injection (r_advcl) graded_9\VBN|according|during|etomidate (r_conj) observed_7\VBN|which|were|and|graded (r_advcl) evaluated_3\VBN|movements|are|,|observed|. (l_nsubjpass) movements_1\NNS|myoclonic
D005045_D010146 NONE etomidate_6\NN|to|injection (r_xcomp) due_4\IN|etomidate (r_prep) severity_1\NN|the|of|due (l_prep) of_2\IN|pain (l_pobj) pain_3\NN|
10462057
D017330_D000741 CID remoxipride_4\NN| (r_compound) metabolites_5\NNS|remoxipride|in|and|cells (r_pobj) by_3\IN|metabolites (r_agent) apoptosis_2\NN|by (r_pobj) of_1\IN|apoptosis (r_prep) Induction_0\NN|of|:|relevance|. (l_appos) relevance_17\NN|potential|to (l_prep) to_18\IN|anemia (l_pobj) anemia_23\NN|induced|aplastic
D017330_D000741 CID remoxipride_19\NN| (r_npadvmod) induced_21\VBN|remoxipride|- (r_amod) anemia_23\NN|induced|aplastic
D017330_D000741 CID remoxipride_4\NN|agent|,|[|(|amide|] (r_nsubjpass) associated_14\VBN|remoxipride|has|been|with|. (l_prep) with_15\IN|anemia (l_pobj) anemia_18\NN|acquired|aplastic
D017330_D000741 CID amide_10\NN|n-[(1-ethyl-2-pyrrolidinyl)methyl]-2,6-dimethoxybenz (r_appos) remoxipride_4\NN|agent|,|[|(|amide|] (r_nsubjpass) associated_14\VBN|remoxipride|has|been|with|. (l_prep) with_15\IN|anemia (l_pobj) anemia_18\NN|acquired|aplastic
D017330_D000741 CID remoxipride_3\NN|and|benzene (r_nsubj) induce_7\VB|that|remoxipride|may|anemia|via|and|apoptosis (l_dobj) anemia_9\NN|aplastic
D017330_D000741 CID remoxipride_3\NN|and|benzene (r_nsubj) induce_7\VB|that|remoxipride|may|anemia|via|and|apoptosis (r_ccomp) propose_1\VBP|we|induce|contribute|. (l_conj) contribute_31\VB|may|to (l_prep) to_32\IN|anemia (l_pobj) anemia_38\NN|mechanism|underlying|acquired|aplastic|associated
D017330_D000741 CID remoxipride_44\NN| (r_pobj) with_43\IN|remoxipride (r_prep) associated_42\VBN|that|has|been|with (r_relcl) anemia_38\NN|mechanism|underlying|acquired|aplastic|associated (r_pobj) to_32\IN|anemia (r_prep) contribute_31\VB|may|to (r_conj) propose_1\VBP|we|induce|contribute|. (l_ccomp) induce_7\VB|that|remoxipride|may|anemia|via|and|apoptosis (l_dobj) anemia_9\NN|aplastic
D017330_D000741 CID remoxipride_44\NN| (r_pobj) with_43\IN|remoxipride (r_prep) associated_42\VBN|that|has|been|with (r_relcl) anemia_38\NN|mechanism|underlying|acquired|aplastic|associated
C084325_D009336 NONE NCQ436_8\NNP| (r_pobj) with_7\IN|ncq436 (r_prep) treated_6\VBN|with (r_acl) cells_5\NNS|treated (r_pobj) in_4\IN|cells (r_prep) observed_3\VBN|necrosis|was|in|but|had (l_nsubjpass) necrosis_1\NN|no
C084325_D009336 NONE NCQ436_8\NNP| (r_pobj) with_7\IN|ncq436 (r_prep) treated_6\VBN|with (r_acl) cells_5\NNS|treated (r_pobj) in_4\IN|cells (r_prep) observed_3\VBN|necrosis|was|in|but|had (l_conj) had_11\VBD|ncq344|effect|,|inducing|. (l_advcl) inducing_20\VBG|apoptosis (l_advmod) apoptosis_21\NN|at (l_prep) at_22\IN|concentrations (l_pobj) concentrations_24\NNS|lower|and|necrosis|at (l_conj) necrosis_26\NN|
C112341_D009336 NONE NCQ344_10\NNP| (r_nsubj) had_11\VBD|ncq344|effect|,|inducing|. (r_conj) observed_3\VBN|necrosis|was|in|but|had (l_nsubjpass) necrosis_1\NN|no
C112341_D009336 NONE NCQ344_10\NNP| (r_nsubj) had_11\VBD|ncq344|effect|,|inducing|. (l_advcl) inducing_20\VBG|apoptosis (l_advmod) apoptosis_21\NN|at (l_prep) at_22\IN|concentrations (l_pobj) concentrations_24\NNS|lower|and|necrosis|at (l_conj) necrosis_26\NN|
D001554_D000741 CID benzene_5\NN| (r_conj) remoxipride_3\NN|and|benzene (r_nsubj) induce_7\VB|that|remoxipride|may|anemia|via|and|apoptosis (l_dobj) anemia_9\NN|aplastic
D001554_D000741 CID benzene_5\NN| (r_conj) remoxipride_3\NN|and|benzene (r_nsubj) induce_7\VB|that|remoxipride|may|anemia|via|and|apoptosis (r_ccomp) propose_1\VBP|we|induce|contribute|. (l_conj) contribute_31\VB|may|to (l_prep) to_32\IN|anemia (l_pobj) anemia_38\NN|mechanism|underlying|acquired|aplastic|associated
C084325_D000741 NONE NCQ436_21\NNP|and|ncq344 (r_pobj) of_20\IN|ncq436 (r_prep) ability_19\NN|the|of|induce (r_nsubj) apoptosis_26\NN|that|ability|in (r_conj) induce_7\VB|that|remoxipride|may|anemia|via|and|apoptosis (l_dobj) anemia_9\NN|aplastic
C084325_D000741 NONE NCQ436_21\NNP|and|ncq344 (r_pobj) of_20\IN|ncq436 (r_prep) ability_19\NN|the|of|induce (r_nsubj) apoptosis_26\NN|that|ability|in (r_conj) induce_7\VB|that|remoxipride|may|anemia|via|and|apoptosis (r_ccomp) propose_1\VBP|we|induce|contribute|. (l_conj) contribute_31\VB|may|to (l_prep) to_32\IN|anemia (l_pobj) anemia_38\NN|mechanism|underlying|acquired|aplastic|associated
C112341_D000741 NONE NCQ344_23\NNP| (r_conj) NCQ436_21\NNP|and|ncq344 (r_pobj) of_20\IN|ncq436 (r_prep) ability_19\NN|the|of|induce (r_nsubj) apoptosis_26\NN|that|ability|in (r_conj) induce_7\VB|that|remoxipride|may|anemia|via|and|apoptosis (l_dobj) anemia_9\NN|aplastic
C112341_D000741 NONE NCQ344_23\NNP| (r_conj) NCQ436_21\NNP|and|ncq344 (r_pobj) of_20\IN|ncq436 (r_prep) ability_19\NN|the|of|induce (r_nsubj) apoptosis_26\NN|that|ability|in (r_conj) induce_7\VB|that|remoxipride|may|anemia|via|and|apoptosis (r_ccomp) propose_1\VBP|we|induce|contribute|. (l_conj) contribute_31\VB|may|to (l_prep) to_32\IN|anemia (l_pobj) anemia_38\NN|mechanism|underlying|acquired|aplastic|associated
1858969
D004049_D004660 CID diethylcarbamazine_9\NN| (r_pobj) with_8\IN|diethylcarbamazine (r_prep) loiasis_7\NN|with (r_pobj) of_6\IN|loiasis (r_prep) treatment_5\NN|of (r_pobj) during_4\IN|treatment (r_prep) cases_1\NNS|five|of|during|. (l_prep) of_2\IN|encephalitis (l_pobj) encephalitis_3\NN|
D004049_D004660 CID diethylcarbamazine_7\NN|dec (r_pobj) with_6\IN|diethylcarbamazine (r_prep) treatment_5\NN|with (r_dobj) following_4\VBG|treatment (r_prep) cases_1\NNS|five|of|following (l_prep) of_2\IN|encephalitis (l_pobj) encephalitis_3\NN|
D004049_D004660 CID DEC_9\NNP|(|) (r_appos) diethylcarbamazine_7\NN|dec (r_pobj) with_6\IN|diethylcarbamazine (r_prep) treatment_5\NN|with (r_dobj) following_4\VBG|treatment (r_prep) cases_1\NNS|five|of|following (l_prep) of_2\IN|encephalitis (l_pobj) encephalitis_3\NN|
D004049_D008118 NONE diethylcarbamazine_9\NN| (r_pobj) with_8\IN|diethylcarbamazine (r_prep) loiasis_7\NN|with
D004049_D005368 NONE diethylcarbamazine_7\NN|dec (r_pobj) with_6\IN|diethylcarbamazine (r_prep) treatment_5\NN|with (r_dobj) following_4\VBG|treatment (r_prep) cases_1\NNS|five|of|following (r_nsubjpass) observed_12\VBN|cases|were|in|with|. (l_prep) with_16\IN|filariasis (l_pobj) filariasis_19\NN|loa|loa
D004049_D005368 NONE DEC_9\NNP|(|) (r_appos) diethylcarbamazine_7\NN|dec (r_pobj) with_6\IN|diethylcarbamazine (r_prep) treatment_5\NN|with (r_dobj) following_4\VBG|treatment (r_prep) cases_1\NNS|five|of|following (r_nsubjpass) observed_12\VBN|cases|were|in|with|. (l_prep) with_16\IN|filariasis (l_pobj) filariasis_19\NN|loa|loa
6631522
C013102_D066126 NONE HA_16\NNP| (r_nsubj) are_17\VBP|that|changes|i-131|ha|not|factor (l_attr) factor_21\NN|the|initiating|in (l_prep) in_22\IN|cardiotoxicity (l_pobj) cardiotoxicity_24\NN|doxorubicin
D004317_D066126 CID doxorubicin_23\NN| (r_compound) cardiotoxicity_24\NN|doxorubicin
19154241
D008094_D006961 CID lithium_3\NN|term (r_compound) therapy_4\NN|lithium|leading (l_acl) leading_5\VBG|to (l_prep) to_6\IN|hyperparathyroidism (l_pobj) hyperparathyroidism_7\NN|
D008094_D006934 CID lithium_6\NN| (r_npadvmod) treated_8\VBN|lithium|- (r_amod) patient_9\NN|a|treated|had (l_relcl) had_11\VBD|who|hypercalcemia|understand (l_dobj) hypercalcemia_13\NN|recurrent
D008094_D006934 CID lithium_6\NN| (r_npadvmod) treated_8\VBN|lithium|- (r_amod) patients_9\NNS|treated (r_pobj) of_5\IN|patients (r_prep) %_4\NN|15|of (r_nsubj) become_10\VBP|%|hypercalcemic|. (l_acomp) hypercalcemic_11\JJ|
D008094_D049950 NONE lithium_16\NN| (r_compound) therapy_17\NN|term|lithium (r_pobj) of_12\IN|therapy (r_prep) effect_11\NN|a|rare|side|of (r_attr) is_2\VBZ|hyperparathyroidism|effect|. (l_nsubj) hyperparathyroidism_1\NN|primary
2625524
D006220_D012640 NONE Haloperidol_0\NNP| (r_nsubj) failed_1\VBD|haloperidol|prevent|,|but|lower|. (l_xcomp) prevent_3\VB|to|seizures (l_dobj) seizures_7\NNS|induced
D006220_D012640 NONE Haloperidol_0\NN| (r_nsubj) decreased_1\VBD|haloperidol|incidence|at|,|but|reach (l_dobj) incidence_3\NN|the|of (l_prep) of_4\IN|seizures (l_pobj) seizures_8\NNS|induced
D006220_D012640 NONE haloperidol_11\NN| (r_appos) blocker_10\NN|the|dopamine|haloperidol|against (r_pobj) for_6\IN|blocker (r_prep) role_5\NN|a|protective|for|without (l_prep) without_20\IN|reducing (l_pcomp) reducing_21\VBG|incidence (l_dobj) incidence_23\NN|the|of (l_prep) of_24\IN|seizures (l_pobj) seizures_25\NNS|
D006220_D012640 NONE haloperidol_3\NN| (r_nsubj) demonstrated_4\VBD|in|,|haloperidol|ability|. (l_dobj) ability_6\NN|an|reduce (l_acl) reduce_8\VB|to|seizures|without (l_dobj) seizures_12\NNS|induced
D000661_D012640 CID amphetamine_4\NN| (r_npadvmod) induced_6\VBN|amphetamine|- (r_amod) seizures_7\NNS|induced
D000661_D012640 CID amphetamine_18\NN| (r_compound) exposure_19\NN|dose|amphetamine (r_pobj) from_14\IN|exposure (r_prep) death_13\NN|from (r_pobj) against_12\IN|death (r_prep) blocker_10\NN|the|dopamine|haloperidol|against (r_pobj) for_6\IN|blocker (r_prep) role_5\NN|a|protective|for|without (l_prep) without_20\IN|reducing (l_pcomp) reducing_21\VBG|incidence (l_dobj) incidence_23\NN|the|of (l_prep) of_24\IN|seizures (l_pobj) seizures_25\NNS|
D003042_D012640 CID cocaine_5\NN| (r_npadvmod) induced_7\VBN|cocaine|- (r_amod) seizures_8\NNS|induced
D003042_D012640 CID cocaine_9\NN| (r_npadvmod) induced_11\VBN|cocaine|- (r_amod) seizures_12\NNS|induced
D004298_D012640 NONE dopamine_9\NN|central (r_compound) blocker_10\NN|the|dopamine|haloperidol|against (r_pobj) for_6\IN|blocker (r_prep) role_5\NN|a|protective|for|without (l_prep) without_20\IN|reducing (l_pcomp) reducing_21\VBG|incidence (l_dobj) incidence_23\NN|the|of (l_prep) of_24\IN|seizures (l_pobj) seizures_25\NNS|
3832950
D002998_D004827 NONE Clonazepam_0\NNP| (r_compound) monotherapy_1\NN|clonazepam|for|in|. (l_prep) for_2\IN|epilepsy (l_pobj) epilepsy_3\NN|
D002998_D004827 NONE clonazepam_23\NN| (r_pobj) with_22\IN|clonazepam (r_prep) treated_21\VBN|patients|were|with|. (l_nsubjpass) patients_1\NNS|sixty|(|range|)|with (l_prep) with_12\IN|types (l_pobj) types_14\NNS|other|of|than (l_prep) of_15\IN|epilepsy (l_pobj) epilepsy_16\NN|
D002998_D013036 NONE clonazepam_23\NN| (r_pobj) with_22\IN|clonazepam (r_prep) treated_21\VBN|patients|were|with|. (l_nsubjpass) patients_1\NNS|sixty|(|range|)|with (l_prep) with_12\IN|types (l_pobj) types_14\NNS|other|of|than (l_prep) than_17\IN|spasms (l_pobj) spasms_19\NNS|infantile
18399341
D004837_D007022 NONE epinephrine_24\NN| (r_amod) infusion_25\NN|,|p=|required|epinephrine|treat|. (l_relcl) treat_27\VB|to|hypotension (l_dobj) hypotension_28\NN|
3088653
D012601_D000647 CID scopolamine_2\NN| (r_npadvmod) induced_4\VBN|scopolamine|- (r_amod) amnesia_5\NN|induced|of
D012601_D000647 CID Scopolamine_0\NNP|,|but|scopolamine (r_nsubj) induced_13\VBD|scopolamine|amnesia|measured|. (l_dobj) amnesia_15\NN|an
D012601_D000647 CID scopolamine_21\NN| (r_npadvmod) induced_23\VBN|scopolamine|- (r_amod) amnesia_24\NN|the|induced
D009270_D000647 NONE naloxone_15\NN|pre- (r_pobj) by_9\IN|naloxone (r_prep) avoidance_8\NN|passive|by (r_pobj) of_6\IN|avoidance (r_prep) amnesia_5\NN|induced|of
D009270_D000647 NONE naloxone_5\NN|mg/kg|as (r_pobj) of_4\IN|naloxone (r_prep) administration_3\NN|training|of|as (r_nsubj) attenuated_19\VBD|administration|also|amnesia|. (l_dobj) amnesia_24\NN|the|induced
D009270_D008569 NONE naloxone_11\NN|on|in (l_prep) on_12\IN|deficit (l_pobj) deficit_18\NN|a|induced|retention
D009270_D008569 NONE Naloxone_0\NN|(|0.3|,|1|,|3|,|and|mg/kg (r_nsubj) injected_12\VBD|naloxone|prior|attenuated|. (l_advcl) attenuated_16\VBD|deficit|with|at (l_dobj) deficit_19\NN|the|retention
D009270_D008569 NONE naloxone_14\NN|training (r_appos) sensitivity_9\NN|pain|naloxone (r_pobj) in_7\IN|sensitivity (r_prep) increase_6\NN|neither|an|in|)|nor|state (r_nsubj) appear_27\VBP|that|increase|be (l_xcomp) be_29\VB|to|responsible (l_acomp) responsible_30\JJ|for (l_prep) for_31\IN|influence (l_pobj) influence_33\NN|the|of (l_prep) of_34\IN|naloxone (l_pobj) naloxone_35\NN|on (l_prep) on_36\IN|deficit (l_pobj) deficit_42\NN|the|induced|retention
D009270_D008569 NONE naloxone_25\NN|(|training (r_appos) state_20\NN|an|induced|aversive|naloxone|) (r_conj) increase_6\NN|neither|an|in|)|nor|state (r_nsubj) appear_27\VBP|that|increase|be (l_xcomp) be_29\VB|to|responsible (l_acomp) responsible_30\JJ|for (l_prep) for_31\IN|influence (l_pobj) influence_33\NN|the|of (l_prep) of_34\IN|naloxone (l_pobj) naloxone_35\NN|on (l_prep) on_36\IN|deficit (l_pobj) deficit_42\NN|the|induced|retention
D009270_D008569 NONE naloxone_35\NN|on (l_prep) on_36\IN|deficit (l_pobj) deficit_42\NN|the|induced|retention
D012601_D008569 NONE scopolamine_14\NN| (r_npadvmod) induced_16\VBN|scopolamine|- (r_amod) deficit_18\NN|a|induced|retention
D012601_D008569 NONE scopolamine_38\NN| (r_npadvmod) induced_40\VBN|scopolamine|- (r_amod) deficit_42\NN|the|induced|retention
D019832_D000647 NONE scopolamine_5\NN|not|methyl|(|mg/kg|)|, (r_conj) Scopolamine_0\NNP|,|but|scopolamine (r_nsubj) induced_13\VBD|scopolamine|amnesia|measured|. (l_dobj) amnesia_15\NN|an
D009270_D010146 NONE naloxone_14\NN|training (r_appos) sensitivity_9\NN|pain|naloxone (l_compound) pain_8\NN|
D009270_D010146 NONE naloxone_25\NN|(|training (r_appos) state_20\NN|an|induced|aversive|naloxone|) (r_conj) increase_6\NN|neither|an|in|)|nor|state (l_prep) in_7\IN|sensitivity (l_pobj) sensitivity_9\NN|pain|naloxone (l_compound) pain_8\NN|
D009270_D010146 NONE naloxone_35\NN|on (r_pobj) of_34\IN|naloxone (r_prep) influence_33\NN|the|of (r_pobj) for_31\IN|influence (r_prep) responsible_30\JJ|for (r_acomp) be_29\VB|to|responsible (r_xcomp) appear_27\VBP|that|increase|be (l_nsubj) increase_6\NN|neither|an|in|)|nor|state (l_prep) in_7\IN|sensitivity (l_pobj) sensitivity_9\NN|pain|naloxone (l_compound) pain_8\NN|
D012601_D010146 NONE scopolamine_38\NN| (r_npadvmod) induced_40\VBN|scopolamine|- (r_amod) deficit_42\NN|the|induced|retention (r_pobj) on_36\IN|deficit (r_prep) naloxone_35\NN|on (r_pobj) of_34\IN|naloxone (r_prep) influence_33\NN|the|of (r_pobj) for_31\IN|influence (r_prep) responsible_30\JJ|for (r_acomp) be_29\VB|to|responsible (r_xcomp) appear_27\VBP|that|increase|be (l_nsubj) increase_6\NN|neither|an|in|)|nor|state (l_prep) in_7\IN|sensitivity (l_pobj) sensitivity_9\NN|pain|naloxone (l_compound) pain_8\NN|
2453942
D001556_D020258 NONE Lindane_0\NN|(|hexachlorocyclohexane|) (r_nsubj) is_6\VBZ|lindane|insecticide|. (l_attr) insecticide_9\NN|an|organochlorine|with (l_prep) with_10\IN|effects (l_pobj) effects_13\NNS|known|neurotoxic (l_amod) neurotoxic_12\JJ|
D001556_D020258 NONE hexachlorocyclohexane_4\NN|gamma|- (r_appos) Lindane_0\NN|(|hexachlorocyclohexane|) (r_nsubj) is_6\VBZ|lindane|insecticide|. (l_attr) insecticide_9\NN|an|organochlorine|with (l_prep) with_10\IN|effects (l_pobj) effects_13\NNS|known|neurotoxic (l_amod) neurotoxic_12\JJ|
D001556_D012640 CID lindane_5\NN| (r_pobj) of_4\IN|lindane (r_prep) effect_3\NN|the|of|(|mg/kg|)|on (r_dobj) studied_1\VBD|we|effect|by|. (l_prep) by_16\IN|measuring (l_pcomp) measuring_17\VBG|concentration|in|at (l_prep) at_31\IN|onset (l_pobj) onset_33\NN|the|of (l_prep) of_34\IN|seizures (l_pobj) seizures_35\NNS|
D001556_D012640 CID lindane_11\NN| (r_compound) administration_12\NN|lindane (r_pobj) after_10\IN|administration (r_prep) min_9\NN|+/-|1.4|after (r_pobj) at_5\IN|min (r_prep) suffered_2\VBD|animals|convulsions|at|. (l_dobj) convulsions_4\NNS|tonic
D005680_D012640 NONE GABA_21\NNP|,|dopamine (r_pobj) of_20\IN|gaba (r_prep) concentration_19\NN|the|of (r_dobj) measuring_17\VBG|concentration|in|at (l_prep) at_31\IN|onset (l_pobj) onset_33\NN|the|of (l_prep) of_34\IN|seizures (l_pobj) seizures_35\NNS|
D004298_D012640 NONE dopamine_23\NN|and|metabolites (r_conj) GABA_21\NNP|,|dopamine (r_pobj) of_20\IN|gaba (r_prep) concentration_19\NN|the|of (r_dobj) measuring_17\VBG|concentration|in|at (l_prep) at_31\IN|onset (l_pobj) onset_33\NN|the|of (l_prep) of_34\IN|seizures (l_pobj) seizures_35\NNS|
12559315
D007213_D018856 CID Indomethacin_0\NNP| (r_nsubj) resulted_1\VBD|indomethacin|in|. (l_prep) in_2\IN|findings (l_pobj) findings_4\NNS|histopathologic|typical (l_amod) typical_5\JJ|of (l_prep) of_6\IN|cystitis (l_pobj) cystitis_8\NN|interstitial|,|as
D007213_D008415 CID Indomethacin_0\NNP| (r_nsubj) resulted_1\VBD|indomethacin|in|. (l_prep) in_2\IN|findings (l_pobj) findings_4\NNS|histopathologic|typical (l_amod) typical_5\JJ|of (l_prep) of_6\IN|cystitis (l_pobj) cystitis_8\NN|interstitial|,|as (l_prep) as_11\IN|such|epithelium (l_pobj) epithelium_14\NN|leaky|bladder|and|mastocytosis (l_conj) mastocytosis_17\NN|mucosal
8188982
D001127_D006973 CID AVP_4\NNP|and|anp (r_pobj) of_3\IN|avp (r_prep) effects_2\NNS|central|cardiovascular|of|in|. (l_prep) in_7\IN|rats (l_pobj) rats_12\NNS|normotensive|hypertensive (l_amod) hypertensive_11\JJ|
D001127_D006973 CID vasopressin_13\NN|central|arginine|(|avp|) (r_pobj) of_10\IN|vasopressin (r_prep) influence_9\NN|of (r_dobj) compare_8\VB|to|influence|and|of|on|and|rats (l_conj) rats_51\NNS|hypertensive|(|shr|) (l_amod) hypertensive_47\JJ|spontaneously
D001127_D006973 CID AVP_15\NNP| (r_appos) vasopressin_13\NN|central|arginine|(|avp|) (r_pobj) of_10\IN|vasopressin (r_prep) influence_9\NN|of (r_dobj) compare_8\VB|to|influence|and|of|on|and|rats (l_conj) rats_51\NNS|hypertensive|(|shr|) (l_amod) hypertensive_47\JJ|spontaneously
D010656_D006973 CID phenylephrine_36\NN| (r_nmod) hypotension_45\NN|phenylephrine|hypertension|nitroprusside|(|sn)-induced (l_nmod) hypertension_39\NN|(|phe)-induced|and|sodium
D010656_D006973 CID Phe)-induced_38\VBN| (r_amod) hypertension_39\NN|(|phe)-induced|and|sodium
D010656_D007022 NONE phenylephrine_36\NN| (r_nmod) hypotension_45\NN|phenylephrine|hypertension|nitroprusside|(|sn)-induced
D010656_D007022 NONE Phe)-induced_38\VBN| (r_amod) hypertension_39\NN|(|phe)-induced|and|sodium (r_nmod) hypotension_45\NN|phenylephrine|hypertension|nitroprusside|(|sn)-induced
D009599_D006973 NONE nitroprusside_42\NN| (r_amod) hypotension_45\NN|phenylephrine|hypertension|nitroprusside|(|sn)-induced (l_nmod) hypertension_39\NN|(|phe)-induced|and|sodium
D009599_D006973 NONE SN)-induced_44\JJ| (r_amod) hypotension_45\NN|phenylephrine|hypertension|nitroprusside|(|sn)-induced (l_nmod) hypertension_39\NN|(|phe)-induced|and|sodium
D009599_D007022 CID nitroprusside_42\NN| (r_amod) hypotension_45\NN|phenylephrine|hypertension|nitroprusside|(|sn)-induced
D009599_D007022 CID SN)-induced_44\JJ| (r_amod) hypotension_45\NN|phenylephrine|hypertension|nitroprusside|(|sn)-induced
D009599_D007022 CID SN_13\NNP| (r_npadvmod) induced_15\VBN|sn|- (r_amod) hypotension_16\NN|induced
D001127_D007022 NONE AVP_11\NNP| (r_pobj) of_10\IN|avp (r_prep) administration_9\NN|lv|of (r_pobj) after_7\IN|administration (r_prep) reduced_2\VBN|ccb|was|in|after|during|. (l_prep) during_12\IN|hypotension (l_pobj) hypotension_16\NN|induced
12677626
C476513_D020258 NONE levobupivacaine_8\NN|for (r_pobj) of_7\IN|levobupivacaine (r_prep) administration_6\NN|the|of (r_dobj) following_4\VBG|administration (r_prep) toxicity_3\NN|central|system|following|:|report|.
C476513_D004830 CID levobupivacaine_13\NN| (r_pobj) of_12\IN|levobupivacaine (r_prep) injection_11\NN|accidental|intravascular|of (r_pobj) following_8\VBG|injection (r_prep) describe_1\VBP|we|cases|following|. (l_dobj) cases_3\NNS|2|of (l_prep) of_4\IN|seizures (l_pobj) seizures_7\NNS|grand|mal
C476513_D004830 CID levobupivacaine_5\NN| (r_pobj) of_4\IN|levobupivacaine (r_prep) administration_3\NN|the|of|% (r_pobj) after_1\IN|administration (r_prep) developed_17\VBD|immediately|after|,|patients|seizures|,|despite|. (l_dobj) seizures_20\NNS|grand|mal
D004837_D004830 NONE epinephrine_9\NN| (r_nmod) mL_13\NNP|epinephrine|microgram|/ (r_pobj) with_8\IN|ml (r_prep) %_7\NN|0.5|with (r_appos) administration_3\NN|the|of|% (r_pobj) after_1\IN|administration (r_prep) developed_17\VBD|immediately|after|,|patients|seizures|,|despite|. (l_dobj) seizures_20\NNS|grand|mal
D004837_D004830 NONE epinephrine_33\NN| (r_compound) administration_34\NN|intravenous|epinephrine (r_pobj) of_31\IN|administration (r_prep) signs_30\NNS|no|clinical|of (r_conj) aspiration_24\NN|negative|for|and|signs (r_pobj) despite_22\IN|aspiration (r_prep) developed_17\VBD|immediately|after|,|patients|seizures|,|despite|. (l_dobj) seizures_20\NNS|grand|mal
D013874_D012640 NONE thiopental_7\VBN|sodium (r_pobj) with_5\IN|thiopental (r_prep) treated_4\VBN|seizures|were|successfully|with|in|. (l_nsubjpass) seizures_1\NNS|the
D013390_D012640 NONE succinylcholine_11\NN|in (r_pobj) to_10\IN|succinylcholine (r_prep) addition_9\NN|to (r_pobj) in_8\IN|addition (r_prep) treated_4\VBN|seizures|were|successfully|with|in|. (l_nsubjpass) seizures_1\NNS|the
C476513_D066126 NONE levobupivacaine_1\PRP| (r_nsubj) have_3\VB|although|levobupivacaine|may|profile (l_dobj) profile_8\NN|a|safer|toxicity|than (l_compound) toxicity_7\NN|cardiac
C476513_D066126 NONE levobupivacaine_17\NN| (r_pobj) of_16\IN|levobupivacaine (r_prep) amounts_15\NNS|adequate|of (r_nsubj) reach_18\VBP|if|amounts|circulation (r_advcl) result_24\VB|have|,|reach|,|it|will|in|. (l_advcl) have_3\VB|although|levobupivacaine|may|profile (l_dobj) profile_8\NN|a|safer|toxicity|than (l_compound) toxicity_7\NN|cardiac
C476513_D012640 NONE levobupivacaine_1\PRP| (r_nsubj) have_3\VB|although|levobupivacaine|may|profile (r_advcl) result_24\VB|have|,|reach|,|it|will|in|. (l_prep) in_25\IN|convulsions (l_pobj) convulsions_26\NNS|
C476513_D012640 NONE levobupivacaine_17\NN| (r_pobj) of_16\IN|levobupivacaine (r_prep) amounts_15\NNS|adequate|of (r_nsubj) reach_18\VBP|if|amounts|circulation (r_advcl) result_24\VB|have|,|reach|,|it|will|in|. (l_prep) in_25\IN|convulsions (l_pobj) convulsions_26\NNS|
D002045_D066126 NONE bupivacaine_11\NN|racemic (r_pobj) than_9\IN|bupivacaine (r_prep) profile_8\NN|a|safer|toxicity|than (l_compound) toxicity_7\NN|cardiac
D002045_D012640 NONE bupivacaine_11\NN|racemic (r_pobj) than_9\IN|bupivacaine (r_prep) profile_8\NN|a|safer|toxicity|than (r_dobj) have_3\VB|although|levobupivacaine|may|profile (r_advcl) result_24\VB|have|,|reach|,|it|will|in|. (l_prep) in_25\IN|convulsions (l_pobj) convulsions_26\NNS|
24464946
D015251_D066126 CID epirubicine_22\NN| (r_npadvmod) based_24\VBN|epirubicine|- (r_amod) chemotherapy_25\NN|based (r_pobj) during_21\IN|chemotherapy (r_prep) detection_16\NN|early|and|prediction|during (l_conj) prediction_18\NN|of (l_prep) of_19\IN|cardiotoxicity (l_pobj) cardiotoxicity_20\NN|
D015251_D009202 NONE epirubicin_25\NNS| (r_compound) exposure_26\NN|epirubicin (r_pobj) after_24\IN|exposure (r_prep) predict_18\VB|whether|alterations|could|dysfunction|after (l_nsubj) alterations_3\NNS|of (l_prep) of_4\IN|strain (l_pobj) strain_6\NN|myocardial|and|t
D015251_D006331 NONE epirubicin_25\NNS| (r_compound) exposure_26\NN|epirubicin (r_pobj) after_24\IN|exposure (r_prep) predict_18\VB|whether|alterations|could|dysfunction|after (l_dobj) dysfunction_21\NN|future|cardiac|in
D015251_D008228 NONE epirubicin_13\NNS| (r_pobj) with_12\IN|epirubicin (r_prep) treated_11\VBN|with (r_acl) patients_5\NNS|five|with|treated (l_prep) with_6\IN|lymphoma (l_pobj) lymphoma_10\NN|hodgkin
D018943_D006331 NONE anthracycline_20\NN| (r_advmod) based_22\VBN|anthracycline|- (r_amod) chemotherapy_23\NN|based (r_dobj) receiving_19\VBG|chemotherapy (r_acl) patients_18\NNS|receiving (r_pobj) in_17\IN|patients (r_prep) dysfunction_16\NN|cardiac|in
18450790
D013792_D010523 CID Thalidomide_0\NNP|and|neurotoxicity|:|study|. (l_conj) neurotoxicity_3\NN|sensory
D013792_D010523 CID thalidomide_17\NN| (r_pobj) of_16\IN|thalidomide (r_prep) doses_15\NNS|different|of (r_pobj) with_13\IN|doses (r_prep) treated_12\VBN|with (r_acl) patients_11\NNS|treated (r_pobj) in_10\IN|patients (r_prep) incidence_5\NN|a|high|of|in (l_prep) of_6\IN|neuropathy (l_pobj) neuropathy_9\NN|sensory|axonal
D013792_D008178 NONE thalidomide_30\NN| (r_pobj) with_29\IN|thalidomide (r_prep) treated_28\VBN|(|cle|with|and|use|. (r_parataxis) were_4\VBD|aims|measure|amplitude|treated (l_punct) amplitude_17\VBP|in (l_prep) in_18\IN|patients (l_pobj) patients_19\NNS|with (l_prep) with_20\IN|erythematosus (l_pobj) erythematosus_24\NN|refractory|lupus
D013792_D008178 NONE thalidomide_30\NN| (r_pobj) with_29\IN|thalidomide (r_prep) treated_28\VBN|(|cle|with|and|use|. (l_nsubj) CLE_26\NNP|)
D013792_D008178 NONE thalidomide_41\NN|and|capacity (r_pobj) of_40\IN|thalidomide (r_prep) potential_39\NN|the|neurotoxic|of (r_dobj) identify_36\VB|to|potential (r_xcomp) use_32\VB|findings|identify (r_conj) treated_28\VBN|(|cle|with|and|use|. (r_parataxis) were_4\VBD|aims|measure|amplitude|treated (l_punct) amplitude_17\VBP|in (l_prep) in_18\IN|patients (l_pobj) patients_19\NNS|with (l_prep) with_20\IN|erythematosus (l_pobj) erythematosus_24\NN|refractory|lupus
D013792_D008178 NONE thalidomide_41\NN|and|capacity (r_pobj) of_40\IN|thalidomide (r_prep) potential_39\NN|the|neurotoxic|of (r_dobj) identify_36\VB|to|potential (r_xcomp) use_32\VB|findings|identify (r_conj) treated_28\VBN|(|cle|with|and|use|. (l_nsubj) CLE_26\NNP|)
D013792_D008178 NONE thalidomide_17\NN| (r_pobj) with_16\IN|thalidomide|and (r_prep) treatment_15\NN|with (r_pobj) during_14\IN|treatment (r_prep) data_7\NNS|clinical|in|during (l_prep) in_8\IN|patients (l_pobj) patients_11\NNS|12|female|with (l_prep) with_12\IN|cle (l_pobj) CLE_13\NNP|
D013792_D020258 NONE thalidomide_30\NN| (r_pobj) with_29\IN|thalidomide (r_prep) treated_28\VBN|(|cle|with|and|use|. (l_conj) use_32\VB|findings|identify (l_xcomp) identify_36\VB|to|potential (l_dobj) potential_39\NN|the|neurotoxic|of (l_amod) neurotoxic_38\JJ|
D013792_D020258 NONE thalidomide_41\NN|and|capacity (r_pobj) of_40\IN|thalidomide (r_prep) potential_39\NN|the|neurotoxic|of (l_amod) neurotoxic_38\JJ|
D013792_D020258 NONE thalidomide_10\NN| (r_pobj) of_9\IN|thalidomide (r_prep) potential_8\NN|subclinical|neurotoxic|of (l_amod) neurotoxic_7\JJ|
1943082
D005978_D007511 NONE glutathione_8\NN|tissue|total (r_pobj) in_4\IN|glutathione (r_prep) change_3\NN|no|in|following (l_prep) following_9\VBG|injury (l_pobj) injury_14\NN|intestinal|reperfusion (l_compound) reperfusion_13\NN|ischemia|- (l_compound) ischemia_11\NN|
D005978_D015427 NONE glutathione_8\NN|tissue|total (r_pobj) in_4\IN|glutathione (r_prep) change_3\NN|no|in|following (l_prep) following_9\VBG|injury (l_pobj) injury_14\NN|intestinal|reperfusion
24275640
D004317_D066126 CID doxorubicin_12\NN| (r_pobj) of_11\IN|doxorubicin (r_prep) doses_10\NNS|single|of (r_pobj) with_6\IN|doses (r_prep) treatment_5\NN|with (r_pobj) after_4\IN|treatment (r_prep) cardiotoxicity_3\NN|after
D004317_D066126 CID doxorubicin_3\NN| (r_pobj) of_2\IN|doxorubicin (r_prep) mechanism_1\NN|the|of (r_nsubj) remains_7\VBZ|mechanism|cardiotoxicity|controversial|. (l_nsubj) cardiotoxicity_6\NN|(|dox)-induced
D004317_D066126 CID DOX)-induced_5\JJ| (r_amod) cardiotoxicity_6\NN|(|dox)-induced
D004317_D066126 CID DOX_17\NNP| (r_pobj) of_16\IN|dox (r_prep) dose_15\NN|a|single|of (r_pobj) by_12\IN|dose (r_agent) induced_11\VBN|by|only (r_acl) cardiotoxicity_10\NN|acute|induced
D004317_D006331 NONE DOX_3\NNP| (r_pobj) of_2\IN|dox (r_prep) dose_1\NN|single|of (r_nsubjpass) associated_5\VBN|dose|was|with|. (l_prep) with_6\IN|disarrangement (l_pobj) disarrangement_9\NN|increased|cardiac|,|necrosis
D004317_D009336 CID DOX_3\NNP| (r_pobj) of_2\IN|dox (r_prep) dose_1\NN|single|of (r_nsubjpass) associated_5\VBN|dose|was|with|. (l_prep) with_6\IN|disarrangement (l_pobj) disarrangement_9\NN|increased|cardiac|,|necrosis (l_conj) necrosis_11\NN|,|and|damage
24975837
D002945_D058186 CID cisplatin_7\RB| (r_npadvmod) induced_9\VBN|cisplatin|- (r_amod) injury_12\NN|induced|acute|renal
D002945_D058186 CID Cisplatin_0\NNP| (r_compound) treatment_1\NN|cisplatin (r_nsubjpass) adopted_4\VBN|treatment|has|been|in (r_ccomp) induce_14\VB|adopted|;|however|,|drug|can|injury|due|,|augment|. (l_dobj) injury_17\NN|acute|kidney
D002945_D058186 CID cisplatin_10\NN| (r_advmod) induced_12\VBN|cisplatin|- (r_amod) injury_15\NN|induced|acute|kidney
D002945_D058186 CID cisplatin_25\NN| (r_pobj) with_24\IN|cisplatin (r_prep) challenged_23\VBN|examine|mice|were|with|. (l_advcl) examine_1\VB|to|role (l_dobj) role_3\NN|the|of (l_prep) of_4\IN|kinin (l_pobj) kinin_6\NN|the|receptor|,|kinin (l_appos) receptor_8\NN|b2|in (l_prep) in_9\IN|injury (l_pobj) injury_15\NN|induced|acute|kidney
D002945_D058186 CID cisplatin_13\NN| (r_advmod) induced_15\VBN|cisplatin|- (r_amod) injury_18\NN|induced|acute|kidney
D002945_D007683 CID Cisplatin_0\NNP| (r_compound) treatment_1\NN|cisplatin (r_nsubjpass) adopted_4\VBN|treatment|has|been|in (r_ccomp) induce_14\VB|adopted|;|however|,|drug|can|injury|due|,|augment|. (l_conj) augment_27\VBP|levels|,|increase (l_conj) increase_35\VB|score (l_dobj) score_40\NN|the|acute|tubular|necrosis|and|cytokines (l_compound) necrosis_39\NN|
D003404_D058186 NONE creatinine_31\NN|and|urea (r_pobj) of_30\IN|creatinine (r_prep) levels_29\NNS|serum|of (r_dobj) augment_27\VBP|levels|,|increase (r_conj) induce_14\VB|adopted|;|however|,|drug|can|injury|due|,|augment|. (l_dobj) injury_17\NN|acute|kidney
D003404_D007683 NONE creatinine_31\NN|and|urea (r_pobj) of_30\IN|creatinine (r_prep) levels_29\NNS|serum|of (r_dobj) augment_27\VBP|levels|,|increase (l_conj) increase_35\VB|score (l_dobj) score_40\NN|the|acute|tubular|necrosis|and|cytokines (l_compound) necrosis_39\NN|
D014508_D058186 NONE urea_33\NN| (r_conj) creatinine_31\NN|and|urea (r_pobj) of_30\IN|creatinine (r_prep) levels_29\NNS|serum|of (r_dobj) augment_27\VBP|levels|,|increase (r_conj) induce_14\VB|adopted|;|however|,|drug|can|injury|due|,|augment|. (l_dobj) injury_17\NN|acute|kidney
D014508_D007683 NONE urea_33\NN| (r_conj) creatinine_31\NN|and|urea (r_pobj) of_30\IN|creatinine (r_prep) levels_29\NNS|serum|of (r_dobj) augment_27\VBP|levels|,|increase (l_conj) increase_35\VB|score (l_dobj) score_40\NN|the|acute|tubular|necrosis|and|cytokines (l_compound) necrosis_39\NN|
D002945_D009336 NONE cisplatin_13\NN| (r_advmod) induced_15\VBN|cisplatin|- (r_amod) injury_18\NN|induced|acute|kidney (r_pobj) in_12\IN|injury (r_prep) involved_11\VBN|that|kinin|is|in|by (l_prep) by_19\IN|mediating (l_pcomp) mediating_20\VBG|process|,|resulting (l_dobj) process_23\NN|the|necrotic|and|expression (l_amod) necrotic_22\JJ|
D002945_D007674 NONE cisplatin_15\NN| (r_amod) therapy_16\NN|cisplatin (r_pobj) by_14\IN|therapy (r_agent) induced_13\VBN|by (r_acl) nephrotoxicity_12\NN|induced
12950111
D006024_D013547 NONE glycopyrrolate_7\NN|topical (r_pobj) with_5\IN|glycopyrrolate (r_prep) hyperhidrosis_4\NN|compensatory|gustatory|with
D006024_D013547 NONE glycopyrrolate_3\NN|topical (r_dobj) applying_1\VBG|glycopyrrolate (r_pcomp) After_0\IN|applying (r_prep) was_8\VBD|after|,|effect|excellent|sweating|. (l_parataxis) sweating_12\NN|(|no|after|)|in|,|and|sweating
D006024_D013547 NONE glycopyrrolate_3\NN|topical (r_dobj) applying_1\VBG|glycopyrrolate (r_pcomp) After_0\IN|applying (r_prep) was_8\VBD|after|,|effect|excellent|sweating|. (l_parataxis) sweating_12\NN|(|no|after|)|in|,|and|sweating (l_conj) sweating_32\NN|fair|(|reduced|)|in
D006024_D013547 NONE glycopyrrolate_5\JJ| (r_compound) pad_6\NN|a|glycopyrrolate (r_pobj) of_3\IN|pad (r_prep) application_2\NN|the|topical|of|method (l_appos) method_20\NN|a|convenient|of|to|in|,|with (l_prep) to_25\TO|symptoms (l_pobj) symptoms_27\NNS|severe|of (l_prep) of_28\IN|hyperhidrosis (l_pobj) hyperhidrosis_30\NN|gustatory
D006024_D014987 NONE glycopyrrolate_17\NN|% (r_appos) patients_13\NNS|2|(|glycopyrrolate|) (r_pobj) in_11\IN|patients (r_prep) throat_10\NN|a|sore|in (r_conj) mouth_6\NN|a|dry|and|throat|,|headache
D006024_D014987 NONE glycopyrrolate_29\NN|(|%|) (r_parataxis) headache_22\NN|a|light|in|glycopyrrolate (r_appos) mouth_6\NN|a|dry|and|throat|,|headache
D006024_D010612 CID glycopyrrolate_17\NN|% (r_appos) patients_13\NNS|2|(|glycopyrrolate|) (r_pobj) in_11\IN|patients (r_prep) throat_10\NN|a|sore|in
D006024_D010612 CID glycopyrrolate_29\NN|(|%|) (r_parataxis) headache_22\NN|a|light|in|glycopyrrolate (r_appos) mouth_6\NN|a|dry|and|throat|,|headache (l_conj) throat_10\NN|a|sore|in
D006024_D006261 CID glycopyrrolate_17\NN|% (r_appos) patients_13\NNS|2|(|glycopyrrolate|) (r_pobj) in_11\IN|patients (r_prep) throat_10\NN|a|sore|in (r_conj) mouth_6\NN|a|dry|and|throat|,|headache (l_appos) headache_22\NN|a|light|in|glycopyrrolate
D006024_D006261 CID glycopyrrolate_29\NN|(|%|) (r_parataxis) headache_22\NN|a|light|in|glycopyrrolate
1423336
D007980_D007022 CID levodopa_6\NN|in (r_pobj) of_5\IN|levodopa (r_prep) effect_4\NN|the|hypotensive|of (l_amod) hypotensive_3\JJ|
D007980_D007022 CID levodopa_7\NN| (r_pobj) of_6\IN|levodopa (r_prep) effect_5\NN|the|hypotensive|of (l_amod) hypotensive_4\JJ|
D007980_D007022 CID levodopa_12\NN|for (r_pobj) with_11\IN|levodopa (r_prep) competing_10\VBG|phenylalanine|with (r_advcl) reduced_22\VBD|competing|,|effects|. (l_dobj) effects_27\NNS|the|hypotensive|of (l_amod) hypotensive_24\JJ|and|antiparkinsonian
D007980_D007022 CID levodopa_29\NN| (r_pobj) of_28\IN|levodopa (r_prep) effects_27\NNS|the|hypotensive|of (l_amod) hypotensive_24\JJ|and|antiparkinsonian
D007980_D007022 CID levodopa_3\NN| (r_nsubj) has_4\VBZ|that|levodopa|action (l_dobj) action_8\NN|a|central|hypotensive|parallels (l_amod) hypotensive_7\JJ|
D007980_D010300 NONE levodopa_6\NN|in (l_prep) in_7\IN|patients (l_pobj) patients_9\NNS|parkinsonian (l_amod) parkinsonian_8\JJ|
D007980_D010300 NONE levodopa_5\NN|i.v. (r_pobj) of_3\IN|levodopa (r_prep) effects_2\NNS|pressure|of (r_nsubjpass) examined_7\VBN|effects|were|in|levodopa|. (l_prep) in_8\IN|patients (l_pobj) patients_10\NNS|parkinsonian|with (l_amod) parkinsonian_9\JJ|
D007980_D010300 NONE levodopa_17\VB|to (r_advcl) examined_7\VBN|effects|were|in|levodopa|. (l_prep) in_8\IN|patients (l_pobj) patients_10\NNS|parkinsonian|with (l_amod) parkinsonian_9\JJ|
D010649_D007022 NONE Phenylalanine_0\NNP|,|acid (r_nsubj) competing_10\VBG|phenylalanine|with (r_advcl) reduced_22\VBD|competing|,|effects|. (l_dobj) effects_27\NNS|the|hypotensive|of (l_amod) hypotensive_24\JJ|and|antiparkinsonian
D000596_D007022 NONE acid_6\NN|a|large|neutral|amino|(|lnaa|) (r_appos) Phenylalanine_0\NNP|,|acid (r_nsubj) competing_10\VBG|phenylalanine|with (r_advcl) reduced_22\VBD|competing|,|effects|. (l_dobj) effects_27\NNS|the|hypotensive|of (l_amod) hypotensive_24\JJ|and|antiparkinsonian
8748050
D000639_D001927 CID amitriptyline_2\NN| (r_compound) therapy_3\NN|amitriptyline (r_pobj) during_1\IN|therapy (r_prep) Encephalopathy_0\VBG|during
D000639_D001927 CID amitriptyline_12\NN| (r_compound) therapy_13\NN|amitriptyline (r_pobj) of_11\IN|therapy (r_prep) course_10\NN|the|of (r_pobj) in_8\IN|course (r_prep) developed_7\VBN|in (r_acl) encephalopathy_6\NN|developed
D000639_D009459 NONE amitriptyline_2\NN| (r_compound) therapy_3\NN|amitriptyline (r_pobj) during_1\IN|therapy (r_prep) Encephalopathy_0\VBG|during (r_nsubj) are_5\VBP|encephalopathy|:|syndrome|? (l_attr) syndrome_8\NN|neuroleptic|malignant|and|disorders
D000639_D020230 NONE amitriptyline_2\NN| (r_compound) therapy_3\NN|amitriptyline (r_pobj) during_1\IN|therapy (r_prep) Encephalopathy_0\VBG|during (r_nsubj) are_5\VBP|encephalopathy|:|syndrome|? (l_attr) syndrome_8\NN|neuroleptic|malignant|and|disorders (l_conj) disorders_13\NNS|serotonin|syndrome|spectrum (l_compound) syndrome_11\NN|
D000639_D003866 NONE amitriptyline_12\NN| (r_compound) therapy_13\NN|amitriptyline (r_pobj) of_11\IN|therapy (r_prep) course_10\NN|the|of (r_pobj) in_8\IN|course (r_prep) developed_7\VBN|in (r_acl) encephalopathy_6\NN|developed (r_pobj) of_5\IN|encephalopathy (r_prep) case_4\NN|a|of (r_dobj) describes_2\VBZ|report|case|,|during|. (l_prep) during_15\IN|remission (l_pobj) remission_17\NN|a|of (l_prep) of_18\IN|depression (l_pobj) depression_20\NN|unipolar
8825380
D011692_D007674 CID aminonucleoside_15\JJ| (r_amod) nephropathy_16\NN|aminonucleoside|in
D011692_D007674 CID aminonucleoside_15\NN| (r_nmod) nephropathy_19\NN|aminonucleoside|(|pan|,|model
D011692_D007674 CID aminonucleoside_15\NN| (r_nmod) nephropathy_19\NN|aminonucleoside|(|pan|,|model (l_appos) model_23\NN|an|experimental|of (l_prep) of_24\IN|disease (l_pobj) disease_26\NN|glomerular
D011692_D007674 CID PAN_17\NNP|) (r_nmod) nephropathy_19\NN|aminonucleoside|(|pan|,|model
D011692_D007674 CID PAN_17\NNP|) (r_nmod) nephropathy_19\NN|aminonucleoside|(|pan|,|model (l_appos) model_23\NN|an|experimental|of (l_prep) of_24\IN|disease (l_pobj) disease_26\NN|glomerular
D011692_D007674 CID PAN_15\NNP| (r_compound) nephropathy_16\NN|chronic|pan
D011692_D007674 CID PAN_9\NNP| (r_pobj) of_8\IN|pan (r_prep) injections_7\NNS|seven|serial|of (r_pobj) by_4\IN|injections (r_agent) induced_3\VBN|glomerulopathy|was|by|over|. (l_nsubjpass) glomerulopathy_1\NN|the
D011692_D007674 CID PAN_6\NNP| (r_compound) nephropathy_7\NN|chronic|pan
D011692_D007674 CID PAN_33\NNP| (r_compound) nephropathy_34\NN|pan
D011692_D007674 CID PAN_3\NNP| (r_compound) nephropathy_4\NN|pan|,|administration
D011692_D007674 CID PAN_19\NNP| (r_compound) nephropathy_20\NN|chronic|pan
D011692_D006130 NONE PAN_15\NNP| (r_compound) nephropathy_16\NN|chronic|pan (r_pobj) with_13\IN|nephropathy (r_prep) rats_12\NNS|with (r_pobj) in_11\IN|rats (r_prep) failure_10\NN|growth|in
D008315_D007674 NONE malondialdehyde_22\NN|cortical (r_compound) content_23\NN|renal|malondialdehyde (r_conj) injury_17\NN|tubulointerstitial|,|or|content (r_conj) glomerulosclerosis_14\NN|increased|segmental|,|injury (r_conj) hypertrophy_10\NN|enhanced|glomerular|or|glomerulosclerosis
D008315_D007674 NONE malondialdehyde_35\NN|cortical (r_compound) content_36\NN|renal|malondialdehyde|,|or|damage (l_conj) damage_42\NN|glomerular
D008315_D005921 NONE malondialdehyde_22\NN|cortical (r_compound) content_23\NN|renal|malondialdehyde (r_conj) injury_17\NN|tubulointerstitial|,|or|content (r_conj) glomerulosclerosis_14\NN|increased|segmental|,|injury
D008315_-1 NONE malondialdehyde_22\NN|cortical (r_compound) content_23\NN|renal|malondialdehyde (r_conj) injury_17\NN|tubulointerstitial|,|or|content
D008315_D011507 NONE malondialdehyde_35\NN|cortical (r_compound) content_36\NN|renal|malondialdehyde|,|or|damage (r_conj) area_31\NN|glomerular|planar|,|content (r_conj) GFR_27\NNP|,|area (r_conj) proteinuria_25\NN|,|gfr
9382023
D004280_D006973 CID dobutamine_3\NN| (r_compound) stress_4\NN|dobutamine (r_compound) echocardiography_5\RB|stress (r_pobj) during_2\IN|echocardiography (r_prep) response_1\NN|hypertensive|during|. (l_amod) Hypertensive_0\JJ|
D004280_D006973 CID dobutamine_2\NN| (r_compound) stress_3\NN|dobutamine (r_compound) echocardiographic_4\JJ|stress (r_amod) studies_5\NNS|3,129|echocardiographic (r_pobj) Among_0\IN|studies (r_prep) response_9\NN|among|,|a|hypertensive|,|defined|or (l_amod) hypertensive_8\JJ|
D004280_D006973 CID dobutamine_20\NN| (r_compound) infusion_21\NN|dobutamine (r_pobj) before_19\IN|infusion (r_prep) had_12\VBD|bp|before (r_conj) had_6\VBD|patients|often|history|and|had|. (l_dobj) history_8\NN|a|of (l_prep) of_9\IN|hypertension (l_pobj) hypertension_10\NN|
18341442
C026098_C562694 NONE Levetiracetam_0\NNP|as|phenobarbital|. (l_advcl) phenobarbital_5\JJ|to|treatment (l_dobj) treatment_6\NN|in (l_prep) in_7\IN|cats (l_pobj) cats_8\NNS|with (l_prep) with_9\IN|epilepsy (l_pobj) epilepsy_12\NN|suspected|idiopathic
C026098_C562694 NONE levetiracetam_10\NN|assess|administered|phenobarbital|. (l_advcl) phenobarbital_16\JJ|to|treatment (l_dobj) treatment_17\NN|in (l_prep) in_18\IN|cats (l_pobj) cats_19\NNS|with (l_prep) with_20\IN|epilepsy (l_pobj) epilepsy_25\NN|controlled|suspected|idiopathic
C026098_C562694 NONE levetiracetam_3\NN| (r_nsubjpass) tolerated_6\VBN|that|levetiracetam|is|well|in|and|be (l_conj) be_11\VB|may|useful (l_acomp) useful_12\JJ|as (l_prep) as_13\IN|adjunct (l_pobj) adjunct_15\NN|an|phenobarbital (l_relcl) phenobarbital_17\JJ|to|treatment (l_dobj) treatment_18\NN|in (l_prep) in_19\IN|cats (l_pobj) cats_20\NNS|with (l_prep) with_21\IN|epilepsy (l_pobj) epilepsy_23\NN|idiopathic
D010634_C562694 NONE phenobarbital_5\JJ|to|treatment (l_dobj) treatment_6\NN|in (l_prep) in_7\IN|cats (l_pobj) cats_8\NNS|with (l_prep) with_9\IN|epilepsy (l_pobj) epilepsy_12\NN|suspected|idiopathic
D010634_C562694 NONE phenobarbital_16\JJ|to|treatment (l_dobj) treatment_17\NN|in (l_prep) in_18\IN|cats (l_pobj) cats_19\NNS|with (l_prep) with_20\IN|epilepsy (l_pobj) epilepsy_25\NN|controlled|suspected|idiopathic
D010634_C562694 NONE phenobarbital_12\JJ| (r_pobj) with_11\IN|phenobarbital (r_prep) controlled_10\VBN|that|was|poorly|with|or|had (r_relcl) epilepsy_6\NN|idiopathic|controlled
D010634_C562694 NONE phenobarbital_22\NN| (r_pobj) with_21\IN|phenobarbital (r_prep) treated_20\VBN|when|with (r_advcl) had_15\VBD|that|effects|treated (r_conj) controlled_10\VBN|that|was|poorly|with|or|had (r_relcl) epilepsy_6\NN|idiopathic|controlled
D010634_C562694 NONE phenobarbital_17\JJ|to|treatment (l_dobj) treatment_18\NN|in (l_prep) in_19\IN|cats (l_pobj) cats_20\NNS|with (l_prep) with_21\IN|epilepsy (l_pobj) epilepsy_23\NN|idiopathic
C026098_D012640 NONE levetiracetam_7\NN| (r_amod) treatment_8\NN|levetiracetam (r_pobj) of_6\IN|treatment (r_prep) initiation_5\NN|of (r_nsubjpass) compared_10\VBN|frequencies|initiation|were|,|and|recorded (l_nsubjpass) frequencies_1\NNS|seizure|before (l_compound) Seizure_0\NN|
C026098_D012640 NONE levetiracetam_7\NN|(|seizures|) (r_pcomp) with_6\IN|levetiracetam (r_prep) treatment_5\NN|with (r_pobj) to_4\IN|treatment (r_prep) prior_3\RB|to (r_advmod) was_14\VBD|frequency|prior|higher|after|,|and|classified (l_nsubj) frequency_2\NN|median|seizure (l_compound) seizure_1\NN|
C026098_D012640 NONE levetiracetam_7\NN|(|seizures|) (l_appos) seizures_10\NNS|2.1|/|mo
C026098_D012640 NONE levetiracetam_7\NN|(|seizures|) (r_pcomp) with_6\IN|levetiracetam (r_prep) treatment_5\NN|with (r_pobj) to_4\IN|treatment (r_prep) prior_3\RB|to (r_advmod) was_14\VBD|frequency|prior|higher|after|,|and|classified (l_acomp) higher_16\JJR|significantly|than (l_prep) than_17\IN|frequency (l_pobj) frequency_20\NN|median|seizure (l_compound) seizure_19\NN|
C026098_D012640 NONE levetiracetam_7\NN|(|seizures|) (r_pcomp) with_6\IN|levetiracetam (r_prep) treatment_5\NN|with (r_pobj) to_4\IN|treatment (r_prep) prior_3\RB|to (r_advmod) was_14\VBD|frequency|prior|higher|after|,|and|classified (l_prep) after_21\IN|initiation (l_pobj) initiation_22\NN|of (l_prep) of_23\IN|treatment (l_pobj) treatment_25\NN|levetiracetam|seizures (l_appos) seizures_28\NNS|(|0.42|/|mo|)
C026098_D012640 NONE levetiracetam_7\NN|(|seizures|) (r_pcomp) with_6\IN|levetiracetam (r_prep) treatment_5\NN|with (r_pobj) to_4\IN|treatment (r_prep) prior_3\RB|to (r_advmod) was_14\VBD|frequency|prior|higher|after|,|and|classified (l_conj) classified_39\VBN|cats|were|as|. (l_prep) as_40\IN|responded (l_pcomp) responded_42\VBN|having|levetiracetam|reduction (l_attr) reduction_49\NN|(|ie|,|in|) (l_prep) in_50\IN|frequency (l_pobj) frequency_52\NN|seizure|of (l_compound) seizure_51\NN|
C026098_D012640 NONE levetiracetam_24\NN| (r_amod) treatment_25\NN|levetiracetam|seizures (r_pobj) of_23\IN|treatment (r_prep) initiation_22\NN|of (r_pobj) after_21\IN|initiation (r_prep) was_14\VBD|frequency|prior|higher|after|,|and|classified (l_nsubj) frequency_2\NN|median|seizure (l_compound) seizure_1\NN|
C026098_D012640 NONE levetiracetam_24\NN| (r_amod) treatment_25\NN|levetiracetam|seizures (r_pobj) of_23\IN|treatment (r_prep) initiation_22\NN|of (r_pobj) after_21\IN|initiation (r_prep) was_14\VBD|frequency|prior|higher|after|,|and|classified (l_advmod) prior_3\RB|to (l_prep) to_4\IN|treatment (l_pobj) treatment_5\NN|with (l_prep) with_6\IN|levetiracetam (l_pcomp) levetiracetam_7\NN|(|seizures|) (l_appos) seizures_10\NNS|2.1|/|mo
C026098_D012640 NONE levetiracetam_24\NN| (r_amod) treatment_25\NN|levetiracetam|seizures (r_pobj) of_23\IN|treatment (r_prep) initiation_22\NN|of (r_pobj) after_21\IN|initiation (r_prep) was_14\VBD|frequency|prior|higher|after|,|and|classified (l_acomp) higher_16\JJR|significantly|than (l_prep) than_17\IN|frequency (l_pobj) frequency_20\NN|median|seizure (l_compound) seizure_19\NN|
C026098_D012640 NONE levetiracetam_24\NN| (r_amod) treatment_25\NN|levetiracetam|seizures (l_appos) seizures_28\NNS|(|0.42|/|mo|)
C026098_D012640 NONE levetiracetam_24\NN| (r_amod) treatment_25\NN|levetiracetam|seizures (r_pobj) of_23\IN|treatment (r_prep) initiation_22\NN|of (r_pobj) after_21\IN|initiation (r_prep) was_14\VBD|frequency|prior|higher|after|,|and|classified (l_conj) classified_39\VBN|cats|were|as|. (l_prep) as_40\IN|responded (l_pcomp) responded_42\VBN|having|levetiracetam|reduction (l_attr) reduction_49\NN|(|ie|,|in|) (l_prep) in_50\IN|frequency (l_pobj) frequency_52\NN|seizure|of (l_compound) seizure_51\NN|
C026098_D012640 NONE levetiracetam_44\VB|to|treatment (r_xcomp) responded_42\VBN|having|levetiracetam|reduction (r_pcomp) as_40\IN|responded (r_prep) classified_39\VBN|cats|were|as|. (r_conj) was_14\VBD|frequency|prior|higher|after|,|and|classified (l_nsubj) frequency_2\NN|median|seizure (l_compound) seizure_1\NN|
C026098_D012640 NONE levetiracetam_44\VB|to|treatment (r_xcomp) responded_42\VBN|having|levetiracetam|reduction (r_pcomp) as_40\IN|responded (r_prep) classified_39\VBN|cats|were|as|. (r_conj) was_14\VBD|frequency|prior|higher|after|,|and|classified (l_advmod) prior_3\RB|to (l_prep) to_4\IN|treatment (l_pobj) treatment_5\NN|with (l_prep) with_6\IN|levetiracetam (l_pcomp) levetiracetam_7\NN|(|seizures|) (l_appos) seizures_10\NNS|2.1|/|mo
C026098_D012640 NONE levetiracetam_44\VB|to|treatment (r_xcomp) responded_42\VBN|having|levetiracetam|reduction (r_pcomp) as_40\IN|responded (r_prep) classified_39\VBN|cats|were|as|. (r_conj) was_14\VBD|frequency|prior|higher|after|,|and|classified (l_acomp) higher_16\JJR|significantly|than (l_prep) than_17\IN|frequency (l_pobj) frequency_20\NN|median|seizure (l_compound) seizure_19\NN|
C026098_D012640 NONE levetiracetam_44\VB|to|treatment (r_xcomp) responded_42\VBN|having|levetiracetam|reduction (r_pcomp) as_40\IN|responded (r_prep) classified_39\VBN|cats|were|as|. (r_conj) was_14\VBD|frequency|prior|higher|after|,|and|classified (l_prep) after_21\IN|initiation (l_pobj) initiation_22\NN|of (l_prep) of_23\IN|treatment (l_pobj) treatment_25\NN|levetiracetam|seizures (l_appos) seizures_28\NNS|(|0.42|/|mo|)
C026098_D012640 NONE levetiracetam_44\VB|to|treatment (r_xcomp) responded_42\VBN|having|levetiracetam|reduction (l_attr) reduction_49\NN|(|ie|,|in|) (l_prep) in_50\IN|frequency (l_pobj) frequency_52\NN|seizure|of (l_compound) seizure_51\NN|
24459006
D015725_D000380 CID Fluconazole_0\NNP| (r_nsubj) associated_1\VBD|fluconazole|agranulocytosis|. (l_dobj) agranulocytosis_2\NN|and|thrombocytopenia
D015725_D000380 CID fluconazole_6\NN| (r_pobj) of_5\IN|fluconazole (r_prep) case_4\NN|a|second|of (r_dobj) describe_1\VBP|we|case|agranulocytosis|. (l_dobj) agranulocytosis_8\NN|associated|with
D015725_D000380 CID fluconazole_21\NN| (r_pobj) with_20\IN|fluconazole (r_prep) therapy_19\NN|with (r_pobj) of_18\IN|therapy (r_prep) result_17\NN|a|of (r_pobj) as_15\IN|result (r_prep) occurred_14\VBD|that|agranulocytosis|as (l_nsubj) agranulocytosis_11\NN|patient|and|thrombocytopenia
D015725_D013921 CID Fluconazole_0\NNP| (r_nsubj) associated_1\VBD|fluconazole|agranulocytosis|. (l_dobj) agranulocytosis_2\NN|and|thrombocytopenia (l_conj) thrombocytopenia_4\NN|
D015725_D013921 CID fluconazole_6\NN| (r_pobj) of_5\IN|fluconazole (r_prep) case_4\NN|a|second|of (r_dobj) describe_1\VBP|we|case|agranulocytosis|. (l_dobj) agranulocytosis_8\NN|associated|with (l_prep) with_9\IN|thrombocytopenia (l_pobj) thrombocytopenia_10\NN|and|recovery
D015725_D013921 CID fluconazole_21\NN| (r_pobj) with_20\IN|fluconazole (r_prep) therapy_19\NN|with (r_pobj) of_18\IN|therapy (r_prep) result_17\NN|a|of (r_pobj) as_15\IN|result (r_prep) occurred_14\VBD|that|agranulocytosis|as (l_nsubj) agranulocytosis_11\NN|patient|and|thrombocytopenia (l_conj) thrombocytopenia_13\NN|
D015725_D001855 NONE fluconazole_13\NN| (r_pobj) of_12\IN|fluconazole (r_prep) initiation_11\NN|the|of|and|abatement (r_pobj) to_9\IN|initiation (r_prep) relationship_4\NN|the|temporal|of|to (l_prep) of_5\IN|suppression (l_pobj) suppression_8\NN|marrow
24345882
D008727_D054198 NONE methotrexate_20\JJ| (r_compound) consequence_21\NN|a|methotrexate (r_appos) risk_3\NN|(|standard|)|and|p9201|protocols|:|consequence (l_appos) protocols_14\NNS|acute|lymphoblastic|leukemia|(|accl0131|) (l_compound) leukemia_13\NN|
D008727_D054198 NONE methotrexate_5\NN|term (r_nmod) neurotoxicity_9\NN|methotrexate|mtx|in (r_pobj) about_1\IN|neurotoxicity (r_prep) Concerns_0\NNS|about (r_nsubj) led_13\VBD|concerns|to|. (l_prep) to_14\IN|modifications (l_pobj) modifications_15\NNS|in (l_prep) in_16\IN|therapy (l_pobj) therapy_21\NN|intrathecal|(|it|)|,|rescue (l_conj) rescue_24\NN|leucovorin|,|and|frequency (l_conj) frequency_27\NN|of|in (l_prep) in_32\IN|children (l_pobj) children_33\NNS|with (l_prep) with_34\IN|leukemia (l_pobj) leukemia_37\NN|acute|lymphoblastic
D008727_D054198 NONE MTX_7\NNP|(|) (r_nmod) neurotoxicity_9\NN|methotrexate|mtx|in (r_pobj) about_1\IN|neurotoxicity (r_prep) Concerns_0\NNS|about (r_nsubj) led_13\VBD|concerns|to|. (l_prep) to_14\IN|modifications (l_pobj) modifications_15\NNS|in (l_prep) in_16\IN|therapy (l_pobj) therapy_21\NN|intrathecal|(|it|)|,|rescue (l_conj) rescue_24\NN|leucovorin|,|and|frequency (l_conj) frequency_27\NN|of|in (l_prep) in_32\IN|children (l_pobj) children_33\NNS|with (l_prep) with_34\IN|leukemia (l_pobj) leukemia_37\NN|acute|lymphoblastic
D008727_D054198 NONE MTX_30\NNP| (r_compound) administration_31\NN|systemic|mtx (r_pobj) of_28\IN|administration (r_prep) frequency_27\NN|of|in (l_prep) in_32\IN|children (l_pobj) children_33\NNS|with (l_prep) with_34\IN|leukemia (l_pobj) leukemia_37\NN|acute|lymphoblastic
D008727_D020258 NONE methotrexate_5\NN|term (r_nmod) neurotoxicity_9\NN|methotrexate|mtx|in
D008727_D020258 NONE MTX_7\NNP|(|) (r_nmod) neurotoxicity_9\NN|methotrexate|mtx|in
D008727_D020258 NONE MTX_30\NNP| (r_compound) administration_31\NN|systemic|mtx (r_pobj) of_28\IN|administration (r_prep) frequency_27\NN|of|in (r_conj) rescue_24\NN|leucovorin|,|and|frequency (r_conj) therapy_21\NN|intrathecal|(|it|)|,|rescue (r_pobj) in_16\IN|therapy (r_prep) modifications_15\NNS|in (r_pobj) to_14\IN|modifications (r_prep) led_13\VBD|concerns|to|. (l_nsubj) Concerns_0\NNS|about (l_prep) about_1\IN|neurotoxicity (l_pobj) neurotoxicity_9\NN|methotrexate|mtx|in
8392553
C056595_D006331 NONE clentiazem_3\NN|against (l_prep) against_4\IN|injury (l_pobj) injury_9\NN|induced|cardiac|in
C056595_D006331 NONE clentiazem_3\NN| (r_npadvmod) attenuated_4\VBD|in|,|clentiazem|injury|,|through|. (l_dobj) injury_9\NN|induced|cardiac
D004837_D006331 NONE epinephrine_5\NN| (r_npadvmod) induced_7\VBN|epinephrine|- (r_amod) injury_9\NN|induced|cardiac|in
D004837_D006331 NONE epinephrine_5\NN| (r_npadvmod) induced_7\VBN|epinephrine|- (r_amod) injury_9\NN|induced|cardiac
C056595_D009202 NONE clentiazem_5\NN| (r_pobj) of_4\IN|clentiazem (r_prep) effects_3\NNS|the|of|,|antagonist|,|on (l_prep) on_12\IN|cardiomyopathy (l_pobj) cardiomyopathy_16\NN|induced|in
C106746_D009202 NONE 1,5-benzothiazepine_8\CD| (r_amod) antagonist_10\NN|a|1,5-benzothiazepine|calcium (r_appos) effects_3\NNS|the|of|,|antagonist|,|on (l_prep) on_12\IN|cardiomyopathy (l_pobj) cardiomyopathy_16\NN|induced|in
D002118_D009202 NONE calcium_9\NN| (r_compound) antagonist_10\NN|a|1,5-benzothiazepine|calcium (r_appos) effects_3\NNS|the|of|,|antagonist|,|on (l_prep) on_12\IN|cardiomyopathy (l_pobj) cardiomyopathy_16\NN|induced|in
D004837_D009202 CID epinephrine_13\NN| (r_npadvmod) induced_15\VBN|epinephrine|- (r_amod) cardiomyopathy_16\NN|induced|in
D004837_D007511 NONE epinephrine_3\NN| (r_compound) infusion_4\NN|2-week|chronic|epinephrine (r_pobj) With_0\IN|infusion (r_prep) died_10\VBD|with|,|rats|within|,|and|observed (l_conj) observed_26\VBN|lesions|were|. (l_nsubjpass) lesions_18\NNS|severe|ischemic|and|fibrosis|of
D004837_D007511 NONE epinephrine_4\RB| (r_npadvmod) induced_6\VBN|epinephrine|- (r_amod) death_7\NN|induced|(|p|) (r_dobj) prevented_3\VBD|treatment|death|,|and|attenuated|. (l_conj) attenuated_15\VBD|lesions|,|in (l_dobj) lesions_19\NNS|the|ventricular|ischemic|and|fibrosis
D004837_D005355 NONE epinephrine_3\NN| (r_compound) infusion_4\NN|2-week|chronic|epinephrine (r_pobj) With_0\IN|infusion (r_prep) died_10\VBD|with|,|rats|within|,|and|observed (l_conj) observed_26\VBN|lesions|were|. (l_nsubjpass) lesions_18\NNS|severe|ischemic|and|fibrosis|of (l_conj) fibrosis_20\NN|
D004837_D005355 NONE epinephrine_4\RB| (r_npadvmod) induced_6\VBN|epinephrine|- (r_amod) death_7\NN|induced|(|p|) (r_dobj) prevented_3\VBD|treatment|death|,|and|attenuated|. (l_conj) attenuated_15\VBD|lesions|,|in (l_dobj) lesions_19\NNS|the|ventricular|ischemic|and|fibrosis (l_conj) fibrosis_21\NN|
C056595_D007511 NONE clentiazem_2\NN| (r_pobj) with_1\IN|clentiazem (r_prep) Treatment_0\NN|with (r_nsubj) prevented_3\VBD|treatment|death|,|and|attenuated|. (l_conj) attenuated_15\VBD|lesions|,|in (l_dobj) lesions_19\NNS|the|ventricular|ischemic|and|fibrosis
C056595_D005355 NONE clentiazem_2\NN| (r_pobj) with_1\IN|clentiazem (r_prep) Treatment_0\NN|with (r_nsubj) prevented_3\VBD|treatment|death|,|and|attenuated|. (l_conj) attenuated_15\VBD|lesions|,|in (l_dobj) lesions_19\NNS|the|ventricular|ischemic|and|fibrosis (l_conj) fibrosis_21\NN|
11799346
D015662_D001714 CID Cotrimoxazole_0\NNP|,|metronidazole (r_nsubjpass) involved_7\VBN|cotrimoxazole|were|in|. (l_prep) in_8\IN|episodes (l_pobj) episodes_12\NNS|15|reported|manic (l_amod) manic_11\JJ|
D008795_D001714 CID metronidazole_2\NNP|,|and|erythromycin (r_conj) Cotrimoxazole_0\NNP|,|metronidazole (r_nsubjpass) involved_7\VBN|cotrimoxazole|were|in|. (l_prep) in_8\IN|episodes (l_pobj) episodes_12\NNS|15|reported|manic (l_amod) manic_11\JJ|
D004917_D001714 CID erythromycin_5\NN| (r_conj) metronidazole_2\NNP|,|and|erythromycin (r_conj) Cotrimoxazole_0\NNP|,|metronidazole (r_nsubjpass) involved_7\VBN|cotrimoxazole|were|in|. (l_prep) in_8\IN|episodes (l_pobj) episodes_12\NNS|15|reported|manic (l_amod) manic_11\JJ|
D017291_D001714 CID clarithromycin_6\NN|and|ciprofloxacin (r_dobj) showed_5\VBD|cases|clarithromycin|be|. (l_xcomp) be_10\VB|to|the (l_attr) the_11\DT|associated (l_acl) associated_14\VBN|frequently|with (l_prep) with_15\IN|development (l_pobj) development_17\NN|the|of (l_prep) of_18\IN|mania (l_pobj) mania_19\NN|
D002939_D001714 CID ciprofloxacin_8\NNS| (r_conj) clarithromycin_6\NN|and|ciprofloxacin (r_dobj) showed_5\VBD|cases|clarithromycin|be|. (l_xcomp) be_10\VB|to|the (l_attr) the_11\DT|associated (l_acl) associated_14\VBN|frequently|with (l_prep) with_15\IN|development (l_pobj) development_17\NN|the|of (l_prep) of_18\IN|mania (l_pobj) mania_19\NN|
9538487
D008094_D006944 CID lithium_5\NN| (r_npadvmod) induced_7\VBN|lithium|- (r_amod) insipidus_10\NN|induced|diabetes (r_pobj) by_4\IN|insipidus (r_agent) precipitated_3\VBD|coma|by|. (l_nsubj) coma_2\NN|hyperosmolar|nonketotic
D008094_D006944 CID lithium_15\NN| (r_pobj) with_14\IN|lithium (r_prep) treated_13\VBN|with (r_acl) depression_12\NN|manic|treated (r_pobj) of_10\IN|depression (r_prep) history_9\NN|a|10-year|of (r_pobj) with_6\IN|history (r_prep) admitted_18\VBN|man|,|with|,|was|with|,|coma|. (l_npadvmod) coma_23\NN|nonketotic
D008094_D018500 CID lithium_5\NN| (r_npadvmod) induced_7\VBN|lithium|- (r_amod) insipidus_10\NN|induced|diabetes
D008094_D018500 CID lithium_25\NN| (r_npadvmod) induced_27\VBN|lithium|- (r_acomp) be_24\VB|to|induced (r_xcomp) likely_22\JJ|be (r_amod) indicated_17\VBD|remained|;|testing|insipidus|,|likely|. (l_dobj) insipidus_20\NN|nephrogenic|diabetes
D008094_D001714 NONE lithium_15\NN| (r_pobj) with_14\IN|lithium (r_prep) treated_13\VBN|with (r_acl) depression_12\NN|manic|treated
D005947_D011141 NONE glucose_20\NN| (r_pobj) for_19\IN|glucose (r_prep) negative_18\JJ|for (r_acomp) been_17\VBN|during|urinalysis|had|negative (r_relcl) history_6\NN|a|year|of|,|been (l_prep) of_7\IN|polyuria (l_pobj) polyuria_8\NN|and|polydipsia
D005947_D011141 NONE glucose_11\NN|blood (r_compound) concentrations_12\NNS|normal|glucose (r_pobj) despite_8\IN|concentrations (r_prep) remained_6\VBD|after|,|he|polyuric|despite (l_acomp) polyuric_7\JJ|
D005947_D059606 NONE glucose_20\NN| (r_pobj) for_19\IN|glucose (r_prep) negative_18\JJ|for (r_acomp) been_17\VBN|during|urinalysis|had|negative (r_relcl) history_6\NN|a|year|of|,|been (l_prep) of_7\IN|polyuria (l_pobj) polyuria_8\NN|and|polydipsia (l_conj) polydipsia_10\NN|
D005947_-1 NONE glucose_11\NN|blood (r_compound) concentrations_12\NNS|normal|glucose (r_pobj) despite_8\IN|concentrations (r_prep) remained_6\VBD|after|,|he|polyuric|despite (l_prep) After_0\IN|recovery (l_pobj) recovery_1\NN|from (l_prep) from_2\IN|hyperglycaemia (l_pobj) hyperglycaemia_3\NN|
D005947_D018500 NONE glucose_11\NN|blood (r_compound) concentrations_12\NNS|normal|glucose (r_pobj) despite_8\IN|concentrations (r_prep) remained_6\VBD|after|,|he|polyuric|despite (r_ccomp) indicated_17\VBD|remained|;|testing|insipidus|,|likely|. (l_dobj) insipidus_20\NN|nephrogenic|diabetes
D008094_-1 NONE lithium_25\NN| (r_npadvmod) induced_27\VBN|lithium|- (r_acomp) be_24\VB|to|induced (r_xcomp) likely_22\JJ|be (r_amod) indicated_17\VBD|remained|;|testing|insipidus|,|likely|. (l_ccomp) remained_6\VBD|after|,|he|polyuric|despite (l_prep) After_0\IN|recovery (l_pobj) recovery_1\NN|from (l_prep) from_2\IN|hyperglycaemia (l_pobj) hyperglycaemia_3\NN|
D008094_D011141 CID lithium_25\NN| (r_npadvmod) induced_27\VBN|lithium|- (r_acomp) be_24\VB|to|induced (r_xcomp) likely_22\JJ|be (r_amod) indicated_17\VBD|remained|;|testing|insipidus|,|likely|. (l_ccomp) remained_6\VBD|after|,|he|polyuric|despite (l_acomp) polyuric_7\JJ|
24055495
D005690_D003072 CID galactose_4\NN|oral (r_compound) treatment_5\NN|term|galactose (r_nsubj) prevents_6\VBZ|treatment|deficits|. (l_dobj) deficits_8\NNS|cognitive|in|treated
D005690_D003072 CID galactose_9\NN|continuous|daily|oral|treatment (l_appos) treatment_18\NN|(|kg|)|on|in (l_prep) on_19\IN|deficits (l_pobj) deficits_21\NNS|cognitive
D005690_D003072 CID galactose_4\NN| (r_compound) treatment_5\NN|oral|galactose (r_pobj) of_2\IN|treatment (r_prep) month_1\NN|one|of (r_nsubj) initiated_6\VBD|month|immediately|after|,|prevented|. (l_conj) prevented_16\VBN|successfully|development (l_dobj) development_17\NN|of (l_prep) of_18\IN|deficits (l_pobj) deficits_26\NNS|the|induced|cognitive
D005690_D003072 CID galactose_1\NN| (r_compound) exposure_2\NN|oral|galactose (r_nsubj) have_4\VB|exposure|might|effects|and|be|. (l_conj) be_14\VB|could|worth (l_acomp) worth_15\JJ|investigating (l_xcomp) investigating_16\VBG|for (l_prep) for_17\IN|improvement (l_pobj) improvement_18\NN|of (l_prep) of_19\IN|deficits (l_pobj) deficits_21\NNS|cognitive|associated
D013311_D003072 CID streptozotocin_16\NNS| (r_pobj) with_15\IN|streptozotocin (r_prep) treated_13\VBD|intracerebroventricularly|with (r_acl) deficits_8\NNS|cognitive|in|treated
D013311_D003072 CID streptozotocin_23\NNS| (r_npadvmod) induced_25\VBN|streptozotocin|- (r_amod) model_32\NN|induced|(|icv|)|rat|of|,|tested (r_pobj) in_22\IN|model (r_prep) treatment_18\NN|(|kg|)|on|in (l_prep) on_19\IN|deficits (l_pobj) deficits_21\NNS|cognitive
D013311_D003072 CID STZ_27\NNP| (r_nmod) icv_29\NN|stz|- (r_nmod) model_32\NN|induced|(|icv|)|rat|of|,|tested (r_pobj) in_22\IN|model (r_prep) treatment_18\NN|(|kg|)|on|in (l_prep) on_19\IN|deficits (l_pobj) deficits_21\NNS|cognitive
D013311_D003072 CID STZ_10\NNP| (r_compound) icv_12\NN|stz|- (r_compound) administration_13\NN|the|icv (r_pobj) after_8\IN|administration (r_prep) initiated_6\VBD|month|immediately|after|,|prevented|. (l_conj) prevented_16\VBN|successfully|development (l_dobj) development_17\NN|of (l_prep) of_18\IN|deficits (l_pobj) deficits_26\NNS|the|induced|cognitive
D013311_D003072 CID STZ_20\NNP| (r_compound) icv_22\NN|stz|- (r_npadvmod) induced_24\VBN|icv|- (r_amod) deficits_26\NNS|the|induced|cognitive
D005947_D003704 NONE glucose_33\NN| (r_compound) transport_34\NN|decreased|glucose|via|and|metabolism (r_pobj) by_31\IN|transport (r_agent) followed_30\VBN|by (r_acl) dysfunction_20\NN|of|followed (r_pobj) with_19\IN|dysfunction (r_prep) associated_18\VBN|that|dementia|is|with (l_nsubjpass) dementia_7\NN|of
D005947_D003704 NONE glucose_36\NN| (r_compound) GLUT4_38\NNPS|glucose|transporter (r_pobj) via_35\IN|glut4 (r_prep) transport_34\NN|decreased|glucose|via|and|metabolism (r_pobj) by_31\IN|transport (r_agent) followed_30\VBN|by (r_acl) dysfunction_20\NN|of|followed (r_pobj) with_19\IN|dysfunction (r_prep) associated_18\VBN|that|dementia|is|with (l_nsubjpass) dementia_7\NN|of
D005947_D003704 NONE glucose_41\NN| (r_compound) metabolism_42\NN|decreased|glucose|in (r_conj) transport_34\NN|decreased|glucose|via|and|metabolism (r_pobj) by_31\IN|transport (r_agent) followed_30\VBN|by (r_acl) dysfunction_20\NN|of|followed (r_pobj) with_19\IN|dysfunction (r_prep) associated_18\VBN|that|dementia|is|with (l_nsubjpass) dementia_7\NN|of
D005947_D000544 CID glucose_33\NN| (r_compound) transport_34\NN|decreased|glucose|via|and|metabolism (r_pobj) by_31\IN|transport (r_agent) followed_30\VBN|by (r_acl) dysfunction_20\NN|of|followed (r_pobj) with_19\IN|dysfunction (r_prep) associated_18\VBN|that|dementia|is|with (l_nsubjpass) dementia_7\NN|of (l_prep) of_8\IN|type (l_pobj) type_16\NN|disease|(|sad|) (l_nmod) disease_12\NN|sporadic|alzheimer
D005947_D000544 CID glucose_36\NN| (r_compound) GLUT4_38\NNPS|glucose|transporter (r_pobj) via_35\IN|glut4 (r_prep) transport_34\NN|decreased|glucose|via|and|metabolism (r_pobj) by_31\IN|transport (r_agent) followed_30\VBN|by (r_acl) dysfunction_20\NN|of|followed (r_pobj) with_19\IN|dysfunction (r_prep) associated_18\VBN|that|dementia|is|with (l_nsubjpass) dementia_7\NN|of (l_prep) of_8\IN|type (l_pobj) type_16\NN|disease|(|sad|) (l_nmod) disease_12\NN|sporadic|alzheimer
D005947_D000544 CID glucose_41\NN| (r_compound) metabolism_42\NN|decreased|glucose|in (r_conj) transport_34\NN|decreased|glucose|via|and|metabolism (r_pobj) by_31\IN|transport (r_agent) followed_30\VBN|by (r_acl) dysfunction_20\NN|of|followed (r_pobj) with_19\IN|dysfunction (r_prep) associated_18\VBN|that|dementia|is|with (l_nsubjpass) dementia_7\NN|of (l_prep) of_8\IN|type (l_pobj) type_16\NN|disease|(|sad|) (l_nmod) disease_12\NN|sporadic|alzheimer
D005690_D008569 NONE galactose_5\NN| (r_pobj) of_4\IN|galactose (r_prep) injections_3\NNS|exclusively|parenteral|daily|of (r_nsubj) induce_6\VBP|injections|deterioration|and|used|,|but|tested (l_dobj) deterioration_8\NN|memory|in
D005690_D008569 NONE galactose_25\NN| (r_compound) treatment_26\NN|oral|galactose|on (r_pobj) of_23\IN|treatment (r_prep) effects_22\NNS|the|of (r_nsubjpass) tested_33\VBN|effects|have|never|been|. (r_conj) induce_6\VBP|injections|deterioration|and|used|,|but|tested (l_dobj) deterioration_8\NN|memory|in
D005690_D018149 NONE galactose_1\NN| (r_compound) exposure_2\NN|oral|galactose (r_nsubj) have_4\VB|exposure|might|effects|and|be|. (l_conj) be_14\VB|could|worth (l_acomp) worth_15\JJ|investigating (l_xcomp) investigating_16\VBG|for (l_prep) for_17\IN|improvement (l_pobj) improvement_18\NN|of (l_prep) of_19\IN|deficits (l_pobj) deficits_21\NNS|cognitive|associated (l_acl) associated_22\VBN|with (l_prep) with_23\IN|hypometabolism (l_pobj) hypometabolism_25\NN|glucose|in
D005690_D000544 NONE galactose_1\NN| (r_compound) exposure_2\NN|oral|galactose (r_nsubj) have_4\VB|exposure|might|effects|and|be|. (l_conj) be_14\VB|could|worth (l_acomp) worth_15\JJ|investigating (l_xcomp) investigating_16\VBG|for (l_prep) for_17\IN|improvement (l_pobj) improvement_18\NN|of (l_prep) of_19\IN|deficits (l_pobj) deficits_21\NNS|cognitive|associated (l_acl) associated_22\VBN|with (l_prep) with_23\IN|hypometabolism (l_pobj) hypometabolism_25\NN|glucose|in (l_prep) in_26\IN|ad (l_pobj) AD_27\NN|
11229942
D003042_D066126 NONE Cocaine_0\NN|,|ethanol|. (l_appos) ethanol_2\NN|,|and|cocaethylene (l_conj) cocaethylene_5\NN|cardiotoxity|in (l_dobj) cardiotoxity_6\NN|
D003042_D066126 NONE cocaine_28\NN| (r_compound) metabolite_29\NN|a|cocaine|formed (r_appos) cocaethylene_22\NN|ce|,|metabolite (r_pobj) due_20\JJ|to|cocaethylene (r_acomp) be_19\VB|be|;|however|,|they|may|also|due|. (l_ccomp) be_5\VB|toxicity|may|due (l_nsubj) toxicity_3\NN|their|combined|cardiac
D003042_D066126 NONE cocaine_17\NN|and|ethanol (r_pobj) of_16\IN|cocaine (r_prep) cardiotoxicity_15\NN|the|combined|of|in
D003042_D019970 NONE Cocaine_0\NN|,|ethanol|. (l_appos) ethanol_2\NN|,|and|cocaethylene (l_conj) cocaethylene_5\NN|cardiotoxity|in (l_prep) in_7\IN|model (l_pobj) model_10\NN|an|animal|of (l_prep) of_11\IN|cocaine (l_pobj) cocaine_12\NN|and|abuse (l_conj) abuse_15\NN|ethanol
D003042_D000437 NONE Cocaine_0\NN|,|ethanol|. (l_appos) ethanol_2\NN|,|and|cocaethylene (l_conj) cocaethylene_5\NN|cardiotoxity|in (l_prep) in_7\IN|model (l_pobj) model_10\NN|an|animal|of (l_prep) of_11\IN|cocaine (l_pobj) cocaine_12\NN|and|abuse (l_conj) abuse_15\NN|ethanol
D000431_D066126 NONE ethanol_2\NN|,|and|cocaethylene (l_conj) cocaethylene_5\NN|cardiotoxity|in (l_dobj) cardiotoxity_6\NN|
D000431_D066126 NONE ethanol_36\NN| (r_pobj) of_35\IN|ethanol (r_prep) presence_34\NN|the|of (r_pobj) in_32\IN|only|presence (r_prep) formed_30\VBN|in (r_acl) metabolite_29\NN|a|cocaine|formed (r_appos) cocaethylene_22\NN|ce|,|metabolite (r_pobj) due_20\JJ|to|cocaethylene (r_acomp) be_19\VB|be|;|however|,|they|may|also|due|. (l_ccomp) be_5\VB|toxicity|may|due (l_nsubj) toxicity_3\NN|their|combined|cardiac
D000431_D066126 NONE ethanol_19\NN| (r_conj) cocaine_17\NN|and|ethanol (r_pobj) of_16\IN|cocaine (r_prep) cardiotoxicity_15\NN|the|combined|of|in
D000431_D019970 NONE ethanol_2\NN|,|and|cocaethylene (l_conj) cocaethylene_5\NN|cardiotoxity|in (l_prep) in_7\IN|model (l_pobj) model_10\NN|an|animal|of (l_prep) of_11\IN|cocaine (l_pobj) cocaine_12\NN|and|abuse (l_conj) abuse_15\NN|ethanol
D000431_D000437 NONE ethanol_2\NN|,|and|cocaethylene (l_conj) cocaethylene_5\NN|cardiotoxity|in (l_prep) in_7\IN|model (l_pobj) model_10\NN|an|animal|of (l_prep) of_11\IN|cocaine (l_pobj) cocaine_12\NN|and|abuse (l_conj) abuse_15\NN|ethanol
C066444_D066126 NONE cocaethylene_5\NN|cardiotoxity|in (l_dobj) cardiotoxity_6\NN|
C066444_D066126 NONE cocaethylene_22\NN|ce|,|metabolite (r_pobj) due_20\JJ|to|cocaethylene (r_acomp) be_19\VB|be|;|however|,|they|may|also|due|. (l_ccomp) be_5\VB|toxicity|may|due (l_nsubj) toxicity_3\NN|their|combined|cardiac
C066444_D066126 NONE CE_24\NNP|(|) (r_appos) cocaethylene_22\NN|ce|,|metabolite (r_pobj) due_20\JJ|to|cocaethylene (r_acomp) be_19\VB|be|;|however|,|they|may|also|due|. (l_ccomp) be_5\VB|toxicity|may|due (l_nsubj) toxicity_3\NN|their|combined|cardiac
C066444_D066126 NONE CE_11\NNP| (r_pobj) of_10\IN|ce (r_prep) role_9\NN|the|of|in (l_prep) in_12\IN|cardiotoxicity (l_pobj) cardiotoxicity_15\NN|the|combined|of|in
C066444_D019970 NONE cocaethylene_5\NN|cardiotoxity|in (l_prep) in_7\IN|model (l_pobj) model_10\NN|an|animal|of (l_prep) of_11\IN|cocaine (l_pobj) cocaine_12\NN|and|abuse (l_conj) abuse_15\NN|ethanol
C066444_D000437 NONE cocaethylene_5\NN|cardiotoxity|in (l_prep) in_7\IN|model (l_pobj) model_10\NN|an|animal|of (l_prep) of_11\IN|cocaine (l_pobj) cocaine_12\NN|and|abuse (l_conj) abuse_15\NN|ethanol
C066444_D002303 CID CE_1\NNP|peak (r_compound) levels_2\NNS|ce (r_nsubjpass) associated_4\VBN|levels|were|with|decrease|. (l_conj) decrease_25\NN|ci|in|(|0.05|)|,|%|)|(|p|)|(|0.025|) (l_prep) in_26\IN|output (l_pobj) output_28\NN|cardiac
C066444_D009202 NONE cocaethylene_2\NN| (r_compound) concentrations_3\NNS|peak|serum|cocaethylene (r_nsubjpass) associated_5\VBN|concentrations|were|with|. (l_prep) with_6\IN|depression (l_pobj) depression_9\NN|prolonged|myocardial
2782734
D000420_D001249 NONE salbutamol_15\NN| (r_dobj) inhaled_14\VBN|tachyphylaxis|salbutamol|in|. (l_prep) in_16\IN|asthmatics (l_pobj) asthmatics_17\NNS|
D000420_D001249 NONE salbutamol_4\NN|inhaled (r_pobj) of_2\IN|salbutamol (r_prep) doses_1\NNS|high|of (r_nsubj) produce_5\VB|doses|improvements|,|and|associated|. (l_dobj) improvements_7\NNS|substantial|in (l_prep) in_8\IN|response (l_pobj) response_10\NN|airway|in (l_prep) in_11\IN|patients (l_pobj) patients_12\NNS|with (l_prep) with_13\IN|asthma (l_pobj) asthma_14\NN|
D000420_D001249 NONE salbutamol_34\NN|inhaled|hds|, (r_appos) dose_32\NN|high|salbutamol (r_pobj) with_30\IN|dose (r_prep) treatment_29\NN|a|14-day|with (r_dobj) given_26\VBN|predicted|were|treatment|daily|salbutamol|. (l_nsubjpass) predicted_10\VBD|patients|%|)|,|requiring|, (l_nsubj) patients_2\NNS|twelve|asthmatic|(|fev1 (l_amod) asthmatic_1\JJ|
D000420_D001249 NONE salbutamol_46\NN|,|inhaled|(|lds|)|,|daily|by|in (r_dobj) given_26\VBN|predicted|were|treatment|daily|salbutamol|. (l_nsubjpass) predicted_10\VBD|patients|%|)|,|requiring|, (l_nsubj) patients_2\NNS|twelve|asthmatic|(|fev1 (l_amod) asthmatic_1\JJ|
24727461
C005975_D028361 NONE Hydroxytyrosol_0\NNP| (r_nsubj) ameliorates_1\VBZ|hydroxytyrosol|stress|in|. (l_dobj) stress_3\NN|oxidative|and|dysfunction (l_conj) dysfunction_6\NN|mitochondrial
C005975_D066126 NONE Hydroxytyrosol_0\NNP| (r_nsubj) ameliorates_1\VBZ|hydroxytyrosol|stress|in|. (l_prep) in_7\IN|cardiotoxicity (l_pobj) cardiotoxicity_11\NN|induced|in
C005975_D066126 NONE hydroxytyrosol_17\NN|the|antioxidant|in (r_pobj) with_14\IN|hydroxytyrosol (r_prep) ameliorated_13\VBN|whether|toxicity|can|be|with (l_nsubjpass) toxicity_10\NN|associated|chronic|cardiac
C005975_D001943 NONE Hydroxytyrosol_0\NNP| (r_nsubj) ameliorates_1\VBZ|hydroxytyrosol|stress|in|. (l_prep) in_7\IN|cardiotoxicity (l_pobj) cardiotoxicity_11\NN|induced|in (l_prep) in_12\IN|rats (l_pobj) rats_13\NNS|with (l_prep) with_14\IN|cancer (l_pobj) cancer_16\NN|breast
C005975_D001943 NONE hydroxytyrosol_17\NN|the|antioxidant|in (l_prep) in_18\IN|rats (l_pobj) rats_19\NNS|with (l_prep) with_20\IN|cancer (l_pobj) cancer_22\NN|breast
C005975_D001943 NONE hydroxytyrosol_17\NN| (r_conj) control_15\NN|,|hydroxytyrosol|week (r_appos) groups_13\NNS|4|:|control|) (r_pobj) into_11\IN|groups (r_prep) divided_10\VBN|induced|were|into|,|doxorubicin|. (l_csubjpass) induced_7\VBD|rats|chemically (l_nsubj) rats_3\NNS|six|bearing (l_acl) bearing_4\VBG|tumors (l_dobj) tumors_6\NNS|breast
C005975_D001943 NONE hydroxytyrosol_40\NN| (r_conj) doxorubicin_38\NN|plus|hydroxytyrosol (r_conj) doxorubicin_28\NN|week|,|and|doxorubicin (r_appos) divided_10\VBN|induced|were|into|,|doxorubicin|. (l_csubjpass) induced_7\VBD|rats|chemically (l_nsubj) rats_3\NNS|six|bearing (l_acl) bearing_4\VBG|tumors (l_dobj) tumors_6\NNS|breast
D004317_D028361 NONE doxorubicin_8\NN| (r_npadvmod) induced_10\VBN|doxorubicin|- (r_amod) cardiotoxicity_11\NN|induced|in (r_pobj) in_7\IN|cardiotoxicity (r_prep) ameliorates_1\VBZ|hydroxytyrosol|stress|in|. (l_dobj) stress_3\NN|oxidative|and|dysfunction (l_conj) dysfunction_6\NN|mitochondrial
D004317_D028361 NONE Doxorubicin_0\NNP| (r_nsubj) causes_1\VBZ|doxorubicin|cardiotoxicity|. (l_dobj) cardiotoxicity_3\NN|significant|characterized (l_acl) characterized_4\VBN|by (l_agent) by_5\IN|increases (l_pobj) increases_7\NNS|marked|in (l_prep) in_8\IN|stress (l_pobj) stress_10\NN|oxidative|and|dysfunction (l_conj) dysfunction_13\NN|mitochondrial
D004317_D066126 NONE doxorubicin_8\NN| (r_npadvmod) induced_10\VBN|doxorubicin|- (r_amod) cardiotoxicity_11\NN|induced|in
D004317_D066126 NONE Doxorubicin_0\NNP| (r_nsubj) causes_1\VBZ|doxorubicin|cardiotoxicity|. (l_dobj) cardiotoxicity_3\NN|significant|characterized
D004317_D066126 NONE doxorubicin_5\RB| (r_npadvmod) associated_7\VBN|doxorubicin|- (r_amod) toxicity_10\NN|associated|chronic|cardiac
D004317_D001943 NONE doxorubicin_8\NN| (r_npadvmod) induced_10\VBN|doxorubicin|- (r_amod) cardiotoxicity_11\NN|induced|in (l_prep) in_12\IN|rats (l_pobj) rats_13\NNS|with (l_prep) with_14\IN|cancer (l_pobj) cancer_16\NN|breast
D004317_D001943 NONE doxorubicin_5\RB| (r_npadvmod) associated_7\VBN|doxorubicin|- (r_amod) toxicity_10\NN|associated|chronic|cardiac (r_nsubjpass) ameliorated_13\VBN|whether|toxicity|can|be|with (l_prep) with_14\IN|hydroxytyrosol (l_pobj) hydroxytyrosol_17\NN|the|antioxidant|in (l_prep) in_18\IN|rats (l_pobj) rats_19\NNS|with (l_prep) with_20\IN|cancer (l_pobj) cancer_22\NN|breast
D004317_D001943 NONE doxorubicin_28\NN|week|,|and|doxorubicin (r_appos) divided_10\VBN|induced|were|into|,|doxorubicin|. (l_csubjpass) induced_7\VBD|rats|chemically (l_nsubj) rats_3\NNS|six|bearing (l_acl) bearing_4\VBG|tumors (l_dobj) tumors_6\NNS|breast
D004317_D001943 NONE doxorubicin_38\NN|plus|hydroxytyrosol (r_conj) doxorubicin_28\NN|week|,|and|doxorubicin (r_appos) divided_10\VBN|induced|were|into|,|doxorubicin|. (l_csubjpass) induced_7\VBD|rats|chemically (l_nsubj) rats_3\NNS|six|bearing (l_acl) bearing_4\VBG|tumors (l_dobj) tumors_6\NNS|breast
D004317_D009369 NONE doxorubicin_28\NN| (r_pobj) as_27\IN|such|doxorubicin (r_prep) drugs_25\NNS|as (r_pobj) of_24\IN|drugs (r_prep) effect_23\NN|the|therapeutic|of (r_dobj) potentiate_20\VB|to|effect (r_xcomp) shown_18\VBN|has|been|potentiate (r_conj) involved_3\VBN|stress|is|in|,|and|shown|. (l_prep) in_4\IN|processes (l_pobj) processes_6\NNS|several|including (l_prep) including_7\VBG|cancer (l_pobj) cancer_8\NN|,|disease
D004317_D002318 NONE doxorubicin_28\NN| (r_pobj) as_27\IN|such|doxorubicin (r_prep) drugs_25\NNS|as (r_pobj) of_24\IN|drugs (r_prep) effect_23\NN|the|therapeutic|of (r_dobj) potentiate_20\VB|to|effect (r_xcomp) shown_18\VBN|has|been|potentiate (r_conj) involved_3\VBN|stress|is|in|,|and|shown|. (l_prep) in_4\IN|processes (l_pobj) processes_6\NNS|several|including (l_prep) including_7\VBG|cancer (l_pobj) cancer_8\NN|,|disease (l_conj) disease_13\NN|aging
C005975_D006331 NONE Hydroxytyrosol_0\NNP| (r_nsubj) improved_1\VBD|hydroxytyrosol|disturbances|. (l_dobj) disturbances_4\NNS|the|cardiac|enhanced
C005975_D006331 NONE hydroxytyrosol_4\JJ|that|damage (l_dobj) damage_8\NN|protect|rat|heart|provoked
D004317_D006331 CID doxorubicin_7\NN| (r_pobj) by_6\IN|doxorubicin (r_agent) enhanced_5\VBN|by|by (r_acl) disturbances_4\NNS|the|cardiac|enhanced
D004317_D006331 CID doxorubicin_11\NN| (r_nmod) decreasing_12\VBG|doxorubicin|damage (r_advcl) demonstrates_2\VBZ|study|hydroxytyrosol|decreasing|. (l_ccomp) hydroxytyrosol_4\JJ|that|damage (l_dobj) damage_8\NN|protect|rat|heart|provoked
19184102
D014635_D065626 CID valproate_5\NN| (r_amod) therapy_6\NN|valproate (r_pobj) during_4\IN|therapy (r_prep) disease_3\NN|nonalcoholic|fatty|liver|during|.
D014635_D065626 CID VPA_20\NNP| (r_compound) treatment_21\NN|vpa (r_pobj) during_19\IN|treatment (r_prep) developed_17\VBD|who|obesity|during (r_relcl) child_15\NN|a|developed (r_pobj) in_13\IN|child (r_prep) arising_12\VBG|in (r_acl) disease_8\NN|nonalcoholic|fatty|liver|(|nafld|)|arising
D014635_D065626 CID VPA_20\NNP| (r_compound) treatment_21\NN|vpa (r_pobj) during_19\IN|treatment (r_prep) developed_17\VBD|who|obesity|during (r_relcl) child_15\NN|a|developed (r_pobj) in_13\IN|child (r_prep) arising_12\VBG|in (r_acl) disease_8\NN|nonalcoholic|fatty|liver|(|nafld|)|arising (l_appos) NAFLD_10\NNP|
D014635_D065626 CID VPA_18\NNP| (r_pobj) with_17\IN|vpa (r_prep) treatment_16\NN|term|with (r_conj) resistance_10\NN|insulin|,|and|treatment (r_conj) hyperinsulinemia_7\NN|,|resistance (r_conj) obesity_5\NN|,|hyperinsulinemia (r_nsubjpass) associated_22\VBN|that|obesity|may|be|all|with (l_prep) with_23\IN|development (l_pobj) development_25\NN|the|of (l_prep) of_26\IN|nafld (l_pobj) NAFLD_27\NNP|
D014635_D065626 CID VPA_35\NNP| (r_compound) withdrawal_36\NN|vpa (r_pobj) after_34\IN|withdrawal (r_prep) is_32\VBZ|suggests|;|effect|reversible|after|. (l_ccomp) suggests_3\VBZ|case|associated (l_ccomp) associated_22\VBN|that|obesity|may|be|all|with (l_prep) with_23\IN|development (l_pobj) development_25\NN|the|of (l_prep) of_26\IN|nafld (l_pobj) NAFLD_27\NNP|
D014635_D004827 NONE acid_1\NN|valproic|(|vpa|) (r_nsubj) is_5\VBZ|acid|effective|,|but|associated (l_acomp) effective_6\JJ|for (l_prep) for_7\IN|treatment (l_pobj) treatment_9\NN|the|of (l_prep) of_10\IN|types (l_pobj) types_12\NNS|many|of (l_prep) of_13\IN|epilepsy (l_pobj) epilepsy_14\NN|
D014635_D004827 NONE VPA_3\NNP| (r_appos) acid_1\NN|valproic|(|vpa|) (r_nsubj) is_5\VBZ|acid|effective|,|but|associated (l_acomp) effective_6\JJ|for (l_prep) for_7\IN|treatment (l_pobj) treatment_9\NN|the|of (l_prep) of_10\IN|types (l_pobj) types_12\NNS|many|of (l_prep) of_13\IN|epilepsy (l_pobj) epilepsy_14\NN|
D014635_D009765 CID VPA_20\NNP| (r_compound) treatment_21\NN|vpa (r_pobj) during_19\IN|treatment (r_prep) developed_17\VBD|who|obesity|during (l_dobj) obesity_18\NN|
D014635_D009765 CID VPA_18\NNP| (r_pobj) with_17\IN|vpa (r_prep) treatment_16\NN|term|with (r_conj) resistance_10\NN|insulin|,|and|treatment (r_conj) hyperinsulinemia_7\NN|,|resistance (r_conj) obesity_5\NN|,|hyperinsulinemia
D014635_D009765 CID VPA_35\NNP| (r_compound) withdrawal_36\NN|vpa (r_pobj) after_34\IN|withdrawal (r_prep) is_32\VBZ|suggests|;|effect|reversible|after|. (l_ccomp) suggests_3\VBZ|case|associated (l_ccomp) associated_22\VBN|that|obesity|may|be|all|with (l_nsubjpass) obesity_5\NN|,|hyperinsulinemia
D014635_D015431 NONE VPA_4\NNP| (r_compound) therapy_5\NN|vpa (r_pobj) of_3\IN|therapy (r_prep) withdrawal_2\NN|the|of (r_pobj) After_0\IN|withdrawal (r_prep) showed_9\VBD|after|,|patient|loss (l_dobj) loss_13\NN|a|significant|weight|,|decrease
D014635_D006946 CID VPA_18\NNP| (r_pobj) with_17\IN|vpa (r_prep) treatment_16\NN|term|with (r_conj) resistance_10\NN|insulin|,|and|treatment (r_conj) hyperinsulinemia_7\NN|,|resistance
D014635_D006946 CID VPA_35\NNP| (r_compound) withdrawal_36\NN|vpa (r_pobj) after_34\IN|withdrawal (r_prep) is_32\VBZ|suggests|;|effect|reversible|after|. (l_ccomp) suggests_3\VBZ|case|associated (l_ccomp) associated_22\VBN|that|obesity|may|be|all|with (l_nsubjpass) obesity_5\NN|,|hyperinsulinemia (l_conj) hyperinsulinemia_7\NN|,|resistance
D014635_D007333 CID VPA_18\NNP| (r_pobj) with_17\IN|vpa (r_prep) treatment_16\NN|term|with (r_conj) resistance_10\NN|insulin|,|and|treatment
D014635_D007333 CID VPA_35\NNP| (r_compound) withdrawal_36\NN|vpa (r_pobj) after_34\IN|withdrawal (r_prep) is_32\VBZ|suggests|;|effect|reversible|after|. (l_ccomp) suggests_3\VBZ|case|associated (l_ccomp) associated_22\VBN|that|obesity|may|be|all|with (l_nsubjpass) obesity_5\NN|,|hyperinsulinemia (l_conj) hyperinsulinemia_7\NN|,|resistance (l_conj) resistance_10\NN|insulin|,|and|treatment
10726030
D006493_D013921 CID heparin_3\NN| (r_npadvmod) induced_5\VBN|heparin|- (r_amod) thrombocytopenia_6\NN|induced|and|thrombosis
D006493_D013921 CID heparin_14\JJ| (r_compound) therapy_15\NN|heparin (r_pobj) of_13\IN|therapy (r_prep) effects_12\NNS|other|side|of (r_conj) thrombosis_8\NN|and|effects (r_conj) thrombocytopenia_6\NN|induced|and|thrombosis
D006493_D013921 CID heparin_7\JJ| (r_compound) therapy_8\NN|heparin (r_pobj) of_6\IN|therapy (r_prep) effects_5\NNS|additional|important|untoward|of (r_nsubj) include_9\VBP|however|,|effects|thrombocytopenia|. (l_dobj) thrombocytopenia_13\NN|induced|,|osteoporosis
D006493_D013921 CID heparin_7\JJ| (r_compound) therapy_8\NN|heparin (r_pobj) of_6\IN|therapy (r_prep) effects_5\NNS|additional|important|untoward|of (r_nsubj) include_9\VBP|however|,|effects|thrombocytopenia|. (l_dobj) thrombocytopenia_13\NN|induced|,|osteoporosis (l_conj) osteoporosis_18\NN|associated|,|eosinophilia (l_conj) eosinophilia_20\NN|,|reactions (l_conj) reactions_23\NNS|skin|,|reactions (l_conj) reactions_26\NNS|allergic|other (l_amod) other_27\JJ|than (l_prep) than_28\IN|thrombocytopenia (l_pobj) thrombocytopenia_29\JJ|,|alopecia
D006493_D013921 CID heparin_10\NN| (r_npadvmod) induced_12\VBN|heparin|- (r_amod) thrombocytopenia_13\NN|induced|,|osteoporosis
D006493_D013921 CID heparin_10\NN| (r_npadvmod) induced_12\VBN|heparin|- (r_amod) thrombocytopenia_13\NN|induced|,|osteoporosis (l_conj) osteoporosis_18\NN|associated|,|eosinophilia (l_conj) eosinophilia_20\NN|,|reactions (l_conj) reactions_23\NNS|skin|,|reactions (l_conj) reactions_26\NNS|allergic|other (l_amod) other_27\JJ|than (l_prep) than_28\IN|thrombocytopenia (l_pobj) thrombocytopenia_29\JJ|,|alopecia
D006493_D013921 CID heparin_15\NN| (r_npadvmod) associated_17\VBN|heparin|- (r_amod) osteoporosis_18\NN|associated|,|eosinophilia (r_conj) thrombocytopenia_13\NN|induced|,|osteoporosis
D006493_D013921 CID heparin_15\NN| (r_npadvmod) associated_17\VBN|heparin|- (r_amod) osteoporosis_18\NN|associated|,|eosinophilia (l_conj) eosinophilia_20\NN|,|reactions (l_conj) reactions_23\NNS|skin|,|reactions (l_conj) reactions_26\NNS|allergic|other (l_amod) other_27\JJ|than (l_prep) than_28\IN|thrombocytopenia (l_pobj) thrombocytopenia_29\JJ|,|alopecia
D006493_D013921 NONE heparin_18\NN| (r_pobj) of_17\IN|heparin (r_prep) use_16\NN|the|widespread|of (r_pobj) given_12\VBN|use (r_prep) are_21\VBP|given|,|some|common|. (l_acomp) common_23\JJ|quite|,|hitt (l_conj) HITT_26\NNP|particularly|and|osteoporosis
D006493_D013927 NONE heparin_3\NN| (r_npadvmod) induced_5\VBN|heparin|- (r_amod) thrombocytopenia_6\NN|induced|and|thrombosis (l_conj) thrombosis_8\NN|and|effects
D006493_D013927 NONE heparin_14\JJ| (r_compound) therapy_15\NN|heparin (r_pobj) of_13\IN|therapy (r_prep) effects_12\NNS|other|side|of (r_conj) thrombosis_8\NN|and|effects
D006493_D013927 NONE Heparin_0\NNP| (r_nsubj) used_3\VBD|heparin|,|first|prevent (r_ccomp) used_16\VBN|used|,|has|been|clinically|treat|. (l_xcomp) treat_18\VB|to|thrombosis|for (l_dobj) thrombosis_19\NN|
D006493_D013927 NONE heparin_9\NN| (r_nsubj) remains_10\VBZ|are|,|heparin|anticoagulant|treat|. (l_xcomp) treat_16\VB|to|episodes (l_dobj) episodes_19\NNS|acute|thrombotic (l_amod) thrombotic_18\JJ|
D006493_D013927 NONE heparin_18\NN| (r_pobj) of_17\IN|heparin (r_prep) use_16\NN|the|widespread|of (r_pobj) given_12\VBN|use (r_prep) are_21\VBP|given|,|some|common|. (l_acomp) common_23\JJ|quite|,|hitt (l_conj) HITT_26\NNP|particularly|and|osteoporosis
D006493_D006470 NONE heparin_7\NN| (r_pobj) of_6\IN|heparin (r_prep) effect_5\NN|the|primary|untoward|of (r_attr) is_1\VBZ|bleeding|effect|. (l_nsubj) Bleeding_0\VBG|
D006493_D006470 NONE heparin_9\JJ| (r_compound) therapy_10\NN|heparin (r_dobj) receiving_8\VBG|therapy (r_acl) patients_7\NNS|receiving (r_pobj) in_6\IN|patients (r_prep) concern_5\NN|primary|in (r_pobj) of_3\IN|concern (r_prep) is_2\VBZ|bleeding|of|. (l_nsubj) bleeding_1\NN|major
D006493_D010024 CID heparin_7\JJ| (r_compound) therapy_8\NN|heparin (r_pobj) of_6\IN|therapy (r_prep) effects_5\NNS|additional|important|untoward|of (r_nsubj) include_9\VBP|however|,|effects|thrombocytopenia|. (l_dobj) thrombocytopenia_13\NN|induced|,|osteoporosis (l_conj) osteoporosis_18\NN|associated|,|eosinophilia
D006493_D010024 CID heparin_10\NN| (r_npadvmod) induced_12\VBN|heparin|- (r_amod) thrombocytopenia_13\NN|induced|,|osteoporosis (l_conj) osteoporosis_18\NN|associated|,|eosinophilia
D006493_D010024 CID heparin_15\NN| (r_npadvmod) associated_17\VBN|heparin|- (r_amod) osteoporosis_18\NN|associated|,|eosinophilia
D006493_D010024 CID heparin_18\NN| (r_pobj) of_17\IN|heparin (r_prep) use_16\NN|the|widespread|of (r_pobj) given_12\VBN|use (r_prep) are_21\VBP|given|,|some|common|. (l_acomp) common_23\JJ|quite|,|hitt (l_conj) HITT_26\NNP|particularly|and|osteoporosis (l_conj) osteoporosis_28\NN|
D006493_D004802 CID heparin_7\JJ| (r_compound) therapy_8\NN|heparin (r_pobj) of_6\IN|therapy (r_prep) effects_5\NNS|additional|important|untoward|of (r_nsubj) include_9\VBP|however|,|effects|thrombocytopenia|. (l_dobj) thrombocytopenia_13\NN|induced|,|osteoporosis (l_conj) osteoporosis_18\NN|associated|,|eosinophilia (l_conj) eosinophilia_20\NN|,|reactions
D006493_D004802 CID heparin_10\NN| (r_npadvmod) induced_12\VBN|heparin|- (r_amod) thrombocytopenia_13\NN|induced|,|osteoporosis (l_conj) osteoporosis_18\NN|associated|,|eosinophilia (l_conj) eosinophilia_20\NN|,|reactions
D006493_D004802 CID heparin_15\NN| (r_npadvmod) associated_17\VBN|heparin|- (r_amod) osteoporosis_18\NN|associated|,|eosinophilia (l_conj) eosinophilia_20\NN|,|reactions
D006493_D012871 CID heparin_7\JJ| (r_compound) therapy_8\NN|heparin (r_pobj) of_6\IN|therapy (r_prep) effects_5\NNS|additional|important|untoward|of (r_nsubj) include_9\VBP|however|,|effects|thrombocytopenia|. (l_dobj) thrombocytopenia_13\NN|induced|,|osteoporosis (l_conj) osteoporosis_18\NN|associated|,|eosinophilia (l_conj) eosinophilia_20\NN|,|reactions (l_conj) reactions_23\NNS|skin|,|reactions
D006493_D012871 CID heparin_10\NN| (r_npadvmod) induced_12\VBN|heparin|- (r_amod) thrombocytopenia_13\NN|induced|,|osteoporosis (l_conj) osteoporosis_18\NN|associated|,|eosinophilia (l_conj) eosinophilia_20\NN|,|reactions (l_conj) reactions_23\NNS|skin|,|reactions
D006493_D012871 CID heparin_15\NN| (r_npadvmod) associated_17\VBN|heparin|- (r_amod) osteoporosis_18\NN|associated|,|eosinophilia (l_conj) eosinophilia_20\NN|,|reactions (l_conj) reactions_23\NNS|skin|,|reactions
D006493_D004342 CID heparin_7\JJ| (r_compound) therapy_8\NN|heparin (r_pobj) of_6\IN|therapy (r_prep) effects_5\NNS|additional|important|untoward|of (r_nsubj) include_9\VBP|however|,|effects|thrombocytopenia|. (l_dobj) thrombocytopenia_13\NN|induced|,|osteoporosis (l_conj) osteoporosis_18\NN|associated|,|eosinophilia (l_conj) eosinophilia_20\NN|,|reactions (l_conj) reactions_23\NNS|skin|,|reactions (l_conj) reactions_26\NNS|allergic|other
D006493_D004342 CID heparin_10\NN| (r_npadvmod) induced_12\VBN|heparin|- (r_amod) thrombocytopenia_13\NN|induced|,|osteoporosis (l_conj) osteoporosis_18\NN|associated|,|eosinophilia (l_conj) eosinophilia_20\NN|,|reactions (l_conj) reactions_23\NNS|skin|,|reactions (l_conj) reactions_26\NNS|allergic|other
D006493_D004342 CID heparin_15\NN| (r_npadvmod) associated_17\VBN|heparin|- (r_amod) osteoporosis_18\NN|associated|,|eosinophilia (l_conj) eosinophilia_20\NN|,|reactions (l_conj) reactions_23\NNS|skin|,|reactions (l_conj) reactions_26\NNS|allergic|other
D006493_D000505 CID heparin_7\JJ| (r_compound) therapy_8\NN|heparin (r_pobj) of_6\IN|therapy (r_prep) effects_5\NNS|additional|important|untoward|of (r_nsubj) include_9\VBP|however|,|effects|thrombocytopenia|. (l_dobj) thrombocytopenia_13\NN|induced|,|osteoporosis (l_conj) osteoporosis_18\NN|associated|,|eosinophilia (l_conj) eosinophilia_20\NN|,|reactions (l_conj) reactions_23\NNS|skin|,|reactions (l_conj) reactions_26\NNS|allergic|other (l_amod) other_27\JJ|than (l_prep) than_28\IN|thrombocytopenia (l_pobj) thrombocytopenia_29\JJ|,|alopecia (l_conj) alopecia_31\NN|,|transaminasemia
D006493_D000505 CID heparin_10\NN| (r_npadvmod) induced_12\VBN|heparin|- (r_amod) thrombocytopenia_13\NN|induced|,|osteoporosis (l_conj) osteoporosis_18\NN|associated|,|eosinophilia (l_conj) eosinophilia_20\NN|,|reactions (l_conj) reactions_23\NNS|skin|,|reactions (l_conj) reactions_26\NNS|allergic|other (l_amod) other_27\JJ|than (l_prep) than_28\IN|thrombocytopenia (l_pobj) thrombocytopenia_29\JJ|,|alopecia (l_conj) alopecia_31\NN|,|transaminasemia
D006493_D000505 CID heparin_15\NN| (r_npadvmod) associated_17\VBN|heparin|- (r_amod) osteoporosis_18\NN|associated|,|eosinophilia (l_conj) eosinophilia_20\NN|,|reactions (l_conj) reactions_23\NNS|skin|,|reactions (l_conj) reactions_26\NNS|allergic|other (l_amod) other_27\JJ|than (l_prep) than_28\IN|thrombocytopenia (l_pobj) thrombocytopenia_29\JJ|,|alopecia (l_conj) alopecia_31\NN|,|transaminasemia
D006493_D006947 CID heparin_7\JJ| (r_compound) therapy_8\NN|heparin (r_pobj) of_6\IN|therapy (r_prep) effects_5\NNS|additional|important|untoward|of (r_nsubj) include_9\VBP|however|,|effects|thrombocytopenia|. (l_dobj) thrombocytopenia_13\NN|induced|,|osteoporosis (l_conj) osteoporosis_18\NN|associated|,|eosinophilia (l_conj) eosinophilia_20\NN|,|reactions (l_conj) reactions_23\NNS|skin|,|reactions (l_conj) reactions_26\NNS|allergic|other (l_amod) other_27\JJ|than (l_prep) than_28\IN|thrombocytopenia (l_pobj) thrombocytopenia_29\JJ|,|alopecia (l_conj) alopecia_31\NN|,|transaminasemia (l_conj) transaminasemia_33\NN|,|hyperkalemia (l_conj) hyperkalemia_35\NN|,|hypoaldosteronism
D006493_D006947 CID heparin_10\NN| (r_npadvmod) induced_12\VBN|heparin|- (r_amod) thrombocytopenia_13\NN|induced|,|osteoporosis (l_conj) osteoporosis_18\NN|associated|,|eosinophilia (l_conj) eosinophilia_20\NN|,|reactions (l_conj) reactions_23\NNS|skin|,|reactions (l_conj) reactions_26\NNS|allergic|other (l_amod) other_27\JJ|than (l_prep) than_28\IN|thrombocytopenia (l_pobj) thrombocytopenia_29\JJ|,|alopecia (l_conj) alopecia_31\NN|,|transaminasemia (l_conj) transaminasemia_33\NN|,|hyperkalemia (l_conj) hyperkalemia_35\NN|,|hypoaldosteronism
D006493_D006947 CID heparin_15\NN| (r_npadvmod) associated_17\VBN|heparin|- (r_amod) osteoporosis_18\NN|associated|,|eosinophilia (l_conj) eosinophilia_20\NN|,|reactions (l_conj) reactions_23\NNS|skin|,|reactions (l_conj) reactions_26\NNS|allergic|other (l_amod) other_27\JJ|than (l_prep) than_28\IN|thrombocytopenia (l_pobj) thrombocytopenia_29\JJ|,|alopecia (l_conj) alopecia_31\NN|,|transaminasemia (l_conj) transaminasemia_33\NN|,|hyperkalemia (l_conj) hyperkalemia_35\NN|,|hypoaldosteronism
D006493_D006994 CID heparin_7\JJ| (r_compound) therapy_8\NN|heparin (r_pobj) of_6\IN|therapy (r_prep) effects_5\NNS|additional|important|untoward|of (r_nsubj) include_9\VBP|however|,|effects|thrombocytopenia|. (l_dobj) thrombocytopenia_13\NN|induced|,|osteoporosis (l_conj) osteoporosis_18\NN|associated|,|eosinophilia (l_conj) eosinophilia_20\NN|,|reactions (l_conj) reactions_23\NNS|skin|,|reactions (l_conj) reactions_26\NNS|allergic|other (l_amod) other_27\JJ|than (l_prep) than_28\IN|thrombocytopenia (l_pobj) thrombocytopenia_29\JJ|,|alopecia (l_conj) alopecia_31\NN|,|transaminasemia (l_conj) transaminasemia_33\NN|,|hyperkalemia (l_conj) hyperkalemia_35\NN|,|hypoaldosteronism (l_conj) hypoaldosteronism_37\NN|,|and|priapism
D006493_D006994 CID heparin_10\NN| (r_npadvmod) induced_12\VBN|heparin|- (r_amod) thrombocytopenia_13\NN|induced|,|osteoporosis (l_conj) osteoporosis_18\NN|associated|,|eosinophilia (l_conj) eosinophilia_20\NN|,|reactions (l_conj) reactions_23\NNS|skin|,|reactions (l_conj) reactions_26\NNS|allergic|other (l_amod) other_27\JJ|than (l_prep) than_28\IN|thrombocytopenia (l_pobj) thrombocytopenia_29\JJ|,|alopecia (l_conj) alopecia_31\NN|,|transaminasemia (l_conj) transaminasemia_33\NN|,|hyperkalemia (l_conj) hyperkalemia_35\NN|,|hypoaldosteronism (l_conj) hypoaldosteronism_37\NN|,|and|priapism
D006493_D006994 CID heparin_15\NN| (r_npadvmod) associated_17\VBN|heparin|- (r_amod) osteoporosis_18\NN|associated|,|eosinophilia (l_conj) eosinophilia_20\NN|,|reactions (l_conj) reactions_23\NNS|skin|,|reactions (l_conj) reactions_26\NNS|allergic|other (l_amod) other_27\JJ|than (l_prep) than_28\IN|thrombocytopenia (l_pobj) thrombocytopenia_29\JJ|,|alopecia (l_conj) alopecia_31\NN|,|transaminasemia (l_conj) transaminasemia_33\NN|,|hyperkalemia (l_conj) hyperkalemia_35\NN|,|hypoaldosteronism (l_conj) hypoaldosteronism_37\NN|,|and|priapism
D006493_D011317 CID heparin_7\JJ| (r_compound) therapy_8\NN|heparin (r_pobj) of_6\IN|therapy (r_prep) effects_5\NNS|additional|important|untoward|of (r_nsubj) include_9\VBP|however|,|effects|thrombocytopenia|. (l_dobj) thrombocytopenia_13\NN|induced|,|osteoporosis (l_conj) osteoporosis_18\NN|associated|,|eosinophilia (l_conj) eosinophilia_20\NN|,|reactions (l_conj) reactions_23\NNS|skin|,|reactions (l_conj) reactions_26\NNS|allergic|other (l_amod) other_27\JJ|than (l_prep) than_28\IN|thrombocytopenia (l_pobj) thrombocytopenia_29\JJ|,|alopecia (l_conj) alopecia_31\NN|,|transaminasemia (l_conj) transaminasemia_33\NN|,|hyperkalemia (l_conj) hyperkalemia_35\NN|,|hypoaldosteronism (l_conj) hypoaldosteronism_37\NN|,|and|priapism (l_conj) priapism_40\NN|
D006493_D011317 CID heparin_10\NN| (r_npadvmod) induced_12\VBN|heparin|- (r_amod) thrombocytopenia_13\NN|induced|,|osteoporosis (l_conj) osteoporosis_18\NN|associated|,|eosinophilia (l_conj) eosinophilia_20\NN|,|reactions (l_conj) reactions_23\NNS|skin|,|reactions (l_conj) reactions_26\NNS|allergic|other (l_amod) other_27\JJ|than (l_prep) than_28\IN|thrombocytopenia (l_pobj) thrombocytopenia_29\JJ|,|alopecia (l_conj) alopecia_31\NN|,|transaminasemia (l_conj) transaminasemia_33\NN|,|hyperkalemia (l_conj) hyperkalemia_35\NN|,|hypoaldosteronism (l_conj) hypoaldosteronism_37\NN|,|and|priapism (l_conj) priapism_40\NN|
D006493_D011317 CID heparin_15\NN| (r_npadvmod) associated_17\VBN|heparin|- (r_amod) osteoporosis_18\NN|associated|,|eosinophilia (l_conj) eosinophilia_20\NN|,|reactions (l_conj) reactions_23\NNS|skin|,|reactions (l_conj) reactions_26\NNS|allergic|other (l_amod) other_27\JJ|than (l_prep) than_28\IN|thrombocytopenia (l_pobj) thrombocytopenia_29\JJ|,|alopecia (l_conj) alopecia_31\NN|,|transaminasemia (l_conj) transaminasemia_33\NN|,|hyperkalemia (l_conj) hyperkalemia_35\NN|,|hypoaldosteronism (l_conj) hypoaldosteronism_37\NN|,|and|priapism (l_conj) priapism_40\NN|
25031906
D017311_D004408 CID Amlodipine_14\NNP| (r_pobj) of_13\IN|amlodipine (r_prep) effect_12\NN|rare|-|of (r_attr) be_4\VB|to|effect (r_xcomp) Going_2\VBG|is|dysguesia|be|? (l_compound) Dysguesia_1\NNP|
D017311_D004408 CID amlodipine_7\NN| (r_pobj) of_6\IN|amlodipine (r_prep) effect_5\NN|a|rare|side|-|of (r_nsubj) is_8\VBZ|effect|dysguesia|. (l_acomp) dysguesia_9\JJ|
D017311_D004408 CID amlodipine_3\NN| (r_nsubj) cause_5\VB|that|amlodipine|can|dysguesia (l_dobj) dysguesia_6\NN|
D017311_D004408 CID amlodipine_13\NN|and|dysguesia (l_conj) dysguesia_15\NN|
D017311_D006973 NONE amlodipine_14\NN| (r_pobj) with_13\IN|amlodipine (r_prep) treatment_12\NN|drug|with (r_pobj) on_10\IN|treatment (r_prep) hypertension_9\NN|essential|on
D017311_D012678 NONE amlodipine_14\NN| (r_pobj) with_13\IN|amlodipine (r_prep) treatment_12\NN|drug|with (r_pobj) on_10\IN|treatment (r_prep) hypertension_9\NN|essential|on (r_pobj) with_7\IN|hypertension (r_prep) female_6\NN|a|with (r_pobj) about_4\IN|female (r_prep) case_3\NN|a|about (r_dobj) report_1\VBP|we|case|loss|. (l_dobj) loss_16\NN|developed|of (l_prep) of_17\IN|sensation (l_pobj) sensation_19\NN|taste
9158667
D014212_D013927 CID acid_12\NN| (r_compound) therapy_13\NN|retinoic|acid (r_pobj) during_6\IN|therapy (r_prep) complications_1\NNS|thrombotic|in|during|. (l_amod) Thrombotic_0\JJ|
D014212_D015473 NONE acid_12\NN| (r_compound) therapy_13\NN|retinoic|acid (r_pobj) during_6\IN|therapy (r_prep) complications_1\NNS|thrombotic|in|during|. (l_prep) in_2\IN|leukemia (l_pobj) leukemia_5\NN|acute|promyelocytic
D014212_D015473 NONE acid_30\NN|retinoic|atra|and|acid (r_pobj) with_24\IN|acid (r_prep) treated_23\VBN|with (r_acl) case_1\NN|a|of|,|due|treated (l_amod) due_7\IN|to|occlusion (l_pobj) occlusion_9\NN|of|in (l_prep) in_13\IN|patient (l_pobj) patient_15\NN|a|with (l_prep) with_16\IN|leukemia (l_pobj) leukemia_19\NN|acute|promyelocytic|(|apl|)
D014212_D015473 NONE acid_30\NN|retinoic|atra|and|acid (r_pobj) with_24\IN|acid (r_prep) treated_23\VBN|with (r_acl) case_1\NN|a|of|,|due|treated (l_amod) due_7\IN|to|occlusion (l_pobj) occlusion_9\NN|of|in (l_prep) in_13\IN|patient (l_pobj) patient_15\NN|a|with (l_prep) with_16\IN|leukemia (l_pobj) leukemia_19\NN|acute|promyelocytic|(|apl|) (l_appos) APL_21\NNP|
D014212_D015473 NONE ATRA_32\NNP|(|) (r_appos) acid_30\NN|retinoic|atra|and|acid (r_pobj) with_24\IN|acid (r_prep) treated_23\VBN|with (r_acl) case_1\NN|a|of|,|due|treated (l_amod) due_7\IN|to|occlusion (l_pobj) occlusion_9\NN|of|in (l_prep) in_13\IN|patient (l_pobj) patient_15\NN|a|with (l_prep) with_16\IN|leukemia (l_pobj) leukemia_19\NN|acute|promyelocytic|(|apl|)
D014212_D015473 NONE ATRA_32\NNP|(|) (r_appos) acid_30\NN|retinoic|atra|and|acid (r_pobj) with_24\IN|acid (r_prep) treated_23\VBN|with (r_acl) case_1\NN|a|of|,|due|treated (l_amod) due_7\IN|to|occlusion (l_pobj) occlusion_9\NN|of|in (l_prep) in_13\IN|patient (l_pobj) patient_15\NN|a|with (l_prep) with_16\IN|leukemia (l_pobj) leukemia_19\NN|acute|promyelocytic|(|apl|) (l_appos) APL_21\NNP|
D014212_D015473 NONE ATRA_14\NNP| (r_pobj) with_13\IN|atra (r_prep) treated_12\VBN|with|alone (r_acl) patient_11\NN|an|apl|treated (l_compound) APL_10\NNP|
D014212_D015473 NONE ATRA_11\NNP| (r_compound) therapy_12\NN|atra|in (l_prep) in_13\IN|patients (l_pobj) patients_15\NNS|apl (l_compound) APL_14\NNP|
D014212_D015473 NONE ATRA_25\NNP| (r_pobj) with_24\IN|atra (r_prep) protocol_23\NN|a|treatment|with (r_pobj) in_20\IN|protocol (r_prep) included_19\VBN|was|in (r_conj) presented_9\VBD|patients|signs|and|included|. (l_dobj) signs_12\NNS|all|the|and|symptoms|of (l_prep) of_15\IN|apl (l_pobj) APL_16\NNP|
D014212_D015473 NONE ATRA_3\NNP| (r_nsubj) is_4\VBZ|that|atra|choice|,|corrected (l_attr) choice_8\NN|a|valid|therapeutic|for (l_prep) for_9\IN|patients (l_pobj) patients_10\NNS|with (l_prep) with_11\IN|apl (l_pobj) APL_12\NNP|
D014212_D058186 CID acid_30\NN|retinoic|atra|and|acid (r_pobj) with_24\IN|acid (r_prep) treated_23\VBN|with (r_acl) case_1\NN|a|of|,|due|treated (l_prep) of_2\IN|failure (l_pobj) failure_5\NN|acute|renal
D014212_D058186 CID ATRA_32\NNP|(|) (r_appos) acid_30\NN|retinoic|atra|and|acid (r_pobj) with_24\IN|acid (r_prep) treated_23\VBN|with (r_acl) case_1\NN|a|of|,|due|treated (l_prep) of_2\IN|failure (l_pobj) failure_5\NN|acute|renal
D014212_D058186 CID ATRA_14\NNP| (r_pobj) with_13\IN|atra (r_prep) treated_12\VBN|with|alone (r_acl) patient_11\NN|an|apl|treated (r_pobj) in_8\IN|patient (r_prep) failure_7\NN|acute|renal|in
D014212_-1 NONE acid_30\NN|retinoic|atra|and|acid (r_pobj) with_24\IN|acid (r_prep) treated_23\VBN|with (r_acl) case_1\NN|a|of|,|due|treated (l_amod) due_7\IN|to|occlusion (l_pobj) occlusion_9\NN|of|in (l_prep) of_10\IN|vessels (l_pobj) vessels_12\NNS|renal
D014212_-1 NONE ATRA_32\NNP|(|) (r_appos) acid_30\NN|retinoic|atra|and|acid (r_pobj) with_24\IN|acid (r_prep) treated_23\VBN|with (r_acl) case_1\NN|a|of|,|due|treated (l_amod) due_7\IN|to|occlusion (l_pobj) occlusion_9\NN|of|in (l_prep) of_10\IN|vessels (l_pobj) vessels_12\NNS|renal
D014148_D058186 NONE acid_36\NN|tranexamic (r_conj) acid_30\NN|retinoic|atra|and|acid (r_pobj) with_24\IN|acid (r_prep) treated_23\VBN|with (r_acl) case_1\NN|a|of|,|due|treated (l_prep) of_2\IN|failure (l_pobj) failure_5\NN|acute|renal
D014148_-1 NONE acid_36\NN|tranexamic (r_conj) acid_30\NN|retinoic|atra|and|acid (r_pobj) with_24\IN|acid (r_prep) treated_23\VBN|with (r_acl) case_1\NN|a|of|,|due|treated (l_amod) due_7\IN|to|occlusion (l_pobj) occlusion_9\NN|of|in (l_prep) of_10\IN|vessels (l_pobj) vessels_12\NNS|renal
D014148_D015473 NONE acid_36\NN|tranexamic (r_conj) acid_30\NN|retinoic|atra|and|acid (r_pobj) with_24\IN|acid (r_prep) treated_23\VBN|with (r_acl) case_1\NN|a|of|,|due|treated (l_amod) due_7\IN|to|occlusion (l_pobj) occlusion_9\NN|of|in (l_prep) in_13\IN|patient (l_pobj) patient_15\NN|a|with (l_prep) with_16\IN|leukemia (l_pobj) leukemia_19\NN|acute|promyelocytic|(|apl|)
D014148_D015473 NONE acid_36\NN|tranexamic (r_conj) acid_30\NN|retinoic|atra|and|acid (r_pobj) with_24\IN|acid (r_prep) treated_23\VBN|with (r_acl) case_1\NN|a|of|,|due|treated (l_amod) due_7\IN|to|occlusion (l_pobj) occlusion_9\NN|of|in (l_prep) in_13\IN|patient (l_pobj) patient_15\NN|a|with (l_prep) with_16\IN|leukemia (l_pobj) leukemia_19\NN|acute|promyelocytic|(|apl|) (l_appos) APL_21\NNP|
D014212_D013923 NONE ATRA_11\NNP| (r_compound) therapy_12\NN|atra|in (r_pobj) with_10\IN|therapy (r_prep) associated_9\VBN|with (r_acl) complications_8\NNS|thromboembolic|associated (l_compound) thromboembolic_7\JJ|
D006493_D013927 NONE heparin_13\NN|dose (r_dobj) using_9\VBG|heparin (r_pcomp) by_8\IN|using (r_prep) avoided_7\VBN|events|,|however|,|could|be|by|. (l_nsubjpass) events_1\NNS|thrombotic (l_amod) Thrombotic_0\JJ|
24684312
D018698_D006930 NONE glutamate_1\NN|intradermal|and|injections|:|variability|. (l_appos) variability_9\NN|intra-|of (l_prep) of_10\IN|hyperalgesia (l_pobj) hyperalgesia_12\NN|provoked|and|allodynia
D018698_D006930 NONE glutamate_1\NN|intradermal|and|injections|:|variability|. (l_appos) variability_9\NN|intra-|of (l_prep) of_10\IN|hyperalgesia (l_pobj) hyperalgesia_12\NN|provoked|and|allodynia (l_conj) allodynia_14\NN|
D018698_D006930 NONE glutamate_3\NN|and|capsaicin (r_pobj) of_2\IN|glutamate (r_prep) injections_1\NNS|intradermal|of (r_nsubj) are_6\VBP|injections|attractive|mimic|. (l_advcl) mimic_19\VBP|because|hyperalgesia|aspects (l_nsubj) hyperalgesia_16\NN|and|allodynia
D018698_D006930 NONE glutamate_3\NN|and|capsaicin (r_pobj) of_2\IN|glutamate (r_prep) injections_1\NNS|intradermal|of (r_nsubj) are_6\VBP|injections|attractive|mimic|. (l_advcl) mimic_19\VBP|because|hyperalgesia|aspects (l_nsubj) hyperalgesia_16\NN|and|allodynia (l_conj) allodynia_18\NN|
D018698_D006930 NONE glutamate_32\NN| (r_compound) injection_33\NN|glutamate (r_pobj) after_31\IN|injection (r_prep) gauges_21\VBZ|60|and|g|(|p|)|after (r_pobj) to_18\IN|frey|gauges (r_prep) response_17\NN|scale|(|vas|)|to (r_pobj) in_9\IN|response (r_prep) increase_8\NN|a|marked|in (r_pobj) as_5\IN|increase (r_prep) observed_4\VBN|hyperalgesia|was|as|. (l_nsubjpass) hyperalgesia_2\NN|pinprick
D018698_D006930 NONE glutamate_3\NN|and|capsaicin (r_nmod) yield_6\NN|glutamate (r_nmod) responses_11\NNS|yield|hyperalgesic|,|and|suited (l_amod) hyperalgesic_8\JJ|reproducible|and|allodynic
D018698_D006930 NONE glutamate_3\NN|and|capsaicin (r_nmod) yield_6\NN|glutamate (r_nmod) responses_11\NNS|yield|hyperalgesic|,|and|suited (l_amod) hyperalgesic_8\JJ|reproducible|and|allodynic (l_conj) allodynic_10\JJ|
D002211_D006930 CID capsaicin_3\NN| (r_compound) injections_4\NNS|capsaicin (r_conj) glutamate_1\NN|intradermal|and|injections|:|variability|. (l_appos) variability_9\NN|intra-|of (l_prep) of_10\IN|hyperalgesia (l_pobj) hyperalgesia_12\NN|provoked|and|allodynia
D002211_D006930 CID capsaicin_3\NN| (r_compound) injections_4\NNS|capsaicin (r_conj) glutamate_1\NN|intradermal|and|injections|:|variability|. (l_appos) variability_9\NN|intra-|of (l_prep) of_10\IN|hyperalgesia (l_pobj) hyperalgesia_12\NN|provoked|and|allodynia (l_conj) allodynia_14\NN|
D002211_D006930 CID capsaicin_5\NN| (r_conj) glutamate_3\NN|and|capsaicin (r_pobj) of_2\IN|glutamate (r_prep) injections_1\NNS|intradermal|of (r_nsubj) are_6\VBP|injections|attractive|mimic|. (l_advcl) mimic_19\VBP|because|hyperalgesia|aspects (l_nsubj) hyperalgesia_16\NN|and|allodynia
D002211_D006930 CID capsaicin_5\NN| (r_conj) glutamate_3\NN|and|capsaicin (r_pobj) of_2\IN|glutamate (r_prep) injections_1\NNS|intradermal|of (r_nsubj) are_6\VBP|injections|attractive|mimic|. (l_advcl) mimic_19\VBP|because|hyperalgesia|aspects (l_nsubj) hyperalgesia_16\NN|and|allodynia (l_conj) allodynia_18\NN|
D002211_D006930 CID capsaicin_1\NN| (r_pobj) For_0\IN|capsaicin (r_prep) detected_7\VBN|for|,|hyperalgesia|was|with|. (l_nsubjpass) hyperalgesia_5\NN|secondary|pinprick
D002211_D006930 CID Capsaicin_0\NN| (r_compound) injection_1\NN|capsaicin (r_nsubj) was_2\VBD|injection|reproducible|>|and|allodynia|. (l_acomp) reproducible_3\JJ|for (l_prep) for_4\IN|hyperalgesia (l_pobj) hyperalgesia_6\NN|secondary
D002211_D006930 CID Capsaicin_0\NN| (r_compound) injection_1\NN|capsaicin (r_nsubj) was_2\VBD|injection|reproducible|>|and|allodynia|. (l_attr) allodynia_13\NN|(|icc|)
D002211_D006930 CID capsaicin_5\NN| (r_conj) glutamate_3\NN|and|capsaicin (r_nmod) yield_6\NN|glutamate (r_nmod) responses_11\NNS|yield|hyperalgesic|,|and|suited (l_amod) hyperalgesic_8\JJ|reproducible|and|allodynic
D002211_D006930 CID capsaicin_5\NN| (r_conj) glutamate_3\NN|and|capsaicin (r_nmod) yield_6\NN|glutamate (r_nmod) responses_11\NNS|yield|hyperalgesic|,|and|suited (l_amod) hyperalgesic_8\JJ|reproducible|and|allodynic (l_conj) allodynic_10\JJ|
D018698_D010146 NONE glutamate_3\NN|and|capsaicin (r_pobj) of_2\IN|glutamate (r_prep) injections_1\NNS|intradermal|of (r_nsubj) are_6\VBP|injections|attractive|mimic|. (l_acomp) attractive_7\JJ|use (l_xcomp) use_9\VB|to|in (l_prep) in_10\IN|models (l_pobj) models_14\NNS|human|experimental|pain (l_compound) pain_13\NN|
D018698_D013001 NONE glutamate_3\NN|and|capsaicin (r_pobj) of_2\IN|glutamate (r_prep) injections_1\NNS|intradermal|of (r_nsubj) are_6\VBP|injections|attractive|mimic|. (l_advcl) mimic_19\VBP|because|hyperalgesia|aspects (l_dobj) aspects_21\NNS|isolated|of (l_prep) of_22\IN|disorders (l_pobj) disorders_25\NNS|clinical|pain
D002211_D010146 NONE capsaicin_5\NN| (r_conj) glutamate_3\NN|and|capsaicin (r_pobj) of_2\IN|glutamate (r_prep) injections_1\NNS|intradermal|of (r_nsubj) are_6\VBP|injections|attractive|mimic|. (l_acomp) attractive_7\JJ|use (l_xcomp) use_9\VB|to|in (l_prep) in_10\IN|models (l_pobj) models_14\NNS|human|experimental|pain (l_compound) pain_13\NN|
D002211_D013001 NONE capsaicin_5\NN| (r_conj) glutamate_3\NN|and|capsaicin (r_pobj) of_2\IN|glutamate (r_prep) injections_1\NNS|intradermal|of (r_nsubj) are_6\VBP|injections|attractive|mimic|. (l_advcl) mimic_19\VBP|because|hyperalgesia|aspects (l_dobj) aspects_21\NNS|isolated|of (l_prep) of_22\IN|disorders (l_pobj) disorders_25\NNS|clinical|pain
1158089
D013752_D005234 CID tetracycline_4\NN| (r_pobj) by_3\IN|tetracycline (r_agent) induced_2\VBN|by|in (r_acl) liver_1\NN|fatty|induced|.
D013752_D005234 CID tetracycline_18\NN| (r_pobj) by_17\IN|tetracycline (r_agent) induced_16\VBN|by (r_acl) relationships_3\NNS|response|,|mechanisms|induced (l_conj) mechanisms_6\NNS|biochemical|,|and|differences (l_conj) differences_10\NNS|sex|in (l_prep) in_11\IN|liver (l_pobj) liver_15\NN|the|experimental|fatty
D013752_D005234 CID tetracycline_37\NN| (r_pobj) to_36\IN|tetracycline (r_prep) response_35\NN|to (r_pobj) in_34\IN|response (r_prep) production_26\NN|the|of|in (l_prep) of_27\IN|liver (l_pobj) liver_33\NN|the|rich|fatty
D019301_D003866 NONE acid_5\NN|adequate|oleic (r_pobj) of_2\IN|acid (r_prep) provision_1\NN|of|as (r_pobj) With_0\IN|provision (r_prep) observed_19\VBN|with|,|relationship|was|between|. (l_prep) between_20\IN|dose (l_pobj) dose_21\NN|of|and|accumulation (l_conj) accumulation_26\NN|both|of|by (l_prep) of_27\IN|triglyceride (l_pobj) triglyceride_28\NN|in (l_prep) in_29\IN|liver (l_pobj) liver_31\NN|the|and|depression|of (l_conj) depression_33\NN|
D013752_D003866 NONE tetracycline_23\NN| (r_pobj) of_22\IN|tetracycline (r_prep) dose_21\NN|of|and|accumulation (l_conj) accumulation_26\NN|both|of|by (l_prep) of_27\IN|triglyceride (l_pobj) triglyceride_28\NN|in (l_prep) in_29\IN|liver (l_pobj) liver_31\NN|the|and|depression|of (l_conj) depression_33\NN|
D013752_D003866 NONE tetracycline_19\NN| (r_pobj) of_18\IN|tetracycline (r_prep) effects_17\NNS|the|of|on (l_prep) on_20\IN|depression (l_pobj) depression_21\NN|of|under
D014280_D003866 NONE triglyceride_28\NN|in (l_prep) in_29\IN|liver (l_pobj) liver_31\NN|the|and|depression|of (l_conj) depression_33\NN|
D014280_D003866 NONE triglyceride_37\NN| (r_pobj) of_36\IN|triglyceride (r_prep) output_35\NN|of (r_pobj) of_34\IN|output (r_prep) liver_31\NN|the|and|depression|of (l_conj) depression_33\NN|
D014280_D003866 NONE triglyceride_25\NN| (r_pobj) of_24\IN|triglyceride (r_prep) output_23\NN|of (r_pobj) of_22\IN|output (r_prep) depression_21\NN|of|under
D014280_D005234 NONE triglyceride_4\NN| (r_pobj) of_3\IN|triglyceride (r_prep) secretion_2\NN|depressed|hepatic|of (r_nsubj) accounted_5\VBD|secretion|%|,|indicating|. (l_advcl) indicating_17\VBG|involved (l_ccomp) involved_23\VBN|that|mechanisms|must|be|in (l_prep) in_24\IN|production (l_pobj) production_26\NN|the|of|in (l_prep) of_27\IN|liver (l_pobj) liver_33\NN|the|rich|fatty
D014280_D005234 NONE triglyceride_15\NN|accumulated|hepatic (r_pobj) of_12\IN|triglyceride (r_prep) %_11\NN|50|of (r_dobj) accounted_5\VBD|secretion|%|,|indicating|. (l_advcl) indicating_17\VBG|involved (l_ccomp) involved_23\VBN|that|mechanisms|must|be|in (l_prep) in_24\IN|production (l_pobj) production_26\NN|the|of|in (l_prep) of_27\IN|liver (l_pobj) liver_33\NN|the|rich|fatty
D014280_D005234 NONE triglyceride_29\NN| (r_npadvmod) rich_31\JJ|triglyceride|- (r_amod) liver_33\NN|the|rich|fatty
16565833
C522803_D066126 NONE monoHER_7\NN| (r_pobj) between_6\IN|monoher (r_prep) interval_5\NN|the|time|between (r_pobj) of_2\IN|interval (r_prep) influence_1\NN|the|of|and|administration|. (l_conj) administration_10\NN|doxorubicin|on (l_prep) on_11\IN|protection (l_pobj) protection_13\NN|the|against (l_prep) against_14\IN|cardiotoxicity (l_pobj) cardiotoxicity_18\NN|induced|in
C522803_D066126 NONE monohydroxyethylrutoside_3\NN|the|semisynthetic|flavonoid|(|monoher|) (r_nsubj) showed_7\VBD|monohydroxyethylrutoside|cardioprotection|. (l_dobj) cardioprotection_8\NN|against (l_prep) against_9\IN|cardiotoxicity (l_pobj) cardiotoxicity_13\NN|induced|through
C522803_D066126 NONE monoHER_5\NN| (r_appos) monohydroxyethylrutoside_3\NN|the|semisynthetic|flavonoid|(|monoher|) (r_nsubj) showed_7\VBD|monohydroxyethylrutoside|cardioprotection|. (l_dobj) cardioprotection_8\NN|against (l_prep) against_9\IN|cardiotoxicity (l_pobj) cardiotoxicity_13\NN|induced|through
D004317_D066126 NONE doxorubicin_9\NN| (r_compound) administration_10\NN|doxorubicin|on (l_prep) on_11\IN|protection (l_pobj) protection_13\NN|the|against (l_prep) against_14\IN|cardiotoxicity (l_pobj) cardiotoxicity_18\NN|induced|in
D004317_D066126 NONE doxorubicin_15\NN| (r_npadvmod) induced_17\VBN|doxorubicin|- (r_amod) cardiotoxicity_18\NN|induced|in
D004317_D066126 NONE doxorubicin_9\NN|despite|,|anthracyclin|dox (l_prep) Despite_0\IN|cardiotoxicity (l_pobj) cardiotoxicity_5\NN|its|known
D004317_D066126 NONE DOX_11\NNP|(|) (r_appos) doxorubicin_9\NN|despite|,|anthracyclin|dox (l_prep) Despite_0\IN|cardiotoxicity (l_pobj) cardiotoxicity_5\NN|its|known
D004317_D066126 NONE DOX_10\NNP| (r_npadvmod) induced_12\VBN|dox|- (r_amod) cardiotoxicity_13\NN|induced|through
D004317_D006331 NONE DOX_0\NNP| (r_npadvmod) induced_2\VBN|dox|- (r_amod) damage_4\NN|induced|cardiac
D004317_D006331 NONE DOX_14\NNP| (r_pobj) by_13\IN|dox (r_prep) radicals_12\NNS|free|by (r_pobj) of_10\IN|radicals (r_prep) formation_9\NN|the|of (r_pobj) from_7\IN|formation (r_prep) results_6\VBZ|damage|presumably|from|. (l_nsubj) damage_4\NN|induced|cardiac
D004317_D006331 NONE DOX_6\NNP| (r_pobj) with_5\IN|dox (r_prep) treatment_4\NN|with|alone (r_nsubj) induced_8\VBD|that|treatment|damage (l_dobj) damage_11\NN|significant|cardiac|in
D005419_D066126 NONE flavonoid_2\NN| (r_compound) monohydroxyethylrutoside_3\NN|the|semisynthetic|flavonoid|(|monoher|) (r_nsubj) showed_7\VBD|monohydroxyethylrutoside|cardioprotection|. (l_dobj) cardioprotection_8\NN|against (l_prep) against_9\IN|cardiotoxicity (l_pobj) cardiotoxicity_13\NN|induced|through
D007501_D066126 NONE iron_19\NN| (r_compound) chelating_20\VBG|iron (r_compound) properties_21\NNS|scavenging|chelating (r_pobj) through_14\IN|properties (r_prep) cardiotoxicity_13\NN|induced|through
15625689
D007980_D010300 NONE levodopa_17\NN| (r_npadvmod) induced_19\VBN|levodopa|- (r_amod) dyskinesia_20\NN|induced (r_pobj) without_16\IN|dyskinesia (r_conj) with_14\IN|and|without (r_prep) characterize_7\VB|to|dynamics|with (l_dobj) dynamics_10\NNS|the|oropharyngeal|in (l_prep) in_11\IN|patients (l_pobj) patients_13\NNS|pd (l_compound) PD_12\NNP|
D007980_D010300 NONE levodopa_6\NN|in (r_pobj) for_5\IN|levodopa (r_prep) role_4\NN|a|for (r_dobj) suggest_2\VBP|results|role|and|confirm|. (l_conj) confirm_14\VB|is (l_ccomp) is_17\VBZ|that|dysphagia|not|predictor (l_attr) predictor_21\NN|a|good|of (l_prep) of_22\IN|alterations (l_pobj) alterations_24\NNS|deglutition|in (l_prep) in_25\IN|pd (l_pobj) PD_26\NNP|
D007980_D004409 CID levodopa_17\NN| (r_npadvmod) induced_19\VBN|levodopa|- (r_amod) dyskinesia_20\NN|induced
D007980_D004409 CID levodopa_23\NN| (r_compound) dose_24\NN|a|greater|levodopa (r_pobj) of_20\IN|dose (r_prep) basis_19\NN|the|of (r_pobj) on_17\IN|basis (r_prep) explained_16\VBN|which|could|be|on (r_relcl) function_11\NN|swallowing|,|explained (r_pobj) in_9\IN|function (r_prep) performed_7\VBD|in|,|patients|better|in|. (l_nsubj) patients_6\NNS|dyskinetic (l_amod) dyskinetic_5\JJ|
D007980_D003680 NONE levodopa_6\NN|in (r_pobj) for_5\IN|levodopa (r_prep) role_4\NN|a|for (r_dobj) suggest_2\VBP|results|role|and|confirm|. (l_conj) confirm_14\VB|is (l_ccomp) is_17\VBZ|that|dysphagia|not|predictor (l_nsubj) dysphagia_16\NN|
16323982
D017373_D003327 NONE CPA_7\NN| (r_compound) treatment_8\NN|cpa (r_pobj) on_6\IN|treatment (r_prep) years_5\NNS|2.5|on (r_pobj) of_3\IN|years (r_prep) period_2\NN|a|of (r_pobj) After_0\IN|period (r_prep) found_18\VBN|after|,|patients|were|affected|. (l_xcomp) affected_21\VBN|to|be|by (l_agent) by_22\IN|disease (l_pobj) disease_25\NN|coronary|heart
D017373_D003324 CID CPA_14\NN| (r_compound) therapy_15\NN|prolonged|cpa (r_pobj) by_12\IN|therapy (r_agent) caused_11\VBN|as|by (r_advcl) arteriosclerosis_2\NN|ischaemic|coronary|with|caused
D017373_D050171 CID CPA_14\NN| (r_compound) therapy_15\NN|prolonged|cpa (r_pobj) by_12\IN|therapy (r_agent) caused_11\VBN|as|by (r_advcl) arteriosclerosis_2\NN|ischaemic|coronary|with|caused (r_nsubjpass) mediated_17\VBN|arteriosclerosis|is|through|,|other|. (l_conj) other_37\JJ|i|than (l_prep) than_38\IN|effect (l_pobj) effect_44\NN|the|known|hyperglyceridemic|caused
D002784_D003324 NONE cholesterol_22\NN|hdl (r_pobj) in_20\IN|cholesterol (r_prep) changes_19\NNS|in (r_pobj) through_18\IN|changes (r_prep) mediated_17\VBN|arteriosclerosis|is|through|,|other|. (l_nsubjpass) arteriosclerosis_2\NN|ischaemic|coronary|with|caused
D002784_D050171 NONE cholesterol_22\NN|hdl (r_pobj) in_20\IN|cholesterol (r_prep) changes_19\NNS|in (r_pobj) through_18\IN|changes (r_prep) mediated_17\VBN|arteriosclerosis|is|through|,|other|. (l_conj) other_37\JJ|i|than (l_prep) than_38\IN|effect (l_pobj) effect_44\NN|the|known|hyperglyceridemic|caused
D004967_D003324 NONE estrogen_47\NN| (r_pobj) by_46\IN|estrogen (r_agent) caused_45\VBN|by (r_acl) effect_44\NN|the|known|hyperglyceridemic|caused (r_pobj) than_38\IN|effect (r_prep) other_37\JJ|i|than (r_conj) mediated_17\VBN|arteriosclerosis|is|through|,|other|. (l_nsubjpass) arteriosclerosis_2\NN|ischaemic|coronary|with|caused
D004967_D050171 NONE estrogen_47\NN| (r_pobj) by_46\IN|estrogen (r_agent) caused_45\VBN|by (r_acl) effect_44\NN|the|known|hyperglyceridemic|caused
24190587
D018817_D008107 NONE Ecstasy_0\NNP|mdma (r_nsubj) is_4\VBZ|ecstasy|drug|. (l_attr) drug_7\NN|a|psychostimulant|associated (l_relcl) associated_11\VBN|which|is|increasingly|with (l_prep) with_12\IN|dysfunction (l_pobj) dysfunction_14\NN|psychobiological
D018817_D008107 NONE MDMA_2\NNP|(|) (r_appos) Ecstasy_0\NNP|mdma (r_nsubj) is_4\VBZ|ecstasy|drug|. (l_attr) drug_7\NN|a|psychostimulant|associated (l_relcl) associated_11\VBN|which|is|increasingly|with (l_prep) with_12\IN|dysfunction (l_pobj) dysfunction_14\NN|psychobiological
D018817_D001008 NONE ecstasy_14\NN| (r_npadvmod) polydrug_16\NN|ecstasy|- (r_compound) users_17\NNS|recreational|polydrug (r_pobj) in_12\IN|users (r_prep) observations_11\NNS|previous|in (r_pobj) with_9\IN|observations (r_prep) line_8\NN|with (r_pobj) in_7\IN|line (r_prep) are_6\VBP|increases|in|. (l_nsubj) increases_1\NNS|the|in (l_prep) in_2\IN|anxiety (l_pobj) anxiety_3\NN|and|depression
D018817_D003866 CID ecstasy_14\NN| (r_npadvmod) polydrug_16\NN|ecstasy|- (r_compound) users_17\NNS|recreational|polydrug (r_pobj) in_12\IN|users (r_prep) observations_11\NNS|previous|in (r_pobj) with_9\IN|observations (r_prep) line_8\NN|with (r_pobj) in_7\IN|line (r_prep) are_6\VBP|increases|in|. (l_nsubj) increases_1\NNS|the|in (l_prep) in_2\IN|anxiety (l_pobj) anxiety_3\NN|and|depression (l_conj) depression_5\NN|
2767010
C043114_D012640 NONE ACC-9653_0\NN|and|have (l_conj) have_4\VBP|sodium|activity|. (l_dobj) activity_7\NN|equivalent|anticonvulsant|against (l_prep) against_8\IN|seizures (l_pobj) seizures_9\NNS|induced
C043114_D012640 NONE sodium_3\NN|phenytoin (r_nsubj) have_4\VBP|sodium|activity|. (l_dobj) activity_7\NN|equivalent|anticonvulsant|against (l_prep) against_8\IN|seizures (l_pobj) seizures_9\NNS|induced
C043114_D017180 NONE sodium_1\NN|phenytoin (r_nsubj) have_2\VBP|sodium|activity|in|. (l_dobj) activity_5\NN|similar|antiarrhythmic|against (l_prep) against_6\IN|tachycardia (l_pobj) tachycardia_11\NN|induced|ventricular
D010042_D017180 CID ouabain_7\NN| (r_npadvmod) induced_9\VBN|ouabain|- (r_amod) tachycardia_11\NN|induced|ventricular
C043114_D001145 NONE ACC-9653_4\NN|or (r_nmod) sodium_7\NN|acc-9653|phenytoin|necessary (l_amod) necessary_8\JJ|convert (l_xcomp) convert_10\VB|to|arrhythmia|to (l_dobj) arrhythmia_12\NN|the
C043114_D001145 NONE sodium_7\NN|acc-9653|phenytoin|necessary (l_amod) necessary_8\JJ|convert (l_xcomp) convert_10\VB|to|arrhythmia|to (l_dobj) arrhythmia_12\NN|the
C043114_D001145 NONE sodium_2\NN|only|phenytoin (r_nsubj) displayed_3\VBD|sodium|in|. (l_prep) in_4\IN|activity (l_pobj) activity_7\NN|vitro|antiarrhythmic|against (l_prep) against_8\IN|arrhythmias (l_pobj) arrhythmias_12\NNS|induced|in
D013327_D001145 CID strophanthidin_9\NN| (r_npadvmod) induced_11\VBN|strophanthidin|- (r_amod) arrhythmias_12\NNS|induced|in
C043114_D064420 NONE ACC-9653_4\NNP|and (r_nmod) sodium_7\NN|acc-9653|phenytoin (r_pobj) of_3\IN|sodium (r_prep) studies_2\NNS|acute|toxicity|of (l_compound) toxicity_1\NN|
C043114_D064420 NONE sodium_7\NN|acc-9653|phenytoin (r_pobj) of_3\IN|sodium (r_prep) studies_2\NNS|acute|toxicity|of (l_compound) toxicity_1\NN|
11299446
C027429_D010302 CID veralipride_7\NN|for (r_pobj) of_6\IN|veralipride (r_prep) use_5\NN|the|of (r_pobj) after_3\IN|use (r_prep) Worsening_0\VBG|of|after (l_prep) of_1\IN|parkinsonism (l_pobj) Parkinsonism_2\NN|
C027429_D010302 CID veralipride_27\NN|,|as|improvement (r_pobj) with_26\IN|veralipride (r_prep) symptoms_25\NNS|related|with (r_appos) therapy_21\NN|of|symptoms (r_pobj) following_20\VBG|therapy (r_prep) shown_12\VBN|who|has|worsening|following (r_relcl) disease_9\NN|stable|parkinson|shown
17159032
D006886_D014786 CID hydroxychloroquine_8\NN| (r_dobj) taking_7\VBG|hydroxychloroquine (r_acl) patients_6\NNS|taking (r_pobj) in_5\IN|patients (r_prep) loss_4\NN|paracentral|visual|field|in|.
D006886_D014786 CID hydroxychloroquine_17\JJ| (r_compound) treatment_18\NN|hydroxychloroquine|in (r_pobj) to_16\IN|treatment (r_prep) attributed_15\VBN|which|were|to (r_relcl) abnormalities_11\NNS|field|,|attributed
24132704
C029036_D006949 NONE Crocin_0\NNS| (r_nsubj) reduced_1\VBD|crocin|inhibition|and|levels|. (l_dobj) inhibition_2\NN|of (l_prep) of_3\IN|activation (l_pobj) activation_5\NN|erk|and|hyperlipemia (l_conj) hyperlipemia_10\NN|induced
C029036_D006949 NONE Crocin_0\NNS| (r_nsubjpass) considered_3\VBN|crocin|may|be|as|through|. (l_prep) as_4\IN|agent (l_pobj) agent_8\NN|a|novel|protective|in (l_prep) in_9\IN|hyperlipemia (l_pobj) hyperlipemia_13\NN|induced
D003976_D006949 CID diazinon_7\NN| (r_npadvmod) induced_9\VBN|diazinon|- (r_amod) hyperlipemia_10\NN|induced
D003976_D006949 CID diazinon_10\NN| (r_npadvmod) induced_12\VBN|diazinon|- (r_amod) hyperlipemia_13\NN|induced
1655018
D000728_D006528 CID androgen_8\JJ|and|corticosteroid (r_pobj) with_7\IN|androgen (r_prep) treated_6\VBN|carcinoma|with|. (l_nsubj) carcinoma_1\NN|hepatocellular|in
D000728_D005199 NONE androgen_8\JJ|and|corticosteroid (r_pobj) with_7\IN|androgen (r_prep) treated_6\VBN|carcinoma|with|. (l_nsubj) carcinoma_1\NN|hepatocellular|in (l_prep) in_2\IN|anemia (l_pobj) anemia_5\NN|fanconi
D000728_D005199 NONE androgens_25\NNS|,|corticosteroids (r_pobj) with_24\IN|androgens (r_prep) treated_23\VBN|was|with (r_conj) known_12\VBN|who|was|have|and|treated (l_xcomp) have_14\VB|to|anemia (l_dobj) anemia_17\NN|fanconi|for
D000728_D005199 NONE androgen-_20\NN|and|treated (r_amod) anemia_27\NN|androgen-|fanconi
D000305_D006528 CID corticosteroid_10\NN| (r_conj) androgen_8\JJ|and|corticosteroid (r_pobj) with_7\IN|androgen (r_prep) treated_6\VBN|carcinoma|with|. (l_nsubj) carcinoma_1\NN|hepatocellular|in
D000305_D005199 NONE corticosteroid_10\NN| (r_conj) androgen_8\JJ|and|corticosteroid (r_pobj) with_7\IN|androgen (r_prep) treated_6\VBN|carcinoma|with|. (l_nsubj) carcinoma_1\NN|hepatocellular|in (l_prep) in_2\IN|anemia (l_pobj) anemia_5\NN|fanconi
D000305_D005199 NONE corticosteroids_27\NNS|and|transfusions (r_conj) androgens_25\NNS|,|corticosteroids (r_pobj) with_24\IN|androgens (r_prep) treated_23\VBN|was|with (r_conj) known_12\VBN|who|was|have|and|treated (l_xcomp) have_14\VB|to|anemia (l_dobj) anemia_17\NN|fanconi|for
D000305_D005199 NONE corticosteroid_22\NN| (r_npadvmod) treated_24\VBN|corticosteroid|- (r_conj) androgen-_20\NN|and|treated (r_amod) anemia_27\NN|androgen-|fanconi
D000728_D008113 NONE androgen-_20\NN|and|treated (r_amod) anemia_27\NN|androgen-|fanconi (r_pobj) with_19\IN|anemia (r_prep) patients_18\NNS|with (r_pobj) in_17\IN|patients (r_prep) develop_16\VB|that|neoplasms|can|in (l_nsubj) neoplasms_12\NNS|metastasizing|hepatic|and|peliosis
D000728_D010382 CID androgen-_20\NN|and|treated (r_amod) anemia_27\NN|androgen-|fanconi (r_pobj) with_19\IN|anemia (r_prep) patients_18\NNS|with (r_pobj) in_17\IN|patients (r_prep) develop_16\VB|that|neoplasms|can|in (l_nsubj) neoplasms_12\NNS|metastasizing|hepatic|and|peliosis (l_conj) peliosis_14\NN|
D000305_D008113 NONE corticosteroid_22\NN| (r_npadvmod) treated_24\VBN|corticosteroid|- (r_conj) androgen-_20\NN|and|treated (r_amod) anemia_27\NN|androgen-|fanconi (r_pobj) with_19\IN|anemia (r_prep) patients_18\NNS|with (r_pobj) in_17\IN|patients (r_prep) develop_16\VB|that|neoplasms|can|in (l_nsubj) neoplasms_12\NNS|metastasizing|hepatic|and|peliosis
D000305_D010382 CID corticosteroid_22\NN| (r_npadvmod) treated_24\VBN|corticosteroid|- (r_conj) androgen-_20\NN|and|treated (r_amod) anemia_27\NN|androgen-|fanconi (r_pobj) with_19\IN|anemia (r_prep) patients_18\NNS|with (r_pobj) in_17\IN|patients (r_prep) develop_16\VB|that|neoplasms|can|in (l_nsubj) neoplasms_12\NNS|metastasizing|hepatic|and|peliosis (l_conj) peliosis_14\NN|
3925479
D006220_D002375 CID haloperidol_6\NN| (r_npadvmod) induced_8\VBN|haloperidol|- (r_amod) catalepsy_9\NN|induced
D006220_D002375 CID haloperidol_19\NN| (r_appos) blocker_17\NN|the|dopaminergic|,|haloperidol (r_pobj) by_14\IN|blocker (r_agent) induced_13\VBN|that|was|by (r_relcl) catalepsy_10\NN|the|induced
D006220_D002375 CID haloperidol_8\NN| (r_npadvmod) induced_10\VBN|haloperidol|- (r_amod) catalepsy_11\NN|induced
D006220_D002375 CID haloperidol_19\NN| (r_pobj) by_18\IN|haloperidol (r_agent) induced_17\VBN|that|is|usually|by (r_relcl) catalepsy_13\NN|the|induced
D006220_D002375 CID haloperidol_15\NN| (r_pobj) as_14\IN|such|haloperidol (r_prep) neuroleptics_12\NNS|as (r_pobj) by_11\IN|neuroleptics (r_agent) produced_10\VBN|that|is|by (r_relcl) catalepsy_7\NN|the|produced
D014150_D002375 NONE neuroleptic_25\RB| (r_amod) induced_27\VBN|neuroleptic|- (r_amod) catalepsy_28\NN|induced (r_pobj) of_24\IN|catalepsy (r_prep) expression_23\NN|full|of (r_pobj) for_21\IN|expression (r_prep) be_19\VB|to|intact|for (r_xcomp) need_17\VBP|that|mechanisms|be (r_conj) promotes_11\VBZ|that|activation|catalepsy|and|need (l_dobj) catalepsy_12\NN|
D014150_D002375 NONE neuroleptic_25\RB| (r_amod) induced_27\VBN|neuroleptic|- (r_amod) catalepsy_28\NN|induced
D014150_D002375 NONE neuroleptics_12\NNS|as (r_pobj) by_11\IN|neuroleptics (r_agent) produced_10\VBN|that|is|by (r_relcl) catalepsy_7\NN|the|produced
D010862_D002375 CID pilocarpine_6\NN| (r_appos) doses_1\NNS|large|of|,|pilocarpine|, (r_nsubj) induce_9\VB|doses|could|catalepsy|blocked|. (l_dobj) catalepsy_10\NN|
D010862_D002375 CID pilocarpine_3\NN| (r_pobj) of_2\IN|pilocarpine (r_prep) doses_1\NNS|low|of (r_nsubj) caused_4\VBD|doses|enhancement|. (l_dobj) enhancement_7\NN|a|pronounced|of (l_prep) of_8\IN|catalepsy (l_pobj) catalepsy_10\NN|the|induced
D001285_D002375 NONE atropine_5\NN| (r_preconj) ,_4\,|atropine (r_punct) disrupted_7\VBD|blocker|,|,|catalepsy|. (l_dobj) catalepsy_11\NN|induced
D000109_D002375 NONE acetylcholine_4\NN| (r_compound) synthesis_6\NN|acetylcholine|- (r_compound) inhibitor_7\NN|an|synthesis|,|hemicholinium (r_pobj) of_2\IN|inhibitor (r_prep) injection_1\NN|intracranial|of (r_nsubj) prevented_11\VBD|injection|,|catalepsy|. (l_dobj) catalepsy_13\NN|the|induced
D006426_D002375 NONE hemicholinium_9\NN| (r_appos) inhibitor_7\NN|an|synthesis|,|hemicholinium (r_pobj) of_2\IN|inhibitor (r_prep) injection_1\NN|intracranial|of (r_nsubj) prevented_11\VBD|injection|,|catalepsy|. (l_dobj) catalepsy_13\NN|the|induced
3297909
D013827_D001649 NONE thiabendazole_5\NN| (r_compound) administration_6\NN|thiabendazole (r_pobj) after_4\IN|administration (r_prep) injury_3\NN|progressive|duct|after|.
D013827_D007565 NONE thiabendazole_12\NN| (r_pobj) to_11\IN|thiabendazole (r_prep) exposure_10\NN|to (r_pobj) after_9\IN|wk|exposure (r_prep) developed_5\VBD|man|jaundice|after|. (l_dobj) jaundice_6\NN|
20024739
D000431_D015658 NONE alcohol_3\NN| (r_compound) use_4\NN|alcohol|with (l_prep) with_5\IN|progression (l_pobj) progression_8\NN|disease|and|health (l_compound) disease_7\NN|hiv
D000431_D015658 NONE alcohol_5\NN| (r_compound) consumption_6\NN|alcohol|and|depression (r_pobj) of_4\IN|consumption (r_prep) association_3\NN|the|of (r_dobj) evaluated_1\VBD|we|association|,|and|effects|. (l_conj) effects_12\NNS|their|on (l_prep) on_13\IN|progression (l_pobj) progression_16\NN|disease|among (l_compound) disease_15\NN|hiv
D000431_D003866 CID alcohol_5\NN| (r_compound) consumption_6\NN|alcohol|and|depression (l_conj) depression_8\NN|
D000431_D003866 CID alcohol_39\NN| (r_compound) use_40\NN|alcohol (r_compound) assessment_41\NN|use|at|,|and|semiannually|. (r_conj) had_2\VBD|participants|examination|(|using|,|and|assessment (l_dobj) examination_4\NN|physical|,|extraction|measurement (l_appos) measurement_19\NN|of (l_prep) of_20\IN|symptoms (l_pobj) symptoms_22\NNS|depression (l_compound) depression_21\NN|
D000431_D003866 CID alcohol_39\NN| (r_compound) use_40\NN|alcohol (r_compound) assessment_41\NN|use|at|,|and|semiannually|. (r_conj) had_2\VBD|participants|examination|(|using|,|and|assessment (l_advcl) using_24\VBG|center|) (l_dobj) Center_29\NNP|the|report|for (l_prep) for_30\IN|scale (l_pobj) Scale_35\NNP|epidemiological|depression (l_compound) Depression_34\NNP|studies|-
D000431_D003866 CID alcohol_3\NN| (r_compound) consumption_4\NN|alcohol|and|depression (l_conj) depression_6\NN|
D000431_D003866 CID alcohol_4\NN| (r_compound) consumption_5\NN|alcohol (r_nsubj) has_6\VBZ|that|consumption|association (l_dobj) association_9\NN|a|direct|with (l_prep) with_10\IN|depression (l_pobj) depression_11\NN|
17572393
D008550_D054220 NONE melatonin_3\NN| (r_pobj) of_2\IN|melatonin (r_prep) effects_1\NNS|neuroprotective|of|upon|. (l_prep) upon_4\IN|cortex (l_pobj) cortex_8\NN|the|offspring|cerebellar|in (l_prep) in_9\IN|model (l_pobj) model_12\NN|the|rat|of (l_prep) of_13\IN|dysplasia (l_pobj) dysplasia_18\NN|induced|cortical
D008550_D054220 NONE melatonin_10\NN|exogenous|upon (l_prep) upon_11\IN|dysplasia (l_pobj) dysplasia_17\NN|cerebellar|induced|cortical
D002330_D054220 CID BCNU_14\NNP| (r_npadvmod) induced_16\VBN|bcnu|- (r_amod) dysplasia_18\NN|induced|cortical
D002330_D054220 CID BCNU_1\NNP|(|)|and|investigate|. (l_conj) investigate_5\VB|to|effects|,|using (l_dobj) effects_7\NNS|the|of (l_prep) of_8\IN|melatonin (l_pobj) melatonin_10\NN|exogenous|upon (l_prep) upon_11\IN|dysplasia (l_pobj) dysplasia_17\NN|cerebellar|induced|cortical
D002330_D054220 CID BCNU_13\NNP| (r_npadvmod) induced_15\VBN|bcnu|- (r_amod) dysplasia_17\NN|cerebellar|induced|cortical
D002330_D054220 CID BCNU_25\NNP| (r_npadvmod) exposed_27\VBN|bcnu|- (r_amod) group_30\NN|exposed|cortical|dysplasia (l_compound) dysplasia_29\NN|
19715529
23846525
C055162_D056486 CID clopidogrel_4\NN| (r_pobj) with_3\IN|clopidogrel (r_prep) associated_2\VBD|with (r_acl) hepatitis_1\NN|acute|associated|:|report|.
C055162_D056486 CID clopidogrel_5\RB| (r_npadvmod) related_7\VBN|clopidogrel|- (r_amod) hepatitis_9\NN|related|acute
C055162_D056486 CID clopidogrel_7\NN| (r_pobj) due_5\JJ|to|clopidogrel (r_amod) Reports_0\NNS|about|due (l_prep) about_1\IN|cases (l_pobj) cases_2\NNS|of (l_prep) of_3\IN|hepatotoxicity (l_pobj) hepatotoxicity_4\NN|
C055162_D056486 CID clopidogrel_19\JJ| (r_nsubjpass) prescribed_21\VBN|when|clopidogrel|is (r_advcl) consider_9\VB|that|physicians|should|carefully|risk|prescribed (l_dobj) risk_11\NN|the|of (l_prep) of_12\IN|injury (l_pobj) injury_17\NN|induced|hepatic
8511251
D003042_D017202 CID Cocaine_0\NN| (r_nsubj) induced_1\VBD|cocaine|ischemia|. (l_dobj) ischemia_3\NN|myocardial
D003042_D017202 CID cocaine_9\NN| (r_pobj) by_8\IN|cocaine (r_agent) induced_7\VBN|by (r_acl) case_3\NN|a|of|induced (l_prep) of_4\IN|ischemia (l_pobj) ischemia_6\NN|myocardial
D005996_D007511 NONE nitroglycerin_11\NN|and|agents (r_pobj) by_10\IN|nitroglycerin (r_agent) reversed_9\VBN|was|by (r_conj) induced_3\VBN|ischemia|probably|by|reversed|. (l_nsubj) ischemia_1\NN|the
D005996_D003329 NONE nitroglycerin_11\NN|and|agents (r_pobj) by_10\IN|nitroglycerin (r_agent) reversed_9\VBN|was|by (r_conj) induced_3\VBN|ischemia|probably|by|reversed|. (l_agent) by_4\IN|spasm (l_pobj) spasm_7\NN|artery
D002118_D007511 NONE calcium_13\NN| (r_npadvmod) blocking_14\VBG|calcium (r_amod) agents_15\NNS|blocking (r_conj) nitroglycerin_11\NN|and|agents (r_pobj) by_10\IN|nitroglycerin (r_agent) reversed_9\VBN|was|by (r_conj) induced_3\VBN|ischemia|probably|by|reversed|. (l_nsubj) ischemia_1\NN|the
D002118_D003329 NONE calcium_13\NN| (r_npadvmod) blocking_14\VBG|calcium (r_amod) agents_15\NNS|blocking (r_conj) nitroglycerin_11\NN|and|agents (r_pobj) by_10\IN|nitroglycerin (r_agent) reversed_9\VBN|was|by (r_conj) induced_3\VBN|ischemia|probably|by|reversed|. (l_agent) by_4\IN|spasm (l_pobj) spasm_7\NN|artery
2173761
D019806_D007022 CID cromakalim_11\NN|and|pinacidil (r_pobj) by_10\IN|cromakalim (r_agent) induced_9\VBN|by (r_acl) Vasodilation_0\NN|of|induced (l_prep) of_1\IN|vessels (l_pobj) vessels_6\NNS|large|coronary|and|hypotension (l_conj) hypotension_8\NN|
D019806_D013610 CID cromakalim_11\NN|and|pinacidil (r_pobj) by_10\IN|cromakalim (r_agent) induced_9\VBN|by (r_acl) Vasodilation_0\NN|of|induced (r_nsubjpass) affected_16\VBN|vasodilation|were|not|by|abolished|. (l_agent) by_17\IN|blockade (l_pobj) blockade_25\VBP|prior|combined|beta|receptors|but|tachycardia (l_conj) tachycardia_30\NN|induced
D020110_D007022 CID pinacidil_13\NN| (r_conj) cromakalim_11\NN|and|pinacidil (r_pobj) by_10\IN|cromakalim (r_agent) induced_9\VBN|by (r_acl) Vasodilation_0\NN|of|induced (l_prep) of_1\IN|vessels (l_pobj) vessels_6\NNS|large|coronary|and|hypotension (l_conj) hypotension_8\NN|
D020110_D013610 CID pinacidil_13\NN| (r_conj) cromakalim_11\NN|and|pinacidil (r_pobj) by_10\IN|cromakalim (r_agent) induced_9\VBN|by (r_acl) Vasodilation_0\NN|of|induced (r_nsubjpass) affected_16\VBN|vasodilation|were|not|by|abolished|. (l_agent) by_17\IN|blockade (l_pobj) blockade_25\VBP|prior|combined|beta|receptors|but|tachycardia (l_conj) tachycardia_30\NN|induced
D000319_D007022 NONE blockade_25\VBP|prior|combined|beta|receptors|but|tachycardia (r_pobj) by_17\IN|blockade (r_agent) affected_16\VBN|vasodilation|were|not|by|abolished|. (l_nsubjpass) Vasodilation_0\NN|of|induced (l_prep) of_1\IN|vessels (l_pobj) vessels_6\NNS|large|coronary|and|hypotension (l_conj) hypotension_8\NN|
D018727_D007022 NONE blockade_25\VBP|prior|combined|beta|receptors|but|tachycardia (r_pobj) by_17\IN|blockade (r_agent) affected_16\VBN|vasodilation|were|not|by|abolished|. (l_nsubjpass) Vasodilation_0\NN|of|induced (l_prep) of_1\IN|vessels (l_pobj) vessels_6\NNS|large|coronary|and|hypotension (l_conj) hypotension_8\NN|
D000319_D013610 NONE blockade_25\VBP|prior|combined|beta|receptors|but|tachycardia (l_conj) tachycardia_30\NN|induced
D018727_D013610 NONE blockade_25\VBP|prior|combined|beta|receptors|but|tachycardia (l_conj) tachycardia_30\NN|induced
3711722
D003035_D009202 CID cobalt_4\NN| (r_compound) cardiomyopathy_5\NN|cobalt
D004317_D006333 CID doxorubicin_4\RB| (r_npadvmod) induced_6\VBN|doxorubicin|- (r_amod) failure_8\NN|induced|heart
26115410
D001152_D009369 CID iAs_14\NNP|life (r_compound) exposure_15\NN|ias|to|,|in (l_prep) in_25\IN|particularly|relationship (l_pobj) relationship_26\NN|to (l_prep) to_27\IN|cancer (l_pobj) cancer_28\NN|
D001152_D009369 CID iAs_25\NNP|life (r_compound) exposure_26\NN|ias (r_pobj) with_21\IN|exposure (r_prep) associated_20\VBN|that|is|with (r_relcl) risk_12\NN|the|increased|of|in|associated (l_prep) of_13\IN|development (l_pobj) development_15\NN|cancer (l_compound) cancer_14\NN|
D001152_D009369 CID iAs_28\NNP|life (r_compound) exposure_29\NN|ias (r_nsubj) elicits_30\VBZ|by|exposure|effects (r_relcl) mechanisms_22\NNS|plausible|underlying|elicits (r_attr) are_19\VBP|reprogramming|,|development|mechanisms|. (l_nsubj) development_11\NN|the|of|,|and|immunomodulation (l_prep) of_12\IN|cells (l_pobj) cells_15\NNS|cancer|stem (l_compound) cancer_13\NN|
D001152_D009369 CID iAs_8\NNP|life (r_compound) exposure_9\NN|ias|and|development (l_conj) development_12\NN|cancer (l_compound) cancer_11\NN|
1360900
D004976_D012640 CID acid_1\NN| (r_npadvmod) induced_3\VBN|acid|- (r_amod) convulsions_4\NNS|ethacrynic|induced|and|neurotransmitters|in|.
D004976_D012640 CID acid_4\NN|ethacrynic|dose (l_appos) dose_9\NN|(|%|convulsive (l_amod) convulsive_8\JJ|
D004976_D012640 CID acid_2\NN| (r_npadvmod) induced_4\VBN|acid|- (r_amod) convulsions_5\NNS|ethacrynic|induced
D012701_D012640 NONE 5-hydroxytryptamine_22\CD|5-ht (r_pobj) of_21\IN|5-hydroxytryptamine (r_prep) turnover_20\NN|the|synthesis|/|of (r_dobj) accelerated_16\VBD|injection|turnover|)|but|suppressed|. (l_nsubj) injection_1\NN|intracerebroventricular|of|mouse (l_prep) of_2\IN|acid (l_pobj) acid_4\NN|ethacrynic|dose (l_appos) dose_9\NN|(|%|convulsive (l_amod) convulsive_8\JJ|
D012701_D012640 NONE 5-HT_24\CD|( (r_appos) 5-hydroxytryptamine_22\CD|5-ht (r_pobj) of_21\IN|5-hydroxytryptamine (r_prep) turnover_20\NN|the|synthesis|/|of (r_dobj) accelerated_16\VBD|injection|turnover|)|but|suppressed|. (l_nsubj) injection_1\NN|intracerebroventricular|of|mouse (l_prep) of_2\IN|acid (l_pobj) acid_4\NN|ethacrynic|dose (l_appos) dose_9\NN|(|%|convulsive (l_amod) convulsive_8\JJ|
D005680_D012640 NONE acid_34\NN|aminobutyric|and|acetylcholine (r_pobj) of_30\IN|acid (r_prep) synthesis_29\NN|the|of (r_dobj) suppressed_27\VBD|synthesis (r_conj) accelerated_16\VBD|injection|turnover|)|but|suppressed|. (l_nsubj) injection_1\NN|intracerebroventricular|of|mouse (l_prep) of_2\IN|acid (l_pobj) acid_4\NN|ethacrynic|dose (l_appos) dose_9\NN|(|%|convulsive (l_amod) convulsive_8\JJ|
D000109_D012640 NONE acetylcholine_36\NN|in (r_conj) acid_34\NN|aminobutyric|and|acetylcholine (r_pobj) of_30\IN|acid (r_prep) synthesis_29\NN|the|of (r_dobj) suppressed_27\VBD|synthesis (r_conj) accelerated_16\VBD|injection|turnover|)|but|suppressed|. (l_nsubj) injection_1\NN|intracerebroventricular|of|mouse (l_prep) of_2\IN|acid (l_pobj) acid_4\NN|ethacrynic|dose (l_appos) dose_9\NN|(|%|convulsive (l_amod) convulsive_8\JJ|
7967231
C059447_D020195 NONE S-312_0\NNP|, (r_punct) S-312-d_2\NNP|s-312|,|but|s-312-l (r_nsubj) showed_15\VBD|s-312-d|effects|;|and|were (l_dobj) effects_17\NNS|anticonvulsant|on (l_prep) on_18\IN|convulsions (l_pobj) convulsions_22\NNS|the|audiogenic|tonic|in
C059447_D020195 NONE S-312-d_2\NNP|s-312|,|but|s-312-l (r_nsubj) showed_15\VBD|s-312-d|effects|;|and|were (l_dobj) effects_17\NNS|anticonvulsant|on (l_prep) on_18\IN|convulsions (l_pobj) convulsions_22\NNS|the|audiogenic|tonic|in
-1_D020195 NONE S-312-l_6\NNP|not|,|antagonists|, (r_conj) S-312-d_2\NNP|s-312|,|but|s-312-l (r_nsubj) showed_15\VBD|s-312-d|effects|;|and|were (l_dobj) effects_17\NNS|anticonvulsant|on (l_prep) on_18\IN|convulsions (l_pobj) convulsions_22\NNS|the|audiogenic|tonic|in
D002118_D020195 NONE calcium_11\NN| (r_compound) channel_12\NN|type|calcium (r_compound) antagonists_13\NNS|channel (r_conj) S-312-l_6\NNP|not|,|antagonists|, (r_conj) S-312-d_2\NNP|s-312|,|but|s-312-l (r_nsubj) showed_15\VBD|s-312-d|effects|;|and|were (l_dobj) effects_17\NNS|anticonvulsant|on (l_prep) on_18\IN|convulsions (l_pobj) convulsions_22\NNS|the|audiogenic|tonic|in
D005444_D020195 NONE flunarizine_57\NN| (r_pobj) of_56\IN|flunarizine (r_prep) that_55\DT|of (r_nsubj) was_58\VBD|while|that|34.0 (r_advcl) were_31\VBD|values|18.4|mg/kg|,|was|p.o. (r_conj) showed_15\VBD|s-312-d|effects|;|and|were (l_dobj) effects_17\NNS|anticonvulsant|on (l_prep) on_18\IN|convulsions (l_pobj) convulsions_22\NNS|the|audiogenic|tonic|in
C059447_D012640 NONE S-312-d_5\NN|in (r_pobj) of_4\IN|s-312-d (r_prep) effects_3\NNS|moderate|anticonvulsant|of (r_nsubjpass) observed_10\VBN|although|effects|were|against (l_prep) against_11\IN|convulsions (l_pobj) convulsions_14\NNS|the|clonic|induced
C059447_D012640 NONE S-312-d_5\NN|in (r_pobj) of_4\IN|s-312-d (r_prep) effects_3\NNS|moderate|anticonvulsant|of (r_nsubjpass) observed_10\VBN|although|effects|were|against (r_advcl) observed_36\VBN|observed|,|effects|were|in|:|mice|. (l_prep) in_37\IN|convulsions (l_pobj) convulsions_38\NNS|induced
D010433_D012640 CID pentylenetetrazole_17\NN|(|mg/kg|)|or|bemegride (r_pobj) by_16\IN|pentylenetetrazole (r_agent) induced_15\VBN|by (r_acl) convulsions_14\NNS|the|clonic|induced
D010433_D012640 CID pentylenetetrazole_17\NN|(|mg/kg|)|or|bemegride (r_pobj) by_16\IN|pentylenetetrazole (r_agent) induced_15\VBN|by (r_acl) convulsions_14\NNS|the|clonic|induced (r_pobj) against_11\IN|convulsions (r_prep) observed_10\VBN|although|effects|were|against (r_advcl) observed_36\VBN|observed|,|effects|were|in|:|mice|. (l_prep) in_37\IN|convulsions (l_pobj) convulsions_38\NNS|induced
D001534_D012640 CID bemegride_25\NN|(|mg/kg|s.c.|) (r_conj) pentylenetetrazole_17\NN|(|mg/kg|)|or|bemegride (r_pobj) by_16\IN|pentylenetetrazole (r_agent) induced_15\VBN|by (r_acl) convulsions_14\NNS|the|clonic|induced
D001534_D012640 CID bemegride_25\NN|(|mg/kg|s.c.|) (r_conj) pentylenetetrazole_17\NN|(|mg/kg|)|or|bemegride (r_pobj) by_16\IN|pentylenetetrazole (r_agent) induced_15\VBN|by (r_acl) convulsions_14\NNS|the|clonic|induced (r_pobj) against_11\IN|convulsions (r_prep) observed_10\VBN|although|effects|were|against (r_advcl) observed_36\VBN|observed|,|effects|were|in|:|mice|. (l_prep) in_37\IN|convulsions (l_pobj) convulsions_38\NNS|induced
D016202_D012640 NONE aspartate_47\NNP|methyl|d|-|,|picrotoxin (r_pobj) by_40\IN|aspartate (r_agent) induced_39\VBN|by|in (r_acl) convulsions_38\NNS|induced (r_pobj) in_37\IN|convulsions (r_prep) observed_36\VBN|observed|,|effects|were|in|:|mice|. (l_advcl) observed_10\VBN|although|effects|were|against (l_prep) against_11\IN|convulsions (l_pobj) convulsions_14\NNS|the|clonic|induced
D016202_D012640 NONE aspartate_47\NNP|methyl|d|-|,|picrotoxin (r_pobj) by_40\IN|aspartate (r_agent) induced_39\VBN|by|in (r_acl) convulsions_38\NNS|induced
D010852_D012640 CID picrotoxin_49\NN|,|or|electroshock (r_conj) aspartate_47\NNP|methyl|d|-|,|picrotoxin (r_pobj) by_40\IN|aspartate (r_agent) induced_39\VBN|by|in (r_acl) convulsions_38\NNS|induced (r_pobj) in_37\IN|convulsions (r_prep) observed_36\VBN|observed|,|effects|were|in|:|mice|. (l_advcl) observed_10\VBN|although|effects|were|against (l_prep) against_11\IN|convulsions (l_pobj) convulsions_14\NNS|the|clonic|induced
D010852_D012640 CID picrotoxin_49\NN|,|or|electroshock (r_conj) aspartate_47\NNP|methyl|d|-|,|picrotoxin (r_pobj) by_40\IN|aspartate (r_agent) induced_39\VBN|by|in (r_acl) convulsions_38\NNS|induced
C059447_D004827 NONE S-312-d_0\NN| (r_nsubj) be_2\VB|s-312-d|may|useful|in|. (l_prep) in_4\IN|therapy (l_pobj) therapy_6\NN|the|of (l_prep) of_7\IN|types (l_pobj) types_9\NNS|certain|of (l_prep) of_10\IN|epilepsy (l_pobj) epilepsy_12\NN|human
24040781
C107135_D011507 CID everolimus_13\NN| (r_pobj) with_12\IN|everolimus (r_prep) treated_11\VBN|with (r_acl) diagnosis_2\NN|an|unexpected|in|treated|:|amyloidosis|. (l_prep) in_3\IN|patient (l_pobj) patient_8\NN|a|transplant|with (l_prep) with_9\IN|proteinuria (l_pobj) proteinuria_10\NN|
C107135_D011507 CID everolimus_33\NN| (r_pobj) to_32\IN|everolimus (r_prep) tacrolimus_31\NN|to (r_pobj) from_30\IN|tacrolimus (r_prep) conversion_29\NN|from (r_pobj) after_28\IN|conversion (r_prep) developed_26\VBD|who|proteinuria|after (l_dobj) proteinuria_27\NN|
C107135_D000686 CID everolimus_13\NN| (r_pobj) with_12\IN|everolimus (r_prep) treated_11\VBN|with (r_acl) diagnosis_2\NN|an|unexpected|in|treated|:|amyloidosis|. (l_appos) amyloidosis_16\NN|al (l_compound) AL_15\NNP|
C107135_D000686 CID everolimus_13\NN| (r_pobj) with_12\IN|everolimus (r_prep) treated_11\VBN|with (r_acl) diagnosis_2\NN|an|unexpected|in|treated|:|amyloidosis|. (l_appos) amyloidosis_16\NN|al
C107135_D000686 CID everolimus_33\NN| (r_pobj) to_32\IN|everolimus (r_prep) tacrolimus_31\NN|to (r_pobj) from_30\IN|tacrolimus (r_prep) conversion_29\NN|from (r_pobj) after_28\IN|conversion (r_prep) developed_26\VBD|who|proteinuria|after (r_relcl) significance_24\NN|undetermined|developed (r_pobj) of_22\IN|significance (r_prep) gammapathy_21\JJ|transplant|monoclonal|of (r_pobj) with_16\IN|gammapathy (r_prep) patient_15\NN|a|transplant|with (r_pobj) in_10\IN|patient (r_prep) diagnosis_7\NN|the|unexpected|of|in (l_prep) of_8\IN|amyloidosis (l_pobj) amyloidosis_9\NN|
D020123_D011507 NONE rapamycin_13\NNS| (r_amod) inhibitors_14\NNS|rapamycin|(|i|) (r_pobj) of_12\IN|inhibitors (r_prep) target_11\NN|mammalian|of (r_pobj) with_9\IN|target (r_prep) treated_8\VBN|with (r_acl) complication_4\NN|an|expected|in|treated (r_attr) is_1\VBZ|proteinuria|complication|. (l_nsubj) Proteinuria_0\NNP|
D016559_D000686 NONE tacrolimus_31\NN|to (r_pobj) from_30\IN|tacrolimus (r_prep) conversion_29\NN|from (r_pobj) after_28\IN|conversion (r_prep) developed_26\VBD|who|proteinuria|after (r_relcl) significance_24\NN|undetermined|developed (r_pobj) of_22\IN|significance (r_prep) gammapathy_21\JJ|transplant|monoclonal|of (r_pobj) with_16\IN|gammapathy (r_prep) patient_15\NN|a|transplant|with (r_pobj) in_10\IN|patient (r_prep) diagnosis_7\NN|the|unexpected|of|in (l_prep) of_8\IN|amyloidosis (l_pobj) amyloidosis_9\NN|
D016559_D011507 NONE tacrolimus_31\NN|to (r_pobj) from_30\IN|tacrolimus (r_prep) conversion_29\NN|from (r_pobj) after_28\IN|conversion (r_prep) developed_26\VBD|who|proteinuria|after (l_dobj) proteinuria_27\NN|
1420650
D002220_D020820 NONE carbamazepine_3\NN| (r_compound) therapy_4\NN|carbamazepine (r_pobj) by_2\IN|therapy (r_agent) induced_1\VBN|asterixis|by|. (l_nsubj) Asterixis_0\NNS|
D002220_D020820 NONE carbamazepine_24\NN|(|cbz|) (r_dobj) adding_23\VBG|carbamazepine|to (r_pcomp) by_22\IN|either|adding (r_prep) triggered_20\VBN|in|asterixis|was|by (l_nsubjpass) asterixis_18\NNS|
D002220_D020820 NONE CBZ_26\NNP| (r_appos) carbamazepine_24\NN|(|cbz|) (r_dobj) adding_23\VBG|carbamazepine|to (r_pcomp) by_22\IN|either|adding (r_prep) triggered_20\VBN|in|asterixis|was|by (l_nsubjpass) asterixis_18\NNS|
D002220_D020820 NONE CBZ_35\NN| (r_pobj) with_34\IN|cbz (r_prep) combination_33\NN|with (r_pobj) in_32\IN|combination (r_prep) used_31\VBN|if|drugs|are|in (r_advcl) consider_1\VBP|we|be|,|used|. (l_ccomp) be_4\VB|asterixis|to|sign (l_nsubj) asterixis_2\NNS|
D008094_D020820 CID lithium_27\NN|or|clozapine (r_pobj) as_26\IN|lithium (r_prep) drugs_25\NNS|certain|as (r_nsubjpass) used_31\VBN|if|drugs|are|in (r_advcl) consider_1\VBP|we|be|,|used|. (l_ccomp) be_4\VB|asterixis|to|sign (l_nsubj) asterixis_2\NNS|
D008094_D020258 NONE lithium_27\NN|or|clozapine (r_pobj) as_26\IN|lithium (r_prep) drugs_25\NNS|certain|as (r_nsubjpass) used_31\VBN|if|drugs|are|in (r_advcl) consider_1\VBP|we|be|,|used|. (l_ccomp) be_4\VB|asterixis|to|sign (l_attr) sign_8\NN|an|overlooked|of (l_prep) of_9\IN|neurotoxicity (l_pobj) neurotoxicity_10\NN|,|occur
D003024_D020820 CID clozapine_29\NN| (r_conj) lithium_27\NN|or|clozapine (r_pobj) as_26\IN|lithium (r_prep) drugs_25\NNS|certain|as (r_nsubjpass) used_31\VBN|if|drugs|are|in (r_advcl) consider_1\VBP|we|be|,|used|. (l_ccomp) be_4\VB|asterixis|to|sign (l_nsubj) asterixis_2\NNS|
D003024_D020258 NONE clozapine_29\NN| (r_conj) lithium_27\NN|or|clozapine (r_pobj) as_26\IN|lithium (r_prep) drugs_25\NNS|certain|as (r_nsubjpass) used_31\VBN|if|drugs|are|in (r_advcl) consider_1\VBP|we|be|,|used|. (l_ccomp) be_4\VB|asterixis|to|sign (l_attr) sign_8\NN|an|overlooked|of (l_prep) of_9\IN|neurotoxicity (l_pobj) neurotoxicity_10\NN|,|occur
D002220_D020258 NONE CBZ_35\NN| (r_pobj) with_34\IN|cbz (r_prep) combination_33\NN|with (r_pobj) in_32\IN|combination (r_prep) used_31\VBN|if|drugs|are|in (r_advcl) consider_1\VBP|we|be|,|used|. (l_ccomp) be_4\VB|asterixis|to|sign (l_attr) sign_8\NN|an|overlooked|of (l_prep) of_9\IN|neurotoxicity (l_pobj) neurotoxicity_10\NN|,|occur
12752472
D010862_D004827 CID pilocarpine_15\NN| (r_npadvmod) induced_17\VBN|pilocarpine|- (r_amod) epilepsy_18\NN|induced
D010862_D006985 NONE pilocarpine_11\NN| (r_npadvmod) treated_13\VBN|pilocarpine|-|and|control (r_amod) rats_16\NNS|treated (r_pobj) in_10\IN|rats (r_prep) ventilation_9\NN|spontaneous|in (r_pobj) in_7\IN|ventilation (r_prep) decrease_6\NN|a|in (r_dobj) caused_4\VBD|:|maneuver|decrease|. (l_nsubj) maneuver_3\NN|the|hyperventilation (l_compound) hyperventilation_2\NN|
11176729
D000806_D006333 NONE inhibitors_9\NNS|converting|enzyme (r_pobj) of_4\IN|inhibitors (r_prep) doses_3\NNS|high|of (r_pobj) of_1\IN|doses (r_prep) Toleration_0\NN|of|in|:|results|. (l_prep) in_10\IN|patients (l_pobj) patients_11\NNS|with (l_prep) with_12\IN|failure (l_pobj) failure_15\NN|chronic|heart
D000806_D006333 NONE inhibitors_9\NNS|enzyme|(|ace|) (r_pobj) with_1\IN|inhibitors (r_prep) Treatment_0\NN|with (r_nsubj) reduces_10\VBZ|treatment|mortality|,|but|receiving (l_dobj) mortality_11\NN|and|morbidity|in (l_prep) in_14\IN|patients (l_pobj) patients_15\NNS|with (l_prep) with_16\IN|failure (l_pobj) failure_19\NN|chronic|heart|chf
D000806_D006333 NONE inhibitors_9\NNS|enzyme|(|ace|) (r_pobj) with_1\IN|inhibitors (r_prep) Treatment_0\NN|with (r_nsubj) reduces_10\VBZ|treatment|mortality|,|but|receiving (l_dobj) mortality_11\NN|and|morbidity|in (l_prep) in_14\IN|patients (l_pobj) patients_15\NNS|with (l_prep) with_16\IN|failure (l_pobj) failure_19\NN|chronic|heart|chf (l_appos) CHF_21\NNP|(|)
D000806_D006333 NONE inhibitor_5\NN| (r_compound) therapy_6\NN|ace|inhibitor|in (l_prep) in_7\IN|patients (l_pobj) patients_9\NNS|most|with (l_prep) with_10\IN|chf (l_pobj) CHF_11\NNP|
D017706_D006333 NONE lisinopril_15\NN|dose|in (l_prep) in_16\IN|chf (l_pobj) CHF_17\NNP|
D000806_D007022 NONE inhibitor_8\NN|an|ace (r_dobj) receiving_5\VBG|not|previously|inhibitor (r_acl) patients_2\NNS|405|receiving (r_pobj) Of_0\IN|patients (r_prep) titrated_18\VBN|of|,|doses|could|not|be|to|because|or|because|. (l_prep) because_26\IN|of|symptoms (l_pobj) symptoms_28\NNS|related (l_acl) related_30\VBD|possibly|to (l_prep) to_31\IN|hypotension (l_pobj) hypotension_32\NN|(|%|)
D000806_D007674 NONE inhibitor_8\NN|an|ace (r_dobj) receiving_5\VBG|not|previously|inhibitor (r_acl) patients_2\NNS|405|receiving (r_pobj) Of_0\IN|patients (r_prep) titrated_18\VBN|of|,|doses|could|not|be|to|because|or|because|. (l_conj) because_38\IN|of|dysfunction (l_pobj) dysfunction_41\NN|renal|or|hyperkalemia|(|%|)
D000806_D006947 NONE inhibitor_8\NN|an|ace (r_dobj) receiving_5\VBG|not|previously|inhibitor (r_acl) patients_2\NNS|405|receiving (r_pobj) Of_0\IN|patients (r_prep) titrated_18\VBN|of|,|doses|could|not|be|to|because|or|because|. (l_conj) because_38\IN|of|dysfunction (l_pobj) dysfunction_41\NN|renal|or|hyperkalemia|(|%|) (l_conj) hyperkalemia_43\NN|
6106951
D005479_D064420 NONE FZP_2\NNP| (r_compound) toxocity_3\NN|fzp|in
D005479_D012798 NONE FZP_2\NNP| (r_compound) toxocity_3\NN|fzp|in (r_pobj) of_1\IN|toxocity (r_prep) Signs_0\NNS|of (r_nsubj) included_6\VBD|signs|salivation|retching|. (l_dobj) salivation_8\NN|excessive|,|behavior
D005479_D014202 NONE FZP_2\NNP| (r_compound) toxocity_3\NN|fzp|in (r_pobj) of_1\IN|toxocity (r_prep) Signs_0\NNS|of (r_nsubj) included_6\VBD|signs|salivation|retching|. (l_advcl) retching_14\NN|,|tremors (l_dobj) tremors_17\NNS|muscle|and|convulsions
D005479_D012640 CID FZP_2\NNP| (r_compound) toxocity_3\NN|fzp|in (r_pobj) of_1\IN|toxocity (r_prep) Signs_0\NNS|of (r_nsubj) included_6\VBD|signs|salivation|retching|. (l_advcl) retching_14\NN|,|tremors (l_dobj) tremors_17\NNS|muscle|and|convulsions (l_conj) convulsions_19\NNS|
D005479_D012640 CID FZP_6\NNP| (r_nsubj) protected_8\VBD|as|,|fzp|first|against|. (l_prep) against_9\IN|convulsions (l_pobj) convulsions_10\NNS|and|death
D005479_D012640 CID FZP_3\NNP| (r_pobj) of_2\IN|fzp (r_prep) doses_1\NNS|these|of (r_nsubj) were_4\VBD|doses|lower|cause|. (l_prep) cause_11\VB|convulsions (l_dobj) convulsions_12\NNS|
D005479_D004827 NONE FZP_9\NNP| (r_pobj) of_8\IN|fzp (r_prep) use_7\NN|the|of|in (l_prep) in_10\IN|situations (l_pobj) situations_12\NNS|clinical|is (l_relcl) is_16\VBZ|in|there|excitability (l_attr) excitability_19\NN|increased|neural|,|as (l_prep) as_22\IN|such|epilepsy (l_pobj) epilepsy_23\NN|or|withdrawal
12644816
D013792_D011471 NONE thalidomide_11\NN|dose|in (l_prep) in_12\IN|cancer (l_pobj) cancer_17\NN|independent|prostate
D013792_D011471 NONE thalidomide_8\NN| (r_dobj) using_7\VBG|thalidomide|daily|for (l_prep) for_13\IN|months (l_pobj) months_17\NNS|6|in (l_prep) in_18\IN|men (l_pobj) men_20\NNS|20|with (l_prep) with_21\IN|cancer (l_pobj) cancer_26\NN|independent|prostate
D000728_D011471 NONE androgen_13\JJ| (r_npadvmod) independent_15\JJ|androgen|- (r_amod) cancer_17\NN|independent|prostate
D000728_D011471 NONE androgen_22\JJ| (r_npadvmod) independent_24\JJ|androgen|- (r_amod) cancer_26\NN|independent|prostate
D013792_D019337 NONE thalidomide_4\NN| (r_pobj) of_3\IN|thalidomide (r_prep) effects_2\NNS|the|antiangiogenic|of (r_nsubjpass) assessed_7\VBN|effects|have|been|in|. (l_prep) in_8\IN|trials (l_pobj) trials_10\NNS|clinical|in (l_prep) in_11\IN|patients (l_pobj) patients_12\NNS|with (l_prep) with_13\IN|malignancies (l_pobj) malignancies_18\NNS|various|solid
D013792_D010523 CID thalidomide_9\NN|, (r_pobj) on_8\IN|thalidomide (r_prep) completed_5\VBD|who|months|on (r_relcl) men_3\NNS|the|seven|completed (r_pobj) In_0\IN|men (r_prep) found_17\VBN|in|evidence|was|in|,|but|in|. (l_nsubjpass) evidence_12\NN|subclinical|of (l_prep) of_13\IN|neuropathy (l_pobj) neuropathy_15\NN|peripheral
D013792_D010523 CID thalidomide_4\NN| (r_nsubj) be_6\VB|that|thalidomide|may|option|, (r_ccomp) indicate_2\VBP|findings|be|provided|. (l_ccomp) provided_19\VBD|maintained (l_dobj) maintained_25\VBN|up|is|for (l_prep) for_26\IN|development (l_pobj) development_27\NN|of (l_prep) of_28\IN|neuropathy (l_pobj) neuropathy_30\NN|peripheral
3831029
C037293_D006333 NONE denopamine_2\NN| (r_pobj) by_1\IN|denopamine (r_prep) Improvement_0\NN|by|of|. (l_prep) of_6\IN|)|failure (l_pobj) failure_11\NN|induced|cardiac|in
C037293_D006333 NONE TA-064_4\NNP|( (r_punct) )_5\-RRB-|ta-064 (r_punct) of_6\IN|)|failure (l_pobj) failure_11\NN|induced|cardiac|in
C037293_D006333 NONE denopamine_3\NN| (r_pobj) of_2\IN|denopamine (r_prep) efficacy_1\NN|the|of|,|agonist|, (r_nsubjpass) assessed_17\VBN|efficacy|in|was|in|. (l_prep) in_12\IN|improving (l_pcomp) improving_13\VBG|failure (l_dobj) failure_15\NN|cardiac
C037293_D006333 NONE denopamine_6\NN| (r_pobj) of_5\IN|denopamine (r_prep) trials_4\NNS|clinical|of|in (l_prep) in_7\IN|treatment (l_pobj) treatment_9\NN|the|of (l_prep) of_10\IN|failure (l_pobj) failure_12\NN|cardiac
D010424_D006333 CID pentobarbital_7\NN| (r_npadvmod) induced_9\VBN|pentobarbital|- (r_amod) failure_11\NN|induced|cardiac|in
C037293_D001145 NONE denopamine_8\NN| (r_pobj) of_7\IN|denopamine (r_prep) doses_6\NNS|these|of (r_pobj) by_4\IN|doses (r_agent) induced_3\VBN|arrhythmias|were|by|. (l_nsubjpass) arrhythmias_1\NNS|no
6627074
D013390_D001049 CID Succinylcholine_0\NN| (r_compound) apnoea_1\NN|succinylcholine|:|attempted|.
D013390_D001049 CID succinylcholine_14\NN| (r_compound) apnoea_15\NN|succinylcholine
D013390_D020879 NONE succinylcholine_15\NN|in (r_pobj) of_14\IN|succinylcholine (r_prep) administration_13\NN|the|of (r_pobj) following_11\VBG|administration (r_prep) blockade_10\NN|prolonged|neuromuscular|following
24999722
D005446_C537630 NONE acetonide_5\NN| (r_compound) implant_7\NN|safety|acetonide|intravitreal|(|mg|)|in|. (l_prep) in_12\IN|retinochoroidopathy (l_pobj) retinochoroidopathy_14\JJ|birdshot
D005446_C537630 NONE acetonide_8\NN| (r_amod) implant_10\NN|acetonide|intravitreal|(|mg|)|in (l_prep) in_15\IN|patients (l_pobj) patients_16\NNS|with (l_prep) with_17\IN|retinochoroidopathy (l_pobj) retinochoroidopathy_19\JJ|birdshot|is
D005446_C537630 NONE acetonide_5\NN| (r_compound) implant_6\NN|acetonide|(|mg|) (r_dobj) fluocinolone_4\NN|that|implant (r_ccomp) suggest_2\VBP|data|fluocinolone|helps|. (l_ccomp) helps_11\VBZ|control (l_xcomp) control_13\VB|to|inflammation (l_dobj) inflammation_14\NN|in (l_prep) in_15\IN|cases (l_pobj) cases_20\NNS|otherwise|refractory|of (l_prep) of_21\IN|retinochoroidopathy (l_pobj) retinochoroidopathy_23\JJ|birdshot
D005446_D007249 NONE acetonide_5\NN| (r_compound) implant_6\NN|acetonide|(|mg|) (r_dobj) fluocinolone_4\NN|that|implant (r_ccomp) suggest_2\VBP|data|fluocinolone|helps|. (l_ccomp) helps_11\VBZ|control (l_xcomp) control_13\VB|to|inflammation (l_dobj) inflammation_14\NN|in
19263707
D002231_D056648 CID Carbimazole_0\NNS| (r_nsubj) induced_1\VBD|carbimazole|vasculitis|. (l_dobj) vasculitis_4\NN|anca|positive
D013956_D006980 NONE drugs_3\NNS|thyroid|,|like (r_nsubjpass) prescribed_14\VBN|drugs|are|commonly|for|. (l_prep) for_15\IN|treatment (l_pobj) treatment_17\NN|the|of (l_prep) of_18\IN|hyperthyroidism (l_pobj) hyperthyroidism_19\NN|
D002231_D006980 NONE carbimazole_6\NN|and|propylthiouracil|ptu (r_pobj) like_5\IN|carbimazole (r_prep) drugs_3\NNS|thyroid|,|like (r_nsubjpass) prescribed_14\VBN|drugs|are|commonly|for|. (l_prep) for_15\IN|treatment (l_pobj) treatment_17\NN|the|of (l_prep) of_18\IN|hyperthyroidism (l_pobj) hyperthyroidism_19\NN|
D011441_D006980 NONE propylthiouracil_8\NN| (r_conj) carbimazole_6\NN|and|propylthiouracil|ptu (r_pobj) like_5\IN|carbimazole (r_prep) drugs_3\NNS|thyroid|,|like (r_nsubjpass) prescribed_14\VBN|drugs|are|commonly|for|. (l_prep) for_15\IN|treatment (l_pobj) treatment_17\NN|the|of (l_prep) of_18\IN|hyperthyroidism (l_pobj) hyperthyroidism_19\NN|
D011441_D006980 NONE PTU_10\NNP|(|) (r_appos) carbimazole_6\NN|and|propylthiouracil|ptu (r_pobj) like_5\IN|carbimazole (r_prep) drugs_3\NNS|thyroid|,|like (r_nsubjpass) prescribed_14\VBN|drugs|are|commonly|for|. (l_prep) for_15\IN|treatment (l_pobj) treatment_17\NN|the|of (l_prep) of_18\IN|hyperthyroidism (l_pobj) hyperthyroidism_19\NN|
D013956_D056648 CID antithyroidmedications_15\NNS| (r_pobj) of_14\IN|antithyroidmedications (r_prep) effect_13\NN|a|threatening|adverse|of (r_attr) is_6\VBZ|antibody|effect|. (l_nsubj) antibody_2\NN|antineutrophil|cytoplasmic|vasculitis (l_appos) vasculitis_5\NN|(|anca)--associated
D002231_D006111 NONE carbimazole_12\NN|anca|positive (r_dobj) developed_9\VBD|who|carbimazole (r_relcl) disease_7\NN|graves|developed
D002231_D014657 NONE carbimazole_12\NN|anca|positive (r_dobj) developed_9\VBD|who|carbimazole (r_relcl) disease_7\NN|graves|developed (r_pobj) with_4\IN|disease (r_prep) patient_3\NN|a|with (r_nsubj) induced_13\VBD|patient|vasculitis (l_dobj) vasculitis_14\NN|
D002231_D014657 NONE carbimazole_12\NN|the|first|anca|positive|induced (l_acl) induced_13\VBD|case (l_dobj) case_15\NN|vasculitis|reported (l_compound) vasculitis_14\JJ|
6529939
D011433_D001146 CID propranolol_9\NN| (r_pobj) by_8\IN|propranolol (r_agent) induced_7\VBN|by (r_xcomp) Alternating_0\VBG|rhythm|induced|. (l_dobj) rhythm_2\NN|sinus|and|block
D011433_D001146 CID propranolol_28\NN|mg|daily (r_pobj) with_25\IN|propranolol (r_prep) angina_24\NN|with (r_pobj) for_23\IN|angina (r_prep) treatment_22\NN|for (r_pobj) under_21\IN|treatment (r_prep) observed_13\VBN|alternating|block|was|in|,|under|. (l_advcl) Alternating_0\VBG|rhythm (l_dobj) rhythm_2\NN|sinus|and|sinoatrial
D011433_D012848 CID propranolol_9\NN| (r_pobj) by_8\IN|propranolol (r_agent) induced_7\VBN|by (r_xcomp) Alternating_0\VBG|rhythm|induced|. (l_dobj) rhythm_2\NN|sinus|and|block (l_conj) block_6\NN|intermittent|sinoatrial
D011433_D012848 CID propranolol_28\NN|mg|daily (r_pobj) with_25\IN|propranolol (r_prep) angina_24\NN|with (r_pobj) for_23\IN|angina (r_prep) treatment_22\NN|for (r_pobj) under_21\IN|treatment (r_prep) observed_13\VBN|alternating|block|was|in|,|under|. (l_nsubjpass) block_11\NN|(|a|)
D011433_D012848 CID propranolol_8\NN| (r_pobj) of_7\IN|propranolol (r_prep) withdrawal_6\NN|the|of|and (r_pobj) with_4\IN|withdrawal (r_prep) disappeared_3\VBD|rhythm|with (r_ccomp) seen_22\VBN|disappeared|restarted|block|was|. (l_nsubjpass) block_20\NN|a|2/1|a
D011433_D000787 NONE propranolol_28\NN|mg|daily (r_pobj) with_25\IN|propranolol (r_prep) angina_24\NN|with
D011433_D019955 NONE propranolol_6\NN| (r_pcomp) for_5\IN|propranolol|being (l_pcomp) being_7\VBG|cause (l_attr) cause_9\NN|the|of (l_prep) of_10\IN|disorder (l_pobj) disorder_13\NN|this|conduction
24220752
D003287_D007674 CID contrast_2\NN| (r_npadvmod) induced_4\VBN|contrast|- (r_amod) nephropathy_5\NN|induced
D003287_D007674 CID contrast_10\NN| (r_npadvmod) induced_12\VBN|contrast|- (r_amod) nephropathy_13\NN|induced|(|cin|)
D003287_D007674 CID Contrast_0\RB| (r_npadvmod) induced_2\VBN|contrast|- (r_amod) nephropathy_3\NN|induced|is
D003287_D009369 NONE contrast_2\NN| (r_npadvmod) induced_4\VBN|contrast|- (r_amod) nephropathy_5\NN|induced (r_pobj) of_1\IN|nephropathy (r_prep) Incidence_0\NN|of|in|. (l_prep) in_6\IN|patients (l_pobj) patients_8\NNS|hospitalised|with (l_prep) with_9\IN|cancer (l_pobj) cancer_10\NN|
D003287_D009369 NONE contrast_10\NN| (r_npadvmod) induced_12\VBN|contrast|- (r_amod) nephropathy_13\NN|induced|(|cin|) (r_pobj) to_9\IN|nephropathy (r_prep) related_8\VBN|to|in (l_prep) in_17\IN|patients (l_pobj) patients_19\NNS|hospitalised|with (l_prep) with_20\IN|cancer (l_pobj) cancer_21\NN|
-1_D006973 NONE bevacizumab_7\NN| (r_amod) irinotecan_9\NN|bevacizumab|/|(|p (r_pobj) with_6\IN|irinotecan (r_prep) treatment_5\NN|with (r_pobj) after_4\IN|more|treatment|and|in (l_conj) in_16\IN|patients (l_pobj) patients_17\NNS|with (l_prep) with_18\IN|hypertension (l_pobj) hypertension_19\NN|(|p|)
-1_D006973 NONE bevacizumab_5\NN| (r_amod) irinotecan_7\NN|bevacizumab|/ (r_pobj) of_4\IN|irinotecan (r_prep) combination_3\NN|the|of (r_conj) Hypertension_0\NN|and|combination
-1_D006973 NONE bevacizumab_4\NN| (r_pobj) with_3\IN|bevacizumab (r_prep) treatment_2\NN|with (r_conj) Hypertension_0\NN|and|treatment
C051890_D006973 NONE irinotecan_9\NN|bevacizumab|/|(|p (r_pobj) with_6\IN|irinotecan (r_prep) treatment_5\NN|with (r_pobj) after_4\IN|more|treatment|and|in (l_conj) in_16\IN|patients (l_pobj) patients_17\NNS|with (l_prep) with_18\IN|hypertension (l_pobj) hypertension_19\NN|(|p|)
C051890_D006973 NONE irinotecan_7\NN|bevacizumab|/ (r_pobj) of_4\IN|irinotecan (r_prep) combination_3\NN|the|of (r_conj) Hypertension_0\NN|and|combination
7147232
D000255_D007022 CID triphosphate_7\NN|adenosine|and|sodium (r_pobj) by_5\IN|triphosphate (r_agent) induced_4\VBN|by (r_acl) effects_1\NNS|cardiovascular|of|induced (l_prep) of_2\IN|hypotension (l_pobj) hypotension_3\NN|
D000255_D007022 CID triphosphate_1\NN|adenosine|(|atp|)|and|sodium (r_nsubj) nitroprusside_7\NN|triphosphate|snp (r_nsubjpass) administered_12\VBN|nitroprusside|are|to|induce|. (l_advcl) induce_16\VB|to|and|control (l_conj) control_18\VB|hypotension (l_dobj) hypotension_19\NN|during
D000255_D007022 CID ATP_3\NNP| (r_appos) triphosphate_1\NN|adenosine|(|atp|)|and|sodium (r_nsubj) nitroprusside_7\NN|triphosphate|snp (r_nsubjpass) administered_12\VBN|nitroprusside|are|to|induce|. (l_advcl) induce_16\VB|to|and|control (l_conj) control_18\VB|hypotension (l_dobj) hypotension_19\NN|during
D000255_D007022 CID ATP_3\NNP| (r_pobj) by_2\IN|atp (r_agent) induced_1\VBN|by (r_acl) Hypotension_0\NN|induced
D000255_D007022 CID ATP_94\NNP| (r_nsubjpass) stopped_96\VBN|after|atp|was (r_advcl) returned_88\VBD|left|;|variables|normal|within|stopped|. (l_ccomp) left_31\VBD|accompanied|,|pressure|pressure|,|resistance (l_ccomp) accompanied_5\VBN|hypotension|was|by (l_nsubjpass) Hypotension_0\NN|induced
D009599_D007022 CID nitroprusside_10\NN|effects|on|. (l_nsubj) effects_1\NNS|cardiovascular|of|induced (l_prep) of_2\IN|hypotension (l_pobj) hypotension_3\NN|
D009599_D007022 CID nitroprusside_7\NN|triphosphate|snp (r_nsubjpass) administered_12\VBN|nitroprusside|are|to|induce|. (l_advcl) induce_16\VB|to|and|control (l_conj) control_18\VB|hypotension (l_dobj) hypotension_19\NN|during
D009599_D007022 CID SNP_9\NNP|(|) (r_appos) nitroprusside_7\NN|triphosphate|snp (r_nsubjpass) administered_12\VBN|nitroprusside|are|to|induce|. (l_advcl) induce_16\VB|to|and|control (l_conj) control_18\VB|hypotension (l_dobj) hypotension_19\NN|during
D009599_D007022 CID SNP_4\NNP| (r_nmod) decreases_6\NNS|snp|similar (r_pobj) by_3\IN|decreases (r_agent) produced_2\VBN|by (r_acl) hypotension_1\NN|produced
D010100_D007022 NONE oxygen_66\NN| (r_compound) consumption_67\NN|body|oxygen|(|0.05|)|,|and|rate (r_conj) resistance_46\NN|total|peripheral|(|0.001|)|,|product|,|consumption (r_dobj) left_31\VBD|accompanied|,|pressure|pressure|,|resistance (l_ccomp) accompanied_5\VBN|hypotension|was|by (l_nsubjpass) Hypotension_0\NN|induced
D010100_D007022 NONE oxygen_65\NN| (r_compound) difference_67\NN|oxygen|content|between|0.05|) (r_conj) product_56\NN|pressure|(|0.001|)|,|and|difference (r_conj) resistance_46\NN|total|peripheral|(|0.001|)|,|product|,|increased (r_appos) observed_8\VBN|during|were|in|p|,|resistance|. (l_prep) During_0\IN|hypotension (l_pobj) hypotension_1\NN|produced
44072
C024986_D001145 CID BaCl2_9\NN| (r_pobj) with_8\IN|bacl2|,|with|, (r_prep) used_6\VBN|types|are|--|with|with|. (l_nsubjpass) types_1\NNS|four|of (l_prep) of_2\IN|arrhythmia (l_pobj) arrhythmia_4\NN|experimental
C024986_D001145 CID BaCl2_32\NN|in (r_pobj) with_31\IN|bacl2 (r_conj) in_25\IN|90|)|and|with (r_prep) causing_13\VBG|inhibition|(|in (r_advcl) manifests_2\VBZ|compound|activity|,|causing|. (l_dobj) activity_4\NN|antiarrhythmic|in|used (l_prep) in_5\IN|models (l_pobj) models_7\NNS|all|of (l_prep) of_8\IN|arrhythmia (l_pobj) arrhythmia_10\NN|experimental
C024986_D001145 CID BaCl2_32\NN|in (r_pobj) with_31\IN|bacl2 (r_conj) in_25\IN|90|)|and|with (r_prep) causing_13\VBG|inhibition|(|in (l_dobj) inhibition_15\NN|greatest|on (l_prep) on_16\IN|arrhythmia (l_pobj) arrhythmia_18\NN|the|induced
D002725_D001145 CID chloroform_12\NN| (r_compound) adrenaline_14\NN|chloroform|- (r_pobj) with_11\IN|adrenaline (r_conj) with_8\IN|bacl2|,|with|, (r_prep) used_6\VBN|types|are|--|with|with|. (l_nsubjpass) types_1\NNS|four|of (l_prep) of_2\IN|arrhythmia (l_pobj) arrhythmia_4\NN|experimental
D002725_D001145 CID chloroform_21\NN| (r_compound) adrenaline_23\NN|chloroform|- (r_pobj) by_20\IN|adrenaline (r_agent) induced_19\VBN|by (r_acl) arrhythmia_18\NN|the|induced (r_pobj) on_16\IN|arrhythmia (r_prep) inhibition_15\NN|greatest|on (r_dobj) causing_13\VBG|inhibition|(|in (r_advcl) manifests_2\VBZ|compound|activity|,|causing|. (l_dobj) activity_4\NN|antiarrhythmic|in|used (l_prep) in_5\IN|models (l_pobj) models_7\NNS|all|of (l_prep) of_8\IN|arrhythmia (l_pobj) arrhythmia_10\NN|experimental
D002725_D001145 CID chloroform_21\NN| (r_compound) adrenaline_23\NN|chloroform|- (r_pobj) by_20\IN|adrenaline (r_agent) induced_19\VBN|by (r_acl) arrhythmia_18\NN|the|induced
D004837_D001145 CID adrenaline_14\NN|chloroform|- (r_pobj) with_11\IN|adrenaline (r_conj) with_8\IN|bacl2|,|with|, (r_prep) used_6\VBN|types|are|--|with|with|. (l_nsubjpass) types_1\NNS|four|of (l_prep) of_2\IN|arrhythmia (l_pobj) arrhythmia_4\NN|experimental
D004837_D001145 CID adrenaline_23\NN|chloroform|- (r_pobj) by_20\IN|adrenaline (r_agent) induced_19\VBN|by (r_acl) arrhythmia_18\NN|the|induced (r_pobj) on_16\IN|arrhythmia (r_prep) inhibition_15\NN|greatest|on (r_dobj) causing_13\VBG|inhibition|(|in (r_advcl) manifests_2\VBZ|compound|activity|,|causing|. (l_dobj) activity_4\NN|antiarrhythmic|in|used (l_prep) in_5\IN|models (l_pobj) models_7\NNS|all|of (l_prep) of_8\IN|arrhythmia (l_pobj) arrhythmia_10\NN|experimental
D004837_D001145 CID adrenaline_23\NN|chloroform|- (r_pobj) by_20\IN|adrenaline (r_agent) induced_19\VBN|by (r_acl) arrhythmia_18\NN|the|induced
D010042_D001145 CID G_18\NN|strophantine (r_pobj) with_16\IN|g|and|with (r_prep) used_6\VBN|types|are|--|with|with|. (l_nsubjpass) types_1\NNS|four|of (l_prep) of_2\IN|arrhythmia (l_pobj) arrhythmia_4\NN|experimental
D000157_D001145 CID aconitine_21\NN| (r_pobj) with_20\IN|aconitine (r_conj) with_16\IN|g|and|with (r_prep) used_6\VBN|types|are|--|with|with|. (l_nsubjpass) types_1\NNS|four|of (l_prep) of_2\IN|arrhythmia (l_pobj) arrhythmia_4\NN|experimental
17445520
D002110_D016584 CID Caffeine_0\NN| (r_amod) test_2\NN|caffeine|challenge|in|. (l_prep) in_3\IN|disorder (l_pobj) disorder_5\NN|panic|and|depression
D002110_D016584 CID Caffeine_0\NN| (r_amod) test_2\NN|caffeine|challenge|in|. (l_prep) in_3\IN|disorder (l_pobj) disorder_5\NN|panic|and|depression (l_conj) depression_7\NN|with (l_prep) with_8\IN|attacks (l_pobj) attacks_10\NNS|panic
D002110_D016584 CID caffeine_51\NN| (r_compound) challenge_52\NN|caffeine (r_compound) test_53\NN|an|oral|challenge (r_pobj) by_48\IN|test (r_prep) attacks_47\NNS|panic|by (r_pobj) of_45\IN|attacks (r_prep) induction_44\NN|the|of (r_pobj) to_42\IN|induction (r_prep) way_41\NN|a|similar|to (r_pobj) in_38\IN|way (r_prep) respond_37\VBP|if|patients|in (l_nsubj) patients_6\NNS|with (l_prep) with_7\IN|disorder (l_pobj) disorder_9\NN|panic|(|pd|)|and|patients
D002110_D016584 CID caffeine_51\NN| (r_compound) challenge_52\NN|caffeine (r_compound) test_53\NN|an|oral|challenge (r_pobj) by_48\IN|test (r_prep) attacks_47\NNS|panic|by (r_pobj) of_45\IN|attacks (r_prep) induction_44\NN|the|of (r_pobj) to_42\IN|induction (r_prep) way_41\NN|a|similar|to (r_pobj) in_38\IN|way (r_prep) respond_37\VBP|if|patients|in (l_nsubj) patients_6\NNS|with (l_prep) with_7\IN|disorder (l_pobj) disorder_9\NN|panic|(|pd|)|and|patients (l_appos) PD_11\NNP|
D002110_D016584 CID caffeine_51\NN| (r_compound) challenge_52\NN|caffeine (r_compound) test_53\NN|an|oral|challenge (r_pobj) by_48\IN|test (r_prep) attacks_47\NNS|panic|by (r_pobj) of_45\IN|attacks (r_prep) induction_44\NN|the|of (r_pobj) to_42\IN|induction (r_prep) way_41\NN|a|similar|to (r_pobj) in_38\IN|way (r_prep) respond_37\VBP|if|patients|in (l_nsubj) patients_6\NNS|with (l_prep) with_7\IN|disorder (l_pobj) disorder_9\NN|panic|(|pd|)|and|patients (l_conj) patients_14\NNS|with (l_prep) with_15\IN|depression (l_pobj) depression_17\NN|major|with (l_prep) with_18\IN|attacks (l_pobj) attacks_20\NNS|panic|(|mdp|)|(|diagnostic|)
D002110_D016584 CID caffeine_51\NN| (r_compound) challenge_52\NN|caffeine (r_compound) test_53\NN|an|oral|challenge (r_pobj) by_48\IN|test (r_prep) attacks_47\NNS|panic|by
D002110_D016584 CID caffeine_56\NN| (r_compound) test_58\NN|the|480-mg|caffeine|challenge|(|chi(2)(3|)|16.22|,|p|) (r_pobj) after_53\IN|test (r_prep) had_49\VBD|total|attack|after|. (l_nsubj) total_1\NN|a|of (l_prep) of_2\IN|% (l_pobj) %_4\NN|58.6|(|n|17|)|of|,|%|)|of|,|%|)|of|,|and|% (l_prep) of_10\IN|patients (l_pobj) patients_11\NNS|with (l_prep) with_12\IN|pd (l_pobj) PD_13\NNP|
D002110_D016584 CID caffeine_56\NN| (r_compound) test_58\NN|the|480-mg|caffeine|challenge|(|chi(2)(3|)|16.22|,|p|) (r_pobj) after_53\IN|test (r_prep) had_49\VBD|total|attack|after|. (l_dobj) attack_52\NN|a|panic
D002110_D016584 CID caffeine_10\NN| (r_pobj) to_9\IN|caffeine (r_prep) sensitive_8\JJ|more|to|were (r_acomp) were_6\VBD|patients|sensitive|. (l_nsubj) patients_1\NNS|the|with (l_prep) with_2\IN|pd (l_pobj) PD_3\NNP|and|mdp
D002110_D016584 CID caffeine_7\NN| (r_npadvmod) free_9\JJ|caffeine|- (r_amod) intake_11\NN|the|free|solution (r_pobj) after_5\IN|intake (r_prep) observed_4\VBN|attack|was|after|. (l_nsubjpass) attack_2\NN|no|panic
D002110_D016584 CID caffeine_26\NN| (r_compound) challenge_27\NN|caffeine (r_compound) test_28\NN|an|oral|challenge (r_pobj) to_23\IN|test (r_prep) hyperreactivity_22\NN|to (r_conj) is_5\VBZ|that|there|association|matter|associated|,|and|hyperreactivity (l_attr) association_7\NN|an|between|, (l_prep) between_8\IN|attacks (l_pobj) attacks_10\NNS|panic
D002110_D016584 CID caffeine_26\NN| (r_compound) challenge_27\NN|caffeine (r_compound) test_28\NN|an|oral|challenge (r_pobj) to_23\IN|test (r_prep) hyperreactivity_22\NN|to (r_conj) is_5\VBZ|that|there|association|matter|associated|,|and|hyperreactivity (l_advcl) associated_15\VBN|if|with (l_prep) with_16\IN|pd (l_pobj) PD_17\NNP|or|mdp
D002110_D016584 NONE caffeine_51\NN| (r_compound) challenge_52\NN|caffeine (r_compound) test_53\NN|an|oral|challenge (r_pobj) by_48\IN|test (r_prep) attacks_47\NNS|panic|by (r_pobj) of_45\IN|attacks (r_prep) induction_44\NN|the|of (r_pobj) to_42\IN|induction (r_prep) way_41\NN|a|similar|to (r_pobj) in_38\IN|way (r_prep) respond_37\VBP|if|patients|in (l_nsubj) patients_6\NNS|with (l_prep) with_7\IN|disorder (l_pobj) disorder_9\NN|panic|(|pd|)|and|patients (l_conj) patients_14\NNS|with (l_prep) with_15\IN|depression (l_pobj) depression_17\NN|major|with (l_prep) with_18\IN|attacks (l_pobj) attacks_20\NNS|panic|(|mdp|)|(|diagnostic|) (l_appos) MDP_22\NNP|
D002110_D016584 NONE caffeine_56\NN| (r_compound) test_58\NN|the|480-mg|caffeine|challenge|(|chi(2)(3|)|16.22|,|p|) (r_pobj) after_53\IN|test (r_prep) had_49\VBD|total|attack|after|. (l_nsubj) total_1\NN|a|of (l_prep) of_2\IN|% (l_pobj) %_4\NN|58.6|(|n|17|)|of|,|%|)|of|,|%|)|of|,|and|% (l_prep) of_22\IN|patients (l_pobj) patients_23\NNS|with (l_prep) with_24\IN|mdp (l_pobj) MDP_25\NNP|
D002110_D016584 NONE caffeine_10\NN| (r_pobj) to_9\IN|caffeine (r_prep) sensitive_8\JJ|more|to|were (r_acomp) were_6\VBD|patients|sensitive|. (l_nsubj) patients_1\NNS|the|with (l_prep) with_2\IN|pd (l_pobj) PD_3\NNP|and|mdp (l_conj) MDP_5\NNP|
D002110_D016584 NONE caffeine_26\NN| (r_compound) challenge_27\NN|caffeine (r_compound) test_28\NN|an|oral|challenge (r_pobj) to_23\IN|test (r_prep) hyperreactivity_22\NN|to (r_conj) is_5\VBZ|that|there|association|matter|associated|,|and|hyperreactivity (l_advcl) associated_15\VBN|if|with (l_prep) with_16\IN|pd (l_pobj) PD_17\NNP|or|mdp (l_conj) MDP_19\NNP|
D002110_D003866 NONE Caffeine_0\NN| (r_amod) test_2\NN|caffeine|challenge|in|. (l_prep) in_3\IN|disorder (l_pobj) disorder_5\NN|panic|and|depression (l_conj) depression_7\NN|with
D002110_D003865 NONE caffeine_51\NN| (r_compound) challenge_52\NN|caffeine (r_compound) test_53\NN|an|oral|challenge (r_pobj) by_48\IN|test (r_prep) attacks_47\NNS|panic|by (r_pobj) of_45\IN|attacks (r_prep) induction_44\NN|the|of (r_pobj) to_42\IN|induction (r_prep) way_41\NN|a|similar|to (r_pobj) in_38\IN|way (r_prep) respond_37\VBP|if|patients|in (l_nsubj) patients_6\NNS|with (l_prep) with_7\IN|disorder (l_pobj) disorder_9\NN|panic|(|pd|)|and|patients (l_conj) patients_14\NNS|with (l_prep) with_15\IN|depression (l_pobj) depression_17\NN|major|with
D002110_D003865 NONE caffeine_51\NN| (r_compound) challenge_52\NN|caffeine (r_compound) test_53\NN|an|oral|challenge (r_pobj) by_48\IN|test (r_prep) attacks_47\NNS|panic|by (r_pobj) of_45\IN|attacks (r_prep) induction_44\NN|the|of (r_pobj) to_42\IN|induction (r_prep) way_41\NN|a|similar|to (r_pobj) in_38\IN|way (r_prep) respond_37\VBP|if|patients|in (l_nsubj) patients_6\NNS|with (l_prep) with_7\IN|disorder (l_pobj) disorder_9\NN|panic|(|pd|)|and|patients (l_conj) patients_14\NNS|with (l_prep) with_15\IN|depression (l_pobj) depression_17\NN|major|with (l_prep) with_18\IN|attacks (l_pobj) attacks_20\NNS|panic|(|mdp|)|(|diagnostic|) (l_appos) MDP_22\NNP|
D002110_D003865 NONE caffeine_56\NN| (r_compound) test_58\NN|the|480-mg|caffeine|challenge|(|chi(2)(3|)|16.22|,|p|) (r_pobj) after_53\IN|test (r_prep) had_49\VBD|total|attack|after|. (l_nsubj) total_1\NN|a|of (l_prep) of_2\IN|% (l_pobj) %_4\NN|58.6|(|n|17|)|of|,|%|)|of|,|%|)|of|,|and|% (l_prep) of_22\IN|patients (l_pobj) patients_23\NNS|with (l_prep) with_24\IN|mdp (l_pobj) MDP_25\NNP|
D002110_D003865 NONE caffeine_56\NN| (r_compound) test_58\NN|the|480-mg|caffeine|challenge|(|chi(2)(3|)|16.22|,|p|) (r_pobj) after_53\IN|test (r_prep) had_49\VBD|total|attack|after|. (l_nsubj) total_1\NN|a|of (l_prep) of_2\IN|% (l_pobj) %_4\NN|58.6|(|n|17|)|of|,|%|)|of|,|%|)|of|,|and|% (l_prep) of_34\IN|patients (l_pobj) patients_35\NNS|with (l_prep) with_36\IN|md (l_pobj) MD_37\NNP|
D002110_D003865 NONE caffeine_10\NN| (r_pobj) to_9\IN|caffeine (r_prep) sensitive_8\JJ|more|to|were (r_acomp) were_6\VBD|patients|sensitive|. (l_nsubj) patients_1\NNS|the|with (l_prep) with_2\IN|pd (l_pobj) PD_3\NNP|and|mdp (l_conj) MDP_5\NNP|
D002110_D003865 NONE caffeine_10\NN| (r_pobj) to_9\IN|caffeine (r_prep) sensitive_8\JJ|more|to|were (l_advcl) were_12\VBD|than|patients (l_nsubj) patients_13\NNS|with (l_prep) with_14\IN|md (l_pobj) MD_15\NNP|and|volunteers
D002110_D003865 NONE caffeine_26\NN| (r_compound) challenge_27\NN|caffeine (r_compound) test_28\NN|an|oral|challenge (r_pobj) to_23\IN|test (r_prep) hyperreactivity_22\NN|to (r_conj) is_5\VBZ|that|there|association|matter|associated|,|and|hyperreactivity (l_advcl) associated_15\VBN|if|with (l_prep) with_16\IN|pd (l_pobj) PD_17\NNP|or|mdp (l_conj) MDP_19\NNP|
D002110_D001523 NONE caffeine_51\NN| (r_compound) challenge_52\NN|caffeine (r_compound) test_53\NN|an|oral|challenge (r_pobj) by_48\IN|test (r_prep) attacks_47\NNS|panic|by (r_pobj) of_45\IN|attacks (r_prep) induction_44\NN|the|of (r_pobj) to_42\IN|induction (r_prep) way_41\NN|a|similar|to (r_pobj) in_38\IN|way (r_prep) respond_37\VBP|if|patients|in (l_nsubj) patients_6\NNS|with (l_prep) with_7\IN|disorder (l_pobj) disorder_9\NN|panic|(|pd|)|and|patients (l_conj) patients_14\NNS|with (l_prep) with_15\IN|depression (l_pobj) depression_17\NN|major|with (l_prep) with_18\IN|attacks (l_pobj) attacks_20\NNS|panic|(|mdp|)|(|diagnostic|) (l_appos) Diagnostic_25\NNP|and|manual|,|criteria (l_conj) Manual_28\NNP|statistical|of (l_prep) of_29\IN|disorders (l_pobj) Disorders_31\NNP|mental
D002110_D001008 NONE caffeine_17\NN|mg|and|solution (r_nsubjpass) administered_28\VBN|in|,|caffeine|were|in|applied|. (l_prep) in_29\IN|scales (l_pobj) scales_35\NNS|a|form (l_nmod) form_32\NN|coffee|and|anxiety (l_conj) anxiety_34\NN|
D002110_D001008 NONE caffeine_20\NN| (r_npadvmod) free_22\JJ|caffeine|- (r_amod) solution_26\NN|a|free|(|placebo|) (r_conj) caffeine_17\NN|mg|and|solution (r_nsubjpass) administered_28\VBN|in|,|caffeine|were|in|applied|. (l_prep) in_29\IN|scales (l_pobj) scales_35\NNS|a|form (l_nmod) form_32\NN|coffee|and|anxiety (l_conj) anxiety_34\NN|
891494
D010672_D001927 CID Phenytoin_0\NNP| (r_compound) encephalopathy_1\NNP|phenytoin|as|:|report|.
D010672_D001927 CID phenytoin_3\NNP| (r_nmod) encephalopathy_7\JJ|phenytoin|(|dph|)|with
D010672_D001927 CID DPH_5\NNP| (r_nmod) encephalopathy_7\JJ|phenytoin|(|dph|)|with
D010672_D012640 NONE phenytoin_3\NNP| (r_nmod) encephalopathy_7\JJ|phenytoin|(|dph|)|with (l_prep) with_8\IN|seizures (l_pobj) seizures_10\NNS|increasing|and|eeg
D010672_D012640 NONE DPH_5\NNP| (r_nmod) encephalopathy_7\JJ|phenytoin|(|dph|)|with (l_prep) with_8\IN|seizures (l_pobj) seizures_10\NNS|increasing|and|eeg
D010672_D012640 NONE DPH_8\NNP| (r_compound) treatment_9\NN|dph (r_dobj) starting_7\VBG|treatment (r_acl) patient_6\NN|a|starting (r_pobj) in_4\IN|patient|increase (l_pobj) increase_12\NN|an|unexpected|in|,|with (l_prep) in_13\IN|seizures (l_pobj) seizures_14\NNS|
D010672_D012640 NONE DPH_34\NNP| (r_dobj) eliminating_33\VBG|dph|from (r_pcomp) for_32\IN|eliminating (r_prep) need_31\NN|the|possible|for (r_pobj) to_28\IN|need (r_prep) alert_25\VB|that|in|,|should|physician|to|,|are (l_prep) in_4\IN|patient|increase (l_pobj) increase_12\NN|an|unexpected|in|,|with (l_prep) in_13\IN|seizures (l_pobj) seizures_14\NNS|
D010672_D005076 NONE DPH_6\NNP|free (r_pobj) of_4\IN|dph (r_prep) concentration_3\NN|the|of (r_nsubj) was_7\VBD|in|concentration|normal (r_ccomp) presented_12\VBD|was|,|patient|rash|during (l_dobj) rash_16\JJ|a|retarded|morbilliform
D010672_D005076 NONE DPH_18\NNP| (r_compound) treatment_19\NN|dph (r_pobj) during_17\IN|treatment (r_prep) presented_12\VBD|was|,|patient|rash|during (l_dobj) rash_16\JJ|a|retarded|morbilliform
D010672_D005076 NONE DPH_29\NNP| (r_compound) injection_30\NN|an|intradermic|dph (r_nsubj) had_31\VBD|injection|effect|. (r_conj) was_23\VBD|presented|,|protidogram|normal|,|and|had (l_ccomp) presented_12\VBD|was|,|patient|rash|during (l_dobj) rash_16\JJ|a|retarded|morbilliform
17879100
D001241_D005334 NONE aspirin_4\JJ| (r_pobj) on_3\IN|aspirin (r_prep) put_2\VBN|he|was|on|following|and|took|. (l_conj) took_8\VBD|ibuprofen|for|for (l_prep) for_10\IN|fever (l_pobj) fever_11\NN|
D007052_D005334 NONE ibuprofen_9\NN| (r_dobj) took_8\VBD|ibuprofen|for|for (l_prep) for_10\IN|fever (l_pobj) fever_11\NN|
2553470
D016291_D013226 NONE MK-801_3\NNP| (r_punct) on_4\IN|mk-801|model (r_prep) epilepticus_12\NN|actions|on|in|.
D016291_D013226 NONE MK-801_2\NNP| (r_punct) 30_3\CD|mk-801|or|60 (r_nummod) min_6\NN|30|after (r_pobj) of_1\IN|min (r_prep) Administration_0\NN|of (r_nsubj) reduced_17\VBD|administration|,|i.e.|,|during|,|gradually|activity|and|enhanced|. (l_prep) during_12\IN|status|epilepticus (l_pobj) epilepticus_14\NN|
D008094_D013226 CID lithium_6\NN| (r_compound) pilocarpine_8\NN|lithium|- (r_compound) model_9\NN|the|pilocarpine|of (r_pobj) on_4\IN|mk-801|model (r_prep) epilepticus_12\NN|actions|on|in|.
D008094_D013226 CID lithium_12\NN|and|pilocarpine (r_pobj) by_11\IN|lithium (r_agent) induced_10\VBN|by|by|prior (r_acl) seizures_9\NNS|induced (r_dobj) block_8\VB|to|seizures (r_xcomp) is_4\VBZ|although|it|easy|block (r_advcl) is_24\VBZ|third|,|is|,|it|difficult|ongoing|. (l_xcomp) ongoing_29\JJ|epilepticus (l_advmod) epilepticus_31\NN|status|and|block
D008094_D013226 CID lithium_20\NN| (r_compound) pilocarpine_22\NN|lithium|- (r_compound) model_23\NN|the|pilocarpine (r_pobj) in_18\IN|model (r_prep) damage_17\NN|status|epilepticus|in (l_amod) epilepticus_14\NN|and|brain
D010862_D013226 CID pilocarpine_8\NN|lithium|- (r_compound) model_9\NN|the|pilocarpine|of (r_pobj) on_4\IN|mk-801|model (r_prep) epilepticus_12\NN|actions|on|in|.
D010862_D013226 CID pilocarpine_14\NN| (r_conj) lithium_12\NN|and|pilocarpine (r_pobj) by_11\IN|lithium (r_agent) induced_10\VBN|by|by|prior (r_acl) seizures_9\NNS|induced (r_dobj) block_8\VB|to|seizures (r_xcomp) is_4\VBZ|although|it|easy|block (r_advcl) is_24\VBZ|third|,|is|,|it|difficult|ongoing|. (l_xcomp) ongoing_29\JJ|epilepticus (l_advmod) epilepticus_31\NN|status|and|block
D010862_D013226 CID pilocarpine_21\NN| (r_pobj) to_20\IN|pilocarpine (r_prep) prior_19\RB|to (r_advmod) induced_10\VBN|by|by|prior (r_acl) seizures_9\NNS|induced (r_dobj) block_8\VB|to|seizures (r_xcomp) is_4\VBZ|although|it|easy|block (r_advcl) is_24\VBZ|third|,|is|,|it|difficult|ongoing|. (l_xcomp) ongoing_29\JJ|epilepticus (l_advmod) epilepticus_31\NN|status|and|block
D010862_D013226 CID pilocarpine_8\NN| (r_pobj) after_7\IN|pilocarpine (r_prep) min_6\NN|30|after (r_pobj) of_1\IN|min (r_prep) Administration_0\NN|of (r_nsubj) reduced_17\VBD|administration|,|i.e.|,|during|,|gradually|activity|and|enhanced|. (l_prep) during_12\IN|status|epilepticus (l_pobj) epilepticus_14\NN|
D010862_D013226 CID pilocarpine_22\NN|lithium|- (r_compound) model_23\NN|the|pilocarpine (r_pobj) in_18\IN|model (r_prep) damage_17\NN|status|epilepticus|in (l_amod) epilepticus_14\NN|and|brain
D010862_D013226 CID pilocarpine_13\NN| (r_conj) NMDA_11\NNP|and|pilocarpine (r_pobj) of_10\IN|nmda (r_prep) doses_9\NNS|that|nonconvulsive|of (r_dobj) showing_6\VBG|doses (r_acl) results_5\NNS|showing (r_pobj) by_4\IN|results (r_agent) supported_3\VBN|this|was|further|by|were|. (l_conj) were_14\VBD|synergistic|,|resulting (l_advcl) resulting_17\VBG|in (l_prep) in_18\IN|mortality (l_pobj) mortality_23\NN|status|epilepticus (l_amod) epilepticus_20\NN|and|subsequent
D016291_D012640 NONE MK-801_0\NNP| (r_punct) tested_18\VBN|mk-801|,|antagonist|was|for|. (l_prep) for_19\IN|effects (l_pobj) effects_21\NNS|anticonvulsant|in|using (l_acl) using_24\VBG|models (l_dobj) models_27\NNS|two|seizure|,|coadministration|of (l_compound) seizure_26\NN|
D016291_D012640 NONE MK-801_4\NNP| (r_punct) produced_5\VBD|first|,|pretreatment|mk-801|action|but|with|,|suggesting|. (l_advcl) suggesting_29\VBG|seizures (l_dobj) seizures_35\NNS|that|different|control|in
D016291_D012640 NONE MK-801_6\NNP| (r_punct) in_7\IN|mk-801|model (r_prep) occurred_14\VBD|second|,|effect|in|only|after|. (l_prep) after_15\IN|periods (l_pobj) periods_17\NNS|initial|of (l_prep) of_18\IN|activity (l_pobj) activity_20\NN|seizure (l_compound) seizure_19\NN|
D016291_D012640 NONE MK-801_2\NNP| (r_punct) 30_3\CD|mk-801|or|60 (r_nummod) min_6\NN|30|after (r_pobj) of_1\IN|min (r_prep) Administration_0\NN|of (r_nsubj) reduced_17\VBD|administration|,|i.e.|,|during|,|gradually|activity|and|enhanced|. (l_dobj) activity_22\NN|seizure (l_compound) seizure_21\NN|electrical
D016202_D012640 NONE aspartate_10\NNP|methyl|-|d|- (r_nmod) antagonist_15\NN|a|noncompetitive|aspartate|(|nmda|)|receptor|, (r_nsubjpass) tested_18\VBN|mk-801|,|antagonist|was|for|. (l_prep) for_19\IN|effects (l_pobj) effects_21\NNS|anticonvulsant|in|using (l_acl) using_24\VBG|models (l_dobj) models_27\NNS|two|seizure|,|coadministration|of (l_compound) seizure_26\NN|
D016202_D012640 NONE NMDA_12\NNP| (r_nmod) antagonist_15\NN|a|noncompetitive|aspartate|(|nmda|)|receptor|, (r_nsubjpass) tested_18\VBN|mk-801|,|antagonist|was|for|. (l_prep) for_19\IN|effects (l_pobj) effects_21\NNS|anticonvulsant|in|using (l_acl) using_24\VBG|models (l_dobj) models_27\NNS|two|seizure|,|coadministration|of (l_compound) seizure_26\NN|
D008094_D012640 NONE lithium_31\NN|and|pilocarpine (r_pobj) of_30\IN|lithium (r_prep) coadministration_29\NN|of|and|administration (r_conj) models_27\NNS|two|seizure|,|coadministration|of (l_compound) seizure_26\NN|
D008094_D012640 NONE lithium_16\NN| (r_compound) pilocarpine_18\NN|lithium|- (r_compound) model_19\NN|the|pilocarpine (r_pobj) with_14\IN|model (r_prep) action_13\NN|an|effective|anticonvulsant|with (r_dobj) produced_5\VBD|first|,|pretreatment|mk-801|action|but|with|,|suggesting|. (l_advcl) suggesting_29\VBG|seizures (l_dobj) seizures_35\NNS|that|different|control|in
D008094_D012640 NONE lithium_9\NN| (r_compound) pilocarpine_11\NN|lithium|- (r_compound) model_12\NN|the|pilocarpine (r_pobj) in_7\IN|mk-801|model (r_prep) occurred_14\VBD|second|,|effect|in|only|after|. (l_prep) after_15\IN|periods (l_pobj) periods_17\NNS|initial|of (l_prep) of_18\IN|activity (l_pobj) activity_20\NN|seizure (l_compound) seizure_19\NN|
D008094_D012640 NONE lithium_12\NN|and|pilocarpine (r_pobj) by_11\IN|lithium (r_agent) induced_10\VBN|by|by|prior (r_acl) seizures_9\NNS|induced
D008094_D012640 NONE lithium_12\NN|and|pilocarpine (r_pobj) by_11\IN|lithium (r_agent) induced_10\VBN|by|by|prior (r_acl) seizures_9\NNS|induced (r_dobj) block_8\VB|to|seizures (r_xcomp) is_4\VBZ|although|it|easy|block (r_advcl) is_24\VBZ|third|,|is|,|it|difficult|ongoing|. (l_xcomp) ongoing_29\JJ|epilepticus (l_advmod) epilepticus_31\NN|status|and|block (l_conj) block_33\VB|lethality (l_dobj) lethality_35\NN|the|of (l_prep) of_36\IN|seizures (l_pobj) seizures_38\NNS|the
D010862_D012640 NONE pilocarpine_33\NN| (r_conj) lithium_31\NN|and|pilocarpine (r_pobj) of_30\IN|lithium (r_prep) coadministration_29\NN|of|and|administration (r_conj) models_27\NNS|two|seizure|,|coadministration|of (l_compound) seizure_26\NN|
D010862_D012640 NONE pilocarpine_41\NN| (r_pobj) of_40\IN|pilocarpine (r_prep) dose_39\NN|a|high|of|alone (r_pobj) of_36\IN|dose (r_prep) models_27\NNS|two|seizure|,|coadministration|of (l_compound) seizure_26\NN|
D010862_D012640 NONE pilocarpine_18\NN|lithium|- (r_compound) model_19\NN|the|pilocarpine (r_pobj) with_14\IN|model (r_prep) action_13\NN|an|effective|anticonvulsant|with (r_dobj) produced_5\VBD|first|,|pretreatment|mk-801|action|but|with|,|suggesting|. (l_advcl) suggesting_29\VBG|seizures (l_dobj) seizures_35\NNS|that|different|control|in
D010862_D012640 NONE pilocarpine_26\NN| (r_pobj) with_25\IN|pilocarpine (r_prep) treated_24\VBN|with|alone (r_acl) rats_23\NNS|treated (r_pobj) with_22\IN|not|rats (r_conj) produced_5\VBD|first|,|pretreatment|mk-801|action|but|with|,|suggesting|. (l_advcl) suggesting_29\VBG|seizures (l_dobj) seizures_35\NNS|that|different|control|in
D010862_D012640 NONE pilocarpine_11\NN|lithium|- (r_compound) model_12\NN|the|pilocarpine (r_pobj) in_7\IN|mk-801|model (r_prep) occurred_14\VBD|second|,|effect|in|only|after|. (l_prep) after_15\IN|periods (l_pobj) periods_17\NNS|initial|of (l_prep) of_18\IN|activity (l_pobj) activity_20\NN|seizure (l_compound) seizure_19\NN|
D010862_D012640 NONE pilocarpine_14\NN| (r_conj) lithium_12\NN|and|pilocarpine (r_pobj) by_11\IN|lithium (r_agent) induced_10\VBN|by|by|prior (r_acl) seizures_9\NNS|induced
D010862_D012640 NONE pilocarpine_14\NN| (r_conj) lithium_12\NN|and|pilocarpine (r_pobj) by_11\IN|lithium (r_agent) induced_10\VBN|by|by|prior (r_acl) seizures_9\NNS|induced (r_dobj) block_8\VB|to|seizures (r_xcomp) is_4\VBZ|although|it|easy|block (r_advcl) is_24\VBZ|third|,|is|,|it|difficult|ongoing|. (l_xcomp) ongoing_29\JJ|epilepticus (l_advmod) epilepticus_31\NN|status|and|block (l_conj) block_33\VB|lethality (l_dobj) lethality_35\NN|the|of (l_prep) of_36\IN|seizures (l_pobj) seizures_38\NNS|the
D010862_D012640 NONE pilocarpine_21\NN| (r_pobj) to_20\IN|pilocarpine (r_prep) prior_19\RB|to (r_advmod) induced_10\VBN|by|by|prior (r_acl) seizures_9\NNS|induced
D010862_D012640 NONE pilocarpine_21\NN| (r_pobj) to_20\IN|pilocarpine (r_prep) prior_19\RB|to (r_advmod) induced_10\VBN|by|by|prior (r_acl) seizures_9\NNS|induced (r_dobj) block_8\VB|to|seizures (r_xcomp) is_4\VBZ|although|it|easy|block (r_advcl) is_24\VBZ|third|,|is|,|it|difficult|ongoing|. (l_xcomp) ongoing_29\JJ|epilepticus (l_advmod) epilepticus_31\NN|status|and|block (l_conj) block_33\VB|lethality (l_dobj) lethality_35\NN|the|of (l_prep) of_36\IN|seizures (l_pobj) seizures_38\NNS|the
D010862_D012640 NONE pilocarpine_8\NN| (r_pobj) after_7\IN|pilocarpine (r_prep) min_6\NN|30|after (r_pobj) of_1\IN|min (r_prep) Administration_0\NN|of (r_nsubj) reduced_17\VBD|administration|,|i.e.|,|during|,|gradually|activity|and|enhanced|. (l_dobj) activity_22\NN|seizure (l_compound) seizure_21\NN|electrical
D016202_D013226 NONE NMDA_6\NNP| (r_compound) receptors_7\NNS|nmda (r_pobj) of_5\IN|receptors (r_prep) activation_4\NN|of (r_nsubj) plays_8\VBZ|that|activation|role (l_dobj) role_11\NN|an|important|in (l_prep) in_12\IN|damage (l_pobj) damage_17\NN|status|epilepticus|in (l_amod) epilepticus_14\NN|and|brain
D016202_D013226 NONE NMDA_11\NNP|and|pilocarpine (r_pobj) of_10\IN|nmda (r_prep) doses_9\NNS|that|nonconvulsive|of (r_dobj) showing_6\VBG|doses (r_acl) results_5\NNS|showing (r_pobj) by_4\IN|results (r_agent) supported_3\VBN|this|was|further|by|were|. (l_conj) were_14\VBD|synergistic|,|resulting (l_advcl) resulting_17\VBG|in (l_prep) in_18\IN|mortality (l_pobj) mortality_23\NN|status|epilepticus (l_amod) epilepticus_20\NN|and|subsequent
D016202_D001930 NONE NMDA_6\NNP| (r_compound) receptors_7\NNS|nmda (r_pobj) of_5\IN|receptors (r_prep) activation_4\NN|of (r_nsubj) plays_8\VBZ|that|activation|role (l_dobj) role_11\NN|an|important|in (l_prep) in_12\IN|damage (l_pobj) damage_17\NN|status|epilepticus|in
D008094_D001930 NONE lithium_20\NN| (r_compound) pilocarpine_22\NN|lithium|- (r_compound) model_23\NN|the|pilocarpine (r_pobj) in_18\IN|model (r_prep) damage_17\NN|status|epilepticus|in
D010862_D001930 NONE pilocarpine_22\NN|lithium|- (r_compound) model_23\NN|the|pilocarpine (r_pobj) in_18\IN|model (r_prep) damage_17\NN|status|epilepticus|in
256433
D014031_D007239 NONE tobramycin_2\NN|continuous|infusion|combined|. (l_acl) combined_3\VBN|with (l_prep) with_4\IN|carbenicillin (l_pobj) carbenicillin_5\NN|for (l_prep) for_6\IN|infections (l_pobj) infections_7\NNS|in
D014031_D009369 NONE tobramycin_2\NN|continuous|infusion|combined|. (l_acl) combined_3\VBN|with (l_prep) with_4\IN|carbenicillin (l_pobj) carbenicillin_5\NN|for (l_prep) for_6\IN|infections (l_pobj) infections_7\NNS|in (l_prep) in_8\IN|patients (l_pobj) patients_10\NNS|cancer (l_compound) cancer_9\NN|
D002228_D007239 NONE carbenicillin_5\NN|for (l_prep) for_6\IN|infections (l_pobj) infections_7\NNS|in
D002228_D009369 NONE carbenicillin_5\NN|for (l_prep) for_6\IN|infections (l_pobj) infections_7\NNS|in (l_prep) in_8\IN|patients (l_pobj) patients_10\NNS|cancer (l_compound) cancer_9\NN|
D014031_D009503 NONE tobramycin_8\JJ| (r_nsubjpass) given_10\VBN|overcome|,|tobramycin|was|by|and|combined|. (l_advcl) overcome_1\VB|to|effects (l_dobj) effects_4\NNS|the|adverse|of (l_prep) of_5\IN|neutropenia (l_pobj) neutropenia_6\NN|
D002228_D009503 NONE carbenicillin_18\NN|intermittent (r_pobj) with_16\IN|carbenicillin (r_prep) combined_15\VBN|with (r_conj) given_10\VBN|overcome|,|tobramycin|was|by|and|combined|. (l_advcl) overcome_1\VB|to|effects (l_dobj) effects_4\NNS|the|adverse|of (l_prep) of_5\IN|neutropenia (l_pobj) neutropenia_6\NN|
D003404_D053099 NONE creatinine_4\NN|serum|dl|greater (r_appos) azotemia_1\NN|major|(|creatinine|)
D014031_D053099 CID tobramycin_10\JJ| (r_amod) concentration_11\NN|therapy|tobramycin (r_pobj) of_6\IN|concentration (r_prep) duration_5\NN|of (r_pobj) to_4\IN|duration (r_prep) related_3\VBN|azotemia|was|not|to|. (l_nsubjpass) Azotemia_0\NNP|
17554526
D003042_D001925 CID cocaine_6\NN|recreational (r_compound) users_7\NNS|regular|cocaine (r_pobj) in_3\IN|users (r_prep) recognition_2\NN|impaired|fear|in|.
D003042_D001925 CID cocaine_21\NN|,|or|ecstasy (r_pobj) of_20\IN|cocaine (r_prep) effects_19\NNS|the|subacute|of (r_pobj) by_16\IN|effects (r_agent) explained_15\VBN|deficit|can|not|be|by|,|were|. (l_nsubjpass) deficit_2\NN|the|selective|in (l_prep) in_3\IN|fear|accuracy (l_pobj) accuracy_6\NN|recognition|manifested (l_compound) recognition_5\NN|
D018817_D001925 NONE ecstasy_24\NN| (r_conj) cocaine_21\NN|,|or|ecstasy (r_pobj) of_20\IN|cocaine (r_prep) effects_19\NNS|the|subacute|of (r_pobj) by_16\IN|effects (r_agent) explained_15\VBN|deficit|can|not|be|by|,|were|. (l_nsubjpass) deficit_2\NN|the|selective|in (l_prep) in_3\IN|fear|accuracy (l_pobj) accuracy_6\NN|recognition|manifested (l_compound) recognition_5\NN|
12498738
C043211_D009202 NONE Carvedilol_0\NNP| (r_nsubj) protects_1\VBZ|carvedilol|against|. (l_prep) against_2\IN|cardiomyopathy (l_pobj) cardiomyopathy_7\NN|induced|mitochondrial
C043211_D009202 NONE carvedilol_7\NN|against (r_pobj) by_6\IN|carvedilol (r_prep) protection_5\NN|this|by (r_nsubj) afford_18\VB|that|protection|may|advantage|in (l_prep) in_22\IN|minimizing (l_pcomp) minimizing_23\VBG|dysfunction (l_dobj) dysfunction_29\NN|the|limiting|mitochondrial|and|cardiomyopathy|accompanies (l_conj) cardiomyopathy_31\NN|
D004317_D009202 CID doxorubicin_3\RB| (r_npadvmod) induced_5\VBN|doxorubicin|- (r_amod) cardiomyopathy_7\NN|induced|mitochondrial
D004317_D009202 CID doxorubicin_18\NN| (r_pobj) by_17\IN|doxorubicin (r_agent) caused_16\VBN|by (r_acl) cardiomyopathy_15\NN|the|limiting|cumulative|caused
D004317_D009202 CID doxorubicin_37\NN| (r_compound) therapy_38\NN|term|doxorubicin (r_dobj) accompanies_33\VBZ|that|therapy|in (r_relcl) dysfunction_29\NN|the|limiting|mitochondrial|and|cardiomyopathy|accompanies (l_conj) cardiomyopathy_31\NN|
C043211_D064420 NONE carvedilol_11\NN|that|,|antagonist|, (r_nsubj) protects_25\VBZ|carvedilol|against (l_prep) against_26\IN|dysfunction (l_pobj) dysfunction_33\NN|the|cardiac|mitochondrial|bioenergetic|associated (l_acl) associated_34\VBN|with (l_prep) with_35\IN|toxicity (l_pobj) toxicity_38\NN|subchronic|doxorubicin
D004317_D064420 NONE doxorubicin_37\JJ| (r_compound) toxicity_38\NN|subchronic|doxorubicin
C043211_D028361 NONE carvedilol_7\NN|against (r_pobj) by_6\IN|carvedilol (r_prep) protection_5\NN|this|by (r_nsubj) afford_18\VB|that|protection|may|advantage|in (l_prep) in_22\IN|minimizing (l_pcomp) minimizing_23\VBG|dysfunction (l_dobj) dysfunction_29\NN|the|limiting|mitochondrial|and|cardiomyopathy|accompanies
C043211_D009369 NONE carvedilol_7\NN|against (r_pobj) by_6\IN|carvedilol (r_prep) protection_5\NN|this|by (r_nsubj) afford_18\VB|that|protection|may|advantage|in (l_prep) in_22\IN|minimizing (l_pcomp) minimizing_23\VBG|dysfunction (l_dobj) dysfunction_29\NN|the|limiting|mitochondrial|and|cardiomyopathy|accompanies (l_relcl) accompanies_33\VBZ|that|therapy|in (l_prep) in_39\IN|patients (l_pobj) patients_41\NNS|cancer (l_compound) cancer_40\NN|
D004317_D028361 NONE doxorubicin_37\NN| (r_compound) therapy_38\NN|term|doxorubicin (r_dobj) accompanies_33\VBZ|that|therapy|in (r_relcl) dysfunction_29\NN|the|limiting|mitochondrial|and|cardiomyopathy|accompanies
D004317_D009369 NONE doxorubicin_37\NN| (r_compound) therapy_38\NN|term|doxorubicin (r_dobj) accompanies_33\VBZ|that|therapy|in (l_prep) in_39\IN|patients (l_pobj) patients_41\NNS|cancer (l_compound) cancer_40\NN|
20859899
D000809_D013575 NONE angiotensin_12\NN| (r_npadvmod) converting_14\VBG|angiotensin|- (r_amod) inhibitor_16\NN|the|converting|enzyme|and|spironolactone (r_pobj) with_10\IN|inhibitor (r_prep) therapy_9\NN|a|combined|with (r_pobj) of_6\IN|therapy (r_prep) use_5\NN|of (r_pobj) during_4\IN|use (r_prep) caused_1\VBD|by|during (r_acl) Syncope_0\NNP|caused|.
D000809_D006947 NONE angiotensin_12\NN| (r_npadvmod) converting_14\VBG|angiotensin|- (r_amod) inhibitor_16\NN|the|converting|enzyme|and|spironolactone (r_pobj) with_10\IN|inhibitor (r_prep) therapy_9\NN|a|combined|with (r_pobj) of_6\IN|therapy (r_prep) use_5\NN|of (r_pobj) during_4\IN|use (r_prep) caused_1\VBD|by|during (l_agent) by_2\IN|hyperkalemia (l_pobj) hyperkalemia_3\NN|
D013148_D013575 NONE spironolactone_18\NN| (r_conj) inhibitor_16\NN|the|converting|enzyme|and|spironolactone (r_pobj) with_10\IN|inhibitor (r_prep) therapy_9\NN|a|combined|with (r_pobj) of_6\IN|therapy (r_prep) use_5\NN|of (r_pobj) during_4\IN|use (r_prep) caused_1\VBD|by|during (r_acl) Syncope_0\NNP|caused|.
D013148_D006947 CID spironolactone_18\NN| (r_conj) inhibitor_16\NN|the|converting|enzyme|and|spironolactone (r_pobj) with_10\IN|inhibitor (r_prep) therapy_9\NN|a|combined|with (r_pobj) of_6\IN|therapy (r_prep) use_5\NN|of (r_pobj) during_4\IN|use (r_prep) caused_1\VBD|by|during (l_agent) by_2\IN|hyperkalemia (l_pobj) hyperkalemia_3\NN|
D013148_D006947 CID spiranolactone_11\NN|,|antagonist (r_pobj) of_10\IN|spiranolactone (r_prep) doses_9\NNS|several|of (r_attr) be_7\VB|to|doses|,|in (r_xcomp) considered_5\VBN|cause|was|be|. (l_nsubjpass) cause_1\NN|the|of (l_prep) of_2\IN|hyperkalemia (l_pobj) hyperkalemia_3\NN|
D000450_D006947 NONE aldosterone_14\NN| (r_compound) antagonist_15\NN|an|aldosterone (r_appos) spiranolactone_11\NN|,|antagonist (r_pobj) of_10\IN|spiranolactone (r_prep) doses_9\NNS|several|of (r_attr) be_7\VB|to|doses|,|in (r_xcomp) considered_5\VBN|cause|was|be|. (l_nsubjpass) cause_1\NN|the|of (l_prep) of_2\IN|hyperkalemia (l_pobj) hyperkalemia_3\NN|
D017257_D006947 CID ramipril_26\NN| (r_pobj) of_25\IN|ramipril (r_prep) intake_24\NN|the|term|of|,|inhibitor (r_pobj) to_19\IN|intake (r_prep) addition_18\NN|to (r_pobj) in_17\IN|addition (r_prep) be_7\VB|to|doses|,|in (r_xcomp) considered_5\VBN|cause|was|be|. (l_nsubjpass) cause_1\NN|the|of (l_prep) of_2\IN|hyperkalemia (l_pobj) hyperkalemia_3\NN|
D011188_D006947 NONE potassium_21\NN| (r_compound) agents_23\NNS|potassium|sparing (r_pobj) with_20\IN|agents (r_prep) combination_19\NN|with (r_pobj) in_18\IN|combination (r_prep) using_14\VBG|arb|in (r_acl) patients_13\NNS|elderly|using (r_pobj) in_11\IN|especially|patients|and|have (r_prep) be_2\VB|clinicians|should|alert|,|in|. (l_acomp) alert_3\JJ|to (l_prep) to_4\IN|possibility (l_pobj) possibility_6\NN|the|of (l_prep) of_7\IN|hyperkalemia (l_pobj) hyperkalemia_8\NN|
D011188_D007674 NONE potassium_21\NN| (r_compound) agents_23\NNS|potassium|sparing (r_pobj) with_20\IN|agents (r_prep) combination_19\NN|with (r_pobj) in_18\IN|combination (r_prep) using_14\VBG|arb|in (r_acl) patients_13\NNS|elderly|using (r_pobj) in_11\IN|especially|patients|and|have (l_conj) have_26\VBP|who|disturbance (l_dobj) disturbance_29\NN|mild|renal
10327032
D005472_D022124 CID 5-fluorouracil_13\CD| (r_punct) with_14\IN|5-fluorouracil|complication (r_prep) received_9\VBD|who|infusion|with (r_relcl) patients_7\NNS|cancer|received (r_pobj) in_5\IN|patients (r_prep) encephalopathy_4\NN|transient|hyperammonemic|in
D005472_D022124 CID 5-fluorouracil_21\CD| (r_punct) 5-FU_23\CD|5-fluorouracil|( (r_pobj) of_20\IN|5-fu (r_prep) infusion_19\NN|continuous|of (r_pobj) to_17\IN|infusion (r_prep) related_16\VBN|to (r_acl) encephalopathy_15\NN|transient|hyperammonemic|related
D005472_D022124 CID 5-FU_23\CD|5-fluorouracil|( (r_pobj) of_20\IN|5-fu (r_prep) infusion_19\NN|continuous|of (r_pobj) to_17\IN|infusion (r_prep) related_16\VBN|to (r_acl) encephalopathy_15\NN|transient|hyperammonemic|related
D005472_D022124 CID 5-FU_42\CD|p=0.0001 (r_pobj) of_41\IN|5-fu (r_prep) doses_32\NNS|high|daily|(|m2|)|of (r_dobj) receiving_29\VBG|doses|respectively (r_acl) patients_28\NNS|nine|receiving (r_pobj) in_26\IN|patients|) (r_prep) seen_11\VBN|levels|were|in|and|in|. (l_nsubjpass) levels_3\NNS|higher|ammonium|and|onset (l_conj) onset_7\NN|rapid|of (l_prep) of_8\IN|hyperammonemia (l_pobj) hyperammonemia_9\NN|
D005472_D022124 CID 5-FU_13\CD| (r_pobj) of_12\IN|5-fu (r_prep) infusion_11\NN|continuous|of (r_dobj) receiving_9\VBG|infusion (r_acl) patients_8\NNS|receiving (r_pobj) in_7\IN|patients (r_prep) occur_6\VB|in|,|encephalopathy|can|in|. (l_nsubj) encephalopathy_4\NN|hyperammonemic
D005472_D001927 CID 5-fluorouracil_13\CD| (r_punct) with_14\IN|5-fluorouracil|complication (r_prep) received_9\VBD|who|infusion|with (r_relcl) patients_7\NNS|cancer|received (r_pobj) in_5\IN|patients (r_prep) encephalopathy_4\NN|transient|hyperammonemic|in
D005472_D001927 CID 5-fluorouracil_21\CD| (r_punct) 5-FU_23\CD|5-fluorouracil|( (r_pobj) of_20\IN|5-fu (r_prep) infusion_19\NN|continuous|of (r_pobj) to_17\IN|infusion (r_prep) related_16\VBN|to (r_acl) encephalopathy_15\NN|transient|hyperammonemic|related
D005472_D001927 CID 5-FU_23\CD|5-fluorouracil|( (r_pobj) of_20\IN|5-fu (r_prep) infusion_19\NN|continuous|of (r_pobj) to_17\IN|infusion (r_prep) related_16\VBN|to (r_acl) encephalopathy_15\NN|transient|hyperammonemic|related
D005472_D001927 CID 5-FU_13\CD| (r_pobj) of_12\IN|5-fu (r_prep) infusion_11\NN|continuous|of (r_dobj) receiving_9\VBG|infusion (r_acl) patients_8\NNS|receiving (r_pobj) in_7\IN|patients (r_prep) occur_6\VB|in|,|encephalopathy|can|in|. (l_nsubj) encephalopathy_4\NN|hyperammonemic
D005472_D009369 NONE 5-fluorouracil_13\CD| (r_punct) with_14\IN|5-fluorouracil|complication (r_prep) received_9\VBD|who|infusion|with (r_relcl) patients_7\NNS|cancer|received (l_compound) cancer_6\NN|
D005472_D009369 NONE 5-fluorouracil_21\CD| (r_punct) 5-FU_23\CD|5-fluorouracil|( (r_pobj) of_20\IN|5-fu (r_prep) infusion_19\NN|continuous|of (r_pobj) to_17\IN|infusion (r_prep) related_16\VBN|to (r_acl) encephalopathy_15\NN|transient|hyperammonemic|related (r_pobj) of_12\IN|encephalopathy (r_prep) episodes_11\NNS|32|of (r_dobj) had_9\VBD|who|episodes (r_relcl) patients_7\NNS|29|cancer|had|) (l_compound) cancer_6\NN|
D005472_D009369 NONE 5-FU_23\CD|5-fluorouracil|( (r_pobj) of_20\IN|5-fu (r_prep) infusion_19\NN|continuous|of (r_pobj) to_17\IN|infusion (r_prep) related_16\VBN|to (r_acl) encephalopathy_15\NN|transient|hyperammonemic|related (r_pobj) of_12\IN|encephalopathy (r_prep) episodes_11\NNS|32|of (r_dobj) had_9\VBD|who|episodes (r_relcl) patients_7\NNS|29|cancer|had|) (l_compound) cancer_6\NN|
D005472_D003681 NONE 5-fluorouracil_13\CD| (r_punct) with_14\IN|5-fluorouracil|complication (l_pobj) complication_16\NN|the|of (l_prep) of_17\IN|dehydration (l_pobj) dehydration_18\NN|and|infection
D005472_D007239 NONE 5-fluorouracil_13\CD| (r_punct) with_14\IN|5-fluorouracil|complication (l_pobj) complication_16\NN|the|of (l_prep) of_17\IN|dehydration (l_pobj) dehydration_18\NN|and|infection (l_conj) infection_20\NN|
D000644_D022124 NONE ammonium_2\NN|plasma (r_compound) levels_3\NNS|higher|ammonium|and|onset (l_conj) onset_7\NN|rapid|of (l_prep) of_8\IN|hyperammonemia (l_pobj) hyperammonemia_9\NN|
D000644_D001424 NONE ammonium_2\NN|plasma (r_compound) levels_3\NNS|higher|ammonium|and|onset (r_nsubjpass) seen_11\VBN|levels|were|in|and|in|. (l_prep) in_12\IN|patients (l_pobj) patients_14\NNS|18|with (l_prep) with_15\IN|infections (l_pobj) infections_17\NNS|bacterial|(|p=0.003|)
D005472_D001424 NONE 5-FU_42\CD|p=0.0001 (r_pobj) of_41\IN|5-fu (r_prep) doses_32\NNS|high|daily|(|m2|)|of (r_dobj) receiving_29\VBG|doses|respectively (r_acl) patients_28\NNS|nine|receiving (r_pobj) in_26\IN|patients|) (r_prep) seen_11\VBN|levels|were|in|and|in|. (l_prep) in_12\IN|patients (l_pobj) patients_14\NNS|18|with (l_prep) with_15\IN|infections (l_pobj) infections_17\NNS|bacterial|(|p=0.003|)
12059909
D003520_D064420 NONE cyclophosphamide_3\NN| (r_pobj) of_2\IN|cyclophosphamide (r_prep) toxicity_1\NN|of
D003520_D064420 NONE CY_1\NNP| (r_compound) toxicity_2\NN|early|cy
D003520_D064420 NONE CY_7\NNP| (r_pobj) of_6\IN|cy (r_prep) toxicity_5\NN|delayed|of|in
D003520_D006470 CID CY_1\NNP| (r_compound) toxicity_2\NN|early|cy (r_nsubj) caused_3\VBD|toxicity|cystitis|. (l_dobj) cystitis_7\NN|a|typical|haemorrhagic|in|repaired (l_amod) haemorrhagic_6\JJ|
D003520_D003556 CID CY_1\NNP| (r_compound) toxicity_2\NN|early|cy (r_nsubj) caused_3\VBD|toxicity|cystitis|. (l_dobj) cystitis_7\NN|a|typical|haemorrhagic|in|repaired
D003520_D003556 CID CY_4\NNP| (r_compound) injection_5\NN|cy|ulcerous (r_pobj) of_3\IN|injection (r_prep) days_2\NNS|30|of (r_pobj) After_0\IN|days (r_prep) appeared_15\VBD|after|forms|in|but|%|. (l_nsubj) forms_11\NNS|ulcerous|of (l_prep) of_12\IN|cystitis (l_pobj) cystitis_14\NN|chronic
2383364
C048279_D002056 NONE diphosphanilate_6\NN|chlorhexidine (r_pobj) of_3\IN|diphosphanilate (r_prep) study_2\NN|tolerance|of|:|agent|. (l_appos) agent_11\NN|a|new|topical|for (l_prep) for_12\IN|burns (l_pobj) burns_13\NNS|
C048279_D002056 NONE phosphanilate_1\NN|chlorhexidine|chp|,|agent|, (r_nsubjpass) evaluated_16\VBN|phosphanilate|has|been|as|,|but|reported (l_prep) as_17\IN|wound (l_pobj) wound_21\NN|a|topical|burn|dressing (l_compound) burn_20\NN|
C048279_D002056 NONE CHP_3\NNP|(|) (r_appos) phosphanilate_1\NN|chlorhexidine|chp|,|agent|, (r_nsubjpass) evaluated_16\VBN|phosphanilate|has|been|as|,|but|reported (l_prep) as_17\IN|wound (l_pobj) wound_21\NN|a|topical|burn|dressing (l_compound) burn_20\NN|
C048279_D002056 NONE CHP_10\NNP| (r_compound) concentrations_11\NNS|four|different|chp (r_pobj) of_7\IN|concentrations (r_prep) each_6\DT|of (r_pobj) with_5\IN|each (r_prep) treated_4\VBN|site|was|with|,|from|,|vehicle|. (l_nsubjpass) site_2\NN|one|burn (l_compound) burn_1\NN|
C048279_D002056 NONE CHP_10\NNP| (r_compound) concentrations_11\NNS|four|different|chp (r_pobj) of_7\IN|concentrations (r_prep) each_6\DT|of (r_pobj) with_5\IN|each (r_prep) treated_4\VBN|site|was|with|,|from|,|vehicle|. (l_dobj) vehicle_23\NN|their|,|and|cream (l_conj) cream_34\NN|1|sulphadiazine|(|agsd|)|,|agent (l_appos) agent_38\NN|an|antimicrobial|used (l_acl) used_40\VBN|frequently|for (l_prep) for_41\IN|treatment (l_pobj) treatment_43\NN|topical|of (l_prep) of_44\IN|wounds (l_pobj) wounds_46\NNS|burn (l_compound) burn_45\NN|
D012837_D002056 NONE sulphadiazine_30\NN|cent|silver (r_nmod) cream_34\NN|1|sulphadiazine|(|agsd|)|,|agent (r_conj) vehicle_23\NN|their|,|and|cream (r_dobj) treated_4\VBN|site|was|with|,|from|,|vehicle|. (l_nsubjpass) site_2\NN|one|burn (l_compound) burn_1\NN|
D012837_D002056 NONE sulphadiazine_30\NN|cent|silver (r_nmod) cream_34\NN|1|sulphadiazine|(|agsd|)|,|agent (l_appos) agent_38\NN|an|antimicrobial|used (l_acl) used_40\VBN|frequently|for (l_prep) for_41\IN|treatment (l_pobj) treatment_43\NN|topical|of (l_prep) of_44\IN|wounds (l_pobj) wounds_46\NNS|burn (l_compound) burn_45\NN|
D012837_D002056 NONE AgSD_32\NNP| (r_nmod) cream_34\NN|1|sulphadiazine|(|agsd|)|,|agent (r_conj) vehicle_23\NN|their|,|and|cream (r_dobj) treated_4\VBN|site|was|with|,|from|,|vehicle|. (l_nsubjpass) site_2\NN|one|burn (l_compound) burn_1\NN|
D012837_D002056 NONE AgSD_32\NNP| (r_nmod) cream_34\NN|1|sulphadiazine|(|agsd|)|,|agent (l_appos) agent_38\NN|an|antimicrobial|used (l_acl) used_40\VBN|frequently|for (l_prep) for_41\IN|treatment (l_pobj) treatment_43\NN|topical|of (l_prep) of_44\IN|wounds (l_pobj) wounds_46\NNS|burn (l_compound) burn_45\NN|
C048279_D010146 CID CHP_6\NNP| (r_compound) concentration_7\NN|chp|and|ratings (l_conj) ratings_11\NNS|patients|of|on (l_prep) of_12\IN|pain (l_pobj) pain_13\NN|
C048279_D010146 CID CHP_4\NNP| (r_compound) cream_5\NN|the|0.25|cent|chp (r_nsubj) was_6\VBD|cream|closest|in (l_prep) in_10\IN|tolerance (l_pobj) tolerance_12\NN|pain (l_compound) pain_11\NN|
D012837_D010146 NONE AgSD_9\NNP| (r_pobj) to_8\IN|agsd (r_prep) closest_7\JJS|to (r_acomp) was_6\VBD|cream|closest|in (l_prep) in_10\IN|tolerance (l_pobj) tolerance_12\NN|pain (l_compound) pain_11\NN|
D012837_D010146 NONE AgSD_23\NNP| (r_pobj) from_22\IN|agsd|or|from (r_prep) differed_20\VBD|was|;|however|,|none|statistically|from|. (l_ccomp) was_6\VBD|cream|closest|in (l_prep) in_10\IN|tolerance (l_pobj) tolerance_12\NN|pain (l_compound) pain_11\NN|
7739955
D002220_D009205 CID carbamazepine_10\NN| (r_npadvmod) induced_12\VBN|carbamazepine|- (r_amod) myocarditis_15\NN|a|induced|acute|eosinophilic (r_dobj) had_8\VBD|had|,|one|myocarditis|,|and|had (l_ccomp) had_2\VBD|patients|myocarditis (l_dobj) myocarditis_5\NN|acute|viral
D002220_D009205 CID carbamazepine_10\NN| (r_npadvmod) induced_12\VBN|carbamazepine|- (r_amod) myocarditis_15\NN|a|induced|acute|eosinophilic
D002220_D004802 CID carbamazepine_10\NN| (r_npadvmod) induced_12\VBN|carbamazepine|- (r_amod) myocarditis_15\NN|a|induced|acute|eosinophilic
D002220_D012770 NONE carbamazepine_10\NN| (r_npadvmod) induced_12\VBN|carbamazepine|- (r_amod) myocarditis_15\NN|a|induced|acute|eosinophilic (r_dobj) had_8\VBD|had|,|one|myocarditis|,|and|had (l_conj) had_19\VBD|one|hemosiderosis|. (l_dobj) hemosiderosis_21\NN|cardiac|resulting (l_acl) resulting_22\VBG|in (l_prep) in_23\IN|shock (l_pobj) shock_26\NN|acute|cardiogenic
3125850
D013390_D005207 CID suxamethonium_5\NN|- (r_npadvmod) induced_7\VBN|suxamethonium (r_amod) fasciculations_9\NNS|induced|muscle|in|:|inhibition
D013390_D005207 CID suxamethonium_9\NN| (r_pobj) by_8\IN|suxamethonium (r_agent) caused_7\VBN|by (r_acl) fasciculations_6\NNS|muscle|caused
D013390_D005207 CID suxamethonium_13\NN|in (r_pobj) by_12\IN|suxamethonium (r_agent) caused_11\VBN|by (r_acl) fasciculations_10\NNS|muscle|caused
D013390_D005207 CID suxamethonium_11\NN| (r_npadvmod) induced_13\VBN|suxamethonium|- (r_amod) fasciculations_15\NNS|induced|muscle
D015760_D005207 NONE alfentanil_15\NN| (r_pobj) by_14\IN|alfentanil (r_prep) inhibition_13\NN|by (r_appos) fasciculations_9\NNS|induced|muscle|in|:|inhibition
D015760_D005207 NONE alfentanil_19\NN| (r_compound) group_20\NN|the|alfentanil (r_pobj) in_17\IN|group (r_prep) than_16\IN|in (r_prep) greater_12\JJR|significantly|in|than (r_acomp) were_10\VBD|incidence|greater|. (l_nsubj) incidence_1\NN|the|and|intensity (l_conj) intensity_3\NN|of (l_prep) of_4\IN|fasciculations (l_pobj) fasciculations_6\NNS|muscle|caused
D015760_D005207 NONE alfentanil_26\NN| (r_compound) group_27\NN|the|alfentanil (r_pobj) in_24\IN|group (r_prep) than_23\IN|in (r_prep) was_6\VBD|pressure|higher|in|than (l_nsubj) pressure_2\NN|the|intragastric|during (l_prep) during_3\IN|fasciculations (l_pobj) fasciculations_5\NNS|muscle
D015760_D005207 NONE Alfentanil_0\NNP|micrograms (r_dep) inhibits_5\VBZ|alfentanil|kg-1|effectively|incidence (l_dobj) incidence_7\NN|the|and|intensity|of (l_prep) of_10\IN|fasciculations (l_pobj) fasciculations_15\NNS|induced|muscle
D014867_D005207 NONE H2O_21\NNP|cm (r_appos) group_12\NN|the|control|(|h2o|) (r_pobj) in_9\IN|group (r_prep) was_6\VBD|pressure|higher|in|than (l_nsubj) pressure_2\NN|the|intragastric|during (l_prep) during_3\IN|fasciculations (l_pobj) fasciculations_5\NNS|muscle
946593
D008727_D010264 CID methotrexate_3\NN|intrathecal (r_dobj) following_1\VBG|methotrexate (r_prep) Paraplegia_0\NNP|following|report
D008727_D010264 CID methotrexate_10\NNP| (r_pobj) of_9\IN|methotrexate (r_prep) instillation_8\NN|the|intrathecal|of (r_pobj) following_5\VBG|instillation (r_prep) developed_3\VBD|who|paraplegia|following (l_dobj) paraplegia_4\NNS|
D008727_D002493 NONE methothexate_34\NN|fluid (r_compound) concentration_35\NN|elevated|cerebrospinal|methothexate|related|;|presence (r_appos) dynamics_15\NNS|abnormal|cerebrospinal|related|,|and|leakage|;|concentration (l_acl) related_16\VBN|to (l_prep) to_17\IN|presence (l_pobj) presence_19\NN|the|of (l_prep) of_20\IN|leukemia (l_pobj) leukemia_24\NN|system
D008727_D002493 NONE methotrexate_46\NN| (r_compound) doses_47\NNS|high|methotrexate|based (r_pobj) to_43\TO|doses (r_conj) related_36\VBN|to|and|to (r_acl) concentration_35\NN|elevated|cerebrospinal|methothexate|related|;|presence (r_appos) dynamics_15\NNS|abnormal|cerebrospinal|related|,|and|leakage|;|concentration (l_acl) related_16\VBN|to (l_prep) to_17\IN|presence (l_pobj) presence_19\NN|the|of (l_prep) of_20\IN|leukemia (l_pobj) leukemia_24\NN|system
D008727_D002493 NONE methotrexate_68\NN| (r_compound) preparations_69\NNS|available|methotrexate|and|diluents (r_pobj) in_65\IN|preparations (r_prep) presence_61\NN|the|of|in|;|and|use (r_conj) concentration_35\NN|elevated|cerebrospinal|methothexate|related|;|presence (r_appos) dynamics_15\NNS|abnormal|cerebrospinal|related|,|and|leakage|;|concentration (l_acl) related_16\VBN|to (l_prep) to_17\IN|presence (l_pobj) presence_19\NN|the|of (l_prep) of_20\IN|leukemia (l_pobj) leukemia_24\NN|system
D008727_D002493 NONE methotrexate_77\NN| (r_compound) diluents_78\NNS|methotrexate|of (r_pobj) of_76\IN|diluents (r_prep) use_75\NN|the|of (r_conj) presence_61\NN|the|of|in|;|and|use (r_conj) concentration_35\NN|elevated|cerebrospinal|methothexate|related|;|presence (r_appos) dynamics_15\NNS|abnormal|cerebrospinal|related|,|and|leakage|;|concentration (l_acl) related_16\VBN|to (l_prep) to_17\IN|presence (l_pobj) presence_19\NN|the|of (l_prep) of_20\IN|leukemia (l_pobj) leukemia_24\NN|system
D008727_D002493 NONE methotrexate_12\NNP| (r_pobj) of_11\IN|methotrexate (r_prep) doses_10\NNS|lower|of (r_dobj) employing_8\VBG|doses|in|,|in (l_prep) in_13\IN|presence (l_pobj) presence_15\NN|the|of (l_prep) of_16\IN|leukemia (l_pobj) leukemia_20\NN|system
D008727_D020258 NONE methothexate_34\NN|fluid (r_compound) concentration_35\NN|elevated|cerebrospinal|methothexate|related|;|presence (l_conj) presence_61\NN|the|of|in|;|and|use (l_prep) of_62\IN|preservatives (l_pobj) preservatives_64\NNS|neurotoxic (l_amod) neurotoxic_63\JJ|
D008727_D020258 NONE methotrexate_46\NN| (r_compound) doses_47\NNS|high|methotrexate|based (r_pobj) to_43\TO|doses (r_conj) related_36\VBN|to|and|to (r_acl) concentration_35\NN|elevated|cerebrospinal|methothexate|related|;|presence (l_conj) presence_61\NN|the|of|in|;|and|use (l_prep) of_62\IN|preservatives (l_pobj) preservatives_64\NNS|neurotoxic (l_amod) neurotoxic_63\JJ|
D008727_D020258 NONE methotrexate_68\NN| (r_compound) preparations_69\NNS|available|methotrexate|and|diluents (r_pobj) in_65\IN|preparations (r_prep) presence_61\NN|the|of|in|;|and|use (l_prep) of_62\IN|preservatives (l_pobj) preservatives_64\NNS|neurotoxic (l_amod) neurotoxic_63\JJ|
D008727_D020258 NONE methotrexate_77\NN| (r_compound) diluents_78\NNS|methotrexate|of (r_pobj) of_76\IN|diluents (r_prep) use_75\NN|the|of (r_conj) presence_61\NN|the|of|in|;|and|use (l_prep) of_62\IN|preservatives (l_pobj) preservatives_64\NNS|neurotoxic (l_amod) neurotoxic_63\JJ|
D008727_D020258 NONE methotrexate_12\NNP| (r_pobj) of_11\IN|methotrexate (r_prep) doses_10\NNS|lower|of (r_dobj) employing_8\VBG|doses|in|,|in (r_pcomp) by_7\IN|employing (r_prep) reduced_6\VBN|incidence|may|be|by|. (l_nsubjpass) incidence_1\NN|the|of (l_prep) of_2\IN|neurotoxicity (l_pobj) neurotoxicity_3\NN|
D008727_D020258 NONE methotrexate_5\NNP|fluid (r_compound) levels_6\NNS|cerebruspinal|methotrexate (r_pobj) of_2\IN|levels (r_prep) monitoring_1\NN|periodic|of (r_nsubj) be_8\VB|monitoring|may|predictive|. (l_acomp) predictive_9\JJ|of (l_prep) of_10\IN|development (l_pobj) development_12\NN|the|of (l_prep) of_13\IN|neurotoxicity (l_pobj) neurotoxicity_15\NN|serious
D008727_C536409 NONE methotrexate_3\NNP| (r_compound) contaminants_4\NNS|methotrexate|,|deficiency (l_conj) deficiency_8\NN|local|folate|,|and|irradiation
D008727_C536409 NONE methotrexate_18\NNP| (r_compound) toxicity_19\NN|intrathecal|methotrexate (r_pobj) of_16\IN|toxicity (r_prep) pathogenesis_15\NN|the|of (r_pobj) in_13\IN|pathogenesis (r_prep) role_1\NN|the|of|in (l_prep) of_2\IN|contaminants (l_pobj) contaminants_4\NNS|methotrexate|,|deficiency (l_conj) deficiency_8\NN|local|folate|,|and|irradiation
D008727_D064420 NONE methotrexate_3\NNP| (r_compound) contaminants_4\NNS|methotrexate|,|deficiency (r_pobj) of_2\IN|contaminants (r_prep) role_1\NN|the|of|in (l_prep) in_13\IN|pathogenesis (l_pobj) pathogenesis_15\NN|the|of (l_prep) of_16\IN|toxicity (l_pobj) toxicity_19\NN|intrathecal|methotrexate
D008727_D064420 NONE methotrexate_18\NNP| (r_compound) toxicity_19\NN|intrathecal|methotrexate
15609701
D013015_D003329 CID Sotalol_0\NNP| (r_npadvmod) induced_2\VBN|sotalol|-|spasm|in|. (l_dobj) spasm_4\NN|coronary
D013015_D003329 CID sotalol_15\NN| (r_pobj) of_14\IN|sotalol (r_prep) properties_13\NNS|the|selective|blocking|of (r_pobj) by_5\IN|properties (r_agent) induced_4\VBN|vasospasm|may|be|by|. (l_nsubjpass) vasospasm_1\NN|coronary
D013015_D002311 NONE Sotalol_0\NNP| (r_npadvmod) induced_2\VBN|sotalol|-|spasm|in|. (l_prep) in_5\IN|patient (l_pobj) patient_7\NN|a|with (l_prep) with_8\IN|cardiomyopathy (l_pobj) cardiomyopathy_10\NN|dilated|associated
D013015_D017180 NONE Sotalol_0\NNP| (r_npadvmod) induced_2\VBN|sotalol|-|spasm|in|. (l_prep) in_5\IN|patient (l_pobj) patient_7\NN|a|with (l_prep) with_8\IN|cardiomyopathy (l_pobj) cardiomyopathy_10\NN|dilated|associated (l_acl) associated_11\VBN|with (l_prep) with_12\IN|tachycardia (l_pobj) tachycardia_15\NN|sustained|ventricular
D013015_D017180 NONE sotalol_6\NN| (r_appos) agent_4\NN|an|alternate|class|iii|,|sotalol (r_nsubj) was_8\VBD|agent|,|also|effective|. (l_acomp) effective_10\JJ|for (l_prep) for_11\IN|prevention (l_pobj) prevention_13\NN|the|of (l_prep) of_14\IN|vt (l_pobj) VT_15\NNP|
C076259_D017180 NONE hydrochloride_5\NN|nifekalant (r_pobj) of_3\IN|hydrochloride (r_prep) administration_2\NN|the|of (r_nsubjpass) terminated_10\VBN|after|administration|,|vt|was|. (l_nsubjpass) VT_8\NNP|sustained
439781
D007213_D007022 CID Indomethacin_0\NNP| (r_nsubj) induced_1\VBD|indomethacin|hypotension|rats|. (l_dobj) hypotension_2\NN|in
D012964_D007022 NONE sodium_4\NN|and|volume (r_npadvmod) depleted_7\VBN|sodium (r_amod) rats_8\NNS|depleted (r_dobj) induced_1\VBD|indomethacin|hypotension|rats|. (l_dobj) hypotension_2\NN|in
7378868
D013390_D014313 CID Suxamethonium_0\NN| (r_npadvmod) induced_2\VBN|suxamethonium|- (r_amod) stiffness_4\NN|induced|jaw|and|myalgia|associated
D013390_D014313 CID suxamethonium_12\NN|in|despite (r_pobj) after_11\IN|suxamethonium (r_prep) occur_10\VB|that|rigidity|may|after (l_nsubj) rigidity_6\NN|prolonged|jaw|and|myalgia
D013390_D063806 CID Suxamethonium_0\NN| (r_npadvmod) induced_2\VBN|suxamethonium|- (r_amod) stiffness_4\NN|induced|jaw|and|myalgia|associated (l_conj) myalgia_6\NN|
D013390_D063806 CID suxamethonium_12\NN|in|despite (r_pobj) after_11\IN|suxamethonium (r_prep) occur_10\VB|that|rigidity|may|after (l_nsubj) rigidity_6\NN|prolonged|jaw|and|myalgia (l_conj) myalgia_8\NN|
D010197_D014313 NONE pancuronium_21\NN| (r_pobj) with_20\IN|pancuronium (r_prep) pretreatment_19\NN|with (r_pobj) despite_18\IN|pretreatment (r_prep) suxamethonium_12\NN|in|despite (r_pobj) after_11\IN|suxamethonium (r_prep) occur_10\VB|that|rigidity|may|after (l_nsubj) rigidity_6\NN|prolonged|jaw|and|myalgia
D010197_D063806 NONE pancuronium_21\NN| (r_pobj) with_20\IN|pancuronium (r_prep) pretreatment_19\NN|with (r_pobj) despite_18\IN|pretreatment (r_prep) suxamethonium_12\NN|in|despite (r_pobj) after_11\IN|suxamethonium (r_prep) occur_10\VB|that|rigidity|may|after (l_nsubj) rigidity_6\NN|prolonged|jaw|and|myalgia (l_conj) myalgia_8\NN|
6893265
D011441_D056486 CID Propylthiouracil_0\NNP| (r_npadvmod) induced_2\VBN|propylthiouracil|- (r_amod) damage_4\NN|induced|hepatic|.
D011441_D056486 CID propylthiouracil_3\NN| (r_npadvmod) induced_5\VBN|propylthiouracil|- (r_amod) damage_7\NN|induced|liver
3191389
D010862_D012640 CID pilocarpine_14\NN| (r_pobj) by_13\IN|pilocarpine (r_agent) produced_12\VBN|by|in (r_acl) seizures_11\NNS|produced
D010862_D012640 CID pilocarpine_4\NN|the|agonist (r_nsubj) induces_5\VBZ|pilocarpine|in|followed|. (l_prep) in_6\IN|seizures (l_pobj) seizures_8\NNS|rats|and|epilepticus
D010862_D012640 CID pilocarpine_35\NN| (r_pobj) by_34\IN|pilocarpine (r_agent) produced_33\VBN|by (r_acl) seizures_32\NNS|produced
D010862_D012640 CID pilocarpine_21\NN| (r_pobj) by_20\IN|pilocarpine (r_agent) produced_19\VBN|by (r_acl) seizures_18\NNS|produced
D010862_D012640 CID pilocarpine_24\NN| (r_pobj) by_23\IN|pilocarpine (r_agent) induced_22\VBN|by (r_acl) damage_21\NN|related|brain|induced (r_pobj) from_16\IN|damage (r_prep) seizures_12\NNS|and|rats|from|,|mg/kg
D010862_D012640 CID pilocarpine_24\NN| (r_pobj) by_23\IN|pilocarpine (r_agent) induced_22\VBN|by (r_acl) damage_21\NN|related|brain|induced (l_amod) related_19\VBN|seizure|- (l_npadvmod) seizure_17\NN|
D010862_D012640 CID pilocarpine_16\NN| (r_npadvmod) induced_18\VBN|pilocarpine|- (r_amod) seizures_19\NNS|induced
D010862_D013226 CID pilocarpine_4\NN|the|agonist (r_nsubj) induces_5\VBZ|pilocarpine|in|followed|. (l_prep) in_6\IN|seizures (l_pobj) seizures_8\NNS|rats|and|epilepticus (l_conj) epilepticus_11\NN|status
D012980_D012640 CID salicylate_20\NN|sodium|,|phenylbutazone (r_conj) drugs_17\NNS|5|steroidal|inflammatory|,|salicylate|, (r_pobj) of_9\IN|drugs (r_prep) effect_8\NN|the|of|on (l_prep) on_31\IN|seizures (l_pobj) seizures_32\NNS|produced
D010653_D012640 CID phenylbutazone_22\NN|,|indomethacin (r_appos) salicylate_20\NN|sodium|,|phenylbutazone (r_conj) drugs_17\NNS|5|steroidal|inflammatory|,|salicylate|, (r_pobj) of_9\IN|drugs (r_prep) effect_8\NN|the|of|on (l_prep) on_31\IN|seizures (l_pobj) seizures_32\NNS|produced
D007213_D012640 NONE indomethacin_24\NN|,|ibuprofen (r_conj) phenylbutazone_22\NN|,|indomethacin (r_appos) salicylate_20\NN|sodium|,|phenylbutazone (r_conj) drugs_17\NNS|5|steroidal|inflammatory|,|salicylate|, (r_pobj) of_9\IN|drugs (r_prep) effect_8\NN|the|of|on (l_prep) on_31\IN|seizures (l_pobj) seizures_32\NNS|produced
D007213_D012640 NONE Indomethacin_0\NNP|,|mg/kg|,|mg/kg|, (r_nsubj) failed_15\VBD|indomethacin|modulate|. (l_xcomp) modulate_17\VB|to|seizures (l_dobj) seizures_18\NNS|produced
D007052_D012640 NONE ibuprofen_26\NNP|and|acid (r_conj) indomethacin_24\NN|,|ibuprofen (r_conj) phenylbutazone_22\NN|,|indomethacin (r_appos) salicylate_20\NN|sodium|,|phenylbutazone (r_conj) drugs_17\NNS|5|steroidal|inflammatory|,|salicylate|, (r_pobj) of_9\IN|drugs (r_prep) effect_8\NN|the|of|on (l_prep) on_31\IN|seizures (l_pobj) seizures_32\NNS|produced
D007052_D012640 NONE ibuprofen_8\NNP| (r_conj) mg/kg_5\NN|1|,|and|ibuprofen (r_conj) Indomethacin_0\NNP|,|mg/kg|,|mg/kg|, (r_nsubj) failed_15\VBD|indomethacin|modulate|. (l_xcomp) modulate_17\VB|to|seizures (l_dobj) seizures_18\NNS|produced
D008528_D012640 NONE acid_29\NN|mefenamic (r_conj) ibuprofen_26\NNP|and|acid (r_conj) indomethacin_24\NN|,|ibuprofen (r_conj) phenylbutazone_22\NN|,|indomethacin (r_appos) salicylate_20\NN|sodium|,|phenylbutazone (r_conj) drugs_17\NNS|5|steroidal|inflammatory|,|salicylate|, (r_pobj) of_9\IN|drugs (r_prep) effect_8\NN|the|of|on (l_prep) on_31\IN|seizures (l_pobj) seizures_32\NNS|produced
D008528_D012640 NONE acid_1\NN|mefenamic|,|26|mg/kg|, (r_nsubj) prevented_11\VBN|acid|seizures|. (l_dobj) seizures_12\NNS|and|rats|from|,|mg/kg
D008528_D012640 NONE acid_1\NN|mefenamic|,|26|mg/kg|, (r_nsubj) prevented_11\VBN|acid|seizures|. (l_dobj) seizures_12\NNS|and|rats|from|,|mg/kg (l_prep) from_16\IN|damage (l_pobj) damage_21\NN|related|brain|induced (l_amod) related_19\VBN|seizure|- (l_npadvmod) seizure_17\NN|
D008528_D001930 NONE acid_1\NN|mefenamic|,|26|mg/kg|, (r_nsubj) prevented_11\VBN|acid|seizures|. (l_dobj) seizures_12\NNS|and|rats|from|,|mg/kg (l_prep) from_16\IN|damage (l_pobj) damage_21\NN|related|brain|induced
D010862_D001930 NONE pilocarpine_24\NN| (r_pobj) by_23\IN|pilocarpine (r_agent) induced_22\VBN|by (r_acl) damage_21\NN|related|brain|induced
19728177
D000082_D017114 CID acetaminophen_27\NN| (r_pobj) from_26\IN|acetaminophen (r_prep) facility_17\NN|a|care|in|from|and (l_prep) in_18\IN|female (l_pobj) female_23\NN|a|old|with (l_prep) with_24\IN|fhf (l_pobj) FHF_25\NNP|
D000082_D017114 CID acetaminophen_5\NN|and|edema (r_pobj) from_4\IN|acetaminophen (r_prep) confirmed_2\VBN|evaluation|fhf|from|. (l_dobj) FHF_3\NNP|
D000082_D017114 CID acetaminophen_8\NN| (r_compound) overdose_9\NN|acetaminophen (r_pobj) from_7\IN|overdose (r_prep) edema_6\NN|cerebral|from (r_conj) FHF_3\NNP|and|edema
D000082_D001929 CID acetaminophen_27\NN| (r_pobj) from_26\IN|acetaminophen (r_prep) facility_17\NN|a|care|in|from|and (r_pobj) in_13\IN|facility (r_prep) observations_3\NNS|based|from|in|edema|. (l_conj) edema_31\NN|resultant|cerebral
D000082_D001929 CID acetaminophen_5\NN|and|edema (l_conj) edema_8\NN|cerebral
D000082_D001929 CID acetaminophen_8\NN| (r_compound) overdose_9\NN|acetaminophen (r_pobj) from_7\IN|overdose (r_prep) edema_6\NN|cerebral|from
D000082_D064420 NONE acetaminophen_16\NN| (r_pobj) from_15\IN|acetaminophen (r_prep) toxicity_14\NN|presumed|from|ingested
D000082_D062787 NONE acetaminophen_8\NN| (r_compound) overdose_9\NN|acetaminophen
D000082_D007035 NONE acetaminophen_8\NN| (r_compound) overdose_9\NN|acetaminophen (r_pobj) from_7\IN|overdose (r_prep) edema_6\NN|cerebral|from (r_conj) FHF_3\NNP|and|edema (r_pobj) with_2\IN|fhf (r_prep) patients_1\NNS|with (r_pobj) In_0\IN|patients (r_prep) used_17\VBN|in|,|hypothermia|could|potentially|be|as|. (l_nsubjpass) hypothermia_13\NN|prolonged|therapeutic
19549709
C107135_D002289 NONE everolimus_2\NN|(|rad001|) (r_pobj) of_1\IN|everolimus (r_prep) Efficacy_0\NN|of|in|. (l_prep) in_6\IN|patients|or|with (l_pobj) patients_7\NNS|with|treated (l_prep) with_8\IN|nsclc (l_pobj) NSCLC_10\NNP|advanced
C107135_D002289 NONE RAD001_4\NNP| (r_appos) everolimus_2\NN|(|rad001|) (r_pobj) of_1\IN|everolimus (r_prep) Efficacy_0\NN|of|in|. (l_prep) in_6\IN|patients|or|with (l_pobj) patients_7\NNS|with|treated (l_prep) with_8\IN|nsclc (l_pobj) NSCLC_10\NNP|advanced
C107135_D002289 NONE RAD001_0\NNP|,|inhibitor|, (r_nsubj) shown_16\VBN|rad001|has|phase|. (l_dobj) phase_17\NN|i|efficacy|in (l_prep) in_20\IN|nsclc (l_pobj) NSCLC_21\NNP|
C107135_D002289 NONE RAD001_41\NNP| (r_dobj) received_40\VBD|methods|rad001|day|until|. (l_nsubj) METHODS_0\NNS|:|iiib|,|with (l_appos) IIIb_3\NNS|stage|or|patients (l_conj) patients_7\NNS|iv|nsclc (l_compound) NSCLC_6\NNP|
C107135_D002289 NONE RAD001_2\NNP| (r_pobj) of_1\IN|rad001 (r_prep) Evaluation_0\NN|of|plus|therapy (r_nsubj) continues_9\VBZ|evaluation|nsclc|. (l_nsubj) NSCLC_8\NNP|
D020123_D002289 NONE rapamycin_10\NNS| (r_nmod) mTOR_12\NNP|rapamycin|(|) (r_pobj) of_9\IN|mtor (r_prep) target_8\NN|the|mammalian|of (r_pobj) of_5\IN|target (r_prep) inhibitor_4\NN|an|oral|of (r_appos) RAD001_0\NNP|,|inhibitor|, (r_nsubj) shown_16\VBN|rad001|has|phase|. (l_dobj) phase_17\NN|i|efficacy|in (l_prep) in_20\IN|nsclc (l_pobj) NSCLC_21\NNP|
D010984_D002289 NONE platinum_18\NN|one (r_nmod) stratum_21\NN|platinum|based|(|1|)|or|chemotherapy|inhibitors (r_appos) regimens_15\NNS|two|prior|chemotherapy|,|stratum|, (r_pobj) with_9\IN|regimens (r_prep) METHODS_0\NNS|:|iiib|,|with (l_appos) IIIb_3\NNS|stage|or|patients (l_conj) patients_7\NNS|iv|nsclc (l_compound) NSCLC_6\NNP|
D010984_D064420 NONE platinum_18\NN|one (r_nmod) stratum_21\NN|platinum|based|(|1|)|or|chemotherapy|inhibitors (r_appos) regimens_15\NNS|two|prior|chemotherapy|,|stratum|, (r_pobj) with_9\IN|regimens (r_prep) METHODS_0\NNS|:|iiib|,|with (r_nsubj) received_40\VBD|methods|rad001|day|until|. (l_prep) until_46\IN|progression (l_pobj) progression_47\NN|or|toxicity (l_conj) toxicity_50\NN|unacceptable
D014443_D002289 NONE tyrosine_32\NN| (r_compound) inhibitors_34\NNS|tyrosine|kinase|(|stratum|) (r_conj) stratum_21\NN|platinum|based|(|1|)|or|chemotherapy|inhibitors (r_appos) regimens_15\NNS|two|prior|chemotherapy|,|stratum|, (r_pobj) with_9\IN|regimens (r_prep) METHODS_0\NNS|:|iiib|,|with (l_appos) IIIb_3\NNS|stage|or|patients (l_conj) patients_7\NNS|iv|nsclc (l_compound) NSCLC_6\NNP|
D014443_D064420 NONE tyrosine_32\NN| (r_compound) inhibitors_34\NNS|tyrosine|kinase|(|stratum|) (r_conj) stratum_21\NN|platinum|based|(|1|)|or|chemotherapy|inhibitors (r_appos) regimens_15\NNS|two|prior|chemotherapy|,|stratum|, (r_pobj) with_9\IN|regimens (r_prep) METHODS_0\NNS|:|iiib|,|with (r_nsubj) received_40\VBD|methods|rad001|day|until|. (l_prep) until_46\IN|progression (l_pobj) progression_47\NN|or|toxicity (l_conj) toxicity_50\NN|unacceptable
C107135_D064420 NONE RAD001_41\NNP| (r_dobj) received_40\VBD|methods|rad001|day|until|. (l_prep) until_46\IN|progression (l_pobj) progression_47\NN|or|toxicity (l_conj) toxicity_50\NN|unacceptable
17484470
D011433_D006333 CID propranolol_6\NN|and|volume|loading (r_pobj) by_5\IN|propranolol (r_agent) induced_4\VBN|failure|was|by (l_nsubjpass) failure_2\NN|acute|heart
D011433_D008944 NONE propranolol_6\NN|and|volume|loading (r_pobj) by_5\IN|propranolol (r_agent) induced_4\VBN|failure|was|by (r_ccomp) confirmed_21\VBN|induced|;|absence|was|by|. (l_nsubjpass) absence_17\NN|an|of (l_prep) of_18\IN|mr (l_pobj) MR_19\NNP|
7176945
D013390_D010146 CID suxamethonium_2\NN|post|- (r_compound) pains_3\NNS|suxamethonium|in|.
D013390_D010146 CID scoline_8\JJ| (r_amod) pain_9\NN|scoline
D013390_D010146 CID scoline_9\JJ| (r_amod) pain_10\NN|scoline
D013390_D010146 CID scoline_20\JJ| (r_amod) pain_21\NN|scoline
D013390_D010146 CID suxamethonium_16\NN|used (r_pobj) of_15\IN|suxamethonium (r_prep) preparation_14\NN|the|salt|of (r_conj) type_2\NN|neither|the|of|nor|preparation|, (r_nsubj) affected_24\VBD|type|incidence|. (l_dobj) incidence_26\NN|the|of (l_prep) of_27\IN|pain (l_pobj) pain_29\NN|scoline
D013390_D010146 CID scoline_28\JJ| (r_amod) pain_29\NN|scoline
C084773_D005207 NONE Fazadinium_12\NNP| (r_pobj) of_11\IN|fazadinium (r_prep) dose_10\NN|(|by|kg|of|) (r_appos) abolition_1\NN|the|of|dose (l_prep) of_2\IN|fasciculations (l_pobj) fasciculations_4\NNS|muscle
C084773_D010146 NONE Fazadinium_12\NNP| (r_pobj) of_11\IN|fazadinium (r_prep) dose_10\NN|(|by|kg|of|) (r_appos) abolition_1\NN|the|of|dose (r_nsubj) influence_16\VB|abolition|did|not|occurrence|. (l_dobj) occurrence_18\NN|the|of (l_prep) of_19\IN|pain (l_pobj) pain_21\NN|scoline
D013390_D005207 CID scoline_20\JJ| (r_amod) pain_21\NN|scoline (r_pobj) of_19\IN|pain (r_prep) occurrence_18\NN|the|of (r_dobj) influence_16\VB|abolition|did|not|occurrence|. (l_nsubj) abolition_1\NN|the|of|dose (l_prep) of_2\IN|fasciculations (l_pobj) fasciculations_4\NNS|muscle
D000530_D010146 NONE Althesin_7\NNP|or|thiopentone (r_appos) agent_5\NN|induction|(|althesin|) (r_pobj) of_3\IN|agent (r_prep) type_2\NN|neither|the|of|nor|preparation|, (r_nsubj) affected_24\VBD|type|incidence|. (l_dobj) incidence_26\NN|the|of (l_prep) of_27\IN|pain (l_pobj) pain_29\NN|scoline
D013874_D010146 NONE Thiopentone_9\NNP| (r_conj) Althesin_7\NNP|or|thiopentone (r_appos) agent_5\NN|induction|(|althesin|) (r_pobj) of_3\IN|agent (r_prep) type_2\NN|neither|the|of|nor|preparation|, (r_nsubj) affected_24\VBD|type|incidence|. (l_dobj) incidence_26\NN|the|of (l_prep) of_27\IN|pain (l_pobj) pain_29\NN|scoline
D002712_D010146 NONE chloride_19\NN|(|or|bromide|) (r_oprd) used_17\VBN|chloride (r_acl) suxamethonium_16\NN|used (r_pobj) of_15\IN|suxamethonium (r_prep) preparation_14\NN|the|salt|of (r_conj) type_2\NN|neither|the|of|nor|preparation|, (r_nsubj) affected_24\VBD|type|incidence|. (l_dobj) incidence_26\NN|the|of (l_prep) of_27\IN|pain (l_pobj) pain_29\NN|scoline
D001965_D010146 NONE bromide_21\NN| (r_conj) chloride_19\NN|(|or|bromide|) (r_oprd) used_17\VBN|chloride (r_acl) suxamethonium_16\NN|used (r_pobj) of_15\IN|suxamethonium (r_prep) preparation_14\NN|the|salt|of (r_conj) type_2\NN|neither|the|of|nor|preparation|, (r_nsubj) affected_24\VBD|type|incidence|. (l_dobj) incidence_26\NN|the|of (l_prep) of_27\IN|pain (l_pobj) pain_29\NN|scoline
8985298
D019259_D006509 NONE Lamivudine_0\NNP| (r_nsubj) is_1\VBZ|lamivudine|effective|. (l_acomp) effective_2\JJ|in (l_prep) in_3\IN|suppressing (l_pcomp) suppressing_4\VBG|dna (l_dobj) DNA_8\NN|virus|in|:|trial (l_compound) virus_7\NN|b (l_compound) B_6\NNP|hepatitis
D019259_D006509 NONE Lamivudine_0\NNP| (r_nsubj) is_1\VBZ|lamivudine|analogue|. (l_attr) analogue_6\NN|a|novel|2',3'-dideoxy|cytosine|has (l_relcl) has_8\VBZ|that|effects|in (l_dobj) effects_11\NNS|potent|inhibitory|on (l_prep) on_12\IN|replication (l_pobj) replication_16\NN|virus (l_compound) virus_15\NN|b (l_compound) B_14\NN|hepatitis
D019259_D006509 NONE cytosine_5\NN| (r_compound) analogue_6\NN|a|novel|2',3'-dideoxy|cytosine|has (l_relcl) has_8\VBZ|that|effects|in (l_dobj) effects_11\NNS|potent|inhibitory|on (l_prep) on_12\IN|replication (l_pobj) replication_16\NN|virus (l_compound) virus_15\NN|b (l_compound) B_14\NN|hepatitis
D019259_D006509 NONE lamivudine_4\NN| (r_dobj) receiving_3\VBG|lamivudine (r_acl) patients_2\NNS|all|36|receiving (r_nsubj) had_5\VBD|patients|decrease|compared|)|. (l_dobj) decrease_7\NN|a|in (l_prep) in_8\IN|virus (l_pobj) virus_11\NN|b|(|values|(|p (l_compound) B_10\NN|hepatitis
D006514_D006509 CID antigen_14\NN|surface (r_compound) carriers_15\NNS|chinese|b|antigen (r_pobj) in_9\IN|carriers (r_prep) DNA_8\NN|virus|in|:|trial (l_compound) virus_7\NN|b (l_compound) B_6\NNP|hepatitis
12523489
D003042_D006948 NONE Cocaine_0\NN| (r_npadvmod) induced_2\VBN|cocaine|- (r_amod) hyperactivity_3\NN|induced
D003042_D006948 NONE Cocaine_0\NN| (r_npadvmod) induced_2\VBN|cocaine|- (r_amod) hyperactivity_3\NN|induced (r_nsubjpass) influenced_6\VBN|hyperactivity|is|more|by|than|. (l_prep) than_11\IN|hyperactivity (l_pobj) hyperactivity_15\NN|induced
D003042_D006948 NONE cocaine_9\NN|-|and|induced (r_nmod) hyperactivity_15\NN|cocaine
D003042_D006948 NONE cocaine_23\NN| (r_npadvmod) induced_25\VBN|cocaine|- (r_amod) hyperactivity_26\NN|induced (r_pobj) in_22\IN|hyperactivity (r_prep) active_21\JJ|in (r_acomp) were_20\VBD|which|active (r_relcl) those_18\DT|were (r_pobj) than_17\IN|those (r_prep) doses_16\NNS|the|higher|than (r_pobj) at_13\IN|doses (r_conj) decreased_6\VBD|similarly|,|agonists|hyperactivity|,|but|at|. (l_dobj) hyperactivity_10\NN|induced
D003042_D006948 NONE cocaine_23\NN| (r_npadvmod) induced_25\VBN|cocaine|- (r_amod) hyperactivity_26\NN|induced
D003042_D006948 NONE cocaine-_15\JJ| (r_dobj) reduce_14\VBP|that|agonists|cocaine-|and|activity|and|indicate (l_conj) indicate_23\VBP|influenced (l_ccomp) influenced_31\VBN|that|hyperactivity|is|more|by|than (l_nsubjpass) hyperactivity_28\NN|induced
D003042_D006948 NONE cocaine-_15\JJ| (r_dobj) reduce_14\VBP|that|agonists|cocaine-|and|activity|and|indicate (l_conj) indicate_23\VBP|influenced (l_ccomp) influenced_31\VBN|that|hyperactivity|is|more|by|than (l_prep) than_41\IN|hyperactivity (l_pobj) hyperactivity_45\NN|induced
D003042_D006948 NONE cocaine_25\NN| (r_npadvmod) induced_27\VBN|cocaine|- (r_amod) hyperactivity_28\NN|induced
D003042_D006948 NONE cocaine_25\NN| (r_npadvmod) induced_27\VBN|cocaine|- (r_amod) hyperactivity_28\NN|induced (r_nsubjpass) influenced_31\VBN|that|hyperactivity|is|more|by|than (l_prep) than_41\IN|hyperactivity (l_pobj) hyperactivity_45\NN|induced
D000241_D006948 NONE adenosine_8\NN| (r_amod) agonists_10\NNS|adenosine|receptor (r_pobj) by_7\IN|agonists (r_agent) influenced_6\VBN|hyperactivity|is|more|by|than|. (l_nsubjpass) hyperactivity_3\NN|induced
D000241_D006948 NONE adenosine_8\NN| (r_amod) agonists_10\NNS|adenosine|receptor (r_pobj) by_7\IN|agonists (r_agent) influenced_6\VBN|hyperactivity|is|more|by|than|. (l_prep) than_11\IN|hyperactivity (l_pobj) hyperactivity_15\NN|induced
D000241_D006948 NONE adenosine_3\NN| (r_amod) agonists_5\NNS|adenosine|receptor|and|antagonists (l_conj) antagonists_7\NNS|on (l_prep) on_8\IN|hyperactivity (l_pobj) hyperactivity_15\NN|cocaine
D000241_D006948 NONE adenosine_3\NN| (r_amod) agonists_5\NNS|all|adenosine|receptor (r_nsubj) decreased_6\VBD|similarly|,|agonists|hyperactivity|,|but|at|. (l_dobj) hyperactivity_10\NN|induced
D000241_D006948 NONE adenosine_3\NN| (r_amod) agonists_5\NNS|all|adenosine|receptor (r_nsubj) decreased_6\VBD|similarly|,|agonists|hyperactivity|,|but|at|. (l_conj) at_13\IN|doses (l_pobj) doses_16\NNS|the|higher|than (l_prep) than_17\IN|those (l_pobj) those_18\DT|were (l_relcl) were_20\VBD|which|active (l_acomp) active_21\JJ|in (l_prep) in_22\IN|hyperactivity (l_pobj) hyperactivity_26\NN|induced
D000241_D006948 NONE adenosine_6\NN| (r_amod) agonists_8\NNS|all|adenosine|receptor|(|a1|) (r_nsubj) reduce_14\VBP|that|agonists|cocaine-|and|activity|and|indicate (l_conj) indicate_23\VBP|influenced (l_ccomp) influenced_31\VBN|that|hyperactivity|is|more|by|than (l_nsubjpass) hyperactivity_28\NN|induced
D000241_D006948 NONE adenosine_6\NN| (r_amod) agonists_8\NNS|all|adenosine|receptor|(|a1|) (r_nsubj) reduce_14\VBP|that|agonists|cocaine-|and|activity|and|indicate (l_conj) indicate_23\VBP|influenced (l_ccomp) influenced_31\VBN|that|hyperactivity|is|more|by|than (l_prep) than_41\IN|hyperactivity (l_pobj) hyperactivity_45\NN|induced
D000241_D006948 NONE adenosine_33\NN| (r_amod) agonists_35\NNS|adenosine|receptor|(|receptors|) (r_pobj) by_32\IN|agonists (r_agent) influenced_31\VBN|that|hyperactivity|is|more|by|than (l_nsubjpass) hyperactivity_28\NN|induced
D000241_D006948 NONE adenosine_33\NN| (r_amod) agonists_35\NNS|adenosine|receptor|(|receptors|) (r_pobj) by_32\IN|agonists (r_agent) influenced_31\VBN|that|hyperactivity|is|more|by|than (l_prep) than_41\IN|hyperactivity (l_pobj) hyperactivity_45\NN|induced
D000661_D006948 NONE amphetamine_12\NN| (r_npadvmod) induced_14\VBN|amphetamine|- (r_amod) hyperactivity_15\NN|induced (r_pobj) than_11\IN|hyperactivity (r_prep) influenced_6\VBN|hyperactivity|is|more|by|than|. (l_nsubjpass) hyperactivity_3\NN|induced
D000661_D006948 NONE amphetamine_12\NN| (r_npadvmod) induced_14\VBN|amphetamine|- (r_amod) hyperactivity_15\NN|induced
D000661_D006948 NONE amphetamine_12\NN| (r_npadvmod) induced_14\VBN|amphetamine|- (r_conj) cocaine_9\NN|-|and|induced (r_nmod) hyperactivity_15\NN|cocaine
D000661_D006948 NONE amphetamine_7\NN| (r_npadvmod) induced_9\VBN|amphetamine|- (r_amod) hyperactivity_10\NN|induced
D000661_D006948 NONE amphetamine_7\NN| (r_npadvmod) induced_9\VBN|amphetamine|- (r_amod) hyperactivity_10\NN|induced (r_dobj) decreased_6\VBD|similarly|,|agonists|hyperactivity|,|but|at|. (l_conj) at_13\IN|doses (l_pobj) doses_16\NNS|the|higher|than (l_prep) than_17\IN|those (l_pobj) those_18\DT|were (l_relcl) were_20\VBD|which|active (l_acomp) active_21\JJ|in (l_prep) in_22\IN|hyperactivity (l_pobj) hyperactivity_26\NN|induced
D000661_D006948 NONE amphetamine_17\NN| (r_npadvmod) induced_19\VBN|amphetamine|- (r_amod) activity_21\NN|induced|locomotor (r_dobj) reduce_14\VBP|that|agonists|cocaine-|and|activity|and|indicate (l_conj) indicate_23\VBP|influenced (l_ccomp) influenced_31\VBN|that|hyperactivity|is|more|by|than (l_nsubjpass) hyperactivity_28\NN|induced
D000661_D006948 NONE amphetamine_17\NN| (r_npadvmod) induced_19\VBN|amphetamine|- (r_amod) activity_21\NN|induced|locomotor (r_dobj) reduce_14\VBP|that|agonists|cocaine-|and|activity|and|indicate (l_conj) indicate_23\VBP|influenced (l_ccomp) influenced_31\VBN|that|hyperactivity|is|more|by|than (l_prep) than_41\IN|hyperactivity (l_pobj) hyperactivity_45\NN|induced
D000661_D006948 NONE amphetamine_42\NN| (r_npadvmod) induced_44\VBN|amphetamine|- (r_amod) hyperactivity_45\NN|induced (r_pobj) than_41\IN|hyperactivity (r_prep) influenced_31\VBN|that|hyperactivity|is|more|by|than (l_nsubjpass) hyperactivity_28\NN|induced
D000661_D006948 NONE amphetamine_42\NN| (r_npadvmod) induced_44\VBN|amphetamine|- (r_amod) hyperactivity_45\NN|induced
D000241_D004409 NONE adenosine_1\NN| (r_amod) agonists_3\NNS|all|adenosine|receptor (r_nsubj) decreased_5\VBD|agonists|significantly|activity|,|and|were (l_dobj) activity_8\NN|the|locomotor|in
6453500
D004221_D056486 CID disulfiram_4\NN| (r_pobj) by_3\IN|disulfiram (r_prep) induced_2\VBN|hepatitis|by|in|. (l_nsubj) hepatitis_1\NN|toxic
D004221_D056486 CID disulfiram_15\NN| (r_pobj) with_14\IN|disulfiram (r_prep) treated_13\VBN|with (r_acl) woman_12\NN|a|alcoholic|treated (r_pobj) in_7\IN|woman (r_prep) observed_6\VBN|damage|was|in|. (l_nsubjpass) damage_4\NN|a|reversible|toxic|liver
17721298
D016578_D003320 CID cocaine_6\NN| (r_compound) use_7\NN|crack|cocaine (r_pobj) with_3\IN|use (r_prep) associated_2\VBN|with (r_acl) ulcers_1\NNS|corneal|associated|.
D016578_D003320 CID cocaine_8\NN| (r_compound) use_9\NN|crack|cocaine (r_pobj) with_6\IN|use (r_prep) associated_5\VBN|with (r_acl) ulcers_4\NNS|corneal|associated
D016578_D003320 CID cocaine_2\NN| (r_compound) use_3\NN|crack|cocaine (r_nsubjpass) associated_6\VBN|use|can|be|with|. (l_prep) with_7\IN|development (l_pobj) development_9\NN|the|of (l_prep) of_10\IN|ulcers (l_pobj) ulcers_12\NNS|corneal
6299641
D001262_D013610 NONE atenolol_10\NN|mg|cardioselective (r_pobj) of_7\IN|atenolol (r_prep) doses_6\NNS|single|of (r_pobj) of_4\IN|doses (r_prep) effects_3\NNS|the|of (r_dobj) compared_1\VBD|we|effects (r_ccomp) propranolol_17\NN|compared|,|mg|(|nonselective|)|,|and|placebo|. (l_conj) placebo_23\NN|on (l_prep) on_24\IN|exercise- (l_pobj) exercise-_26\JJ|both|and|tachycardia|in (l_conj) tachycardia_31\NN|induced
D011433_D013610 NONE propranolol_17\NN|compared|,|mg|(|nonselective|)|,|and|placebo|. (l_conj) placebo_23\NN|on (l_prep) on_24\IN|exercise- (l_pobj) exercise-_26\JJ|both|and|tachycardia|in (l_conj) tachycardia_31\NN|induced
D007545_D013610 CID isoproterenol_28\NN| (r_npadvmod) induced_30\VBN|isoproterenol|- (r_amod) tachycardia_31\NN|induced
D007545_D013610 CID isoproterenol_3\NN| (r_compound) tachycardia_4\NNS|isoproterenol
D007545_D013610 CID isoproterenol_29\NN| (r_nsubj) activates_30\VBZ|whereas|isoproterenol|1-|remains|blocked (r_advcl) are_2\VBP|data|consistent|,|activates|. (l_acomp) consistent_3\JJ|with (l_prep) with_4\IN|hypothesis (l_pobj) hypothesis_6\NN|the|results (l_relcl) results_12\NNS|that|tachycardia|largely|from (l_nsubj) tachycardia_11\NN|induced
D001285_D013610 NONE atropine_10\NN| (r_pobj) after_9\IN|atropine (r_prep) IV_14\NNP|after|mg/kg (r_conj) before_7\RB|and|iv (r_prep) determined_6\VBN|effects|were|before|)|. (l_nsubjpass) effects_1\NNS|the|on (l_prep) on_2\IN|tachycardia (l_pobj) tachycardia_4\NNS|isoproterenol
24923469
20513036
C542870_D010243 NONE botox_3\JJ| (r_compound) injection_4\NN|botox|for (r_pobj) after_2\IN|injection (r_prep) paralysis_1\NN|abductor|after|.
C542870_D010243 NONE Botox_10\NNP| (r_compound) injections_11\NNS|botox|for|,|complication (r_pobj) following_9\VBG|injections (r_prep) report_2\VBP|here|we|cases|following|. (l_dobj) cases_4\NNS|multiple|of (l_prep) of_5\IN|paralysis (l_pobj) paralysis_8\NN|bilateral|abductor
C542870_D010243 NONE Botox_12\NNP| (r_compound) dose_13\NN|paralytic|botox|,|dose (r_conj) sex_9\NN|,|dose (r_conj) age_7\NN|,|sex (r_conj) paralysis_5\NN|bilateral|abductor|,|age
C542870_D010243 NONE Botox_12\NNP| (r_compound) dose_13\NN|paralytic|botox|,|dose (l_conj) dose_17\NN|prior|botox|,|and|course|paralysis (l_conj) paralysis_22\NN|following
C542870_D010243 NONE Botox_16\NNP| (r_compound) dose_17\NN|prior|botox|,|and|course|paralysis (r_conj) dose_13\NN|paralytic|botox|,|dose (r_conj) sex_9\NN|,|dose (r_conj) age_7\NN|,|sex (r_conj) paralysis_5\NN|bilateral|abductor|,|age
C542870_D010243 NONE Botox_16\NNP| (r_compound) dose_17\NN|prior|botox|,|and|course|paralysis (l_conj) paralysis_22\NN|following
C542870_D010243 NONE Botox_6\NNP| (r_compound) injection_7\NN|botox|for (r_pobj) after_5\IN|injection (r_prep) incidence_1\NN|the|of|after (l_prep) of_2\IN|paralysis (l_pobj) paralysis_4\NN|abductor
C542870_D010243 NONE Botox_8\NNP| (r_compound) injections_9\NNS|botox|for (r_pobj) of_7\IN|injections (r_prep) complication_6\NN|a|rare|of (r_attr) is_3\VBZ|paralysis|complication|,|causing|. (l_nsubj) paralysis_2\NN|bilateral|abductor
C542870_D010243 NONE Botox_8\NNP| (r_pobj) of_7\IN|botox (r_prep) diffusion_6\NN|of|around (r_attr) is_5\VBZ|mechanism|diffusion|. (l_nsubj) mechanism_2\NN|the|likely|of (l_prep) of_3\IN|paralysis (l_pobj) paralysis_4\NN|
C542870_D014826 CID botox_3\JJ| (r_compound) injection_4\NN|botox|for (l_prep) for_5\IN|dysphonia (l_pobj) dysphonia_8\NN|adductor|spasmodic
C542870_D014826 CID Botox_3\NNP| (r_appos) toxin_1\NN|botulinum|(|botox|)|injections (r_nsubj) are_10\VBP|toxin|standard|. (l_attr) standard_13\NN|the|current|of|for (l_prep) for_16\IN|dysphonia (l_pobj) dysphonia_19\NN|adductor|spasmodic|(|adsd|)
C542870_D014826 CID Botox_3\NNP| (r_appos) toxin_1\NN|botulinum|(|botox|)|injections (r_nsubj) are_10\VBP|toxin|standard|. (l_attr) standard_13\NN|the|current|of|for (l_prep) for_16\IN|dysphonia (l_pobj) dysphonia_19\NN|adductor|spasmodic|(|adsd|) (l_appos) ADSD_21\NNP|
C542870_D014826 CID Botox_10\NNP| (r_compound) injections_11\NNS|botox|for|,|complication (l_prep) for_12\IN|adsd (l_pobj) ADSD_13\NNP|
C542870_D014826 CID Botox_7\NNP| (r_dobj) receiving_6\VBG|botox (r_acl) patients_5\NNS|452|receiving (r_pobj) of_3\IN|patients (r_prep) database_2\NN|a|of (r_pobj) From_0\IN|database (r_prep) diagnosed_13\VBN|from|,|patients|had|been|with|. (l_prep) with_14\IN|adsd (l_pobj) ADSD_15\NNP|
C542870_D014826 CID Botox_6\NNP| (r_compound) injection_7\NN|botox|for (l_prep) for_8\IN|adsd (l_pobj) ADSD_9\NNP|
C542870_D014826 CID Botox_8\NNP| (r_compound) injections_9\NNS|botox|for (l_prep) for_10\IN|adsd (l_pobj) ADSD_11\NNP|
C542870_D055154 NONE Botox_5\NNP| (r_compound) injections_6\NNS|botox (r_dobj) received_4\VBD|that|injections|for (l_prep) for_7\IN|dysphonia (l_pobj) dysphonia_9\NN|spasmodic|between
10764869
D016559_D009901 CID tacrolimus_10\NN|(|fk506|)|therapy (r_pobj) on_9\IN|tacrolimus (r_prep) patient_8\NN|a|on (r_pobj) in_6\IN|patient (r_prep) case_1\NN|a|of|in|after|. (l_prep) of_2\IN|neuropathy (l_pobj) neuropathy_5\NN|optic
D016559_D009901 CID FK506_12\NNP| (r_appos) tacrolimus_10\NN|(|fk506|)|therapy (r_pobj) on_9\IN|tacrolimus (r_prep) patient_8\NN|a|on (r_pobj) in_6\IN|patient (r_prep) case_1\NN|a|of|in|after|. (l_prep) of_2\IN|neuropathy (l_pobj) neuropathy_5\NN|optic
D016559_D009901 CID tacrolimus_12\NN|(|fk|;|usa (r_dobj) receiving_11\NN|tacrolimus (r_acl) patient_10\NN|a|receiving (r_pobj) in_8\IN|patient (r_prep) case_3\NN|a|of|in|)|for (l_prep) of_4\IN|neuropathy (l_pobj) neuropathy_7\NN|optic
D016559_D009901 CID 506_15\CD| (r_nummod) FK_14\NNP|506|,|prograf (r_appos) tacrolimus_12\NN|(|fk|;|usa (r_dobj) receiving_11\NN|tacrolimus (r_acl) patient_10\NN|a|receiving (r_pobj) in_8\IN|patient (r_prep) case_3\NN|a|of|in|)|for (l_prep) of_4\IN|neuropathy (l_pobj) neuropathy_7\NN|optic
D016559_D009901 CID Tacrolimus_0\NNP|and|agents (r_nsubjpass) associated_7\VBN|tacrolimus|may|be|with|. (l_prep) with_8\IN|toxicity (l_pobj) toxicity_11\NN|optic|nerve
D016559_D015354 NONE tacrolimus_8\NN|the (r_pobj) of_6\IN|tacrolimus (r_prep) discontinuation_5\NN|of (r_pobj) despite_4\IN|discontinuation (r_prep) occurred_3\VBD|deterioration|despite|. (l_nsubj) Deterioration_0\NN|of (l_prep) of_1\IN|vision (l_pobj) vision_2\NN|
24842192
D008687_D018487 NONE metformin_3\NN| (r_pobj) with_2\IN|metformin (r_prep) treatment_1\NN|chronic|with (r_nsubj) suppresses_4\VBZ|treatment|receptor|and|attenuates|left|. (l_conj) left_13\VBN|dysfunction (l_dobj) dysfunction_15\NN|ventricular|following
D008687_D018487 NONE metformin_18\NN| (r_pobj) of_17\IN|metformin (r_prep) kg_16\NNS|25|/|of (r_pobj) with_11\IN|kg (r_prep) treated_10\VBN|with (r_acl) groups_9\NNS|the|treated (r_pobj) in_7\IN|groups (r_prep) was_4\VBD|dysfunction|lower|in|. (l_nsubj) dysfunction_3\NN|the|left|ventricular
D008687_D009203 NONE metformin_3\NN| (r_pobj) with_2\IN|metformin (r_prep) treatment_1\NN|chronic|with (r_nsubj) suppresses_4\VBZ|treatment|receptor|and|attenuates|left|. (l_conj) left_13\VBN|dysfunction (l_dobj) dysfunction_15\NN|ventricular|following (l_prep) following_16\VBG|infarction (l_pobj) infarction_18\NN|myocardial
D008687_D009203 NONE metformin_3\NN| (r_pobj) with_2\IN|metformin (r_prep) treatment_1\NN|acute|with (r_nsubj) has_4\VBZ|treatment|effect|due|. (l_dobj) effect_7\NN|a|protective|in|by (l_prep) in_8\IN|infarction (l_pobj) infarction_10\NN|myocardial
D008687_D009203 NONE metformin_13\NN|in|,|effect|with|on (r_nmod) activities_26\NNS|metformin|(|tlr4|)|following (l_acl) following_27\VBG|infarction (l_pobj) infarction_29\NN|myocardial|and|relation
D008687_D009203 NONE metformin_5\NN|treatment|with (r_nsubj) reduces_6\VBZ|metformin|dysfunction|and|suppresses|. (l_dobj) dysfunction_12\NN|myocardial|infarction|cardiac (l_nmod) infarction_10\NN|
D000667_D009203 NONE AMP_20\NNP| (r_npadvmod) activated_22\VBN|amp|- (r_amod) kinase_24\NN|activated|protein|ampk (r_pobj) of_19\IN|kinase (r_prep) activation_18\NN|of (r_pobj) due_16\JJ|to|activation (r_prep) has_4\VBZ|treatment|effect|due|. (l_dobj) effect_7\NN|a|protective|in|by (l_prep) in_8\IN|infarction (l_pobj) infarction_10\NN|myocardial
D008687_D006331 NONE metformin_13\NN|in|,|effect|with|on (l_prep) on_14\IN|dysfunction (l_pobj) dysfunction_16\NN|cardiac|and|receptor
D007545_D009203 CID Isoproterenol_0\NNP|kg (r_nsubjpass) injected_7\VBN|isoproterenol|was|subcutaneously|on|induce|. (l_advcl) induce_16\VB|to|infarction (l_dobj) infarction_19\NN|acute|myocardial
D007545_D009369 NONE isoproterenol_3\NN| (r_npadvmod) induced_5\VBN|isoproterenol|- (r_amod) elevation_6\NN|induced|in (r_dobj) lowered_2\VBD|metfromin|markedly|elevation|,|myeloid|. (l_advcl) myeloid_14\NN|protein|in (l_dobj) protein_16\NN|differentiation|88|myd88|,|factor|) (l_appos) factor_24\NN|necrosis|-|alpha|,|and|interleukin (l_compound) necrosis_23\NN|tumor (l_compound) tumor_22\NN|
D007545_D009336 NONE isoproterenol_3\NN| (r_npadvmod) induced_5\VBN|isoproterenol|- (r_amod) elevation_6\NN|induced|in (r_dobj) lowered_2\VBD|metfromin|markedly|elevation|,|myeloid|. (l_advcl) myeloid_14\NN|protein|in (l_dobj) protein_16\NN|differentiation|88|myd88|,|factor|) (l_appos) factor_24\NN|necrosis|-|alpha|,|and|interleukin (l_compound) necrosis_23\NN|tumor
8096565
D018170_D009203 CID sumatriptan_4\NNP| (r_pobj) with_3\IN|sumatriptan (r_prep) infarction_2\NN|transmural|myocardial|with|.
D018170_D009203 CID sumatriptan_15\NNP| (r_pobj) of_14\IN|sumatriptan (r_prep) administration_13\NN|of (r_pobj) after_12\IN|administration (r_prep) infarction_11\NN|an|acute|myocardial|after|subcutaneously|for
D018170_D003027 NONE sumatriptan_15\NNP| (r_pobj) of_14\IN|sumatriptan (r_prep) administration_13\NN|of (r_pobj) after_12\IN|administration (r_prep) infarction_11\NN|an|acute|myocardial|after|subcutaneously|for (l_prep) for_19\IN|headache (l_pobj) headache_21\NN|cluster
6615679
D013999_D001919 CID timolol_6\NN|and|pilocarpine (r_nmod) drops_10\NNS|timolol|eye (r_pobj) with_5\IN|drops (r_prep) associated_4\VBN|with (r_acl) hypotension_3\NN|associated (r_conj) bradycardia_1\NNP|intraoperative|and|hypotension|.
D013999_D001919 CID maleate_16\NN| (r_amod) drops_18\NNS|maleate|eye (r_dobj) timolol_15\NN|drops (r_conj) nitrate_13\NN|pilocarpine|and|timolol (r_pobj) with_11\IN|nitrate (r_prep) treated_10\VBN|who|was|concurrently|being|with (r_relcl) man_4\NN|a|old|,|treated|, (r_nsubj) developed_20\VBD|man|bradycardia|and|became|. (l_dobj) bradycardia_22\NN|a
D013999_D007022 CID timolol_6\NN|and|pilocarpine (r_nmod) drops_10\NNS|timolol|eye (r_pobj) with_5\IN|drops (r_prep) associated_4\VBN|with (r_acl) hypotension_3\NN|associated
D013999_D007022 CID maleate_16\NN| (r_amod) drops_18\NNS|maleate|eye (r_dobj) timolol_15\NN|drops (r_conj) nitrate_13\NN|pilocarpine|and|timolol (r_pobj) with_11\IN|nitrate (r_prep) treated_10\VBN|who|was|concurrently|being|with (r_relcl) man_4\NN|a|old|,|treated|, (r_nsubj) developed_20\VBD|man|bradycardia|and|became|. (l_conj) became_24\VBD|hypotensive|during (l_acomp) hypotensive_25\JJ|
D010862_D001919 CID pilocarpine_8\VB| (r_conj) timolol_6\NN|and|pilocarpine (r_nmod) drops_10\NNS|timolol|eye (r_pobj) with_5\IN|drops (r_prep) associated_4\VBN|with (r_acl) hypotension_3\NN|associated (r_conj) bradycardia_1\NNP|intraoperative|and|hypotension|.
D010862_D001919 CID nitrate_13\NN|pilocarpine|and|timolol (r_pobj) with_11\IN|nitrate (r_prep) treated_10\VBN|who|was|concurrently|being|with (r_relcl) man_4\NN|a|old|,|treated|, (r_nsubj) developed_20\VBD|man|bradycardia|and|became|. (l_dobj) bradycardia_22\NN|a
D010862_D007022 CID pilocarpine_8\VB| (r_conj) timolol_6\NN|and|pilocarpine (r_nmod) drops_10\NNS|timolol|eye (r_pobj) with_5\IN|drops (r_prep) associated_4\VBN|with (r_acl) hypotension_3\NN|associated
D010862_D007022 CID nitrate_13\NN|pilocarpine|and|timolol (r_pobj) with_11\IN|nitrate (r_prep) treated_10\VBN|who|was|concurrently|being|with (r_relcl) man_4\NN|a|old|,|treated|, (r_nsubj) developed_20\VBD|man|bradycardia|and|became|. (l_conj) became_24\VBD|hypotensive|during (l_acomp) hypotensive_25\JJ|
D006221_D001919 NONE halothane_27\NN| (r_compound) anaesthesia_28\NN|halothane (r_pobj) during_26\IN|anaesthesia (r_prep) became_24\VBD|hypotensive|during (r_conj) developed_20\VBD|man|bradycardia|and|became|. (l_dobj) bradycardia_22\NN|a
D006221_D001919 NONE halothane_11\NN| (r_compound) anaesthesia_12\NN|halothane|with (l_prep) with_13\IN|bradycardia (l_pobj) bradycardia_15\NN|resultant|and|hypotension
D006221_D007022 NONE halothane_27\NN| (r_compound) anaesthesia_28\NN|halothane (r_pobj) during_26\IN|anaesthesia (r_prep) became_24\VBD|hypotensive|during (l_acomp) hypotensive_25\JJ|
D006221_D007022 NONE halothane_11\NN| (r_compound) anaesthesia_12\NN|halothane|with (l_prep) with_13\IN|bradycardia (l_pobj) bradycardia_15\NN|resultant|and|hypotension (l_conj) hypotension_17\NN|
2484903
D011441_D056486 CID propylthiouracil_3\NN| (r_npadvmod) associated_5\VBN|propylthiouracil|- (r_amod) hepatitis_7\NN|associated|acute
D011441_D056486 CID propylthiouracil_22\NN| (r_npadvmod) associated_24\VBN|propylthiouracil|- (r_amod) syndrome_28\NN|associated|like (r_pobj) of_21\IN|syndrome (r_prep) case_20\NN|one|of (r_conj) case_10\NN|one|of|and|case (r_appos) cases_1\NNS|two|of|,|case (l_prep) of_2\IN|hepatitis (l_pobj) hepatitis_7\NN|associated|acute
D011441_D047508 NONE propylthiouracil_3\NN| (r_npadvmod) associated_5\VBN|propylthiouracil|- (r_amod) hepatitis_7\NN|associated|acute (r_pobj) of_2\IN|hepatitis (r_prep) cases_1\NNS|two|of|,|case (l_appos) case_10\NN|one|of|and|case (l_prep) of_11\IN|necrosis (l_pobj) necrosis_17\NN|fatal|associated|hepatocellular
D011441_D047508 NONE propylthiouracil_22\NN| (r_npadvmod) associated_24\VBN|propylthiouracil|- (r_amod) syndrome_28\NN|associated|like (r_pobj) of_21\IN|syndrome (r_prep) case_20\NN|one|of (r_conj) case_10\NN|one|of|and|case (l_prep) of_11\IN|necrosis (l_pobj) necrosis_17\NN|fatal|associated|hepatocellular
D011441_D008180 CID propylthiouracil_3\NN| (r_npadvmod) associated_5\VBN|propylthiouracil|- (r_amod) hepatitis_7\NN|associated|acute (r_pobj) of_2\IN|hepatitis (r_prep) cases_1\NNS|two|of|,|case (l_appos) case_10\NN|one|of|and|case (l_conj) case_20\NN|one|of (l_prep) of_21\IN|syndrome (l_pobj) syndrome_28\NN|associated|like
D011441_D008180 CID propylthiouracil_22\NN| (r_npadvmod) associated_24\VBN|propylthiouracil|- (r_amod) syndrome_28\NN|associated|like
D008713_D056486 NONE methimazole_13\NN| (r_npadvmod) associated_15\VBN|methimazole|- (r_amod) necrosis_17\NN|fatal|associated|hepatocellular (r_pobj) of_11\IN|necrosis (r_prep) case_10\NN|one|of|and|case (r_appos) cases_1\NNS|two|of|,|case (l_prep) of_2\IN|hepatitis (l_pobj) hepatitis_7\NN|associated|acute
D008713_D047508 CID methimazole_13\NN| (r_npadvmod) associated_15\VBN|methimazole|- (r_amod) necrosis_17\NN|fatal|associated|hepatocellular
D008713_D008180 NONE methimazole_13\NN| (r_npadvmod) associated_15\VBN|methimazole|- (r_amod) necrosis_17\NN|fatal|associated|hepatocellular (r_pobj) of_11\IN|necrosis (r_prep) case_10\NN|one|of|and|case (l_conj) case_20\NN|one|of (l_prep) of_21\IN|syndrome (l_pobj) syndrome_28\NN|associated|like
24438483
D002045_D002318 NONE bupivacaine_4\NN| (r_npadvmod) induced_6\VBN|bupivacaine|- (r_amod) depression_8\NN|induced|cardiovascular
D015742_D002318 NONE propofol_14\NN| (r_pobj) of_13\IN|propofol (r_prep) formulations_12\NNS|different|lipid|of (r_dobj) using_9\VBG|treatment|formulations|. (l_nsubj) treatment_2\NN|pre|-|of (l_prep) of_3\IN|depression (l_pobj) depression_8\NN|induced|cardiovascular
D002045_D066126 CID bupivacaine_12\NN| (r_pobj) of_11\IN|bupivacaine (r_prep) doses_10\NNS|lethal|of (r_dobj) increase_8\VB|to|doses (r_xcomp) shown_6\VBN|treatment|has|been|increase|,|and|alleviate (l_conj) alleviate_21\VB|content|may|cardiotoxicity|. (l_dobj) cardiotoxicity_25\NN|induced
D002045_D066126 CID bupivacaine_22\NN| (r_npadvmod) induced_24\VBN|bupivacaine|- (r_amod) cardiotoxicity_25\NN|induced
D002045_D066126 CID bupivacaine_18\NN| (r_npadvmod) induced_20\VBN|bupivacaine|- (r_compound) cardiotoxicity_21\NN|induced
D002045_D066126 CID bupivacaine_23\NN| (r_pobj) of_22\IN|bupivacaine (r_prep) onset_21\NN|the|of (r_dobj) delayed_19\VBD|,|onset (r_conj) conclude_1\VBP|we|propofol|delayed|induced|. (l_conj) induced_25\VBN|-|effects (l_dobj) effects_27\NNS|cardiotoxic|as|levels (l_amod) cardiotoxic_26\JJ|
D002045_D066126 CID bupivacaine_33\NN|plasma (r_compound) levels_34\NNS|bupivacaine (r_conj) effects_27\NNS|cardiotoxic|as|levels (l_amod) cardiotoxic_26\JJ|
D015742_D066126 NONE propofol_19\NN| (r_pobj) of_18\IN|propofol (r_prep) content_17\NN|the|lipid|of (r_nsubj) alleviate_21\VB|content|may|cardiotoxicity|. (l_dobj) cardiotoxicity_25\NN|induced
D015742_D066126 NONE propofol_11\NN|in (l_prep) in_12\IN|intralipid (l_pobj) intralipid_13\NN|or|emulsions (l_conj) emulsions_16\NNS|medialipid|on (l_prep) on_17\IN|cardiotoxicity (l_pobj) cardiotoxicity_21\NN|induced
D015742_D066126 NONE propofol_7\NN|that|with|in|,|compared (r_dobj) conclude_1\VBP|we|propofol|delayed|induced|. (l_conj) induced_25\VBN|-|effects (l_dobj) effects_27\NNS|cardiotoxic|as|levels (l_amod) cardiotoxic_26\JJ|
D015742_D066126 NONE propofol_13\NN|in (r_pcomp) with_12\IN|propofol (r_prep) compared_11\VBN|with (r_prep) propofol_7\NN|that|with|in|,|compared (r_dobj) conclude_1\VBP|we|propofol|delayed|induced|. (l_conj) induced_25\VBN|-|effects (l_dobj) effects_27\NNS|cardiotoxic|as|levels (l_amod) cardiotoxic_26\JJ|
D002045_D001145 NONE bupivacaine_37\NN| (r_compound) consumption_38\NN|bupivacaine (r_pobj) of_36\IN|consumption (r_prep) amount_35\NN|total|of (r_conj) time_30\NN|asystole|amount (r_conj) pressure_27\NN|mean|arterial|,|and|time (r_conj) times_9\NNS|respective|to|and|pressure (r_npadvmod) recorded_1\VBD|we|time|to|,|times|. (l_prep) to_3\IN|occurrence (l_pobj) occurrence_6\NN|first|dysrhythmia (l_amod) dysrhythmia_5\NN|
D002045_D006323 CID bupivacaine_37\NN| (r_compound) consumption_38\NN|bupivacaine (r_pobj) of_36\IN|consumption (r_prep) amount_35\NN|total|of (r_conj) time_30\NN|asystole|amount (l_relcl) asystole_32\NN|to|and
1424076
D014750_D007177 CID vincristine_9\NN|infusional (r_pobj) after_7\IN|vincristine (r_prep) Syndrome_0\NN|of|after|. (l_prep) of_1\IN|secretion (l_pobj) secretion_3\NN|inappropriate|of (l_prep) of_4\IN|hormone (l_pobj) hormone_6\NN|antidiuretic
D014750_D007177 CID vincristine_16\NN| (r_compound) infusion_17\NN|the|vincristine (r_pobj) to_14\IN|infusion (r_prep) attributed_13\VBN|which|was|to (r_relcl) hormone_9\NN|antidiuretic|,|attributed
D014750_D009101 NONE vincristine_18\NN| (r_pobj) of_17\IN|vincristine (r_prep) infusion_16\NN|a|4-day|continuous|intravenous|of|and|doxorubicin (r_pobj) with_11\IN|infusion (r_prep) treated_10\VBN|woman|was|with|. (l_nsubjpass) woman_4\NN|a|old|with (l_prep) with_5\IN|myeloma (l_pobj) myeloma_8\NN|refractory|multiple
D004317_D009101 NONE doxorubicin_20\NN|and|days (r_conj) infusion_16\NN|a|4-day|continuous|intravenous|of|and|doxorubicin (r_pobj) with_11\IN|infusion (r_prep) treated_10\VBN|woman|was|with|. (l_nsubjpass) woman_4\NN|a|old|with (l_prep) with_5\IN|myeloma (l_pobj) myeloma_8\NN|refractory|multiple
D003907_D009101 NONE dexamethasone_26\NN|oral (r_pobj) of_24\IN|dexamethasone (r_prep) days_23\NNS|4|of (r_conj) doxorubicin_20\NN|and|days (r_conj) infusion_16\NN|a|4-day|continuous|intravenous|of|and|doxorubicin (r_pobj) with_11\IN|infusion (r_prep) treated_10\VBN|woman|was|with|. (l_nsubjpass) woman_4\NN|a|old|with (l_prep) with_5\IN|myeloma (l_pobj) myeloma_8\NN|refractory|multiple
9889429
D009543_D006973 NONE nifedipine_8\JJ| (r_amod) tablets_12\NNS|nifedipine|release|for (l_prep) for_13\IN|cyclosporin (l_pobj) cyclosporin_14\NN|hypertension (l_dobj) hypertension_18\NN|induced|in
D009543_D006973 NONE nifedipine_26\NN|release (r_dobj) treated_13\VBN|patients|were|for|with|,|nifedipine|,|study|. (l_nsubjpass) patients_2\NNS|thirteen|psoriatic|with|during (l_prep) with_3\IN|hypertension (l_pobj) hypertension_4\NN|
D009543_D006973 NONE nifedipine_7\NN|that|release (r_nsubj) is_8\VBZ|nifedipine|useful|for|,|but|monitored (l_prep) for_10\IN|patients (l_pobj) patients_13\NNS|hypertensive|psoriatic|under (l_amod) hypertensive_11\JJ|
D009543_D011565 NONE nifedipine_8\JJ| (r_amod) tablets_12\NNS|nifedipine|release|for (l_prep) for_13\IN|cyclosporin (l_pobj) cyclosporin_14\NN|hypertension (l_dobj) hypertension_18\NN|induced|in (l_prep) in_19\IN|patients (l_pobj) patients_20\NNS|with (l_prep) with_21\IN|psoriasis (l_pobj) psoriasis_22\NN|
D009543_D011565 NONE nifedipine_26\NN|release (r_dobj) treated_13\VBN|patients|were|for|with|,|nifedipine|,|study|. (l_nsubjpass) patients_2\NNS|thirteen|psoriatic|with|during (l_amod) psoriatic_1\JJ|
D009543_D011565 NONE nifedipine_7\NN|that|release (r_nsubj) is_8\VBZ|nifedipine|useful|for|,|but|monitored (l_prep) for_10\IN|patients (l_pobj) patients_13\NNS|hypertensive|psoriatic|under (l_amod) psoriatic_12\JJ|
D016572_D006973 CID A_15\NNP| (r_npadvmod) induced_17\VBN|a|- (r_amod) hypertension_18\NN|induced|in
D016572_D006973 CID A_10\NNP| (r_det) therapy_11\NN|a (r_pobj) of_8\IN|cyclosporin|therapy (r_prep) course_7\NN|the|of (r_pobj) during_5\IN|course (r_prep) patients_2\NNS|thirteen|psoriatic|with|during (l_prep) with_3\IN|hypertension (l_pobj) hypertension_4\NN|
D016572_D006973 CID A_13\NNP| (r_det) therapy_14\NN|a (r_dobj) cyclosporin_12\NN|therapy (r_pcomp) before_11\IN|cyclosporin (r_prep) exhibited_6\VBN|seven|had|state|before|. (l_dobj) state_10\NN|a|subclinical|hypertensive (l_amod) hypertensive_9\JJ|
D016572_D006973 CID A_21\NN|cyclosporin (r_pobj) with_19\IN|a (r_prep) treatment_18\NN|term|with (r_pobj) under_14\IN|treatment (r_prep) patients_13\NNS|hypertensive|psoriatic|under (l_amod) hypertensive_11\JJ|
D016572_D011565 NONE A_15\NNP| (r_npadvmod) induced_17\VBN|a|- (r_amod) hypertension_18\NN|induced|in (l_prep) in_19\IN|patients (l_pobj) patients_20\NNS|with (l_prep) with_21\IN|psoriasis (l_pobj) psoriasis_22\NN|
D016572_D011565 NONE A_10\NNP| (r_det) therapy_11\NN|a (r_pobj) of_8\IN|cyclosporin|therapy (r_prep) course_7\NN|the|of (r_pobj) during_5\IN|course (r_prep) patients_2\NNS|thirteen|psoriatic|with|during (l_amod) psoriatic_1\JJ|
D016572_D011565 NONE A_21\NN|cyclosporin (r_pobj) with_19\IN|a (r_prep) treatment_18\NN|term|with (r_pobj) under_14\IN|treatment (r_prep) patients_13\NNS|hypertensive|psoriatic|under (l_amod) psoriatic_12\JJ|
D002118_D011565 NONE calcium_19\NN| (r_compound) channel_20\NN|calcium (r_compound) blocker_21\NN|a|channel (r_pobj) with_17\IN|blocker (r_prep) treated_13\VBN|patients|were|for|with|,|nifedipine|,|study|. (l_nsubjpass) patients_2\NNS|thirteen|psoriatic|with|during (l_amod) psoriatic_1\JJ|
D002118_D006973 NONE calcium_19\NN| (r_compound) channel_20\NN|calcium (r_compound) blocker_21\NN|a|channel (r_pobj) with_17\IN|blocker (r_prep) treated_13\VBN|patients|were|for|with|,|nifedipine|,|study|. (l_nsubjpass) patients_2\NNS|thirteen|psoriatic|with|during (l_prep) with_3\IN|hypertension (l_pobj) hypertension_4\NN|
D016572_D005885 CID A_8\NN|cyclosporin|and|nifedipine (r_pobj) with_6\IN|a (r_prep) therapy_5\NN|combined|with (r_pobj) during_3\IN|therapy (r_prep) events_2\NNS|the|adverse|during (r_nsubj) included_11\VBD|events|increase|. (l_dobj) increase_13\NN|an|in|in|in (l_prep) in_19\IN|9 (l_pobj) 9_20\CD|of (l_prep) of_21\IN|patients (l_pobj) patients_24\NNS|the|13|and|development|of (l_prep) of_27\IN|hyperplasia (l_pobj) hyperplasia_29\NN|gingival
D016572_D005885 CID A_21\NN|cyclosporin (r_pobj) with_19\IN|a (r_prep) treatment_18\NN|term|with (r_pobj) under_14\IN|treatment (r_prep) patients_13\NNS|hypertensive|psoriatic|under (r_pobj) for_10\IN|patients (r_prep) is_8\VBZ|nifedipine|useful|for|,|but|monitored (l_conj) monitored_29\VBN|that|patients|should|be|for (l_prep) for_30\IN|hyperplasia (l_pobj) hyperplasia_32\NN|gingival
D009543_D005885 CID nifedipine_10\NN| (r_conj) A_8\NN|cyclosporin|and|nifedipine (r_pobj) with_6\IN|a (r_prep) therapy_5\NN|combined|with (r_pobj) during_3\IN|therapy (r_prep) events_2\NNS|the|adverse|during (r_nsubj) included_11\VBD|events|increase|. (l_dobj) increase_13\NN|an|in|in|in (l_prep) in_19\IN|9 (l_pobj) 9_20\CD|of (l_prep) of_21\IN|patients (l_pobj) patients_24\NNS|the|13|and|development|of (l_prep) of_27\IN|hyperplasia (l_pobj) hyperplasia_29\NN|gingival
D009543_D005885 CID nifedipine_7\NN|that|release (r_nsubj) is_8\VBZ|nifedipine|useful|for|,|but|monitored (l_conj) monitored_29\VBN|that|patients|should|be|for (l_prep) for_30\IN|hyperplasia (l_pobj) hyperplasia_32\NN|gingival
D001806_D005885 NONE nitrogen_17\NN| (r_compound) levels_18\NNS|urea|nitrogen (r_pobj) in_14\IN|levels (r_prep) increase_13\NN|an|in|in|in (l_prep) in_19\IN|9 (l_pobj) 9_20\CD|of (l_prep) of_21\IN|patients (l_pobj) patients_24\NNS|the|13|and|development|of (l_prep) of_27\IN|hyperplasia (l_pobj) hyperplasia_29\NN|gingival
24067251
C418563_D007674 NONE fumarate_17\NN|tenofovir|disoproxil (r_pobj) to_14\IN|fumarate (r_prep) exposed_13\VBN|to (r_acl) persons_12\NNS|positive|exposed (r_pobj) in_8\IN|persons (r_prep) injury_7\NN|kidney|in
C418563_D007674 NONE TDF_12\NNP| (r_npadvmod) related_14\VBN|tdf|- (r_amod) disease_16\NN|related|kidney|,|%|)
C418563_D007674 NONE TDF_12\NNP| (r_npadvmod) related_14\VBN|tdf|- (r_amod) disease_16\NN|related|kidney|,|%|) (r_pobj) for_11\IN|disease (r_prep) criteria_10\NNS|,|106|satisfied|for (r_dobj) analysed_6\VBN|criteria (r_acl) records_5\NNS|the|407|card|analysed (r_pobj) Of_0\IN|records (r_prep) had_25\VBD|of|features|found|had|. (l_dobj) features_26\NNS|of|,|35|(|%|) (l_prep) of_27\IN|dysfunction (l_pobj) dysfunction_30\NN|kidney|tubular
C418563_D007674 NONE TDF_12\NNP| (r_npadvmod) related_14\VBN|tdf|- (r_amod) disease_16\NN|related|kidney|,|%|) (r_pobj) for_11\IN|disease (r_prep) criteria_10\NNS|,|106|satisfied|for (r_dobj) analysed_6\VBN|criteria (r_acl) records_5\NNS|the|407|card|analysed (r_pobj) Of_0\IN|records (r_prep) had_25\VBD|of|features|found|had|. (l_conj) found_38\VBN|were|have (l_advcl) have_40\VB|to|features (l_dobj) features_41\NNS|of|and|% (l_prep) of_42\IN|dysfunction (l_pobj) dysfunction_44\NN|glomerular
C418563_D005198 CID TDF_12\NNP| (r_npadvmod) related_14\VBN|tdf|- (r_amod) disease_16\NN|related|kidney|,|%|) (r_pobj) for_11\IN|disease (r_prep) criteria_10\NNS|,|106|satisfied|for (r_dobj) analysed_6\VBN|criteria (r_acl) records_5\NNS|the|407|card|analysed (r_pobj) Of_0\IN|records (r_prep) had_25\VBD|of|features|found|had|. (l_conj) had_51\VBD|syndrome (l_dobj) syndrome_53\NN|fanconi
C418563_D005198 CID TDF_5\NNP| (r_compound) effects_8\NNS|tdf|kidney|adverse (r_pobj) for_4\IN|effects (r_prep) hospitalisation_3\NN|for (r_pobj) of_2\IN|hospitalisation (r_prep) incidence_1\NN|the|of (r_nsubj) was_9\VBD|incidence|high|,|amongst|. (l_prep) amongst_13\IN|particularly|patients (l_pobj) patients_14\NNS|with (l_prep) with_15\IN|features (l_pobj) features_16\NNS|of (l_prep) of_17\IN|syndrome (l_pobj) syndrome_19\NN|fanconi
23949582
D015080_D030342 NONE Mesna_0\NNP| (r_nsubj) reduces_2\VBZ|mesna|significantly|genotoxicity|,|acts|. (l_dobj) genotoxicity_5\NN|ifo
D007069_D030342 NONE IFO_3\NNP|'s (r_poss) genotoxicity_5\NN|ifo
15627798
D005839_D009395 CID gentamicin_12\NN| (r_pobj) by_11\IN|gentamicin (r_agent) induced_10\VBN|by (r_acl) nephritis_9\NN|tubulointerstitial|induced
D005839_D009395 CID gentamicin_15\NN| (r_pobj) by_14\IN|gentamicin (r_agent) induced_13\VBN|by (r_advcl) attenuates_10\VBZ|that|inhibition|nephritis|induced (l_dobj) nephritis_12\NN|tubulointerstitial
D005839_D005355 NONE gentamicin_3\NN| (r_pobj) with_2\IN|gentamicin (r_prep) treated_1\VBN|with (r_acl) Animals_0\NNS|treated (r_nsubj) show_5\VB|animals|can|areas|. (l_dobj) areas_7\NNS|residual|of|in (l_prep) of_8\IN|fibrosis (l_pobj) fibrosis_10\NN|interstitial
12912689
D016190_D012175 NONE carboplatin_5\VBP|after|subtenon|chemotherapy|for (l_prep) for_7\IN|retinoblastoma (l_pobj) retinoblastoma_8\NN|
D016190_D012175 NONE carboplatin_2\NN|subtenon|used|. (l_ccomp) used_7\VBN|injections|have|recently|been|as (l_prep) as_8\IN|adjunct (l_pobj) adjunct_14\NN|a|free|to (l_prep) to_15\IN|chemotherapy (l_pobj) chemotherapy_17\NN|systemic|for (l_prep) for_18\IN|retinoblastoma (l_pobj) retinoblastoma_20\NN|intraocular
D016190_D012175 NONE carboplatin_15\NN| (r_ccomp) noted_1\VBD|we|motility|carboplatin|. (l_dobj) motility_4\NN|abnormal|ocular|in (l_prep) in_5\IN|patients (l_pobj) patients_8\NNS|10|consecutive|with (l_prep) with_9\IN|retinoblastoma (l_pobj) retinoblastoma_10\NN|received
D016190_D012175 NONE carboplatin_24\NN|as (r_advmod) detected_5\VBN|limitation|was|in|carboplatin|. (l_prep) in_6\IN|eyes (l_pobj) eyes_9\NNS|all|12|of (l_prep) of_10\IN|patients (l_pobj) patients_12\NNS|10|treated (l_acl) treated_13\VBN|for|with (l_prep) for_14\IN|retinoblastoma (l_pobj) retinoblastoma_16\NN|intraocular
D016190_D064420 NONE carboplatin_2\NN|subtenon|used|. (l_ccomp) used_7\VBN|injections|have|recently|been|as (l_prep) as_8\IN|adjunct (l_pobj) adjunct_14\NN|a|free|to (l_amod) free_13\JJ|presumably|toxicity|- (l_npadvmod) toxicity_11\NN|
D016190_D064420 NONE carboplatin_1\NN|subtenon (r_nsubj) is_2\VBZ|carboplatin|not|free|,|and|restricted (l_acomp) free_4\JJ|of (l_prep) of_5\IN|toxicity (l_pobj) toxicity_6\NN|
D016190_D015835 CID carboplatin_14\NN| (r_amod) chemotherapy_15\NN|carboplatin (r_dobj) treated_11\VBN|with|chemotherapy (r_acl) patients_10\NNS|treated (r_pobj) in_9\IN|patients (r_prep) motility_8\NN|abnormal|ocular|in
D016190_D015835 CID carboplatin_15\NN| (r_ccomp) noted_1\VBD|we|motility|carboplatin|. (l_dobj) motility_4\NN|abnormal|ocular|in
D016190_D005355 CID carboplatin_1\NN|subtenon|associated|. (l_ccomp) associated_4\VBN|chemotherapy|is|with|,|leading (l_prep) with_5\IN|fibrosis (l_pobj) fibrosis_7\NN|significant|of
8308951
D014859_D002543 CID warfarin_3\VB| (r_npadvmod) like_5\JJ|warfarin|- (r_amod) anticoagulant_6\NN|like (r_pobj) to_2\IN|anticoagulant (r_prep) exposure_1\NN|cutaneous|to|causing|:|report|. (l_acl) causing_7\VBG|hemorrhage (l_dobj) hemorrhage_10\NN|an|intracerebral
D014859_D006406 NONE warfarin_7\RB| (r_npadvmod) induced_9\VBN|warfarin|- (r_amod) coagulopathy_10\NN|induced (r_pobj) due_5\IN|to|coagulopathy (r_prep) case_1\NN|a|of|due (l_prep) of_2\IN|hematoma (l_pobj) hematoma_4\NN|intercerebral
D014859_D001778 NONE warfarin_7\RB| (r_npadvmod) induced_9\VBN|warfarin|- (r_amod) coagulopathy_10\NN|induced
D014859_D001778 NONE warfarin_3\JJ| (r_pobj) of_2\IN|warfarin (r_prep) absorption_1\NN|percutaneous|of|causing (l_acl) causing_4\VBG|coagulopathy (l_dobj) coagulopathy_5\NN|
D010894_D001778 NONE piroxicam_5\NN| (r_pobj) with_4\IN|piroxicam (r_prep) interaction_3\NN|an|adverse|drug|with|,|took (r_nsubj) exacerbated_14\VBN|interaction|,|may|have|coagulopathy|. (l_dobj) coagulopathy_16\NN|the
1522360
D012293_D006461 CID rifampin_8\NN| (r_amod) therapy_9\NN|intermittent|rifampin (r_dobj) following_6\VBG|therapy (r_prep) hemolysis_1\NN|intravascular|and|failure|following|.
D012293_D006461 CID rifampin_8\NN| (r_advmod) is_10\VBZ|hemolysis|rifampin|therapy|rare|. (l_nsubj) hemolysis_1\NN|intravascular|leading
D012293_D006461 CID rifampin_12\NN| (r_pobj) following_11\VBG|rifampin (r_prep) developed_5\VBD|who|failure|following (l_dobj) failure_10\NN|hemolysis|acute|renal (l_nmod) hemolysis_6\NN|and
D012293_D058186 CID rifampin_8\NN| (r_amod) therapy_9\NN|intermittent|rifampin (r_dobj) following_6\VBG|therapy (r_prep) hemolysis_1\NN|intravascular|and|failure|following|. (l_conj) failure_5\NN|acute|renal
D012293_D058186 CID rifampin_8\NN| (r_advmod) is_10\VBZ|hemolysis|rifampin|therapy|rare|. (l_nsubj) hemolysis_1\NN|intravascular|leading (l_acl) leading_2\VBG|to (l_prep) to_3\IN|failure (l_pobj) failure_6\NN|acute|renal|following
D012293_D058186 CID rifampin_12\NN| (r_pobj) following_11\VBG|rifampin (r_prep) developed_5\VBD|who|failure|following (l_dobj) failure_10\NN|hemolysis|acute|renal
D012293_D051437 NONE rifampin_11\NN| (r_pobj) of_10\IN|rifampin (r_prep) use_9\NN|the|of (r_pobj) with_7\IN|use (r_prep) associated_6\VBN|with (r_acl) complication_5\NN|a|rare|associated (r_attr) is_2\VBZ|failure|complication|. (l_nsubj) failure_1\NN|renal
D012293_D007918 NONE rifampin_12\NN| (r_pobj) following_11\VBG|rifampin (r_prep) developed_5\VBD|who|failure|following (r_relcl) patients_1\NNS|two|with|developed (l_prep) with_2\IN|leprosy (l_pobj) leprosy_3\NN|
23892921
C467567_D009101 NONE lenalidomide_12\NN|and|dexamethasone (r_pobj) of_11\IN|lenalidomide (r_prep) efficacy_8\NN|the|and|safety|of (r_pobj) on_6\IN|efficacy (r_prep) data_5\NNS|"|world|"|on|in|:|study|. (l_prep) in_15\IN|patients (l_pobj) patients_16\NNS|with (l_prep) with_17\IN|myeloma (l_pobj) myeloma_22\NN|relapsed|refractory|multiple|treated
C467567_D009101 NONE lenalidomide_12\NN|and|dexamethasone (r_pobj) of_11\IN|lenalidomide (r_prep) efficacy_8\NN|the|and|safety|of (r_pobj) on_6\IN|efficacy (r_prep) data_5\NNS|"|world|"|on|in|:|study|. (l_appos) study_34\NN|a|of (l_prep) of_35\IN|group (l_pobj) Group_40\NNP|the|greek|myeloma|study (l_compound) Myeloma_38\NNP|
C467567_D009101 NONE Lenalidomide_0\NNP|and|dexamethasone (r_nsubj) is_6\VBZ|lenalidomide|standard|,|but|is (l_attr) standard_8\NN|a|of|for (l_prep) for_11\IN|myeloma (l_pobj) myeloma_16\NN|relapsed|refractory|multiple|rrmm
C467567_D009101 NONE Lenalidomide_0\NNP|and|dexamethasone (r_nsubj) is_6\VBZ|lenalidomide|standard|,|but|is (l_attr) standard_8\NN|a|of|for (l_prep) for_11\IN|myeloma (l_pobj) myeloma_16\NN|relapsed|refractory|multiple|rrmm (l_appos) RRMM_18\NNP|(|)
C467567_D009101 NONE RD_4\NNP|(|) (r_appos) dexamethasone_2\NN|rd (r_conj) Lenalidomide_0\NNP|and|dexamethasone (r_nsubj) is_6\VBZ|lenalidomide|standard|,|but|is (l_attr) standard_8\NN|a|of|for (l_prep) for_11\IN|myeloma (l_pobj) myeloma_16\NN|relapsed|refractory|multiple|rrmm
C467567_D009101 NONE RD_4\NNP|(|) (r_appos) dexamethasone_2\NN|rd (r_conj) Lenalidomide_0\NNP|and|dexamethasone (r_nsubj) is_6\VBZ|lenalidomide|standard|,|but|is (l_attr) standard_8\NN|a|of|for (l_prep) for_11\IN|myeloma (l_pobj) myeloma_16\NN|relapsed|refractory|multiple|rrmm (l_appos) RRMM_18\NNP|(|)
C467567_D009101 NONE RD_7\NNP| (r_dobj) received_6\VBD|who|rd|in (r_relcl) patients_4\NNS|212|rrmm|received (l_compound) RRMM_3\NNP|
C467567_D009101 NONE RD_4\NNP| (r_nsubj) is_5\VBZ|that|rd|effective|in (l_acomp) effective_6\JJ|and|safe (l_conj) safe_8\JJ|in (l_prep) in_9\IN|rrmm (l_pobj) RRMM_10\NNP|
D003907_D009101 NONE dexamethasone_14\NN| (r_conj) lenalidomide_12\NN|and|dexamethasone (r_pobj) of_11\IN|lenalidomide (r_prep) efficacy_8\NN|the|and|safety|of (r_pobj) on_6\IN|efficacy (r_prep) data_5\NNS|"|world|"|on|in|:|study|. (l_prep) in_15\IN|patients (l_pobj) patients_16\NNS|with (l_prep) with_17\IN|myeloma (l_pobj) myeloma_22\NN|relapsed|refractory|multiple|treated
D003907_D009101 NONE dexamethasone_14\NN| (r_conj) lenalidomide_12\NN|and|dexamethasone (r_pobj) of_11\IN|lenalidomide (r_prep) efficacy_8\NN|the|and|safety|of (r_pobj) on_6\IN|efficacy (r_prep) data_5\NNS|"|world|"|on|in|:|study|. (l_appos) study_34\NN|a|of (l_prep) of_35\IN|group (l_pobj) Group_40\NNP|the|greek|myeloma|study (l_compound) Myeloma_38\NNP|
D003907_D009101 NONE dexamethasone_2\NN|rd (r_conj) Lenalidomide_0\NNP|and|dexamethasone (r_nsubj) is_6\VBZ|lenalidomide|standard|,|but|is (l_attr) standard_8\NN|a|of|for (l_prep) for_11\IN|myeloma (l_pobj) myeloma_16\NN|relapsed|refractory|multiple|rrmm
D003907_D009101 NONE dexamethasone_2\NN|rd (r_conj) Lenalidomide_0\NNP|and|dexamethasone (r_nsubj) is_6\VBZ|lenalidomide|standard|,|but|is (l_attr) standard_8\NN|a|of|for (l_prep) for_11\IN|myeloma (l_pobj) myeloma_16\NN|relapsed|refractory|multiple|rrmm (l_appos) RRMM_18\NNP|(|)
D003907_D009101 NONE RD_4\NNP|(|) (r_appos) dexamethasone_2\NN|rd (r_conj) Lenalidomide_0\NNP|and|dexamethasone (r_nsubj) is_6\VBZ|lenalidomide|standard|,|but|is (l_attr) standard_8\NN|a|of|for (l_prep) for_11\IN|myeloma (l_pobj) myeloma_16\NN|relapsed|refractory|multiple|rrmm
D003907_D009101 NONE RD_4\NNP|(|) (r_appos) dexamethasone_2\NN|rd (r_conj) Lenalidomide_0\NNP|and|dexamethasone (r_nsubj) is_6\VBZ|lenalidomide|standard|,|but|is (l_attr) standard_8\NN|a|of|for (l_prep) for_11\IN|myeloma (l_pobj) myeloma_16\NN|relapsed|refractory|multiple|rrmm (l_appos) RRMM_18\NNP|(|)
D003907_D009101 NONE RD_7\NNP| (r_dobj) received_6\VBD|who|rd|in (r_relcl) patients_4\NNS|212|rrmm|received (l_compound) RRMM_3\NNP|
D003907_D009101 NONE RD_4\NNP| (r_nsubj) is_5\VBZ|that|rd|effective|in (l_acomp) effective_6\JJ|and|safe (l_conj) safe_8\JJ|in (l_prep) in_9\IN|rrmm (l_pobj) RRMM_10\NNP|
3439580
D007099_D006973 CID imipramine_5\NN| (r_pobj) by_4\IN|imipramine (r_prep) induced_3\VBN|hypertension|by|. (l_nsubj) Hypertension_0\NN|in
D007099_D006973 CID Imipramine_23\NNP| (r_dobj) given_22\VBN|who|was|imipramine|control (r_relcl) neuroblastoma_19\NN|given (r_pobj) with_18\IN|neuroblastoma (r_prep) girl_17\NN|a|old|with (r_pobj) in_12\IN|girl (r_prep) pressure_9\NN|(|blood|190/160|)|in (r_appos) hypertension_6\NN|severe|pressure
D007099_D006973 CID Imipramine_16\NNP|the (r_pobj) of_14\IN|imipramine (r_prep) discontinuation_13\NN|of (r_dobj) following_12\VBG|discontinuation (r_acl) none_11\NN|following|(|was|) (r_conj) elevation_6\NN|no|pressure|at|and|none (r_dobj) had_2\VBD|since|she|elevation (r_advcl) believe_27\VBP|had|,|we|caused|. (l_ccomp) caused_37\VBD|that|drug|hypertension (l_dobj) hypertension_39\NN|her
D007099_D009447 NONE imipramine_5\NN| (r_pobj) by_4\IN|imipramine (r_prep) induced_3\VBN|hypertension|by|. (l_nsubj) Hypertension_0\NN|in (l_prep) in_1\IN|neuroblastoma (l_pobj) neuroblastoma_2\NN|
D007099_D009447 NONE Imipramine_23\NNP| (r_dobj) given_22\VBN|who|was|imipramine|control (r_relcl) neuroblastoma_19\NN|given
D007099_D002653 NONE Imipramine_23\NNP| (r_dobj) given_22\VBN|who|was|imipramine|control (l_advcl) control_25\VB|to|disorder (l_dobj) disorder_28\NN|a|behavior
24928523
C400082_D009101 NONE bortezomib_2\NNS|, (r_pobj) of_1\IN|bortezomib (r_prep) Combination_0\NN|of|thalidomide|as|. (l_prep) as_11\IN|therapy (l_pobj) therapy_14\NN|a|consolidation|after (l_prep) after_15\IN|transplantation (l_pobj) transplantation_19\NN|autologous|cell|for (l_prep) for_20\IN|myeloma (l_pobj) myeloma_23\NN|symptomatic|multiple|in
C400082_D009101 NONE bortezomib_15\NNS|,|thalidomide (r_pobj) of_14\IN|bortezomib (r_prep) regimen_13\NNS|combination|of (r_pobj) of_11\IN|regimen (r_prep) safety_8\NN|the|and|efficacy|of (r_dobj) analyzed_6\VBD|in|,|we|retrospectively|safety|as|. (l_prep) as_24\IN|therapy (l_pobj) therapy_26\NN|consolidation|in (l_prep) in_27\IN|patients (l_pobj) patients_30\NNS|24|japanese|with (l_prep) with_31\IN|mm (l_pobj) MM_34\NNP|diagnosed
D013792_D009101 NONE thalidomide_4\NN|,|and|dexamethasone (r_conj) Combination_0\NN|of|thalidomide|as|. (l_prep) as_11\IN|therapy (l_pobj) therapy_14\NN|a|consolidation|after (l_prep) after_15\IN|transplantation (l_pobj) transplantation_19\NN|autologous|cell|for (l_prep) for_20\IN|myeloma (l_pobj) myeloma_23\NN|symptomatic|multiple|in
D013792_D009101 NONE thalidomide_17\NN|,|and|dexamethasone (r_conj) bortezomib_15\NNS|,|thalidomide (r_pobj) of_14\IN|bortezomib (r_prep) regimen_13\NNS|combination|of (r_pobj) of_11\IN|regimen (r_prep) safety_8\NN|the|and|efficacy|of (r_dobj) analyzed_6\VBD|in|,|we|retrospectively|safety|as|. (l_prep) as_24\IN|therapy (l_pobj) therapy_26\NN|consolidation|in (l_prep) in_27\IN|patients (l_pobj) patients_30\NNS|24|japanese|with (l_prep) with_31\IN|mm (l_pobj) MM_34\NNP|diagnosed
D003907_D009101 NONE dexamethasone_7\NN|(|vtd|) (r_conj) thalidomide_4\NN|,|and|dexamethasone (r_conj) Combination_0\NN|of|thalidomide|as|. (l_prep) as_11\IN|therapy (l_pobj) therapy_14\NN|a|consolidation|after (l_prep) after_15\IN|transplantation (l_pobj) transplantation_19\NN|autologous|cell|for (l_prep) for_20\IN|myeloma (l_pobj) myeloma_23\NN|symptomatic|multiple|in
D003907_D009101 NONE dexamethasone_20\NN|(|vtd|) (r_conj) thalidomide_17\NN|,|and|dexamethasone (r_conj) bortezomib_15\NNS|,|thalidomide (r_pobj) of_14\IN|bortezomib (r_prep) regimen_13\NNS|combination|of (r_pobj) of_11\IN|regimen (r_prep) safety_8\NN|the|and|efficacy|of (r_dobj) analyzed_6\VBD|in|,|we|retrospectively|safety|as|. (l_prep) as_24\IN|therapy (l_pobj) therapy_26\NN|consolidation|in (l_prep) in_27\IN|patients (l_pobj) patients_30\NNS|24|japanese|with (l_prep) with_31\IN|mm (l_pobj) MM_34\NNP|diagnosed
12535818
D000638_D001919 CID Amiodarone_0\NN|and|risk|. (l_conj) risk_3\NN|the|of|requiring (l_prep) of_4\IN|bradyarrhythmia (l_pobj) bradyarrhythmia_5\JJ|
D000638_D001919 CID amiodarone_14\NN|in (r_pobj) of_13\IN|amiodarone (r_prep) use_12\NN|the|of (r_nsubj) increases_23\VBZ|whether|use|)|risk (l_dobj) risk_25\NN|the|of|requiring (l_prep) of_26\IN|bradyarrhythmia (l_pobj) bradyarrhythmia_27\NNS|
D000638_D001919 CID amiodarone_5\NN| (r_compound) therapy_6\NN|amiodarone (r_pobj) during_4\IN|therapy (r_prep) bradyarrhythmia_3\NN|severe|during
D000638_D001919 CID amiodarone_7\NN|in (r_pobj) of_6\IN|amiodarone (r_prep) use_5\NN|the|of|and|mi (r_nsubj) increases_17\VBZ|that|use|risk (l_dobj) risk_19\NN|the|of|requiring (l_prep) of_20\IN|bradyarrhythmia (l_pobj) bradyarrhythmia_21\NNS|
D000638_D001281 NONE Amiodarone_0\NN|and|risk|. (l_conj) risk_3\NN|the|of|requiring (l_acl) requiring_6\VBG|pacemaker (l_dobj) pacemaker_8\NN|permanent|in (l_prep) in_9\IN|patients (l_pobj) patients_11\NNS|elderly|with (l_prep) with_12\IN|fibrillation (l_pobj) fibrillation_14\NN|atrial|and|infarction
D000638_D001281 NONE amiodarone_14\NN|in (l_prep) in_15\IN|patients (l_pobj) patients_16\NNS|with (l_prep) with_17\IN|fibrillation (l_pobj) fibrillation_19\NN|atrial|(|af
D000638_D001281 NONE amiodarone_14\NN|in (l_prep) in_15\IN|patients (l_pobj) patients_16\NNS|with (l_prep) with_17\IN|fibrillation (l_pobj) fibrillation_19\NN|atrial|(|af (l_appos) AF_21\NNP|
D000638_D001281 NONE amiodarone_7\NN|in (l_prep) in_8\IN|patients (l_pobj) patients_10\NNS|elderly|with (l_prep) with_11\IN|af (l_pobj) AF_12\NNP|
D000638_D009203 NONE Amiodarone_0\NN|and|risk|. (l_conj) risk_3\NN|the|of|requiring (l_acl) requiring_6\VBG|pacemaker (l_dobj) pacemaker_8\NN|permanent|in (l_prep) in_9\IN|patients (l_pobj) patients_11\NNS|elderly|with (l_prep) with_12\IN|fibrillation (l_pobj) fibrillation_14\NN|atrial|and|infarction (l_conj) infarction_18\NN|prior|myocardial
D000638_D009203 NONE amiodarone_7\NN|in (r_pobj) of_6\IN|amiodarone (r_prep) use_5\NN|the|of|and|mi (l_conj) MI_16\NNP|a|previous
D000638_D001145 NONE amiodarone_5\NN| (r_compound) therapy_6\NN|amiodarone (r_pobj) during_4\IN|therapy (r_prep) bradyarrhythmia_3\NN|severe|during (r_pobj) of_1\IN|bradyarrhythmia (r_prep) Reports_0\NNS|of (r_nsubj) are_7\VBP|reports|infrequent|. (l_acomp) infrequent_8\JJ|and|limited (l_conj) limited_10\VBN|to (l_prep) to_11\IN|studies (l_pobj) studies_12\NNS|assessing (l_acl) assessing_13\VBG|use (l_dobj) use_17\NN|therapy|in (l_prep) in_18\IN|management (l_pobj) management_20\NN|the|of (l_prep) of_21\IN|patients (l_pobj) patients_22\NNS|with (l_prep) with_23\IN|arrhythmias (l_pobj) arrhythmias_25\NNS|ventricular
89511
D004967_D014591 NONE oestrogen_10\NN| (r_compound) therapy_11\NN|oestrogen (r_dobj) receiving_9\VBG|therapy (r_acl) women_8\NNS|climacteric|receiving (r_pobj) in_6\IN|women (r_prep) Prevention_0\NN|and|treatment|of|in|. (l_prep) of_3\IN|disease (l_pobj) disease_5\NN|endometrial
D004967_D014591 NONE oestrogen_16\NN| (r_compound) therapy_17\NN|oestrogen (r_dobj) receiving_15\VBG|therapy (r_acl) women_14\NNS|850|climacteric|receiving (r_pobj) among_11\IN|women (r_prep) described_4\VBN|regimens|are|in|among|. (l_prep) in_5\IN|patients (l_pobj) patients_7\NNS|74|with (l_prep) with_8\IN|disease (l_pobj) disease_10\NN|endometrial
D004967_D006965 CID oestrogen_6\NN| (r_compound) therapy_7\NN|unopposed|oestrogen (r_pobj) with_4\IN|therapy (r_prep) associated_3\VBN|hyperplasia|was|with|without|. (l_nsubjpass) hyperplasia_1\NN|cystic
D004967_D006965 CID oestrogen_16\NN| (r_compound) therapy_17\NN|inappropriate|unopposed|oestrogen|and|difficulty (l_conj) difficulty_20\NN|the|in (l_prep) in_21\IN|distinguishing (l_pcomp) distinguishing_22\VBG|hyperplasia|from (l_dobj) hyperplasia_24\NN|severe
D011372_D006965 NONE progestagen_9\NN| (r_pobj) without_8\IN|progestagen (r_prep) associated_3\VBN|hyperplasia|was|with|without|. (l_nsubjpass) hyperplasia_1\NN|cystic
D009640_D006965 NONE norethisterone_8\NN|daily (r_amod) mg_7\NN|5|norethisterone (r_pobj) of_5\IN|mg (r_prep) days_4\NNS|21|of (r_pobj) of_2\IN|days (r_prep) courses_1\NNS|two|of (r_nsubj) caused_10\VBN|courses|reversion|and|6|. (l_dobj) reversion_11\NN|to|in (l_prep) in_14\IN|cases (l_pobj) cases_17\NNS|all|57|of (l_prep) of_18\IN|hyperplasia (l_pobj) hyperplasia_20\NN|cystic
D009640_D006965 NONE norethisterone_8\NN|daily (r_amod) mg_7\NN|5|norethisterone (r_pobj) of_5\IN|mg (r_prep) days_4\NNS|21|of (r_pobj) of_2\IN|days (r_prep) courses_1\NNS|two|of (r_nsubj) caused_10\VBN|courses|reversion|and|6|. (l_conj) 6_22\CD|of (l_prep) of_23\IN|cases (l_pobj) cases_26\NNS|the|8|of (l_prep) of_27\IN|hyperplasia (l_pobj) hyperplasia_29\NN|atypical
D004967_D016889 NONE oestrogen_16\NN| (r_compound) therapy_17\NN|inappropriate|unopposed|oestrogen|and|difficulty (r_pobj) of_11\IN|therapy (r_prep) problems_10\NNS|the|of (r_dobj) demonstrated_8\VBD|referred|problems|. (l_csubj) referred_5\VBD|cases|from (l_nsubj) cases_1\NNS|4|of (l_prep) of_2\IN|carcinoma (l_pobj) carcinoma_4\NN|endometrial
D004967_D009369 NONE oestrogen_16\NN| (r_compound) therapy_17\NN|inappropriate|unopposed|oestrogen|and|difficulty (l_conj) difficulty_20\NN|the|in (l_prep) in_21\IN|distinguishing (l_pcomp) distinguishing_22\VBG|hyperplasia|from (l_prep) from_25\IN|malignancy (l_pobj) malignancy_26\NN|
D004967_D004714 NONE oestrogen_4\NN| (r_compound) therapy_5\NN|cyclical|dose|oestrogen|with (r_nsubj) seem_15\VB|therapy|does|not|increase|. (l_xcomp) increase_17\VB|to|risk (l_dobj) risk_19\NN|the|of (l_prep) of_20\IN|hyperplasia (l_pobj) hyperplasia_22\NN|endometrial|or|carcinoma
D004967_D002277 NONE oestrogen_4\NN| (r_compound) therapy_5\NN|cyclical|dose|oestrogen|with (r_nsubj) seem_15\VB|therapy|does|not|increase|. (l_xcomp) increase_17\VB|to|risk (l_dobj) risk_19\NN|the|of (l_prep) of_20\IN|hyperplasia (l_pobj) hyperplasia_22\NN|endometrial|or|carcinoma (l_conj) carcinoma_24\NN|
D011372_D004714 NONE progestagen_12\NN| (r_pobj) of_11\IN|progestagen (r_prep) days_10\NNS|-13|of (r_pobj) with_6\IN|days (r_prep) therapy_5\NN|cyclical|dose|oestrogen|with (r_nsubj) seem_15\VB|therapy|does|not|increase|. (l_xcomp) increase_17\VB|to|risk (l_dobj) risk_19\NN|the|of (l_prep) of_20\IN|hyperplasia (l_pobj) hyperplasia_22\NN|endometrial|or|carcinoma
D011372_D002277 NONE progestagen_12\NN| (r_pobj) of_11\IN|progestagen (r_prep) days_10\NNS|-13|of (r_pobj) with_6\IN|days (r_prep) therapy_5\NN|cyclical|dose|oestrogen|with (r_nsubj) seem_15\VB|therapy|does|not|increase|. (l_xcomp) increase_17\VB|to|risk (l_dobj) risk_19\NN|the|of (l_prep) of_20\IN|hyperplasia (l_pobj) hyperplasia_22\NN|endometrial|or|carcinoma (l_conj) carcinoma_24\NN|
2818777
D010672_D056486 NONE Phenytoin_0\NNP| (r_nsubj) induced_1\VBD|phenytoin|injury|. (l_dobj) injury_4\NN|fatal|hepatic
D010672_D017093 CID phenytoin_10\NN| (r_compound) administration_11\NN|phenytoin (r_pobj) after_9\IN|administration (r_prep) failure_8\NN|a|old|female|developed|fatal|hepatic|after|.
8318674
D003561_D011654 CID C_10\NN|dose|aracytine|-|for (r_pobj) after_4\IN|c (r_prep) edema_1\NN|pulmonary|and|shock|after|;|role|.
D003561_D012769 CID C_10\NN|dose|aracytine|-|for (r_pobj) after_4\IN|c (r_prep) edema_1\NN|pulmonary|and|shock|after|;|role|. (l_conj) shock_3\NN|
D003561_D012769 CID C_29\NNP|dose|ara|- (r_nsubjpass) associated_32\VBN|that|c|may|be|with (r_ccomp) hypothesize_22\VBP|thought|,|we|associated|. (l_advcl) thought_5\VBN|as|tnf|are|involved (l_xcomp) involved_8\VBN|to|be|in (l_prep) in_9\IN|development (l_pobj) development_11\NN|the|of (l_prep) of_12\IN|shock (l_pobj) shock_14\NN|septic|and|syndrome
D003561_D008223 NONE C_10\NN|dose|aracytine|-|for (l_prep) for_11\IN|lymphoma (l_pobj) lymphoma_12\NN|
D003561_D008223 NONE C_13\NNP|dose|ara|- (r_pobj) with_7\IN|c (r_prep) treated_6\VBN|with|for|in (l_prep) for_14\IN|lymphomas (l_pobj) lymphomas_15\NNS|
D003561_D012128 NONE C_29\NNP|dose|ara|- (r_nsubjpass) associated_32\VBN|that|c|may|be|with (r_ccomp) hypothesize_22\VBP|thought|,|we|associated|. (l_advcl) thought_5\VBN|as|tnf|are|involved (l_xcomp) involved_8\VBN|to|be|in (l_prep) in_9\IN|development (l_pobj) development_11\NN|the|of (l_prep) of_12\IN|shock (l_pobj) shock_14\NN|septic|and|syndrome (l_conj) syndrome_19\NN|adult|distress
24733133
C031942_D055499 NONE argatroban_2\NN|and|directed (r_amod) thrombolysis_7\NN|argatroban|with|in
C031942_D055499 NONE argatroban_21\NN|plus (r_amod) thrombolysis_26\NN|argatroban|directed|(|cdt|)
C031942_D013921 NONE argatroban_2\NN|and|directed (r_amod) thrombolysis_7\NN|argatroban|with|in (l_prep) in_10\IN|patient (l_pobj) patient_13\NN|an|oncology|with (l_prep) with_14\IN|thrombocytopenia (l_pobj) thrombocytopenia_18\NN|induced|with
C031942_D013921 NONE argatroban_21\NN|plus (r_amod) thrombolysis_26\NN|argatroban|directed|(|cdt|) (r_pobj) with_20\IN|thrombolysis (r_prep) treated_19\VBN|was|with|with (r_conj) developed_7\VBD|who|thrombocytopenia|and|treated (l_dobj) thrombocytopenia_11\NN|induced|with
C031942_D013921 NONE argatroban_21\NN|plus (r_amod) thrombolysis_26\NN|argatroban|directed|(|cdt|) (r_pobj) with_20\IN|thrombolysis (r_prep) treated_19\VBN|was|with|with (r_conj) developed_7\VBD|who|thrombocytopenia|and|treated (l_dobj) thrombocytopenia_11\NN|induced|with (l_prep) with_12\IN|thrombosis (l_pobj) thrombosis_13\NN|hitt (l_appos) HITT_15\NNP|(|)
C031942_D013921 NONE argatroban_18\NN|and|cdt (r_amod) with_17\IN|argatroban (r_prep) treated_16\VBN|man|was|successfully|with|with|. (l_nsubjpass) man_4\NN|a|old|with|to (l_prep) to_12\IN|hitt (l_pobj) HITT_13\NNP|
C031942_D013927 NONE argatroban_2\NN|and|directed (r_amod) thrombolysis_7\NN|argatroban|with|in (l_prep) in_10\IN|patient (l_pobj) patient_13\NN|an|oncology|with (l_prep) with_14\IN|thrombocytopenia (l_pobj) thrombocytopenia_18\NN|induced|with (l_prep) with_19\IN|thrombosis (l_pobj) thrombosis_20\NN|
C031942_D013927 NONE argatroban_21\NN|plus (r_amod) thrombolysis_26\NN|argatroban|directed|(|cdt|) (r_pobj) with_20\IN|thrombolysis (r_prep) treated_19\VBN|was|with|with (r_conj) developed_7\VBD|who|thrombocytopenia|and|treated (l_dobj) thrombocytopenia_11\NN|induced|with (l_prep) with_12\IN|thrombosis (l_pobj) thrombosis_13\NN|hitt
C031942_D013927 NONE argatroban_21\NN|plus (r_amod) thrombolysis_26\NN|argatroban|directed|(|cdt|) (r_pobj) with_20\IN|thrombolysis (r_prep) treated_19\VBN|was|with|with (r_conj) developed_7\VBD|who|thrombocytopenia|and|treated (l_dobj) thrombocytopenia_11\NN|induced|with (l_prep) with_12\IN|thrombosis (l_pobj) thrombosis_13\NN|hitt (l_appos) HITT_15\NNP|(|)
C031942_D013927 NONE argatroban_18\NN|and|cdt (r_amod) with_17\IN|argatroban (r_prep) treated_16\VBN|man|was|successfully|with|with|. (l_nsubjpass) man_4\NN|a|old|with|to (l_prep) to_12\IN|hitt (l_pobj) HITT_13\NNP|
D006493_D055499 NONE heparin_15\NN| (r_npadvmod) induced_17\VBN|heparin|- (r_amod) thrombocytopenia_18\NN|induced|with (r_pobj) with_14\IN|thrombocytopenia (r_prep) patient_13\NN|an|oncology|with (r_pobj) in_10\IN|patient (r_prep) thrombolysis_7\NN|argatroban|with|in
D006493_D055499 NONE heparin_8\NN| (r_npadvmod) induced_10\VBN|heparin|- (r_amod) thrombocytopenia_11\NN|induced|with (r_dobj) developed_7\VBD|who|thrombocytopenia|and|treated (l_conj) treated_19\VBN|was|with|with (l_prep) with_20\IN|thrombolysis (l_pobj) thrombolysis_26\NN|argatroban|directed|(|cdt|)
D006493_D013921 CID heparin_15\NN| (r_npadvmod) induced_17\VBN|heparin|- (r_amod) thrombocytopenia_18\NN|induced|with
D006493_D013921 CID heparin_8\NN| (r_npadvmod) induced_10\VBN|heparin|- (r_amod) thrombocytopenia_11\NN|induced|with
D006493_D013921 CID heparin_38\NN| (r_npadvmod) induced_40\VBN|heparin|- (r_amod) thrombocytopenia_41\NN|induced
D006493_D013921 NONE heparin_8\NN| (r_npadvmod) induced_10\VBN|heparin|- (r_amod) thrombocytopenia_11\NN|induced|with (l_prep) with_12\IN|thrombosis (l_pobj) thrombosis_13\NN|hitt (l_appos) HITT_15\NNP|(|)
D006493_D013927 NONE heparin_15\NN| (r_npadvmod) induced_17\VBN|heparin|- (r_amod) thrombocytopenia_18\NN|induced|with (l_prep) with_19\IN|thrombosis (l_pobj) thrombosis_20\NN|
D006493_D013927 NONE heparin_8\NN| (r_npadvmod) induced_10\VBN|heparin|- (r_amod) thrombocytopenia_11\NN|induced|with (l_prep) with_12\IN|thrombosis (l_pobj) thrombosis_13\NN|hitt
D006493_D013927 NONE heparin_8\NN| (r_npadvmod) induced_10\VBN|heparin|- (r_amod) thrombocytopenia_11\NN|induced|with (l_prep) with_12\IN|thrombosis (l_pobj) thrombosis_13\NN|hitt (l_appos) HITT_15\NNP|(|)
D006493_D000686 NONE heparin_38\NN| (r_npadvmod) induced_40\VBN|heparin|- (r_amod) thrombocytopenia_41\NN|induced (r_pobj) to_37\IN|thrombocytopenia (r_prep) secondary_36\JJ|to (r_amod) embolism_35\NN|pulmonary|secondary (r_conj) thrombosis_29\NN|extensive|bilateral|extremity|venous|(|dvt|)|and|embolism (r_dobj) developed_21\VBD|man|thrombosis|. (l_nsubj) man_5\NN|a|old|caucasian|with (l_prep) with_6\IN|amyloidosis (l_pobj) amyloidosis_8\NN|renal|undergoing
D006493_D056824 NONE heparin_38\NN| (r_npadvmod) induced_40\VBN|heparin|- (r_amod) thrombocytopenia_41\NN|induced (r_pobj) to_37\IN|thrombocytopenia (r_prep) secondary_36\JJ|to (r_amod) embolism_35\NN|pulmonary|secondary (r_conj) thrombosis_29\NN|extensive|bilateral|extremity|venous|(|dvt|)|and|embolism
D006493_D020246 CID heparin_38\NN| (r_npadvmod) induced_40\VBN|heparin|- (r_amod) thrombocytopenia_41\NN|induced (r_pobj) to_37\IN|thrombocytopenia (r_prep) secondary_36\JJ|to (r_amod) embolism_35\NN|pulmonary|secondary (r_conj) thrombosis_29\NN|extensive|bilateral|extremity|venous|(|dvt|)|and|embolism (l_appos) DVT_31\NNP|
D006493_D011655 CID heparin_38\NN| (r_npadvmod) induced_40\VBN|heparin|- (r_amod) thrombocytopenia_41\NN|induced (r_pobj) to_37\IN|thrombocytopenia (r_prep) secondary_36\JJ|to (r_amod) embolism_35\NN|pulmonary|secondary
C031942_D004844 NONE argatroban_13\NN| (r_amod) on_12\IN|argatroban (r_prep) restarted_11\VBN|patient|was|on|. (r_conj) resolved_2\VBD|epistaxis|day|,|and|restarted (l_nsubj) epistaxis_1\NN|the
C031942_D000686 NONE argatroban_18\NN|and|cdt (r_amod) with_17\IN|argatroban (r_prep) treated_16\VBN|man|was|successfully|with|with|. (l_nsubjpass) man_4\NN|a|old|with|to (l_prep) with_5\IN|amyloidosis (l_pobj) amyloidosis_7\NN|renal|and|syndrome
C031942_D013479 NONE argatroban_18\NN|and|cdt (r_amod) with_17\IN|argatroban (r_prep) treated_16\VBN|man|was|successfully|with|with|. (l_nsubjpass) man_4\NN|a|old|with|to (l_prep) with_5\IN|amyloidosis (l_pobj) amyloidosis_7\NN|renal|and|syndrome (l_conj) syndrome_10\NN|svc|secondary
1361574
D002243_D012640 NONE carboline_8\NN|this|beta|- (r_pobj) of_4\IN|carboline (r_prep) mg/kg_3\NNS|0.05|of (r_nsubj) reduced_9\VBD|moreover|,|mg/kg|markedly|increase|and|convulsions|. (l_conj) convulsions_19\NNS|the|induced
C037476_D012640 NONE 35S]TBPS_15\NNP| (r_nummod) binding_16\NN|[|35s]tbps (r_pobj) of_13\IN|binding (r_prep) increase_12\NN|the|of (r_dobj) reduced_9\VBD|moreover|,|mg/kg|markedly|increase|and|convulsions|. (l_conj) convulsions_19\NNS|the|induced
D007538_D012640 CID isoniazid_22\NN|(|s.c.|) (r_pobj) by_21\IN|isoniazid (r_agent) induced_20\VBN|by (r_acl) convulsions_19\NNS|the|induced
3084231
D014635_D003704 CID acid_2\NN| (r_npadvmod) induced_4\VBN|acid|- (r_amod) dementia_5\NN|reversible|valproic|induced|:|report|.
D014635_D003704 CID acid_2\NN| (r_npadvmod) induced_4\VBN|acid|- (r_amod) dementia_5\NN|reversible|valproic|induced
D014635_D004827 NONE acid_2\NN| (r_npadvmod) induced_4\VBN|acid|- (r_amod) dementia_5\NN|reversible|valproic|induced (r_nsubjpass) documented_7\VBN|dementia|was|in|. (l_prep) in_8\IN|man (l_pobj) man_13\NN|a|old|with|had (l_prep) with_14\IN|epilepsy (l_pobj) epilepsy_15\NN|
D014635_D022124 CID acid_25\NN|valproic (r_pobj) of_23\IN|acid (r_prep) effect_22\NN|toxic|of (r_appos) system_17\NN|a|direct|central|nervous|(|cns|)|effect|;|effect (l_appos) effect_30\NN|a|paradoxical|epileptogenic|secondary|;|and|effect (l_conj) effect_41\NN|an|indirect|cns|toxic|mediated (l_acl) mediated_42\VBN|through (l_prep) through_43\IN|hyperammonemia (l_pobj) hyperammonemia_48\NN|valproic|induced
D014635_D022124 CID acid_45\NN| (r_npadvmod) induced_47\VBN|acid|- (r_amod) hyperammonemia_48\NN|valproic|induced
1395192
D001971_D009203 CID bromocriptine_8\NN| (r_dobj) receiving_7\VBG|bromocriptine (r_acl) patient_6\NN|a|postpartum|receiving (r_pobj) in_3\IN|patient (r_prep) infarction_2\NN|recurrent|myocardial|in|.
D001971_D009203 CID Bromocriptine_0\NNP| (r_nsubjpass) implicated_3\VBN|bromocriptine|has|been|in|. (l_prep) in_4\IN|reports (l_pobj) reports_8\NNS|several|previous|case|of (l_prep) of_9\IN|infarction (l_pobj) infarction_11\NN|myocardial|in
2217015
D008528_D009503 CID acid_1\NN|mefenamic (r_npadvmod) induced_3\VBN|acid|-|neutropenia|. (l_dobj) neutropenia_4\NN|and|failure|in|with
D008528_D009503 CID acid_3\NN| (r_npadvmod) induced_5\VBN|acid|- (r_amod) failure_10\NN|mefenamic|induced|oliguric|renal|and|occurring (l_conj) occurring_14\VBG|neutropenia|simultaneously|in (l_compound) neutropenia_13\NN|severe
D008528_D051437 CID acid_1\NN|mefenamic (r_npadvmod) induced_3\VBN|acid|-|neutropenia|. (l_dobj) neutropenia_4\NN|and|failure|in|with (l_conj) failure_7\NN|renal
D008528_D051437 CID acid_3\NN| (r_npadvmod) induced_5\VBN|acid|- (r_amod) failure_10\NN|mefenamic|induced|oliguric|renal|and|occurring
D008528_D007037 NONE acid_1\NN|mefenamic (r_npadvmod) induced_3\VBN|acid|-|neutropenia|. (l_dobj) neutropenia_4\NN|and|failure|in|with (l_prep) with_11\IN|hypothyroidism (l_pobj) hypothyroidism_12\NN|
D008528_D007037 NONE acid_10\NN|mefenamic (r_dobj) use_8\VB|not|to|acid|in|corrected (l_prep) in_11\IN|patients (l_pobj) patients_13\NNS|hypothyroid (l_amod) hypothyroid_12\JJ|
D008528_D007037 NONE acid_10\NN|mefenamic (r_dobj) use_8\VB|not|to|acid|in|corrected (l_advcl) corrected_19\VBN|until|hypothyroidism|has|been (l_nsubjpass) hypothyroidism_16\NN|the
10986547
C076029_D001714 NONE olanzapine_2\NN| (r_pobj) of_1\IN|olanzapine (r_prep) Efficacy_0\NN|of|in|:|study|. (l_prep) in_3\IN|mania (l_pobj) mania_6\NN|acute|bipolar
C076029_D001714 NONE olanzapine_7\NN|vs (r_pobj) of_6\IN|olanzapine (r_prep) efficacy_3\NN|the|and|safety|of|for (l_prep) for_10\IN|treatment (l_pobj) treatment_12\NN|the|of (l_prep) of_13\IN|mania (l_pobj) mania_16\NN|acute|bipolar
C076029_D001714 NONE olanzapine_22\NN|to|,|20 (r_xcomp) randomized_20\VBN|total|,|were|olanzapine|. (l_nsubjpass) total_1\NN|a|of (l_prep) of_2\IN|patients (l_pobj) patients_4\NNS|115|with (l_prep) with_5\IN|diagnosis (l_pobj) diagnosis_10\NN|a|iv|of (l_prep) of_11\IN|disorder (l_pobj) disorder_13\NN|bipolar|,|manic
C076029_D001714 NONE olanzapine_22\NN|to|,|20 (r_xcomp) randomized_20\VBN|total|,|were|olanzapine|. (l_nsubjpass) total_1\NN|a|of (l_prep) of_2\IN|patients (l_pobj) patients_4\NNS|115|with (l_prep) with_5\IN|diagnosis (l_pobj) diagnosis_10\NN|a|iv|of (l_prep) of_11\IN|disorder (l_pobj) disorder_13\NN|bipolar|,|manic (l_amod) manic_15\JJ|or|mixed
C076029_D001714 NONE Olanzapine_0\NNP| (r_nsubj) demonstrated_1\VBD|olanzapine|efficacy|and|tolerated|. (l_dobj) efficacy_3\NN|greater|than (l_prep) than_4\IN|placebo (l_pobj) placebo_5\NN|in (l_prep) in_6\IN|treatment (l_pobj) treatment_8\NN|the|of (l_prep) of_9\IN|mania (l_pobj) mania_12\NN|acute|bipolar
C076029_D015430 CID olanzapine_2\RB| (r_npadvmod) treated_4\VBN|olanzapine|- (r_amod) patients_5\NNS|treated (r_nsubj) had_6\VBD|however|,|patients|mean|. (l_dobj) mean_11\JJ|a|significant|greater|(|gain (l_appos) gain_17\NN|+/-|sd|)|weight|than|and|experienced
C076029_D006970 CID olanzapine_2\RB| (r_npadvmod) treated_4\VBN|olanzapine|- (r_amod) patients_5\NNS|treated (r_nsubj) had_6\VBD|however|,|patients|mean|. (l_dobj) mean_11\JJ|a|significant|greater|(|gain (l_appos) gain_17\NN|+/-|sd|)|weight|than|and|experienced (l_conj) experienced_37\VBD|also|somnolence (l_dobj) somnolence_42\NN|more|emergent|(|patients|)
7644931
D017239_D002289 NONE Paclitaxel_0\NNP|taxol|company (r_nsubjpass) combined_18\VBN|paclitaxel|was|with|in|. (l_prep) in_21\IN|phase (l_pobj) phase_23\NN|a|directed (l_acl) directed_28\VBN|study|to (l_prep) to_29\IN|patients (l_pobj) patients_30\NNS|with (l_prep) with_31\IN|cancer (l_pobj) cancer_37\NN|small|lung
D017239_D002289 NONE Taxol_2\NNP|( (r_appos) Paclitaxel_0\NNP|taxol|company (r_nsubjpass) combined_18\VBN|paclitaxel|was|with|in|. (l_prep) in_21\IN|phase (l_pobj) phase_23\NN|a|directed (l_acl) directed_28\VBN|study|to (l_prep) to_29\IN|patients (l_pobj) patients_30\NNS|with (l_prep) with_31\IN|cancer (l_pobj) cancer_37\NN|small|lung
D016190_D002289 NONE carboplatin_20\NN| (r_pobj) with_19\IN|carboplatin (r_prep) combined_18\VBN|paclitaxel|was|with|in|. (l_prep) in_21\IN|phase (l_pobj) phase_23\NN|a|directed (l_acl) directed_28\VBN|study|to (l_prep) to_29\IN|patients (l_pobj) patients_30\NNS|with (l_prep) with_31\IN|cancer (l_pobj) cancer_37\NN|small|lung
D017239_D064420 NONE paclitaxel_14\NN| (r_pobj) of_13\IN|paclitaxel (r_prep) trial_12\NN|i|of|alone (r_dobj) compared_2\VBN|toxicities|were|with|trial|. (l_nsubjpass) Toxicities_0\NNS|
D016190_D006402 NONE Carboplatin_0\NNP| (r_nsubj) appear_3\VB|carboplatin|did|not|add|,|and|dosed (l_xcomp) add_5\VB|to|to (l_prep) to_6\IN|toxicities (l_pobj) toxicities_9\NNS|the|hematologic|observed
D016190_D006402 NONE carboplatin_16\NN|paclitaxel|/ (r_compound) combination_17\NN|the|carboplatin (r_nsubjpass) dosed_20\VBN|combination|could|be|weeks|. (r_conj) appear_3\VB|carboplatin|did|not|add|,|and|dosed (l_xcomp) add_5\VB|to|to (l_prep) to_6\IN|toxicities (l_pobj) toxicities_9\NNS|the|hematologic|observed
D017239_D006402 CID paclitaxel_14\NN| (r_nmod) carboplatin_16\NN|paclitaxel|/ (r_compound) combination_17\NN|the|carboplatin (r_nsubjpass) dosed_20\VBN|combination|could|be|weeks|. (r_conj) appear_3\VB|carboplatin|did|not|add|,|and|dosed (l_xcomp) add_5\VB|to|to (l_prep) to_6\IN|toxicities (l_pobj) toxicities_9\NNS|the|hematologic|observed
4082466
D009020_D012640 CID Morphine_0\NNP| (r_npadvmod) induced_2\VBN|morphine|- (r_amod) seizures_3\NNS|induced|in|.
D009020_D012640 CID sulfate_12\NN|intravenous|morphine|for (r_pobj) of_9\IN|sulfate (r_prep) course_8\NN|the|of (r_pobj) during_6\IN|course (r_prep) suffered_2\VBD|neonates|from|during|. (l_prep) from_3\IN|seizures (l_pobj) seizures_5\NNS|generalized
D009020_D012640 CID morphine_18\NN| (r_pobj) of_17\IN|morphine (r_prep) cessation_16\NN|of (r_pobj) after_15\IN|hours|cessation (r_prep) stopped_11\VBD|convulsions|after|and|reoccur|. (r_conj) ruled_6\VBN|reasons|were|out|and|stopped (l_nsubjpass) reasons_2\NNS|other|known|for (l_prep) for_3\IN|seizures (l_pobj) seizures_4\NNS|
D009020_D012640 CID morphine_18\NN| (r_pobj) of_17\IN|morphine (r_prep) cessation_16\NN|of (r_pobj) after_15\IN|hours|cessation (r_prep) stopped_11\VBD|convulsions|after|and|reoccur|. (l_nsubj) convulsions_10\NNS|the
1905439
D016595_D003693 CID misoprostol_10\NNP| (r_pobj) of_9\IN|misoprostol (r_prep) administration_8\NN|of (r_pobj) with_7\IN|administration (r_prep) associated_6\VBN|possibly|with (r_acl) woman_4\NN|an|elderly|associated (r_pobj) in_1\IN|woman (r_prep) Delirium_0\NN|in|.
D016595_D003693 CID misoprostol_5\NNP| (r_nsubjpass) discontinued_7\VBN|after|misoprostol|was|and|returned (r_advcl) improved_3\VBD|delirium|significantly|discontinued|. (l_nsubj) delirium_1\NN|her
D016595_D003693 CID misoprostol_20\NNP| (r_compound) therapy_21\NN|misoprostol (r_pobj) from_19\IN|therapy (r_prep) resulted_18\VBD|changed|,|delirium|possibly|from|. (l_nsubj) delirium_12\NN|the|experienced
D016595_D006261 NONE Misoprostol_0\NNP| (r_nsubjpass) associated_3\VBN|misoprostol|has|been|with|. (l_prep) with_4\IN|reactions (l_pobj) reactions_6\NNS|adverse|,|including (l_prep) including_8\VBG|symptoms (l_pobj) symptoms_10\NNS|gastrointestinal|,|problems (l_conj) problems_13\NNS|gynecologic|,|and|headache (l_conj) headache_16\NN|
20566328
D003042_D028361 NONE cocaine_4\NN| (r_npadvmod) induced_6\VBN|cocaine|- (r_amod) dysfunction_8\NN|induced|cardiac (r_pobj) to_3\IN|dysfunction (r_prep) contributes_2\VBZ|impairment|to|: (l_nsubj) impairment_1\NN|mitochondrial|prevention
D003042_D028361 NONE cocaine_15\NN| (r_pobj) to_14\IN|cocaine (r_prep) exposure_13\NN|term|to (r_pobj) after_9\IN|exposure (r_prep) was_6\VBD|effect|not|detectable|after|,|suggesting|. (l_advcl) suggesting_17\VBG|were (l_ccomp) were_22\VBD|that|abnormalities|event (l_nsubj) abnormalities_21\NNS|these|mitochondrial
D003042_D028361 NONE cocaine_35\NN| (r_pobj) to_34\IN|cocaine (r_prep) response_33\NN|the|pathological|to (r_pobj) in_30\IN|response (r_prep) event_29\NN|a|late|a|primary|in (r_attr) were_22\VBD|that|abnormalities|event (l_nsubj) abnormalities_21\NNS|these|mitochondrial
D003042_D028361 NONE cocaine_11\NN| (r_npadvmod) induced_13\VBN|cocaine|- (r_amod) dysfunction_15\NN|induced|cardiac (r_nsubj) be_17\VB|that|dysfunction|may|due (l_acomp) due_18\JJ|to (l_prep) to_19\IN|defect (l_pobj) defect_22\NN|a|mitochondrial
D003042_D006331 CID cocaine_4\NN| (r_npadvmod) induced_6\VBN|cocaine|- (r_amod) dysfunction_8\NN|induced|cardiac
D003042_D006331 CID cocaine_18\NN| (r_npadvmod) induced_20\VBN|cocaine|- (r_amod) dysfunction_22\NN|induced|cardiac
D003042_D006331 CID cocaine_11\NN| (r_npadvmod) induced_13\VBN|cocaine|- (r_amod) dysfunction_15\NN|induced|cardiac
C476756_D028361 NONE MitoQ._15\NNP|the|targeted|antioxidant (r_pobj) by_11\IN|mitoq. (r_prep) Prevention_10\NN|by (r_appos) impairment_1\NN|mitochondrial|prevention
C476756_D028361 NONE MitoQ_0\NNP|,|antioxidant|, (r_nsubjpass) shown_9\VBN|mitoq|was|prevent|. (l_xcomp) prevent_12\VB|to|completely|abnormalities (l_dobj) abnormalities_15\NNS|these|mitochondrial|as|dysfunction
C476756_D006331 NONE MitoQ._15\NNP|the|targeted|antioxidant (r_pobj) by_11\IN|mitoq. (r_prep) Prevention_10\NN|by (r_appos) impairment_1\NN|mitochondrial|prevention (r_nsubj) contributes_2\VBZ|impairment|to|: (l_prep) to_3\IN|dysfunction (l_pobj) dysfunction_8\NN|induced|cardiac
C476756_D006331 NONE MitoQ_0\NNP|,|antioxidant|, (r_nsubjpass) shown_9\VBN|mitoq|was|prevent|. (l_xcomp) prevent_12\VB|to|completely|abnormalities (l_dobj) abnormalities_15\NNS|these|mitochondrial|as|dysfunction (l_conj) dysfunction_20\NN|cardiac|characterized
C476756_-1 NONE MitoQ_0\NNP|,|antioxidant|, (r_nsubjpass) shown_9\VBN|mitoq|was|prevent|. (l_xcomp) prevent_12\VB|to|completely|abnormalities (l_dobj) abnormalities_15\NNS|these|mitochondrial|as|dysfunction (l_conj) dysfunction_20\NN|cardiac|characterized (l_acl) characterized_21\VBN|here|by (l_agent) by_23\IN|dysfunction (l_pobj) dysfunction_26\NN|a|diastolic|studied
8667442
D002117_D006934 CID 1,25(OH)2D_6\CD| (r_pobj) by_5\IN|1,25(oh)2d (r_agent) induced_4\VBN|by|in (r_acl) syndrome_3\NN|alkali|induced|.
D002117_D006934 CID calcitriol_14\NN| (r_conj) carbonate_12\NN|calcium|and|calcitriol (r_pobj) with_10\IN|carbonate (r_prep) treated_9\VBN|who|was|with|resulting (l_advcl) resulting_15\VBG|in (l_prep) in_16\IN|admissions (l_pobj) admissions_18\NNS|two|to|for (l_prep) for_22\IN|syndrome (l_pobj) syndrome_26\NN|alkali
D002117_D007011 NONE 1,25(OH)2D_6\CD| (r_pobj) by_5\IN|1,25(oh)2d (r_agent) induced_4\VBN|by|in (l_prep) in_7\IN|patient (l_pobj) patient_9\NN|a|with (l_prep) with_10\IN|hypoparathyroidism (l_pobj) hypoparathyroidism_11\NN|
D002117_D007011 NONE calcitriol_14\NN| (r_conj) carbonate_12\NN|calcium|and|calcitriol (r_pobj) with_10\IN|carbonate (r_prep) treated_9\VBN|who|was|with|resulting (r_relcl) hypoparathyroidism_6\NN|treated
D002118_D006934 CID calcium_24\NN|and|alkali (r_pobj) of_23\IN|calcium (r_prep) amounts_22\NNS|large|of (r_pobj) with_20\IN|amounts (r_prep) treatment_15\NN|the|of|with (r_pobj) of_13\IN|treatment (r_prep) context_12\NN|the|of (r_pobj) in_10\IN|context (r_prep) described_6\VBN|syndrome|was|first|ago|in|. (l_nsubjpass) syndrome_3\NN|alkali
D002118_D010437 NONE calcium_24\NN|and|alkali (r_pobj) of_23\IN|calcium (r_prep) amounts_22\NNS|large|of (r_pobj) with_20\IN|amounts (r_prep) treatment_15\NN|the|of|with (l_prep) of_16\IN|disease (l_pobj) disease_19\NN|peptic|ulcer
D000468_D006934 CID alkali_26\NN| (r_conj) calcium_24\NN|and|alkali (r_pobj) of_23\IN|calcium (r_prep) amounts_22\NNS|large|of (r_pobj) with_20\IN|amounts (r_prep) treatment_15\NN|the|of|with (r_pobj) of_13\IN|treatment (r_prep) context_12\NN|the|of (r_pobj) in_10\IN|context (r_prep) described_6\VBN|syndrome|was|first|ago|in|. (l_nsubjpass) syndrome_3\NN|alkali
D000468_D010437 NONE alkali_26\NN| (r_conj) calcium_24\NN|and|alkali (r_pobj) of_23\IN|calcium (r_prep) amounts_22\NNS|large|of (r_pobj) with_20\IN|amounts (r_prep) treatment_15\NN|the|of|with (l_prep) of_16\IN|disease (l_pobj) disease_19\NN|peptic|ulcer
D009853_D014456 NONE omeprazole_9\NN|,|and|sucralfate (r_conj) blockers_7\NNS|,|omeprazole|) (r_conj) therapy_4\NN|current|ulcer|(|h-2|blockers (l_compound) ulcer_3\NN|
D009853_D006934 NONE omeprazole_9\NN|,|and|sucralfate (r_conj) blockers_7\NNS|,|omeprazole|) (r_conj) therapy_4\NN|current|ulcer|(|h-2|blockers (r_pobj) with_1\IN|although|therapy (r_advcl) decreased_23\VBN|with|,|frequency|has|significantly|, (l_nsubj) frequency_16\NN|the|of (l_prep) of_17\IN|syndrome (l_pobj) syndrome_21\NN|alkali
D009853_D006934 NONE omeprazole_9\NN|,|and|sucralfate (r_conj) blockers_7\NNS|,|omeprazole|) (r_conj) therapy_4\NN|current|ulcer|(|h-2|blockers (r_pobj) with_1\IN|although|therapy (r_advcl) decreased_23\VBN|with|,|frequency|has|significantly|, (r_ccomp) remains_37\VBZ|decreased|triad|hallmark|. (l_nsubj) triad_28\NN|the|classic|of (l_prep) of_29\IN|hypercalcemia (l_pobj) hypercalcemia_30\NN|,|alkalosis
D009853_D000471 NONE omeprazole_9\NN|,|and|sucralfate (r_conj) blockers_7\NNS|,|omeprazole|) (r_conj) therapy_4\NN|current|ulcer|(|h-2|blockers (r_pobj) with_1\IN|although|therapy (r_advcl) decreased_23\VBN|with|,|frequency|has|significantly|, (r_ccomp) remains_37\VBZ|decreased|triad|hallmark|. (l_nsubj) triad_28\NN|the|classic|of (l_prep) of_29\IN|hypercalcemia (l_pobj) hypercalcemia_30\NN|,|alkalosis (l_conj) alkalosis_32\NN|,|and|impairment
D009853_D051437 NONE omeprazole_9\NN|,|and|sucralfate (r_conj) blockers_7\NNS|,|omeprazole|) (r_conj) therapy_4\NN|current|ulcer|(|h-2|blockers (r_pobj) with_1\IN|although|therapy (r_advcl) decreased_23\VBN|with|,|frequency|has|significantly|, (r_ccomp) remains_37\VBZ|decreased|triad|hallmark|. (l_nsubj) triad_28\NN|the|classic|of (l_prep) of_29\IN|hypercalcemia (l_pobj) hypercalcemia_30\NN|,|alkalosis (l_conj) alkalosis_32\NN|,|and|impairment (l_conj) impairment_36\NN|renal
D013392_D014456 NONE sucralfate_12\JJ| (r_conj) omeprazole_9\NN|,|and|sucralfate (r_conj) blockers_7\NNS|,|omeprazole|) (r_conj) therapy_4\NN|current|ulcer|(|h-2|blockers (l_compound) ulcer_3\NN|
D013392_D006934 NONE sucralfate_12\JJ| (r_conj) omeprazole_9\NN|,|and|sucralfate (r_conj) blockers_7\NNS|,|omeprazole|) (r_conj) therapy_4\NN|current|ulcer|(|h-2|blockers (r_pobj) with_1\IN|although|therapy (r_advcl) decreased_23\VBN|with|,|frequency|has|significantly|, (l_nsubj) frequency_16\NN|the|of (l_prep) of_17\IN|syndrome (l_pobj) syndrome_21\NN|alkali
D013392_D006934 NONE sucralfate_12\JJ| (r_conj) omeprazole_9\NN|,|and|sucralfate (r_conj) blockers_7\NNS|,|omeprazole|) (r_conj) therapy_4\NN|current|ulcer|(|h-2|blockers (r_pobj) with_1\IN|although|therapy (r_advcl) decreased_23\VBN|with|,|frequency|has|significantly|, (r_ccomp) remains_37\VBZ|decreased|triad|hallmark|. (l_nsubj) triad_28\NN|the|classic|of (l_prep) of_29\IN|hypercalcemia (l_pobj) hypercalcemia_30\NN|,|alkalosis
D013392_D000471 NONE sucralfate_12\JJ| (r_conj) omeprazole_9\NN|,|and|sucralfate (r_conj) blockers_7\NNS|,|omeprazole|) (r_conj) therapy_4\NN|current|ulcer|(|h-2|blockers (r_pobj) with_1\IN|although|therapy (r_advcl) decreased_23\VBN|with|,|frequency|has|significantly|, (r_ccomp) remains_37\VBZ|decreased|triad|hallmark|. (l_nsubj) triad_28\NN|the|classic|of (l_prep) of_29\IN|hypercalcemia (l_pobj) hypercalcemia_30\NN|,|alkalosis (l_conj) alkalosis_32\NN|,|and|impairment
D013392_D051437 NONE sucralfate_12\JJ| (r_conj) omeprazole_9\NN|,|and|sucralfate (r_conj) blockers_7\NNS|,|omeprazole|) (r_conj) therapy_4\NN|current|ulcer|(|h-2|blockers (r_pobj) with_1\IN|although|therapy (r_advcl) decreased_23\VBN|with|,|frequency|has|significantly|, (r_ccomp) remains_37\VBZ|decreased|triad|hallmark|. (l_nsubj) triad_28\NN|the|classic|of (l_prep) of_29\IN|hypercalcemia (l_pobj) hypercalcemia_30\NN|,|alkalosis (l_conj) alkalosis_32\NN|,|and|impairment (l_conj) impairment_36\NN|renal
D002119_D007011 NONE carbonate_12\NN|calcium|and|calcitriol (r_pobj) with_10\IN|carbonate (r_prep) treated_9\VBN|who|was|with|resulting (r_relcl) hypoparathyroidism_6\NN|treated
D002119_D006934 CID carbonate_12\NN|calcium|and|calcitriol (r_pobj) with_10\IN|carbonate (r_prep) treated_9\VBN|who|was|with|resulting (l_advcl) resulting_15\VBG|in (l_prep) in_16\IN|admissions (l_pobj) admissions_18\NNS|two|to|for (l_prep) for_22\IN|syndrome (l_pobj) syndrome_26\NN|alkali
C019248_D006934 NONE pamidronate_3\NN|intravenous|as|presents (l_advcl) presents_14\VBZ|when|syndrome|as (l_nsubj) syndrome_13\NN|alkali
C019248_D006934 NONE pamidronate_3\NN|intravenous|as|presents (l_advcl) presents_14\VBZ|when|syndrome|as (l_prep) as_15\IN|emergency (l_pobj) emergency_17\NN|hypercalcemic
10985896
D004317_D010051 NONE doxorubicin_5\NN|liposomal|)|) (r_pobj) of_3\IN|doxorubicin (r_prep) trial_2\NN|phase|of|in|. (l_prep) in_13\IN|cancers (l_pobj) cancers_23\NNS|refractory|ovarian|and|carcinoma
D004317_D010051 NONE doxorubicin_5\NN|liposomal|doxil (r_dobj) demonstrated_3\VBN|studies|have|doxorubicin|be|being|. (l_advcl) be_10\VB|to|agent|,|with|q (l_attr) agent_14\NN|an|active|antineoplastic|in (l_prep) in_15\IN|cancer (l_pobj) cancer_20\NN|resistant|ovarian
D004317_D010051 NONE Doxil_7\NNS|(|) (r_appos) doxorubicin_5\NN|liposomal|doxil (r_dobj) demonstrated_3\VBN|studies|have|doxorubicin|be|being|. (l_advcl) be_10\VB|to|agent|,|with|q (l_attr) agent_14\NN|an|active|antineoplastic|in (l_prep) in_15\IN|cancer (l_pobj) cancer_20\NN|resistant|ovarian
D004317_D010051 NONE doxorubicin_41\NN|liposomal (r_pobj) with_39\IN|doxorubicin (r_prep) treated_38\VBN|patients|were|with|at|weeks|. (l_nsubjpass) Patients_0\NNS|with (l_prep) with_1\IN|cancers (l_pobj) cancers_6\NNS|ovarian|tube|or|carcinoma
D004317_D005185 NONE doxorubicin_5\NN|liposomal|)|) (r_pobj) of_3\IN|doxorubicin (r_prep) trial_2\NN|phase|of|in|. (l_prep) in_13\IN|cancers (l_pobj) cancers_23\NNS|refractory|ovarian|and|carcinoma
D004317_D005185 NONE doxorubicin_41\NN|liposomal (r_pobj) with_39\IN|doxorubicin (r_prep) treated_38\VBN|patients|were|with|at|weeks|. (l_nsubjpass) Patients_0\NNS|with (l_prep) with_1\IN|cancers (l_pobj) cancers_6\NNS|ovarian|tube|or|carcinoma
D004317_D010534 NONE doxorubicin_5\NN|liposomal|)|) (r_pobj) of_3\IN|doxorubicin (r_prep) trial_2\NN|phase|of|in|. (l_prep) in_13\IN|cancers (l_pobj) cancers_23\NNS|refractory|ovarian|and|carcinoma (l_conj) carcinoma_26\NN|primary|of (l_prep) of_27\IN|peritoneum (l_pobj) peritoneum_29\NN|the
D004317_D010534 NONE doxorubicin_41\NN|liposomal (r_pobj) with_39\IN|doxorubicin (r_prep) treated_38\VBN|patients|were|with|at|weeks|. (l_nsubjpass) Patients_0\NNS|with (l_prep) with_1\IN|cancers (l_pobj) cancers_6\NNS|ovarian|tube|or|carcinoma (l_conj) carcinoma_10\NN|primary|peritoneal|with
D010984_D010051 NONE platinum_14\NN| (r_nmod) refractory_18\JJ|platinum|/|paclitaxel|- (r_amod) cancers_23\NNS|refractory|ovarian|and|carcinoma
D010984_D010051 NONE platinum_16\NN| (r_npadvmod) resistant_18\JJ|platinum|- (r_amod) cancer_20\NN|resistant|ovarian
D010984_D010051 NONE platinum_12\NN| (r_nmod) disease_17\NN|platinum|/|refractory|(|disease|months|) (r_pobj) with_11\IN|disease (r_prep) carcinoma_10\NN|primary|peritoneal|with (r_conj) cancers_6\NNS|ovarian|tube|or|carcinoma
D010984_D010051 NONE platinum-_15\NN|and|paclitaxel|refractory (r_nmod) cancer_21\NN|defined|platinum-|ovarian
D010984_D005185 NONE platinum_14\NN| (r_nmod) refractory_18\JJ|platinum|/|paclitaxel|- (r_amod) cancers_23\NNS|refractory|ovarian|and|carcinoma
D010984_D005185 NONE platinum_12\NN| (r_nmod) disease_17\NN|platinum|/|refractory|(|disease|months|) (r_pobj) with_11\IN|disease (r_prep) carcinoma_10\NN|primary|peritoneal|with (r_conj) cancers_6\NNS|ovarian|tube|or|carcinoma
D010984_D010534 NONE platinum_14\NN| (r_nmod) refractory_18\JJ|platinum|/|paclitaxel|- (r_amod) cancers_23\NNS|refractory|ovarian|and|carcinoma (l_conj) carcinoma_26\NN|primary|of (l_prep) of_27\IN|peritoneum (l_pobj) peritoneum_29\NN|the
D010984_D010534 NONE platinum_12\NN| (r_nmod) disease_17\NN|platinum|/|refractory|(|disease|months|) (r_pobj) with_11\IN|disease (r_prep) carcinoma_10\NN|primary|peritoneal|with
D017239_D010051 NONE paclitaxel_16\NN| (r_compound) refractory_18\JJ|platinum|/|paclitaxel|- (r_amod) cancers_23\NNS|refractory|ovarian|and|carcinoma
D017239_D010051 NONE paclitaxel_14\NN| (r_compound) refractory_16\JJ|paclitaxel|- (r_amod) disease_17\NN|platinum|/|refractory|(|disease|months|) (r_pobj) with_11\IN|disease (r_prep) carcinoma_10\NN|primary|peritoneal|with (r_conj) cancers_6\NNS|ovarian|tube|or|carcinoma
D017239_D010051 NONE paclitaxel_17\NN| (r_conj) platinum-_15\NN|and|paclitaxel|refractory (r_nmod) cancer_21\NN|defined|platinum-|ovarian
D017239_D005185 NONE paclitaxel_16\NN| (r_compound) refractory_18\JJ|platinum|/|paclitaxel|- (r_amod) cancers_23\NNS|refractory|ovarian|and|carcinoma
D017239_D005185 NONE paclitaxel_14\NN| (r_compound) refractory_16\JJ|paclitaxel|- (r_amod) disease_17\NN|platinum|/|refractory|(|disease|months|) (r_pobj) with_11\IN|disease (r_prep) carcinoma_10\NN|primary|peritoneal|with (r_conj) cancers_6\NNS|ovarian|tube|or|carcinoma
D017239_D010534 NONE paclitaxel_16\NN| (r_compound) refractory_18\JJ|platinum|/|paclitaxel|- (r_amod) cancers_23\NNS|refractory|ovarian|and|carcinoma (l_conj) carcinoma_26\NN|primary|of (l_prep) of_27\IN|peritoneum (l_pobj) peritoneum_29\NN|the
D017239_D010534 NONE paclitaxel_14\NN| (r_compound) refractory_16\JJ|paclitaxel|- (r_amod) disease_17\NN|platinum|/|refractory|(|disease|months|) (r_pobj) with_11\IN|disease (r_prep) carcinoma_10\NN|primary|peritoneal|with
D004317_D064420 NONE doxorubicin_5\NN|liposomal|doxil (r_dobj) demonstrated_3\VBN|studies|have|doxorubicin|be|being|. (l_advcl) be_10\VB|to|agent|,|with|q (l_prep) with_22\IN|toxicity (l_pobj) toxicity_25\NN|dose|limiting|of
D004317_D064420 NONE Doxil_7\NNS|(|) (r_appos) doxorubicin_5\NN|liposomal|doxil (r_dobj) demonstrated_3\VBN|studies|have|doxorubicin|be|being|. (l_advcl) be_10\VB|to|agent|,|with|q (l_prep) with_22\IN|toxicity (l_pobj) toxicity_25\NN|dose|limiting|of
D004317_D064420 NONE doxorubicin_3\NN| (r_compound) regimen_4\NN|doxorubicin (r_compound) results_5\VBZ|this|modified|liposomal|regimen|in|than|. (l_prep) in_6\IN|toxicity (l_pobj) toxicity_8\NN|less|(|stomatitis|)
D004317_D060831 CID doxorubicin_5\NN|liposomal|doxil (r_dobj) demonstrated_3\VBN|studies|have|doxorubicin|be|being|. (l_advcl) being_41\VBG|erythrodysesthesia (l_attr) erythrodysesthesia_43\NN|severe|syndrome
D004317_D060831 CID doxorubicin_5\NN|liposomal|doxil (r_dobj) demonstrated_3\VBN|studies|have|doxorubicin|be|being|. (l_advcl) being_41\VBG|erythrodysesthesia (l_attr) erythrodysesthesia_43\NN|severe|syndrome (l_appos) syndrome_49\NN|(|"|foot|"|)|and|stomatitis
D004317_D060831 CID Doxil_7\NNS|(|) (r_appos) doxorubicin_5\NN|liposomal|doxil (r_dobj) demonstrated_3\VBN|studies|have|doxorubicin|be|being|. (l_advcl) being_41\VBG|erythrodysesthesia (l_attr) erythrodysesthesia_43\NN|severe|syndrome
D004317_D060831 CID Doxil_7\NNS|(|) (r_appos) doxorubicin_5\NN|liposomal|doxil (r_dobj) demonstrated_3\VBN|studies|have|doxorubicin|be|being|. (l_advcl) being_41\VBG|erythrodysesthesia (l_attr) erythrodysesthesia_43\NN|severe|syndrome (l_appos) syndrome_49\NN|(|"|foot|"|)|and|stomatitis
D004317_D060831 CID doxorubicin_3\NN| (r_compound) regimen_4\NN|doxorubicin (r_compound) results_5\VBZ|this|modified|liposomal|regimen|in|than|. (l_prep) in_6\IN|toxicity (l_pobj) toxicity_8\NN|less|(|stomatitis|) (l_appos) stomatitis_10\NN|,|syndrome (l_appos) syndrome_15\NN|foot
D004317_D013280 CID doxorubicin_5\NN|liposomal|doxil (r_dobj) demonstrated_3\VBN|studies|have|doxorubicin|be|being|. (l_advcl) being_41\VBG|erythrodysesthesia (l_attr) erythrodysesthesia_43\NN|severe|syndrome (l_appos) syndrome_49\NN|(|"|foot|"|)|and|stomatitis (l_conj) stomatitis_53\NN|
D004317_D013280 CID Doxil_7\NNS|(|) (r_appos) doxorubicin_5\NN|liposomal|doxil (r_dobj) demonstrated_3\VBN|studies|have|doxorubicin|be|being|. (l_advcl) being_41\VBG|erythrodysesthesia (l_attr) erythrodysesthesia_43\NN|severe|syndrome (l_appos) syndrome_49\NN|(|"|foot|"|)|and|stomatitis (l_conj) stomatitis_53\NN|
D004317_D013280 CID doxorubicin_3\NN| (r_compound) regimen_4\NN|doxorubicin (r_compound) results_5\VBZ|this|modified|liposomal|regimen|in|than|. (l_prep) in_6\IN|toxicity (l_pobj) toxicity_8\NN|less|(|stomatitis|) (l_appos) stomatitis_10\NN|,|syndrome
D010984_D064420 NONE platinum_16\NN| (r_npadvmod) resistant_18\JJ|platinum|- (r_amod) cancer_20\NN|resistant|ovarian (r_pobj) in_15\IN|cancer (r_prep) agent_14\NN|an|active|antineoplastic|in (r_attr) be_10\VB|to|agent|,|with|q (l_prep) with_22\IN|toxicity (l_pobj) toxicity_25\NN|dose|limiting|of
D010984_D060831 NONE platinum_16\NN| (r_npadvmod) resistant_18\JJ|platinum|- (r_amod) cancer_20\NN|resistant|ovarian (r_pobj) in_15\IN|cancer (r_prep) agent_14\NN|an|active|antineoplastic|in (r_attr) be_10\VB|to|agent|,|with|q (r_advcl) demonstrated_3\VBN|studies|have|doxorubicin|be|being|. (l_advcl) being_41\VBG|erythrodysesthesia (l_attr) erythrodysesthesia_43\NN|severe|syndrome
D010984_D060831 NONE platinum_16\NN| (r_npadvmod) resistant_18\JJ|platinum|- (r_amod) cancer_20\NN|resistant|ovarian (r_pobj) in_15\IN|cancer (r_prep) agent_14\NN|an|active|antineoplastic|in (r_attr) be_10\VB|to|agent|,|with|q (r_advcl) demonstrated_3\VBN|studies|have|doxorubicin|be|being|. (l_advcl) being_41\VBG|erythrodysesthesia (l_attr) erythrodysesthesia_43\NN|severe|syndrome (l_appos) syndrome_49\NN|(|"|foot|"|)|and|stomatitis
D010984_D013280 NONE platinum_16\NN| (r_npadvmod) resistant_18\JJ|platinum|- (r_amod) cancer_20\NN|resistant|ovarian (r_pobj) in_15\IN|cancer (r_prep) agent_14\NN|an|active|antineoplastic|in (r_attr) be_10\VB|to|agent|,|with|q (r_advcl) demonstrated_3\VBN|studies|have|doxorubicin|be|being|. (l_advcl) being_41\VBG|erythrodysesthesia (l_attr) erythrodysesthesia_43\NN|severe|syndrome (l_appos) syndrome_49\NN|(|"|foot|"|)|and|stomatitis (l_conj) stomatitis_53\NN|
18189308
D003520_D003556 CID cyclophosphamide_12\NN| (r_npadvmod) induced_14\VBN|cyclophosphamide|- (r_amod) cystitis_15\NN|induced
D003520_D003556 CID cyclophosphamide_27\NN|cyp (r_pobj) by_26\IN|cyclophosphamide (r_agent) induced_25\VBN|by (r_acl) durations_21\NNS|various|of|induced (l_prep) of_22\IN|inflammation (l_pobj) inflammation_24\NN|bladder
D003520_D003556 CID CYP_29\NNP|(|) (r_appos) cyclophosphamide_27\NN|cyp (r_pobj) by_26\IN|cyclophosphamide (r_agent) induced_25\VBN|by (r_acl) durations_21\NNS|various|of|induced (l_prep) of_22\IN|inflammation (l_pobj) inflammation_24\NN|bladder
D003520_D003556 CID CYP_0\NNP| (r_npadvmod) induced_2\VBN|cyp|- (r_amod) cystitis_3\NN|induced
D003520_D003556 CID CYP_27\NNP| (r_npadvmod) induced_29\VBN|cyp|- (r_amod) cystitis_30\NN|induced|(|acute|)
D003520_D003556 CID CYP_7\NNP| (r_npadvmod) induced_9\VBN|intermediate|cyp|- (r_amod) cystitis_10\NN|induced
D014443_D003556 NONE tyrosine_9\NN| (r_det) receptors_11\NNS|tyrosine|kinase|(|trks|) (r_pobj) of_8\IN|receptors (r_prep) expression_5\NN|the|and|regulation|of (r_dobj) examined_3\VBN|studies|have|expression|in|. (l_prep) in_15\IN|reflexes (l_pobj) reflexes_17\NNS|micturition|with (l_prep) with_18\IN|inflammation (l_pobj) inflammation_21\NN|bladder
26002693
C031763_D015464 NONE 1,3-Butadiene_0\CD|,|cml|: (l_conj) CML_2\NNP|and|translocation
C031763_D015464 NONE 1,3-butadiene_3\CD| (r_pobj) of_2\IN|1,3-butadiene (r_prep) studies_1\NNS|epidemiological|of (r_nsubj) suggest_5\VBN|studies|have|associated|. (l_ccomp) associated_11\VBN|that|exposures|are|with (l_prep) with_12\IN|leukemia (l_pobj) leukemia_15\NN|chronic|myeloid|(|cml|)
C031763_D015464 NONE 1,3-butadiene_3\CD| (r_pobj) of_2\IN|1,3-butadiene (r_prep) studies_1\NNS|epidemiological|of (r_nsubj) suggest_5\VBN|studies|have|associated|. (l_ccomp) associated_11\VBN|that|exposures|are|with (l_prep) with_12\IN|leukemia (l_pobj) leukemia_15\NN|chronic|myeloid|(|cml|) (l_appos) CML_17\NNP|
18945509
-1_D003324 NONE sulphonylurea_8\JJ| (r_compound) treatment_9\NN|initial|sulphonylurea|of (r_pobj) with_6\IN|treatment (r_prep) associated_5\VBN|with (r_acl) disease_4\NN|coronary|artery|associated
-1_D003324 NONE sulphonylureas_25\NNS|different (r_pobj) with_23\IN|sulphonylureas (r_prep) diabetes_22\NNS|2|with (r_dobj) developing_8\VBG|disease|diabetes (l_dobj) disease_11\NN|coronary|artery|(|cad|)|associated
-1_D003324 NONE sulphonylureas_25\NNS|different (r_pobj) with_23\IN|sulphonylureas (r_prep) diabetes_22\NNS|2|with (r_dobj) developing_8\VBG|disease|diabetes (l_dobj) disease_11\NN|coronary|artery|(|cad|)|associated (l_appos) CAD_13\NNP|
-1_D003924 NONE sulphonylurea_8\JJ| (r_compound) treatment_9\NN|initial|sulphonylurea|of (l_prep) of_10\IN|patients (l_pobj) patients_11\NNS|with (l_prep) with_12\IN|diabetes (l_pobj) diabetes_15\NNS|type
-1_D003924 NONE sulphonylureas_25\NNS|different (r_pobj) with_23\IN|sulphonylureas (r_prep) diabetes_22\NNS|2|with
D005905_D003324 CID glibenclamide_25\NN| (r_pobj) with_24\IN|glibenclamide (r_prep) increased_14\VBN|by|with (r_acl) treatment_13\NN|initial|increased (r_pobj) with_11\IN|treatment (r_prep) associated_10\VBN|with (r_acl) hazard_1\NN|the|of|associated|;|2-fold|. (l_prep) of_2\IN|developing (l_pcomp) developing_3\VBG|cad (l_dobj) CAD_4\NNP|ci|)
D005905_D003324 CID glibenclamide_7\NN|or|glipizide (r_pobj) with_6\IN|glibenclamide (r_prep) diabetes_5\NNS|2|with (r_dobj) Initiating_0\VBG|treatment|diabetes (r_csubjpass) associated_11\VBN|initiating|is|with|. (l_prep) with_12\IN|risk (l_pobj) risk_14\NN|increased|of|in (l_prep) of_15\IN|cad (l_pobj) CAD_16\NNP|
D005913_D003324 NONE glipizide_36\NN| (r_pobj) with_35\IN|glipizide (r_prep) 2-fold_27\JJ|0.9|,|p=0.099|)|with|;|2.9-fold|and|was (r_appos) hazard_1\NN|the|of|associated|;|2-fold|. (l_prep) of_2\IN|developing (l_pcomp) developing_3\VBG|cad (l_dobj) CAD_4\NNP|ci|)
D005913_D003324 NONE glipizide_9\NN| (r_conj) glibenclamide_7\NN|or|glipizide (r_pobj) with_6\IN|glibenclamide (r_prep) diabetes_5\NNS|2|with (r_dobj) Initiating_0\VBG|treatment|diabetes (r_csubjpass) associated_11\VBN|initiating|is|with|. (l_prep) with_12\IN|risk (l_pobj) risk_14\NN|increased|of|in (l_prep) of_15\IN|cad (l_pobj) CAD_16\NNP|
D008687_D003324 NONE metformin_53\NN| (r_pobj) with_52\IN|metformin (r_prep) unchanged_51\JJ|with (r_acomp) was_50\VBD|unchanged (r_conj) 2-fold_27\JJ|0.9|,|p=0.099|)|with|;|2.9-fold|and|was (r_appos) hazard_1\NN|the|of|associated|;|2-fold|. (l_prep) of_2\IN|developing (l_pcomp) developing_3\VBG|cad (l_dobj) CAD_4\NNP|ci|)
D005905_D003924 NONE glibenclamide_7\NN|or|glipizide (r_pobj) with_6\IN|glibenclamide (r_prep) diabetes_5\NNS|2|with
D005913_D003924 NONE glipizide_9\NN| (r_conj) glibenclamide_7\NN|or|glipizide (r_pobj) with_6\IN|glibenclamide (r_prep) diabetes_5\NNS|2|with
D005907_D003924 NONE gliclazide_20\VB|or|glimepiride (r_pobj) to_19\TO|gliclazide (r_prep) comparison_18\NN|to (r_pobj) in_17\IN|comparison (r_prep) risk_14\NN|increased|of|in (r_pobj) with_12\IN|risk (r_prep) associated_11\VBN|initiating|is|with|. (l_csubjpass) Initiating_0\VBG|treatment|diabetes (l_dobj) diabetes_5\NNS|2|with
D005907_D003324 NONE gliclazide_20\VB|or|glimepiride (r_pobj) to_19\TO|gliclazide (r_prep) comparison_18\NN|to (r_pobj) in_17\IN|comparison (r_prep) risk_14\NN|increased|of|in (l_prep) of_15\IN|cad (l_pobj) CAD_16\NNP|
C057619_D003924 NONE glimepiride_22\NN| (r_conj) gliclazide_20\VB|or|glimepiride (r_pobj) to_19\TO|gliclazide (r_prep) comparison_18\NN|to (r_pobj) in_17\IN|comparison (r_prep) risk_14\NN|increased|of|in (r_pobj) with_12\IN|risk (r_prep) associated_11\VBN|initiating|is|with|. (l_csubjpass) Initiating_0\VBG|treatment|diabetes (l_dobj) diabetes_5\NNS|2|with
C057619_D003324 NONE glimepiride_22\NN| (r_conj) gliclazide_20\VB|or|glimepiride (r_pobj) to_19\TO|gliclazide (r_prep) comparison_18\NN|to (r_pobj) in_17\IN|comparison (r_prep) risk_14\NN|increased|of|in (l_prep) of_15\IN|cad (l_pobj) CAD_16\NNP|
4631913
D014750_D011552 CID sulfate_3\NN|vincristine|on (l_prep) on_4\IN|infections (l_pobj) infections_6\NNS|pseudomonas|in
D014750_D007970 CID sulfate_11\NN|vincristine (r_pobj) of_9\IN|sulfate (r_prep) mg_8\NN|of (r_quantmod) 2.5_7\CD|2.0|to|mg (r_pobj) of_4\IN|2.5 (r_prep) inoculation_3\NN|intratracheal|of (r_conj) Intravenous_0\JJ|or|inoculation (r_nsubjpass) followed_13\VBN|intravenous|was|by|. (l_agent) by_14\IN|leukopenia (l_pobj) leukopenia_15\NN|in
3975902
D010424_D002318 NONE pentobarbital_6\NN| (r_amod) dysfunction_1\NN|cardiovascular|and|hypersensitivity|pentobarbital
D010424_D004342 NONE pentobarbital_6\NN| (r_amod) dysfunction_1\NN|cardiovascular|and|hypersensitivity|pentobarbital (l_conj) hypersensitivity_3\NN|to
D010424_D004342 NONE pentobarbital_18\NN| (r_amod) hypersensitivity_11\NN|a|demonstrated|of|to|pentobarbital
D010424_D004342 NONE pentobarbital_24\NN| (r_appos) contractility_5\NN|the|altered|cardiac|and|characteristics|,|disturbances|pentobarbital (l_conj) disturbances_13\NNS|the|myocardial|metabolic|,|and|hypersensitivity (l_conj) hypersensitivity_17\NN|the|of|to
C024986_D002318 NONE chloride_11\NN|barium (r_compound) ingestion_12\NN|chronic|chloride (r_pobj) by_8\IN|ingestion (r_agent) induced_7\VBN|dysfunction|by|. (l_nsubj) dysfunction_1\NN|cardiovascular|and|hypersensitivity|pentobarbital
C024986_D004342 NONE chloride_11\NN|barium (r_compound) ingestion_12\NN|chronic|chloride (r_pobj) by_8\IN|ingestion (r_agent) induced_7\VBN|dysfunction|by|. (l_nsubj) dysfunction_1\NN|cardiovascular|and|hypersensitivity|pentobarbital (l_conj) hypersensitivity_3\NN|to
D001464_D006973 NONE Barium_0\NN| (r_npadvmod) supplemented_2\VBN|barium|- (r_amod) rats_7\NNS|supplemented|evans|hooded (r_nsubjpass) characterized_9\VBN|rats|were|by|. (l_agent) by_10\IN|hypertension (l_pobj) hypertension_13\NN|a|persistent|was
D001464_D006973 NONE barium_21\NN| (r_pobj) of_20\IN|barium (r_prep) month_19\NN|1|of|treatment (r_pobj) after_17\IN|month (r_prep) was_15\VBD|that|evident|after (r_relcl) hypertension_13\NN|a|persistent|was
D001464_D002318 NONE barium_18\NN| (r_npadvmod) induced_20\VBN|barium|- (r_amod) disturbances_21\NNS|other|significant|induced|within (l_prep) within_22\IN|system (l_pobj) system_25\NN|the|cardiovascular
D001464_D004342 NONE barium_6\NN| (r_compound) effect_7\NN|the|barium (r_pobj) of_4\IN|effect (r_prep) aspect_3\NN|the|distinctive|of (r_nsubj) was_8\VBD|aspect|hypersensitivity|. (l_attr) hypersensitivity_11\NN|a|demonstrated|of|to|pentobarbital
D001464_D004342 NONE barium_37\NN| (r_compound) exposure_38\NN|chronic|barium (r_pobj) by_35\IN|exposure (r_agent) induced_34\VBN|by (r_acl) disorder_33\NN|a|undescribed|cardiomyopathic|induced (r_pobj) of_28\IN|disorder (r_prep) existence_27\NN|the|of (r_dobj) suggest_25\VBP|overall|,|contractility|existence|. (l_nsubj) contractility_5\NN|the|altered|cardiac|and|characteristics|,|disturbances|pentobarbital (l_conj) disturbances_13\NNS|the|myocardial|metabolic|,|and|hypersensitivity (l_conj) hypersensitivity_17\NN|the|of|to
D010424_D008659 NONE pentobarbital_24\NN| (r_appos) contractility_5\NN|the|altered|cardiac|and|characteristics|,|disturbances|pentobarbital (l_conj) disturbances_13\NNS|the|myocardial|metabolic|,|and|hypersensitivity
D010424_D009202 NONE pentobarbital_24\NN| (r_appos) contractility_5\NN|the|altered|cardiac|and|characteristics|,|disturbances|pentobarbital (r_nsubj) suggest_25\VBP|overall|,|contractility|existence|. (l_dobj) existence_27\NN|the|of (l_prep) of_28\IN|disorder (l_pobj) disorder_33\NN|a|undescribed|cardiomyopathic|induced
D001464_D008659 NONE barium_37\NN| (r_compound) exposure_38\NN|chronic|barium (r_pobj) by_35\IN|exposure (r_agent) induced_34\VBN|by (r_acl) disorder_33\NN|a|undescribed|cardiomyopathic|induced (r_pobj) of_28\IN|disorder (r_prep) existence_27\NN|the|of (r_dobj) suggest_25\VBP|overall|,|contractility|existence|. (l_nsubj) contractility_5\NN|the|altered|cardiac|and|characteristics|,|disturbances|pentobarbital (l_conj) disturbances_13\NNS|the|myocardial|metabolic|,|and|hypersensitivity
D001464_D009202 NONE barium_37\NN| (r_compound) exposure_38\NN|chronic|barium (r_pobj) by_35\IN|exposure (r_agent) induced_34\VBN|by (r_acl) disorder_33\NN|a|undescribed|cardiomyopathic|induced
11474137
D003300_D034381 NONE copper_2\NN| (r_npadvmod) superoxide_6\NN|copper|/|zinc|- (r_amod) dismutase_7\NN|superoxide (r_pobj) of_1\IN|dismutase (r_prep) Overexpression_0\NN|of (r_nsubj) protects_8\VBZ|overexpression|from|. (l_prep) from_9\IN|loss (l_pobj) loss_14\NN|induced|hearing
D015032_D034381 NONE zinc_4\NN| (r_npadvmod) superoxide_6\NN|copper|/|zinc|- (r_amod) dismutase_7\NN|superoxide (r_pobj) of_1\IN|dismutase (r_prep) Overexpression_0\NN|of (r_nsubj) protects_8\VBZ|overexpression|from|. (l_prep) from_9\IN|loss (l_pobj) loss_14\NN|induced|hearing
D013481_D034381 NONE superoxide_6\NN|copper|/|zinc|- (r_amod) dismutase_7\NN|superoxide (r_pobj) of_1\IN|dismutase (r_prep) Overexpression_0\NN|of (r_nsubj) protects_8\VBZ|overexpression|from|. (l_prep) from_9\IN|loss (l_pobj) loss_14\NN|induced|hearing
D007612_D034381 CID kanamycin_10\NN| (r_npadvmod) induced_12\VBN|kanamycin|- (r_amod) loss_14\NN|induced|hearing
D010100_D006311 NONE oxygen_4\NN| (r_compound) species_5\NNS|reactive|oxygen|in (l_prep) in_6\IN|ototoxicity (l_pobj) ototoxicity_10\NN|induced
D010100_D006311 NONE oxygen_4\NN| (r_compound) species_5\NNS|reactive|oxygen|in (r_pobj) of_2\IN|species (r_prep) participation_1\NN|the|of (r_nsubjpass) deduced_13\VBN|participation|has|been|from|. (l_prep) from_14\IN|observations (l_pobj) observations_15\NNS|catalyze (l_acl) catalyze_21\VBP|that|complexes|formation|and|attenuate (l_conj) attenuate_32\VBP|that|antioxidants|ototoxicity (l_dobj) ototoxicity_33\NN|in
D000617_D006311 NONE aminoglycoside_7\NN| (r_npadvmod) induced_9\VBN|aminoglycoside|- (r_amod) ototoxicity_10\NN|induced
D000617_D006311 NONE aminoglycoside_7\NN| (r_npadvmod) induced_9\VBN|aminoglycoside|- (r_amod) ototoxicity_10\NN|induced (r_pobj) in_6\IN|ototoxicity (r_prep) species_5\NNS|reactive|oxygen|in (r_pobj) of_2\IN|species (r_prep) participation_1\NN|the|of (r_nsubjpass) deduced_13\VBN|participation|has|been|from|. (l_prep) from_14\IN|observations (l_pobj) observations_15\NNS|catalyze (l_acl) catalyze_21\VBP|that|complexes|formation|and|attenuate (l_conj) attenuate_32\VBP|that|antioxidants|ototoxicity (l_dobj) ototoxicity_33\NN|in
D000617_D006311 NONE aminoglycoside_17\NN| (r_compound) iron_19\NN|aminoglycoside|- (r_compound) complexes_20\NNS|iron (r_nsubj) catalyze_21\VBP|that|complexes|formation|and|attenuate (r_acl) observations_15\NNS|catalyze (r_pobj) from_14\IN|observations (r_prep) deduced_13\VBN|participation|has|been|from|. (l_nsubjpass) participation_1\NN|the|of (l_prep) of_2\IN|species (l_pobj) species_5\NNS|reactive|oxygen|in (l_prep) in_6\IN|ototoxicity (l_pobj) ototoxicity_10\NN|induced
D000617_D006311 NONE aminoglycoside_17\NN| (r_compound) iron_19\NN|aminoglycoside|- (r_compound) complexes_20\NNS|iron (r_nsubj) catalyze_21\VBP|that|complexes|formation|and|attenuate (l_conj) attenuate_32\VBP|that|antioxidants|ototoxicity (l_dobj) ototoxicity_33\NN|in
D000617_D006311 NONE aminoglycoside_18\NN| (r_npadvmod) induced_20\VBN|aminoglycoside|- (r_amod) ototoxicity_21\NN|induced
D007501_D006311 NONE iron_19\NN|aminoglycoside|- (r_compound) complexes_20\NNS|iron (r_nsubj) catalyze_21\VBP|that|complexes|formation|and|attenuate (r_acl) observations_15\NNS|catalyze (r_pobj) from_14\IN|observations (r_prep) deduced_13\VBN|participation|has|been|from|. (l_nsubjpass) participation_1\NN|the|of (l_prep) of_2\IN|species (l_pobj) species_5\NNS|reactive|oxygen|in (l_prep) in_6\IN|ototoxicity (l_pobj) ototoxicity_10\NN|induced
D007501_D006311 NONE iron_19\NN|aminoglycoside|- (r_compound) complexes_20\NNS|iron (r_nsubj) catalyze_21\VBP|that|complexes|formation|and|attenuate (l_conj) attenuate_32\VBP|that|antioxidants|ototoxicity (l_dobj) ototoxicity_33\NN|in
D013481_D006311 NONE superoxide_25\JJ| (r_amod) radicals_26\NNS|superoxide|in (r_pobj) of_24\IN|radicals (r_prep) formation_23\NN|the|of (r_dobj) catalyze_21\VBP|that|complexes|formation|and|attenuate (r_acl) observations_15\NNS|catalyze (r_pobj) from_14\IN|observations (r_prep) deduced_13\VBN|participation|has|been|from|. (l_nsubjpass) participation_1\NN|the|of (l_prep) of_2\IN|species (l_pobj) species_5\NNS|reactive|oxygen|in (l_prep) in_6\IN|ototoxicity (l_pobj) ototoxicity_10\NN|induced
D013481_D006311 NONE superoxide_25\JJ| (r_amod) radicals_26\NNS|superoxide|in (r_pobj) of_24\IN|radicals (r_prep) formation_23\NN|the|of (r_dobj) catalyze_21\VBP|that|complexes|formation|and|attenuate (l_conj) attenuate_32\VBP|that|antioxidants|ototoxicity (l_dobj) ototoxicity_33\NN|in
D013481_D006311 NONE superoxide_10\NN|zn|- (r_amod) dismutase_11\NN|cu|/|superoxide|(|sod1|) (r_pobj) of_5\IN|dismutase (r_prep) overexpression_4\NN|that|of (r_nsubj) protect_18\VB|overexpression|should|mice|from (l_prep) from_21\IN|ototoxicity (l_pobj) ototoxicity_22\NN|
D013481_D006311 NONE superoxide_5\NN| (r_amod) dismutase_6\NN|superoxide (r_pobj) of_4\IN|dismutase (r_prep) overexpression_3\NN|of (r_pobj) by_2\IN|overexpression (r_prep) protection_1\NN|the|by (r_nsubj) supports_7\VBZ|protection|hypothesis|. (l_dobj) hypothesis_9\NN|the|plays (l_acl) plays_13\VBZ|that|stress|role (l_dobj) role_16\NN|a|significant|in (l_prep) in_17\IN|ototoxicity (l_pobj) ototoxicity_21\NN|induced
D003300_D006311 NONE Cu_6\NNP| (r_nmod) dismutase_11\NN|cu|/|superoxide|(|sod1|) (r_pobj) of_5\IN|dismutase (r_prep) overexpression_4\NN|that|of (r_nsubj) protect_18\VB|overexpression|should|mice|from (l_prep) from_21\IN|ototoxicity (l_pobj) ototoxicity_22\NN|
D015032_D006311 NONE Zn_8\NNP| (r_compound) superoxide_10\NN|zn|- (r_amod) dismutase_11\NN|cu|/|superoxide|(|sod1|) (r_pobj) of_5\IN|dismutase (r_prep) overexpression_4\NN|that|of (r_nsubj) protect_18\VB|overexpression|should|mice|from (l_prep) from_21\IN|ototoxicity (l_pobj) ototoxicity_22\NN|
24717468
D020927_D007022 CID dexmedetomidine_14\NN| (r_dobj) receive_13\VBP|who|dexmedetomidine|or|propofol (r_relcl) patients_11\NNS|neurocritical|care|receive (r_pobj) in_8\IN|patients (r_prep) prevalence_7\NN|similar|in (r_pobj) at_5\IN|prevalence (r_prep) occur_4\VBP|hypotension|at|. (l_nsubj) hypotension_1\NN|severe|and|bradycardia
D020927_D001919 CID dexmedetomidine_14\NN| (r_dobj) receive_13\VBP|who|dexmedetomidine|or|propofol (r_relcl) patients_11\NNS|neurocritical|care|receive (r_pobj) in_8\IN|patients (r_prep) prevalence_7\NN|similar|in (r_pobj) at_5\IN|prevalence (r_prep) occur_4\VBP|hypotension|at|. (l_nsubj) hypotension_1\NN|severe|and|bradycardia (l_conj) bradycardia_3\NN|
D015742_D007022 CID propofol_16\NN| (r_conj) receive_13\VBP|who|dexmedetomidine|or|propofol (r_relcl) patients_11\NNS|neurocritical|care|receive (r_pobj) in_8\IN|patients (r_prep) prevalence_7\NN|similar|in (r_pobj) at_5\IN|prevalence (r_prep) occur_4\VBP|hypotension|at|. (l_nsubj) hypotension_1\NN|severe|and|bradycardia
D015742_D001919 CID propofol_16\NN| (r_conj) receive_13\VBP|who|dexmedetomidine|or|propofol (r_relcl) patients_11\NNS|neurocritical|care|receive (r_pobj) in_8\IN|patients (r_prep) prevalence_7\NN|similar|in (r_pobj) at_5\IN|prevalence (r_prep) occur_4\VBP|hypotension|at|. (l_nsubj) hypotension_1\NN|severe|and|bradycardia (l_conj) bradycardia_3\NN|
11401944
D013015_D016171 CID sotalol_32\NN|dl|-|and|azimilide (r_pobj) by_29\IN|sotalol (r_agent) induced_28\VBN|by (r_acl) prolongation_27\NN|qt|induced (r_pobj) with_25\IN|prolongation (r_prep) initiate_18\VB|to|pointes|with (l_dobj) pointes_21\FW|torsade|de|(|tdp|)
D013015_D016171 CID sotalol_32\NN|dl|-|and|azimilide (r_pobj) by_29\IN|sotalol (r_agent) induced_28\VBN|by (r_acl) prolongation_27\NN|qt|induced (r_pobj) with_25\IN|prolongation (r_prep) initiate_18\VB|to|pointes|with (l_dobj) pointes_21\FW|torsade|de|(|tdp|) (l_appos) TdP_23\NN|
D013015_D016171 CID sotalol_7\NN|dl|- (r_pobj) by_4\IN|sotalol (r_prep) increase_1\NN|an|in|by (r_nsubj) facilitated_8\VBN|increase|propagation|. (l_dobj) propagation_10\NN|transmural|of|initiated (l_relcl) initiated_14\VBD|that|episodes|in (l_dobj) episodes_16\NNS|multiple|of (l_prep) of_17\IN|tdp (l_pobj) TdP_19\NN|spontaneous
D013015_D008133 CID sotalol_32\NN|dl|-|and|azimilide (r_pobj) by_29\IN|sotalol (r_agent) induced_28\VBN|by (r_acl) prolongation_27\NN|qt|induced
D013015_D008133 CID Sotalol_2\NNP|dl|- (r_nsubj) prolonged_4\VBD|sotalol|preferentially|duration|in|,|leading|. (l_advcl) leading_26\VBG|to (l_prep) to_27\IN|prolongation (l_pobj) prolongation_29\NN|qt|and|increase
D013015_D008133 CID sotalol_4\NNS|both|dl|-|and|azimilide (r_nsubj) induced_8\VBD|although|sotalol|rarely|eads (r_advcl) produced_16\VBD|induced|,|they|eads|in|,|pronounced|. (l_relcl) pronounced_25\VBN|in|more|seen (l_ccomp) seen_29\VBN|prolongation|was (l_nsubjpass) prolongation_27\NN|qt
C086123_D016171 NONE azimilide_34\NN| (r_conj) sotalol_32\NN|dl|-|and|azimilide (r_pobj) by_29\IN|sotalol (r_agent) induced_28\VBN|by (r_acl) prolongation_27\NN|qt|induced (r_pobj) with_25\IN|prolongation (r_prep) initiate_18\VB|to|pointes|with (l_dobj) pointes_21\FW|torsade|de|(|tdp|)
C086123_D016171 NONE azimilide_34\NN| (r_conj) sotalol_32\NN|dl|-|and|azimilide (r_pobj) by_29\IN|sotalol (r_agent) induced_28\VBN|by (r_acl) prolongation_27\NN|qt|induced (r_pobj) with_25\IN|prolongation (r_prep) initiate_18\VB|to|pointes|with (l_dobj) pointes_21\FW|torsade|de|(|tdp|) (l_appos) TdP_23\NN|
C086123_D008133 NONE azimilide_34\NN| (r_conj) sotalol_32\NN|dl|-|and|azimilide (r_pobj) by_29\IN|sotalol (r_agent) induced_28\VBN|by (r_acl) prolongation_27\NN|qt|induced
C086123_D008133 NONE azimilide_6\NN| (r_conj) sotalol_4\NNS|both|dl|-|and|azimilide (r_nsubj) induced_8\VBD|although|sotalol|rarely|eads (r_advcl) produced_16\VBD|induced|,|they|eads|in|,|pronounced|. (l_relcl) pronounced_25\VBN|in|more|seen (l_ccomp) seen_29\VBN|prolongation|was (l_nsubjpass) prolongation_27\NN|qt
2904523
D004837_D006973 CID adrenaline_2\NN| (r_compound) hypertension_4\NN|adrenaline|-
D004837_D006973 CID adrenaline_14\NN| (r_compound) infusion_15\NN|hours|adrenaline (r_pobj) after_11\IN|infusion (r_prep) effect_10\NN|hour|pressor|after (r_appos) Support_0\NN|for|:|effect|. (l_prep) for_1\IN|hypothesis (l_pobj) hypothesis_5\NN|hypertension (l_compound) hypertension_4\NN|adrenaline|-
D004837_D006973 CID adrenaline_7\NN| (r_compound) hypertension_9\NN|adrenaline|-
1359137
D014150_D006966 CID Neuroleptic_0\RB| (r_npadvmod) associated_2\VBN|neuroleptic|- (r_amod) hyperprolactinemia_3\NN|associated|.
D014150_D006966 CID neuroleptic_12\NN| (r_npadvmod) associated_14\VBN|neuroleptic|- (r_amod) hyperprolactinemia_15\NN|associated|and|galactorrhea
D014150_D009839 CID medications_5\NNS|their|neuroleptic (r_pobj) with_2\IN|medications (r_prep) associated_1\VBN|oligomenorrhea|with|treated|. (l_nsubj) oligomenorrhea_0\NN|
D001971_D009839 NONE bromocriptine_9\NN| (r_pobj) with_8\IN|bromocriptine (r_prep) treated_7\VBN|were|with (r_advcl) associated_1\VBN|oligomenorrhea|with|treated|. (l_nsubj) oligomenorrhea_0\NN|
D001971_D011618 CID bromocriptine_11\NN| (r_dobj) taking_10\VBG|while|bromocriptine (r_advcl) developed_5\VBN|woman|,|however|,|symptoms|taking|,|and|discontinued (l_dobj) symptoms_8\NNS|worsened|psychiatric
D001971_D006966 NONE bromocriptine_3\NN| (r_nsubjpass) evaluated_7\VBN|that|bromocriptine|should|be|further|as (l_prep) as_8\IN|therapy (l_pobj) therapy_10\NN|potential|for (l_prep) for_11\IN|hyperprolactinemia (l_pobj) hyperprolactinemia_15\NN|associated|and|galactorrhea
D001971_D000568 NONE bromocriptine_3\NN| (r_nsubjpass) evaluated_7\VBN|that|bromocriptine|should|be|further|as (l_prep) as_8\IN|therapy (l_pobj) therapy_10\NN|potential|for (l_prep) for_11\IN|hyperprolactinemia (l_pobj) hyperprolactinemia_15\NN|associated|and|galactorrhea (l_conj) galactorrhea_19\NN|amenorrhea|/ (l_nmod) amenorrhea_17\NN|
D001971_D005687 NONE bromocriptine_3\NN| (r_nsubjpass) evaluated_7\VBN|that|bromocriptine|should|be|further|as (l_prep) as_8\IN|therapy (l_pobj) therapy_10\NN|potential|for (l_prep) for_11\IN|hyperprolactinemia (l_pobj) hyperprolactinemia_15\NN|associated|and|galactorrhea (l_conj) galactorrhea_19\NN|amenorrhea|/
D014150_D000568 CID neuroleptic_12\NN| (r_npadvmod) associated_14\VBN|neuroleptic|- (r_amod) hyperprolactinemia_15\NN|associated|and|galactorrhea (l_conj) galactorrhea_19\NN|amenorrhea|/ (l_nmod) amenorrhea_17\NN|
D014150_D005687 NONE neuroleptic_12\NN| (r_npadvmod) associated_14\VBN|neuroleptic|- (r_amod) hyperprolactinemia_15\NN|associated|and|galactorrhea (l_conj) galactorrhea_19\NN|amenorrhea|/
1280054
D014750_D001927 CID vincristine_5\NN| (r_compound) administration_6\NN|intrathecal|vincristine (r_pobj) due_2\IN|to|administration (r_prep) myeloencephalopathy_1\NN|fatal|due|.
D014750_D001927 CID Vincristine_0\NNP| (r_nsubjpass) given_3\VBN|vincristine|was|accidentally|intrathecally|to|,|producing|. (l_advcl) producing_11\VBG|dysfunction (l_dobj) dysfunction_15\NN|sensory|followed (l_acl) followed_16\VBN|by (l_agent) by_17\IN|encephalopathy (l_pobj) encephalopathy_18\JJ|and|death
D014750_D007938 NONE Vincristine_0\NNP| (r_nsubjpass) given_3\VBN|vincristine|was|accidentally|intrathecally|to|,|producing|. (l_dative) to_5\IN|child (l_pobj) child_7\NN|a|with (l_prep) with_8\IN|leukaemia (l_pobj) leukaemia_9\NN|
D014750_D007049 CID Vincristine_0\NNP| (r_nsubjpass) given_3\VBN|vincristine|was|accidentally|intrathecally|to|,|producing|. (l_advcl) producing_11\VBG|dysfunction (l_dobj) dysfunction_15\NN|sensory|followed
2983630
D002110_D016584 NONE caffeine_4\NN| (r_pobj) of_3\IN|caffeine (r_prep) effects_2\NNS|increased|anxiogenic|of|in|. (l_prep) in_5\IN|disorders (l_pobj) disorders_7\NNS|panic
D002110_D016584 NONE caffeine_6\NN| (r_pobj) of_5\IN|caffeine (r_prep) administration_4\NN|oral|of (r_pobj) of_2\IN|administration (r_prep) effects_1\NNS|the|of|(|mg/kg|)|on (r_nsubjpass) determined_31\VBN|effects|were|in|meeting|. (l_advcl) meeting_39\VBG|patients|criteria (l_dobj) criteria_43\NNS|iii|for (l_prep) for_44\IN|agoraphobia (l_pobj) agoraphobia_45\NN|with (l_prep) with_46\IN|attacks (l_pobj) attacks_48\NNS|panic|or|disorder
D002110_D016584 NONE caffeine_6\NN| (r_pobj) of_5\IN|caffeine (r_prep) administration_4\NN|oral|of (r_pobj) of_2\IN|administration (r_prep) effects_1\NNS|the|of|(|mg/kg|)|on (r_nsubjpass) determined_31\VBN|effects|were|in|meeting|. (l_advcl) meeting_39\VBG|patients|criteria (l_dobj) criteria_43\NNS|iii|for (l_prep) for_44\IN|agoraphobia (l_pobj) agoraphobia_45\NN|with (l_prep) with_46\IN|attacks (l_pobj) attacks_48\NNS|panic|or|disorder (l_conj) disorder_51\NN|panic
D002110_D016584 NONE caffeine_13\NN| (r_pobj) of_12\IN|caffeine (r_prep) effects_11\NNS|the|behavioral|of (r_nsubj) were_14\VBD|that|effects|similar (l_acomp) similar_15\JJ|to (l_prep) to_16\IN|those (l_pobj) those_17\DT|experienced (l_acl) experienced_18\VBN|during (l_prep) during_19\IN|attacks (l_pobj) attacks_21\NNS|panic
D002110_D016584 NONE caffeine_1\NN| (r_nsubj) is_2\VBZ|because|caffeine|antagonist (r_advcl) suggest_10\VBP|is|,|results|have|. (l_ccomp) have_17\VB|that|patients|may|abnormalities (l_nsubj) patients_15\NNS|some|disorder (l_compound) disorder_14\NN|panic
D002110_D000379 NONE caffeine_6\NN| (r_pobj) of_5\IN|caffeine (r_prep) administration_4\NN|oral|of (r_pobj) of_2\IN|administration (r_prep) effects_1\NNS|the|of|(|mg/kg|)|on (r_nsubjpass) determined_31\VBN|effects|were|in|meeting|. (l_advcl) meeting_39\VBG|patients|criteria (l_dobj) criteria_43\NNS|iii|for (l_prep) for_44\IN|agoraphobia (l_pobj) agoraphobia_45\NN|with
D008734_D000379 NONE 3-methoxy-4-hydroxyphenethyleneglycol_24\CD|(|mhpg|)|and|cortisol (r_pobj) of_23\IN|3-methoxy-4-hydroxyphenethyleneglycol (r_prep) pressure_19\NN|blood|and|levels|of (r_conj) symptoms_16\NNS|somatic|,|pressure (r_conj) ratings_13\NNS|behavioral|,|symptoms (r_pobj) on_11\IN|ratings (r_prep) effects_1\NNS|the|of|(|mg/kg|)|on (r_nsubjpass) determined_31\VBN|effects|were|in|meeting|. (l_advcl) meeting_39\VBG|patients|criteria (l_dobj) criteria_43\NNS|iii|for (l_prep) for_44\IN|agoraphobia (l_pobj) agoraphobia_45\NN|with
D008734_D000379 NONE MHPG_26\RB| (r_appos) 3-methoxy-4-hydroxyphenethyleneglycol_24\CD|(|mhpg|)|and|cortisol (r_pobj) of_23\IN|3-methoxy-4-hydroxyphenethyleneglycol (r_prep) pressure_19\NN|blood|and|levels|of (r_conj) symptoms_16\NNS|somatic|,|pressure (r_conj) ratings_13\NNS|behavioral|,|symptoms (r_pobj) on_11\IN|ratings (r_prep) effects_1\NNS|the|of|(|mg/kg|)|on (r_nsubjpass) determined_31\VBN|effects|were|in|meeting|. (l_advcl) meeting_39\VBG|patients|criteria (l_dobj) criteria_43\NNS|iii|for (l_prep) for_44\IN|agoraphobia (l_pobj) agoraphobia_45\NN|with
D008734_D016584 NONE 3-methoxy-4-hydroxyphenethyleneglycol_24\CD|(|mhpg|)|and|cortisol (r_pobj) of_23\IN|3-methoxy-4-hydroxyphenethyleneglycol (r_prep) pressure_19\NN|blood|and|levels|of (r_conj) symptoms_16\NNS|somatic|,|pressure (r_conj) ratings_13\NNS|behavioral|,|symptoms (r_pobj) on_11\IN|ratings (r_prep) effects_1\NNS|the|of|(|mg/kg|)|on (r_nsubjpass) determined_31\VBN|effects|were|in|meeting|. (l_advcl) meeting_39\VBG|patients|criteria (l_dobj) criteria_43\NNS|iii|for (l_prep) for_44\IN|agoraphobia (l_pobj) agoraphobia_45\NN|with (l_prep) with_46\IN|attacks (l_pobj) attacks_48\NNS|panic|or|disorder
D008734_D016584 NONE 3-methoxy-4-hydroxyphenethyleneglycol_24\CD|(|mhpg|)|and|cortisol (r_pobj) of_23\IN|3-methoxy-4-hydroxyphenethyleneglycol (r_prep) pressure_19\NN|blood|and|levels|of (r_conj) symptoms_16\NNS|somatic|,|pressure (r_conj) ratings_13\NNS|behavioral|,|symptoms (r_pobj) on_11\IN|ratings (r_prep) effects_1\NNS|the|of|(|mg/kg|)|on (r_nsubjpass) determined_31\VBN|effects|were|in|meeting|. (l_advcl) meeting_39\VBG|patients|criteria (l_dobj) criteria_43\NNS|iii|for (l_prep) for_44\IN|agoraphobia (l_pobj) agoraphobia_45\NN|with (l_prep) with_46\IN|attacks (l_pobj) attacks_48\NNS|panic|or|disorder (l_conj) disorder_51\NN|panic
D008734_D016584 NONE MHPG_26\RB| (r_appos) 3-methoxy-4-hydroxyphenethyleneglycol_24\CD|(|mhpg|)|and|cortisol (r_pobj) of_23\IN|3-methoxy-4-hydroxyphenethyleneglycol (r_prep) pressure_19\NN|blood|and|levels|of (r_conj) symptoms_16\NNS|somatic|,|pressure (r_conj) ratings_13\NNS|behavioral|,|symptoms (r_pobj) on_11\IN|ratings (r_prep) effects_1\NNS|the|of|(|mg/kg|)|on (r_nsubjpass) determined_31\VBN|effects|were|in|meeting|. (l_advcl) meeting_39\VBG|patients|criteria (l_dobj) criteria_43\NNS|iii|for (l_prep) for_44\IN|agoraphobia (l_pobj) agoraphobia_45\NN|with (l_prep) with_46\IN|attacks (l_pobj) attacks_48\NNS|panic|or|disorder
D008734_D016584 NONE MHPG_26\RB| (r_appos) 3-methoxy-4-hydroxyphenethyleneglycol_24\CD|(|mhpg|)|and|cortisol (r_pobj) of_23\IN|3-methoxy-4-hydroxyphenethyleneglycol (r_prep) pressure_19\NN|blood|and|levels|of (r_conj) symptoms_16\NNS|somatic|,|pressure (r_conj) ratings_13\NNS|behavioral|,|symptoms (r_pobj) on_11\IN|ratings (r_prep) effects_1\NNS|the|of|(|mg/kg|)|on (r_nsubjpass) determined_31\VBN|effects|were|in|meeting|. (l_advcl) meeting_39\VBG|patients|criteria (l_dobj) criteria_43\NNS|iii|for (l_prep) for_44\IN|agoraphobia (l_pobj) agoraphobia_45\NN|with (l_prep) with_46\IN|attacks (l_pobj) attacks_48\NNS|panic|or|disorder (l_conj) disorder_51\NN|panic
D006854_D000379 NONE cortisol_29\NN| (r_conj) 3-methoxy-4-hydroxyphenethyleneglycol_24\CD|(|mhpg|)|and|cortisol (r_pobj) of_23\IN|3-methoxy-4-hydroxyphenethyleneglycol (r_prep) pressure_19\NN|blood|and|levels|of (r_conj) symptoms_16\NNS|somatic|,|pressure (r_conj) ratings_13\NNS|behavioral|,|symptoms (r_pobj) on_11\IN|ratings (r_prep) effects_1\NNS|the|of|(|mg/kg|)|on (r_nsubjpass) determined_31\VBN|effects|were|in|meeting|. (l_advcl) meeting_39\VBG|patients|criteria (l_dobj) criteria_43\NNS|iii|for (l_prep) for_44\IN|agoraphobia (l_pobj) agoraphobia_45\NN|with
D006854_D016584 NONE cortisol_29\NN| (r_conj) 3-methoxy-4-hydroxyphenethyleneglycol_24\CD|(|mhpg|)|and|cortisol (r_pobj) of_23\IN|3-methoxy-4-hydroxyphenethyleneglycol (r_prep) pressure_19\NN|blood|and|levels|of (r_conj) symptoms_16\NNS|somatic|,|pressure (r_conj) ratings_13\NNS|behavioral|,|symptoms (r_pobj) on_11\IN|ratings (r_prep) effects_1\NNS|the|of|(|mg/kg|)|on (r_nsubjpass) determined_31\VBN|effects|were|in|meeting|. (l_advcl) meeting_39\VBG|patients|criteria (l_dobj) criteria_43\NNS|iii|for (l_prep) for_44\IN|agoraphobia (l_pobj) agoraphobia_45\NN|with (l_prep) with_46\IN|attacks (l_pobj) attacks_48\NNS|panic|or|disorder
D006854_D016584 NONE cortisol_29\NN| (r_conj) 3-methoxy-4-hydroxyphenethyleneglycol_24\CD|(|mhpg|)|and|cortisol (r_pobj) of_23\IN|3-methoxy-4-hydroxyphenethyleneglycol (r_prep) pressure_19\NN|blood|and|levels|of (r_conj) symptoms_16\NNS|somatic|,|pressure (r_conj) ratings_13\NNS|behavioral|,|symptoms (r_pobj) on_11\IN|ratings (r_prep) effects_1\NNS|the|of|(|mg/kg|)|on (r_nsubjpass) determined_31\VBN|effects|were|in|meeting|. (l_advcl) meeting_39\VBG|patients|criteria (l_dobj) criteria_43\NNS|iii|for (l_prep) for_44\IN|agoraphobia (l_pobj) agoraphobia_45\NN|with (l_prep) with_46\IN|attacks (l_pobj) attacks_48\NNS|panic|or|disorder (l_conj) disorder_51\NN|panic
D002110_D001008 CID Caffeine_0\NN| (r_nsubj) produced_1\VBD|caffeine|increases|compared|. (l_dobj) increases_4\NNS|greater|in (l_prep) in_5\IN|anxiety (l_pobj) anxiety_9\NN|rated|,|nervousness|in
D002110_D001008 CID caffeine_8\NN| (r_npadvmod) containing_10\VBG|caffeine|- (r_amod) foods_11\NNS|containing|and|beverages (r_dobj) avoiding_7\VBG|foods (r_pcomp) by_6\IN|avoiding (r_prep) benefit_5\VB|patients|may|by|. (l_nsubj) Patients_0\NNS|with (l_prep) with_1\IN|disorders (l_pobj) disorders_3\NNS|anxiety
D002110_D009325 CID Caffeine_0\NN| (r_nsubj) produced_1\VBD|caffeine|increases|compared|. (l_dobj) increases_4\NNS|greater|in (l_prep) in_5\IN|anxiety (l_pobj) anxiety_9\NN|rated|,|nervousness|in (l_conj) nervousness_11\NN|,|fear (l_conj) fear_13\NN|,|nausea (l_conj) nausea_15\NN|,|palpitations
D002110_-1 NONE Caffeine_0\NN| (r_nsubj) produced_1\VBD|caffeine|increases|compared|. (l_dobj) increases_4\NNS|greater|in (l_prep) in_5\IN|anxiety (l_pobj) anxiety_9\NN|rated|,|nervousness|in (l_conj) nervousness_11\NN|,|fear (l_conj) fear_13\NN|,|nausea (l_conj) nausea_15\NN|,|palpitations (l_conj) palpitations_17\NNS|,|restlessness
D002110_D011595 NONE Caffeine_0\NN| (r_nsubj) produced_1\VBD|caffeine|increases|compared|. (l_dobj) increases_4\NNS|greater|in (l_prep) in_5\IN|anxiety (l_pobj) anxiety_9\NN|rated|,|nervousness|in (l_conj) nervousness_11\NN|,|fear (l_conj) fear_13\NN|,|nausea (l_conj) nausea_15\NN|,|palpitations (l_conj) palpitations_17\NNS|,|restlessness (l_conj) restlessness_19\NN|,|and|tremors
D002110_D014202 CID Caffeine_0\NN| (r_nsubj) produced_1\VBD|caffeine|increases|compared|. (l_dobj) increases_4\NNS|greater|in (l_prep) in_5\IN|anxiety (l_pobj) anxiety_9\NN|rated|,|nervousness|in (l_conj) nervousness_11\NN|,|fear (l_conj) fear_13\NN|,|nausea (l_conj) nausea_15\NN|,|palpitations (l_conj) palpitations_17\NNS|,|restlessness (l_conj) restlessness_19\NN|,|and|tremors (l_conj) tremors_22\NNS|
D002110_D009421 NONE caffeine_1\NN| (r_nsubj) is_2\VBZ|because|caffeine|antagonist (r_advcl) suggest_10\VBP|is|,|results|have|. (l_ccomp) have_17\VB|that|patients|may|abnormalities (l_dobj) abnormalities_18\NNS|in (l_prep) in_19\IN|systems (l_pobj) systems_21\NNS|neuronal|involving
D000241_D016584 NONE adenosine_4\NN| (r_amod) antagonist_6\NN|an|adenosine|receptor (r_attr) is_2\VBZ|because|caffeine|antagonist (r_advcl) suggest_10\VBP|is|,|results|have|. (l_ccomp) have_17\VB|that|patients|may|abnormalities (l_nsubj) patients_15\NNS|some|disorder (l_compound) disorder_14\NN|panic
D000241_D016584 NONE adenosine_23\NN| (r_dobj) involving_22\VBG|adenosine (r_acl) systems_21\NNS|neuronal|involving (r_pobj) in_19\IN|systems (r_prep) abnormalities_18\NNS|in (r_dobj) have_17\VB|that|patients|may|abnormalities (l_nsubj) patients_15\NNS|some|disorder (l_compound) disorder_14\NN|panic
D000241_D009421 NONE adenosine_4\NN| (r_amod) antagonist_6\NN|an|adenosine|receptor (r_attr) is_2\VBZ|because|caffeine|antagonist (r_advcl) suggest_10\VBP|is|,|results|have|. (l_ccomp) have_17\VB|that|patients|may|abnormalities (l_dobj) abnormalities_18\NNS|in (l_prep) in_19\IN|systems (l_pobj) systems_21\NNS|neuronal|involving
D000241_D009421 NONE adenosine_23\NN| (r_dobj) involving_22\VBG|adenosine (r_acl) systems_21\NNS|neuronal|involving
24671324
C400082_D019115 CID bortezomib_3\NNS|and (r_amod) regimen_8\NN|bortezomib|containing|in (r_pobj) after_2\IN|regimen (r_prep) fasciitis_1\NN|necrotising|after|.
C400082_D019115 CID bortezomib_24\NNS| (r_amod) dexamethasone_29\NN|bortezomib|,|dose|and|rituximab (r_pobj) with_23\IN|dexamethasone (r_prep) treatment_22\NN|the|combination|with (r_pobj) after_19\IN|treatment (r_prep) suffered_14\VBD|who|fasciitis|without|after (l_dobj) fasciitis_16\NN|necrotising
C400082_D008258 NONE bortezomib_3\NNS|and (r_amod) regimen_8\NN|bortezomib|containing|in (l_prep) in_9\IN|patient (l_pobj) patient_12\NN|an|elderly|of (l_prep) of_13\IN|macroglobulinaemia (l_pobj) macroglobulinaemia_15\NN|waldenstrom
C400082_D008258 NONE bortezomib_24\NNS| (r_amod) dexamethasone_29\NN|bortezomib|,|dose|and|rituximab (r_pobj) with_23\IN|dexamethasone (r_prep) treatment_22\NN|the|combination|with (r_pobj) after_19\IN|treatment (r_prep) suffered_14\VBD|who|fasciitis|without|after (r_relcl) man_9\NN|a|old|with|suffered (l_prep) with_10\IN|macroglobulinaemia (l_pobj) macroglobulinaemia_12\NN|waldenstrom
D003907_D019115 CID dexamethasone_5\NN| (r_npadvmod) containing_7\VBG|dexamethasone|- (r_amod) regimen_8\NN|bortezomib|containing|in (r_pobj) after_2\IN|regimen (r_prep) fasciitis_1\NN|necrotising|after|.
D003907_D019115 CID dexamethasone_29\NN|bortezomib|,|dose|and|rituximab (r_pobj) with_23\IN|dexamethasone (r_prep) treatment_22\NN|the|combination|with (r_pobj) after_19\IN|treatment (r_prep) suffered_14\VBD|who|fasciitis|without|after (l_dobj) fasciitis_16\NN|necrotising
D003907_D008258 NONE dexamethasone_5\NN| (r_npadvmod) containing_7\VBG|dexamethasone|- (r_amod) regimen_8\NN|bortezomib|containing|in (l_prep) in_9\IN|patient (l_pobj) patient_12\NN|an|elderly|of (l_prep) of_13\IN|macroglobulinaemia (l_pobj) macroglobulinaemia_15\NN|waldenstrom
D003907_D008258 NONE dexamethasone_29\NN|bortezomib|,|dose|and|rituximab (r_pobj) with_23\IN|dexamethasone (r_prep) treatment_22\NN|the|combination|with (r_pobj) after_19\IN|treatment (r_prep) suffered_14\VBD|who|fasciitis|without|after (r_relcl) man_9\NN|a|old|with|suffered (l_prep) with_10\IN|macroglobulinaemia (l_pobj) macroglobulinaemia_12\NN|waldenstrom
C400082_D001424 NONE Bortezomib_0\NNP|and|regimens (r_nsubjpass) considered_10\VBN|bortezomib|are|be|. (l_xcomp) be_12\VB|to|tolerable (l_acomp) tolerable_14\JJ|generally|with (l_prep) with_15\IN|infections (l_pobj) infections_19\NNS|few|severe|bacterial|in
C400082_D001424 NONE bortezomib_11\NNS|plus (r_amod) dexamethasone_16\NN|bortezomib|dose|in (r_pobj) to_10\IN|dexamethasone (r_prep) related_9\VBN|to (r_acl) infections_8\NNS|fatal|bacterial|related
C400082_D009369 NONE Bortezomib_0\NNP|and|regimens (r_nsubjpass) considered_10\VBN|bortezomib|are|be|. (l_xcomp) be_12\VB|to|tolerable (l_acomp) tolerable_14\JJ|generally|with (l_prep) with_15\IN|infections (l_pobj) infections_19\NNS|few|severe|bacterial|in (l_prep) in_20\IN|patients (l_pobj) patients_21\NNS|with (l_prep) with_22\IN|malignancies (l_pobj) malignancies_26\NNS|cell
D003907_D001424 NONE dexamethasone_5\NN| (r_npadvmod) containing_7\VBG|dexamethasone|- (r_amod) regimens_8\NNS|dose|containing (r_conj) Bortezomib_0\NNP|and|regimens (r_nsubjpass) considered_10\VBN|bortezomib|are|be|. (l_xcomp) be_12\VB|to|tolerable (l_acomp) tolerable_14\JJ|generally|with (l_prep) with_15\IN|infections (l_pobj) infections_19\NNS|few|severe|bacterial|in
D003907_D001424 NONE dexamethasone_16\NN|bortezomib|dose|in (r_pobj) to_10\IN|dexamethasone (r_prep) related_9\VBN|to (r_acl) infections_8\NNS|fatal|bacterial|related
D003907_D009369 NONE dexamethasone_5\NN| (r_npadvmod) containing_7\VBG|dexamethasone|- (r_amod) regimens_8\NNS|dose|containing (r_conj) Bortezomib_0\NNP|and|regimens (r_nsubjpass) considered_10\VBN|bortezomib|are|be|. (l_xcomp) be_12\VB|to|tolerable (l_acomp) tolerable_14\JJ|generally|with (l_prep) with_15\IN|infections (l_pobj) infections_19\NNS|few|severe|bacterial|in (l_prep) in_20\IN|patients (l_pobj) patients_21\NNS|with (l_prep) with_22\IN|malignancies (l_pobj) malignancies_26\NNS|cell
C400082_D009503 NONE bortezomib_24\NNS| (r_amod) dexamethasone_29\NN|bortezomib|,|dose|and|rituximab (r_pobj) with_23\IN|dexamethasone (r_prep) treatment_22\NN|the|combination|with (r_pobj) after_19\IN|treatment (r_prep) suffered_14\VBD|who|fasciitis|without|after (l_prep) without_17\IN|neutropenia (l_pobj) neutropenia_18\NN|
D003907_D009503 NONE dexamethasone_29\NN|bortezomib|,|dose|and|rituximab (r_pobj) with_23\IN|dexamethasone (r_prep) treatment_22\NN|the|combination|with (r_pobj) after_19\IN|treatment (r_prep) suffered_14\VBD|who|fasciitis|without|after (l_prep) without_17\IN|neutropenia (l_pobj) neutropenia_18\NN|
612112
D005045_D009207 CID etomidate_5\NN| (r_nsubj) prove_7\VB|that|etomidate|will|be (l_xcomp) be_9\VB|to|hypnotic|because (l_prep) because_22\IN|of|incidence (l_pobj) incidence_26\NN|the|high|of|after (l_prep) of_27\IN|myoclonia (l_pobj) myoclonia_28\NN|
24088636
C098010_D009901 CID Linezolid_0\NNP| (r_npadvmod) induced_2\VBN|linezolid|- (r_amod) neuropathy_4\NN|induced|optic|.
C098010_D014786 NONE linezolid_11\NN| (r_amod) therapy_12\NN|linezolid (r_pobj) with_10\IN|therapy (r_prep) associated_9\VBN|with (r_acl) vision_8\NN|associated
C098010_D014786 NONE linezolid_20\NN|and|ethambutol (r_pobj) including_19\VBG|linezolid (r_prep) drugs_18\NNS|multiple|line|tuberculous|including (r_pobj) with_10\IN|drugs (r_prep) treatment_9\NN|with (r_pobj) on_8\IN|treatment (r_prep) was_7\VBD|who|on (r_relcl) patient_5\NN|a|old|male|was (r_nsubj) presented_34\VBN|patient|to|with|. (l_prep) with_37\IN|loss (l_pobj) loss_40\NN|painless|progressive|of|in (l_prep) of_41\IN|vision (l_pobj) vision_42\NN|
C098010_D054908 NONE linezolid_20\NN|and|ethambutol (l_conj) ethambutol_22\NN|for (l_prep) for_23\IN|tuberculosis (l_pobj) tuberculosis_28\NN|resistant|tb
C098010_D054908 NONE linezolid_20\NN|and|ethambutol (l_conj) ethambutol_22\NN|for (l_prep) for_23\IN|tuberculosis (l_pobj) tuberculosis_28\NN|resistant|tb (l_appos) TB_32\NNP|(|xdr|-|)
D004977_D054908 NONE ethambutol_22\NN|for (l_prep) for_23\IN|tuberculosis (l_pobj) tuberculosis_28\NN|resistant|tb
D004977_D054908 NONE ethambutol_22\NN|for (l_prep) for_23\IN|tuberculosis (l_pobj) tuberculosis_28\NN|resistant|tb (l_appos) TB_32\NNP|(|xdr|-|)
D004977_D014786 NONE ethambutol_22\NN|for (r_conj) linezolid_20\NN|and|ethambutol (r_pobj) including_19\VBG|linezolid (r_prep) drugs_18\NNS|multiple|line|tuberculous|including (r_pobj) with_10\IN|drugs (r_prep) treatment_9\NN|with (r_pobj) on_8\IN|treatment (r_prep) was_7\VBD|who|on (r_relcl) patient_5\NN|a|old|male|was (r_nsubj) presented_34\VBN|patient|to|with|. (l_prep) with_37\IN|loss (l_pobj) loss_40\NN|painless|progressive|of|in (l_prep) of_41\IN|vision (l_pobj) vision_42\NN|
D004977_D009901 NONE Ethambutol_0\NNP| (r_npadvmod) induced_2\VBN|ethambutol|- (r_amod) neuropathy_5\NN|induced|optic
D004977_D009901 NONE ethambutol_10\NN|tablet (r_nsubjpass) withdrawn_12\VBN|ethambutol|was|. (r_conj) suspected_7\VBN|neuropathy|was|and|withdrawn (l_nsubjpass) neuropathy_5\NN|induced|optic
D004977_D015354 NONE ethambutol_7\NN| (r_pobj) of_6\IN|ethambutol (r_prep) withdrawal_5\NN|of (r_pobj) despite_4\IN|withdrawal (r_prep) occurred_3\VBD|deterioration|despite|. (l_nsubj) Deterioration_0\NN|of (l_prep) of_1\IN|vision (l_pobj) vision_2\NN|
9782254
D007980_D010300 NONE DOPA_28\NNP| (r_npadvmod) induced_30\VBN|l|-|dopa|- (r_amod) dyskinesias_31\NNS|induced (r_conj) rigidity_23\NN|,|and|dyskinesias (r_conj) bradykinesia_21\NN|,|rigidity (r_pobj) of_20\IN|bradykinesia (r_prep) treatment_19\NN|of (r_pobj) for_18\IN|treatment (r_prep) underwent_8\VBD|patients|pallidotomy|between|for|. (l_nsubj) patients_1\NNS|51|with (l_prep) with_2\IN|disease (l_pobj) disease_7\NN|refractory|parkinson
D007980_D018476 NONE DOPA_28\NNP| (r_npadvmod) induced_30\VBN|l|-|dopa|- (r_amod) dyskinesias_31\NNS|induced (r_conj) rigidity_23\NN|,|and|dyskinesias (r_conj) bradykinesia_21\NN|,|rigidity
D007980_D009127 NONE DOPA_28\NNP| (r_npadvmod) induced_30\VBN|l|-|dopa|- (r_amod) dyskinesias_31\NNS|induced (r_conj) rigidity_23\NN|,|and|dyskinesias
D007980_D004409 CID DOPA_28\NNP| (r_npadvmod) induced_30\VBN|l|-|dopa|- (r_amod) dyskinesias_31\NNS|induced
12165618
D019469_-1 NONE indinavir_18\NNS| (r_pobj) with_17\IN|indinavir (r_prep) treated_16\VBN|with (r_acl) children_15\NNS|1-infected|treated (r_dobj) associated_4\VBN|leukocyturia|is|with|children|. (l_nsubjpass) leukocyturia_2\NN|persistent|sterile
D019469_-1 NONE indinavir_30\NNS| (r_pobj) of_29\IN|indinavir (r_prep) level_28\NN|a|peak|serum|of (r_conj) L_21\NN|19|mg|/|x|h|or|level (r_appos) >_17\XX|l (r_meta) found_8\VBN|incidence|was|in|> (l_nsubjpass) incidence_3\NN|a|higher|cumulative|of (l_prep) of_4\IN|leukocyturia (l_pobj) leukocyturia_6\NN|persistent
D019469_-1 NONE indinavir_3\NNS| (r_pobj) with_2\IN|indinavir (r_prep) treated_1\VBN|children|with (r_csubj) have_4\VBP|treated|incidence|. (l_dobj) incidence_8\NN|a|high|cumulative|of (l_prep) of_9\IN|leukocyturia (l_pobj) leukocyturia_12\NN|persistent|sterile
D019469_-1 NONE Indinavir_0\NNP| (r_npadvmod) associated_2\VBN|indinavir|- (r_amod) nephrotoxicity_3\NN|associated (r_nsubjpass) monitored_6\VBN|nephrotoxicity|must|be|closely|,|in|age (l_prep) in_10\IN|especially|children (l_pobj) children_11\NNS|with (l_prep) with_12\IN|factors (l_pobj) factors_14\NNS|risk|as (l_prep) as_16\IN|such|leukocyturia (l_pobj) leukocyturia_19\NN|persistent|sterile|,
D019469_-1 NONE indinavir_32\NNS| (r_pobj) of_31\IN|indinavir (r_prep) curve_30\NN|the|of (r_pobj) under_28\IN|curve (r_prep) area_27\NN|an|under (r_appos) age_21\NN|<|years|,|area (r_appos) monitored_6\VBN|nephrotoxicity|must|be|closely|,|in|age (l_prep) in_10\IN|especially|children (l_pobj) children_11\NNS|with (l_prep) with_12\IN|factors (l_pobj) factors_14\NNS|risk|as (l_prep) as_16\IN|such|leukocyturia (l_pobj) leukocyturia_19\NN|persistent|sterile|,
D019469_D007674 CID indinavir_18\NNS| (r_pobj) with_17\IN|indinavir (r_prep) treated_16\VBN|with (r_acl) children_15\NNS|1-infected|treated (r_dobj) associated_4\VBN|leukocyturia|is|with|children|. (l_prep) with_5\IN|function (l_pobj) function_8\NN|impaired|renal|in
D019469_D007674 CID indinavir_5\NNS| (r_npadvmod) related_7\VBN|indinavir|- (r_amod) nephrotoxicity_8\NN|related
D019469_D007674 CID indinavir_22\NNS| (r_pobj) with_21\IN|indinavir (r_prep) treated_20\VBN|with (r_acl) children_19\NNS|type|1-infected|treated (r_pobj) of_12\IN|children (r_prep) cohort_11\NN|a|of (r_pobj) in_9\IN|cohort (r_prep) monitor_4\VB|to|nephrotoxicity|in (l_dobj) nephrotoxicity_8\NN|related
D019469_D007674 CID indinavir_4\NNS| (r_nsubjpass) discontinued_6\VBN|in|,|indinavir|was|of|. (l_prep) of_8\IN|because|nephrotoxicity (l_pobj) nephrotoxicity_9\NN|
D019469_D007674 CID Indinavir_0\NNP| (r_npadvmod) associated_2\VBN|indinavir|- (r_amod) nephrotoxicity_3\NN|associated
D019469_D007674 CID indinavir_32\NNS| (r_pobj) of_31\IN|indinavir (r_prep) curve_30\NN|the|of (r_pobj) under_28\IN|curve (r_prep) area_27\NN|an|under (r_appos) age_21\NN|<|years|,|area (r_appos) monitored_6\VBN|nephrotoxicity|must|be|closely|,|in|age (l_nsubjpass) nephrotoxicity_3\NN|associated
D019469_D015658 NONE indinavir_18\NNS| (r_pobj) with_17\IN|indinavir (r_prep) treated_16\VBN|with (r_acl) children_15\NNS|1-infected|treated (l_amod) 1-infected_14\VBN|
D019469_D015658 NONE indinavir_5\NNS| (r_npadvmod) related_7\VBN|indinavir|- (r_amod) nephrotoxicity_8\NN|related (r_dobj) monitor_4\VB|to|nephrotoxicity|in (l_prep) in_9\IN|cohort (l_pobj) cohort_11\NN|a|of (l_prep) of_12\IN|children (l_pobj) children_19\NNS|type|1-infected|treated (l_amod) 1-infected_18\VBN|
D019469_D015658 NONE indinavir_22\NNS| (r_pobj) with_21\IN|indinavir (r_prep) treated_20\VBN|with (r_acl) children_19\NNS|type|1-infected|treated (l_amod) 1-infected_18\VBN|
D003404_-1 NONE creatinine_15\NN|/ (r_compound) ratio_16\NN|albumin|creatinine (r_appos) urine_12\NN|the|ratio (r_pobj) in_10\IN|urine|and|by (r_prep) increase_9\NN|a|mild|in (r_pobj) with_6\IN|increase (r_prep) associated_5\VBN|leukocyturia|was|frequently|with|. (l_nsubjpass) leukocyturia_2\NN|persistent|sterile
D003404_-1 NONE creatinine_9\JJ| (r_compound) levels_10\NNS|serum|creatinine|of (r_dobj) had_7\VBD|children|frequently|levels|without|. (l_nsubj) Children_0\NNS|with (l_prep) with_1\IN|leukocyturia (l_pobj) leukocyturia_4\NN|persistent|sterile
D003404_-1 NONE creatinine_9\JJ| (r_compound) levels_10\NNS|serum|creatinine|of (r_dobj) had_7\VBD|children|frequently|levels|without|. (l_prep) without_19\IN|leukocyturia (l_pobj) leukocyturia_22\NN|persistent|sterile
D003404_-1 NONE creatinine_4\NN| (r_compound) levels_5\NNS|the|serum|creatinine (r_nsubj) decreased_6\VBD|subsequently|,|levels|,|returned (l_conj) returned_14\VBD|ratios|to|,|and|disappeared (l_conj) disappeared_21\VBD|leukocyturia|within|. (l_nsubj) leukocyturia_20\NN|the
D003404_-1 NONE creatinine_12\NN|/ (r_compound) ratios_13\NNS|urine|albumin|creatinine (r_nsubj) returned_14\VBD|ratios|to|,|and|disappeared (l_conj) disappeared_21\VBD|leukocyturia|within|. (l_nsubj) leukocyturia_20\NN|the
D003404_-1 NONE creatinine_12\NN| (r_compound) levels_13\NNS|serum|creatinine|of (r_pobj) in_10\IN|levels (r_prep) increase_9\NN|an|in|above (r_dobj) had_7\VBD|children|frequently|increase|. (l_nsubj) Children_0\NNS|with (l_prep) with_1\IN|leukocyturia (l_pobj) leukocyturia_4\NN|persistent|sterile
D003404_D006417 NONE creatinine_15\NN|/ (r_compound) ratio_16\NN|albumin|creatinine (r_appos) urine_12\NN|the|ratio (r_pobj) in_10\IN|urine|and|by (l_conj) by_18\IN|hematuria (l_pobj) hematuria_20\NN|microscopic
9759693
D018170_D017091 CID sumatriptan_3\JJ| (r_amod) use_4\NN|sumatriptan (r_conj) colitis_1\NN|ischemic|and|use|.
D018170_D017091 CID sumatriptan_18\NNP| (r_pobj) with_17\IN|sumatriptan (r_prep) treated_16\VBN|with (r_acl) migraine_15\NN|treated (r_pobj) with_14\IN|migraine (r_prep) patients_13\NNS|with (r_pobj) in_12\IN|patients (r_prep) development_4\NN|the|of|in (l_prep) of_5\IN|cases (l_pobj) cases_8\NNS|8|serious|of (l_prep) of_9\IN|colitis (l_pobj) colitis_11\NN|ischemic
D018170_D003329 NONE sumatriptan_16\JJ| (r_compound) use_17\NN|sumatriptan (r_pobj) after_15\IN|use (r_prep) occurring_14\VBG|after (r_acl) infarction_13\NN|myocardial|occurring (r_conj) ischemia_9\NN|myocardial|,|and|infarction (r_conj) vasospasm_6\NN|coronary|,|ischemia
D018170_D017202 NONE sumatriptan_16\JJ| (r_compound) use_17\NN|sumatriptan (r_pobj) after_15\IN|use (r_prep) occurring_14\VBG|after (r_acl) infarction_13\NN|myocardial|occurring (r_conj) ischemia_9\NN|myocardial|,|and|infarction
D018170_D009203 NONE sumatriptan_16\JJ| (r_compound) use_17\NN|sumatriptan (r_pobj) after_15\IN|use (r_prep) occurring_14\VBG|after (r_acl) infarction_13\NN|myocardial|occurring
D018170_D008881 NONE sumatriptan_18\NNP| (r_pobj) with_17\IN|sumatriptan (r_prep) treated_16\VBN|with (r_acl) migraine_15\NN|treated
26033014
C051786_D009369 NONE metolachlor_3\JJ| (r_amod) use_4\NN|metolachlor|in (r_conj) incidence_1\NN|cancer|and|use (l_compound) Cancer_0\NN|
C051786_D009369 NONE metolachlor_22\NN| (r_dobj) using_21\VBG|ever|metolachlor (r_xcomp) reported_19\VBD|%|using (r_advcl) evaluated_1\VBD|we|incidence|through|for|reported|. (l_dobj) incidence_3\NN|cancer (l_compound) cancer_2\NN|
C051786_D009369 NONE metolachlor_11\JJ| (r_amod) use_12\NN|metolachlor (r_pobj) of_10\IN|use (r_prep) metrics_9\NNS|two|of|(|days|)|and|incidence (l_conj) incidence_25\NN|cancer (l_compound) cancer_24\NN|
C051786_D009369 NONE metolachlor_5\JJ| (r_amod) use_6\NN|metolachlor|and|incidence|5,701 (l_conj) incidence_8\NN|of (l_prep) of_9\IN|cancers (l_pobj) cancers_11\NNS|all
C051786_D009369 NONE metolachlor_5\JJ| (r_amod) use_6\NN|metolachlor|and|incidence|5,701 (r_pobj) between_4\IN|use (r_prep) association_3\NN|no|between|with (l_prep) with_17\IN|lag (l_pobj) lag_20\NN|a|5-year|)|or|cancers (l_conj) cancers_27\NNS|most|specific
C051786_D008113 CID Metolachlor_0\NNP|,|herbicide|, (r_nsubjpass) classified_8\VBN|metolachlor|is|as|by|based|. (l_prep) based_20\VBN|on (l_prep) on_21\IN|neoplasms (l_pobj) neoplasms_24\NNS|increased|liver|in
C051786_D008113 CID metolachlor_6\NN|and (r_nmod) cancer_9\NN|metolachlor|liver|among
C051786_D008113 CID metolachlor_6\NN|and (r_nmod) cancer_9\NN|metolachlor|liver|among (r_pobj) between_5\IN|cancer (r_prep) association_4\NN|an|between (r_pobj) of_2\IN|association (r_prep) suggestion_1\NN|this|of (r_nsubj) is_13\VBZ|suggestion|finding|. (l_attr) finding_16\NN|a|novel|and|echoes (l_conj) echoes_18\VBZ|observation|in (l_dobj) observation_19\NN|of (l_prep) of_20\IN|neoplasms (l_pobj) neoplasms_23\NNS|increased|liver
C051786_D008113 CID metolachlor_21\JJ| (r_amod) use_22\NN|metolachlor|from (r_pobj) of_20\IN|use (r_prep) effects_19\NNS|differentiate|of (r_pobj) to_16\TO|effects (r_prep) up_15\NN|warrant|follow|-|to (r_conj) cancer_7\NN|both|liver|and|up
C051786_D008175 NONE metolachlor_12\JJ| (r_amod) use_13\NN|metolachlor|in (r_pobj) of_11\IN|use (r_prep) levels_10\NNS|high|of (r_pobj) at_8\IN|levels (r_prep) risk_7\NN|increased|cancer|at (l_compound) cancer_6\NN|lung
C051786_D008223 NONE metolachlor_21\JJ| (r_amod) use_22\NN|metolachlor|from (r_pobj) of_20\IN|use (r_prep) effects_19\NNS|differentiate|of (r_pobj) to_16\TO|effects (r_prep) up_15\NN|warrant|follow|-|to (l_compound) warrant_12\NN|lymphoma (l_compound) lymphoma_11\NN|cell
24675088
D004317_D066126 NONE doxorubicin_12\RB| (r_npadvmod) induced_14\VBN|doxorubicin|- (r_amod) cardiotoxicity_15\NN|induced
D004317_D009202 CID doxorubicin_12\NN|progressive|cardiomyopathy (l_appos) cardiomyopathy_15\NN|(|dox)-induced
D004317_D009202 CID DOX)-induced_14\VBN| (r_amod) cardiomyopathy_15\NN|(|dox)-induced
D004317_D064420 NONE doxorubicin_12\NN|progressive|cardiomyopathy (r_pobj) of_10\IN|doxorubicin (r_prep) model_9\NN|a|rat|of (r_dobj) utilized_6\VBN|in|,|we|have|model|,|applying|. (l_advcl) applying_17\VBG|approaches|,|provide (l_conj) provide_31\VB|to|characterization (l_dobj) characterization_35\NN|the|comprehensive|to (l_prep) to_36\IN|date (l_pobj) date_37\NN|of (l_prep) of_38\IN|timecourse (l_pobj) timecourse_40\NN|the|of (l_prep) of_41\IN|events (l_pobj) events_48\NNS|serological|underlying (l_acl) underlying_49\VBG|toxicity (l_dobj) toxicity_51\NN|this
D004317_D064420 NONE DOX)-induced_14\VBN| (r_amod) cardiomyopathy_15\NN|(|dox)-induced (r_appos) doxorubicin_12\NN|progressive|cardiomyopathy (r_pobj) of_10\IN|doxorubicin (r_prep) model_9\NN|a|rat|of (r_dobj) utilized_6\VBN|in|,|we|have|model|,|applying|. (l_advcl) applying_17\VBG|approaches|,|provide (l_conj) provide_31\VB|to|characterization (l_dobj) characterization_35\NN|the|comprehensive|to (l_prep) to_36\IN|date (l_pobj) date_37\NN|of (l_prep) of_38\IN|timecourse (l_pobj) timecourse_40\NN|the|of (l_prep) of_41\IN|events (l_pobj) events_48\NNS|serological|underlying (l_acl) underlying_49\VBG|toxicity (l_dobj) toxicity_51\NN|this
D005682_D018754 NONE gadolinium_9\NN|delayed (r_compound) enhancement_11\NN|gadolinium|contrast|,|grading (l_conj) grading_14\NN|histopathological|,|and|dysfunction (l_conj) dysfunction_18\NN|diastolic
17384765
D004113_D003072 CID Succimer_0\NNP| (r_compound) chelation_1\NN|succimer (r_nsubj) improves_2\VBZ|chelation|learning|but|produces|. (l_conj) produces_16\VBZ|impairment|in (l_dobj) impairment_19\NN|lasting|cognitive
D004113_D003072 NONE succimer_3\JJ| (r_amod) treatment_4\NN|succimer|of|exposed (r_nsubj) produced_12\VBD|in|,|treatment|dysfunction|. (l_dobj) dysfunction_19\NN|cognitive|affective|comparable
D007854_D003072 NONE lead_11\NN| (r_npadvmod) exposed_13\VBN|lead|- (r_amod) rats_14\NNS|exposed (r_pobj) in_10\IN|rats (r_prep) regulation_9\NN|arousal|in (r_conj) attention_5\NN|,|and|regulation (r_conj) learning_3\VBG|,|attention (r_xcomp) improves_2\VBZ|chelation|learning|but|produces|. (l_conj) produces_16\VBZ|impairment|in (l_dobj) impairment_19\NN|lasting|cognitive
D007854_D003072 NONE lead_24\JJ| (r_amod) exposure_25\NN|lead (r_pobj) of_23\IN|exposure (r_prep) absence_22\NN|the|of (r_pobj) in_20\IN|absence (r_prep) produces_16\VBZ|impairment|in (l_dobj) impairment_19\NN|lasting|cognitive
D007854_D003072 NONE Pb_11\NNP| (r_pobj) to_10\IN|pb (r_prep) exposed_9\VBN|not|previously|to (r_acl) treatment_4\NN|succimer|of|exposed (r_nsubj) produced_12\VBD|in|,|treatment|dysfunction|. (l_dobj) dysfunction_19\NN|cognitive|affective|comparable
D007854_D003072 NONE Pb_29\NNP| (r_compound) regimen_31\NN|the|higher|pb|exposure (r_pobj) by_26\IN|regimen (r_agent) produced_25\VBN|by (r_acl) that_24\DT|produced (r_pobj) to_23\IN|that (r_prep) magnitude_22\NN|to (r_pobj) in_21\IN|magnitude (r_prep) comparable_20\JJ|in (r_amod) dysfunction_19\NN|cognitive|affective|comparable
D007854_D003072 NONE Pb_24\NNP| (r_compound) exposure_25\NN|pb (r_pobj) due_22\IN|to|exposure (r_prep) alleviate_19\VB|can|deficits|due (l_dobj) deficits_21\NNS|cognitive
D007854_D007855 NONE Pb_17\NNP| (r_compound) exposure_18\NN|pb|and|treatment|with|,|agent (l_appos) agent_28\NN|a|used|chelating|for (l_prep) for_29\IN|treatment (l_pobj) treatment_31\NN|the|of (l_prep) of_32\IN|poisoning (l_pobj) poisoning_34\NN|pb
D004113_D007855 NONE succimer_22\NN| (r_pobj) with_21\IN|succimer (r_prep) exposure_18\NN|pb|and|treatment|with|,|agent (l_appos) agent_28\NN|a|used|chelating|for (l_prep) for_29\IN|treatment (l_pobj) treatment_31\NN|the|of (l_prep) of_32\IN|poisoning (l_pobj) poisoning_34\NN|pb
D007854_D007859 CID Pb_0\NNP| (r_amod) exposure_1\NN|pb (r_nsubj) produced_2\VBD|exposure|impairments|paralleling|. (l_dobj) impairments_4\NNS|lasting|in (l_prep) in_5\IN|learning (l_pobj) learning_6\NN|,|attention (l_conj) attention_8\NN|,|control (l_conj) control_11\NN|inhibitory|,|and|regulation (l_conj) regulation_15\NN|arousal|,
D007854_D007859 CID Pb_24\NNP| (r_npadvmod) exposed_26\VBN|pb|- (r_amod) children_27\NNS|exposed (r_pobj) in_23\IN|children (r_prep) seen_22\VBN|in (r_acl) dysfunction_21\NN|seen (r_pobj) of_20\IN|dysfunction (r_prep) areas_19\NNS|the|of (r_dobj) paralleling_17\VBG|areas (r_advcl) produced_2\VBD|exposure|impairments|paralleling|. (l_dobj) impairments_4\NNS|lasting|in (l_prep) in_5\IN|learning (l_pobj) learning_6\NN|,|attention (l_conj) attention_8\NN|,|control (l_conj) control_11\NN|inhibitory|,|and|regulation (l_conj) regulation_15\NN|arousal|,
D007854_D019958 CID Pb_0\NNP| (r_amod) exposure_1\NN|pb (r_nsubj) produced_2\VBD|exposure|impairments|paralleling|. (l_dobj) impairments_4\NNS|lasting|in (l_prep) in_5\IN|learning (l_pobj) learning_6\NN|,|attention (l_conj) attention_8\NN|,|control (l_conj) control_11\NN|inhibitory|,|and|regulation (l_conj) regulation_15\NN|arousal|,
D007854_D019958 CID Pb_24\NNP| (r_npadvmod) exposed_26\VBN|pb|- (r_amod) children_27\NNS|exposed (r_pobj) in_23\IN|children (r_prep) seen_22\VBN|in (r_acl) dysfunction_21\NN|seen (r_pobj) of_20\IN|dysfunction (r_prep) areas_19\NNS|the|of (r_dobj) paralleling_17\VBG|areas (r_advcl) produced_2\VBD|exposure|impairments|paralleling|. (l_dobj) impairments_4\NNS|lasting|in (l_prep) in_5\IN|learning (l_pobj) learning_6\NN|,|attention (l_conj) attention_8\NN|,|control (l_conj) control_11\NN|inhibitory|,|and|regulation (l_conj) regulation_15\NN|arousal|,
D004113_D019964 NONE succimer_3\JJ| (r_amod) treatment_4\NN|succimer|of|exposed (r_nsubj) produced_12\VBD|in|,|treatment|dysfunction|. (l_dobj) dysfunction_19\NN|cognitive|affective|comparable
D007854_D019964 NONE Pb_11\NNP| (r_pobj) to_10\IN|pb (r_prep) exposed_9\VBN|not|previously|to (r_acl) treatment_4\NN|succimer|of|exposed (r_nsubj) produced_12\VBD|in|,|treatment|dysfunction|. (l_dobj) dysfunction_19\NN|cognitive|affective|comparable
D007854_D019964 NONE Pb_29\NNP| (r_compound) regimen_31\NN|the|higher|pb|exposure (r_pobj) by_26\IN|regimen (r_agent) produced_25\VBN|by (r_acl) that_24\DT|produced (r_pobj) to_23\IN|that (r_prep) magnitude_22\NN|to (r_pobj) in_21\IN|magnitude (r_prep) comparable_20\JJ|in (r_amod) dysfunction_19\NN|cognitive|affective|comparable
12051122
D014750_D007010 CID Vincristine_14\NNP|:|representation (r_pobj) of_13\IN|vincristine (r_prep) use_12\NN|the|of (r_pobj) with_10\IN|use (r_prep) reported_9\VBN|with (r_acl) hormone_8\NN|inappropriate|-|diuretic|reported (r_pobj) of_3\IN|hormone (r_prep) syndrome_2\NN|of (r_conj) Hyponatremia_0\NNP|and|syndrome|?
D014750_D007010 CID vincristine_32\NN| (r_npadvmod) treated_34\VBN|vincristine|- (r_amod) patients_35\NNS|treated (r_pobj) among_31\IN|patients (r_prep) SIADH_29\NNP|(|)|among (r_appos) hormone_27\NN|-|diuretic|siadh (r_pobj) of_23\IN|hormone (r_prep) secretion_22\NN|inappropriate|of (r_pobj) of_20\IN|secretion (r_prep) syndrome_19\NN|of (r_conj) hyponatremia_17\NN|and/or|syndrome
D014750_D007010 CID vincristine_33\NN| (r_pobj) of_32\IN|vincristine (r_prep) use_31\NN|the|of (r_pobj) during_29\IN|use (r_prep) reported_28\VBN|that|had|been|during (r_relcl) Lilly_4\NNP|the|eli|and|database|reported (l_conj) database_11\NN|company|computerized|event|for (l_prep) for_12\IN|cases (l_pobj) cases_15\NNS|all|reported|of (l_prep) of_16\IN|hyponatremia (l_pobj) hyponatremia_17\NN|and/or|siadh
D014750_D007010 CID vincristine_11\NN| (r_compound) use_12\NN|vincristine (r_pobj) with_10\IN|use (r_prep) associated_9\VBD|with (r_acl) total_1\NN|a|of|associated (l_prep) of_2\IN|cases (l_pobj) cases_4\NNS|76|of (l_prep) of_5\IN|hyponatremia (l_pobj) hyponatremia_6\NN|and/or|siadh
D014750_D007010 CID vincristine_17\NN| (r_compound) use_18\NN|vincristine (r_pobj) with_16\IN|use (r_prep) associated_15\VBD|with (r_acl) risk_10\NN|increased|of|associated (l_prep) of_11\IN|hyponatremia (l_pobj) hyponatremia_12\NN|and/or|siadh
D014750_D007177 CID Vincristine_14\NNP|:|representation (r_pobj) of_13\IN|vincristine (r_prep) use_12\NN|the|of (r_pobj) with_10\IN|use (r_prep) reported_9\VBN|with (r_acl) hormone_8\NN|inappropriate|-|diuretic|reported
D014750_D007177 CID vincristine_32\NN| (r_npadvmod) treated_34\VBN|vincristine|- (r_amod) patients_35\NNS|treated (r_pobj) among_31\IN|patients (r_prep) SIADH_29\NNP|(|)|among (r_appos) hormone_27\NN|-|diuretic|siadh
D014750_D007177 CID vincristine_32\NN| (r_npadvmod) treated_34\VBN|vincristine|- (r_amod) patients_35\NNS|treated (r_pobj) among_31\IN|patients (r_prep) SIADH_29\NNP|(|)|among
D014750_D007177 CID vincristine_33\NN| (r_pobj) of_32\IN|vincristine (r_prep) use_31\NN|the|of (r_pobj) during_29\IN|use (r_prep) reported_28\VBN|that|had|been|during (r_relcl) Lilly_4\NNP|the|eli|and|database|reported (l_conj) database_11\NN|company|computerized|event|for (l_prep) for_12\IN|cases (l_pobj) cases_15\NNS|all|reported|of (l_prep) of_16\IN|hyponatremia (l_pobj) hyponatremia_17\NN|and/or|siadh (l_conj) SIADH_19\NNP|
D014750_D007177 CID vincristine_11\NN| (r_compound) use_12\NN|vincristine (r_pobj) with_10\IN|use (r_prep) associated_9\VBD|with (r_acl) total_1\NN|a|of|associated (l_prep) of_2\IN|cases (l_pobj) cases_4\NNS|76|of (l_prep) of_5\IN|hyponatremia (l_pobj) hyponatremia_6\NN|and/or|siadh (l_conj) SIADH_8\NNP|
D014750_D007177 CID vincristine_17\NN| (r_compound) use_18\NN|vincristine (r_pobj) with_16\IN|use (r_prep) associated_15\VBD|with (r_acl) risk_10\NN|increased|of|associated (l_prep) of_11\IN|hyponatremia (l_pobj) hyponatremia_12\NN|and/or|siadh (l_conj) SIADH_14\NNP|
D014750_D007177 CID vincristine_9\NN| (r_pobj) with_8\IN|vincristine (r_prep) associated_7\VBN|with (r_acl) rate_4\NN|the|overall|reported|of|associated (l_prep) of_5\IN|siadh (l_pobj) SIADH_6\NNP|
24283660
D016559_D012640 CID Tacrolimus_0\NNP| (r_npadvmod) related_2\VBN|tacrolimus|- (r_amod) seizure_3\NN|related|after|--|experience|.
D016559_D012640 CID TAC_41\NNP| (r_compound) level_42\NN|tac (r_pobj) trough_40\NN|level (r_conj) bilirubin_35\NN|total|after|,|and|trough (r_conj) score_29\NN|showed|,|pugh|before|,|bilirubin|. (l_ccomp) showed_2\VBD|analysis|included (l_ccomp) included_13\VBD|that|factors|after|lt|gender (l_nsubj) factors_6\NNS|the|risk|associated (l_acl) associated_7\VBN|with (l_prep) with_8\IN|seizures (l_pobj) seizures_9\NNS|
D016559_D012640 CID TAC_5\NNP| (r_compound) level_6\NN|trough|tac (r_nsubj) was_7\VBD|that|level|factor (l_attr) factor_12\NN|the|only|independent|risk|associated (l_acl) associated_13\VBN|with (l_prep) with_14\IN|seizures (l_pobj) seizures_16\NNS|the
D016559_D012640 CID TAC_2\NNP| (r_compound) level_3\NN|high|trough|tac (r_nsubj) was_4\VBD|level|factor|. (l_attr) factor_7\NN|the|predominant|contributed (l_relcl) contributed_9\VBD|that|to (l_prep) to_10\IN|seizures (l_pobj) seizures_11\NNS|in
D016559_D012640 CID TAC_22\NNP| (r_npadvmod) related_24\VBN|tac|- (r_amod) seizures_25\NNS|related
D001663_D012640 NONE bilirubin_35\NN|total|after|,|and|trough (r_conj) score_29\NN|showed|,|pugh|before|,|bilirubin|. (l_ccomp) showed_2\VBD|analysis|included (l_ccomp) included_13\VBD|that|factors|after|lt|gender (l_nsubj) factors_6\NNS|the|risk|associated (l_acl) associated_7\VBN|with (l_prep) with_8\IN|seizures (l_pobj) seizures_9\NNS|
D001663_D058625 NONE bilirubin_35\NN|total|after|,|and|trough (r_conj) score_29\NN|showed|,|pugh|before|,|bilirubin|. (l_ccomp) showed_2\VBD|analysis|included (l_ccomp) included_13\VBD|that|factors|after|lt|gender (l_dobj) gender_14\NN|,|score (l_conj) score_22\NN|disease|before (l_compound) disease_21\NN|pediatric|stage|liver
D016559_D058625 NONE TAC_41\NNP| (r_compound) level_42\NN|tac (r_pobj) trough_40\NN|level (r_conj) bilirubin_35\NN|total|after|,|and|trough (r_conj) score_29\NN|showed|,|pugh|before|,|bilirubin|. (l_ccomp) showed_2\VBD|analysis|included (l_ccomp) included_13\VBD|that|factors|after|lt|gender (l_dobj) gender_14\NN|,|score (l_conj) score_22\NN|disease|before (l_compound) disease_21\NN|pediatric|stage|liver
448423
D000614_D013345 NONE acid_6\NN| (r_compound) therapy_7\NN|aminocaproic|acid|and|thrombosis (r_pobj) with_4\IN|therapy (r_prep) associated_3\VBN|with (r_acl) hemorrhage_2\NN|recurrent|subarachnoid|associated|.
D000614_D007674 NONE acid_6\NN| (r_compound) therapy_7\NN|aminocaproic|acid|and|thrombosis (l_conj) thrombosis_12\NN|acute|renal|artery
D015119_D013345 CID acid_2\NN|epsilon|aminocaproic|eaca (r_nsubjpass) used_8\VBN|acid|has|been|prevent|. (l_xcomp) prevent_10\VB|to|rebleeding (l_dobj) rebleeding_11\NN|in|with (l_prep) with_14\IN|hemorrhage (l_pobj) hemorrhage_16\NN|subarachnoid|(|sah|)
D015119_D013345 CID acid_2\NN|epsilon|aminocaproic|eaca (r_nsubjpass) used_8\VBN|acid|has|been|prevent|. (l_xcomp) prevent_10\VB|to|rebleeding (l_dobj) rebleeding_11\NN|in|with (l_prep) with_14\IN|hemorrhage (l_pobj) hemorrhage_16\NN|subarachnoid|(|sah|) (l_appos) SAH_18\NNP|
D015119_D013345 CID EACA_4\NNP|(|) (r_appos) acid_2\NN|epsilon|aminocaproic|eaca (r_nsubjpass) used_8\VBN|acid|has|been|prevent|. (l_xcomp) prevent_10\VB|to|rebleeding (l_dobj) rebleeding_11\NN|in|with (l_prep) with_14\IN|hemorrhage (l_pobj) hemorrhage_16\NN|subarachnoid|(|sah|)
D015119_D013345 CID EACA_4\NNP|(|) (r_appos) acid_2\NN|epsilon|aminocaproic|eaca (r_nsubjpass) used_8\VBN|acid|has|been|prevent|. (l_xcomp) prevent_10\VB|to|rebleeding (l_dobj) rebleeding_11\NN|in|with (l_prep) with_14\IN|hemorrhage (l_pobj) hemorrhage_16\NN|subarachnoid|(|sah|) (l_appos) SAH_18\NNP|
D015119_D013345 CID EACA_27\NNP|,|or|phenomena (r_pobj) with_26\IN|eaca (r_prep) treated_25\VBN|with (r_acl) syndromes_24\NNS|fibrinolytic|treated (r_pobj) with_22\IN|syndromes (r_prep) patients_21\NNS|with (r_pobj) in_20\IN|patients (r_prep) capillary_17\JJ|thrombi|in (r_conj) arteriolar_15\JJ|and|capillary (r_conj) SAH_13\NNP|,|arteriolar
D015119_D013345 CID EACA_4\NNP| (r_compound) therapy_5\NN|eaca|in (l_prep) in_6\IN|patient (l_pobj) patient_8\NN|a|with (l_prep) with_9\IN|sah|documentation (l_pobj) SAH_10\NNP|and
D015119_D013345 CID EACA_4\NNP| (r_compound) therapy_5\NN|eaca|in (l_prep) in_6\IN|patient (l_pobj) patient_8\NN|a|with (l_prep) with_9\IN|sah|documentation (l_pobj) documentation_13\NN|histopathological|of (l_prep) of_14\IN|sah (l_pobj) SAH_16\NNP|recurrent
D015119_D013927 CID EACA_17\NNP| (r_compound) therapy_18\NN|eaca (r_pobj) of_16\IN|therapy (r_prep) complications_15\NNS|thrombotic|of (l_amod) thrombotic_14\JJ|
D015119_D013927 CID EACA_27\NNP|,|or|phenomena (r_pobj) with_26\IN|eaca (r_prep) treated_25\VBN|with (r_acl) syndromes_24\NNS|fibrinolytic|treated (r_pobj) with_22\IN|syndromes (r_prep) patients_21\NNS|with (r_pobj) in_20\IN|patients (r_prep) capillary_17\JJ|thrombi|in (l_dobj) thrombi_19\NN|fibrin
D015119_D013927 CID EACA_13\NNP| (r_nsubjpass) implicated_17\VBN|observed|,|eaca|should|not|be|in|. (l_advcl) observed_6\VBN|since|thrombi|are|often|in (l_nsubjpass) thrombi_3\NN|intravascular|fibrin
D015119_D013927 CID EACA_13\NNP| (r_nsubjpass) implicated_17\VBN|observed|,|eaca|should|not|be|in|. (l_prep) in_18\IN|pathogenesis (l_pobj) pathogenesis_20\NN|the|of (l_prep) of_21\IN|thrombi (l_pobj) thrombi_23\NN|fibrin|in
D015119_D020767 CID EACA_27\NNP|,|or|phenomena (r_pobj) with_26\IN|eaca (r_prep) treated_25\VBN|with (r_acl) syndromes_24\NNS|fibrinolytic|treated (r_pobj) with_22\IN|syndromes (r_prep) patients_21\NNS|with (r_pobj) in_20\IN|patients (r_prep) capillary_17\JJ|thrombi|in (r_conj) arteriolar_15\JJ|and|capillary (r_conj) SAH_13\NNP|,|arteriolar (r_pobj) with_12\IN|sah (r_prep) patients_11\NNS|with (r_pobj) in_10\IN|patients (r_prep) deterioration_5\NN|clinical|and|thrombosis|in (l_conj) thrombosis_9\NN|intracranial|vascular
D015119_D013923 NONE EACA_27\NNP|,|or|phenomena (l_conj) phenomena_32\NNS|other|thromboembolic
D015119_D004211 NONE EACA_13\NNP| (r_nsubjpass) implicated_17\VBN|observed|,|eaca|should|not|be|in|. (l_prep) in_18\IN|pathogenesis (l_pobj) pathogenesis_20\NN|the|of (l_prep) of_21\IN|thrombi (l_pobj) thrombi_23\NN|fibrin|in (l_prep) in_24\IN|patients (l_pobj) patients_25\NNS|with (l_prep) with_26\IN|coagulation (l_pobj) coagulation_29\NN|disseminated|intravascular|or|coagulopathies
D015119_D004211 NONE EACA_13\NNP| (r_nsubjpass) implicated_17\VBN|observed|,|eaca|should|not|be|in|. (l_prep) in_18\IN|pathogenesis (l_pobj) pathogenesis_20\NN|the|of (l_prep) of_21\IN|thrombi (l_pobj) thrombi_23\NN|fibrin|in (l_prep) in_24\IN|patients (l_pobj) patients_25\NNS|with (l_prep) with_26\IN|coagulation (l_pobj) coagulation_29\NN|disseminated|intravascular|or|coagulopathies (l_conj) coagulopathies_34\NNS|other|"|consumption
7492040
D008012_D009203 NONE lidocaine_3\NN| (r_pobj) of_2\IN|lidocaine (r_prep) safety_1\NN|clinical|of|in|. (l_prep) in_4\IN|patients (l_pobj) patients_5\NNS|with (l_prep) with_6\IN|infarction (l_pobj) infarction_11\NN|associated|myocardial
D008012_D009203 NONE lidocaine_8\NN| (r_pobj) of_7\IN|lidocaine (r_prep) safety_6\NN|the|of|in (l_prep) in_9\IN|setting (l_pobj) setting_11\NN|the|of (l_prep) of_12\IN|infarction (l_pobj) infarction_17\NN|induced|myocardial|(|mi|)
D008012_D009203 NONE lidocaine_8\NN| (r_pobj) of_7\IN|lidocaine (r_prep) safety_6\NN|the|of|in (l_prep) in_9\IN|setting (l_pobj) setting_11\NN|the|of (l_prep) of_12\IN|infarction (l_pobj) infarction_17\NN|induced|myocardial|(|mi|) (l_appos) MI_19\NNP|
D008012_D009203 NONE lidocaine_10\NN| (r_dobj) received_9\VBD|who|lidocaine|in (r_relcl) Patients_2\NNS|with|received (l_prep) with_3\IN|mi (l_pobj) MI_7\NNP|associated
D008012_D009203 NONE lidocaine_5\NN| (r_dobj) received_4\VBD|who|lidocaine|in (l_prep) in_6\IN|setting (l_pobj) setting_8\NN|the|of (l_prep) of_9\IN|mi (l_pobj) MI_13\NNP|associated
D008012_D009203 NONE lidocaine_35\NN| (r_pobj) of_34\IN|lidocaine (r_prep) administration_33\NN|of|interval (r_pobj) after_32\IN|administration (r_prep) seizures_31\NNS|experienced|after (r_conj) bradydysrhythmias_20\NNS|,|tachycardia|;|or|seizures (r_dobj) exhibited_19\VBN|died|;|bradydysrhythmias|. (l_ccomp) died_17\VBD|patients|,|patient (l_nsubj) patients_2\NNS|29|received (l_relcl) received_4\VBD|who|lidocaine|in (l_prep) in_6\IN|setting (l_pobj) setting_8\NN|the|of (l_prep) of_9\IN|mi (l_pobj) MI_13\NNP|associated
D008012_D009203 NONE lidocaine_4\NN| (r_nsubj) enhance_6\VB|that|lidocaine|may|toxicity (r_acl) concerns_2\NNS|theoretical|enhance (r_pobj) Despite_0\IN|concerns (r_prep) associated_23\VBN|despite|,|use|was|not|with|. (l_nsubjpass) use_11\NN|the|of|in (l_prep) in_14\IN|patients (l_pobj) patients_15\NNS|with (l_prep) with_16\IN|mi (l_pobj) MI_20\NNP|associated
D008012_D009203 NONE lidocaine_13\NN| (r_pobj) of_12\IN|lidocaine (r_prep) use_11\NN|the|of|in (l_prep) in_14\IN|patients (l_pobj) patients_15\NNS|with (l_prep) with_16\IN|mi (l_pobj) MI_20\NNP|associated
D003042_D009203 CID cocaine_7\NN| (r_npadvmod) associated_9\VBN|cocaine|- (r_amod) infarction_11\NN|associated|myocardial
D003042_D009203 CID cocaine_13\NN| (r_npadvmod) induced_15\VBN|cocaine|- (r_amod) infarction_17\NN|induced|myocardial|(|mi|)
D003042_D009203 CID cocaine_13\NN| (r_npadvmod) induced_15\VBN|cocaine|- (r_amod) infarction_17\NN|induced|myocardial|(|mi|) (l_appos) MI_19\NNP|
D003042_D009203 CID cocaine_4\NN| (r_npadvmod) associated_6\VBN|cocaine|- (r_amod) MI_7\NNP|associated
D003042_D009203 CID cocaine_10\NN| (r_npadvmod) associated_12\VBN|cocaine|- (r_amod) MI_13\NNP|associated
D003042_D009203 CID cocaine_7\NN| (r_compound) toxicity_8\NN|cocaine (r_dobj) enhance_6\VB|that|lidocaine|may|toxicity (r_acl) concerns_2\NNS|theoretical|enhance (r_pobj) Despite_0\IN|concerns (r_prep) associated_23\VBN|despite|,|use|was|not|with|. (l_nsubjpass) use_11\NN|the|of|in (l_prep) in_14\IN|patients (l_pobj) patients_15\NNS|with (l_prep) with_16\IN|mi (l_pobj) MI_20\NNP|associated
D003042_D009203 CID cocaine_17\NN| (r_npadvmod) associated_19\VBN|cocaine|- (r_amod) MI_20\NNP|associated
D008012_D001919 NONE lidocaine_5\NN| (r_dobj) received_4\VBD|who|lidocaine|in (r_relcl) patients_2\NNS|29|received (r_nsubj) died_17\VBD|patients|,|patient (r_ccomp) exhibited_19\VBN|died|;|bradydysrhythmias|. (l_dobj) bradydysrhythmias_20\NNS|,|tachycardia|;|or|seizures
D008012_D001919 NONE lidocaine_35\NN| (r_pobj) of_34\IN|lidocaine (r_prep) administration_33\NN|of|interval (r_pobj) after_32\IN|administration (r_prep) seizures_31\NNS|experienced|after (r_conj) bradydysrhythmias_20\NNS|,|tachycardia|;|or|seizures
D008012_D017180 NONE lidocaine_5\NN| (r_dobj) received_4\VBD|who|lidocaine|in (r_relcl) patients_2\NNS|29|received (r_nsubj) died_17\VBD|patients|,|patient (r_ccomp) exhibited_19\VBN|died|;|bradydysrhythmias|. (l_dobj) bradydysrhythmias_20\NNS|,|tachycardia|;|or|seizures (l_conj) tachycardia_23\NN|ventricular|,|or|fibrillation
D008012_D017180 NONE lidocaine_35\NN| (r_pobj) of_34\IN|lidocaine (r_prep) administration_33\NN|of|interval (r_pobj) after_32\IN|administration (r_prep) seizures_31\NNS|experienced|after (r_conj) bradydysrhythmias_20\NNS|,|tachycardia|;|or|seizures (l_conj) tachycardia_23\NN|ventricular|,|or|fibrillation
D008012_D014693 NONE lidocaine_5\NN| (r_dobj) received_4\VBD|who|lidocaine|in (r_relcl) patients_2\NNS|29|received (r_nsubj) died_17\VBD|patients|,|patient (r_ccomp) exhibited_19\VBN|died|;|bradydysrhythmias|. (l_dobj) bradydysrhythmias_20\NNS|,|tachycardia|;|or|seizures (l_conj) tachycardia_23\NN|ventricular|,|or|fibrillation (l_conj) fibrillation_27\NN|ventricular
D008012_D014693 NONE lidocaine_35\NN| (r_pobj) of_34\IN|lidocaine (r_prep) administration_33\NN|of|interval (r_pobj) after_32\IN|administration (r_prep) seizures_31\NNS|experienced|after (r_conj) bradydysrhythmias_20\NNS|,|tachycardia|;|or|seizures (l_conj) tachycardia_23\NN|ventricular|,|or|fibrillation (l_conj) fibrillation_27\NN|ventricular
D008012_D012640 NONE lidocaine_5\NN| (r_dobj) received_4\VBD|who|lidocaine|in (r_relcl) patients_2\NNS|29|received (r_nsubj) died_17\VBD|patients|,|patient (r_ccomp) exhibited_19\VBN|died|;|bradydysrhythmias|. (l_dobj) bradydysrhythmias_20\NNS|,|tachycardia|;|or|seizures (l_conj) seizures_31\NNS|experienced|after
D008012_D012640 NONE lidocaine_35\NN| (r_pobj) of_34\IN|lidocaine (r_prep) administration_33\NN|of|interval (r_pobj) after_32\IN|administration (r_prep) seizures_31\NNS|experienced|after
D003042_D001919 NONE cocaine_10\NN| (r_npadvmod) associated_12\VBN|cocaine|- (r_amod) MI_13\NNP|associated (r_pobj) of_9\IN|mi (r_prep) setting_8\NN|the|of (r_pobj) in_6\IN|setting (r_prep) received_4\VBD|who|lidocaine|in (r_relcl) patients_2\NNS|29|received (r_nsubj) died_17\VBD|patients|,|patient (r_ccomp) exhibited_19\VBN|died|;|bradydysrhythmias|. (l_dobj) bradydysrhythmias_20\NNS|,|tachycardia|;|or|seizures
D003042_D017180 NONE cocaine_10\NN| (r_npadvmod) associated_12\VBN|cocaine|- (r_amod) MI_13\NNP|associated (r_pobj) of_9\IN|mi (r_prep) setting_8\NN|the|of (r_pobj) in_6\IN|setting (r_prep) received_4\VBD|who|lidocaine|in (r_relcl) patients_2\NNS|29|received (r_nsubj) died_17\VBD|patients|,|patient (r_ccomp) exhibited_19\VBN|died|;|bradydysrhythmias|. (l_dobj) bradydysrhythmias_20\NNS|,|tachycardia|;|or|seizures (l_conj) tachycardia_23\NN|ventricular|,|or|fibrillation
D003042_D014693 NONE cocaine_10\NN| (r_npadvmod) associated_12\VBN|cocaine|- (r_amod) MI_13\NNP|associated (r_pobj) of_9\IN|mi (r_prep) setting_8\NN|the|of (r_pobj) in_6\IN|setting (r_prep) received_4\VBD|who|lidocaine|in (r_relcl) patients_2\NNS|29|received (r_nsubj) died_17\VBD|patients|,|patient (r_ccomp) exhibited_19\VBN|died|;|bradydysrhythmias|. (l_dobj) bradydysrhythmias_20\NNS|,|tachycardia|;|or|seizures (l_conj) tachycardia_23\NN|ventricular|,|or|fibrillation (l_conj) fibrillation_27\NN|ventricular
D003042_D012640 NONE cocaine_10\NN| (r_npadvmod) associated_12\VBN|cocaine|- (r_amod) MI_13\NNP|associated (r_pobj) of_9\IN|mi (r_prep) setting_8\NN|the|of (r_pobj) in_6\IN|setting (r_prep) received_4\VBD|who|lidocaine|in (r_relcl) patients_2\NNS|29|received (r_nsubj) died_17\VBD|patients|,|patient (r_ccomp) exhibited_19\VBN|died|;|bradydysrhythmias|. (l_dobj) bradydysrhythmias_20\NNS|,|tachycardia|;|or|seizures (l_conj) seizures_31\NNS|experienced|after
D008012_D064420 NONE lidocaine_4\NN| (r_nsubj) enhance_6\VB|that|lidocaine|may|toxicity (l_dobj) toxicity_8\NN|cocaine
D008012_D064420 NONE lidocaine_13\NN| (r_pobj) of_12\IN|lidocaine (r_prep) use_11\NN|the|of|in (r_nsubjpass) associated_23\VBN|despite|,|use|was|not|with|. (l_prep) Despite_0\IN|concerns (l_pobj) concerns_2\NNS|theoretical|enhance (l_acl) enhance_6\VB|that|lidocaine|may|toxicity (l_dobj) toxicity_8\NN|cocaine
D008012_D002318 NONE lidocaine_4\NN| (r_nsubj) enhance_6\VB|that|lidocaine|may|toxicity (r_acl) concerns_2\NNS|theoretical|enhance (r_pobj) Despite_0\IN|concerns (r_prep) associated_23\VBN|despite|,|use|was|not|with|. (l_prep) with_24\IN|toxicity (l_pobj) toxicity_31\NN|significant|system
D008012_D002318 NONE lidocaine_13\NN| (r_pobj) of_12\IN|lidocaine (r_prep) use_11\NN|the|of|in (r_nsubjpass) associated_23\VBN|despite|,|use|was|not|with|. (l_prep) with_24\IN|toxicity (l_pobj) toxicity_31\NN|significant|system
D008012_D002493 NONE lidocaine_4\NN| (r_nsubj) enhance_6\VB|that|lidocaine|may|toxicity (r_acl) concerns_2\NNS|theoretical|enhance (r_pobj) Despite_0\IN|concerns (r_prep) associated_23\VBN|despite|,|use|was|not|with|. (l_prep) with_24\IN|toxicity (l_pobj) toxicity_31\NN|significant|system
D008012_D002493 NONE lidocaine_13\NN| (r_pobj) of_12\IN|lidocaine (r_prep) use_11\NN|the|of|in (r_nsubjpass) associated_23\VBN|despite|,|use|was|not|with|. (l_prep) with_24\IN|toxicity (l_pobj) toxicity_31\NN|significant|system
D003042_D064420 NONE cocaine_7\NN| (r_compound) toxicity_8\NN|cocaine
D003042_D064420 NONE cocaine_17\NN| (r_npadvmod) associated_19\VBN|cocaine|- (r_amod) MI_20\NNP|associated (r_pobj) with_16\IN|mi (r_prep) patients_15\NNS|with (r_pobj) in_14\IN|patients (r_prep) use_11\NN|the|of|in (r_nsubjpass) associated_23\VBN|despite|,|use|was|not|with|. (l_prep) Despite_0\IN|concerns (l_pobj) concerns_2\NNS|theoretical|enhance (l_acl) enhance_6\VB|that|lidocaine|may|toxicity (l_dobj) toxicity_8\NN|cocaine
D003042_D002318 NONE cocaine_7\NN| (r_compound) toxicity_8\NN|cocaine (r_dobj) enhance_6\VB|that|lidocaine|may|toxicity (r_acl) concerns_2\NNS|theoretical|enhance (r_pobj) Despite_0\IN|concerns (r_prep) associated_23\VBN|despite|,|use|was|not|with|. (l_prep) with_24\IN|toxicity (l_pobj) toxicity_31\NN|significant|system
D003042_D002318 NONE cocaine_17\NN| (r_npadvmod) associated_19\VBN|cocaine|- (r_amod) MI_20\NNP|associated (r_pobj) with_16\IN|mi (r_prep) patients_15\NNS|with (r_pobj) in_14\IN|patients (r_prep) use_11\NN|the|of|in (r_nsubjpass) associated_23\VBN|despite|,|use|was|not|with|. (l_prep) with_24\IN|toxicity (l_pobj) toxicity_31\NN|significant|system
D003042_D002493 NONE cocaine_7\NN| (r_compound) toxicity_8\NN|cocaine (r_dobj) enhance_6\VB|that|lidocaine|may|toxicity (r_acl) concerns_2\NNS|theoretical|enhance (r_pobj) Despite_0\IN|concerns (r_prep) associated_23\VBN|despite|,|use|was|not|with|. (l_prep) with_24\IN|toxicity (l_pobj) toxicity_31\NN|significant|system
D003042_D002493 NONE cocaine_17\NN| (r_npadvmod) associated_19\VBN|cocaine|- (r_amod) MI_20\NNP|associated (r_pobj) with_16\IN|mi (r_prep) patients_15\NNS|with (r_pobj) in_14\IN|patients (r_prep) use_11\NN|the|of|in (r_nsubjpass) associated_23\VBN|despite|,|use|was|not|with|. (l_prep) with_24\IN|toxicity (l_pobj) toxicity_31\NN|significant|system
24729111
D000638_D007037 CID Amiodarone_0\NN| (r_npadvmod) induced_2\VBN|amiodarone|- (r_amod) myxoedema_3\NN|induced (r_compound) coma_4\NN|myxoedema|.
D000638_D007037 CID amiodarone_5\NN| (r_npadvmod) induced_7\VBN|amiodarone|- (r_amod) myxoedema_8\NN|induced (r_compound) coma_9\NN|myxoedema|in
D000638_D007037 CID amiodarone_9\NN| (r_npadvmod) induced_11\VBN|amiodarone|- (r_amod) myxoedema_12\NN|induced (r_compound) coma_13\NN|myxoedema|with
D000638_D003128 CID Amiodarone_0\NN| (r_npadvmod) induced_2\VBN|amiodarone|- (r_amod) myxoedema_3\NN|induced (r_compound) coma_4\NN|myxoedema|.
D000638_D003128 CID amiodarone_5\NN| (r_npadvmod) induced_7\VBN|amiodarone|- (r_amod) myxoedema_8\NN|induced (r_compound) coma_9\NN|myxoedema|in
D000638_D003128 CID amiodarone_9\NN| (r_npadvmod) induced_11\VBN|amiodarone|- (r_amod) myxoedema_12\NN|induced (r_compound) coma_13\NN|myxoedema|with
D000638_D001919 CID amiodarone_20\NN| (r_compound) therapy_21\NN|amiodarone (r_pobj) of_19\IN|therapy (r_prep) initiation_18\NN|of|for (r_pobj) after_17\IN|weeks|initiation (r_prep) have_8\VB|to|bradycardia|after (l_dobj) bradycardia_9\VBN|,|hypothermia
D000638_D007035 CID amiodarone_20\NN| (r_compound) therapy_21\NN|amiodarone (r_pobj) of_19\IN|therapy (r_prep) initiation_18\NN|of|for (r_pobj) after_17\IN|weeks|initiation (r_prep) have_8\VB|to|bradycardia|after (l_dobj) bradycardia_9\VBN|,|hypothermia (l_conj) hypothermia_11\NN|and|failure
D000638_D012131 CID amiodarone_20\NN| (r_compound) therapy_21\NN|amiodarone (r_pobj) of_19\IN|therapy (r_prep) initiation_18\NN|of|for (r_pobj) after_17\IN|weeks|initiation (r_prep) have_8\VB|to|bradycardia|after (l_dobj) bradycardia_9\VBN|,|hypothermia (l_conj) hypothermia_11\NN|and|failure (l_conj) failure_14\NN|respiratory
D000638_D001281 NONE amiodarone_20\NN| (r_compound) therapy_21\NN|amiodarone (r_pobj) of_19\IN|therapy (r_prep) initiation_18\NN|of|for (l_prep) for_22\IN|fibrillation (l_pobj) fibrillation_24\NN|atrial
D000638_D013959 NONE amiodarone_9\NN| (r_npadvmod) induced_11\VBN|amiodarone|- (r_amod) myxoedema_12\NN|induced (r_compound) coma_13\NN|myxoedema|with (l_prep) with_14\IN|history (l_pobj) history_16\NN|a|significant (l_amod) significant_17\JJ|for (l_prep) for_18\IN|disease (l_pobj) disease_21\NN|subclinical|thyroid
6695685
D014700_D001145 CID verapamil_5\NN| (r_compound) therapy_6\NN|oral|verapamil (r_pobj) during_3\IN|therapy (r_prep) rhythms_2\NNS|accelerated|junctional|during|.
D014700_D001145 CID verapamil_20\NN|oral (r_dobj) receiving_18\VBG|verapamil (r_acl) patients_17\NNS|59|receiving (r_pobj) in_15\IN|patients (r_prep) accelerated_12\VBD|rhythms|in (l_dobj) rhythms_14\NNS|junctional
D014700_D002637 NONE verapamil_8\NN| (r_nsubj) increased_10\VBD|in|,|verapamil|neither|frequency|nor|suppressed|. (l_prep) In_0\IN|patients (l_pobj) patients_1\NNS|with (l_prep) with_2\IN|syndromes (l_pobj) syndromes_6\NNS|various|chest|pain (l_compound) pain_5\NN|
17028363
D000880_D058186 NONE anthraquinones_11\NNS| (r_dobj) containing_10\VBG|anthraquinones (r_acl) pills_9\NNS|slimming|containing (r_pobj) of_7\IN|pills (r_prep) intake_6\NN|prolonged|of (r_pobj) with_4\IN|intake (r_prep) associated_3\VBN|with (r_acl) failure_2\NN|acute|renal|associated|.
D000880_D058186 NONE anthraquinone_24\NN| (r_compound) derivatives_25\NNS|anthraquinone (r_dobj) contained_23\VBD|that|derivatives (r_relcl) pill_21\NN|a|proprietary|chinese|herbal|slimming|contained|, (r_pobj) of_15\IN|pill (r_prep) use_14\NN|prolonged|of|extracted (r_pobj) following_12\VBG|use (r_prep) developed_8\VBD|who|failure|following (l_dobj) failure_11\NN|acute|renal
D000880_D058186 NONE anthraquinone_9\NN| (r_npadvmod) containing_11\VBG|anthraquinone|- (r_amod) agent_13\NN|an|containing|herbal|and|injury (l_conj) injury_16\NN|renal
D004365_D007674 NONE herbs_4\NNS|chinese (r_pobj) by_2\IN|herbs (r_agent) caused_1\VBN|by (r_acl) Nephropathy_0\NNP|caused
D034341_D007674 NONE acids_16\NNS|aristolochic (r_pobj) of_14\IN|acids (r_prep) use_13\NN|the|of (r_dobj) involving_11\VBG|usually|use (r_advcl) reported_8\VBN|nephropathy|has|previously|been|,|involving|. (l_nsubjpass) Nephropathy_0\NNP|caused
D004365_D058186 CID herbal_19\JJ| (r_amod) pill_21\NN|a|proprietary|chinese|herbal|slimming|contained|, (r_pobj) of_15\IN|pill (r_prep) use_14\NN|prolonged|of|extracted (r_pobj) following_12\VBG|use (r_prep) developed_8\VBD|who|failure|following (l_dobj) failure_11\NN|acute|renal
D004008_D058186 CID diclofenac_20\NN| (r_appos) drug_18\NN|a|steroidal|inflammatory|,|diclofenac (r_pobj) of_10\IN|drug (r_prep) intake_9\NN|the|concomitant|of (r_pobj) by_6\IN|intake (r_agent) aggravated_5\VBN|injury|was|probably|by|. (l_nsubjpass) injury_2\NN|the|renal
D000880_D007674 NONE anthraquinone_9\NN| (r_npadvmod) containing_11\VBG|anthraquinone|- (r_amod) agent_13\NN|an|containing|herbal|and|injury (r_pobj) of_7\IN|agent (r_prep) use_6\NN|the|of (r_pobj) between_4\IN|use (r_prep) relationship_3\NN|a|causal|between (r_nsubj) remains_17\VBZ|although|relationship|proven (r_advcl) considered_29\VBN|remains|,|nephropathy|should|be|in|. (l_nsubjpass) nephropathy_26\NN|associated|interstitial
D000880_D051437 NONE anthraquinone_9\NN| (r_npadvmod) containing_11\VBG|anthraquinone|- (r_amod) agent_13\NN|an|containing|herbal|and|injury (r_pobj) of_7\IN|agent (r_prep) use_6\NN|the|of (r_pobj) between_4\IN|use (r_prep) relationship_3\NN|a|causal|between (r_nsubj) remains_17\VBZ|although|relationship|proven (r_advcl) considered_29\VBN|remains|,|nephropathy|should|be|in|. (l_prep) in_30\IN|patients (l_pobj) patients_31\NNS|present (l_relcl) present_33\VBP|who|with (l_prep) with_34\IN|failure (l_pobj) failure_37\NN|unexplained|renal
9272404
D002245_D010146 NONE CO2_10\NN| (r_pobj) of_9\IN|co2 (r_prep) pulses_8\NNS|short|of (r_pobj) of_6\IN|pulses (r_prep) means_5\NNS|of (r_pobj) by_4\IN|means (r_agent) applied_3\VBN|pain|was|by|to|duration (l_nsubjpass) pain_1\NN|phasic
D002245_D010146 NONE CO2_10\NN| (r_pobj) of_9\IN|co2 (r_prep) pulses_8\NNS|short|of (r_pobj) of_6\IN|pulses (r_prep) means_5\NNS|of (r_pobj) by_4\IN|means (r_agent) applied_3\VBN|pain|was|by|to|duration (l_parataxis) duration_17\NN|(|stimulus|ms|,|interval|,|and|induced (l_conj) induced_31\VBN|pain|was|in|by|%|)|. (l_nsubjpass) pain_29\NN|tonic
D002245_D010146 NONE CO2_17\NN| (r_compound) stimuli_18\NNS|the|co2 (r_pobj) to_15\IN|stimuli (r_prep) response_14\NN|to (r_pobj) in_13\IN|response (r_prep) obtained_12\VBN|csseps|were|in|. (l_nsubjpass) CSSEPs_1\NNS|both|as|as (l_prep) as_6\IN|correlates (l_pobj) correlates_8\NNS|peripheral|of (l_prep) of_9\IN|pain (l_pobj) pain_10\NN|
D007052_D010146 CID ibuprofen_6\NNP| (r_pobj) of_5\IN|ibuprofen (r_prep) administration_4\NN|of (r_nsubjpass) followed_8\VBN|described|,|administration|was|by|,|indicating|. (l_agent) by_9\IN|decrease (l_pobj) decrease_11\NN|a|in|-|increase (l_prep) in_12\IN|pain (l_pobj) pain_14\NN|tonic|but|relative
D007052_D010146 CID ibuprofen_6\NNP| (r_pobj) of_5\IN|ibuprofen (r_prep) administration_4\NN|of (r_nsubjpass) followed_8\VBN|described|,|administration|was|by|,|indicating|. (l_agent) by_9\IN|decrease (l_pobj) decrease_11\NN|a|in|-|increase (l_appos) increase_22\NN|an|in (l_prep) in_23\IN|correlates (l_pobj) correlates_24\NNS|of (l_prep) of_25\IN|pain (l_pobj) pain_27\NN|phasic
D007052_D010146 CID ibuprofen_6\NNP| (r_pobj) of_5\IN|ibuprofen (r_prep) administration_4\NN|of (r_nsubjpass) followed_8\VBN|described|,|administration|was|by|,|indicating|. (l_advcl) indicating_29\VBG|effect (l_dobj) effect_32\NN|a|specific|of|on (l_prep) on_35\IN|interaction (l_pobj) interaction_37\NN|the|between (l_prep) between_38\IN|stimuli (l_pobj) stimuli_41\NNS|the|pain|under (l_compound) pain_40\NN|
D007052_D010146 CID ibuprofen_34\NN| (r_pobj) of_33\IN|ibuprofen (r_prep) effect_32\NN|a|specific|of|on (r_dobj) indicating_29\VBG|effect (r_advcl) followed_8\VBN|described|,|administration|was|by|,|indicating|. (l_agent) by_9\IN|decrease (l_pobj) decrease_11\NN|a|in|-|increase (l_prep) in_12\IN|pain (l_pobj) pain_14\NN|tonic|but|relative
D007052_D010146 CID ibuprofen_34\NN| (r_pobj) of_33\IN|ibuprofen (r_prep) effect_32\NN|a|specific|of|on (r_dobj) indicating_29\VBG|effect (r_advcl) followed_8\VBN|described|,|administration|was|by|,|indicating|. (l_agent) by_9\IN|decrease (l_pobj) decrease_11\NN|a|in|-|increase (l_appos) increase_22\NN|an|in (l_prep) in_23\IN|correlates (l_pobj) correlates_24\NNS|of (l_prep) of_25\IN|pain (l_pobj) pain_27\NN|phasic
D007052_D010146 CID ibuprofen_34\NN| (r_pobj) of_33\IN|ibuprofen (r_prep) effect_32\NN|a|specific|of|on (l_prep) on_35\IN|interaction (l_pobj) interaction_37\NN|the|between (l_prep) between_38\IN|stimuli (l_pobj) stimuli_41\NNS|the|pain|under (l_compound) pain_40\NN|
24709919
D036145_D006930 NONE ginsenosides_2\NNS|on (l_prep) on_3\IN|hyperalgesia (l_pobj) hyperalgesia_7\NN|induced|in
C049864_D006930 NONE ginsenosides_15\NNS|re|,|components|,|on (l_prep) on_23\IN|oih (l_pobj) OIH_24\NNP|
C049864_D006930 NONE Re_0\IN|(|mg/kg|. (l_appos) mg/kg_3\NNS|300|oih|in (l_dobj) OIH_6\NNP|)|inhibited
C049864_D006930 NONE Re_6\IN|, (r_prep) ginsenoside_5\NN|the|re|but|rg1 (r_nsubj) contribute_15\VB|that|ginsenoside|,|may|toward (l_prep) toward_16\IN|reversal (l_pobj) reversal_17\NN|of (l_prep) of_18\IN|oih (l_pobj) OIH_19\NNP|
C035054_D006930 NONE ginsenosides_15\NNS|re|,|components|,|on (l_prep) on_23\IN|oih (l_pobj) OIH_24\NNP|
C035054_D006930 NONE ginsenosides_6\NNS|the|rg1 (r_nsubj) failed_7\VBD|however|,|ginsenosides|prevent|. (l_xcomp) prevent_9\VB|to|oih|in (l_dobj) OIH_10\NNP|
C035054_D006930 NONE Rg1_2\NNP| (r_nsubj) showed_3\VBD|furthermore|,|rg1|tendency|. (l_dobj) tendency_5\NN|a|aggravate (l_acl) aggravate_7\VB|to|oih|in (l_dobj) OIH_8\NNP|
C035054_D006930 NONE Rg1_10\NN|not|or|rb1 (r_conj) ginsenoside_5\NN|the|re|but|rg1 (r_nsubj) contribute_15\VB|that|ginsenoside|,|may|toward (l_prep) toward_16\IN|reversal (l_pobj) reversal_17\NN|of (l_prep) of_18\IN|oih (l_pobj) OIH_19\NNP|
C442759_D006930 NONE ginsenosides_15\NNS|re|,|components|,|on (l_prep) on_23\IN|oih (l_pobj) OIH_24\NNP|
C442759_D006930 NONE ginsenosides_6\NNS|the|rg1 (r_nsubj) failed_7\VBD|however|,|ginsenosides|prevent|. (l_xcomp) prevent_9\VB|to|oih|in (l_dobj) OIH_10\NNP|
C442759_D006930 NONE Rb1_12\NN| (r_conj) Rg1_10\NN|not|or|rb1 (r_conj) ginsenoside_5\NN|the|re|but|rg1 (r_nsubj) contribute_15\VB|that|ginsenoside|,|may|toward (l_prep) toward_16\IN|reversal (l_pobj) reversal_17\NN|of (l_prep) of_18\IN|oih (l_pobj) OIH_19\NNP|
D009020_D006930 CID morphine_9\NN| (r_pobj) of_8\IN|morphine (r_prep) administration_7\NN|subcutaneous|of (r_pobj) after_5\IN|administration (r_prep) achieved_2\VBN|oih|was|in|after|for|. (l_nsubjpass) OIH_0\NNP|
D019342_D006930 NONE acid_16\NN| (r_npadvmod) induced_18\VBN|acid|-|writhing (r_advcl) acetic_15\JJ|the|induced (r_conj) test_12\NN|both|the|sensitivity|and|acetic (r_pobj) in_7\IN|test (r_prep) mg/kg_3\NNS|300|oih|in (l_dobj) OIH_6\NNP|)|inhibited
D019342_D006930 NONE acid_12\NN| (r_npadvmod) induced_14\VBN|the|acetic|acid|- (r_amod) writhing_15\VBG|induced (r_compound) test_16\NN|writhing (r_pobj) in_9\IN|test (r_prep) aggravate_7\VB|to|oih|in (l_dobj) OIH_8\NNP|
15696449
D008558_D058186 CID melphalan_7\NN|dose|in (r_pobj) after_3\IN|melphalan (r_prep) insufficiency_2\NN|acute|renal|after|.
D008558_D058186 CID melphalan_12\NN| (r_compound) conditioning_13\NN|melphalan (r_pobj) after_11\IN|immediately|conditioning (r_prep) development_5\NN|the|of|after (l_prep) of_6\IN|insufficiency (l_pobj) insufficiency_9\NN|acute|renal
D008558_D058186 CID melphalan_10\NN|dose (r_nsubjpass) defined_12\VBN|insufficiency|after|melphalan|was|by|. (l_nsubjpass) insufficiency_2\NN|acute|renal|(|ari|)
D008558_D058186 CID melphalan_10\NN|dose (r_nsubjpass) defined_12\VBN|insufficiency|after|melphalan|was|by|. (l_nsubjpass) insufficiency_2\NN|acute|renal|(|ari|) (l_appos) ARI_4\NNP|
D008558_D058186 CID melphalan_18\NN|dose (r_pobj) after_14\IN|melphalan (r_prep) developed_7\VBD|of|,|ari|in|after|. (l_nsubj) ARI_6\NNP|
D008558_D058186 CID melphalan_8\NN|dose (r_nsubj) underwent_9\VBD|patients|melphalan|dialysis|often|p|,|and|had|. (l_nsubj) Patients_0\NNS|had (l_relcl) had_2\VBD|who|ari|after (l_dobj) ARI_3\NNP|
D008558_D058186 CID melphalan_7\NN|as (r_dobj) suggests_6\VBZ|timing|strongly|melphalan|. (l_nsubj) timing_1\NN|the|of (l_prep) of_2\IN|injury (l_pobj) injury_4\NN|renal
D008558_D058186 CID melphalan_11\NN| (r_pobj) by_10\IN|melphalan (r_prep) injury_9\NN|renal|by
D008558_C531616 NONE melphalan_7\NN|dose|in (l_prep) in_8\IN|patients (l_pobj) patients_9\NNS|with (l_prep) with_10\IN|amyloidosis (l_pobj) amyloidosis_13\NN|primary|systemic|during
D003404_D058186 NONE creatinine_31\NN| (r_compound) level_32\NN|the|serum|creatinine (r_pobj) in_28\IN|level (r_prep) increase_16\NN|a|minimum|of|in|is (r_pobj) by_13\IN|increase (r_agent) defined_12\VBN|insufficiency|after|melphalan|was|by|. (l_nsubjpass) insufficiency_2\NN|acute|renal|(|ari|)
D003404_D058186 NONE creatinine_31\NN| (r_compound) level_32\NN|the|serum|creatinine (r_pobj) in_28\IN|level (r_prep) increase_16\NN|a|minimum|of|in|is (r_pobj) by_13\IN|increase (r_agent) defined_12\VBN|insufficiency|after|melphalan|was|by|. (l_nsubjpass) insufficiency_2\NN|acute|renal|(|ari|) (l_appos) ARI_4\NNP|
D008558_-1 NONE melphalan_11\NN| (r_pobj) by_10\IN|melphalan (r_prep) injury_9\NN|renal|by (r_pobj) for_7\IN|injury (r_prep) prerequisite_6\NN|a|for (r_attr) be_4\VB|injury|may|prerequisite|evidenced|. (l_nsubj) injury_2\NN|ongoing|tubular
8312983
D005473_D003693 CID fluoxetine_2\NN| (r_amod) treatment_3\NN|fluoxetine (r_pobj) during_1\IN|treatment (r_prep) Delirium_0\NN|during|.
D005473_D003693 CID fluoxetine_18\NN| (r_nmod) concentration_24\NN|a|total|fluoxetine|(|fluoxetine|) (r_pobj) with_13\IN|concentration (r_prep) connected_12\VBN|with (r_acl) delirium_11\NN|acute|hyperkinetic|connected
D005473_D003693 CID fluoxetine_20\NN|plus|desmethylfluoxetine (r_nmod) concentration_24\NN|a|total|fluoxetine|(|fluoxetine|) (r_pobj) with_13\IN|concentration (r_prep) connected_12\VBN|with (r_acl) delirium_11\NN|acute|hyperkinetic|connected
D015283_D006970 NONE citalopram_9\NN| (r_pobj) of_8\IN|citalopram (r_prep) concentration_7\NN|a|high|serum|of|l|in (r_nsubjpass) associated_22\VBN|in|,|concentration|has|been|with|. (l_prep) with_23\IN|somnolence (l_pobj) somnolence_25\NN|increased|and|difficulties
D015283_D020820 NONE citalopram_9\NN| (r_pobj) of_8\IN|citalopram (r_prep) concentration_7\NN|a|high|serum|of|l|in (r_nsubjpass) associated_22\VBN|in|,|concentration|has|been|with|. (l_prep) with_23\IN|somnolence (l_pobj) somnolence_25\NN|increased|and|difficulties (l_conj) difficulties_28\NNS|movement
D005473_D006948 CID fluoxetine_18\NN| (r_nmod) concentration_24\NN|a|total|fluoxetine|(|fluoxetine|) (r_pobj) with_13\IN|concentration (r_prep) connected_12\VBN|with (r_acl) delirium_11\NN|acute|hyperkinetic|connected (l_amod) hyperkinetic_10\JJ|
D005473_D006948 CID fluoxetine_20\NN|plus|desmethylfluoxetine (r_nmod) concentration_24\NN|a|total|fluoxetine|(|fluoxetine|) (r_pobj) with_13\IN|concentration (r_prep) connected_12\VBN|with (r_acl) delirium_11\NN|acute|hyperkinetic|connected (l_amod) hyperkinetic_10\JJ|
C036139_D006948 NONE desmethylfluoxetine_22\NN| (r_conj) fluoxetine_20\NN|plus|desmethylfluoxetine (r_nmod) concentration_24\NN|a|total|fluoxetine|(|fluoxetine|) (r_pobj) with_13\IN|concentration (r_prep) connected_12\VBN|with (r_acl) delirium_11\NN|acute|hyperkinetic|connected (l_amod) hyperkinetic_10\JJ|
C036139_D003693 NONE desmethylfluoxetine_22\NN| (r_conj) fluoxetine_20\NN|plus|desmethylfluoxetine (r_nmod) concentration_24\NN|a|total|fluoxetine|(|fluoxetine|) (r_pobj) with_13\IN|concentration (r_prep) connected_12\VBN|with (r_acl) delirium_11\NN|acute|hyperkinetic|connected
7949506
D003000_D054537 CID clonidine_10\NN|and|verapamil (r_pobj) between_9\IN|clonidine (r_prep) interaction_8\NN|a|possible|adverse|between|resulting (l_acl) resulting_13\VBG|in (l_prep) in_14\IN|block (l_pobj) block_19\NN|atrioventricular|(|av|)|in
D003000_D054537 CID clonidine_8\NN| (r_pobj) of_7\IN|clonidine (r_prep) dose_6\NN|a|minimal|of|bid (r_pobj) of_3\IN|dose (r_prep) addition_2\NN|the|of (r_pobj) After_0\IN|addition (r_prep) developed_16\VBD|after|,|she|block (l_dobj) block_19\NN|complete|av|and|hypotension|,|resolved
D003000_D054537 CID clonidine_4\JJ| (r_pobj) of_3\IN|clonidine (r_prep) addition_2\NN|the|of (r_pobj) After_0\IN|addition|bid (r_prep) developed_9\VBD|after|she|block|. (l_dobj) block_12\NN|complete|av|,|resolved
D003000_D007022 CID clonidine_10\NN|and|verapamil (r_pobj) between_9\IN|clonidine (r_prep) interaction_8\NN|a|possible|adverse|between|resulting (l_acl) resulting_13\VBG|in (l_prep) in_14\IN|block (l_pobj) block_19\NN|atrioventricular|(|av|)|in (l_prep) in_20\IN|patients (l_pobj) patients_22\NNS|both|and|hypotension (l_conj) hypotension_25\NN|severe|in
D003000_D007022 CID clonidine_8\NN| (r_pobj) of_7\IN|clonidine (r_prep) dose_6\NN|a|minimal|of|bid (r_pobj) of_3\IN|dose (r_prep) addition_2\NN|the|of (r_pobj) After_0\IN|addition (r_prep) developed_16\VBD|after|,|she|block (l_dobj) block_19\NN|complete|av|and|hypotension|,|resolved (l_conj) hypotension_22\NN|severe
D014700_D054537 CID verapamil_12\NN| (r_conj) clonidine_10\NN|and|verapamil (r_pobj) between_9\IN|clonidine (r_prep) interaction_8\NN|a|possible|adverse|between|resulting (l_acl) resulting_13\VBG|in (l_prep) in_14\IN|block (l_pobj) block_19\NN|atrioventricular|(|av|)|in
D014700_D007022 CID verapamil_12\NN| (r_conj) clonidine_10\NN|and|verapamil (r_pobj) between_9\IN|clonidine (r_prep) interaction_8\NN|a|possible|adverse|between|resulting (l_acl) resulting_13\VBG|in (l_prep) in_14\IN|block (l_pobj) block_19\NN|atrioventricular|(|av|)|in (l_prep) in_20\IN|patients (l_pobj) patients_22\NNS|both|and|hypotension (l_conj) hypotension_25\NN|severe|in
D014700_D006929 NONE verapamil_10\NN| (r_pobj) with_9\IN|verapamil (r_prep) treated_8\VBN|woman|was|with|d|and|spironolactone|. (l_nsubjpass) woman_4\NN|a|old|with (l_prep) with_5\IN|hyperaldosteronism (l_pobj) hyperaldosteronism_6\NN|
D013148_D006929 NONE spironolactone_16\CD|d (r_conj) treated_8\VBN|woman|was|with|d|and|spironolactone|. (l_nsubjpass) woman_4\NN|a|old|with (l_prep) with_5\IN|hyperaldosteronism (l_pobj) hyperaldosteronism_6\NN|
25119790
D003474_D007674 NONE Curcumin_0\NN| (r_nsubj) prevents_1\VBZ|curcumin|nephrotoxicity (l_dobj) nephrotoxicity_5\NN|induced|:|relation
D003474_D007674 NONE curcumin_8\NN|the|dietary|antioxidant|(|day|) (r_pobj) of_4\IN|curcumin (r_prep) effect_3\NN|the|potential|protective|of|against (l_prep) against_20\IN|injury (l_pobj) injury_23\NN|the|renal|induced
D003474_D007674 NONE curcumin_4\NN| (r_nsubj) is_5\VBZ|that|curcumin|able (l_acomp) able_6\JJ|attenuate (l_xcomp) attenuate_8\VB|to|in (l_prep) in_9\IN|nephropathy|and|in (l_pobj) nephropathy_14\NN|vivo|induced
C030272_D007674 CID maleate_2\NN| (r_npadvmod) induced_4\VBN|maleate|- (r_amod) nephrotoxicity_5\NN|induced|:|relation
C030272_D007674 CID maleate_26\NN| (r_pobj) by_25\IN|maleate (r_agent) induced_24\VBN|by (r_acl) injury_23\NN|the|renal|induced
C030272_D007674 CID Maleate_0\NNP| (r_npadvmod) induced_2\VBN|maleate|- (r_amod) injury_4\NN|induced|renal
C030272_D007674 CID Maleate_0\NNP| (r_npadvmod) induced_2\VBN|maleate|- (r_amod) injury_4\NN|induced|renal (r_nsubj) included_5\VBD|injury|increase|,|determined (l_conj) determined_75\VBN|upregulation|was|by|. (l_nsubjpass) upregulation_45\NN|of|decrease (l_prep) of_46\IN|molecule (l_pobj) molecule_49\NN|kidney|injury (l_compound) injury_48\NN|
C030272_D007674 CID maleate_11\NN| (r_npadvmod) induced_13\VBN|maleate|- (r_amod) nephropathy_14\NN|vivo|induced
D010100_D007674 NONE oxygen_16\NN| (r_compound) consumption_17\NN|mitochondrial|oxygen|and|activity|of (r_conj) stress_13\NN|oxidative|,|consumption (r_conj) alterations_10\NNS|hemodynamic|,|stress (r_pobj) to_8\IN|alterations (r_prep) relation_7\NN|to (r_appos) nephrotoxicity_5\NN|induced|:|relation
C030272_D011507 CID maleate_12\NN|(|mg/kg|) (r_pobj) of_11\IN|maleate (r_prep) injection_10\NN|a|single|of|in (r_pobj) by_7\IN|injection (r_agent) induced_6\VBN|proteinuria|were|by|. (l_nsubjpass) proteinuria_1\NN|tubular|and|stress
C030272_D009336 CID Maleate_0\NNP| (r_npadvmod) induced_2\VBN|maleate|- (r_amod) injury_4\NN|induced|renal (r_nsubj) included_5\VBD|injury|increase|,|determined (l_conj) determined_75\VBN|upregulation|was|by|. (l_nsubjpass) upregulation_45\NN|of|decrease (l_parataxis) decrease_53\NN|(|kim)-1|,|in|besides|and|apoptosis (l_prep) besides_61\IN|of (l_prep) of_62\IN|necrosis (l_pobj) necrosis_63\NN|
D005947_D007674 NONE glucose_20\NN|,|sodium (r_conj) protein_18\NN|total|,|glucose (r_pobj) of_16\IN|protein (r_prep) excretion_15\NN|the|urinary|of (r_pobj) in_12\IN|excretion (r_conj) increase_6\NN|in|and|in (r_dobj) included_5\VBD|injury|increase|,|determined (l_nsubj) injury_4\NN|induced|renal
D005947_D007674 NONE glucose_20\NN|,|sodium (r_conj) protein_18\NN|total|,|glucose (r_pobj) of_16\IN|protein (r_prep) excretion_15\NN|the|urinary|of (r_pobj) in_12\IN|excretion (r_conj) increase_6\NN|in|and|in (r_dobj) included_5\VBD|injury|increase|,|determined (l_conj) determined_75\VBN|upregulation|was|by|. (l_nsubjpass) upregulation_45\NN|of|decrease (l_prep) of_46\IN|molecule (l_pobj) molecule_49\NN|kidney|injury (l_compound) injury_48\NN|
D005947_D009336 NONE glucose_20\NN|,|sodium (r_conj) protein_18\NN|total|,|glucose (r_pobj) of_16\IN|protein (r_prep) excretion_15\NN|the|urinary|of (r_pobj) in_12\IN|excretion (r_conj) increase_6\NN|in|and|in (r_dobj) included_5\VBD|injury|increase|,|determined (l_conj) determined_75\VBN|upregulation|was|by|. (l_nsubjpass) upregulation_45\NN|of|decrease (l_parataxis) decrease_53\NN|(|kim)-1|,|in|besides|and|apoptosis (l_prep) besides_61\IN|of (l_prep) of_62\IN|necrosis (l_pobj) necrosis_63\NN|
D012964_D007674 NONE sodium_22\NN|,|lipocalin (r_conj) glucose_20\NN|,|sodium (r_conj) protein_18\NN|total|,|glucose (r_pobj) of_16\IN|protein (r_prep) excretion_15\NN|the|urinary|of (r_pobj) in_12\IN|excretion (r_conj) increase_6\NN|in|and|in (r_dobj) included_5\VBD|injury|increase|,|determined (l_nsubj) injury_4\NN|induced|renal
D012964_D007674 NONE sodium_22\NN|,|lipocalin (r_conj) glucose_20\NN|,|sodium (r_conj) protein_18\NN|total|,|glucose (r_pobj) of_16\IN|protein (r_prep) excretion_15\NN|the|urinary|of (r_pobj) in_12\IN|excretion (r_conj) increase_6\NN|in|and|in (r_dobj) included_5\VBD|injury|increase|,|determined (l_conj) determined_75\VBN|upregulation|was|by|. (l_nsubjpass) upregulation_45\NN|of|decrease (l_prep) of_46\IN|molecule (l_pobj) molecule_49\NN|kidney|injury (l_compound) injury_48\NN|
D012964_D009336 NONE sodium_22\NN|,|lipocalin (r_conj) glucose_20\NN|,|sodium (r_conj) protein_18\NN|total|,|glucose (r_pobj) of_16\IN|protein (r_prep) excretion_15\NN|the|urinary|of (r_pobj) in_12\IN|excretion (r_conj) increase_6\NN|in|and|in (r_dobj) included_5\VBD|injury|increase|,|determined (l_conj) determined_75\VBN|upregulation|was|by|. (l_nsubjpass) upregulation_45\NN|of|decrease (l_parataxis) decrease_53\NN|(|kim)-1|,|in|besides|and|apoptosis (l_prep) besides_61\IN|of (l_prep) of_62\IN|necrosis (l_pobj) necrosis_63\NN|
15987266
D003513_D004827 NONE cycloheximide_16\NN| (r_pobj) with_15\IN|cycloheximide (r_prep) treated_14\VBN|expression|with|. (l_nsubj) expression_5\NN|protein|43|in (l_prep) in_6\IN|layer (l_pobj) layer_9\NN|hippocampal|molecular|of (l_prep) of_10\IN|rats (l_pobj) rats_13\NNS|chronic|epileptic (l_amod) epileptic_12\JJ|
D010862_D013226 CID pilocarpine_46\NN|pilo (r_pobj) by_45\IN|pilocarpine (r_agent) induced_44\VBN|epilepticus|by (l_amod) epilepticus_43\NN|
D010862_D013226 CID Pilo_48\NNP|(|) (r_appos) pilocarpine_46\NN|pilo (r_pobj) by_45\IN|pilocarpine (r_agent) induced_44\VBN|epilepticus|by (l_amod) epilepticus_43\NN|
D003513_D013226 NONE cycloheximide_56\NN| (r_pobj) with_55\IN|not|cycloheximide (r_conj) injected_52\VBN|previously|or|with|chx (r_conj) assessed_13\VBD|investigate|,|we|intensity|,|injected|. (l_dobj) intensity_15\NN|the|(|densitometry|of|induced (l_acl) induced_44\VBN|epilepticus|by (l_amod) epilepticus_43\NN|
D003513_D013226 NONE CHX_58\NNP|(|)|,|shown (r_appos) injected_52\VBN|previously|or|with|chx (r_conj) assessed_13\VBD|investigate|,|we|intensity|,|injected|. (l_dobj) intensity_15\NN|the|(|densitometry|of|induced (l_acl) induced_44\VBN|epilepticus|by (l_amod) epilepticus_43\NN|
1117341
D015119_D006943 CID amino_3\JJ| (r_compound) compounds_4\NNS|amino (r_pobj) of_2\IN|compounds (r_prep) effect_1\NN|hyperglycemic|of (l_amod) Hyperglycemic_0\JJ|
D015119_D006943 CID amino_17\JJ| (r_amod) derivatives_18\NNS|certain|amino|of (r_pobj) of_15\IN|derivatives (r_prep) amounts_5\NNS|small|(|%|)|of (r_pobj) of_3\IN|amounts (r_prep) feeding_2\NN|the|chronic|of (r_nsubj) resulted_21\VBD|feeding|in|. (l_prep) in_22\IN|hyperglycemia (l_pobj) hyperglycemia_23\NN|,|curve
C037652_D006943 NONE caproate_8\NN|to|in (r_xcomp) related_6\VBN|effect|structurally|caproate|. (l_nsubj) effect_1\NN|hyperglycemic|of (l_amod) Hyperglycemic_0\JJ|
C037652_D006943 NONE caproate_20\NN| (r_pobj) of_19\IN|caproate (r_prep) derivatives_18\NNS|certain|amino|of (r_pobj) of_15\IN|derivatives (r_prep) amounts_5\NNS|small|(|%|)|of (r_pobj) of_3\IN|amounts (r_prep) feeding_2\NN|the|chronic|of (r_nsubj) resulted_21\VBD|feeding|in|. (l_prep) in_22\IN|hyperglycemia (l_pobj) hyperglycemia_23\NN|,|curve
D015119_D006030 NONE amino_17\JJ| (r_amod) derivatives_18\NNS|certain|amino|of (r_pobj) of_15\IN|derivatives (r_prep) amounts_5\NNS|small|(|%|)|of (r_pobj) of_3\IN|amounts (r_prep) feeding_2\NN|the|chronic|of (r_nsubj) resulted_21\VBD|feeding|in|. (l_prep) in_22\IN|hyperglycemia (l_pobj) hyperglycemia_23\NN|,|curve (l_appos) curve_29\NN|an|elevated|tolerance|and|,|occasionally|,|glucosuria (l_conj) glucosuria_34\NN|
C037652_D006030 NONE caproate_20\NN| (r_pobj) of_19\IN|caproate (r_prep) derivatives_18\NNS|certain|amino|of (r_pobj) of_15\IN|derivatives (r_prep) amounts_5\NNS|small|(|%|)|of (r_pobj) of_3\IN|amounts (r_prep) feeding_2\NN|the|chronic|of (r_nsubj) resulted_21\VBD|feeding|in|. (l_prep) in_22\IN|hyperglycemia (l_pobj) hyperglycemia_23\NN|,|curve (l_appos) curve_29\NN|an|elevated|tolerance|and|,|occasionally|,|glucosuria (l_conj) glucosuria_34\NN|
D005947_D006943 NONE glucose_27\NN| (r_compound) tolerance_28\NN|glucose (r_compound) curve_29\NN|an|elevated|tolerance|and|,|occasionally|,|glucosuria (r_appos) hyperglycemia_23\NN|,|curve
D005947_D006030 NONE glucose_27\NN| (r_compound) tolerance_28\NN|glucose (r_compound) curve_29\NN|an|elevated|tolerance|and|,|occasionally|,|glucosuria (l_conj) glucosuria_34\NN|
17543491
12487093
D004837_D006973 CID Adrenaline_0\NN| (r_npadvmod) induced_2\VBN|adrenaline|- (r_amod) hypertension_3\NN|induced
D004837_D006973 CID adrenaline_27\NN| (r_dobj) giving_26\VBG|adrenaline|for (r_pcomp) after_25\IN|just|giving (r_prep) staining_19\NN|of|after (r_appos) triphenyltetrazolium_15\NN|ttc|)|staining (r_dobj) using_14\VBG|triphenyltetrazolium (r_advcl) evaluated_13\VBN|which|was|using (r_relcl) BBB_9\NN|the|,|evaluated (r_dobj) destroy_7\VB|to|bbb (r_xcomp) used_5\VBN|hypertension|was|destroy (l_nsubjpass) hypertension_3\NN|induced
C009591_D006973 NONE triphenyltetrazolium_15\NN|ttc|)|staining (r_dobj) using_14\VBG|triphenyltetrazolium (r_advcl) evaluated_13\VBN|which|was|using (r_relcl) BBB_9\NN|the|,|evaluated (r_dobj) destroy_7\VB|to|bbb (r_xcomp) used_5\VBN|hypertension|was|destroy (l_nsubjpass) hypertension_3\NN|induced
C009591_D006973 NONE TTC_17\NNP|( (r_appos) triphenyltetrazolium_15\NN|ttc|)|staining (r_dobj) using_14\VBG|triphenyltetrazolium (r_advcl) evaluated_13\VBN|which|was|using (r_relcl) BBB_9\NN|the|,|evaluated (r_dobj) destroy_7\VB|to|bbb (r_xcomp) used_5\VBN|hypertension|was|destroy (l_nsubjpass) hypertension_3\NN|induced
25006961
D008094_D018500 CID lithium_6\NN| (r_npadvmod) induced_8\VBN|lithium|- (r_amod) insipidus_11\NN|induced|diabetes
D008094_D018500 CID Lithium_0\NN|,|antipsychotic|, (r_nsubj) induces_6\VBZ|lithium|insipidus|in|. (l_dobj) insipidus_9\NN|nephrogenic|diabetes|(|ndi|)
D008094_D018500 CID Lithium_0\NN|,|antipsychotic|, (r_nsubj) induces_6\VBZ|lithium|insipidus|in|. (l_dobj) insipidus_9\NN|nephrogenic|diabetes|(|ndi|) (l_appos) NDI_11\NNP|
D008094_D018500 CID lithium_18\NN| (r_npadvmod) induced_20\VBN|lithium|- (r_amod) NDI_21\NNP|induced
D008094_D018500 CID lithium_33\NN| (r_compound) therapy_34\NN|lithium (r_pobj) with_32\IN|therapy (r_prep) associated_31\VBN|with (r_acl) polyuria_30\NN|the|severe|associated (r_pobj) of_27\IN|polyuria (r_prep) development_26\NN|the|of (r_dobj) prevents_24\VBZ|development (r_conj) preserves_7\VBZ|that|ablation|expression|in|,|and|prevents (l_prep) in_17\IN|ndi (l_pobj) NDI_21\NNP|induced
D008094_D011141 CID lithium_20\NN| (r_npadvmod) induced_22\VBN|lithium|- (r_amod) polyuria_23\NN|induced
D008094_D011141 CID lithium_18\NN| (r_npadvmod) induced_20\VBN|lithium|- (r_amod) NDI_21\NNP|induced (r_pobj) in_17\IN|ndi (r_prep) preserves_7\VBZ|that|ablation|expression|in|,|and|prevents (l_conj) prevents_24\VBZ|development (l_dobj) development_26\NN|the|of (l_prep) of_27\IN|polyuria (l_pobj) polyuria_30\NN|the|severe|associated
D008094_D011141 CID lithium_33\NN| (r_compound) therapy_34\NN|lithium (r_pobj) with_32\IN|therapy (r_prep) associated_31\VBN|with (r_acl) polyuria_30\NN|the|severe|associated
20682692
D013311_D003928 CID streptozotocin_15\NNS| (r_npadvmod) induced_17\VBN|streptozotocin|- (r_amod) nephropathy_19\NN|induced|diabetic
D013311_D003928 CID STZ_22\NNP| (r_npadvmod) induced_24\VBN|stz|- (r_amod) nephropathy_26\NN|induced|diabetic|in
D013311_D003928 CID STZ_20\NNP| (r_npadvmod) induced_22\VBN|stz|- (r_amod) nephropathy_24\NN|induced|diabetic
D000804_D003922 NONE angiotensin_13\NN|renin|- (r_compound) system_14\NN|the|angiotensin (r_pobj) of_9\IN|system (r_prep) blockade_8\NN|early|of|in (l_prep) in_15\IN|patients (l_pobj) patients_16\NNS|with (l_prep) with_17\IN|diabetes (l_pobj) diabetes_20\NNS|type|and|normoalbuminuria
D000804_D007674 NONE angiotensin_13\NN|renin|- (r_compound) system_14\NN|the|angiotensin (r_pobj) of_9\IN|system (r_prep) blockade_8\NN|early|of|in (r_nsubj) retard_25\VB|that|blockade|did|not|progression|,|suggesting (l_dobj) progression_27\NN|the|of (l_prep) of_28\IN|nephropathy (l_pobj) nephropathy_29\NN|
D000804_D003928 NONE angiotensin_13\NN|renin|- (r_compound) system_14\NN|the|angiotensin (r_pobj) of_9\IN|system (r_prep) blockade_8\NN|early|of|in (r_nsubj) retard_25\VB|that|blockade|did|not|progression|,|suggesting (l_advcl) suggesting_31\VBG|involved (l_ccomp) involved_37\VBN|that|mechanism(s|)|are|in (l_prep) in_38\IN|pathogenesis (l_pobj) pathogenesis_40\NN|the|of (l_prep) of_41\IN|nephropathy (l_pobj) nephropathy_44\NN|early|diabetic|(|nephropathy|)
D000804_D003928 NONE angiotensin_13\NN|renin|- (r_compound) system_14\NN|the|angiotensin (r_pobj) of_9\IN|system (r_prep) blockade_8\NN|early|of|in (r_nsubj) retard_25\VB|that|blockade|did|not|progression|,|suggesting (l_advcl) suggesting_31\VBG|involved (l_ccomp) involved_37\VBN|that|mechanism(s|)|are|in (l_prep) in_38\IN|pathogenesis (l_pobj) pathogenesis_40\NN|the|of (l_prep) of_41\IN|nephropathy (l_pobj) nephropathy_44\NN|early|diabetic|(|nephropathy|) (l_appos) nephropathy_47\NN|diabetic
D013311_D005355 NONE streptozotocin_28\JJ| (r_nmod) diabetes_31\NNS|streptozotocin|(|stz)-induced (r_pobj) with_27\IN|diabetes (r_prep) mice_26\NNS|with (r_pobj) in_25\IN|mice (r_prep) development_17\NN|the|early|of|of|in (l_prep) of_18\IN|fibrosis (l_pobj) fibrosis_21\NN|renal|interstitial
D013311_D005355 NONE STZ)-induced_30\VBN| (r_amod) diabetes_31\NNS|streptozotocin|(|stz)-induced (r_pobj) with_27\IN|diabetes (r_prep) mice_26\NNS|with (r_pobj) in_25\IN|mice (r_prep) development_17\NN|the|early|of|of|in (l_prep) of_18\IN|fibrosis (l_pobj) fibrosis_21\NN|renal|interstitial
D013311_D003920 NONE streptozotocin_28\JJ| (r_nmod) diabetes_31\NNS|streptozotocin|(|stz)-induced
D013311_D003920 NONE STZ)-induced_30\VBN| (r_amod) diabetes_31\NNS|streptozotocin|(|stz)-induced
15366550
D008094_D059606 NONE lithium_24\NN| (r_compound) use_25\NN|standing|lithium (r_conj) polydipsia_19\NN|and|use
D008094_D018500 CID Lithium_0\NN| (r_nsubjpass) implicated_2\VBN|lithium|is|in|,|and|changed (l_prep) in_3\IN|di (l_pobj) DI_8\NNP|induced|nephrogenic
D008094_D018500 CID Lithium_0\NN| (r_nsubjpass) implicated_2\VBN|lithium|is|in|,|and|changed (l_conj) changed_27\VBD|received|,|treatment|focus|. (l_advcl) focus_29\VB|to|on (l_prep) on_30\IN|di (l_pobj) DI_32\NNP|nephrogenic
D008094_D018500 CID lithium_17\NN| (r_dobj) received_16\VBN|because|patient|had|not|lithium|since (r_advcl) changed_27\VBD|received|,|treatment|focus|. (r_conj) implicated_2\VBN|lithium|is|in|,|and|changed (l_prep) in_3\IN|di (l_pobj) DI_8\NNP|induced|nephrogenic
D008094_D018500 CID lithium_17\NN| (r_dobj) received_16\VBN|because|patient|had|not|lithium|since (r_advcl) changed_27\VBD|received|,|treatment|focus|. (l_advcl) focus_29\VB|to|on (l_prep) on_30\IN|di (l_pobj) DI_32\NNP|nephrogenic
D008094_D018500 CID lithium_32\NN| (r_npadvmod) induced_34\VBN|lithium|- (r_amod) DI_36\NNP|his|induced|nephrogenic
D008094_D018500 CID lithium_32\NN| (r_npadvmod) induced_34\VBN|lithium|- (r_amod) DI_36\NNP|his|induced|nephrogenic (r_dobj) treating_30\VBG|been|self|-|di|and|developed (l_conj) developed_38\VBN|di|brain (l_dobj) DI_40\NNP|neurogenic|secondary
D008094_D001930 NONE lithium_32\NN| (r_npadvmod) induced_34\VBN|lithium|- (r_amod) DI_36\NNP|his|induced|nephrogenic (r_dobj) treating_30\VBG|been|self|-|di|and|developed (l_conj) developed_38\VBN|di|brain (l_advcl) brain_43\NN|to|trauma (l_dobj) trauma_44\NN|
17297207
D011803_D001145 NONE Quinine_0\NN| (r_npadvmod) induced_2\VBN|quinine|- (r_amod) arrhythmia_3\NN|induced|in|.
D011803_D001145 NONE quinine_25\NN| (r_compound) infusion_26\NN|quinine (r_nsubjpass) reported_28\VBN|infusion|was (r_ccomp) getting_24\VBG|while|reported (r_advcl) was_5\VBD|that|there|case|)|getting (l_attr) case_7\NN|a|of|contraction (l_prep) of_8\IN|patient (l_pobj) patient_11\NN|severe|malaria|with (l_prep) with_12\IN|jaundice (l_pobj) jaundice_13\NN|presented (l_relcl) presented_15\VBD|who|with (l_prep) with_16\IN|arrhythmia (l_pobj) arrhythmia_17\NN|
D011803_D001145 NONE Quinine_0\NN| (r_nsubj) is_5\VBZ|quinine|,|like|,|alkaloid|,|arrhythmic|. (l_attr) alkaloid_8\NN|a|chincona|has (l_relcl) has_10\VBZ|that|property (l_dobj) property_14\NN|arrhythmic (l_amod) arrhythmic_13\JJ|-
D011803_D001145 NONE Quinine_0\NN| (r_nsubj) is_5\VBZ|quinine|,|like|,|alkaloid|,|arrhythmic|. (l_advcl) arrhythmic_21\JJ|although|it|also|-|cause
D011803_D001145 NONE Quinine_0\NN| (r_nsubj) is_5\VBZ|quinine|,|like|,|alkaloid|,|arrhythmic|. (l_advcl) arrhythmic_21\JJ|although|it|also|-|cause (l_ccomp) cause_24\VB|that|can|arrhythmias (l_dobj) arrhythmias_26\NNS|various|,|including
D011803_D001145 NONE Quinine_0\NN| (r_nsubj) is_5\VBZ|quinine|,|like|,|alkaloid|,|arrhythmic|. (l_advcl) arrhythmic_21\JJ|although|it|also|-|cause (l_ccomp) cause_24\VB|that|can|arrhythmias (l_dobj) arrhythmias_26\NNS|various|,|including (l_prep) including_28\VBG|arrhythmia (l_pobj) arrhythmia_30\NN|severe|as
D011803_D001145 NONE quinine_3\NN|parenteral (r_pobj) of_1\IN|quinine (r_prep) Administration_0\NN|of (r_nsubjpass) done_6\VBN|administration|must|be|carefully|and|with|because|. (l_prep) because_12\IN|of|effect (l_pobj) effect_18\NN|its|arrhythmic|,|in (l_amod) arrhythmic_17\JJ|pro|-
D011803_D016778 NONE Quinine_0\NN| (r_npadvmod) induced_2\VBN|quinine|- (r_amod) arrhythmia_3\NN|induced|in|. (l_prep) in_4\IN|patient (l_pobj) patient_6\NN|a|with (l_prep) with_7\IN|malaria (l_pobj) malaria_9\NN|severe
D011803_D016778 NONE quinine_25\NN| (r_compound) infusion_26\NN|quinine (r_nsubjpass) reported_28\VBN|infusion|was (r_ccomp) getting_24\VBG|while|reported (r_advcl) was_5\VBD|that|there|case|)|getting (l_attr) case_7\NN|a|of|contraction (l_prep) of_8\IN|patient (l_pobj) patient_11\NN|severe|malaria|with (l_compound) malaria_10\NN|
D011803_D016778 NONE quinine_11\NN| (r_compound) infusion_12\NN|quinine|in (r_dobj) got_10\VBD|infusion|% (r_conj) diagnosed_3\VBN|patient|was|as|and|got|. (l_prep) as_4\IN|malaria (l_pobj) malaria_6\NN|severe|with
D011803_D007565 NONE quinine_25\NN| (r_compound) infusion_26\NN|quinine (r_nsubjpass) reported_28\VBN|infusion|was (r_ccomp) getting_24\VBG|while|reported (r_advcl) was_5\VBD|that|there|case|)|getting (l_attr) case_7\NN|a|of|contraction (l_prep) of_8\IN|patient (l_pobj) patient_11\NN|severe|malaria|with (l_prep) with_12\IN|jaundice (l_pobj) jaundice_13\NN|presented
D011803_D007565 NONE quinine_11\NN| (r_compound) infusion_12\NN|quinine|in (r_dobj) got_10\VBD|infusion|% (r_conj) diagnosed_3\VBN|patient|was|as|and|got|. (l_prep) as_4\IN|malaria (l_pobj) malaria_6\NN|severe|with (l_prep) with_7\IN|jaundice (l_pobj) jaundice_8\NN|
D011803_D018879 CID quinine_25\NN| (r_compound) infusion_26\NN|quinine (r_nsubjpass) reported_28\VBN|infusion|was (r_ccomp) getting_24\VBG|while|reported (r_advcl) was_5\VBD|that|there|case|)|getting (l_attr) case_7\NN|a|of|contraction (l_appos) contraction_21\NN|(|premature|ventricular
D011803_D018879 CID quinine_4\NN| (r_compound) infusion_5\NN|quinine (r_pobj) of_3\IN|infusion (r_prep) hours_2\NNS|30|of (r_pobj) After_0\IN|hours (r_prep) felt_8\VBD|after|patient|palpitation|showed (l_parataxis) showed_16\VBD|(|recording|contraction|wave|. (l_dobj) contraction_19\NN|premature|ventricular|pvc|>
D011803_D018879 CID quinine_4\NN| (r_compound) infusion_5\NN|quinine (r_pobj) of_3\IN|infusion (r_prep) hours_2\NNS|30|of (r_pobj) After_0\IN|hours (r_prep) felt_8\VBD|after|patient|palpitation|showed (l_parataxis) showed_16\VBD|(|recording|contraction|wave|. (l_dobj) contraction_19\NN|premature|ventricular|pvc|> (l_appos) PVC_21\NN|(|)
D011803_D018879 CID Quinine_0\NN| (r_nsubj) is_5\VBZ|quinine|,|like|,|alkaloid|,|arrhythmic|. (l_advcl) arrhythmic_21\JJ|although|it|also|-|cause (l_ccomp) cause_24\VB|that|can|arrhythmias (l_dobj) arrhythmias_26\NNS|various|,|including (l_prep) including_28\VBG|arrhythmia (l_pobj) arrhythmia_30\NN|severe|as (l_prep) as_32\IN|such|pvc (l_pobj) PVC_34\NN|multiple
D005947_D016778 NONE dextrose_14\NN| (r_pobj) in_13\IN|dextrose (r_prep) infusion_12\NN|quinine|in (r_dobj) got_10\VBD|infusion|% (r_conj) diagnosed_3\VBN|patient|was|as|and|got|. (l_prep) as_4\IN|malaria (l_pobj) malaria_6\NN|severe|with
D005947_D007565 NONE dextrose_14\NN| (r_pobj) in_13\IN|dextrose (r_prep) infusion_12\NN|quinine|in (r_dobj) got_10\VBD|infusion|% (r_conj) diagnosed_3\VBN|patient|was|as|and|got|. (l_prep) as_4\IN|malaria (l_pobj) malaria_6\NN|severe|with (l_prep) with_7\IN|jaundice (l_pobj) jaundice_8\NN|
D011803_-1 NONE quinine_4\NN| (r_compound) infusion_5\NN|quinine (r_pobj) of_3\IN|infusion (r_prep) hours_2\NNS|30|of (r_pobj) After_0\IN|hours (r_prep) felt_8\VBD|after|patient|palpitation|showed (l_dobj) palpitation_9\NN|and|electrocardiography
D011803_D012848 NONE quinine_4\NN| (r_compound) infusion_5\NN|quinine (r_pobj) of_3\IN|infusion (r_prep) hours_2\NNS|30|of (r_pobj) After_0\IN|hours (r_prep) felt_8\VBD|after|patient|palpitation|showed (l_parataxis) showed_16\VBD|(|recording|contraction|wave|. (l_ccomp) wave_39\VBP|block|,|positive|u (l_nmod) block_35\NN|minute|,|trigemini|,|type|sinoatrial
D011188_D018879 NONE potassium_29\NN| (r_compound) level_30\NN|potassium (r_nsubj) was_31\VBD|reduced|,|level|meq/ (l_ccomp) reduced_12\VBN|felt|,|frequency|to|was (l_nsubj) frequency_9\NN|the|of (l_prep) of_10\IN|pvc (l_pobj) PVC_11\NNP|
D011802_D001145 NONE quinidine_3\NN| (r_pobj) like_2\IN|quinidine (r_prep) is_5\VBZ|quinine|,|like|,|alkaloid|,|arrhythmic|. (l_attr) alkaloid_8\NN|a|chincona|has (l_relcl) has_10\VBZ|that|property (l_dobj) property_14\NN|arrhythmic (l_amod) arrhythmic_13\JJ|-
D011802_D001145 NONE quinidine_3\NN| (r_pobj) like_2\IN|quinidine (r_prep) is_5\VBZ|quinine|,|like|,|alkaloid|,|arrhythmic|. (l_advcl) arrhythmic_21\JJ|although|it|also|-|cause
D011802_D001145 NONE quinidine_3\NN| (r_pobj) like_2\IN|quinidine (r_prep) is_5\VBZ|quinine|,|like|,|alkaloid|,|arrhythmic|. (l_advcl) arrhythmic_21\JJ|although|it|also|-|cause (l_ccomp) cause_24\VB|that|can|arrhythmias (l_dobj) arrhythmias_26\NNS|various|,|including
D011802_D001145 NONE quinidine_3\NN| (r_pobj) like_2\IN|quinidine (r_prep) is_5\VBZ|quinine|,|like|,|alkaloid|,|arrhythmic|. (l_advcl) arrhythmic_21\JJ|although|it|also|-|cause (l_ccomp) cause_24\VB|that|can|arrhythmias (l_dobj) arrhythmias_26\NNS|various|,|including (l_prep) including_28\VBG|arrhythmia (l_pobj) arrhythmia_30\NN|severe|as
D011802_D018879 NONE quinidine_3\NN| (r_pobj) like_2\IN|quinidine (r_prep) is_5\VBZ|quinine|,|like|,|alkaloid|,|arrhythmic|. (l_advcl) arrhythmic_21\JJ|although|it|also|-|cause (l_ccomp) cause_24\VB|that|can|arrhythmias (l_dobj) arrhythmias_26\NNS|various|,|including (l_prep) including_28\VBG|arrhythmia (l_pobj) arrhythmia_30\NN|severe|as (l_prep) as_32\IN|such|pvc (l_pobj) PVC_34\NN|multiple
D011803_D006331 NONE quinine_3\NN|parenteral (r_pobj) of_1\IN|quinine (r_prep) Administration_0\NN|of (r_nsubjpass) done_6\VBN|administration|must|be|carefully|and|with|because|. (l_prep) because_12\IN|of|effect (l_pobj) effect_18\NN|its|arrhythmic|,|in (l_prep) in_21\IN|especially|patients (l_pobj) patients_23\NNS|older|have (l_relcl) have_25\VBP|who|diseases (l_dobj) diseases_27\NNS|heart|or|patients
D011803_D014883 NONE quinine_3\NN|parenteral (r_pobj) of_1\IN|quinine (r_prep) Administration_0\NN|of (r_nsubjpass) done_6\VBN|administration|must|be|carefully|and|with|because|. (l_prep) because_12\IN|of|effect (l_pobj) effect_18\NN|its|arrhythmic|,|in (l_prep) in_21\IN|especially|patients (l_pobj) patients_23\NNS|older|have (l_relcl) have_25\VBP|who|diseases (l_dobj) diseases_27\NNS|heart|or|patients (l_conj) patients_29\NNS|with (l_prep) with_30\IN|disorder (l_pobj) disorder_32\NN|electrolyte|(|hypokalemia|)|occurs
D011803_D007008 NONE quinine_3\NN|parenteral (r_pobj) of_1\IN|quinine (r_prep) Administration_0\NN|of (r_nsubjpass) done_6\VBN|administration|must|be|carefully|and|with|because|. (l_prep) because_12\IN|of|effect (l_pobj) effect_18\NN|its|arrhythmic|,|in (l_prep) in_21\IN|especially|patients (l_pobj) patients_23\NNS|older|have (l_relcl) have_25\VBP|who|diseases (l_dobj) diseases_27\NNS|heart|or|patients (l_conj) patients_29\NNS|with (l_prep) with_30\IN|disorder (l_pobj) disorder_32\NN|electrolyte|(|hypokalemia|)|occurs (l_appos) hypokalemia_34\NN|
D011803_D014839 NONE quinine_3\NN|parenteral (r_pobj) of_1\IN|quinine (r_prep) Administration_0\NN|of (r_nsubjpass) done_6\VBN|administration|must|be|carefully|and|with|because|. (l_prep) because_12\IN|of|effect (l_pobj) effect_18\NN|its|arrhythmic|,|in (l_prep) in_21\IN|especially|patients (l_pobj) patients_23\NNS|older|have (l_relcl) have_25\VBP|who|diseases (l_dobj) diseases_27\NNS|heart|or|patients (l_conj) patients_29\NNS|with (l_prep) with_30\IN|disorder (l_pobj) disorder_32\NN|electrolyte|(|hypokalemia|)|occurs (l_relcl) occurs_38\VBZ|which|frequently|due|vomiting (l_advcl) vomiting_41\NN|and|or|diarrhea
D011803_D003967 NONE quinine_3\NN|parenteral (r_pobj) of_1\IN|quinine (r_prep) Administration_0\NN|of (r_nsubjpass) done_6\VBN|administration|must|be|carefully|and|with|because|. (l_prep) because_12\IN|of|effect (l_pobj) effect_18\NN|its|arrhythmic|,|in (l_prep) in_21\IN|especially|patients (l_pobj) patients_23\NNS|older|have (l_relcl) have_25\VBP|who|diseases (l_dobj) diseases_27\NNS|heart|or|patients (l_conj) patients_29\NNS|with (l_prep) with_30\IN|disorder (l_pobj) disorder_32\NN|electrolyte|(|hypokalemia|)|occurs (l_relcl) occurs_38\VBZ|which|frequently|due|vomiting (l_advcl) vomiting_41\NN|and|or|diarrhea (l_conj) diarrhea_44\NN|in
D011803_D008288 NONE quinine_3\NN|parenteral (r_pobj) of_1\IN|quinine (r_prep) Administration_0\NN|of (r_nsubjpass) done_6\VBN|administration|must|be|carefully|and|with|because|. (l_prep) because_12\IN|of|effect (l_pobj) effect_18\NN|its|arrhythmic|,|in (l_prep) in_21\IN|especially|patients (l_pobj) patients_23\NNS|older|have (l_relcl) have_25\VBP|who|diseases (l_dobj) diseases_27\NNS|heart|or|patients (l_conj) patients_29\NNS|with (l_prep) with_30\IN|disorder (l_pobj) disorder_32\NN|electrolyte|(|hypokalemia|)|occurs (l_relcl) occurs_38\VBZ|which|frequently|due|vomiting (l_advcl) vomiting_41\NN|and|or|diarrhea (l_conj) diarrhea_44\NN|in (l_prep) in_45\IN|cases (l_pobj) cases_47\NNS|malaria (l_compound) malaria_46\NN|
8135424
D005442_D012640 CID Flumazenil_0\NNP| (r_nsubj) induces_1\VBZ|flumazenil|seizures|. (l_dobj) seizures_2\NNS|and|death|in
D005442_D012640 CID flumazenil_8\JJ| (r_appos) Administration_3\NN|of|flumazenil (r_nsubj) unmask_10\VB|administration|may|seizures (l_dobj) seizures_11\NNS|in
D005442_D012640 CID Flumazenil_0\NNP| (r_nsubj) unmask_2\VB|flumazenil|can|seizures|and|increase|. (l_dobj) seizures_3\NNS|
D003042_D012640 CID cocaine_7\NN| (r_compound) diazepam_9\NN|cocaine|- (r_compound) intoxications_10\NNS|mixed|diazepam (r_pobj) in_5\IN|intoxications (r_prep) seizures_2\NNS|and|death|in
D003042_D012640 CID cocaine_14\NN| (r_compound) benzodiazepine_16\NN|cocaine|- (r_amod) intoxication_17\NN|mixed|benzodiazepine (r_pobj) in_12\IN|intoxication (r_prep) seizures_11\NNS|in
D003042_D012640 CID cocaine_15\NN| (r_compound) diazepam_17\NN|cocaine|- (r_compound) intoxications_18\NNS|combined|diazepam (r_pobj) of_13\IN|intoxications (r_prep) model_12\NN|a|of (r_pobj) in_10\IN|model (r_prep) increase_5\VB|incidence|in (r_conj) unmask_2\VB|flumazenil|can|seizures|and|increase|. (l_dobj) seizures_3\NNS|
D003975_D012640 CID diazepam_9\NN|cocaine|- (r_compound) intoxications_10\NNS|mixed|diazepam (r_pobj) in_5\IN|intoxications (r_prep) seizures_2\NNS|and|death|in
D003975_D012640 CID diazepam_17\NN|cocaine|- (r_compound) intoxications_18\NNS|combined|diazepam (r_pobj) of_13\IN|intoxications (r_prep) model_12\NN|a|of (r_pobj) in_10\IN|model (r_prep) increase_5\VB|incidence|in (r_conj) unmask_2\VB|flumazenil|can|seizures|and|increase|. (l_dobj) seizures_3\NNS|
D001569_D012640 NONE benzodiazepine_6\JJ| (r_amod) antagonist_7\NN|the|benzodiazepine (r_pobj) of_4\IN|antagonist (r_prep) Administration_3\NN|of|flumazenil (r_nsubj) unmask_10\VB|administration|may|seizures (l_dobj) seizures_11\NNS|in
D001569_D012640 NONE benzodiazepine_16\NN|cocaine|- (r_amod) intoxication_17\NN|mixed|benzodiazepine (r_pobj) in_12\IN|intoxication (r_prep) seizures_11\NNS|in
10401555
C096012_D007859 NONE Nociceptin_0\NNP| (r_nmod) orphanin_2\NN|nociceptin|/ (r_compound) FQ_3\NNP|orphanin|and|nocistatin|. (l_conj) nocistatin_5\NNS|on (l_prep) on_6\IN|impairment (l_pobj) impairment_10\NN|learning|induced
C096012_D007859 NONE FQ_3\NNP|orphanin|and|nocistatin|. (l_conj) nocistatin_5\NNS|on (l_prep) on_6\IN|impairment (l_pobj) impairment_10\NN|learning|induced
C096012_D007859 NONE nociceptin_8\NN| (r_nmod) orphanin_10\VB|nociceptin|/ (r_compound) FQ_11\NNP|orphanin|and|nocistatin (r_nsubj) modulate_15\VB|whether|fq|could|impairment|using (l_dobj) impairment_16\NN|of|induced (l_prep) of_17\IN|learning (l_pobj) learning_18\NN|and|memory (l_conj) memory_20\NN|
C096012_D007859 NONE FQ_11\NNP|orphanin|and|nocistatin (r_nsubj) modulate_15\VB|whether|fq|could|impairment|using (l_dobj) impairment_16\NN|of|induced (l_prep) of_17\IN|learning (l_pobj) learning_18\NN|and|memory (l_conj) memory_20\NN|
C096012_D008569 NONE Nociceptin_0\NNP| (r_nmod) orphanin_2\NN|nociceptin|/ (r_compound) FQ_3\NNP|orphanin|and|nocistatin|. (l_conj) nocistatin_5\NNS|on (l_prep) on_6\IN|impairment (l_pobj) impairment_10\NN|learning|induced
C096012_D008569 NONE FQ_3\NNP|orphanin|and|nocistatin|. (l_conj) nocistatin_5\NNS|on (l_prep) on_6\IN|impairment (l_pobj) impairment_10\NN|learning|induced
C096012_D008569 NONE nociceptin_8\NN| (r_nmod) orphanin_10\VB|nociceptin|/ (r_compound) FQ_11\NNP|orphanin|and|nocistatin (r_nsubj) modulate_15\VB|whether|fq|could|impairment|using (l_dobj) impairment_16\NN|of|induced (l_prep) of_17\IN|learning (l_pobj) learning_18\NN|and|memory (l_conj) memory_20\NN|
C096012_D008569 NONE FQ_11\NNP|orphanin|and|nocistatin (r_nsubj) modulate_15\VB|whether|fq|could|impairment|using (l_dobj) impairment_16\NN|of|induced (l_prep) of_17\IN|learning (l_pobj) learning_18\NN|and|memory (l_conj) memory_20\NN|
C111148_D007859 NONE nocistatin_5\NNS|on (l_prep) on_6\IN|impairment (l_pobj) impairment_10\NN|learning|induced
C111148_D007859 NONE nocistatin_13\NN| (r_conj) FQ_11\NNP|orphanin|and|nocistatin (r_nsubj) modulate_15\VB|whether|fq|could|impairment|using (l_dobj) impairment_16\NN|of|induced (l_prep) of_17\IN|learning (l_pobj) learning_18\NN|and|memory (l_conj) memory_20\NN|
C111148_D008569 NONE nocistatin_5\NNS|on (l_prep) on_6\IN|impairment (l_pobj) impairment_10\NN|learning|induced
C111148_D008569 NONE nocistatin_13\NN| (r_conj) FQ_11\NNP|orphanin|and|nocistatin (r_nsubj) modulate_15\VB|whether|fq|could|impairment|using (l_dobj) impairment_16\NN|of|induced (l_prep) of_17\IN|learning (l_pobj) learning_18\NN|and|memory (l_conj) memory_20\NN|
D012601_D007859 CID scopolamine_13\NN| (r_pobj) by_12\IN|scopolamine (r_agent) induced_11\VBN|by|in (r_acl) impairment_10\NN|learning|induced
D012601_D007859 CID scopolamine_23\NN|,|antagonist|, (r_pobj) by_22\IN|scopolamine (r_agent) induced_21\VBN|by (r_acl) impairment_16\NN|of|induced (l_prep) of_17\IN|learning (l_pobj) learning_18\NN|and|memory (l_conj) memory_20\NN|
D012601_D008569 CID scopolamine_13\NN| (r_pobj) by_12\IN|scopolamine (r_agent) induced_11\VBN|by|in (r_acl) impairment_10\NN|learning|induced
D012601_D008569 CID scopolamine_23\NN|,|antagonist|, (r_pobj) by_22\IN|scopolamine (r_agent) induced_21\VBN|by (r_acl) impairment_16\NN|of|induced (l_prep) of_17\IN|learning (l_pobj) learning_18\NN|and|memory (l_conj) memory_20\NN|
C111148_D006930 NONE nocistatin_5\NN| (r_advmod) isolated_8\VBN|on|,|nocistatin|is|recently|from|. (l_prep) from_9\IN|precursor (l_pobj) precursor_12\NN|the|same|as (l_prep) as_13\IN|nociceptin|allodynia (l_pobj) allodynia_20\NN|induced|and|hyperalgesia
C111148_D006930 NONE nocistatin_5\NN| (r_advmod) isolated_8\VBN|on|,|nocistatin|is|recently|from|. (l_prep) from_9\IN|precursor (l_pobj) precursor_12\NN|the|same|as (l_prep) as_13\IN|nociceptin|allodynia (l_pobj) allodynia_20\NN|induced|and|hyperalgesia (l_conj) hyperalgesia_22\NN|
C096012_D006930 NONE nociceptin_14\NN|and|blocks (r_amod) as_13\IN|nociceptin|allodynia (l_pobj) allodynia_20\NN|induced|and|hyperalgesia
C096012_D006930 NONE nociceptin_14\NN|and|blocks (r_amod) as_13\IN|nociceptin|allodynia (l_pobj) allodynia_20\NN|induced|and|hyperalgesia (l_conj) hyperalgesia_22\NN|
C096012_D006930 NONE nociceptin_17\RB| (r_advmod) induced_19\VBN|nociceptin|- (r_amod) allodynia_20\NN|induced|and|hyperalgesia
C096012_D006930 NONE nociceptin_17\RB| (r_advmod) induced_19\VBN|nociceptin|- (r_amod) allodynia_20\NN|induced|and|hyperalgesia (l_conj) hyperalgesia_22\NN|
12948256
D004977_D009901 CID Ethambutol_0\NNP|and|optic (r_nmod) neuropathy_3\NN|ethambutol|.
D004977_D009901 CID ethambutol_5\NN|and|optic (r_amod) neuropathy_8\NN|ethambutol
D004977_D009901 CID ethambutol_10\NN|for (r_pobj) with_9\IN|ethambutol (r_prep) treated_8\VBN|being|with (r_pcomp) after_6\IN|treated (r_prep) developed_3\VBD|who|neuropathy|after (l_dobj) neuropathy_5\NN|optic
D004977_D009901 CID ethambutol_19\NN| (r_amod) therapy_20\NN|ethambutol (r_dobj) starting_18\VBG|therapy|at (r_pcomp) after_17\IN|starting (r_prep) had_3\VBD|:|patients|neuropathy|)|after|. (l_dobj) neuropathy_5\NN|optic|between
D004977_D009901 CID ethambutol_11\NN| (r_amod) therapy_12\NN|ethambutol (r_pobj) with_10\IN|therapy (r_prep) patients_9\NNS|with (r_pobj) in_8\IN|patients (r_prep) considered_7\VBN|recognition|should|be|in|. (l_nsubjpass) recognition_1\NN|early|of (l_prep) of_2\IN|neuropathy (l_pobj) neuropathy_4\NN|optic
D004977_D014397 NONE ethambutol_10\NN|for (l_prep) for_11\IN|tuberculosis (l_pobj) tuberculosis_12\NN|of (l_prep) of_13\IN|node (l_pobj) node_18\NN|the|lung|at
D004977_D014388 NONE ethambutol_10\NN|for (l_prep) for_11\IN|tuberculosis (l_pobj) tuberculosis_12\NN|of (l_prep) of_13\IN|node (l_pobj) node_18\NN|the|lung|at
16906379
D008911_D014657 NONE Minocycline_0\NNP| (r_npadvmod) induced_2\VBN|minocycline|- (r_amod) vasculitis_3\NN|induced|fulfilling|.
D008911_D014657 NONE minocycline_10\NN| (r_npadvmod) induced_12\VBN|minocycline|- (r_amod) vasculitis_13\NN|induced|satisfying
D008911_D010488 CID Minocycline_0\NNP| (r_npadvmod) induced_2\VBN|minocycline|- (r_amod) vasculitis_3\NN|induced|fulfilling|. (l_acl) fulfilling_4\VBG|criteria (l_dobj) criteria_6\NNS|the|of (l_prep) of_7\IN|nodosa (l_pobj) nodosa_9\NN|polyarteritis
D008911_D011565 NONE minocycline_9\NN| (r_dobj) taking_8\VBG|who|had|been|minocycline|for|with (l_prep) for_10\IN|fever (l_pobj) fever_14\NN|pustulosis|developed|,|myalgias|, (l_nmod) pustulosis_12\NN|palmoplantar
D008911_D005334 NONE minocycline_9\NN| (r_dobj) taking_8\VBG|who|had|been|minocycline|for|with (l_prep) for_10\IN|fever (l_pobj) fever_14\NN|pustulosis|developed|,|myalgias|,
D008911_D063806 NONE minocycline_9\NN| (r_dobj) taking_8\VBG|who|had|been|minocycline|for|with (l_prep) for_10\IN|fever (l_pobj) fever_14\NN|pustulosis|developed|,|myalgias|, (l_conj) myalgias_16\NNS|,|polyneuropathy
D008911_D011115 NONE minocycline_9\NN| (r_dobj) taking_8\VBG|who|had|been|minocycline|for|with (l_prep) for_10\IN|fever (l_pobj) fever_14\NN|pustulosis|developed|,|myalgias|, (l_conj) myalgias_16\NNS|,|polyneuropathy (l_conj) polyneuropathy_18\VBP|,|and|pain
D008911_D013733 NONE minocycline_9\NN| (r_dobj) taking_8\VBG|who|had|been|minocycline|for|with (l_prep) for_10\IN|fever (l_pobj) fever_14\NN|pustulosis|developed|,|myalgias|, (l_conj) myalgias_16\NNS|,|polyneuropathy (l_conj) polyneuropathy_18\VBP|,|and|pain (l_conj) pain_22\NN|testicular
920167
D014859_D005315 NONE warfarin_3\RB| (r_npadvmod) induced_5\VBN|warfarin|- (r_amod) embryopathy_6\JJ|induced|with
D014859_-1 NONE warfarin_3\RB| (r_npadvmod) induced_5\VBN|warfarin|- (r_amod) embryopathy_6\JJ|induced|with (l_prep) with_7\IN|hypoplasia (l_pobj) hypoplasia_9\NN|nasal|and|epiphyses
D014859_-1 NONE warfarin_19\NN| (r_pobj) with_18\IN|warfarin (r_prep) treated_17\VBN|with|during (r_acl) mothers_16\NNS|treated (r_pobj) to_15\IN|mothers (r_prep) born_14\VBN|to (r_acl) infants_13\NNS|11|born (r_pobj) in_11\IN|infants (r_prep) reported_10\VBN|hypoplasia|has|now|been|in|,|and|is (l_nsubjpass) hypoplasia_1\NN|nasal|with
D014859_D002806 CID warfarin_3\RB| (r_npadvmod) induced_5\VBN|warfarin|- (r_amod) embryopathy_6\JJ|induced|with (l_prep) with_7\IN|hypoplasia (l_pobj) hypoplasia_9\NN|nasal|and|epiphyses (l_conj) epiphyses_12\NNS|stippled|(|punctata|)
D014859_D002806 CID warfarin_3\RB| (r_npadvmod) induced_5\VBN|warfarin|- (r_amod) embryopathy_6\JJ|induced|with (l_prep) with_7\IN|hypoplasia (l_pobj) hypoplasia_9\NN|nasal|and|epiphyses (l_conj) epiphyses_12\NNS|stippled|(|punctata|) (l_appos) punctata_15\NN|chondrodysplasia
D014859_D002806 CID warfarin_19\NN| (r_pobj) with_18\IN|warfarin (r_prep) treated_17\VBN|with|during (r_acl) mothers_16\NNS|treated (r_pobj) to_15\IN|mothers (r_prep) born_14\VBN|to (r_acl) infants_13\NNS|11|born (r_pobj) in_11\IN|infants (r_prep) reported_10\VBN|hypoplasia|has|now|been|in|,|and|is (l_nsubjpass) hypoplasia_1\NN|nasal|with (l_prep) with_2\IN|or|without (l_conj) without_4\IN|epiphyses (l_pobj) epiphyses_6\NNS|stippled
9125676
D013015_-1 NONE sotalol_11\NN|,|l|-|for (r_pobj) of_6\IN|d|sotalol (r_prep) use_5\NN|the|of (r_pobj) with_3\IN|use (r_prep) proarrhythmia_2\NN|with
D013015_D017180 NONE sotalol_11\NN|,|l|-|for (l_prep) for_12\IN|tachyarrhythmias (l_pobj) tachyarrhythmias_15\NNS|sustained|ventricular
D013015_D017180 NONE sotalol_32\NN|,|l|-|for (l_prep) for_33\IN|tachyarrhythmias (l_pobj) tachyarrhythmias_36\NNS|sustained|ventricular
D013015_D017180 NONE sotalol_32\NN|d|,|l|- (r_dobj) received_26\VBD|patients|sotalol|prevent|. (l_nsubj) patients_4\NNS|one|consecutive|(|54|with (l_prep) with_18\IN|tachycardia (l_pobj) tachycardia_22\NN|inducible|sustained|ventricular|or|fibrillation
D013015_D017180 NONE sotalol_32\NN|d|,|l|- (r_dobj) received_26\VBD|patients|sotalol|prevent|. (l_advcl) prevent_34\VB|to|induction (l_dobj) induction_35\NN|of (l_prep) of_36\IN|tachyarrhythmia (l_pobj) tachyarrhythmia_39\NN|the|ventricular
D013015_D017180 NONE sotalol_8\NN|l|- (r_nsubj) prevented_9\VBN|in|,|sotalol|induction (l_dobj) induction_10\NN|of (l_prep) of_11\IN|tachycardia (l_pobj) tachycardia_13\NN|ventricular|or|fibrillation
D013015_D017180 NONE sotalol_13\NN|l|-|in|patients (r_dep) remained_25\VBD|d|,|sotalol|;|tachyarrhythmia|inducible|in (r_conj) prevented_6\VBN|induction|was|by|remained|;|and|tolerate (l_nsubjpass) Induction_0\NN|of (l_prep) of_1\IN|tachyarrhythmia (l_pobj) tachyarrhythmia_4\NN|the|ventricular
D013015_D017180 NONE sotalol_13\NN|l|-|in|patients (r_dep) remained_25\VBD|d|,|sotalol|;|tachyarrhythmia|inducible|in (l_nsubj) tachyarrhythmia_24\NN|the|ventricular
D013015_D017180 NONE sotalol_53\NN|,|l|- (r_pobj) of_48\IN|d|sotalol (r_prep) mg_47\NN|40|of (r_dobj) tolerate_44\VB|patients|did|not|mg|daily|. (r_conj) prevented_6\VBN|induction|was|by|remained|;|and|tolerate (l_nsubjpass) Induction_0\NN|of (l_prep) of_1\IN|tachyarrhythmia (l_pobj) tachyarrhythmia_4\NN|the|ventricular
D013015_D017180 NONE sotalol_53\NN|,|l|- (r_pobj) of_48\IN|d|sotalol (r_prep) mg_47\NN|40|of (r_dobj) tolerate_44\VB|patients|did|not|mg|daily|. (r_conj) prevented_6\VBN|induction|was|by|remained|;|and|tolerate (l_conj) remained_25\VBD|d|,|sotalol|;|tachyarrhythmia|inducible|in (l_nsubj) tachyarrhythmia_24\NN|the|ventricular
D013015_D016171 CID sotalol_32\NN|,|l|-|for (r_pobj) with_27\IN|d|sotalol (r_prep) treated_26\VBN|with (r_acl) patients_25\NNS|treated (r_pobj) in_24\IN|patients (r_prep) pointes_23\FW|torsades|de|in (r_pobj) for_20\IN|pointes (r_prep) factors_19\NNS|the|presumable|risk|for (r_conj) incidence_9\NN|the|of|,|and|factors (l_prep) of_10\IN|pointes (l_pobj) pointes_13\FW|torsades|de
D013015_D016171 CID sotalol_32\NN|,|l|-|for (r_pobj) with_27\IN|d|sotalol (r_prep) treated_26\VBN|with (r_acl) patients_25\NNS|treated (r_pobj) in_24\IN|patients (r_prep) pointes_23\FW|torsades|de|in
D013015_D016171 CID sotalol_21\NN|d|,|l|- (r_pobj) with_16\IN|sotalol (r_prep) treatment_15\NN|the|initial|oral|with (r_pobj) during_11\IN|treatment (r_prep) had_6\VBD|patients|from|during|. (l_prep) from_7\IN|pointes (l_pobj) pointes_10\FW|torsades|de
D013015_D016171 CID sotalol_10\NN|l|- (r_nsubj) was_11\VBD|however|,|dose|,|sotalol|lower|in|. (l_prep) in_14\IN|patients (l_pobj) patients_15\NNS|with (l_prep) with_16\IN|pointes (l_pobj) pointes_19\FW|torsades|de|(|46|;|0.0017|)
D013015_D016171 CID sotalol_23\NN|d|,|l|- (r_pobj) with_18\IN|sotalol (r_prep) treatment_17\NN|successful|with (r_pobj) of_15\IN|treatment (r_prep) years_14\NNS|2|of (r_pobj) after_12\IN|years (r_prep) had_7\VBD|patient|pointes|after|. (l_dobj) pointes_11\NNS|torsades|de
D013015_D016171 CID sotalol_17\NN|d|,|l|- (r_pobj) of_11\IN|sotalol (r_prep) doses_10\NNS|low|of (r_pobj) with_8\IN|even|doses (r_prep) treatment_6\NN|with (r_pobj) during_5\IN|treatment (r_prep) occurred_3\VBD|pointes|early|during|. (l_nsubj) pointes_2\NNS|torsades|de
D013015_D016171 CID sotalol_26\NN|l|- (r_nsubj) identify_28\VB|pronounced|d|,|sotalol|might|subgroup|. (l_dobj) subgroup_30\NN|a|of (l_prep) of_31\IN|patients (l_pobj) patients_32\NNS|with (l_prep) with_33\IN|risk (l_pobj) risk_36\NN|an|increased|for (l_prep) for_37\IN|pointes (l_pobj) pointes_40\FW|torsades|de
D013015_D016171 CID sotalol_11\NN|l|- (r_nsubj) identify_14\VB|parameters|,|sotalol|did|not|patients|at|. (l_prep) at_16\IN|risk (l_pobj) risk_18\NN|increased|for (l_prep) for_19\IN|pointes (l_pobj) pointes_22\FW|torsades|de
D013015_D003324 NONE sotalol_32\NN|d|,|l|- (r_dobj) received_26\VBD|patients|sotalol|prevent|. (l_nsubj) patients_4\NNS|one|consecutive|(|54|with (l_appos) 54_6\CD|with|,|and|20 (l_prep) with_7\IN|disease (l_pobj) disease_10\NN|coronary|artery
D013015_D002311 NONE sotalol_32\NN|d|,|l|- (r_dobj) received_26\VBD|patients|sotalol|prevent|. (l_nsubj) patients_4\NNS|one|consecutive|(|54|with (l_appos) 54_6\CD|with|,|and|20 (l_conj) 20_13\CD|with|) (l_prep) with_14\IN|cardiomyopathy (l_pobj) cardiomyopathy_16\NN|dilated
D013015_D014693 NONE sotalol_32\NN|d|,|l|- (r_dobj) received_26\VBD|patients|sotalol|prevent|. (l_nsubj) patients_4\NNS|one|consecutive|(|54|with (l_prep) with_18\IN|tachycardia (l_pobj) tachycardia_22\NN|inducible|sustained|ventricular|or|fibrillation (l_conj) fibrillation_25\NN|ventricular
D013015_D014693 NONE sotalol_8\NN|l|- (r_nsubj) prevented_9\VBN|in|,|sotalol|induction (l_dobj) induction_10\NN|of (l_prep) of_11\IN|tachycardia (l_pobj) tachycardia_13\NN|ventricular|or|fibrillation (l_conj) fibrillation_16\NN|ventricular
D013015_D006331 NONE sotalol_23\NN|d|,|l|- (r_pobj) with_18\IN|sotalol (r_prep) treatment_17\NN|successful|with (r_pobj) of_15\IN|treatment (r_prep) years_14\NNS|2|of (r_pobj) after_12\IN|years (r_prep) had_7\VBD|patient|pointes|after|. (l_nsubj) patient_2\NN|one|female|with (l_prep) with_3\IN|disease (l_pobj) disease_6\NN|stable|cardiac
16731636
D007545_D006332 CID isoproterenol_1\NN| (r_npadvmod) induced_3\VBN|isoproterenol|- (r_amod) hypertrophy_5\NN|enhanced|induced|cardiac|in|.
D007545_D006332 CID Iso_4\NNP| (r_compound) treatment_5\NN|iso (r_pobj) by_3\IN|treatment (r_agent) induced_2\VBN|hypertrophy|by (l_nsubj) hypertrophy_1\NN|lv
8808730
D009569_D001745 NONE oxide_5\NN| (r_compound) synthase_6\NN|neuronal|nitric|oxide|in (r_pobj) of_2\IN|synthase (r_prep) expression_1\NN|increased|of|following|. (l_prep) following_11\VBG|irritation (l_pobj) irritation_14\NN|chronic|bladder
D009569_D014570 NONE oxide_13\NN| (r_compound) synthase_14\NN|neuronal|nitric|oxide|(|nos|)|in (r_pobj) of_10\IN|synthase (r_prep) expression_9\NN|the|of (r_pobj) in_7\IN|expression (r_prep) alterations_6\NNS|in|following (l_prep) following_21\VBG|irritation (l_pobj) irritation_25\NN|acute|of (l_prep) of_26\IN|tract (l_pobj) tract_29\NN|the|urinary|of
D003520_D003556 CID cyclophosphamide_5\NN|cyp (r_pobj) by_4\IN|cyclophosphamide (r_agent) induced_3\VBN|cystitis|was|by (l_nsubjpass) cystitis_1\NN|chemical
D003520_D003556 CID CYP_7\NNP|(|)|metabolized (r_appos) cyclophosphamide_5\NN|cyp (r_pobj) by_4\IN|cyclophosphamide (r_agent) induced_3\VBN|cystitis|was|by (l_nsubjpass) cystitis_1\NN|chemical
D000171_D003556 NONE acrolein_13\NN| (r_pobj) to_12\IN|acrolein (r_prep) metabolized_11\VBN|which|is|to (r_relcl) CYP_7\NNP|(|)|metabolized (r_appos) cyclophosphamide_5\NN|cyp (r_pobj) by_4\IN|cyclophosphamide (r_agent) induced_3\VBN|cystitis|was|by (l_nsubjpass) cystitis_1\NN|chemical
20595935
D014700_D006966 NONE Verapamil_0\NNP| (r_compound) test_2\NN|verapamil|stimulation|in|:|loss|. (l_prep) in_3\IN|hyperprolactinemia (l_pobj) hyperprolactinemia_4\NN|
D014700_D006966 NONE Verapamil_0\NNP| (r_compound) test_2\NN|verapamil|stimulation (r_nsubjpass) investigated_5\VBN|test|was|previously|as|,|but|with|. (l_prep) as_6\IN|tool (l_pobj) tool_8\NN|a|for (l_prep) for_9\IN|diagnosis (l_pobj) diagnosis_11\NN|differential|of (l_prep) of_12\IN|hyperprolactinemia (l_pobj) hyperprolactinemia_13\NN|
D014700_D006966 NONE verapamil_3\NN| (r_pobj) to_2\IN|verapamil (r_prep) responses_1\NNS|prolactin|to|in|with (l_prep) with_16\IN|hyperprolactinemia (l_pobj) hyperprolactinemia_17\NN|
D014700_D006966 NONE verapamil_7\NN| (r_pobj) to_6\IN|verapamil (r_prep) unresponsiveness_5\NN|to (r_nsubj) defined_8\VBN|that|unresponsiveness|as (r_ccomp) revealed_3\VBD|analysis|defined|,|discriminated|. (l_conj) discriminated_15\VBD|effect|sensitivity|respectively (l_npadvmod) sensitivity_22\NN|(|:|%|)|associated|, (l_acl) associated_46\VBN|with (l_prep) with_47\IN|pseudoprolactinoma (l_pobj) pseudoprolactinoma_48\NN|or|hyperprolactinemia (l_conj) hyperprolactinemia_53\NN|induced
D014700_D006966 NONE Verapamil_0\NNP| (r_compound) responsiveness_1\NN|verapamil (r_nsubj) is_2\VBZ|responsiveness|not|finding|. (l_attr) finding_6\NN|a|reliable|for (l_prep) for_7\IN|diagnosis (l_pobj) diagnosis_10\NN|the|differential|of (l_prep) of_11\IN|hyperprolactinemia (l_pobj) hyperprolactinemia_12\NN|
D014700_D006966 NONE verapamil_2\NN| (r_compound) unresponsiveness_3\NN|verapamil (r_nsubj) discriminates_4\VBZ|however|,|unresponsiveness|effect|. (l_dobj) effect_6\NN|stalk|inhibited (l_parataxis) inhibited_13\JJ|(|i.e.|,|anatomically|functionally|tonus|)|from (l_prep) from_17\IN|causes (l_pobj) causes_19\NNS|other|of|with (l_prep) of_20\IN|hyperprolactinemia (l_pobj) hyperprolactinemia_21\NN|
D014700_D015175 NONE verapamil_12\NN| (r_pobj) of_11\IN|verapamil (r_prep) value_10\NN|the|diagnostic|of|in (l_prep) in_13\IN|population (l_pobj) population_15\NN|a|screened (l_relcl) screened_19\VBN|who|were|all|for (l_prep) for_20\IN|macroprolactinemia (l_pobj) macroprolactinemia_21\NN|
D014700_D015175 NONE Verapamil_1\NNP| (r_nsubj) increased_3\VBD|:|verapamil|significantly|levels|in|macroprolactinoma (l_advcl) macroprolactinoma_19\NN|prl
D014700_D015175 NONE Verapamil_1\NNP| (r_nsubj) increased_3\VBD|:|verapamil|significantly|levels|in|macroprolactinoma (l_advcl) macroprolactinoma_19\NN|prl (l_appos) PRL_24\NN|(|n.|,|:|%|)|,|microprolactinoma|,|macroprolactinemia (l_conj) microprolactinoma_30\NN|prl
D014700_D015175 NONE Verapamil_1\NNP| (r_nsubj) increased_3\VBD|:|verapamil|significantly|levels|in|macroprolactinoma (l_advcl) macroprolactinoma_19\NN|prl (l_appos) PRL_24\NN|(|n.|,|:|%|)|,|microprolactinoma|,|macroprolactinemia (l_appos) macroprolactinemia_41\JJ|
D018967_-1 NONE risperidone_25\NN| (r_npadvmod) induced_27\VBN|risperidone|- (r_amod) hyperprolactinemia_28\NN|induced|prl|. (r_conj) PRL_4\NN|(|n.|,|:|%|)|,|but|in|prl|,|and|hyperprolactinemia (l_conj) in_12\IN|not|pseudoprolactinoma (l_pobj) pseudoprolactinoma_13\NN|
D018967_-1 NONE risperidone_50\NN| (r_npadvmod) induced_52\VBN|risperidone|- (r_amod) hyperprolactinemia_53\NN|induced (r_conj) pseudoprolactinoma_48\NN|or|hyperprolactinemia
D018967_D006966 CID risperidone_25\NN| (r_npadvmod) induced_27\VBN|risperidone|- (r_amod) hyperprolactinemia_28\NN|induced|prl|.
D018967_D006966 CID risperidone_50\NN| (r_npadvmod) induced_52\VBN|risperidone|- (r_amod) hyperprolactinemia_53\NN|induced
D014700_-1 NONE verapamil_7\NN| (r_pobj) to_6\IN|verapamil (r_prep) unresponsiveness_5\NN|to (r_nsubj) defined_8\VBN|that|unresponsiveness|as (r_ccomp) revealed_3\VBD|analysis|defined|,|discriminated|. (l_conj) discriminated_15\VBD|effect|sensitivity|respectively (l_npadvmod) sensitivity_22\NN|(|:|%|)|associated|, (l_acl) associated_46\VBN|with (l_prep) with_47\IN|pseudoprolactinoma (l_pobj) pseudoprolactinoma_48\NN|or|hyperprolactinemia
1564030
D005473_D001714 CID fluoxetine_3\NN| (r_amod) treatment_4\NN|fluoxetine|in (r_pobj) with_2\IN|treatment (r_prep) associated_1\VBN|with (r_acl) Mania_0\NNP|associated|.
D005473_D001714 CID fluoxetine_8\NN| (r_nsubjpass) reported_11\VBN|safe|,|fluoxetine|has|been|induce|. (l_xcomp) induce_13\VB|to|mania (l_dobj) mania_14\NN|
D005473_D001714 CID fluoxetine_20\NN| (r_pobj) with_19\IN|fluoxetine (r_prep) pharmacotherapy_18\NN|with (r_pobj) during_17\IN|pharmacotherapy (r_prep) developed_15\VBD|who|mania|during (l_dobj) mania_16\NN|
D005473_D001714 CID fluoxetine_11\NN| (r_amod) pharmacotherapy_12\NN|fluoxetine|in (r_pobj) during_10\IN|pharmacotherapy (r_prep) hypomania_9\NN|during (r_conj) development_5\NN|the|of|or|hypomania (l_prep) of_6\IN|mania (l_pobj) mania_7\NN|
D005473_D001714 CID fluoxetine_11\NN| (r_amod) pharmacotherapy_12\NN|fluoxetine|in (r_pobj) during_10\IN|pharmacotherapy (r_prep) hypomania_9\NN|during
D005473_D001714 CID fluoxetine_11\NN| (r_amod) pharmacotherapy_12\NN|fluoxetine|in (r_pobj) during_10\IN|pharmacotherapy (r_prep) hypomania_9\NN|during (r_conj) development_5\NN|the|of|or|hypomania (r_pobj) for_3\IN|development (r_prep) factors_2\NNS|apparent|risk|for|depression (l_appos) depression_30\NN|major|with|;|history (l_conj) history_37\NN|a|family|of|;|and|diagnosis (l_prep) of_38\IN|disorder (l_pobj) disorder_40\NN|affective|,|disorder (l_appos) disorder_44\NN|especially|bipolar
D005473_D001714 CID fluoxetine_11\NN| (r_amod) pharmacotherapy_12\NN|fluoxetine|in (r_pobj) during_10\IN|pharmacotherapy (r_prep) hypomania_9\NN|during (r_conj) development_5\NN|the|of|or|hypomania (r_pobj) for_3\IN|development (r_prep) factors_2\NNS|apparent|risk|for|depression (l_appos) depression_30\NN|major|with|;|history (l_conj) history_37\NN|a|family|of|;|and|diagnosis (l_conj) diagnosis_48\NN|a|of (l_prep) of_49\IN|disorder (l_pobj) disorder_51\NN|bipolar
D005473_D001714 CID fluoxetine_19\VB| (r_advmod) induced_20\VBN|fluoxetine (r_amod) mania_21\NN|induced|in
D005473_D003866 NONE Fluoxetine_0\NNP|,|inhibitor|, (r_nsubj) gaining_9\VBG|fluoxetine|is|acceptance|. (l_dobj) acceptance_11\NN|increased|in (l_prep) in_12\IN|treatment (l_pobj) treatment_14\NN|the|of (l_prep) of_15\IN|depression (l_pobj) depression_17\NN|adolescent
D005473_D003866 NONE fluoxetine_20\NN| (r_pobj) with_19\IN|fluoxetine (r_prep) pharmacotherapy_18\NN|with (r_pobj) during_17\IN|pharmacotherapy (r_prep) developed_15\VBD|who|mania|during (r_relcl) cases_1\NNS|the|of|,|years|,|developed|, (l_prep) of_2\IN|adolescents (l_pobj) adolescents_5\NNS|five|depressed (l_amod) depressed_4\JJ|
D005473_D003866 NONE fluoxetine_11\NN| (r_amod) pharmacotherapy_12\NN|fluoxetine|in (r_pobj) during_10\IN|pharmacotherapy (r_prep) hypomania_9\NN|during (r_conj) development_5\NN|the|of|or|hypomania (r_pobj) for_3\IN|development (r_prep) factors_2\NNS|apparent|risk|for|depression (l_appos) depression_30\NN|major|with|;|history
D012701_D003866 NONE serotonin_4\NN| (r_compound) inhibitor_6\NN|a|selective|serotonin|reuptake (r_appos) Fluoxetine_0\NNP|,|inhibitor|, (r_nsubj) gaining_9\VBG|fluoxetine|is|acceptance|. (l_dobj) acceptance_11\NN|increased|in (l_prep) in_12\IN|treatment (l_pobj) treatment_14\NN|the|of (l_prep) of_15\IN|depression (l_pobj) depression_17\NN|adolescent
D005473_D001289 NONE fluoxetine_11\NN| (r_amod) pharmacotherapy_12\NN|fluoxetine|in (r_pobj) during_10\IN|pharmacotherapy (r_prep) hypomania_9\NN|during (r_conj) development_5\NN|the|of|or|hypomania (r_pobj) for_3\IN|development (r_prep) factors_2\NNS|apparent|risk|for|depression (r_nsubj) were_16\VBD|factors|combination|;|. (l_attr) combination_18\NN|the|of (l_prep) of_19\IN|disorder (l_pobj) disorder_24\NN|hyperactivity|and|instability
D005473_D011618 NONE fluoxetine_11\NN| (r_amod) pharmacotherapy_12\NN|fluoxetine|in (r_pobj) during_10\IN|pharmacotherapy (r_prep) hypomania_9\NN|during (r_conj) development_5\NN|the|of|or|hypomania (r_pobj) for_3\IN|development (r_prep) factors_2\NNS|apparent|risk|for|depression (l_appos) depression_30\NN|major|with|;|history (l_prep) with_31\IN|features (l_pobj) features_33\NNS|psychotic (l_amod) psychotic_32\JJ|
D005473_D019964 NONE fluoxetine_11\NN| (r_amod) pharmacotherapy_12\NN|fluoxetine|in (r_pobj) during_10\IN|pharmacotherapy (r_prep) hypomania_9\NN|during (r_conj) development_5\NN|the|of|or|hypomania (r_pobj) for_3\IN|development (r_prep) factors_2\NNS|apparent|risk|for|depression (l_appos) depression_30\NN|major|with|;|history (l_conj) history_37\NN|a|family|of|;|and|diagnosis (l_prep) of_38\IN|disorder (l_pobj) disorder_40\NN|affective|,|disorder
3708328
D010862_D012640 CID pilocarpine_5\NN| (r_pobj) by_4\IN|pilocarpine (r_agent) produced_3\VBN|by|in (r_acl) seizures_2\NNS|produced
D010862_D012640 CID Pilocarpine_0\NNP| (r_nsubj) reproduces_7\VBZ|pilocarpine|,|given|,|sequelae|and|provides|. (l_conj) provides_16\VBZ|model (l_dobj) model_20\NN|a|relevant|animal|for (l_prep) for_21\IN|studying (l_pcomp) studying_22\VBG|mechanisms (l_dobj) mechanisms_23\NNS|of (l_prep) of_24\IN|buildup (l_pobj) buildup_25\NN|of (l_prep) of_26\IN|activity (l_pobj) activity_28\NN|convulsive|and|pathways|operative (l_amod) convulsive_27\JJ|
D010862_D012640 CID Pilocarpine_0\NNP| (r_nsubj) reproduces_7\VBZ|pilocarpine|,|given|,|sequelae|and|provides|. (l_conj) provides_16\VBZ|model (l_dobj) model_20\NN|a|relevant|animal|for (l_prep) for_21\IN|studying (l_pcomp) studying_22\VBG|mechanisms (l_dobj) mechanisms_23\NNS|of (l_prep) of_24\IN|buildup (l_pobj) buildup_25\NN|of (l_prep) of_26\IN|activity (l_pobj) activity_28\NN|convulsive|and|pathways|operative (l_amod) operative_31\JJ|in (l_prep) in_32\IN|generalization (l_pobj) generalization_34\NN|the|and|propagation|of (l_prep) of_37\IN|seizures (l_pobj) seizures_38\NNS|within
D010862_D012640 CID pilocarpine_29\NN| (r_pobj) by_28\IN|pilocarpine (r_agent) produced_27\VBN|by|in (r_acl) seizures_26\NNS|produced
D010862_D012640 CID pilocarpine_45\NN| (r_pobj) of_44\IN|pilocarpine (r_prep) doses_43\NNS|-|convulsant|of|,|mg/kg|, (r_nsubj) resulted_52\VBD|in|doses|in|. (l_prep) in_53\IN|seizures (l_pobj) seizures_57\NNS|severe|motor|limbic|and|epilepticus
D010862_D012640 CID pilocarpine_12\NN| (r_npadvmod) induced_14\VBN|pilocarpine|- (r_amod) convulsions_15\NNS|induced
D010862_D012640 CID pilocarpine_36\NN| (r_pobj) with_35\IN|pilocarpine (r_prep) observed_34\VBN|which|is|typically|with|in (r_relcl) formation_17\NN|the|hippocampal|,|thalamus|,|observed (r_pobj) to_14\IN|formation (r_prep) damage_13\NN|related|to (l_amod) related_12\VBN|seizure|- (l_npadvmod) seizure_10\NN|
D010862_D012640 CID pilocarpine_11\NN| (r_pobj) by_10\IN|pilocarpine (r_agent) produced_9\VBN|by (r_acl) seizures_8\NNS|produced|,|mg/kg
D010862_D012640 CID pilocarpine_28\NN| (r_pobj) by_27\IN|pilocarpine (r_agent) produced_26\VBN|by (r_acl) seizures_25\NNS|electrographic|produced
D010862_D012640 CID pilocarpine_27\NN| (r_pobj) by_26\IN|pilocarpine (r_agent) produced_25\VBN|by (r_acl) convulsions_24\NNS|produced
D010862_D012640 CID pilocarpine_7\NN| (r_npadvmod) induced_9\VBN|pilocarpine|- (r_amod) seizures_10\NNS|induced|in
D007538_D012640 NONE isoniazid_11\NN|or|gaba (r_pobj) of_10\IN|isoniazid (r_prep) microinjection_9\NN|of|into (r_pobj) after_8\IN|microinjection (r_prep) rats_7\NNS|after (r_pobj) in_6\IN|rats (r_prep) produced_3\VBN|by|in (r_acl) seizures_2\NNS|produced
D007538_D012640 NONE isoniazid_6\NN| (r_pobj) of_5\IN|isoniazid (r_prep) microinjections_4\NNS|of|,|micrograms (r_pobj) with_3\IN|microinjections (r_prep) pretreated_2\VBN|with (r_acl) animals_1\NNS|pretreated (r_pobj) In_0\IN|animals (r_prep) resulted_52\VBD|in|doses|in|. (l_prep) in_53\IN|seizures (l_pobj) seizures_57\NNS|severe|motor|limbic|and|epilepticus
D007538_D012640 NONE isoniazid_4\NN| (r_pobj) of_3\IN|isoniazid (r_prep) injections_2\NNS|bilateral|intrastriatal|of (r_nsubj) augment_7\VB|injections|did|not|seizures|. (l_dobj) seizures_8\NNS|produced|,|mg/kg
D020888_D012640 NONE GABA_17\NNP|gamma|-|vinyl|- (r_conj) isoniazid_11\NN|or|gaba (r_pobj) of_10\IN|isoniazid (r_prep) microinjection_9\NN|of|into (r_pobj) after_8\IN|microinjection (r_prep) rats_7\NNS|after (r_pobj) in_6\IN|rats (r_prep) produced_3\VBN|by|in (r_acl) seizures_2\NNS|produced
D020888_D012640 NONE acid_6\NN|l-4-amino|hex-5-enoic|) (r_appos) D_1\NNP|,|acid|,|micrograms|,|into (r_nsubj) suppressed_18\VBD|(|d|,|bilaterally|,|appearance|,|mg/kg|. (l_dobj) appearance_20\NN|the|of (l_prep) of_21\IN|seizures (l_pobj) seizures_25\NNS|electrographic|produced
D020888_D012640 NONE GABA_6\NNP|gamma|-|vinyl|-|,|micrograms|, (r_pobj) of_1\IN|gaba (r_prep) Microinjections_0\NNS|of|into (r_nsubj) failed_18\VBD|microinjections|,|bilaterally|,|prevent|,|mg/kg|. (l_xcomp) prevent_20\VB|to|development (l_dobj) development_22\NN|the|of (l_prep) of_23\IN|convulsions (l_pobj) convulsions_24\NNS|produced
D010862_D004833 NONE Pilocarpine_0\NNP| (r_nsubj) reproduces_7\VBZ|pilocarpine|,|given|,|sequelae|and|provides|. (l_dobj) sequelae_10\NNS|the|neuropathological|of (l_prep) of_11\IN|epilepsy (l_pobj) epilepsy_14\NN|temporal|lobe
D005680_D012640 NONE acid_16\NN|the|aminobutyric (r_pobj) of_11\IN|acid (r_prep) activity_10\NN|the|of (r_dobj) manipulating_8\VBG|activity (r_pcomp) of_7\IN|manipulating (r_prep) effects_6\NNS|the|of|inhibition (l_appos) inhibition_20\NN|(|gaba)-mediated|synaptic|within|on (l_prep) on_25\IN|seizures (l_pobj) seizures_26\NNS|produced
D005680_D012640 NONE GABA)-mediated_18\VBN| (r_amod) inhibition_20\NN|(|gaba)-mediated|synaptic|within|on (l_prep) on_25\IN|seizures (l_pobj) seizures_26\NNS|produced
D005680_D012640 NONE GABA_17\NNP| (r_npadvmod) synthesizing_19\VBG|gaba|- (r_amod) enzyme_20\NN|the|synthesizing|,|decarboxylase|,|into (r_pobj) of_15\IN|enzyme (r_prep) activity_14\NN|of (r_pobj) of_13\IN|activity (r_prep) inhibitor_12\NN|an|of (r_appos) micrograms_9\NNS|150|,|inhibitor (r_conj) microinjections_4\NNS|of|,|micrograms (r_pobj) with_3\IN|microinjections (r_prep) pretreated_2\VBN|with (r_acl) animals_1\NNS|pretreated (r_pobj) In_0\IN|animals (r_prep) resulted_52\VBD|in|doses|in|. (l_prep) in_53\IN|seizures (l_pobj) seizures_57\NNS|severe|motor|limbic|and|epilepticus
D005680_D012640 NONE GABA_20\NNP| (r_npadvmod) mediated_22\VBN|gaba|- (r_amod) inhibition_24\NN|the|mediated|synaptic|within (r_pobj) of_18\IN|inhibition (r_prep) regulation_17\NN|the|of (r_pobj) to_15\IN|regulation (r_prep) subjected_14\VBN|that|threshold|is|to (l_nsubjpass) threshold_5\NN|the|for (l_prep) for_6\IN|seizures (l_pobj) seizures_10\NNS|induced|in
D007538_D013226 NONE isoniazid_6\NN| (r_pobj) of_5\IN|isoniazid (r_prep) microinjections_4\NNS|of|,|micrograms (r_pobj) with_3\IN|microinjections (r_prep) pretreated_2\VBN|with (r_acl) animals_1\NNS|pretreated (r_pobj) In_0\IN|animals (r_prep) resulted_52\VBD|in|doses|in|. (l_prep) in_53\IN|seizures (l_pobj) seizures_57\NNS|severe|motor|limbic|and|epilepticus (l_conj) epilepticus_60\NN|status
D005680_D013226 NONE GABA_17\NNP| (r_npadvmod) synthesizing_19\VBG|gaba|- (r_amod) enzyme_20\NN|the|synthesizing|,|decarboxylase|,|into (r_pobj) of_15\IN|enzyme (r_prep) activity_14\NN|of (r_pobj) of_13\IN|activity (r_prep) inhibitor_12\NN|an|of (r_appos) micrograms_9\NNS|150|,|inhibitor (r_conj) microinjections_4\NNS|of|,|micrograms (r_pobj) with_3\IN|microinjections (r_prep) pretreated_2\VBN|with (r_acl) animals_1\NNS|pretreated (r_pobj) In_0\IN|animals (r_prep) resulted_52\VBD|in|doses|in|. (l_prep) in_53\IN|seizures (l_pobj) seizures_57\NNS|severe|motor|limbic|and|epilepticus (l_conj) epilepticus_60\NN|status
D018698_D012640 NONE acid_25\NN| (r_compound) decarboxylase_26\NN|glutamic|acid (r_appos) enzyme_20\NN|the|synthesizing|,|decarboxylase|,|into (r_pobj) of_15\IN|enzyme (r_prep) activity_14\NN|of (r_pobj) of_13\IN|activity (r_prep) inhibitor_12\NN|an|of (r_appos) micrograms_9\NNS|150|,|inhibitor (r_conj) microinjections_4\NNS|of|,|micrograms (r_pobj) with_3\IN|microinjections (r_prep) pretreated_2\VBN|with (r_acl) animals_1\NNS|pretreated (r_pobj) In_0\IN|animals (r_prep) resulted_52\VBD|in|doses|in|. (l_prep) in_53\IN|seizures (l_pobj) seizures_57\NNS|severe|motor|limbic|and|epilepticus
D018698_D013226 NONE acid_25\NN| (r_compound) decarboxylase_26\NN|glutamic|acid (r_appos) enzyme_20\NN|the|synthesizing|,|decarboxylase|,|into (r_pobj) of_15\IN|enzyme (r_prep) activity_14\NN|of (r_pobj) of_13\IN|activity (r_prep) inhibitor_12\NN|an|of (r_appos) micrograms_9\NNS|150|,|inhibitor (r_conj) microinjections_4\NNS|of|,|micrograms (r_pobj) with_3\IN|microinjections (r_prep) pretreated_2\VBN|with (r_acl) animals_1\NNS|pretreated (r_pobj) In_0\IN|animals (r_prep) resulted_52\VBD|in|doses|in|. (l_prep) in_53\IN|seizures (l_pobj) seizures_57\NNS|severe|motor|limbic|and|epilepticus (l_conj) epilepticus_60\NN|status
D010862_D013226 NONE pilocarpine_45\NN| (r_pobj) of_44\IN|pilocarpine (r_prep) doses_43\NNS|-|convulsant|of|,|mg/kg|, (r_nsubj) resulted_52\VBD|in|doses|in|. (l_prep) in_53\IN|seizures (l_pobj) seizures_57\NNS|severe|motor|limbic|and|epilepticus (l_conj) epilepticus_60\NN|status
816141
D002512_D000743 CID Cephalothin_0\NNP| (r_npadvmod) induced_2\VBN|cephalothin|- (r_amod) anemia_5\NN|induced|immune|hemolytic|.
D002512_D000743 CID cephalothin_13\JJ| (r_compound) therapy_14\NN|cephalothin (r_dobj) receiving_12\VBG|while|therapy (r_advcl) developed_5\VBD|patient|anemia|receiving|. (l_dobj) anemia_10\NN|positive|hemolytic
D002512_D007674 NONE cephalothin_13\JJ| (r_compound) therapy_14\NN|cephalothin (r_dobj) receiving_12\VBG|while|therapy (r_advcl) developed_5\VBD|patient|anemia|receiving|. (l_nsubj) patient_1\NN|a|with (l_prep) with_2\IN|disease (l_pobj) disease_4\NN|renal
2131034
D013852_D011115 CID thiotepa_7\NNS|intrathecal (r_compound) combination_8\NN|thiotepa (r_compound) chemotherapy_9\NN|combination|:|description (r_pobj) after_5\IN|chemotherapy (r_prep) polyneuropathy_1\NN|severe|and|loss|after|.
D013852_D020258 CID thiotepa_19\NNS|tspa (r_pobj) including_18\VBG|thiotepa (r_prep) chemotherapy_17\NN|intrathecal|it|combination|including (r_pobj) of_11\IN|chemotherapy (r_prep) administration_10\NN|the|of (r_pobj) to_8\IN|administration (r_prep) related_7\VBN|to (r_acl) toxicity_6\NN|severe|delayed|neurologic|related
D013852_D020258 CID TSPA_21\NNS|(|) (r_appos) thiotepa_19\NNS|tspa (r_pobj) including_18\VBG|thiotepa (r_prep) chemotherapy_17\NN|intrathecal|it|combination|including (r_pobj) of_11\IN|chemotherapy (r_prep) administration_10\NN|the|of (r_pobj) to_8\IN|administration (r_prep) related_7\VBN|to (r_acl) toxicity_6\NN|severe|delayed|neurologic|related
D013852_D020258 CID TSPA_17\NNP|it|- (r_conj) arabinoside_13\NN|,|cytosine|and|tspa (r_conj) methotrexate_8\NNP|it|-|arabinoside (r_pobj) with_5\IN|methotrexate (r_prep) described_4\VBN|toxicities|have|been|with|. (l_nsubjpass) toxicities_1\NNS|neurologic
D013852_D020258 CID TSPA_6\NNP| (r_nsubj) is_7\VBZ|that|tspa|agent (r_acl) fact_4\NN|the|is (r_pobj) of_2\IN|fact (r_prep) spite_1\NN|of (r_pobj) In_0\IN|spite (r_prep) cause_24\VB|in|,|combination|could|neurotoxicity|. (l_dobj) neurotoxicity_26\NN|severe
D008727_D020258 CID methotrexate_8\NNP|it|-|arabinoside (r_pobj) with_5\IN|methotrexate (r_prep) described_4\VBN|toxicities|have|been|with|. (l_nsubjpass) toxicities_1\NNS|neurologic
D008727_D020258 CID MTX_16\NNP|,|c (r_pobj) with_15\IN|mtx (r_prep) combination_14\NN|its|with (r_nsubj) cause_24\VB|in|,|combination|could|neurotoxicity|. (l_dobj) neurotoxicity_26\NN|severe
D003561_D020258 CID arabinoside_13\NN|,|cytosine|and|tspa (r_conj) methotrexate_8\NNP|it|-|arabinoside (r_pobj) with_5\IN|methotrexate (r_prep) described_4\VBN|toxicities|have|been|with|. (l_nsubjpass) toxicities_1\NNS|neurologic
D003561_D020258 CID C_20\NN|ara|-|and|radiotherapy (r_conj) MTX_16\NNP|,|c (r_pobj) with_15\IN|mtx (r_prep) combination_14\NN|its|with (r_nsubj) cause_24\VB|in|,|combination|could|neurotoxicity|. (l_dobj) neurotoxicity_26\NN|severe
2710809
D001712_D001919 CID biperiden_3\VBN|bradycardia|. (l_nsubj) Bradycardia_0\NNS|due
D001712_D001919 CID biperiden_3\VBN| (r_pobj) by_2\IN|biperiden (r_agent) induced_1\VBN|by (r_acl) Bradycardia_0\NNS|induced
C036432_D006562 NONE lactate_21\NN|mg|biperiden (r_pobj) of_17\IN|lactate (r_prep) application_16\NN|intravenous|of (r_nsubj) led_22\VBD|in|,|application|to|. (l_prep) In_0\IN|patient (l_pobj) patient_6\NN|a|old|male|suffering (l_acl) suffering_7\NN|from (l_prep) from_8\IN|neuralgia (l_pobj) neuralgia_13\NN|a|severe|postzosteric|trigeminal (l_nmod) postzosteric_11\JJ|
C036432_D014277 NONE lactate_21\NN|mg|biperiden (r_pobj) of_17\IN|lactate (r_prep) application_16\NN|intravenous|of (r_nsubj) led_22\VBD|in|,|application|to|. (l_prep) In_0\IN|patient (l_pobj) patient_6\NN|a|old|male|suffering (l_acl) suffering_7\NN|from (l_prep) from_8\IN|neuralgia (l_pobj) neuralgia_13\NN|a|severe|postzosteric|trigeminal
C036432_D001919 NONE lactate_21\NN|mg|biperiden (r_pobj) of_17\IN|lactate (r_prep) application_16\NN|intravenous|of (r_nsubj) led_22\VBD|in|,|application|to|. (l_prep) to_23\IN|reaction (l_pobj) reaction_29\NN|a|lasting|paradoxical|characterized (l_acl) characterized_30\VBN|by (l_agent) by_31\IN|bradycardia (l_pobj) bradycardia_33\NN|considerable|,|dysarthria
C036432_D004401 NONE lactate_21\NN|mg|biperiden (r_pobj) of_17\IN|lactate (r_prep) application_16\NN|intravenous|of (r_nsubj) led_22\VBD|in|,|application|to|. (l_prep) to_23\IN|reaction (l_pobj) reaction_29\NN|a|lasting|paradoxical|characterized (l_acl) characterized_30\VBN|by (l_agent) by_31\IN|bradycardia (l_pobj) bradycardia_33\NN|considerable|,|dysarthria (l_conj) dysarthria_35\NN|,|and|dysphagia
C036432_D003680 NONE lactate_21\NN|mg|biperiden (r_pobj) of_17\IN|lactate (r_prep) application_16\NN|intravenous|of (r_nsubj) led_22\VBD|in|,|application|to|. (l_prep) to_23\IN|reaction (l_pobj) reaction_29\NN|a|lasting|paradoxical|characterized (l_acl) characterized_30\VBN|by (l_agent) by_31\IN|bradycardia (l_pobj) bradycardia_33\NN|considerable|,|dysarthria (l_conj) dysarthria_35\NN|,|and|dysphagia (l_conj) dysphagia_38\NN|
D001285_D001919 NONE atropine_20\NN| (r_npadvmod) like_22\JJ|atropine|- (r_amod) drugs_23\NNS|like (r_pobj) of_19\IN|drugs (r_prep) effect_18\NN|a|related|dual|of|on (r_pobj) to_12\IN|effect (r_conj) to_6\IN|speed|and|to (r_prep) attributed_5\VBN|bradycardia|is|to|. (l_nsubjpass) Bradycardia_0\NNS|induced
D009116_D001919 NONE muscarine_25\NN| (r_compound) receptors_26\NNS|muscarine (r_pobj) on_24\IN|receptors (r_prep) effect_18\NN|a|related|dual|of|on (r_pobj) to_12\IN|effect (r_conj) to_6\IN|speed|and|to (r_prep) attributed_5\VBN|bradycardia|is|to|. (l_nsubjpass) Bradycardia_0\NNS|induced
3109094
D003520_D001745 CID cyclophosphamide_5\NN| (r_npadvmod) induced_7\VBN|cyclophosphamide|- (r_amod) lesions_8\NNS|the|induced|of|and|prevention (l_prep) of_9\IN|bladder (l_pobj) bladder_12\NN|the|urinary|of
D015080_D001745 NONE mesna_20\NN| (r_pobj) by_19\IN|mesna (r_prep) prevention_18\NN|their|by (r_conj) lesions_8\NNS|the|induced|of|and|prevention (l_prep) of_9\IN|bladder (l_pobj) bladder_12\NN|the|urinary|of
D003520_D003556 NONE cyclophosphamide_2\NN| (r_npadvmod) induced_4\VBN|cyclophosphamide|- (r_amod) cystitis_5\NN|developed|induced
D003520_D004487 NONE cyclophosphamide_2\NN| (r_npadvmod) induced_4\VBN|cyclophosphamide|- (r_amod) cystitis_5\NN|developed|induced (r_nsubjpass) characterized_7\VBN|cystitis|is|by|edema|. (l_dobj) edema_18\NN|,|severe|submucosal|owing
D003520_D009336 NONE cyclophosphamide_2\NN| (r_npadvmod) induced_4\VBN|cyclophosphamide|- (r_amod) cystitis_5\NN|developed|induced (r_nsubjpass) characterized_7\VBN|cystitis|is|by|edema|. (l_dobj) edema_18\NN|,|severe|submucosal|owing (l_acl) owing_19\VBG|to (l_prep) to_20\IN|damage (l_pobj) damage_21\NN|to (l_prep) to_22\IN|bed (l_pobj) bed_25\NN|the|microvascular|and|necroses (l_conj) necroses_29\NNS|focal|muscle
2907577
-1_D058186 NONE alkylxanthines_2\NNS|on (l_prep) on_3\IN|failure (l_pobj) failure_9\NN|induced|acute|renal|in
-1_D058186 NONE alkylxanthines_9\NNS|three|with (r_pobj) of_7\IN|alkylxanthines (r_prep) effects_6\NNS|the|of (r_nsubjpass) examined_23\VBN|in|,|effects|,|were|in|)|. (l_prep) in_24\IN|rats (l_pobj) rats_25\NNS|developing (l_acl) developing_26\VBG|failure|after (l_dobj) failure_29\NN|acute|renal
-1_D058186 NONE alkylxanthines_10\NNS|the|tested (r_pobj) with_8\IN|alkylxanthines (r_prep) noted_7\VBN|lack|with|indicates|. (l_ccomp) indicates_16\VBZ|plays (l_ccomp) plays_19\VBZ|that|adenosine|little|,|role (l_dobj) role_26\NN|any|,|pathophysiological|in (l_prep) in_27\IN|arf (l_pobj) ARF_31\NN|induced
D005839_D058186 CID gentamicin_4\NN| (r_npadvmod) induced_6\VBN|gentamicin|- (r_amod) failure_9\NN|induced|acute|renal|in
D005839_D058186 CID gentamicin_35\NN| (r_pobj) of_34\IN|gentamicin (r_prep) injections_33\NNS|4|daily|of|(|kg-1 (r_pobj) after_30\IN|injections (r_prep) developing_26\VBG|failure|after (l_dobj) failure_29\NN|acute|renal
D005839_D058186 CID gentamicin_28\NN| (r_npadvmod) induced_30\VBN|gentamicin|- (r_amod) ARF_31\NN|induced
D000241_D007511 NONE Adenosine_0\NNP| (r_amod) antagonists_1\NNS|adenosine (r_nsubjpass) shown_5\VBN|antagonists|have|been|previously|be|. (l_xcomp) be_7\VB|to|of|in (l_prep) in_10\IN|models (l_pobj) models_15\NNS|some|ischaemic|of (l_amod) ischaemic_12\JJ|and|nephrotoxic
D000241_D007674 NONE Adenosine_0\NNP| (r_amod) antagonists_1\NNS|adenosine (r_nsubjpass) shown_5\VBN|antagonists|have|been|previously|be|. (l_xcomp) be_7\VB|to|of|in (l_prep) in_10\IN|models (l_pobj) models_15\NNS|some|ischaemic|of (l_amod) ischaemic_12\JJ|and|nephrotoxic (l_conj) nephrotoxic_14\JJ|
D000241_D058186 NONE Adenosine_0\NNP| (r_amod) antagonists_1\NNS|adenosine (r_nsubjpass) shown_5\VBN|antagonists|have|been|previously|be|. (l_xcomp) be_7\VB|to|of|in (l_prep) in_10\IN|models (l_pobj) models_15\NNS|some|ischaemic|of (l_prep) of_16\IN|failure (l_pobj) failure_19\NN|acute|renal|(|arf|)
D000241_D058186 NONE Adenosine_0\NNP| (r_amod) antagonists_1\NNS|adenosine (r_nsubjpass) shown_5\VBN|antagonists|have|been|previously|be|. (l_xcomp) be_7\VB|to|of|in (l_prep) in_10\IN|models (l_pobj) models_15\NNS|some|ischaemic|of (l_prep) of_16\IN|failure (l_pobj) failure_19\NN|acute|renal|(|arf|) (l_appos) ARF_21\NNP|
D000241_D058186 NONE adenosine_14\NN| (r_amod) antagonists_15\NNS|adenosine|,|theophylline (r_pobj) as_13\IN|antagonists (r_prep) potencies_12\NNS|different|as (r_pobj) with_10\IN|potencies (r_prep) alkylxanthines_9\NNS|three|with (r_pobj) of_7\IN|alkylxanthines (r_prep) effects_6\NNS|the|of (r_nsubjpass) examined_23\VBN|in|,|effects|,|were|in|)|. (l_prep) in_24\IN|rats (l_pobj) rats_25\NNS|developing (l_acl) developing_26\VBG|failure|after (l_dobj) failure_29\NN|acute|renal
D000241_D058186 NONE adenosine_18\NN| (r_nsubj) plays_19\VBZ|that|adenosine|little|,|role (l_dobj) role_26\NN|any|,|pathophysiological|in (l_prep) in_27\IN|arf (l_pobj) ARF_31\NN|induced
C028322_D058186 NONE 8-phenyltheophylline_16\NN| (r_punct) ,_17\,|8-phenyltheophylline (r_punct) antagonists_15\NNS|adenosine|,|theophylline (r_pobj) as_13\IN|antagonists (r_prep) potencies_12\NNS|different|as (r_pobj) with_10\IN|potencies (r_prep) alkylxanthines_9\NNS|three|with (r_pobj) of_7\IN|alkylxanthines (r_prep) effects_6\NNS|the|of (r_nsubjpass) examined_23\VBN|in|,|effects|,|were|in|)|. (l_prep) in_24\IN|rats (l_pobj) rats_25\NNS|developing (l_acl) developing_26\VBG|failure|after (l_dobj) failure_29\NN|acute|renal
D013806_D058186 NONE theophylline_18\NN|and|enprofylline (r_amod) antagonists_15\NNS|adenosine|,|theophylline (r_pobj) as_13\IN|antagonists (r_prep) potencies_12\NNS|different|as (r_pobj) with_10\IN|potencies (r_prep) alkylxanthines_9\NNS|three|with (r_pobj) of_7\IN|alkylxanthines (r_prep) effects_6\NNS|the|of (r_nsubjpass) examined_23\VBN|in|,|effects|,|were|in|)|. (l_prep) in_24\IN|rats (l_pobj) rats_25\NNS|developing (l_acl) developing_26\VBG|failure|after (l_dobj) failure_29\NN|acute|renal
C034347_D058186 NONE enprofylline_20\NN| (r_conj) theophylline_18\NN|and|enprofylline (r_amod) antagonists_15\NNS|adenosine|,|theophylline (r_pobj) as_13\IN|antagonists (r_prep) potencies_12\NNS|different|as (r_pobj) with_10\IN|potencies (r_prep) alkylxanthines_9\NNS|three|with (r_pobj) of_7\IN|alkylxanthines (r_prep) effects_6\NNS|the|of (r_nsubjpass) examined_23\VBN|in|,|effects|,|were|in|)|. (l_prep) in_24\IN|rats (l_pobj) rats_25\NNS|developing (l_acl) developing_26\VBG|failure|after (l_dobj) failure_29\NN|acute|renal
D014508_D009336 NONE urea_8\NN|biochemical|(|plasma|and|creatinine|)|,|analysis (l_conj) analysis_16\NN|functional|(|urine|and|clearances|and|degree|indices (l_conj) degree_31\NN|morphological|(|of|) (l_prep) of_32\IN|necrosis (l_pobj) necrosis_33\NN|
D003404_D009336 NONE creatinine_10\NN| (r_conj) urea_8\NN|biochemical|(|plasma|and|creatinine|)|,|analysis (l_conj) analysis_16\NN|functional|(|urine|and|clearances|and|degree|indices (l_conj) degree_31\NN|morphological|(|of|) (l_prep) of_32\IN|necrosis (l_pobj) necrosis_33\NN|
D010130_D009336 NONE acid_25\NN| (r_compound) clearances_26\NNS|3h]inulin|acid|) (r_conj) analysis_16\NN|functional|(|urine|and|clearances|and|degree|indices (l_conj) degree_31\NN|morphological|(|of|) (l_prep) of_32\IN|necrosis (l_pobj) necrosis_33\NN|
24812279
D018943_D066126 NONE anthracycline_6\NN| (r_amod) cardiotoxicity_7\NN|stage|anthracycline
D004317_D009369 NONE Doxorubicin_2\NNP|dox|) (r_nsubj) is_6\VBZ|doxorubicin|therapeutic|,|but|associated (l_attr) therapeutic_12\NN|an|effective|cancer (l_compound) cancer_11\NN|anti|-
D004317_D009369 NONE DOX_4\NNP|( (r_appos) Doxorubicin_2\NNP|dox|) (r_nsubj) is_6\VBZ|doxorubicin|therapeutic|,|but|associated (l_attr) therapeutic_12\NN|an|effective|cancer (l_compound) cancer_11\NN|anti|-
D004317_D066126 NONE Doxorubicin_2\NNP|dox|) (r_nsubj) is_6\VBZ|doxorubicin|therapeutic|,|but|associated (l_conj) associated_16\VBN|is|with (l_prep) with_17\IN|cardiotoxicity (l_pobj) cardiotoxicity_24\NN|acute
D004317_D066126 NONE DOX_4\NNP|( (r_appos) Doxorubicin_2\NNP|dox|) (r_nsubj) is_6\VBZ|doxorubicin|therapeutic|,|but|associated (l_conj) associated_16\VBN|is|with (l_prep) with_17\IN|cardiotoxicity (l_pobj) cardiotoxicity_24\NN|acute
D004317_D066126 NONE DOX_13\NNP| (r_compound) cardiotoxicity_14\NN|stage|dox
D004317_D006333 CID DOX_5\NNP| (r_npadvmod) induced_7\VBN|dox|- (r_amod) failure_9\NN|induced|heart
16034922
D004967_D020521 CID oestrogen_3\NN|- (r_compound) HT_6\NNP|term|oestrogen (r_nsubj) increased_9\VBD|ht|also|significantly|risk|. (l_dobj) risk_11\NN|the|of (l_prep) of_12\IN|disease (l_pobj) disease_16\NN|stroke (l_nmod) stroke_13\NN|and|gallbladder
D004967_D005705 CID oestrogen_3\NN|- (r_compound) HT_6\NNP|term|oestrogen (r_nsubj) increased_9\VBD|ht|also|significantly|risk|. (l_dobj) risk_11\NN|the|of (l_prep) of_12\IN|disease (l_pobj) disease_16\NN|stroke
1756784
D010862_D001930 CID pilocarpine_7\NN| (r_npadvmod) induced_9\VBN|pilocarpine|- (r_amod) status_10\NN|induced (r_pobj) during_6\IN|status (r_prep) Damage_0\NN|of|during (l_prep) of_1\IN|reticulata (l_pobj) reticulata_5\NNS|substantia|pars
D010862_D013226 CID pilocarpine_7\NN| (r_npadvmod) induced_9\VBN|pilocarpine|- (r_amod) status_10\NN|induced (r_pobj) during_6\IN|status (r_prep) Damage_0\NN|of|during (r_nsubj) epilepticus_11\NN|damage|in|:|study|.
D010862_D013226 CID pilocarpine_12\NN| (r_pobj) of_11\IN|pilocarpine (r_prep) injection_10\NN|systemic|of|in (r_pobj) by_8\IN|injection (r_agent) induced_7\VBN|in|,|epilepticus|was|by|. (l_nsubjpass) epilepticus_5\NN|status
D002118_D009422 NONE calcium_10\NN| (r_npadvmod) binding_12\VBG|calcium|- (r_amod) protein_13\NN|the|specific|binding|,|parvalbumin (r_pobj) against_5\IN|protein (r_prep) staining_2\VBG|nissl|-|and|antibodies|against|, (r_nsubj) served_17\VBD|staining|detect|. (l_xcomp) detect_19\VB|to|damage (l_dobj) damage_21\NN|neuronal|in
2974281
D011433_D006332 NONE propranolol_3\NN|and|24/76 (r_pobj) of_2\IN|propranolol (r_prep) effects_1\NNS|subacute|of|on|. (l_prep) on_7\IN|hypertrophy (l_pobj) hypertrophy_13\NN|induced|rat|heart|in
D011433_D006332 NONE propranolol_15\NN|that|blockers|and|have (l_conj) have_19\VBP|24/76|potency|prevent (l_advcl) prevent_23\VB|to|isoproterenol|from (l_prep) from_25\IN|producing (l_pcomp) producing_26\VBG|hypertrophy (l_dobj) hypertrophy_28\NN|heart
D007545_D006332 CID isoproterenol_8\NN| (r_npadvmod) induced_10\VBN|isoproterenol|- (r_amod) hypertrophy_13\NN|induced|rat|heart|in
D007545_D006332 CID isoproterenol_9\NN| (r_npadvmod) induced_11\VBN|isoproterenol|- (r_amod) hypertrophy_13\NN|induced|heart|in
D007545_D006332 CID isoproterenol_24\NN| (r_dobj) prevent_23\VB|to|isoproterenol|from (l_prep) from_25\IN|producing (l_pcomp) producing_26\VBG|hypertrophy (l_dobj) hypertrophy_28\NN|heart
D009952_D006332 NONE ornithine_7\NN| (r_compound) decarboxylase_8\NN|ornithine (r_compound) activity_9\NN|the|increased|decarboxylase|with (l_prep) with_10\IN|blockers (l_pobj) blockers_14\NNS|both|beta|-|in (l_prep) in_15\IN|hearts (l_pobj) hearts_17\NNS|hypertrophied
D011433_D006984 NONE propranolol_1\NN|neither|nor|24/76 (r_csubj) stop_6\VB|propranolol|could|changes|. (l_dobj) changes_8\NNS|the|in (l_prep) in_9\IN|myosin|pattern (l_pobj) pattern_14\NN|isoenzyme|of (l_prep) of_15\IN|heart (l_pobj) heart_19\NN|the|hypertrophied|rat (l_amod) hypertrophied_17\JJ|
24072398
D008694_D020258 NONE methamphetamine_5\NN| (r_pobj) of_4\IN|methamphetamine (r_prep) dose_3\NN|a|single|neurotoxic|of (l_amod) neurotoxic_2\JJ|
D008694_D003866 CID methamphetamine_5\NN| (r_pobj) of_4\IN|methamphetamine (r_prep) dose_3\NN|a|single|neurotoxic|of (r_nsubj) induces_6\VBZ|dose|behaviour|. (l_dobj) behaviour_14\NN|a|lasting|like|in (l_amod) like_13\JJ|depressive|- (l_amod) depressive_11\JJ|
D008694_D003866 CID Methamphetamine_0\NN|(|meth|) (r_nsubj) triggers_4\VBZ|methamphetamine|disruption|leads|. (l_conj) leads_14\VBZ|abuse|to (l_prep) to_15\IN|states (l_pobj) states_18\NNS|negative|emotional|including (l_prep) including_19\VBG|symptoms (l_pobj) symptoms_21\NNS|depressive|during
D008694_D003866 CID METH_2\NNP| (r_appos) Methamphetamine_0\NN|(|meth|) (r_nsubj) triggers_4\VBZ|methamphetamine|disruption|leads|. (l_conj) leads_14\VBZ|abuse|to (l_prep) to_15\IN|states (l_pobj) states_18\NNS|negative|emotional|including (l_prep) including_19\VBG|symptoms (l_pobj) symptoms_21\NNS|depressive|during
D008694_D003866 CID METH_12\NNP| (r_compound) abuse_13\NN|meth (r_nsubj) leads_14\VBZ|abuse|to (l_prep) to_15\IN|states (l_pobj) states_18\NNS|negative|emotional|including (l_prep) including_19\VBG|symptoms (l_pobj) symptoms_21\NNS|depressive|during
D008694_D003866 CID METH_12\NNP| (r_pobj) of_11\IN|meth (r_prep) dosage_10\NN|the|acute|toxic|of (r_nsubj) causes_14\VBZ|if|dosage|also|phenotype (l_dobj) phenotype_20\NN|a|lasting|depressive|and|deficits (l_amod) depressive_19\JJ|
D008694_D003866 CID METH_23\NNP| (r_compound) dose_24\NN|a|single|high|meth|mg/kg (r_pobj) following_19\VBG|dose (r_prep) assessed_4\VBD|thus|,|we|now|behaviour|at|following|. (l_dobj) behaviour_9\NN|the|like|in (l_amod) like_8\JJ|depressive|- (l_npadvmod) depressive_6\JJ|
D008694_D003866 CID METH_7\NNP| (r_pobj) by_6\IN|meth (r_agent) induced_5\VBN|by (r_acl) profile_4\NN|this|like|induced (l_amod) like_3\JJ|depressive|- (l_npadvmod) depressive_1\JJ|
D008694_D003866 CID METH_13\NNP| (r_pobj) of_12\IN|meth (r_prep) dose_11\NN|a|single|high|of (r_nsubj) induces_14\VBZ|that|dose|behaviour (l_dobj) behaviour_21\NN|lasting|like|in (l_amod) like_20\JJ|depressive|- (l_amod) depressive_18\JJ|
D004298_D003866 NONE dopamine_29\NN| (r_pobj) of_28\IN|dopamine (r_prep) levels_27\NNS|the|of (r_pobj) in_25\IN|levels (r_prep) reduction_24\NN|a|in (r_pobj) by_22\IN|reduction (r_agent) indicated_21\VBN|by|,|dopac (r_advcl) accompanied_9\VBN|profile|was|by|,|indicated|,|observed|. (l_nsubjpass) profile_4\NN|this|like|induced (l_amod) like_3\JJ|depressive|- (l_npadvmod) depressive_1\JJ|
D015102_D003866 NONE DOPAC_31\NNP|and|hva|,|hydroxylase (r_conj) indicated_21\VBN|by|,|dopac (r_advcl) accompanied_9\VBN|profile|was|by|,|indicated|,|observed|. (l_nsubjpass) profile_4\NN|this|like|induced (l_amod) like_3\JJ|depressive|- (l_npadvmod) depressive_1\JJ|
D006719_D003866 NONE HVA_33\NNP| (r_conj) DOPAC_31\NNP|and|hva|,|hydroxylase (r_conj) indicated_21\VBN|by|,|dopac (r_advcl) accompanied_9\VBN|profile|was|by|,|indicated|,|observed|. (l_nsubjpass) profile_4\NN|this|like|induced (l_amod) like_3\JJ|depressive|- (l_npadvmod) depressive_1\JJ|
D014443_D003866 NONE tyrosine_35\JJ| (r_compound) hydroxylase_36\NN|tyrosine|and|serotonin (r_conj) DOPAC_31\NNP|and|hva|,|hydroxylase (r_conj) indicated_21\VBN|by|,|dopac (r_advcl) accompanied_9\VBN|profile|was|by|,|indicated|,|observed|. (l_nsubjpass) profile_4\NN|this|like|induced (l_amod) like_3\JJ|depressive|- (l_npadvmod) depressive_1\JJ|
D012701_D003866 NONE serotonin_38\NN| (r_conj) hydroxylase_36\NN|tyrosine|and|serotonin (r_conj) DOPAC_31\NNP|and|hva|,|hydroxylase (r_conj) indicated_21\VBN|by|,|dopac (r_advcl) accompanied_9\VBN|profile|was|by|,|indicated|,|observed|. (l_nsubjpass) profile_4\NN|this|like|induced (l_amod) like_3\JJ|depressive|- (l_npadvmod) depressive_1\JJ|
24333387
D013311_D020258 NONE Streptozotocin_12\NNP|icv (r_pobj) in_11\IN|streptozotocin (r_prep) events_10\NNS|the|key|in (r_nsubj) induced_16\VBN|events|impairment (r_acl) activation_1\NN|glial|and|neurotoxicity|:|induced|. (l_conj) neurotoxicity_6\NN|synaptic
D013311_D020258 NONE STZ_0\NNP| (r_compound) treatment_1\NN|stz (r_nsubj) showed_2\VBD|treatment|expression|camkiia|and|psd-95|remains (l_conj) remains_25\VBZ|,|while|,|expression|neurotoxicity|. (l_nsubj) neurotoxicity_31\NN|unaltered|indicating|selective|synaptic
D013311_D020258 NONE STZ_0\NNP| (r_nsubj) induced_1\VBN|stz|activation|. (l_dobj) activation_3\NN|glial|,|death (l_conj) death_7\NN|apoptotic|cell|and|post (l_conj) post_9\VB|neurotoxicity (l_dobj) neurotoxicity_11\NN|synaptic|in
D013311_D020258 NONE STZ_16\NNP| (r_pobj) in_15\IN|stz (r_prep) factors_14\NNS|the|key|in|induced (r_attr) are_11\VBP|that|activation|factors (l_nsubj) activation_6\NN|glial|and|post (l_conj) post_8\VB|neurotoxicity (l_dobj) neurotoxicity_10\NN|synaptic
D013311_D008569 CID Streptozotocin_12\NNP|icv (r_pobj) in_11\IN|streptozotocin (r_prep) events_10\NNS|the|key|in (r_nsubj) induced_16\VBN|events|impairment (l_dobj) impairment_18\NN|memory|in
D013311_D008569 CID Streptozotocin_15\NNP|icv|stz (r_pobj) in_13\IN|streptozotocin (r_prep) activation_8\NN|glial|and|toxicity|in (r_pobj) of_6\IN|activation (r_prep) role_5\NN|the|of (r_dobj) study_3\NN|the|present|role (r_pobj) In_0\IN|study (r_prep) induced_19\VBN|in|explored|. (l_ccomp) explored_24\VBN|rats|was (l_nsubjpass) rats_22\NNS|impaired (l_amod) impaired_21\VBN|memory
D013311_D008569 CID STZ_17\NNP|(|) (r_appos) Streptozotocin_15\NNP|icv|stz (r_pobj) in_13\IN|streptozotocin (r_prep) activation_8\NN|glial|and|toxicity|in (r_pobj) of_6\IN|activation (r_prep) role_5\NN|the|of (r_dobj) study_3\NN|the|present|role (r_pobj) In_0\IN|study (r_prep) induced_19\VBN|in|explored|. (l_ccomp) explored_24\VBN|rats|was (l_nsubjpass) rats_22\NNS|impaired (l_amod) impaired_21\VBN|memory
D013311_D008569 CID STZ_21\NNP|icv (r_pobj) after_20\IN|days|stz (r_prep) found_9\VBN|in|:|deficit|was|in|after|. (l_nsubjpass) deficit_7\NN|memory
D013311_D008569 CID STZ_16\NNP| (r_pobj) in_15\IN|stz (r_prep) factors_14\NNS|the|key|in|induced (l_acl) induced_17\VBN|impairment (l_dobj) impairment_19\NN|memory|and|death
D013311_D064420 NONE Streptozotocin_15\NNP|icv|stz (r_pobj) in_13\IN|streptozotocin (r_prep) activation_8\NN|glial|and|toxicity|in (l_conj) toxicity_12\NN|post|synaptic
D013311_D064420 NONE STZ_17\NNP|(|) (r_appos) Streptozotocin_15\NNP|icv|stz (r_pobj) in_13\IN|streptozotocin (r_prep) activation_8\NN|glial|and|toxicity|in (l_conj) toxicity_12\NN|post|synaptic
D013311_D064420 NONE STZ_0\NNP| (r_nsubj) increased_3\VBD|stz|also|significantly|level|)|and|reduced|. (l_conj) reduced_15\VBD|activity (l_dobj) activity_18\NN|the|mitochondrial|in (l_prep) in_19\IN|preparation (l_pobj) preparation_21\NN|synaptosomal|illustrating (l_acl) illustrating_22\VBG|generation (l_dobj) generation_25\NN|free|radical|and|excitotoxicity (l_conj) excitotoxicity_27\NN|
D013311_D007249 CID STZ_0\NN| (r_nsubj) causes_1\VBZ|stz|expression|. (l_dobj) expression_3\NN|increased|of (l_prep) of_4\IN|gfap (l_pobj) GFAP_5\NNP|,|cd11b|-|activation (l_appos) activation_14\NN|a|indicating|glial|and|neuroinflammation (l_conj) neuroinflammation_16\NN|
D009573_D064420 NONE nitrite_9\NN|,|ca(2 (r_appos) ROS_7\NNP|,|nitrite (r_pobj) of_6\IN|ros (r_prep) level_5\NN|the|of (r_dobj) increased_3\VBD|stz|also|significantly|level|)|and|reduced|. (l_conj) reduced_15\VBD|activity (l_dobj) activity_18\NN|the|mitochondrial|in (l_prep) in_19\IN|preparation (l_pobj) preparation_21\NN|synaptosomal|illustrating (l_acl) illustrating_22\VBG|generation (l_dobj) generation_25\NN|free|radical|and|excitotoxicity (l_conj) excitotoxicity_27\NN|
D002118_D064420 NONE Ca(2_11\NNP|+ (r_conj) nitrite_9\NN|,|ca(2 (r_appos) ROS_7\NNP|,|nitrite (r_pobj) of_6\IN|ros (r_prep) level_5\NN|the|of (r_dobj) increased_3\VBD|stz|also|significantly|level|)|and|reduced|. (l_conj) reduced_15\VBD|activity (l_dobj) activity_18\NN|the|mitochondrial|in (l_prep) in_19\IN|preparation (l_pobj) preparation_21\NN|synaptosomal|illustrating (l_acl) illustrating_22\VBG|generation (l_dobj) generation_25\NN|free|radical|and|excitotoxicity (l_conj) excitotoxicity_27\NN|
12678199
D000638_D016171 CID Amiodarone_0\NN| (r_npadvmod) induced_2\VBN|amiodarone|- (r_amod) torsade_3\NN|induced (r_nmod) pointes_5\FW|torsade|de|during|:|presentation|.
D000638_D016171 CID amiodarone_23\NN| (r_compound) therapy_24\NN|oral|amiodarone (r_pobj) with_21\IN|therapy (r_prep) associated_20\VBN|with (r_acl) pointes_16\FW|torsade|de|(|tdp|)|associated
D000638_D016171 CID amiodarone_23\NN| (r_compound) therapy_24\NN|oral|amiodarone (r_pobj) with_21\IN|therapy (r_prep) associated_20\VBN|with (r_acl) pointes_16\FW|torsade|de|(|tdp|)|associated (l_appos) TdP_18\NN|
D000638_D016171 CID amiodarone_4\NN| (r_compound) therapy_5\NN|amiodarone (r_pobj) of_3\IN|therapy (r_prep) absence_2\NN|the|of (r_pobj) In_0\IN|absence (r_prep) induce_13\VB|in|,|irrigation|did|not|tdp|despite|. (l_dobj) TdP_14\NN|
D004077_D016171 NONE digoxin_19\JJ| (r_compound) excess_20\NN|digoxin (r_conj) hypokalemia_17\NN|and|excess (r_pobj) including_16\VBG|hypokalemia (r_prep) factors_15\NNS|multiple|exacerbating|including (r_pobj) of_12\IN|factors (r_prep) context_11\NN|the|of (r_pobj) in_9\IN|context (r_prep) occurred_8\VBD|consistent|case|in|. (l_nsubj) case_5\NN|this|of (l_prep) of_6\IN|tdp (l_pobj) TdP_7\NNP|
D004077_D007008 NONE digoxin_19\JJ| (r_compound) excess_20\NN|digoxin (r_conj) hypokalemia_17\NN|and|excess
D000638_-1 NONE amiodarone_20\NN| (r_compound) therapy_21\NN|amiodarone (r_pobj) of_19\IN|therapy (r_prep) context_18\NN|the|of (r_pobj) in_16\IN|context (r_prep) resulted_22\VBD|that|tone|in|in (l_prep) in_23\IN|proarrhythmia (l_pobj) proarrhythmia_27\NN|induced
D000638_-1 NONE amiodarone_24\NN| (r_npadvmod) induced_26\VBN|amiodarone|- (r_amod) proarrhythmia_27\NN|induced
D000638_D007008 NONE amiodarone_4\NN| (r_compound) therapy_5\NN|amiodarone (r_pobj) of_3\IN|therapy (r_prep) absence_2\NN|the|of (r_pobj) In_0\IN|absence (r_prep) induce_13\VB|in|,|irrigation|did|not|tdp|despite|. (l_prep) despite_15\IN|hypokalemia (l_pobj) hypokalemia_16\NN|and|hypomagnesemia
D000638_C537153 NONE amiodarone_4\NN| (r_compound) therapy_5\NN|amiodarone (r_pobj) of_3\IN|therapy (r_prep) absence_2\NN|the|of (r_pobj) In_0\IN|absence (r_prep) induce_13\VB|in|,|irrigation|did|not|tdp|despite|. (l_prep) despite_15\IN|hypokalemia (l_pobj) hypokalemia_16\NN|and|hypomagnesemia (l_conj) hypomagnesemia_18\NN|
2021990
D002927_D007022 CID cimetidine_15\NN|iv (r_pobj) by_13\IN|cimetidine (r_agent) caused_12\VBN|by (r_acl) hypotension_11\NN|caused
D002927_D007022 CID cimetidine_22\NN| (r_pobj) of_21\IN|cimetidine (r_prep) activity_20\NN|the|vasodilating|of (r_nsubjpass) mediated_24\VBN|since|activity|is|,|in|,|through (r_advcl) be_7\VB|that|antagonist|may|useful|,|mediated (l_acomp) useful_8\JJ|in (l_prep) in_9\IN|preventing (l_pcomp) preventing_10\VBG|hypotension (l_dobj) hypotension_11\NN|caused
24234943
C086816_D007177 CID desvenlafaxine_8\NN| (r_pobj) with_7\IN|desvenlafaxine (r_prep) associated_6\VBN|with (r_acl) secretion_5\NN|inappropriate|antidiuretic|hormone|associated (l_compound) hormone_4\NN|
C086816_D007177 CID desvenlafaxine_18\NN| (r_pobj) with_17\IN|desvenlafaxine (r_prep) associated_16\VBN|with (r_acl) secretion_15\NN|inappropriate|hormone|(|siadh|)|associated (l_nmod) hormone_11\NN|-|diuretic
C086816_D007177 CID desvenlafaxine_18\NN| (r_pobj) with_17\IN|desvenlafaxine (r_prep) associated_16\VBN|with (r_acl) secretion_15\NN|inappropriate|hormone|(|siadh|)|associated (l_nmod) SIADH_13\NNP|
C086816_D009325 CID desvenlafaxine_3\NN| (r_dobj) included_2\VBD|medications|desvenlafaxine|,|and|included (l_conj) included_7\VBD|symptoms|nausea|. (l_dobj) nausea_8\NN|,|anxiety
C086816_D001008 CID desvenlafaxine_3\NN| (r_dobj) included_2\VBD|medications|desvenlafaxine|,|and|included (l_conj) included_7\VBD|symptoms|nausea|. (l_dobj) nausea_8\NN|,|anxiety (l_conj) anxiety_10\NN|and|confusion
C086816_D003221 CID desvenlafaxine_3\NN| (r_dobj) included_2\VBD|medications|desvenlafaxine|,|and|included (l_conj) included_7\VBD|symptoms|nausea|. (l_dobj) nausea_8\NN|,|anxiety (l_conj) anxiety_10\NN|and|confusion (l_conj) confusion_12\NN|
D012964_D007177 NONE sodium_2\NN|the|serum|at (r_nsubj) was_6\VBD|sodium|l (r_ccomp) was_14\VBD|was|,|osmolality|mosmol|. (l_attr) mosmol_16\NN|263|/|kg|,|osmolality|,|consistent (l_amod) consistent_34\JJ|with (l_prep) with_35\IN|diagnosis (l_pobj) diagnosis_37\NN|a|of (l_prep) of_38\IN|siadh (l_pobj) SIADH_39\NNP|
D012964_D007177 NONE sodium_28\NN|urine (r_conj) kg_25\NNS|mosmol|/|and|sodium|l (r_appos) osmolality_21\NN|urine|kg (r_appos) mosmol_16\NN|263|/|kg|,|osmolality|,|consistent (l_amod) consistent_34\JJ|with (l_prep) with_35\IN|diagnosis (l_pobj) diagnosis_37\NN|a|of (l_prep) of_38\IN|siadh (l_pobj) SIADH_39\NNP|
C086816_D007010 CID desvenlafaxine_5\NN| (r_nsubj) cause_7\VB|that|desvenlafaxine|might|hyponatremia (l_dobj) hyponatremia_10\NN|significant
6321816
D014667_D006973 NONE Vasopressin_0\NNP|as|. (l_prep) as_1\IN|contributor (l_pobj) contributor_4\NN|a|possible|to (l_prep) to_5\IN|hypertension (l_pobj) hypertension_6\NN|
D014667_D006973 NONE vasopressin_3\NN| (r_pobj) of_2\IN|vasopressin (r_prep) role_1\NN|the|of|as (l_prep) as_4\IN|agent (l_pobj) agent_7\NN|a|pressor|to (l_prep) to_8\IN|process (l_pobj) process_11\NN|the|hypertensive (l_amod) hypertensive_10\JJ|
D014667_D006973 NONE Vasopressin_0\NNP| (r_nsubj) plays_1\VBZ|vasopressin|role|in|,|was|. (l_prep) in_5\IN|pathogenesis (l_pobj) pathogenesis_7\NN|the|of (l_prep) of_8\IN|hypertension (l_pobj) hypertension_12\NN|salt
D014667_D006973 NONE vasopressin_6\NN| (r_pobj) of_5\IN|vasopressin (r_prep) action_4\NN|the|pressor|of (r_nsubj) appears_7\VBZ|furthermore|,|action|be|,|observed|. (l_xcomp) be_9\VB|to|important|in (l_prep) in_11\IN|development (l_pobj) development_13\NN|the|of (l_prep) of_14\IN|model (l_pobj) model_16\NN|this|of (l_prep) of_17\IN|hypertension (l_pobj) hypertension_18\NN|
D014667_D006973 NONE vasopressin_6\NN| (r_pobj) of_5\IN|vasopressin (r_prep) action_4\NN|the|pressor|of (r_nsubj) appears_7\VBZ|furthermore|,|action|be|,|observed|. (l_advcl) observed_29\VBN|since|responsiveness|was|in (l_prep) in_30\IN|stage (l_pobj) stage_33\NN|the|initial|of (l_prep) of_34\IN|hypertension (l_pobj) hypertension_35\NN|
D014667_D006973 NONE vasopressin_3\NN| (r_pobj) of_2\IN|vasopressin (r_prep) secretion_1\NN|increased|of|from (r_nsubj) promotes_7\VBZ|secretion|also|function|. (l_dobj) function_9\NN|the|of|as (l_prep) as_13\IN|factor (l_pobj) factor_16\NN|a|pathogenetic|in (l_prep) in_17\IN|hypertension (l_pobj) hypertension_18\NN|
D014667_D006973 NONE vasopressin_5\NN| (r_pobj) of_4\IN|vasopressin (r_prep) role_3\NN|the|of (r_nsubj) remains_6\VBZ|however|,|role|determined|. (l_xcomp) determined_9\VBN|to|be|in (l_prep) in_10\IN|hypertension (l_pobj) hypertension_13\NN|human|essential
D014667_D003919 NONE Vasopressin_0\NNP| (r_nsubj) plays_1\VBZ|vasopressin|role|in|,|was|. (l_advcl) was_20\VBD|since|elevation|not|substantial|after (l_acomp) substantial_22\JJ|in (l_prep) in_23\IN|rats (l_pobj) rats_25\NNS|the|with (l_prep) with_26\IN|insipidus (l_pobj) insipidus_31\NN|diabetes
D003900_D006973 CID DOCA_9\NNP| (r_compound) salt_11\NN|doca|- (r_compound) hypertension_12\NN|salt
D003900_D006973 CID DOCA_33\NNP| (r_compound) salt_35\NN|doca|- (r_compound) treatment_36\NN|salt (r_pobj) after_32\IN|treatment (r_prep) was_20\VBD|since|elevation|not|substantial|after (r_advcl) plays_1\VBZ|vasopressin|role|in|,|was|. (l_prep) in_5\IN|pathogenesis (l_pobj) pathogenesis_7\NN|the|of (l_prep) of_8\IN|hypertension (l_pobj) hypertension_12\NN|salt
D003900_D003919 NONE DOCA_9\NNP| (r_compound) salt_11\NN|doca|- (r_compound) hypertension_12\NN|salt (r_pobj) of_8\IN|hypertension (r_prep) pathogenesis_7\NN|the|of (r_pobj) in_5\IN|pathogenesis (r_prep) plays_1\VBZ|vasopressin|role|in|,|was|. (l_advcl) was_20\VBD|since|elevation|not|substantial|after (l_acomp) substantial_22\JJ|in (l_prep) in_23\IN|rats (l_pobj) rats_25\NNS|the|with (l_prep) with_26\IN|insipidus (l_pobj) insipidus_31\NN|diabetes
D003900_D003919 NONE DOCA_33\NNP| (r_compound) salt_35\NN|doca|- (r_compound) treatment_36\NN|salt (r_pobj) after_32\IN|treatment (r_prep) was_20\VBD|since|elevation|not|substantial|after (l_acomp) substantial_22\JJ|in (l_prep) in_23\IN|rats (l_pobj) rats_25\NNS|the|with (l_prep) with_26\IN|insipidus (l_pobj) insipidus_31\NN|diabetes
D008094_D006973 NONE lithium_27\NN| (r_npadvmod) treated_29\VBN|lithium|- (r_amod) diabetes_30\NN|treated (r_compound) insipidus_31\NN|diabetes (r_pobj) with_26\IN|insipidus (r_prep) rats_25\NNS|the|with (r_pobj) in_23\IN|rats (r_prep) substantial_22\JJ|in (r_acomp) was_20\VBD|since|elevation|not|substantial|after (r_advcl) plays_1\VBZ|vasopressin|role|in|,|was|. (l_prep) in_5\IN|pathogenesis (l_pobj) pathogenesis_7\NN|the|of (l_prep) of_8\IN|hypertension (l_pobj) hypertension_12\NN|salt
D008094_D003919 CID lithium_27\NN| (r_npadvmod) treated_29\VBN|lithium|- (r_amod) diabetes_30\NN|treated (r_compound) insipidus_31\NN|diabetes
17496739
C085143_D012640 NONE tazobactam_2\NN| (r_advmod) induced_4\VBN|piperacillin|/|tazobactam|- (r_amod) seizure_5\NN|induced
D010878_D020258 NONE piperacillin_4\NN| (r_pobj) of_3\IN|piperacillin (r_prep) use_2\NN|popular|of (r_pobj) Despite_0\IN|use (r_prep) goes_13\VBZ|despite|,|neurotoxicity|still|unrecognized|,|leading|. (l_nsubj) neurotoxicity_8\NN|the|dire|associated
D010878_D020258 NONE piperacillin_11\NN| (r_pobj) with_10\IN|piperacillin (r_prep) associated_9\VBN|with (r_acl) neurotoxicity_8\NN|the|dire|associated
C085143_D007676 NONE tazobactam_54\NN|/|(|2|mg|) (r_conj) confusion_34\NN|progressive|mental|,|and|episodes|tazobactam (r_conj) behavior_30\NN|bizarre|,|confusion (r_conj) tremor_27\NN|,|behavior (r_conj) speech_25\NN|slurred|,|tremor (r_dobj) developed_23\VBD|who|speech (r_relcl) dialysis_17\NN|continuous|ambulatory|peritoneal|(|capd|)|,|developed (r_dobj) receiving_13\VBG|dialysis (r_acl) disease_12\NN|stage|renal|receiving
C085143_D014202 CID tazobactam_54\NN|/|(|2|mg|) (r_conj) confusion_34\NN|progressive|mental|,|and|episodes|tazobactam (r_conj) behavior_30\NN|bizarre|,|confusion (r_conj) tremor_27\NN|,|behavior
C085143_D003221 CID tazobactam_54\NN|/|(|2|mg|) (r_conj) confusion_34\NN|progressive|mental|,|and|episodes|tazobactam
C085143_D004830 CID tazobactam_54\NN|/|(|2|mg|) (r_conj) confusion_34\NN|progressive|mental|,|and|episodes|tazobactam (l_conj) episodes_38\NNS|2|of|gtcs (l_prep) of_39\IN|seizure (l_pobj) seizure_44\NN|generalized|clonic
C085143_D004830 CID tazobactam_54\NN|/|(|2|mg|) (r_conj) confusion_34\NN|progressive|mental|,|and|episodes|tazobactam (l_conj) episodes_38\NNS|2|of|gtcs (l_parataxis) GTCS_46\NNP|(|)|after
C085143_D004830 CID tazobactam_18\NN|dose|/ (r_pobj) after_11\IN|tazobactam (r_prep) recurred_10\VBD|despite|,|episode|after|. (l_nsubj) episode_9\NN|another|gtcs (l_amod) GTCS_8\NNP|
C085143_D001987 NONE tazobactam_54\NN|/|(|2|mg|) (r_conj) confusion_34\NN|progressive|mental|,|and|episodes|tazobactam (r_conj) behavior_30\NN|bizarre|,|confusion (r_conj) tremor_27\NN|,|behavior (r_conj) speech_25\NN|slurred|,|tremor (r_dobj) developed_23\VBD|who|speech (r_relcl) dialysis_17\NN|continuous|ambulatory|peritoneal|(|capd|)|,|developed (r_dobj) receiving_13\VBG|dialysis (r_acl) disease_12\NN|stage|renal|receiving (r_pobj) with_7\IN|disease (r_prep) woman_6\NN|a|old|with (r_nsubjpass) given_61\VBN|woman|were|for (l_prep) for_62\IN|bronchiectasis (l_pobj) bronchiectasis_63\NN|with
C085143_D060085 NONE tazobactam_54\NN|/|(|2|mg|) (r_conj) confusion_34\NN|progressive|mental|,|and|episodes|tazobactam (r_conj) behavior_30\NN|bizarre|,|confusion (r_conj) tremor_27\NN|,|behavior (r_conj) speech_25\NN|slurred|,|tremor (r_dobj) developed_23\VBD|who|speech (r_relcl) dialysis_17\NN|continuous|ambulatory|peritoneal|(|capd|)|,|developed (r_dobj) receiving_13\VBG|dialysis (r_acl) disease_12\NN|stage|renal|receiving (r_pobj) with_7\IN|disease (r_prep) woman_6\NN|a|old|with (r_nsubjpass) given_61\VBN|woman|were|for (l_prep) for_62\IN|bronchiectasis (l_pobj) bronchiectasis_63\NN|with (l_prep) with_64\IN|infection (l_pobj) infection_66\NN|secondary
D000641_D007964 NONE ammonia_8\NN| (r_compound) levels_9\NNS|electrolyte|ammonia|but|leukocytosis (l_conj) leukocytosis_11\NN|
D010878_D001927 NONE Piperacillin_0\NNP| (r_npadvmod) induced_2\VBN|piperacillin|- (r_amod) encephalopathy_3\NN|induced
D010878_D001927 NONE piperacillin_5\NN| (r_dobj) removing_4\VBG|piperacillin (r_pcomp) in_3\IN|removing (r_prep) inefficient_2\JJ|in (r_acomp) is_1\VBZ|capd|inefficient|,|terminate|. (l_advcl) terminate_11\VB|whereas|hemodialysis|can|rapidly|encephalopathy (l_dobj) encephalopathy_16\NN|the|induced
D010878_D001927 NONE piperacillin_13\NN| (r_npadvmod) induced_15\VBN|piperacillin|- (r_amod) encephalopathy_16\NN|the|induced
D010878_D006463 NONE Piperacillin_0\NNP| (r_npadvmod) induced_2\VBN|piperacillin|- (r_amod) encephalopathy_3\NN|induced (r_nsubjpass) considered_6\VBN|encephalopathy|should|be|in|. (l_prep) in_7\IN|patients (l_pobj) patients_10\NNS|any|uremic|with (l_amod) uremic_9\JJ|
6316193
D010852_D012640 CID picrotoxin_12\NN| (r_npadvmod) induced_14\VBN|picrotoxin|- (r_amod) seizures_15\NNS|induced|by
D010852_D012640 CID picrotoxin_24\NN| (r_pobj) by_23\IN|picrotoxin (r_agent) induced_22\VBN|by|in (r_acl) seizures_21\NNS|induced
D010852_D012640 CID picrotoxin_31\NN| (r_npadvmod) induced_33\VBN|picrotoxin|- (r_amod) seizures_34\NNS|induced|and|mortality
D002766_D012640 NONE cholecystokinin_17\NN|,|fragments|in (r_pobj) by_16\IN|cholecystokinin (r_prep) seizures_15\NNS|induced|by
D002766_D012640 NONE cholecystokinin_23\NN| (r_pobj) of_22\IN|cholecystokinin (r_prep) analogues_21\NNS|of (r_conj) fragments_19\NNS|and|analogues (r_conj) cholecystokinin_17\NN|,|fragments|in (r_pobj) by_16\IN|cholecystokinin (r_prep) seizures_15\NNS|induced|by
D012844_D012640 NONE octapeptide_4\JJ| (r_compound) ester_6\NN|octapeptide|sulphate (r_appos) cholecystokinin_3\NN|ester (r_pobj) of_2\IN|cholecystokinin (r_prep) administration_1\NN|intraperitoneal|of|cck-8-se|and|cholecystokinin (r_nsubj) enhanced_17\VBD|administration|latency|. (l_dobj) latency_19\NN|the|of (l_prep) of_20\IN|seizures (l_pobj) seizures_21\NNS|induced
D012844_D012640 NONE CCK-8-SE_8\NNP|(|) (r_parataxis) administration_1\NN|intraperitoneal|of|cck-8-se|and|cholecystokinin (r_nsubj) enhanced_17\VBD|administration|latency|. (l_dobj) latency_19\NN|the|of (l_prep) of_20\IN|seizures (l_pobj) seizures_21\NNS|induced
D012844_D012640 NONE octapeptide_13\RB|cck-8-ns (r_appos) cholecystokinin_12\NN|nonsulphated|octapeptide|) (r_conj) administration_1\NN|intraperitoneal|of|cck-8-se|and|cholecystokinin (r_nsubj) enhanced_17\VBD|administration|latency|. (l_dobj) latency_19\NN|the|of (l_prep) of_20\IN|seizures (l_pobj) seizures_21\NNS|induced
D012844_D012640 NONE CCK-8-NS_15\NNP|( (r_appos) octapeptide_13\RB|cck-8-ns (r_appos) cholecystokinin_12\NN|nonsulphated|octapeptide|) (r_conj) administration_1\NN|intraperitoneal|of|cck-8-se|and|cholecystokinin (r_nsubj) enhanced_17\VBD|administration|latency|. (l_dobj) latency_19\NN|the|of (l_prep) of_20\IN|seizures (l_pobj) seizures_21\NNS|induced
D003975_D012640 NONE diazepam_27\NN| (r_preconj) ,_26\,|diazepam (r_punct) prevented_30\VBD|mumol|,|,|totally|seizures (l_dobj) seizures_34\NNS|induced|and|mortality
16369751
D005472_D066126 NONE 5-Fluorouracil_0\CD| (r_punct) cardiotoxicity_1\NN|5-fluorouracil|induced|.
D005472_D066126 NONE 5-fluorouracil_7\CD| (r_punct) is_1\VBZ|cardiotoxicity|complication|5-fluorouracil (l_nsubj) Cardiotoxicity_0\NNP|
D005472_D066126 NONE 5-FU_12\CD| (r_npadvmod) induced_14\VBN|5-fu|- (r_amod) cardiotoxicity_15\NN|induced|,|observed
D005472_D066126 NONE 5-FU_14\CD| (r_npadvmod) induced_16\VBN|5-fu|- (r_compound) cardiotoxicity_17\NN|induced
D005472_D066126 NONE 5-FU_22\CD| (r_pobj) of_21\IN|5-fu (r_prep) administration_20\NN|the|of (r_nsubjpass) abandoned_24\VBN|considered|,|administration|was|. (l_advcl) considered_8\VBN|as|pain|was|been (l_xcomp) been_11\VBN|to|have|due (l_acomp) due_12\JJ|to (l_prep) to_13\IN|cardiotoxicity (l_pobj) cardiotoxicity_17\NN|induced
D005472_D066126 NONE 5-FU_20\CD| (r_npadvmod) induced_22\VBN|5-fu|- (r_compound) cardiotoxicity_23\NN|induced
D005472_D066126 NONE 5-FU_8\CD| (r_npadvmod) induced_10\VBN|5-fu|- (r_amod) cardiotoxicity_11\NN|induced
C032348_D066126 NONE alanine_10\NN|alpha|fluoro|beta|- (r_pobj) by_3\IN|alanine (r_agent) induced_2\VBN|by (r_acl) cardiotoxicity_1\NN|5-fluorouracil|induced|.
C032348_D066126 NONE alanine_30\NN|fluoro|beta|- (r_pobj) of_23\IN|alanine (r_prep) level_22\NN|a|high|serum|of (r_nsubjpass) observed_35\VBN|in|level|(|)|was (r_relcl) cardiotoxicity_15\NN|induced|,|observed
C032348_D066126 NONE FBAL_32\NNP| (r_preconj) (_31\-LRB-|fbal (r_punct) observed_35\VBN|in|level|(|)|was (r_relcl) cardiotoxicity_15\NN|induced|,|observed
C032348_D066126 NONE FBAL_16\NNP| (r_nsubjpass) related_18\VBN|that|fbal|is|to (l_prep) to_19\IN|cardiotoxicity (l_pobj) cardiotoxicity_23\NN|induced
D005472_D009369 NONE 5-FU_1\CD| (r_nummod) treatment_3\NN|(|5-fu|)|for|. (l_prep) for_4\IN|malignancies (l_pobj) malignancies_5\NNS|
D005472_D002637 CID 5-FU_11\CD|day (r_pobj) of_10\IN|5-fu (r_prep) infusion_9\NN|a|continuous|intravenous|of|,|occurred (l_relcl) occurred_28\VBD|during|pain|concomitantly|with (l_nsubj) pain_22\NN|precordial|with
D005472_D002637 CID 5-FU_14\CD| (r_pobj) of_13\IN|5-fu (r_prep) discontinuation_12\NN|the|of (r_pobj) after_10\IN|discontinuation (r_prep) disappeared_8\VBD|pain|spontaneously|after|. (l_nsubj) pain_3\NN|both|the|precordial|and|changes
D005472_D002637 CID 5-FU_14\CD| (r_npadvmod) induced_16\VBN|5-fu|- (r_compound) cardiotoxicity_17\NN|induced (r_pobj) to_13\IN|cardiotoxicity (r_prep) due_12\JJ|to (r_acomp) been_11\VBN|to|have|due (r_xcomp) considered_8\VBN|as|pain|was|been (l_nsubjpass) pain_3\NN|the|precordial|in
D005472_D002637 CID 5-FU_22\CD| (r_pobj) of_21\IN|5-fu (r_prep) administration_20\NN|the|of (r_nsubjpass) abandoned_24\VBN|considered|,|administration|was|. (l_advcl) considered_8\VBN|as|pain|was|been (l_nsubjpass) pain_3\NN|the|precordial|in
D005472_D002037 CID 5-FU_11\CD|day (r_pobj) of_10\IN|5-fu (r_prep) infusion_9\NN|a|continuous|intravenous|of|,|occurred (l_relcl) occurred_28\VBD|during|pain|concomitantly|with (l_nsubj) pain_22\NN|precordial|with (l_prep) with_23\IN|block (l_pobj) block_27\NN|right|bundle|branch
C032348_D002637 NONE FBAL_34\NNP| (r_compound) concentration_35\NN|serum|fbal|of (r_pobj) with_30\IN|concentration (r_prep) occurred_28\VBD|during|pain|concomitantly|with (l_nsubj) pain_22\NN|precordial|with
C032348_D002037 NONE FBAL_34\NNP| (r_compound) concentration_35\NN|serum|fbal|of (r_pobj) with_30\IN|concentration (r_prep) occurred_28\VBD|during|pain|concomitantly|with (l_nsubj) pain_22\NN|precordial|with (l_prep) with_23\IN|block (l_pobj) block_27\NN|right|bundle|branch
3375885
D007213_D006947 CID indomethacin_3\NN|and|naproxen (r_pobj) by_2\IN|indomethacin (r_prep) induced_1\VBN|hyperkalemia|by|and|reversed|. (l_nsubj) Hyperkalemia_0\NNP|
D007213_D006947 CID indomethacin_26\NN|both|and|naproxen (r_pobj) by_24\IN|indomethacin (r_agent) caused_23\VBN|in|hyperkalemia|were|by|,|without (l_nsubjpass) hyperkalemia_18\NN|and|inappropriate|hypoaldosteronism
D007213_D006947 CID indomethacin_22\NN| (r_compound) therapy_23\NN|indomethacin (r_nsubjpass) continued_26\VBN|therapy|to|be|safely (r_ccomp) allowing_21\VBG|continued (r_conj) correcting_17\VBG|hyperkalemia|and|allowing (l_dobj) hyperkalemia_19\NN|the
D009288_D006947 CID naproxen_5\NN| (r_conj) indomethacin_3\NN|and|naproxen (r_pobj) by_2\IN|indomethacin (r_prep) induced_1\VBN|hyperkalemia|by|and|reversed|. (l_nsubj) Hyperkalemia_0\NNP|
D009288_D006947 CID naproxen_28\NN| (r_conj) indomethacin_26\NN|both|and|naproxen (r_pobj) by_24\IN|indomethacin (r_agent) caused_23\VBN|in|hyperkalemia|were|by|,|without (l_nsubjpass) hyperkalemia_18\NN|and|inappropriate|hypoaldosteronism
D005438_D006947 NONE fludrocortisone_9\NN| (r_pobj) by_8\IN|fludrocortisone (r_agent) reversed_7\VBN|by (r_conj) induced_1\VBN|hyperkalemia|by|and|reversed|. (l_nsubj) Hyperkalemia_0\NNP|
D005438_D006947 NONE fludrocortisone_13\NN| (r_nsubjpass) added_15\VBN|was|,|fludrocortisone|was|,|correcting|. (l_advcl) correcting_17\VBG|hyperkalemia|and|allowing (l_dobj) hyperkalemia_19\NN|the
D008528_D001172 NONE acid_14\NN| (r_compound) nephropathy_15\NN|mefenamic|acid|caused (r_pobj) of_12\IN|nephropathy (r_prep) history_11\NN|a|of (r_conj) arthritis_8\NN|severe|rheumatoid|and|history
D008528_D007674 CID acid_14\NN| (r_compound) nephropathy_15\NN|mefenamic|acid|caused
D008528_D006947 NONE acid_14\NN| (r_compound) nephropathy_15\NN|mefenamic|acid|caused (l_relcl) caused_23\VBN|in|hyperkalemia|were|by|,|without (l_nsubjpass) hyperkalemia_18\NN|and|inappropriate|hypoaldosteronism
D008528_D006994 NONE acid_14\NN| (r_compound) nephropathy_15\NN|mefenamic|acid|caused (l_relcl) caused_23\VBN|in|hyperkalemia|were|by|,|without (l_nsubjpass) hyperkalemia_18\NN|and|inappropriate|hypoaldosteronism (l_conj) hypoaldosteronism_21\NN|
D007213_D001172 NONE indomethacin_26\NN|both|and|naproxen (r_pobj) by_24\IN|indomethacin (r_agent) caused_23\VBN|in|hyperkalemia|were|by|,|without (r_relcl) nephropathy_15\NN|mefenamic|acid|caused (r_pobj) of_12\IN|nephropathy (r_prep) history_11\NN|a|of (r_conj) arthritis_8\NN|severe|rheumatoid|and|history
D007213_D007674 NONE indomethacin_26\NN|both|and|naproxen (r_pobj) by_24\IN|indomethacin (r_agent) caused_23\VBN|in|hyperkalemia|were|by|,|without (r_relcl) nephropathy_15\NN|mefenamic|acid|caused
D007213_D006994 CID indomethacin_26\NN|both|and|naproxen (r_pobj) by_24\IN|indomethacin (r_agent) caused_23\VBN|in|hyperkalemia|were|by|,|without (l_nsubjpass) hyperkalemia_18\NN|and|inappropriate|hypoaldosteronism (l_conj) hypoaldosteronism_21\NN|
D009288_D001172 NONE naproxen_28\NN| (r_conj) indomethacin_26\NN|both|and|naproxen (r_pobj) by_24\IN|indomethacin (r_agent) caused_23\VBN|in|hyperkalemia|were|by|,|without (r_relcl) nephropathy_15\NN|mefenamic|acid|caused (r_pobj) of_12\IN|nephropathy (r_prep) history_11\NN|a|of (r_conj) arthritis_8\NN|severe|rheumatoid|and|history
D009288_D007674 NONE naproxen_28\NN| (r_conj) indomethacin_26\NN|both|and|naproxen (r_pobj) by_24\IN|indomethacin (r_agent) caused_23\VBN|in|hyperkalemia|were|by|,|without (r_relcl) nephropathy_15\NN|mefenamic|acid|caused
D009288_D006994 CID naproxen_28\NN| (r_conj) indomethacin_26\NN|both|and|naproxen (r_pobj) by_24\IN|indomethacin (r_agent) caused_23\VBN|in|hyperkalemia|were|by|,|without (l_nsubjpass) hyperkalemia_18\NN|and|inappropriate|hypoaldosteronism (l_conj) hypoaldosteronism_21\NN|
D011453_D007674 NONE prostaglandin_17\JJ| (r_amod) inhibitors_19\NNS|prostaglandin|synthetase (r_pobj) with_16\IN|inhibitors (r_prep) type_11\VB|to|acidosis|with (r_advcl) predisposed_7\VBD|that|disease|patient|type (l_nsubj) disease_6\NN|preexisting|renal
D011453_D006994 NONE prostaglandin_17\JJ| (r_amod) inhibitors_19\NNS|prostaglandin|synthetase (r_pobj) with_16\IN|inhibitors (r_prep) type_11\VB|to|acidosis|with (l_dobj) acidosis_15\NN|iv|renal|tubular
16920333
C416835_D012640 NONE acetate_4\NN|eslicarbazepine|093 (r_pobj) of_2\IN|acetate (r_prep) effect_1\NN|anticonvulsant|of|on|. (l_prep) on_11\IN|seizures (l_pobj) seizures_12\NNS|induced
C416835_D012640 NONE 093_9\CD|(|bia|2|-|) (r_appos) acetate_4\NN|eslicarbazepine|093 (r_pobj) of_2\IN|acetate (r_prep) effect_1\NN|anticonvulsant|of|on|. (l_prep) on_11\IN|seizures (l_pobj) seizures_12\NNS|induced
C416835_D012640 NONE acetate_10\NN|eslicarbazepine|on (l_prep) on_11\IN|model (l_pobj) model_16\NN|a|animal|elicited (l_relcl) elicited_23\VBN|in|seizures|can|be|repeatedly|on|without (l_nsubjpass) seizures_20\NNS|partial
C416835_D012640 NONE acetate_10\NN|eslicarbazepine|on (l_prep) on_11\IN|model (l_pobj) model_16\NN|a|animal|elicited (l_relcl) elicited_23\VBN|in|seizures|can|be|repeatedly|on|without (l_prep) without_28\IN|changes (l_pobj) changes_29\NNS|in (l_prep) in_30\IN|threshold (l_pobj) threshold_31\NN|or|patterns (l_conj) patterns_34\NNS|seizure (l_compound) seizure_33\NN|
D010852_D012640 CID picrotoxin_17\NN| (r_pobj) of_16\IN|picrotoxin (r_prep) microperfusion_15\NN|of|in (r_pobj) by_14\IN|microperfusion (r_agent) induced_13\VBN|by (r_acl) seizures_12\NNS|induced
D010852_D012640 CID picrotoxin_8\NN| (r_pobj) of_7\IN|picrotoxin (r_prep) doses_6\NNS|threshold|of (r_pobj) with_4\IN|doses (r_prep) treated_3\VBN|with (r_acl) animals_2\NNS|the|treated (r_pobj) In_0\IN|animals (r_prep) was_15\VBD|in|,|number|2.3+/-1.2|,|and|was (l_nsubj) number_12\NN|the|average|of (l_prep) of_13\IN|seizures (l_pobj) seizures_14\NNS|
D010852_D012640 CID picrotoxin_8\NN| (r_pobj) of_7\IN|picrotoxin (r_prep) doses_6\NNS|threshold|of (r_pobj) with_4\IN|doses (r_prep) treated_3\VBN|with (r_acl) animals_2\NNS|the|treated (r_pobj) In_0\IN|animals (r_prep) was_15\VBD|in|,|number|2.3+/-1.2|,|and|was (l_conj) was_22\VBD|duration|39.5+/-8.4s|. (l_nsubj) duration_21\NN|average|seizure (l_compound) seizure_20\NN|
D010852_D012640 CID picrotoxin_11\NN| (r_compound) microperfusion_12\NN|picrotoxin (r_nsubj) prevented_13\VBD|treatment|before|microperfusion|seizures|in|. (l_dobj) seizures_14\NNS|
2614930
D009543_D001919 CID Nifedipine_0\NNP| (r_nsubj) induced_1\VBD|nifedipine|bradycardia|in|. (l_dobj) bradycardia_2\NNP|
D009543_D009422 NONE Nifedipine_0\NNP| (r_nsubj) induced_1\VBD|nifedipine|bradycardia|in|. (l_prep) in_3\IN|patient (l_pobj) patient_5\NN|a|with (l_prep) with_6\IN|neuropathy (l_pobj) neuropathy_8\NN|autonomic
D009543_D001282 NONE nifedipine_21\NN|when|mg|in (r_advcl) slowed_14\VBD|which|down|to|nifedipine (r_relcl) rate_10\NN|a|ventricular|of|slowed (r_pobj) at_7\IN|rate (r_prep) have_4\VB|to|flutter|at (l_dobj) flutter_6\NN|atrial
D009543_D013610 CID nifedipine_10\NN| (r_nsubj) induces_11\VBZ|that|nifedipine|tachycardia|in (l_dobj) tachycardia_12\VBG|
7315949
D009638_D013035 CID norepinephrine_9\NN|l|- (r_pobj) by_6\IN|norepinephrine (r_agent) induced_5\VBN|by (r_acl) changes_1\NNS|medial|in|induced|. (l_prep) in_2\IN|spasm (l_pobj) spasm_4\NN|arterial
D009638_D006547 NONE norepinephrine_17\NN|l|- (r_pobj) by_14\IN|norepinephrine (r_agent) induced_13\VBN|by (r_acl) vasoconstriction_12\NN|induced (r_nsubj) produced_18\VBD|in|,|vasoconstriction|hernias|within|. (l_dobj) hernias_25\NNS|many|cell
19681452
D003042_D002543 NONE cocaine_8\NN|and|alcohol (r_nmod) intoxication_11\NN|cocaine (r_pobj) after_7\IN|intoxication (r_prep) pallidus_6\NN|the|globus|after
D003042_D020520 NONE cocaine_8\NN|and|alcohol (r_nmod) intoxication_11\NN|cocaine (r_pobj) after_7\IN|intoxication (r_prep) pallidus_6\NN|the|globus|after
D003042_D020520 NONE cocaine_8\NN| (r_pobj) of_7\IN|cocaine (r_prep) use_6\NN|the|of (r_pobj) after_4\IN|use (r_prep) infarcts_3\NNS|bilateral|basal|ganglia|after|,|without|,
D000431_D002543 NONE alcohol_10\NN| (r_conj) cocaine_8\NN|and|alcohol (r_nmod) intoxication_11\NN|cocaine (r_pobj) after_7\IN|intoxication (r_prep) pallidus_6\NN|the|globus|after
D000431_D020520 NONE alcohol_10\NN| (r_conj) cocaine_8\NN|and|alcohol (r_nmod) intoxication_11\NN|cocaine (r_pobj) after_7\IN|intoxication (r_prep) pallidus_6\NN|the|globus|after
D003042_D002544 NONE Cocaine_0\NN| (r_nsubj) is_1\VBZ|cocaine|factor|. (l_attr) factor_4\NN|a|risk|for (l_prep) for_5\IN|stroke (l_pobj) stroke_10\NN|ischemic
D003042_D020521 NONE Cocaine_0\NN| (r_nsubj) is_1\VBZ|cocaine|factor|. (l_attr) factor_4\NN|a|risk|for (l_prep) for_5\IN|stroke (l_pobj) stroke_10\NN|ischemic
D000431_D002545 NONE alcohol_19\NN|excessive|and|use (r_pobj) after_17\IN|alcohol (r_prep) case_3\NN|the|of|after (l_prep) of_4\IN|man (l_pobj) man_9\NN|a|old|with (l_prep) with_10\IN|ischemia (l_pobj) ischemia_12\NN|bilateral|of (l_prep) of_13\IN|pallidus (l_pobj) pallidus_16\NN|the|globus
D003042_D002545 CID cocaine_22\NN| (r_compound) use_23\NN|intranasal|cocaine (r_conj) alcohol_19\NN|excessive|and|use (r_pobj) after_17\IN|alcohol (r_prep) case_3\NN|the|of|after (l_prep) of_4\IN|man (l_pobj) man_9\NN|a|old|with (l_prep) with_10\IN|ischemia (l_pobj) ischemia_12\NN|bilateral|of (l_prep) of_13\IN|pallidus (l_pobj) pallidus_16\NN|the|globus
D003932_D020520 CID heroin_11\NN| (r_pobj) with_10\IN|heroin (r_prep) associated_9\VBN|infarctions|are|often|with|. (l_nsubjpass) infarctions_5\NNS|related|pallidus
D003932_D020520 CID heroin_12\NN| (r_compound) use_13\NN|concurrent|heroin (r_pobj) without_10\IN|use (r_prep) infarcts_3\NNS|bilateral|basal|ganglia|after|,|without|,
D003042_D001145 NONE cocaine_12\NN|and/or|use (r_pobj) to_11\IN|cocaine (r_prep) related_10\VBN|to (r_acl) arrhythmia_6\NN|transient|cardiac|or|dysfunction|related
D003042_D012131 NONE cocaine_12\NN|and/or|use (r_pobj) to_11\IN|cocaine (r_prep) related_10\VBN|to (r_acl) arrhythmia_6\NN|transient|cardiac|or|dysfunction|related (l_conj) dysfunction_9\NN|respiratory
D003042_-1 NONE cocaine_12\NN|and/or|use (r_pobj) to_11\IN|cocaine (r_prep) related_10\VBN|to (r_acl) arrhythmia_6\NN|transient|cardiac|or|dysfunction|related (r_nsubj) were_16\VBD|in|,|arrhythmia|causes|. (l_attr) causes_20\NNS|the|likely|of (l_prep) of_21\IN|hypoperfusion (l_pobj) hypoperfusion_23\NN|cerebral
D000431_D001145 NONE ethanol_14\NN| (r_compound) use_15\NN|ethanol (r_conj) cocaine_12\NN|and/or|use (r_pobj) to_11\IN|cocaine (r_prep) related_10\VBN|to (r_acl) arrhythmia_6\NN|transient|cardiac|or|dysfunction|related
D000431_D012131 NONE ethanol_14\NN| (r_compound) use_15\NN|ethanol (r_conj) cocaine_12\NN|and/or|use (r_pobj) to_11\IN|cocaine (r_prep) related_10\VBN|to (r_acl) arrhythmia_6\NN|transient|cardiac|or|dysfunction|related (l_conj) dysfunction_9\NN|respiratory
D000431_-1 NONE ethanol_14\NN| (r_compound) use_15\NN|ethanol (r_conj) cocaine_12\NN|and/or|use (r_pobj) to_11\IN|cocaine (r_prep) related_10\VBN|to (r_acl) arrhythmia_6\NN|transient|cardiac|or|dysfunction|related (r_nsubj) were_16\VBD|in|,|arrhythmia|causes|. (l_attr) causes_20\NNS|the|likely|of (l_prep) of_21\IN|hypoperfusion (l_pobj) hypoperfusion_23\NN|cerebral
20009434
D008727_D058186 CID methotrexate_7\NN| (r_compound) therapy_8\NN|dose|methotrexate|in (r_pobj) after_3\IN|therapy (r_prep) failure_2\NN|acute|renal|after|.
D008727_D058186 CID MTX_11\NNP|hd|- (r_compound) therapy_12\NN|mtx|in (r_pobj) after_8\IN|therapy (r_prep) report_1\VBP|we|case|after (l_dobj) case_3\NN|a|of (l_prep) of_4\IN|failure (l_pobj) failure_7\NN|acute|renal
D008727_D058186 CID MTX_3\NNP|hd|- (r_compound) therapy_4\NN|subsequent|mtx (r_nsubj) caused_5\VBD|therapy|failure|. (l_dobj) failure_8\NN|acute|renal|required
D008727_D002051 NONE methotrexate_3\NN|dose|mtx|) (r_nsubj) is_9\VBZ|methotrexate|treatment|,|but|cause|. (l_attr) treatment_12\NN|an|important|for (l_prep) for_13\IN|lymphoma (l_pobj) lymphoma_15\NN|burkitt
D008727_D002051 NONE MTX_7\NNP|(|hd|- (r_appos) methotrexate_3\NN|dose|mtx|) (r_nsubj) is_9\VBZ|methotrexate|treatment|,|but|cause|. (l_attr) treatment_12\NN|an|important|for (l_prep) for_13\IN|lymphoma (l_pobj) lymphoma_15\NN|burkitt
D008727_D056486 NONE methotrexate_3\NN|dose|mtx|) (r_nsubj) is_9\VBZ|methotrexate|treatment|,|but|cause|. (l_conj) cause_19\VB|can|toxicity|delayed (l_dobj) toxicity_23\NN|hepatic
D008727_D056486 NONE MTX_7\NNP|(|hd|- (r_appos) methotrexate_3\NN|dose|mtx|) (r_nsubj) is_9\VBZ|methotrexate|treatment|,|but|cause|. (l_conj) cause_19\VB|can|toxicity|delayed (l_dobj) toxicity_23\NN|hepatic
D008727_D007674 NONE methotrexate_3\NN|dose|mtx|) (r_nsubj) is_9\VBZ|methotrexate|treatment|,|but|cause|. (l_conj) cause_19\VB|can|toxicity|delayed (l_dobj) toxicity_23\NN|hepatic
D008727_D007674 NONE MTX_7\NNP|(|hd|- (r_appos) methotrexate_3\NN|dose|mtx|) (r_nsubj) is_9\VBZ|methotrexate|treatment|,|but|cause|. (l_conj) cause_19\VB|can|toxicity|delayed (l_dobj) toxicity_23\NN|hepatic
D008727_D001656 NONE MTX_11\NNP|hd|- (r_compound) therapy_12\NN|mtx|in (r_pobj) after_8\IN|therapy (r_prep) report_1\VBP|we|case|after (r_ccomp) was_21\VBD|report|,|patient|boy|. (l_attr) boy_26\NN|a|old|received (l_relcl) received_29\VBN|who|had|transplantation (l_dobj) transplantation_35\NN|a|related|liver|for (l_prep) for_36\IN|atresia (l_pobj) atresia_39\NN|congenital|biliary
24897009
D004977_D010523 NONE ethambutol_6\NN| (r_amod) overtreatment_7\NN|ethambutol (r_pobj) due_4\IN|to|overtreatment (r_prep) Optochiasmatic_0\JJ|and|neuropathy|due|. (l_conj) neuropathy_3\NN|peripheral
D004977_D009901 CID Ethambutol_0\NNP| (r_nsubjpass) known_2\VBN|ethambutol|is|cause|and|polyneuropathy (l_xcomp) cause_4\VB|to|neuropathy (l_dobj) neuropathy_6\NN|optic
D004977_D011115 CID Ethambutol_0\NNP| (r_nsubjpass) known_2\VBN|ethambutol|is|cause|and|polyneuropathy (l_conj) polyneuropathy_13\NN|,|axonal|.
D004977_D014786 CID ethambutol_32\NN| (r_pobj) of_31\IN|ethambutol (r_prep) dose_30\NN|a|supratherapeutic|of (r_pobj) to_27\IN|dose (r_prep) exposure_26\NN|to (r_pobj) of_25\IN|exposure (r_prep) weeks_24\NNS|11|of (r_pobj) after_22\IN|weeks (r_prep) developed_17\VBD|who|loss|after (l_dobj) loss_19\NN|visual|and|paresthesias
D004977_D010292 CID ethambutol_32\NN| (r_pobj) of_31\IN|ethambutol (r_prep) dose_30\NN|a|supratherapeutic|of (r_pobj) to_27\IN|dose (r_prep) exposure_26\NN|to (r_pobj) of_25\IN|exposure (r_prep) weeks_24\NNS|11|of (r_pobj) after_22\IN|weeks (r_prep) developed_17\VBD|who|loss|after (l_dobj) loss_19\NN|visual|and|paresthesias (l_conj) paresthesias_21\NNS|
D004977_D064420 NONE ethambutol_15\VB|to|toxicity (l_dobj) toxicity_16\NN|
24091473
D004837_D066126 NONE epinephrine_4\NN|,|or|both (l_conj) both_7\DT|in (l_prep) in_8\IN|toxicity (l_pobj) toxicity_13\NN|induced|cardiac|in
C476513_D066126 NONE levobupivacaine_9\NN| (r_npadvmod) induced_11\VBN|levobupivacaine|- (r_amod) toxicity_13\NN|induced|cardiac|in
D004837_D064420 NONE epinephrine_8\NN|,|or|both (r_conj) emulsion_6\NN|lipid|,|epinephrine (r_pobj) of_4\IN|emulsion (r_prep) regimens_3\NNS|the|optimal|dosing|of (r_nsubjpass) determined_15\VBN|regimens|are|not|yet|in|. (l_prep) in_16\IN|neonates (l_pobj) neonates_17\NNS|in (l_prep) in_18\IN|cases (l_pobj) cases_19\NNS|of (l_prep) of_20\IN|toxicity (l_pobj) toxicity_24\NN|local|anaesthetic|systemic|(|last|)
C476513_D002318 CID levobupivacaine_3\PRP| (r_dobj) received_2\VBD|piglets|levobupivacaine|occurred|. (l_advcl) occurred_7\VBD|until|collapse (l_nsubj) collapse_6\NN|cardiovascular
24881749
D013747_D009459 CID tetrabenazine_8\NN|and|tiapride|in (r_pobj) with_7\IN|tetrabenazine (r_prep) induced_3\VBN|syndrome|by|with|. (l_nsubj) syndrome_2\NN|neuroleptic|malignant
D013747_D009459 CID tetrabenazine_35\NN|(|day|) (r_conj) initiation_22\NN|the|of|with|(|day|)|and|tetrabenazine|for (r_pobj) after_20\IN|days|initiation (r_prep) occurred_17\VBD|that|after (r_relcl) woman_11\NN|an|old|japanese|with|occurred (l_prep) with_12\IN|syndrome (l_pobj) syndrome_15\NN|neuroleptic|malignant
D013747_D009459 CID tetrabenazine_18\NN|and|tiapride (r_pobj) with_17\IN|tetrabenazine (r_prep) therapy_16\NN|combination|with (r_pobj) due_13\IN|to|therapy (r_prep) occurrence_8\NN|the|of|due (l_prep) of_9\IN|syndrome (l_pobj) syndrome_12\NN|neuroleptic|malignant
D013747_D006816 NONE tetrabenazine_8\NN|and|tiapride|in (l_prep) in_11\IN|patient (l_pobj) patient_14\NN|a|japanese|with (l_prep) with_15\IN|disease (l_pobj) disease_18\NN|huntington|at
D013747_D006816 NONE tetrabenazine_35\NN|(|day|) (r_conj) initiation_22\NN|the|of|with|(|day|)|and|tetrabenazine|for (l_prep) for_42\IN|disease (l_pobj) disease_45\NN|huntington
D013747_D001943 NONE tetrabenazine_8\NN|and|tiapride|in (l_prep) in_11\IN|patient (l_pobj) patient_14\NN|a|japanese|with (l_prep) with_15\IN|disease (l_pobj) disease_18\NN|huntington|at (l_prep) at_19\IN|stage (l_pobj) stage_22\NN|the|terminal|of (l_prep) of_23\IN|cancer (l_pobj) cancer_26\NN|recurrent|breast
D063325_D009459 CID tiapride_10\NN| (r_conj) tetrabenazine_8\NN|and|tiapride|in (r_pobj) with_7\IN|tetrabenazine (r_prep) induced_3\VBN|syndrome|by|with|. (l_nsubj) syndrome_2\NN|neuroleptic|malignant
D063325_D009459 CID tiapride_27\NN| (r_pobj) with_26\IN|tiapride (r_prep) initiation_22\NN|the|of|with|(|day|)|and|tetrabenazine|for (r_pobj) after_20\IN|days|initiation (r_prep) occurred_17\VBD|that|after (r_relcl) woman_11\NN|an|old|japanese|with|occurred (l_prep) with_12\IN|syndrome (l_pobj) syndrome_15\NN|neuroleptic|malignant
D063325_D009459 CID tiapride_20\NN| (r_conj) tetrabenazine_18\NN|and|tiapride (r_pobj) with_17\IN|tetrabenazine (r_prep) therapy_16\NN|combination|with (r_pobj) due_13\IN|to|therapy (r_prep) occurrence_8\NN|the|of|due (l_prep) of_9\IN|syndrome (l_pobj) syndrome_12\NN|neuroleptic|malignant
D063325_D006816 NONE tiapride_10\NN| (r_conj) tetrabenazine_8\NN|and|tiapride|in (l_prep) in_11\IN|patient (l_pobj) patient_14\NN|a|japanese|with (l_prep) with_15\IN|disease (l_pobj) disease_18\NN|huntington|at
D063325_D006816 NONE tiapride_27\NN| (r_pobj) with_26\IN|tiapride (r_prep) initiation_22\NN|the|of|with|(|day|)|and|tetrabenazine|for (l_prep) for_42\IN|disease (l_pobj) disease_45\NN|huntington
D063325_D001943 NONE tiapride_10\NN| (r_conj) tetrabenazine_8\NN|and|tiapride|in (l_prep) in_11\IN|patient (l_pobj) patient_14\NN|a|japanese|with (l_prep) with_15\IN|disease (l_pobj) disease_18\NN|huntington|at (l_prep) at_19\IN|stage (l_pobj) stage_22\NN|the|terminal|of (l_prep) of_23\IN|cancer (l_pobj) cancer_26\NN|recurrent|breast
3533179
D003520_D066126 NONE Cyclophosphamide_0\NNP| (r_compound) cardiotoxicity_1\NN|cyclophosphamide|:|analysis|.
D003520_D066126 NONE CYA_5\NNP| (r_pobj) of_4\IN|cya (r_prep) doses_3\NNS|these|high|of (r_pobj) At_0\IN|doses (r_prep) occur_10\VB|at|,|cardiotoxicity|may|,|but|described (l_nsubj) cardiotoxicity_8\NN|serious
D003520_D066126 NONE CYA_5\NNP| (r_pobj) of_4\IN|cya (r_prep) doses_3\NNS|these|high|of (r_pobj) At_0\IN|doses (r_prep) occur_10\VB|at|,|cardiotoxicity|may|,|but|described (l_conj) described_25\VBN|factors|have|not|been|. (l_nsubjpass) factors_15\NNS|definitive|risk|for (l_prep) for_16\IN|development (l_pobj) development_18\NN|the|of (l_prep) of_19\IN|cardiotoxicity (l_pobj) cardiotoxicity_21\NN|such
D003520_D066126 NONE CYA_19\NNP| (r_pobj) of_18\IN|cya (r_prep) dose_17\NN|the|of|in (r_dobj) calculated_15\VBD|correlates|,|we|retrospectively|dose|determine|. (l_advcl) determine_27\VB|to|correlated (l_ccomp) correlated_34\VBN|whether|incidence|with (l_nsubj) incidence_30\NN|the|of (l_prep) of_31\IN|cardiotoxicity (l_pobj) cardiotoxicity_33\NN|cya
D003520_D066126 NONE CYA_32\NNP| (r_compound) cardiotoxicity_33\NN|cya
D003520_D066126 NONE CYA_14\NNP| (r_compound) cardiotoxicity_15\NN|cya
D003520_D066126 NONE CYA_26\NNP| (r_pobj) of_25\IN|cya (r_prep) doses_24\NNS|4|of (r_dobj) receiving_20\VBG|doses (r_pcomp) of_19\IN|receiving (r_prep) days_18\NNS|ten|of (r_pobj) within_16\IN|days (r_prep) had_8\VBD|patients|symptoms|within|. (l_dobj) symptoms_9\NNS|and|signs|consistent (l_amod) consistent_12\JJ|with (l_prep) with_13\IN|cardiotoxicity (l_pobj) cardiotoxicity_15\NN|cya
D003520_D066126 NONE CYA_8\NNP| (r_pobj) to_7\IN|cya (r_prep) related_6\VBN|to|be|to (r_xcomp) thought_3\VBN|that|was|related (r_relcl) Cardiotoxicity_0\NN|thought
D003520_D066126 NONE CYA_4\NNP| (r_compound) cardiotoxicity_5\NN|the|cya
D003520_D066126 NONE CYA_4\NNP| (r_compound) cardiotoxicity_5\NN|the|cya (r_nsubj) correlates_6\VBZ|that|cardiotoxicity|with|calculated|,|and|prepared (l_conj) prepared_28\VBN|that|patients|can|be|effectively|for (l_prep) for_29\IN|grafting (l_pobj) grafting_32\VBG|marrow|at|with (l_prep) with_45\IN|incidence (l_pobj) incidence_48\NN|a|lower|of (l_prep) of_49\IN|cardiotoxicity (l_pobj) cardiotoxicity_50\NN|than
D003520_D066126 NONE CYA_8\NNP| (r_compound) dosage_9\NN|cya (r_pobj) with_7\IN|dosage (r_prep) correlates_6\VBZ|that|cardiotoxicity|with|calculated|,|and|prepared (l_nsubj) cardiotoxicity_5\NN|the|cya
D003520_D066126 NONE CYA_8\NNP| (r_compound) dosage_9\NN|cya (r_pobj) with_7\IN|dosage (r_prep) correlates_6\VBZ|that|cardiotoxicity|with|calculated|,|and|prepared (l_conj) prepared_28\VBN|that|patients|can|be|effectively|for (l_prep) for_29\IN|grafting (l_pobj) grafting_32\VBG|marrow|at|with (l_prep) with_45\IN|incidence (l_pobj) incidence_48\NN|a|lower|of (l_prep) of_49\IN|cardiotoxicity (l_pobj) cardiotoxicity_50\NN|than
D003520_D066126 NONE CYA_35\NNP| (r_compound) dose_36\NN|a|cya|of (r_pobj) at_33\IN|dose (r_prep) grafting_32\VBG|marrow|at|with (r_pobj) for_29\IN|grafting (r_prep) prepared_28\VBN|that|patients|can|be|effectively|for (r_conj) correlates_6\VBZ|that|cardiotoxicity|with|calculated|,|and|prepared (l_nsubj) cardiotoxicity_5\NN|the|cya
D003520_D066126 NONE CYA_35\NNP| (r_compound) dose_36\NN|a|cya|of (r_pobj) at_33\IN|dose (r_prep) grafting_32\VBG|marrow|at|with (l_prep) with_45\IN|incidence (l_pobj) incidence_48\NN|a|lower|of (l_prep) of_49\IN|cardiotoxicity (l_pobj) cardiotoxicity_50\NN|than
D003520_D066126 NONE CYA_54\NNP| (r_compound) dosage_55\NN|whose|cya (r_nsubjpass) calculated_57\VBN|dosage|is|based (r_relcl) patients_52\NNS|calculated (r_pobj) than_51\IN|patients (r_prep) cardiotoxicity_50\NN|than (r_pobj) of_49\IN|cardiotoxicity (r_prep) incidence_48\NN|a|lower|of (r_pobj) with_45\IN|incidence (r_prep) grafting_32\VBG|marrow|at|with (r_pobj) for_29\IN|grafting (r_prep) prepared_28\VBN|that|patients|can|be|effectively|for (r_conj) correlates_6\VBZ|that|cardiotoxicity|with|calculated|,|and|prepared (l_nsubj) cardiotoxicity_5\NN|the|cya
D003520_D066126 NONE CYA_54\NNP| (r_compound) dosage_55\NN|whose|cya (r_nsubjpass) calculated_57\VBN|dosage|is|based (r_relcl) patients_52\NNS|calculated (r_pobj) than_51\IN|patients (r_prep) cardiotoxicity_50\NN|than
D003520_D064420 NONE CYA_19\NNP| (r_pobj) of_18\IN|cya (r_prep) dose_17\NN|the|of|in (r_dobj) calculated_15\VBD|correlates|,|we|retrospectively|dose|determine|. (l_advcl) correlates_5\VBZ|since|toxicity|generally|with (l_nsubj) toxicity_3\NN|agent
D003520_D064420 NONE CYA_32\NNP| (r_compound) cardiotoxicity_33\NN|cya (r_pobj) of_31\IN|cardiotoxicity (r_prep) incidence_30\NN|the|of (r_nsubj) correlated_34\VBN|whether|incidence|with (r_ccomp) determine_27\VB|to|correlated (r_advcl) calculated_15\VBD|correlates|,|we|retrospectively|dose|determine|. (l_advcl) correlates_5\VBZ|since|toxicity|generally|with (l_nsubj) toxicity_3\NN|agent
D003520_D000741 NONE CYA_6\NNP|kg (r_dobj) receive_5\VB|to|cya (r_xcomp) were_3\VBD|who|receive (r_relcl) patients_1\NNS|eighty|were (r_nsubj) underwent_21\VBD|patients|d|for|total|,|syndrome|. (l_dobj) total_23\NN|a|of (l_prep) of_24\IN|transplants (l_pobj) transplants_26\NNS|84|for (l_prep) for_27\IN|anemia (l_pobj) anemia_29\NN|aplastic
D003520_D000741 NONE CYA_4\NNP| (r_compound) cardiotoxicity_5\NN|the|cya (r_nsubj) correlates_6\VBZ|that|cardiotoxicity|with|calculated|,|and|prepared (l_conj) prepared_28\VBN|that|patients|can|be|effectively|for (l_nsubjpass) patients_19\NNS|with (l_prep) with_20\IN|anemia (l_pobj) anemia_22\NN|aplastic|and|immunodeficiencies
D003520_D000741 NONE CYA_8\NNP| (r_compound) dosage_9\NN|cya (r_pobj) with_7\IN|dosage (r_prep) correlates_6\VBZ|that|cardiotoxicity|with|calculated|,|and|prepared (l_conj) prepared_28\VBN|that|patients|can|be|effectively|for (l_nsubjpass) patients_19\NNS|with (l_prep) with_20\IN|anemia (l_pobj) anemia_22\NN|aplastic|and|immunodeficiencies
D003520_D000741 NONE CYA_35\NNP| (r_compound) dose_36\NN|a|cya|of (r_pobj) at_33\IN|dose (r_prep) grafting_32\VBG|marrow|at|with (r_pobj) for_29\IN|grafting (r_prep) prepared_28\VBN|that|patients|can|be|effectively|for (l_nsubjpass) patients_19\NNS|with (l_prep) with_20\IN|anemia (l_pobj) anemia_22\NN|aplastic|and|immunodeficiencies
D003520_D000741 NONE CYA_54\NNP| (r_compound) dosage_55\NN|whose|cya (r_nsubjpass) calculated_57\VBN|dosage|is|based (r_relcl) patients_52\NNS|calculated (r_pobj) than_51\IN|patients (r_prep) cardiotoxicity_50\NN|than (r_pobj) of_49\IN|cardiotoxicity (r_prep) incidence_48\NN|a|lower|of (r_pobj) with_45\IN|incidence (r_prep) grafting_32\VBG|marrow|at|with (r_pobj) for_29\IN|grafting (r_prep) prepared_28\VBN|that|patients|can|be|effectively|for (l_nsubjpass) patients_19\NNS|with (l_prep) with_20\IN|anemia (l_pobj) anemia_22\NN|aplastic|and|immunodeficiencies
D003520_D014923 NONE CYA_6\NNP|kg (r_dobj) receive_5\VB|to|cya (r_xcomp) were_3\VBD|who|receive (r_relcl) patients_1\NNS|eighty|were (r_nsubj) underwent_21\VBD|patients|d|for|total|,|syndrome|. (l_conj) syndrome_34\NN|aldrich|,|or|syndrome
D003520_D016511 NONE CYA_6\NNP|kg (r_dobj) receive_5\VB|to|cya (r_xcomp) were_3\VBD|who|receive (r_relcl) patients_1\NNS|eighty|were (r_nsubj) underwent_21\VBD|patients|d|for|total|,|syndrome|. (l_conj) syndrome_34\NN|aldrich|,|or|syndrome (l_conj) syndrome_40\NN|severe|combined|immunodeficiency
D003520_D007153 NONE CYA_4\NNP| (r_compound) cardiotoxicity_5\NN|the|cya (r_nsubj) correlates_6\VBZ|that|cardiotoxicity|with|calculated|,|and|prepared (l_conj) prepared_28\VBN|that|patients|can|be|effectively|for (l_nsubjpass) patients_19\NNS|with (l_prep) with_20\IN|anemia (l_pobj) anemia_22\NN|aplastic|and|immunodeficiencies (l_conj) immunodeficiencies_24\NNS|
D003520_D007153 NONE CYA_8\NNP| (r_compound) dosage_9\NN|cya (r_pobj) with_7\IN|dosage (r_prep) correlates_6\VBZ|that|cardiotoxicity|with|calculated|,|and|prepared (l_conj) prepared_28\VBN|that|patients|can|be|effectively|for (l_nsubjpass) patients_19\NNS|with (l_prep) with_20\IN|anemia (l_pobj) anemia_22\NN|aplastic|and|immunodeficiencies (l_conj) immunodeficiencies_24\NNS|
D003520_D007153 NONE CYA_35\NNP| (r_compound) dose_36\NN|a|cya|of (r_pobj) at_33\IN|dose (r_prep) grafting_32\VBG|marrow|at|with (r_pobj) for_29\IN|grafting (r_prep) prepared_28\VBN|that|patients|can|be|effectively|for (l_nsubjpass) patients_19\NNS|with (l_prep) with_20\IN|anemia (l_pobj) anemia_22\NN|aplastic|and|immunodeficiencies (l_conj) immunodeficiencies_24\NNS|
D003520_D007153 NONE CYA_54\NNP| (r_compound) dosage_55\NN|whose|cya (r_nsubjpass) calculated_57\VBN|dosage|is|based (r_relcl) patients_52\NNS|calculated (r_pobj) than_51\IN|patients (r_prep) cardiotoxicity_50\NN|than (r_pobj) of_49\IN|cardiotoxicity (r_prep) incidence_48\NN|a|lower|of (r_pobj) with_45\IN|incidence (r_prep) grafting_32\VBG|marrow|at|with (r_pobj) for_29\IN|grafting (r_prep) prepared_28\VBN|that|patients|can|be|effectively|for (l_nsubjpass) patients_19\NNS|with (l_prep) with_20\IN|anemia (l_pobj) anemia_22\NN|aplastic|and|immunodeficiencies (l_conj) immunodeficiencies_24\NNS|
3895875
D008012_D009203 NONE lidocaine_1\NN|prophylactic|in|. (l_prep) in_2\IN|phase (l_pobj) phase_5\NN|the|early|of (l_prep) of_6\IN|infarction (l_pobj) infarction_9\NN|suspected|myocardial
D008012_D009203 NONE lidocaine_25\NN|vs (r_pobj) of_24\IN|lidocaine (r_prep) trial_23\NN|a|blind|randomized|of (r_dobj) entered_17\VBD|patients|trial|. (l_nsubj) patients_3\NNS|two|with (l_prep) with_4\IN|infarction (l_pobj) infarction_7\NN|suspected|myocardial|seen
D008012_D009203 NONE lidocaine_3\NN|plasma (r_compound) level_4\NN|the|average|lidocaine|after (l_prep) after_7\IN|minutes|administration (l_pobj) administration_8\NN|for (l_prep) for_9\IN|patients (l_pobj) patients_10\NNS|without (l_prep) without_11\IN|infarction (l_pobj) infarction_14\NN|a|myocardial
D008012_D009203 NONE lidocaine_7\NN| (r_pobj) of_6\IN|lidocaine (r_prep) administration_5\NN|the|of (r_dobj) advocate_3\VB|we|can|not|administration|prophylactically|in|. (l_prep) in_9\IN|hours (l_pobj) hours_12\NNS|the|early|of (l_prep) of_13\IN|infarction (l_pobj) infarction_16\NN|suspected|myocardial
D008012_D017180 NONE Lidocaine_0\NN| (r_nsubj) prevent_17\VB|lidocaine|,|given|,|did|not|tachycardia|,|was|)|. (l_dobj) tachycardia_20\NN|sustained|ventricular
D008012_D017180 NONE lidocaine_45\NN| (r_pobj) of_44\IN|lidocaine (r_prep) administration_43\NN|the|of|0.05 (r_pobj) after_41\IN|minutes|administration (r_prep) was_24\VBD|although|there|reduction|after (r_advcl) prevent_17\VB|lidocaine|,|given|,|did|not|tachycardia|,|was|)|. (l_dobj) tachycardia_20\NN|sustained|ventricular
D008012_D001145 NONE Lidocaine_0\NN| (r_nsubj) prevent_17\VB|lidocaine|,|given|,|did|not|tachycardia|,|was|)|. (l_advcl) was_24\VBD|although|there|reduction|after (l_attr) reduction_27\NN|a|significant|in (l_prep) in_28\IN|number (l_pobj) number_30\NN|the|of (l_prep) of_31\IN|patients (l_pobj) patients_32\NNS|with (l_prep) with_33\IN|warning (l_pcomp) warning_34\VBG|arrhythmias (l_dobj) arrhythmias_35\NNS|
D008012_D001145 NONE lidocaine_45\NN| (r_pobj) of_44\IN|lidocaine (r_prep) administration_43\NN|the|of|0.05 (r_pobj) after_41\IN|minutes|administration (r_prep) was_24\VBD|although|there|reduction|after (l_attr) reduction_27\NN|a|significant|in (l_prep) in_28\IN|number (l_pobj) number_30\NN|the|of (l_prep) of_31\IN|patients (l_pobj) patients_32\NNS|with (l_prep) with_33\IN|warning (l_pcomp) warning_34\VBG|arrhythmias (l_dobj) arrhythmias_35\NNS|
D008012_D007238 NONE lidocaine_3\NN|plasma (r_compound) level_4\NN|the|average|lidocaine|after (r_nsubj) was_15\VBD|level|higher|for|. (l_prep) for_20\IN|patients (l_pobj) patients_21\NNS|with (l_prep) with_22\IN|infarction (l_pobj) infarction_25\NN|an|acute
D008012_D007022 CID lidocaine_19\NN| (r_compound) group_20\NN|the|lidocaine (r_pobj) in_17\IN|group (r_prep) greater_16\JJR|significantly|in (r_acomp) was_14\VBD|during|,|incidence|greater (r_ccomp) occurred_23\VBD|was|,|hypotension|in|,|and|died (l_nsubj) hypotension_22\NN|
D008012_D007022 CID lidocaine_33\NN| (r_dobj) received_32\VBN|nine|had|lidocaine (r_relcl) patients_26\NNS|11|,|received (r_pobj) in_24\IN|patients (r_prep) occurred_23\VBD|was|,|hypotension|in|,|and|died (l_nsubj) hypotension_22\NN|
D008012_D007022 CID lidocaine_47\NN| (r_dobj) had_46\VBN|three|had|lidocaine (r_conj) died_38\VBD|patients|from|,|had|. (r_conj) occurred_23\VBD|was|,|hypotension|in|,|and|died (l_nsubj) hypotension_22\NN|
D008012_D006323 NONE lidocaine_19\NN| (r_compound) group_20\NN|the|lidocaine (r_pobj) in_17\IN|group (r_prep) greater_16\JJR|significantly|in (r_acomp) was_14\VBD|during|,|incidence|greater (r_ccomp) occurred_23\VBD|was|,|hypotension|in|,|and|died (l_conj) died_38\VBD|patients|from|,|had|. (l_prep) from_39\IN|asystole (l_pobj) asystole_40\NN|
D008012_D006323 NONE lidocaine_33\NN| (r_dobj) received_32\VBN|nine|had|lidocaine (r_relcl) patients_26\NNS|11|,|received (r_pobj) in_24\IN|patients (r_prep) occurred_23\VBD|was|,|hypotension|in|,|and|died (l_conj) died_38\VBD|patients|from|,|had|. (l_prep) from_39\IN|asystole (l_pobj) asystole_40\NN|
D008012_D006323 NONE lidocaine_47\NN| (r_dobj) had_46\VBN|three|had|lidocaine (r_conj) died_38\VBD|patients|from|,|had|. (l_prep) from_39\IN|asystole (l_pobj) asystole_40\NN|
24100257
C089750_D054549 CID Zolmitriptan_10\NNP| (r_pobj) to_9\IN|zolmitriptan (r_prep) secondary_8\JJ|to (r_amod) syndrome_6\NN|ballooning|)|secondary|. (r_conj) syndrome_1\NN|takotsubo|(|or|syndrome
C089750_D054549 CID Zolmitriptan_10\NNP| (r_pobj) to_9\IN|zolmitriptan (r_prep) secondary_8\JJ|to (r_amod) syndrome_6\NN|ballooning|)|secondary|.
C089750_D054549 CID zolmitriptan_12\NN|to (r_advcl) vasospasm_9\NN|artery|secondary|zolmitriptan (r_pobj) of_6\IN|vasospasm (r_prep) cases_5\NNS|multiple|of (r_dobj) revealed_3\VBD|search|cases|,|but|associated (l_conj) associated_20\VBN|none|were|with|. (l_prep) with_21\IN|ts (l_pobj) TS_22\NNP|
C089750_D008881 NONE zolmitriptan_9\NN| (r_dobj) took_8\VBD|that|patient|zolmitriptan|sparingly|had (l_advcl) had_14\VBD|only|when|she|migraines (l_dobj) migraines_15\NNS|
C089750_D008881 NONE zolmitriptan_8\JJ| (r_dobj) taking_7\VBG|but|before|,|she|was|zolmitriptan|2|daily|for|because|. (l_prep) because_17\IN|of|headache (l_pobj) headache_22\NN|a|persistent|migraine
C089750_D003329 CID zolmitriptan_12\NN|to (r_advcl) vasospasm_9\NN|artery|secondary|zolmitriptan
24158386
C056507_D006689 NONE GEM_0\NN| (r_compound) P_2\NN|gem|- (r_compound) chemotherapy_3\NN|p (r_nsubj) is_4\VBZ|chemotherapy|active|. (l_acomp) active_5\JJ|in (l_prep) in_6\IN|treatment (l_pobj) treatment_8\NN|the|of (l_prep) of_9\IN|lymphoma (l_pobj) lymphoma_12\NN|relapsed|hodgkin
C056507_D006689 NONE Gemcitabine_0\NNP|and|cisplatin (r_nsubj) have_3\VBP|gemcitabine|activity|,|and|delivered|. (l_dobj) activity_4\NN|in (l_prep) in_5\IN|toxicity (l_pobj) toxicity_11\NN|overlapping|with (l_amod) overlapping_10\VBG|hl|- (l_npadvmod) HL_6\NNP|
C056507_D006689 NONE gemcitabine_16\NN| (r_amod) day_22\NN|gemcitabine|)|(|d)1|; (r_pobj) with_15\IN|day (r_prep) treated_14\VBN|in|,|patients|with|methylprednisolone|;|and|included (l_nsubj) patients_8\NNS|with (l_prep) with_9\IN|hl (l_pobj) HL_13\NN|relapsed
C056507_D006689 NONE GEM_50\NNP| (r_compound) P_52\NNP|gem|- (r_appos) days_48\NNS|every|28|(|p|) (r_appos) D15_44\NNP|m(2|)|,|days (r_dobj) cisplatin_38\NN|d15 (r_nsubjpass) included_55\VBN|cisplatin|were|. (r_conj) treated_14\VBN|in|,|patients|with|methylprednisolone|;|and|included (l_nsubj) patients_8\NNS|with (l_prep) with_9\IN|hl (l_pobj) HL_13\NN|relapsed
C056507_D006689 NONE GEM_0\NN| (r_compound) P_2\NNP|gem|- (r_nsubj) is_3\VBZ|p|chemotherapy|,|leading|,|in|. (l_prep) in_21\IN|treatment (l_pobj) treatment_23\NN|the|of (l_prep) of_24\IN|hl (l_pobj) HL_28\NN|relapsed
C056507_D064420 NONE Gemcitabine_0\NNP|and|cisplatin (r_nsubj) have_3\VBP|gemcitabine|activity|,|and|delivered|. (l_dobj) activity_4\NN|in (l_prep) in_5\IN|toxicity (l_pobj) toxicity_11\NN|overlapping|with
D002945_D006689 NONE cisplatin_2\NN| (r_conj) Gemcitabine_0\NNP|and|cisplatin (r_nsubj) have_3\VBP|gemcitabine|activity|,|and|delivered|. (l_dobj) activity_4\NN|in (l_prep) in_5\IN|toxicity (l_pobj) toxicity_11\NN|overlapping|with (l_amod) overlapping_10\VBG|hl|- (l_npadvmod) HL_6\NNP|
D002945_D006689 NONE cisplatin_38\NN|d15 (r_nsubjpass) included_55\VBN|cisplatin|were|. (r_conj) treated_14\VBN|in|,|patients|with|methylprednisolone|;|and|included (l_nsubj) patients_8\NNS|with (l_prep) with_9\IN|hl (l_pobj) HL_13\NN|relapsed
D002945_D064420 NONE cisplatin_2\NN| (r_conj) Gemcitabine_0\NNP|and|cisplatin (r_nsubj) have_3\VBP|gemcitabine|activity|,|and|delivered|. (l_dobj) activity_4\NN|in (l_prep) in_5\IN|toxicity (l_pobj) toxicity_11\NN|overlapping|with
D008775_D006689 NONE methylprednisolone_30\NN|5 (r_advcl) treated_14\VBN|in|,|patients|with|methylprednisolone|;|and|included (l_nsubj) patients_8\NNS|with (l_prep) with_9\IN|hl (l_pobj) HL_13\NN|relapsed
10510854
D006220_D002375 CID haloperidol_9\NN| (r_pobj) by_8\IN|haloperidol (r_agent) induced_7\VBN|by (r_acl) reversal_4\NN|a|high|of|induced|indicating (l_prep) of_5\IN|catalepsy (l_pobj) catalepsy_6\NN|
24100055
D006493_D013921 CID heparin_2\NN| (r_npadvmod) induced_4\VBN|heparin|- (r_amod) II_7\NNP|induced|thrombocytopenia|type
D006493_D013921 CID heparin_6\NN| (r_npadvmod) induced_8\VBN|heparin|- (r_amod) II_11\NNP|mediated|induced|thrombocytopenia|type|(|ii|)
D006493_D013921 CID heparin_6\NN| (r_npadvmod) induced_8\VBN|heparin|- (r_amod) II_11\NNP|mediated|induced|thrombocytopenia|type|(|ii|) (l_appos) II_15\NNP|hit|type
D006493_D013921 CID heparin_6\NN| (r_npadvmod) induced_8\VBN|heparin|- (r_amod) II_11\NNP|mediated|induced|thrombocytopenia|type|(|ii|) (r_pobj) of_2\IN|ii (r_prep) impact_1\NN|the|of|as (l_prep) as_17\IN|cause (l_pobj) cause_19\NN|a|of (l_prep) of_20\IN|thrombocytopenia (l_pobj) thrombocytopenia_21\NN|after
D006493_D013921 CID heparin_12\NN|intravenous (r_pobj) of_10\IN|heparin (r_prep) use_9\NN|the|of (r_nsubjpass) avoided_15\VBN|for|,|use|should|be|and|performed (l_prep) For_0\IN|reduction (l_pobj) reduction_2\NN|further|of (l_prep) of_3\IN|ii (l_pobj) II_6\NNP|hit|type
D006493_D013921 CID heparin_29\NN|weight (r_pobj) with_23\IN|heparin (r_prep) performed_22\VBN|anticoagulation|should|be|with|after|. (r_conj) avoided_15\VBN|for|,|use|should|be|and|performed (l_prep) For_0\IN|reduction (l_pobj) reduction_2\NN|further|of (l_prep) of_3\IN|ii (l_pobj) II_6\NNP|hit|type
3339945
D013806_D020258 NONE Theophylline_0\NNP| (r_amod) neurotoxicity_1\NN|theophylline|in|.
D013806_D020258 NONE theophylline_12\NN| (r_pobj) of_11\IN|theophylline (r_prep) neurotoxicity_10\NN|the|of
D013806_D020258 NONE theophylline_15\NN| (r_pobj) to_14\IN|theophylline (r_prep) response_13\NN|the|neurotoxic|to|in (l_amod) neurotoxic_12\JJ|
D000628_D012640 CID aminophylline_21\NN| (r_pobj) of_20\IN|aminophylline (r_prep) infusions_19\NNS|of (r_dobj) received_18\VBD|rats|infusions|until|. (l_prep) until_22\IN|onset (l_pobj) onset_23\NN|of (l_prep) of_24\IN|seizures (l_pobj) seizures_26\NNS|maximal|occurred
3987172
D011433_D006973 NONE Propranolol_0\NNP| (r_compound) antagonism_1\NN|propranolol|of|. (l_prep) of_2\IN|hypertension (l_pobj) hypertension_6\NN|induced
D011433_D006973 NONE propranolol_7\NN|in (l_prep) in_8\IN|treatment (l_pobj) treatment_10\NN|the|of (l_prep) of_11\IN|hypertension (l_pobj) hypertension_15\NN|induced
D010665_D006973 CID phenylpropanolamine_3\NN| (r_npadvmod) induced_5\VBN|phenylpropanolamine|- (r_amod) hypertension_6\NN|induced
D010665_D006973 CID Phenylpropanolamine_0\NNP| (r_nmod) overdose_4\NN|phenylpropanolamine|(|ppa|) (r_nsubj) cause_6\VB|overdose|can|hypertension|. (l_dobj) hypertension_8\NN|severe|,|hemorrhage
D010665_D006973 CID PPA_2\NNP| (r_nmod) overdose_4\NN|phenylpropanolamine|(|ppa|) (r_nsubj) cause_6\VB|overdose|can|hypertension|. (l_dobj) hypertension_8\NN|severe|,|hemorrhage
D010665_D006973 CID PPA_12\NN| (r_npadvmod) induced_14\VBN|ppa|- (r_amod) hypertension_15\NN|induced
D010665_D062787 NONE Phenylpropanolamine_0\NNP| (r_nmod) overdose_4\NN|phenylpropanolamine|(|ppa|)
D010665_D062787 NONE PPA_2\NNP| (r_nmod) overdose_4\NN|phenylpropanolamine|(|ppa|)
D010665_D002543 NONE Phenylpropanolamine_0\NNP| (r_nmod) overdose_4\NN|phenylpropanolamine|(|ppa|) (r_nsubj) cause_6\VB|overdose|can|hypertension|. (l_dobj) hypertension_8\NN|severe|,|hemorrhage (l_conj) hemorrhage_11\NN|intracerebral|,|and|death
D010665_D002543 NONE PPA_2\NNP| (r_nmod) overdose_4\NN|phenylpropanolamine|(|ppa|) (r_nsubj) cause_6\VB|overdose|can|hypertension|. (l_dobj) hypertension_8\NN|severe|,|hemorrhage (l_conj) hemorrhage_11\NN|intracerebral|,|and|death
D010665_D020521 NONE PPA_10\NNP| (r_nsubj) increased_11\VBD|that|ppa|volume|%|from|ml|) (l_dobj) volume_14\NN|the|stroke (l_compound) stroke_13\NN|
24659727
D008130_D008223 NONE lomustine_2\NN|in|in (l_prep) in_7\IN|dogs (l_pobj) dogs_8\NNS|with (l_prep) with_9\IN|lymphoma (l_pobj) lymphoma_10\NN|
D008130_D008223 NONE lomustine_10\NN|(|ccnu|)|and|cyclophosphamide (r_pobj) of_9\IN|lomustine (r_prep) protocol_8\NN|a|of|in (l_prep) in_19\IN|dogs (l_pobj) dogs_20\NNS|with (l_prep) with_21\IN|lymphoma (l_pobj) lymphoma_22\NN|
D008130_D008223 NONE CCNU_12\NNP| (r_appos) lomustine_10\NN|(|ccnu|)|and|cyclophosphamide (r_pobj) of_9\IN|lomustine (r_prep) protocol_8\NN|a|of|in (l_prep) in_19\IN|dogs (l_pobj) dogs_20\NNS|with (l_prep) with_21\IN|lymphoma (l_pobj) lymphoma_22\NN|
D003520_D008223 NONE cyclophosphamide_6\NN| (r_pobj) with_5\IN|cyclophosphamide (r_prep) combination_4\NN|with (r_pobj) in_3\IN|combination (r_prep) lomustine_2\NN|in|in (l_prep) in_7\IN|dogs (l_pobj) dogs_8\NNS|with (l_prep) with_9\IN|lymphoma (l_pobj) lymphoma_10\NN|
D003520_D008223 NONE cyclophosphamide_15\NN|(|ctx|) (r_conj) lomustine_10\NN|(|ccnu|)|and|cyclophosphamide (r_pobj) of_9\IN|lomustine (r_prep) protocol_8\NN|a|of|in (l_prep) in_19\IN|dogs (l_pobj) dogs_20\NNS|with (l_prep) with_21\IN|lymphoma (l_pobj) lymphoma_22\NN|
D003520_D008223 NONE CTX_17\NNP| (r_appos) cyclophosphamide_15\NN|(|ctx|) (r_conj) lomustine_10\NN|(|ccnu|)|and|cyclophosphamide (r_pobj) of_9\IN|lomustine (r_prep) protocol_8\NN|a|of|in (l_prep) in_19\IN|dogs (l_pobj) dogs_20\NNS|with (l_prep) with_21\IN|lymphoma (l_pobj) lymphoma_22\NN|
D008130_D064420 NONE lomustine_10\NN|(|ccnu|)|and|cyclophosphamide (r_pobj) of_9\IN|lomustine (r_prep) protocol_8\NN|a|of|in (r_pobj) with_6\IN|protocol (r_prep) associated_5\VBN|with (r_acl) toxicity_4\NN|associated
D008130_D064420 NONE CCNU_12\NNP| (r_appos) lomustine_10\NN|(|ccnu|)|and|cyclophosphamide (r_pobj) of_9\IN|lomustine (r_prep) protocol_8\NN|a|of|in (r_pobj) with_6\IN|protocol (r_prep) associated_5\VBN|with (r_acl) toxicity_4\NN|associated
D003520_D064420 NONE cyclophosphamide_15\NN|(|ctx|) (r_conj) lomustine_10\NN|(|ccnu|)|and|cyclophosphamide (r_pobj) of_9\IN|lomustine (r_prep) protocol_8\NN|a|of|in (r_pobj) with_6\IN|protocol (r_prep) associated_5\VBN|with (r_acl) toxicity_4\NN|associated
D003520_D064420 NONE CTX_17\NNP| (r_appos) cyclophosphamide_15\NN|(|ctx|) (r_conj) lomustine_10\NN|(|ccnu|)|and|cyclophosphamide (r_pobj) of_9\IN|lomustine (r_prep) protocol_8\NN|a|of|in (r_pobj) with_6\IN|protocol (r_prep) associated_5\VBN|with (r_acl) toxicity_4\NN|associated
D008130_D009503 CID CCNU_20\NNP| (r_nmod) CTX_22\NNP|ccnu|/ (r_pobj) of_19\IN|ctx (r_prep) treatment_18\NN|the|first|of (r_pobj) after_15\IN|treatment (r_prep) neutropenia_14\NN|frequency|after (r_conj) was_1\VBD|neutropenia|effect|,|and|neutropenia|was|. (l_nsubj) Neutropenia_0\NNP|
D008130_D009503 CID CCNU_20\NNP| (r_nmod) CTX_22\NNP|ccnu|/ (r_pobj) of_19\IN|ctx (r_prep) treatment_18\NN|the|first|of (r_pobj) after_15\IN|treatment (r_prep) neutropenia_14\NN|frequency|after
D003520_D009503 CID CTX_22\NNP|ccnu|/ (r_pobj) of_19\IN|ctx (r_prep) treatment_18\NN|the|first|of (r_pobj) after_15\IN|treatment (r_prep) neutropenia_14\NN|frequency|after (r_conj) was_1\VBD|neutropenia|effect|,|and|neutropenia|was|. (l_nsubj) Neutropenia_0\NNP|
D003520_D009503 CID CTX_22\NNP|ccnu|/ (r_pobj) of_19\IN|ctx (r_prep) treatment_18\NN|the|first|of (r_pobj) after_15\IN|treatment (r_prep) neutropenia_14\NN|frequency|after
15229250
D008694_D001930 CID methamphetamine_20\NN|chronic|abuse (r_pobj) with_18\IN|methamphetamine (r_prep) associated_17\VBN|with (r_acl) brain_16\NN|the|human|associated
D008694_D001930 CID MA_22\NNP| (r_nmod) abuse_24\NN|(|ma|) (r_appos) methamphetamine_20\NN|chronic|abuse (r_pobj) with_18\IN|methamphetamine (r_prep) associated_17\VBN|with (r_acl) brain_16\NN|the|human|associated
D008694_D001930 CID MA_34\NNP|and|controls (r_dobj) used_33\VBD|who|ma (r_relcl) subjects_31\NNS|22|human|used (r_pobj) in_28\IN|subjects (r_prep) ventricles_27\NNS|in
D008694_D001930 CID MA_10\NNP| (r_compound) abuse_11\NN|ma (r_pobj) of_9\IN|abuse (r_prep) symptoms_8\NNS|the|of (r_pobj) for_6\IN|symptoms (r_prep) account_5\VB|for (r_xcomp) help_4\VB|substrates|may|account|,|providing|. (l_advcl) providing_13\VBG|targets (l_dobj) targets_15\NNS|therapeutic|for (l_prep) for_16\IN|injury (l_pobj) injury_21\NN|induced|brain
D008694_D008659 NONE MA_7\NNP| (r_dobj) used_6\VBN|who|have|ma (r_relcl) subjects_3\NNS|human|used (r_pobj) of_1\IN|subjects (r_prep) Studies_0\NNS|of (r_nsubj) revealed_10\VBN|studies|chronically|have|deficits|. (l_dobj) deficits_11\NNS|in (l_prep) in_12\IN|systems (l_pobj) systems_16\NNS|dopaminergic|and|abnormalities (l_conj) abnormalities_20\NNS|cerebral|metabolic
D008694_D003072 NONE MA_26\NNP| (r_compound) abuse_27\NN|chronic|ma|in (r_pobj) with_24\IN|abuse (r_prep) associated_23\VBN|with (r_acl) alterations_22\NNS|structural|brain|associated (r_pobj) of_19\IN|alterations (r_prep) pattern_18\NN|the|of (r_dobj) determined_16\VBD|using|,|we|pattern|and|related|. (l_conj) related_32\VBD|deficits|to (l_prep) to_35\IN|impairment (l_pobj) impairment_37\NN|cognitive
D008694_D006984 NONE MA_3\NNP| (r_compound) abusers_4\NNS|ma (r_nsubj) had_5\VBD|on|,|abusers|volumes|0.05|. (l_dobj) 0.05_29\CD|;|0.01|;|right|,|p|<|)|and|hypertrophy (l_conj) hypertrophy_36\NN|significant|matter|(|%|;|0.01|)
D008694_D008569 CID methamphetamine_7\NN| (r_compound) abuse_8\NN|chronic|methamphetamine (r_nsubj) causes_9\VBZ|that|abuse|pattern (l_dobj) pattern_12\NN|a|selective|of (l_prep) of_13\IN|deterioration (l_pobj) deterioration_15\NN|cerebral|contributes (l_relcl) contributes_17\VBZ|that|to (l_prep) to_18\IN|performance (l_pobj) performance_21\NN|impaired|memory
3685052
D005481_D012640 NONE Flurothyl_0\JJ| (r_compound) thresholds_2\NNS|flurothyl|seizure|in (l_compound) seizure_1\NN|
D005481_D012640 NONE Flurothyl_0\JJ| (r_compound) thresholds_2\NNS|flurothyl|seizure|in (r_nsubj) treated_5\VBD|thresholds|neonatally|with|:|evaluation|. (l_dobj) evaluation_18\NN|of (l_prep) of_19\IN|parameters (l_pobj) parameters_21\NNS|experimental|in (l_prep) in_22\IN|testing (l_pobj) testing_25\NN|flurothyl|seizure (l_compound) seizure_24\NN|
D005481_D012640 NONE flurothyl_23\JJ| (r_compound) testing_25\NN|flurothyl|seizure (r_pobj) in_22\IN|testing (r_prep) parameters_21\NNS|experimental|in (r_pobj) of_19\IN|parameters (r_prep) evaluation_18\NN|of (r_dobj) treated_5\VBD|thresholds|neonatally|with|:|evaluation|. (l_nsubj) thresholds_2\NNS|flurothyl|seizure|in (l_compound) seizure_1\NN|
D005481_D012640 NONE flurothyl_23\JJ| (r_compound) testing_25\NN|flurothyl|seizure (l_compound) seizure_24\NN|
D005481_D012640 NONE flurothyl_1\JJ| (r_nmod) technique_5\NN|a|flurothyl|ether|screening (l_compound) screening_4\NN|seizure (l_compound) seizure_3\NN|
D005481_D012640 NONE flurothyl_1\JJ| (r_nmod) technique_5\NN|a|flurothyl|ether|screening (r_nsubjpass) used_7\VBN|technique|was|evaluate|)|. (l_xcomp) evaluate_9\VB|to|susceptibility (l_dobj) susceptibility_11\NN|seizure|in|received (l_compound) seizure_10\NN|
D005481_D012640 NONE Flurothyl_0\NNP| (r_compound) ether_1\NN|flurothyl (r_nsubj) produced_2\VBD|ether|hypothermia (r_ccomp) was_23\VBD|produced|;|however|,|relationship|unclear|. (l_nsubj) relationship_17\NN|the|of|to (l_prep) to_20\IN|induction (l_pobj) induction_22\NN|seizure (l_compound) seizure_21\NN|
D005481_D012640 NONE flurothyl_11\JJ| (r_compound) exposure_12\NN|flurothyl (r_pobj) of_10\IN|exposure (r_prep) duration_9\NN|the|of (r_pobj) with_7\IN|duration (r_prep) correlated_6\VBN|which|was|with (r_relcl) hypothermia_3\NN|correlated (r_dobj) produced_2\VBD|ether|hypothermia (r_ccomp) was_23\VBD|produced|;|however|,|relationship|unclear|. (l_nsubj) relationship_17\NN|the|of|to (l_prep) to_20\IN|induction (l_pobj) induction_22\NN|seizure (l_compound) seizure_21\NN|
D005481_D012640 NONE Flurothyl_0\JJ| (r_compound) testing_2\NN|flurothyl|seizure (l_compound) seizure_1\NN|
D005481_D012640 NONE Flurothyl_0\JJ| (r_compound) testing_2\NN|flurothyl|seizure (r_nsubj) proved_3\VBD|testing|be|. (l_xcomp) be_5\VB|to|technique (l_attr) technique_10\NN|a|rapid|evaluate (l_relcl) evaluate_14\VB|with|to|susceptibility (l_dobj) susceptibility_16\NN|seizure (l_compound) seizure_15\NN|
D012970_D012640 NONE glutamate_13\NN|monosodium|msg (r_pobj) of_11\IN|glutamate (r_prep) injection_10\NN|a|single|of (r_pobj) with_7\IN|injection (r_prep) treated_5\VBD|thresholds|neonatally|with|:|evaluation|. (l_nsubj) thresholds_2\NNS|flurothyl|seizure|in (l_compound) seizure_1\NN|
D012970_D012640 NONE glutamate_13\NN|monosodium|msg (r_pobj) of_11\IN|glutamate (r_prep) injection_10\NN|a|single|of (r_pobj) with_7\IN|injection (r_prep) treated_5\VBD|thresholds|neonatally|with|:|evaluation|. (l_dobj) evaluation_18\NN|of (l_prep) of_19\IN|parameters (l_pobj) parameters_21\NNS|experimental|in (l_prep) in_22\IN|testing (l_pobj) testing_25\NN|flurothyl|seizure (l_compound) seizure_24\NN|
D012970_D012640 NONE MSG_15\NNP|(|) (r_appos) glutamate_13\NN|monosodium|msg (r_pobj) of_11\IN|glutamate (r_prep) injection_10\NN|a|single|of (r_pobj) with_7\IN|injection (r_prep) treated_5\VBD|thresholds|neonatally|with|:|evaluation|. (l_nsubj) thresholds_2\NNS|flurothyl|seizure|in (l_compound) seizure_1\NN|
D012970_D012640 NONE MSG_15\NNP|(|) (r_appos) glutamate_13\NN|monosodium|msg (r_pobj) of_11\IN|glutamate (r_prep) injection_10\NN|a|single|of (r_pobj) with_7\IN|injection (r_prep) treated_5\VBD|thresholds|neonatally|with|:|evaluation|. (l_dobj) evaluation_18\NN|of (l_prep) of_19\IN|parameters (l_pobj) parameters_21\NNS|experimental|in (l_prep) in_22\IN|testing (l_pobj) testing_25\NN|flurothyl|seizure (l_compound) seizure_24\NN|
D012970_D012640 NONE glutamate_1\NN|monosodium (r_nmod) administration_5\NN|glutamate|(|msg|)|to (r_nsubj) produces_9\VBZ|administration|convulsions|in|. (l_dobj) convulsions_10\NNS|and|results
D012970_D012640 NONE MSG_3\NNP| (r_nmod) administration_5\NN|glutamate|(|msg|)|to (r_nsubj) produces_9\VBZ|administration|convulsions|in|. (l_dobj) convulsions_10\NNS|and|results
D012970_D012640 NONE MSG_10\NNP| (r_pobj) of_9\IN|msg (r_prep) administration_8\NN|neonatal|of (r_nsubj) produced_11\VBD|if|administration|alterations (l_dobj) alterations_13\NNS|permanent|in (l_prep) in_14\IN|susceptibility (l_pobj) susceptibility_16\NN|seizure (l_compound) seizure_15\NN|
D012970_D012640 NONE MSG_20\NNP| (r_pobj) of_19\IN|msg (r_prep) injections_18\NNS|neonatal|of|g (r_dobj) received_16\VBD|that|injections (r_relcl) susceptibility_11\NN|seizure|in|received (r_dobj) evaluate_9\VB|to|susceptibility (r_xcomp) used_7\VBN|technique|was|evaluate|)|. (l_nsubjpass) technique_5\NN|a|flurothyl|ether|screening (l_compound) screening_4\NN|seizure (l_compound) seizure_3\NN|
D012970_D012640 NONE MSG_20\NNP| (r_pobj) of_19\IN|msg (r_prep) injections_18\NNS|neonatal|of|g (r_dobj) received_16\VBD|that|injections (r_relcl) susceptibility_11\NN|seizure|in|received (l_compound) seizure_10\NN|
D012970_D012640 NONE MSG_0\NNP| (r_compound) treatment_1\NN|msg (r_nsubj) resulted_2\VBD|treatment|in|but|alter|. (l_conj) alter_13\VB|did|not|threshold (l_dobj) threshold_15\NN|seizure (l_compound) seizure_14\NN|
D012970_D012640 NONE MSG_19\NNP| (r_npadvmod) treated_21\VBN|msg|- (r_amod) mice_22\NNS|treated (r_pobj) of_18\IN|mice (r_prep) control_17\NN|either|of (r_pobj) of_15\IN|control (r_prep) thresholds_14\NNS|the|seizure|of (l_compound) seizure_13\NN|
D004986_D012640 NONE ether_2\NN| (r_compound) technique_5\NN|a|flurothyl|ether|screening (l_compound) screening_4\NN|seizure (l_compound) seizure_3\NN|
D004986_D012640 NONE ether_2\NN| (r_compound) technique_5\NN|a|flurothyl|ether|screening (r_nsubjpass) used_7\VBN|technique|was|evaluate|)|. (l_xcomp) evaluate_9\VB|to|susceptibility (l_dobj) susceptibility_11\NN|seizure|in|received (l_compound) seizure_10\NN|
D004986_D012640 NONE ether_1\NN|flurothyl (r_nsubj) produced_2\VBD|ether|hypothermia (r_ccomp) was_23\VBD|produced|;|however|,|relationship|unclear|. (l_nsubj) relationship_17\NN|the|of|to (l_prep) to_20\IN|induction (l_pobj) induction_22\NN|seizure (l_compound) seizure_21\NN|
D009270_D012640 NONE naloxone_1\NN|a (r_nmod) challenge_6\NN|naloxone|(|mg/kg|) (r_nsubj) was_7\VBD|challenge|also|ineffective|in|. (l_prep) in_10\IN|altering (l_pcomp) altering_11\VBG|thresholds (l_dobj) thresholds_14\NNS|the|seizure|of (l_compound) seizure_13\NN|
D005481_D007035 CID Flurothyl_0\NNP| (r_compound) ether_1\NN|flurothyl (r_nsubj) produced_2\VBD|ether|hypothermia (l_dobj) hypothermia_3\NN|correlated
D005481_D007035 CID Flurothyl_0\NNP| (r_compound) ether_1\NN|flurothyl (r_nsubj) produced_2\VBD|ether|hypothermia (r_ccomp) was_23\VBD|produced|;|however|,|relationship|unclear|. (l_nsubj) relationship_17\NN|the|of|to (l_prep) of_18\IN|hypothermia (l_pobj) hypothermia_19\NN|
D005481_D007035 CID flurothyl_11\JJ| (r_compound) exposure_12\NN|flurothyl (r_pobj) of_10\IN|exposure (r_prep) duration_9\NN|the|of (r_pobj) with_7\IN|duration (r_prep) correlated_6\VBN|which|was|with (r_relcl) hypothermia_3\NN|correlated
D005481_D007035 CID flurothyl_11\JJ| (r_compound) exposure_12\NN|flurothyl (r_pobj) of_10\IN|exposure (r_prep) duration_9\NN|the|of (r_pobj) with_7\IN|duration (r_prep) correlated_6\VBN|which|was|with (r_relcl) hypothermia_3\NN|correlated (r_dobj) produced_2\VBD|ether|hypothermia (r_ccomp) was_23\VBD|produced|;|however|,|relationship|unclear|. (l_nsubj) relationship_17\NN|the|of|to (l_prep) of_18\IN|hypothermia (l_pobj) hypothermia_19\NN|
D004986_D007035 NONE ether_1\NN|flurothyl (r_nsubj) produced_2\VBD|ether|hypothermia (l_dobj) hypothermia_3\NN|correlated
D004986_D007035 NONE ether_1\NN|flurothyl (r_nsubj) produced_2\VBD|ether|hypothermia (r_ccomp) was_23\VBD|produced|;|however|,|relationship|unclear|. (l_nsubj) relationship_17\NN|the|of|to (l_prep) of_18\IN|hypothermia (l_pobj) hypothermia_19\NN|
16801510
D008691_D008133 CID methadone_11\NN|:|frequency (r_dobj) receiving_10\VBG|methadone (r_acl) users_9\NNS|drug|receiving (r_pobj) in_6\IN|users (r_prep) syndrome_5\NN|induced|long|qt|in|.
D008691_D008133 CID methadone_12\NN| (r_compound) treatment_13\NN|methadone (r_pobj) with_11\IN|treatment (r_prep) prolongation_10\NN|qt|interval|with
D008691_D008133 CID methadone_3\NN| (r_compound) dose_4\NN|methadone (r_pobj) to_2\IN|dose (r_prep) addition_1\NN|to (r_pobj) In_0\IN|addition (r_prep) considered_15\VBN|in|,|variables|were|as|. (l_prep) as_16\IN|factors (l_pobj) factors_19\NNS|potential|risk|for (l_prep) for_20\IN|prolongation (l_pobj) prolongation_22\NN|qt
D008691_D008133 CID methadone_4\NN| (r_compound) patients_6\NNS|methadone|maintenance|hospitalized (r_pobj) in_3\IN|patients (r_prep) prolongation_2\NN|qt|interval|in
D008691_D008133 CID methadone_9\NN| (r_pobj) of_8\IN|methadone (r_prep) doses_7\NNS|low|of (r_pobj) with_5\IN|doses (r_prep) occur_4\VB|syndrome|can|with|. (l_nsubj) syndrome_2\NN|long|qt
D008691_D016171 NONE methadone_8\NN| (r_compound) group_9\NN|the|methadone (r_pobj) in_6\IN|group (r_prep) patients_1\NNS|six|(|%|)|in (r_nsubj) presented_10\VBD|patients|pointes|. (l_dobj) pointes_13\FW|torsades|de
D008691_D007008 NONE methadone_12\NN| (r_compound) dose_13\NN|methadone (r_pobj) to_11\IN|dose (r_prep) attribution_4\NN|of|to (r_dobj) allowed_3\VBD|analysis|attribution|cytochrome|. (l_conj) cytochrome_15\NN|,|interactions (l_dobj) interactions_21\NNS|3a4|drug|,|hypokalemia (l_appos) hypokalemia_23\NN|,|and|function
D011188_D008133 NONE potassium_3\NN| (r_compound) level_4\NN|potassium|,|and|function (r_conj) inhibitors_1\NNS|3a4|,|level (r_nsubj) contribute_9\VBP|inhibitors|to|. (l_prep) to_10\IN|prolongation (l_pobj) prolongation_12\NN|qt
2400986
D002066_D020258 NONE busulfan_8\NNS|dose|in (r_pobj) of_4\IN|busulfan (r_prep) neurotoxicity_3\NN|dependent|of|:|study|.
D002066_D020258 NONE Busulfan_0\NNPS| (r_nsubjpass) known_2\VBN|busulfan|is|be|,|but|remains (l_xcomp) be_4\VB|to|neurotoxic (l_acomp) neurotoxic_5\JJ|in
D002066_D020258 NONE Busulfan_0\NNPS| (r_nsubjpass) known_2\VBN|busulfan|is|be|,|but|remains (l_conj) remains_15\VBZ|neurotoxicity|characterized|. (l_nsubj) neurotoxicity_14\NN|its|acute
D002066_D020258 NONE busulfan_3\NNS| (r_compound) dose_4\NN|the|total|busulfan (r_nsubjpass) taken_6\VBN|when|dose|was|into (r_advcl) was_11\VBD|taken|,|there|difference|. (l_attr) difference_14\NN|a|significant|in|and|patients (l_prep) in_15\IN|terms (l_pobj) terms_16\NNS|of (l_prep) of_17\IN|incidence (l_pobj) incidence_19\JJ|neurotoxicity|among (l_compound) neurotoxicity_18\NN|
D002066_D020258 NONE busulfan_4\NNS| (r_amod) neurotoxicity_5\NN|busulfan
D002066_D020258 NONE busulfan_1\NNS| (r_compound) dose_2\NN|a|busulfan|calculated|,|resulting|, (r_nsubjpass) followed_21\VBN|dose|was|by|,|close|observed|. (l_agent) by_22\IN|neurotoxicity (l_pobj) neurotoxicity_24\NN|increased
D002066_D020258 NONE busulfan_1\NNS| (r_compound) dose_2\NN|a|busulfan|calculated|,|resulting|, (r_nsubjpass) followed_21\VBN|dose|was|by|,|close|observed|. (l_advmod) close_26\JJ|to (l_prep) to_27\IN|incidence (l_pobj) incidence_29\NN|neurotoxicity (l_compound) neurotoxicity_28\NN|
D002066_D009369 NONE busulfan_20\NNS|dose|in (r_dobj) receiving_16\VBG|busulfan|before (l_prep) before_24\IN|transplantation (l_pobj) transplantation_27\NN|bone|marrow|for (l_prep) for_28\IN|tumors (l_pobj) tumors_31\NNS|malignant|solid
D002066_D001932 NONE busulfan_20\NNS|dose|in (r_dobj) receiving_16\VBG|busulfan|before (r_acl) study_5\NN|a|retrospective|of|receiving (r_dobj) report_1\VBP|we|here|study|,|excluded (l_conj) excluded_35\VBD|tumors|. (l_nsubj) tumors_34\NNS|brain
D002066_D012640 CID busulfan_23\NNS| (r_amod) course_24\NN|the|busulfan (r_pobj) of_21\IN|course (r_prep) days_20\NNS|the|4|of|or|within (r_pobj) during_17\IN|days (r_prep) developed_15\VBN|given|;|%|seizures|during|. (l_dobj) seizures_16\NNS|
D002066_D009461 NONE busulfan_10\NNS|m2 (r_nmod) dose_12\NN|a|busulfan|total|with (r_dobj) given_5\VBN|patients|were|dose (r_ccomp) had_21\VBD|given|;|none|symptoms|. (l_dobj) symptoms_24\NNS|any|neurological
D002998_D009461 NONE clonazepam_18\NN| (r_pobj) of_17\IN|clonazepam (r_prep) infusion_16\NN|continuous|i.v.|of (r_pobj) with_13\IN|infusion (r_prep) dose_12\NN|a|busulfan|total|with (r_dobj) given_5\VBN|patients|were|dose (r_ccomp) had_21\VBD|given|;|none|symptoms|. (l_dobj) symptoms_24\NNS|any|neurological
D002066_D002493 NONE Busulfan_0\NNS| (r_compound) levels_1\NNS|busulfan (r_nsubjpass) measured_3\VBN|levels|were|by|was (l_agent) by_4\IN|assay (l_pobj) assay_11\NN|a|gas|mass|spectrometry|in|without|under (l_prep) without_21\IN|disease (l_pobj) disease_25\NN|central|nervous|system
D002066_D002493 NONE busulfan_31\NNS|m2|with (r_pobj) under_26\IN|busulfan (r_prep) assay_11\NN|a|gas|mass|spectrometry|in|without|under (l_prep) without_21\IN|disease (l_pobj) disease_25\NN|central|nervous|system
D002066_D002493 NONE busulfan_35\NNS| (r_amod) ratio_40\NN|busulfan|cerebrospinal|fluid|:|plasma (r_nsubj) was_41\VBD|ratio|1.39|. (r_conj) measured_3\VBN|levels|were|by|was (l_agent) by_4\IN|assay (l_pobj) assay_11\NN|a|gas|mass|spectrometry|in|without|under (l_prep) without_21\IN|disease (l_pobj) disease_25\NN|central|nervous|system
D002998_D002493 NONE clonazepam_33\NN|: (r_pobj) with_32\IN|clonazepam (r_prep) busulfan_31\NNS|m2|with (r_pobj) under_26\IN|busulfan (r_prep) assay_11\NN|a|gas|mass|spectrometry|in|without|under (l_prep) without_21\IN|disease (l_pobj) disease_25\NN|central|nervous|system
D002998_D020258 NONE clonazepam_16\NN| (r_pobj) by_15\IN|clonazepam (r_agent) prevented_14\VBN|efficiently|by (r_conj) is_6\VBZ|that|neurotoxicity|dependent|and|prevented (l_nsubj) neurotoxicity_5\NN|busulfan
16867246
D002746_D001480 CID chlorpromazine_5\NN| (r_npadvmod) induced_7\VBN|chlorpromazine|- (r_conj) polymorphisms_3\NNS|drd2|and|induced (r_nmod) syndrome_9\NN|polymorphisms|extrapyramidal|in
D002746_D001480 CID chlorpromazine_11\NN| (r_npadvmod) induced_13\VBN|chlorpromazine|- (r_amod) EPS_14\NNP|induced|in
D002746_D001480 CID chlorpromazine_38\NN| (r_pobj) with_37\IN|chlorpromazine (r_prep) treated_36\VBN|taqib|,|rs6275|with|after|. (l_nsubj) rs6275_6\ADD|ser311cys|,|,|rs6277|)|in (l_prep) in_12\IN|gene (l_pobj) gene_15\NN|the|drd2|in (l_prep) in_16\IN|inpatients (l_pobj) inpatients_19\NNS|146|schizophrenic|(|59|according (l_appos) 59_21\CD|with|and|87 (l_prep) with_22\IN|eps (l_pobj) EPS_23\NNP|
D002746_D001480 CID chlorpromazine_38\NN| (r_pobj) with_37\IN|chlorpromazine (r_prep) treated_36\VBN|taqib|,|rs6275|with|after|. (l_nsubj) rs6275_6\ADD|ser311cys|,|,|rs6277|)|in (l_prep) in_12\IN|gene (l_pobj) gene_15\NN|the|drd2|in (l_prep) in_16\IN|inpatients (l_pobj) inpatients_19\NNS|146|schizophrenic|(|59|according (l_appos) 59_21\CD|with|and|87 (l_conj) 87_25\CD|without (l_prep) without_26\IN|eps (l_pobj) EPS_27\NNP|
D002746_D012559 NONE chlorpromazine_5\NN| (r_npadvmod) induced_7\VBN|chlorpromazine|- (r_conj) polymorphisms_3\NNS|drd2|and|induced (r_nmod) syndrome_9\NN|polymorphisms|extrapyramidal|in (l_prep) in_10\IN|patients (l_pobj) patients_13\NNS|chinese|schizophrenic (l_amod) schizophrenic_12\JJ|
D002746_D012559 NONE chlorpromazine_11\NN| (r_npadvmod) induced_13\VBN|chlorpromazine|- (r_amod) EPS_14\NNP|induced|in (l_prep) in_15\IN|patients (l_pobj) patients_17\NNS|schizophrenic (l_amod) schizophrenic_16\JJ|
D002746_D012559 NONE chlorpromazine_38\NN| (r_pobj) with_37\IN|chlorpromazine (r_prep) treated_36\VBN|taqib|,|rs6275|with|after|. (l_nsubj) rs6275_6\ADD|ser311cys|,|,|rs6277|)|in (l_prep) in_12\IN|gene (l_pobj) gene_15\NN|the|drd2|in (l_prep) in_16\IN|inpatients (l_pobj) inpatients_19\NNS|146|schizophrenic|(|59|according (l_amod) schizophrenic_18\JJ|
D002746_D012559 NONE chlorpromazine_30\NN| (r_pobj) by_29\IN|chlorpromazine (r_agent) induced_28\VBN|by (r_acl) effect_27\NN|the|variable|adverse|induced (r_pobj) in_22\IN|effect (r_prep) plays_18\VBZ|that|variation|role|in|,|in (l_prep) in_34\IN|least|patients (l_pobj) patients_36\NNS|chinese|with (l_prep) with_37\IN|schizophrenia (l_pobj) schizophrenia_38\NN|
8755612
D004967_D009369 NONE estrogen_10\NN| (r_npadvmod) induced_12\VBN|estrogen|- (r_amod) tumor_13\NN|an|induced (r_pobj) in_8\IN|tumor (r_prep) separation_1\NN|genetic|of|in|. (l_prep) of_2\IN|growth (l_pobj) growth_4\NN|tumor|and|phenotypes (l_compound) tumor_3\NN|
D004967_D009369 NONE estrogen_10\NN| (r_npadvmod) induced_12\VBN|estrogen|- (r_amod) tumor_13\NN|an|induced
D004967_D006470 NONE estrogen_10\NN| (r_npadvmod) induced_12\VBN|estrogen|- (r_amod) tumor_13\NN|an|induced (r_pobj) in_8\IN|tumor (r_prep) separation_1\NN|genetic|of|in|. (l_prep) of_2\IN|growth (l_pobj) growth_4\NN|tumor|and|phenotypes (l_conj) phenotypes_7\NNS|hemorrhagic (l_amod) hemorrhagic_6\JJ|
D004967_D006470 NONE estrogen_3\NN| (r_pobj) of_2\IN|estrogen (r_prep) administration_1\NN|chronic|of|to (r_nsubj) induces_12\VBZ|administration|growth|. (l_dobj) growth_13\NN|of (l_prep) of_14\IN|tumors (l_pobj) tumors_19\NNS|large|,|hemorrhagic|pituitary (l_amod) hemorrhagic_17\JJ|
D004967_D010911 NONE estrogen_3\NN| (r_pobj) of_2\IN|estrogen (r_prep) administration_1\NN|chronic|of|to (r_nsubj) induces_12\VBZ|administration|growth|. (l_dobj) growth_13\NN|of (l_prep) of_14\IN|tumors (l_pobj) tumors_19\NNS|large|,|hemorrhagic|pituitary
D004054_D006470 NONE diethylstilbestrol_3\NN| (r_nmod) treatment_7\NN|diethylstilbestrol|(|des|) (r_pobj) of_2\IN|treatment (r_prep) weeks_1\NNS|ten|of (r_nsubj) caused_8\VBD|weeks|grow|. (l_ccomp) grow_14\VB|pituitaries|to|to|versus|,|and|become (l_conj) become_39\VB|to|hemorrhagic (l_acomp) hemorrhagic_41\JJ|highly
D004054_D006470 NONE DES_5\NNP| (r_nmod) treatment_7\NN|diethylstilbestrol|(|des|) (r_pobj) of_2\IN|treatment (r_prep) weeks_1\NNS|ten|of (r_nsubj) caused_8\VBD|weeks|grow|. (l_ccomp) grow_14\VB|pituitaries|to|to|versus|,|and|become (l_conj) become_39\VB|to|hemorrhagic (l_acomp) hemorrhagic_41\JJ|highly
D004054_D006470 NONE DES_3\NNP| (r_npadvmod) induced_5\VBN|des|- (r_amod) growth_7\NN|induced|pituitary (r_nsubj) exhibited_8\VBD|while|growth|inheritance (r_advcl) exhibited_17\VBD|however|,|exhibited|,|phenotype|inheritance|. (l_nsubj) phenotype_16\NN|the|hemorrhagic (l_amod) hemorrhagic_15\JJ|
9881641
D005905_D007022 NONE Glibenclamide_0\NN| (r_npadvmod) sensitive_2\JJ|glibenclamide|- (r_amod) hypotension_3\NN|sensitive|produced|.
D005905_D007022 NONE glibenclamide_9\NN|,|abolished (r_pobj) by_8\IN|glibenclamide (r_agent) attenuated_7\VBN|hypotension|was|significantly|by|. (l_nsubjpass) Hypotension_0\NN|induced
D005905_D007022 NONE glibenclamide_15\NN| (r_npadvmod) sensitive_17\JJ|glibenclamide|- (r_amod) channels_19\NNS|sensitive|k+|channels|,|exist (r_pobj) of_14\IN|channels (r_prep) activation_13\NN|the|of (r_pobj) to_11\IN|activation (r_prep) attributable_10\JJ|partly|to (r_acomp) is_8\VBZ|that|hypotension|attributable (l_nsubj) hypotension_7\NN|produced
C040442_D007022 CID helodermin_6\NN|assessed (r_pobj) by_5\IN|helodermin (r_agent) produced_4\VBN|by (r_acl) hypotension_3\NN|sensitive|produced|.
C040442_D007022 CID Helodermin_0\NNP| (r_nsubj) produced_1\VBD|helodermin|hypotension|. (l_dobj) hypotension_2\NN|in
C040442_D007022 CID helodermin_4\NN| (r_npadvmod) induced_6\VBN|helodermin|- (r_amod) hypotension_7\NN|induced
C040442_D007022 CID helodermin_4\NN| (r_npadvmod) induced_6\VBN|helodermin|- (r_amod) hypotension_7\NN|induced (r_dobj) affect_3\VB|oxyhemoglobin|did|not|hypotension|,|shortened|. (l_advcl) shortened_11\VBD|whereas|it|duration (l_dobj) duration_13\NN|the|of (l_prep) of_14\IN|acetylcholine (l_pobj) acetylcholine_15\NN|hypotension (l_appos) hypotension_18\NN|(|ach)-produced
C040442_D007022 CID helodermin_4\NN| (r_npadvmod) produced_6\VBN|helodermin|- (r_amod) hypotension_7\NN|produced
D019806_D007022 CID levcromakalim_14\RB| (r_npadvmod) produced_16\VBN|levcromakalim|- (r_amod) decrease_17\NN|a|produced|in (r_dobj) abolished_12\VBD|which|decrease (r_relcl) glibenclamide_9\NN|,|abolished (r_pobj) by_8\IN|glibenclamide (r_agent) attenuated_7\VBN|hypotension|was|significantly|by|. (l_nsubjpass) Hypotension_0\NN|induced
D000109_D007022 CID acetylcholine_15\NN|hypotension (r_pobj) of_14\IN|acetylcholine (r_prep) duration_13\NN|the|of (r_dobj) shortened_11\VBD|whereas|it|duration (r_advcl) affect_3\VB|oxyhemoglobin|did|not|hypotension|,|shortened|. (l_dobj) hypotension_7\NN|induced
D000109_D007022 CID acetylcholine_15\NN|hypotension (l_appos) hypotension_18\NN|(|ach)-produced
D000109_D007022 CID ACh)-produced_17\JJ| (r_amod) hypotension_18\NN|(|ach)-produced (r_appos) acetylcholine_15\NN|hypotension (r_pobj) of_14\IN|acetylcholine (r_prep) duration_13\NN|the|of (r_dobj) shortened_11\VBD|whereas|it|duration (r_advcl) affect_3\VB|oxyhemoglobin|did|not|hypotension|,|shortened|. (l_dobj) hypotension_7\NN|induced
D000109_D007022 CID ACh)-produced_17\JJ| (r_amod) hypotension_18\NN|(|ach)-produced
D011188_D007022 NONE K+_18\NNP| (r_amod) channels_19\NNS|sensitive|k+|channels|,|exist (r_pobj) of_14\IN|channels (r_prep) activation_13\NN|the|of (r_pobj) to_11\IN|activation (r_prep) attributable_10\JJ|partly|to (r_acomp) is_8\VBZ|that|hypotension|attributable (l_nsubj) hypotension_7\NN|produced
D011188_D007022 NONE K(ATP_21\NNP| (r_nmod) channels_23\NNS|(|k(atp|)|) (r_appos) channels_19\NNS|sensitive|k+|channels|,|exist (r_pobj) of_14\IN|channels (r_prep) activation_13\NN|the|of (r_pobj) to_11\IN|activation (r_prep) attributable_10\JJ|partly|to (r_acomp) is_8\VBZ|that|hypotension|attributable (l_nsubj) hypotension_7\NN|produced
D000255_D007022 NONE K(ATP_21\NNP| (r_nmod) channels_23\NNS|(|k(atp|)|) (r_appos) channels_19\NNS|sensitive|k+|channels|,|exist (r_pobj) of_14\IN|channels (r_prep) activation_13\NN|the|of (r_pobj) to_11\IN|activation (r_prep) attributable_10\JJ|partly|to (r_acomp) is_8\VBZ|that|hypotension|attributable (l_nsubj) hypotension_7\NN|produced
D009569_D007022 NONE oxide_7\NN|factor)/nitric (r_dobj) relaxing_5\VBG|oxide (r_xcomp) derived_4\VBN|endothelium|-|relaxing (r_acl) EDRF_0\NN|(|derived (r_nsubj) seem_10\VB|edrf|does|not|play|. (l_xcomp) play_12\VB|to|role (l_dobj) role_15\NN|an|important|in (l_prep) in_16\IN|hypotension (l_pobj) hypotension_21\NN|the|produced
6985297
D015764_D001919 CID bepridil_6\NN| (r_pcomp) by_5\IN|bepridil (r_prep) induced_4\VBN|studies|by|. (l_nsubj) Studies_0\NNS|on (l_prep) on_1\IN|bradycardia (l_pobj) bradycardia_3\NN|the
D015764_D001919 CID Bepridil_0\NN| (r_advmod) induced_13\VBD|bepridil|,|compound|,|bradycardia (l_dobj) bradycardia_15\NNS|persistent|and|effect
D015764_D000787 NONE Bepridil_0\NN| (r_advmod) induced_13\VBD|bepridil|,|compound|,|bradycardia (l_nsubj) compound_5\NN|a|novel|active|for (l_prep) for_6\IN|treatment (l_pobj) treatment_8\NN|prophylactic|of (l_prep) of_9\IN|attacks (l_pobj) attacks_11\NNS|anginal
D015764_D013610 NONE Bepridil_0\NN| (r_advmod) induced_13\VBD|bepridil|,|compound|,|bradycardia (l_dobj) bradycardia_15\NNS|persistent|and|effect (l_conj) effect_24\NN|a|tachycardial (l_amod) tachycardial_23\JJ|-
15094729
D020888_D014786 CID Vigabatrin_4\NNP| (r_pobj) of_3\IN|vigabatrin (r_prep) history_2\NN|the|natural|of (r_nsubj) associated_5\VBD|history|defects|. (l_dobj) defects_8\NNS|visual|field|in
D020888_D014786 CID Vigabatrin_17\NN| (r_npadvmod) associated_19\VBN|vigabatrin|- (r_amod) changes_20\NNS|associated|elected (r_dobj) have_16\VB|to|changes (r_xcomp) known_14\VBN|have (r_acl) patients_13\NNS|known (r_pobj) of_12\IN|patients (r_prep) group_11\NN|a|of (r_pobj) in_9\IN|group (r_prep) defects_8\NNS|visual|field|in
D020888_D014786 CID Vigabatrin_9\NNP| (r_compound) therapy_10\NN|vigabatrin (r_pobj) to_8\IN|therapy (r_prep) due_7\JJ|to (r_acomp) be_6\VB|to|due (r_xcomp) presumed_4\VBN|defects|be (l_nsubj) defects_3\NNS|established|visual|field
D020888_D014786 CID Vigabatrin_11\NNP| (r_npadvmod) associated_13\VBN|vigabatrin|- (r_amod) defects_16\NNS|associated|visual|field
D020888_D012640 NONE Vigabatrin_17\NN| (r_npadvmod) associated_19\VBN|vigabatrin|- (r_amod) changes_20\NNS|associated|elected (l_relcl) elected_22\VBD|who|continue (l_xcomp) continue_24\VB|to|medication|because (l_prep) because_27\IN|of|control (l_pobj) control_31\NN|good|seizure (l_compound) seizure_30\NN|
D020888_D064420 NONE Vigabatrin_11\NNP| (r_npadvmod) associated_13\VBN|vigabatrin|- (r_amod) defects_16\NNS|associated|visual|field (r_pobj) of_10\IN|defects (r_prep) pathogenesis_9\NN|the|of (r_nsubj) be_18\VB|that|pathogenesis|may|reaction (l_attr) reaction_23\NN|an|idiosyncratic|adverse|drug|than (l_cc) than_25\IN|rather|toxicity (l_pobj) toxicity_29\NN|dependent
24068571
D013874_D003693 CID thiopentone_3\NN| (r_pobj) of_2\IN|thiopentone (r_prep) use_1\NN|the|of (r_nsubjpass) associated_6\VBN|use|was|significantly|with|compared|. (l_prep) with_7\IN|risk (l_pobj) risk_14\NN|an|higher|for (l_prep) for_15\IN|delirium (l_pobj) delirium_16\NN|
D015742_D003693 NONE propofol_19\NN|(|%|; (r_pcomp) to_18\IN|propofol (r_prep) compared_17\VBN|to|df (r_prep) associated_6\VBN|use|was|significantly|with|compared|. (l_prep) with_7\IN|risk (l_pobj) risk_14\NN|an|higher|for (l_prep) for_15\IN|delirium (l_pobj) delirium_16\NN|
25041770
D019821_D012206 CID simvastatin_4\NN|and|dosage (r_nmod) increment_7\NN|simvastatin|in (r_pobj) with_3\IN|increment (r_prep) association_2\NN|with (r_pobj) in_1\IN|association (r_prep) Rhabdomyolysis_0\NNP|in|.
D019821_D012206 CID statin_10\NN| (r_pobj) with_9\IN|statin (r_prep) associated_8\VBN|that|elevation|could|be|with|induced|,|warrant (l_conj) induced_11\VBN|rhabdomyolysis (l_dobj) rhabdomyolysis_12\NN|
D017291_D012206 CID clarithromycin_9\NN| (r_pobj) in_8\IN|clarithromycin (r_prep) increment_7\NN|simvastatin|in (r_pobj) with_3\IN|increment (r_prep) association_2\NN|with (r_pobj) in_1\IN|association (r_prep) Rhabdomyolysis_0\NNP|in|.
D017291_D012206 CID clarithromycin_17\NN| (r_pobj) of_16\IN|clarithromycin (r_prep) dose_15\NN|the|of (r_pobj) in_13\IN|dose (r_prep) increase_12\NN|an|in (r_pobj) after_10\IN|increase (r_prep) occurred_9\VBD|only|after (r_advcl) is_3\VBZ|case|of|occurred|. (l_prep) of_4\IN|interest (l_pobj) interest_5\NN|as (l_prep) as_6\IN|rhabdomyolysis (l_pobj) rhabdomyolysis_7\NN|
18987260
D004317_D007674 NONE adriamycin_3\JJ| (r_amod) nephropathy_4\NN|adriamycin
D004317_D007674 NONE adriamycin_37\NNS| (r_nmod) nephropathy_41\NN|adriamycin|(|adr|) (r_pobj) with_36\IN|nephropathy (r_prep) progression_28\NN|renal|disease|in|with (l_compound) disease_27\NN|
D004317_D007674 NONE adriamycin_37\NNS| (r_nmod) nephropathy_41\NN|adriamycin|(|adr|)
D004317_D007674 NONE ADR_39\NNP| (r_nmod) nephropathy_41\NN|adriamycin|(|adr|) (r_pobj) with_36\IN|nephropathy (r_prep) progression_28\NN|renal|disease|in|with (l_compound) disease_27\NN|
D004317_D007674 NONE ADR_39\NNP| (r_nmod) nephropathy_41\NN|adriamycin|(|adr|)
D004317_D007674 NONE ADR_9\NNP| (r_compound) nephropathy_10\NN|advanced|adr|in
D004317_D007674 NONE ADR_15\NNP| (r_compound) nephropathy_16\NN|adr
D004317_D006973 NONE adriamycin_3\JJ| (r_amod) nephropathy_4\NN|adriamycin (r_pobj) of_2\IN|nephropathy (r_prep) progression_1\NN|reduced|of|in|. (l_prep) in_5\IN|rats (l_pobj) rats_8\NNS|hypertensive|treated (l_amod) hypertensive_7\JJ|spontaneously
D004317_D006973 NONE adriamycin_37\NNS| (r_nmod) nephropathy_41\NN|adriamycin|(|adr|) (r_pobj) with_36\IN|nephropathy (r_prep) progression_28\NN|renal|disease|in|with (l_prep) in_29\IN|rats (l_pobj) rats_32\NNS|hypertensive|(|shr|) (l_amod) hypertensive_31\JJ|spontaneously
D004317_D006973 NONE ADR_39\NNP| (r_nmod) nephropathy_41\NN|adriamycin|(|adr|) (r_pobj) with_36\IN|nephropathy (r_prep) progression_28\NN|renal|disease|in|with (l_prep) in_29\IN|rats (l_pobj) rats_32\NNS|hypertensive|(|shr|) (l_amod) hypertensive_31\JJ|spontaneously
D019808_D007674 NONE losartan_11\NN| (r_pobj) by_10\IN|losartan (r_agent) treated_9\VBN|by (r_acl) rats_8\NNS|hypertensive|treated (r_pobj) in_5\IN|rats (r_prep) progression_1\NN|reduced|of|in|. (l_prep) of_2\IN|nephropathy (l_pobj) nephropathy_4\NN|adriamycin
D019808_D007674 NONE losartan_18\NN|,|and|potential (l_conj) potential_22\NN|its|in (l_prep) in_23\IN|slowing (l_pcomp) slowing_24\VBG|down|progression (l_dobj) progression_28\NN|renal|disease|in|with (l_compound) disease_27\NN|
D019808_D007674 NONE losartan_18\NN|,|and|potential (l_conj) potential_22\NN|its|in (l_prep) in_23\IN|slowing (l_pcomp) slowing_24\VBG|down|progression (l_dobj) progression_28\NN|renal|disease|in|with (l_prep) with_36\IN|nephropathy (l_pobj) nephropathy_41\NN|adriamycin|(|adr|)
D019808_D007674 NONE Losartan_0\NNP| (r_nsubj) reduced_1\VBD|losartan|uraemia|and|increased|. (l_conj) increased_4\VBN|clearance (l_dobj) clearance_6\NN|urea|in (l_prep) in_7\IN|nephropathy (l_pobj) nephropathy_10\NN|advanced|adr|in
D019808_D007674 NONE losartan_4\NN| (r_nsubj) prevent_6\VB|that|losartan|could|atrophy (l_dobj) atrophy_8\NN|tubular|,|infiltration|in (l_prep) in_14\IN|nephropathy (l_pobj) nephropathy_16\NN|adr
D019808_D006973 NONE losartan_11\NN| (r_pobj) by_10\IN|losartan (r_agent) treated_9\VBN|by (r_acl) rats_8\NNS|hypertensive|treated (l_amod) hypertensive_7\JJ|spontaneously
D019808_D006973 NONE losartan_18\NN|,|and|potential (l_conj) potential_22\NN|its|in (l_prep) in_23\IN|slowing (l_pcomp) slowing_24\VBG|down|progression (l_dobj) progression_28\NN|renal|disease|in|with (l_prep) in_29\IN|rats (l_pobj) rats_32\NNS|hypertensive|(|shr|) (l_amod) hypertensive_31\JJ|spontaneously
D000804_D007674 NONE II_13\CD| (r_compound) blocker_16\NN|ii|type-1|receptor|,|losartan (l_conj) losartan_18\NN|,|and|potential (l_conj) potential_22\NN|its|in (l_prep) in_23\IN|slowing (l_pcomp) slowing_24\VBG|down|progression (l_dobj) progression_28\NN|renal|disease|in|with (l_compound) disease_27\NN|
D000804_D007674 NONE II_13\CD| (r_compound) blocker_16\NN|ii|type-1|receptor|,|losartan (l_conj) losartan_18\NN|,|and|potential (l_conj) potential_22\NN|its|in (l_prep) in_23\IN|slowing (l_pcomp) slowing_24\VBG|down|progression (l_dobj) progression_28\NN|renal|disease|in|with (l_prep) with_36\IN|nephropathy (l_pobj) nephropathy_41\NN|adriamycin|(|adr|)
D000804_D006973 NONE II_13\CD| (r_compound) blocker_16\NN|ii|type-1|receptor|,|losartan (l_conj) losartan_18\NN|,|and|potential (l_conj) potential_22\NN|its|in (l_prep) in_23\IN|slowing (l_pcomp) slowing_24\VBG|down|progression (l_dobj) progression_28\NN|renal|disease|in|with (l_prep) in_29\IN|rats (l_pobj) rats_32\NNS|hypertensive|(|shr|) (l_amod) hypertensive_31\JJ|spontaneously
D019808_D005921 NONE losartan_4\NN| (r_amod) treatment_5\NN|term|losartan (r_nsubj) improved_11\VBD|:|treatment|,|besides|,|rate|. (l_dobj) rate_14\NN|glomerular|filtration|and|glomerulosclerosis|resulting (l_conj) glomerulosclerosis_17\NN|ameliorated
D019808_D005921 NONE losartan_3\NN| (r_pobj) with_2\IN|losartan (r_prep) treatment_1\NN|prolonged|with (r_nsubj) showed_4\VBD|treatment|reduction|,|preventing|. (l_dobj) reduction_6\NN|further|of (l_prep) of_7\IN|glomerulosclerosis (l_pobj) glomerulosclerosis_8\NN|associated
D019808_D011507 NONE losartan_4\NN| (r_amod) treatment_5\NN|term|losartan (r_nsubj) improved_11\VBD|:|treatment|,|besides|,|rate|. (l_dobj) rate_14\NN|glomerular|filtration|and|glomerulosclerosis|resulting (l_acl) resulting_18\VBG|in (l_prep) in_19\IN|proteinuria (l_pobj) proteinuria_21\NN|decreased
D019808_D011507 NONE losartan_3\NN| (r_pobj) with_2\IN|losartan (r_prep) treatment_1\NN|prolonged|with (r_nsubj) showed_4\VBD|treatment|reduction|,|preventing|. (l_advcl) preventing_21\VBG|thus|proteinuria (l_dobj) proteinuria_23\NN|heavy|and|failure
D019808_D001284 NONE losartan_3\NN| (r_pobj) with_2\IN|losartan (r_prep) treatment_1\NN|prolonged|with (r_nsubj) showed_4\VBD|treatment|reduction|,|preventing|. (l_dobj) reduction_6\NN|further|of (l_prep) of_7\IN|glomerulosclerosis (l_pobj) glomerulosclerosis_8\NN|associated (l_acl) associated_9\VBN|with (l_prep) with_10\IN|progression (l_pobj) progression_12\NN|reduced|of (l_prep) of_13\IN|atrophy (l_pobj) atrophy_15\NN|tubular|and|fibrosis
D019808_D001284 NONE losartan_4\NN| (r_nsubj) prevent_6\VB|that|losartan|could|atrophy (l_dobj) atrophy_8\NN|tubular|,|infiltration|in
D019808_D005355 NONE losartan_3\NN| (r_pobj) with_2\IN|losartan (r_prep) treatment_1\NN|prolonged|with (r_nsubj) showed_4\VBD|treatment|reduction|,|preventing|. (l_dobj) reduction_6\NN|further|of (l_prep) of_7\IN|glomerulosclerosis (l_pobj) glomerulosclerosis_8\NN|associated (l_acl) associated_9\VBN|with (l_prep) with_10\IN|progression (l_pobj) progression_12\NN|reduced|of (l_prep) of_13\IN|atrophy (l_pobj) atrophy_15\NN|tubular|and|fibrosis (l_conj) fibrosis_18\NN|interstitial
D019808_D005355 NONE losartan_4\NN| (r_nsubj) prevent_6\VB|that|losartan|could|atrophy (l_dobj) atrophy_8\NN|tubular|,|infiltration|in (l_conj) infiltration_11\NN|interstitial|and|fibrosis (l_conj) fibrosis_13\NN|
D019808_D007676 NONE losartan_3\NN| (r_pobj) with_2\IN|losartan (r_prep) treatment_1\NN|prolonged|with (r_nsubj) showed_4\VBD|treatment|reduction|,|preventing|. (l_advcl) preventing_21\VBG|thus|proteinuria (l_dobj) proteinuria_23\NN|heavy|and|failure (l_conj) failure_27\NN|chronic|renal
D019808_D007676 NONE Losartan_0\NNP| (r_nsubj) reduces_1\VBZ|losartan|rate|to|. (l_prep) to_13\IN|disease (l_pobj) disease_18\NN|stage|renal|in
D019808_D014511 NONE Losartan_0\NNP| (r_nsubj) reduced_1\VBD|losartan|uraemia|and|increased|. (l_dobj) uraemia_2\RB|
D014508_D014511 NONE urea_5\NN| (r_compound) clearance_6\NN|urea|in (r_dobj) increased_4\VBN|clearance (r_conj) reduced_1\VBD|losartan|uraemia|and|increased|. (l_dobj) uraemia_2\RB|
D014508_D007674 NONE urea_5\NN| (r_compound) clearance_6\NN|urea|in (l_prep) in_7\IN|nephropathy (l_pobj) nephropathy_10\NN|advanced|adr|in
D004317_D014511 CID ADR_9\NNP| (r_compound) nephropathy_10\NN|advanced|adr|in (r_pobj) in_7\IN|nephropathy (r_prep) clearance_6\NN|urea|in (r_dobj) increased_4\VBN|clearance (r_conj) reduced_1\VBD|losartan|uraemia|and|increased|. (l_dobj) uraemia_2\RB|
D004317_D001284 NONE ADR_15\NNP| (r_compound) nephropathy_16\NN|adr (r_pobj) in_14\IN|nephropathy (r_prep) atrophy_8\NN|tubular|,|infiltration|in
D004317_D005355 NONE ADR_15\NNP| (r_compound) nephropathy_16\NN|adr (r_pobj) in_14\IN|nephropathy (r_prep) atrophy_8\NN|tubular|,|infiltration|in (l_conj) infiltration_11\NN|interstitial|and|fibrosis (l_conj) fibrosis_13\NN|
D019808_D005923 NONE Losartan_0\NNP| (r_nsubj) reduces_1\VBZ|losartan|rate|to|. (l_dobj) rate_3\NN|the|of (l_prep) of_4\IN|progression (l_pobj) progression_5\NN|of (l_prep) of_6\IN|glomerulosclerosis (l_pobj) glomerulosclerosis_12\NN|induced|focal|segmental
D004317_D005923 CID ADR_7\NNP| (r_npadvmod) induced_9\VBN|adr|- (r_amod) glomerulosclerosis_12\NN|induced|focal|segmental
D004317_D007676 NONE ADR_7\NNP| (r_npadvmod) induced_9\VBN|adr|- (r_amod) glomerulosclerosis_12\NN|induced|focal|segmental (r_pobj) of_6\IN|glomerulosclerosis (r_prep) progression_5\NN|of (r_pobj) of_4\IN|progression (r_prep) rate_3\NN|the|of (r_dobj) reduces_1\VBZ|losartan|rate|to|. (l_prep) to_13\IN|disease (l_pobj) disease_18\NN|stage|renal|in
8819482
D002118_D017202 NONE calcium_4\NN| (r_compound) antagonist_5\NN|a|new|calcium|, (r_pobj) of_1\IN|antagonist (r_prep) Effects_0\NNS|of|,|on|. (l_prep) on_9\IN|ischemia (l_pobj) ischemia_14\NN|induced|myocardial|in
D002118_D023921 NONE calcium_4\NN| (r_compound) antagonist_5\NN|a|new|calcium|, (r_pobj) of_1\IN|antagonist (r_prep) Effects_0\NNS|of|,|on|. (l_prep) on_9\IN|ischemia (l_pobj) ischemia_14\NN|induced|myocardial|in (l_prep) in_15\IN|dogs (l_pobj) dogs_16\NNS|with (l_prep) with_17\IN|stenosis (l_pobj) stenosis_20\NN|partial|coronary
C082828_D017202 NONE CD-832_7\NNP| (r_punct) ,_8\,|cd-832 (r_punct) Effects_0\NNS|of|,|on|. (l_prep) on_9\IN|ischemia (l_pobj) ischemia_14\NN|induced|myocardial|in
C082828_D017202 NONE CD-832_2\NNP| (r_pobj) of_1\IN|cd-832 (r_prep) Effects_0\NNS|of|on (r_nsubjpass) studied_10\VBN|effects|ischemia|were|in|compared|. (l_nsubjpass) ischemia_8\NN|iso)-induced|myocardial
C082828_D017202 NONE CD-832_4\NNP| (r_nsubj) improves_5\VBZ|that|cd-832|ischemia|during|and|suggest (l_dobj) ischemia_7\NN|myocardial
C082828_D017202 NONE CD-832_21\NNP| (r_punct) plays_22\VBZ|that|property|cd-832|role|in (r_ccomp) suggest_14\VBP|plays (r_conj) improves_5\VBZ|that|cd-832|ischemia|during|and|suggest (l_dobj) ischemia_7\NN|myocardial
C082828_D017202 NONE CD-832_31\NNP| (r_pobj) of_30\IN|cd-832 (r_prep) effects_29\NNS|the|beneficial|of (r_pobj) in_26\IN|effects (r_prep) plays_22\VBZ|that|property|cd-832|role|in (r_ccomp) suggest_14\VBP|plays (r_conj) improves_5\VBZ|that|cd-832|ischemia|during|and|suggest (l_dobj) ischemia_7\NN|myocardial
C082828_D023921 NONE CD-832_7\NNP| (r_punct) ,_8\,|cd-832 (r_punct) Effects_0\NNS|of|,|on|. (l_prep) on_9\IN|ischemia (l_pobj) ischemia_14\NN|induced|myocardial|in (l_prep) in_15\IN|dogs (l_pobj) dogs_16\NNS|with (l_prep) with_17\IN|stenosis (l_pobj) stenosis_20\NN|partial|coronary
C082828_D023921 NONE CD-832_2\NNP| (r_pobj) of_1\IN|cd-832 (r_prep) Effects_0\NNS|of|on (r_nsubjpass) studied_10\VBN|effects|ischemia|were|in|compared|. (l_prep) in_11\IN|dogs (l_pobj) dogs_12\NNS|with (l_prep) with_13\IN|stenosis (l_pobj) stenosis_16\NN|partial|coronary|of
D007545_D017202 CID isoproterenol_10\NN| (r_npadvmod) induced_12\VBN|isoproterenol|- (r_amod) ischemia_14\NN|induced|myocardial|in
D007545_D017202 CID isoproterenol_4\NN| (r_pobj) on_3\IN|isoproterenol (r_prep) Effects_0\NNS|of|on (r_nsubjpass) studied_10\VBN|effects|ischemia|were|in|compared|. (l_nsubjpass) ischemia_8\NN|iso)-induced|myocardial
D007545_D017202 CID ISO)-induced_6\VBN|( (r_nmod) ischemia_8\NN|iso)-induced|myocardial
D007545_D017202 CID ISO_9\NN| (r_compound) infusion_10\NN|iso|with (r_pobj) during_8\IN|infusion (r_prep) improves_5\VBZ|that|cd-832|ischemia|during|and|suggest (l_dobj) ischemia_7\NN|myocardial
D007545_D023921 NONE isoproterenol_10\NN| (r_npadvmod) induced_12\VBN|isoproterenol|- (r_amod) ischemia_14\NN|induced|myocardial|in (l_prep) in_15\IN|dogs (l_pobj) dogs_16\NNS|with (l_prep) with_17\IN|stenosis (l_pobj) stenosis_20\NN|partial|coronary
D007545_D023921 NONE isoproterenol_4\NN| (r_pobj) on_3\IN|isoproterenol (r_prep) Effects_0\NNS|of|on (r_nsubjpass) studied_10\VBN|effects|ischemia|were|in|compared|. (l_prep) in_11\IN|dogs (l_pobj) dogs_12\NNS|with (l_prep) with_13\IN|stenosis (l_pobj) stenosis_16\NN|partial|coronary|of
D007545_D023921 NONE ISO)-induced_6\VBN|( (r_nmod) ischemia_8\NN|iso)-induced|myocardial (r_nsubjpass) studied_10\VBN|effects|ischemia|were|in|compared|. (l_prep) in_11\IN|dogs (l_pobj) dogs_12\NNS|with (l_prep) with_13\IN|stenosis (l_pobj) stenosis_16\NN|partial|coronary|of
D007545_D023921 NONE ISO_12\NNP| (r_compound) infusion_13\NN|intracoronary|iso (r_pobj) of_10\IN|infusion (r_prep) periods_9\NNS|3-min|of|min (r_nsubj) increased_22\VBN|in|,|periods|rate|. (l_prep) In_0\IN|presence (l_pobj) presence_2\NN|the|of (l_prep) of_3\IN|stenosis (l_pobj) stenosis_6\NN|coronary|artery
D009543_D017202 NONE nifedipine_30\NN|or|diltiazem (r_pobj) for_29\IN|nifedipine (r_prep) those_28\DT|for (r_pobj) with_27\IN|those (r_prep) compared_26\VBN|were|with (r_prep) studied_10\VBN|effects|ischemia|were|in|compared|. (l_nsubjpass) ischemia_8\NN|iso)-induced|myocardial
D009543_D023921 NONE nifedipine_30\NN|or|diltiazem (r_pobj) for_29\IN|nifedipine (r_prep) those_28\DT|for (r_pobj) with_27\IN|those (r_prep) compared_26\VBN|were|with (r_prep) studied_10\VBN|effects|ischemia|were|in|compared|. (l_prep) in_11\IN|dogs (l_pobj) dogs_12\NNS|with (l_prep) with_13\IN|stenosis (l_pobj) stenosis_16\NN|partial|coronary|of
D004110_D017202 NONE diltiazem_32\NN| (r_conj) nifedipine_30\NN|or|diltiazem (r_pobj) for_29\IN|nifedipine (r_prep) those_28\DT|for (r_pobj) with_27\IN|those (r_prep) compared_26\VBN|were|with (r_prep) studied_10\VBN|effects|ischemia|were|in|compared|. (l_nsubjpass) ischemia_8\NN|iso)-induced|myocardial
D004110_D023921 NONE diltiazem_32\NN| (r_conj) nifedipine_30\NN|or|diltiazem (r_pobj) for_29\IN|nifedipine (r_prep) those_28\DT|for (r_pobj) with_27\IN|those (r_prep) compared_26\VBN|were|with (r_prep) studied_10\VBN|effects|ischemia|were|in|compared|. (l_prep) in_11\IN|dogs (l_pobj) dogs_12\NNS|with (l_prep) with_13\IN|stenosis (l_pobj) stenosis_16\NN|partial|coronary|of
D007545_D003251 NONE ISO_3\NN| (r_compound) infusion_4\NN|iso|with (l_prep) with_5\IN|stenosis (l_pobj) stenosis_6\NN|
D007545_D003251 NONE ISO_64\NN| (r_compound) infusion_65\NN|iso|with (l_prep) with_66\IN|stenosis (l_pobj) stenosis_67\NN|
D007545_D003251 NONE ISO_60\NN| (r_compound) infusion_61\NN|iso|with (l_prep) with_62\IN|stenosis (l_pobj) stenosis_63\NN|
D007545_D003251 NONE ISO_9\NN| (r_compound) infusion_10\NN|iso|with (l_prep) with_11\IN|stenosis (l_pobj) stenosis_12\NN|
C082828_D003251 NONE CD-832_13\NNP| (r_punct) performed_8\VBN|after|infusion|was|,|doses|cd-832 (l_nsubjpass) infusion_4\NN|iso|with (l_prep) with_5\IN|stenosis (l_pobj) stenosis_6\NN|
C082828_D003251 NONE CD-832_5\NNP|min (r_nsubj) prevented_14\VBD|in|,|cd-832|decrease|and|elevation|. (l_conj) elevation_44\NN|segment|from|to|at (l_prep) at_60\IN|min (l_pobj) min_62\NN|3|after (l_prep) after_63\IN|infusion (l_pobj) infusion_65\NN|iso|with (l_prep) with_66\IN|stenosis (l_pobj) stenosis_67\NN|
C082828_D003251 NONE CD-832_4\NNP| (r_nsubj) improves_5\VBZ|that|cd-832|ischemia|during|and|suggest (l_prep) during_8\IN|infusion (l_pobj) infusion_10\NN|iso|with (l_prep) with_11\IN|stenosis (l_pobj) stenosis_12\NN|
C082828_D003251 NONE CD-832_21\NNP| (r_punct) plays_22\VBZ|that|property|cd-832|role|in (r_ccomp) suggest_14\VBP|plays (r_conj) improves_5\VBZ|that|cd-832|ischemia|during|and|suggest (l_prep) during_8\IN|infusion (l_pobj) infusion_10\NN|iso|with (l_prep) with_11\IN|stenosis (l_pobj) stenosis_12\NN|
C082828_D003251 NONE CD-832_31\NNP| (r_pobj) of_30\IN|cd-832 (r_prep) effects_29\NNS|the|beneficial|of (r_pobj) in_26\IN|effects (r_prep) plays_22\VBZ|that|property|cd-832|role|in (r_ccomp) suggest_14\VBP|plays (r_conj) improves_5\VBZ|that|cd-832|ischemia|during|and|suggest (l_prep) during_8\IN|infusion (l_pobj) infusion_10\NN|iso|with (l_prep) with_11\IN|stenosis (l_pobj) stenosis_12\NN|
D009543_D003251 NONE nifedipine_3\NN| (r_pobj) to_2\IN|nifedipine (r_prep) contrast_1\NN|to (r_pobj) In_0\IN|contrast (r_prep) prevented_14\VBD|in|,|cd-832|decrease|and|elevation|. (l_conj) elevation_44\NN|segment|from|to|at (l_prep) at_60\IN|min (l_pobj) min_62\NN|3|after (l_prep) after_63\IN|infusion (l_pobj) infusion_65\NN|iso|with (l_prep) with_66\IN|stenosis (l_pobj) stenosis_67\NN|
D004110_D003251 NONE Diltiazem_0\NNP| (r_nsubj) prevented_10\VBD|diltiazem|(|micrograms|also|decrease|to|and|elevation|. (l_conj) elevation_40\NN|segment|from (l_prep) from_41\IN|mv|to|at (l_prep) at_56\IN|min (l_pobj) min_58\NN|3|after (l_prep) after_59\IN|infusion (l_pobj) infusion_61\NN|iso|with (l_prep) with_62\IN|stenosis (l_pobj) stenosis_63\NN|
8701013
D015738_D003693 CID Famotidine_0\NN| (r_npadvmod) associated_2\VBN|famotidine|- (r_amod) delirium_3\NN|associated|.
D015738_D003693 CID famotidine_25\NN| (r_pobj) with_24\IN|famotidine (r_prep) associated_23\VBN|shown|,|cases|have|been|with|. (l_advcl) shown_9\VBN|although|all|have|propensity (l_dobj) propensity_11\NN|the|cause (l_acl) cause_13\VB|to|delirium (l_dobj) delirium_14\NN|
D015738_D003693 CID famotidine_7\NN| (r_npadvmod) associated_9\VBN|famotidine|- (r_amod) delirium_10\NN|associated|in
D015738_D003693 CID famotidine_20\NN| (r_pobj) of_19\IN|famotidine (r_prep) removal_18\NN|of (r_pobj) upon_17\IN|removal (r_prep) cleared_15\VBD|who|completely|upon (r_relcl) patients_13\NNS|hospitalized|cleared (r_pobj) in_11\IN|patients (r_prep) delirium_10\NN|associated|in
D015738_D014456 NONE Famotidine_0\NNP| (r_nsubj) is_1\VBZ|famotidine|antagonist|and|showing|. (l_attr) antagonist_5\NN|a|histamine|h2-receptor|used (l_acl) used_6\VBD|in (l_prep) in_7\IN|settings (l_pobj) settings_9\NNS|inpatient|for (l_prep) for_10\IN|prevention (l_pobj) prevention_11\NN|of (l_prep) of_12\IN|ulcers (l_pobj) ulcers_14\NNS|stress
2884595
D006632_D014917 NONE histamine_2\NN| (r_compound) receptors_4\NNS|histamine|h1 (r_pobj) of_1\IN|receptors (r_prep) Blockade_0\NN|of (r_nsubj) reduce_6\VB|blockade|may|mortality|. (l_dobj) mortality_7\NN|in (l_prep) in_8\IN|encephalopathy (l_pobj) encephalopathy_13\NN|pertussis|induced|in (l_compound) pertussis_9\NN|
D006632_D001927 NONE histamine_2\NN| (r_compound) receptors_4\NNS|histamine|h1 (r_pobj) of_1\IN|receptors (r_prep) Blockade_0\NN|of (r_nsubj) reduce_6\VB|blockade|may|mortality|. (l_dobj) mortality_7\NN|in (l_prep) in_8\IN|encephalopathy (l_pobj) encephalopathy_13\NN|pertussis|induced|in
1556529
D015215_D056486 CID Zidovudine_0\RB| (r_npadvmod) induced_2\VBN|zidovudine|- (r_amod) hepatitis_3\NN|induced|.
D015215_D056486 CID zidovudine_7\NNP| (r_pobj) by_6\IN|zidovudine (r_agent) induced_5\VBN|by|in (r_acl) case_1\NN|a|of|induced (l_prep) of_2\IN|hepatitis (l_pobj) hepatitis_4\NN|acute
D015215_D000163 NONE zidovudine_7\NNP| (r_pobj) by_6\IN|zidovudine (r_agent) induced_5\VBN|by|in (l_prep) in_8\IN|patient (l_pobj) patient_13\NN|a|old|with (l_prep) with_14\IN|aids (l_pobj) AIDS_15\NNP|
1280707
D002045_D001145 CID bupivacaine_3\NN|the (r_dobj) determining_1\VBG|bupivacaine|ad50 (r_pcomp) After_0\IN|determining (r_prep) determined_27\VBD|after|(|,|we|effect|. (l_punct) (_5\-LRB-|concentration (l_preconj) concentration_7\NN|the|of|caused|) (l_relcl) caused_11\VBD|that|% (l_dobj) %_13\NN|50|of (l_prep) of_14\IN|all|beating (l_pcomp) beating_16\VBG|cultures|become (l_advcl) become_22\VB|to|arrhythmic (l_acomp) arrhythmic_23\JJ|
D002045_D001145 CID bupivacaine_9\NN| (r_pobj) of_8\IN|bupivacaine (r_prep) concentration_7\NN|the|of|caused|) (l_relcl) caused_11\VBD|that|% (l_dobj) %_13\NN|50|of (l_prep) of_14\IN|all|beating (l_pcomp) beating_16\VBG|cultures|become (l_advcl) become_22\VB|to|arrhythmic (l_acomp) arrhythmic_23\JJ|
D002045_D001145 CID bupivacaine_2\NN| (r_compound) arrhythmia_3\NN|bupivacaine
D011374_D001145 CID progesterone_32\NN| (r_compound) HCl_33\NN|progesterone (r_compound) exposure_34\NN|1-hour|hcl|on (r_pobj) of_30\IN|exposure (r_prep) effect_29\NN|the|of (r_dobj) determined_27\VBD|after|(|,|we|effect|. (l_punct) (_5\-LRB-|concentration (l_preconj) concentration_7\NN|the|of|caused|) (l_relcl) caused_11\VBD|that|% (l_dobj) %_13\NN|50|of (l_prep) of_14\IN|all|beating (l_pcomp) beating_16\VBG|cultures|become (l_advcl) become_22\VB|to|arrhythmic (l_acomp) arrhythmic_23\JJ|
D006851_D001145 NONE HCl_33\NN|progesterone (r_compound) exposure_34\NN|1-hour|hcl|on (r_pobj) of_30\IN|exposure (r_prep) effect_29\NN|the|of (r_dobj) determined_27\VBD|after|(|,|we|effect|. (l_punct) (_5\-LRB-|concentration (l_preconj) concentration_7\NN|the|of|caused|) (l_relcl) caused_11\VBD|that|% (l_dobj) %_13\NN|50|of (l_prep) of_14\IN|all|beating (l_pcomp) beating_16\VBG|cultures|become (l_advcl) become_22\VB|to|arrhythmic (l_acomp) arrhythmic_23\JJ|
1735570
D014294_D007022 CID trimethaphan_1\RB| (r_npadvmod) induced_3\VBN|trimethaphan|- (r_amod) hypotension_4\NN|the|induced
D014294_D001919 NONE trimethaphan_1\RB| (r_npadvmod) induced_3\VBN|trimethaphan|- (r_amod) hypotension_4\NN|the|induced (r_nsubjpass) accompanied_6\VBN|hypotension|was|by|. (l_agent) by_7\IN|bradycardia (l_pobj) bradycardia_10\NN|a|significant|in
D014294_D013610 CID trimethaphan_1\RB| (r_npadvmod) induced_3\VBN|trimethaphan|- (r_amod) hypotension_4\NN|the|induced (r_nsubjpass) accompanied_6\VBN|hypotension|was|by|. (l_agent) by_7\IN|bradycardia (l_pobj) bradycardia_10\NN|a|significant|in (l_prep) in_11\IN|rats (l_pobj) rats_13\NNS|lesioned|(|-32|beats (l_appos) beats_18\NNS|+/-|13|per|)|but|tachycardia (l_conj) tachycardia_24\NN|a|in|(|+|beats
689020
D005280_D014202 CID hydrobromide_6\NN|fenoterol|- (r_compound) infusion_7\NN|hydrobromide (r_pobj) of_3\IN|infusion (r_prep) end_2\NN|the|of (r_pobj) After_0\IN|end (r_prep) decreased_11\VBD|after|,|amplitudes|faster|. (l_nsubj) amplitudes_10\NNS|tremor (l_compound) tremor_9\NN|
D012312_D014202 CID HCl_19\NN|ritodrin|- (r_compound) infusion_20\NN|hcl (r_pobj) following_16\VBG|infusion (r_acl) those_15\DT|following (r_pobj) than_14\IN|those (r_prep) faster_13\RBR|significantly|than (r_advmod) decreased_11\VBD|after|,|amplitudes|faster|. (l_nsubj) amplitudes_10\NNS|tremor (l_compound) tremor_9\NN|
8829135
C058876_D000647 NONE Nefiracetam_0\NNP|(|dm-9384|) (r_nsubj) reverses_4\VBZ|nefiracetam|amnesia (l_dobj) amnesia_8\NN|induced|of
C058876_D000647 NONE DM-9384_2\NNP| (r_appos) Nefiracetam_0\NNP|(|dm-9384|) (r_nsubj) reverses_4\VBZ|nefiracetam|amnesia (l_dobj) amnesia_8\NN|induced|of
C058876_D000647 NONE nefiracetam_28\NN| (r_pobj) of_27\IN|nefiracetam (r_prep) ability_26\NN|the|of|attenuate (l_acl) attenuate_30\VB|to|amnesia (l_dobj) amnesia_31\NN|induced
C058876_D000647 NONE nefiracetam_4\NN| (r_pobj) of_3\IN|nefiracetam (r_prep) administration_2\NN|of|during (r_nsubj) reversed_8\VBD|however|,|administration|completely|amnesia|and|was (l_dobj) amnesia_10\NN|the|induced
D001058_D000647 CID apomorphine_5\NN| (r_npadvmod) induced_7\VBN|apomorphine|- (r_amod) amnesia_8\NN|induced|of
D001058_D000647 CID apomorphine_2\NN|that (r_pobj) Given_0\VBN|apomorphine (r_prep) inhibits_3\VBZ|given|retention|given (r_ccomp) evaluated_24\VBD|inhibits|,|we|ability|. (l_dobj) ability_26\NN|the|of|attenuate (l_acl) attenuate_30\VB|to|amnesia (l_dobj) amnesia_31\NN|induced
D001058_D000647 CID apomorphine_13\NN| (r_pobj) by_12\IN|apomorphine (r_agent) induced_11\VBN|by|at (r_acl) amnesia_10\NN|the|induced
C058876_D007859 NONE Nefiracetam_0\NNP| (r_nsubj) is_1\VBZ|nefiracetam|derivative|. (l_attr) derivative_5\NN|a|novel|pyrrolidone|attenuates (l_relcl) attenuates_7\VBZ|which|learning (l_dobj) learning_11\NN|induced|and|deficits (l_conj) deficits_17\NNS|training|consolidation
D011760_D007859 NONE pyrrolidone_4\NN| (r_compound) derivative_5\NN|a|novel|pyrrolidone|attenuates (l_relcl) attenuates_7\VBZ|which|learning (l_dobj) learning_11\NN|induced|and|deficits (l_conj) deficits_17\NNS|training|consolidation
D012601_D007859 CID scopolamine_8\NN| (r_npadvmod) induced_10\VBN|scopolamine|- (r_amod) learning_11\NN|induced|and|deficits (l_conj) deficits_17\NNS|training|consolidation
12359538
D003042_D002637 NONE cocaine_7\NN| (r_npadvmod) associated_9\VBN|cocaine|- (r_amod) pain_11\NN|associated|chest
D003042_D002637 NONE cocaine_24\NN| (r_npadvmod) associated_26\VBN|cocaine|- (r_amod) pain_28\NN|associated|chest
D003042_D002637 NONE cocaine_10\NN| (r_compound) chest_11\NN|cocaine (r_compound) pain_12\NN|chest
D003042_D002637 NONE cocaine_19\NN| (r_npadvmod) associated_21\VBN|cocaine|- (r_amod) pain_23\NN|associated|chest|and|mi
D003042_D009202 NONE cocaine_24\NN| (r_npadvmod) associated_26\VBN|cocaine|- (r_amod) pain_28\NN|associated|chest (r_pobj) with_23\IN|pain (r_prep) patients_22\NNS|with (r_pobj) in_21\IN|patients (r_prep) difficult_20\JJ|in (r_ccomp) make_11\VBP|abnormalities|diagnosis|difficult|. (l_nsubj) abnormalities_2\NNS|baseline|electrocardiogram|and|elevations|associated (l_acl) associated_7\VBN|not|with (l_prep) with_8\IN|necrosis (l_pobj) necrosis_10\NN|myocardial
D003042_D009203 CID cocaine_24\NN| (r_npadvmod) associated_26\VBN|cocaine|- (r_amod) pain_28\NN|associated|chest (r_pobj) with_23\IN|pain (r_prep) patients_22\NNS|with (r_pobj) in_21\IN|patients (r_prep) difficult_20\JJ|in (r_ccomp) make_11\VBP|abnormalities|diagnosis|difficult|. (l_dobj) diagnosis_13\NN|accurate|of (l_prep) of_14\IN|infarction (l_pobj) infarction_16\NN|myocardial|(|mi|)
D003042_D009203 CID cocaine_24\NN| (r_npadvmod) associated_26\VBN|cocaine|- (r_amod) pain_28\NN|associated|chest (r_pobj) with_23\IN|pain (r_prep) patients_22\NNS|with (r_pobj) in_21\IN|patients (r_prep) difficult_20\JJ|in (r_ccomp) make_11\VBP|abnormalities|diagnosis|difficult|. (l_dobj) diagnosis_13\NN|accurate|of (l_prep) of_14\IN|infarction (l_pobj) infarction_16\NN|myocardial|(|mi|) (l_appos) MI_18\NNP|
D003042_D009203 CID cocaine_10\NN| (r_compound) chest_11\NN|cocaine (r_compound) pain_12\NN|chest (r_pobj) with_9\IN|pain (r_prep) patients_8\NNS|with (r_pobj) in_7\IN|patients (r_prep) positivity_6\NN|troponin|in|admitted (l_acl) admitted_13\VBD|for (l_prep) for_14\IN|exclusion (l_pobj) exclusion_15\NN|of (l_prep) of_16\IN|mi (l_pobj) MI_17\NNP|
D003042_D009203 CID cocaine_10\NN| (r_compound) use_11\NN|cocaine (r_pobj) after_9\IN|use (r_prep) admitted_5\VBN|for|after (l_prep) for_6\IN|mi (l_pobj) MI_8\NNP|possible
D003042_D009203 CID cocaine_19\NN| (r_npadvmod) associated_21\VBN|cocaine|- (r_amod) pain_23\NN|associated|chest|and|mi (l_conj) MI_26\NNP|suspected
D003042_D009336 NONE cocaine_19\NN| (r_npadvmod) associated_21\VBN|cocaine|- (r_amod) pain_23\NN|associated|chest|and|mi (r_pobj) with_18\IN|pain (r_prep) patients_17\NNS|with (r_pobj) in_16\IN|patients (r_prep) necrosis_15\NN|in
3289726
D005047_D009422 NONE etoposide_7\NN| (r_compound) therapy_8\NN|dose|etoposide|for (r_pobj) after_3\IN|therapy (r_prep) dysfunction_2\NN|acute|neurologic|after|.
D005047_D005910 NONE etoposide_7\NN| (r_compound) therapy_8\NN|dose|etoposide|for (l_prep) for_9\IN|glioma (l_pobj) glioma_11\NN|malignant
D005047_D005910 NONE etoposide_13\NN| (r_compound) therapy_14\NN|dose|etoposide|for (l_prep) for_15\IN|glioma (l_pobj) glioma_17\NN|malignant
D005047_D009369 NONE Etoposide_0\NNP|) (r_nsubjpass) used_8\VBN|etoposide|has|been|in|. (l_prep) in_9\IN|treatment (l_pobj) treatment_11\NN|the|of (l_prep) of_12\IN|tumors (l_pobj) tumors_15\NNS|many|solid|and|malignancies
D005047_D009369 NONE 213_4\CD|- (r_punct) )_5\-RRB-|vp-16|213 (r_punct) Etoposide_0\NNP|) (r_nsubjpass) used_8\VBN|etoposide|has|been|in|. (l_prep) in_9\IN|treatment (l_pobj) treatment_11\NN|the|of (l_prep) of_12\IN|tumors (l_pobj) tumors_15\NNS|many|solid|and|malignancies
D005047_D019337 NONE Etoposide_0\NNP|) (r_nsubjpass) used_8\VBN|etoposide|has|been|in|. (l_prep) in_9\IN|treatment (l_pobj) treatment_11\NN|the|of (l_prep) of_12\IN|tumors (l_pobj) tumors_15\NNS|many|solid|and|malignancies (l_conj) malignancies_18\NNS|hematologic
D005047_D019337 NONE 213_4\CD|- (r_punct) )_5\-RRB-|vp-16|213 (r_punct) Etoposide_0\NNP|) (r_nsubjpass) used_8\VBN|etoposide|has|been|in|. (l_prep) in_9\IN|treatment (l_pobj) treatment_11\NN|the|of (l_prep) of_12\IN|tumors (l_pobj) tumors_15\NNS|many|solid|and|malignancies (l_conj) malignancies_18\NNS|hematologic
D005047_D064420 NONE etoposide_13\NN| (r_compound) therapy_14\NN|dose|etoposide|for (r_pobj) of_9\IN|therapy (r_prep) toxicity_8\NN|a|significant|new|of
19531695
D005424_D003693 CID flecainide_6\JJ| (r_amod) concentrations_8\NNS|toxic|flecainide|plasma (r_pobj) with_4\IN|concentrations (r_prep) patient_3\NN|a|with (r_pobj) in_1\IN|patient (r_prep) Delirium_0\NN|in|:|role|.
D005424_D003693 CID flecainide_5\RB| (r_advmod) induced_7\VBN|flecainide|- (r_amod) delirium_8\NN|induced|associated
D005424_D003693 CID Flecainide_0\NNP|and|similar (r_amod) agents_4\NNS|flecainide|interact (r_nsubj) cause_11\VB|agents|may|delirium|. (l_dobj) delirium_12\NN|in
D005424_D003693 CID flecainide_17\NN| (r_pobj) between_16\IN|flecainide (r_prep) interaction_15\NN|the|between (r_pobj) on_13\IN|interaction (r_prep) study_12\NN|pharmacokinetic|on|,|substrate (l_conj) substrate_21\NN|a|cyp2d6|,|and|paroxetine (l_conj) paroxetine_24\NN|,|inhibitor (l_appos) inhibitor_28\NN|a|cyp2d6|,|as|reports (l_conj) reports_35\NNS|3|case|of (l_prep) of_36\IN|delirium (l_pobj) delirium_40\NN|induced
D005424_D003693 CID flecainide_37\RB| (r_advmod) induced_39\VBN|flecainide|- (r_amod) delirium_40\NN|induced
D005424_D003693 CID flecainide_7\NN| (r_advmod) was_8\VBD|according|,|flecainide|cause (l_attr) cause_11\NN|the|probable|of (l_prep) of_12\IN|delirium (l_pobj) delirium_16\NN|patient
D005424_D003693 CID flecainide_31\NN|and|paroxetine (r_pobj) between_30\IN|flecainide (r_prep) interaction_29\NN|a|possible|pharmacokinetic|drug|between (r_dobj) indicates_24\VBZ|was|;|scale|interaction|. (l_ccomp) was_8\VBD|according|,|flecainide|cause (l_attr) cause_11\NN|the|probable|of (l_prep) of_12\IN|delirium (l_pobj) delirium_16\NN|patient
D005424_D003693 CID flecainide_1\JJ| (r_amod) concentrations_3\NNS|supratherapeutic|flecainide|plasma (r_nsubj) cause_5\VB|concentrations|may|delirium|. (l_dobj) delirium_6\NN|
D017374_D003693 CID paroxetine_18\NN| (r_pobj) with_17\IN|paroxetine (r_prep) interaction_16\NN|a|pharmacokinetic|drug|with (r_pobj) of_12\IN|interaction (r_prep) role_11\NN|the|of (r_appos) Delirium_0\NN|in|:|role|.
D017374_D003693 CID paroxetine_16\NN| (r_pobj) with_15\IN|paroxetine (r_prep) interaction_14\NN|a|pharmacokinetic|drug|with (r_pobj) with_10\IN|interaction (r_prep) associated_9\VBN|with (r_acl) delirium_8\NN|induced|associated
D017374_D003693 CID paroxetine_24\NN|,|inhibitor (l_appos) inhibitor_28\NN|a|cyp2d6|,|as|reports (l_conj) reports_35\NNS|3|case|of (l_prep) of_36\IN|delirium (l_pobj) delirium_40\NN|induced
D017374_D003693 CID paroxetine_33\NN| (r_conj) flecainide_31\NN|and|paroxetine (r_pobj) between_30\IN|flecainide (r_prep) interaction_29\NN|a|possible|pharmacokinetic|drug|between (r_dobj) indicates_24\VBZ|was|;|scale|interaction|. (l_ccomp) was_8\VBD|according|,|flecainide|cause (l_attr) cause_11\NN|the|probable|of (l_prep) of_12\IN|delirium (l_pobj) delirium_16\NN|patient
D005424_D001281 NONE Flecainide_0\NNP| (r_nsubjpass) started_3\VBN|flecainide|had|been|prior|. (l_advmod) prior_6\RB|weeks|for (l_prep) for_7\IN|fibrillation (l_pobj) fibrillation_9\NN|atrial
D012964_D003693 NONE sodium_8\NN| (r_compound) channels_9\NNS|sodium (r_pobj) with_7\IN|channels (r_prep) interact_6\VBP|that|with (r_relcl) agents_4\NNS|flecainide|interact (r_nsubj) cause_11\VB|agents|may|delirium|. (l_dobj) delirium_12\NN|in
D005424_D064420 NONE flecainide_5\JJ| (r_nsubjpass) prescribed_7\VBN|when|flecainide|is|with (r_advcl) occur_3\VB|because|toxicity|may|prescribed (l_nsubj) toxicity_1\NN|
D005424_D064420 NONE flecainide_16\JJ| (r_amod) concentrations_18\NNS|flecainide|plasma (r_conj) paroxetine_9\NN|and|inhibitors|,|concentrations (r_pobj) with_8\IN|paroxetine (r_prep) prescribed_7\VBN|when|flecainide|is|with (r_advcl) occur_3\VB|because|toxicity|may|prescribed (l_nsubj) toxicity_1\NN|
D017374_D064420 NONE paroxetine_9\NN|and|inhibitors|,|concentrations (r_pobj) with_8\IN|paroxetine (r_prep) prescribed_7\VBN|when|flecainide|is|with (r_advcl) occur_3\VB|because|toxicity|may|prescribed (l_nsubj) toxicity_1\NN|
3798047
D008775_D001919 CID methylprednisolone_6\NN| (r_compound) therapy_7\NN|dose|intravenous|methylprednisolone (r_pobj) after_1\IN|therapy (r_prep) Bradycardia_0\NNS|after|.
D008775_D001172 NONE methylprednisolone_13\NN|intravenous|dose|therapy (r_dobj) received_8\VBD|who|methylprednisolone|daily|for|) (r_relcl) patients_3\NNS|5|consecutive|with|received (l_prep) with_4\IN|arthritis (l_pobj) arthritis_6\NN|rheumatoid
D008775_D001172 NONE MP_15\NNP| (r_nmod) therapy_17\NN|(|mp|)|( (r_appos) methylprednisolone_13\NN|intravenous|dose|therapy (r_dobj) received_8\VBD|who|methylprednisolone|daily|for|) (r_relcl) patients_3\NNS|5|consecutive|with|received (l_prep) with_4\IN|arthritis (l_pobj) arthritis_6\NN|rheumatoid
D008775_D006331 NONE MP_3\NNP|dose (r_nsubjpass) contraindicated_6\VBN|mp|may|be|in|. (l_prep) in_7\IN|patients (l_pobj) patients_8\NNS|with (l_prep) with_9\IN|disease (l_pobj) disease_12\NN|known|heart
24587916
D003907_D006973 CID dexamethasone_6\NN| (r_npadvmod) induced_8\VBN|dexamethasone|- (r_amod) hypertension_9\NN|induced|in
D003907_D006973 CID Dexamethasone-_0\NNP|dex- (r_nsubj) induced_4\VBN|dexamethasone-|associated|. (l_ccomp) associated_7\VBN|hypertension|is|with (l_nsubjpass) hypertension_5\NN|
D003907_D006973 CID Dex-_2\NNP|(|) (r_appos) Dexamethasone-_0\NNP|dex- (r_nsubj) induced_4\VBN|dexamethasone-|associated|. (l_ccomp) associated_7\VBN|hypertension|is|with (l_nsubjpass) hypertension_5\NN|
D003907_D006973 CID Dex_19\NNP| (r_compound) administration_20\NN|dex (r_pobj) upon_18\IN|administration (r_prep) stress_15\NN|oxidative|and|hypertension|upon (l_conj) hypertension_17\NN|
D003907_D006973 CID Dex_0\NNP| (r_npadvmod) induced_2\VBN|dex|- (r_amod) hypertension_3\NN|induced|.
D003907_D006973 CID Dex_18\NNP| (r_npadvmod) induced_20\VBN|dex|- (r_amod) hypertension_21\NN|induced
D006861_D015431 NONE H2O2_11\NNP|the|elevated|plasma (r_dobj) reduced_7\VBD|significantly|h2o2|and|increased (r_conj) prevented_1\VBD|lf|loss|and|reduced|. (l_dobj) loss_4\NN|body|weight
15276093
C451780_D006937 NONE lovastatin_5\NN|release|/ (r_appos) Niacin_0\NNP|lovastatin (r_nsubj) is_6\VBZ|niacin|product|. (l_attr) product_10\NN|a|new|combination|approved (l_acl) approved_11\VBN|for (l_prep) for_12\IN|treatment (l_pobj) treatment_13\NN|of (l_prep) of_14\IN|hypercholesterolemia (l_pobj) hypercholesterolemia_16\NN|primary|and|dyslipidemia
C451780_D050171 NONE lovastatin_5\NN|release|/ (r_appos) Niacin_0\NNP|lovastatin (r_nsubj) is_6\VBZ|niacin|product|. (l_attr) product_10\NN|a|new|combination|approved (l_acl) approved_11\VBN|for (l_prep) for_12\IN|treatment (l_pobj) treatment_13\NN|of (l_prep) of_14\IN|hypercholesterolemia (l_pobj) hypercholesterolemia_16\NN|primary|and|dyslipidemia (l_conj) dyslipidemia_19\NN|mixed
C451780_D050171 NONE lovastatin_30\NN|release|/ (r_conj) dyslipidemia_23\NN|and|niacin|lovastatin
D003401_D009135 NONE creatine_3\NN| (r_compound) phosphokinase_4\NN|creatine (r_pobj) of_2\IN|phosphokinase (r_prep) increase_1\NN|an|of|to (r_nsubj) occurred_14\VBD|increase|limit|in|,|and|observed (l_conj) observed_30\VBN|cases|were|. (l_nsubjpass) cases_23\NNS|no|of (l_prep) of_24\IN|myopathy (l_pobj) myopathy_28\NNS|induced
23535177
D007980_D010300 NONE levodopa_19\RB| (r_npadvmod) induced_21\VBN|levodopa|- (r_amod) dyskinesias_22\NNS|induced|(|lids|) (r_conj) disease_14\NN|parkinson|(|pd|)|and|dyskinesias
D007980_D010300 NONE levodopa_19\RB| (r_npadvmod) induced_21\VBN|levodopa|- (r_amod) dyskinesias_22\NNS|induced|(|lids|) (r_conj) disease_14\NN|parkinson|(|pd|)|and|dyskinesias (l_appos) PD_16\NNP|
D007980_D004409 CID levodopa_19\RB| (r_npadvmod) induced_21\VBN|levodopa|- (r_amod) dyskinesias_22\NNS|induced|(|lids|)
D007980_D004409 CID levodopa_19\RB| (r_npadvmod) induced_21\VBN|levodopa|- (r_amod) dyskinesias_22\NNS|induced|(|lids|) (l_appos) LIDs_24\NNPS|
19515070
D019343_D064420 NONE citrate_6\NN| (r_compound) anticoagulation_7\NN|unsafe|regional|citrate|in (r_attr) is_2\VBZ|anticoagulation|anticoagulation|carries|. (l_conj) carries_15\VBZ|risk (l_dobj) risk_17\NN|the|of (l_prep) of_18\IN|toxicity (l_pobj) toxicity_20\NN|citrate
D019343_D064420 NONE citrate_19\JJ| (r_compound) toxicity_20\NN|citrate
D019343_D064420 NONE citrate_10\JJ| (r_compound) toxicity_11\NN|citrate
D000082_D017114 CID acetaminophen_11\RB| (r_advmod) induced_13\VBN|acetaminophen|- (r_amod) failure_16\NN|induced|fulminant|liver|with
D000082_D058186 CID acetaminophen_11\RB| (r_advmod) induced_13\VBN|acetaminophen|- (r_amod) failure_16\NN|induced|fulminant|liver|with (l_prep) with_17\IN|aki (l_pobj) AKI_19\NNP|associated|underwent
D019343_D017114 NONE citrate_30\NN| (r_compound) dialysate_31\NN|citrate (r_pobj) with_29\IN|dialysate (r_prep) anticoagulated_28\VBN|with|during (r_acl) transplantation_27\NN|liver|anticoagulated (r_pobj) during_25\IN|transplantation (r_prep) underwent_21\VBD|who|support|during (r_relcl) AKI_19\NNP|associated|underwent (r_pobj) with_17\IN|aki (r_prep) failure_16\NN|induced|fulminant|liver|with
D019343_D017114 NONE Citrate_0\NNP| (r_compound) dialysate_1\NN|citrate (r_nsubj) is_2\VBZ|dialysate|alternative|. (l_attr) alternative_5\NN|a|safe|for (l_prep) for_6\IN|support (l_pobj) support_8\NN|intradialytic|of|in (l_prep) in_12\IN|failure (l_pobj) failure_15\NN|fulminant|liver
D019343_D058186 NONE citrate_30\NN| (r_compound) dialysate_31\NN|citrate (r_pobj) with_29\IN|dialysate (r_prep) anticoagulated_28\VBN|with|during (r_acl) transplantation_27\NN|liver|anticoagulated (r_pobj) during_25\IN|transplantation (r_prep) underwent_21\VBD|who|support|during (r_relcl) AKI_19\NNP|associated|underwent
7477981
D007980_D004409 NONE Levodopa_0\NNP| (r_npadvmod) induced_2\VBN|levodopa|- (r_amod) dyskinesias_3\NNS|induced
D007980_D004409 NONE levodopa_11\JJ| (r_npadvmod) responsive_13\JJ|levodopa|- (r_amod) patients_14\NNS|seven|responsive|with (r_pobj) in_9\IN|patients (r_prep) dyskinesias_8\NNS|in
D007980_D004409 NONE levodopa-_12\JJ|or|dopamine (r_nmod) dyskinesias_18\NNS|levodopa-|induced
D005473_D004409 CID fluoxetine_7\NN| (r_pobj) by_6\IN|fluoxetine (r_agent) improved_5\VBN|dyskinesias|are|by|. (l_nsubjpass) dyskinesias_3\NNS|induced
D005473_D004409 CID fluoxetine_37\NN| (r_pobj) of_36\IN|fluoxetine (r_prep) administration_35\NN|the|of (r_pobj) after_33\IN|administration|twice (r_conj) before_31\RB|and|after (r_prep) evaluated_1\VBD|we|severity|after|,|before|)|for|. (l_dobj) severity_3\NN|the|of|and|dyskinesias (l_conj) dyskinesias_8\NNS|in
D005473_D004409 CID fluoxetine_1\NN| (r_amod) treatment_2\NN|fluoxetine (r_pobj) After_0\IN|treatment (r_prep) was_5\VBD|after|,|there|improvement|induced|. (l_advcl) induced_19\VBN|-|dyskinesias|without (l_dobj) dyskinesias_20\NNS|
D005473_D004409 CID fluoxetine_9\NN| (r_pobj) with_8\IN|fluoxetine (r_prep) transmission_7\NN|increased|serotoninergic|with (r_nsubj) reduce_11\VB|that|transmission|may|dyskinesias|without (l_dobj) dyskinesias_18\NNS|levodopa-|induced
D007980_D009069 NONE levodopa_11\JJ| (r_npadvmod) responsive_13\JJ|levodopa|- (r_amod) patients_14\NNS|seven|responsive|with (r_pobj) in_9\IN|patients (r_prep) dyskinesias_8\NNS|in (r_conj) severity_3\NN|the|of|and|dyskinesias (l_prep) of_4\IN|disability (l_pobj) disability_6\NN|motor
D007980_D009069 NONE levodopa-_12\JJ|or|dopamine (r_nmod) dyskinesias_18\NNS|levodopa-|induced (r_dobj) reduce_11\VB|that|transmission|may|dyskinesias|without (l_prep) without_19\IN|disability (l_pobj) disability_23\NN|aggravating|parkinsonian|motor
D007980_D010300 NONE levodopa_11\JJ| (r_npadvmod) responsive_13\JJ|levodopa|- (r_amod) patients_14\NNS|seven|responsive|with (l_prep) with_15\IN|disease (l_pobj) disease_18\NN|parkinson
D007980_D010300 NONE levodopa-_12\JJ|or|dopamine (r_nmod) dyskinesias_18\NNS|levodopa-|induced (r_dobj) reduce_11\VB|that|transmission|may|dyskinesias|without (l_prep) without_19\IN|disability (l_pobj) disability_23\NN|aggravating|parkinsonian|motor (l_amod) parkinsonian_21\JJ|
D004298_D009069 NONE dopamine_26\NN|mixed (r_compound) agonist_27\NN|the|dopamine|,|apomorphine (r_pobj) with_23\IN|agonist (r_prep) challenge_22\NN|an|acute|with (r_pobj) after_19\IN|challenge (r_prep) evaluated_1\VBD|we|severity|after|,|before|)|for|. (l_dobj) severity_3\NN|the|of|and|dyskinesias (l_prep) of_4\IN|disability (l_pobj) disability_6\NN|motor
D004298_D009069 NONE dopamine_14\NN| (r_conj) levodopa-_12\JJ|or|dopamine (r_nmod) dyskinesias_18\NNS|levodopa-|induced (r_dobj) reduce_11\VB|that|transmission|may|dyskinesias|without (l_prep) without_19\IN|disability (l_pobj) disability_23\NN|aggravating|parkinsonian|motor
D004298_D004409 NONE dopamine_26\NN|mixed (r_compound) agonist_27\NN|the|dopamine|,|apomorphine (r_pobj) with_23\IN|agonist (r_prep) challenge_22\NN|an|acute|with (r_pobj) after_19\IN|challenge (r_prep) evaluated_1\VBD|we|severity|after|,|before|)|for|. (l_dobj) severity_3\NN|the|of|and|dyskinesias (l_conj) dyskinesias_8\NNS|in
D004298_D004409 NONE dopamine_14\NN| (r_conj) levodopa-_12\JJ|or|dopamine (r_nmod) dyskinesias_18\NNS|levodopa-|induced
D004298_D010300 NONE dopamine_26\NN|mixed (r_compound) agonist_27\NN|the|dopamine|,|apomorphine (r_pobj) with_23\IN|agonist (r_prep) challenge_22\NN|an|acute|with (r_pobj) after_19\IN|challenge (r_prep) evaluated_1\VBD|we|severity|after|,|before|)|for|. (l_dobj) severity_3\NN|the|of|and|dyskinesias (l_conj) dyskinesias_8\NNS|in (l_prep) in_9\IN|patients (l_pobj) patients_14\NNS|seven|responsive|with (l_prep) with_15\IN|disease (l_pobj) disease_18\NN|parkinson
D004298_D010300 NONE dopamine_14\NN| (r_conj) levodopa-_12\JJ|or|dopamine (r_nmod) dyskinesias_18\NNS|levodopa-|induced (r_dobj) reduce_11\VB|that|transmission|may|dyskinesias|without (l_prep) without_19\IN|disability (l_pobj) disability_23\NN|aggravating|parkinsonian|motor (l_amod) parkinsonian_21\JJ|
D001058_D009069 NONE apomorphine_29\NN| (r_appos) agonist_27\NN|the|dopamine|,|apomorphine (r_pobj) with_23\IN|agonist (r_prep) challenge_22\NN|an|acute|with (r_pobj) after_19\IN|challenge (r_prep) evaluated_1\VBD|we|severity|after|,|before|)|for|. (l_dobj) severity_3\NN|the|of|and|dyskinesias (l_prep) of_4\IN|disability (l_pobj) disability_6\NN|motor
D001058_D009069 NONE apomorphine_17\NN| (r_pobj) of_16\IN|apomorphine (r_prep) improvement_10\NN|a|significant|%|(|0.05|)|of (r_attr) was_5\VBD|after|,|there|improvement|induced|. (l_advcl) induced_19\VBN|-|dyskinesias|without (l_prep) without_21\IN|modification (l_pobj) modification_22\NN|of (l_prep) of_23\IN|disability (l_pobj) disability_26\NN|parkinsonian|motor
D001058_D004409 CID apomorphine_29\NN| (r_appos) agonist_27\NN|the|dopamine|,|apomorphine (r_pobj) with_23\IN|agonist (r_prep) challenge_22\NN|an|acute|with (r_pobj) after_19\IN|challenge (r_prep) evaluated_1\VBD|we|severity|after|,|before|)|for|. (l_dobj) severity_3\NN|the|of|and|dyskinesias (l_conj) dyskinesias_8\NNS|in
D001058_D004409 CID apomorphine_17\NN| (r_pobj) of_16\IN|apomorphine (r_prep) improvement_10\NN|a|significant|%|(|0.05|)|of (r_attr) was_5\VBD|after|,|there|improvement|induced|. (l_advcl) induced_19\VBN|-|dyskinesias|without (l_dobj) dyskinesias_20\NNS|
D001058_D010300 NONE apomorphine_29\NN| (r_appos) agonist_27\NN|the|dopamine|,|apomorphine (r_pobj) with_23\IN|agonist (r_prep) challenge_22\NN|an|acute|with (r_pobj) after_19\IN|challenge (r_prep) evaluated_1\VBD|we|severity|after|,|before|)|for|. (l_dobj) severity_3\NN|the|of|and|dyskinesias (l_conj) dyskinesias_8\NNS|in (l_prep) in_9\IN|patients (l_pobj) patients_14\NNS|seven|responsive|with (l_prep) with_15\IN|disease (l_pobj) disease_18\NN|parkinson
D001058_D010300 NONE apomorphine_17\NN| (r_pobj) of_16\IN|apomorphine (r_prep) improvement_10\NN|a|significant|%|(|0.05|)|of (r_attr) was_5\VBD|after|,|there|improvement|induced|. (l_advcl) induced_19\VBN|-|dyskinesias|without (l_prep) without_21\IN|modification (l_pobj) modification_22\NN|of (l_prep) of_23\IN|disability (l_pobj) disability_26\NN|parkinsonian|motor (l_amod) parkinsonian_24\JJ|
D005473_D009069 NONE fluoxetine_37\NN| (r_pobj) of_36\IN|fluoxetine (r_prep) administration_35\NN|the|of (r_pobj) after_33\IN|administration|twice (r_conj) before_31\RB|and|after (r_prep) evaluated_1\VBD|we|severity|after|,|before|)|for|. (l_dobj) severity_3\NN|the|of|and|dyskinesias (l_prep) of_4\IN|disability (l_pobj) disability_6\NN|motor
D005473_D009069 NONE fluoxetine_1\NN| (r_amod) treatment_2\NN|fluoxetine (r_pobj) After_0\IN|treatment (r_prep) was_5\VBD|after|,|there|improvement|induced|. (l_advcl) induced_19\VBN|-|dyskinesias|without (l_prep) without_21\IN|modification (l_pobj) modification_22\NN|of (l_prep) of_23\IN|disability (l_pobj) disability_26\NN|parkinsonian|motor
D005473_D009069 NONE fluoxetine_9\NN| (r_pobj) with_8\IN|fluoxetine (r_prep) transmission_7\NN|increased|serotoninergic|with (r_nsubj) reduce_11\VB|that|transmission|may|dyskinesias|without (l_prep) without_19\IN|disability (l_pobj) disability_23\NN|aggravating|parkinsonian|motor
D005473_D010300 NONE fluoxetine_37\NN| (r_pobj) of_36\IN|fluoxetine (r_prep) administration_35\NN|the|of (r_pobj) after_33\IN|administration|twice (r_conj) before_31\RB|and|after (r_prep) evaluated_1\VBD|we|severity|after|,|before|)|for|. (l_dobj) severity_3\NN|the|of|and|dyskinesias (l_conj) dyskinesias_8\NNS|in (l_prep) in_9\IN|patients (l_pobj) patients_14\NNS|seven|responsive|with (l_prep) with_15\IN|disease (l_pobj) disease_18\NN|parkinson
D005473_D010300 NONE fluoxetine_1\NN| (r_amod) treatment_2\NN|fluoxetine (r_pobj) After_0\IN|treatment (r_prep) was_5\VBD|after|,|there|improvement|induced|. (l_advcl) induced_19\VBN|-|dyskinesias|without (l_prep) without_21\IN|modification (l_pobj) modification_22\NN|of (l_prep) of_23\IN|disability (l_pobj) disability_26\NN|parkinsonian|motor (l_amod) parkinsonian_24\JJ|
D005473_D010300 NONE fluoxetine_9\NN| (r_pobj) with_8\IN|fluoxetine (r_prep) transmission_7\NN|increased|serotoninergic|with (r_nsubj) reduce_11\VB|that|transmission|may|dyskinesias|without (l_prep) without_19\IN|disability (l_pobj) disability_23\NN|aggravating|parkinsonian|motor (l_amod) parkinsonian_21\JJ|
9725303
D019469_D014517 NONE indinavir_11\NNS| (r_compound) therapy_12\NN|indinavir (r_dobj) undergoing_10\VBG|therapy (r_acl) patients_7\NNS|with|undergoing (r_pobj) in_6\IN|patients (r_prep) causing_3\VBG|obstruction|in (l_dobj) obstruction_5\NN|ureteric
D019469_D014517 NONE indinavir_5\JJ| (r_compound) crystals_6\NNS|precipitated|indinavir (r_pobj) by_3\IN|crystals (r_agent) caused_2\VBN|by (r_acl) obstruction_1\NN|ureteric|caused
D019469_D014517 NONE indinavir_25\NNS| (r_compound) therapy_26\NN|indinavir (r_dobj) receive_24\VBP|who|therapy (r_relcl) patients_19\NNS|with|receive (r_pobj) in_18\IN|patients (r_prep) stones_15\NNS|ureteric|or|obstruction|in (l_conj) obstruction_17\NN|
D019469_D014514 CID indinavir_17\NNS| (r_dobj) receiving_16\VBG|indinavir (r_acl) patients_15\NNS|six|infected|receiving (r_pobj) in_10\IN|patients (r_prep) describe_2\VBP|:|we|features|in|,|inhibitor|. (l_dobj) features_6\NNS|the|unique|ct|of (l_prep) of_7\IN|calculi (l_pobj) calculi_9\NNS|ureteric
D019469_D014514 NONE indinavir_25\NNS| (r_compound) therapy_26\NN|indinavir (r_dobj) receive_24\VBP|who|therapy (r_relcl) patients_19\NNS|with|receive (r_pobj) in_18\IN|patients (r_prep) stones_15\NNS|ureteric|or|obstruction|in (l_conj) obstruction_17\NN|
D019469_D015658 NONE indinavir_17\NNS| (r_dobj) receiving_16\VBG|indinavir (r_acl) patients_15\NNS|six|infected|receiving (l_amod) infected_14\VBN|hiv|-
D019469_D015658 NONE indinavir_25\NNS| (r_compound) therapy_26\NN|indinavir (r_dobj) receive_24\VBP|who|therapy (r_relcl) patients_19\NNS|with|receive (l_prep) with_20\IN|infection (l_pobj) infection_22\NN|hiv
D019469_D052878 NONE indinavir_17\NNS| (r_dobj) receiving_16\VBG|indinavir (r_acl) patients_15\NNS|six|infected|receiving (r_pobj) in_10\IN|patients (r_prep) describe_2\VBP|:|we|features|in|,|inhibitor|. (l_dobj) inhibitor_25\NN|the|used|protease|,|associated (l_relcl) associated_29\VBN|which|is|with (l_prep) with_30\IN|incidence (l_pobj) incidence_33\NN|an|increased|of (l_prep) of_34\IN|urolithiasis (l_pobj) urolithiasis_35\NN|
10427794
C065757_D056486 CID Meloxicam_0\NNP| (r_npadvmod) induced_2\VBN|meloxicam|- (r_amod) toxicity_4\NN|induced|liver|.
C065757_D056486 CID meloxicam_18\NN| (r_pobj) due_16\IN|to|meloxicam (r_prep) developed_12\VBD|who|hepatitis|due (l_dobj) hepatitis_15\NN|acute|cytolytic
C065757_D056486 CID meloxicam_7\NNP| (r_compound) administration_8\NN|meloxicam (r_pobj) after_6\IN|administration (r_prep) occurred_4\VBD|hepatitis|rapidly|after|and|associated|. (l_nsubj) hepatitis_3\NN|the|acute|cytolytic
C065757_D056486 CID meloxicam_4\NNP| (r_nmod) toxicity_7\NN|meloxicam|related|liver
C065757_D056486 CID meloxicam_4\NNP| (r_nmod) toxicity_7\NN|meloxicam|related|liver (r_pobj) of_3\IN|toxicity (r_prep) case_2\NN|this|first|of (r_nsubj) demonstrates_8\VBZ|case|potential|induce|. (l_xcomp) induce_15\VB|to|damage (l_dobj) damage_17\NN|hepatic
C065757_D001172 NONE meloxicam_18\NN| (r_pobj) due_16\IN|to|meloxicam (r_prep) developed_12\VBD|who|hepatitis|due (r_relcl) arthritis_10\NN|rheumatoid|developed
C065757_D004342 CID meloxicam_7\NNP| (r_compound) administration_8\NN|meloxicam (r_pobj) after_6\IN|administration (r_prep) occurred_4\VBD|hepatitis|rapidly|after|and|associated|. (l_conj) associated_11\VBN|was|with|suggesting (l_advcl) suggesting_18\VBG|mechanism (l_dobj) mechanism_21\NN|a|hypersensitivity (l_compound) hypersensitivity_20\NN|
11425091
D003042_D007235 CID cocaine_1\NN|prenatal (r_compound) exposure_2\NN|cocaine|and|findings|in|. (l_prep) in_7\IN|infants (l_pobj) infants_9\NNS|preterm
D003042_D007235 CID cocaine_6\NN|prenatal (r_compound) exposure_7\NN|cocaine (r_nsubj) increases_8\VBZ|if|exposure|incidence (l_dobj) incidence_10\NN|the|of (l_prep) of_11\IN|cysts (l_pobj) cysts_13\NNS|subependymal|in (l_prep) in_14\IN|infants (l_pobj) infants_16\NNS|preterm
D003042_D007235 CID cocaine_16\NN|prenatally (r_pobj) to_15\IN|cocaine (r_prep) exposed_14\VBN|who|were|to (r_relcl) infants_11\NNS|preterm|exposed
D003042_D006470 NONE cocaine_1\NN|prenatal (r_compound) exposure_2\NN|cocaine (r_nsubjpass) linked_5\VBN|exposure|has|been|with|. (l_prep) with_6\IN|hemorrhage (l_pobj) hemorrhage_8\NN|subependymal|and|formation
D003042_D003560 CID cocaine_1\NN|prenatal (r_compound) exposure_2\NN|cocaine (r_nsubjpass) linked_5\VBN|exposure|has|been|with|. (l_prep) with_6\IN|hemorrhage (l_pobj) hemorrhage_8\NN|subependymal|and|formation (l_conj) formation_11\NN|the|of|are (l_prep) of_12\IN|cysts (l_pobj) cysts_13\NNS|
D003042_D003560 CID cocaine_6\NN|prenatal (r_compound) exposure_7\NN|cocaine (r_nsubj) increases_8\VBZ|if|exposure|incidence (l_dobj) incidence_10\NN|the|of (l_prep) of_11\IN|cysts (l_pobj) cysts_13\NNS|subependymal|in
D003042_D003560 CID cocaine_9\NN| (r_pobj) to_8\IN|cocaine (r_prep) exposed_7\VBN|to|prenatally (r_acl) infants_6\NNS|exposed (r_pobj) in_5\IN|infants (r_prep) cysts_4\NNS|subependymal|in
D003042_D003560 CID cocaine_16\NN|prenatally (r_pobj) to_15\IN|cocaine (r_prep) exposed_14\VBN|who|were|to (r_relcl) infants_11\NNS|preterm|exposed (r_pobj) in_9\IN|infants (r_prep) formation_8\NN|subependymal|cyst|in (l_compound) cyst_7\NN|
D003042_D001927 CID cocaine_6\NN|prenatal (r_compound) exposure_7\NN|cocaine (r_nsubj) increases_8\VBZ|if|exposure|incidence (l_dobj) incidence_10\NN|the|of (l_prep) of_11\IN|cysts (l_pobj) cysts_13\NNS|subependymal|in
D003042_D001927 CID cocaine_9\NN| (r_pobj) to_8\IN|cocaine (r_prep) exposed_7\VBN|to|prenatally (r_acl) infants_6\NNS|exposed (r_pobj) in_5\IN|infants (r_prep) cysts_4\NNS|subependymal|in
D003042_D001927 CID cocaine_16\NN|prenatally (r_pobj) to_15\IN|cocaine (r_prep) exposed_14\VBN|who|were|to (r_relcl) infants_11\NNS|preterm|exposed (r_pobj) in_9\IN|infants (r_prep) formation_8\NN|subependymal|cyst|in (l_compound) cyst_7\NN|
D003042_D019970 NONE cocaine_5\NN| (r_npadvmod) exposed_7\VBN|cocaine|- (r_amod) group_8\NN|the|exposed (r_pobj) to_3\IN|group (r_prep) assigned_2\VBN|infants|were|to|was|. (l_advcl) was_11\VBD|if|there|history|were (l_attr) history_14\NN|a|maternal|of|or (l_prep) of_15\IN|abuse (l_pobj) abuse_17\NN|cocaine|during
978847
D006145_D006973 NONE guanethidine_13\NN| (r_pobj) of_12\IN|guanethidine (r_prep) injection_11\NN|the|intravenous|(|i.v.|)|of|(|mg|)|,|hexamethonium (r_pobj) by_5\IN|injection (r_agent) reduced_4\VBN|response|was|significantly|by|,|and|potentiated|. (l_conj) potentiated_34\VBN|conversely|,|by|,|propranolol (l_advcl) propranolol_44\NN|while|mg|i.v.|inhibited (l_conj) inhibited_51\VBD|selectively|enlargement (l_dobj) enlargement_53\NN|the|of|and|tachycardia (l_prep) of_54\IN|pressure (l_pobj) pressure_56\NN|pulse
D006145_D013610 NONE guanethidine_13\NN| (r_pobj) of_12\IN|guanethidine (r_prep) injection_11\NN|the|intravenous|(|i.v.|)|of|(|mg|)|,|hexamethonium (r_pobj) by_5\IN|injection (r_agent) reduced_4\VBN|response|was|significantly|by|,|and|potentiated|. (l_conj) potentiated_34\VBN|conversely|,|by|,|propranolol (l_advcl) propranolol_44\NN|while|mg|i.v.|inhibited (l_conj) inhibited_51\VBD|selectively|enlargement (l_dobj) enlargement_53\NN|the|of|and|tachycardia (l_conj) tachycardia_59\NNS|the|following
D018738_D006973 NONE hexamethonium_19\NN|(|mg|)|or|phentolamine (r_conj) injection_11\NN|the|intravenous|(|i.v.|)|of|(|mg|)|,|hexamethonium (r_pobj) by_5\IN|injection (r_agent) reduced_4\VBN|response|was|significantly|by|,|and|potentiated|. (l_conj) potentiated_34\VBN|conversely|,|by|,|propranolol (l_advcl) propranolol_44\NN|while|mg|i.v.|inhibited (l_conj) inhibited_51\VBD|selectively|enlargement (l_dobj) enlargement_53\NN|the|of|and|tachycardia (l_prep) of_54\IN|pressure (l_pobj) pressure_56\NN|pulse
D018738_D013610 NONE hexamethonium_19\NN|(|mg|)|or|phentolamine (r_conj) injection_11\NN|the|intravenous|(|i.v.|)|of|(|mg|)|,|hexamethonium (r_pobj) by_5\IN|injection (r_agent) reduced_4\VBN|response|was|significantly|by|,|and|potentiated|. (l_conj) potentiated_34\VBN|conversely|,|by|,|propranolol (l_advcl) propranolol_44\NN|while|mg|i.v.|inhibited (l_conj) inhibited_51\VBD|selectively|enlargement (l_dobj) enlargement_53\NN|the|of|and|tachycardia (l_conj) tachycardia_59\NNS|the|following
D010646_D006973 NONE phentolamine_25\NN|mg (r_conj) hexamethonium_19\NN|(|mg|)|or|phentolamine (r_conj) injection_11\NN|the|intravenous|(|i.v.|)|of|(|mg|)|,|hexamethonium (r_pobj) by_5\IN|injection (r_agent) reduced_4\VBN|response|was|significantly|by|,|and|potentiated|. (l_conj) potentiated_34\VBN|conversely|,|by|,|propranolol (l_advcl) propranolol_44\NN|while|mg|i.v.|inhibited (l_conj) inhibited_51\VBD|selectively|enlargement (l_dobj) enlargement_53\NN|the|of|and|tachycardia (l_prep) of_54\IN|pressure (l_pobj) pressure_56\NN|pulse
D010646_D013610 NONE phentolamine_25\NN|mg (r_conj) hexamethonium_19\NN|(|mg|)|or|phentolamine (r_conj) injection_11\NN|the|intravenous|(|i.v.|)|of|(|mg|)|,|hexamethonium (r_pobj) by_5\IN|injection (r_agent) reduced_4\VBN|response|was|significantly|by|,|and|potentiated|. (l_conj) potentiated_34\VBN|conversely|,|by|,|propranolol (l_advcl) propranolol_44\NN|while|mg|i.v.|inhibited (l_conj) inhibited_51\VBD|selectively|enlargement (l_dobj) enlargement_53\NN|the|of|and|tachycardia (l_conj) tachycardia_59\NNS|the|following
D003891_D006973 CID desmethylimipramine_37\NN|i.v.|(|mg|) (r_pobj) by_35\IN|desmethylimipramine (r_agent) potentiated_34\VBN|conversely|,|by|,|propranolol (l_advcl) propranolol_44\NN|while|mg|i.v.|inhibited (l_conj) inhibited_51\VBD|selectively|enlargement (l_dobj) enlargement_53\NN|the|of|and|tachycardia (l_prep) of_54\IN|pressure (l_pobj) pressure_56\NN|pulse
D003891_D013610 NONE desmethylimipramine_37\NN|i.v.|(|mg|) (r_pobj) by_35\IN|desmethylimipramine (r_agent) potentiated_34\VBN|conversely|,|by|,|propranolol (l_advcl) propranolol_44\NN|while|mg|i.v.|inhibited (l_conj) inhibited_51\VBD|selectively|enlargement (l_dobj) enlargement_53\NN|the|of|and|tachycardia (l_conj) tachycardia_59\NNS|the|following
D011433_D006973 NONE propranolol_44\NN|while|mg|i.v.|inhibited (l_conj) inhibited_51\VBD|selectively|enlargement (l_dobj) enlargement_53\NN|the|of|and|tachycardia (l_prep) of_54\IN|pressure (l_pobj) pressure_56\NN|pulse
D011433_D013610 NONE propranolol_44\NN|while|mg|i.v.|inhibited (l_conj) inhibited_51\VBD|selectively|enlargement (l_dobj) enlargement_53\NN|the|of|and|tachycardia (l_conj) tachycardia_59\NNS|the|following
D002217_D006973 CID carbachol_62\NN|i.c.|(|mug|) (r_dobj) following_60\VBG|carbachol (r_acl) tachycardia_59\NNS|the|following (r_conj) enlargement_53\NN|the|of|and|tachycardia (l_prep) of_54\IN|pressure (l_pobj) pressure_56\NN|pulse
D002217_D013610 CID carbachol_62\NN|i.c.|(|mug|) (r_dobj) following_60\VBG|carbachol (r_acl) tachycardia_59\NNS|the|following
9428298
D000420_D001249 NONE albuterol_2\NN|nebulized|in|:|study|. (l_prep) in_3\IN|exacerbations (l_pobj) exacerbations_5\NNS|severe|of|in (l_prep) of_6\IN|asthma (l_pobj) asthma_7\NN|
D000420_D001249 NONE albuterol_25\NN| (r_nmod) CNA_27\NNP|nebulized|albuterol|(|) (r_dobj) received_22\VBD|who|cna|versus (r_relcl) exacerbations_18\NNS|severe|of|received (l_prep) of_19\IN|asthma (l_pobj) asthma_20\NN|
D000420_D001249 NONE albuterol_31\NN| (r_nmod) treatments_35\NNS|intermittent|albuterol|(|ina|) (r_pobj) versus_29\IN|treatments (r_prep) received_22\VBD|who|cna|versus (r_relcl) exacerbations_18\NNS|severe|of|received (l_prep) of_19\IN|asthma (l_pobj) asthma_20\NN|
18801087
D000638_D055370 CID Amiodarone_0\NN| (r_npadvmod) related_2\VBN|amiodarone|- (r_amod) mass_4\NN|related|pulmonary|and|glomerulonephritis|in|:|pitfall|.
D000638_D055370 CID amiodarone_36\NN| (r_pobj) with_35\IN|amiodarone (r_prep) treatment_34\NN|with|for (r_pobj) after_33\IN|treatment (r_prep) developed_15\VBD|who|mass|after (l_dobj) mass_18\NN|a|lung|(|cm|(|day|)
D000638_D055370 CID amiodarone_47\NN| (r_npadvmod) related_49\VBN|amiodarone|- (r_amod) lesion_50\NN|an|related (r_attr) was_45\VBD|that|it|lesion (r_ccomp) indicating_42\VBG|was (r_advcl) composed_22\VBN|histologically|lesion|was|of|,|indicating|. (r_conj) suspected_5\VBN|mass|was|highly|be|,|but|composed (l_nsubjpass) mass_2\NN|the|lung
D000638_D055370 CID amiodarone_11\NN| (r_npadvmod) related_13\VBN|amiodarone|- (r_amod) lesion_15\NN|an|related|pulmonary|and|neoplasm
D000638_D055370 CID amiodarone_36\NN| (r_compound) treatment_37\NN|amiodarone (r_pobj) of_35\IN|treatment (r_prep) complication_34\NN|another|possible|of (r_attr) be_31\VB|that|glomerulonephritis|might|complication (r_ccomp) suggests_26\VBZ|be (r_conj) highlights_3\VBZ|case|possibility|,|and|suggests|. (l_dobj) possibility_5\NN|the|be (l_acl) be_20\VB|that|diagnosis|can|difficult|radiologically (l_nsubj) diagnosis_8\NN|differential|between (l_prep) between_9\IN|lesion (l_pobj) lesion_15\NN|an|related|pulmonary|and|neoplasm
D000638_D015433 CID Amiodarone_0\NN| (r_npadvmod) related_2\VBN|amiodarone|- (r_amod) mass_4\NN|related|pulmonary|and|glomerulonephritis|in|:|pitfall|. (l_conj) glomerulonephritis_8\NN|unique|membranous
D000638_D015433 CID amiodarone_11\NN| (r_npadvmod) related_13\VBN|amiodarone|- (r_amod) lesion_15\NN|an|related|pulmonary|and|neoplasm (r_pobj) between_9\IN|lesion (r_prep) diagnosis_8\NN|differential|between (r_nsubj) be_20\VB|that|diagnosis|can|difficult|radiologically (r_acl) possibility_5\NN|the|be (r_dobj) highlights_3\VBZ|case|possibility|,|and|suggests|. (l_conj) suggests_26\VBZ|be (l_ccomp) be_31\VB|that|glomerulonephritis|might|complication (l_nsubj) glomerulonephritis_29\NN|membranous
D000638_D015433 CID amiodarone_36\NN| (r_compound) treatment_37\NN|amiodarone (r_pobj) of_35\IN|treatment (r_prep) complication_34\NN|another|possible|of (r_attr) be_31\VB|that|glomerulonephritis|might|complication (l_nsubj) glomerulonephritis_29\NN|membranous
D000638_D006349 NONE Amiodarone_0\NN| (r_npadvmod) related_2\VBN|amiodarone|- (r_amod) mass_4\NN|related|pulmonary|and|glomerulonephritis|in|:|pitfall|. (l_prep) in_9\IN|patient (l_pobj) patient_11\NN|a|with (l_prep) with_12\IN|disease (l_pobj) disease_15\NN|valvular|heart
D000638_D006349 NONE amiodarone_36\NN| (r_pobj) with_35\IN|amiodarone (r_prep) treatment_34\NN|with|for (r_pobj) after_33\IN|treatment (r_prep) developed_15\VBD|who|mass|after (r_relcl) patient_13\NN|a|developed (r_pobj) in_11\IN|patient (r_prep) Reported_0\VBN|herein|is|in|. (l_auxpass) is_2\VBZ|case|, (l_attr) case_5\NN|an|autopsy|of (l_prep) of_6\IN|disease (l_pobj) disease_9\NN|valvular|heart
D000638_D001145 NONE Amiodarone_0\NN| (r_nsubj) is_1\VBZ|amiodarone|drug|,|but|reported (l_attr) drug_6\NN|an|arrhythmic|for (l_amod) arrhythmic_5\JJ|-
D000638_D013610 NONE Amiodarone_0\NN| (r_nsubj) is_1\VBZ|amiodarone|drug|,|but|reported (l_attr) drug_6\NN|an|arrhythmic|for (l_prep) for_7\IN|tachycardia (l_pobj) tachycardia_11\NN|threatening
D000638_D011507 NONE amiodarone_36\NN| (r_pobj) with_35\IN|amiodarone (r_prep) treatment_34\NN|with|for (r_pobj) after_33\IN|treatment (r_prep) developed_15\VBD|who|mass|after (l_dobj) mass_18\NN|a|lung|(|cm|(|day|) (l_appos) cm_21\NNS|1.5|in|)|and|proteinuria (l_conj) proteinuria_26\NN|
D000638_D008175 NONE amiodarone_47\NN| (r_npadvmod) related_49\VBN|amiodarone|- (r_amod) lesion_50\NN|an|related (r_attr) was_45\VBD|that|it|lesion (r_ccomp) indicating_42\VBG|was (r_advcl) composed_22\VBN|histologically|lesion|was|of|,|indicating|. (r_conj) suspected_5\VBN|mass|was|highly|be|,|but|composed (l_xcomp) be_7\VB|to|cancer (l_attr) cancer_9\NN|lung|on
D000638_D009369 NONE amiodarone_11\NN| (r_npadvmod) related_13\VBN|amiodarone|- (r_amod) lesion_15\NN|an|related|pulmonary|and|neoplasm (l_conj) neoplasm_18\NN|a
D000638_D009369 NONE amiodarone_36\NN| (r_compound) treatment_37\NN|amiodarone (r_pobj) of_35\IN|treatment (r_prep) complication_34\NN|another|possible|of (r_attr) be_31\VB|that|glomerulonephritis|might|complication (r_ccomp) suggests_26\VBZ|be (r_conj) highlights_3\VBZ|case|possibility|,|and|suggests|. (l_dobj) possibility_5\NN|the|be (l_acl) be_20\VB|that|diagnosis|can|difficult|radiologically (l_nsubj) diagnosis_8\NN|differential|between (l_prep) between_9\IN|lesion (l_pobj) lesion_15\NN|an|related|pulmonary|and|neoplasm (l_conj) neoplasm_18\NN|a
24571687
D020927_D019462 CID dexmedetomidine_7\NN|intranasal|for (r_dobj) following_5\VBG|dexmedetomidine (r_prep) bradycardia_4\NNS|severe|following (r_conj) syncope_1\NN|vasovagal|and|bradycardia|.
D020927_D001919 CID dexmedetomidine_7\NN|intranasal|for (r_dobj) following_5\VBG|dexmedetomidine (r_prep) bradycardia_4\NNS|severe|following
D020927_D001919 CID dexmedetomidine_15\NN|intranasal|for (r_pobj) of_13\IN|dexmedetomidine (r_prep) administration_12\NN|of (r_pobj) following_11\VBG|administration (r_acl) girl_10\NN|an|old|following (r_pobj) in_5\IN|girl (r_prep) bradycardia_4\NN|in
D020927_D013575 NONE dexmedetomidine_15\NN|intranasal|for (r_pobj) of_13\IN|dexmedetomidine (r_prep) administration_12\NN|of (r_pobj) following_11\VBG|administration (r_acl) girl_10\NN|an|old|following (r_pobj) in_5\IN|girl (r_prep) bradycardia_4\NN|in (r_conj) syncope_2\NN|and|bradycardia
15096374
D016559_D003872 NONE tacrolimus_11\NN| (r_compound) ointment_12\NN|tacrolimus (r_pobj) with_10\IN|ointment (r_prep) dermatoses_9\NNS|facial|inflammatory|with (r_pobj) of_6\IN|dermatoses (r_prep) treatment_5\NN|of (r_pobj) during_4\IN|treatment (r_prep) Induction_0\NN|of|during|. (l_prep) of_1\IN|dermatitis (l_pobj) dermatitis_3\NN|rosaceiform
D016559_D003872 NONE tacrolimus_11\NN| (r_compound) ointment_12\NN|tacrolimus (r_pobj) with_10\IN|ointment (r_prep) treatment_9\NN|with (r_pobj) of_8\IN|treatment (r_prep) complication_7\NN|a|of (r_pobj) as_5\IN|complication (r_prep) report_1\VBP|we|on|as|. (l_prep) on_2\IN|dermatitis (l_pobj) dermatitis_4\NN|rosaceiform
D016559_D003872 NONE tacrolimus_15\NN| (r_compound) ointment_16\NN|tacrolimus (r_pobj) with_14\IN|ointment (r_prep) treatment_13\NN|with (r_pobj) of_12\IN|treatment (r_prep) complication_11\NN|a|of (r_pobj) as_9\IN|complication (r_prep) spectrum_5\NN|the|of|as (l_prep) of_6\IN|dermatitis (l_pobj) dermatitis_8\NN|rosaceiform
D016559_D005148 NONE tacrolimus_11\NN| (r_compound) ointment_12\NN|tacrolimus (r_pobj) with_10\IN|ointment (r_prep) dermatoses_9\NNS|facial|inflammatory|with
D016559_D005148 NONE tacrolimus_10\NN| (r_compound) ointment_11\NN|tacrolimus (r_pobj) with_9\IN|ointment (r_prep) treated_8\VBN|patients|were|with|because|. (l_nsubjpass) patients_2\NNS|six|adult|with (l_prep) with_3\IN|dermatoses (l_pobj) dermatoses_6\NNS|inflammatory|facial
D016559_D012393 CID Tacrolimus_0\NNP| (r_compound) ointment_1\NN|tacrolimus (r_nsubjpass) used_4\VBN|ointment|is|increasingly|for|,|and|indicate (l_conj) indicate_21\VBP|observations|is|. (l_ccomp) is_25\VBZ|that|treatment|effective (l_acomp) effective_26\JJ|in (l_prep) in_27\IN|rosacea (l_pobj) rosacea_31\NN|aggravated|and|dermatitis
D016559_D019557 NONE Tacrolimus_0\NNP| (r_compound) ointment_1\NN|tacrolimus (r_nsubjpass) used_4\VBN|ointment|is|increasingly|for|,|and|indicate (l_conj) indicate_21\VBP|observations|is|. (l_ccomp) is_25\VBZ|that|treatment|effective (l_acomp) effective_26\JJ|in (l_prep) in_27\IN|rosacea (l_pobj) rosacea_31\NN|aggravated|and|dermatitis (l_conj) dermatitis_34\NN|perioral
D013256_D012393 NONE steroid_28\NN| (r_npadvmod) aggravated_30\VBN|steroid|- (r_amod) rosacea_31\NN|aggravated|and|dermatitis
D013256_D019557 NONE steroid_28\NN| (r_npadvmod) aggravated_30\VBN|steroid|- (r_amod) rosacea_31\NN|aggravated|and|dermatitis (l_conj) dermatitis_34\NN|perioral
753803
D014810_D009135 NONE E_6\NNS|vitamin|and|myopathy (r_pobj) of_4\IN|e (r_prep) lack_3\NN|of|induced (r_pobj) due_1\IN|to|lack (r_amod) Myopathy_0\NNP|due
D014810_D009135 NONE E_6\NNS|vitamin|and|myopathy (l_conj) myopathy_8\NNS|
D014810_D009135 NONE E._46\NNP| (r_punct) encouraged_16\VBN|results|have|authors|investigate|e. (l_nsubj) results_2\NNS|the|encouraging|obtained (l_acl) obtained_3\VBN|in|by (l_prep) in_4\IN|departments (l_pobj) departments_7\NNS|various|authoratative|in (l_prep) in_8\IN|patients (l_pobj) patients_10\NNS|myopathic (l_amod) myopathic_9\JJ|
D014810_D009135 NONE E._46\NNP| (r_punct) encouraged_16\VBN|results|have|authors|investigate|e. (l_xcomp) investigate_20\VB|to|effects (l_dobj) effects_23\NNS|the|beneficial|of|at (l_prep) at_33\IN|doses (l_pobj) doses_35\NNS|high|in (l_prep) in_36\IN|rats (l_pobj) rats_37\NNS|rendered (l_acl) rendered_38\VBN|myopathic|by (l_oprd) myopathic_39\JJ|
D014810_D009135 NONE E_91\NN|vitamin (r_pobj) of_89\IN|e (r_prep) lack_88\NN|the|of|but|something (r_attr) is_84\VBZ|finally|because|agent|certainly|not|lack (r_conj) occurs_58\VBZ|because|injury|often|at|;|and|is (r_advcl) have_19\VBP|they|reservations|;|occurs|. (r_conj) conclude_2\VBP|authors|by|,|but|have (l_prep) by_3\IN|affirming (l_pcomp) affirming_4\VBG|efficacy (l_dobj) efficacy_7\NN|the|undoubted|of|in (l_prep) in_12\IN|disease (l_pobj) disease_15\NN|experimental|myopathic
D014810_D009136 CID E._15\NNP|vitamin (r_pobj) in_13\IN|e. (r_prep) lacking_12\VBG|in (r_acl) diet_11\NN|a|lacking (r_dobj) giving_8\VBG|it|diet (r_pcomp) by_7\IN|giving (r_prep) induced_2\VBD|authors|myodystrophy|by (l_dobj) myodystrophy_3\NN|in
D013256_D009135 NONE steroids_14\NNS|anabolizing (r_dobj) using_12\VBG|steroids (r_pcomp) by_11\IN|using (r_prep) obtained_3\VBN|in|by (l_prep) in_4\IN|departments (l_pobj) departments_7\NNS|various|authoratative|in (l_prep) in_8\IN|patients (l_pobj) patients_10\NNS|myopathic (l_amod) myopathic_9\JJ|
D013256_D009135 NONE steroids_14\NNS|anabolizing (r_dobj) using_12\VBG|steroids (r_pcomp) by_11\IN|using (r_prep) obtained_3\VBN|in|by (r_acl) results_2\NNS|the|encouraging|obtained (r_nsubj) encouraged_16\VBN|results|have|authors|investigate|e. (l_xcomp) investigate_20\VB|to|effects (l_dobj) effects_23\NNS|the|beneficial|of|at (l_prep) at_33\IN|doses (l_pobj) doses_35\NNS|high|in (l_prep) in_36\IN|rats (l_pobj) rats_37\NNS|rendered (l_acl) rendered_38\VBN|myopathic|by (l_oprd) myopathic_39\JJ|
D013256_D009135 NONE steroids_11\NNS|the|anabolizing (r_pobj) of_8\IN|steroids (r_prep) efficacy_7\NN|the|undoubted|of|in (l_prep) in_12\IN|disease (l_pobj) disease_15\NN|experimental|myopathic
D008696_D009135 NONE Dianabol_29\NNP|,|ciba (r_appos) agent_27\NN|one|anabolizing|(|dianabol|) (r_pobj) of_24\IN|agent (r_prep) effects_23\NNS|the|beneficial|of|at (r_dobj) investigate_20\VB|to|effects (r_xcomp) encouraged_16\VBN|results|have|authors|investigate|e. (l_nsubj) results_2\NNS|the|encouraging|obtained (l_acl) obtained_3\VBN|in|by (l_prep) in_4\IN|departments (l_pobj) departments_7\NNS|various|authoratative|in (l_prep) in_8\IN|patients (l_pobj) patients_10\NNS|myopathic (l_amod) myopathic_9\JJ|
D008696_D009135 NONE Dianabol_29\NNP|,|ciba (r_appos) agent_27\NN|one|anabolizing|(|dianabol|) (r_pobj) of_24\IN|agent (r_prep) effects_23\NNS|the|beneficial|of|at (l_prep) at_33\IN|doses (l_pobj) doses_35\NNS|high|in (l_prep) in_36\IN|rats (l_pobj) rats_37\NNS|rendered (l_acl) rendered_38\VBN|myopathic|by (l_oprd) myopathic_39\JJ|
-1_D009135 NONE CIBA_31\NNP| (r_appos) Dianabol_29\NNP|,|ciba (r_appos) agent_27\NN|one|anabolizing|(|dianabol|) (r_pobj) of_24\IN|agent (r_prep) effects_23\NNS|the|beneficial|of|at (r_dobj) investigate_20\VB|to|effects (r_xcomp) encouraged_16\VBN|results|have|authors|investigate|e. (l_nsubj) results_2\NNS|the|encouraging|obtained (l_acl) obtained_3\VBN|in|by (l_prep) in_4\IN|departments (l_pobj) departments_7\NNS|various|authoratative|in (l_prep) in_8\IN|patients (l_pobj) patients_10\NNS|myopathic (l_amod) myopathic_9\JJ|
-1_D009135 NONE CIBA_31\NNP| (r_appos) Dianabol_29\NNP|,|ciba (r_appos) agent_27\NN|one|anabolizing|(|dianabol|) (r_pobj) of_24\IN|agent (r_prep) effects_23\NNS|the|beneficial|of|at (l_prep) at_33\IN|doses (l_pobj) doses_35\NNS|high|in (l_prep) in_36\IN|rats (l_pobj) rats_37\NNS|rendered (l_acl) rendered_38\VBN|myopathic|by (l_oprd) myopathic_39\JJ|
19841052
D016578_D015658 NONE cocaine_3\NN| (r_dobj) crack_2\VB|cocaine|as (l_prep) as_4\IN|factor (l_pobj) factor_7\NN|a|risk|for (l_prep) for_8\IN|infection (l_pobj) infection_10\NN|hiv|among
D016578_D015658 NONE cocaine_10\NN| (r_dobj) crack_9\VBP|that|smoking|cocaine (r_relcl) role_6\NN|the|possible|crack|has (l_acl) has_11\VBZ|on (l_prep) on_12\IN|incidence (l_pobj) incidence_14\NN|the|of (l_prep) of_15\IN|infection (l_pobj) infection_17\NN|hiv
D016578_D015658 NONE cocaine_6\NN|crack (r_pobj) of_4\IN|cocaine (r_prep) use_3\NN|the|increasing|of (r_pobj) Given_0\VBN|use (r_prep) sought_9\VBD|given|,|we|examine|. (l_xcomp) examine_11\VB|to|become (l_ccomp) become_19\VBN|whether|use|has|factor (l_attr) factor_22\NN|a|risk|for (l_prep) for_23\IN|infection (l_pobj) infection_25\NN|hiv
D016578_D006679 CID cocaine_13\NN| (r_pobj) of_11\IN|crack|cocaine (r_prep) smokers_10\NNS|daily|of (r_pobj) among_8\IN|smokers (r_prep) seroconversion_7\NN|hiv|among
D016578_D006679 CID cocaine_22\NN| (r_dobj) crack_21\VB|cocaine (r_pcomp) of_20\IN|crack (r_prep) smokers_19\NNS|daily|of (r_attr) were_17\VBD|who|smokers (r_relcl) participants_15\NNS|were (r_pobj) among_14\IN|participants (r_prep) seroconversion_13\NN|hiv|among
D016578_D006679 CID cocaine_3\NN| (r_pobj) of_1\IN|crack|cocaine (r_prep) Smoking_0\NN|of (r_nsubjpass) found_5\VBN|smoking|was|be|. (l_xcomp) be_7\VB|to|factor (l_attr) factor_11\NN|an|independent|risk|for (l_prep) for_12\IN|seroconversion (l_pobj) seroconversion_14\NN|hiv|among
8957205
D000324_D006935 NONE corticotropin_1\NN| (r_npadvmod) releasing_3\VBG|corticotropin|- (r_amod) hormone_4\NN|human|releasing|and (r_nmod) hormone_9\NN|hormone|releasing (r_nsubj) modulate_10\VBP|hormone|response|. (l_dobj) response_14\NN|the|hypercapnic|ventilatory|in (l_amod) hypercapnic_12\JJ|
D013972_D006935 NONE thyrotropin_6\NN| (r_npadvmod) releasing_8\VBG|thyrotropin|- (r_amod) hormone_9\NN|hormone|releasing (r_nsubj) modulate_10\VBP|hormone|response|. (l_dobj) response_14\NN|the|hypercapnic|ventilatory|in (l_amod) hypercapnic_12\JJ|
17223814
D015251_D054537 CID epirubicin_11\NNS|and|paclitaxel (r_pobj) with_10\IN|epirubicin (r_prep) chemotherapy_9\NN|with (r_pobj) of_8\IN|chemotherapy (r_prep) result_7\NN|a|of (r_pobj) as_5\IN|result (r_prep) block_4\NN|operative|atrioventricular|as|.
D017239_D054537 CID paclitaxel_13\NN| (r_conj) epirubicin_11\NNS|and|paclitaxel (r_pobj) with_10\IN|epirubicin (r_prep) chemotherapy_9\NN|with (r_pobj) of_8\IN|chemotherapy (r_prep) result_7\NN|a|of (r_pobj) as_5\IN|result (r_prep) block_4\NN|operative|atrioventricular|as|.
23952588
D007980_D004409 CID levodopa_5\NN| (r_npadvmod) induced_7\VBN|levodopa|- (r_amod) dyskinesia_8\NN|induced|among|with
D007980_D004409 CID levodopa_2\NN| (r_compound) therapy_3\NN|chronic|pulsatile|levodopa|for (r_nsubj) leads_11\VBZ|therapy|to|. (l_prep) to_12\IN|development (l_pobj) development_14\NN|the|of (l_prep) of_15\IN|fluctuations (l_pobj) fluctuations_17\NNS|motor|and|dyskinesia (l_conj) dyskinesia_19\NN|
D007980_D004409 CID levodopa_7\NN| (r_npadvmod) induced_9\VBN|levodopa|- (r_amod) dyskinesia_10\NN|induced|among
D007980_D004409 CID levodopa_13\NN| (r_compound) therapy_14\NN|median|levodopa|of (r_pobj) with_11\IN|therapy (r_prep) present_2\JJ|in|with (r_acomp) was_1\VBD|dyskinesia|present|. (l_nsubj) Dyskinesia_0\NNP|
D007980_D004409 CID levodopa_16\NN| (r_compound) therapy_17\NN|levodopa (r_pobj) of_15\IN|therapy (r_prep) duration_14\NN|longer|of|0.001|,|duration|,|dose (r_dobj) had_3\VBD|patients|age|,|duration|. (l_nsubj) Patients_0\NNS|with (l_prep) with_1\IN|dyskinesia (l_pobj) dyskinesia_2\JJ|
D007980_D004409 CID levodopa_16\NN| (r_compound) therapy_17\NN|levodopa (r_pobj) of_15\IN|therapy (r_prep) duration_14\NN|longer|of|0.001|,|duration|,|dose (l_appos) dose_37\NN|higher|total|levodopa|0.001|,|and|scores (l_conj) scores_48\NNS|higher|total|updrs|(|p (l_appos) p_50\NN|0.005|)|than (l_prep) than_54\IN|patients (l_pobj) patients_55\NNS|without (l_prep) without_56\IN|dyskinesia (l_pobj) dyskinesia_57\JJ|
D007980_D004409 CID levodopa_36\NN|daily (r_compound) dose_37\NN|higher|total|levodopa|0.001|,|and|scores (r_appos) duration_14\NN|longer|of|0.001|,|duration|,|dose (r_dobj) had_3\VBD|patients|age|,|duration|. (l_nsubj) Patients_0\NNS|with (l_prep) with_1\IN|dyskinesia (l_pobj) dyskinesia_2\JJ|
D007980_D004409 CID levodopa_36\NN|daily (r_compound) dose_37\NN|higher|total|levodopa|0.001|,|and|scores (l_conj) scores_48\NNS|higher|total|updrs|(|p (l_appos) p_50\NN|0.005|)|than (l_prep) than_54\IN|patients (l_pobj) patients_55\NNS|without (l_prep) without_56\IN|dyskinesia (l_pobj) dyskinesia_57\JJ|
D007980_D004409 CID levodopa_9\NN| (r_compound) therapy_10\NN|levodopa|,|age (r_pobj) of_8\IN|therapy (r_prep) duration_7\NN|of (r_attr) were_6\VBD|predictors|duration|. (l_nsubj) predictors_3\NNS|the|three|significant|of (l_prep) of_4\IN|dyskinesia (l_pobj) dyskinesia_5\JJ|
D007980_D004409 CID levodopa_18\NN| (r_compound) dose_19\NN|total|daily|levodopa (r_conj) age_13\NN|onset|,|and|dose (r_conj) therapy_10\NN|levodopa|,|age (r_pobj) of_8\IN|therapy (r_prep) duration_7\NN|of (r_attr) were_6\VBD|predictors|duration|. (l_nsubj) predictors_3\NNS|the|three|significant|of (l_prep) of_4\IN|dyskinesia (l_pobj) dyskinesia_5\JJ|
D007980_D004409 CID levodopa_3\NN| (r_npadvmod) induced_5\VBN|levodopa|- (r_amod) dyskinesia_6\NN|induced
D007980_D010300 NONE levodopa_5\NN| (r_npadvmod) induced_7\VBN|levodopa|- (r_amod) dyskinesia_8\NN|induced|among|with (l_prep) with_12\IN|disease (l_pobj) disease_15\NN|parkinson
D007980_D010300 NONE levodopa_2\NN| (r_compound) therapy_3\NN|chronic|pulsatile|levodopa|for (l_prep) for_4\IN|disease (l_pobj) disease_7\NN|parkinson|(|pd|)
D007980_D010300 NONE levodopa_2\NN| (r_compound) therapy_3\NN|chronic|pulsatile|levodopa|for (l_prep) for_4\IN|disease (l_pobj) disease_7\NN|parkinson|(|pd|) (l_appos) PD_9\NNP|
D007980_D010300 NONE levodopa_7\NN| (r_npadvmod) induced_9\VBN|levodopa|- (r_amod) dyskinesia_10\NN|induced|among (l_prep) among_11\IN|patients (l_pobj) patients_14\NNS|multiethnic|malaysian|with (l_prep) with_15\IN|pd (l_pobj) PD_16\NNP|
D007980_D010300 NONE levodopa_14\NN| (r_compound) therapy_15\NN|uninterrupted|levodopa (r_pobj) on_12\IN|therapy (r_prep) patients_9\NNS|95|with|on (l_prep) with_10\IN|pd (l_pobj) PD_11\NNP|
20408947
D000082_D017114 CID acetaminophen_8\RB| (r_advmod) induced_10\VBN|acetaminophen|- (r_amod) failure_13\NN|induced|acute|liver
D000082_D017114 CID Acetaminophen_0\NNP| (r_npadvmod) induced_2\VBN|acetaminophen|- (r_amod) hepatotoxicity_3\NN|induced (r_nsubj) is_4\VBZ|hepatotoxicity|cause|. (l_attr) cause_8\NN|the|common|of (l_prep) of_9\IN|failure (l_pobj) failure_12\NN|acute|liver|(|alf|in
D000082_D017114 CID Acetaminophen_0\NNP| (r_npadvmod) induced_2\VBN|acetaminophen|- (r_amod) hepatotoxicity_3\NN|induced (r_nsubj) is_4\VBZ|hepatotoxicity|cause|. (l_attr) cause_8\NN|the|common|of (l_prep) of_9\IN|failure (l_pobj) failure_12\NN|acute|liver|(|alf|in (l_appos) ALF_14\NNP|)
D000082_D017114 CID acetaminophen_34\RB| (r_advmod) induced_36\VBN|acetaminophen|- (r_amod) ALF_37\NNP|induced|n=36
D000082_D017114 CID acetaminophen_34\RB| (r_advmod) induced_36\VBN|acetaminophen|- (r_amod) ALF_37\NNP|induced|n=36 (l_appos) n=36_39\NNP|(|)|with (l_prep) with_41\IN|patients (l_pobj) patients_47\NNS|age-|matched|undergoing (l_acl) undergoing_48\VBG|lt (l_dobj) LT_50\NN|emergent|for (l_prep) for_51\IN|alf (l_pobj) ALF_57\NNP|induced|(|n=35|)|and|lt
D000082_D017114 CID acetaminophen_54\RB| (r_advmod) induced_56\VBN|non|-|acetaminophen|- (r_amod) ALF_57\NNP|induced|(|n=35|)|and|lt (r_pobj) for_51\IN|alf (r_prep) LT_50\NN|emergent|for (r_dobj) undergoing_48\VBG|lt (r_acl) patients_47\NNS|age-|matched|undergoing (r_pobj) with_41\IN|patients (r_prep) n=36_39\NNP|(|)|with (r_appos) ALF_37\NNP|induced|n=36
D000082_D017114 CID acetaminophen_54\RB| (r_advmod) induced_56\VBN|non|-|acetaminophen|- (r_amod) ALF_57\NNP|induced|(|n=35|)|and|lt
D000082_D017114 CID Acetaminophen_0\NNP| (r_npadvmod) induced_2\VBN|acetaminophen|- (r_amod) patients_4\NNS|induced|alf|undergoing (l_compound) ALF_3\NNP|
D000082_D017114 CID acetaminophen_5\RB| (r_advmod) induced_7\VBN|acetaminophen|- (r_amod) patients_9\NNS|twenty|(|%|induced|alf (l_compound) ALF_8\NNP|
D000082_D017114 CID acetaminophen_5\RB| (r_advmod) induced_7\VBN|acetaminophen|- (r_amod) patients_9\NNS|twenty|(|%|induced|alf (r_nsubj) had_10\VBD|patients|diagnosis|before (l_prep) before_15\IN|lt (l_pobj) LT_16\NNP|alf=0/35 (l_appos) ALF=0/35_23\NNP|non|induced|,|cld=2/34
D000082_D017114 CID acetaminophen_20\RB| (r_advmod) induced_22\VBN|acetaminophen|- (r_amod) ALF=0/35_23\NNP|non|induced|,|cld=2/34 (r_appos) LT_16\NNP|alf=0/35 (r_pobj) before_15\IN|lt (r_prep) had_10\VBD|patients|diagnosis|before (l_nsubj) patients_9\NNS|twenty|(|%|induced|alf (l_compound) ALF_8\NNP|
D000082_D017114 CID acetaminophen_20\RB| (r_advmod) induced_22\VBN|acetaminophen|- (r_amod) ALF=0/35_23\NNP|non|induced|,|cld=2/34
D000082_D017114 CID acetaminophen_31\RB| (r_advmod) induced_33\VBN|acetaminophen|- (r_amod) ALF_34\NNP|induced|year
D000082_D017114 CID acetaminophen_31\RB| (r_advmod) induced_33\VBN|acetaminophen|- (r_amod) ALF_34\NNP|induced|year (r_appos) groups_29\NNS|the|(|alf|;|alf (l_appos) ALF_50\NNP|non|%|;
D000082_D017114 CID acetaminophen_47\RB| (r_advmod) induced_49\VBN|acetaminophen|- (r_acomp) non_45\AFX|-|induced (r_nmod) ALF_50\NNP|non|%|; (r_appos) groups_29\NNS|the|(|alf|;|alf (l_appos) ALF_34\NNP|induced|year
D000082_D017114 CID acetaminophen_47\RB| (r_advmod) induced_49\VBN|acetaminophen|- (r_acomp) non_45\AFX|-|induced (r_nmod) ALF_50\NNP|non|%|;
D000082_D017114 CID acetaminophen_1\RB| (r_advmod) induced_3\VBN|acetaminophen|- (r_amod) patients_5\NNS|two|induced|alf (l_compound) ALF_4\NNP|
D000082_D017114 CID acetaminophen_14\RB| (r_advmod) induced_16\VBN|acetaminophen|- (r_amod) ALF_17\NNP|induced
D000082_D017114 CID acetaminophen_14\RB| (r_advmod) induced_16\VBN|acetaminophen|- (r_amod) ALF_17\NNP|induced (r_pobj) for_13\IN|alf (r_prep) transplanted_11\VBN|emergently|for (r_acl) patients_10\NNS|transplanted (r_pobj) for_9\IN|patients (r_prep) outcomes_8\NNS|for (r_nsubj) were_18\VBD|despite|,|outcomes|comparable|. (l_acomp) comparable_19\JJ|to (l_prep) to_20\IN|those (l_pobj) those_21\DT|transplanted (l_acl) transplanted_22\VBN|for|for (l_prep) for_23\IN|alf|and (l_pobj) ALF_29\NNP|induced
D000082_D017114 CID acetaminophen_26\RB| (r_advmod) induced_28\VBN|non|-|acetaminophen|- (r_amod) ALF_29\NNP|induced (r_pobj) for_23\IN|alf|and (r_prep) transplanted_22\VBN|for|for (r_acl) those_21\DT|transplanted (r_pobj) to_20\IN|those (r_prep) comparable_19\JJ|to (r_acomp) were_18\VBD|despite|,|outcomes|comparable|. (l_nsubj) outcomes_8\NNS|for (l_prep) for_9\IN|patients (l_pobj) patients_10\NNS|transplanted (l_acl) transplanted_11\VBN|emergently|for (l_prep) for_13\IN|alf (l_pobj) ALF_17\NNP|induced
D000082_D017114 CID acetaminophen_26\RB| (r_advmod) induced_28\VBN|non|-|acetaminophen|- (r_amod) ALF_29\NNP|induced
D000082_D056486 CID Acetaminophen_0\NNP| (r_npadvmod) induced_2\VBN|acetaminophen|- (r_amod) hepatotoxicity_3\NN|induced
D000082_D008107 NONE acetaminophen_34\RB| (r_advmod) induced_36\VBN|acetaminophen|- (r_amod) ALF_37\NNP|induced|n=36 (l_appos) n=36_39\NNP|(|)|with (l_prep) with_41\IN|patients (l_pobj) patients_47\NNS|age-|matched|undergoing (l_acl) undergoing_48\VBG|lt (l_dobj) LT_50\NN|emergent|for (l_prep) for_51\IN|alf (l_pobj) ALF_57\NNP|induced|(|n=35|)|and|lt (l_conj) LT_63\NN|elective|for (l_prep) for_64\IN|disease (l_pobj) disease_67\NN|chronic|liver|(|cld|)
D000082_D008107 NONE acetaminophen_34\RB| (r_advmod) induced_36\VBN|acetaminophen|- (r_amod) ALF_37\NNP|induced|n=36 (l_appos) n=36_39\NNP|(|)|with (l_prep) with_41\IN|patients (l_pobj) patients_47\NNS|age-|matched|undergoing (l_acl) undergoing_48\VBG|lt (l_dobj) LT_50\NN|emergent|for (l_prep) for_51\IN|alf (l_pobj) ALF_57\NNP|induced|(|n=35|)|and|lt (l_conj) LT_63\NN|elective|for (l_prep) for_64\IN|disease (l_pobj) disease_67\NN|chronic|liver|(|cld|) (l_appos) CLD_69\NNP|,|n=34
D000082_D008107 NONE acetaminophen_54\RB| (r_advmod) induced_56\VBN|non|-|acetaminophen|- (r_amod) ALF_57\NNP|induced|(|n=35|)|and|lt (l_conj) LT_63\NN|elective|for (l_prep) for_64\IN|disease (l_pobj) disease_67\NN|chronic|liver|(|cld|)
D000082_D008107 NONE acetaminophen_54\RB| (r_advmod) induced_56\VBN|non|-|acetaminophen|- (r_amod) ALF_57\NNP|induced|(|n=35|)|and|lt (l_conj) LT_63\NN|elective|for (l_prep) for_64\IN|disease (l_pobj) disease_67\NN|chronic|liver|(|cld|) (l_appos) CLD_69\NNP|,|n=34
D000082_D008107 NONE acetaminophen_5\RB| (r_advmod) induced_7\VBN|acetaminophen|- (r_amod) patients_9\NNS|twenty|(|%|induced|alf (r_nsubj) had_10\VBD|patients|diagnosis|before (l_prep) before_15\IN|lt (l_pobj) LT_16\NNP|alf=0/35 (l_appos) ALF=0/35_23\NNP|non|induced|,|cld=2/34 (l_appos) CLD=2/34_25\NNP|
D000082_D008107 NONE acetaminophen_20\RB| (r_advmod) induced_22\VBN|acetaminophen|- (r_amod) ALF=0/35_23\NNP|non|induced|,|cld=2/34 (l_appos) CLD=2/34_25\NNP|
D000082_D008107 NONE acetaminophen_31\RB| (r_advmod) induced_33\VBN|acetaminophen|- (r_amod) ALF_34\NNP|induced|year (r_appos) groups_29\NNS|the|(|alf|;|alf (r_pobj) between_27\IN|groups (r_prep) failure_24\NN|graft|or|survival|between (r_conj) differences_14\NNS|no|significant|in|,|failure|cld (l_conj) CLD_57\NNP|%
D000082_D008107 NONE acetaminophen_47\RB| (r_advmod) induced_49\VBN|acetaminophen|- (r_acomp) non_45\AFX|-|induced (r_nmod) ALF_50\NNP|non|%|; (r_appos) groups_29\NNS|the|(|alf|;|alf (r_pobj) between_27\IN|groups (r_prep) failure_24\NN|graft|or|survival|between (r_conj) differences_14\NNS|no|significant|in|,|failure|cld (l_conj) CLD_57\NNP|%
D000082_D008107 NONE acetaminophen_14\RB| (r_advmod) induced_16\VBN|acetaminophen|- (r_amod) ALF_17\NNP|induced (r_pobj) for_13\IN|alf (r_prep) transplanted_11\VBN|emergently|for (r_acl) patients_10\NNS|transplanted (r_pobj) for_9\IN|patients (r_prep) outcomes_8\NNS|for (r_nsubj) were_18\VBD|despite|,|outcomes|comparable|. (l_acomp) comparable_19\JJ|to (l_prep) to_20\IN|those (l_pobj) those_21\DT|transplanted (l_acl) transplanted_22\VBN|for|for (l_prep) for_32\IN|electively|cld (l_pobj) CLD_33\NNP|
D000082_D008107 NONE acetaminophen_26\RB| (r_advmod) induced_28\VBN|non|-|acetaminophen|- (r_amod) ALF_29\NNP|induced (r_pobj) for_23\IN|alf|and (r_prep) transplanted_22\VBN|for|for (l_prep) for_32\IN|electively|cld (l_pobj) CLD_33\NNP|
24614773
D014635_D001927 NONE valproate_4\VBP|solely|induced (r_acl) encephalopathy_1\NN|normoammonemic|:|valproate|?
D014635_D001927 NONE valproate_4\NN| (r_npadvmod) induced_6\VBN|valproate|- (r_amod) encephalopathy_7\JJ|induced|and|encephalitis
D014635_D010291 NONE valproate_25\NN|for (r_conj) started_23\VBN|had|been|on|valproate (r_conj) had_7\VBD|in|,|patient|number|,|and|started|. (l_dobj) number_9\NN|a|of (l_prep) of_10\IN|admissions (l_pobj) admissions_11\NNS|with (l_prep) with_12\IN|hemiparesis (l_pobj) hemiparesis_15\NN|transient|unilateral|with
D014635_D020325 NONE valproate_25\NN|for (l_prep) for_26\IN|migraine (l_pobj) migraine_29\NN|presumed|hemiplegic
D016202_D001927 NONE aspartate_20\NNP|d|- (r_nmod) antibodies_25\NNS|low|titre|aspartate|receptor (r_conj) encephalopathy_9\JJ|,|and|antibodies
D016202_D001927 NONE NMDA_22\NNP| (r_nmod) receptor_24\NN|(|nmda|) (r_compound) antibodies_25\NNS|low|titre|aspartate|receptor (r_conj) encephalopathy_9\JJ|,|and|antibodies
D016202_D001927 NONE NMDA_9\NNP| (r_nmod) encephalitis_13\NN|nmda|associated (r_conj) encephalopathy_7\JJ|induced|and|encephalitis
D014635_D004660 NONE valproate_4\NN| (r_npadvmod) induced_6\VBN|valproate|- (r_amod) encephalopathy_7\JJ|induced|and|encephalitis (l_conj) encephalitis_13\NN|nmda|associated
D016202_D004660 NONE NMDA_9\NNP| (r_nmod) encephalitis_13\NN|nmda|associated
6728873
D002110_D012640 CID caffeine_28\NN| (r_compound) doses_29\NNS|various|caffeine|in|under (r_pobj) at_26\IN|doses (r_prep) scored_25\VBN|characteristics|were|at|. (l_nsubjpass) characteristics_2\NNS|five|phenotypic|--|activity|righting|-- (l_acl) righting_7\VBG|ability (l_dobj) ability_8\NN|,|induction (l_conj) induction_12\NN|seizure|,|lethality (l_compound) seizure_11\NN|clonic
-1_D064420 NONE alkylxanthines_8\NNS| (r_pobj) of_7\IN|alkylxanthines (r_prep) testing_6\NN|behavioral|toxicity|of|in (l_compound) toxicity_5\NN|
17351238
D005996_D007022 CID GTN_8\NNP| (r_compound) administration_9\NN|prehospital|gtn (r_pobj) following_6\VBG|administration (r_prep) drop_2\NN|a|dramatic|in|following|. (l_prep) in_3\IN|pressure (l_pobj) pressure_5\NN|blood
D005996_D007022 CID GTN_4\NNP|the|patient (r_nsubj) experienced_7\VBD|minutes|after|gtn|drop (l_dobj) drop_10\NN|a|sudden|in (l_prep) in_11\IN|pressure (l_pobj) pressure_13\NN|blood|and|rate
D001285_D007022 NONE sulphate_23\NN|atropine|and|challenge (r_pobj) by_21\IN|sulphate (r_agent) rectified_20\VBN|experienced|,|this|was|by|. (l_advcl) experienced_7\VBD|minutes|after|gtn|drop (l_dobj) drop_10\NN|a|sudden|in (l_prep) in_11\IN|pressure (l_pobj) pressure_13\NN|blood|and|rate
24209900
D007069_D001927 NONE Ifosfamide_0\IN| (r_nmod) encephalopathy_2\NN|ifosfamide|related|:|need|.
D007069_D001927 NONE ifosfamide_16\NN|dose|iv (r_dobj) receiving_11\VBG|ifosfamide (r_acl) patients_10\NNS|receiving (r_pobj) of_9\IN|patients (r_prep) %_8\NN|40|of (r_pobj) in_4\IN|% (r_prep) reported_3\VBN|encephalopathy|has|been|in|. (l_nsubjpass) Encephalopathy_0\NNP|
D007069_D001927 NONE ifosfamide_16\JJ| (r_advmod) related_17\VBN|ifosfamide (r_amod) encephalopathy_18\NN|related
D007069_D001927 NONE ifosfamide_29\RB| (r_advmod) related_30\VBN|ifosfamide (r_amod) encephalopathy_32\NN|related|acute
D007069_D001927 NONE ifosfamide_17\RB| (r_advmod) receiving_16\VBG|ifosfamide (r_advcl) experienced_4\VBD|:|patients|symptoms|after|(|within|)|receiving|. (l_dobj) symptoms_5\NNS|of (l_prep) of_6\IN|encephalopathy (l_pobj) encephalopathy_7\JJ|
D007069_D001927 NONE ifosfamide_2\JJ| (r_advmod) related_3\JJ|ifosfamide (r_amod) encephalopathy_4\JJ|related
D007069_D001927 NONE ifosfamide_9\RB|develop (l_relcl) develop_11\VBP|who|features (l_dobj) features_12\NNS|of (l_prep) of_13\IN|encephalopathy (l_pobj) encephalopathy_14\NN|
D007069_D009369 NONE Ifosfamide_0\NNP| (r_nsubj) is_1\VBZ|ifosfamide|agent|. (l_attr) agent_4\NN|an|alkylating|useful (l_amod) useful_5\JJ|in (l_prep) in_6\IN|treatment (l_pobj) treatment_8\NN|the|of (l_prep) of_9\IN|range (l_pobj) range_12\NN|a|wide|of (l_prep) of_13\IN|cancers (l_pobj) cancers_14\NNS|including
D007069_D009369 NONE Ifosfamide_0\NNP| (r_nsubj) is_1\VBZ|ifosfamide|agent|. (l_attr) agent_4\NN|an|alkylating|useful (l_amod) useful_5\JJ|in (l_prep) in_6\IN|treatment (l_pobj) treatment_8\NN|the|of (l_prep) of_9\IN|range (l_pobj) range_12\NN|a|wide|of (l_prep) of_13\IN|cancers (l_pobj) cancers_14\NNS|including (l_prep) including_15\VBG|sarcomas (l_pobj) sarcomas_16\NNS|,|cancers (l_conj) cancers_23\NNS|lymphoma|gynecologic
D007069_D009369 NONE ifosfamide_29\RB| (r_advmod) related_30\VBN|ifosfamide (r_amod) encephalopathy_32\NN|related|acute (r_dobj) developed_28\VBD|who|encephalopathy (r_relcl) done_10\VBN|review|was|on|,|admitted|,|developed|. (l_advcl) admitted_15\VBN|to|between (l_prep) to_16\IN|center (l_pobj) Center_20\NNP|md|anderson|cancer (l_compound) Cancer_19\NNP|
D007069_D012509 NONE Ifosfamide_0\NNP| (r_nsubj) is_1\VBZ|ifosfamide|agent|. (l_attr) agent_4\NN|an|alkylating|useful (l_amod) useful_5\JJ|in (l_prep) in_6\IN|treatment (l_pobj) treatment_8\NN|the|of (l_prep) of_9\IN|range (l_pobj) range_12\NN|a|wide|of (l_prep) of_13\IN|cancers (l_pobj) cancers_14\NNS|including (l_prep) including_15\VBG|sarcomas (l_pobj) sarcomas_16\NNS|,|cancers
D007069_D008223 NONE Ifosfamide_0\NNP| (r_nsubj) is_1\VBZ|ifosfamide|agent|. (l_attr) agent_4\NN|an|alkylating|useful (l_amod) useful_5\JJ|in (l_prep) in_6\IN|treatment (l_pobj) treatment_8\NN|the|of (l_prep) of_9\IN|range (l_pobj) range_12\NN|a|wide|of (l_prep) of_13\IN|cancers (l_pobj) cancers_14\NNS|including (l_prep) including_15\VBG|sarcomas (l_pobj) sarcomas_16\NNS|,|cancers (l_conj) cancers_23\NNS|lymphoma|gynecologic (l_nmod) lymphoma_18\NN|,
11915580
D005996_D004412 NONE trinitrate_4\NN|glyceryl|with|for (l_prep) for_7\IN|treatment (l_pobj) treatment_9\NN|the|of (l_prep) of_10\IN|dysmenorrhea (l_pobj) dysmenorrhea_12\NN|primary
D005996_D004412 NONE trinitrate_13\NN|glyceryl|(|gtn|)|,|donor|, (r_pobj) of_11\IN|trinitrate (r_prep) efficacy_10\NN|the|of (r_dobj) determine_8\VB|to|efficacy|in (l_prep) in_22\IN|resolution (l_pobj) resolution_24\NN|the|of|in (l_prep) of_25\IN|dysmenorrhea (l_pobj) dysmenorrhea_27\NN|primary
D005996_D004412 NONE GTN_15\NNP| (r_appos) trinitrate_13\NN|glyceryl|(|gtn|)|,|donor|, (r_pobj) of_11\IN|trinitrate (r_prep) efficacy_10\NN|the|of (r_dobj) determine_8\VB|to|efficacy|in (l_prep) in_22\IN|resolution (l_pobj) resolution_24\NN|the|of|in (l_prep) of_25\IN|dysmenorrhea (l_pobj) dysmenorrhea_27\NN|primary
D005996_D004412 NONE GTN_4\NNP| (r_nsubj) has_5\VBZ|that|gtn|efficacy|by (l_prep) by_11\IN|comparison (l_pobj) comparison_12\NN|with|in (l_prep) in_15\IN|treatment (l_pobj) treatment_17\NN|the|of (l_prep) of_18\IN|dysmenorrhea (l_pobj) dysmenorrhea_20\NN|primary
D004008_D004412 NONE diclofenac_6\NN| (r_pobj) with_5\IN|diclofenac (r_prep) trinitrate_4\NN|glyceryl|with|for (l_prep) for_7\IN|treatment (l_pobj) treatment_9\NN|the|of (l_prep) of_10\IN|dysmenorrhea (l_pobj) dysmenorrhea_12\NN|primary
D004008_D004412 NONE diclofenac_31\NNP|dcf (r_pobj) with_30\IN|diclofenac (r_prep) comparison_29\NN|with (r_pobj) in_28\IN|comparison (r_prep) resolution_24\NN|the|of|in (l_prep) of_25\IN|dysmenorrhea (l_pobj) dysmenorrhea_27\NN|primary
D004008_D004412 NONE DCF_33\NNP|(|) (r_appos) diclofenac_31\NNP|dcf (r_pobj) with_30\IN|diclofenac (r_prep) comparison_29\NN|with (r_pobj) in_28\IN|comparison (r_prep) resolution_24\NN|the|of|in (l_prep) of_25\IN|dysmenorrhea (l_pobj) dysmenorrhea_27\NN|primary
D004008_D004412 NONE DCF_14\NNP| (r_pobj) with_13\IN|dcf (r_prep) comparison_12\NN|with|in (l_prep) in_15\IN|treatment (l_pobj) treatment_17\NN|the|of (l_prep) of_18\IN|dysmenorrhea (l_pobj) dysmenorrhea_20\NN|primary
D011453_D004412 NONE prostaglandins_16\NNS|endometrial (r_pobj) of_14\IN|prostaglandins (r_prep) hypersecretion_13\NN|a|of (r_pobj) by_11\IN|hypersecretion (r_agent) caused_10\VBN|by (r_acl) contractility_9\NN|painful|uterine|caused (r_pobj) by_6\IN|contractility (r_agent) characterized_5\VBN|by (r_acl) syndrome_4\NN|a|characterized (r_attr) is_2\VBZ|dysmenorrhea|syndrome|are|. (l_nsubj) dysmenorrhea_1\NN|primary
D009569_D004412 NONE NO_19\JJ| (r_det) donor_20\NN|an|no (r_appos) trinitrate_13\NN|glyceryl|(|gtn|)|,|donor|, (r_pobj) of_11\IN|trinitrate (r_prep) efficacy_10\NN|the|of (r_dobj) determine_8\VB|to|efficacy|in (l_prep) in_22\IN|resolution (l_pobj) resolution_24\NN|the|of|in (l_prep) of_25\IN|dysmenorrhea (l_pobj) dysmenorrhea_27\NN|primary
D004008_D017699 NONE DCF_2\NNP| (r_nsubj) continued_3\VBD|however|,|dcf|be|,|remained|. (l_xcomp) be_5\VB|to|effective (l_acomp) effective_6\JJ|in (l_prep) in_7\IN|reducing (l_pcomp) reducing_8\VBG|pain|for (l_dobj) pain_10\NN|pelvic
D005996_D017699 NONE GTN_16\NNP| (r_compound) scores_17\NNS|gtn (r_nsubj) remained_18\VBD|whereas|scores|stable|after|and|higher|(|after|:|gtn (r_advcl) continued_3\VBD|however|,|dcf|be|,|remained|. (l_xcomp) be_5\VB|to|effective (l_acomp) effective_6\JJ|in (l_prep) in_7\IN|reducing (l_pcomp) reducing_8\VBG|pain|for (l_dobj) pain_10\NN|pelvic
D005996_D017699 NONE GTN_38\NNP|,|-12.8|+/-|;|dfc|-18.9|16.6|after|:|gtn|-23.7|20.5|;|dfc (r_npadvmod) remained_18\VBD|whereas|scores|stable|after|and|higher|(|after|:|gtn (r_advcl) continued_3\VBD|however|,|dcf|be|,|remained|. (l_xcomp) be_5\VB|to|effective (l_acomp) effective_6\JJ|in (l_prep) in_7\IN|reducing (l_pcomp) reducing_8\VBG|pain|for (l_dobj) pain_10\NN|pelvic
D005996_D017699 NONE GTN_54\NNP|, (r_appos) GTN_38\NNP|,|-12.8|+/-|;|dfc|-18.9|16.6|after|:|gtn|-23.7|20.5|;|dfc (r_npadvmod) remained_18\VBD|whereas|scores|stable|after|and|higher|(|after|:|gtn (r_advcl) continued_3\VBD|however|,|dcf|be|,|remained|. (l_xcomp) be_5\VB|to|effective (l_acomp) effective_6\JJ|in (l_prep) in_7\IN|reducing (l_pcomp) reducing_8\VBG|pain|for (l_dobj) pain_10\NN|pelvic
D005996_D006261 CID GTN_5\NNP| (r_pobj) by_4\IN|gtn|but|not (r_agent) increased_3\VBN|headache|was|significantly|by|by|. (l_nsubjpass) Headache_0\NNP|
D005996_D006261 CID GTN_4\NNP| (r_dobj) using_3\VBG|gtn (r_xcomp) stopped_2\VBD|patients|using|became|. (l_advcl) became_13\VBD|because|headache|intolerable (l_nsubj) headache_6\NN|--|attributed|--
D004008_D006261 NONE DCF_9\NNP| (r_pobj) by_8\IN|dcf (r_prep) increased_3\VBN|headache|was|significantly|by|by|. (l_nsubjpass) Headache_0\NNP|
3812624
D002220_D009759 NONE carbamazepine_9\NN| (r_pobj) with_8\IN|carbamazepine (r_prep) associated_7\VBN|with (r_acl) cases_1\NNS|two|of|associated|. (l_prep) of_2\IN|nystagmus (l_pobj) nystagmus_4\NN|downbeat|and|oscillopsia
D002220_D009759 NONE carbamazepine_14\NN| (r_compound) therapy_15\NN|carbamazepine (r_pobj) to_13\IN|therapy (r_prep) related_12\VBN|to (r_amod) nystagmus_11\NN|reversible|downbeat|related
D002220_D009759 NONE carbamazepine_11\NN|serum (r_compound) levels_12\NNS|the|carbamazepine (r_pobj) of_8\IN|levels (r_prep) reduction_7\NN|of (r_pobj) after_6\IN|reduction (r_prep) resolved_5\VBN|nystagmus|after|. (l_nsubj) nystagmus_1\NN|the|of
D002220_D015835 CID carbamazepine_9\NN| (r_pobj) with_8\IN|carbamazepine (r_prep) associated_7\VBN|with (r_acl) cases_1\NNS|two|of|associated|. (l_prep) of_2\IN|nystagmus (l_pobj) nystagmus_4\NN|downbeat|and|oscillopsia (l_conj) oscillopsia_6\NN|
10960401
D009020_D009759 CID morphine_10\NN| (r_pobj) of_9\IN|morphine (r_prep) administration_8\NN|intravenous|controlled|of (r_pobj) with_3\IN|administration (r_prep) associated_2\VBN|with (r_acl) nystagmus_1\NN|downbeat|associated|.
D009020_D009759 CID morphine_23\NN|iv|controlled|analgesia (r_pobj) of_17\IN|morphine (r_prep) dose_16\NN|a|large|of (r_dobj) receiving_12\VBG|while|dose (r_advcl) developed_6\VBD|who|dizziness|with|receiving (l_prep) with_8\IN|nystagmus (l_pobj) nystagmus_10\NN|downbeating
D009020_D004244 CID morphine_23\NN|iv|controlled|analgesia (r_pobj) of_17\IN|morphine (r_prep) dose_16\NN|a|large|of (r_dobj) receiving_12\VBG|while|dose (r_advcl) developed_6\VBD|who|dizziness|with|receiving (l_dobj) dizziness_7\NN|
17069550
D005702_D001321 NONE galantamine_8\NN| (r_pobj) of_7\IN|galantamine (r_prep) trial_6\NN|a|prospective|,|label|of|in|. (l_prep) in_9\IN|disorder (l_pobj) disorder_11\NN|autistic
D005702_D001321 NONE galantamine_11\NN|,|inhibitor|, (r_pobj) of_10\IN|galantamine (r_prep) use_9\NN|the|of|in (l_prep) in_21\IN|treatment (l_pobj) treatment_23\NN|the|of (l_prep) of_24\IN|interfering (l_pcomp) interfering_25\VBG|behaviors (l_dobj) behaviors_26\NNS|in (l_prep) in_27\IN|children (l_pobj) children_28\NNS|with (l_prep) with_29\IN|autism (l_pobj) autism_30\NN|
D005702_D001321 NONE galantamine_26\NN| (r_pobj) of_25\IN|galantamine (r_prep) trial_24\NN|a|12-week|,|label|of (r_pobj) in_17\IN|trial (r_prep) participated_16\VBD|children|in|. (l_nsubj) children_4\NNS|thirteen|free|with|) (l_prep) with_5\IN|autism (l_pobj) autism_6\NN|(|age|+/-
D005702_D001321 NONE galantamine_5\NN| (r_nsubj) was_6\VBD|in|,|galantamine|tolerated|and|appeared|. (l_conj) appeared_11\VBD|be (l_xcomp) be_13\VB|to|beneficial (l_acomp) beneficial_14\JJ|for (l_prep) for_15\IN|treatment (l_pobj) treatment_17\NN|the|of (l_prep) of_18\IN|interfering (l_pcomp) interfering_19\VBG|behaviors (l_dobj) behaviors_20\NNS|in (l_prep) in_21\IN|children (l_pobj) children_22\NNS|with (l_prep) with_23\IN|autism (l_pobj) autism_24\NN|,|aggression
D005702_D006261 CID galantamine_2\NN| (r_nsubj) was_3\VBD|overall|,|galantamine|tolerated|,|with|. (l_prep) with_8\IN|effects (l_pobj) effects_12\NNS|no|significant|adverse|apart (l_advmod) apart_13\RB|from (l_prep) from_14\IN|headaches (l_pobj) headaches_15\NNS|in
D005702_D001523 NONE galantamine_5\NN| (r_nsubj) was_6\VBD|in|,|galantamine|tolerated|and|appeared|. (l_conj) appeared_11\VBD|be (l_xcomp) be_13\VB|to|beneficial (l_acomp) beneficial_14\JJ|for (l_prep) for_15\IN|treatment (l_pobj) treatment_17\NN|the|of (l_prep) of_18\IN|interfering (l_pcomp) interfering_19\VBG|behaviors (l_dobj) behaviors_20\NNS|in (l_prep) in_21\IN|children (l_pobj) children_22\NNS|with (l_prep) with_23\IN|autism (l_pobj) autism_24\NN|,|aggression (l_appos) aggression_27\NN|particularly|,|dyscontrol
D005702_D002653 NONE galantamine_5\NN| (r_nsubj) was_6\VBD|in|,|galantamine|tolerated|and|appeared|. (l_conj) appeared_11\VBD|be (l_xcomp) be_13\VB|to|beneficial (l_acomp) beneficial_14\JJ|for (l_prep) for_15\IN|treatment (l_pobj) treatment_17\NN|the|of (l_prep) of_18\IN|interfering (l_pcomp) interfering_19\VBG|behaviors (l_dobj) behaviors_20\NNS|in (l_prep) in_21\IN|children (l_pobj) children_22\NNS|with (l_prep) with_23\IN|autism (l_pobj) autism_24\NN|,|aggression (l_appos) aggression_27\NN|particularly|,|dyscontrol (l_conj) dyscontrol_30\NN|behavioral|,|and|inattention
D005702_D019958 NONE galantamine_5\NN| (r_nsubj) was_6\VBD|in|,|galantamine|tolerated|and|appeared|. (l_conj) appeared_11\VBD|be (l_xcomp) be_13\VB|to|beneficial (l_acomp) beneficial_14\JJ|for (l_prep) for_15\IN|treatment (l_pobj) treatment_17\NN|the|of (l_prep) of_18\IN|interfering (l_pcomp) interfering_19\VBG|behaviors (l_dobj) behaviors_20\NNS|in (l_prep) in_21\IN|children (l_pobj) children_22\NNS|with (l_prep) with_23\IN|autism (l_pobj) autism_24\NN|,|aggression (l_appos) aggression_27\NN|particularly|,|dyscontrol (l_conj) dyscontrol_30\NN|behavioral|,|and|inattention (l_conj) inattention_33\NN|
24802403
D008687_D012640 NONE Metformin_0\NNP| (r_nsubj) protects_1\VBZ|metformin|against|. (l_prep) against_2\IN|seizures (l_pobj) seizures_3\NNS|,|learning|impairments
D008687_D012640 NONE metformin_10\NN| (r_pobj) of_9\IN|metformin (r_prep) effects_8\NNS|the|ameliorative|of|on|observed (l_prep) on_11\IN|seizures (l_pobj) seizures_12\NNS|,|impairment
D008687_D012640 NONE metformin_6\NN| (r_nsubj) be_8\VB|that|metformin|may|agent (l_attr) agent_11\NN|a|potential|for (l_prep) for_12\IN|treatment (l_pobj) treatment_14\NN|the|of|as|medicine (l_conj) medicine_22\NN|a|protective|against|induced (l_acl) induced_26\VBN|by (l_agent) by_27\IN|seizures (l_pobj) seizures_28\NNS|
D008687_D007859 NONE Metformin_0\NNP| (r_nsubj) protects_1\VBZ|metformin|against|. (l_prep) against_2\IN|seizures (l_pobj) seizures_3\NNS|,|learning|impairments (l_conj) impairments_8\NNS|and|damage|induced
D008687_D008569 NONE Metformin_0\NNP| (r_nsubj) protects_1\VBZ|metformin|against|. (l_prep) against_2\IN|seizures (l_pobj) seizures_3\NNS|,|learning|impairments (l_conj) impairments_8\NNS|and|damage|induced
D010433_D012640 CID pentylenetetrazole_14\NN| (r_npadvmod) induced_16\VBN|pentylenetetrazole|- (r_amod) kindling_17\NN|induced|in (r_pobj) by_13\IN|kindling (r_agent) induced_12\VBN|by (r_acl) impairments_8\NNS|and|damage|induced (r_conj) seizures_3\NNS|,|learning|impairments
D010433_D012640 CID pentylenetetrazole_23\NN| (r_npadvmod) induced_25\VBN|pentylenetetrazole|- (r_amod) animals_27\NNS|induced|kindling (r_pobj) in_22\IN|animals (r_prep) observed_21\VBN|in (r_acl) effects_8\NNS|the|ameliorative|of|on|observed (l_prep) on_11\IN|seizures (l_pobj) seizures_12\NNS|,|impairment
D010433_D007859 CID pentylenetetrazole_14\NN| (r_npadvmod) induced_16\VBN|pentylenetetrazole|- (r_amod) kindling_17\NN|induced|in (r_pobj) by_13\IN|kindling (r_agent) induced_12\VBN|by (r_acl) impairments_8\NNS|and|damage|induced
D010433_D008569 CID pentylenetetrazole_14\NN| (r_npadvmod) induced_16\VBN|pentylenetetrazole|- (r_amod) kindling_17\NN|induced|in (r_pobj) by_13\IN|kindling (r_agent) induced_12\VBN|by (r_acl) impairments_8\NNS|and|damage|induced
D008687_D003072 NONE metformin_10\NN| (r_pobj) of_9\IN|metformin (r_prep) effects_8\NNS|the|ameliorative|of|on|observed (l_prep) on_11\IN|seizures (l_pobj) seizures_12\NNS|,|impairment (l_conj) impairment_15\NN|cognitive|and|markers
D008687_D003072 NONE metformin_3\NN| (r_nsubj) suppressed_4\VBD|that|metformin|progression|,|ameliorated (l_conj) ameliorated_10\VBD|impairment|and|decreased (l_dobj) impairment_13\NN|the|cognitive
D008687_D003072 NONE metformin_6\NN| (r_nsubj) be_8\VB|that|metformin|may|agent (l_attr) agent_11\NN|a|potential|for (l_prep) for_12\IN|treatment (l_pobj) treatment_14\NN|the|of|as|medicine (l_conj) medicine_22\NN|a|protective|against|induced (l_prep) against_23\IN|impairment (l_pobj) impairment_25\NN|cognitive
D010433_D003072 CID pentylenetetrazole_23\NN| (r_npadvmod) induced_25\VBN|pentylenetetrazole|- (r_amod) animals_27\NNS|induced|kindling (r_pobj) in_22\IN|animals (r_prep) observed_21\VBN|in (r_acl) effects_8\NNS|the|ameliorative|of|on|observed (l_prep) on_11\IN|seizures (l_pobj) seizures_12\NNS|,|impairment (l_conj) impairment_15\NN|cognitive|and|markers
D008687_D004827 NONE metformin_6\NN| (r_nsubj) be_8\VB|that|metformin|may|agent (l_attr) agent_11\NN|a|potential|for (l_prep) for_12\IN|treatment (l_pobj) treatment_14\NN|the|of|as|medicine (l_prep) of_15\IN|epilepsy (l_pobj) epilepsy_16\NN|
24126708
D007980_D010300 NONE levodopa_9\JJ| (r_amod) effects_11\NNS|levodopa|adverse|in (l_prep) in_12\IN|patients (l_pobj) patients_16\NNS|parkinson|disease (l_compound) disease_15\NN|
D007980_D010300 NONE Levodopa_0\NNP| (r_nsubj) is_1\VBZ|levodopa|therapy|,|but|lead (l_attr) therapy_6\NN|the|effective|symptomatic|for (l_prep) for_7\IN|disease (l_pobj) disease_10\NN|parkinson
D007980_D004409 CID Levodopa_0\NNP| (r_nsubj) is_1\VBZ|levodopa|therapy|,|but|lead (l_conj) lead_17\VB|use|could|to|. (l_prep) to_18\IN|outcomes (l_pobj) outcomes_21\NNS|chronic|adverse|,|as (l_prep) as_24\IN|such|fluctuations (l_pobj) fluctuations_26\NNS|motor|,|dyskinesia (l_conj) dyskinesia_28\JJ|and|hallucinations
D007980_D006212 CID Levodopa_0\NNP| (r_nsubj) is_1\VBZ|levodopa|therapy|,|but|lead (l_conj) lead_17\VB|use|could|to|. (l_prep) to_18\IN|outcomes (l_pobj) outcomes_21\NNS|chronic|adverse|,|as (l_prep) as_24\IN|such|fluctuations (l_pobj) fluctuations_26\NNS|motor|,|dyskinesia (l_conj) dyskinesia_28\JJ|and|hallucinations (l_conj) hallucinations_31\NNS|visual
7661171
D016595_D007674 NONE misoprostol_6\NN| (r_pobj) of_5\IN|misoprostol (r_prep) effect_4\NN|the|dependent|of|on|. (l_prep) on_7\IN|dysfunction (l_pobj) dysfunction_12\NN|induced|renal|in
D016595_D007674 NONE Misoprostol_0\NNP|micrograms (r_nsubjpass) shown_7\VBN|misoprostol|has|been|counteract|. (l_xcomp) counteract_10\VB|to|acutely|dysfunction (l_dobj) dysfunction_16\NN|the|induced|renal|in
D016595_D005355 NONE misoprostol_6\NN| (r_pobj) of_5\IN|misoprostol (r_prep) effect_4\NN|the|dependent|of|on|. (l_prep) on_7\IN|dysfunction (l_pobj) dysfunction_12\NN|induced|renal|in (l_prep) in_13\IN|cirrhosis (l_pobj) cirrhosis_16\NN|compensated
D016595_D005355 NONE Misoprostol_0\NNP|micrograms (r_nsubjpass) shown_7\VBN|misoprostol|has|been|counteract|. (l_xcomp) counteract_10\VB|to|acutely|dysfunction (l_dobj) dysfunction_16\NN|the|induced|renal|in (l_prep) in_17\IN|patients (l_pobj) patients_21\NNS|compensated|cirrhotic (l_amod) cirrhotic_20\JJ|
D016595_D005355 NONE misoprostol_36\NN| (r_pobj) of_35\IN|misoprostol (r_prep) doses_34\NNS|various|of (r_conj) mg_29\NN|50|of|and|doses (r_pobj) of_27\IN|mg (r_prep) combination_26\NN|an|oral|of (r_pobj) after_23\IN|combination (r_conj) before_21\RB|and|after (r_prep) assessed_11\VBN|parameters|were|by|in|before|. (l_prep) in_15\IN|patients (l_pobj) patients_20\NNS|26|compensated|cirrhotic (l_amod) cirrhotic_19\JJ|
D016595_D005355 NONE misoprostol_10\NNP| (r_pobj) of_9\IN|misoprostol (r_prep) micrograms_8\NNS|200|of (r_pobj) of_6\IN|micrograms (r_prep) ability_5\NN|this|apparent|of|prevent (r_nsubjpass) confirmed_22\VBN|however|,|until|ability|is|with (r_advcl) be_30\VB|confirmed|,|it|would|prudent|avoid|. (l_xcomp) avoid_33\VB|to|therapy (l_dobj) therapy_38\NN|nonsteroidal|inflammatory|in (l_prep) in_39\IN|patients (l_pobj) patients_40\NNS|with (l_prep) with_41\IN|cirrhosis (l_pobj) cirrhosis_42\NN|
D007213_D007674 CID indomethacin_8\NN| (r_npadvmod) induced_10\VBN|indomethacin|- (r_amod) dysfunction_12\NN|induced|renal|in
D007213_D007674 CID indomethacin_12\NN| (r_npadvmod) induced_14\VBN|indomethacin|- (r_amod) dysfunction_16\NN|the|induced|renal|in
D007213_D005355 NONE indomethacin_8\NN| (r_npadvmod) induced_10\VBN|indomethacin|- (r_amod) dysfunction_12\NN|induced|renal|in (l_prep) in_13\IN|cirrhosis (l_pobj) cirrhosis_16\NN|compensated
D007213_D005355 NONE indomethacin_12\NN| (r_npadvmod) induced_14\VBN|indomethacin|- (r_amod) dysfunction_16\NN|the|induced|renal|in (l_prep) in_17\IN|patients (l_pobj) patients_21\NNS|compensated|cirrhotic (l_amod) cirrhotic_20\JJ|
D007213_D005355 NONE indomethacin_31\NN| (r_pobj) of_30\IN|indomethacin (r_prep) mg_29\NN|50|of|and|doses (r_pobj) of_27\IN|mg (r_prep) combination_26\NN|an|oral|of (r_pobj) after_23\IN|combination (r_conj) before_21\RB|and|after (r_prep) assessed_11\VBN|parameters|were|by|in|before|. (l_prep) in_15\IN|patients (l_pobj) patients_20\NNS|26|compensated|cirrhotic (l_amod) cirrhotic_19\JJ|
D007213_D005355 NONE indomethacin_17\NN|on (r_pobj) of_16\IN|indomethacin (r_prep) effects_15\NNS|the|adverse|of (r_dobj) prevent_12\VB|to|effects (r_acl) ability_5\NN|this|apparent|of|prevent (r_nsubjpass) confirmed_22\VBN|however|,|until|ability|is|with (r_advcl) be_30\VB|confirmed|,|it|would|prudent|avoid|. (l_xcomp) avoid_33\VB|to|therapy (l_dobj) therapy_38\NN|nonsteroidal|inflammatory|in (l_prep) in_39\IN|patients (l_pobj) patients_40\NNS|with (l_prep) with_41\IN|cirrhosis (l_pobj) cirrhosis_42\NN|
D012964_D005355 NONE sodium_6\NN|tubular|and|water (r_conj) hemodynamics_3\NNS|renal|and|sodium (r_pobj) of_1\IN|hemodynamics (r_prep) Parameters_0\NNS|of|handling (r_nsubjpass) assessed_11\VBN|parameters|were|by|in|before|. (l_prep) in_15\IN|patients (l_pobj) patients_20\NNS|26|compensated|cirrhotic (l_amod) cirrhotic_19\JJ|
7369302
D011803_D000550 CID quinine_10\NN| (r_compound) amblyopia_11\NN|quinine
D011803_D001766 CID sulfate_30\NN|quinine|for (r_pobj) of_28\IN|sulfate (r_prep) use_27\NN|the|of (r_pobj) after_25\IN|use (r_prep) developed_18\VBN|in|after (r_acl) potentials_17\NNS|abnormal|evoked|developed (r_conj) supersensitivity_10\NN|denervation|,|and|potentials (r_conj) response_7\NN|a|transient|tonic|pupillary|,|supersensitivity (r_pobj) with_2\IN|response (r_prep) blindness_1\NN|total|with|.
D011803_D015845 CID sulfate_30\NN|quinine|for (r_pobj) of_28\IN|sulfate (r_prep) use_27\NN|the|of (r_pobj) after_25\IN|use (r_prep) developed_18\VBN|in|after (r_acl) potentials_17\NNS|abnormal|evoked|developed (r_conj) supersensitivity_10\NN|denervation|,|and|potentials (r_conj) response_7\NN|a|transient|tonic|pupillary|,|supersensitivity (l_amod) pupillary_6\JJ|
D011803_D015845 CID quinine_16\NN| (r_compound) toxicity_17\NN|quinine (r_pobj) in_15\IN|toxicity (r_prep) potentials_14\NNS|abnormal|evoked|in (r_conj) supersensitivity_7\NN|denervation|,|and|potentials (r_conj) response_4\NN|a|transient|tonic|pupillary|,|supersensitivity|,|to (l_amod) pupillary_3\JJ|
D011803_D009120 NONE sulfate_30\NN|quinine|for (l_prep) for_31\IN|cramps (l_pobj) cramps_33\NNS|leg
D011803_D064420 NONE quinine_16\NN| (r_compound) toxicity_17\NN|quinine
3833372
D013999_D006973 NONE maleate_23\NN|timolol (r_pobj) of_21\IN|maleate (r_prep) mg_20\NN|10|of|and|mg (r_dobj) containing_18\VBG|mg (r_acl) combination_17\NN|a|ratio|containing|,|administered (l_acl) administered_30\VBN|daily|for|to (l_prep) to_36\IN|patients (l_pobj) patients_38\NNS|hypertensive (l_amod) hypertensive_37\JJ|
D006852_D006973 NONE hydrochlorothiazide_28\NN| (r_pobj) of_27\IN|hydrochlorothiazide (r_prep) mg_26\NN|25|of (r_conj) mg_20\NN|10|of|and|mg (r_dobj) containing_18\VBG|mg (r_acl) combination_17\NN|a|ratio|containing|,|administered (l_acl) administered_30\VBN|daily|for|to (l_prep) to_36\IN|patients (l_pobj) patients_38\NNS|hypertensive (l_amod) hypertensive_37\JJ|
22836123
D016559_D007674 NONE tacrolimus_8\NN|and|prednisolone (r_pobj) by_7\IN|tacrolimus (r_agent) induced_6\VBN|crisis|by (l_nsubj) crisis_5\NN|onset|scleroderma|renal
D016559_D007674 NONE tacrolimus_12\NNS|and|corticosteroids (r_pobj) by_11\IN|tacrolimus (r_agent) induced_10\VBN|by (r_acl) patient_7\NN|a|with|induced (l_prep) with_8\IN|src (l_pobj) SRC_9\NNP|
D011239_D007674 NONE prednisolone_10\NN| (r_conj) tacrolimus_8\NN|and|prednisolone (r_pobj) by_7\IN|tacrolimus (r_agent) induced_6\VBN|crisis|by (l_nsubj) crisis_5\NN|onset|scleroderma|renal
D000305_D007674 NONE corticosteroid_4\NN| (r_compound) use_5\NN|high|dose|corticosteroid (r_pobj) to_1\IN|use (r_prep) Moderate_0\JJ|to (r_nsubjpass) recognized_7\VBN|moderate|is|as|. (l_prep) as_8\IN|factor (l_pobj) factor_12\NN|a|major|risk|for (l_prep) for_13\IN|src (l_pobj) SRC_14\NNP|
D000305_D007674 NONE corticosteroids_14\NNS| (r_conj) tacrolimus_12\NNS|and|corticosteroids (r_pobj) by_11\IN|tacrolimus (r_agent) induced_10\VBN|by (r_acl) patient_7\NN|a|with|induced (l_prep) with_8\IN|src (l_pobj) SRC_9\NNP|
D016572_D057049 CID cyclosporine_11\NN|in (r_pobj) by_10\IN|cyclosporine (r_agent) precipitated_9\VBN|by (r_acl) microangiopathy_8\NN|thrombotic|precipitated
D016572_D012595 NONE cyclosporine_11\NN|in (l_prep) in_12\IN|patients (l_pobj) patients_13\NNS|with (l_prep) with_14\IN|ssc (l_pobj) SSc_15\NNS|
D016559_D012595 CID tacrolimus_13\NN| (r_compound) use_14\NN|tacrolimus|in (l_prep) in_15\IN|patients (l_pobj) patients_16\NNS|with (l_prep) with_17\IN|ssc (l_pobj) SSc_18\NNS|
2650911
D004967_D002292 NONE estrogen_3\NN| (r_nmod) sites_5\NNS|estrogen|binding|in (r_pobj) of_2\IN|sites (r_prep) evidence_1\NN|autoradiographic|of (r_nsubj) induced_10\VBN|evidence|carcinomas|. (l_dobj) carcinomas_13\NNS|hamster|renal
D004967_D002292 NONE Estrogen_0\NN| (r_nmod) sites_2\NNS|estrogen|binding (r_nsubjpass) demonstrated_4\VBN|sites|were|by|induced|. (l_conj) induced_14\VBD|carcinomas|in (l_dobj) carcinomas_16\NNS|renal
D004967_D002292 NONE estrogen_13\NN| (r_pobj) of_12\IN|estrogen (r_prep) binding_11\NN|vivo|of (r_pobj) in_9\IN|binding (r_prep) preferential_8\NN|the|in (r_dobj) documenting_6\VBG|preferential|to (r_acl) report_5\NN|the|first|published|documenting|induced (l_acl) induced_20\VBD|carcinomas (l_dobj) carcinomas_23\NNS|hamster|renal
D004967_D002292 NONE estrogen_19\NN| (r_pobj) in_18\IN|estrogen (r_prep) cells_17\NNS|in (r_pobj) of_16\IN|cells (r_prep) nuclei_15\NNS|of (r_pobj) to_14\IN|nuclei (r_prep) documenting_6\VBG|preferential|to (r_acl) report_5\NN|the|first|published|documenting|induced (l_acl) induced_20\VBD|carcinomas (l_dobj) carcinomas_23\NNS|hamster|renal
D004054_D002292 CID diethylstilbesterol_9\NN| (r_pobj) of_8\IN|diethylstilbesterol (r_prep) nuclei_7\NNS|of (r_pobj) in_6\IN|nuclei (r_prep) sites_5\NNS|estrogen|binding|in (r_pobj) of_2\IN|sites (r_prep) evidence_1\NN|autoradiographic|of (r_nsubj) induced_10\VBN|evidence|carcinomas|. (l_dobj) carcinomas_13\NNS|hamster|renal
D004054_D002292 CID diethylstilbesterol_13\NN|one|transplantable|primary (r_pobj) in_7\IN|diethylstilbesterol (r_prep) autoradiography_6\NN|in (r_pobj) by_5\IN|autoradiography (r_agent) demonstrated_4\VBN|sites|were|by|induced|. (l_conj) induced_14\VBD|carcinomas|in (l_dobj) carcinomas_16\NNS|renal
D004958_D009369 NONE estradiol_10\NN|3h-17|beta (r_pobj) of_7\IN|estradiol (r_prep) injection_6\NN|the|in|vivo|of (r_pobj) following_2\VBG|injection (r_prep) increased_13\VBN|radiolabelling|,|following|,|was|over (l_prep) over_15\IN|only|nuclei (l_pobj) nuclei_17\NNS|the|of (l_prep) of_18\IN|cells (l_pobj) cells_20\NNS|tumor (l_compound) tumor_19\NN|
D012834_D009369 NONE silver_33\NN| (r_compound) grains_34\NNS|reduced|silver|over|than (r_pobj) of_31\IN|grains (r_prep) concentration_30\NN|a|6.7-times|higher|of (r_dobj) revealed_24\VBD|increased|;|analysis|concentration|. (l_ccomp) increased_13\VBN|radiolabelling|,|following|,|was|over (l_prep) over_15\IN|only|nuclei (l_pobj) nuclei_17\NNS|the|of (l_prep) of_18\IN|cells (l_pobj) cells_20\NNS|tumor (l_compound) tumor_19\NN|
10087562
D004280_D016171 CID dobutamine_9\NN| (r_compound) treatment_10\NN|low|dose|intermittent|dobutamine|in (r_pobj) during_5\IN|treatment (r_prep) pointes_2\VBZ|torsade|de|tachycardia|during|.
D004280_D016171 CID dobutamine_52\NN|dose|kg (r_pobj) of_40\IN|dobutamine (r_prep) cycle_39\NN|one|of (r_pobj) during_37\IN|cycle (r_prep) developed_28\VBD|who|prolongation|during (l_dobj) prolongation_30\NN|qt|and|tachycardia (l_conj) tachycardia_36\NN|pointes|ventricular (l_nmod) pointes_34\FW|torsade|de
D004280_D016171 CID dobutamine_10\NN|intermittent (r_pobj) during_8\IN|dobutamine (r_prep) report_1\NN|this|of|during (l_prep) of_2\IN|tachycardia (l_pobj) tachycardia_7\NN|pointes|ventricular (l_nmod) pointes_5\FW|torsade|de
D004280_D017180 NONE dobutamine_9\NN| (r_compound) treatment_10\NN|low|dose|intermittent|dobutamine|in (r_pobj) during_5\IN|treatment (r_prep) pointes_2\VBZ|torsade|de|tachycardia|during|. (l_appos) tachycardia_4\NN|ventricular
D004280_D017180 NONE dobutamine_52\NN|dose|kg (r_pobj) of_40\IN|dobutamine (r_prep) cycle_39\NN|one|of (r_pobj) during_37\IN|cycle (r_prep) developed_28\VBD|who|prolongation|during (l_dobj) prolongation_30\NN|qt|and|tachycardia (l_conj) tachycardia_36\NN|pointes|ventricular
D004280_D017180 NONE dobutamine_10\NN|intermittent (r_pobj) during_8\IN|dobutamine (r_prep) report_1\NN|this|of|during (l_prep) of_2\IN|tachycardia (l_pobj) tachycardia_7\NN|pointes|ventricular
D004280_D002311 NONE dobutamine_9\NN| (r_compound) treatment_10\NN|low|dose|intermittent|dobutamine|in (l_prep) in_11\IN|patient (l_pobj) patient_13\NN|a|with (l_prep) with_14\IN|failure (l_pobj) failure_20\NN|dilated|cardiomyopathy|heart (l_amod) cardiomyopathy_16\NN|and|congestive
D004280_D002311 NONE dobutamine_52\NN|dose|kg (r_pobj) of_40\IN|dobutamine (r_prep) cycle_39\NN|one|of (r_pobj) during_37\IN|cycle (r_prep) developed_28\VBD|who|prolongation|during (r_relcl) arrhythmias_26\NNS|significant|ventricular|developed (r_pobj) of_23\IN|arrhythmias (r_prep) absence_22\NN|of (r_conj) dilated_19\VBN|to|cardiomyopathy|and|absence (l_advmod) cardiomyopathy_20\NN|
D004280_D006333 NONE dobutamine_9\NN| (r_compound) treatment_10\NN|low|dose|intermittent|dobutamine|in (l_prep) in_11\IN|patient (l_pobj) patient_13\NN|a|with (l_prep) with_14\IN|failure (l_pobj) failure_20\NN|dilated|cardiomyopathy|heart
D004280_D006333 NONE dobutamine_52\NN|dose|kg (r_pobj) of_40\IN|dobutamine (r_prep) cycle_39\NN|one|of (r_pobj) during_37\IN|cycle (r_prep) developed_28\VBD|who|prolongation|during (r_relcl) arrhythmias_26\NNS|significant|ventricular|developed (r_pobj) of_23\IN|arrhythmias (r_prep) absence_22\NN|of (r_conj) dilated_19\VBN|to|cardiomyopathy|and|absence (r_xcomp) describe_2\VBP|authors|case|dilated|. (l_dobj) case_4\NN|the|of (l_prep) of_5\IN|woman (l_pobj) woman_10\NN|a|old|with (l_prep) with_11\IN|failure (l_pobj) failure_16\NN|chronic|,|severe|heart|secondary
D004280_D001145 NONE dobutamine_52\NN|dose|kg (r_pobj) of_40\IN|dobutamine (r_prep) cycle_39\NN|one|of (r_pobj) during_37\IN|cycle (r_prep) developed_28\VBD|who|prolongation|during (r_relcl) arrhythmias_26\NNS|significant|ventricular|developed
D004280_D001145 NONE dobutamine_10\NN|intermittent (r_pobj) during_8\IN|dobutamine (r_prep) report_1\NN|this|of|during (r_nsubj) supports_11\VBZ|report|hypothesis|. (l_dobj) hypothesis_13\NN|the|occur (l_acl) occur_19\VB|that|arrhythmias|may|with (l_nsubj) arrhythmias_17\NNS|unpredictable|fatal
D004280_D008133 NONE dobutamine_52\NN|dose|kg (r_pobj) of_40\IN|dobutamine (r_prep) cycle_39\NN|one|of (r_pobj) during_37\IN|cycle (r_prep) developed_28\VBD|who|prolongation|during (l_dobj) prolongation_30\NN|qt|and|tachycardia
23871786
C006780_D001008 CID A_4\DT|bisphenol (r_pobj) to_2\IN|a (r_prep) exposure_1\NN|pubertal|to (r_nsubj) increases_5\VBZ|exposure|behavior|and|decreases|. (l_dobj) behavior_9\NN|like (l_amod) like_8\JJ|anxiety|- (l_npadvmod) anxiety_6\NN|
C006780_D001008 CID BPA_17\NNP| (r_pobj) to_16\IN|bpa (r_prep) exposed_15\VBN|to (r_acl) mice_14\NNS|exposed (r_pobj) in_13\IN|mice (r_prep) increased_12\VBN|that|behavior|was|in (l_nsubjpass) behavior_10\NN|like (l_amod) like_9\JJ|anxiety|- (l_npadvmod) anxiety_7\NN|
C006780_D001008 CID BPA_5\NNP| (r_compound) exposure_6\NN|pubertal|bpa (r_nsubj) increased_7\VBN|that|exposure|behavior (l_dobj) behavior_11\NN|like|,|associated (l_amod) like_10\JJ|anxiety (l_npadvmod) anxiety_8\NN|-
23666265
D003520_D003556 CID cyclophosphamide_10\NN| (r_npadvmod) induced_12\VBN|cyclophosphamide|- (r_amod) cystitis_13\NN|induced|in
D003520_D003556 CID cyclophosphamide_17\NN| (r_pobj) on_16\IN|cyclophosphamide (r_prep) antagonists_15\NNS|p2x3|on|(|cystitis (l_appos) cystitis_20\NN|cyp)-induced|in
D003520_D003556 CID CYP)-induced_19\VBN| (r_amod) cystitis_20\NN|cyp)-induced|in
D003520_D003556 CID CYP_1\NNP| (r_npadvmod) induced_3\VBN|cyp|- (r_amod) cystitis_4\NN|induced|,|expression|increased
D003520_D010146 CID CYP_7\NNP| (r_pobj) of_6\IN|cyp (r_prep) administration_5\NN|the|of (r_pobj) following_3\VBG|administration (r_prep) behaviors_2\NNS|spontaneous|pain|following (l_compound) pain_1\NN|
D003520_D010146 CID Cyclophosphamide_0\NNP| (r_compound) treatment_1\NN|cyclophosphamide (r_nsubj) increased_2\VBD|treatment|scores|. (l_dobj) scores_7\NNS|behaviors (l_compound) behaviors_6\NNS|the|spontaneous|pain (l_compound) pain_5\NN|
23872883
D007545_D066126 CID isoproterenol_18\NN| (r_npadvmod) induced_20\VBN|isoproterenol|- (r_amod) cardiotoxicity_21\NN|induced|in
25071004
C039726_D000740 NONE artesunate_6\NN|injectable|in (r_pobj) with_4\IN|artesunate (r_prep) treatment_3\NN|with (r_pobj) after_2\IN|treatment (r_prep) Delayed_0\JJ|anemia|after|:|issue|. (l_dobj) anemia_1\NN|
C039726_D000743 CID artesunate_12\NN|injectable (r_pobj) with_10\IN|artesunate (r_prep) treatment_9\NN|with (r_pobj) after_8\IN|treatment (r_prep) described_7\VBN|cases|have|been|after|,|organization (l_nsubjpass) Cases_0\NNS|of (l_prep) of_1\IN|anemia (l_pobj) anemia_4\NN|delayed|hemolytic
C039726_D008288 NONE artesunate_12\NN|injectable (r_pobj) with_10\IN|artesunate (r_prep) treatment_9\NN|with (r_pobj) after_8\IN|treatment (r_prep) described_7\VBN|cases|have|been|after|,|organization (l_appos) Organization_18\NNP|the|current|world|health|who)-recommended (l_parataxis) WHO)-recommended_20\VBN|(|drug|. (l_dobj) drug_24\NN|line|for (l_prep) for_25\IN|treatment (l_pobj) treatment_27\NN|the|of (l_prep) of_28\IN|malaria (l_pobj) malaria_30\NN|severe
C039726_D008288 NONE artesunate_36\NN|injectable|for (l_prep) for_37\IN|malaria (l_pobj) malaria_39\NN|severe|in
6687006
D003913_D006948 CID amphetamine_6\NN|d|-|kg (r_pobj) by_3\IN|amphetamine (r_agent) induced_2\VBN|by (r_acl) hyperactivity_1\NN|the|induced|)
C012102_D006948 NONE DSP4_17\NNP| (r_compound) pretreatment_18\NN|dsp4 (r_pobj) by_16\IN|pretreatment (r_agent) reduced_15\VBN|hyperactivity|was|significantly|by|. (l_nsubjpass) hyperactivity_1\NN|the|induced|)
C012102_D006948 NONE DSP4_7\NNP| (r_pobj) by_6\IN|dsp4 (r_agent) induced_5\VBN|by (r_acl) reduction_1\NN|the|of|induced (l_prep) of_2\IN|hyperactivity (l_pobj) hyperactivity_4\NN|amphetamine
C012102_D006948 NONE DSP4_28\NNP| (r_pobj) of_27\IN|dsp4 (r_prep) action_26\NN|the|neurotoxic|of (r_dobj) prevents_23\VBZ|which|action (r_relcl) agent_18\NN|the|uptake|blocking|,|desipramine|,|prevents (r_pobj) with_12\IN|agent (r_prep) pretreatment_11\NN|with (r_pobj) by_10\IN|pretreatment (r_agent) blocked_9\VBN|reduction|was|by|. (l_nsubjpass) reduction_1\NN|the|of|induced (l_prep) of_2\IN|hyperactivity (l_pobj) hyperactivity_4\NN|amphetamine
D000661_D019956 NONE amphetamine_7\NN| (r_npadvmod) induced_9\VBN|amphetamine|- (r_amod) stereotypies_10\NNS|the|induced
C012102_D019956 NONE DSP4_17\NNP| (r_pobj) with_16\IN|dsp4 (r_prep) pretreatment_15\NN|with (r_pobj) by_14\IN|pretreatment (r_agent) blocked_13\VBN|however|,|rearings|were|not|by|. (l_nsubjpass) rearings_4\NNS|the|increased|and|stereotypies (l_conj) stereotypies_10\NNS|the|induced
D000661_D006948 NONE amphetamine_3\NN| (r_compound) hyperactivity_4\NN|amphetamine
D000661_D020258 NONE amphetamine_3\NN| (r_compound) hyperactivity_4\NN|amphetamine (r_pobj) of_2\IN|hyperactivity (r_prep) reduction_1\NN|the|of|induced (r_nsubjpass) blocked_9\VBN|reduction|was|by|. (l_agent) by_10\IN|pretreatment (l_pobj) pretreatment_11\NN|with (l_prep) with_12\IN|agent (l_pobj) agent_18\NN|the|uptake|blocking|,|desipramine|,|prevents (l_relcl) prevents_23\VBZ|which|action (l_dobj) action_26\NN|the|neurotoxic|of (l_amod) neurotoxic_25\JJ|
C012102_D020258 NONE DSP4_7\NNP| (r_pobj) by_6\IN|dsp4 (r_agent) induced_5\VBN|by (r_acl) reduction_1\NN|the|of|induced (r_nsubjpass) blocked_9\VBN|reduction|was|by|. (l_agent) by_10\IN|pretreatment (l_pobj) pretreatment_11\NN|with (l_prep) with_12\IN|agent (l_pobj) agent_18\NN|the|uptake|blocking|,|desipramine|,|prevents (l_relcl) prevents_23\VBZ|which|action (l_dobj) action_26\NN|the|neurotoxic|of (l_amod) neurotoxic_25\JJ|
C012102_D020258 NONE DSP4_28\NNP| (r_pobj) of_27\IN|dsp4 (r_prep) action_26\NN|the|neurotoxic|of (l_amod) neurotoxic_25\JJ|
D009638_D006948 NONE noradrenaline_14\NN| (r_amod) uptake_16\NN|noradrenaline|- (r_compound) agent_18\NN|the|uptake|blocking|,|desipramine|,|prevents (r_pobj) with_12\IN|agent (r_prep) pretreatment_11\NN|with (r_pobj) by_10\IN|pretreatment (r_agent) blocked_9\VBN|reduction|was|by|. (l_nsubjpass) reduction_1\NN|the|of|induced (l_prep) of_2\IN|hyperactivity (l_pobj) hyperactivity_4\NN|amphetamine
D009638_D020258 NONE noradrenaline_14\NN| (r_amod) uptake_16\NN|noradrenaline|- (r_compound) agent_18\NN|the|uptake|blocking|,|desipramine|,|prevents (l_relcl) prevents_23\VBZ|which|action (l_dobj) action_26\NN|the|neurotoxic|of (l_amod) neurotoxic_25\JJ|
D003891_D006948 NONE desipramine_20\NN| (r_appos) agent_18\NN|the|uptake|blocking|,|desipramine|,|prevents (r_pobj) with_12\IN|agent (r_prep) pretreatment_11\NN|with (r_pobj) by_10\IN|pretreatment (r_agent) blocked_9\VBN|reduction|was|by|. (l_nsubjpass) reduction_1\NN|the|of|induced (l_prep) of_2\IN|hyperactivity (l_pobj) hyperactivity_4\NN|amphetamine
D003891_D020258 NONE desipramine_20\NN| (r_appos) agent_18\NN|the|uptake|blocking|,|desipramine|,|prevents (l_relcl) prevents_23\VBZ|which|action (l_dobj) action_26\NN|the|neurotoxic|of (l_amod) neurotoxic_25\JJ|
12699527
D002712_D009224 NONE chloride_14\NN| (r_compound) channel_15\NN|chloride (r_compound) function_16\NN|the|muscle|channel|, (r_pobj) in_10\IN|function (r_prep) defect_9\NN|a|in|cause (r_pobj) by_7\IN|defect (r_agent) caused_6\VBN|congenita|is|by|. (l_nsubjpass) congenita_1\NN|myotonia|(|mc|)
D002712_D009224 NONE chloride_14\NN| (r_compound) channel_15\NN|chloride (r_compound) function_16\NN|the|muscle|channel|, (r_pobj) in_10\IN|function (r_prep) defect_9\NN|a|in|cause (r_pobj) by_7\IN|defect (r_agent) caused_6\VBN|congenita|is|by|. (l_nsubjpass) congenita_1\NN|myotonia|(|mc|) (l_appos) MC_3\NNP|
D002712_-1 NONE chloride_14\NN| (r_compound) channel_15\NN|chloride (r_compound) function_16\NN|the|muscle|channel|, (r_pobj) in_10\IN|function (r_prep) defect_9\NN|a|in|cause (l_relcl) cause_20\VB|which|may|depolarisation (l_dobj) depolarisation_23\NN|sustained|membrane
D013390_D013035 CID suxamethonium_26\NN| (r_pobj) of_25\IN|suxamethonium (r_prep) injection_24\NN|a|preoperative|of (r_pobj) following_21\VBG|injection (r_prep) developed_10\VBD|who|spasm|following (l_dobj) spasm_16\NN|a|threatening|muscle|and|difficulties
4010471
D009538_D012640 CID nicotine_2\NN| (r_npadvmod) induced_4\VBN|nicotine|- (r_amod) seizures_5\NNS|induced|and|receptors
D009538_D012640 CID nicotine_15\NN| (r_npadvmod) induced_17\VBN|nicotine|- (r_amod) seizures_18\NNS|induced|and|concentration
D009538_D012640 CID nicotine_7\NN| (r_pobj) of_6\IN|nicotine (r_prep) effects_5\NNS|the|convulsant|of (r_pobj) to_2\IN|effects (r_prep) sensitive_1\JJ|to (r_amod) Mice_0\NNS|sensitive (r_nsubj) had_8\VBD|mice|binding|. (l_dobj) binding_13\NN|greater|bungarotoxin|in|than (l_prep) than_17\IN|mice (l_pobj) mice_20\NNS|seizure|insensitive (l_nmod) seizure_18\NN|
D004229_D012640 NONE dithiothreitol_15\NN|,|trypsin (r_pobj) with_14\IN|dithiothreitol (r_prep) treatment_13\NN|with (r_pobj) by_12\IN|treatment (r_agent) affected_11\VBN|sites|were|equally|by|. (l_nsubjpass) sites_2\NNS|the|binding|from (l_prep) from_3\IN|mice (l_pobj) mice_8\NNS|sensitive (l_amod) sensitive_5\JJ|seizure|and|resistant (l_npadvmod) seizure_4\NN|
20431083
D014859_-1 NONE warfarin_57\NN| (r_amod) users_58\NNS|warfarin|(|difference=0.01|) (r_pobj) in_56\IN|users (r_prep) range_50\NN|(|,|3.5|)|in (r_parataxis) 3.4_40\CD|9.7|)|in|range (r_appos) range_38\NN|5.7|(|,|3.4 (r_pobj) to_35\IN|range (r_prep) ratio_24\NN|(|odds|;|range|in|to (r_pobj) from_20\IN|2.8|ratio (r_prep) increased_19\VBD|excess|from|. (r_conj) were_2\VBD|,|mb|frequent|in|vs|,|but|increased (l_nsubj) MB_1\NNS|
D014859_-1 NONE warfarin_8\JJ| (r_amod) users_9\NNS|warfarin|vs (r_pobj) in_7\IN|users (r_prep) excess_4\NN|an|of|in (l_prep) of_5\IN|mb (l_pobj) MB_6\NN|
D014859_-1 NONE warfarin_32\JJ| (r_amod) users_33\NNS|warfarin|with (r_pobj) in_31\IN|users (r_prep) none_30\NN|in (r_attr) was_1\VBD|there|also|excess|but|none|. (l_attr) excess_4\NN|an|of|in (l_prep) of_5\IN|mb (l_pobj) MB_6\NN|
D014859_-1 NONE warfarin_5\JJ| (r_amod) users_6\NNS|warfarin|with (r_pobj) in_4\IN|users (r_prep) excess_1\NN|the|of|in|compared (l_prep) of_2\IN|mb (l_pobj) MB_3\NN|
D014859_-1 NONE warfarin_5\JJ| (r_amod) users_6\NNS|warfarin|with (r_pobj) in_4\IN|users (r_prep) excess_1\NN|the|of|in|compared (r_nsubj) suggests_13\VBZ|excess|increase|. (l_ccomp) increase_16\VBP|that|mb|risk (l_nsubj) MB_15\NN|
D014859_-1 NONE warfarin_20\NN| (r_npadvmod) associated_22\VBN|warfarin|- (r_amod) ICH_23\NNP|associated (r_pobj) of_19\IN|ich (r_prep) risk_18\NN|the|of (r_dobj) increase_16\VBP|that|mb|risk (r_ccomp) suggests_13\VBZ|excess|increase|. (l_nsubj) excess_1\NN|the|of|in|compared (l_prep) of_2\IN|mb (l_pobj) MB_3\NN|
D014859_-1 NONE warfarin_20\NN| (r_npadvmod) associated_22\VBN|warfarin|- (r_amod) ICH_23\NNP|associated (r_pobj) of_19\IN|ich (r_prep) risk_18\NN|the|of (r_dobj) increase_16\VBP|that|mb|risk (l_nsubj) MB_15\NN|
D014859_D002543 CID warfarin_57\NN| (r_amod) users_58\NNS|warfarin|(|difference=0.01|) (r_pobj) in_56\IN|users (r_prep) range_50\NN|(|,|3.5|)|in (r_parataxis) 3.4_40\CD|9.7|)|in|range (r_appos) range_38\NN|5.7|(|,|3.4 (r_pobj) to_35\IN|range (r_prep) ratio_24\NN|(|odds|;|range|in|to (r_pobj) from_20\IN|2.8|ratio (r_prep) increased_19\VBD|excess|from|. (r_conj) were_2\VBD|,|mb|frequent|in|vs|,|but|increased (l_prep) in_5\IN|ich (l_pobj) ICH_6\NNP|
D014859_D002543 CID warfarin_8\JJ| (r_amod) users_9\NNS|warfarin|vs (l_prep) vs_10\IN|nonusers (l_pobj) nonusers_11\NNS|with (l_prep) with_12\IN|ich (l_pobj) ICH_13\NNP|(|or|;|ci
D014859_D002543 CID warfarin_32\JJ| (r_amod) users_33\NNS|warfarin|with (r_pobj) in_31\IN|users (r_prep) none_30\NN|in (r_attr) was_1\VBD|there|also|excess|but|none|. (l_attr) excess_4\NN|an|of|in (l_prep) in_7\IN|users (l_pobj) users_9\NNS|warfarin|vs (l_prep) vs_10\IN|nonusers (l_pobj) nonusers_11\NNS|with (l_prep) with_12\IN|ich (l_pobj) ICH_13\NNP|(|or|;|ci
D014859_D002543 CID warfarin_5\JJ| (r_amod) users_6\NNS|warfarin|with (l_prep) with_7\IN|ich (l_pobj) ICH_8\NNP|
D014859_D002543 CID warfarin_5\JJ| (r_amod) users_6\NNS|warfarin|with (r_pobj) in_4\IN|users (r_prep) excess_1\NN|the|of|in|compared (r_nsubj) suggests_13\VBZ|excess|increase|. (l_ccomp) increase_16\VBP|that|mb|risk (l_dobj) risk_18\NN|the|of (l_prep) of_19\IN|ich (l_pobj) ICH_23\NNP|associated
D014859_D002543 CID warfarin_20\NN| (r_npadvmod) associated_22\VBN|warfarin|- (r_amod) ICH_23\NNP|associated (r_pobj) of_19\IN|ich (r_prep) risk_18\NN|the|of (r_dobj) increase_16\VBP|that|mb|risk (r_ccomp) suggests_13\VBZ|excess|increase|. (l_nsubj) excess_1\NN|the|of|in|compared (l_prep) in_4\IN|users (l_pobj) users_6\NNS|warfarin|with (l_prep) with_7\IN|ich (l_pobj) ICH_8\NNP|
D014859_D002543 CID warfarin_20\NN| (r_npadvmod) associated_22\VBN|warfarin|- (r_amod) ICH_23\NNP|associated
D014859_D002544 NONE warfarin_57\NN| (r_amod) users_58\NNS|warfarin|(|difference=0.01|) (r_pobj) in_56\IN|users (r_prep) range_50\NN|(|,|3.5|)|in (r_parataxis) 3.4_40\CD|9.7|)|in|range (r_appos) range_38\NN|5.7|(|,|3.4 (r_pobj) to_35\IN|range (r_prep) ratio_24\NN|(|odds|;|range|in|to (r_pobj) from_20\IN|2.8|ratio (r_prep) increased_19\VBD|excess|from|. (r_conj) were_2\VBD|,|mb|frequent|in|vs|,|but|increased (l_prep) vs_7\IN|tia (l_pobj) TIA_10\NNP|is|/|in (l_nmod) IS_8\NNP|
D014859_D002544 NONE warfarin_8\JJ| (r_amod) users_9\NNS|warfarin|vs (r_pobj) in_7\IN|users (r_prep) excess_4\NN|an|of|in (r_attr) was_1\VBD|there|also|excess|but|none|. (l_attr) none_30\NN|in (l_prep) in_31\IN|users (l_pobj) users_33\NNS|warfarin|with (l_prep) with_34\IN|tia (l_pobj) TIA_37\NNP|is|/|(|or|;|ci|) (l_nmod) IS_35\NNP|
D014859_D002544 NONE warfarin_32\JJ| (r_amod) users_33\NNS|warfarin|with (l_prep) with_34\IN|tia (l_pobj) TIA_37\NNP|is|/|(|or|;|ci|) (l_nmod) IS_35\NNP|
D014859_D002546 NONE warfarin_57\NN| (r_amod) users_58\NNS|warfarin|(|difference=0.01|) (r_pobj) in_56\IN|users (r_prep) range_50\NN|(|,|3.5|)|in (r_parataxis) 3.4_40\CD|9.7|)|in|range (r_appos) range_38\NN|5.7|(|,|3.4 (r_pobj) to_35\IN|range (r_prep) ratio_24\NN|(|odds|;|range|in|to (r_pobj) from_20\IN|2.8|ratio (r_prep) increased_19\VBD|excess|from|. (r_conj) were_2\VBD|,|mb|frequent|in|vs|,|but|increased (l_prep) vs_7\IN|tia (l_pobj) TIA_10\NNP|is|/|in
D014859_D002546 NONE warfarin_8\JJ| (r_amod) users_9\NNS|warfarin|vs (r_pobj) in_7\IN|users (r_prep) excess_4\NN|an|of|in (r_attr) was_1\VBD|there|also|excess|but|none|. (l_attr) none_30\NN|in (l_prep) in_31\IN|users (l_pobj) users_33\NNS|warfarin|with (l_prep) with_34\IN|tia (l_pobj) TIA_37\NNP|is|/|(|or|;|ci|)
D014859_D002546 NONE warfarin_32\JJ| (r_amod) users_33\NNS|warfarin|with (l_prep) with_34\IN|tia (l_pobj) TIA_37\NNP|is|/|(|or|;|ci|)
9071336
D017239_D001943 NONE Paclitaxel_0\NNP|,|,|and|acid (l_conj) acid_6\NN|folinic|in|: (l_prep) in_7\IN|cancer (l_pobj) cancer_10\NN|metastatic|breast
D017239_D001943 NONE paclitaxel_3\NN| (r_conj) acid_1\NN|folinic|and|paclitaxel (r_nsubj) are_17\VBP|acid|taxol|therapies|. (l_attr) therapies_20\NNS|effective|salvage|for (l_prep) for_21\IN|patients (l_pobj) patients_25\NNS|metastatic|cancer (l_compound) cancer_24\NN|breast
D017239_D001943 NONE Taxol_5\NNP|(|;|company|) (r_nsubj) are_17\VBP|acid|taxol|therapies|. (l_attr) therapies_20\NNS|effective|salvage|for (l_prep) for_21\IN|patients (l_pobj) patients_25\NNS|metastatic|cancer (l_compound) cancer_24\NN|breast
D017239_D001943 NONE paclitaxel_7\NN| (r_pobj) of_6\IN|paclitaxel (r_prep) trial_5\NN|ii|of (r_dobj) performed_1\VBD|we|phase|trial|m2|. (l_dobj) phase_3\NN|a|followed (l_relcl) followed_18\VBD|i|by (l_agent) by_19\IN|acid (l_pobj) acid_21\NN|folinic|before|on|days|in (l_prep) in_44\IN|women (l_pobj) women_45\NNS|with (l_prep) with_46\IN|cancer (l_pobj) cancer_49\NN|metastatic|breast
D005472_D001943 NONE 5-fluorouracil_2\CD| (r_punct) ,_3\,|5-fluorouracil (r_punct) Paclitaxel_0\NNP|,|,|and|acid (l_conj) acid_6\NN|folinic|in|: (l_prep) in_7\IN|cancer (l_pobj) cancer_10\NN|metastatic|breast
D005472_D001943 NONE 5-fluorouracil_28\CD| (r_punct) m2_32\NN|5-fluorouracil|350|mg|/ (r_pobj) before_27\IN|hour|m2 (r_prep) acid_21\NN|folinic|before|on|days|in (l_prep) in_44\IN|women (l_pobj) women_45\NNS|with (l_prep) with_46\IN|cancer (l_pobj) cancer_49\NN|metastatic|breast
D002955_D001943 NONE acid_6\NN|folinic|in|: (l_prep) in_7\IN|cancer (l_pobj) cancer_10\NN|metastatic|breast
D002955_D001943 NONE acid_1\NN|folinic|and|paclitaxel (r_nsubj) are_17\VBP|acid|taxol|therapies|. (l_attr) therapies_20\NNS|effective|salvage|for (l_prep) for_21\IN|patients (l_pobj) patients_25\NNS|metastatic|cancer (l_compound) cancer_24\NN|breast
D002955_D001943 NONE acid_21\NN|folinic|before|on|days|in (l_prep) in_44\IN|women (l_pobj) women_45\NNS|with (l_prep) with_46\IN|cancer (l_pobj) cancer_49\NN|metastatic|breast
D017239_D064420 NONE Paclitaxel_0\NNP|and (r_nsubj) have_3\VBP|paclitaxel|5-fluorouracil|cytotoxicity|. (l_dobj) cytotoxicity_5\NN|additive|in
D005472_D064420 NONE 5-fluorouracil_2\CD| (r_punct) have_3\VBP|paclitaxel|5-fluorouracil|cytotoxicity|. (l_dobj) cytotoxicity_5\NN|additive|in
D016179_D009503 NONE factor_54\NN|granulocyte|stimulating (r_dobj) required_49\VBN|reported|;|cycles|factor|due (l_ccomp) reported_2\VBN|analysis|is|on|associated (l_ccomp) associated_32\VBN|cycles|were|with (l_prep) with_33\IN|hospitalization (l_pobj) hospitalization_38\NN|3/4|neutropenia|requiring (l_det) neutropenia_36\NN|
D016179_D009503 NONE factor_54\NN|granulocyte|stimulating (r_dobj) required_49\VBN|reported|;|cycles|factor|due (l_prep) due_55\JJ|to|neutropenia (l_pobj) neutropenia_57\NN|
19178808
D015742_D006470 NONE propofol_54\NN| (r_compound) remifentanil_56\NN|propofol|- (r_compound) total_57\JJ|remifentanil (r_amod) anesthesia_59\NN|total|i.v.|(|tiva|) (r_pobj) by_53\IN|anesthesia (r_agent) induced_52\VBN|by (r_acl) anesthesia_51\NN|controlled|hypotension|induced (r_dobj) maintaining_48\VBG|anesthesia (r_pcomp) in_47\IN|maintaining (r_prep) using_32\VBG|airway|versus|in (r_advcl) compare_7\VB|to|conditions|during|using (l_dobj) conditions_9\NNS|surgical|,|including|, (l_prep) including_11\VBG|amount (l_pobj) amount_13\NN|the|of (l_prep) of_14\IN|bleeding (l_pobj) bleeding_16\NN|intraoperative|as|pressure
D015742_D007022 CID propofol_54\NN| (r_compound) remifentanil_56\NN|propofol|- (r_compound) total_57\JJ|remifentanil (r_amod) anesthesia_59\NN|total|i.v.|(|tiva|) (r_pobj) by_53\IN|anesthesia (r_agent) induced_52\VBN|by (r_acl) anesthesia_51\NN|controlled|hypotension|induced (l_compound) hypotension_50\NN|
D015742_D007022 CID propofol_19\JJ| (r_compound) TIVA_23\NNP|propofol|-|remifentanil|- (r_pobj) by_18\IN|tiva (r_agent) caused_17\VBN|by (r_acl) anesthesia_16\NN|controlled|hypotension|caused (l_compound) hypotension_15\NN|
C071741_D006470 NONE remifentanil_56\NN|propofol|- (r_compound) total_57\JJ|remifentanil (r_amod) anesthesia_59\NN|total|i.v.|(|tiva|) (r_pobj) by_53\IN|anesthesia (r_agent) induced_52\VBN|by (r_acl) anesthesia_51\NN|controlled|hypotension|induced (r_dobj) maintaining_48\VBG|anesthesia (r_pcomp) in_47\IN|maintaining (r_prep) using_32\VBG|airway|versus|in (r_advcl) compare_7\VB|to|conditions|during|using (l_dobj) conditions_9\NNS|surgical|,|including|, (l_prep) including_11\VBG|amount (l_pobj) amount_13\NN|the|of (l_prep) of_14\IN|bleeding (l_pobj) bleeding_16\NN|intraoperative|as|pressure
C071741_D007022 CID remifentanil_56\NN|propofol|- (r_compound) total_57\JJ|remifentanil (r_amod) anesthesia_59\NN|total|i.v.|(|tiva|) (r_pobj) by_53\IN|anesthesia (r_agent) induced_52\VBN|by (r_acl) anesthesia_51\NN|controlled|hypotension|induced (l_compound) hypotension_50\NN|
C071741_D007022 CID remifentanil_21\NN| (r_compound) TIVA_23\NNP|propofol|-|remifentanil|- (r_pobj) by_18\IN|tiva (r_agent) caused_17\VBN|by (r_acl) anesthesia_16\NN|controlled|hypotension|caused (l_compound) hypotension_15\NN|
C071741_D007022 CID remifentanil_15\NN| (r_compound) infusion_16\NN|remifentanil (r_pobj) of_14\IN|infusion (r_prep) rates_13\NNS|lower|of (r_dobj) using_11\VBG|rates|and (r_xcomp) using_8\VBG|mask|using (r_acl) period_7\NN|a|shorter|using (r_pobj) within_4\IN|period (r_prep) achieved_3\VBN|hypotension|was|within|dose|. (l_nsubjpass) hypotension_1\NN|controlled
C071741_D007022 CID remifentanil_22\NN| (r_pobj) of_21\IN|remifentanil (r_prep) dose_20\NN|lower|total|of (r_dobj) achieved_3\VBN|hypotension|was|within|dose|. (l_nsubjpass) hypotension_1\NN|controlled
C071741_D007022 CID remifentanil_39\NN| (r_pobj) of_38\IN|remifentanil (r_prep) doses_37\NNS|low|of (r_pobj) with_35\IN|doses (r_prep) hypotension_34\NN|convenient|induced|with|during|in (r_pobj) for_31\IN|hypotension (r_prep) allowed_30\VBN|for (r_conj) using_9\VBG|management|frlma|during|and|allowed (l_prep) during_11\IN|anesthesia (l_pobj) anesthesia_14\NN|controlled|hypotension|provided (l_compound) hypotension_13\NN|
C071741_D007022 CID remifentanil_39\NN| (r_pobj) of_38\IN|remifentanil (r_prep) doses_37\NNS|low|of (r_pobj) with_35\IN|doses (r_prep) hypotension_34\NN|convenient|induced|with|during|in
7931490
D017829_D009325 NONE granisetron_4\NN| (r_pobj) of_3\IN|granisetron (r_prep) Efficacy_0\NN|and|safety|of|,|antagonist|,|in|. (l_prep) in_12\IN|prevention (l_pobj) prevention_14\NN|the|of|and|vomiting|induced (l_prep) of_15\IN|nausea (l_pobj) nausea_16\NN|
D017829_D009325 NONE granisetron_13\NN| (r_pobj) of_12\IN|granisetron (r_prep) doses_11\NNS|four|different|of|(|kytril|;|pharmaceuticals|) (r_pobj) of_8\IN|doses (r_prep) profile_7\NN|safety|of (r_conj) effects_4\NNS|the|antiemetic|and|profile (r_dobj) assess_1\VB|to|effects|administered|. (l_advcl) administered_26\VBN|when|as|dose (l_dobj) dose_34\NN|for (l_prep) for_35\IN|prophylaxis (l_pobj) prophylaxis_36\NN|of (l_prep) of_37\IN|nausea (l_pobj) nausea_41\NN|induced|and|vomiting
D017829_D009325 NONE Kytril_15\NNP| (r_appos) doses_11\NNS|four|different|of|(|kytril|;|pharmaceuticals|) (r_pobj) of_8\IN|doses (r_prep) profile_7\NN|safety|of (r_conj) effects_4\NNS|the|antiemetic|and|profile (r_dobj) assess_1\VB|to|effects|administered|. (l_advcl) administered_26\VBN|when|as|dose (l_dobj) dose_34\NN|for (l_prep) for_35\IN|prophylaxis (l_pobj) prophylaxis_36\NN|of (l_prep) of_37\IN|nausea (l_pobj) nausea_41\NN|induced|and|vomiting
D017829_D014839 NONE granisetron_4\NN| (r_pobj) of_3\IN|granisetron (r_prep) Efficacy_0\NN|and|safety|of|,|antagonist|,|in|. (l_prep) in_12\IN|prevention (l_pobj) prevention_14\NN|the|of|and|vomiting|induced (l_conj) vomiting_18\VBG|
D017829_D014839 NONE granisetron_13\NN| (r_pobj) of_12\IN|granisetron (r_prep) doses_11\NNS|four|different|of|(|kytril|;|pharmaceuticals|) (r_pobj) of_8\IN|doses (r_prep) profile_7\NN|safety|of (r_conj) effects_4\NNS|the|antiemetic|and|profile (r_dobj) assess_1\VB|to|effects|administered|. (l_advcl) administered_26\VBN|when|as|dose (l_dobj) dose_34\NN|for (l_prep) for_35\IN|prophylaxis (l_pobj) prophylaxis_36\NN|of (l_prep) of_37\IN|nausea (l_pobj) nausea_41\NN|induced|and|vomiting (l_conj) vomiting_43\NN|
D017829_D014839 NONE Kytril_15\NNP| (r_appos) doses_11\NNS|four|different|of|(|kytril|;|pharmaceuticals|) (r_pobj) of_8\IN|doses (r_prep) profile_7\NN|safety|of (r_conj) effects_4\NNS|the|antiemetic|and|profile (r_dobj) assess_1\VB|to|effects|administered|. (l_advcl) administered_26\VBN|when|as|dose (l_dobj) dose_34\NN|for (l_prep) for_35\IN|prophylaxis (l_pobj) prophylaxis_36\NN|of (l_prep) of_37\IN|nausea (l_pobj) nausea_41\NN|induced|and|vomiting (l_conj) vomiting_43\NN|
D017829_D014839 NONE granisetron_1\NN| (r_compound) doses_2\NNS|granisetron|of|,|10 (l_appos) 10_6\CD|20|,|and|micrograms (l_conj) micrograms_12\NNS|40|/|kg|,|response (l_appos) response_18\NN|a|major|(|vomiting|,|and|rescue (l_acl) vomiting_24\NN|<|or|retching
D017829_D014839 NONE granisetron_1\NN| (r_compound) doses_2\NNS|granisetron|of|,|10 (r_pobj) After_0\IN|doses (r_prep) recorded_35\VBN|after|was|in|and|response|. (l_conj) response_57\NN|a|complete|(|vomiting|)|in (l_appos) vomiting_60\NN|no|or|retching|,|and|rescue
D017829_D014839 NONE granisetron_10\NN| (r_pobj) of_9\IN|granisetron (r_prep) dose_8\NN|kg|of (r_conj) 20-_2\CD|,|or|dose (r_conj) 10-_0\LS|,|20- (r_nsubj) was_11\VBD|10-|effective|. (l_acomp) effective_12\JJ|in (l_prep) in_13\IN|controlling (l_pcomp) controlling_14\VBG|vomiting (l_dobj) vomiting_15\NN|in
D017829_D014839 NONE granisetron_10\NN| (r_pobj) of_9\IN|granisetron (r_prep) dose_8\NN|kg|of (r_conj) 20-_2\CD|,|or|dose (r_conj) 10-_0\LS|,|20- (r_nsubj) was_11\VBD|10-|effective|. (l_acomp) effective_12\JJ|in (l_prep) in_13\IN|controlling (l_pcomp) controlling_14\VBG|vomiting (l_dobj) vomiting_15\NN|in (l_prep) in_16\IN|% (l_pobj) %_21\NN|60|of (l_prep) of_22\IN|patients (l_pobj) patients_23\NNS|received (l_relcl) received_25\VBD|who|cisplatin|at|and|prevented (l_conj) prevented_37\VBN|totally|vomiting|to (l_dobj) vomiting_38\VBG|in
D012701_D009325 NONE 5-hydroxytryptamine-3_8\CD| (r_nummod) antagonist_10\NN|a|selective|5-hydroxytryptamine-3|receptor (r_appos) Efficacy_0\NN|and|safety|of|,|antagonist|,|in|. (l_prep) in_12\IN|prevention (l_pobj) prevention_14\NN|the|of|and|vomiting|induced (l_prep) of_15\IN|nausea (l_pobj) nausea_16\NN|
D012701_D014839 NONE 5-hydroxytryptamine-3_8\CD| (r_nummod) antagonist_10\NN|a|selective|5-hydroxytryptamine-3|receptor (r_appos) Efficacy_0\NN|and|safety|of|,|antagonist|,|in|. (l_prep) in_12\IN|prevention (l_pobj) prevention_14\NN|the|of|and|vomiting|induced (l_conj) vomiting_18\VBG|
D002945_D009325 CID cisplatin_24\NN|dose (r_pobj) by_20\IN|cisplatin (r_agent) induced_19\VBN|by (r_acl) prevention_14\NN|the|of|and|vomiting|induced (l_prep) of_15\IN|nausea (l_pobj) nausea_16\NN|
D002945_D009325 CID cisplatin_38\NN| (r_advmod) induced_40\VBN|cisplatin|- (r_amod) nausea_41\NN|induced|and|vomiting
D002945_D014839 CID cisplatin_24\NN|dose (r_pobj) by_20\IN|cisplatin (r_agent) induced_19\VBN|by (r_acl) prevention_14\NN|the|of|and|vomiting|induced (l_conj) vomiting_18\VBG|
D002945_D014839 CID cisplatin_38\NN| (r_advmod) induced_40\VBN|cisplatin|- (r_amod) nausea_41\NN|induced|and|vomiting (l_conj) vomiting_43\NN|
D002945_D014839 CID cisplatin_26\NN| (r_dobj) received_25\VBD|who|cisplatin|at|and|prevented (r_relcl) patients_23\NNS|received (r_pobj) of_22\IN|patients (r_prep) %_21\NN|60|of (r_pobj) in_16\IN|% (r_prep) vomiting_15\NN|in
D002945_D014839 CID cisplatin_26\NN| (r_dobj) received_25\VBD|who|cisplatin|at|and|prevented (l_conj) prevented_37\VBN|totally|vomiting|to (l_dobj) vomiting_38\VBG|in
9061777
D016291_D012640 CID MK-801_0\NNP| (r_punct) augments_1\VBZ|mk-801|seizure|but|protects|. (l_dobj) seizure_6\NN|induced|electrographic
D016291_D012640 CID MK-801_7\NNP| (r_punct) on_8\IN|mk-801|model (l_pobj) model_14\NN|the|induced|seizure (l_compound) seizure_13\NN|
D016291_D012640 CID MK-801_20\NNP| (r_punct) 0.5_22\CD|mk-801|( (r_nummod) mg/kg_23\NN|0.5 (r_conj) prevented_11\VBN|scopolamine|development|but|mg/kg|) (l_dobj) development_12\NN|of (l_prep) of_13\IN|seizure (l_pobj) seizure_18\NN|induced|behavioral
D016291_D012640 CID MK-801_11\NNP| (r_punct) treatment_12\NN|mk-801 (r_nsubj) augmented_13\VBD|treatment|seizure (r_conj) blocked_3\VBD|scopolamine|seizure|,|augmented|. (l_dobj) seizure_9\NN|the|induced|electrographic
D016291_D012640 CID MK-801_11\NNP| (r_punct) treatment_12\NN|mk-801 (r_nsubj) augmented_13\VBD|treatment|seizure (l_dobj) seizure_16\NN|the|electrographic|induced
D016291_D001930 NONE MK-801_0\NNP| (r_punct) augments_1\VBZ|mk-801|seizure|but|protects|. (l_conj) protects_8\VBZ|against (l_prep) against_9\IN|damage (l_pobj) damage_11\NN|brain|in
D016291_D001930 NONE MK-801_4\NNP| (r_punct) protected_5\VBD|mk-801|damage (l_dobj) damage_8\NN|the|brain|by
D016291_D001930 NONE MK-801-treated_15\JJ| (r_amod) group_16\NN|the|mk-801-treated (r_pobj) in_13\IN|group (r_prep) appeared_23\VBD|pentobarbital|,|though|in|,|cells|darker|. (l_nsubj) Pentobarbital_0\JJ|,|scopolamine (l_appos) scopolamine_2\NN|and|protected (l_conj) protected_5\VBD|mk-801|damage (l_dobj) damage_8\NN|the|brain|by
D010862_D012640 CID pilocarpine_2\NN| (r_npadvmod) induced_4\VBN|pilocarpine|- (r_amod) seizure_6\NN|induced|electrographic
D010862_D012640 CID pilocarpine_10\NN| (r_npadvmod) induced_12\VBN|pilocarpine|- (r_amod) model_14\NN|the|induced|seizure (l_compound) seizure_13\NN|
D010862_D012640 CID pilocarpine_3\NN| (r_pobj) of_2\IN|pilocarpine (r_prep) injection_1\NN|intraperitoneal|of|mg/kg (r_nsubj) induced_8\VBN|injection|seizure|. (l_dobj) seizure_12\NN|tonic
D010862_D012640 CID pilocarpine_14\NN| (r_npadvmod) induced_16\VBN|pilocarpine|- (r_amod) seizure_18\NN|induced|behavioral
D010862_D012640 CID pilocarpine_10\NN| (r_npadvmod) treated_12\VBN|pilocarpine|- (r_amod) group_13\NN|the|treated (r_pobj) in_8\IN|group (r_prep) appeared_7\VBD|seizure|in|. (l_nsubj) seizure_2\NN|an|electrical|measured
D010862_D012640 CID pilocarpine_5\NN| (r_npadvmod) induced_7\VBN|pilocarpine|- (r_amod) seizure_9\NN|the|induced|electrographic
D010862_D012640 CID pilocarpine_5\NN| (r_npadvmod) induced_7\VBN|pilocarpine|- (r_amod) seizure_9\NN|the|induced|electrographic (r_dobj) blocked_3\VBD|scopolamine|seizure|,|augmented|. (l_conj) augmented_13\VBD|treatment|seizure (l_dobj) seizure_16\NN|the|electrographic|induced
D010862_D012640 CID pilocarpine_19\NN| (r_pobj) by_18\IN|pilocarpine (r_agent) induced_17\VBN|by (r_acl) seizure_16\NN|the|electrographic|induced (r_dobj) augmented_13\VBD|treatment|seizure (r_conj) blocked_3\VBD|scopolamine|seizure|,|augmented|. (l_dobj) seizure_9\NN|the|induced|electrographic
D010862_D012640 CID pilocarpine_19\NN| (r_pobj) by_18\IN|pilocarpine (r_agent) induced_17\VBN|by (r_acl) seizure_16\NN|the|electrographic|induced
D010862_D001930 NONE pilocarpine_2\NN| (r_npadvmod) induced_4\VBN|pilocarpine|- (r_amod) seizure_6\NN|induced|electrographic (r_dobj) augments_1\VBZ|mk-801|seizure|but|protects|. (l_conj) protects_8\VBZ|against (l_prep) against_9\IN|damage (l_pobj) damage_11\NN|brain|in
D010862_D001930 NONE pilocarpine_10\NN| (r_pobj) by_9\IN|pilocarpine (r_prep) damage_8\NN|the|brain|by
D010862_D001930 NONE pilocarpine_8\NN| (r_pobj) by_7\IN|pilocarpine (r_agent) induced_6\VBN|epilepticus|by (r_acl) status_4\NN|induced (r_nsubjpass) initiated_10\VBN|that|status|is|by|and|propagated (r_ccomp) indicate_2\VBP|results|initiated (r_ccomp) cause_25\VB|indicate|,|elevation|may|damage|. (l_dobj) damage_27\NN|brain|through
D012601_D012640 NONE Scopolamine_0\NNP|mg/kg|and|pentobarbital (r_nsubj) prevented_11\VBN|scopolamine|development|but|mg/kg|) (l_dobj) development_12\NN|of (l_prep) of_13\IN|seizure (l_pobj) seizure_18\NN|induced|behavioral
D012601_D012640 NONE Scopolamine_0\NNP|and|pentobarbital (r_nsubj) blocked_3\VBD|scopolamine|seizure|,|augmented|. (l_dobj) seizure_9\NN|the|induced|electrographic
D012601_D012640 NONE Scopolamine_0\NNP|and|pentobarbital (r_nsubj) blocked_3\VBD|scopolamine|seizure|,|augmented|. (l_conj) augmented_13\VBD|treatment|seizure (l_dobj) seizure_16\NN|the|electrographic|induced
D010424_D012640 NONE pentobarbital_6\NN|mg/kg (r_conj) Scopolamine_0\NNP|mg/kg|and|pentobarbital (r_nsubj) prevented_11\VBN|scopolamine|development|but|mg/kg|) (l_dobj) development_12\NN|of (l_prep) of_13\IN|seizure (l_pobj) seizure_18\NN|induced|behavioral
D010424_D012640 NONE pentobarbital_2\NN| (r_conj) Scopolamine_0\NNP|and|pentobarbital (r_nsubj) blocked_3\VBD|scopolamine|seizure|,|augmented|. (l_dobj) seizure_9\NN|the|induced|electrographic
D010424_D012640 NONE pentobarbital_2\NN| (r_conj) Scopolamine_0\NNP|and|pentobarbital (r_nsubj) blocked_3\VBD|scopolamine|seizure|,|augmented|. (l_conj) augmented_13\VBD|treatment|seizure (l_dobj) seizure_16\NN|the|electrographic|induced
D010862_D009410 CID Pilocarpine_0\NNP| (r_nsubj) produced_1\VBD|pilocarpine|death|. (l_dobj) death_3\NN|neuronal|in
D010424_D001930 NONE Pentobarbital_0\JJ|,|scopolamine (l_appos) scopolamine_2\NN|and|protected (l_conj) protected_5\VBD|mk-801|damage (l_dobj) damage_8\NN|the|brain|by
D012601_D001930 NONE scopolamine_2\NN|and|protected (l_conj) protected_5\VBD|mk-801|damage (l_dobj) damage_8\NN|the|brain|by
D010862_D013226 CID pilocarpine_8\NN| (r_pobj) by_7\IN|pilocarpine (r_agent) induced_6\VBN|epilepticus|by (l_advmod) epilepticus_5\NN|
D016202_D013226 NONE NMDA_31\NNP| (r_compound) mechanism_35\NN|an|excitatory|nmda|mediated (r_pobj) through_28\IN|mechanism (r_prep) damage_27\NN|brain|through (r_dobj) cause_25\VB|indicate|,|elevation|may|damage|. (l_ccomp) indicate_2\VBP|results|initiated (l_ccomp) initiated_10\VBN|that|status|is|by|and|propagated (l_nsubjpass) status_4\NN|induced (l_acl) induced_6\VBN|epilepticus|by (l_advmod) epilepticus_5\NN|
D016202_D001930 NONE NMDA_31\NNP| (r_compound) mechanism_35\NN|an|excitatory|nmda|mediated (r_pobj) through_28\IN|mechanism (r_prep) damage_27\NN|brain|through
11105626
D015474_D065817 CID isotretinoin_21\VB| (r_pobj) to_20\IN|isotretinoin (r_prep) exposure_19\NN|to|within (r_pobj) due_17\IN|to|exposure (r_prep) report_1\VBP|we|infant|due|. (l_dobj) infant_4\NN|a|newborn|with (l_prep) with_5\IN|anomalies (l_pobj) anomalies_8\NNS|multiple|congenital|(|anotia|) (l_appos) anotia_10\NN|and|malformation
D015474_D004310 CID isotretinoin_21\VB| (r_pobj) to_20\IN|isotretinoin (r_prep) exposure_19\NN|to|within (r_pobj) due_17\IN|to|exposure (r_prep) report_1\VBP|we|infant|due|. (l_dobj) infant_4\NN|a|newborn|with (l_prep) with_5\IN|anomalies (l_pobj) anomalies_8\NNS|multiple|congenital|(|anotia|) (l_appos) anotia_10\NN|and|malformation (l_conj) malformation_15\NN|bing
19967075
D012964_D007674 NONE Na_3\NNP| (r_nmod) ATPase_7\NNP|na|/|k|-|,|nhe3|in (l_prep) in_16\IN|nephropathy (l_pobj) Nephropathy_20\NNP|induced
D012964_D007674 NONE Na(+)/K(+)-ATPase_17\NNP|,|nhe3 (r_pobj) of_16\IN|na(+)/k(+)-atpase (r_prep) expression_15\NN|a|decreased|of (r_pobj) with_12\IN|expression (r_prep) related_11\VBN|nephropathy|may|in|be|causally|with|. (l_nsubjpass) nephropathy_3\NN|induced
D011188_D007674 NONE K_5\NNP| (r_compound) ATPase_7\NNP|na|/|k|-|,|nhe3|in (l_prep) in_16\IN|nephropathy (l_pobj) Nephropathy_20\NNP|induced
D011188_D007674 NONE Na(+)/K(+)-ATPase_17\NNP|,|nhe3 (r_pobj) of_16\IN|na(+)/k(+)-atpase (r_prep) expression_15\NN|a|decreased|of (r_pobj) with_12\IN|expression (r_prep) related_11\VBN|nephropathy|may|in|be|causally|with|. (l_nsubjpass) nephropathy_3\NN|induced
D005839_D007674 CID Gentamicin_17\NNP| (r_npadvmod) induced_19\VBN|gentamicin|- (r_amod) Nephropathy_20\NNP|induced
D005839_D007674 CID gentamicin_17\NN| (r_npadvmod) induced_19\VBN|gentamicin|- (r_amod) nephropathy_20\NN|induced
D005839_D007674 CID Gentamicin_0\NNP| (r_npadvmod) induced_2\VBN|gentamicin|- (r_amod) nephropathy_3\NN|induced
25907210
D010755_D009369 NONE organophosphate_10\NN| (r_amod) diazinon_12\NN|the|organophosphate|insecticide|in (r_pobj) to_8\IN|diazinon (r_prep) exposed_7\VBN|to (r_acl) applicators_6\NNS|pesticide|exposed (r_pobj) among_4\IN|applicators (r_prep) tumours_3\NNS|solid|among
D010755_D009369 NONE organophosphate_4\NN| (r_compound) insecticide_5\NN|a|common|organophosphate|with (r_appos) Diazinon_0\NNP|,|insecticide|, (r_nsubjpass) associated_12\VBN|diazinon|was|previously|with (r_ccomp) examined_32\VBN|associated|studies|have|risk|. (l_dobj) risk_37\NN|associated|cancer (l_compound) cancer_36\NN|
D003976_D009369 NONE diazinon_12\NN|the|organophosphate|insecticide|in (r_pobj) to_8\IN|diazinon (r_prep) exposed_7\VBN|to (r_acl) applicators_6\NNS|pesticide|exposed (r_pobj) among_4\IN|applicators (r_prep) tumours_3\NNS|solid|among
D003976_D009369 NONE Diazinon_0\NNP|,|insecticide|, (r_nsubjpass) associated_12\VBN|diazinon|was|previously|with (r_ccomp) examined_32\VBN|associated|studies|have|risk|. (l_dobj) risk_37\NN|associated|cancer (l_compound) cancer_36\NN|
D003976_D009369 NONE diazinon_33\NN| (r_npadvmod) associated_35\VBN|diazinon|- (r_amod) risk_37\NN|associated|cancer (l_compound) cancer_36\NN|
D003976_D009369 NONE diazinon_3\NN| (r_compound) exposure_4\NN|updated|diazinon|and|information (l_conj) information_8\NN|cancer|incidence (l_compound) cancer_6\NN|
D003976_D009369 NONE diazinon_3\NN| (r_compound) exposure_4\NN|updated|diazinon|and|information (r_dobj) used_1\VBD|we|exposure|evaluate|. (l_xcomp) evaluate_10\VB|to|risk|in (l_dobj) risk_13\NN|solid|tumour (l_compound) tumour_12\NN|
D003976_D009369 NONE diazinon_10\NN|lifetime (r_compound) use_11\NN|diazinon|at (r_dobj) reported_8\VBD|applicators|use (r_ccomp) assessed_32\VBN|reported|;|incidence|was|through|)|. (l_nsubjpass) incidence_30\NN|cancer (l_compound) cancer_29\NN|
D003976_D008175 CID Diazinon_0\NNP|,|insecticide|, (r_nsubjpass) associated_12\VBN|diazinon|was|previously|with (l_prep) with_13\IN|cancer (l_pobj) cancer_15\NN|lung|in|but
D003976_D008175 CID diazinon_33\NN| (r_npadvmod) associated_35\VBN|diazinon|- (r_amod) risk_37\NN|associated|cancer (r_dobj) examined_32\VBN|associated|studies|have|risk|. (l_ccomp) associated_12\VBN|diazinon|was|previously|with (l_prep) with_13\IN|cancer (l_pobj) cancer_15\NN|lung|in|but
D003976_D008175 CID diazinon_34\NN| (r_compound) use_35\NN|diazinon (r_pobj) of_33\IN|use (r_prep) days_32\NNS|iw|of|(|rr=1.41|; (r_conj) Ptrend=0.02_28\LS|)|and|days (r_appos) CI_23\NNP|%|1.11|to|;|ptrend=0.02|% (r_npadvmod) observed_2\VBD|:|we|risks|;|ci|. (l_dobj) risks_6\NNS|elevated|cancer|(|n=283|)|among (l_compound) cancer_5\NN|lung
D003976_D008175 CID diazinon_4\NNS| (r_pobj) of_3\IN|diazinon (r_prep) evaluation_2\NN|our|updated|of (r_nsubj) provides_5\VBZ|evaluation|evidence|. (l_dobj) evidence_7\NN|additional|of (l_prep) of_8\IN|association (l_pobj) association_10\NN|an|with (l_prep) with_11\IN|risk (l_pobj) risk_14\NN|cancer (l_compound) cancer_13\NN|lung
D010755_D008175 NONE organophosphate_4\NN| (r_compound) insecticide_5\NN|a|common|organophosphate|with (r_appos) Diazinon_0\NNP|,|insecticide|, (r_nsubjpass) associated_12\VBN|diazinon|was|previously|with (l_prep) with_13\IN|cancer (l_pobj) cancer_15\NN|lung|in|but
2765447
D019793_D012640 NONE fluorescein_3\NN| (r_amod) angiography_4\NN|intravenous|fluorescein (r_dobj) following_1\VBG|angiography (r_prep) Convulsion_0\NNP|following|.
D019793_D004830 CID fluorescein_6\NN| (r_amod) injection_7\NN|intravenous|fluorescein|for|in (r_dobj) followed_4\VBD|seizures|injection|. (l_nsubj) seizures_3\NNS|clonic
12865514
D007980_D010300 NONE levodopa_29\RB| (r_npadvmod) induced_31\VBN|levodopa|- (r_amod) dyskinesias_32\NNS|induced (r_conj) rigidity_26\NN|,|and|dyskinesias (r_conj) bradykinesia_24\JJ|particularly|,|rigidity (r_conj) scale_19\NN|stages|)|and|,|bradykinesia (r_appos) patients_3\NNS|three|suffering|scale (l_acl) suffering_4\VBG|from (l_prep) from_5\IN|disease (l_pobj) disease_9\NN|severe|parkinson
D007980_D018476 NONE levodopa_29\RB| (r_npadvmod) induced_31\VBN|levodopa|- (r_amod) dyskinesias_32\NNS|induced (r_conj) rigidity_26\NN|,|and|dyskinesias (r_conj) bradykinesia_24\JJ|particularly|,|rigidity
D007980_D009127 NONE levodopa_29\RB| (r_npadvmod) induced_31\VBN|levodopa|- (r_amod) dyskinesias_32\NNS|induced (r_conj) rigidity_26\NN|,|and|dyskinesias
D007980_D004409 CID levodopa_29\RB| (r_npadvmod) induced_31\VBN|levodopa|- (r_amod) dyskinesias_32\NNS|induced
D007980_D004409 CID levodopa_4\JJ| (r_compound) dose_5\NN|the|levodopa (r_pobj) in_2\IN|dose (r_prep) reduction_1\NN|the|in (r_nsubj) is_6\VBZ|reduction|useful|. (l_acomp) useful_7\JJ|in (l_prep) in_8\IN|controlling (l_pcomp) controlling_9\VBG|dyskinesias (l_dobj) dyskinesias_13\NNS|induced
16880771
D004298_D020521 NONE dopamine_3\NN| (r_compound) precursor_4\NN|dopamine (r_compound) levodopa_5\NN|the|precursor (r_pobj) of_1\IN|levodopa (r_prep) Administration_0\NN|of (r_nsubj) enhances_6\VBZ|administration|learning|. (l_dobj) learning_7\VBG|in (l_prep) in_8\IN|subjects (l_pobj) subjects_10\NNS|healthy|and|patients (l_conj) patients_13\NNS|stroke (l_compound) stroke_12\NN|
D004298_D020521 NONE dopamine_12\NN| (r_nsubj) enhances_13\VBZ|by|dopamine|learning (l_dobj) learning_15\NN|associative|in (l_prep) in_16\IN|subjects (l_pobj) subjects_18\NNS|healthy|and|patients (l_conj) patients_21\NNS|stroke (l_compound) stroke_20\NN|
D007980_D020521 NONE levodopa_5\NN|the|precursor (r_pobj) of_1\IN|levodopa (r_prep) Administration_0\NN|of (r_nsubj) enhances_6\VBZ|administration|learning|. (l_dobj) learning_7\VBG|in (l_prep) in_8\IN|subjects (l_pobj) subjects_10\NNS|healthy|and|patients (l_conj) patients_13\NNS|stroke (l_compound) stroke_12\NN|
D004298_D007859 NONE dopamine_1\NN| (r_compound) agonist_2\NN|the|dopamine (r_nsubj) impaired_4\JJ|agonist|significantly (r_amod) learning_7\NN|impaired|word|compared|.
10713017
D005277_D006976 CID fenfluramines_9\NNS|only|the (r_nsubj) had_10\VBD|however|,|of|,|fenfluramines|association|compared|. (l_dobj) association_14\NN|a|significant|preferential|with (l_prep) with_15\IN|pph (l_pobj) PPH_16\NNP|
D005277_D006976 CID fenfluramines_22\NNS| (r_pobj) for_21\IN|fenfluramines (r_prep) specificity_20\NN|the|for (r_conj) association_4\NN|the|with|and|specificity (l_prep) with_5\IN|pph (l_pobj) PPH_6\NNP|,|increase|,
D005277_D006976 CID fenfluramines_22\NNS| (r_pobj) for_21\IN|fenfluramines (r_prep) specificity_20\NN|the|for (r_conj) association_4\NN|the|with|and|specificity (r_pobj) of_2\IN|association (r_prep) magnitude_1\NN|the|of (r_nsubj) are_23\VBP|magnitude|consistent|. (l_acomp) consistent_24\JJ|with (l_prep) with_25\IN|studies (l_pobj) studies_27\NNS|previous|indicating (l_acl) indicating_28\VBG|related (l_ccomp) related_33\VBN|that|fenfluramines|are|causally|to (l_prep) to_34\IN|pph (l_pobj) PPH_35\NNP|
D005277_D006976 CID fenfluramines_30\NNS| (r_nsubjpass) related_33\VBN|that|fenfluramines|are|causally|to (r_ccomp) indicating_28\VBG|related (r_acl) studies_27\NNS|previous|indicating (r_pobj) with_25\IN|studies (r_prep) consistent_24\JJ|with (r_acomp) are_23\VBP|magnitude|consistent|. (l_nsubj) magnitude_1\NN|the|of (l_prep) of_2\IN|association (l_pobj) association_4\NN|the|with|and|specificity (l_prep) with_5\IN|pph (l_pobj) PPH_6\NNP|,|increase|,
D005277_D006976 CID fenfluramines_30\NNS| (r_nsubjpass) related_33\VBN|that|fenfluramines|are|causally|to (l_prep) to_34\IN|pph (l_pobj) PPH_35\NNP|
24753331
C106487_D020964 CID S-53482_0\NNS|and|s-23121 (r_nsubj) are_3\VBP|s-53482|herbicides|. (l_attr) herbicides_7\NNS|phenylimide|and|embryolethality|,|teratogenicity|,|and|retardation (l_conj) embryolethality_10\NN|produced
C106487_D064793 CID S-53482_0\NNS|and|s-23121 (r_nsubj) are_3\VBP|s-53482|herbicides|. (l_attr) herbicides_7\NNS|phenylimide|and|embryolethality|,|teratogenicity|,|and|retardation (l_conj) teratogenicity_12\NN|(|defects|)
C106487_D064793 CID S-53482_5\NNS|and|s-23121 (r_nsubj) were_8\VBD|based|,|s-53482|teratogenic|administered|. (l_acomp) teratogenic_9\JJ|
C106487_D006345 CID S-53482_0\NNS|and|s-23121 (r_nsubj) are_3\VBP|s-53482|herbicides|. (l_attr) herbicides_7\NNS|phenylimide|and|embryolethality|,|teratogenicity|,|and|retardation (l_conj) teratogenicity_12\NN|(|defects|) (l_conj) defects_17\NNS|ventricular|septal|and|ribs
C106487_D005317 CID S-53482_0\NNS|and|s-23121 (r_nsubj) are_3\VBP|s-53482|herbicides|. (l_attr) herbicides_7\NNS|phenylimide|and|embryolethality|,|teratogenicity|,|and|retardation (l_conj) retardation_25\NN|growth|in
C106487_D064420 NONE S-53482_0\NNS|and|s-23121 (r_nsubj) are_3\VBP|s-53482|herbicides|. (l_attr) herbicides_7\NNS|phenylimide|and|embryolethality|,|teratogenicity|,|and|retardation (l_conj) retardation_25\NN|growth|in (l_prep) in_26\IN|rats (l_pobj) rats_27\NNS|in (l_prep) in_28\IN|studies (l_pobj) studies_33\NNS|conventional|oral|toxicity (l_compound) toxicity_32\NN|developmental
C106487_D064420 NONE S-53482_5\NNS| (r_pobj) to_4\IN|s-53482 (r_prep) exposure_1\NN|dermal|of|to|at|. (l_prep) at_6\IN|patterns (l_pobj) patterns_10\NNS|mg/kg|produced|of (l_prep) of_11\IN|toxicity (l_pobj) toxicity_13\NN|developmental|similar
C083440_D020964 CID S-23121_2\NN| (r_conj) S-53482_0\NNS|and|s-23121 (r_nsubj) are_3\VBP|s-53482|herbicides|. (l_attr) herbicides_7\NNS|phenylimide|and|embryolethality|,|teratogenicity|,|and|retardation (l_conj) embryolethality_10\NN|produced
C083440_D020964 CID S-23121_3\NN| (r_pobj) of_2\IN|s-23121 (r_prep) administration_1\NN|dermal|of|at (r_nsubj) resulted_7\VBD|administration|in|,|but|observed (l_prep) in_8\IN|incidence (l_pobj) incidence_11\NN|an|increased|of (l_prep) of_12\IN|death (l_pobj) death_14\NN|embryonic|and|defect
C083440_D020964 CID S-23121_34\NN| (r_pobj) to_33\IN|s-23121 (r_prep) exposure_32\NN|oral|to (r_dobj) following_30\VBG|as|it|was|exposure (r_advcl) observed_26\VBN|growth|was|not|following|. (r_conj) resulted_7\VBD|administration|in|,|but|observed (l_prep) in_8\IN|incidence (l_pobj) incidence_11\NN|an|increased|of (l_prep) of_12\IN|death (l_pobj) death_14\NN|embryonic|and|defect
C083440_D064793 CID S-23121_2\NN| (r_conj) S-53482_0\NNS|and|s-23121 (r_nsubj) are_3\VBP|s-53482|herbicides|. (l_attr) herbicides_7\NNS|phenylimide|and|embryolethality|,|teratogenicity|,|and|retardation (l_conj) teratogenicity_12\NN|(|defects|)
C083440_D064793 CID S-23121_7\NN| (r_conj) S-53482_5\NNS|and|s-23121 (r_nsubj) were_8\VBD|based|,|s-53482|teratogenic|administered|. (l_acomp) teratogenic_9\JJ|
C083440_D006345 CID S-23121_2\NN| (r_conj) S-53482_0\NNS|and|s-23121 (r_nsubj) are_3\VBP|s-53482|herbicides|. (l_attr) herbicides_7\NNS|phenylimide|and|embryolethality|,|teratogenicity|,|and|retardation (l_conj) teratogenicity_12\NN|(|defects|) (l_conj) defects_17\NNS|ventricular|septal|and|ribs
C083440_D006345 CID S-23121_3\NN| (r_pobj) of_2\IN|s-23121 (r_prep) administration_1\NN|dermal|of|at (r_nsubj) resulted_7\VBD|administration|in|,|but|observed (l_prep) in_8\IN|incidence (l_pobj) incidence_11\NN|an|increased|of (l_prep) of_12\IN|death (l_pobj) death_14\NN|embryonic|and|defect (l_conj) defect_18\NN|ventricular|septal
C083440_D006345 CID S-23121_34\NN| (r_pobj) to_33\IN|s-23121 (r_prep) exposure_32\NN|oral|to (r_dobj) following_30\VBG|as|it|was|exposure (r_advcl) observed_26\VBN|growth|was|not|following|. (r_conj) resulted_7\VBD|administration|in|,|but|observed (l_prep) in_8\IN|incidence (l_pobj) incidence_11\NN|an|increased|of (l_prep) of_12\IN|death (l_pobj) death_14\NN|embryonic|and|defect (l_conj) defect_18\NN|ventricular|septal
C083440_D005317 CID S-23121_2\NN| (r_conj) S-53482_0\NNS|and|s-23121 (r_nsubj) are_3\VBP|s-53482|herbicides|. (l_attr) herbicides_7\NNS|phenylimide|and|embryolethality|,|teratogenicity|,|and|retardation (l_conj) retardation_25\NN|growth|in
C083440_D064420 NONE S-23121_2\NN| (r_conj) S-53482_0\NNS|and|s-23121 (r_nsubj) are_3\VBP|s-53482|herbicides|. (l_attr) herbicides_7\NNS|phenylimide|and|embryolethality|,|teratogenicity|,|and|retardation (l_conj) retardation_25\NN|growth|in (l_prep) in_26\IN|rats (l_pobj) rats_27\NNS|in (l_prep) in_28\IN|studies (l_pobj) studies_33\NNS|conventional|oral|toxicity (l_compound) toxicity_32\NN|developmental
24911645
C573355_D012640 NONE FC_9\NNP|garcinielliptone (r_pobj) with_7\IN|fc (r_prep) pretreated_6\VBN|with|in (l_prep) in_10\IN|seizures (l_pobj) seizures_14\NNS|induced
C573355_D012640 NONE GFC_7\NNP| (r_compound) effects_8\NNS|the|gfc|at (l_prep) at_9\IN|doses (l_pobj) doses_10\NNS|of|on (l_prep) on_18\IN|parameters (l_pobj) parameters_20\NNS|seizure (l_compound) seizure_19\NN|
C573355_D012640 NONE GFC_7\NNP| (r_compound) effects_8\NNS|the|gfc|at (r_dobj) evaluate_5\VB|to|effects|determine (r_xcomp) aimed_3\VBN|evaluate (r_acl) study_2\NN|the|present|aimed|) (r_nsubj) levels_47\NNS|study|as|on|. (l_prep) on_51\IN|acetylcholinesterase (l_pobj) acetylcholinesterase_52\NN|(|ache|)|activity (l_appos) activity_56\NN|in (l_prep) in_57\IN|hippocampus (l_pobj) hippocampus_59\NN|mice|after (l_prep) after_60\IN|seizures (l_pobj) seizures_61\NNS|
C573355_D012640 NONE GFC_0\NNP| (r_nsubj) produced_1\VBD|gfc|latency|,|at|kg|. (l_dobj) latency_4\NN|an|increased|to (l_prep) to_5\IN|seizure (l_pobj) seizure_7\NN|first
C573355_D012640 NONE GFC_4\NNP| (r_nsubj) exert_6\VB|that|gfc|can|activity|and|reduce (l_conj) reduce_10\VB|frequency|epilepticus|,|demonstrated (l_advcl) demonstrated_23\VBN|as|by (l_agent) by_24\IN|increase (l_pobj) increase_25\NN|in|to|and|decrease (l_prep) to_28\IN|seizure (l_pobj) seizure_30\NN|first
D010862_D012640 CID pilocarpine_11\NN| (r_npadvmod) induced_13\VBN|pilocarpine|- (r_amod) seizures_14\NNS|induced
D010862_D012640 CID pilocarpine_16\NN| (r_npadvmod) induced_18\VBN|pilocarpine|- (r_amod) status_19\NN|induced (r_pobj) of_15\IN|status (r_prep) installation_14\NN|of (r_pobj) of_13\IN|installation (r_prep) frequency_12\NN|the|of (r_dobj) reduce_10\VB|frequency|epilepticus|,|demonstrated (l_advcl) demonstrated_23\VBN|as|by (l_agent) by_24\IN|increase (l_pobj) increase_25\NN|in|to|and|decrease (l_prep) to_28\IN|seizure (l_pobj) seizure_30\NN|first
D000596_D012640 NONE acid_31\NN|amino|acid (r_pobj) on_29\IN|acid (r_prep) effects_28\NNS|its|on (r_conj) activity_25\NN|their|anticonvulsant|and|effects (r_dobj) determine_22\VB|to|activity (r_advcl) evaluate_5\VB|to|effects|determine (l_dobj) effects_8\NNS|the|gfc|at (l_prep) at_9\IN|doses (l_pobj) doses_10\NNS|of|on (l_prep) on_18\IN|parameters (l_pobj) parameters_20\NNS|seizure (l_compound) seizure_19\NN|
D000596_D012640 NONE acid_31\NN|amino|acid (r_pobj) on_29\IN|acid (r_prep) effects_28\NNS|its|on (r_conj) activity_25\NN|their|anticonvulsant|and|effects (r_dobj) determine_22\VB|to|activity (r_advcl) evaluate_5\VB|to|effects|determine (r_xcomp) aimed_3\VBN|evaluate (r_acl) study_2\NN|the|present|aimed|) (r_nsubj) levels_47\NNS|study|as|on|. (l_prep) on_51\IN|acetylcholinesterase (l_pobj) acetylcholinesterase_52\NN|(|ache|)|activity (l_appos) activity_56\NN|in (l_prep) in_57\IN|hippocampus (l_pobj) hippocampus_59\NN|mice|after (l_prep) after_60\IN|seizures (l_pobj) seizures_61\NNS|
D005680_D012640 NONE acid_36\NN|(|aminobutyric|gaba|,|glutamine (r_appos) acid_31\NN|amino|acid (r_pobj) on_29\IN|acid (r_prep) effects_28\NNS|its|on (r_conj) activity_25\NN|their|anticonvulsant|and|effects (r_dobj) determine_22\VB|to|activity (r_advcl) evaluate_5\VB|to|effects|determine (l_dobj) effects_8\NNS|the|gfc|at (l_prep) at_9\IN|doses (l_pobj) doses_10\NNS|of|on (l_prep) on_18\IN|parameters (l_pobj) parameters_20\NNS|seizure (l_compound) seizure_19\NN|
D005680_D012640 NONE acid_36\NN|(|aminobutyric|gaba|,|glutamine (r_appos) acid_31\NN|amino|acid (r_pobj) on_29\IN|acid (r_prep) effects_28\NNS|its|on (r_conj) activity_25\NN|their|anticonvulsant|and|effects (r_dobj) determine_22\VB|to|activity (r_advcl) evaluate_5\VB|to|effects|determine (r_xcomp) aimed_3\VBN|evaluate (r_acl) study_2\NN|the|present|aimed|) (r_nsubj) levels_47\NNS|study|as|on|. (l_prep) on_51\IN|acetylcholinesterase (l_pobj) acetylcholinesterase_52\NN|(|ache|)|activity (l_appos) activity_56\NN|in (l_prep) in_57\IN|hippocampus (l_pobj) hippocampus_59\NN|mice|after (l_prep) after_60\IN|seizures (l_pobj) seizures_61\NNS|
D005680_D012640 NONE GABA_38\NNP|(|) (r_appos) acid_36\NN|(|aminobutyric|gaba|,|glutamine (r_appos) acid_31\NN|amino|acid (r_pobj) on_29\IN|acid (r_prep) effects_28\NNS|its|on (r_conj) activity_25\NN|their|anticonvulsant|and|effects (r_dobj) determine_22\VB|to|activity (r_advcl) evaluate_5\VB|to|effects|determine (l_dobj) effects_8\NNS|the|gfc|at (l_prep) at_9\IN|doses (l_pobj) doses_10\NNS|of|on (l_prep) on_18\IN|parameters (l_pobj) parameters_20\NNS|seizure (l_compound) seizure_19\NN|
D005680_D012640 NONE GABA_38\NNP|(|) (r_appos) acid_36\NN|(|aminobutyric|gaba|,|glutamine (r_appos) acid_31\NN|amino|acid (r_pobj) on_29\IN|acid (r_prep) effects_28\NNS|its|on (r_conj) activity_25\NN|their|anticonvulsant|and|effects (r_dobj) determine_22\VB|to|activity (r_advcl) evaluate_5\VB|to|effects|determine (r_xcomp) aimed_3\VBN|evaluate (r_acl) study_2\NN|the|present|aimed|) (r_nsubj) levels_47\NNS|study|as|on|. (l_prep) on_51\IN|acetylcholinesterase (l_pobj) acetylcholinesterase_52\NN|(|ache|)|activity (l_appos) activity_56\NN|in (l_prep) in_57\IN|hippocampus (l_pobj) hippocampus_59\NN|mice|after (l_prep) after_60\IN|seizures (l_pobj) seizures_61\NNS|
D018698_D012640 NONE glutamine_41\NN|,|aspartate (r_appos) acid_36\NN|(|aminobutyric|gaba|,|glutamine (r_appos) acid_31\NN|amino|acid (r_pobj) on_29\IN|acid (r_prep) effects_28\NNS|its|on (r_conj) activity_25\NN|their|anticonvulsant|and|effects (r_dobj) determine_22\VB|to|activity (r_advcl) evaluate_5\VB|to|effects|determine (l_dobj) effects_8\NNS|the|gfc|at (l_prep) at_9\IN|doses (l_pobj) doses_10\NNS|of|on (l_prep) on_18\IN|parameters (l_pobj) parameters_20\NNS|seizure (l_compound) seizure_19\NN|
D018698_D012640 NONE glutamine_41\NN|,|aspartate (r_appos) acid_36\NN|(|aminobutyric|gaba|,|glutamine (r_appos) acid_31\NN|amino|acid (r_pobj) on_29\IN|acid (r_prep) effects_28\NNS|its|on (r_conj) activity_25\NN|their|anticonvulsant|and|effects (r_dobj) determine_22\VB|to|activity (r_advcl) evaluate_5\VB|to|effects|determine (r_xcomp) aimed_3\VBN|evaluate (r_acl) study_2\NN|the|present|aimed|) (r_nsubj) levels_47\NNS|study|as|on|. (l_prep) on_51\IN|acetylcholinesterase (l_pobj) acetylcholinesterase_52\NN|(|ache|)|activity (l_appos) activity_56\NN|in (l_prep) in_57\IN|hippocampus (l_pobj) hippocampus_59\NN|mice|after (l_prep) after_60\IN|seizures (l_pobj) seizures_61\NNS|
D001224_D012640 NONE aspartate_43\NN|and|glutathione (r_conj) glutamine_41\NN|,|aspartate (r_appos) acid_36\NN|(|aminobutyric|gaba|,|glutamine (r_appos) acid_31\NN|amino|acid (r_pobj) on_29\IN|acid (r_prep) effects_28\NNS|its|on (r_conj) activity_25\NN|their|anticonvulsant|and|effects (r_dobj) determine_22\VB|to|activity (r_advcl) evaluate_5\VB|to|effects|determine (l_dobj) effects_8\NNS|the|gfc|at (l_prep) at_9\IN|doses (l_pobj) doses_10\NNS|of|on (l_prep) on_18\IN|parameters (l_pobj) parameters_20\NNS|seizure (l_compound) seizure_19\NN|
D001224_D012640 NONE aspartate_43\NN|and|glutathione (r_conj) glutamine_41\NN|,|aspartate (r_appos) acid_36\NN|(|aminobutyric|gaba|,|glutamine (r_appos) acid_31\NN|amino|acid (r_pobj) on_29\IN|acid (r_prep) effects_28\NNS|its|on (r_conj) activity_25\NN|their|anticonvulsant|and|effects (r_dobj) determine_22\VB|to|activity (r_advcl) evaluate_5\VB|to|effects|determine (r_xcomp) aimed_3\VBN|evaluate (r_acl) study_2\NN|the|present|aimed|) (r_nsubj) levels_47\NNS|study|as|on|. (l_prep) on_51\IN|acetylcholinesterase (l_pobj) acetylcholinesterase_52\NN|(|ache|)|activity (l_appos) activity_56\NN|in (l_prep) in_57\IN|hippocampus (l_pobj) hippocampus_59\NN|mice|after (l_prep) after_60\IN|seizures (l_pobj) seizures_61\NNS|
D005978_D012640 NONE glutathione_45\NN| (r_conj) aspartate_43\NN|and|glutathione (r_conj) glutamine_41\NN|,|aspartate (r_appos) acid_36\NN|(|aminobutyric|gaba|,|glutamine (r_appos) acid_31\NN|amino|acid (r_pobj) on_29\IN|acid (r_prep) effects_28\NNS|its|on (r_conj) activity_25\NN|their|anticonvulsant|and|effects (r_dobj) determine_22\VB|to|activity (r_advcl) evaluate_5\VB|to|effects|determine (l_dobj) effects_8\NNS|the|gfc|at (l_prep) at_9\IN|doses (l_pobj) doses_10\NNS|of|on (l_prep) on_18\IN|parameters (l_pobj) parameters_20\NNS|seizure (l_compound) seizure_19\NN|
D005978_D012640 NONE glutathione_45\NN| (r_conj) aspartate_43\NN|and|glutathione (r_conj) glutamine_41\NN|,|aspartate (r_appos) acid_36\NN|(|aminobutyric|gaba|,|glutamine (r_appos) acid_31\NN|amino|acid (r_pobj) on_29\IN|acid (r_prep) effects_28\NNS|its|on (r_conj) activity_25\NN|their|anticonvulsant|and|effects (r_dobj) determine_22\VB|to|activity (r_advcl) evaluate_5\VB|to|effects|determine (r_xcomp) aimed_3\VBN|evaluate (r_acl) study_2\NN|the|present|aimed|) (r_nsubj) levels_47\NNS|study|as|on|. (l_prep) on_51\IN|acetylcholinesterase (l_pobj) acetylcholinesterase_52\NN|(|ache|)|activity (l_appos) activity_56\NN|in (l_prep) in_57\IN|hippocampus (l_pobj) hippocampus_59\NN|mice|after (l_prep) after_60\IN|seizures (l_pobj) seizures_61\NNS|
C573355_D013226 NONE GFC_4\NNP| (r_nsubj) exert_6\VB|that|gfc|can|activity|and|reduce (l_conj) reduce_10\VB|frequency|epilepticus|,|demonstrated (l_advmod) epilepticus_20\NN|
D010862_D013226 CID pilocarpine_16\NN| (r_npadvmod) induced_18\VBN|pilocarpine|- (r_amod) status_19\NN|induced (r_pobj) of_15\IN|status (r_prep) installation_14\NN|of (r_pobj) of_13\IN|installation (r_prep) frequency_12\NN|the|of (r_dobj) reduce_10\VB|frequency|epilepticus|,|demonstrated (l_advmod) epilepticus_20\NN|
15614572
D014196_D009062 NONE trazodone_5\NN| (r_pobj) with_4\IN|trazodone (r_prep) pretreatment_3\NN|with|on (l_prep) on_6\IN|stereotypies (l_pobj) stereotypies_13\NNS|induced|oral
D014196_D002375 NONE trazodone_5\NN| (r_pobj) with_4\IN|trazodone (r_prep) pretreatment_3\NN|with|on (r_pobj) of_2\IN|pretreatment (r_prep) effect_1\NN|the|of (r_nsubjpass) studied_47\VBN|effect|,|on|,|on|was|in|. (l_prep) on_15\IN|catalepsy (l_pobj) catalepsy_16\NN|induced
D014196_D002375 NONE trazodone_4\NN| (r_nsubj) induces_5\VBZ|whether|trazodone|catalepsy|in (l_dobj) catalepsy_6\NN|
D014196_D002375 NONE Trazodone_0\NNP|at|i.p. (r_nsubj) induce_9\VB|trazodone|did|not|catalepsy|,|and|antagonize|. (l_dobj) catalepsy_10\NN|
D014196_D002375 NONE Trazodone_0\NNP|at|i.p. (r_nsubj) induce_9\VB|trazodone|did|not|catalepsy|,|and|antagonize|. (l_conj) antagonize_15\VB|did|not|apomorphine|catalepsy (l_dobj) catalepsy_31\NN|stereotypy|kg)-induced
D014196_D002375 NONE trazodone_11\NNP| (r_nmod) stereotypy_14\NN|,|i.p.|trazodone|enhanced|dexamphetamine (r_pobj) with_3\IN|5|stereotypy (r_prep) pretreatment_2\NN|however|,|with|,|and|antagonized|. (l_conj) antagonized_17\VBD|catalepsy (l_dobj) catalepsy_19\NN|haloperidol|,|behavior
D014196_D002375 NONE Trazodone_0\NNP|at (r_nsubj) induced_9\VBN|trazodone|,|mg/kg|i.p.|catalepsy|and|antagonized|. (l_dobj) catalepsy_10\NN|
D014196_D002375 NONE trazodone_3\NNP|mg/kg|,|by (r_nsubj) releases_20\VBZ|that|trazodone|,|neurons|,|and|potentiates (l_conj) potentiates_34\VBZ|thereby|stereotypy|and|antagonizes (l_conj) antagonizes_38\VBZ|catalepsy (l_dobj) catalepsy_40\NN|haloperidol
D003913_D009062 NONE dexamphetamine-_7\FW|and|apomorphine (r_npadvmod) induced_11\VBN|dexamphetamine-|- (r_amod) stereotypies_13\NNS|induced|oral
D003913_D002375 NONE dexamphetamine-_7\FW|and|apomorphine (r_npadvmod) induced_11\VBN|dexamphetamine-|- (r_amod) stereotypies_13\NNS|induced|oral (r_pobj) on_6\IN|stereotypies (r_prep) pretreatment_3\NN|with|on (r_pobj) of_2\IN|pretreatment (r_prep) effect_1\NN|the|of (r_nsubjpass) studied_47\VBN|effect|,|on|,|on|was|in|. (l_prep) on_15\IN|catalepsy (l_pobj) catalepsy_16\NN|induced
D003913_D002375 NONE dexamphetamine_13\NN| (r_compound) stereotypy_14\NN|,|i.p.|trazodone|enhanced|dexamphetamine (r_pobj) with_3\IN|5|stereotypy (r_prep) pretreatment_2\NN|however|,|with|,|and|antagonized|. (l_conj) antagonized_17\VBD|catalepsy (l_dobj) catalepsy_19\NN|haloperidol|,|behavior
D003913_D002375 NONE dexamphetamine_15\NN| (r_compound) stereotypies_16\NNS|dexamphetamine (r_conj) apomorphine_13\NN|and|stereotypies (r_dobj) antagonized_12\VBN|apomorphine (r_conj) induced_9\VBN|trazodone|,|mg/kg|i.p.|catalepsy|and|antagonized|. (l_dobj) catalepsy_10\NN|
D003913_D002375 NONE dexamphetamine_35\NN| (r_compound) stereotypy_36\NN|dexamphetamine (r_dobj) potentiates_34\VBZ|thereby|stereotypy|and|antagonizes (l_conj) antagonizes_38\VBZ|catalepsy (l_dobj) catalepsy_40\NN|haloperidol
D001058_D009062 NONE apomorphine_9\NN| (r_conj) dexamphetamine-_7\FW|and|apomorphine (r_npadvmod) induced_11\VBN|dexamphetamine-|- (r_amod) stereotypies_13\NNS|induced|oral
D001058_D009062 NONE apomorphine_21\NN| (r_conj) haloperidol_19\NN|and|apomorphine|mg/kg (r_pobj) by_18\IN|haloperidol (r_agent) induced_17\VBN|by (r_acl) catalepsy_16\NN|induced (r_pobj) on_15\IN|catalepsy (r_prep) studied_47\VBN|effect|,|on|,|on|was|in|. (l_nsubjpass) effect_1\NN|the|of (l_prep) of_2\IN|pretreatment (l_pobj) pretreatment_3\NN|with|on (l_prep) on_6\IN|stereotypies (l_pobj) stereotypies_13\NNS|induced|oral
D001058_D002375 CID apomorphine_9\NN| (r_conj) dexamphetamine-_7\FW|and|apomorphine (r_npadvmod) induced_11\VBN|dexamphetamine-|- (r_amod) stereotypies_13\NNS|induced|oral (r_pobj) on_6\IN|stereotypies (r_prep) pretreatment_3\NN|with|on (r_pobj) of_2\IN|pretreatment (r_prep) effect_1\NN|the|of (r_nsubjpass) studied_47\VBN|effect|,|on|,|on|was|in|. (l_prep) on_15\IN|catalepsy (l_pobj) catalepsy_16\NN|induced
D001058_D002375 CID apomorphine_21\NN| (r_conj) haloperidol_19\NN|and|apomorphine|mg/kg (r_pobj) by_18\IN|haloperidol (r_agent) induced_17\VBN|by (r_acl) catalepsy_16\NN|induced
D001058_D002375 CID apomorphine_16\NN| (r_dobj) antagonize_15\VB|did|not|apomorphine|catalepsy (r_conj) induce_9\VB|trazodone|did|not|catalepsy|,|and|antagonize|. (l_dobj) catalepsy_10\NN|
D001058_D002375 CID apomorphine_16\NN| (r_dobj) antagonize_15\VB|did|not|apomorphine|catalepsy (l_dobj) catalepsy_31\NN|stereotypy|kg)-induced
D001058_D002375 CID apomorphine_25\NN| (r_conj) stereotypy_23\NN|(|mg/kg|)|and|apomorphine (r_nmod) catalepsy_31\NN|stereotypy|kg)-induced (r_dobj) antagonize_15\VB|did|not|apomorphine|catalepsy (r_conj) induce_9\VB|trazodone|did|not|catalepsy|,|and|antagonize|. (l_dobj) catalepsy_10\NN|
D001058_D002375 CID apomorphine_25\NN| (r_conj) stereotypy_23\NN|(|mg/kg|)|and|apomorphine (r_nmod) catalepsy_31\NN|stereotypy|kg)-induced
D001058_D002375 CID apomorphine_13\NN|and|stereotypies (r_dobj) antagonized_12\VBN|apomorphine (r_conj) induced_9\VBN|trazodone|,|mg/kg|i.p.|catalepsy|and|antagonized|. (l_dobj) catalepsy_10\NN|
D006220_D009062 NONE haloperidol_19\NN|and|apomorphine|mg/kg (r_pobj) by_18\IN|haloperidol (r_agent) induced_17\VBN|by (r_acl) catalepsy_16\NN|induced (r_pobj) on_15\IN|catalepsy (r_prep) studied_47\VBN|effect|,|on|,|on|was|in|. (l_nsubjpass) effect_1\NN|the|of (l_prep) of_2\IN|pretreatment (l_pobj) pretreatment_3\NN|with|on (l_prep) on_6\IN|stereotypies (l_pobj) stereotypies_13\NNS|induced|oral
D006220_D002375 CID haloperidol_19\NN|and|apomorphine|mg/kg (r_pobj) by_18\IN|haloperidol (r_agent) induced_17\VBN|by (r_acl) catalepsy_16\NN|induced
D006220_D002375 CID haloperidol_18\NN| (r_det) catalepsy_19\NN|haloperidol|,|behavior
D006220_D002375 CID haloperidol_39\NN| (r_det) catalepsy_40\NN|haloperidol
D004874_D009062 NONE ergometrine_30\NN| (r_advmod) induced_32\VBN|ergometrine|- (r_amod) behavior_39\NN|induced|shake|(|wds|)|and|erections (r_pobj) on_29\IN|behavior (r_prep) studied_47\VBN|effect|,|on|,|on|was|in|. (l_nsubjpass) effect_1\NN|the|of (l_prep) of_2\IN|pretreatment (l_pobj) pretreatment_3\NN|with|on (l_prep) on_6\IN|stereotypies (l_pobj) stereotypies_13\NNS|induced|oral
D004874_D002375 NONE ergometrine_30\NN| (r_advmod) induced_32\VBN|ergometrine|- (r_amod) behavior_39\NN|induced|shake|(|wds|)|and|erections (r_pobj) on_29\IN|behavior (r_prep) studied_47\VBN|effect|,|on|,|on|was|in|. (l_prep) on_15\IN|catalepsy (l_pobj) catalepsy_16\NN|induced
D004874_D002375 NONE ergometrine_21\NN| (r_advmod) induced_23\VBN|ergometrine|- (r_amod) behavior_25\NN|induced|wds|and|erections (r_conj) catalepsy_19\NN|haloperidol|,|behavior
D005473_D009062 NONE fluoxetine_41\NN| (r_advmod) induced_43\VBN|fluoxetine|- (r_amod) erections_45\NNS|induced|penile (r_conj) behavior_39\NN|induced|shake|(|wds|)|and|erections (r_pobj) on_29\IN|behavior (r_prep) studied_47\VBN|effect|,|on|,|on|was|in|. (l_nsubjpass) effect_1\NN|the|of (l_prep) of_2\IN|pretreatment (l_pobj) pretreatment_3\NN|with|on (l_prep) on_6\IN|stereotypies (l_pobj) stereotypies_13\NNS|induced|oral
D005473_D002375 NONE fluoxetine_41\NN| (r_advmod) induced_43\VBN|fluoxetine|- (r_amod) erections_45\NNS|induced|penile (r_conj) behavior_39\NN|induced|shake|(|wds|)|and|erections (r_pobj) on_29\IN|behavior (r_prep) studied_47\VBN|effect|,|on|,|on|was|in|. (l_prep) on_15\IN|catalepsy (l_pobj) catalepsy_16\NN|induced
D005473_D002375 NONE fluoxetine_27\NN| (r_advmod) induced_29\VBN|fluoxetine|- (r_amod) erections_31\NNS|induced|penile (r_conj) behavior_25\NN|induced|wds|and|erections (r_conj) catalepsy_19\NN|haloperidol|,|behavior
D012701_D002375 NONE 5-HT_16\CD| (r_compound) 2C_17\NNP|5-ht (r_compound) receptors_18\NNS|the|2c (r_dobj) blocking_14\VBG|receptors (r_pcomp) by_13\IN|blocking (r_prep) trazodone_3\NNP|mg/kg|,|by (r_nsubj) releases_20\VBZ|that|trazodone|,|neurons|,|and|potentiates (l_conj) potentiates_34\VBZ|thereby|stereotypy|and|antagonizes (l_conj) antagonizes_38\VBZ|catalepsy (l_dobj) catalepsy_40\NN|haloperidol
D012701_D002375 NONE 5-HT_30\CD| (r_pobj) by_29\IN|5-ht (r_agent) caused_28\VBN|by (r_acl) inhibition_27\NN|tonic|caused (r_pobj) from_25\IN|inhibition (r_prep) neurons_24\NNS|the|nigrostriatal|daergic|from (r_dobj) releases_20\VBZ|that|trazodone|,|neurons|,|and|potentiates (l_conj) potentiates_34\VBZ|thereby|stereotypy|and|antagonizes (l_conj) antagonizes_38\VBZ|catalepsy (l_dobj) catalepsy_40\NN|haloperidol
16083708
D001663_D017114 NONE bilirubin_54\NN| (r_compound) value_55\NN|higher|plasma|bilirubin|ci (r_conj) .009_47\CD|p|<|)|,|and|value (r_appos) were_9\VBD|factors|sex|1.6|;|.009|. (l_nsubj) Factors_0\NNS|associated (l_acl) associated_1\VBN|with (l_prep) with_2\IN|development (l_pobj) development_4\NN|the|of (l_prep) of_5\IN|failure (l_pobj) failure_8\NN|fulminant|hepatic
D019980_D056486 CID clavulanate_2\NNP|amoxicillin|- (r_nsubj) stands_3\VBZ|clavulanate|out|as|. (l_prep) as_5\IN|drug (l_pobj) drug_9\NN|the|common|related (l_acl) related_10\VBN|to (l_prep) to_11\IN|dili (l_pobj) DILI_12\NNP|
10677406
D004280_D018487 CID dobutamine_13\NN|both|and|exercise (r_pobj) after_11\IN|dobutamine (r_mark) induced_16\VBN|after|ischaemia (r_advcl) occurs_4\VBZ|dysfunction|in|induced|. (l_nsubj) dysfunction_3\NN|prolonged|left|ventricular
D004280_D018487 CID dobutamine_7\NN| (r_nsubj) induced_8\VBN|in|,|dobutamine|results|in|,|presumed|. (l_prep) in_11\IN|dysfunction (l_pobj) dysfunction_16\NN|prolonged|reversible|left|ventricular
D004280_D003324 NONE dobutamine_13\NN|both|and|exercise (r_pobj) after_11\IN|dobutamine (r_mark) induced_16\VBN|after|ischaemia (r_advcl) occurs_4\VBZ|dysfunction|in|induced|. (l_prep) in_5\IN|patients (l_pobj) patients_6\NNS|with (l_prep) with_7\IN|disease (l_pobj) disease_10\NN|coronary|artery
D004280_D003324 NONE dobutamine_7\NN| (r_nsubj) induced_8\VBN|in|,|dobutamine|results|in|,|presumed|. (l_prep) In_0\IN|patients (l_pobj) patients_1\NNS|with (l_prep) with_2\IN|disease (l_pobj) disease_5\NN|coronary|artery
D004280_D003324 NONE Dobutamine_0\NNP| (r_nsubj) induced_1\VBD|dobutamine|ischaemia (r_csubjpass) used_6\VBN|induced|could|therefore|be|study|. (l_xcomp) study_8\VB|to|pathophysiology|further|in (l_prep) in_15\IN|patients (l_pobj) patients_16\NNS|with (l_prep) with_17\IN|disease (l_pobj) disease_20\NN|coronary|artery
D004280_D017202 NONE dobutamine_13\NN|both|and|exercise (r_pobj) after_11\IN|dobutamine (r_mark) induced_16\VBN|after|ischaemia (l_dobj) ischaemia_18\NN|myocardial
D004280_D007511 NONE dobutamine_17\NN| (r_conj) exercise_15\NN|and|dobutamine (r_pobj) after_14\IN|exercise (r_prep) study_3\NN|a|randomised|crossover|of|after (r_nsubj) induced_18\VBN|study|ischaemia|. (l_dobj) ischaemia_19\NN|
D004280_D007511 NONE dobutamine_7\NN| (r_nsubj) induced_8\VBN|in|,|dobutamine|results|in|,|presumed|. (l_dobj) results_10\NNS|ischaemia (l_compound) ischaemia_9\NN|
D004280_D007511 NONE Dobutamine_0\NNP| (r_nsubj) induced_1\VBD|dobutamine|ischaemia (l_dobj) ischaemia_2\NN|
D004280_D017682 CID dobutamine_7\NN| (r_nsubj) induced_8\VBN|in|,|dobutamine|results|in|,|presumed|. (l_conj) presumed_18\VBN|be (l_xcomp) be_20\VB|to|similar (l_acomp) similar_24\JJ|myocardial|stunning|to (l_amod) stunning_22\JJ|,
11988250
D007052_D006976 CID ibuprofen_3\NNP| (r_compound) prophylaxis_4\NN|ibuprofen|in (r_pobj) after_2\IN|prophylaxis (r_prep) hypertension_1\NN|pulmonary|after|.
D007052_D000860 CID ibuprofen_8\NNP| (r_compound) administration_9\NN|ibuprofen (r_pobj) after_7\IN|administration (r_prep) report_1\VBP|we|cases|after|during|. (l_dobj) cases_3\NNS|three|of (l_prep) of_4\IN|hypoxaemia (l_pobj) hypoxaemia_6\JJ|severe
D007052_D000860 CID ibuprofen_23\NN| (r_pobj) with_22\IN|ibuprofen (r_prep) treatment_17\NN|prophylactic|of|with (r_pobj) of_15\IN|treatment (r_prep) trial_14\NN|a|randomised|controlled|of|in (r_pobj) during_10\IN|trial (r_prep) report_1\VBP|we|cases|after|during|. (l_dobj) cases_3\NNS|three|of (l_prep) of_4\IN|hypoxaemia (l_pobj) hypoxaemia_6\JJ|severe
D007052_D000860 CID ibuprofen_21\NNP| (r_pobj) of_20\IN|ibuprofen (r_prep) administration_19\NN|prophylactic|of (r_pobj) after_17\IN|administration (r_prep) occurs_16\VBZ|if|hypoxaemia|after (l_nsubj) hypoxaemia_15\JJ|
D007052_D004374 NONE ibuprofen_8\NNP| (r_compound) administration_9\NN|ibuprofen (r_pobj) after_7\IN|administration (r_prep) report_1\VBP|we|cases|after|during|. (l_prep) during_10\IN|trial (l_pobj) trial_14\NN|a|randomised|controlled|of|in (l_prep) of_15\IN|treatment (l_pobj) treatment_17\NN|prophylactic|of|with (l_prep) of_18\IN|arteriosus (l_pobj) arteriosus_21\NN|ductus
D007052_D004374 NONE ibuprofen_23\NN| (r_pobj) with_22\IN|ibuprofen (r_prep) treatment_17\NN|prophylactic|of|with (l_prep) of_18\IN|arteriosus (l_pobj) arteriosus_21\NN|ductus
D009569_D000860 NONE oxide_6\NN| (r_compound) therapy_7\NN|inhaled|nitric|oxide (r_pobj) on_3\IN|therapy (r_prep) resolved_1\VBD|hypoxaemia|quickly|on|. (l_nsubj) Hypoxaemia_0\NNP|
18165598
D002045_D010146 NONE bupivacaine_4\NN| (r_pobj) of_3\IN|bupivacaine (r_prep) effects_2\NNS|the|differential|of|and|lidocaine|. (l_conj) lidocaine_6\NN|on (l_prep) on_7\IN|release (l_pobj) release_10\NN|prostaglandin|e2|,|expression|in (l_conj) expression_14\NN|cyclooxygenase|gene|and|pain (l_conj) pain_16\NN|
D002045_D010146 NONE bupivacaine_4\NN| (r_pobj) of_3\IN|bupivacaine (r_prep) effects_2\NNS|the|differential|of|and|lidocaine|. (l_conj) lidocaine_6\NN|on (l_prep) on_7\IN|release (l_pobj) release_10\NN|prostaglandin|e2|,|expression|in (l_prep) in_17\IN|model (l_pobj) model_21\NN|a|clinical|pain (l_compound) pain_20\NN|
D002045_D010146 NONE bupivacaine_1\NN| (r_nmod) rofecoxib_3\NN|bupivacaine|/ (r_compound) group_4\NN|the|rofecoxib (r_nsubj) reported_5\VBD|group|pain|,|assessed|,|compared (l_dobj) pain_8\NN|less
D002045_D010146 NONE bupivacaine_3\NN| (r_nmod) placebo_5\NN|bupivacaine|/ (r_compound) group_6\NN|the|placebo (r_nsubj) reported_7\VBD|however|,|group|pain|at|during|were|. (l_dobj) pain_10\NN|more
D002045_D010146 NONE bupivacaine_4\NN|that (r_nsubj) stimulates_5\VBZ|bupivacaine|expression|after|dissipates (l_prep) after_9\IN|injury (l_pobj) injury_11\NN|tissue|,|associated (l_relcl) associated_15\VBN|which|is|with (l_prep) with_16\IN|production (l_pobj) production_19\NN|higher|pge2|and|pain (l_conj) pain_21\NN|
D008012_D010146 NONE lidocaine_6\NN|on (l_prep) on_7\IN|release (l_pobj) release_10\NN|prostaglandin|e2|,|expression|in (l_conj) expression_14\NN|cyclooxygenase|gene|and|pain (l_conj) pain_16\NN|
D008012_D010146 NONE lidocaine_6\NN|on (l_prep) on_7\IN|release (l_pobj) release_10\NN|prostaglandin|e2|,|expression|in (l_prep) in_17\IN|model (l_pobj) model_21\NN|a|clinical|pain (l_compound) pain_20\NN|
D015232_D010146 NONE E2_9\NNP| (r_compound) release_10\NN|prostaglandin|e2|,|expression|in (l_conj) expression_14\NN|cyclooxygenase|gene|and|pain (l_conj) pain_16\NN|
D015232_D010146 NONE E2_9\NNP| (r_compound) release_10\NN|prostaglandin|e2|,|expression|in (l_prep) in_17\IN|model (l_pobj) model_21\NN|a|clinical|pain (l_compound) pain_20\NN|
D015232_D010146 NONE PGE2_15\NNP| (r_conj) h_13\NN|and|pge2 (r_nmod) levels_16\NNS|24|h (r_pobj) at_11\IN|levels (r_prep) reported_7\VBD|however|,|group|pain|at|during|were|. (l_dobj) pain_10\NN|more
D015232_D010146 NONE PGE2_18\NNP| (r_compound) production_19\NN|higher|pge2|and|pain (l_conj) pain_21\NN|
D002045_D010149 CID bupivacaine_11\NN|on (l_prep) on_12\IN|expression (l_pobj) expression_26\NN|production|(|cox|)|gene|increases (l_relcl) increases_28\VBZ|that|pain (l_dobj) pain_30\NN|postoperative|in
D015232_D010149 NONE E2_15\NNP|(|pge2 (r_nmod) production_19\NN|local|prostaglandin|e2|and|cyclooxygenase (r_nmod) expression_26\NN|production|(|cox|)|gene|increases (l_relcl) increases_28\VBZ|that|pain (l_dobj) pain_30\NN|postoperative|in
D015232_D010149 NONE PGE2_17\NNP|) (r_appos) E2_15\NNP|(|pge2 (r_nmod) production_19\NN|local|prostaglandin|e2|and|cyclooxygenase (r_nmod) expression_26\NN|production|(|cox|)|gene|increases (l_relcl) increases_28\VBZ|that|pain (l_dobj) pain_30\NN|postoperative|in
C116926_D010146 NONE rofecoxib_3\NN|bupivacaine|/ (r_compound) group_4\NN|the|rofecoxib (r_nsubj) reported_5\VBD|group|pain|,|assessed|,|compared (l_dobj) pain_8\NN|less
D002045_D017695 NONE bupivacaine_4\NN|that (r_nsubj) stimulates_5\VBZ|bupivacaine|expression|after|dissipates (l_prep) after_9\IN|injury (l_pobj) injury_11\NN|tissue|,|associated
D015232_D017695 NONE PGE2_18\NNP| (r_compound) production_19\NN|higher|pge2|and|pain (r_pobj) with_16\IN|production (r_prep) associated_15\VBN|which|is|with (r_relcl) injury_11\NN|tissue|,|associated
7121659
D012293_D051437 NONE rifampicin_4\NN| (r_npadvmod) associated_6\VBN|rifampicin|- (r_amod) failure_8\NN|acute|associated|renal
D012293_D058186 NONE rifampicin_18\NNS| (r_pobj) of_17\IN|rifampicin (r_prep) reintroduction_16\NN|the|of (r_pobj) by_14\IN|reintroduction (r_agent) induced_13\VBN|by (r_acl) patients_1\NNS|5|with|3|induced (l_prep) with_2\IN|failure (l_pobj) failure_5\NN|acute|renal
D012293_D013921 CID rifampicin_18\NNS| (r_pobj) of_17\IN|rifampicin (r_prep) reintroduction_16\NN|the|of (r_pobj) by_14\IN|reintroduction (r_agent) induced_13\VBN|by (r_acl) patients_1\NNS|5|with|3|induced (l_appos) 3_7\CD|(|with|) (l_prep) with_8\IN|thrombopenia (l_pobj) thrombopenia_9\NN|and|hemolysis
D012293_D006461 CID rifampicin_18\NNS| (r_pobj) of_17\IN|rifampicin (r_prep) reintroduction_16\NN|the|of (r_pobj) by_14\IN|reintroduction (r_agent) induced_13\VBN|by (r_acl) patients_1\NNS|5|with|3|induced (l_appos) 3_7\CD|(|with|) (l_prep) with_8\IN|thrombopenia (l_pobj) thrombopenia_9\NN|and|hemolysis (l_conj) hemolysis_11\NN|
20046642
D008668_D003072 NONE MT_9\NNP| (r_compound) induction_10\NN|mt|on (l_prep) on_11\IN|carmustine (l_pobj) carmustine_12\NN|dysfunction (l_appos) dysfunction_17\NN|(|bcnu)-induced|hippocampal|cognitive|in
D002330_D003072 CID carmustine_12\NN|dysfunction (l_appos) dysfunction_17\NN|(|bcnu)-induced|hippocampal|cognitive|in
D002330_D003072 CID BCNU)-induced_14\VBN| (r_amod) dysfunction_17\NN|(|bcnu)-induced|hippocampal|cognitive|in
D002330_D007859 CID BCNU_1\NNP|mg/kg|i.v|,|once|) (r_nsubj) revealed_16\VBD|then|bcnu|after|data|resulted|. (l_ccomp) resulted_20\VBD|that|administration|in|,|measured (l_prep) in_21\IN|deterioration (l_pobj) deterioration_22\NN|of (l_prep) of_23\IN|learning (l_pobj) learning_24\NN|and|memory (l_conj) memory_29\NN|term|stm
D002330_D007859 CID BCNU_18\NNP| (r_compound) administration_19\NN|bcnu (r_nsubj) resulted_20\VBD|that|administration|in|,|measured (l_prep) in_21\IN|deterioration (l_pobj) deterioration_22\NN|of (l_prep) of_23\IN|learning (l_pobj) learning_24\NN|and|memory (l_conj) memory_29\NN|term|stm
D002330_D008569 CID BCNU_1\NNP|mg/kg|i.v|,|once|) (r_nsubj) revealed_16\VBD|then|bcnu|after|data|resulted|. (l_ccomp) resulted_20\VBD|that|administration|in|,|measured (l_prep) in_21\IN|deterioration (l_pobj) deterioration_22\NN|of (l_prep) of_23\IN|learning (l_pobj) learning_24\NN|and|memory (l_conj) memory_29\NN|term|stm
D002330_D008569 CID BCNU_18\NNP| (r_compound) administration_19\NN|bcnu (r_nsubj) resulted_20\VBD|that|administration|in|,|measured (l_prep) in_21\IN|deterioration (l_pobj) deterioration_22\NN|of (l_prep) of_23\IN|learning (l_pobj) learning_24\NN|and|memory (l_conj) memory_29\NN|term|stm
D005978_D007859 NONE glutathione_47\NN| (r_compound) reductase_48\NN|decreased|hippocampal|glutathione|activity (r_pobj) with_44\IN|reductase (r_prep) accompanied_43\VBN|with (r_conj) measured_35\VBN|as|by|,|accompanied (r_advcl) resulted_20\VBD|that|administration|in|,|measured (l_prep) in_21\IN|deterioration (l_pobj) deterioration_22\NN|of (l_prep) of_23\IN|learning (l_pobj) learning_24\NN|and|memory (l_conj) memory_29\NN|term|stm
D005978_D007859 NONE glutathione_55\NN|reduced (r_nmod) content_59\NN|glutathione|(|gsh (r_conj) activity_52\NN|(|gr|)|and|content (r_appos) reductase_48\NN|decreased|hippocampal|glutathione|activity (r_pobj) with_44\IN|reductase (r_prep) accompanied_43\VBN|with (r_conj) measured_35\VBN|as|by|,|accompanied (r_advcl) resulted_20\VBD|that|administration|in|,|measured (l_prep) in_21\IN|deterioration (l_pobj) deterioration_22\NN|of (l_prep) of_23\IN|learning (l_pobj) learning_24\NN|and|memory (l_conj) memory_29\NN|term|stm
D005978_D007859 NONE GSH_57\NNP|) (r_nmod) content_59\NN|glutathione|(|gsh (r_conj) activity_52\NN|(|gr|)|and|content (r_appos) reductase_48\NN|decreased|hippocampal|glutathione|activity (r_pobj) with_44\IN|reductase (r_prep) accompanied_43\VBN|with (r_conj) measured_35\VBN|as|by|,|accompanied (r_advcl) resulted_20\VBD|that|administration|in|,|measured (l_prep) in_21\IN|deterioration (l_pobj) deterioration_22\NN|of (l_prep) of_23\IN|learning (l_pobj) learning_24\NN|and|memory (l_conj) memory_29\NN|term|stm
D005978_D008569 NONE glutathione_47\NN| (r_compound) reductase_48\NN|decreased|hippocampal|glutathione|activity (r_pobj) with_44\IN|reductase (r_prep) accompanied_43\VBN|with (r_conj) measured_35\VBN|as|by|,|accompanied (r_advcl) resulted_20\VBD|that|administration|in|,|measured (l_prep) in_21\IN|deterioration (l_pobj) deterioration_22\NN|of (l_prep) of_23\IN|learning (l_pobj) learning_24\NN|and|memory (l_conj) memory_29\NN|term|stm
D005978_D008569 NONE glutathione_55\NN|reduced (r_nmod) content_59\NN|glutathione|(|gsh (r_conj) activity_52\NN|(|gr|)|and|content (r_appos) reductase_48\NN|decreased|hippocampal|glutathione|activity (r_pobj) with_44\IN|reductase (r_prep) accompanied_43\VBN|with (r_conj) measured_35\VBN|as|by|,|accompanied (r_advcl) resulted_20\VBD|that|administration|in|,|measured (l_prep) in_21\IN|deterioration (l_pobj) deterioration_22\NN|of (l_prep) of_23\IN|learning (l_pobj) learning_24\NN|and|memory (l_conj) memory_29\NN|term|stm
D005978_D008569 NONE GSH_57\NNP|) (r_nmod) content_59\NN|glutathione|(|gsh (r_conj) activity_52\NN|(|gr|)|and|content (r_appos) reductase_48\NN|decreased|hippocampal|glutathione|activity (r_pobj) with_44\IN|reductase (r_prep) accompanied_43\VBN|with (r_conj) measured_35\VBN|as|by|,|accompanied (r_advcl) resulted_20\VBD|that|administration|in|,|measured (l_prep) in_21\IN|deterioration (l_pobj) deterioration_22\NN|of (l_prep) of_23\IN|learning (l_pobj) learning_24\NN|and|memory (l_conj) memory_29\NN|term|stm
D002330_D009369 NONE BCNU_2\NNP| (r_compound) administration_3\NN|bcnu (r_nsubj) increased_4\VBD|also|,|administration|contents|. (l_dobj) contents_22\NNS|factor|(|mda|)|as|activity (l_nmod) factor_8\NN|necrosis|-|alpha (l_compound) necrosis_7\NN|tumor (l_compound) tumor_6\NN|serum
D002330_D009336 NONE BCNU_2\NNP| (r_compound) administration_3\NN|bcnu (r_nsubj) increased_4\VBD|also|,|administration|contents|. (l_dobj) contents_22\NNS|factor|(|mda|)|as|activity (l_nmod) factor_8\NN|necrosis|-|alpha (l_compound) necrosis_7\NN|tumor
D008668_D009369 NONE MT_16\NNP|hippocampal|and|malondialdehyde (r_appos) alpha_10\NN|tnfalpha|,|mt (r_appos) factor_8\NN|necrosis|-|alpha (l_compound) necrosis_7\NN|tumor (l_compound) tumor_6\NN|serum
D008668_D009336 NONE MT_16\NNP|hippocampal|and|malondialdehyde (r_appos) alpha_10\NN|tnfalpha|,|mt (r_appos) factor_8\NN|necrosis|-|alpha (l_compound) necrosis_7\NN|tumor
D008315_D009369 NONE malondialdehyde_18\NN| (r_conj) MT_16\NNP|hippocampal|and|malondialdehyde (r_appos) alpha_10\NN|tnfalpha|,|mt (r_appos) factor_8\NN|necrosis|-|alpha (l_compound) necrosis_7\NN|tumor (l_compound) tumor_6\NN|serum
D008315_D009369 NONE MDA_20\NNP| (r_nmod) contents_22\NNS|factor|(|mda|)|as|activity (l_nmod) factor_8\NN|necrosis|-|alpha (l_compound) necrosis_7\NN|tumor (l_compound) tumor_6\NN|serum
D008315_D009336 NONE malondialdehyde_18\NN| (r_conj) MT_16\NNP|hippocampal|and|malondialdehyde (r_appos) alpha_10\NN|tnfalpha|,|mt (r_appos) factor_8\NN|necrosis|-|alpha (l_compound) necrosis_7\NN|tumor
D008315_D009336 NONE MDA_20\NNP| (r_nmod) contents_22\NNS|factor|(|mda|)|as|activity (l_nmod) factor_8\NN|necrosis|-|alpha (l_compound) necrosis_7\NN|tumor
D008668_D064420 NONE MT_3\NNP| (r_compound) induction_4\NN|mt (r_nsubj) halts_5\VBZ|in|,|induction|toxicity|prevented|. (l_dobj) toxicity_10\NN|induced|hippocampal
D002330_D064420 NONE BCNU_6\NNP| (r_npadvmod) induced_8\VBN|bcnu|- (r_amod) toxicity_10\NN|induced|hippocampal
D005978_D064420 NONE GSH_17\NNP| (r_compound) depletion_18\NN|gsh (r_conj) inhibition_15\NN|gr|and|depletion (r_dobj) prevented_13\VBD|as|it|inhibition|and|counteracted (r_advcl) halts_5\VBZ|in|,|induction|toxicity|prevented|. (l_dobj) toxicity_10\NN|induced|hippocampal
D008315_D064420 NONE MDA_27\NNP|and|activity (r_conj) TNFalpha_25\NNP|,|mda (r_pobj) of_24\IN|tnfalpha (r_prep) levels_23\NNS|the|increased|of (r_dobj) counteracted_20\VBD|levels (r_conj) prevented_13\VBD|as|it|inhibition|and|counteracted (r_advcl) halts_5\VBZ|in|,|induction|toxicity|prevented|. (l_dobj) toxicity_10\NN|induced|hippocampal
146391
D010672_D012010 CID diphenylhydantoin_13\NN| (r_dobj) taking_12\VBG|diphenylhydantoin (r_acl) patient_11\NN|a|taking (r_pobj) in_9\IN|patient (r_prep) lymphadenopathy_8\NN|in (r_conj) dermatitis_6\NN|toxic|and|lymphadenopathy (r_conj) aplasia_3\NN|pure|cell|,|dermatitis|.
D010672_D012010 CID diphenylhydantoin_3\NN| (r_dobj) taking_2\VBG|diphenylhydantoin|for (r_acl) patient_1\NN|a|taking (r_nsubj) developed_7\VBD|patient|rash|. (l_dobj) rash_11\NN|a|generalized|skin|,|aplasia (l_appos) aplasia_18\NN|lymphadenopathy|pure|cell
D010672_D012010 CID diphenylhydantoin_6\NN| (r_compound) medication_7\NN|diphenylhydantoin (r_pobj) with_5\IN|medication (r_prep) associated_4\VBN|with (r_acl) aplasia_3\NN|pure|cell|associated
D010672_D012010 CID diphenylhydantoin_10\NN| (r_pobj) of_9\IN|diphenylhydantoin (r_prep) ingestion_8\NN|the|of|and|occurrence (l_conj) occurrence_13\NN|the|of (l_prep) of_14\IN|rash (l_pobj) rash_17\NN|the|skin|,|lymphadenopathy (l_conj) lymphadenopathy_19\JJ|and|aplasia (l_conj) aplasia_24\NN|pure|red|cell
D010672_D003875 CID diphenylhydantoin_13\NN| (r_dobj) taking_12\VBG|diphenylhydantoin (r_acl) patient_11\NN|a|taking (r_pobj) in_9\IN|patient (r_prep) lymphadenopathy_8\NN|in (r_conj) dermatitis_6\NN|toxic|and|lymphadenopathy
D010672_D008206 CID diphenylhydantoin_13\NN| (r_dobj) taking_12\VBG|diphenylhydantoin (r_acl) patient_11\NN|a|taking (r_pobj) in_9\IN|patient (r_prep) lymphadenopathy_8\NN|in
D010672_D008206 CID diphenylhydantoin_3\NN| (r_dobj) taking_2\VBG|diphenylhydantoin|for (r_acl) patient_1\NN|a|taking (r_nsubj) developed_7\VBD|patient|rash|. (l_dobj) rash_11\NN|a|generalized|skin|,|aplasia (l_appos) aplasia_18\NN|lymphadenopathy|pure|cell (l_amod) lymphadenopathy_13\JJ|and
D010672_D008206 CID diphenylhydantoin_9\NN| (r_compound) treatment_10\NN|diphenylhydantoin (r_pobj) of_8\IN|treatment (r_prep) complication_7\NN|a|known|of (r_attr) is_2\VBZ|rash|complication|is|. (l_advcl) is_12\VBZ|as|lymphadenopathy (l_acomp) lymphadenopathy_16\NN|benign
D010672_D008206 CID diphenylhydantoin_10\NN| (r_pobj) of_9\IN|diphenylhydantoin (r_prep) ingestion_8\NN|the|of|and|occurrence (l_conj) occurrence_13\NN|the|of (l_prep) of_14\IN|rash (l_pobj) rash_17\NN|the|skin|,|lymphadenopathy (l_conj) lymphadenopathy_19\JJ|and|aplasia
D010672_D005076 NONE diphenylhydantoin_3\NN| (r_dobj) taking_2\VBG|diphenylhydantoin|for (r_acl) patient_1\NN|a|taking (r_nsubj) developed_7\VBD|patient|rash|. (l_dobj) rash_11\NN|a|generalized|skin|,|aplasia
D010672_D005076 NONE diphenylhydantoin_9\NN| (r_compound) treatment_10\NN|diphenylhydantoin (r_pobj) of_8\IN|treatment (r_prep) complication_7\NN|a|known|of (r_attr) is_2\VBZ|rash|complication|is|. (l_nsubj) rash_1\NN|skin
D010672_D005076 NONE diphenylhydantoin_10\NN| (r_pobj) of_9\IN|diphenylhydantoin (r_prep) ingestion_8\NN|the|of|and|occurrence (l_conj) occurrence_13\NN|the|of (l_prep) of_14\IN|rash (l_pobj) rash_17\NN|the|skin|,|lymphadenopathy
24742750
D016593_D016171 CID Terfenadine_6\NNP|and|citalopram (r_appos) blockers_4\NNS|finally|,|ikr|,|terfenadine|,|reported|. (l_relcl) reported_12\VBN|which|are|cause (l_xcomp) cause_14\VB|to|produced (l_ccomp) produced_25\VBD|pointes|ead|) (l_nsubj) Pointes_17\NNP|torsade|de|(|tdp|)|in|,
D016593_D016171 CID Terfenadine_6\NNP|and|citalopram (r_appos) blockers_4\NNS|finally|,|ikr|,|terfenadine|,|reported|. (l_relcl) reported_12\VBN|which|are|cause (l_xcomp) cause_14\VB|to|produced (l_ccomp) produced_25\VBD|pointes|ead|) (l_nsubj) Pointes_17\NNP|torsade|de|(|tdp|)|in|, (l_appos) TdP_19\NNP|
D015283_D016171 CID Citalopram_8\NNP| (r_conj) Terfenadine_6\NNP|and|citalopram (r_appos) blockers_4\NNS|finally|,|ikr|,|terfenadine|,|reported|. (l_relcl) reported_12\VBN|which|are|cause (l_xcomp) cause_14\VB|to|produced (l_ccomp) produced_25\VBD|pointes|ead|) (l_nsubj) Pointes_17\NNP|torsade|de|(|tdp|)|in|,
D015283_D016171 CID Citalopram_8\NNP| (r_conj) Terfenadine_6\NNP|and|citalopram (r_appos) blockers_4\NNS|finally|,|ikr|,|terfenadine|,|reported|. (l_relcl) reported_12\VBN|which|are|cause (l_xcomp) cause_14\VB|to|produced (l_ccomp) produced_25\VBD|pointes|ead|) (l_nsubj) Pointes_17\NNP|torsade|de|(|tdp|)|in|, (l_appos) TdP_19\NNP|
6884395
D003276_D000784 CID contraceptives_19\NNS|oral (r_conj) smoke_15\NN|,|and|contraceptives (r_conj) hypertension_13\NN|,|smoke (r_pobj) with_12\IN|hypertension (r_prep) association_11\NN|with (r_pobj) in_10\IN|association (r_prep) artery_9\NN|the|basilar|in (r_pobj) of_6\IN|artery (r_prep) aneurysm_5\NN|dissecting|of
D003276_D006973 NONE contraceptives_19\NNS|oral (r_conj) smoke_15\NN|,|and|contraceptives (r_conj) hypertension_13\NN|,|smoke
D003276_D011782 NONE contraceptives_19\NNS|oral (r_conj) smoke_15\NN|,|and|contraceptives (r_conj) hypertension_13\NN|,|smoke (r_pobj) with_12\IN|hypertension (r_prep) association_11\NN|with (r_pobj) in_10\IN|association (r_prep) artery_9\NN|the|basilar|in (r_pobj) of_6\IN|artery (r_prep) aneurysm_5\NN|dissecting|of (r_pobj) of_2\IN|aneurysm (r_prep) case_1\NN|a|of (r_nsubjpass) reported_21\VBN|case|is|in|. (l_prep) in_22\IN|patient (l_pobj) patient_26\NN|a|young|female|with (l_prep) with_27\IN|syndrome (l_pobj) syndrome_32\NN|a|locked
10975596
C118667_D009203 NONE dronedarone_5\NN|and|amiodarone (l_conj) amiodarone_7\NN|in|with (l_prep) with_10\IN|infarction (l_pobj) infarction_14\NN|a|healed|myocardial
C118667_D009203 NONE dronedarone_6\NN| (r_pobj) of_5\IN|dronedarone (r_prep) effects_4\NNS|the|hemodynamic|of|,|related|, (r_nsubjpass) compared_17\VBN|effects|were|with|. (l_prep) with_18\IN|those (l_pobj) those_19\DT|of|after|,|at (l_prep) at_28\IN|both|rest|and|during (l_conj) during_31\IN|stimulation (l_pobj) stimulation_33\NN|sympathetic|in (l_prep) in_34\IN|dogs (l_pobj) dogs_36\NNS|conscious|with (l_prep) with_37\IN|infarction (l_pobj) infarction_41\NN|a|healed|myocardial
D000638_D009203 NONE amiodarone_7\NN|in|with (l_prep) with_10\IN|infarction (l_pobj) infarction_14\NN|a|healed|myocardial
D000638_D009203 NONE amiodarone_14\NN| (r_pobj) to_13\IN|amiodarone (r_prep) related_12\VBN|compound|structurally|to (r_amod) effects_4\NNS|the|hemodynamic|of|,|related|, (r_nsubjpass) compared_17\VBN|effects|were|with|. (l_prep) with_18\IN|those (l_pobj) those_19\DT|of|after|,|at (l_prep) at_28\IN|both|rest|and|during (l_conj) during_31\IN|stimulation (l_pobj) stimulation_33\NN|sympathetic|in (l_prep) in_34\IN|dogs (l_pobj) dogs_36\NNS|conscious|with (l_prep) with_37\IN|infarction (l_pobj) infarction_41\NN|a|healed|myocardial
D000638_D009203 NONE amiodarone_21\NN| (r_pobj) of_20\IN|amiodarone (r_prep) those_19\DT|of|after|,|at (l_prep) at_28\IN|both|rest|and|during (l_conj) during_31\IN|stimulation (l_pobj) stimulation_33\NN|sympathetic|in (l_prep) in_34\IN|dogs (l_pobj) dogs_36\NNS|conscious|with (l_prep) with_37\IN|infarction (l_pobj) infarction_41\NN|a|healed|myocardial
C118667_D013610 NONE dronedarone_1\NN|both|and|amiodarone (r_nsubj) reduced_5\VBD|dronedarone|significantly|tachycardia|and|,|decreased (l_dobj) tachycardia_10\NN|the|induced
C118667_D013610 NONE dronedarone_1\NN|both|and|amiodarone (r_nsubj) reduced_5\VBD|dronedarone|significantly|tachycardia|and|,|decreased (l_conj) decreased_18\VBD|at|,|tachycardia|. (l_dobj) tachycardia_23\NN|the|induced
D000638_D013610 NONE amiodarone_3\NN| (r_conj) dronedarone_1\NN|both|and|amiodarone (r_nsubj) reduced_5\VBD|dronedarone|significantly|tachycardia|and|,|decreased (l_dobj) tachycardia_10\NN|the|induced
D000638_D013610 NONE amiodarone_3\NN| (r_conj) dronedarone_1\NN|both|and|amiodarone (r_nsubj) reduced_5\VBD|dronedarone|significantly|tachycardia|and|,|decreased (l_conj) decreased_18\VBD|at|,|tachycardia|. (l_dobj) tachycardia_23\NN|the|induced
D007545_D013610 CID isoproterenol_20\NN| (r_npadvmod) induced_22\VBN|isoproterenol|- (r_amod) tachycardia_23\NN|the|induced (r_dobj) decreased_18\VBD|at|,|tachycardia|. (r_conj) reduced_5\VBD|dronedarone|significantly|tachycardia|and|,|decreased (l_dobj) tachycardia_10\NN|the|induced
D007545_D013610 CID isoproterenol_20\NN| (r_npadvmod) induced_22\VBN|isoproterenol|- (r_amod) tachycardia_23\NN|the|induced
C118667_D001145 NONE dronedarone_2\NN| (r_nsubj) be_4\VB|consequently|,|dronedarone|might|suitable|,|without|. (l_acomp) suitable_6\JJ|particularly|for (l_prep) for_7\IN|treatment (l_pobj) treatment_9\NN|the|and|prevention|of (l_prep) of_12\IN|arrhythmias (l_pobj) arrhythmias_15\NNS|various|clinical
24114426
D018817_D003866 CID 3,4-methylenedioxymethamphetamine_15\NNP| (r_pobj) of_14\IN|3,4-methylenedioxymethamphetamine|ecstasy (r_prep) users_13\NNS|polydrug|of|) (r_conj) Depression_0\NN|,|impulsiveness|in|and|users|.
D018817_D003866 CID MDMA_17\NNP|(|, (r_nmod) ecstasy_19\NN|mdma (r_pobj) of_14\IN|3,4-methylenedioxymethamphetamine|ecstasy (r_prep) users_13\NNS|polydrug|of|) (r_conj) Depression_0\NN|,|impulsiveness|in|and|users|.
D018817_D003866 CID ecstasy_19\NN|mdma (r_pobj) of_14\IN|3,4-methylenedioxymethamphetamine|ecstasy (r_prep) users_13\NNS|polydrug|of|) (r_conj) Depression_0\NN|,|impulsiveness|in|and|users|.
D018817_D003866 CID ecstasy_26\NN| (r_compound) users_27\NNS|ecstasy (r_pobj) of_25\IN|users (r_prep) generation_24\NN|the|current|of (r_pobj) for_21\IN|generation (r_prep) prognosis_20\NN|the|for (r_nsubj) is_28\VBZ|given|,|prognosis|cause|. (l_prep) Given_0\VBN|record (l_pobj) record_2\NN|this|of (l_prep) of_3\IN|memory (l_pobj) memory_5\NN|impaired|and|levels (l_conj) levels_9\NNS|significant|of (l_prep) of_10\IN|depression (l_pobj) depression_11\NN|,|impulsiveness
D018817_D010554 CID 3,4-methylenedioxymethamphetamine_15\NNP| (r_pobj) of_14\IN|3,4-methylenedioxymethamphetamine|ecstasy (r_prep) users_13\NNS|polydrug|of|) (r_conj) Depression_0\NN|,|impulsiveness|in|and|users|. (l_conj) impulsiveness_2\NN|,|sleep
D018817_D010554 CID MDMA_17\NNP|(|, (r_nmod) ecstasy_19\NN|mdma (r_pobj) of_14\IN|3,4-methylenedioxymethamphetamine|ecstasy (r_prep) users_13\NNS|polydrug|of|) (r_conj) Depression_0\NN|,|impulsiveness|in|and|users|. (l_conj) impulsiveness_2\NN|,|sleep
D018817_D010554 CID ecstasy_19\NN|mdma (r_pobj) of_14\IN|3,4-methylenedioxymethamphetamine|ecstasy (r_prep) users_13\NNS|polydrug|of|) (r_conj) Depression_0\NN|,|impulsiveness|in|and|users|. (l_conj) impulsiveness_2\NN|,|sleep
D018817_D010554 CID ecstasy_26\NN| (r_compound) users_27\NNS|ecstasy (r_pobj) of_25\IN|users (r_prep) generation_24\NN|the|current|of (r_pobj) for_21\IN|generation (r_prep) prognosis_20\NN|the|for (r_nsubj) is_28\VBZ|given|,|prognosis|cause|. (l_prep) Given_0\VBN|record (l_pobj) record_2\NN|this|of (l_prep) of_3\IN|memory (l_pobj) memory_5\NN|impaired|and|levels (l_conj) levels_9\NNS|significant|of (l_prep) of_10\IN|depression (l_pobj) depression_11\NN|,|impulsiveness (l_conj) impulsiveness_13\NN|,|and|disturbance
D018817_D008569 NONE ecstasy_26\NN| (r_compound) users_27\NNS|ecstasy (r_pobj) of_25\IN|users (r_prep) generation_24\NN|the|current|of (r_pobj) for_21\IN|generation (r_prep) prognosis_20\NN|the|for (r_nsubj) is_28\VBZ|given|,|prognosis|cause|. (l_prep) Given_0\VBN|record (l_pobj) record_2\NN|this|of (l_prep) of_3\IN|memory (l_pobj) memory_5\NN|impaired|and|levels
D018817_D020920 CID ecstasy_26\NN| (r_compound) users_27\NNS|ecstasy (r_pobj) of_25\IN|users (r_prep) generation_24\NN|the|current|of (r_pobj) for_21\IN|generation (r_prep) prognosis_20\NN|the|for (r_nsubj) is_28\VBZ|given|,|prognosis|cause|. (l_prep) Given_0\VBN|record (l_pobj) record_2\NN|this|of (l_prep) of_3\IN|memory (l_pobj) memory_5\NN|impaired|and|levels (l_conj) levels_9\NNS|significant|of (l_prep) of_10\IN|depression (l_pobj) depression_11\NN|,|impulsiveness (l_conj) impulsiveness_13\NN|,|and|disturbance (l_conj) disturbance_17\NN|sleep
3423103
D003000_D007022 CID clonidine_11\NN| (r_npadvmod) induced_13\VBN|clonidine|- (r_amod) hypotension_14\NN|induced|and|bradycardia
D003000_D007022 CID clonidine_1\NN| (r_npadvmod) induced_3\VBN|clonidine|- (r_amod) hypotension_4\NN|the|induced
D003000_D007022 CID clonidine_13\NN| (r_npadvmod) induced_15\VBN|clonidine|- (r_amod) hypotension_16\NN|induced|and|bradycardia
D003000_D001919 CID clonidine_11\NN| (r_npadvmod) induced_13\VBN|clonidine|- (r_amod) hypotension_14\NN|induced|and|bradycardia (l_conj) bradycardia_16\NN|
D003000_D001919 CID clonidine_6\NN| (r_npadvmod) induced_8\VBN|clonidine|- (r_amod) bradycardia_9\NN|the|induced
D003000_D001919 CID clonidine_29\NN|to|microinjected (r_advcl) reduced_18\VBD|furthermore|,|destruction|magnitude|clonidine|. (l_dobj) magnitude_20\NN|the|of (l_prep) of_21\IN|vasodepressor (l_pobj) vasodepressor_23\NN|the|or|responses (l_conj) responses_27\NNS|the|bradycardiac (l_compound) bradycardiac_26\NN|
D003000_D001919 CID clonidine_13\NN| (r_npadvmod) induced_15\VBN|clonidine|- (r_amod) hypotension_16\NN|induced|and|bradycardia (l_conj) bradycardia_18\NN|
D012701_D001919 NONE 5-HT_7\CD| (r_nummod) nerves_8\NNS|spinal|5-ht|,|produced|, (r_pobj) of_4\IN|nerves (r_prep) destruction_3\NN|selective|of (r_nsubj) reduced_18\VBD|furthermore|,|destruction|magnitude|clonidine|. (l_dobj) magnitude_20\NN|the|of (l_prep) of_21\IN|vasodepressor (l_pobj) vasodepressor_23\NN|the|or|responses (l_conj) responses_27\NNS|the|bradycardiac (l_compound) bradycardiac_26\NN|
D015116_D001919 NONE 5,7-dihydroxytryptamine_16\CD| (r_pobj) of_15\IN|5,7-dihydroxytryptamine (r_prep) injection_14\NN|bilateral|spinal|of (r_pobj) by_11\IN|injection (r_agent) produced_10\VBN|by (r_acl) nerves_8\NNS|spinal|5-ht|,|produced|, (r_pobj) of_4\IN|nerves (r_prep) destruction_3\NN|selective|of (r_nsubj) reduced_18\VBD|furthermore|,|destruction|magnitude|clonidine|. (l_dobj) magnitude_20\NN|the|of (l_prep) of_21\IN|vasodepressor (l_pobj) vasodepressor_23\NN|the|or|responses (l_conj) responses_27\NNS|the|bradycardiac (l_compound) bradycardiac_26\NN|
16810074
D009569_D006973 CID oxide_6\NN|nitric (r_nmod) deficiency_10\NN|oxide|(|no|) (r_pobj) by_4\IN|deficiency (r_agent) induced_3\VBN|mechanisms|by (l_nsubj) Mechanisms_0\NNS|of (l_prep) of_1\IN|hypertension (l_pobj) hypertension_2\NN|
D009569_D006973 CID NO_8\NNP| (r_intj) deficiency_10\NN|oxide|(|no|) (r_pobj) by_4\IN|deficiency (r_agent) induced_3\VBN|mechanisms|by (l_nsubj) Mechanisms_0\NNS|of (l_prep) of_1\IN|hypertension (l_pobj) hypertension_2\NN|
D009569_D006973 CID oxide_7\NN|endothelial|derived|nitric|(|no|in (l_prep) in_11\IN|hypertension (l_pobj) hypertension_12\NN|
D009569_D006973 CID NO_9\NNP|) (r_appos) oxide_7\NN|endothelial|derived|nitric|(|no|in (l_prep) in_11\IN|hypertension (l_pobj) hypertension_12\NN|
D009569_D006973 CID NO_7\UH| (r_pobj) of_6\IN|no (r_prep) removal_5\NN|the|of (r_pobj) by_3\IN|removal (r_agent) created_2\VBN|by (r_acl) hypertension_1\NN|experimental|created
D009569_D006973 CID NO_5\DT| (r_det) deficiency_6\NN|no (r_nsubj) increases_7\VBZ|while|deficiency|stress|in (r_advcl) make_26\VB|that|increases|,|impact|does|not|contribution (l_dobj) contribution_29\NN|a|major|to (l_prep) to_30\IN|form (l_pobj) form_32\NN|this|of (l_prep) of_33\IN|hypertension (l_pobj) hypertension_34\NN|
D009569_D018754 NONE oxide_7\NN|endothelial|derived|nitric|(|no|in (r_pobj) of_1\IN|oxide (r_prep) Loss_0\NN|of (r_nsubj) is_13\VBZ|loss|hallmark|. (l_attr) hallmark_15\NN|a|of (l_prep) of_16\IN|dysfunction (l_pobj) dysfunction_18\NN|arterial
D009569_D018754 NONE NO_9\NNP|) (r_appos) oxide_7\NN|endothelial|derived|nitric|(|no|in (r_pobj) of_1\IN|oxide (r_prep) Loss_0\NN|of (r_nsubj) is_13\VBZ|loss|hallmark|. (l_attr) hallmark_15\NN|a|of (l_prep) of_16\IN|dysfunction (l_pobj) dysfunction_18\NN|arterial
D019335_D006973 NONE arginine_21\NN|nomega|-|nitro|-|l|- (r_nmod) hypertension_25\NN|arginine|lnna|)|through
D019335_D006973 NONE LNNA_23\NNP|( (r_nmod) hypertension_25\NN|arginine|lnna|)|through
D019335_D006973 NONE LNNA_17\NNP| (r_compound) hypertension_18\NN|lnna
D019335_D006973 NONE LNNA_25\NNP| (r_pobj) after_24\IN|weeks|lnna (r_prep) elevated_15\VBN|pressure|an|in|,|was|not|in|at|after|. (l_prep) in_16\IN|hypertension (l_pobj) hypertension_18\NN|lnna
D019335_D006973 NONE LNNA_12\NNS| (r_nmod) rats_14\NNS|lnna|hypertensive|(|hg|) (l_amod) hypertensive_13\JJ|
D018738_D006973 NONE hexamethonium_5\NN| (r_pobj) with_4\IN|hexamethonium (r_prep) blockade_3\NN|ganglionic|with (r_nsubj) caused_6\VBD|similarly|,|blockade|fall|compared|. (l_dobj) fall_10\NN|a|greater|in (l_prep) in_11\IN|rats (l_pobj) rats_14\NNS|lnna|hypertensive|(|hg|) (l_amod) hypertensive_13\JJ|
7479194
D015662_D064420 NONE sulfamethoxazole_12\NN|trimethoprim|-|,|trimethoprim (r_pobj) of_9\IN|sulfamethoxazole (r_prep) study_8\NN|a|large|based|up|of|for|. (l_prep) for_18\IN|toxicity (l_pobj) toxicity_22\NN|uncommon|serious|drug
D014295_D064420 NONE trimethoprim_14\NN|,|and|cephalexin (r_conj) sulfamethoxazole_12\NN|trimethoprim|-|,|trimethoprim (r_pobj) of_9\IN|sulfamethoxazole (r_prep) study_8\NN|a|large|based|up|of|for|. (l_prep) for_18\IN|toxicity (l_pobj) toxicity_22\NN|uncommon|serious|drug
D002506_D064420 NONE cephalexin_17\NN| (r_conj) trimethoprim_14\NN|,|and|cephalexin (r_conj) sulfamethoxazole_12\NN|trimethoprim|-|,|trimethoprim (r_pobj) of_9\IN|sulfamethoxazole (r_prep) study_8\NN|a|large|based|up|of|for|. (l_prep) for_18\IN|toxicity (l_pobj) toxicity_22\NN|uncommon|serious|drug
D015662_D008107 CID SMZ_15\NNP|tmp|- (r_nmod) 5.2/100,000_17\CD|smz|(|) (r_dobj) prescribed_12\VBN|5.2/100,000 (r_acl) persons_11\NNS|prescribed (r_pobj) for_10\IN|persons (r_prep) similar_9\JJ|for (r_acomp) was_8\VBD|risk|similar|and|trimethoprim (l_nsubj) risk_1\NN|the|of (l_prep) of_2\IN|disease (l_pobj) disease_7\NN|important|idiopathic|liver
D015662_D008107 NONE sulfamethoxazole_19\NN|trimethoprim|- (r_compound) SMZ_23\NNP|sulfamethoxazole|(|tmp|-|) (r_dobj) prescribed_16\VBN|who|were|smz (r_relcl) people_13\NNS|232,390|prescribed (r_pobj) of_11\IN|people (r_prep) study_10\NN|a|based|45-day|follow|of (r_dobj) conducted_1\VBD|we|study|prescribed|estimate|. (l_advcl) estimate_37\VB|to|risk (l_dobj) risk_39\NN|the|of (l_prep) of_40\IN|liver (l_pobj) liver_42\NN|serious|,|blood (l_conj) blood_44\NN|,|skin (l_conj) skin_46\NN|,|and|disorders (l_conj) disorders_50\NNS|renal|resulting
D015662_D008107 NONE SMZ_23\NNP|sulfamethoxazole|(|tmp|-|) (r_dobj) prescribed_16\VBN|who|were|smz (r_relcl) people_13\NNS|232,390|prescribed (r_pobj) of_11\IN|people (r_prep) study_10\NN|a|based|45-day|follow|of (r_dobj) conducted_1\VBD|we|study|prescribed|estimate|. (l_advcl) estimate_37\VB|to|risk (l_dobj) risk_39\NN|the|of (l_prep) of_40\IN|liver (l_pobj) liver_42\NN|serious|,|blood (l_conj) blood_44\NN|,|skin (l_conj) skin_46\NN|,|and|disorders (l_conj) disorders_50\NNS|renal|resulting
D015662_D006402 NONE sulfamethoxazole_19\NN|trimethoprim|- (r_compound) SMZ_23\NNP|sulfamethoxazole|(|tmp|-|) (r_dobj) prescribed_16\VBN|who|were|smz (r_relcl) people_13\NNS|232,390|prescribed (r_pobj) of_11\IN|people (r_prep) study_10\NN|a|based|45-day|follow|of (r_dobj) conducted_1\VBD|we|study|prescribed|estimate|. (l_advcl) estimate_37\VB|to|risk (l_dobj) risk_39\NN|the|of (l_prep) of_40\IN|liver (l_pobj) liver_42\NN|serious|,|blood (l_conj) blood_44\NN|,|skin (l_conj) skin_46\NN|,|and|disorders (l_conj) disorders_50\NNS|renal|resulting
D015662_D006402 NONE SMZ_23\NNP|sulfamethoxazole|(|tmp|-|) (r_dobj) prescribed_16\VBN|who|were|smz (r_relcl) people_13\NNS|232,390|prescribed (r_pobj) of_11\IN|people (r_prep) study_10\NN|a|based|45-day|follow|of (r_dobj) conducted_1\VBD|we|study|prescribed|estimate|. (l_advcl) estimate_37\VB|to|risk (l_dobj) risk_39\NN|the|of (l_prep) of_40\IN|liver (l_pobj) liver_42\NN|serious|,|blood (l_conj) blood_44\NN|,|skin (l_conj) skin_46\NN|,|and|disorders (l_conj) disorders_50\NNS|renal|resulting
D015662_D012871 NONE sulfamethoxazole_19\NN|trimethoprim|- (r_compound) SMZ_23\NNP|sulfamethoxazole|(|tmp|-|) (r_dobj) prescribed_16\VBN|who|were|smz (r_relcl) people_13\NNS|232,390|prescribed (r_pobj) of_11\IN|people (r_prep) study_10\NN|a|based|45-day|follow|of (r_dobj) conducted_1\VBD|we|study|prescribed|estimate|. (l_advcl) estimate_37\VB|to|risk (l_dobj) risk_39\NN|the|of (l_prep) of_40\IN|liver (l_pobj) liver_42\NN|serious|,|blood (l_conj) blood_44\NN|,|skin (l_conj) skin_46\NN|,|and|disorders (l_conj) disorders_50\NNS|renal|resulting
D015662_D012871 NONE SMZ_23\NNP|sulfamethoxazole|(|tmp|-|) (r_dobj) prescribed_16\VBN|who|were|smz (r_relcl) people_13\NNS|232,390|prescribed (r_pobj) of_11\IN|people (r_prep) study_10\NN|a|based|45-day|follow|of (r_dobj) conducted_1\VBD|we|study|prescribed|estimate|. (l_advcl) estimate_37\VB|to|risk (l_dobj) risk_39\NN|the|of (l_prep) of_40\IN|liver (l_pobj) liver_42\NN|serious|,|blood (l_conj) blood_44\NN|,|skin (l_conj) skin_46\NN|,|and|disorders (l_conj) disorders_50\NNS|renal|resulting
D015662_D007674 NONE sulfamethoxazole_19\NN|trimethoprim|- (r_compound) SMZ_23\NNP|sulfamethoxazole|(|tmp|-|) (r_dobj) prescribed_16\VBN|who|were|smz (r_relcl) people_13\NNS|232,390|prescribed (r_pobj) of_11\IN|people (r_prep) study_10\NN|a|based|45-day|follow|of (r_dobj) conducted_1\VBD|we|study|prescribed|estimate|. (l_advcl) estimate_37\VB|to|risk (l_dobj) risk_39\NN|the|of (l_prep) of_40\IN|liver (l_pobj) liver_42\NN|serious|,|blood (l_conj) blood_44\NN|,|skin (l_conj) skin_46\NN|,|and|disorders (l_conj) disorders_50\NNS|renal|resulting
D015662_D007674 NONE SMZ_23\NNP|sulfamethoxazole|(|tmp|-|) (r_dobj) prescribed_16\VBN|who|were|smz (r_relcl) people_13\NNS|232,390|prescribed (r_pobj) of_11\IN|people (r_prep) study_10\NN|a|based|45-day|follow|of (r_dobj) conducted_1\VBD|we|study|prescribed|estimate|. (l_advcl) estimate_37\VB|to|risk (l_dobj) risk_39\NN|the|of (l_prep) of_40\IN|liver (l_pobj) liver_42\NN|serious|,|blood (l_conj) blood_44\NN|,|skin (l_conj) skin_46\NN|,|and|disorders (l_conj) disorders_50\NNS|renal|resulting
D014295_D008107 CID trimethoprim_22\NN|those|prescribed|alone|. (r_conj) was_8\VBD|risk|similar|and|trimethoprim (l_nsubj) risk_1\NN|the|of (l_prep) of_2\IN|disease (l_pobj) disease_7\NN|important|idiopathic|liver
D014295_D008107 NONE trimethoprim_28\NN|alone (r_dobj) prescribed_27\VBD|,|266,951|trimethoprim|,|and|cephalexin (r_conj) conducted_1\VBD|we|study|prescribed|estimate|. (l_advcl) estimate_37\VB|to|risk (l_dobj) risk_39\NN|the|of (l_prep) of_40\IN|liver (l_pobj) liver_42\NN|serious|,|blood (l_conj) blood_44\NN|,|skin (l_conj) skin_46\NN|,|and|disorders (l_conj) disorders_50\NNS|renal|resulting
D014295_D006402 NONE trimethoprim_28\NN|alone (r_dobj) prescribed_27\VBD|,|266,951|trimethoprim|,|and|cephalexin (r_conj) conducted_1\VBD|we|study|prescribed|estimate|. (l_advcl) estimate_37\VB|to|risk (l_dobj) risk_39\NN|the|of (l_prep) of_40\IN|liver (l_pobj) liver_42\NN|serious|,|blood (l_conj) blood_44\NN|,|skin (l_conj) skin_46\NN|,|and|disorders (l_conj) disorders_50\NNS|renal|resulting
D014295_D012871 NONE trimethoprim_28\NN|alone (r_dobj) prescribed_27\VBD|,|266,951|trimethoprim|,|and|cephalexin (r_conj) conducted_1\VBD|we|study|prescribed|estimate|. (l_advcl) estimate_37\VB|to|risk (l_dobj) risk_39\NN|the|of (l_prep) of_40\IN|liver (l_pobj) liver_42\NN|serious|,|blood (l_conj) blood_44\NN|,|skin (l_conj) skin_46\NN|,|and|disorders (l_conj) disorders_50\NNS|renal|resulting
D014295_D007674 NONE trimethoprim_28\NN|alone (r_dobj) prescribed_27\VBD|,|266,951|trimethoprim|,|and|cephalexin (r_conj) conducted_1\VBD|we|study|prescribed|estimate|. (l_advcl) estimate_37\VB|to|risk (l_dobj) risk_39\NN|the|of (l_prep) of_40\IN|liver (l_pobj) liver_42\NN|serious|,|blood (l_conj) blood_44\NN|,|skin (l_conj) skin_46\NN|,|and|disorders (l_conj) disorders_50\NNS|renal|resulting
D002506_D008107 NONE cephalexin_34\NN|196,397|prescribed|, (r_conj) prescribed_27\VBD|,|266,951|trimethoprim|,|and|cephalexin (r_conj) conducted_1\VBD|we|study|prescribed|estimate|. (l_advcl) estimate_37\VB|to|risk (l_dobj) risk_39\NN|the|of (l_prep) of_40\IN|liver (l_pobj) liver_42\NN|serious|,|blood (l_conj) blood_44\NN|,|skin (l_conj) skin_46\NN|,|and|disorders (l_conj) disorders_50\NNS|renal|resulting
D002506_D006402 NONE cephalexin_34\NN|196,397|prescribed|, (r_conj) prescribed_27\VBD|,|266,951|trimethoprim|,|and|cephalexin (r_conj) conducted_1\VBD|we|study|prescribed|estimate|. (l_advcl) estimate_37\VB|to|risk (l_dobj) risk_39\NN|the|of (l_prep) of_40\IN|liver (l_pobj) liver_42\NN|serious|,|blood (l_conj) blood_44\NN|,|skin (l_conj) skin_46\NN|,|and|disorders (l_conj) disorders_50\NNS|renal|resulting
D002506_D012871 NONE cephalexin_34\NN|196,397|prescribed|, (r_conj) prescribed_27\VBD|,|266,951|trimethoprim|,|and|cephalexin (r_conj) conducted_1\VBD|we|study|prescribed|estimate|. (l_advcl) estimate_37\VB|to|risk (l_dobj) risk_39\NN|the|of (l_prep) of_40\IN|liver (l_pobj) liver_42\NN|serious|,|blood (l_conj) blood_44\NN|,|skin (l_conj) skin_46\NN|,|and|disorders (l_conj) disorders_50\NNS|renal|resulting
D002506_D007674 NONE cephalexin_34\NN|196,397|prescribed|, (r_conj) prescribed_27\VBD|,|266,951|trimethoprim|,|and|cephalexin (r_conj) conducted_1\VBD|we|study|prescribed|estimate|. (l_advcl) estimate_37\VB|to|risk (l_dobj) risk_39\NN|the|of (l_prep) of_40\IN|liver (l_pobj) liver_42\NN|serious|,|blood (l_conj) blood_44\NN|,|skin (l_conj) skin_46\NN|,|and|disorders (l_conj) disorders_50\NNS|renal|resulting
D015662_D004892 NONE SMZ_15\NNP|tmp|- (r_pobj) to_12\IN|smz (r_prep) exposed_11\VBN|one|was|to (r_relcl) disorders_5\NNS|blood|,|exposed|;|of (l_prep) of_17\IN|seven (l_pobj) seven_18\CD|with (l_prep) with_19\IN|multiforme (l_pobj) multiforme_21\NNS|erythema|and|syndrome
D015662_D004892 NONE SMZ_34\NNP|tmp|- (r_pobj) to_31\IN|smz (r_prep) exposed_30\VBN|experienced|,|four|were|to|. (l_ccomp) experienced_3\VBD|patients|disorders (l_dobj) disorders_5\NNS|blood|,|exposed|;|of (l_prep) of_17\IN|seven (l_pobj) seven_18\CD|with (l_prep) with_19\IN|multiforme (l_pobj) multiforme_21\NNS|erythema|and|syndrome
D015662_D013262 CID SMZ_15\NNP|tmp|- (r_pobj) to_12\IN|smz (r_prep) exposed_11\VBN|one|was|to (r_relcl) disorders_5\NNS|blood|,|exposed|;|of (l_prep) of_17\IN|seven (l_pobj) seven_18\CD|with (l_prep) with_19\IN|multiforme (l_pobj) multiforme_21\NNS|erythema|and|syndrome (l_conj) syndrome_26\NN|johnson
D015662_D013262 CID SMZ_34\NNP|tmp|- (r_pobj) to_31\IN|smz (r_prep) exposed_30\VBN|experienced|,|four|were|to|. (l_ccomp) experienced_3\VBD|patients|disorders (l_dobj) disorders_5\NNS|blood|,|exposed|;|of (l_prep) of_17\IN|seven (l_pobj) seven_18\CD|with (l_prep) with_19\IN|multiforme (l_pobj) multiforme_21\NNS|erythema|and|syndrome (l_conj) syndrome_26\NN|johnson
D002506_D013262 CID cephalexin_13\NN| (r_dobj) took_12\VBD|who|cephalexin (r_relcl) patient_10\NN|a|took (r_pobj) in_8\IN|patient (r_prep) occurred_7\VBD|case|in|. (l_nsubj) case_2\NN|the|one|of (l_prep) of_3\IN|necrolysis (l_pobj) necrolysis_6\NN|toxic|epidermal
15815446
D010656_D002545 NONE phenylephrine_8\NN| (r_npadvmod) induced_10\VBN|phenylephrine|- (r_amod) hypertension_11\NN|induced (r_pobj) of_7\IN|hypertension (r_prep) effect_6\NN|of|during (r_appos) ischemia_2\NN|focal|cerebral|in|:|effect|.
D010656_D006973 CID phenylephrine_8\NN| (r_npadvmod) induced_10\VBN|phenylephrine|- (r_amod) hypertension_11\NN|induced
D010656_D006973 CID phenylephrine_17\NN| (r_npadvmod) induced_19\VBN|phenylephrine|- (r_amod) hypertension_20\NN|induced|on (r_pobj) of_16\IN|hypertension (r_prep) effect_15\NN|the|of (r_nsubj) was_31\VBD|after|,|effect (l_prep) After_0\IN|min (l_pobj) min_2\NN|180|of (l_prep) of_3\IN|occlusion (l_pobj) occlusion_8\NN|temporary|middle|cerebral|artery|in (l_prep) in_9\IN|rats (l_pobj) rats_12\NNS|hypertensive (l_amod) hypertensive_11\JJ|spontaneously
D010656_D006973 CID phenylephrine_17\NN| (r_npadvmod) induced_19\VBN|phenylephrine|- (r_amod) hypertension_20\NN|induced|on
D010656_D020244 NONE phenylephrine_17\NN| (r_npadvmod) induced_19\VBN|phenylephrine|- (r_amod) hypertension_20\NN|induced|on (r_pobj) of_16\IN|hypertension (r_prep) effect_15\NN|the|of (r_nsubj) was_31\VBD|after|,|effect (l_prep) After_0\IN|min (l_pobj) min_2\NN|180|of (l_prep) of_3\IN|occlusion (l_pobj) occlusion_8\NN|temporary|middle|cerebral|artery|in
D010656_D001930 NONE phenylephrine_17\NN| (r_npadvmod) induced_19\VBN|phenylephrine|- (r_amod) hypertension_20\NN|induced|on (l_prep) on_21\IN|injury (l_pobj) injury_24\NN|ischemic|brain|and|permeability
C009591_D001930 NONE chloride_18\NN|2,3,5-triphenyltetrazolium|and|edema (r_dobj) using_16\VBG|chloride (r_advcl) staining_14\VBG|tissue|using (r_pcomp) by_13\IN|staining (r_prep) evaluated_12\VBN|a|,|for|was|by (l_prep) for_3\IN|rats (l_pobj) rats_5\NNS|eight|in (l_prep) in_6\IN|injury (l_pobj) injury_10\NN|each|group|brain
C009591_D004487 NONE chloride_18\NN|2,3,5-triphenyltetrazolium|and|edema (l_conj) edema_20\NN|
D005070_D006973 NONE Blue_1\NNP|evans|(|g-1|) (r_nsubj) was_9\VBD|blue|greater|. (l_acomp) greater_10\JJR|in (l_prep) in_11\IN|group (l_pobj) group_14\NN|the|90/htn|(|6.0|)|versus|(|+/-|)|,|was (l_nummod) 90/HTN_13\CD|
D005070_D006973 NONE Blue_1\NNP|evans|(|g-1|) (r_nsubj) was_9\VBD|blue|greater|. (l_acomp) greater_10\JJR|in (l_prep) in_11\IN|group (l_pobj) group_14\NN|the|90/htn|(|6.0|)|versus|(|+/-|)|,|was (l_relcl) was_31\VBD|which|in|greater (l_acomp) greater_34\JJR|than (l_prep) than_35\IN|group (l_pobj) group_38\NN|the|15/htn|(|+/-|) (l_compound) 15/HTN_37\CD|
20129423
D002220_D004802 CID carbamazepine_1\NN|fatal (r_nsubj) induced_2\VBD|carbamazepine|hypersensitivity|. (l_dobj) hypersensitivity_6\NN|fulminant|eosinophilic|(|)|myocarditis|emphasis (l_amod) eosinophilic_4\JJ|
D002220_D004342 CID carbamazepine_1\NN|fatal (r_nsubj) induced_2\VBD|carbamazepine|hypersensitivity|. (l_dobj) hypersensitivity_6\NN|fulminant|eosinophilic|(|)|myocarditis|emphasis
D002220_D004342 CID carbamazepine_1\NN|fatal (r_nsubj) induced_2\VBD|carbamazepine|hypersensitivity|. (l_dobj) hypersensitivity_6\NN|fulminant|eosinophilic|(|)|myocarditis|emphasis (l_appos) emphasis_10\NN|on (l_prep) on_11\IN|characteristics (l_pobj) characteristics_15\NNS|anatomical|,|mechanisms|of (l_prep) of_20\IN|hypersensitivity (l_pobj) hypersensitivity_22\NN|drug|and|diagnosis
D002220_D004342 CID carbamazepine_10\NN| (r_pobj) of_9\IN|carbamazepine (r_prep) effect_8\NN|rare|side|of (r_nsubj) necrotizing_12\VBG|fatal|,|although|effect|is|myocarditis|. (l_oprd) myocarditis_17\NN|eosinophilic|hypersensitivity (l_nmod) hypersensitivity_15\NN|(|)
D002220_D004342 CID carbamazepine_11\NN| (r_pobj) of_10\IN|carbamazepine (r_prep) administration_9\NN|of (r_pobj) to_8\IN|administration (r_prep) secondary_7\JJ|myocarditis|to (r_amod) hypersensitivity_5\NN|secondary
D002220_D009205 CID carbamazepine_1\NN|fatal (r_nsubj) induced_2\VBD|carbamazepine|hypersensitivity|. (l_dobj) hypersensitivity_6\NN|fulminant|eosinophilic|(|)|myocarditis|emphasis (l_amod) myocarditis_8\NN|:
D002220_D009205 CID carbamazepine_10\NN| (r_pobj) of_9\IN|carbamazepine (r_prep) effect_8\NN|rare|side|of (r_nsubj) necrotizing_12\VBG|fatal|,|although|effect|is|myocarditis|. (l_oprd) myocarditis_17\NN|eosinophilic|hypersensitivity
D002220_D009205 CID carbamazepine_11\NN| (r_pobj) of_10\IN|carbamazepine (r_prep) administration_9\NN|of (r_pobj) to_8\IN|administration (r_prep) secondary_7\JJ|myocarditis|to (l_advmod) myocarditis_6\NN|
D002220_D009205 CID carbamazepine_12\NN|fatal (r_pobj) of_10\IN|carbamazepine (r_prep) case_9\NN|the|second|of|induced (l_acl) induced_13\VBN|myocarditis (l_dobj) myocarditis_14\NN|reported
19655282
D003042_D002637 CID cocaine_13\NN| (r_npadvmod) associated_15\VBN|cocaine|- (r_amod) pain_17\NN|associated|chest
D003042_D002637 CID cocaine_10\NN| (r_npadvmod) associated_12\VBN|cocaine|- (r_amod) pain_14\NN|associated|chest
D003042_D002637 CID cocaine_12\NN| (r_npadvmod) associated_14\VBN|cocaine|- (r_amod) pain_16\NN|associated|chest
D003042_D002637 CID cocaine_10\NN| (r_npadvmod) associated_12\VBN|cocaine|- (r_amod) pain_14\NN|associated|chest
D003042_D002637 CID cocaine_6\NN| (r_npadvmod) associated_8\VBN|cocaine|- (r_amod) pain_10\NN|associated|chest
D003042_D002637 CID cocaine_1\NN| (r_npadvmod) associated_3\VBN|cocaine|- (r_amod) ischemia_5\NN|associated|myocardial (r_nsubj) result_7\VB|although|ischemia|can|from|. (l_prep) from_8\IN|vasoconstriction (l_pobj) vasoconstriction_10\NN|coronary|,|discharged (l_acl) discharged_35\VBN|patients|may|be|safely|from|after|with (l_nsubjpass) patients_12\NNS|with (l_prep) with_13\IN|cocaine (l_pobj) cocaine_14\NN|associated (l_acl) associated_15\VBN|pain (l_dobj) pain_17\NN|chest|,|ecg
D003042_D002637 CID cocaine_14\NN|associated (l_acl) associated_15\VBN|pain (l_dobj) pain_17\NN|chest|,|ecg
D003042_D054058 NONE cocaine_10\NN| (r_npadvmod) associated_12\VBN|cocaine|- (r_amod) pain_14\NN|associated|chest (r_pobj) with_9\IN|pain (r_prep) presenting_2\VBG|to|with (r_acl) patients_1\NNS|most|presenting (r_nsubjpass) admitted_16\VBN|patients|are|for|and|receive|. (l_conj) receive_23\VB|protocol|prior (l_dobj) protocol_32\NN|a|"|rule|acute|syndrome|"|,|with (l_nmod) syndrome_30\NN|coronary
D003042_D003329 NONE cocaine_12\NN| (r_npadvmod) associated_14\VBN|cocaine|- (r_amod) pain_16\NN|associated|chest (r_pobj) in_11\IN|pain (r_prep) efficacious_10\JJ|in (r_acomp) be_9\VB|whether|strategy|would|efficacious|,|account (l_advcl) account_22\VB|as|vasospasm|may|for (l_nsubj) vasospasm_20\NN|coronary
D003042_D007511 NONE cocaine_12\NN| (r_npadvmod) associated_14\VBN|cocaine|- (r_amod) pain_16\NN|associated|chest (r_pobj) in_11\IN|pain (r_prep) efficacious_10\JJ|in (r_acomp) be_9\VB|whether|strategy|would|efficacious|,|account (l_advcl) account_22\VB|as|vasospasm|may|for (l_prep) for_23\IN|some (l_pobj) some_24\DT|of (l_prep) of_25\IN|ischemia (l_pobj) ischemia_27\NN|the
D003042_D007511 NONE cocaine_1\NN| (r_npadvmod) associated_3\VBN|cocaine|- (r_amod) ischemia_5\NN|associated|myocardial (r_nsubj) result_7\VB|although|ischemia|can|from|. (l_prep) from_8\IN|vasoconstriction (l_pobj) vasoconstriction_10\NN|coronary|,|discharged (l_acl) discharged_35\VBN|patients|may|be|safely|from|after|with (l_nsubjpass) patients_12\NNS|with (l_prep) with_13\IN|cocaine (l_pobj) cocaine_14\NN|associated (l_acl) associated_15\VBN|pain (l_dobj) pain_17\NN|chest|,|ecg (l_conj) ECG_23\NNP|a|ischemic|,|and|2 (l_amod) ischemic_22\JJ|non|-
D003042_D007511 NONE cocaine_14\NN|associated (l_acl) associated_15\VBN|pain (l_dobj) pain_17\NN|chest|,|ecg (l_conj) ECG_23\NNP|a|ischemic|,|and|2 (l_amod) ischemic_22\JJ|non|-
D003042_D017202 CID cocaine_1\NN| (r_npadvmod) associated_3\VBN|cocaine|- (r_amod) ischemia_5\NN|associated|myocardial
D003042_D017202 CID cocaine_14\NN|associated (r_pobj) with_13\IN|cocaine (r_prep) patients_12\NNS|with (r_nsubjpass) discharged_35\VBN|patients|may|be|safely|from|after|with (r_acl) vasoconstriction_10\NN|coronary|,|discharged (r_pobj) from_8\IN|vasoconstriction (r_prep) result_7\VB|although|ischemia|can|from|. (l_nsubj) ischemia_5\NN|associated|myocardial
733189
D000305_D015356 NONE corticosteroid_13\NN| (r_compound) suspensions_14\NNS|acting|corticosteroid|in (r_pobj) of_9\IN|suspensions (r_prep) injection_8\NN|the|of (r_pobj) following_6\VBG|injection (r_prep) artery_2\NN|bilateral|retinal|and|occlusion|following|:|studies|. (l_conj) occlusion_5\NN|choriocapillaris
C000873_D015356 CID acetate_24\NN|methylprednisolone (r_pobj) with_22\IN|acetate (r_prep) injection_21\NN|head|tissue|with|in (r_dobj) following_14\VBG|injection (r_prep) blindness_13\NN|following (r_pobj) with_12\IN|blindness (r_prep) occlusions_11\NNS|choriocapillaris|with
C000873_D001766 NONE acetate_24\NN|methylprednisolone (r_pobj) with_22\IN|acetate (r_prep) injection_21\NN|head|tissue|with|in (r_dobj) following_14\VBG|injection (r_prep) blindness_13\NN|following
D008012_D015356 NONE lidocaine_28\NN|,|epinephrine (r_pobj) with_27\IN|lidocaine (r_prep) combination_26\NN|with (r_pobj) in_25\IN|combination (r_prep) injection_21\NN|head|tissue|with|in (r_dobj) following_14\VBG|injection (r_prep) blindness_13\NN|following (r_pobj) with_12\IN|blindness (r_prep) occlusions_11\NNS|choriocapillaris|with
D008012_D001766 NONE lidocaine_28\NN|,|epinephrine (r_pobj) with_27\IN|lidocaine (r_prep) combination_26\NN|with (r_pobj) in_25\IN|combination (r_prep) injection_21\NN|head|tissue|with|in (r_dobj) following_14\VBG|injection (r_prep) blindness_13\NN|following
D004837_D015356 NONE epinephrine_30\NN|,|or|penicillin (r_conj) lidocaine_28\NN|,|epinephrine (r_pobj) with_27\IN|lidocaine (r_prep) combination_26\NN|with (r_pobj) in_25\IN|combination (r_prep) injection_21\NN|head|tissue|with|in (r_dobj) following_14\VBG|injection (r_prep) blindness_13\NN|following (r_pobj) with_12\IN|blindness (r_prep) occlusions_11\NNS|choriocapillaris|with
D004837_D001766 NONE epinephrine_30\NN|,|or|penicillin (r_conj) lidocaine_28\NN|,|epinephrine (r_pobj) with_27\IN|lidocaine (r_prep) combination_26\NN|with (r_pobj) in_25\IN|combination (r_prep) injection_21\NN|head|tissue|with|in (r_dobj) following_14\VBG|injection (r_prep) blindness_13\NN|following
D010406_D015356 NONE penicillin_33\NN| (r_conj) epinephrine_30\NN|,|or|penicillin (r_conj) lidocaine_28\NN|,|epinephrine (r_pobj) with_27\IN|lidocaine (r_prep) combination_26\NN|with (r_pobj) in_25\IN|combination (r_prep) injection_21\NN|head|tissue|with|in (r_dobj) following_14\VBG|injection (r_prep) blindness_13\NN|following (r_pobj) with_12\IN|blindness (r_prep) occlusions_11\NNS|choriocapillaris|with
D010406_D001766 NONE penicillin_33\NN| (r_conj) epinephrine_30\NN|,|or|penicillin (r_conj) lidocaine_28\NN|,|epinephrine (r_pobj) with_27\IN|lidocaine (r_prep) combination_26\NN|with (r_pobj) in_25\IN|combination (r_prep) injection_21\NN|head|tissue|with|in (r_dobj) following_14\VBG|injection (r_prep) blindness_13\NN|following
20495512
D006493_D013921 CID Heparin_0\NNP| (r_npadvmod) induced_2\VBN|heparin|- (r_amod) thrombocytopenia_3\NN|induced|:|review|.
D006493_D013921 CID Heparin_0\NNP| (r_npadvmod) induced_2\VBN|heparin|- (r_amod) thrombocytopenia_3\NN|induced|hit
D006493_D013921 CID Heparin_0\NNP| (r_npadvmod) induced_2\VBN|heparin|- (r_amod) thrombocytopenia_3\NN|induced|hit (l_appos) HIT_5\NN|(|)
D006493_D013921 CID heparin_16\JJ| (r_compound) exposure_17\NN|heparin (r_pobj) after_15\IN|exposure (r_prep) occurs_14\VBZ|whenever|thrombosis|after (r_ccomp) suspected_11\VBN|occurs (r_conj) acknowledged_3\VBN|hit|must|be|for|and|suspected|. (l_nsubjpass) HIT_0\NNP|
D006493_D013921 CID heparin_10\JJ| (r_compound) exposure_11\NN|all|heparin|and|institution (r_pobj) of_8\IN|exposure (r_prep) cessation_7\NN|an|immediate|of (r_dobj) mandates_4\NNS|treatment|cessation|,|using|. (l_nsubj) treatment_1\NN|the|of (l_prep) of_2\IN|hit (l_pobj) HIT_3\NNP|
D006493_D013921 CID heparin_11\NN|in (l_prep) in_12\IN|patients (l_pobj) patients_13\NNS|with (l_prep) with_14\IN|history (l_pobj) history_16\NN|a|of|,|need (l_prep) of_17\IN|hit (l_pobj) HIT_18\NN|
D006493_D013921 CID heparin_1\NN| (r_nsubj) remains_2\VBZ|as|heparin|one|today|with (l_prep) with_11\IN|potential (l_pobj) potential_12\NN|for|with (l_prep) for_13\IN|hit (l_pobj) HIT_14\NN|
D006493_D013921 CID heparin_17\JJ| (r_compound) exposure_18\NN|every|heparin (r_pobj) with_15\IN|exposure (r_prep) potential_12\NN|for|with (l_prep) for_13\IN|hit (l_pobj) HIT_14\NN|
D006493_D013921 CID heparin_30\JJ| (r_nsubjpass) initiated_32\VBN|whenever|heparin|is (r_advcl) practiced_28\VBN|remains|,|vigilance|must|be|initiated|. (l_advcl) remains_2\VBZ|as|heparin|one|today|with (l_prep) with_11\IN|potential (l_pobj) potential_12\NN|for|with (l_prep) for_13\IN|hit (l_pobj) HIT_14\NN|
D006493_D013927 CID heparin_16\JJ| (r_compound) exposure_17\NN|heparin (r_pobj) after_15\IN|exposure (r_prep) occurs_14\VBZ|whenever|thrombosis|after (r_ccomp) suspected_11\VBN|occurs (r_conj) acknowledged_3\VBN|hit|must|be|for|and|suspected|. (l_prep) for_4\IN|predilection (l_pobj) predilection_7\NN|its|intense|for (l_prep) for_8\IN|thrombosis (l_pobj) thrombosis_9\NN|
D006493_D013927 CID heparin_16\JJ| (r_compound) exposure_17\NN|heparin (r_pobj) after_15\IN|exposure (r_prep) occurs_14\VBZ|whenever|thrombosis|after (l_nsubj) thrombosis_13\NN|
D000991_D013921 NONE inhibitor_26\NN|a|direct|thrombin (r_dobj) using_22\VBG|commonly|inhibitor (r_advcl) mandates_4\NNS|treatment|cessation|,|using|. (l_nsubj) treatment_1\NN|the|of (l_prep) of_2\IN|hit (l_pobj) HIT_3\NNP|
D000991_D013921 NONE inhibitors_2\NNS|direct|thrombin (r_nsubj) are_3\VBP|inhibitors|alternatives|. (l_attr) alternatives_9\NNS|appropriate|,|based|to (l_prep) to_10\IN|heparin (l_pobj) heparin_11\NN|in (l_prep) in_12\IN|patients (l_pobj) patients_13\NNS|with (l_prep) with_14\IN|history (l_pobj) history_16\NN|a|of|,|need (l_prep) of_17\IN|hit (l_pobj) HIT_18\NN|
10933650
D000666_D007674 NONE B._13\NNP| (r_appos) Attenuation_0\NN|of|by|b. (l_prep) of_1\IN|nephrotoxicity (l_pobj) nephrotoxicity_2\NN|
D000666_D007674 NONE B_12\NNP|amphotericin (r_pobj) of_10\IN|b (r_prep) incorporation_9\NN|of|into (r_nsubj) attenuates_18\VBZ|that|incorporation|ns-718|nephrotoxicity (l_dobj) nephrotoxicity_20\NN|the|of
D000666_D007674 NONE B._23\NNP|amphotericin (r_pobj) of_21\IN|b. (r_prep) nephrotoxicity_20\NN|the|of
D000666_D064420 NONE B_7\NN|amphotericin (r_dobj) incorporating_5\VBG|nanosphere|b (r_acl) lipid_3\NN|a|incorporating (r_nsubj) is_9\VBZ|ns-718|,|lipid|,|effective|and|has|. (l_conj) has_15\VBZ|toxicity (l_dobj) toxicity_17\NN|low
D000666_D064420 NONE Fungizone_9\NNP| (r_nmod) deoxycholate_15\NN|fungizone|(|sodium (r_pobj) of_8\IN|deoxycholate (r_prep) that_7\DT|of (r_pobj) with_6\IN|ns-718|that (r_punct) ;_16\:|with (r_punct) using_23\VBG|;|amb|cultures|and|in|by|following (r_advcl) compared_1\VBD|we|toxicity|using|. (l_dobj) toxicity_3\NN|the|of
D000666_D064420 NONE B_44\NNP|amphotericin (r_pobj) of_42\IN|b (r_prep) study_41\NN|pharmacokinetic|of (r_conj) kidney_38\NN|the|and|study (r_pobj) of_36\IN|kidney (r_prep) study_35\NN|histopathological|of (r_appos) analysis_32\NN|biochemical|,|study (r_pobj) by_30\IN|analysis (r_prep) using_23\VBG|;|amb|cultures|and|in|by|following (r_advcl) compared_1\VBD|we|toxicity|using|. (l_dobj) toxicity_3\NN|the|of
C059765_D064420 NONE deoxycholate_15\NN|fungizone|(|sodium (r_pobj) of_8\IN|deoxycholate (r_prep) that_7\DT|of (r_pobj) with_6\IN|ns-718|that (r_punct) ;_16\:|with (r_punct) using_23\VBG|;|amb|cultures|and|in|by|following (r_advcl) compared_1\VBD|we|toxicity|using|. (l_dobj) toxicity_3\NN|the|of
C059765_D064420 NONE AmB_19\NNP|d|-|)|in (r_nsubj) using_23\VBG|;|amb|cultures|and|in|by|following (r_advcl) compared_1\VBD|we|toxicity|using|. (l_dobj) toxicity_3\NN|the|of
C059765_D007683 CID AmB_11\VBN|- (r_dep) treated_13\VBN|amb|- (r_amod) rats_14\NNS|d|treated (r_pobj) in_8\IN|rats (r_prep) necrosis_7\NN|tubular|in
24451297
C065180_D056486 CID Fluvastatin_10\NNP| (r_compound) Therapy_11\NNP|fluvastatin (r_pobj) After_9\IN|therapy (r_prep) Hours_8\NNS|12|after (r_pobj) Within_6\IN|hours (r_prep) Injury_5\NN|induced|acute|liver|within|.
C065180_D056486 CID fluvastatin_19\NN| (r_pobj) with_18\IN|fluvastatin (r_prep) treatment_17\NN|with (r_dobj) beginning_16\VBG|treatment (r_pcomp) after_15\IN|hours|beginning (r_prep) appeared_12\VBD|which|after (r_relcl) damage_9\NN|liver|,|appeared
D019161_D056486 NONE statins_1\NNS| (r_nsubj) are_2\VBP|although|statins|generally|drugs (r_advcl) reported_23\VBN|are|,|cases|have|been|. (l_nsubjpass) cases_10\NNS|recent|of|associated (l_prep) of_11\IN|injury (l_pobj) injury_16\NN|induced|liver
1615846
D015248_D006951 NONE Gemfibrozil_0\NNP| (r_compound) lovastatin_2\NN|gemfibrozil|- (r_amod) therapy_3\NN|lovastatin|for|. (l_prep) for_4\IN|hyperlipoproteinemias (l_pobj) hyperlipoproteinemias_6\NNS|primary
D008148_D006951 NONE lovastatin_2\NN|gemfibrozil|- (r_amod) therapy_3\NN|lovastatin|for|. (l_prep) for_4\IN|hyperlipoproteinemias (l_pobj) hyperlipoproteinemias_6\NNS|primary
D015248_D006949 NONE gemfibrozil_30\NN| (r_compound) lovastatin_32\NN|gemfibrozil|- (r_amod) treatment_33\NN|label|lovastatin|in (l_prep) in_34\IN|patients (l_pobj) patients_36\NNS|80|with (l_prep) with_37\IN|hyperlipidemia (l_pobj) hyperlipidemia_40\NN|primary|mixed|(
D015248_D002340 NONE gemfibrozil_30\NN| (r_compound) lovastatin_32\NN|gemfibrozil|- (r_amod) treatment_33\NN|label|lovastatin|in (r_conj) safety_12\NN|and|efficacy|of|,|treatment|had (l_relcl) had_46\VBD|%|disease (l_dobj) disease_49\NN|atherosclerotic|vascular
D008148_D006949 NONE lovastatin_32\NN|gemfibrozil|- (r_amod) treatment_33\NN|label|lovastatin|in (l_prep) in_34\IN|patients (l_pobj) patients_36\NNS|80|with (l_prep) with_37\IN|hyperlipidemia (l_pobj) hyperlipidemia_40\NN|primary|mixed|(
D008148_D002340 NONE lovastatin_32\NN|gemfibrozil|- (r_amod) treatment_33\NN|label|lovastatin|in (r_conj) safety_12\NN|and|efficacy|of|,|treatment|had (l_relcl) had_46\VBD|%|disease (l_dobj) disease_49\NN|atherosclerotic|vascular
D003401_D009220 NONE creatine_28\NN|high (r_compound) phosphokinase_29\NN|concurrent|creatine (r_pobj) with_25\IN|phosphokinase (r_prep) %_24\NN|1|with|liter (r_pobj) in_22\IN|% (r_prep) had_39\VBD|in|;|patients|rhabdomyolysis|. (r_conj) occurred_14\VBD|myositis|in|,|and|had (l_nsubj) Myositis_0\NNP|,|attributable|,
D003401_D012206 NONE creatine_28\NN|high (r_compound) phosphokinase_29\NN|concurrent|creatine (r_pobj) with_25\IN|phosphokinase (r_prep) %_24\NN|1|with|liter (r_pobj) in_22\IN|% (r_prep) had_39\VBD|in|;|patients|rhabdomyolysis|. (l_dobj) rhabdomyolysis_40\NN|or|myoglobinuria
D003401_D009212 NONE creatine_28\NN|high (r_compound) phosphokinase_29\NN|concurrent|creatine (r_pobj) with_25\IN|phosphokinase (r_prep) %_24\NN|1|with|liter (r_pobj) in_22\IN|% (r_prep) had_39\VBD|in|;|patients|rhabdomyolysis|. (l_dobj) rhabdomyolysis_40\NN|or|myoglobinuria (l_conj) myoglobinuria_42\NNS|
